-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Fj53FyqSAGfjq1EqPFbRHhC78eb46iUKxvv+XfJWr40uH/gNvIb7fQSOv3pO7Q7E
 +Mmp1XplROIVGINyKRQiBQ==

<SEC-DOCUMENT>0000950123-09-068899.txt : 20091207
<SEC-HEADER>0000950123-09-068899.hdr.sgml : 20091207
<ACCEPTANCE-DATETIME>20091207171151
ACCESSION NUMBER:		0000950123-09-068899
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		16
FILED AS OF DATE:		20091207
DATE AS OF CHANGE:		20091207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Concord Medical Services Holdings Ltd
		CENTRAL INDEX KEY:			0001472072
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-163155
		FILM NUMBER:		091226737

	BUSINESS ADDRESS:	
		STREET 1:		ROOM 2001-2002, 20TH FLOOR, TOWER A
		STREET 2:		GLOBAL TRADE CTR, 36 NORTH THIRD RING RD
		CITY:			DONGCHENG DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100013
		BUSINESS PHONE:		(86)10-5825-6867

	MAIL ADDRESS:	
		STREET 1:		ROOM 2001-2002, 20TH FLOOR, TOWER A
		STREET 2:		GLOBAL TRADE CTR, 36 NORTH THIRD RING RD
		CITY:			DONGCHENG DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100013
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>h03611a4fv1za.htm
<DESCRIPTION>F-1/A
<TEXT>
<HTML>
<HEAD>
<TITLE>fv1za</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">As filed
    with the Securities and Exchange Commission on December&#160;7,
    2009</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B> Registration No.&#160;333-163155</B>
</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 14pt">SECURITIES AND EXCHANGE
    COMMISSION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">Washington,&#160;D.C.
    20549</FONT></B>
</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Amendment No.&#160;4 to</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 18pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times"><FONT style="white-space: nowrap">Form&#160;F-1</FONT><BR>
    <BR>
    <FONT style="font-size: 12pt">REGISTRATION STATEMENT<BR>
    UNDER<BR>
    THE SECURITIES ACT OF 1933</FONT></FONT></B>
</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 24pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Concord
    Medical Services Holdings Limited</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Exact name of registrant as
    specified in its charter)</FONT></I>
</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Not Applicable</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Translation of
    registrant&#146;s name into English)</FONT></I>
</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="35%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="31%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="31%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    <B>Cayman Islands</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>8011</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>Not Applicable</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(State or other jurisdiction
    of<BR>
    incorporation or organization)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(Primary Standard Industrial<BR>
    Classification Code Number)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(I.R.S. Employer<BR>
    Identification Number) </FONT></I>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>18/F, Tower A, Global Trade Center</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>36 North Third Ring Road East, Dongcheng District</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Beijing 100013</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>People&#146;s Republic of China</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>(86 10)&#160;5903-6688</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Address, including zip code,
    and telephone number, including area code, of registrant&#146;s
    principal executive offices)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>National Registered Agents, Inc.</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>875 Avenue of the Americas, Suite&#160;501</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>New York, New York 10001</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="white-space: nowrap">(888)&#160;336-3926</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Name, address, including zip
    code, and telephone number, including area code, of agent for
    service)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Copies to:</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="49%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    <B>Leiming Chen</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>Portia Ku</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <B>Simpson Thacher&#160;&#038; Bartlett LLP</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>O&#146;Melveny &#038; Myers LLP</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <B>35th&#160;Floor, ICBC Tower</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>37/F Plaza 66, 1266 Nanjing Road W</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <B>3 Garden Road</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>Shanghai, People&#146;s Republic of China</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <B>Central, Hong Kong</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>(86&#160;21) 2307-7000</B>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    <B><FONT style="white-space: nowrap">(852)&#160;2514-7600</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Approximate date of commencement of proposed sale to the
    public: </B>As soon as practicable after the effective date of
    this registration statement
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If any of the securities being registered on this form are to be
    offered on a delayed or continuous basis pursuant to
    Rule&#160;415 under the Securities Act of 1933, check the
    following
    box.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is filed to register additional securities for an
    offering pursuant to Rule&#160;462(b) under the Securities Act,
    check the following box and list the Securities Act registration
    statement number of the earlier effective registration statement
    for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<U>&#160;&#160;</U>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(c) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<U>&#160;&#160;</U>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(d) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earliest effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<U>&#160;&#160;</U>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CALCULATION
    OF REGISTRATION FEE</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutterright -->
    <TD width="7%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="11%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="11%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutterright -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    <B>Proposed Maximum<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Offering Price<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Proposed<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Title of Each Class of<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Amount to Be<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>per Ordinary<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Maximum Aggregate<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Amount of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Securities to be Registered</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Registered<SUP style="font-size: 85%; vertical-align: top">(1)(2)</SUP></B>

</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Share<SUP style="font-size: 85%; vertical-align: top">(1)</SUP></B>

</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Offering
    Price<SUP style="font-size: 85%; vertical-align: top">(1)</SUP></B>

</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>registration fee</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom" style="border-top: 1px solid #000000">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Ordinary shares, par value US$0.0001 per
    share<SUP style="font-size: 85%; vertical-align: top">(2)(3)</SUP></B>

</DIV>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    <B>41,400,000</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    <B>US$3.8333</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    <B>US$158,700,000</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    <B>US$8,855<SUP style="font-size: 85%; vertical-align: top">(4)</SUP></B>

</TD>
</TR>
<TR style="font-size: 1pt">
<TD colspan="13" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD colspan="13" align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Estimated solely for the purpose of
    determining the amount of registration fee in accordance with
    Rule&#160;457(a) under the Securities Act of 1933.
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Includes ordinary shares initially
    offered and sold outside the United States that may be resold
    from time to time in the United States either as part of their
    distribution or within 40&#160;days after the later of the
    effective date of this registration statement and the date the
    shares are first bona fide offered to the public, and also
    includes ordinary shares that may be purchased by the
    underwriters pursuant to an over-allotment option. These
    ordinary shares are not being registered for the purposes of
    sales outside of the United States.
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">American depositary shares issuable
    upon deposit of the ordinary shares registered hereby will be
    registered under a separate registration statement on
    <FONT style="white-space: nowrap">Form&#160;F-6</FONT>
    (Registration
    <FONT style="white-space: nowrap">No.&#160;333-&#160;&#160;&#160;&#160;&#160;).</FONT>
    Each American depositary share represents three ordinary shares.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Previously paid.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>The Registrant hereby amends this Registration Statement on
    such date or dates as may be necessary to delay its effective
    date until the Registrant shall file a further amendment which
    specifically states that this Registration Statement shall
    thereafter become effective in accordance with Section&#160;8(a)
    of the Securities Act of 1933, as amended or until the
    Registration Statement shall become effective on such date as
    the Securities and Exchange Commission, acting pursuant to such
    Section&#160;8(a), may determine.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE style="color: #FF0000" width="100%" border="1" cellpadding="5"><TR><TD>
<B><FONT style="font-size: 9pt; font-family: Arial, Helvetica; color: #F93F26">The
information in this prospectus is not complete and may be
changed. Neither we nor the selling shareholders may sell these
securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus
is not an offer to sell these securities and we are not
soliciting offers to buy these securities in any state where the
offer or sale is not permitted.<BR>
</FONT></B>
</TD></TR></TABLE>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 89%; margin-left: 5%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 12pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times; color: #F93F26">PROSPECTUS
    (Subject to Completion) <BR>
    <FONT style="font-size: 11pt">Issued&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2009</FONT></FONT></I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 18pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">12,000,000
    American Depositary Shares</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611a4h0361100.gif" alt="(CONCORD MEDICAL SERVICES HOLDING LIMITED LOGO)"><FONT style="font-size: 18pt">
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 24pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concord
    Medical Services Holdings Limited</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 12pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">REPRESENTING
    36,000,000 ORDINARY SHARES</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Concord Medical Services Holdings Limited is offering
    12,000,000 American Depositary Shares, or ADSs. Each ADS
    represents three ordinary shares, par value US$0.0001 per share.
    This is our initial public offering and no public market exists
    for our ADSs or our ordinary shares. We anticipate that the
    initial public offering price will be between US$9.50 and
    US$11.50 per ADS.</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have received approval to list the ADSs on the New York
    Stock Exchange under the symbol &#145;&#145;CCM.&#148;</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 12pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Investing in the ADSs involves risks. See &#147;Risk
    Factors&#148; beginning on page 18.</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">PRICE
    $&#160;&#160;&#160;&#160;&#160; AN ADS</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="60%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="12%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="9%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B><I>Underwriting<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B><I>Discounts<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B><I>Price to<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B><I>and<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B><I>Proceeds to<BR>
    </I></B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Public</I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Commissions</I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Company</I></B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Per ADS
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <I>$&#160;</I>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <I>$&#160;</I>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <I>$&#160;</I>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <I>$&#160;&#160;&#160;&#160;&#160;</I>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <I>$&#160;&#160;&#160;&#160;&#160;</I>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <I>$&#160;&#160;&#160;&#160;&#160;</I>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The selling shareholders identified in this prospectus have
    granted the underwriters the right to purchase up to an
    aggregate of 1,800,000&#160;additional ADSs to cover
    over-allotments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Securities and Exchange Commission and state securities
    regulators have not approved or disapproved these securities, or
    determined if this prospectus is truthful or complete. Any
    representation to the contrary is a criminal offense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters expect to deliver the ADSs to purchasers on or
    about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2009.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="33%"></TD>
    <TD width="33%"></TD>
    <TD width="33%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">    <I><FONT style="font-size: 18pt; font-family: 'Times New Roman', Times">MORGAN
    STANLEY</FONT></I></TD>
    <TD nowrap align="center">    <I><FONT style="font-size: 18pt; font-family: 'Times New Roman', Times">
    J.P.MORGAN</FONT></I></TD>
    <TD nowrap align="right">    <I><FONT style="font-size: 18pt; font-family: 'Times New Roman', Times">
    CICC</FONT></I></TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">December&#160;&#160;&#160;,
    2009
    </FONT>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">
<IMG src="h03611a4h03611146.gif" alt="(GRAPHICS)">
</DIV>


<TABLE width="90%">
<TR>
<TD style="font-size: 1pt; color: #FFFFFF">
Cms
O J centers in .30 cities*
Concord Medical operates the largest network of radiotherapy and diagnostic imaging centers in
China**
1 As ot September&nbsp;30,2009.
&#148; In terms of revenues and the total number of centers in operation in 2008, according to a
Frost &#038;
Sullivan report commissioned by Concord Medical.</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 89%; margin-left: 5%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#101'>Prospectus Summary</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#102'>Risk Factors</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#103'>Special Note Regarding Forward-Looking
    Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#104'>Use of Proceeds</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#105'>Dividend Policy</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#106'>Capitalization</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#107'>Dilution</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#108'>Exchange Rate Information</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#109'>Enforceability of Civil Liabilities</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#110'>Our History and Corporate Structure</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#111'>Selected Consolidated Financial and Operating
    Data</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#112'>Management&#146;s Discussion and Analysis of
    Financial Condition and Results of Operations</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#113'>Our Industry</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#114'>Business</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#115'>Regulation of Our Industry</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    117
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#116'>Management</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#117'>Principal and Selling Shareholders</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    133
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#118'>Related Party Transactions</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    136
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#130'>Description of Share Capital</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#119'>Description of American Depositary Shares</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    148
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#120'>Shares Eligible for Future Sale</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    157
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#121'>Taxation</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    159
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#122'>Underwriting</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    165
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#123'>Expenses Related to this Offering</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#124'>Legal Matters</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    172
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#125'>Experts</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    172
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#126'>Where You Can Find Additional Information</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    173
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#127'>Index to Consolidated Financial Statements of
    Concord Medical Services Holdings Limited</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#128'>Index to Consolidated Financial Statements of
    China Medstar Pte. Limited</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-75
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#129'>Index to Unaudited Pro Forma Condensed Combined
    Financial Statement of Concord Medical Services Holdings
    Limited</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    P-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611a4exv1w1.htm">EX-1.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611a4exv4w3.htm">EX-4.3</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611a4exv4w19.htm">EX-4.19</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611a4exv10w21.htm">EX-10.21</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611a4exv23w1.htm">EX-23.1</A></FONT></TD></TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 21%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=456 length=96 -->

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You should rely only on the information contained in this
    prospectus or any free writing prospectus filed with the
    Securities and Exchange Commission, or the SEC, in connection
    with this offering. We have not authorized anyone to provide you
    with information that is different from that contained in this
    prospectus or in any filed free writing prospectus. We are
    offering to sell, and seeking offers to buy, the ADSs only in
    jurisdictions where offers and sales are permitted. The
    information contained in this prospectus or in any filed free
    writing prospectus is current only as of its date, regardless of
    the time of its delivery or of any sale of the ADSs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have not taken any action to permit a public offering of the
    ADSs outside of the Untied States or to permit the possession or
    distribution of this prospectus or any filed free writing
    prospectus outside the United States. Persons outside of the
    United States who come into possession of this prospectus or any
    filed free writing prospectus must inform themselves about and
    observe any restrictions relating to the offering of the ADSs
    and the distribution of this prospectus or any filed free
    writing prospectus outside of the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Until
    </B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    <B>(the 25th&#160;day after the date of this prospectus), all
    dealers that buy, sell or trade ADSs, whether or not
    participating in this offering, may be required to deliver a
    prospectus. This is in addition to the obligation of dealers to
    deliver a prospectus when acting as underwriters and with
    respect to their unsold allotments or subscriptions.</B>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    i
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<A name='101'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROSPECTUS
    SUMMARY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The following summary is qualified in its entirety by, and
    should be read in conjunction with, the more detailed
    information and financial statements appearing elsewhere in this
    prospectus. In addition to this summary, we urge you to read the
    entire prospectus carefully, especially the risks of investing
    in the ADSs discussed under &#147;Risk Factors,&#148; before
    deciding whether to buy our ADSs. Unless the context indicates
    otherwise, all share and per share data in this prospectus give
    effect to a 1-for-100 share split that became effective on
    November&#160;17, 2009.</I>
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Business</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We operate the largest network of radiotherapy and diagnostic
    imaging centers in China in terms of revenues and the total
    number of centers in operation in 2008, according to a report by
    Frost&#160;&#038; Sullivan commissioned by us that compared our
    pro forma revenues against the revenues of our competitors in
    2008 and our number of centers and units of equipment against
    those of our competitors as of the end of 2008. As of
    September&#160;30, 2009, our network comprised 83&#160;centers
    based in 55&#160;hospitals, spanning 36&#160;cities across
    21&#160;provinces and administrative regions in China. These
    hospitals are substantially comprised of 3A hospitals, the
    highest ranked hospitals by quality and size in China as
    determined in accordance with the standards of the Ministry of
    Health, or the MOH. Cancer was the leading cause of death in
    China in 2008 according to the MOH, and there is a relatively
    low penetration of radiotherapy and diagnostic imaging equipment
    compared to developed countries. We believe that our leading
    network and our experience and expertise uniquely position us to
    address the underserved market in China for radiotherapy and
    diagnostic imaging services.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Most of the centers in our network are established through
    long-term lease and management services arrangements entered
    into with our hospital partners. Under these arrangements, we
    receive a contracted percentage of each center&#146;s revenue
    net of specified operating expenses. Each center is located on
    the premises of our hospital partners and is typically equipped
    with a primary unit of advanced radiotherapy or diagnostic
    imaging equipment, such as a linear accelerator, head gamma
    knife system, body gamma knife system, positron emission
    tomography-computed tomography scanner, or PET-CT scanner, or
    magnetic resonance imaging scanner, or MRI scanner. We provide
    clinical support services to doctors who work in the centers in
    our network, which include developing treatment protocols for
    doctors and organizing joint diagnosis between doctors in our
    network and clinical research. In addition, we help recruit and
    determine the compensation of doctors and other medical
    personnel in our network and are typically in charge of most of
    the non-clinical aspects of the centers&#146; daily operations,
    including marketing, training and administrative duties. Our
    hospital partners are responsible for the centers&#146; clinical
    activities, the medical decisions made by doctors, and the
    employment of the doctors in accordance with regulations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that our success is largely due to the high quality
    clinical care provided at our network of centers and our
    market-oriented management culture and practices. Many of the
    doctors who work in our network have extensive clinical
    experience in radiotherapy, some of whom are recognized as
    leading experts in radiation oncology in China. We enhance the
    quality of clinical care in our network through established
    training of, and on-going clinical education for, doctors in our
    network. We believe that our market-oriented management culture
    and practices allow us to manage centers more efficiently and
    offer more consistent and better patient services than our
    competitors. We believe that our success has given us a strong
    reputation within the medical community, which in turn gives us
    a competitive advantage in gaining patient referrals and
    establishing new centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To complement our organic growth, we have also selectively
    acquired businesses to expand our network. In July 2008, we
    acquired China Medstar Pte. Ltd., or China Medstar, a company
    then publicly listed on the Alternative Investment Market of the
    London Stock Exchange, or the AIM, for approximately
    &#163;17.1&#160;million or approximately RMB238.7&#160;million
    (US$35.0&#160;million). At the time of the acquisition, China
    Medstar jointly managed 23 centers with its hospital partners
    across 14&#160;cities in China.
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To further enhance our reputation and to employ high quality
    doctors, we plan to establish and operate specialty cancer
    hospitals in China. We intend for our specialty cancer hospitals
    to be centers of excellence. Our first specialty cancer
    hospital, the Chang&#146;an CMS International Cancer Center, in
    Xi&#146;an, Shaanxi Province, is expected to commence operation
    in early 2010. We are also in the process of establishing the
    Beijing Proton Medical Center, another specialty cancer
    hospital, which is expected to commence operation in 2012. We
    expect that the Beijing Proton Medical Center will be the first
    proton beam therapy treatment center in China equipped with a
    proton beam therapy system licensed for clinical use.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business has grown significantly in recent years through
    development of new centers, increases in the number of patient
    cases of existing centers and acquisitions. We have increased
    the number of centers in our network from 41 at the end of 2007
    to 72 at the end of 2008 and to 83 as of September&#160;30,
    2009. Our total net revenues were RMB67.4&#160;million,
    RMB14.0&#160;million and RMB171.8&#160;million
    (US$25.2&#160;million) for the period from January&#160;1, 2007
    to October&#160;30, 2007, the period from September&#160;10,
    2007 to December&#160;31, 2007 and for the year ended
    December&#160;31, 2008. Our total net revenues increased to
    RMB205.7&#160;million (US$30.1&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB102.0&#160;million for the
    same period in 2008, due primarily to an increase in the number
    of centers in our network, including centers added to our
    network as a result of our acquisition of China Medstar, and an
    increase in the number of patient cases in existing centers. For
    periods prior to October&#160;30, 2007, our predecessor is
    deemed the reporting entity for financial reporting purposes as
    a result of our reorganization. We report the financial
    statements of our successor entity from September&#160;10, 2007,
    the date of inception of our successor entity. For additional
    information as to our history and reorganization and our
    financial presentation, see &#147;Our History and Corporate
    Structure&#148; and &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Industry</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The radiotherapy and diagnostic imaging market in China has
    several favorable characteristics. The market is expected to
    grow, with a compound annual growth rate, or CAGR, of 22.4%
    between 2008 and 2015, according to a report by
    Frost&#160;&#038; Sullivan, due to the increasing incidence rate
    of cancer in China and awareness among physicians and patients
    and their adoption of advanced radiotherapy and diagnostic
    imaging technologies, rising household disposable income and
    government healthcare expenditures that will increase the
    affordability of such cancer treatment and diagnosis
    technologies. Moreover, China&#146;s relatively underdeveloped
    medical infrastructure has resulted in significant unmet demand
    for cancer radiotherapy and diagnostic imaging services, with
    the per capita number of units of such medical equipment in
    China being significantly lower than in developed countries. For
    example, Frost&#160;&#038; Sullivan estimates that China had
    only 0.7 linear accelerators per million people at the end of
    2008 compared to 9.5 in the United States, 6.6 in Japan, 5.6 in
    France and 3.0 in the United Kingdom. Hospitals in China often
    lack the financial resources to purchase, and the experienced
    radiation oncologists and radiologists to operate, advanced
    radiotherapy and diagnostic imaging equipment. We believe that
    we are well positioned to benefit from these market dynamics
    through our ability to provide equipment and expertise to
    hospitals in China to establish and operate radiotherapy and
    diagnostic imaging centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Competitive Strengths</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the following competitive strengths have, and
    will continue to, uniquely position us to capitalize on growth
    opportunities in the cancer treatment market in China:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    leading market position and successful track record;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    doctors with extensive cancer treatment experience developed and
    supported by our network;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market-oriented management of centers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    successful track record of new center development and
    acquisitions; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    strong and experienced management team.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Strategies</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to further strengthen our leading position in
    radiotherapy and diagnostic imaging market in China by pursuing
    the following strategies:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    continue to develop new radiotherapy and diagnostic imaging
    centers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    increase marketing efforts to drive growth in patient cases at
    our existing centers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish specialty cancer hospitals;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    introduce advanced cancer treatment options and diagnostic
    technology in our network;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    complement our development of new centers with selected
    acquisitions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Challenges</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the following are some of the major risks and
    uncertainties that may materially affect us:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we may encounter difficulties in successfully opening new
    centers or renewing agreements for existing centers due to the
    limited number of suitable hospital partners and their potential
    ability to finance the purchase of medical equipment directly;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we have historically derived a significant portion of our
    revenues from centers located at a limited number of our
    hospital partners and regions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we conduct our business in a heavily regulated industry;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any failure by our hospital partners to make contracted payments
    to us or any disputes over, or significant delays in receiving,
    such payments could have a material adverse effect on our
    business and financial condition;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our business may be harmed by technological and therapeutic
    changes or by shifts in doctors&#146; or patients&#146;
    preferences for alternative treatments.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See &#147;Risk Factors&#148; and other information included in
    this prospectus for a discussion of these and other risks and
    uncertainties.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    History and Corporate Structure</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Concord Medical Services Holdings Limited, or Concord Medical,
    was incorporated in the Cayman Islands on November&#160;27, 2007
    and became our ultimate holding company on March&#160;7, 2008,
    when the shareholders of Ascendium Group Limited, or Ascendium,
    a holding company incorporated in the British Virgin Islands on
    September&#160;10, 2007, exchanged all of their shares for
    shares of Concord Medical. Prior to that, on October&#160;30,
    2007, Ascendium had acquired 100% of the equity interest in Our
    Medical Services,&#160;Ltd., or OMS, resulting in a change in
    control. We refer to this transaction as the OMS reorganization
    in this prospectus. Prior to the OMS reorganization, OMS,
    together with Shenzhen Aohua Medical
    Services&#160;Co.,&#160;Ltd., or Aohua Medical, in which OMS
    effectively held all of the equity interest at the time,
    operated all of our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aohua Medical was incorporated by OMS on July&#160;23, 1997 and
    OMS contributed RMB4.8&#160;million to Aohua Medical,
    representing 90% of the equity interest in Aohua Medical. The
    other 10% of Aohua Medical was held by two nominees who acted as
    the custodians of such equity interest. On June&#160;10, 2009,
    this 10% equity interest was transferred to our subsidiary
    Shenzhen Aohua Medical Leasing and Services&#160;Co.,&#160;Ltd.,
    or Aohua Leasing. The two nominees have not maintained their
    required capital contributions at any time subsequent to the
    incorporation of Aohua Medical. Due to this capital deficiency
    as well as other legal conditions, the two nominees had no legal
    rights to participate either retrospectively or prospectively at
    any time in any profits or losses of Aohua Medical  or to share
    in any residual assets or any proceeds in the event that Aohua
    Medical encountered a liquidation event. For these reasons, we
    do not account for this 10% equity interest as a minority
    interest in our consolidated results of operations or financial
    position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, our subsidiary Ascendium acquired 100% of
    the equity interest in China Medstar together with its wholly
    owned PRC subsidiary, Medstar (Shanghai) Leasing Co., Ltd., or
    Shanghai Medstar, for
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    approximately &#163;17.1&#160;million or approximately
    RMB238.7&#160;million (US$35.0&#160;million). China Medstar,
    through its then subsidiary Shanghai Medstar, engaged in the
    provision of medical equipment leasing and management services
    to hospitals in the PRC. On August&#160;17, 2009, 100% of the
    equity interest in Shanghai Medstar was transferred from China
    Medstar to Ascendium.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;28, 2008, we acquired control of Beijing Xing
    Heng Feng Medical Technology Co., Ltd., or Xing Heng Feng
    Medical, through our subsidiaries Aohua Leasing and CMS Hospital
    Management Co., Ltd., or CMS Hospital Management, by acquiring
    100% of its equity interest, which corresponded to its then
    paid-in registered capital. We paid total consideration of
    approximately RMB35.0&#160;million (US$5.1&#160;million) for
    this acquisition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We currently conduct substantially all of our operations through
    the following subsidiaries in the PRC:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Shenzhen Aohua Medical Services Co., Ltd., our wholly owned
    subsidiary incorporated in the PRC that engages in the provision
    of radiotherapy and diagnostic center management services to
    hospitals in the PRC;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Shenzhen Aohua Medical Leasing and Services Co., Ltd., our
    wholly owned subsidiary incorporated in the PRC that engages in
    the provision of radiotherapy and diagnostic equipment leasing
    services to hospitals in the PRC;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Medstar (Shanghai) Leasing Co., Ltd., our wholly owned
    subsidiary incorporated in the PRC that engages in the sale of
    medical equipment and the provision of radiotherapy and
    diagnostic equipment leasing and management services to
    hospitals in the PRC;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    CMS Hospital Management Co., Ltd., our wholly owned subsidiary
    incorporated in the PRC that engages in the provision of
    radiotherapy and diagnostic equipment management services to
    hospitals in the PRC;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Beijing Xing Heng Feng Medical Technology Co., Ltd., our wholly
    owned subsidiary incorporated in the PRC that engages in the
    provision of radiotherapy and diagnostic equipment management
    services to hospitals in the PRC.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following diagram illustrates our corporate structure and
    the place of organization of each of our subsidiaries as of the
    date of this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611a4h0361101.gif" alt="">
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Corporate
    Information</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our principal executive offices are located at 18/F, Tower A,
    Global Trade Center, 36&#160;North Third Ring Road East,
    Dongcheng District, Beijing, People&#146;s Republic of China,
    100013. Our telephone number at this address is
    <FONT style="white-space: nowrap">(86&#160;10)&#160;5903-6688</FONT>
    and our fax number is
    <FONT style="white-space: nowrap">(86&#160;10)&#160;5957-5252.</FONT>
    Our registered office in the Cayman Islands is at Scotia Centre,
    4th&#160;Floor, P.O.&#160;Box&#160;2804, George Town, Grand
    Cayman, Cayman Islands KY1-1112.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Investor inquiries should be directed to us at the address and
    telephone number of our principal executive offices set forth
    above. Our website is www.cmsholdings.com. The information
    contained on our website is not part of this prospectus. Our
    agent for service of process in the United States is National
    Registered Agents, Inc., located at 875 Avenue of the Americas,
    Suite&#160;501, New York, New York 10001.
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Conventions
    That Apply to This Prospectus</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, references in this prospectus to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;ADRs&#148; are to the American depositary receipts, which,
    if issued, evidence our ADSs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;ADSs&#148; are to our American depositary shares, each of
    which represents three ordinary shares;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;China&#148; and the &#147;PRC&#148; are to the
    People&#146;s Republic of China, excluding, for the purposes of
    this prospectus only, Taiwan and the special administrative
    regions of Hong Kong and Macau;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;ordinary shares&#148; are to our ordinary shares, par
    value US$0.0001 per share;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;PRC subsidiaries&#148; are to our subsidiaries
    incorporated in the People&#146;s Republic of China, including
    Aohua Medical, Aohua Leasing, Shanghai Medstar, CMS Hospital
    Management Co., Ltd., or CMS Hospital Management, and Xing Heng
    Feng Medical;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;RMB&#148; and &#147;Renminbi&#148; are to the legal
    currency of China;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;US$&#148; and &#147;U.S.&#160;dollars&#148; are to the
    legal currency of the United States;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;we,&#148; &#147;us,&#148; &#147;our company&#148; and
    &#147;our&#148; are to Concord Medical Services Holdings
    Limited, its predecessor entities and its consolidated
    subsidiaries;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;&#163;&#148; is to the legal currency of the United
    Kingdom of Great Britain and Northern Ireland.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, information in this prospectus:
    (i)&#160;assumes that the underwriters do not exercise their
    option to purchase up to an aggregate of
    1,800,000&#160;additional ADSs representing
    5,400,000&#160;ordinary shares from the selling shareholders,
    and (ii)&#160;does not include 4,765,800 ordinary shares
    reserved for issuance under our 2008&#160;share incentive plan.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus contains translations of certain Renminbi
    amounts into U.S.&#160;dollars at specified rates. For all dates
    through December&#160;31, 2008, all translations from Renminbi
    to U.S.&#160;dollars were made at the noon buying rate in the
    City of New York for cable transfers in Renminbi per
    U.S.&#160;dollar as certified for customs purposes by the
    Federal Reserve Bank of New York, or the noon buying rate. For
    January&#160;1, 2009 and all later dates and periods, the
    exchange rate refers to the noon buying rate as set forth in the
    H.10 statistical release of the Federal Reserve Board. Unless
    otherwise stated, the translation of Renminbi into
    U.S.&#160;dollars has been made at the noon buying rate in
    effect on September&#160;30, 2009, which was RMB6.8262 to
    US$1.00. We make no representation that the Renminbi or
    U.S.&#160;dollar amounts referred to in this prospectus could
    have been or could be converted into U.S.&#160;dollars or
    Renminbi, as the case may be, at any particular rate or at all.
    See &#147;Risk Factors&#160;&#151; Risks Related to Doing
    Business in China&#160;&#151; Fluctuations in the value of the
    Renminbi may have a material adverse effect on your
    investment.&#148; On November&#160;27, 2009, the noon buying
    rate was RMB6.8272 to US$1.00.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
  <!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">THE
    OFFERING</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="36%"></TD>
    <TD width="1%"></TD>
    <TD width="63%"></TD>
</TR>

<TR>
    <TD valign="top">
    Price per ADS</TD>
    <TD></TD>
    <TD valign="bottom">
    We currently estimate that the initial public offering price
    will be between US$9.50 and US$11.50 per ADS.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    ADS offered by us</TD>
    <TD></TD>
    <TD valign="bottom">
    12,000,000&#160;ADSs</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    The ADSs</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    Each ADS represents three ordinary shares, par value US$0.0001
    per share. The ADSs may be evidenced by an ADR.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    The depositary will be the holder of the ordinary shares
    underlying the ADSs and you will have the rights of an ADS
    holder as provided in the deposit agreement among us, the
    depositary and owners and beneficial owners of ADSs from time to
    time.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    You may surrender your ADSs to the depositary to withdraw the
    ordinary shares underlying your ADSs. The depositary will charge
    you a fee for such an exchange.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    We may amend or terminate the deposit agreement for any reason
    without your consent. If an amendment becomes effective, you
    will be bound by the deposit agreement as amended if you
    continue to hold your ADSs.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    To better understand the terms of the ADSs, you should carefully
    read the section in this prospectus entitled &#147;Description
    of American Depositary Shares.&#148; We also encourage you to
    read the deposit agreement, which is an exhibit to the
    registration statement that includes this prospectus.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Over-allotment option</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    The selling shareholders identified in this prospectus have
    granted the underwriters an option, exercisable within
    30&#160;days from the date of this prospectus, to purchase up to
    an aggregate of 1,800,000&#160;additional ADSs representing
    5,400,000&#160;ordinary shares.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Ordinary shares outstanding<BR>
    immediately after the<BR>
    offering</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    147,455,500&#160;ordinary shares, excluding
    4,765,800&#160;ordinary shares reserved for issuance under our
    2008&#160;share incentive plan.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    ADSs outstanding immediately<BR>
    after the offering</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    12,000,000&#160;ADSs (or 13,800,000&#160;ADSs if the
    underwriters exercise the option to purchase additional ADSs in
    full).</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Use of proceeds</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    We estimate that we will receive net proceeds from this offering
    of approximately US$113.9&#160;million, after deducting the
    underwriting discounts and commissions and estimated aggregate
    offering expenses payable by us. This estimate is based upon an
    assumed initial public offering price of US$10.50&#160;per ADS,
    the midpoint of the range shown on the front cover of this
    prospectus. We intend to use a portion of the net proceeds we
    receive from this offering for the following purposes:</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    &#149;&#160;approximately US$50&#160;million to
    US$60&#160;million to expand our network of centers;</DIV>
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    &#149;&#160;approximately US$25&#160;million to
    US$30&#160;million to develop our Beijing Proton Medical
    Center;&#160;and</DIV>
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    &#149;&#160;approximately US$20&#160;million to
    US$25&#160;million to develop our Chang&#146;an CMS
    International Cancer Center.</DIV>
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="36%"></TD>
    <TD width="1%"></TD>
    <TD width="63%"></TD>
</TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    We will use any remaining portion of the net proceeds we receive
    from this offering for general corporate purposes, including
    potential acquisitions of, or investments in, other businesses
    or technologies that we believe will complement our current
    operations and expansion strategies. See &#147;Use of
    Proceeds&#148; for additional information.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    We will not receive any of the proceeds from the sale of the
    ADSs by the selling shareholders.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Listing</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    We have received approval to list our ADSs on the New York Stock
    Exchange, or the NYSE. Our ordinary shares will not be listed on
    any exchange or quoted for trading on any over-the-counter
    trading system.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    NYSE trading symbol</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    CCM</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    <FONT style="white-space: nowrap">Lock-up</FONT></DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    We, our directors, executive officers and all existing
    shareholders have agreed with the underwriters, subject to
    certain exceptions, not to sell, transfer or dispose of any of
    our ADSs, ordinary shares or similar securities for a period of
    180&#160;days after the date of this prospectus. See
    &#147;Underwriting.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Reserved ADSs</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    At our request, the underwriters have reserved for sale, at the
    public offering price, up to an aggregate of 600,000&#160;ADSs
    offered by this prospectus to our directors, officers,
    employees, business associates and related persons through a
    reserved share program.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Depositary</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    JPMorgan Chase Bank, N. A.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Payment and settlement</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    The ADSs are expected to be delivered against payment
    on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2009. The ADSs will be deposited with a custodian for, and
    registered in the name of a nominee of, The Depository
    Trust&#160;Company, or DTC, in New York, New York. Initially,
    beneficial interests in the ADSs will be shown on, and transfers
    of these beneficial interest will be effected through, records
    maintained by DTC and its direct and indirect participants.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Risk factors</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    See &#147;Risk Factors&#148; and other information included in
    this prospectus for a discussion of factors you should carefully
    consider before deciding to invest in the ADSs.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    CONSOLIDATED FINANCIAL AND OPERATING DATA</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Concord Medical was incorporated on November&#160;27, 2007. On
    March&#160;7, 2008, the shareholders of Ascendium exchanged
    their shares in Ascendium for shares of Concord Medical. As a
    result, Concord Medical became our ultimate holding company. Our
    financial statements have been prepared as if the current
    corporate structure had been in existence from
    September&#160;10, 2007, the date on which Ascendium was
    incorporated. Prior to the OMS reorganization, which became
    effective on October&#160;30, 2007, OMS, together with Aohua
    Medical, in which OMS effectively held all of the equity
    interest at the time, operated all of the business of our
    company. As a result of the OMS reorganization, there was a
    change in control of OMS with the Ascendium shareholders
    effectively acquiring OMS from the OMS shareholders. For
    additional information relating to our history and
    reorganization, see &#147;Our History and Corporate
    Structure.&#148; For financial statements reporting purposes,
    OMS is deemed to be the predecessor reporting entity for periods
    prior to October&#160;30, 2007. In our discussion for the year
    ended December&#160;31, 2007, we refer to certain financial
    statement line items as &#147;combined&#148; for comparative
    purposes, which do not comply with U.S.&#160;GAAP. The unaudited
    combined amounts represent the addition of the amounts for
    certain financial statement line items of OMS, our predecessor,
    for the period from January&#160;1, 2007 to October&#160;30,
    2007, and the amounts for the corresponding line items of
    Concord Medical for the period from September&#160;10, 2007 to
    December&#160;31, 2007. We have included these unaudited
    combined amounts as we believe they are helpful for the reader
    to gain a better understanding of results of operations for a
    complete fiscal year and to improve the comparative analysis
    against the results of operations for the year ended
    December&#160;31, 2008. These unaudited combined amounts do not
    purport to represent what our financial position, results of
    operations or cash flows would have been if the OMS
    reorganization had occurred on January&#160;1, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following summary consolidated statements of operations and
    other consolidated financial data for the period from
    January&#160;1, 2007 to October&#160;30, 2007, for the period
    from September&#160;10, 2007 to December&#160;31, 2007 and for
    the year ended December&#160;31, 2008 (other than income (loss)
    per ADS data) and the summary consolidated balance sheet data as
    of December&#160;31, 2007 and 2008 have been derived from our
    audited consolidated financial statements, which are included
    elsewhere in this prospectus. The following summary consolidated
    statements of operations and other consolidated financial data
    for the nine months ended September&#160;30, 2008 and 2009
    (other than income (loss) per ADS data) and summary consolidated
    balance sheet data as of September&#160;30, 2009 have been
    derived from our unaudited condensed consolidated financial
    statements, which are included elsewhere in this prospectus. We
    have prepared the unaudited condensed consolidated financial
    statements on the same basis as our audited consolidated
    financial statements. The unaudited condensed consolidated
    financial statements include all adjustments, consisting only of
    normal and recurring adjustments, which we consider necessary
    for a fair presentation of our financial position and operating
    results for the periods presented. You should read the summary
    consolidated financial data in conjunction with those financial
    statements and the related notes and &#147;Management&#146;s
    Discussion and Analysis of Financial Condition and Results of
    Operations&#148; included elsewhere in this prospectus. Our
    consolidated financial statements are prepared and presented in
    accordance with United&#160;States generally accepted accounting
    principles, or US&#160;GAAP. Our historical results are not
    necessarily indicative of our results expected for future
    periods.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="28%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD colspan="34" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Concord<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>January&#160;1,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>September&#160;10, <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>October&#160;30,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>Year Ended <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="32" nowrap align="center" valign="bottom">
    <B>(in thousands, except share, per share and per ADS data)</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    <B>Summary Consolidated Statements of Operations Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Revenues, net of business tax, value-added tax and related
    surcharges:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,716
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,092
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,322
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,422
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,405
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    205,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,396
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,046
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,669
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (42,144
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,174
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,003
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,388
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,987
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,416
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,914
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24,330
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,597
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,680
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,361
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (62,541
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,162
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Gross profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,075
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,632
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143,116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,601
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (757
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,358
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (805
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,275
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,463
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (654
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    General and administrative
    expenses<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,467
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (57,171
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (65,638
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,764
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,468
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,687
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,884
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Operating income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,938
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (47,859
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,921
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Other (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (649
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,143
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    578
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,275
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (626
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    (Loss) income before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,064
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,627
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,691
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income tax (expense) benefit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,832
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,418
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,611
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,734
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,770
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Net (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,896
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,343
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (39,604
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (262,286
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,851
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (44,646
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (38,383
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,623
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Net income (loss) attributable to ordinary shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,896
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (496,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72,667
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (222,270
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,914
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income (loss) per share&#160;&#151; basic and
    diluted<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.97
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.58
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.26
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.06
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income (loss) per ADS&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.91
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.74
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25.89
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.78
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11.01
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Shares used in computation&#160;&#151; basic and
    diluted<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,621,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    ADSs used in computation&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,666,667
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,666,667
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,666,667
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,160,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,160,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,207,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,476,033
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,476,033
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Our general and administrative
    expenses include share-based compensation expenses related to
    certain share options granted in 2007 that amounted to
    RMB49.5&#160;million, RMB4.2&#160;million (US$0.6&#160;million)
    and RMB4.2&#160;million in 2007, 2008 and for the nine months
    ended September&#160;30, 2008, respectively. We did not
    recognize any
    <FONT style="white-space: nowrap">share-based</FONT>
    compensation expenses for the nine months ended
    September&#160;30, 2009.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">On November&#160;17, 2009, we
    effected a share split whereby all of our issued and outstanding
    704,281 ordinary shares of a par value of US$0.01 per share were
    split into 70,428,100 ordinary shares of US$0.0001 par value per
    share and the number of our authorized ordinary shares was
    increased from 4,500,000 to 450,000,000. The share split has
    been retroactively reflected in this prospectus so that share
    numbers, per share price and par value data are presented as if
    the share split had occurred from our inception.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="52%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Actual</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>Pro Forma as<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>As of September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>Adjusted as of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">September&#160;30,
    2009<SUP style="font-size: 85%; vertical-align: top">(1)</SUP></FONT></B>

</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="27" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Summary Consolidated Balance Sheet Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    285,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063,207
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,754
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,135
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    492,978
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72,219
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    466,487
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,243,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182,238
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Property, plant and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    349,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,661
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,661
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Acquired intangible assets, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    181,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,450
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,450
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543,023
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,673,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,450,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    359,022
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term bank borrowings, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,836
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term bank borrowings, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;A contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    269,017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;B contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    434,036
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total shareholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    591,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,072,139
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    303,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total liabilities and shareholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543,023
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,673,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,450,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    359,022
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Pro forma as adjusted summary
    consolidated balance sheet data take into account (i)&#160;the
    automatic conversion of all our outstanding contingently
    redeemable convertible preferred shares into 41,027,400 of our
    ordinary shares immediately upon the completion of this offering
    and (ii)&#160;the issuance and sale of 36,000,000&#160;ordinary
    shares in the form of ADSs by us in this offering, assuming an
    initial public offering price of US$10.50&#160;per ADS, the
    midpoint of the estimated range of the initial public offering
    price, after deducting estimated underwriting discounts and
    commissions and estimated aggregate offering expenses payable by
    us and assuming no exercise of the underwriters&#146; option to
    purchase additional ADSs and no other change to the number of
    ADSs sold by us as set forth on the cover of this prospectus.
    Assuming the number of ADSs offered by us as set forth on the
    cover page of this prospectus remains the same, and after
    deduction of underwriting discounts and commissions and the
    estimated offering expenses payable by us, a US$1.00 increase
    (decrease) in the assumed initial public offering price of
    US$10.50&#160;per ADS would increase (decrease) each of cash,
    total current assets, total assets, total shareholders&#146;
    equity and total liabilities and shareholders&#146; equity by
    US$11.2&#160;million.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="31%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD colspan="30" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="23" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>from<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>January&#160;1,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>September&#160;10, <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" nowrap align="center" valign="bottom">
    <B>Nine Months Ended<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>October&#160;30,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>Year Ended <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="28" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Selected Consolidated Statements of Cash Flow Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,774
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,308
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash used in investing
    activities<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (50,452
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30,441
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (376,371
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (55,136
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (300,692
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (223,426
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32,731
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    649,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95,147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    278,407
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,448
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,698
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (834
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,949
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (191
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net increase (decrease) in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    314,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (864
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68,288
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,004
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Net cash used in investing
    activities in 2008 and for the nine months ended September 30,
    2008 and 2009 includes cash used for acquisitions, net of cash
    acquired, of RMB231.5&#160;million (US$33.9&#160;million),
    RMB219.1&#160;million and RMB21.5 million (US$3.2 million),
    respectively.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="21%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD colspan="34" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Concord<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>from <BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>January&#160;1,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>September&#160;10, <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" nowrap align="center" valign="bottom">
    <B>Nine Months Ended <BR>
    </B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>October&#160;30,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December 31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>Year Ended <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="32" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Non-GAAP&#160;Financial Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Adjusted
    EBITDA<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,844
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,753
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59,597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    144,167
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    85,188
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174,455
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,556
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Adjusted EBITDA is defined as net
    (loss) income plus interest, taxes, depreciation and
    amortization, share-based compensation expenses and other
    adjustments. Adjusted EBITDA is used by management to evaluate
    our financial performance and determine the allocation of
    resources and provides the management with the ability to
    determine our return on capital expenditure relating to our
    purchase of medical equipment used in our network of centers and
    businesses acquired. Items that are eliminated from the
    calculation of Adjusted EBITDA are collectively managed by our
    senior executive officers, taking into consideration our
    strategic, business and financial goals. Depreciation and
    amortization are primarily managed by our chief executive
    officer, our chief operating officer and our chief financial
    officer. Share-based compensation expense is primarily managed
    by our chief executive officer and our financial officers.
    Interest expense and income, income tax expense or benefit and
    all other items eliminated from the calculation of Adjusted
    EBITDA are primarily managed by our chief executive officer, our
    financial controller and corporate vice president. In addition,
    we believe that Adjusted EBITDA will be a key metric analyzed in
    determining the amount of new debt financing that may be
    available to us and, therefore, we believe this measure provides
    investors with additional information about our ability to fund
    our growth through debt financing, if needed. Furthermore,
    Adjusted EBITDA eliminates the impact of items that we do not
    consider indicative of the performance of our network of
    centers. For example, depreciation and amortization expenses
    relating to the medical equipment used in our network of centers
    and acquired intangibles represented historical accrued
    expenditures that are not indicative of the operating
    performance of our network of centers during the periods
    presented. We believe investors will similarly use Adjusted
    EBITDA as one of the key metrics to evaluate our financial
    performance and to compare our current operating results with
    corresponding historical periods and with other companies in the
    healthcare services industry. The presentation of Adjusted
    EBITDA should not be construed as an indication that our future
    results will be unaffected by other charges and gains we
    consider to be outside the ordinary course of our business.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The use of Adjusted EBITDA has
    certain limitations. Items excluded from Adjusted EBITDA are
    significant components in understanding and assessing our
    operating and financial performance. Depreciation and
    amortization expense, income tax expense, interest expense and
    interest income as well as share-based compensation expenses
    have been and will be incurred in our business and are not
    reflected in the presentation of Adjusted EBITDA. Each of these
    items should also be considered in the overall evaluation of our
    results. Additionally, Adjusted EBITDA does not consider capital
    expenditures and other investing activities and should not be
    considered as a measure of our liquidity. We compensate for
    these limitations by providing the relevant disclosure of our
    depreciation and amortization expense, interest expense and
    interest income, income tax expense, capital expenditures as
    well as share-based compensation expenses and other relevant
    items both in our reconciliations to the U.S. GAAP financial
    measures and in our consolidated financial statements, all of
    which should be considered when evaluating our performance. The
    term Adjusted EBITDA is not defined under U.S.&#160;GAAP, and
    Adjusted EBITDA is not a measure of net income, operating
    income, operating performance or liquidity presented in
    accordance with U.S.&#160;GAAP. When assessing our operating and
    financial performance, you should not consider this data in
    isolation or as a substitute for our net income, operating
    income or any other operating performance measure that is
    calculated in accordance with U.S.&#160;GAAP. In addition, our
    Adjusted EBITDA may not be comparable to Adjusted EBITDA or
    similarly titled measures utilized by other companies since such
    other companies may not calculate Adjusted EBITDA in the same
    manner as we do.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The following table is a
    reconciliation of Adjusted EBITDA to net income, the most
    directly comparable financial measure calculated and presented
    in accordance with U.S.&#160;GAAP:
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="21%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD colspan="34" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Concord<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>January&#160;1,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>September&#160;10, <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>October&#160;30,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December 31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>Year Ended <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="32" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Net (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,896
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Interest expense, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    939
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    279
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,057
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Income tax expense (benefit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (182
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,832
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,335
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,418
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,611
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,770
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,906
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,086
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,992
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,126
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,585
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,129
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Share-based compensation expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    617
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Other adjustments*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,555
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,925
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,603
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,114
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Adjusted EBITDA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,844
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,753
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59,597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    144,167
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    85,188
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174,455
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,556
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#160;&#160;&#160;&#160;<FONT style="word-spacing: 100pt; white-space: nowrap; font-size: 1pt; color: #000000"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=456 length=48 -->
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;*&#160;&#160;Other
    adjustments include change in fair value of convertible notes,
    foreign exchange loss and other income.
    </FONT>
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>As of September&#160;30,<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Operating
    Data</B><SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Number of primary medical equipment owned:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Linear accelerators
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Head gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Body gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    PET-CT scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    MRI scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Others<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;64
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;81
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Number of patient cases treated or diagnosed by our primary
    medical equipment:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Linear accelerators
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    697
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,554
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Head gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,455
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Body gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,635
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,057
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,706
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    PET-CT scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,766
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    MRI scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,830
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,827
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="29%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD colspan="26" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from <BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>September&#160;1,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>Nine Months <BR>
    </B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>Ended <BR>
    </B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>to October&#160;30,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD colspan="26" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="24" nowrap align="center" valign="bottom">
    <B>(in RMB thousands)</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total net revenues generated by our primary medical equipment
    under lease and management services arrangements:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Linear accelerators
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,206
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    877
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,506
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,588
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Head gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,408
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,139
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Body gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,537
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,102
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,071
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    PET-CT scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    578
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,289
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    MRI scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,899
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    437
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,123
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,515
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,618
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Others<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    391
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,423
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,755
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,970
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total net revenues&#160;&#151; lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Excluding data from seven, eight
    and two centers under service-only agreements as of
    December&#160;31, 2007, December&#160;31, 2008 and
    September&#160;30, 2009, respectively.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Including a MM50
    intensity-modulated radiation therapy system.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Other primary medical equipment
    used includes computed tomography scanners, or CT scanners, and
    emission computed tomography scanners, or ECT scanners, for
    diagnostic imaging, electroencephalography for the diagnosis of
    epilepsy, thermotherapy to increase the efficacy of and for pain
    relief after radiotherapy and chemotherapy, high intensity
    focused ultrasound therapy for the treatment of cancer,
    stereotactic radiofrequency ablation for the treatment of
    Parkinson&#146;s Disease and refraction and tonometry for the
    diagnosis of ophthalmic conditions.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    UNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL DATA<BR>
    FOR THE YEAR ENDED DECEMBER 31, 2008</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following summary unaudited pro forma combined financial
    information has been derived by the application of pro forma
    adjustments to the historical consolidated financial statements
    of Concord Medical and the financial statements of China Medstar
    for the year ended December&#160;31, 2008. Concord
    Medical&#146;s and China Medstar&#146;s historical information
    has been derived from their respective audited financial
    statements, included elsewhere in this prospectus. The unaudited
    pro forma combined income statement data give effect to our
    acquisition of China Medstar as if it had been completed on
    January&#160;1, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following unaudited pro forma combined financial information
    should be read in conjunction with our and China Medstar&#146;s
    historical financial statements and the related notes and
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations&#148; included elsewhere in
    this prospectus. The preparation of the unaudited pro forma
    combined financial data appearing below is based on financial
    statements prepared in accordance with U.S.&#160;GAAP. These
    principles require the use of estimates that affect the reported
    amounts of assets, liabilities, revenues and expenses. Actual
    results could differ from those estimates. While the unaudited
    pro forma combined financial information is helpful in showing
    the financial characteristics of the combined companies, it is
    not intended to show how the combined companies would have
    actually performed if the events described above had in fact
    occurred on the dates assumed or to project the results of
    operations for any future date or period. We have included in
    the unaudited pro forma combined financial statements all the
    adjustments, consisting of normal recurring adjustments,
    necessary for a fair presentation of the results of operations
    in the historical periods. The actual consolidated results of
    operations may differ significantly from the pro forma amounts
    reflected below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="42%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>China Medstar</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Adjustment</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Seven-month<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">December&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">July&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" nowrap align="center" valign="bottom">
    <B>(in thousands, except share, per share and per ADS data)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Summary Unaudited Pro Forma Condensed Combined Statement of
    Operations Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Revenue, net of business tax, value-added tax and related
    surcharges:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,745
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    203,806
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,856
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,026
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,148
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,873
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    234,662
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,377
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,046
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,806
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,624
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34,228
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,743
</TD>
<TD nowrap align="left" valign="bottom">
    )<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26,240
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,844
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (117
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,597
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (60,585
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,875
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Gross profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,501
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,581
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,078
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,340
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (27,209
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,986
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Operating income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    139,790
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,478
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,455
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,585
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,040
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,324
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (325
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (230
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (81
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Loss from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    462
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other income (expense)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (200
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,534
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,104
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Income before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138,385
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,273
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Income tax expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,445
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21<SUP style="font-size: 85%; vertical-align: top">(2</SUP>

</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31,759
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,653
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net income from continuing operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,655
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,620
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Pro forma income per share from continuing operations</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.27
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Weighted average number of ordinary shares outstanding:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The aggregate purchase price of
    approximately &#163;17.1&#160;million (RMB238.7&#160;million or
    US$35.0&#160;million) for the purchase of China Medstar is
    comprised of the following:
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="86%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,210
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,107
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Long-term receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,397
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,377
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    217,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,931
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other intangible assets- customer relationships and operating
    leases
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,380
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Deposit for property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,505
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,089
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,529
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,835
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Liabilities assumed
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (233,323
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34,180
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total consideration paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    238,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The preliminary purchase price
    allocation and preliminary intangible asset valuations described
    above were based on valuation work determined by us with the
    assistance of American Appraisal China Limited, an independent
    valuation firm. The valuation report utilizes and considers
    generally accepted valuation methodologies such as the income,
    market, cost and actual transaction of shares approach. We have
    incorporated certain assumptions which include projected cash
    flows and replacement costs.
    </FONT></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">This adjustment of
    RMB5.6&#160;million reflects an additional seven full months of
    amortization of the acquired intangibles recorded as a result of
    our acquisition of China Medstar on July&#160;31, 2008 as if the
    acquisition had been consummated on January&#160;1, 2008.
    </FONT></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">This adjustment of
    RMB5.7&#160;million reflects an additional reduction in
    depreciation expense as if the acquisition had been consummated
    on January&#160;1, 2008 related to medical equipment because the
    assigned estimated fair values are lower than the net book
    values as at the acquisition date.
    </FONT></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Reflects the adjustment to income
    tax expense based on the pro forma adjusting entries to
    depreciation expense and amortization expense discussed above.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
</DIV><!-- End box 1 -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='102'>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RISK
    FACTORS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>You should carefully consider the risks described below in
    conjunction with the other information and the financial
    statements and related notes included elsewhere in this
    prospectus before making an investment decision. Our business,
    financial condition or results of operations could be materially
    and adversely affected by any of these risks. The trading price
    of our ADSs could decline due to any of these risks, and you may
    lose all or part of your investment. This prospectus also
    contains
    <FONT style="white-space: nowrap">forward-looking</FONT>
    statements relating to events subject to risks and
    uncertainties. Our actual results could differ materially from
    those anticipated in these forward-looking statements due to the
    material risks that we face described below.</I>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Our Company</FONT></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    encounter difficulties in successfully opening new centers or
    renewing agreements for existing centers due to the limited
    number of suitable hospital partners and their potential ability
    to finance the purchase of medical equipment
    directly.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our growth was driven by our ability to expand our network of
    radiotherapy and diagnostic imaging centers by primarily
    entering into new agreements with top-tier hospitals in China,
    which are 3A hospitals, the highest ranked hospitals by quality
    and size in China as determined in accordance with the standards
    of the MOH. The agreements that hospitals enter into with us and
    our competitors are typically long-term in nature with terms of
    up to 20&#160;years. As a result, in any locality or at any
    given time, there may only be a limited number of top-tier
    hospitals that have not yet entered into long-term agreements
    with us or our competitors and with which we are able to enter
    into new agreements. In addition, quotas imposed by government
    authorities as to the number and type of certain medical
    equipment that can be purchased, such as head gamma knife
    systems or PET-CT scanners, will further limit the number of
    top-tier hospitals that we or our competitors can enter into
    agreements within a given period. See &#147;&#151;&#160;Risks
    Related to Our Industry&#160;&#151; Healthcare administrative
    authorities in China currently set procurement quotas for
    certain types of medical equipment.&#148; Due to the limited
    supply of suitable top-tier hospitals and increasing
    competition, we may not be able to enter into agreements with
    new hospital partners or renew agreements with existing hospital
    partners on terms as favorable as those that we have been able
    to obtain in the past, or at all. Agreements with our hospital
    partners for three of the centers in our network, which
    accounted for 10.0% of our total net revenues in the nine months
    ended September 30, 2009, will expire in 2010. Some of our
    competitors may have greater financial resources than us, which
    may provide them with an advantage in negotiating new agreements
    with hospitals, including our existing hospital partners. In
    addition, if adequate funding becomes available for hospitals to
    purchase medical equipment directly, hospitals may choose to
    purchase and manage radiotherapy and diagnostic imaging
    equipment on their own instead of entering into or renewing
    agreements with us or our competitors. If we are unable to
    compete effectively in entering into agreements with new
    hospital partners or to renew existing agreements on favorable
    terms, or at all, or if hospitals choose to purchase and manage
    their own medical equipment, our growth prospects could be
    materially and adversely affected. Finally, the development of
    new centers generally involves a ramp-up period during which
    time the operating efficiency of such centers may be lower than
    our established centers, which may negatively affect our
    profitability.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    have historically derived a significant portion of our revenues
    from centers located at a limited number of our hospital
    partners and regions in which we operate and our accounts
    receivable are also concentrated with a few hospital
    partners.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have historically derived a large portion of our total net
    revenues from a limited number of our partner hospitals. For the
    period from January&#160;1, 2007 to October&#160;30, 2007, the
    period from September&#160;10, 2007 to December&#160;31, 2007,
    for the year ended December&#160;31, 2008 and for the nine
    months ended September&#160;30, 2008 and 2009, net revenues
    derived from our top five hospital partners amounted to
    approximately 61.6%, 64.7%, 37.8%, 42.2% and 34.1% of our total
    net revenues, respectively. For these same five periods, three,
    three, one, one and two of our hospital partners, respectively,
    accounted for more than 10.0% of our total net revenues, and our
    largest hospital partner accounted for 21.7%, 24.2%, 13.5%,
    14.4% and 10.7% of our total net revenues during those periods,
    respectively. In addition, centers located in Beijing, Henan
    province and Guangdong province accounted for 26.1%, 11.0% and
    8.0% of our total net revenues in 2008, respectively, and 21.9%,
    10.6% and 9.0% of our total net revenues for the nine months
    ended September&#160;30, 2009, respectively. We may continue to
    experience such
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    revenue concentration in the future. Due to the concentration of
    our revenues and dependence on a limited number of hospital
    partners, any one or more of the following events, among others,
    may cause material fluctuations or declines in our revenues and
    could have a material adverse effect on our financial condition,
    results of operations and prospects:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reduction in the number of patient cases at the centers located
    at these partner hospitals;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    loss of key experienced medical professionals;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    decrease in the profitability of such centers;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    failure to maintain or renew our agreements with these hospital
    partners;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any failure of these hospital partners to pay us our contracted
    percentage of any such center&#146;s revenue net of specified
    operating expenses;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any regulatory changes in the geographic areas where our
    hospital partners are located;&#160;or
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any other disputes with these hospital partners.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, three of our hospital partners, including two of
    our top five hospital partners, accounted for 36.4% of our total
    accounts receivable as of September&#160;30, 2009. Any
    significant delay in the payment of such accounts receivable
    could have a material impact on our financial condition and
    results of operations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    conduct our business in a heavily regulated
    industry.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The operation of our network of centers is subject to various
    laws and regulations issued by a number of government agencies
    at the national and local levels. Such rules and regulations
    relate mainly to the procurement of large medical equipment, the
    pricing of medical services, the operation of radiotherapy and
    diagnostic imaging equipment, the licensing and operation of
    medical institutions, the licensing of medical staff and the
    prohibition on non-profit civilian medical institutions from
    entering into cooperation agreements with third parties to set
    up for-profit centers that are not independent legal entities.
    Our growth prospects may be constrained by such rules and
    regulations, particularly those relating to the procurement of
    large medical equipment. See &#147;Regulation of Our
    Industry&#148; for a discussion of the regulations applicable to
    us and our business. Also, for a detailed discussion of the
    specific regulatory risks we face, see &#147;&#151;&#160;Risks
    Related to Our Industry.&#148; If we or our hospital partners
    fail to comply with such applicable laws and regulations, we
    could be required to make significant changes to our business
    and operations or suffer fines or penalties, including the
    potential loss of our business licenses, the suspension from use
    of our medical equipment, and the suspension or cessation of
    operations at centers in our network. In addition, many of the
    agreements we have entered into with our hospital partners
    provide for termination in the event of major government policy
    changes that cause the agreements to become inexecutable. Our
    hospital partners may invoke such termination right to our
    disadvantage.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    depend on our hospital partners to recruit and retain qualified
    doctors and other medical professionals to ensure the high
    quality of treatment services provided in our network of
    centers.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our success is dependent in part upon our hospital
    partners&#146; ability to recruit and retain doctors and other
    medical professionals and on our and our hospital partners&#146;
    ability to train and manage these medical professionals.
    Although we may help our hospital partners to identify and
    recruit suitable, qualified doctors and other medical
    professionals, almost all of these medical professionals are
    employed by our partner hospitals rather than by us. As a
    result, we may have little control over whether such medical
    professionals will continue to work in the centers in our
    network. In addition, there is a limited pool of qualified
    medical professionals with expertise and experience in
    radiotherapy and diagnostic imaging in China, and our hospital
    partners face competition for such qualified medical
    professionals from other public hospitals, private healthcare
    providers, research and academic institutions and other
    organizations. In the event that our hospital partners fail to
    recruit and retain a sufficient number of these medical
    professionals, the resulting shortage could adversely affect the
    operation of centers in our network and our growth prospects.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Any
    failure by our hospital partners to make contracted payments to
    us or any disputes over, or significant delays in receiving,
    such payments could have a material adverse effect on our
    business and financial condition.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Most of the centers in our network are established through
    long-term lease and management services arrangements entered
    into with our hospital partners. We also provide management
    services to certain radiotherapy and diagnostic imaging centers
    through service-only agreements. Payments for treatment and
    diagnostic imaging services provided in the centers in our
    network are typically collected by our hospital partners who
    then pass on to us our contracted percentage of such revenue net
    of specific operating expenses on a periodic basis. Our total
    outstanding accounts receivable from our hospital partners were
    RMB92.8&#160;million (US$13.6&#160;million) and
    RMB119.1&#160;million (US$17.5&#160;million) as of
    December&#160;31, 2008 and September&#160;30, 2009,
    respectively. As of September&#160;30, 2009, approximately 22.6%
    of our accounts receivable reported on our consolidated balance
    sheet as of December&#160;31, 2008 were still outstanding. The
    average turnover days of the accounts receivable for the nine
    months ended September&#160;30, 2009 were 117&#160;days. Any
    failure by our hospital partners to pay us our contracted
    percentage, or any disputes over or significant delays in
    receiving such payments from our hospital partners, for any
    reason, could negatively impact our financial condition.
    Accordingly, any failure by us to maintain good working
    relationships with our hospital partners, or any dissatisfaction
    on the part of our hospital partners with our services, could
    negatively affect the operation of the centers and our ability
    to collect revenue, reduce the likelihood that our agreements
    with hospital partners will be renewed, damage our reputation
    and otherwise have a material adverse effect on our business,
    financial condition and results of operation.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    not be able to effectively manage the expansion of our
    operations through new acquisitions or joint ventures or to
    successfully realize the anticipated benefits of any such
    acquisition or joint venture.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have historically complemented our organic development of new
    centers through the selective acquisition of complementary
    businesses or assets or the formation of joint ventures, and we
    may continue to do so in the future. For example, we recently
    experienced a significant growth in our business and increase in
    our results of operations as a result of our acquisition of
    China Medstar and other businesses. The identification of
    suitable acquisition targets or joint venture candidates can be
    difficult, time consuming and costly, and we may not be able to
    successfully capitalize on identified opportunities. We may not
    be able to continue to grow our business as anticipated if we
    are unable to successfully identify and complete potential
    acquisitions in the future. Even if we successfully complete an
    acquisition or establish a joint venture, we may not be able to
    successfully integrate the acquired businesses or assets or
    cooperate successfully with the joint venture partner.
    Integration of the acquired business or assets or cooperation
    with the joint venture partners can be expensive, time consuming
    and may strain our resources. Such integration or cooperation
    could also require significant attention from our management
    team, which may prevent key members of our management from
    focusing on other important aspects of our business.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, we may be unable to successfully integrate or
    retain employees or management of the acquired businesses or
    assets or retain the acquired entity&#146;s patients, suppliers
    or other partners. Consequently, we may not achieve the
    anticipated benefits of any acquisitions or joint ventures.
    Furthermore, future acquisitions or joint ventures could result
    in potentially dilutive issuances of equity or equity-linked
    securities or the incurrence of debt, contingent liabilities or
    expenses, or other charges, any of which could have a material
    adverse effect on our business, financial condition and results
    of operations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    not be successful in negotiating the conversion of a few of our
    cooperation agreements with our partner hospitals into lease and
    management agreements due to regulatory changes.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since the effectiveness in September 2000 of the
    <I>Implementation Opinions on the Classified Management of Urban
    Medical Institutions</I>, which was promulgated by the MOH, the
    State Administration of Traditional Chinese Medicine, the
    Ministry of Finance and the National Development Reform
    Committee, or NDRC, non-profit civilian medical institutions are
    no longer permitted to enter into cooperation agreements or to
    continue to operate under existing cooperation agreements with
    third parties pursuant to which the parties jointly invest in or
    cooperate to set up for-profit centers or units that are not
    independent legal entities. However, according to the
    <I>Opinions on Certain Issues Regarding Classified Management of
    Urban Medical Institutions </I>issued in July 2001 by the same
    authorities, a non-profit civilian medical institution may, if
    lacking sufficient funds to purchase medical equipment outright,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    enter into a leasing agreement pursuant to which the medical
    institution leases medical equipment from its partner at market
    rates. To comply with these regulatory changes, we have
    transitioned most of our cooperation agreements with non-profit
    civilian hospitals to lease and management agreements. However,
    we are still negotiating the transition of our cooperation
    agreements relating to 13 of our centers located at eight of our
    partner hospitals, which centers&#146; combined revenues in 2008
    and for the nine months ended September&#160;30, 2009
    constituted approximately 17.3% and 11.6% of our total net
    revenues during those two periods, respectively. Although
    neither we nor any of our hospital partners have incurred any
    penalties to date for continuing to operate under cooperation
    agreements at these centers, there can be no assurance that we
    will not incur penalties in the future or that we will be able
    to successfully negotiate the conversion of these agreements. If
    we are unable to successfully negotiate the conversion of our
    cooperation agreements with these hospitals or if government
    authorities decide to assess penalties against either us or our
    hospital partners or to suspend the operation of these centers
    before we are able to complete the transition, our business,
    financial condition and results of operation could be materially
    and adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are not aware of any similar restriction imposed by military
    healthcare administrative authorities on the cooperation
    agreements that we have entered into with military hospitals,
    which are hospitals regulated by the military but most of which
    are otherwise the same as other government-owned civilian
    hospitals open to the public. Accordingly, we have maintained
    our cooperation agreements with nine military hospitals as of
    September&#160;30, 2009. However, as military hospitals are also
    government-owned, if military hospitals are required by military
    healthcare administrative authorities to transition away from
    cooperation agreements in the future, we will have to negotiate
    a similar conversion of the agreements with our military
    hospital partners. If we are unable to successfully negotiate
    lease and management or other alternative agreements with our
    existing military hospital partners on terms not less favorable
    than those under our cooperation agreements, our business,
    financial condition and results of operation may be adversely
    affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    cannot assure you that government authorities will not interpret
    regulations differently from us to find that our lease and
    management agreements are still not in compliance with relevant
    regulations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Based on the opinion of our PRC counsel, Jingtian&#160;&#038;
    Gongcheng Attorneys At Law, we believe that our lease and
    management agreements with civilian public hospital partners,
    which terms continue to provide that our revenues from
    hospital-based centers are to be calculated based on contracted
    percentages of each center&#146;s revenue net of specified
    operating expenses, are in compliance with the <I>Implementation
    Opinions on the Classified Management of Urban Medical
    Institutions </I>and the <I>Opinions on Certain Issues Regarding
    Classified Management of Urban Medical Institutions</I>.
    However, we and our PRC counsel cannot assure you that the MOH
    or other competent authorities will not interpret these
    regulations differently to find that our lease and management
    agreements are still not in compliance with such regulations, in
    which instance, such authorities could, among other things,
    declare our lease and management agreements to be void, order
    our civilian hospital partners to terminate such agreements with
    us, order our civilian hospitals partners to suspend or cease
    operation of the centers governed by such agreements, suspend
    the use of our medical equipment, or confiscate revenues
    generated under the noncompliant agreements. Furthermore, we may
    have to change our business model which may not be successful.
    If any of the above were to occur, our business, financial
    condition and results of operation could be materially and
    adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">There
    may be corrupt practices in the healthcare industry in China,
    which may place us at a competitive disadvantage if our
    competitors engage in such practices and may harm our reputation
    if our hospital partners and the medical personnel who work in
    our centers, over whom we have limited control, engage in such
    practices.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There may be corrupt practices in the healthcare industry in
    China. For example, in order to secure agreements with hospital
    partners or to increase direct sales of medical equipment or
    patient referrals, our competitors, other service providers or
    their personnel or equipment manufacturers may engage in corrupt
    practices in order to influence hospital personnel or other
    decision-makers in violation of the anti-corruption laws of
    China and the U.S.&#160;Foreign Corrupt Practices Act, or the
    FCPA. We have adopted a policy regarding compliance with the
    anti-corruption laws of China and the FCPA to prevent, detect
    and correct such corrupt practice. However, as competition
    persists and intensifies in our industry, we may lose potential
    hospital partners, patient referrals and other opportunities to
    the extent that our competitors engage in such practices or
    other illegal activities. In
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    addition, our partner hospitals or the doctors or other medical
    personnel who work in our network of centers may engage in
    corrupt practices without our knowledge to procure the referral
    of patients to centers in our network. Although our policies
    prohibit such practices, we have limited control over the
    actions of our hospital partners or over the actions of the
    doctors and other medical personnel who work in our network of
    centers since they are not employed by us. If any of them were
    to engage in such illegal practices with respect to patient
    referrals or other matters, we or the centers in our network may
    be subject to sanctions or fines and our reputation could be
    adversely affected by any negative publicity stemming from such
    incidents.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We are
    planning to establish and operate specialty cancer hospitals
    that will be majority owned by us and are subject to significant
    risks.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As part of our growth strategy we plan to establish specialty
    cancer hospitals that will focus on providing radiotherapy
    services as well as diagnostic imaging services, chemotherapy
    and surgery. In addition, at the Beijing Proton Medical Center,
    one of our planned specialty cancer hospitals, we plan to offer
    proton beam therapy treatment services with which we have had no
    prior experience. Since we do not have experience in operating
    our own specialty cancer hospital, or in providing many of the
    services that we plan to offer in our specialty cancer
    hospitals, such as chemotherapy treatments, surgical procedures
    or proton beam therapy, we may not be able to provide as high a
    level of service quality for those treatment options as for the
    other treatments that are currently offered at our network of
    centers, which may result in damage to our reputation and our
    future growth prospects. In addition, we may not be successful
    in recruiting qualified medical professionals to effectively
    provide the services that we intend to offer in our specialty
    cancer hospitals. Furthermore, although our brand name is well
    known among referring doctors, patients are not currently
    familiar with our brand as we do not carry our own brand name in
    our network of centers under our existing agreements with our
    hospital partners. Therefore, when we establish our own
    specialty cancer hospitals under our brand name, we may not be
    able to immediately gain wide acceptance among patients and,
    thus, may be unable to attract a sufficient number of patients
    to our new hospitals.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We could also face increased exposure to liability claims at our
    specialty cancer hospitals, including claims for medical
    malpractice. We may need to obtain medical malpractice insurance
    and other types of insurance that we do not currently carry,
    each of which could increase our expenses and decrease our
    profitability. In addition, there can be no assurance that such
    insurance will be available at a reasonable price or that we
    will be able to maintain adequate levels of liability insurance
    coverage, if at all. In addition, our specialty cancer hospitals
    will also be required to obtain various quotas, permits and
    authorizations, which are currently the responsibility of our
    hospital partners under our existing agreements. See
    &#147;&#151;&#160;Risks Related to Our Industry&#160;&#151;
    Healthcare administrative authorities in China currently set
    procurement quotas for certain types of medical equipment&#148;
    and &#147;&#151;&#160;Risks Related to Our Industry&#160;&#151;
    We or our hospital partners may be unable to obtain various
    permits and authorizations from regulatory authorities in China
    relating to our medical equipment, which could delay the
    installation or interrupt the operation of our equipment.&#148;
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Finally, if our plans change for any reason or the anticipated
    timetable or costs of development change for our specialty
    cancer hospitals, our business and future prospects may be
    negatively impacted. We currently expect to obtain bank loans of
    approximately RMB190.0&#160;million (US$27.8&#160;million) in
    2010 to fund the development of our specialty cancer hospitals.
    We may not be able to obtain such loans on terms acceptable to
    us, or at all. Furthermore, such loans would increase our
    interest expenses and could subject us to various covenants that
    may, among other things, restrict our ability to pay dividends
    or to obtain additional financing. If we are not able to obtain
    these bank loans, we may not be able to complete the planned
    specialty cancer hospitals on our expected timeline, or at all.
    There can be no assurance that the planned specialty cancer
    hospitals will be completed or that, if completed, they will
    achieve sufficient patient cases to generate positive operating
    margins. In addition, as our currently planned specialty cancer
    hospitals are to be established through joint ventures with
    other parties, we also may not be successful in cooperating with
    such joint venture partners in operating our specialty cancer
    hospitals. See &#147;&#151;&#160;Risk Factors Related to Our
    Business&#160;&#151; We may not be able to effectively manage
    the expansion of our operations through any new acquisitions or
    joint ventures, which we may not be able to successfully
    execute.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    rely on the doctors and other medical professionals providing
    services in our network of centers to make proper clinical
    decisions and we rely on our hospital partners to maintain
    proper control over the clinical aspects of the operation of our
    network of centers.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We rely on the doctors and other medical professionals who work
    in our network to make proper clinical decisions regarding the
    diagnosis and treatment of their patients. Although we develop
    treatment protocols for doctors, provide periodic training for
    medical professionals in our network of centers on proper
    treatment procedures and techniques and host seminars and
    conferences to facilitate consultation among doctors providing
    services in our network of centers, we ultimately rely on our
    hospital partners to maintain proper control over the clinical
    activities of each center and over the doctors and other medical
    professionals who work in such centers. Any incorrect clinical
    decisions on the part of doctors and other medical professionals
    or any failure by our hospital partners to properly manage the
    clinical activities of each center may result in unsatisfactory
    treatment outcomes, patient injury or possibly death. Although
    part of the liability for any such incidents may rest with our
    partner hospitals and the doctors and other medical
    professionals they employ, we may be made a party to any such
    liability claim which, regardless of its merit or eventual
    outcome, could result in significant legal defense costs for us,
    harm our reputation, and otherwise have a material adverse
    effect on our business, financial condition and results of
    operations. The centers in our network have experienced claims
    as to a limited number of medical disputes since they commenced
    operations. As of September&#160;30, 2009, three centers in our
    network agreed to pay an aggregate amount of approximately
    RMB100,000 (US$14,649) to settle such claims. Any expenses
    resulting from such liability claims are generally required to
    be accounted for as expenses of the relevant center, which could
    reduce our revenue derived from such center. We do not carry
    malpractice or other liability insurance at many of the centers
    in our network, and at those centers that do carry such
    insurance, it may not be sufficient to cover any potential
    liability that may result from such claims. For our specialty
    cancer hospitals that are currently under development, we will
    likely face direct liability claims for any such incidents.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Any
    failures or defects of the medical equipment in our network of
    centers or any failure of the medical personnel who work at the
    centers in our network to properly operate our medical equipment
    could subject us to liability claims and we may not have
    sufficient insurance to cover any potential
    liability.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business exposes us to liability risks that are inherent in
    the operation of complex medical equipment, which may contain
    defects or experience failures. We rely to a large degree on
    equipment manufacturers to provide technical training to the
    medical technicians who work in our network of centers on the
    proper operation of our complex medical systems. If such medical
    technicians are not properly and adequately trained by the
    equipment manufacturers or by us, they may misuse or
    ineffectively use the complex medical equipment in our network
    of centers. These medical technicians may also make errors in
    the operation of the complex medical equipment even if they are
    properly trained. Any medical equipment defects or failures or
    any failure of the medical personnel who work in the centers to
    properly operate the medical equipment could result in
    unsatisfactory treatment outcomes, patient injury or possibly
    death. Although the liability for any such incidents rests with
    the equipment manufacturers or the medical technicians, we may
    be made a party to any such liability claim which, regardless of
    its merit or eventual outcome, could result in significant legal
    defense costs for us, harm our reputation, and otherwise have a
    material adverse effect on our business, financial condition and
    results of operations. In addition, any expenses resulting from
    such liability claims may be accounted for as expenses of the
    center, which could reduce our revenue derived from such center.
    We do not carry product liability insurance at any of the
    centers in our network.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Any
    downtime for maintenance and repair of our medical equipment
    could lead to business interruptions that could be expensive and
    harmful to our reputation and to our business.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant downtime associated with the maintenance and repair
    of medical equipment used in our network of centers would result
    in the inability of the centers to provide radiotherapy
    treatment or diagnostic imaging services to patients in a timely
    manner. We primarily rely on equipment manufacturers or third
    party service companies for maintenance and repair services. The
    failure of manufacturers or third party service companies to
    provide timely repairs on our equipment could interrupt the
    operation of centers in our network for extended periods of
    time. Such extended downtime could result in lost revenues for
    us and our partner hospitals, dissatisfaction on the part of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    patients and our partner hospitals and damage to the reputation
    of the centers in our network, our partner hospitals and our
    company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    rely on a limited number of equipment
    manufacturers.</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Much of the medical equipment used in our network of centers is
    highly complex and is produced by a limited number of equipment
    manufacturers. These equipment manufacturers provide training on
    the proper operation of our medical equipment to the medical
    personnel who work in the centers in our network as well as
    maintenance and repair services for such equipment. Any
    disruption in the supply of the medical equipment or services
    from these manufacturers, including as a result of failure by
    any such manufacturers to obtain the requisite third-party
    consents and licenses for the intellectual property used in the
    equipment they manufacture, may delay the development of new
    centers or negatively affect the operation of existing centers
    and could have a material adverse effect on our business,
    financial condition and results of operations.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    fail to protect our intellectual property rights or we may be
    exposed to misappropriation and infringement claims by third
    parties, either of which may have a material adverse effect as
    to our business.</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have applied in the PRC for the registration of our trademark
    &#147;Medstar&#148; to protect our corporate name. We also own
    the rights to 146 domain names that we use in connection with
    the operation of our business. We believe that such domain names
    provide us with the opportunity to enhance our marketing efforts
    for the treatments and services provided in our network and
    enhance patients&#146; knowledge as to cancers, the benefits of
    radiotherapy and the various treatment options that are
    available. Our failure to protect our trademark or such domain
    names may undermine our marketing efforts and result in harm to
    our reputation and the growth of our business.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Furthermore, we cannot be certain that the equipment
    manufacturers from whom we purchase equipment have all requisite
    third-party consents and licenses for the intellectual property
    used in the equipment they manufacture. As a result, those
    equipment manufacturers may be exposed to risks associated with
    intellectual property infringement and misappropriation claims
    by third parties which, in turn, may subject us to claims that
    the equipment we have purchased infringes the intellectual
    property rights of third parties. We have in the past been
    subject to, and may in the future continue to be subject to,
    such claims by third parties. As a result, we may be named as a
    defendant in, or joined as a party to, any intellectual property
    infringement proceedings against equipment manufacturers
    relating to any equipment we have purchased. If a court
    determines that any equipment we have purchased from our
    equipment manufacturers infringes the intellectual property
    rights of any third party, we may be required to pay damages to
    such third party and the centers in our network may be
    prohibited from using such equipment, either of which could
    damage our reputation and have a material adverse effect on our
    business prospects, financial condition and results of
    operations. In addition, any such proceeding may also be costly
    to defend and may divert our management&#146;s attention and
    other resources away from our business. Furthermore, the
    standard equipment purchase agreements that we enter into with
    our equipment manufacturers typically do not contain
    indemnification provisions for intellectual property claims.
    Although we have obtained specific indemnity from one equipment
    manufacturer for a patent infringement claim, there can be no
    assurance that we would be able to recover any damages, lost
    profits or litigation costs resulting from any intellectual
    property infringement claims or proceedings in which we are
    named as a party.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;4, 2009, we received a notice that a legal
    proceeding was initiated against us that alleges a gamma knife
    system currently in use in certain centers in our network was
    previously found to infringe upon the patent of a third party.
    This claim relates to a patent used in the head gamma knife
    system manufactured by one of our equipment manufacturers, Our
    Medical New Technology Co., Ltd., or Our Medical New Technology.
    A previous legal proceeding involving such patent was initiated
    in June 2000 against Our Medical New Technology, its related
    parties and our subsidiary, AMS. The relevant PRC court
    determined in 2004 that all head gamma knife systems
    manufactured by Our Medical New Technology after the patent
    owner began to contest the use of such patent on
    December&#160;23, 1999 were manufactured without the requisite
    consent to use the patent in question. The relevant PRC court
    also ordered the use of such equipment to cease. We are
    currently assessing the validity and the potential impact of the
    claim filed against us. Based on our current assessment, we have
    identified one head gamma knife system in one of the centers in
    our network that may be subject to such claim. Revenue derived
    from such
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     center represented approximately 1.5% and 1.0% of our total net
    revenues in 2008 and for the nine months ended
    September&#160;30, 2009, respectively. Our Medical New
    Technology, the manufacturer of the head gamma knife system that
    may be subject to this claim, has agreed to indemnify us for any
    damages or losses that we may incur from any intellectual
    property infringement by such system. We are also continuing to
    assess whether there is any other medical equipment in our
    network that might be subject to this claim.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    business depends substantially on the continuing efforts of our
    executive officers and other key personnel, and our business may
    be severely disrupted if we lose their services.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We depend on key members of our management team, which includes
    Mr.&#160;Jianyu Yang, a director and our chief executive officer
    and president, Dr.&#160;Zheng Cheng, a co-chairman of our board
    of directors and our chief operating officer, Mr.&#160;Steve
    Sun, a co-chairman of our board of directors and our chief
    financial officer, Mr.&#160;Jing Zhang, a director and our
    executive president, Mr.&#160;Yaw Kong Yap, a director and our
    financial controller, and Mr.&#160;Boxun Zhang, our corporate
    vice president, as well as other key personnel for the continued
    growth of our business. The loss of any of these members of our
    management team or other key employees could delay the
    implementation of our business strategy and adversely affect our
    operations. Our future success will also depend in large part on
    our continued ability to attract and retain highly qualified
    management personnel. The process of hiring suitable, qualified
    personnel is often lengthy and such talented and highly
    qualified management personnel is often in short supply in
    China. If our recruitment and retention efforts are unsuccessful
    in the future, it may be more difficult for us to execute our
    business strategy. Although none of the key members of our
    management team is nearing retirement age in the near future and
    we are not aware of any key members of our management team or
    other key personnel planning to retire or leave us, if one or
    more of such personnel are unable or unwilling to continue in
    their present positions, we may not be able to replace them
    readily, if at all. Consequently, our business may be severely
    disrupted, and we may incur additional expenses to recruit and
    retain new officers. In addition, we do not maintain key
    employee insurance. We have entered into employment agreements
    and confidentiality agreements with all of the key members of
    our management team and other key personnel. However, if any
    disputes arise between any of our key members of our management
    team or other key personnel and us, we cannot assure you, in
    light of uncertainties associated with the PRC legal system, the
    extent to which any of these agreements could be enforced in
    China, where all key members of our management team and other
    key personnel reside and hold some of their assets. See
    &#147;&#151;&#160;Risks Related to Doing Business in
    China&#160;&#151; Uncertainties with respect to the PRC legal
    system could have a material adverse effect on us.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    reported earnings could decline if we recognize impairment
    losses on intangible assets and goodwill relating to the OMS
    reorganization and other acquisitions.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of the OMS reorganization in October 2007 and our
    acquisitions of China Medstar and other businesses in 2008, we
    have recorded goodwill as well as certain acquired intangibles,
    which intangibles are amortized over their respective estimated
    useful lives. In addition, we may continue to selectively
    acquire complementary businesses in the future that may result
    in increases in recorded goodwill and acquired intangibles. Such
    goodwill is tested for impairment by us annually or more
    frequently if an event occurs or a circumstance develops that
    would require more frequent assessments. Examples of such events
    or circumstances include, but are not limited to, a significant
    adverse change in the legal or business climate, an adverse
    regulatory action or unanticipated competition. See
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations&#160;&#151; Critical
    Accounting Policies&#160;&#151; Goodwill;&#160;&#151; Acquired
    Intangible Assets, net.&#148; In the future, we could recognize
    impairment losses on the intangible assets and goodwill, which
    could result in a charge to our reported results of operations
    and cause our reported earnings to decline.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We do
    not have insurance coverage for some of our medical equipment
    and do not carry any business interruption
    insurance.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not have insurance for six units of our medical equipment,
    which are electroencephalography and thermotherapy equipment
    from which centers we derived less than 1.0% of our total
    revenues in 2008 and for the nine months ended
    September&#160;30, 2009. Damage to, or the loss of, such
    uninsured equipment due to natural disasters, such as fires,
    floods or earthquakes, could have an adverse effect on our
    financial condition and results of operation. In addition, the
    operations in our network of centers may be particularly
    vulnerable to natural disasters
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    that disrupt transportation since many patients travel long
    distances to reach such centers. Also, we do not have any
    business interruption insurance. Any business disruption could
    result in substantial expenses and diversion of resources and
    could have a material adverse effect on our business, financial
    condition and results of operations. For example, the strong
    earthquake that struck Sichuan Province in May 2008 resulted in
    the suspension of operations at three of our centers in Chengdu,
    the provincial capital of Sichuan Province, for approximately
    one month due to the diversion of hospital resources toward the
    treatment of earthquake victims.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Most
    of our radiotherapy and diagnostic imaging equipment contains
    radioactive materials or emits radiation during
    operation.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Most of the radiotherapy and diagnostic imaging equipment in our
    network of centers, including gamma knife systems, proton beam
    therapy systems, linear accelerators and PET-CT systems, contain
    radioactive materials or emit radiation during operation.
    Radiation and radioactive materials are extremely hazardous
    unless properly managed and contained. Any accident or
    malfunction that results in radiation contamination could cause
    significant harm to human beings and could subject us to
    significant legal expenses and result in harm to our reputation.
    Although equipment manufacturers and our hospital partners and
    their staff may bear some or all of the liability and costs
    associated with any accidents or malfunctions, if we are found
    to be liable in any way we may also face severe fines, legal
    reparations and possible suspension of our operating permits,
    all of which could have a material and adverse effect on our
    business, results of operations and financial condition. Also,
    certain of our medical equipment require the periodic
    replacement of their radioactive source materials. We do not
    directly oversee the handling of radioactive materials during
    the replacement or reloading process or during the disposal
    process, and any failure on the part of our hospital partners to
    handle or dispose of such radioactive materials in accordance
    with PRC laws and regulations may have an adverse effect on the
    operation of such centers.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Any
    change in the regulations governing the use of medical data in
    China, which are still in development, could adversely affect
    our ability to use our medical data and could potentially
    subject us to liability for our past use of such medical
    data.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The centers in our network collect and store medical data from
    radiotherapy treatments for purposes of analysis, use in
    training doctors providing services in our network and improving
    the effectiveness of the treatments provided in our network of
    centers. In addition, doctors in our network utilize such
    medical data to conduct clinical research. We do not make any
    such medical data public and only keep such medical data for our
    internal use and for research purposes by doctors upon the
    approval of our medical affairs department and our hospital
    partners. Chinese regulations governing the use of such medical
    data are still in development but currently do not impose any
    restrictions on the internal use of such data by us as long as
    we have the permission of our hospital partners who have
    ownership of such data. Any change in the regulations governing
    the use of such medical data could adversely affect our ability
    to use such medical data and could subject us to liability for
    past use of such data, either of which could have a material
    adverse effect on our business, operations and financial results.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    directors, executive officers and significant shareholders have
    substantial influence over our company and their interests may
    not be aligned with the interests of our other
    shareholders.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of the date of this prospectus, our directors, executive
    officers and significant shareholders beneficially owned
    approximately 86.0% of our outstanding share capital prior to
    this offering and will beneficially own approximately 65.0% of
    our outstanding share capital upon completion of this offering,
    assuming no exercise of the over-allotment option. As such, they
    have substantial influence over our business, including
    decisions regarding mergers, consolidations and the sale of all
    or substantially all of our assets, election of directors and
    other significant corporate actions. This concentration of
    ownership may discourage, delay or prevent a change in control
    of our company, which could deprive our shareholders of an
    opportunity to receive a premium for their shares as part of a
    sale of our company and might reduce the price of our ADSs.
    These actions may be taken even if they are opposed by our other
    shareholders, including those who purchase ADSs in this offering.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    articles of association contain anti-takeover provisions that
    could adversely affect the rights of holders of our ordinary
    shares and ADSs.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our third amended and restated articles of association will
    become effective immediately upon the completion of this
    offering. Our new articles of association limit the ability of
    others to acquire control of our company or cause us to engage
    in change-of-control transactions. These provisions could have
    the effect of depriving our shareholders of an opportunity to
    sell their shares at a premium over prevailing market prices by
    discouraging third parties from seeking to obtain control of our
    company in a tender offer or similar transaction. For example,
    our board of directors has the authority, without further action
    by our shareholders, to issue preferred shares in one or more
    series and to fix their designations, powers, preferences,
    privileges, and relative participating, optional or special
    rights and the qualifications, limitations or restrictions,
    including dividend rights, conversion rights, voting rights,
    terms of redemption and liquidation preferences, any or all of
    which may be greater than the rights associated with our
    ordinary shares, in the form of ADS or otherwise. Preferred
    shares could be issued quickly with terms calculated to delay or
    prevent a change in control of our company or to make removal of
    management more difficult. If our board of directors issues
    preferred shares, the price of our ADSs may fall and the voting
    and other rights of the holders of our ordinary shares and ADSs
    may be adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    be unable to establish and maintain an effective system of
    internal control over financial reporting, and as a result we
    may be unable to accurately report our financial results or
    prevent fraud.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, we have been a private company with
    limited accounting personnel and other resources with which to
    address our internal controls and procedures. In connection with
    the audits of our consolidated financial statements for the
    period from January&#160;1, 2007 to December&#160;31, 2008, our
    independent registered public accounting firm communicated to us
    a material weakness and certain significant and other
    deficiencies in our internal control procedures, which could
    adversely affect our ability to initiate, authorize, record,
    process and report financial data reliably in accordance with
    U.S.&#160;GAAP. As a result, there is more than a remote
    likelihood that a more than inconsequential misstatement of our
    consolidated financial statements will not be prevented or
    detected. Specifically, the material weakness identified
    consists of an ineffective control environment over financial
    reporting due to (i)&#160;an insufficient number of financial
    reporting personnel with an appropriate level of knowledge,
    experience and training; (ii)&#160;insufficient controls around
    the establishment and maintenance of an oversight function and
    communication of internal controls, policies and procedures to
    support our financial reporting obligations; and (iii)&#160;a
    lack of a comprehensive set of internal control policies and
    procedures and related controls to monitor the operating
    effectiveness of these controls. The significant deficiencies
    identified consist of (i)&#160;a lack of a timely formal review
    process for outstanding accounts receivable; (ii)&#160;a lack of
    a process to document investment proposals and lack of a formal
    policy for equipment impairment assessment; and (iii)&#160;a
    lack of controls over agreements and contracts with our hospital
    partners. We are in the process of remediating such material
    weakness and significant and other deficiencies. See
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations&#160;&#151; Internal Control
    Over Financial Reporting.&#148; However, the remedial measures
    that we have taken or intend to take may not fully address such
    material weakness and significant and other deficiencies, and
    additional material weakness and significant and other
    deficiencies, in our internal control over financial reporting
    may be identified in the future.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon the completion of this offering, we will become a public
    company in the United States subject to the Sarbanes-Oxley Act
    of 2002, or the Sarbanes-Oxley Act. Section&#160;404 of the
    Sarbanes-Oxley Act, or Section&#160;404, will require that we
    include a management assessment of, and a report by our
    independent registered public accounting firm on, the
    effectiveness of our internal control over financial reporting
    in our annual report on
    <FONT style="white-space: nowrap">Form&#160;20-F</FONT>
    beginning with our annual report for the fiscal year ending
    December&#160;31, 2010. During the assessment process that we
    will undertake for compliance with Section&#160;404, we may
    identify material weaknesses or significant deficiencies in our
    internal control over financial reporting that we may not be
    able to remediate in time to meet the deadline imposed by
    Section&#160;404, and our management may conclude that our
    internal control over financial reporting is not effective. In
    addition, even if our management concludes that our internal
    control over financial reporting is effective, our independent
    registered public accounting firm may determine that our
    internal controls over financial reporting is not effective and
    may issue an adverse opinion on the effectiveness of our
    internal control over financial reporting. Our failure to
    establish and maintain effective internal control over financial
    reporting
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    could increase the risk of material misstatements in our
    financial statements and cause failure to meet our financial and
    other reporting obligations, which would likely cause investors
    to lose confidence in our reported financial information and
    lead to a significant decline in the trading price of our ADSs.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, unlike most companies, our internal controls over
    financial reporting will need to be designed to cover a
    significant number of our hospital partners located in cities
    throughout China due to the fact that we are heavily dependent
    on timely and accurate receipt of key financial information from
    our hospital partners so we can complete our financial reporting
    process. We may identify control deficiencies as a result of the
    assessment process that we will undertake to comply with
    Section&#160;404, including but not limited to internal audit
    resources and formalized and documented closing and reporting
    processes. We plan to remediate control deficiencies identified
    in time to meet the deadline imposed by the requirements of
    Section&#160;404 but we may be unable to do so. Our failure to
    establish and maintain effective internal control over financial
    reporting could result in the loss of investor confidence in the
    reliability of our financial reporting processes, which in turn
    could harm our business and negatively impact the trading price
    of our ADSs.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    require additional funding to finance our operations, which
    financing may not be available on terms acceptable to us or at
    all, and if we are able to raise funds, the value of your
    investment in us may be negatively impacted.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business operations may require expenditures that exceed our
    available capital resources. We currently expect to obtain bank
    loans of approximately RMB190.0&#160;million
    (US$27.8&#160;million) in 2010 to fund the development of our
    specialty cancer hospitals. Although we currently do not expect
    that we will require funding in addition to these bank loans to
    finance our future growth, to the extent that our funding
    requirements exceed our financial resources, we will be required
    to seek additional financing or to defer planned expenditures.
    There can be no assurance that we can obtain these bank loans or
    additional funds on terms acceptable to us, or at all. In
    addition, our ability to raise additional funds in the future is
    subject to a variety of uncertainties, including, but not
    limited to:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our future financial condition, results of operations and cash
    flows;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    general market conditions for capital raising and debt financing
    activities; and
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    economic, political and other conditions in China and elsewhere.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Furthermore, if we raise additional funds through equity or
    <FONT style="white-space: nowrap">equity-linked</FONT>
    financings, your equity interest in our company may be diluted.
    Alternatively, if we raise additional funds by incurring debt
    obligations, we may be subject to various covenants under the
    relevant debt instruments that may, among other things, restrict
    our ability to pay dividends or obtain additional financing.
    Servicing such debt obligations could also be burdensome to our
    operations. If we fail to service such debt obligations or are
    unable to comply with any of these covenants, we could be in
    default under such debt obligations and our liquidity and
    financial condition could be materially and adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have granted security interests over certain of our
    medical equipment in order to secure bank borrowings. Any
    failure to satisfy our obligations under such borrowings could
    lead to the forced sale of such equipment.</I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to secure bank loans in an aggregate amount of
    RMB112.8&#160;million (US$16.5&#160;million) and
    RMB179.8&#160;million (US$26.3&#160;million) as of
    December&#160;31, 2008 and September&#160;30, 2009,
    respectively, we have granted security interests in equipment
    with a net carrying value of RMB81.6&#160;million
    (US$12.0&#160;million) and RMB217.6&#160;million
    (US$31.9&#160;million), respectively, representing 23.4% and
    39.0% of the net value of our net property, plant and equipment
    of RMB349.1&#160;million (US$51.1&#160;million) and
    RMB557.4&#160;million (US$81.7&#160;million), respectively. Any
    failure on our part to satisfy our obligations under these loans
    could lead to the forced sale of our medical equipment that
    secure these loans, the suspension of the operation of the
    centers in which such medical equipment is used, or otherwise
    damage our relationship with our hospital partners and our
    reputation in the medical community, all of which could have a
    material adverse effect on our business, financial condition and
    results of operation. We may grant additional security interests
    in our equipment in order to secure future bank borrowings,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    including the bank borrowings of approximately
    RMB190.0&#160;million (US$27.8&#160;million) that we expect to
    obtain in 2010 to fund the development of our specialty cancer
    hospitals.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our business may be adversely affected by fluctuations in
    the value of the Renminbi as a significant portion of our
    capital expenditures relates to the purchase of medical
    equipment priced in U.S.&#160;dollars.</I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A significant portion of our capital expenditures relates to the
    purchase of radiotherapy and diagnostic imaging equipment from
    manufacturers outside of China. As the price of such equipment
    is denominated almost exclusively in U.S.&#160;dollars, any
    depreciation in the value of the Renminbi against the
    U.S.&#160;dollar could cause a significant increase our capital
    expenditures, reduce the profitability of our network of centers
    and have a material and adverse effect on our business, results
    of operations and financial condition.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If we
    grant employee share options, restricted shares or other equity
    incentives in the future, our net income could be adversely
    affected.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We adopted our 2008&#160;share incentive plan on
    October&#160;16, 2008, which was subsequently amended on
    November&#160;17, 2009. We are required to account for
    share-based compensation in accordance with Financial Accounting
    Standards Board, or FASB, Statement No.&#160;123(R), Share-Based
    Payment, which requires a company to recognize, as an expense,
    the fair value of share options and other equity incentives to
    employees based on the fair value of equity awards on the date
    of the grant, with the compensation expense recognized over the
    period in which the recipient is required to provide service in
    exchange for the equity award. On November&#160;27, 2009, we
    granted options to purchase an aggregate of
    4,765,800&#160;ordinary shares under our 2008 share incentive
    plan, of which options to purchase an aggregate of 1,716,500
    ordinary shares were granted to our executive officers and
    directors, and the remainder to other employees. We also granted
    share options in 2007, before adopting our 2008&#160;share
    incentive plan, to certain executive officers that were
    subsequently exercised in 2008. As a result, we have incurred
    share-based compensation expenses of approximately
    RMB49.5&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007 and RMB4.2&#160;million
    (US$0.6&#160;million) in 2008 related to such options, which
    resulted in us incurring a net loss for the period from
    September&#160;10, 2007 to December&#160;31, 2007 of
    RMB48.3&#160;million. If we grant more options, restricted
    shares or other equity incentives in the future, we could incur
    significant compensation charges and our results of operations
    could be adversely affected. See &#147;Management&#146;s
    Discussion and Analysis of Financial Condition and Results of
    Operations&#160;&#151; Critical Accounting Policies&#148; and
    Note&#160;19 to our consolidated financial statements included
    in this prospectus for a more detailed presentation of
    accounting for our share-based compensation plan.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We are
    a Cayman Islands company and, because judicial precedent
    regarding the rights of shareholders is more limited under
    Cayman Islands law than that under U.S. law, you may have less
    protection for your shareholder rights than you would under U.S.
    law.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our corporate affairs are governed by our memorandum and
    articles of association, as amended and restated from time to
    time, the Companies Law (as amended) of the Cayman Islands and
    the common law of the Cayman Islands. The rights of shareholders
    to take action against the directors, actions by minority
    shareholders and the fiduciary responsibilities of our directors
    to us under Cayman Islands law are to a large extent governed by
    the common law of the Cayman Islands. The common law of the
    Cayman Islands is derived in part from comparatively limited
    judicial precedent in the Cayman Islands as well as from English
    common law, which has persuasive, but not binding, authority on
    a court in the Cayman Islands. The rights of our shareholders
    and the fiduciary responsibilities of our directors under Cayman
    Islands law are not as clearly established as they would be
    under statutes or judicial precedent in some jurisdictions in
    the United States. In particular, the Cayman Islands has a less
    developed body of securities laws than the United States. In
    addition, some U.S.&#160;states, such as Delaware, have more
    fully developed and judicially interpreted bodies of corporate
    law than the Cayman Islands.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of all of the above, public shareholders may have
    more difficulty in protecting their interests in the face of
    actions taken by management, members of the board of directors
    or controlling shareholders than they would as shareholders of a
    U.S.&#160;public company.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">You
    may have difficulty enforcing judgments obtained against
    us.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are a Cayman Islands company and substantially all of our
    assets are located outside of the United States. Substantially
    all of our current operations are conducted in the PRC. In
    addition, most of our directors and officers are nationals and
    residents of countries other than the United States. As a
    result, it may be difficult for you to effect service of process
    within the United States upon these persons. It may also be
    difficult for you to enforce judgments obtained in
    U.S.&#160;courts based on the civil liability provisions of the
    U.S.&#160;federal securities laws against us and our officers
    and directors, most of whom are not residents in the United
    States and the substantial majority of whose assets are located
    outside of the United States. In addition, there is uncertainty
    as to whether the courts of the Cayman Islands or the PRC would
    recognize or enforce judgments of U.S.&#160;courts against us or
    such persons predicated upon the civil liability provisions of
    the securities laws of the United States or any state and it is
    uncertain whether such Cayman Islands or PRC courts would be
    competent to hear original actions brought in the Cayman Islands
    or the PRC against us or such persons predicated upon the
    securities laws of the United States or any state. See
    &#147;Enforceability of Civil Liabilities.&#148;
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We are
    exempt from certain corporate governance requirements of the
    NYSE.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are exempt from certain corporate governance requirements of
    the NYSE by virtue of being a foreign private issuer. We are
    required to provide a brief description of the significant
    differences between our corporate governance practices and the
    corporate governance practices required to be followed by
    U.S.&#160;domestic companies under the NYSE rules. The standards
    applicable to us are considerably different than the standards
    applied to U.S.&#160;domestic issuers. The significantly
    different standards applicable to us do not require us to:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    have a majority of the board be independent (other than due to
    the requirements for the audit committee under the United States
    Securities Exchange Act of 1934, as amended, or the Exchange
    Act);
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    have a minimum of three members in our audit committee;
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    have a compensation committee, a nominating or corporate
    governance committee;
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide annual certification by our chief executive officer that
    he or she is not aware of any non-compliance with any corporate
    governance rules of the NYSE;
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    have regularly scheduled executive sessions with only
    non-management directors;
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    have at least one executive session of solely independent
    directors each year;
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    seek shareholder approval for (i)&#160;the implementation and
    material revisions of the terms of share incentive plans,
    (ii)&#160;the issuance of more than 1% of our outstanding
    ordinary shares or 1% of the voting power outstanding to a
    related party, (iii)&#160;the issuance of more than 20% of our
    outstanding ordinary shares, and (iv)&#160;an issuance that
    would result in a change of control;
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    adopt and disclose corporate governance guidelines;&#160;or
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    adopt and disclose a code of business conduct and ethics for
    directors, officers and employees.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to rely on all such exemptions provided by the NYSE to
    a foreign private issuer, except that we will establish a
    compensation committee, seek shareholder approval for the
    implementation of share incentive plans and for the increase in
    the number of shares available to be granted under share
    incentive plans and adopt and disclose corporate governance
    guidelines and a code of business conduct and ethics for
    directors, officers and employees. As a result, you may not be
    provided with the benefits of certain corporate governance
    requirements of the NYSE.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    be classified as a passive foreign investment company, which
    could result in adverse United States federal income tax
    consequences to United States Holders.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not expect to be considered a &#147;passive foreign
    investment company,&#148; or PFIC, for United States federal
    income tax purposes for our taxable year ending
    December&#160;31, 2009. However, we must make a separate
    determination each year as to whether we are a PFIC and we
    cannot assure you that we will not be a PFIC for our
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    taxable year ending December&#160;31, 2009 or any future taxable
    year. A
    <FONT style="white-space: nowrap">non-U.S.&#160;corporation</FONT>
    will be considered a PFIC for any taxable year if either
    (i)&#160;at least 75% of its gross income is passive income or
    (ii)&#160;at least 50% of the value of its assets (based on an
    average of the quarterly values of the assets during a taxable
    year) is attributable to assets that produce or are held for the
    production of passive income. The market value of our assets may
    be determined in large part by the market price of our ADSs and
    ordinary shares, which is likely to fluctuate after this
    offering. In addition, the composition of our income and assets
    will be affected by how, and how quickly, we spend the cash we
    raise in this offering. If we are treated as a PFIC for any
    taxable year during which United States Holders (as defined in
    &#147;Taxation&#160;&#151; United States Federal Income
    Taxation&#148;) hold ADSs or ordinary shares, certain adverse
    United States federal income tax consequences could apply to
    such United States Holders. See &#147;Taxation&#160;&#151;
    United States Federal Income Taxation&#160;&#151; Passive
    Foreign Investment Company.&#148;
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Our Industry</FONT></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Healthcare
    administrative authorities in China currently set procurement
    quotas for certain types of medical equipment.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The procurement, installation and operation of large medical
    equipment in China are regulated by the <I>Rules on Procurement
    and Use of Large Medical Equipment </I>issued on
    December&#160;31, 2004 by the MOH, the NDRC, and the Ministry of
    Finance. Pursuant to these rules, quotas for large medical
    equipment are set by the NDRC and the MOH or the relevant
    provincial healthcare administrative authorities, and hospitals
    must obtain a large medical equipment procurement license prior
    to the procurement of any such equipment. For medical equipment
    classified as Class&#160;A large medical equipment, which
    includes gamma knife systems, proton beam therapy systems and
    PET-CT scanners, procurement planning and approval are conducted
    by the MOH and the NDRC and large medical equipment procurement
    licenses are issued by the MOH. For medical equipment classified
    as Class&#160;B large medical equipment, which includes linear
    accelerators and MRI and CT scanners, procurement planning and
    approval are conducted by the relevant provincial healthcare
    administrative authorities with ratification by the MOH and the
    large medical equipment procurement licenses are issued by the
    relevant provincial healthcare administrative authorities. These
    rules apply to all public and private civilian medical
    institutions, whether non-profit or for-profit. Although these
    rules do not directly apply to military hospitals in China,
    which are hospitals regulated by the military but most of which
    are otherwise the same as other government-owned civilian
    hospitals open to the public, they are used as a reference by
    the healthcare administrative authority of the general logistics
    department of the PRC People&#146;s Liberation Army, or the PLA,
    in approving the procurement of such medical equipment. The
    procurement regulations stipulate that from 2007 to 2010, the
    issuance of procurement licenses for no more than 60 head gamma
    knife systems shall be approved nationwide. Of these 60 systems,
    37 have already been allocated as of the date of this
    prospectus, out of which four have been allocated to our
    hospital partners. In addition, procurement regulations
    stipulate that from 2008 to 2010, the total number of
    <FONT style="white-space: nowrap">PET-CT</FONT> large
    medical equipment procurement licenses issued in China cannot
    exceed&#160;38. Of these 38&#160;systems, 26&#160;have already
    been allocated as of the date of this prospectus, out of which
    none has been allocated to our hospital partners since all of
    our partner hospitals where our
    <FONT style="white-space: nowrap">PET-CT</FONT>
    scanners are located are military hospitals as of the date of
    this prospectus. There is currently no guidance as to the total
    number of Class&#160;A large medical equipment procurement
    licenses that may be issued for other types of Class&#160;A
    large medical equipment that the centers in our network operate.
    In addition, many provincial administrative authorities do not
    provide the general public with information on their procurement
    planning and quotas for Class&#160;B large medical equipment
    procurement licenses, if any. Although we do not expect the
    current number of procurement licenses available to have a
    significant impact on our existing expansion plan until the end
    of 2010, any unexpected change as to the number of procurement
    licenses currently available as a result of any change in
    government policy, increases in competition and the number of
    applicants for the procurement licenses or other factors, or any
    failure of our hospital partners to obtain such licenses as
    expected, could all adversely affect our existing expansion plan
    resulting in a material and adverse effect on our business,
    financial condition and results of operations. In addition, the
    limitation on the number of procurement licenses available and
    any adverse change to such procurement licenses available in the
    future may affect our expansion plan after 2010, which could
    have a material adverse effect on our future prospects.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, for most of the medical equipment that we intend to
    install and operate in our specialty cancer hospitals, we will
    need to obtain large medical equipment procurement licenses from
    the MOH or provincial level healthcare
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    administrative authorities. Such licenses might not be obtained
    in a timely manner or at all, which could delay or prevent the
    opening of our specialty cancer hospitals, and could have a
    material adverse effect on our growth strategy and results of
    operations. See &#147;&#151;&#160;Risks Related to Our
    Business&#160;&#151; We are planning to establish and operate
    specialty cancer hospitals that are majority owned by us and are
    subject to significant risks.&#148;
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Certain
    of our hospital partners have not received large medical
    equipment procurement licenses or interim procurement permits
    for some of the medical equipment in our network of centers
    which could result in fines or the suspension from use of such
    medical equipment.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The quota requirement for large medical equipment procurement
    became effective in March 2005. A medical institution that
    houses equipment purchased prior to that time is required to
    retroactively apply for and obtain a large medical equipment
    procurement license. If a medical institution is unable to
    obtain a procurement license as a result of a lack of
    procurement quotas for such medical equipment allocated to the
    region in which the medical institution is located, an interim
    procurement permit for large medical equipment must be obtained
    in lieu thereof. As of the date of this prospectus, of the
    73&#160;units of medical equipment in the centers in our network
    that are subject to large medical equipment procurement quota
    requirements, 41 were issued with a procurement license, three
    were issued with an interim procurement permit subsequent to the
    implementation of the quota requirement, 21 were issued with
    procurement permits or authorizations by competent regulatory
    authorities prior to the implementation of the quota requirement
    but have not received new procurement licenses or interim
    procurement permits under the quota requirements that became
    effective in 2005, and eight, which accounted for approximately
    8.4% and 7.2% of our total net revenues in 2008 and for the nine
    months ended September&#160;30, 2009, respectively, have not yet
    been issued with any procurement license or permit. Although our
    hospital partners have applied to the competent regulatory
    authorities for procurement licenses for these last 29 centers,
    we cannot assure you that they will be successful. If our
    hospital partners fail to receive either a procurement license
    or an interim procurement permit, the centers in our network
    operating such medical equipment may be required to discontinue
    operations and may be deprived of the revenue derived from the
    operation of such equipment or assessed a fine, any of which
    could have a material adverse effect on our business, financial
    condition and results of operation.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Based on the opinion of our PRC counsel, Jingtian&#160;&#038;
    Gongcheng Attorneys At Law, we believe that the 21&#160;units of
    equipment, for which procurement permits or authorizations were
    obtained from the regulatory authorities prior to the
    implementation of the quota requirement but no new procurement
    licenses or interim procurement permits under the 2005 quota
    requirements have been issued, are unlikely to face fines or
    other penalties from such regulatory authorities, although we
    cannot be certain. These 21&#160;units of equipment accounted
    for approximately 28.6% and 19.6% of our total net revenues in
    2008 and for the nine months ended September&#160;30, 2009,
    respectively. In addition, for the three&#160;units of medical
    equipment that were issued with interim procurement permits
    subsequent to the implementation of the quota requirement, the
    relevant regulations require that hospitals pay taxes derived
    from the use of equipment covered by such interim permits, which
    may increase the operating costs of the centers in our network
    that operate such equipment. Also, upon the expiration of the
    useful life of medical equipment issued with interim procurement
    permits, hospitals are not permitted to replace such medical
    equipment with a newer model, in which case we may not be able
    to continue or renew our agreements with such hospital partners
    with interim procurement permits for medical equipment reaching
    the end of its life unless they are able to obtain a new
    procurement license.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Pricing
    for the services provided by our network of centers may be
    adversely affected by reductions in treatment and examination
    fees set by the Chinese government.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Centers in our network are primarily located in non-profit
    civilian and military hospitals in China. The medical service
    fees charged by these non-profit hospitals are subject to price
    ceilings set by the relevant provincial or regional price
    control authorities and healthcare administrative authorities in
    accordance with the <I>Opinion Concerning the Reform of Medical
    Service Pricing Management </I>issued on July&#160;20, 2000 by
    the NDRC and the MOH. See &#147;Regulation of Our
    Industry.&#148; These price ceilings can be adjusted by those
    authorities downwards or upwards from time to time. For example,
    in 2006, treatment fees for the head gamma knife in one of the
    centers in our network decreased by approximately 30% and in
    2007, and treatment fees for the body gamma knife in one of the
    centers in our network decreased by approximately 25%. However,
    overall, the average medical service fees for each of the
    treatments and diagnostic imaging services provided across our
    network of centers have remained stable
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    since 2007. The relevant price control authorities and
    healthcare administrative authorities provide notices to
    hospitals, who in turn provide immediate notice to us, as to any
    change in the pricing ceiling for medical services. The timing
    between when notices are provided by the relevant price control
    authorities and healthcare administrative authorities and the
    effective date of such pricing change varies in different cities
    and regions as well as the relevant medical services in
    question, but typically ranges from one to three months.
    According to the <I>Implementation Plan for the Recent
    Priorities of the Health Care System Reform
    <FONT style="white-space: nowrap">(2009-2011)</FONT></I>,
    which was issued by the State Council on March&#160;18, 2009,
    the Chinese government is aiming to reduce the examination fees
    for large medical equipment. In addition, according to the
    <I>Opinion on the Reform of Pharmaceuticals and Healthcare
    Service Pricing Structures </I>issued on November&#160;9, 2009
    by the NDRC, the MOH and the Ministry of Human Resources and
    Social Security, or the MHRSS, the Chinese government is also
    aiming to reduce the treatment fees for large medical equipment.
    If the examination or treatment fees for the services provided
    by the centers in our network are reduced by the government
    under these or other policies, our contracted percentage of each
    center&#146;s revenue net of specified operating expenses may
    decrease, hospitals may be discouraged from entering into or
    renewing their agreements with us, and our business, financial
    condition and results of operations may be materially and
    adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    business may be harmed by technological and therapeutic changes
    or by shifts in doctors&#146; or patients&#146; preferences for
    alternative treatments.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The treatment of cancer patients is subject to potentially
    revolutionary technological and therapeutic changes. Future
    technological developments could render our equipment and the
    services provided in our network of centers obsolete. We may
    incur significant costs in replacing or modifying equipment in
    which we have already made a substantial investment prior to the
    end of its anticipated useful life. In addition, there may be
    significant advances in other cancer treatment methods, such as
    chemotherapy, surgery, biological therapy, or in cancer
    prevention techniques, which could reduce demand or even
    eliminate the need for the radiotherapy services that we
    provide. Also, patients and doctors may choose alternative
    cancer therapies over radiotherapy due to any number of reasons.
    Any shifts in doctors&#146; or patients&#146; preferences for
    other cancer therapies over radiotherapy may have a material
    adverse effect on our business, financial condition and results
    of operations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    technology used in some of our radiotherapy equipment,
    particularly our body gamma knife and our proton beam therapy
    system, has been in use for a limited period of time and the
    international medical community has not yet developed a large
    quantity of peer-reviewed literature that supports their safe
    and effective use.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The technology in some of our radiotherapy equipment,
    particularly the body gamma knife system and the proton beam
    therapy system, has been in use for a limited period of time,
    and the international medical community has not yet developed a
    large quantity of peer-reviewed literature that supports their
    safe and effective use. As a result, such technology may not
    continue to gain acceptance by doctors and patients in China or
    may lose any acceptance such technology has previously gained if
    negative information were to emerge concerning their
    effectiveness or safety. As our agreements with manufacturers do
    not directly address such contingencies, we cannot assure you
    that equipment manufacturers would allow us to return their
    equipment or to otherwise reimburse us for any losses that we
    may suffer under all such circumstances. Since each unit of our
    medical equipment represents a significant investment, any of
    the foregoing could have a material adverse effect on our
    business, financial condition and results of operation.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    business may be adversely affected by impending healthcare
    reforms in China.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2009, the Chinese government approved in principle a
    healthcare reform plan to address the affordability of
    healthcare services, the rural healthcare system and healthcare
    service quality in China. In March, 2009, the Chinese government
    published the healthcare reform plan for 2009 to 2010, which
    broadly addressed medical insurance coverage, essential
    medicines, provision of basic healthcare services and reform of
    public hospitals. The published healthcare reform plan also
    called for additional government spending on healthcare over the
    next three years of RMB850.0&#160;billion to support the reform
    plan. According to the <I>Implementation Plan for the Recent
    Priorities of the Health Care System Reform
    <FONT style="white-space: nowrap">(2009-2011)</FONT></I>,
    which was issued by the State Council on March&#160;18, 2009,
    the Chinese government is aiming to reduce the examination fees
    for large medical equipment. In
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    addition, according to the <I>Opinion on the Reform of
    Pharmaceuticals and Healthcare Service Pricing Structures
    </I>issued on November&#160;9, 2009 by the NDRC, the MOH and the
    MHRSS, the Chinese government is also aiming to reduce the
    treatment fees for large medical equipment. Although many
    details related to the implementation of the healthcare reform
    plan are not yet clear, the implementation of any policy that
    reduces examination or treatment fees for large medical
    equipment or provides more funding for hospitals to purchase
    their own equipment may have a material and adverse effect on
    our business, financial condition and results of operations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Some details of the implementation of the healthcare reform that
    have been published, including a policy drafted jointly by five
    ministries, including the Ministry of Finance, NDRC and MOH,
    providing general principles and guidelines for government
    subsidies and investments in the public healthcare system, a
    policy statement allowing doctors to practice in up to three
    hospital within the same province, and the release of a list of
    307 essential drugs whose prices are subject to central
    government guidelines and provincial government tenders. The
    distribution of these drugs is expected to encompass all
    government-owned healthcare facilities by 2020.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the government has implemented a pilot plan as to
    the new rural healthcare insurance program whereby patients are
    required to pay hospitals only a portion of their medical
    expenses upfront and hospitals are required to seek payment of
    the balance from the government. Any resulting disputes or late
    or delinquent reimbursement payments may affect the collection
    of revenue at our network of centers and could increase our
    accounts receivables days.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We or
    our hospital partners may be unable to obtain various permits
    and authorizations from regulatory authorities in China relating
    to our medical equipment, which could delay the installation or
    interrupt the operation of our equipment.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For our hospital-based centers, our hospital partners are
    required to obtain a radiation safety permit from the Ministry
    of Environmental Protection, or MEP, and a radiotherapy permit
    from the competent healthcare administrative authorities in
    order to operate the medical equipment in our network of centers
    that contains radioactive materials or emit radiation during
    operation. Our hospital partners are also required to obtain a
    radiation worker permit from the competent provincial healthcare
    administrative authorities for each medical technician who
    operates such equipment. Any failure on the part of our hospital
    partners to obtain approvals or renewals of these permits from
    the MEP or the competent healthcare administrative authorities
    could delay the installation, or interrupt the operation, of our
    medical equipment, either of which could have a material adverse
    effect on our business, financial condition and results of
    operation.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each of our planned specialty cancer hospitals that will be
    majority owned by us will be required to obtain a radiation
    safety permit from the MEP and a radiotherapy permit as well as
    a medical institution practicing license and radiation worker
    permits for our staff from the relevant provincial healthcare
    administrative authorities. Any failure on our part to obtain
    approvals or renewals of these permits could delay the opening,
    or interrupt the operation, of our specialty cancer hospitals,
    which could have a material adverse effect on our business,
    financial condition and results of operation. For more
    information on risks related to our planned specialty cancer
    hospitals, see &#147;&#151;&#160;Risks Related to Our
    Business&#160;&#151; We are planning to establish and operate
    specialty cancer hospitals that are majority owned by us and are
    subject to significant risks.&#148;
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If the
    government and public insurers in the PRC do not continue to
    provide sufficient coverage and reimbursement for the
    radiotherapy and diagnostic imaging services provided by our
    network of centers, our revenues could be adversely
    affected.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Although self payments account for a high percentage of total
    medical expenses in China, approximately 20.4% of total medical
    expenses were sourced from direct payments by the government and
    approximately 34.5% of total medical expenses were sourced from
    government-directed public medical insurance schemes, commercial
    insurance plans and employers in 2007, according to the MOH. For
    public servants and others covered by <I>1989 Administrative
    Measure on Public Health Service </I>and the <I>1997 Circular of
    Reimbursement Coverage of Large Medical Equipment of Public
    Health Service</I>, the government currently either fully or
    partially reimburses medical expenses for certain approved
    cancer diagnosis and radiotherapy treatment services, including
    treatments utilizing linear accelerators and diagnostic imaging
    services utilizing CT and MRI scanners. However, gamma knife
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    treatments and PET scans are currently not eligible for
    reimbursement under this plan. Urban residents in China are
    covered by one of two urban public medical insurance schemes and
    rural residents are covered under a new rural healthcare
    insurance program launched in 2003. The urban employees basic
    medical insurance scheme, which covers employed urban residents,
    partially reimburses urban workers for treatments utilizing
    linear accelerators and gamma knife systems and diagnostic
    imaging services utilizing CT and MRI scanners, with
    reimbursement levels varying from province to province. For
    urban non-workers and rural residents, the types of cancer
    diagnosis and radiotherapy treatments that are covered are
    generally set with reference to the policy for urban employees
    in the same region of the country, but the reimbursement levels
    for covered medical expenses for urban non-workers and rural
    residents, which vary widely from region to region and treatment
    to treatment, are generally lower than those for urban employees
    in the same region. See &#147;Regulation of Our
    Industry&#160;&#151; Medical Insurance Coverage&#148; for more
    information. We cannot assure you that the current coverage or
    reimbursement levels for cancer diagnosis or radiotherapy
    treatments will persist. If the national or provincial
    authorities in China decide to reduce the coverage or
    reimbursement levels for the radiotherapy and diagnostic imaging
    services provided by our network of centers, patients may opt
    for or be forced to resort to other forms of cancer therapy and
    our business, financial condition and results of operation could
    be materially and adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Doing Business in China</FONT></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Adverse
    changes in political, economic and other policies of the Chinese
    government could have a material adverse effect on the overall
    economic growth of China, which could materially and adversely
    affect the growth of our business and our competitive
    position.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All of our business operations are conducted in China.
    Accordingly, our business, financial condition, results of
    operations and prospects are affected significantly by economic,
    political and legal developments in China. The Chinese economy
    differs from the economies of most developed countries in many
    respects, including:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the degree of government involvement;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the level of development;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the growth rate;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the control of foreign exchange;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the allocation of resources;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an evolving regulatory system;&#160;and
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    lack of sufficient transparency in the regulatory process.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    While the Chinese economy has experienced significant growth in
    the past 30&#160;years, growth has been uneven, both
    geographically and among various sectors of the economy. The
    Chinese economy has also experienced certain adverse effects due
    to the recent global financial crisis. The Chinese government
    has implemented various measures to encourage economic growth
    and guide the allocation of resources. Some of these measures
    benefit the overall Chinese economy, but may also have a
    negative effect on us. For example, our financial condition and
    results of operations may be adversely affected by government
    control over capital investments or changes in tax regulations
    that are applicable to us.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Chinese economy has been transitioning from a planned
    economy to a more market-oriented economy. Although in recent
    years the Chinese government has implemented measures
    emphasizing the utilization of market forces for economic
    reform, the reduction of state ownership of productive assets
    and the establishment of sound corporate governance in business
    enterprises, a substantial portion of the productive assets in
    China is still owned by the Chinese government. The continued
    control of these assets and other aspects of the national
    economy by the Chinese government could materially and adversely
    affect our business. The Chinese government also exercises
    significant control over Chinese economic growth through the
    allocation of resources, controlling payment of foreign
    currency-denominated obligations, setting monetary policy and
    providing preferential treatment to particular industries or
    companies.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any adverse change in the economic conditions or government
    policies in China could have a material adverse effect on
    overall economic growth and the level of healthcare investments
    and expenditures in China, which in turn could lead to a
    reduction in demand for our products and consequently have a
    material adverse effect on our businesses.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Uncertainties
    with respect to the PRC legal system could have a material
    adverse effect on us.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The PRC legal system is based on written statutes. Prior court
    decisions may be cited for reference but have limited
    precedential value. In 1979, the PRC government began to
    promulgate a comprehensive system of laws and regulations
    governing economic matters in general. The overall effect of
    legislation since then has been to significantly enhance the
    protections afforded to various forms of foreign investments in
    China. We conduct all of our business through our subsidiaries
    established in China. These subsidiaries are generally subject
    to laws and regulations applicable to foreign investment in
    China and, in particular, laws applicable to foreign-invested
    enterprises. However, since these laws and regulations are
    relatively new and the PRC legal system continues to rapidly
    evolve, the interpretations of many laws, regulations and rules
    are not always uniform and enforcement of these laws,
    regulations and rules involves uncertainties, which may limit
    legal protections available to us. In addition, some regulatory
    requirements issued by certain PRC government authorities may
    not be consistently applied by other government authorities
    (including local government authorities), thus making strict
    compliance with all regulatory requirements impractical, or in
    some circumstances, impossible. For example, we may have to
    resort to administrative and court proceedings to enforce the
    legal protection that we enjoy either by law or contract.
    However, since PRC administrative and court authorities have
    significant discretion in interpreting and implementing
    statutory and contractual terms, it may be more difficult to
    evaluate the outcome of administrative and court proceedings and
    the level of legal protection we enjoy than in more developed
    legal systems. These uncertainties may impede our ability to
    enforce the contracts we have entered into with our business
    partners, customers and suppliers. In addition, such
    uncertainties, including the inability to enforce our contracts,
    together with any development or interpretation of PRC law that
    is adverse to us, could materially and adversely affect our
    business and operations. Furthermore, intellectual property
    rights and confidentiality protections in China may not be as
    effective as in the United States or other countries.
    Accordingly, we cannot predict the effect of future developments
    in the PRC legal system, including the promulgation of new laws,
    changes to existing laws or the interpretation or enforcement
    thereof, or the preemption of local regulations by national
    laws. These uncertainties could limit the legal protections
    available to us and other foreign investors, including you. In
    addition, any litigation in China may be protracted and result
    in substantial costs and diversion of our resources and
    management attention.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    approval of the PRC Securities Regulatory Commission, or the
    CSRC, may be required in connection with this offering under a
    recently adopted PRC regulation.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;8, 2006, six PRC regulatory agencies, including
    the CSRC, promulgated the &#147;Provisions Regarding Mergers and
    Acquisitions of Domestic Enterprises by Foreign Investors,&#148;
    or the M&#038;A rule, which took effect on September&#160;8,
    2006, to more effectively regulate foreign investment in PRC
    domestic enterprises. The M&#038;A rule also contains a
    provision requiring offshore special purpose vehicles, or SPVs,
    formed for overseas listing purposes and controlled by PRC
    individuals to obtain the approval of the CSRC prior to publicly
    listing their securities on an overseas stock exchange.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The application of this M&#038;A rule is currently unclear.
    However, our PRC counsel, Jingtian&#160;&#038; Gongcheng
    Attorneys At Law, has advised us that based on its understanding
    of the current PRC laws, rules and regulations and the M&#038;A
    rule, the M&#038;A rule does not require us to obtain prior CSRC
    approval for the listing and trading of our ADSs on the NYSE,
    because our acquisition of the equity interest in our PRC
    subsidiaries is not subject to the M&#038;A rule due to the fact
    that Aohua Medical and Shanghai Medstar were already
    foreign-invested enterprises before September&#160;8, 2006, the
    effective date of the M&#038;A rule. Jingtian&#160;&#038;
    Gongcheng Attorneys At Law has further advised us that their
    opinions summarized above are subject to the timing and content
    of any new laws, rules and regulations or clear implementations
    and interpretations from the CSRC in any form relating to the
    M&#038;A rule.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, if the CSRC or another PRC regulatory agency
    subsequently determines that prior CSRC approval was required,
    we may face regulatory actions or other sanctions from the CSRC
    or other PRC regulatory agencies. These regulatory agencies may
    impose fines and penalties on our operations, limit our
    operating privileges, delay or
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    restrict the repatriation of the proceeds from this offering
    into China or payment or distribution of dividends by our PRC
    subsidiaries, or take other actions that could have a material
    adverse effect on our business, financial condition, results of
    operations, reputation and prospects, as well as the trading
    price of our ADSs. The CSRC or other PRC regulatory agencies
    also may take actions requiring us, or making it advisable for
    us, to halt this offering before settlement and delivery of the
    ADSs offered hereby. Consequently, if you engage in market
    trading or other activities in anticipation of and prior to
    settlement and delivery, you do so at the risk that settlement
    and delivery may not occur. Also, if the CSRC later requires
    that we obtain its approval, we may be unable to obtain a waiver
    of the CSRC approval requirements, if and when procedures are
    established to obtain such a waiver. Any uncertainties or
    negative publicity regarding this CSRC approval requirement
    could have a material adverse effect on the trading price of our
    ADSs.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We cannot predict when the CSRC may promulgate additional
    implementing rules or other guidance, if at all. If implementing
    rules or guidance is issued prior to the completion of this
    offering and consequently we conclude we are required to obtain
    CSRC approval, this offering will be delayed until we obtain
    CSRC approval, which may take several months or longer.
    Furthermore, any delay in the issuance of such implementing
    rules or guidance may create additional uncertainties with
    respect to this offering. Moreover, implementing rules or
    guidance, to the extent issued, may fail to resolve current
    ambiguities under the M&#038;A Rule. Uncertainties
    <FONT style="white-space: nowrap">and/or</FONT>
    negative publicity regarding the M&#038;A Rule could have a
    material adverse effect on the trading price of our ADSs.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    M&#038;A rule establishes more complex procedures for some
    acquisitions of Chinese companies by foreign investors, which
    could make it more difficult for us to pursue growth through
    acquisitions in China.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The M&#038;A rule establishes additional procedures and
    requirements that could make some acquisitions of Chinese
    companies by foreign investors more time-consuming and complex,
    including requirements in some instances that the Ministry of
    Commerce be notified in advance of any change-of-control
    transaction in which a foreign investor takes control of a
    Chinese domestic enterprise. We may grow our business in part by
    acquiring complementary businesses. Complying with the
    requirements of the M&#038;A rule to complete such transactions
    could be time-consuming, and any required approval processes,
    including obtaining approval from the Ministry of Commerce, may
    delay or inhibit our ability to complete such transactions,
    which could affect our ability to expand our business or
    maintain our market share.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Recent
    PRC regulations, particularly SAFE Circular No.&#160;75 relating
    to acquisitions of PRC companies by foreign entities, may limit
    our ability to acquire PRC companies and adversely affect the
    implementation of our strategy as well as our business and
    prospects.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2005, the State Administration of Foreign Exchange, or the
    SAFE issued a number of rules regarding offshore investments by
    PRC residents. The currently effective rule, <I>the Notice on
    Issues Relating to the Administration of Foreign Exchange in
    Fund-Raising and Return Investment Activities of Domestic
    Residents Conducted Via Offshore Special Purpose Companies</I>,
    known as SAFE Circular No.&#160;75, was issued on
    October&#160;21, 2005 and further clarified by Circular
    No.&#160;106 issued by the SAFE on May&#160;29, 2007. SAFE
    Circular No.&#160;75 requires PRC residents to register with and
    receive approvals from the SAFE in connection with certain
    offshore investment activities. Since we are a Cayman Islands
    company that is controlled by PRC residents, we are affected by
    the registration requirements imposed by SAFE Circular
    No.&#160;75. Also, any failure by our shareholders who are PRC
    residents to comply with SAFE Circular No.&#160;75, or change in
    SAFE policy and regulations in respect of SAFE Circular
    No.&#160;75, could adversely affect us in a variety of ways.
    SAFE Circular No.&#160;75 provides, among other things, that
    prior to establishing or assuming control of an offshore company
    for the purpose of transferring to that offshore company assets
    of, or equity interests in, an enterprise in the PRC, each PRC
    resident (whether a natural or legal person) who is an ultimate
    controller of the offshore company must complete prescribed
    registration procedures with the relevant local branch of the
    SAFE. Such PRC resident must amend his or her SAFE registration
    under certain circumstances, including upon any further transfer
    of equity interests in, or assets of, an onshore enterprise to
    the offshore company as well as any material change in the
    capital of the offshore company, including by way of a transfer
    or swap of shares, a merger or division, a long-term equity or
    debt investment or the creation of any security interests in
    favor of third parties. The registration and filing procedures
    under SAFE rules are prerequisites for other approval and
    registration procedures necessary for capital inflow from the
    offshore entity, such as inbound
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    investments or shareholder loans, or capital outflow to the
    offshore entity, such as the payment of profits or dividends,
    liquidating distributions, equity sale proceeds, or the return
    of funds upon a capital reduction. SAFE Circular No.&#160;75
    applies retroactively and to indirect shareholdings. PRC
    residents who have established or acquired direct or indirect
    control of offshore companies that have made onshore investments
    in the PRC in the past are required to complete the registration
    procedures by March&#160;31, 2006. The failure or inability of a
    PRC resident shareholder to receive any required approvals or
    make any required registrations could subject the PRC subsidiary
    to fines and legal sanctions, restrict the offshore
    company&#146;s additional investments in the PRC subsidiary, or
    limit the PRC subsidiary&#146;s ability to make distributions or
    pay dividends offshore. Due in part to the uncertainties
    relating to the interpretation and implementation of SAFE
    Circular No.&#160;75, its effect on companies such as ours is
    difficult to predict.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Currently, several of our shareholders who are residents in the
    PRC and are subject to the above registration or amendment of
    registration requirements have applied to SAFE&#146;s local
    branches to make the required make-up SAFE registration with
    respect to their existing investments in our company. Because of
    the current suspension of acceptance of such make-up
    registration by the SAFE authorities due to reportedly
    forthcoming new SAFE regulations, such shareholders&#146;
    applications are still pending. We cannot assure you that these
    shareholders&#146; pending applications will eventually be
    approved by the authorities. Furthermore, there may be
    additional PRC shareholders, whose identities we may not be
    aware of and whose actions we do not control, who are not in
    compliance with the registration procedures set forth in SAFE
    Circular No.&#160;75. If the SAFE determines that any of our PRC
    shareholders failed to make filings that they should have made
    with respect to any of our offshore entities, we could be
    subject to fines and legal penalties, or the SAFE could impose
    restrictions on our foreign exchange activities, including the
    payment of dividends and other distributions to us or our
    affiliates and our PRC subsidiaries&#146; ability to receive
    capital from us. Any of these actions could, among other things,
    materially and adversely affect our business operations,
    acquisition opportunities and financing alternatives.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">PRC
    regulation of loans and direct investment by offshore holding
    companies to PRC entities may delay or prevent us from using the
    proceeds of this offering to make loans or additional capital
    contributions to our PRC subsidiaries.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In utilizing the proceeds from this public offering or any
    further offerings, as an offshore holding company of our PRC
    subsidiaries, we may make loans to our PRC subsidiaries, or we
    may make additional capital contributions to our PRC
    subsidiaries. Any loans to our PRC subsidiaries are subject to
    PRC regulations and approvals. For example, loans by us to our
    wholly owned PRC subsidiaries in China, each of which is a
    foreign-invested enterprise, to finance their activities cannot
    exceed statutory limits and must be registered with the SAFE or
    its local counterpart.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may also decide to finance our PRC subsidiaries through
    capital contributions. These capital contributions must be
    approved by the Ministry of Commerce in China or its local
    counterpart. We cannot assure you that we will be able to obtain
    these government registrations or approvals on a timely basis,
    if at all, with respect to future loans or capital contributions
    by us to our subsidiaries or any of their respective
    subsidiaries. If we fail to receive such registrations or
    approvals, our ability to use the proceeds of this offering and
    to capitalize our PRC operations may be negatively affected,
    which could adversely and materially affect our liquidity and
    our ability to fund and expand our business.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Governmental
    control of currency conversion may limit our ability to use our
    revenues effectively and the ability of our PRC subsidiaries to
    obtain financing.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive all of our revenues in Renminbi, which currently is
    not a freely convertible currency. Restrictions on currency
    conversion imposed by the PRC government may limit our ability
    to use revenues generated in Renminbi to fund our expenditures
    denominated in foreign currencies or our business activities
    outside China, if any. Under China&#146;s existing foreign
    exchange regulations, Renminbi may be freely converted into
    foreign currency for payments relating to &#147;current account
    transactions,&#148; which include among other things dividend
    payments and payments for the import of goods and services, by
    complying with certain procedural requirements. Our PRC
    subsidiaries are able to pay dividends in foreign currencies to
    us without prior approval from the SAFE, by complying with
    certain procedural requirements. Our PRC subsidiaries may also
    retain foreign currency their
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    respective current account bank accounts for use in payment of
    international current account transactions. However, we cannot
    assure you that the PRC government will not take measures in the
    future to restrict access to foreign currencies for current
    account transactions.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Conversion of Renminbi into foreign currencies, and of foreign
    currencies into Renminbi, for payments relating to &#147;capital
    account transactions,&#148; which principally includes
    investments and loans, generally requires the approval of SAFE
    and other relevant PRC governmental authorities. Restrictions on
    the convertibility of the Renminbi for capital account
    transactions could affect the ability of our PRC subsidiaries to
    make investments overseas or to obtain foreign currency through
    debt or equity financing, including by means of loans or capital
    contributions from us. In particular, if our PRC subsidiaries
    borrow foreign currency from us or other foreign lenders, they
    must do so within approved limits that satisfy their approval
    documentation and PRC debt to equity ratio requirements.
    Further, such loans must be registered with the SAFE or its
    local counterpart. In practice, it could be time-consuming to
    complete such SAFE registration process.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we finance our PRC subsidiaries through additional capital
    contributions, the amount of these capital contributions must be
    approved by the Ministry of Commerce in China or its local
    counterpart. On August&#160;29, 2008, SAFE promulgated Circular
    142, a notice regulating the conversion by a foreign-invested
    company of foreign currency into Renminbi by restricting how the
    converted Renminbi may be used. The notice requires that
    Renminbi converted from the foreign currency-denominated capital
    of a foreign-invested company may only be used for purposes
    within the business scope approved by the applicable
    governmental authority and may not be used for equity
    investments within the PRC unless specifically provided for
    otherwise in its business scope. In addition, SAFE strengthened
    its oversight of the flow and use of Renminbi funds converted
    from the foreign currency-denominated capital of a
    foreign-invested company. The use of such Renminbi may not be
    changed without approval from SAFE, and may not be used to repay
    Renminbi loans if the proceeds of such loans have not yet been
    used for purposes within the company&#146;s approved business
    scope. Violations of Circular 142&#160;may result in severe
    penalties, including substantial fines as set forth in the
    Foreign Exchange Administration Regulations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We cannot assure you that we will be able to complete the
    necessary government registrations or obtain the necessary
    government approvals on a timely basis, if at all, with respect
    to future loans by us to our PRC subsidiaries or with respect to
    future capital contributions by us to our PRC subsidiaries. If
    we fail to complete such registrations or obtain such approvals,
    our ability to use the proceeds we receive from this offering
    and to capitalize or otherwise fund our PRC operations may be
    negatively affected, which could adversely and materially affect
    our liquidity and our ability to fund and expand our business
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fluctuations
    in the value of the Renminbi may have a material adverse effect
    on your investment.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The value of the Renminbi against the U.S.&#160;dollar and other
    currencies may fluctuate and is affected by, among other things,
    changes in China&#146;s political and economic conditions. The
    conversion of Renminbi into foreign currencies, including
    U.S.&#160;dollars, has historically been set by the
    People&#146;s Bank of China. On July&#160;21, 2005, the PRC
    government changed its policy of pegging the value of the
    Renminbi to the U.S.&#160;dollar. Under the new policy, the
    Renminbi is permitted to fluctuate within a band against a
    basket of certain foreign currencies, determined by the Bank of
    China, against which it can rise or fall by as much as 0.3% each
    day.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There remains significant international pressure on the PRC
    government to further liberalize its currency policy, which
    could result in a further and more significant appreciation in
    the value of the Renminbi against the U.S.&#160;dollar. In
    addition, as we rely entirely on dividends paid to us by our PRC
    subsidiaries, any significant revaluation of the Renminbi may
    have a material adverse effect on our revenues and financial
    condition, and the value of any dividends payable on our ADSs in
    foreign currency terms. For example, to the extent that we need
    to convert U.S.&#160;dollars that we receive from our initial
    public offering into Renminbi for our operations, appreciation
    of the Renminbi against the U.S.&#160;dollar would have an
    adverse effect on the Renminbi amount that we receive from the
    conversion. Conversely, if we decide to convert our Renminbi
    into U.S.&#160;dollars for the purpose of making payments for
    dividends on our ordinary shares or ADSs or for other business
    purposes, appreciation of the U.S.&#160;dollar against the
    Renminbi would have a negative effect on the U.S.&#160;dollar
    amount available to us. In addition, appreciation or
    depreciation in the value of the Renminbi relative to the
    U.S.&#160;dollar would affect our financial results reported in
    U.S.&#160;dollar terms without giving effect to any underlying
    change in our business or results of operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    increase in the PRC enterprise income tax and the
    discontinuation of the preferential tax treatment currently
    available to us could, in each case, result in a decrease of our
    net income and materially and adversely affect our financial
    condition and results of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our PRC subsidiaries are incorporated in the PRC and are
    governed by applicable PRC income tax laws and regulations.
    Prior to January&#160;1, 2008, entities established in the PRC
    were generally subject to a 30% state and 3% local enterprise
    income tax rate. There were various preferential tax treatments
    promulgated by national tax authorities that were available to
    foreign-invested enterprises or enterprises located in certain
    areas of China. In addition, some local tax authorities may
    allow enterprises registered in their tax jurisdiction to enjoy
    lower preferential tax treatments according to local
    preferential tax policy. For example, Shanghai Medstar was
    entitled to a reduced enterprise income tax rate of 15% before
    January&#160;1, 2008 due to its status as a foreign-invested
    manufacturing enterprise registered in the Shanghai Waigaoqiao
    free trade zone.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The PRC Enterprise Income Tax Law, or the EIT Law, was enacted
    on March&#160;16, 2007 and became effective on January&#160;1,
    2008. The implementation regulations under the EIT Law issued by
    the PRC State Council became effective January&#160;1, 2008.
    Under the EIT Law and the implementation regulations, the PRC
    has adopted a uniform tax rate of 25% for all enterprises
    (including foreign-invested enterprises) and revoked the
    previous tax exemption, reduction and preferential treatments
    applicable to foreign-invested enterprises. However, there is a
    transition period for enterprises, whether foreign-invested or
    domestic, that received preferential tax treatments granted in
    accordance with the then prevailing tax laws and regulations
    prior to January&#160;1, 2008. Enterprises that were subject to
    an enterprise income tax rate lower than 25% prior to
    January&#160;1, 2008&#160;may continue to enjoy the lower rate
    and gradually transition to the new tax rate within five years
    after the effective date of the EIT Law. In 2009, our
    subsidiaries Aohua Medical and Shanghai Medstar each had a
    preferential income tax rate of 20% that is scheduled to
    increase to 22% in 2010, 24% in 2011 and 25% in 2012. We cannot
    assure you that the preferential income tax rates that we enjoy
    will not be phased out at a faster rate or will not be
    discontinued altogether, either of which could result in a
    decrease of our net income and materially and adversely affect
    our financial condition and results of operations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Also, the reduced enterprise income tax rate of 15%, as
    described above, that our subsidiary Shanghai Medstar enjoyed
    before January&#160;1, 2008, for which only foreign-invested
    manufacturing enterprises registered in the Shanghai Waigaoqiao
    free trade zone were eligible, was granted based on Shanghai tax
    authorities&#146; local preferential tax policy. It is uncertain
    whether the transitional tax rates under the EIT Law would apply
    to companies that enjoyed a preferential reduced tax rate of 15%
    under a local preferential tax policy. If Shanghai Medstar
    cannot enjoy the such transitional tax rates under the EIT Law,
    it will be subject to the standard enterprise income tax rate,
    which is currently 25%, and our income tax expenses would
    increase, which would have a material adverse effect on our net
    income and results of operation. In addition, under current PRC
    regulations, if it is determined that a taxpayer has underpaid
    tax due to prior incorrect advice from relevant tax authorities,
    the taxpayer may still be required to retroactively pay the full
    amount of unpaid tax within three years of such determination,
    although the taxpayer would not be subject to any penalty or
    late payment fee. If we are required to make such retroactive
    tax payments due to the retroactive cancellation of Shanghai
    Medstar&#146;s preferential reduced enterprise income tax rate
    of 15%, our financial condition and results of operation could
    be materially and adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    rely on dividends paid by our subsidiaries for our cash needs,
    and any limitation on the ability of our subsidiaries to make
    payments to us could have a material adverse effect on our
    ability to conduct our business.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We conduct all of our business through our consolidated
    subsidiaries incorporated in China. We rely on dividends paid by
    these consolidated subsidiaries for our cash needs, including
    the funds necessary to pay any dividends and other cash
    distributions to our shareholders, to service any debt we may
    incur and to pay our operating expenses. The payment of
    dividends by entities established in China is subject to
    limitations. Regulations in China currently permit payment of
    dividends only out of accumulated profits as determined in
    accordance with accounting standards and regulations in China.
    Each of our PRC subsidiaries, including wholly foreign-owned
    enterprises, or WFOEs, and joint venture enterprises is also
    required to set aside at least 10% of its after-tax profit based
    on PRC accounting standards each year to its general reserves or
    statutory capital reserve fund until the aggregate amount of
    such reserves reaches 50% of its respective registered capital.
    Our statutory reserves are not distributable as loans, advances
    or cash dividends. We
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    anticipate that in the foreseeable future our PRC subsidiaries
    will need to continue to set aside 10% of their respective
    <FONT style="white-space: nowrap">after-tax</FONT>
    profits to their statutory reserves. In addition, if any of our
    PRC subsidiaries incurs debt on its own behalf in the future,
    the instruments governing the debt may restrict its ability to
    pay dividends or make other distributions to us. Any limitations
    on the ability of our PRC subsidiaries to transfer funds to us
    could materially and adversely limit our ability to grow, make
    investments or acquisitions that could be beneficial to our
    business, pay dividends and otherwise fund and conduct our
    business.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, under the EIT law, the <I>Notice of the State
    Administration of Taxation on Negotiated Reduction of Dividends
    and Interest Rates</I>, or Notice 112, which was issued on
    January&#160;29, 2008, the <I>Arrangement between the PRC and
    the Hong Kong Special Administrative Region on the Avoidance of
    Double Taxation and Prevention of Fiscal Evasion</I>, or the
    Double Taxation Arrangement (Hong Kong), which became effective
    on December&#160;8, 2006, and the <I>Notice of the State
    Administration of Taxation Regarding Interpretation and
    Recognition of Beneficial Owners under Tax Treaties</I>, or
    Notice 601, which became effective on October 27, 2009,
    dividends from our PRC subsidiaries paid to us through our Hong
    Kong subsidiary may be subject to a withholding tax at a rate of
    10%, or at a rate of 5% if our Hong Kong subsidiary is
    considered as a &#147;beneficial owner&#148; that is generally
    engaged in substantial business activities and entitled to
    treaty benefits under the Double Taxation Arrangement (Hong
    Kong). Furthermore, the ultimate tax rate will be determined by
    treaty between the PRC and the tax residence of the holder of
    the PRC subsidiary. We are actively monitoring the proposed
    withholding tax and are evaluating appropriate organizational
    changes to minimize the corresponding tax impact.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Dividends
    we receive from our operating subsidiaries located in the PRC
    may be subject to PRC withholding tax.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The EIT Law provides that a maximum income tax rate of 20% may
    be applicable to dividends payable to non-PRC investors that are
    &#147;non-resident enterprises,&#148; to the extent such
    dividends are derived from sources within the PRC, and the State
    Council has reduced such rate to 10%, in the absence of any
    applicable tax treaties that may reduce such rate, through the
    implementation regulations. We are a Cayman Islands holding
    company and substantially all of our income may be derived from
    dividends we receive from our operating subsidiaries located in
    the PRC. If we are required under the EIT Law to pay income tax
    for any dividends we receive from our subsidiaries, the amount
    of dividends, if any, we may pay to our shareholders and ADS
    holders may be materially and adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to the Double Taxation Arrangement (Hong Kong), Notice
    112 and Notice&#160;601, dividends paid to enterprises
    incorporated in Hong Kong are subject to a withholding tax of 5%
    provided that a Hong Kong resident enterprise owns over 25% of
    the PRC enterprise distributing the dividend and can be
    considered as a &#147;beneficial owner&#148; and entitled to
    treaty benefits under the Double Taxation Arrangement (Hong
    Kong). Thus, as Cyber Medical Network Limited, or Cyber Medical,
    is a Hong Kong company and owns 100% of CMS Hospital Management,
    under the aforementioned arrangement dividends paid to us
    through Cyber Medical by CMS Hospital Management may be subject
    to the 5% income tax if we and Cyber Medical are considered as
    &#147;non-resident enterprises&#148; under the EIT Law and Cyber
    Medical is considered as a &#147;beneficial owner&#148; and
    entitled to treaty benefits under the Double Taxation
    Arrangement (Hong Kong). If Cyber Medical is not regarded as the
    beneficial owner of any such dividends, it will not be entitled
    to the treaty benefits under the Double Taxation Arrangement
    (Hong Kong). As a result, such dividends would be subject to
    normal withholding income tax of 10% as provided by the PRC
    domestic law rather than the favorable rate of 5% applicable
    under the Double Taxation Arrangement (Hong Kong).
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The British Virgin Islands, where OMS, the direct holding
    company of Aohua Medical and Aohua Leasing, is incorporated,
    does not have a tax treaty with the PRC. Thus, if OMS is
    considered a &#147;non-resident enterprise&#148; under the EIT
    law, the 10% withholding tax would be imposed on our dividend
    income received from Aohua Medical and Aohua Leasing.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    be classified as a &#147;resident enterprise&#148; for PRC
    enterprise income tax purposes, which could result in
    unfavorable tax consequences to us and our non-PRC
    shareholders.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The EIT Law provides that enterprises established outside of
    China whose &#147;de facto management bodies&#148; are located
    in China are considered &#147;resident enterprises&#148; and are
    generally subject to the uniform 25% enterprise income tax rate
    on their worldwide income. In addition, a recent circular issued
    by the State Administration of Taxation on April&#160;22, 2009
    regarding the standards used to classify certain
    Chinese-invested enterprises controlled by Chinese enterprises
    or Chinese group enterprises and established outside of China as
    &#147;resident enterprises&#148; clarified that dividends and
    other income paid by such &#147;resident enterprises&#148; will
    be considered to be PRC source income, subject to PRC
    withholding tax, currently at a rate of 10%, when recognized by
    non-PRC enterprise shareholders. This recent circular also
    subjects such &#147;resident enterprises&#148; to various
    reporting requirements with the PRC tax authorities. Under the
    implementation regulations to the enterprise income tax, a
    &#147;de facto management body&#148; is defined as a body that
    has material and overall management and control over the
    manufacturing and business operations, personnel and human
    resources, finances and properties of an enterprise. In
    addition, the recent circular mentioned above sets out criteria
    for determining whether &#147;de facto management bodies&#148;
    are located in China for overseas incorporated, domestically
    controlled enterprises. However, as this circular only applies
    to enterprises established outside of China that are controlled
    by PRC enterprises or groups of PRC enterprises, it remains
    unclear how the tax authorities will determine the location of
    &#147;de facto management bodies&#148; for overseas incorporated
    enterprises that are controlled by individual PRC residents like
    us and some of our subsidiaries. Therefore, although
    substantially all of our management is currently located in the
    PRC, it remains unclear whether the PRC tax authorities would
    require or permit our overseas registered entities to be treated
    as PRC resident enterprises. We do not currently consider our
    company to be a PRC resident enterprise. However, if the PRC tax
    authorities disagree with our assessment and determine that we
    are a &#147;resident enterprise,&#148; we may be subject to
    enterprise income tax at a rate of 25% on our worldwide income
    and dividends paid by us to our non-PRC shareholders as well as
    capital gains recognized by them with respect to the sale of our
    shares may be subject to a PRC withholding tax. This will have
    an impact on our effective tax rate, a material adverse effect
    on our net income and results of operations, and may require us
    to withhold tax on our non-PRC shareholders.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Dividends
    payable by us to our foreign investors and gains on the sale of
    our ADSs or ordinary shares may become subject to taxes under
    PRC tax laws.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the EIT Law and implementation regulations issued by the
    State Council, a 10% PRC income tax is applicable to dividends
    payable to investors that are &#147;non-resident
    enterprises,&#148; which do not have an establishment or place
    of business in the PRC or which have such establishment or place
    of business but have income not effectively connected with the
    establishment or place of business, to the extent such dividends
    are derived from sources within the PRC. Similarly, any gain
    realized on the transfer of ADSs or shares by such investors is
    also subject to a 10% PRC income tax if such gain is regarded as
    income derived from sources within the PRC. It is unclear
    whether dividends paid on our ordinary shares or ADSs, or any
    gain realized from the transfer of our ordinary shares or ADSs,
    would be treated as income derived from sources within the PRC
    and would as a result be subject to PRC tax. If we are
    considered a PRC &#147;resident enterprise,&#148; then any
    dividends paid to our overseas shareholders or ADS holders that
    are &#147;non-resident enterprises&#148; may be regarded as
    being derived from PRC sources and, as a result, would be
    subject to PRC withholding tax at a rate of 10%. In addition, if
    we are considered a PRC &#147;resident enterprise,&#148;
    non-resident enterprise shareholders of our ordinary shares or
    ADSs may be eligible for the benefits of income tax treaties
    entered into between China and other countries. If we are
    required under the EIT Law to withhold PRC income tax on
    dividends payable to our non-PRC investors that are
    &#147;non-resident enterprises,&#148; or if you are required to
    pay PRC income tax on the transfer of our ordinary shares or
    ADSs, the value of your investment in our ordinary shares or
    ADSs may be materially and adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If we
    are found to have failed to comply with applicable laws, we may
    incur additional expenditures or be subject to significant fines
    and penalties.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our operations are subject to PRC laws and regulations
    applicable to us. However, the scope of many PRC laws and
    regulations are uncertain, and their implementation could differ
    significantly in different localities. In certain instances,
    local implementation rules and their implementation are not
    necessarily consistent with the regulations at the national
    level. Although we strive to comply with all applicable PRC laws
    and regulations, we cannot assure you
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    42
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    that the relevant PRC government authorities will not determine
    that we have not been in compliance with certain laws or
    regulations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    face risks related to natural disasters and health epidemics in
    China, which could have a material adverse effect on our
    business and results of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business could be materially and adversely affected by
    natural disasters or the outbreak of health epidemics in China.
    For example, in May 2008, Sichuan Province experienced a strong
    earthquake, measuring approximately 8.0 on the Richter scale,
    that caused widespread damage and casualties. In addition, as
    our network of radiotherapy and diagnostic imaging centers are
    located in hospitals across China, our operations may be
    particularly vulnerable to any health epidemic. In the last
    decade, the PRC has suffered health epidemics related to the
    outbreak of avian influenza and severe acute respiratory
    syndrome, or SARS. In April 2009, an outbreak of the H1N1 virus,
    also commonly referred to as &#147;swine flu&#148;, occurred in
    Mexico and has spread to other countries, including China. If
    the outbreak of swine flu were to become widespread in China or
    increase in severity, it could have an adverse effect on
    economic activity in China, and our business and operations
    could be adversely affected. Any future natural disasters or
    health epidemics in the PRC could also have a material adverse
    effect on our business and results of operations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to This Offering</FONT></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">There
    has been no public market for our ordinary shares or ADSs prior
    to this offering, and you may not be able to resell our ADSs at
    or above the price you paid, or at all.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have received approval to list our ADSs on the NYSE. However,
    prior to this initial public offering, there has been no public
    market for our ordinary shares or ADSs. In addition, our
    ordinary shares will not be listed on any exchange or quoted for
    trading on any over-the-counter trading system. If an active
    trading market for our ADSs does not develop after this
    offering, the market price and liquidity of our ADSs will be
    materially and adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The initial public offering price for our ADSs will be
    determined by negotiations between us and the underwriters and
    may bear no relationship to the market price for our ADSs after
    this initial public offering. We cannot assure you that an
    active trading market for our ADSs will develop or that the
    market price of our ADSs will not decline below the initial
    public offering price.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    market price for our ADSs may be volatile.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The market price for our ADSs is likely to be highly volatile
    and subject to wide fluctuations in response to factors
    including the following:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    announcements of technological or competitive developments;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    regulatory developments in China affecting us or our competitors;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    announcements of studies and reports relating to the
    effectiveness or safety of the services provided in our network
    of centers or those of our competitors;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    actual or anticipated fluctuations in our quarterly operating
    results and changes or revisions of our expected results;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in financial estimates by securities research analysts;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in the economic performance or market valuations of
    other medical services companies;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    addition or departure of our senior management and other key
    personnel;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    release or expiry of
    <FONT style="white-space: nowrap">lock-up</FONT> or
    other transfer restrictions on our outstanding ordinary shares
    or ADSs;&#160;and
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    sales or perceived sales of additional ordinary shares or ADSs.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the securities market has from time to time
    experienced significant price and volume fluctuations that are
    not related to the operating performance of particular
    companies. These market fluctuations may also have a material
    adverse effect on the market price of our ADSs. In the past,
    following periods of volatility in the market
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    43
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    price of a company&#146;s securities, shareholders have often
    instituted securities class action litigation against that
    company. If we were involved in a class action suit or other
    securities litigation, it would divert the attention of our
    senior management, require us to incur significant expense and,
    whether or not adversely determined, could have a material
    adverse effect on our business, financial condition, results of
    operations and prospects.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Because
    the initial public offering price is substantially higher than
    our net tangible book value per share, you will incur immediate
    and substantial dilution.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you purchase ADSs in this offering, you will pay more for
    your ADSs than the amount paid by our existing shareholders for
    their ordinary shares on a per ADS basis. As a result, you will
    experience immediate and substantial dilution of approximately
    US$5.79&#160;per ADS, representing the difference between our
    net tangible book value per ADS as of September&#160;30, 2009
    after giving effect to this offering. In addition, you may
    experience further dilution to the extent that our ordinary
    shares are issued upon the exercise of stock options. See
    &#147;Dilution&#148; for a more complete description.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Substantial
    future sales or perceived sales of our ADSs in the public market
    could cause the price of our ADSs to decline.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sales of our ADSs or ordinary shares in the public market after
    this offering, or the perception that these sales could occur,
    could cause the market price of our ADSs to decline. Upon
    completion of this offering and assuming the underwriters do not
    exercise the option to purchase additional ADSs, we will have
    147,455,500&#160;ordinary shares outstanding, including
    36,000,000&#160;ordinary shares represented by
    12,000,000&#160;ADSs. All ADSs sold in this offering will be
    freely transferable without restriction or additional
    registration under the Securities Act of 1933, as amended, or
    the Securities Act. The remaining ordinary shares outstanding
    after this offering will be available for sale, upon the
    expiration of the
    <FONT style="white-space: nowrap">180-day</FONT>
    <FONT style="white-space: nowrap">lock-up</FONT>
    period beginning from the date of this prospectus, subject to
    volume and other restrictions as applicable under Rule&#160;144
    and Rule&#160;701 under the Securities Act. Any or all of these
    shares may be released prior to expiration of the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period at the discretion of the underwriters. To the extent
    shares are released before the expiration of the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period and these shares are sold into the market, the market
    price of our ADSs could decline. In addition, we have granted
    holders of our Series&#160;A and Series&#160;B contingently
    redeemable convertible preferred shares certain registration
    rights. Such registration rights provide that no later than
    181&#160;days after this offering or the expiration of the
    lock-up agreements entered into in connection with this
    offering, whichever date is later, we shall file a shelf
    registration statement with the SEC covering the resale of all
    of the registrable securities held by such shareholders. We
    shall use our best efforts to cause such shelf registration
    statement to become effective on or prior to the 90th&#160;day
    following the filing of the shelf registration statement and to
    keep such shelf registration statement effective until all of
    the registrable securities held by the holders of our
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares have been resold.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Holders
    of ADSs have fewer rights than shareholders and must act through
    the depositary to exercise those rights.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of ADSs do not have the same rights as our shareholders
    and may only exercise voting rights with respect to the
    underlying ordinary shares in accordance with the provisions of
    the deposit agreement. Under the deposit agreement, if the vote
    is by show of hands, the depositary will vote the deposited
    securities in accordance with the voting instructions received
    from a majority of holders of ADSs that provided timely voting
    instructions. If the vote is by poll, the depositary will vote
    the deposited securities in accordance with the voting
    instructions it timely receives from ADS holders. In the event
    of poll voting, deposited securities for which no instructions
    are received will not be voted. Under our third amended and
    restated articles of association, the minimum notice period
    required to convene a general meeting is seven days. When a
    general meeting is convened, you may not receive sufficient
    notice of a shareholders&#146; meeting to permit you to your
    ordinary shares to allow you to cast your vote with respect to
    any specific matter. In addition, the depositary and its agents
    may not be able to send voting instructions to you or carry out
    your voting instructions in a timely manner. We will make all
    reasonable efforts to cause the depositary to extend voting
    rights to you in a timely manner, but we cannot assure you that
    you will receive the voting materials in time to ensure that you
    can instruct the depositary to vote your shares. Furthermore,
    the depositary and its agents will not be responsible for any
    failure to carry out any instructions to vote, for the manner
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    44
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    in which any vote is cast or for the effect of any such vote. As
    a result, you may not be able to exercise your right to vote and
    you may lack recourse if your ordinary shares are not voted as
    you requested. In addition, in your capacity as an ADS holder,
    you will not be able to call a shareholder meeting.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">You
    may be subject to limitations on transfers of your
    ADSs.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Your ADSs are transferable on the books of the depositary.
    However, the depositary may close its transfer books at any time
    or from time to time when it deems is expedient to do so in
    connection with the performance of its duties. In addition, the
    depositary may refuse to deliver, transfer or register transfers
    of ADSs generally when our books or the books of the depositary
    are closed, or at any time if we or the depositary deem it
    advisable to do so because of any requirement of law or of any
    government or governmental body, or under any provision of the
    deposit agreement, or for any other reason.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Your
    right to participate in any future rights offerings may be
    limited, which may cause dilution to your holdings and you may
    not receive cash dividends if it is impractical to make them
    available to you.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may, from time to time, distribute rights to our
    shareholders, including rights to acquire our securities.
    However, we cannot make any such rights available to you in the
    United States unless we register such rights and the securities
    to which such rights relate under the Securities Act or an
    exemption from the registration requirements is available. Also,
    under the deposit agreement, the depositary bank will not make
    rights available to you unless the distribution to ADS holders
    of both the rights and any related securities are either
    registered under the Securities Act, or exempted from
    registration under the Securities Act. We are under no
    obligation to file a registration statement with respect to any
    such rights or securities or to endeavor to cause such a
    registration statement to be declared effective. Moreover, we
    may not be able to establish an exemption from registration
    under the Securities Act. Accordingly, you may be unable to
    participate in our rights offerings and may experience dilution
    in your holdings.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the depositary has agreed to pay to you the cash
    dividends or other distributions it or the custodian receives on
    our ordinary shares or other deposited securities after
    deducting its fees and expenses. You will receive these
    distributions in proportion to the number of ordinary shares
    your ADSs represent. However, the depositary may, at its
    discretion, decide that it is inequitable or impractical to make
    a distribution available to any holders of ADSs. For example,
    the depositary may determine that it is not practicable to
    distribute certain property through the mail, or that the value
    of certain distributions may be less than the cost of mailing
    them. In these cases, the depositary may decide not to
    distribute such property and you will not receive such
    distribution.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    have not determined any specific use for a portion of the net
    proceeds to us from this offering and we may use such portion of
    the net proceeds in ways with which you may not
    agree.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have not allocated a portion of the net proceeds to us from
    this offering for any specific purpose. Rather, our management
    will have considerable discretion in the application of such
    portion of the net proceeds received by us. See &#147;Use of
    Proceeds.&#148; You will not have the opportunity, as part of
    your investment decision, to assess whether such proceeds are
    being used appropriately. You must rely on the judgment of our
    management regarding the application of such proceeds that we
    receive from this offering. Such proceeds may be used for
    corporate purposes that do not improve our profitability or
    increase our ADS price or may also be placed in investments that
    do not produce income or that may lose value.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    will incur increased costs as a result of being a public
    company.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, we will become a public
    company in the United States. As a public company, we will incur
    significant legal, accounting and other expenses that we did not
    incur as a private company. In addition, the Sarbanes-Oxley Act
    of 2002, or the Sarbanes-Oxley Act, as well as rules and
    regulations implemented by the SEC and the NYSE, require
    significantly heightened corporate governance practices to be
    kept by public companies. We expect that these rules and
    regulations will increase our legal, accounting and financial
    compliance costs and will make certain corporate activities more
    time-consuming and costly. Compliance with these rules and
    requirements may be especially difficult and costly for us
    because we may have difficulty locating sufficient
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    45
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    personnel in China with experience and expertise relating to
    U.S.&#160;GAAP and U.S.&#160;public-company reporting
    requirements, and such personnel may command high salaries
    relative to what similarly experienced personnel would command
    in the United States. If we cannot employ sufficient personnel
    to ensure compliance with these rules and regulations, we may
    need to rely more on outside legal, accounting and financial
    experts, which may be very costly. In addition, we will incur
    additional costs associated with our public company reporting
    requirements. We cannot predict or estimate the amount of
    additional costs that we may incur or the timing of such costs.
    If we fail to comply with these rules and requirements, or are
    perceived to have weaknesses with respect to our compliance, we
    could become the subject of a governmental enforcement action
    and investor confidence could be negatively impacted and the
    market price of our ADSs could decline.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    46
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='103'>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SPECIAL
    NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus contains forward-looking statements that relate
    to our current expectations and views of future events. The
    forward-looking statements are contained principally in the
    sections entitled &#147;Prospectus Summary,&#148; &#147;Risk
    Factors,&#148; &#147;Use of Proceeds,&#148;
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations&#148;, &#147;Our
    Industry&#148; and &#147;Business.&#148; These statements relate
    to events that involve known and unknown risks, uncertainties
    and other factors, including those listed under &#147;Risk
    Factors,&#148; which may cause our actual results, performance
    or achievements to be materially different from any future
    results, performance or achievements expressed or implied by the
    forward-looking statements.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In some cases, these forward-looking statements can be
    identified by words or phrases such as &#147;may,&#148;
    &#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148;
    &#147;aim,&#148; &#147;estimate,&#148; &#147;intend,&#148;
    &#147;plan,&#148; &#147;believe,&#148; &#147;potential,&#148;
    &#147;continue,&#148; &#147;is/are likely to&#148; or other
    similar expressions. We have based these forward-looking
    statements largely on our current expectations and projections
    about future events and financial trends that we believe may
    affect our financial condition, results of operations, business
    strategy and financial needs. These forward-looking statements
    include, among other things, statements relating to:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the risks, challenges and uncertainties in the radiotherapy and
    diagnostic imaging industry and for our business generally;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our beliefs regarding our strengths and strategies;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our current expansion strategy, including our ability to expand
    our network of centers and to establish specialty cancer
    hospitals;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to maintain strong working relationships with our
    hospital partners;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our expectations regarding patients&#146; and their referring
    doctors&#146; demand for and acceptance of the radiotherapy and
    diagnostic imaging services offered by our centers;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in the healthcare industry in China, including changes
    in the healthcare policies and regulations of the PRC government;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    technological or therapeutic changes affecting the field of
    cancer treatment and diagnostic imaging;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to comply with all relevant environmental, health
    and safety laws and regulations;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to obtain and maintain permits, licenses and
    registrations to carry on our business;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our planned use of proceeds;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our future prospects, business development, results of
    operations and financial condition;&#160;and
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    fluctuations in general economic and business conditions in
    China.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The forward-looking statements made in this prospectus relate
    only to events or information as of the date on which the
    statements are made in this prospectus. Except as required by
    law, we undertake no obligation to update or revise publicly any
    forward-looking statements, whether as a result of new
    information, future events or otherwise, after the date on which
    the statements are made or to reflect the occurrence of
    unanticipated events. You should read this prospectus and the
    documents that we reference in this prospectus and have filed as
    exhibits to the registration statement, of which this prospectus
    is a part, completely and with the understanding that our actual
    future results may be materially different from what we expect.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    47
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='104'>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">USE OF
    PROCEEDS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We estimate that we will receive net proceeds from this offering
    of approximately US$113.9&#160;million, after deducting the
    underwriting discounts and commissions and estimated offering
    expenses payable by us. This estimate is based upon an assumed
    initial offering price of US$10.50&#160;per ADS, the midpoint of
    the range shown on the front cover page of this prospectus. A
    US$1.00 increase (decrease) in the assumed initial public
    offering price of US$10.50&#160;per ADS would increase
    (decrease) the net proceeds to us from this offering by
    US$11.2&#160;million, after deducting the estimated underwriting
    discounts and commissions and estimated offering expenses
    payable by us and no other change to the number of ADSs offered
    by us as set forth on the cover page of this prospectus.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to use a portion of the net proceeds we receive from
    this offering for the following purposes:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approximately US$50&#160;million to US$60&#160;million to expand
    our network of centers;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approximately US$25&#160;million to US$30&#160;million to
    develop our Beijing Proton Medical Center; and
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approximately US$20&#160;million to US$25&#160;million to
    develop our Chang&#146;an CMS International Cancer Center.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will use any remaining portion of the net proceeds we receive
    from this offering for general corporate purposes, including
    potential acquisitions of, or investments in, other businesses
    or technologies that we believe will complement our current
    operations and expansion strategies.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The foregoing use of our net proceeds from this offering
    represents our current intentions based upon our present plans
    and business condition. The amounts and timing of any
    expenditure will vary depending on the amount of cash generated
    from our operations, competitive developments and the rate of
    growth, if any, of our business. Accordingly, our management
    will have significant discretion in the allocation of the net
    proceeds we will receive from this offering. Depending on future
    events and other changes in the business climate, we may
    determine at a later time to use the net proceeds for different
    purposes. Pending their use, we intend to place our net proceeds
    in short-term bank deposits.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In utilizing the proceeds of this offering, we, as an offshore
    holding company, are permitted under PRC laws and regulations to
    provide funding to our PRC subsidiaries only through loans or
    capital contributions and to other entities only through loans.
    Subject to satisfaction of applicable government registration
    and approval requirements, we may extend inter-company loans to
    our PRC subsidiaries or make additional capital contributions to
    our PRC subsidiaries to fund their capital expenditures or
    working capital. We cannot assure you that we will be able to
    obtain these government registrations or approvals on a timely
    basis, if at all. See &#147;Risk Factors&#160;&#151; Risks
    Related to Doing Business in China&#160;&#151; PRC regulation of
    loans and direct investment by offshore holding companies to PRC
    entities may delay or prevent us from using the proceeds of this
    offering to make loans or additional capital contributions to
    our PRC subsidiaries.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will not receive any of the proceeds from the sale of the
    ADSs by the selling shareholders.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    48
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='105'>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DIVIDEND
    POLICY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our board of directors has complete discretion on whether to pay
    dividends on our ordinary shares. If our board of directors
    decides to pay dividends on our ordinary shares, the form,
    frequency and amount will depend upon our future operations and
    earnings, capital requirements and surplus, general financial
    condition, contractual restrictions and other factors that the
    board of directors may deem relevant. Shareholders of our
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares are entitled to an annual dividend
    equal to the higher of (a)&#160;the product of the number of
    ordinary shares into which such Series&#160;A and Series&#160;B
    contingently redeemable convertible preferred shares may then be
    converted multiplied by the dividend amount declared on each
    ordinary share or (b)&#160;5% of the original issuance price of
    each Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred share.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2009, we declared a dividend on our
    ordinary shares that amounted to an aggregate of approximately
    US$2.4&#160;million payable to holders of our ordinary shares on
    record as of November&#160;17, 2009. On November&#160;17, 2009,
    we also declared a dividend that amounted to an aggregate of
    approximately US$1.6&#160;million payable to shareholders of our
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares. Dividends declared for our
    ordinary shares and our Series&#160;A and Series&#160;B
    contingently redeemable convertible preferred shares were paid
    on November&#160;27, 2009. Other than such dividends, we have
    never declared or paid any other dividends since our
    incorporation, nor do we have any present plan to pay any cash
    dividends on our ordinary shares in the foreseeable future. We
    currently intend to retain most, if not all, of our available
    funds and any future earnings to operate and expand our
    business. If we pay any dividends, we will pay our ADS holders
    to the same extent as holders of our ordinary shares, subject to
    the terms of the deposit agreement, including the fees and
    expenses payable thereunder. See &#147;Description of American
    Depositary Shares.&#148; Cash dividends on our ordinary shares,
    if any, will be paid in U.S.&#160;dollars.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are a holding company incorporated in the Cayman Islands. In
    order for us to distribute any dividends to our shareholders and
    ADS holders, we will rely on dividends distributed by our PRC
    subsidiaries. Certain payments from our PRC subsidiaries to us
    are subject to PRC taxes, such as withholding income tax. In
    addition, regulations in the PRC currently permit payment of
    dividends of a PRC company only out of accumulated profits as
    determined in accordance with its articles of association and
    the accounting standards and regulations in China. Each of our
    PRC subsidiaries is required to set aside at least 10% of its
    after-tax profit based on PRC accounting standards every year to
    a statutory common reserve fund until the aggregate amount of
    such reserve fund reaches 50% of the registered capital of such
    subsidiary. Such statutory reserves are not distributable as
    loans, advances or cash dividends. Also, our PRC subsidiaries
    may set aside a portion of its after-tax profits to staff
    welfare and bonus funds, which allocated portion may not be
    distributed as cash dividends. The amount to be provided is
    discretionary and is determined by each such subsidiary&#146;s
    ultimate decision-making body each calendar year. Instruments
    governing debt incurred by our PRC subsidiaries may also
    restrict their ability to pay dividends or make other
    distributions to us. See &#147;Risk Factors&#160;&#151; Risks
    Related to Doing Business in China&#160;&#151; We rely on
    dividends paid by our subsidiaries for our cash needs, and any
    limitation on the ability of our subsidiaries to make payments
    to us could have a material adverse effect on our ability to
    conduct our business.&#148; Under PRC tax law, dividends paid
    from our PRC subsidiaries to us through our Hong Kong
    subsidiary, Cyber Medical Network Limited, or Cyber Medical, are
    subject to a 5% withholding tax, provided that such Hong Kong
    subsidiary is not considered to be a PRC tax resident enterprise
    and is considered to be a &#147;beneficial owner&#148; and
    entitled to treaty benefits under the Double Taxation
    Arrangement (Hong Kong). Any dividends paid by our PRC
    subsidiaries to us through our non-Hong Kong subsidiaries
    outside of China will be subject to a 10% withholding tax,
    provided that such subsidiaries outside of China are not
    considered to be a PRC tax resident enterprise. Such withholding
    tax on dividends may be exempted or reduced by the PRC State
    Council. However, if we or our subsidiaries outside of China are
    considered to be a PRC tax resident enterprise
    &#147;domiciled&#148; in the PRC for tax purposes, then any
    dividends we pay to our overseas shareholders or ADS holders
    that are non-PRC resident enterprises may be regarded as income
    derived from sources within the PRC, and as a result subject to
    PRC withholding tax at a rate of up to 10%. The ultimate tax
    rate will be determined by a treaty between the PRC and the tax
    residence of the holder of the PRC subsidiary. For additional
    information, see &#147;Taxation&#160;&#150; People&#146;s
    Republic of China Taxation.&#148; We are actively monitoring
    withholding taxes and evaluating appropriate organizational
    changes to minimize the corresponding tax impact.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    49
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='106'>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CAPITALIZATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our capitalization as of
    September&#160;30, 2009:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on an actual basis; and
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on a pro forma as adjusted basis to reflect (i)&#160;the
    automatic conversion of all our outstanding Series A and B
    contingently redeemable convertible preferred shares into
    41,027,400 of our ordinary shares immediately upon the
    completion of this offering and (ii)&#160;the issuance and sale
    of 36,000,000 ordinary shares represented by 12,000,000 ADSs by
    us in this offering, assuming an initial public offering price
    of US$10.50&#160;per ADS, the midpoint of the estimated range of
    the initial public offering price, after deducting estimated
    underwriting discounts and commissions and estimated aggregate
    offering expenses payable by us and assuming no exercise of the
    underwriters&#146; option to purchase additional ADSs and no
    other change to the number of ADSs sold by us as set forth on
    the cover page of this prospectus.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The pro forma as adjusted information below is illustrative only
    and our capitalization following the completion of this offering
    is subject to adjustment based on the actual initial public
    offering price of our ADSs and other terms of this offering
    determined at pricing. You should read this table together with
    our consolidated financial statements and the related notes
    included elsewhere in this prospectus and the information under
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations.&#148;
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="54%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of September&#160;30, 2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Actual</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Pro Forma as Adjusted</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term bank borrowings, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Obligations under capitalized leases, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;A contingently redeemable convertible preferred
    shares: US$0.01&#160;par value, 200,000&#160;shares authorized;
    176,942&#160;shares issued and outstanding on an actual basis;
    and nil shares issued and outstanding on a pro forma as adjusted
    basis
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    269,017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;B contingently redeemable convertible preferred
    shares: US$0.01&#160;par value, 300,000&#160;shares authorized;
    233,332&#160;shares issued and outstanding on an actual basis;
    and nil shares issued and outstanding on a pro forma as adjusted
    basis
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    434,036
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ordinary shares: US$0.0001&#160;par value,
    450,000,000&#160;shares authorized; 70,428,100&#160;shares
    issued and outstanding on an actual basis; and
    147,455,500&#160;shares issued and outstanding on a pro forma as
    adjusted
    basis<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Additional paid-in
    capital<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,593,708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    379,964
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (592
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (592
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (517,640
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75,831
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (517,640
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75,831
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total shareholders&#146;
    equity<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    591,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,072,139
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    303,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
    capitalization<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,408,266
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    206,303
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,185,770
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    320,203
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">On November&#160;17, 2009, we
    effected a share split whereby all of our issued and outstanding
    704,281 ordinary shares of a par value of US$0.01 per share were
    split into 70,428,100 ordinary shares of US$0.0001 par value per
    share and the number of our authorized  ordinary shares was
    increased from 4,500,000 to 450,000,000. The share split has
    been retroactively reflected in this prospectus so that share
    numbers, per share price and par value data are presented as if
    the share split had occurred from our inception.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Assuming the number of ADSs offered
    by us as set forth on the cover page of this prospectus remains
    the same, and after deduction of underwriting discounts and
    commissions and the estimated offering expenses payable by us, a
    US$1.00 increase (decrease) in the assumed initial public
    offering price of US$10.50&#160;per ADS would increase
    (decrease) each of additional paid-in capital, total
    shareholders&#146; equity and total capitalization by
    US$11.2&#160;million.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    50
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='107'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DILUTION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you invest in our ADSs, your interest will be diluted to the
    extent of the difference between the initial public offering
    price per ADS and our net tangible book value per ADS after this
    offering. Dilution results from the fact that the initial public
    offering price per ordinary share is substantially in excess of
    the book value per ordinary share attributable to the existing
    shareholders for our presently outstanding ordinary shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our net tangible book value as of September&#160;30, 2009 was
    approximately RMB806.4&#160;million (US$118.1&#160;million), or
    RMB7.24 (US$1.06) per ordinary share and US$3.18 per ADS, after
    giving effect to the conversion of all our outstanding Series A
    and B contingently redeemable convertible preferred shares into
    ordinary shares upon the completion of this offering. Net
    tangible book value represents the amount of our total
    consolidated assets, excluding deferred tax assets, deferred IPO
    costs, goodwill and intangible assets, net of total consolidated
    liabilities. Without taking into account any other changes in
    such net tangible book value after September&#160;30, 2009 other
    than to give effect to our sale of the ADSs offered in this
    offering at the assumed initial public offering price of
    $10.50&#160;per ADS, the midpoint of the estimated range of the
    initial public offering price, and after deduction of
    underwriting discounts and commissions and estimated offering
    expenses of this offering payable by us, our adjusted net
    tangible book value as of September&#160;30, 2009 would have
    increased to US$232.0&#160;million or US$1.57&#160;per ordinary
    share and US$4.71&#160;per ADS. This represents an immediate
    increase in net tangible book value of US$0.51&#160;per ordinary
    share and US$1.53&#160;per ADS to the existing shareholders and
    an immediate dilution in net tangible book value of
    US$1.93&#160;per ordinary share and US$5.79&#160;per ADS to
    investors purchasing ADSs in this offering. The following table
    illustrates such per share dilution:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="90%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Estimated initial public offering price per ordinary share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    3.50
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net tangible book value per ordinary share as of
    September&#160;30,
    2009<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    1.06
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amount of dilution in net tangible book value per ordinary share
    to new investors in this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    1.93
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amount of dilution in net tangible book value per ADS to new
    investors in this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    5.79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">After giving effect to the
    conversion of all our outstanding Series A and B contingently
    redeemable convertible preferred shares into ordinary shares
    upon the completion of this offering.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A US$1.00 increase (decrease) in the assumed initial public
    offering price of US$10.50&#160;per ADS would increase
    (decrease) our pro forma net tangible book value after giving
    effect to the offering by US$11.2&#160;million, or by US$0.08
    per ordinary share and by US$0.24 per ADS, assuming no change to
    the number of ADSs offered by us as set forth on the cover page
    of this prospectus, and after deducting underwriting discounts
    and commissions and other expenses of the offering. The pro
    forma information discussed above is illustrative only. Our net
    tangible book value following the completion of this offering is
    subject to adjustment based on the actual initial public
    offering price of our ADSs and other terms of this offering
    determined at pricing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table summarizes, on a pro forma basis as of
    September&#160;30, 2009, the differences between existing
    shareholders and the new investors with respect to the number of
    ordinary shares (in the form of ADSs or shares) purchased from
    us, the total consideration paid and the average price per
    ordinary share and per ADS. In the case of ADS purchased by new
    investors, the consideration and price amounts are paid before
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses, assuming an initial public offering
    price of US$10.50&#160;per ADS, the midpoint of the estimated
    range of the initial public offering price. The total number of
    ordinary shares in the following table does not include ordinary
    shares underlying the ADSs issuable upon the exercise of the
    option to purchase additional ADSs granted to the underwriters.
    The information in the following table is illustrative only and
    the total consideration paid and the average price per ordinary
    share and per ADS for
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    51
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    new investors is subject to adjustment based on the actual
    initial public offering price of our ADSs and the number of
    ordinary shares newly issued and to be sold in this offering as
    determined at pricing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="28%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Ordinary Shares <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Purchased</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total Consideration</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>per Ordinary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Number</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Percent</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Amount</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Percent</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Share</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">per ADSs</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" nowrap align="center" valign="bottom">
    <B>(in thousands, except for percentages)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Existing shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111,456
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75.6
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    115,996
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47.9
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    1.04
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    3.12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    New investors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    126,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    3.50
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    10.50
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147,456
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    241,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Includes US$5.5&#160;million paid
    to OMS, the predecessor entity.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A US$1.00 increase (decrease) in the assumed initial public
    offering price of US$10.50&#160;per ADS would increase
    (decrease) total consideration paid by new investors, total
    consideration paid by all shareholders and the average price per
    ADS paid by all shareholders by US$11.2&#160;million,
    US$11.2&#160;million and US$0.24, respectively, assuming no
    change in the number of ADSs sold by us as set forth on the
    cover page of this prospectus and without deducting underwriting
    discounts and commissions and other expenses of the offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The discussion and tables above also assume no exercise of any
    outstanding share options. As of September&#160;30, 2009, there
    were 1,321,800&#160;ordinary shares available for future
    issuance upon the exercise of future grants under our share
    incentive plan. The number of ordinary shares available for
    future issuance upon the exercise of future grants under our
    share incentive plan was increased to 4,765,800 through an
    amendment to our 2008 share incentive plan on November&#160;17,
    2009. On November&#160;27, 2009, we granted options to purchase
    an aggregate of 4,765,800 ordinary shares under our 2008 share
    incentive plan. To the extent that any of these options are
    exercised, there will be further dilution to new investors.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    52
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='108'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXCHANGE
    RATE INFORMATION</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business is primarily conducted in China and all of our
    revenues are denominated in Renminbi. Periodic reports made to
    shareholders will be expressed in Renminbi with translations of
    Renminbi amounts into U.S.&#160;dollars at the then current
    exchange rate solely for the convenience of the reader.
    Conversions of Renminbi into U.S.&#160;dollars in this
    prospectus are based on, for all dates through December&#160;31,
    2008, at the noon buying rate in the City of New York for cable
    transfers in Renminbi per U.S.&#160;dollar as certified for
    customs purposes by the Federal Reserve Bank of New York, or the
    noon buying rate, and for January&#160;1, 2009 and all later
    dates and periods, the noon buying rate as set forth in the H.10
    statistical release of the Federal Reserve Board. Unless
    otherwise noted, all translations from Renminbi to
    U.S.&#160;dollars and from U.S.&#160;dollars to Renminbi in this
    prospectus were made at a rate of RMB6.8262 to US$1.00, the noon
    buying rate in effect as of September&#160;30, 2009. We make no
    representation that any Renminbi or U.S.&#160;dollar amounts
    could have been, or could be, converted into U.S.&#160;dollars
    or Renminbi, as the case may be, at any particular rate, the
    rates stated below, or at all. The PRC government imposes
    control over its foreign currency reserves in part through
    direct regulation of the conversion of Renminbi into foreign
    exchange and through restrictions on foreign trade. On
    November&#160;27, 2009, the noon buying rate was RMB6.8272 to
    US$1.00.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information concerning exchange
    rates between the RMB and the U.S.&#160;dollar for the periods
    indicated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="53%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Noon Buying Rate</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Period</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Period End</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Average<SUP style="font-size: 85%; vertical-align: top">(1)</SUP></FONT></B>

</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Low</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">High</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom">
    <B>(RMB per US$1.00)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2004
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2768
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2774
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.0702
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.1826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.0702
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2006
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.8041
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.9579
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.0702
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.8041
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.2946
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.5806
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.8127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.2946
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.9193
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.2946
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.7800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009 (through September&#160;30)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8470
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    May
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8227
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8221
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8265
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    June
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8302
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8334
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8371
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8264
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    July
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8319
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.9186
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8342
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    August
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8299
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8323
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8299
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    September
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8303
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    October
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8264
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8292
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8248
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    November (through November&#160;27)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8272
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 9pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Annual averages are calculated from
    month-end rates. Monthly averages are calculated using the
    average of the daily rates during the relevant period.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    53
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='109'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">ENFORCEABILITY
    OF CIVIL LIABILITIES</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are incorporated in the Cayman Islands to take advantage of
    certain benefits associated with being a Cayman Islands exempted
    company, such as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    political and economic stability;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an effective judicial system;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a favorable tax system;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the absence of exchange control or currency restrictions; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the availability of professional and support services.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, certain disadvantages accompany incorporation in the
    Cayman Islands. These disadvantages include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the Cayman Islands has a less developed body of securities laws
    as compared to the United States and provides significantly less
    protection to investors;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Cayman Islands companies do not have standing to sue before the
    federal courts of the United States.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our constituent documents do not contain provisions requiring
    that disputes, including those arising under the securities laws
    of the United States, between us, our officers, directors and
    shareholders, be arbitrated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Substantially all of our current operations are conducted in
    China, and substantially all of our assets are located in China.
    A majority of our directors and officers are nationals or
    residents of jurisdictions other than the United States and a
    substantial portion of their assets are located outside the
    United States. As a result, it may be difficult for a
    shareholder to effect service of process within the United
    States upon us or such persons, or to enforce against us or them
    judgments obtained in United States courts, including judgments
    predicated upon the civil liability provisions of the securities
    laws of the United States or any state in the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have appointed National Registered Agents, Inc. as our agent
    to receive service of process with respect to any action brought
    against us in the United States District Court for the Southern
    District of New York under the federal securities laws of the
    United States or of any state in the United States or any action
    brought against us in the Supreme Court of the State of New York
    in the County of New York under the securities laws of the State
    of New York.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Walkers, our counsel as to Cayman Islands law, and
    Jingtian&#160;&#038; Gongcheng Attorneys At Law, our counsel as
    to PRC law, have advised us, respectively, that there is
    uncertainty as to whether the courts of the Cayman Islands and
    the PRC, respectively, would:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recognize or enforce judgments of United States courts obtained
    against us or our directors or officers predicated upon the
    civil liability provisions of the securities laws of the United
    States or any state in the United States;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    entertain original actions brought in each respective
    jurisdiction against us or our directors or officers predicated
    upon the securities laws of the United States or any state in
    the United States.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Walkers has further advised us that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a final and conclusive judgment in the federal or state courts
    of the United States under which a sum of money is payable,
    other than a sum payable in respect of taxes, fines, penalties
    or similar charges, and which was neither obtained in a waiver
    nor is of a kind of enforcement which is contrary to natural
    justice or the public policy of the Cayman Islands, may be
    subject to enforcement proceedings as a debt in the courts of
    the Cayman Islands under common law; and
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    54
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    it is unlikely that a monetary award ordered by a
    U.S.&#160;court as a result of a fine or a penalty arising under
    the U.S.&#160;federal securities laws would be recognized as
    valid, or enforced, by the courts of the Cayman Islands.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Jingtian&#160;&#038; Gongcheng Attorneys At Law has advised us
    further that the recognition and enforcement of foreign
    judgments are provided for under the PRC Civil Procedures Law.
    PRC courts may recognize and enforce foreign judgments in
    accordance with the requirements of the PRC Civil Procedures Law
    based either on treaties between the PRC and the country where
    the judgment is made or on reciprocity between jurisdictions,
    provided that the foreign judgments do not violate the basic
    principles of laws of the PRC or its sovereignty, security or
    social and public interests. As there is currently no treaty or
    other form of reciprocity between the PRC and the United States
    governing the recognition of judgments, there is uncertainty on
    whether
    <FONT style="white-space: nowrap">and/or</FONT> upon
    what basis a PRC court would enforce judgments rendered by
    courts in the United States.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    55
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='110'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">OUR
    HISTORY AND CORPORATE STRUCTURE</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    History</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Concord Medical was incorporated in the Cayman Islands on
    November&#160;27, 2007 and became our ultimate holding company
    on March&#160;7, 2008, when the shareholders of Ascendium, a
    holding company incorporated in the British Virgin Islands on
    September&#160;10, 2007, exchanged all of their shares for
    shares of Concord Medical. Prior to that, on October&#160;30,
    2007, Ascendium had acquired 100% of the equity interest in Our
    Medical Services, Ltd., or OMS, resulting in a change in
    control. We refer to this transaction as the OMS reorganization
    in this prospectus. Prior to the OMS reorganization, OMS,
    together with Aohua Medical, in which OMS effectively held all
    of the equity interest at the time, operated all of our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aohua Medical was incorporated by OMS on July&#160;23, 1997 and
    OMS contributed RMB4.8&#160;million to Aohua Medical,
    representing 90% of the equity interest in Aohua Medical. The
    other 10% of Aohua Medical was held by two nominees who acted as
    the custodians of such equity interest. On June&#160;10, 2009,
    this 10% equity interest was transferred to our subsidiary
    Shenzhen Aohua Medical Leasing and Services Co., Ltd., or Aohua
    Leasing. The two nominees have not maintained their required
    capital contributions at any time subsequent to the
    incorporation of Aohua Medical. Due to this capital deficiency
    as well as other legal conditions, the two nominees had no legal
    rights to participate either retrospectively or prospectively at
    any time in any profits or losses of Aohua Medical or to share
    in any residual assets or any proceeds in the event that Aohua
    Medical encountered a liquidation event. For these reasons, we
    do not account for this 10% equity interest as a minority
    interest in our consolidated results of operations or financial
    position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, our subsidiary Ascendium acquired 100% of
    the equity interest in China Medstar, a Singapore company,
    together with its wholly owned PRC subsidiary, Medstar
    (Shanghai) Leasing Co., Ltd., or Shanghai Medstar, for
    approximately &#163;17.1&#160;million or approximately
    RMB238.7&#160;million (US$35.0&#160;million). China Medstar,
    through its then subsidiary Shanghai Medstar, engaged in the
    provision of medical equipment leasing and management services
    to hospitals in the PRC. On August&#160;17, 2009, 100% of the
    equity interest in Shanghai Medstar was transferred from China
    Medstar to Ascendium.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;28, 2008, we acquired control of Beijing Xing
    Heng Feng Medical Technology Co., Ltd., or Xing Heng Feng
    Medical, through our subsidiaries Aohua Leasing and CMS Hospital
    Management Co., Ltd., or CMS Hospital Management, by acquiring
    100% of its equity interest, which corresponded to its then
    paid-in registered capital. We paid total consideration of
    approximately RMB35.0&#160;million (US$5.1&#160;million) for
    this acquisition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We currently conduct substantially all of our operations through
    the following subsidiaries in the PRC:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Shenzhen Aohua Medical Services Co., Ltd., our wholly owned
    subsidiary incorporated in the PRC that engages in the provision
    of radiotherapy and diagnostic center management services to
    hospitals in the PRC;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Shenzhen Aohua Medical Leasing and Services Co., Ltd., our
    wholly owned subsidiary incorporated in the PRC that engages in
    the provision of radiotherapy and diagnostic equipment leasing
    services to hospitals in the PRC;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Medstar (Shanghai) Leasing Co., Ltd., our wholly owned
    subsidiary incorporated in the PRC that engages in the sale of
    medical equipment and the provision of radiotherapy and
    diagnostic equipment leasing and management services to
    hospitals in the PRC;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    CMS Hospital Management Co., Ltd., our wholly owned subsidiary
    incorporated in the PRC that engages in the provision of
    radiotherapy and diagnostic equipment management services to
    hospitals in the PRC;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Beijing Xing Heng Feng Medical Technology Co., Ltd., our wholly
    owned subsidiary incorporated in the PRC that engages in the
    provision of radiotherapy and diagnostic equipment management
    services to hospitals in the PRC.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    56
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Corporate Structure</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following diagram illustrates our corporate structure and
    the place of organization of each of our subsidiaries as of the
    date of this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611a4h0361101.gif" alt="">
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    57
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='111'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SELECTED
    CONSOLIDATED FINANCIAL AND OPERATING DATA</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following tables set forth the selected consolidated
    financial and operating data of us and our predecessor, OMS, for
    the periods indicated. Concord Medical was incorporated on
    November&#160;27, 2007. On March&#160;7, 2008, the shareholders
    of Ascendium exchanged their shares in Ascendium for shares of
    Concord Medical at the rate of 10&#160;shares in Concord Medical
    for one share in Ascendium. As a result, Concord Medical became
    our ultimate holding company. Our financial statements have been
    prepared as if the current corporate structure had been in
    existence from September&#160;10, 2007, the date on which
    Ascendium was incorporated. Prior to the OMS reorganization,
    which became effective on October&#160;30, 2007, OMS, together
    with Aohua Medical, in which OMS effectively held all of the
    equity interest at the time, operated all of the business of our
    company. As a result of the OMS reorganization, there was a
    change in control of OMS with the Ascendium shareholders
    effectively acquiring OMS from the OMS shareholders. For
    additional information relating to our history and
    reorganization, see &#147;Our History and Corporate
    Structure.&#148; For financial statements reporting purposes,
    OMS is deemed to be the predecessor reporting entity for periods
    prior to October&#160;30, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following selected consolidated statements of operations and
    other consolidated financial data for the period from
    January&#160;1, 2007 to October&#160;30, 2007, for the period
    from September&#160;10, 2007 to December&#160;31, 2007 and for
    the year ended December&#160;31, 2008 (other than the income
    (loss) per ADS data) and the selected consolidated balance sheet
    data as of December&#160;31, 2007 and 2008 have been derived
    from our audited consolidated financial statements, which are
    included elsewhere in this prospectus. The following selected
    consolidated statements of operations for the year ended
    December&#160;31, 2006 and the selected consolidated balance
    sheet data as of December&#160;31, 2006 have been derived from
    our unaudited consolidated financial statements, which are not
    included in this prospectus. The following selected consolidated
    statements of operations and other consolidated financial data
    for the nine months ended September&#160;30, 2008 and 2009
    (other than the income (loss) per ADS data) and selected
    consolidated balance sheet data as of September&#160;30, 2009
    have been derived from our unaudited interim condensed
    consolidated financial statements, which are included elsewhere
    in this prospectus. We have prepared the unaudited interim
    condensed consolidated financial statements on the same basis as
    our audited consolidated financial statements. The unaudited
    interim condensed consolidated financial statements include all
    adjustments, consisting only of normal and recurring
    adjustments, which we consider necessary for a fair presentation
    of our financial position and operating results for the periods
    presented. You should read the selected consolidated financial
    data in conjunction with those financial statements and the
    related notes and &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations&#148;
    included elsewhere in this prospectus. Our historical results do
    not necessarily indicate our results expected for any future
    periods. Our consolidated financial statements are prepared and
    presented in accordance with U.S.&#160;GAAP. The consolidated
    financial statements of each of us and our predecessor are
    prepared and presented in accordance with U.S.&#160;GAAP. Our
    historical results are not necessarily indicative of our results
    expected for any future periods.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    58
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="31%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD colspan="33" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Nine Months Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>October&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="31" nowrap align="center" valign="bottom">
    <B>(in thousands, except share, per share and per ADS data) </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    <B>Selected Consolidated Statements of Operations Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Revenues, net of business tax, value-added tax and related
    surcharges:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 15pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61,440
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,716
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,092
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 15pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    876
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 15pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,422
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    205,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 15pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,388
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,396
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,046
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,669
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (42,144
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,174
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 15pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,003
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,388
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,987
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 15pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,412
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,416
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,914
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,597
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,680
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,361
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (62,541
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,162
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Gross profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,904
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,632
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143,116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 15pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,267
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,601
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (757
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (805
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,275
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,463
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (654
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 15pt">
    General and administrative
    expenses<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,600
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,467
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (57,171
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,764
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,468
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,687
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,884
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Operating income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,037
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,938
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (47,859
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,710
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (954
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (279
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,455
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,092
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,293
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,880
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (715
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (341
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (325
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (218
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    (Loss) gain from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (469
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    392
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    823
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Other income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income (loss) before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,926
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,627
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,691
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income tax (expenses) benefit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,097
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,418
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,611
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,734
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,770
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Net income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,343
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (39,604
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (262,286
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,851
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (44,646
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (38,383
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,623
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Net income (loss) attributable to ordinary shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (496,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72,667
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (222,270
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,914
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income (loss) per share&#160;&#151; basic and
    diluted<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.97
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.26
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.06
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income (loss) per ADS&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.02
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.91
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25.89
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.78
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11.01
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Shares used in computation&#160;&#151; basic and
    diluted<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,621,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    ADSs used in computation&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,666,667
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,666,667
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,666,667
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,160,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,160,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,207,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,476,033
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,476,033
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Our general and administrative
    expenses include share-based compensation expenses related to
    certain share options granted in 2007 that amounted to
    RMB49.5&#160;million, RMB4.2&#160;million (US$0.6&#160;million)
    and RMB4.2&#160;million in 2007, 2008 and for the nine months
    ended September&#160;30, 2008, respectively. We did not
    recognize any share-based compensation expenses in 2006 and for
    the nine months ended September&#160;30, 2009.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"> On November&#160;17, 2009, we
    effected a share split whereby all of our issued and outstanding
    704,281 ordinary shares of a par value of US$0.01 per share were
    split into 70,428,100 ordinary shares of US$0.0001 par value per
    share and the number of our authorized ordinary shares was
    increased from 4,500,000 to 450,000,000. The share split has
    been retroactively reflected in this prospectus so that share
    numbers, per share price and par value data are presented as if
    the share split had occurred from our inception.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    59
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Selected Consolidated Balance Sheet Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    285,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,333
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,135
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    492,978
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72,219
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    466,487
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Property, plant and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    231,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    349,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,661
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Acquired intangible assets, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    181,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,450
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    256,330
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543,023
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,673,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Long-term bank borrowings, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,836
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Long-term bank borrowings, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Series&#160;A contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    269,017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Series&#160;B contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    434,036
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total shareholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    134,264
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    591,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total liabilities and shareholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    256,330
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543,023
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,673,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="23%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="29" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>October&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Year Ended December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Selected Consolidated Statements of Cash Flow Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,774
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,308
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash used in investing
    activities<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (50,452
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30,441
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (376,371
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (55,136
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (300,692
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (223,426
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32,731
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    649,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95,147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    278,407
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,448
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,698
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (834
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,949
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (191
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net increase (decrease) in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    314,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (864
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68,288
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,004
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Net cash used in investing
    activities in 2008 and for the nine months ended September 30,
    2008 and 2009 includes acquisition, net of cash acquired, of
    RMB231.5&#160;million (US$33.9&#160;million).
    RMB219.2&#160;million and RMB21.5&#160;million
    (US$3.2&#160;million), respectively.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    60
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="48%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As of September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<B><FONT style="font-size: 9pt">Operating
Data</FONT></B><FONT style="font-size: 9pt"><SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Number of primary medical equipment owned:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Linear accelerators
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Head gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Body gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    PET-CT scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    MRI scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Others<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;64
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;81
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="48%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Number of patient cases treated or diagnosed by our primary
    medical equipment:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Linear accelerators
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    697
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,554
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Head gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,455
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Body gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,635
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,057
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,706
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    PET-CT scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,766
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    MRI scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,830
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,827
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="29%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD colspan="26" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from <BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>September&#160;1,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>Nine Months <BR>
    </B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>to October&#160;30,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Ended September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD colspan="26" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="24" nowrap align="center" valign="bottom">
    <B>(in RMB thousands)</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total net revenues generated by our primary medical equipment
    under lease and management services arrangements:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Linear accelerators
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,206
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    877
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,506
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,588
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Head gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,408
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,139
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Body gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,537
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,102
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,071
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    PET-CT scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    578
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,289
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    MRI scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,899
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    437
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,123
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,515
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,618
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Others<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    391
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,423
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,755
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,970
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Total net revenues&#160;&#151; lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Excluding data from seven, eight
    and two centers under service-only agreements as of
    December&#160;31, 2007, December&#160;31, 2008 and
    September&#160;30, 2009, respectively.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Including a MM50
    intensity-modulated radiation therapy system.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Other primary medical equipment
    used includes CT scanners and ECT scanners for diagnostic
    imaging, electroencephalography for the diagnosis of epilepsy,
    thermotherapy to increase the efficacy of and for pain relief
    after radiotherapy and chemotherapy, high intensity focused
    ultrasound therapy for the treatment of cancer, stereotactic
    radiofrequency ablation for the treatment of Parkinson&#146;s
    Disease and refraction and tonometry for the diagnosis of
    ophthalmic conditions.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    61
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='112'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANAGEMENT&#146;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION<BR>
    AND RESULTS OF OPERATIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>You should read the following discussion and analysis of our
    financial condition and results of operations in conjunction
    with the section entitled &#147;Selected Consolidated Financial
    Data&#148; and our consolidated financial statements and the
    related notes included elsewhere in this prospectus. This
    discussion contains forward-looking statements that involve
    risks and uncertainties. Our actual results and the timing of
    selected events could differ materially from those anticipated
    in these forward-looking statements as a result of various
    factors, including those set forth under &#147;Risk
    Factors&#148; and elsewhere in this prospectus.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Concord Medical was incorporated on November&#160;27, 2007. On
    March&#160;7, 2008, the shareholders of Ascendium exchanged
    their shares in Ascendium for shares of Concord Medical. As a
    result, Concord Medical became our ultimate holding company. Our
    financial statements have been prepared as if the current
    corporate structure had been in existence from
    September&#160;10, 2007, the date on which Ascendium was
    incorporated. Prior to the OMS reorganization, which became
    effective on October&#160;30, 2007, OMS, together with Aohua
    Medical, in which OMS effectively held all of the equity
    interest at the time, operated all of the business of our
    company. As a result of the OMS reorganization, there was a
    change in control of OMS with the Ascendium shareholders
    effectively acquiring OMS from the OMS shareholders. For
    additional information relating to our history and
    reorganization, see &#147;Our History and Corporate
    Structure.&#148; In our discussion for the year ended
    December&#160;31, 2007, we refer to certain financial statement
    line items as &#147;combined&#148; for comparative purposes,
    which do not comply with U.S.&#160;GAAP. The unaudited combined
    amounts represent the addition of the amounts for certain
    financial statement line items of OMS, our predecessor, for the
    period from January&#160;1, 2007 to October&#160;30, 2007, and
    the amounts for the corresponding line items of Concord Medical
    for the period from September&#160;10, 2007 to December&#160;31,
    2007. We have included these unaudited combined amounts as we
    believe they are helpful for the reader to gain a better
    understanding of results of operations for a complete fiscal
    year and to improve the comparative analysis against the results
    of operations for the year ended December&#160;31, 2008. These
    unaudited combined amounts do not purport to represent what our
    financial position, results of operations or cash flows would
    have been if our reorganization had occurred on January&#160;1,
    2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We operate the largest network of radiotherapy and diagnostic
    imaging centers in China in terms of revenues and the total
    number of centers in operation in 2008, according to a report by
    Frost&#160;&#038; Sullivan commissioned by us that compared our
    pro forma revenues against the revenues of our competitors in
    2008 and our number of centers and units of equipment against
    those of our competitors as of the end of 2008. Most of the
    centers in our network are established through long-term lease
    and management services arrangements typically ranging from six
    to 20&#160;years entered into with hospitals. Under these
    arrangements, we receive a contracted percentage of each
    center&#146;s revenue net of specified operating expenses. Such
    contracted percentages typically range from 50% to 90% and are
    adjusted based on a declining scale over the term of the
    arrangement but in certain circumstances, are fixed for the
    duration of the arrangement. Each center is located on the
    premises of our hospital partners and is typically equipped with
    a primary unit of advanced radiotherapy or diagnostic imaging
    equipment, such as a linear accelerator, head gamma knife
    system, body gamma knife system, PET-CT scanner or MRI scanner.
    We manage each center jointly with our hospital partner and we
    purchase the medical equipment used in our network of centers
    and lease such equipment to our hospital partners.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To complement our organic growth, we have also selectively
    acquired businesses to expand our network. In July 2008, we
    acquired China Medstar, a company then publicly listed on the
    AIM, for approximately &#163;17.1&#160;million or approximately
    RMB238.7&#160;million (US$35.0&#160;million). At the time of the
    acquisition, China Medstar jointly managed 23 centers with its
    hospital partners across 14&#160;cities in China. In addition to
    our acquisition of China Medstar, we have also acquired other
    businesses in 2008, including Xing Heng Feng Medical, a company
    that managed two centers providing
    <FONT style="white-space: nowrap">PET-CT</FONT> scan
    diagnosis with its hospital partners, in October 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To further enhance our reputation as a leading provider of
    radiotherapy treatment service and attract high quality doctors,
    we plan to establish and operate specialty cancer hospitals in
    China. Our first specialty cancer hospital, the Chang&#146;an
    CMS International Cancer Center, in Xi&#146;an, Shaanxi
    Province, is expected to commence
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    62
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    operation in early 2010. In addition, we are in the process of
    establishing another specialty cancer hospital, the Beijing
    Proton Medical Center, which is expected to commence operation
    in 2012.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business has grown significantly in recent years through
    development of new centers, increases in the number of patient
    cases in our network and acquisitions. We have increased the
    number of centers in our network from 41 at the end of 2007 to
    72&#160;at the end of 2008 and to 83 as of September&#160;30,
    2009. Our total net revenues were RMB67.4&#160;million,
    RMB14.0&#160;million and RMB171.8&#160;million
    (US$25.2&#160;million) for the period from January&#160;1, 2007
    to October&#160;30, 2007, the period from September&#160;10,
    2007 to December&#160;31, 2007 and in 2008, respectively. Our
    total net revenues in 2008 on a pro forma basis, which gives
    effect to our acquisition of China Medstar as if it had been
    completed on January&#160;1, 2008, were RMB234.7&#160;million
    (US$34.4&#160;million). Our total net revenues increased to
    RMB205.7&#160;million (US$30.1&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB102.0&#160;million for the
    same period in 2008, due primarily to an increase in the number
    of centers in our network, including centers added to our
    network as a result of our acquisition of China Medstar, and an
    increase in the number of patient cases in existing centers. On
    a pro forma basis, which gives effect to our acquisition of
    China Medstar as if it had been completed on January 1, 2008,
    our total net revenues for the nine months ended
    September&#160;30, 2008 were RMB164.9&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Factors
    Affecting Our Results of Operations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our financial performance and results of operations are
    generally affected by the number of cancer patients in China.
    According to a report by Frost&#160;&#038; Sullivan, patients
    diagnosed with cancer in China increased from approximately
    2.8&#160;million patients in 2003 to 3.5&#160;million patients
    in 2008. Frost&#160;&#038; Sullivan further estimates that new
    cancer cases will increase to approximately 4.1&#160;million in
    China in 2015. Based on a survey conducted by the MOH, the
    increase in cancer cases is primarily attributable to
    demographic changes and urbanization. With the continued
    increase in disposable income, government healthcare spending
    and medical insurance coverage, there has been a considerable
    increase in demand for cancer diagnosis and treatments and we
    have been able to grow our business significantly by providing
    high quality radiotherapy and diagnostic imaging services in
    China to address such needs. In addition, public hospitals
    generally lack the financial resources to purchase, or the
    expertise to operate, radiotherapy and diagnostic imaging
    centers. Such factors combined have contributed favorably to the
    growth of our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the radiotherapy and diagnostic imaging market
    will continue to be favorable in the future. However, changes in
    the cancer treatment market in China, whether due to changes in
    government policy or any decrease in the number of cancer cases
    treated by radiotherapy in China, may have an adverse effect on
    our results of operations. See &#147;Regulation of Our
    Industry.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to general industry and regulatory factors, our
    financial performance and results of operations are affected by
    company-specific factors. We believe that the most significant
    of these factors are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to expand our network of centers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the number of patient cases treated in our network;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the operational arrangements with our hospital partners;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the range and mix of services provided in our network;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of our medical equipment.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    Ability to Expand Our Network of Centers</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our ability to expand our network of centers is one of the most
    important factors affecting our results of operation and
    financial condition. Historically, our business growth has been
    primarily driven by developing new centers through entering into
    new arrangements with hospital partners or acquisitions from
    third parties and we expect this to continue to be the key
    driver for our future growth. Each additional center that we
    develop increases the number of patient cases treated in our
    network and contributes to our continued revenue growth.
    However, new centers developed through our entering into new
    arrangements with hospital partners generally involve a ramp-up
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    63
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    period during which time the operating efficiency of such
    centers may be lower than that of our established centers, which
    may negatively affect our profitability. In addition, if we
    establish additional centers through acquisition, our acquired
    intangible assets will increase and the resulting amortization
    expenses may, to a significant extent, offset the benefit of the
    increase in revenues generated from centers established through
    acquisitions. Further, other factors such as the financial
    resources and know-how of hospitals in China to purchase medical
    equipment directly and to operate radiotherapy and diagnostic
    imaging centers independently, and the number of units of
    radiotherapy and diagnostic imaging equipment that are allocated
    by the PRC government for purchase, will also affect our ability
    to expand our network. Our ability to expand our network will
    depend on a number of factors, such as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the reputation of our existing network of centers and doctors
    providing services in our network of centers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our financial resources;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to timely establish and manage new centers in
    conjunction with our hospital partners;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our relationship with our hospital partners.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2008, we added 32 new centers under lease and management
    services arrangements, of which 25 were added through various
    acquisitions in 2008. During the nine months ended
    September&#160;30, 2009, we added 19 new centers to our network
    under similar lease and management services arrangements, five
    of which were converted in August 2009 from six centers that
    were previously managed under service-only agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Number of Patient Cases Treated in Our Network</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Increasing the number of patient cases diagnosed and treated at
    our existing centers is important for the continued growth of
    our business. The number of patient cases is primarily driven by
    doctor referrals. Doctors decide whether to refer patients to
    centers in our network based on factors such as the reputation
    of the center, the location of the center and the reputation of
    the doctors who provide services in the center. In addition, the
    referring doctors&#146; awareness of the efficacy and benefits
    of radiotherapy treatments and their preference as to other
    cancer treatment methods also contribute to their willingness to
    refer cases for diagnosis and treatment to the centers in our
    network. Accordingly, we have focused our marketing efforts on
    increasing referring doctors&#146; awareness of the efficacy of
    radiotherapy treatments and the advantages of the treatment
    options available to their patients in our network of centers.
    There is also typically a
    <FONT style="white-space: nowrap">ramp-up</FONT>
    period for newly established centers during which time
    acceptance by doctors and patients of such new centers gradually
    pick up and the number of patient cases increase.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Operational Arrangements with Our Hospital
    Partners</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The majority of our total net revenues is derived from our lease
    and management services arrangements with our hospital partners
    which typically range from six to 20&#160;years and under which
    we receive a contracted percentage of each center&#146;s revenue
    net of specified operating expenses. Such contracted percentages
    typically ranges from 50% to 90% and are typically adjusted
    based on a declining scale over the term of the arrangement but
    in certain circumstances, are fixed for the duration of the
    arrangement. In the event that specified operating expenses
    exceed the revenues of the center, we would collect no revenues
    from such center. As a result, our ability to negotiate a higher
    contracted percentage and our ability to contain operating
    expenses will have a significant effect on our revenues and
    profitability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In negotiations with hospitals as to our contracted percentage,
    we consider factors such as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the size and location of potential hospital partner;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the length of the arrangement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the type of medical equipment to be installed in the
    hospital&#146;s center;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the capabilities of the doctors that will provide services at
    the centers;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the potential growth of such center.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    64
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our ability to achieve a higher contracted percentage also
    depends on our bargaining power relative to our potential
    hospital partners and on the purchase price of the medical
    equipment to be used at the new centers. We believe that our
    contracted percentage of centers&#146; revenue for new
    arrangements will generally decline over time as the purchase
    prices of the primary medical equipment used in our network of
    centers decrease due to technological advancement and increased
    competition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also provide management services to a small number of centers
    through service-only agreements where we receive a management
    fee equal to a contracted percentage of each center&#146;s
    revenue net of specified operating expenses. Such service-only
    agreements typically increase our profitability as we do not own
    the medical equipment used by such centers, and thus do not
    incur the associated depreciation expenses. However,
    service-only agreements are usually short-term in nature, and
    the risk of non-renewal of such agreements is high. We also
    typically receive a lower contracted percentage under such
    service-only agreements compared to the percentage we receive
    from centers managed under lease and management services
    arrangements. Accordingly, we do not intend to substantially
    increase the number of service-only agreements in the future. In
    addition, we have in August 2009 converted six centers under
    service-only agreements to five centers managed under lease and
    management services arrangements by purchasing from
    Chang&#146;an Hospital Co., Ltd., or Chang&#146;an Hospital, six
    units of radiotherapy and diagnostic imaging equipment that were
    located at the six centers managed under service-only agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Further, we are also currently in the process of establishing
    specialty cancer hospitals that will be majority owned and
    operated by us. For such hospitals, we will need to hire a
    significant number of medical and other personnel and incur
    other
    <FONT style="white-space: nowrap">start-up</FONT>
    costs that will result in an increase in our operating expenses
    without a corresponding increase in revenues during the initial
    <FONT style="white-space: nowrap">ramp-up</FONT>
    period. As a result, our profitability may be negatively
    affected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Range and Mix of Services Provided in Our Network</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The medical service fees charged for the services provided in
    our network of centers vary by the type of medical equipment
    used as well as the provinces or regions in China in which such
    centers are located due to the varying applicable price
    ceilings. Medical service fees in China are subject to
    government controlled price ceilings established by the relevant
    government authorities in the different provinces and regions.
    See &#147;Risk Factors&#160;&#151; Risks Related to Our
    Industry&#160;&#151; Pricing for the services provided by our
    network of centers may be adversely affected by reductions in
    treatment and examination fees set by the Chinese
    government&#148;&#160;and &#147;Regulation of Our
    Industry&#160;&#151; Pricing of Medical Services.&#148; The
    maximum medical service fees for the same treatment using the
    same equipment may differ between provinces and regions. Centers
    established in provinces or regions with a significantly higher
    price ceiling may result in an increase in our revenues derived
    from such centers and higher profit margin for the centers,
    resulting in an increase in our profitability. In addition,
    certain medical services allow us to charge higher fees than
    other types of medical services. For example, medical service
    fees for treatments provided through head gamma knife systems
    typically range from approximately RMB9,000 to RMB20,000 per
    patient case, with each treatment lasting one session for
    approximately 10 to 30 minutes, medical service fees for
    treatments provided through body gamma knife systems typically
    range from approximately RMB12,500 to RMB25,000 per patient
    case, with each treatment lasting five to 10 sessions and 10 to
    20 minutes each, and medical service fees for treatments
    provided through linear accelerators range from approximately
    RMB8,000 to RMB20,000 per patient case, with each treatment
    lasting from 20 to 40 sessions and 10 to 20 minutes each. In
    addition, linear accelerators can be integrated with specialized
    computer software and advanced imaging and detection equipment
    to provide more effective and advanced treatments such as
    three-dimensional conformal radiation therapy, which
    significantly increase the medical service fees per treatment.
    Furthermore, diagnostic imaging services typically have a lower
    profit margin than radiotherapy treatment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Cost of Our Medical Equipment</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Depreciation expense associated with the medical equipment that
    we purchase and use in the centers represents a significant
    portion of our cost of revenues. Our ability to reduce the price
    of medical equipment purchased, thereby reducing the
    depreciation expense associated with the medical equipment
    purchased, will serve to increase our profitability. Our
    extensive network of centers has provided us with increased
    bargaining power with equipment manufacturers. We have entered
    into strategic agreements with certain medical equipment
    manufacturers in order to lower the average cost of our
    equipment. Such agreements provide that we will
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    65
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    receive preferential pricing if we purchase a certain number of
    units of equipment from a manufacturer within a given period of
    time. However, we are not required by such agreements to commit
    to purchase a minimum number of units of equipment from such
    manufacturers or precluded from purchasing equipment from other
    manufacturers. We aim to continue to enter into additional
    strategic agreements with medical equipment manufacturers to
    further reduce the cost of our equipment in the future.
    Furthermore, we expect the purchase prices of our primary
    medical equipment to decrease over time as a result of
    technological advancement and increased competition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Financial
    Impact of Our Reorganization and Acquisitions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to the OMS reorganization on October&#160;30, 2007, OMS,
    together with Aohua Medical, in which OMS effectively held all
    of the equity interest at the time, operated all of our
    business. As part of the OMS reorganization, there was a change
    in control of OMS whereby the Ascendium shareholders effectively
    acquired OMS from the OMS shareholders through the issuance of
    Ascendium shares. For financial statements reporting purposes,
    OMS is deemed to be our predecessor reporting entity for periods
    prior to October&#160;30, 2007. The purchase price for the
    acquisition was determined to be RMB393.4&#160;million
    (US$57.6&#160;million), which represented the fair value of the
    Ascendium shares issued as consideration to the OMS
    shareholders. This transaction established a new basis of
    accounting with the purchase price allocated to OMS&#146;s
    tangible and identifiable intangible assets and liabilities
    based on their estimated fair value as of October&#160;30, 2007,
    including RMB259.3&#160;million as to goodwill,
    RMB132.0&#160;million as to other intangible assets&#160;&#151;
    customer relationships and operating leases and
    RMB53.8&#160;million (new basis) in property, plant and
    equipment. The effect of the new basis includes the reduction of
    the book value of medical equipment used in our network of
    centers to their fair value as at October&#160;30, 2007, which
    reduces the depreciation expenses of the medical equipment, and
    results in an incremental amortization expense of the acquired
    intangible assets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We completed the following acquisition of four businesses in
    2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    China Medstar in July 2008 for approximately
    &#163;17.1&#160;million or approximately RMB238.7&#160;million
    (US$35.0&#160;million);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Xing Heng Feng Medical in October 2008 for approximately
    RMB35.0&#160;million (US$5.1&#160;million);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    certain medical equipment located in Tianjin People&#146;s
    Liberation Army 272 Hospital and the related business from a
    third party for RMB14.0&#160;million
    (US$2.1&#160;million);&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    certain medical equipment located in People&#146;s Liberation
    Army 254 Hospital and the related business from another third
    party for RMB4.0&#160;million (US$0.6&#160;million).
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The consideration paid for each acquisition was allocated to the
    net assets acquired at estimated fair value, with the acquired
    intangible assets amortized over the period of expected benefits
    to be realized. The results of operations of China Medstar were
    consolidated into our results of operations commencing in August
    2008 and the results of operations of Xing Heng Feng Medical
    were consolidated into our results of operations commencing in
    November 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Revenues</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The majority of our revenues are directly related to the number
    of patient cases treated in our network. We receive a contracted
    percentage of each center&#146;s revenue net of specified
    operating expenses. Such revenues are derived from medical
    service fees received by our hospital partners for the services
    provided in the centers. The specified operating expenses of
    centers typically include variable expenses, such as salaries
    and benefits of the medical and other personnel at the center,
    the cost of medical consumables, marketing expenses, training
    expenses, utility expenses and routine equipment repair and
    maintenance expenses. Corporate level expenses that cannot be
    directly attributable to one center are typically accounted for
    as our cost of revenues. In addition, under certain lease and
    management services arrangements with our hospital partners,
    certain of the center-incurred expenses may be accounted for as
    our cost of revenues rather than as the expenses of the centers.
    Our contracted percentages typically range from 50% to 90% and
    are typically adjusted on a declining scale over the term of the
    arrangement. In certain circumstances, the contracted
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    66
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    percentage is fixed for the duration of the arrangement.
    Revenues derived from such centers are accounted for as
    &#147;lease and management services&#148; on our consolidated
    statement of operation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also provide management services to a limited number of
    centers through service-only agreements under which the medical
    equipment is owned by the hospital or other third parties. We
    typically receive a management fee from each center equal to a
    contracted percentage of the center&#146;s revenue net of
    specified operating expenses. We also provide management
    services to Chang&#146;an Hospital through a service-only
    agreement under which we receive a management fee equal to a
    percentage of the total revenues of the general hospital.
    Revenues derived from providing management services through
    service-only agreements are accounted for as &#147;management
    services&#148; on our consolidated statement of operation. As of
    September&#160;30, 2009, we managed two centers under
    service-only agreements. We converted six centers managed under
    service-only agreements in August 2009 to five centers managed
    under lease and management services arrangement by purchasing
    the medical equipment housed in the six centers. As a result, we
    expect our total net revenues from management services to
    decrease in the near future due to a decrease in the number of
    centers under service-only agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also generate revenues, which are reported as net, from the
    sale of medical equipment we have purchased to hospitals and
    receive commissions from manufacturers for acting as their agent
    for the sale of such medical equipment to hospitals. We
    typically enter into a separate purchase agreement with
    manufacturers or the distributors of such manufacturers each
    time we purchase medical equipment for sale.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth the breakdown of our total net
    revenues for the periods indicated:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="23%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=11 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=11 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=11 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=11 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B><SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="38" align="center" valign="bottom">
    (in thousands, except for percentages)
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,716
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,092
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,322
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,405
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    205,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represent the addition of the
    amounts for the specific line items of OMS, our predecessor, for
    the period from January&#160;1, 2007 to October&#160;30, 2007,
    and the amounts for the corresponding line items of Concord
    Medical for the period from September&#160;10, 2007 to
    December&#160;31, 2007. For the period from September&#160;10,
    2007, the date of inception of Ascendium, to October&#160;30,
    2007, during which period the financial statements of our
    predecessor and those of Concord Medical overlap, Ascendium did
    not engage in any business or operations. The unaudited combined
    financial data for the year ended December&#160;31, 2007 do not
    comply with U.S. GAAP.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Fees for medical services provided at the centers are paid
    directly to our hospital partners by patients and we are not
    responsible for patient billing and fee collection. Medical
    service fees in China are typically paid in full upfront by
    patients prior to receiving services. Generally, patients claim
    reimbursements, if any is available under the applicable public
    or private medical insurance plans. As a result, hospitals do
    not generally experience bad debt problems. However, the
    healthcare reform announced by the PRC government in January
    2009 has introduced pilot public medical insurance plans. Under
    these plans patients are only responsible for paying their
    deductible amounts upfront and hospitals are responsible for
    seeking reimbursements from the relevant government authorities
    after the treatments are provided. Certain of the hospitals in
    which some of the centers in our network are based, as well as
    Chang&#146;an Hospital, are involved in such pilot medical
    insurance plan. We do not expect such change in payment timing
    to have a direct effect on our ability to collect our contracted
    percentage from our hospital partners. However, the ability of
    our hospital partners to collect medical service fees from the
    government authorities in a timely manner may affect the timing
    of payments made by our hospital partners to us as a result.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    67
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the past, we have recorded limited amounts of uncollectible
    accounts receivable. Our allowance for doubtful accounts
    amounted to RMB3.8&#160;million (US$0.6&#160;million) and
    RMB3.8&#160;million (US$0.6&#160;million) as of
    December&#160;31, 2008 and September&#160;30, 2009, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have historically derived a large portion of our total net
    revenues from a limited number of our hospital partners. For the
    period from January&#160;1, 2007 to October&#160;30, 2007, the
    period from September&#160;10, 2007 to December&#160;31, 2007,
    for the year ended December&#160;31, 2008 and for the nine
    months ended September&#160;30, 2008 and 2009, net revenue
    derived from our top five hospital partners amounted to
    approximately 61.6%, 64.7%, 37.8%, 42.2% and 34.1%,
    respectively, of our total net revenues. For these same five
    periods, three, three, one, one and two, respectively, of our
    hospital partners, accounted for more than 10.0% of our total
    net revenues, and our largest hospital partner accounted for
    21.7%, 24.2%, 13.5%, 14.4% and 10.7%, respectively, of our total
    net revenues during those periods. We expect this revenue
    concentration to decline over time as our network of centers
    continues to expand.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our largest hospital partner in terms of revenue contribution
    for the nine months ended September&#160;30, 2009 was the
    Chinese People&#146;s Liberation Army Navy General Hospital. We
    have entered into lease and management services arrangements for
    six centers with such hospital partner, with terms that range
    from 10 to 20&#160;years. A lease and management services
    arrangement for one of the centers was newly entered into in
    July 2009 and such center has not begun operation as of
    September&#160;30, 2009, but is expected to begin operation at
    the end of 2009. We receive from our largest hospital partner a
    contracted percentage of each center&#146;s revenue net of
    specified operating expenses, which include variable expenses
    such as the salaries and benefits of the medical and other
    personnel at the center, the cost of medical consummables,
    marketing expenses, training expenses, utility expenses and
    routine equipment repair and maintenance expenses. The
    contracted percentages are typically adjusted based on a
    declining scale over the term of the arrangements. Typically,
    these arrangements may be terminated upon the mutual agreement
    of the parties if the centers experience an operating loss for a
    specified period of time or failed to achieve certain operating
    targets. In addition, the arrangements typically can be
    terminated upon the default or failure by either party to
    perform its respective obligations under the arrangement. Under
    the arrangements for certain centers and in the event of early
    termination as a result of adjustments of relevant policies, our
    largest hospital partner may be required to purchase the medical
    equipment from us at the price set forth in the agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Chang&#146;an Hospital accounted for approximately 10.1% of our
    total net revenues for the nine months ended September&#160;30,
    2009. We provide management services to Chang&#146;an Hospital
    through a service-only agreement and receive a management fee
    equal to a percentage of the total revenues of Chang&#146;an
    Hospital. In addition, we will be eligible to receive annual
    bonuses from Chang&#146;an Hospital calculated on the basis of
    the annual growth rates of Chang&#146;an Hospital&#146;s total
    revenues. Under the service-only agreement, we are required to
    pay a performance deposit of RMB15.0&#160;million
    (US$2.2&#160;million), which will be refunded to us after the
    termination or expiration of the agreement. The service-only
    agreement can be terminated upon the default or failure by
    either party to perform its respective obligations under the
    agreement. We also managed six centers in Chang&#146;an Hospital
    prior to August 2009 through service-only agreements. In August
    2009, we purchased the six units of the medical equipment housed
    in these six centers from Chang&#146;an Hospital. Two of the six
    units of medical equipment were combined into one center and we
    subsequently entered into a long-term lease and management
    services arrangement with Chang&#146;an Hospital to manage all
    the five centers. Under the lease and management services
    arrangement with Chang&#146;an Hospital, we receive a contracted
    percentage of each center&#146;s revenue net of specified
    operating expenses. The contracted percentage is adjusted based
    on a declining scale over the term of the arrangement. The
    arrangement may be terminated due to changes in government
    policies that prohibit the lease of such medical equipment and
    Chang&#146;an Hospital will be required to pay us an amount
    equal to the purchase price of the medical equipment less
    depreciation. In addition, the arrangement can be terminated by
    us upon the default or failure by Chang&#146;an Hospital to
    perform its obligations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are subject to approximately 5% business tax and related
    surcharges on certain of our revenues. Such taxes and surcharges
    amounted to RMB0.4&#160;million, RMB0.2&#160;million,
    RMB4.5&#160;million (US$0.7&#160;million), RMB1.9&#160;million
    and RMB7.5&#160;million (US$1.1&#160;million) for the period
    from January&#160;1, 2007 to October&#160;30, 2007, the period
    from September&#160;10, 2007 to December&#160;31, 2007, in 2008
    and for the nine months ended September&#160;30, 2008 and 2009,
    respectively, and are deducted prior to deriving our total net
    revenues. In addition,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    68
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    revenue derived from the sale of medical equipment are net of
    value-added tax of 17% which amounted to RMB0.9&#160;million
    (US$0.1&#160;million) and RMB0.1&#160;million (US$15,000) in
    2008 and for the nine months ended September&#160;30, 2009,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are also currently in the process of establishing two
    specialty cancer hospitals in China that will be majority owned
    and operated by us. The Chang&#146;an CMS International Cancer
    Center is expected to commence operation in early 2010 and the
    Beijing Proton Medical Center is expected to commence operation
    in 2012. We expect such specialty cancer hospitals to contribute
    favorably to our total net revenues in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cost of
    Revenues and Operating Expenses</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our cost of revenues and
    operating expenses in absolute amounts and as percentage of our
    total net revenues for the periods indicated:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="28%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=11 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=11 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=11 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=11 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B><SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="38" align="center" valign="bottom">
    (in thousands, except for percentages)
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,304
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,046
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,669
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,174
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,002
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,497
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,987
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,330
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,680
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,361
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,541
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Gross Profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,075
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,632
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143,116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,497
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    805
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,463
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    654
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    General and administrative
    expenses<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,869
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,687
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,884
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total operating expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,366
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,569
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represent the addition of the
    amounts for the specific line items of OMS, our predecessor, for
    the period from January&#160;1, 2007 to October&#160;30, 2007,
    and the amounts for the corresponding line items of Concord
    Medical for the period from September&#160;10, 2007 to
    December&#160;31, 2007. For the period from September&#160;10,
    2007, the date of inception of Ascendium, to October&#160;30,
    2007, during which the financial statements of our predecessor
    and those of Concord Medical overlap, Ascendium did not engage
    in any business or operations. The unaudited combined financial
    data for the year ended December&#160;31, 2007 do not comply
    with U.S. GAAP.
    </FONT></TD>
</TR>





<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Our general and administrative
    expenses include share-based compensation expenses related to
    certain share options granted in 2007 that amounted to
    RMB49.5&#160;million, RMB4.2&#160;million (US$0.6&#160;million)
    and RMB4.2&#160;million in 2007, 2008 and for the nine months
    ended September&#160;30, 2008, respectively. We did not
    recognize any share-based compensation expenses for the nine
    months ended September&#160;30, 2009.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Cost
    of Revenues</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our cost of revenues primarily consists of the amortization of
    acquired intangibles and the depreciation of medical equipment
    purchased, installed and operated in our network of centers.
    With the exception of the amortization of acquired intangible
    assets, we expect such cost of revenues to increase in the
    future in line with the growth in our total net revenues as we
    continue to expand our network of centers and purchase more
    medical equipment. Our cost of revenues also include salaries
    and benefits for personnel employed by us and assigned to
    centers in our network, such as our project managers, as well as
    other costs that include certain training, marketing and selling
    and equipment repair and maintenance expenses that are not
    accounted for as the centers&#146; operating expenses in
    accordance with the terms of our lease and management services
    arrangements with our hospital partners. In addition, certain
    expenses are allocated as our cost of revenues instead of
    centers&#146; operating expenses if such expenses are incurred
    across several centers and cannot be allocated to one individual
    center. In addition, as a result of the OMS reorganization, the
    acquisitions of China Medstar, Xing Heng Feng Medical and
    certain other businesses, our cost of revenues also include
    amortization of acquired intangibles during the period
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    69
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    starting from September&#160;10, 2007 to December&#160;31, 2007.
    We expect our amortization of acquired intangibles in connection
    with the OMS reorganization and the acquisition of China Medstar
    and other businesses in 2008 to be between approximately
    RMB26.8&#160;million (US$3.9&#160;million) and
    RMB18.9&#160;million (US$2.8&#160;million) annually between 2009
    and 2013.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Once our specialty cancer hospitals are established, our cost of
    revenues will also include costs associated with the operations
    of such hospitals. We expect such costs of revenue to include
    depreciation and amortization of the properties, buildings and
    equipment that are used by our specialty cancer hospitals, the
    salaries and benefits associated with our medical and
    non-medical personnel and overhead costs, which include the cost
    of materials for medical procedures and utility, repair and
    maintenance expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Selling
    Expenses</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Selling expenses consist primarily of expenses associated with
    the development of new centers and specialty cancer hospitals,
    such as salaries and benefits for our business development
    personnel, marketing expenses and travel related expenses.
    Selling expenses have increased in absolute amount from 2007 to
    2008 and from the nine months ended September&#160;30, 2008 to
    the nine months ended September&#160;30, 2009 as a result of
    increased efforts to expand our network of centers and our
    specialty cancer hospitals. We expect our selling expenses to
    increase in absolute amount in the future, in line with the
    expansion of our network and the growth in our total net
    revenues.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">General
    and Administrative Expenses</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    General and administrative expenses consist primarily of
    salaries and benefits for our finance, human resources and
    administrative personnel, fees and expenses of legal, accounting
    and other professional services, insurance expenses, travel
    related expenses, depreciation of equipment and facilities used
    for administrative purposes, and other expenses. Our general and
    administrative expenses also include share-based compensation
    expenses in 2007, 2008 and for the nine months ended
    September&#160;30, 2008 that amounted to RMB49.5&#160;million,
    RMB4.2&#160;million (US$0.6&#160;million) and
    RMB4.2&#160;million, respectively, which significantly increased
    our general and administrative expenses for those periods. See
    &#147;&#151;&#160;Share-based Compensation.&#148; On
    November&#160;27, 2009, we granted options to purchase an
    aggregate of 4,765,800 ordinary shares to our executive
    officers, directors and other employees pursuant to our 2008
    share incentive plan. Consequently, we expect to start recording
    share-based compensation expense associated with this grant
    commencing in the quarter ending December&#160;31, 2009. Without
    taking into account the share-based compensation expenses, our
    general and administrative expenses have increased in absolute
    dollar terms as we have recruited additional general and
    administrative employees and have incurred additional costs
    related to the growth of our business. We expect such expenses
    to continue to increase in absolute dollar terms in the future,
    in line with the expansion of our network of centers and the
    growth in our total net revenues.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Share-based
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2007, OMS, the predecessor of our company,
    adopted a share option plan, or the OMS option plan, pursuant to
    which OMS granted to three of its executive directors,
    Mr.&#160;Haifeng Liu, Mr.&#160;Jianyu Yang and Mr.&#160;Steve
    Sun, or the OMS grantees, options to purchase a total of up to
    25,000,000 ordinary shares, or the OMS share options, to
    purchase the ordinary shares of OMS at an exercise price of
    US$0.80 per share, which the board of OMS determined to become
    vested upon the satisfaction of a number of performance
    conditions that related to the completion of the OMS
    reorganization, achievement of net profit target of OMS, and the
    raising of new financing. The OMS share options were exercisable
    from the date of completion of the 2007 audited consolidated
    financial statements of OMS to December&#160;31, 2008 and were
    transferrable to any individuals designated by the OMS grantees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;18, 2008, the board of directors of OMS
    contemplated that the OMS grantees had achieved all performance
    conditions outlined in the OMS option plan. However, as the
    capital structure of our company had changed at that time such
    that we had replaced OMS as the ultimate holding company of our
    subsidiaries, the board of directors of OMS resolved that the
    OMS option plan would be settled in vested options to purchase
    21,184,600 ordinary shares to purchase shares of our company,
    with each option having an exercise price of US$0.79 exercisable
    before December&#160;31, 2008. On the same day, two of the OMS
    grantees, Mr.&#160;Jianyu Yang and Mr.&#160;Steve
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    70
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sun, exercised their respective options to purchase an aggregate
    of 6,355,400&#160;ordinary shares of our company, with total
    proceeds from such exercise received by us amounting to
    approximately RMB34.4&#160;million (US$5.0&#160;million). We
    recorded share-based compensation expense of approximately
    RMB49.5&#160;million in 2007 related to these options granted,
    which was recorded in general and administrative expenses. The
    third OMS grantee, Mr.&#160;Haifeng Liu, sold all of his vested
    options to purchase 14,829,200 ordinary shares of our company to
    three former directors of China Medstar who are now our
    directors and executive officers as employment incentive for
    such directors. The three executive directors subsequently
    exercised the vested options with total proceeds from such
    exercise received by us amounting to approximately
    US$11.7&#160;million. Given the transfer of the OMS share
    options to the three directors was provided as an employment
    incentive, we recorded additional share-based compensation
    expense of approximately RMB4.2&#160;million
    (US$0.6&#160;million) in 2008, which was recorded in general and
    administrative expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;16, 2008, our board of directors adopted the
    2008&#160;share incentive plan, which was subsequently amended
    on November&#160;17, 2009 to increase the number of ordinary
    shares available for grant under the plan. The plan provides for
    the grant of options, share appreciation rights, or other
    share-based awards to key employees, directors or consultants.
    Our board of directors and shareholders authorized the issuance
    of up to 4,765,800 ordinary shares upon exercise of awards
    granted under our 2008&#160;share incentive plan. On
    November&#160;27, 2009, we granted options to purchase 4,765,800
    ordinary shares, of which options to purchase 1,716,500 ordinary
    shares were granted to our executive officers and directors, and
    the remainder to other employees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Accretion
    of Series&#160;A and Series&#160;B Contingently Redeemable
    Convertible Preferred Shares</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the terms of the Amended and Restated Shareholders&#146;
    Agreement dated as of October&#160;20, 2008, which was
    subsequently amended on November&#160;17, 2009 and on
    December&#160;7, 2009, by and among us, our shareholders and
    certain other parties named therein, holders of the
    Series&#160;A and Series&#160;B redeemable convertible preferred
    shares have the right to require us to repurchase their
    preferred shares if (i)&#160;three years after the closing date
    of the subscription of the Series&#160;B contingently redeemable
    convertible preferred shares a qualified initial public offering
    has not taken place, (ii)&#160;any of certain of our key
    directors has resigned which resulted in or would be likely to
    result in a material adverse effect on our business, or
    (iii)&#160;we or any of our subsidiaries have breached or failed
    to be in compliance with any applicable laws which has had or
    would be reasonably likely to have a material adverse effect on
    our business. In the event of a repurchase under this right, we
    are required to repurchase all of the outstanding Series&#160;A
    or Series&#160;B contingently redeemable convertible preferred
    shares at a repurchase price equal to the original issue price
    of the preferred shares, plus an amount which would have accrued
    on the original issue price at a compound annual rate of at
    least 12.5% from the date of issuance up to and including the
    date on which such repurchase price is paid. The accretion of
    the Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares is reflected as a charge against
    net income (loss) attributable to ordinary shareholders and
    totaled RMB270.3&#160;million (US$39.6&#160;million) and
    RMB304.8&#160;million (US$44.6&#160;million) in 2008 for
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares, respectively. Such accretion
    charge is not expected to continue after our initial public
    offering since all of our Series&#160;A and Series&#160;B
    contingently redeemable convertible preferred shares will be
    converted into ordinary shares at that time.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Taxation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Cayman
    Islands</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are incorporated in the Cayman Islands. Under the current law
    of the Cayman Islands, we are not subject to income or capital
    gains tax. In addition, dividend payments made by us are not
    subject to withholding tax in the Cayman Islands.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">British
    Virgin Islands</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain of our subsidiaries are established in the British
    Virgin Islands and under the current laws of the British Virgin
    Islands, such subsidiaries are not subject to income tax.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    71
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Hong
    Kong</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We did not have any assessable profits subject to the Hong Kong
    profits tax in 2007 and 2008. We do not anticipate having any
    income subject to income taxes in Hong Kong in the foreseeable
    future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Singapore</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We did not have any assessable profits subject to the Singapore
    profits tax in 2007 and 2008. We do not anticipate having any
    income subject to income taxes in Singapore in the foreseeable
    future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">People&#146;s
    Republic of China</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our PRC subsidiaries are incorporated in the PRC and are
    governed by applicable PRC income tax laws and regulations. The
    EIT Law was enacted on March&#160;16, 2007 and became effective
    on January&#160;1, 2008. The implementation regulations under
    the EIT Law issued by the PRC State Council became effective
    January&#160;1, 2008. Under the EIT Law and the implementation
    regulations, the PRC has adopted a uniform tax rate of 25% for
    all enterprises (including foreign-invested enterprises) and has
    revoked the previous tax exemption, reduction and preferential
    treatments applicable to foreign-invested enterprises. However,
    there is a transition period for enterprises, whether
    foreign-invested or domestic, that were registered on or before
    March&#160;16, 2007 and received preferential tax treatments
    granted by relevant tax authorities prior to January&#160;1,
    2008. Some enterprises that were subject to an enterprise income
    tax rate lower than 25% prior to January&#160;1, 2008&#160;may
    continue to enjoy the lower rate and gradually transition to the
    new tax rate within five years after the effective date of the
    EIT Law. In 2008, our subsidiaries Aohua Medical and Shanghai
    Medstar each had a preferential income tax rate of 18% that is
    scheduled to increase to 20% in 2009, 22% in 2010, 24% in 2011
    and 25% in 2012. Our other PRC subsidiaries are subject to the
    tax rate of 25% in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The EIT Law provides that enterprises established outside of
    China whose &#147;de facto management bodies&#148; are located
    in China are considered &#147;resident enterprises&#148; and are
    generally subject to the uniform 25% enterprise income tax rate
    on their worldwide income. In addition, a recent circular issued
    by the State Administration of Taxation regarding the standards
    used to classify certain Chinese-invested enterprises controlled
    by Chinese enterprises or Chinese group enterprises and
    established outside of China as &#147;resident enterprises&#148;
    clarified that dividends and other income paid by such
    &#147;resident enterprises&#148; will be considered to be PRC
    source income, subject to PRC withholding tax, currently at a
    rate of 10%, when recognized by non-PRC enterprise shareholders.
    This recent circular also subjects such &#147;resident
    enterprises&#148; to various reporting requirements with the PRC
    tax authorities. Under the implementation regulations to the EIT
    Law, a &#147;de facto management body&#148; is defined as a body
    that has material and overall management and control over the
    manufacturing and business operations, personnel and human
    resources, finances and properties of an enterprise. In
    addition, the recent circular mentioned above details that
    certain Chinese-invested enterprises controlled by Chinese
    enterprises or Chinese group enterprises will be classified as
    &#147;resident enterprises&#148; if all of the following are
    located or resident in China: senior management personnel and
    departments that are responsible for daily production, operation
    and management; financial and personnel decision making bodies;
    key properties, accounting books, company seal, and minutes of
    board meetings and shareholders&#146; meetings; and half or more
    of the directors with voting rights or senior management.
    However, as this circular only applies to enterprises
    established outside of China that are controlled by PRC
    enterprises or groups of PRC enterprises, it remains unclear how
    the tax authorities will determine the location of &#147;de
    facto management bodies&#148; for overseas incorporated
    enterprises that are controlled by individual PRC residents like
    us and some of our subsidiaries. Therefore, although
    substantially all of our management is currently located in the
    PRC, it remains unclear whether the PRC tax authorities would
    require or permit our overseas registered entities to be treated
    as PRC resident enterprises. If the PRC tax authorities
    determine that we are a &#147;resident enterprise,&#148; we may
    be subject to enterprise income tax at a rate of 25% on our
    worldwide income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the EIT Law, a maximum withholding income tax rate of 20%
    may be applicable to dividends payable to non-PRC investors that
    are &#147;non-resident enterprises,&#148; to the extent such
    dividends are derived from sources within the PRC, and the State
    Council has reduced such rate to 10% through the implementation
    regulations. We are a Cayman Islands holding company and
    substantially all of our income may be derived from dividends we
    receive from our operating subsidiaries located in the PRC.
    According to the <I>Double Taxation Arrangement (Hong Kong)</I>,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    72
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    dividends paid to enterprises incorporated in Hong Kong are
    subject to a withholding tax of 5% provided that a Hong Kong
    resident enterprise owns no less than 25% of the PRC enterprise
    distributing the dividend and can be considered as a
    &#147;beneficial owner&#148; and entitled to treaty benefits
    under the Double Taxation Arrangement (Hong Kong). Thus,
    dividends paid to us through our Hong Kong subsidiary by our
    subsidiaries in China may be subject to the 5% income tax if the
    Cayman Islands holding company and our Hong Kong subsidiary are
    considered as &#147;non-resident enterprises&#148; under the EIT
    Law and our Hong Kong subsidiary is considered to be a
    &#147;beneficial owner&#148; and entitled to treaty benefits
    under the Double Taxation Arrangement (Hong Kong). If we are
    required under the EIT Law to pay income tax for any dividends
    we receive from our subsidiaries, it will materially and
    adversely affect the amount of dividends, if any, we may pay to
    our shareholders and ADS holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Critical
    Accounting Policies</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We prepare our consolidated financial statements in accordance
    with U.S.&#160;GAAP, which requires us to make judgments,
    estimates and assumptions that affect (i)&#160;the reported
    amounts of assets and liabilities, (ii)&#160;disclosure of
    contingent assets and liabilities at the end of each reporting
    period and (iii)&#160;the reported amounts of revenue and
    expenses during each reporting period. We continually evaluate
    these estimates and assumptions based on historical experience,
    knowledge and assessment of current business and other
    conditions, expectations regarding the future based on available
    information and reasonable assumptions, which together form a
    basis for making judgments about matters not readily apparent
    from other sources. Since the use of estimates is an integral
    component of the financial reporting process, actual results
    could differ from those estimates. Some of our accounting
    policies require higher degrees of judgment than others in their
    application. When reviewing our financial statements, you should
    consider (i)&#160;our selection of critical accounting policies,
    (ii)&#160;the judgment and other uncertainties affecting the
    application of such policies and (iii)&#160;the sensitivity of
    reported results to changes in conditions and assumptions. We
    consider the policies discussed below to be critical to an
    understanding of our financial statements as their application
    places the most significant demands on the judgment of our
    management.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Lease and Management Services.</I>&#160;&#160;The majority of
    our revenues are derived directly from hospitals that enter into
    medical equipment lease and management service arrangements with
    us. A lease and management service arrangement will typically
    include the purchase and installation of diagnostic imaging
    <FONT style="white-space: nowrap">and/or</FONT>
    radiation oncology system (&#147;medical equipment&#148;) at the
    hospital, and the full-time deployment of a qualified system
    technician that are responsible for certain management services
    of managing radiotherapy or diagnostic services such that the
    hospital and doctors can provide specialized services to their
    patients. Under lease and management service arrangements with
    independent hospitals, with terms ranging from six to
    20&#160;years in duration, we receive a specified percentage of
    the net profit of the hospital unit that delivers the diagnostic
    imaging
    <FONT style="white-space: nowrap">and/or</FONT>
    radiation oncology services determined in accordance with the
    terms of the arrangement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have determined that the lease and management service
    arrangements contain a lease of medical equipment pursuant to
    FASB&#160;ASC Subtopic 840-10, Leases&#160;&#151; Overall, or
    <FONT style="white-space: nowrap">ASC&#160;840-10,</FONT>
    (formerly referenced as
    <FONT style="white-space: nowrap">EITF&#160;01-8,</FONT>
    &#147;Determining Whether an Arrangement Contains a Lease&#148;,
    or
    <FONT style="white-space: nowrap">EITF&#160;01-8).</FONT>
    The hospital has the ability and the right to operate the
    medical equipment while obtaining more than a minor amount of
    the output. The arrangement also contains a non-lease
    deliverable as the management service element. The arrangement
    consideration is allocated between the lease element and the
    non-lease deliverables on a relative fair value basis.
    FASB&#160;ASC&#160;840 Leases, or ASC&#160;840, (formerly
    referenced as SFAS&#160;13, &#147;Accounting for leases&#148;,
    or SFAS&#160;13) is applied to the lease elements of the
    arrangement and SEC Staff Accounting Bulletin&#160;No.&#160;104,
    or SAB&#160;104, is applied to other elements of the arrangement
    not within the scope of ASC&#160;840.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenues generated by the lease arrangement are based purely on
    a profit share formula. Certain of the lease and management
    services arrangements may include a transfer of ownership or
    bargain purchase option at the end of the lease term. Due to the
    length of the lease term, the collectibility of these minimum
    lease payments are not considered predictable and there are
    important uncertainties regarding the future costs to be
    incurred by us relating to the arrangement. Therefore, the
    lessor&#146;s additional criteria for capital lease
    classification in FASB&#160;ASC 840-10-25-42 to 840-10-25-44,
    Leases&#160;&#151; Overall&#160;&#151; Recognition&#160;&#151;
    Lessors (&#147;ASC&#160;840-10-25-42 to
    ASC&#160;840-10-25-44&#148;) (formerly referenced as
    SFAS&#160;13&#160;par. 8 (a)&#160;and (b))&#160;was not met even
    if any of the ASC&#160;840-10-25-1, Leases&#160;&#151;
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    73
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Overall&#160;&#151; Recognition&#160;&#151; General, or
    ASC&#160;840-10-25-1, (formerly referenced as SFAS&#160;13
    par.&#160;7) criteria for capital leases are met. Consequently,
    we account for all lease arrangements as operating leases. As
    the collectability of the minimum lease rental is not considered
    predictable, and the remaining rental is considered contingent,
    we recognize revenue when the lease payments under the
    arrangement become due, that is, when the profit share under the
    arrangement is determined and agreed upon by both parties to the
    agreement. For the service element of the arrangement, revenue
    is only considered determinable at the time the payments under
    the arrangement become due, that is, when the profit share under
    the arrangement is determined and agreed upon by both parties.
    Revenue is recognized when determined if all other basic
    criteria have also been met.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenue derived from the lease and management service
    arrangement is recorded under &#147;Lease and management
    service&#148; in the consolidated statements of operations and
    is recorded net of business tax of 5%
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Management Services.</I>&#160;&#160;To a lesser extent, we
    provide stand-alone management services to certain hospitals
    which are already in possession of medical equipment. The fee
    for the management service arrangement is either based on a
    contracted percentage of monthly revenue generated by the
    specified hospital unit (&#147;revenue share&#148;) or in
    limited instances on a fixed monthly fee. The consideration that
    is based on a contracted percentage of revenue is recognized
    when the monthly fees under the arrangement become due, when the
    revenue share under the arrangement is determined and agreed
    upon by both parties to the arrangement. Revenue derived from
    stand-alone management services is recorded under
    &#147;Management Services&#148; in the consolidated statements
    of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Medical Equipment Sales.</I>&#160;&#160;Revenues arising from
    sales of medical equipment and services are recognized when
    there is persuasive evidence of an arrangement, the fee is fixed
    or determinable, collectability is reasonably assured and the
    delivery of the medical equipment or services has occurred. When
    the fees associated with an arrangement containing extended
    payment terms are not considered to be fixed or determinable at
    the outset of arrangement, revenue is recognized as payments
    become due, and all of the other criteria above have been met.
    Pursuant to the application of FASB ASC Subtopic 605-45, Revenue
    Recognition&#160;&#151; Principal Agent Consideration, or
    <FONT style="white-space: nowrap">ASC&#160;605-45,</FONT>
    (formerly referenced as
    <FONT style="white-space: nowrap">EITF&#160;99-19,</FONT>
    &#147;Reporting Revenue Gross as Principal versus Net as an
    Agent&#148;, or
    <FONT style="white-space: nowrap">EITF&#160;99-19,)</FONT>
    we record revenue related to medical equipment sales on a net
    basis when the equipment is delivered to the customer and the
    sales price is determinable. Revenue derived from Medical
    Equipment sales is recorded under &#147;Other&#148; in the
    consolidated statements of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounts
    receivable and allowance for doubtful accounts</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We consider many factors in assessing the collectability of our
    receivables due from our customers, such as the aging of the
    amounts due, the customer&#146;s payment history and
    credit-worthiness. An allowance for doubtful accounts is
    recorded in the period in which uncollectability is determined
    to be probable. Accounts receivable balances are written off
    after all collection efforts have been exhausted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Goodwill</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Goodwill represents the excess of the purchase price over the
    fair value of net tangible and identifiable intangible assets
    acquired in a business combination. Under FASB ASC&#160;350,
    Intangibles&#160;&#151; Goodwill and other, (formerly referenced
    as Statement of Financial Accounting Standards No.&#160;142
    &#147;Goodwill and Other Intangible Assets&#148;, or
    SFAS&#160;142) goodwill is tested for impairment annually or
    more frequently if events or changes in circumstances indicate
    that it might be impaired. We assess goodwill for impairment in
    accordance with ASC&#160;350 at the reporting unit level.
    ASC&#160;350 describes the reporting unit as an operating
    segment or one level below the operating segment, depending on
    whether certain criteria are met. We determined that we have
    only one reporting unit and have assigned goodwill to the
    reporting unit and tested for impairment annually as of
    December&#160;31.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An impairment loss must be measured if the sum of the expected
    future undiscounted cash flows from the use and eventual
    disposition of the asset is less than the net book value of the
    asset. The amount of the impairment loss will generally be
    measured as the difference between the net book value of the
    asset and their estimated fair value. The Company determined it
    has one reporting unit in which all goodwill was tested for
    impairment at each reporting period end resulting in no
    impairment charge.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    74
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Acquired
    Intangible Asset, net</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We depreciate and amortize our property, plant and equipment and
    acquired intangibles over the shorter of their estimated useful
    lives or contract terms using the straight-line method of
    accounting of the assets which closely approximates the pattern
    in which the economic benefits of the asset are consumed. We
    make estimates of the useful lives in order to determine the
    amount of depreciation and amortization expense to be recorded
    during each reporting period. We estimate the useful lives at
    the time the assets are acquired based on historical experience
    with similar assets as well as anticipated technological or
    other changes. If technological changes were to occur more
    rapidly than anticipated or in a different form than
    anticipated, we might shorten the useful lives assigned to these
    assets, which would result in the recognition of increased
    depreciation and amortization expense in future periods. There
    has been no change to the estimated useful lives during the
    period presented.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We evaluate long-lived assets, including property, plant and
    equipment and acquired intangibles, which are subject to
    depreciation and amortization, for impairment whenever events or
    changes in circumstances indicate that the carrying amount of an
    asset may not be recoverable. We assess recoverability by
    comparing the carrying amount of an asset to its estimated
    undiscounted future cash flows expected to be generated by the
    asset. If the carrying amount of an asset exceeds its estimated
    undiscounted future cash flows, we recognize an impairment
    charge based on the amount by which the carrying amount of the
    asset exceeds the fair value of the asset. We estimate the fair
    value of the asset based on the best information available,
    including prices for similar assets and in the absence of an
    observable market price, the results of using a present value
    technique to estimate the fair value of the asset.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Share-based
    Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We account for share-based compensation under FASB ASC&#160;718,
    or ASC&#160;718, Compensation&#160;&#151; Stock Compensation
    (formerly referenced as Statement of Financial Accounting
    Standards
    <FONT style="white-space: nowrap">No.&#160;123-R,</FONT>
    &#147;Share-Based Payment&#148;, or SFAS&#160;No.&#160;123R).
    Under ASC&#160;718, the cost of all share-based payment
    transactions must be recognized in our consolidated financial
    statements based on their grant-date fair value over the
    required period, which is generally the period from the date of
    grant to the date when the share compensation is no longer
    contingent upon additional service from the employee, or the
    vesting period. This statement also requires us to adopt a fair
    value- based method of measuring the compensation expense
    related to share-based compensation. For options granted to
    employees, we record share-based compensation expenses for the
    fair value of the options at the grant date. Currently,
    consistent with the job functions of the grantees, we categorize
    these share-based compensation expenses in our general and
    administrative expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The determination of fair value of equity awards such as options
    requires making complex and subjective judgments about the
    projected financial and operating results of the subject
    company. It also requires making certain assumptions such as
    cost of capital, general market and macroeconomic conditions,
    industry trends, comparable companies, share price volatility of
    the subject company, expected lives of options and discount
    rates. These assumptions are inherently uncertain. Changes in
    these assumptions could significantly affect the amount of
    employee share-based compensation expense we recognize on our
    consolidated financial statements. We engaged an independent
    valuation firm to assist us in assessing the fair value of our
    share options and underlying ordinary shares on a
    contemporaneous basis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Changes in our estimates and assumptions regarding the expected
    volatility of our ordinary shares could significantly impact the
    estimated fair values of our share options and, as a result, our
    net income and the net income available to our ordinary
    shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Business
    combinations</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have made a number of acquisitions and may make strategically
    important acquisitions in the future. When recording an
    acquisition, we allocate the purchase price of the acquired
    company to the tangible and identifiable intangible assets
    acquired and liabilities assumed based on their estimated fair
    values. With the assistance of a valuation firm, we determined
    the fair values of identifiable intangible assets, including
    acquired lease agreements. These valuations require us to make
    significant estimates and assumptions which include future
    expected cash flows from the acquired lease agreements, discount
    rates, and assumptions regarding the period of time the acquired
    lease agreements, services agreements and customer relationships
    will continue. Such assumptions may be incomplete or
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    75
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    inaccurate, and unanticipated events and circumstances may occur
    which may affect the accuracy or validity of such assumptions
    and estimates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Assessing
    the Fair Value of the Company&#146;s Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Determining the fair value of our ordinary shares also requires
    making complex and subjective judgments regarding projected
    financial and operating results, our unique business risks, the
    liquidity of our shares and our operating history and prospects
    at the time of grant. The assumptions used in deriving the fair
    value of our ordinary shares include: i)&#160;there will be no
    material change in the existing political, legal, technological,
    fiscal or economic condition of China that may adversely affect
    our business; ii)&#160;the contracts and agreements we entered
    into will be honored; and iii)&#160;our competitive advantages
    and disadvantages do not change significantly during the period
    under consideration. These assumptions are inherently uncertain.
    If different assumptions were used, our share-based compensation
    expenses, net income and income per share could have been
    significantly different.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In determining our enterprise value at each measurement date,
    the independent valuation firm considered the results of both
    the income approach (discounted cash flow method) and the market
    approach (guideline company method). There was no significant
    difference between the enterprise value of our valuation derived
    using the income approach and the enterprise value derived using
    the market approach. For the market approach, the independent
    valuation firm considered the market profile and performance of
    guideline companies with businesses similar to those of us to
    derive market multiples and then calculated the following three
    multiples for the guideline companies: enterprise value to sales
    multiple, enterprise value to earnings before interest, tax,
    depreciation and amortization, or EBITDA, multiple and
    enterprise value to earnings before interest and tax, or EBIT,
    multiple. Due to the different growth rates, profit margins and
    risk levels of us and the guideline companies, price multiple
    adjustments were made.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the income approach, the value depends on the present worth
    of future economic benefits to be derived from our projected
    sales income. Indications of value are developed by discounting
    projected future net cash flows available for payment of
    shareholders&#146; interest to their present worth at a discount
    rate that reflects a number of factors, including the current
    cost of financing and the risk considered inherent in the
    business. A discount rate represents an estimate of the rate of
    return required by a third party investor for an investment of
    this type. The rate of return expected from an investment by an
    investor relates to the perceived risk of the investment. The
    calculation of the discount rate is based on the
    weighted-average cost of capital, or WACC, of the company. The
    WACC takes into account both the cost of equity and the cost of
    debt depending on the capital structure of the company. To
    determine the cost of equity, the independent valuation firm
    applied the Capital Asset Pricing Model, which takes into
    account the risk free rates, beta of selected comparable medical
    equipment leasing companies, market returns in comparative
    markets in each respective valuation periods and our company
    specific risks, including business risk, small size risk and
    country risk. The independent valuation firm determined our
    company&#146;s WACC, which was used a discount rate, of 19% to
    22%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The independent valuation firm also applied a discount for lack
    of marketability of 17% to 19% in the valuation of our
    enterprise value between November 2007 and October 2008 to
    reflect the fact that there is no readily available market for
    shares in a closely held company like ours. Because ownership
    interests in closely held companies are typically not readily
    marketable compared to similar public companies, we believe, a
    share in a privately held company is usually worth less than an
    otherwise comparable share in a publicly held company and,
    therefore, applied a discount for the lack of marketability of
    the privately held shares. When determining the discount for
    lack of marketability, the Black-Scholes option model was used.
    Under option pricing method, the cost of the put option, which
    can hedge the price change before the privately held shares can
    be sold, was considered as a basis to determine the discount for
    lack of marketability. The option pricing method was used
    because it takes into account certain company-specific factors,
    including the size of our business and volatility of the share
    price of comparable companies engaged in the same industry.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    76
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Significant
    Factors, Assumptions and Methodologies Used in Determining the
    Fair Value of Series&#160;A and B Contingently Redeemable
    Convertible Preferred Shares, Employee Share Options and
    Convertible Notes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Because the interest in the equity value of our company includes
    both contingently redeemable convertible preferred shares and
    ordinary shares, the fair value of the equity interest is
    allocated to contingently redeemable convertible preferred
    shares and ordinary shares using the option-pricing method.
    Under the option-pricing method, the independent valuation firm
    treats ordinary shares and contingently redeemable convertible
    preferred shares as call options on our company&#146;s value,
    with exercise prices based on the value of the liquidation
    preference of the contingently redeemable convertible preferred
    shares. Because a call option is used, the Black-Scholes model,
    which is commonly adopted in the option-pricing method, is
    applied to price the call option. The independent valuation firm
    considered various terms of the contingently redeemable
    convertible preferred shares and ordinary shares, including the
    level of seniority, dividend policy, conversion ratios,
    probability of the completion of an IPO, special redemption
    terms and preferential allocation upon liquidation of the
    enterprise in the option-pricing method.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have granted employee share options which are required to be
    recorded at the fair value of the options measured on the grant
    date. An independent valuation firm applied a Binomial-Lattice
    model to estimate the fair value of the share-based awards on
    the respective grant dates. The Binomial-Lattice model requires
    certain subjective inputs including the risk-free interest rate,
    the company&#146;s dividend yield, the sub optimal early
    exercise factor, and the expected volatility range of our
    ordinary shares. We applied a risk-free rate as relevant to
    conducting financing activities in China. Our company has not
    declared dividends since inception and therefore the dividend
    yield was assessed to be nil. The sub optimal early exercise
    factor is an estimate that an employee will exercise the share
    option immediately once the company&#146;s underlying share
    price reaches 1.5 times the exercise price.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The expected volatility of our ordinary shares was based on the
    price volatility of the shares of comparable companies in the
    medical equipment leasing business, which are listed and
    publicly traded over the most recent period, equal to the
    expected term to expiry of the issued share options. These
    companies were used for comparative purposes because we did not
    have a trading history at the time the share options were issued
    and, therefore, did not have sufficient share price history to
    calculate our own historical volatility. The selection of such
    comparable companies is highly subjective. The estimated fair
    value of our ordinary shares on the date of grant was determined
    by contemporaneous valuations as of their respective measurement
    dates, performed by an independent valuation firm.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Tranche&#160;A and Tranche&#160;B Convertible Notes, or
    convertible notes, are accounted for in accordance with FASB
    ASC&#160;480, Distinguishing Liabilities from Equity,
    &#147;ASC&#160;480&#148; (formerly referenced as SFAS&#160;150,
    &#147;Accounting for Certain Financial Instruments with
    Characteristics of both Liabilities and Equity&#148; or
    SFAS&#160;150,) as a liability recorded at fair value, because
    the convertible notes are convertible into Series&#160;A
    Preferred Shares which are redeemable instruments. An
    independent valuation firm determined the fair value of the
    convertible notes using the binomial model, which requires the
    development of a complex model requiring many highly subjective
    inputs including identifying conditions that lead to specific
    outcomes and the respective probabilities of achieving those
    conditions. Some of the conditions that may lead to differences
    in the fair value of the convertible notes include the
    underlying value of a Series&#160;A contingently redeemable
    preferred share, the probability of completing an initial public
    offering, the level of net income earned in 2008, and the value
    of the underlying debt component.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Internal
    Control Over Financial Reporting</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, we have been a private company with
    limited accounting personnel and other resources to address our
    internal controls and procedures. In connection with the audits
    of our consolidated financial statements for the period from
    January&#160;1, 2007 to December&#160;31, 2008, our independent
    registered public accounting firm identified and communicated to
    us a material weakness and certain significant and other
    deficiencies. As a result, there is more than a remote
    likelihood that a more than inconsequential misstatement of our
    consolidated financial statements will not be prevented or
    detected. Specifically, the material weakness identified
    consists of an ineffective control environment over financial
    reporting due to (i)&#160;an insufficient number of financial
    reporting personnel with an appropriate level of knowledge,
    experience and training; (ii)&#160;insufficient controls around
    the establishment and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    77
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    maintenance of an oversight function and communication of
    internal controls, policies and procedures to support our
    financial reporting obligations; and (iii)&#160;a lack of a
    comprehensive set of internal control policies and procedures
    and related controls to monitor the operating effectiveness of
    these controls. The significant deficiencies identified consist
    of (i)&#160;a lack of a timely formal review process for
    outstanding accounts receivable; (ii)&#160;a lack of a process
    to document investment proposals and lack of a formal policy for
    equipment impairment assessment; and (iii)&#160;a lack of
    controls over agreements and contracts with our hospital
    partners.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Following the identification of the material weakness and the
    significant and other deficiencies, we are in the process of
    implementing a number of measures to improve our internal
    control over financial reporting, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    hiring a professional consulting firm to help us to improve
    internal control in preparation for compliance with the
    Sarbanes-Oxley Act and other applicable SEC rules and
    regulations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    hiring additional qualified personnel with U.S.&#160;GAAP
    expertise and SEC reporting experience to further build an
    internal finance team and a dedicated internal audit department;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    improving internal control procedures and standards, including
    compiling an internal accounting policies and procedures manual,
    and implementing policies as to the inspections and reporting of
    the medical equipment used in our network of centers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enhancing the periodic and systematic physical inspections of
    the medical equipment used in our network of centers to monitor
    the working condition of the equipment and to report damages in
    a timely manner;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enhancing the management of agreements with our hospital
    partners and establishing standard policies and procedures
    governing agreement terms and approval process;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    conducting accounting and financial reporting training for our
    existing personnel as part of our commitment to provide ongoing
    U.S.&#160;GAAP trainings to our employees.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, upon the completion of this offering, we will
    appoint an independent director with extensive knowledge of
    U.S.&#160;GAAP and SEC reporting experience and will establish
    an audit committee under our board of directors in accordance
    with the applicable SEC and NYSE requirements to provide
    adequate independent oversight with respect to our accounting
    and financial reporting. However, the process of designing and
    implementing an effective financial reporting system is a
    continuous effort that requires us to anticipate and react to
    changes in our business and the economic and regulatory
    environments and to devote significant resources to maintain a
    financial reporting system that is adequate to satisfy our
    reporting obligations. The remedial measures that we intend to
    take may not fully address the material weaknesses or
    significant and other deficiencies that have been identified by
    our independent registered public accounting firm, and material
    weaknesses or significant deficiencies in our internal control
    over financial reporting may be identified in the future. See
    Risk Factors &#147;Risks Related to Our Company&#160;&#151; We
    may be unable to establish and maintain an effective system of
    internal control over financial reporting, and as a result we
    may be unable to accurately report our financial results or
    prevent fraud.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    78
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Results of Operations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth a summary of our statements of
    income for the periods indicated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="35%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=11 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=11 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=11 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=11 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=12 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=12 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=12 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=12 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=13 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=13 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=13 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=13 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=14 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=14 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=14 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=14 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=15 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=15 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=15 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=15 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Concord Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="30" nowrap align="center" valign="bottom">
    <B>Concord Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="30" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>October&#160;30, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>%</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>%</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>%</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>%</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>%</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>%</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="55" nowrap align="center" valign="bottom">
    <B>(in thousands, except for percentages)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    <B>Summary Consolidated Statements of Operation Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Revenues, net of business tax, value-added tax and related
    surcharges:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,716
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,092
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,322
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,422
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,405
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    205,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,396
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (27.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,046
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,669
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (42,144
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,174
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,003
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,388
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,987
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,416
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,914
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24,330
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,597
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,680
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,361
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (27.8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (62,541
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,162
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Gross profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,075
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,632
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143,116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,601
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (757
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,358
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (805
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,275
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,463
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (654
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    General and administrative
    expenses<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,467
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (57,171
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (408.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (65,638
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (80.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,764
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,468
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,687
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,884
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Operating income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,938
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (47,859
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (342.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,921
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (954
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (279
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,233
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,455
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,092
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,293
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,880
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (715
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (341
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (341
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (325
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (218
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    (Loss) gain from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,580
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    392
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    823
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Other income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income (loss) before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (346.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,064
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,627
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,691
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income tax (expenses) benefit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,832
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,418
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,611
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,734
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,770
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Net income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (345.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,896
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (35.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Our general and administrative
    expenses include share-based compensation expenses related to
    certain share options granted in 2007 that amounted to RMB49.5
    million, RMB4.2 million (US$0.6 million) and RMB4.2&#160;million
    in 2007, 2008 and for the nine months ended September&#160;30,
    2008, respectively. We did not recognize any share-based
    compensation expenses for the nine months ended
    September&#160;30, 2009.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    79
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of our acquisition of China Medstar on July&#160;31,
    2008, China Medstar became our consolidated subsidiary and its
    results of operations from August 2008 to December&#160;31, 2008
    have been consolidated in our results of operations for the year
    ended December&#160;31, 2008. As a result, our results of
    operations for the year ended December&#160;31, 2008 and for the
    nine months ended September&#160;30, 2009 are not necessarily
    comparable to our results of operations for the year ended
    December&#160;31, 2007 as presented on a &#147;combined&#148;
    basis and for the nine months ended September&#160;30, 2008,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Nine
    Months Ended September&#160;30, 2009 Compared to Nine Months
    Ended September&#160;30, 2008</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Total Net Revenues.</I>&#160;&#160;Our total net revenues
    increased by 101.6% to RMB205.7&#160;million
    (US$30.1&#160;million) for the nine months ended
    September&#160;30, 2009 from RMB102.0&#160;million for the same
    period in 2008 principally as a result of an increase in the
    number of centers in our network, including the 23&#160;centers
    added as a result of our acquisition of China Medstar, and an
    increase in patient cases from existing centers. The increase in
    our total net revenues was also due to the increase in
    management services as a result of revenues derived from
    Chang&#146;an Hospital during the nine months ended
    September&#160;30, 2009 that we did not have during the same
    period in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Cost of Revenues.</I>&#160;&#160;Total cost of revenues
    increased by 120.5% to RMB62.5&#160;million
    (US$9.2&#160;million) for the nine months ended
    September&#160;30, 2009 from RMB28.4&#160;million for the same
    period in 2008. This increase was due primarily to an increase
    in our cost of revenues for lease and management services to
    RMB42.1&#160;million (US$6.2&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB14.7&#160;million for the
    same period in 2008. This was a result of an increase in the
    number of centers in our network principally as a result of our
    acquisition of China Medstar and the resulting increase in
    salaries and benefits to additional personnel employed by us and
    assigned to the centers, as well as other expenses associated
    with marketing and training activities. The increase in our cost
    of revenues is also due to an increase in amortization of
    acquired intangibles to RMB20.4&#160;million
    (US$3.0&#160;million) from RMB13.7&#160;million as a result of
    our acquisition of China Medstar in August 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost of revenues as a percentage of our total net revenues
    increased to 30.4% for the nine months ended September&#160;30,
    2009 from 27.8% for the same period in 2008. This increase was
    due primarily to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an increase in the number of new centers that are in operation
    and the higher cost of revenues as a percentage of total net
    revenues associated with such centers during their
    <FONT style="white-space: nowrap">ramp-up</FONT>
    period; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an increase in the number of new centers that offer diagnostic
    imaging services, which have a higher cost of revenues as a
    percentage of total net revenues as compared to radiotherapy
    treatments.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This increase in cost of revenues as a percentage of total net
    revenues was partially offset by an increase in net revenues
    derived from centers managed under service-only agreements as a
    percentage of our total net revenues to 9.8% for the nine months
    ended September&#160;30, 2009 from 7.4% for the same period in
    2008. Centers managed under service-only agreements have a lower
    cost of revenues as a percentage of total net revenues as
    compared to centers managed under lease and management services
    arrangements. This is because we do not purchase the medical
    equipment used in the centers managed under service-only
    agreements and, as a result, do not incur the associated
    equipment depreciation and amortization expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gross Profit and Gross Margin.</I>&#160;&#160;As a result of
    the foregoing, our gross profit increased by 94.4% to
    RMB143.1&#160;million (US$21.0&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB73.6&#160;million for the
    same period in 2008. Our gross margin decreased to 69.6% for the
    nine months ended September&#160;30, 2009 from 72.2% for the
    same period in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Operating Expenses.</I>&#160;&#160;Our operating expenses
    increased by 53.4% to RMB24.2&#160;million (US$3.5&#160;million)
    for the nine months ended September&#160;30, 2009 from
    RMB15.7&#160;million for the same period in 2008 due primarily
    to an increase in salaries and benefits payment associated with
    an increased headcount primarily as a result of our acquisition
    of China Medstar. Operating expenses as a percentage of our
    total net revenues decreased to 11.7% for the nine months ended
    September&#160;30, 2009 from 15.4% for the same period in 2008
    due primarily to increased economies of scale.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    80
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Selling Expenses.</I>&#160;&#160;Our selling expenses
    increased by 36.3% to RMB4.5&#160;million (US$0.6&#160;million)
    for the nine months ended September&#160;30, 2009 from
    RMB3.3&#160;million for the same period in 2008. This increase
    in our selling expenses was due primarily to an increase in
    salaries and benefits payment associated with an increased
    headcount as a result of our acquisition of China Medstar, an
    increase in marketing expenses and salaries and benefits payment
    in connection with an increase in our business development
    efforts for the nine months ended September&#160;30, 2009 as
    compared to the same period in 2008 to increase the number of
    new centers and for the development of specialty cancer
    hospitals. Selling expenses as a percentage of our total net
    revenues decreased to 2.1% for the nine months ended
    September&#160;30, 2009 from 3.2% for the same period in 2008.
    This was due primarily to increased economies of scale.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>General and Administrative Expenses.</I>&#160;&#160;Our
    general and administrative expenses increased by 57.9% to
    RMB19.7&#160;million (US$2.9&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB12.5&#160;million for the
    same period in 2008. This increase was due primarily to
    increases in salaries and benefits payment in connection with
    the increased headcount of our personnel and their travel
    related expenses principally as a result of our acquisition of
    China Medstar and also in connection with the continued
    expansion of our business. Our general and administrative
    expenses include charges of RMB4.2&#160;million for the nine
    months ended September&#160;30, 2008 related to share-based
    compensation. General and administrative expenses as a
    percentage of our total net revenues decreased to 9.6% for the
    nine months ended September&#160;30, 2009 from 12.2% for the
    same period in 2008. This was due primarily to
    <FONT style="white-space: nowrap">share-based</FONT>
    compensation expenses that were incurred during the nine months
    ended September&#160;30, 2008 that we did not incur for the same
    period in 2009. On November&#160;27, 2009, we granted options to
    purchase pursuant to our 2008 share incentive plan an aggregate
    of 4,765,800 ordinary shares to our executive officers,
    directors and other employees. Consequently, we expect to start
    recording share-based compensation expense associated with this
    grant commencing in the quarter ending December&#160;31, 2009.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Operating Income.</I>&#160;&#160;As a result of the
    foregoing, our operating income increased by 105.5% to
    RMB119.0&#160;million (US$17.4&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB57.9&#160;million for the
    same period in 2008. Operating margin increased to 57.9% for the
    nine months ended September&#160;30, 2009 from 56.8% for the
    same period in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest Expense.</I>&#160;&#160;Our interest expense
    decreased by 7.8% to RMB4.9&#160;million (US$0.7&#160;million)
    for the nine months ended September&#160;30, 2009 from
    RMB5.3&#160;million for the same period in 2008. This decrease
    was due primarily to a decrease in interest rate on our
    borrowings for the nine months ended September&#160;30, 2009
    from the same period in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Change in Fair Value of Convertible Notes.</I>&#160;&#160;We
    recorded a gain of RMB0.5&#160;million from change in fair value
    of convertible notes for the nine months ended
    September&#160;30, 2008. As all convertible notes were converted
    into our Series&#160;A contingently redeemable preferred shares
    in 2008, we did not record such gain for the nine months ended
    September&#160;30, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Foreign Exchange Loss.</I>&#160;&#160;Our foreign exchange
    loss increased by 1,576.9% to RMB0.2&#160;million (US$32,000)
    for the nine months ended September&#160;30, 2009 from RMB13,000
    for the same period in 2008. This was due primarily to
    depreciation of our cash balances held in U.S. dollars against
    the Renminbi.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gain from Disposal of Equipment.</I>&#160;&#160;We recorded a
    gain of RMB0.4&#160;million from the disposal of equipment for
    the nine months ended September&#160;30, 2008 while we did not
    dispose of any equipment for the same period in 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest Income.</I>&#160;&#160;Our interest income increased
    by 609.5% to RMB0.8&#160;million (US$0.1&#160;million) for the
    nine months ended September&#160;30, 2009 from RMB0.1 million
    for the same period in 2008. This increase was due primarily to
    an increase in cash balances during the nine months ended
    September&#160;30, 2009 as compared to the same period in 2008
    primarily as a result of proceeds received from the issuance of
    our Series B contingently convertible preferred shares in
    October 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Income Tax Expense.</I>&#160;&#160;Our income tax expense
    increased by 104.1% to RMB25.7&#160;million
    (US$3.8&#160;million) for the nine months ended
    September&#160;30, 2009 from RMB12.6&#160;million for the same
    period in 2008. This increase
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    81
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    was due primarily to increase in our taxable profits and to a
    lesser extent, a higher effective enterprise income tax rate for
    the nine months ended September&#160;30, 2009 as compared to the
    same period in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Net Income and Net Margin.</I>&#160;&#160;As a result of the
    foregoing, our net income increased by 122.3% to
    RMB89.0&#160;million (US$13.0&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB40.0&#160;million for the
    same period in 2008. Net margin increased to 43.3% for the nine
    months ended September&#160;30, 2009 from 39.2% for the same
    period in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Year Ended December&#160;31, 2008 (Successor Period) Compared to
    the Period From January&#160;1, 2007 to October&#160;30, 2007
    (Predecessor Period)&#160;and the Period from September&#160;10,
    2007 to December&#160;31, 2007 (Successor Period)</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Total Net Revenues.</I>&#160;&#160;Our total net revenues
    were RMB171.8&#160;million (US$25.2&#160;million) in 2008. Our
    total net revenues from leasing and management services were
    RMB155.1&#160;million (US$22.7&#160;million) in 2008, which
    accounted for approximately 37.6% of the total medical service
    fees received in our network of centers in 2008. Our total net
    revenues were RMB67.4&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and
    RMB14.0&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2008, our total net revenues increased due to the addition of
    China Medstar&#146;s network of 23&#160;centers that became
    consolidated in our results of operations from August 2008
    onwards, the revenue contribution from the additional centers
    established by us during 2008 and an increase in patient cases
    for existing centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our total net revenues also increased due to additional revenue
    from management services provided under service-only agreements
    as a result of an increase in the number of patients at centers
    managed under service-only agreements and revenue derived from
    Chang&#146;an Hospital that we began to manage in 2008. Total
    net revenues derived from our management services increased from
    6.4% for the period from January&#160;1, 2007 to
    October&#160;30, 2007, to 7.0% for the period from
    September&#160;10, 2007 to December&#160;31, 2007 and to 7.4% in
    2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Cost of Revenues.</I>&#160;&#160;Our cost of revenues was
    RMB45.6&#160;million (US$6.7&#160;million) in 2008. Our cost of
    revenues was RMB20.4&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and
    RMB3.9&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007. Our cost of revenue as a percentage
    of total net revenues was 26.5% in 2008. Our cost of revenues as
    a percentage of total net revenues was 30.3% for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and 28.0% for the
    period from September&#160;10, 2007 to December&#160;31, 2007.
    Our cost of revenue as a percentage of our total net revenues
    for the period from September&#160;10, 2007 to December&#160;31,
    2007 and in 2008 was affected by the downward purchase price
    adjustment to the fair value of the medical equipment used in
    our network of centers and a decrease in depreciation expenses
    as a result, which was partially offset by the increase in
    amortization of acquired intangibles. Our cost of revenues as a
    percentage of total net revenues is also affected by the
    increase in net revenues derived from service-only agreements as
    a percentage of our total revenue. Service-only agreements do
    not require us to the purchase medical equipment and, as a
    result, we do not incur the associated depreciation expenses for
    the medical equipment used in centers that we manage under
    service-only agreements, resulting in a lower cost of revenues
    as a percentage of total net revenues.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gross Profit and Gross Margin.</I>&#160;&#160;As a result of
    the foregoing, our gross profit was RMB126.2&#160;million
    (US$18.5&#160;million) in 2008. Our gross profit was
    RMB47.0&#160;million for the period from January&#160;1, 2007 to
    October&#160;30, 2007 and RMB10.1&#160;million for the period
    from September&#160;10, 2007 to December&#160;31, 2007. Our
    gross margin was 73.5% in 2008. Our gross margin was 69.7% for
    the period from January&#160;1, 2007 to October&#160;30, 2007
    and 72.0% for the period from September&#160;10, 2007 to
    December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Operating Expenses.</I>&#160;&#160;Our operating expenses
    were RMB24.4&#160;million (US$3.6&#160;million) in 2008. Our
    operating expenses were RMB10.1&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and
    RMB57.9&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007. Our operating expenses as a
    percentage of total net revenues were 14.2% in 2008. Our
    operating expenses as a percentage of total net revenues were
    14.9% for the period from January&#160;1, 2007 to
    October&#160;30, 2007 and 414.3% for the period from
    September&#160;10, 2007 to December&#160;31, 2007.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    82
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Selling Expenses.</I>&#160;&#160;Our selling expenses were
    RMB5.5&#160;million (US$0.8&#160;million) in 2008. Our selling
    expenses were RMB1.6&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and
    RMB0.8&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007. Our selling expenses as a percentage
    of total net revenues were 3.2% in 2008. Our selling expenses as
    a percentage of total net revenues were 2.4% for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and 5.4% for the
    period from September&#160;10, 2007 to December&#160;31, 2007.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>General and Administrative Expenses.</I>&#160;&#160;Our
    general and administrative expenses were RMB18.9&#160;million
    (US$2.8&#160;million) in 2008. Our general and administrative
    expenses were RMB8.5&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and
    RMB57.2&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007. Our general and administrative
    expenses as a percentage of total net revenues were 11.0% in
    2008. Our general and administrative expenses as a percentage of
    total net revenues were 12.6% for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and 408.9% for the
    period from September&#160;10, 2007 to December&#160;31, 2007.
    The general and administrative expenses for the period from
    September&#160;10, 2007 to December&#160;31, 2007 were affected
    by the share-based compensation expenses from the grant of
    certain OMS share options, which amounted to
    RMB49.5&#160;million. The general and administrative expenses in
    2008 were also affected by the share-based compensation expenses
    that amounted to RMB4.2&#160;million (US$0.6&#160;million) from
    the transfer of vested options of certain OMS share options to
    three of our executive directors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Operating (Loss) Income.</I>&#160;&#160;As a result of the
    foregoing, our operating income was RMB101.8&#160;million
    (US$14.9&#160;million) in 2008. Our operating income was
    RMB36.9&#160;million for the period from January&#160;1, 2007 to
    October&#160;30, 2007 and we had an operating loss of
    RMB47.9&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest Expense.</I>&#160;&#160;Our interest expenses was
    RMB7.5&#160;million (US$1.1&#160;million) in 2008. Our interest
    expenses was RMB1.0&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and
    RMB0.3&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Change in Fair Value of Convertible Notes.</I>&#160;&#160;We
    recorded a loss from change in fair value of convertible notes
    of RMB0.5&#160;million (US$68,000) in 2008. We recorded a loss
    from change in fair value of convertible notes was
    RMB0.3&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007 while we did not record such loss for
    the period from January&#160;1, 2007 to October&#160;30, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Foreign Exchange Loss.</I>&#160;&#160;Our foreign exchanges
    loss was RMB0.3&#160;million (US$48,000) in 2008. Our foreign
    exchange loss was RMB4,000 for the period from
    September&#160;10, 2007 to December&#160;31, 2007 while we did
    not record any foreign exchange loss for the period from
    January&#160;1, 2007 to October&#160;30, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>(Loss) Gain from Disposal of Equipment.</I>&#160;&#160;Our
    gain from disposal of equipment under capital lease was
    RMB0.7&#160;million (US$0.1&#160;million) in 2008. Our loss from
    disposal of equipment under capital lease was
    RMB1.6&#160;million for the period from January&#160;1, 2007 to
    October&#160;30, 2007 and was RMB25,000 for the period from
    September&#160;10, 2007 to December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest Income.</I>&#160;&#160;Our interest income was
    RMB0.4&#160;million (US$63,000) in 2008. Our interest income was
    RMB15,000 for the period from January&#160;1, 2007 to
    October&#160;30, 2007 while we did not record such income for
    the period from September&#160;10, 2007 to December&#160;31,
    2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Income.</I>&#160;&#160;We had other income of
    RMB7.7&#160;million (US$1.1&#160;million) in 2008 that was the
    result of restitution payments from certain employees and former
    employees related to the return of corporate funds that they had
    misappropriated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Income Tax Expense.</I>&#160;&#160;Our income tax expense was
    RMB23.3&#160;million (US$3.4&#160;million) in 2008. Our income
    tax expense was RMB15.0&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and our income tax
    benefit was RMB0.2&#160;million for the period from
    September&#160;10, 2007 to December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Net (Loss) Income and Net Margin.</I>&#160;&#160;As a result
    of the foregoing, our net income was RMB79.1&#160;million
    (US$11.6&#160;million) in 2008. Our net income was
    RMB19.4&#160;million for the period from January&#160;1, 2007 to
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    83
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    October&#160;30, 2007 and our net loss was RMB48.3&#160;million
    for the period from September&#160;10, 2007 to December&#160;31,
    2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Year
    Ended December&#160;31, 2008 Compared to Year Ended
    December&#160;31, 2007 on a Combined Basis</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Total Net Revenues.</I>&#160;Our total net revenues increased
    by 111.1% to RMB171.8&#160;million (US$25.2&#160;million) in
    2008 from RMB81.4&#160;million in 2007. This increase was due
    primarily to the increase in lease and management services
    revenues which was a result of 23 centers of China Medstar that
    are consolidated in our results of operations from August 2008,
    seven new centers that we established in 2008 and an increase in
    patient cases from existing centers. The increase in our total
    net revenues was also due to the increase in an increase in the
    number of patients for centers managed under service-only
    agreements and revenues derived from Chang&#146;an Hospital that
    we began to manage in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Cost of Revenues.</I>&#160;Total cost of revenues increased
    by 87.7% to RMB45.6&#160;million (US$6.7&#160;million) in 2008
    from RMB24.3&#160;million in 2007. This increase in our cost of
    revenues was due primarily to an increase in amortization of
    acquired intangibles to RMB20.5&#160;million
    (US$3.0&#160;million) from RMB2.0&#160;million as a result of
    the OMS reorganization, our acquisition of China Medstar in 2008
    and an increase in the number of centers in our network from
    2007 to 2008, which has resulted in an increase in salaries and
    benefits to additional personnel employed by us and assigned to
    the centers and other expenses associated with marketing and
    training activities. Cost of revenues as a percentage of our
    total net revenues decreased to 26.5% in 2008 from 29.9% in
    2007. This decrease was due primarily to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the downward purchase price adjustment to the fair value of the
    medical equipment used in our network of centers and a decrease
    in depreciation expenses as a result;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an increase in net revenues derived from centers managed under
    service-only agreements as a percentage of our total net
    revenues to 7.4% in 2008 from 6.5% in 2007. Centers managed
    under service-only agreements have a lower cost of revenues as a
    percentage of total net revenues as compared to centers managed
    under lease and management services arrangements. This is
    because we do not purchase the medical equipment used in the
    centers managed under service-only agreements and, as a result,
    do not incur the associated equipment depreciation
    expenses;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our acquisition of China Medstar, which had a lower cost of
    revenues as a percentage of total net revenues as compared to
    our company. This was because of the higher cost of certain of
    our installed medical equipment as compared to the cost of China
    Medstar&#146;s medical equipment, which had a higher
    depreciation expenses.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gross Profit and Gross Margin.</I>&#160;As a result of the
    foregoing, our gross profit increased by 121.1% to
    RMB126.2&#160;million (US$18.5&#160;million) in 2008 from
    RMB57.1&#160;million in 2007. Our gross margin increased to
    73.5% in 2008 from 70.1% in 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Operating Expenses.</I>&#160;Our operating expenses decreased
    by 64.1% to RMB24.4&#160;million (US$3.6&#160;million) in 2008
    from RMB68.0&#160;million in 2007 due primarily to a significant
    decrease in our general and administrative expenses as a result
    of a decrease in share-based compensation expenses in 2008 as
    compared to 2007. Operating expenses as a percentage of our
    total net revenues decreased to 14.2% in 2008 from 83.5% in 2007
    due primarily to a decrease in share-based compensation expenses
    in 2008 as compared to 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Selling Expenses.</I>&#160;Our selling expenses increased by
    129.2% to RMB5.5&#160;million (US$0.8&#160;million) in 2008 from
    RMB2.4&#160;million in 2007. This increase in our selling
    expenses was due primarily to an increase in marketing expenses
    and salaries and benefits payment in connection with an increase
    in our business development efforts in 2008 as compared to 2007
    to increase the number of new centers and for the development of
    specialty cancer hospitals. Selling expenses as a percentage of
    our total net revenues in 2008 remained in line with 2007 and
    increased slightly to 3.2% in 2008 from 2.9% in 2007.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>General and Administrative Expenses.</I>&#160;Our general and
    administrative expenses decreased by 71.2% to
    RMB18.9&#160;million (US$2.8&#160;million) in 2008 from
    RMB65.6&#160;million in 2007. Our general and administrative
    expenses include charges of RMB4.2&#160;million
    (US$0.6&#160;million) and RMB49.5&#160;million in 2008 and 2007,
</TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    84
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    respectively, related to share-based compensation. Our general
    and administrative expenses, not including the share-based
    compensation expenses, have also increased in 2008 from 2007,
    which was due primarily to increases in salaries and benefits
    payments in connection with the increased headcount of our
    personnel as well as their travel related expenses.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Operating Income (Loss).</I>&#160;As a result of the
    foregoing, we had operating income of RMB101.8&#160;million
    (US$14.9&#160;million) in 2008 as compared to an operating loss
    of RMB10.9&#160;million in 2007. Operating margin in 2008 was
    59.3% as compared to a negative 13.4% in 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest Expense.</I>&#160;Our interest expense increased by
    525.0% to RMB7.5&#160;million (US$1.1&#160;million) in 2008 from
    RMB1.2&#160;million in 2007. This increase was due primarily to
    increased bank borrowings in 2008 and the increase in the
    average balance of convertible notes that were outstanding
    during 2008 as compared to 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Change in Fair Value of Convertible
    Notes.</I>&#160;&#160;Loss from change in fair value of
    convertible notes we recorded increased by 36.1% to
    RMB0.5&#160;million (US$68,000) in 2008 from RMB0.3&#160;million
    in 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Foreign Exchange Loss.</I>&#160;Our foreign exchange loss
    increased by 8,025.0% to RMB0.3&#160;million (US$48,000) in 2008
    from RMB4,000 in 2007. This increase was due primarily to an
    increase in average foreign currency balance in 2008 as compared
    to 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>(Loss) Gain from Disposal of Equipment.</I>&#160;We recorded
    a gain of RMB0.7&#160;million (US$0.1&#160;million) from the
    disposal of equipment in 2008 while we incurred a loss of
    RMB1.6&#160;million from the disposal of equipment in 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest Income.</I>&#160;Our interest income increased by
    2,766.7% to RMB0.4&#160;million in 2008 from RMB15,000 in 2007.
    This increase was due primarily to an increase in cash balances
    in 2008 as compared to 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Income.</I>&#160;We had other income of
    RMB7.7&#160;million (US$1.1&#160;million) in 2008 that was the
    result of restitution payments from certain employees and former
    employees related to the return of corporate funds that they had
    misappropriated. We did not record such other income in 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Income Tax Expense.</I>&#160;Our income tax expense increased
    by 57.3% to RMB23.3&#160;million (US$3.4&#160;million) in 2008
    from RMB14.8&#160;million in 2007. This increase was due
    primarily to increase in our taxable profits and higher
    effective enterprise income tax rate in 2008 as compared to 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Net (Loss) Income and Net Margin.</I>&#160;As a result of the
    foregoing, our net income was RMB79.1&#160;million
    (US$11.6&#160;million) in 2008 as compared to a net loss of
    RMB28.9&#160;million in 2007. Net margin was 46.0% 2008 as
    compared to negative 35.5% in 2007.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    85
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Selected
    Quarterly Results</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our unaudited consolidated
    quarterly results for the seven quarters ended
    September&#160;30, 2009. You should read the following table in
    conjunction with our audited consolidated financial statements
    and related notes contained elsewhere in this prospectus. The
    consolidated quarterly results information includes all
    adjustments, consisting only of normal recurring adjustments,
    that we consider necessary for a fair presentation of our
    financial position and operating results for the quarters
    presented. These quarterly operating results are not indicative
    of results that may be expected for any future quarters or for a
    full year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="26" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September.&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="26" align="center" valign="bottom">
    <B>(in RMB thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Revenues, net of business tax, value-added tax and related
    surcharges:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,672
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,813
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,811
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,349
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,696
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,892
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,751
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,755
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,158
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,323
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,689
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,873
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    137
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    408
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,685
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,564
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69,796
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,751
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    71,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,092
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,244
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,375
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,171
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,270
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,703
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Amortization of acquired intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,008
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,008
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,655
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,826
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,882
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,882
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,624
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,107
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,350
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,904
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,236
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,056
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,156
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,329
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Gross profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,578
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,214
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,560
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,695
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,761
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (799
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,053
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,423
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,222
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,316
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,476
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,407
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,742
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,319
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,401
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,754
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,722
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,211
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Operating income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,372
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,419
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,098
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,625
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,368
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,973
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,006
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,732
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,162
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,638
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,571
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (883
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,297
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (878
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Foreign exchange (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (76
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    109
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (46
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (312
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    542
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (97
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Gain from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    265
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    266
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    314
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    423
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Income before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,272
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,945
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,777
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,548
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,762
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Income tax expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,062
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,651
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,724
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,709
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,826
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,199
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,348
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,621
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,047
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,839
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,936
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    86
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our unaudited consolidated
    selected quarterly results, as a percentage of our total net
    revenues, for the seven quarters ended September&#160;30, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="37%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="26" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Revenues, net of business tax, value-added tax and related
    surcharges:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91.1
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89.6
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94.4
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    87.1
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84.9
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92.7
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90.9
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Amortization of acquired intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17.7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10.8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9.7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (27.7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24.7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30.8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Gross profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    71.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Operating income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4.8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Foreign exchange (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Gain from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Income before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    71.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Income tax expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business is subject to seasonality factors that have
    resulted in fluctuations in our total net revenues and net
    income in the seven quarters ended September&#160;30, 2009. Our
    network of centers typically treats fewer patients during the
    first quarter as compared to other quarters as a result of the
    Chinese New Year holidays in the first quarter of every year.
    Patients typically choose not to undergo radiotherapy treatment
    or receive diagnostic imaging services during holidays. We
    believe that our revenues will continue to be affected in the
    future by the seasonality of our business. Our business is also
    subject to the effect of acquisitions. We experienced a
    significant increase in our total net revenues and results of
    operations in the three months ended December&#160;31, 2008,
    which was primarily the result of our acquisition of China
    Medstar that added 23 centers into our network of centers. We
    plan to continue the expansion of our network of centers through
    selective strategic acquisitions in the future, and therefore
    our results in future quarters may be materially impacted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our cost of revenues varies from quarter to quarter and does not
    necessarily correspond to changes in our total net revenues. Our
    cost of revenues are primarily comprised of depreciation and
    amortization expenses associated with the costs of the medical
    equipment and our acquired intangible assets, which are not
    necessarily indicative of the performance of our network of
    centers during the relevant quarter.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    87
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Liquidity
    and Capital Resources</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth a summary of our net cash flows
    for the periods indicated:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="37%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Nine Months Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>October 30,&#160;2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="27" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,774
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,308
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash used in investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (50,452
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30,441
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (376,371
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (55,136
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (300,692
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (223,426
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32,731
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    649,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95,147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    278,407
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,448
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,698
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (834
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,949
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (191
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net increase (decrease) in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    314,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (864
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68,288
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,004
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash at beginning of the period/year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash at end of the period/year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    285,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To date, we have financed our operations primarily through cash
    flows from operations and short- and long-term bank borrowings,
    as well as the issuance of convertible notes and contingently
    redeemable convertible preferred shares. As of December&#160;31,
    2007 and 2008 and as of September&#160;30, 2009, we had
    RMB39.8&#160;million, RMB354.0&#160;million
    (US$51.9&#160;million) and RMB285.7&#160;million
    (US$41.9&#160;million) in cash, respectively. As of
    September&#160;30, 2009, we had RMB30.0&#160;million
    (US$4.4&#160;million) in short-term borrowings outstanding and
    RMB149.8&#160;million (US$21.9&#160;million) in long-term
    borrowings outstanding, including the current portion of such
    long-term borrowings outstanding. As of December&#160;31, 2008,
    we had RMB20.8&#160;million (US$3.0&#160;million) in short-term
    bank borrowings outstanding and RMB92.0&#160;million
    (US$13.5&#160;million) in long-term bank borrowings outstanding,
    including the current portion of such long-term borrowings
    outstanding. We did not have any short-term and long-term bank
    borrowings outstanding as of December&#160;31, 2007. Our cash
    primarily consists of cash on hand and bank deposits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2009, we entered into a framework strategic
    cooperation agreement with China Construction Bank Company
    Limited, Shenzhen Branch, or CCB Shenzhen. Under the agreement,
    subject to compliance by CCB Shenzhen with relevant laws and
    regulations, credit approval by CCB Shenzhen and the negotiation
    and signing of definitive loan agreements, CCB Shenzhen intends
    to grant us credit facilities up to an amount equivalent to
    RMB1.5&#160;billion (US$219.7&#160;million), either in RMB or in
    foreign currencies, over the course of the next three years to
    support our development. The credit facilities may be in the
    form of, among others, working capital loans, fixed asset
    project loans, bridge loans or guarantees.  No assurance can be
    given that any portion of such credit facilities will be
    eventually granted to us as currently contemplated in this
    agreement or at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Operating
    Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The primary factors affecting our operating cash flow is the
    amount and timing of payments of our contractual percentage of
    each center&#146;s revenue net of specified operating expenses
    that we received from our hospital partners and cash payments
    that we made in connection with establishing new centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from operating activities increased by 281.8%
    to RMB104.5&#160;million (US$15.3&#160;million) for the nine
    months ended September&#160;30, 2009 from RMB27.4&#160;million
    for the same period in 2008. Net cash generated from operating
    activities for the nine months ended September&#160;30, 2009 was
    due primarily to cash received from an increased number of
    hospital partners which, in turn, was primarily a result of our
    acquisition of China Medstar. This increase was partially offset
    by an increase in accounts receivable and a decrease in accrued
    expenses and other liabilities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from operating activities in 2008 was
    RMB46.8&#160;million (US$6.9&#160;million). Net cash generated
    from operating activities was due primarily to cash received
    from our hospital partners, which was
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    88
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    partially offset by deposits made by us that amounted to
    RMB15.0&#160;million (US$2.2&#160;million) to Chang&#146;an
    Hospital as performance guarantee, a decrease in accounts
    payable that amounted to RMB20.2&#160;million
    (US$3.0&#160;million) and an increase in accounts receivable
    that amounted to RMB19.3&#160;million (US$2.8&#160;million).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from operating activities for the period from
    September&#160;10, 2007 to December&#160;31, 2007 was
    RMB6.1&#160;million. Net cash generated from operating
    activities was due primarily to an increase in accrued expenses
    and other liabilities that amounted to RMB2.0&#160;million and a
    decrease in advance made to a hospital of RMB2.7&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from operating activities for the period from
    January&#160;1, 2007 to October&#160;30, 2007 was
    RMB44.6&#160;million. Net cash generated from operating
    activities was due primarily to cash received from our hospital
    partners and an increase in accrued expenses and other
    liabilities of RMB4.1&#160;million, which was partially offset
    by an increase in accounts receivable of RMB5.4&#160;million and
    an increase in prepayments and other current assets of
    RMB4.8&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Investing
    Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used in investing activities for the nine months ended
    September&#160;30, 2009 was RMB223.4&#160;million
    (US$32.7&#160;million). Net cash used in investing activities
    for the nine months ended September&#160;30, 2009 was due
    primarily to (i)&#160;deposits paid for the purchase of medical
    equipment for new centers that amounted to RMB116.1&#160;million
    (US$17.0&#160;million), (ii)&#160;the purchase of medical
    equipment for new centers (including the purchase from
    Chang&#146;an Hospital of the six units of radiotherapy and
    diagnostic imaging equipment) that amounted to
    RMB74.0&#160;million (US$10.8&#160;million) and (iii)&#160;the
    payment of the remaining acquisition consideration for Xing Heng
    Feng Medical and certain other business of RMB21.5&#160;million
    (US$3.2&#160;million).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used in investing activities in 2008 was
    RMB376.4&#160;million (US$55.1&#160;million). Net cash used in
    investing activities in 2008 was due primarily to our
    acquisitions of China Medstar, Xing Heng Feng Medical and
    certain other businesses to expand our network that amounted to
    RMB231.5&#160;million (US$33.9&#160;million), deposits paid for
    the purchase of medical equipment for new centers that amounted
    to RMB95.1&#160;million (US$13.9&#160;million) and the purchase
    of medical equipment for new centers that amounted to
    RMB31.6&#160;million (US$4.6&#160;million).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used in investing activities for the period from
    September&#160;10, 2007 to December&#160;31, 2007 was
    RMB30.4&#160;million. Net cash used in investing activities for
    the period was due primarily to the purchase of medical
    equipment for new centers that amounted to RMB22.5&#160;million
    and the deposits paid for the purchase of medical equipment for
    new centers that amounted to RMB13.6&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used in investing activities for the period from
    January&#160;1, 2007 to October&#160;30, 2007 was
    RMB50.5&#160;million. Net cash used in investing activities for
    the period was due primarily to the purchase of medical
    equipment for new centers that amounted to RMB43.4&#160;million
    and the deposits paid for the purchase of medical equipment for
    new centers that amounted to RMB13.0&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Financing
    Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from financing activities for the nine months
    ended September&#160;30, 2009 was RMB50.8&#160;million
    (US$7.4&#160;million). Net cash generated from financing
    activities for the nine months ended September&#160;30, 2009 was
    due primarily to the proceeds from long-term bank borrowings of
    RMB128.8&#160;million (US$18.9&#160;million) and the proceeds
    from short-term bank borrowings of RMB19.0&#160;million
    (US$2.8&#160;million), which were partially offset by the
    repayment of long-term bank borrowings of RMB70.9&#160;million
    (US$10.4&#160;million), the repayment of short-term bank
    borrowings of RMB9.8&#160;million (US$1.4&#160;million) and an
    increase in restricted cash of RMB7.2&#160;million
    (US$1.1&#160;million).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from financing activities in 2008 was
    RMB649.5&#160;million (US$95.1&#160;million). Net cash generated
    from financing activities in 2008 was due primarily to proceeds
    received from the issuance of our Series&#160;A and
    Series&#160;B contingently redeemable convertible preferred
    shares and convertible notes that amounted to
    RMB613.2&#160;million (US$89.8&#160;million), proceeds received
    from the exercise of share options that amounted to
    RMB114.6&#160;million (US$16.8&#160;million) and proceeds from
    short-term bank borrowings of RMB20.8&#160;million
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    89
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (US$3.0&#160;million), which was partially offset by repayments
    of loans from certain related parties that amounted to
    RMB41.7&#160;million (US$6.1&#160;million), the repayment of
    long-term bank borrowings of RMB37.9&#160;million
    (US$5.6&#160;million) and the repayment of short-term bank
    borrowings of RMB21.5&#160;million (US$3.1&#160;million).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from financing activities for the period from
    September&#160;10, 2007 to December&#160;31, 2007 was
    RMB63.2&#160;million. Net cash generated from financing
    activities for the period was due primarily to proceeds received
    from the issuance of our convertible notes that amounted to
    RMB36.5&#160;million and loan received from certain shareholders
    that amounted to RMB32.4&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from financing activities for the period from
    January&#160;1, 2007 to October&#160;30, 2007 was
    RMB6.0&#160;million. Net cash generated from financing
    activities for the period was due primarily to loan received
    from certain shareholders that amounted to RMB6.8&#160;million
    which was partially offset by repayment of obligations under
    capitalized leases of RMB0.8&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Acquisitions
    and Capital Expenditures</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In July 2008, we acquired China Medstar for
    &#163;17.1&#160;million, or approximately RMB238.7&#160;million
    (US$35.0&#160;million) in cash. The transaction was accepted by
    the shareholders of China Medstar and closed on July&#160;31,
    2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also acquired control of Xing Heng Feng Medical in October
    2008 for total consideration of RMB35.0&#160;million
    (US$5.1&#160;million). As of December&#160;31, 2008,
    RMB18.0&#160;million (US$2.6&#160;million) of the acquisition
    consideration was still payable which was subsequently paid in
    January 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also acquired certain other businesses related to
    radiotherapy and diagnostic imaging centers managed by third
    parties for total consideration of RMB14.0&#160;million
    (US$2.0&#160;million). As of September&#160;30, 2009, the
    acquisition consideration of RMB6.5&#160;million
    (US$1.0&#160;million) was still payable. We expect to pay the
    remaining RMB6.5&#160;million (US$1.0&#160;million) before the
    end of 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007 and 2008 and for the nine months ended
    September&#160;30, 2009, our capital expenditures totaled
    RMB65.9&#160;million, RMB31.6&#160;million (US$4.6&#160;million)
    and RMB74.0&#160;million (US$10.8&#160;million), respectively.
    In past years, our capital expenditures related primarily to the
    purchase of medical equipment and the acquisition of assets from
    third parties. Capital expenditure decreased in 2008 as compared
    to 2007 due to our expansion of our network through the
    acquisitions of China Medstar, Xing Heng Feng Medical and other
    businesses in 2008. In August 2009, we purchased from
    Chang&#146;an Hospital the six units of radiotherapy and
    diagnostic imaging equipment that were located at the six
    centers that we previously managed under service-only agreements
    with Chang&#146;an Hospital. The total agreed upon consideration
    for such equipment was approximately RMB72.7&#160;million
    (US$10.7&#160;million), of which RMB50.0&#160;million
    (US$7.3&#160;million) was paid as of September&#160;30, 2009. We
    paid an additional RMB20.0&#160;million (US$2.9&#160;million) of
    the consideration in October 2009 and we expect to pay the
    remaining RMB2.7&#160;million (US$0.5&#160;million) before the
    end of 2009. We subsequently entered into a long-term lease and
    management services arrangement with Chang&#146;an Hospital
    pursuant to which we leased these six units of equipment to
    Chang&#146;an Hospital. Two of the six units of equipment were
    combined into one center and we provide lease and management
    services to the five remaining centers in which these six units
    of equipment are located. We estimate that our aggregate capital
    expenditures for the balance of 2009 and in 2010 will be
    approximately RMB1,200.0&#160;million (US$175.8&#160;million),
    which we will use mainly for the continued expansion of our
    network, including for the purchase of medical equipment and for
    the establishment of our specialty cancer hospitals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that our current levels of cash and cash flows from
    operations, combined with the net proceeds from this offering
    and bank loans of approximately RMB190.0&#160;million
    (US$27.8&#160;million) that we expect to obtain in 2010 to fund
    the development of our specialty cancer hospitals, will be
    sufficient to meet our anticipated cash needs for at least the
    next 12&#160;months following this offering. However, we may
    need additional cash resources in the future if we experience
    changed business conditions or other developments or if we find
    and wish to pursue opportunities for investment, acquisition,
    strategic cooperation or other similar actions. If we ever
    determine that our cash requirements exceed our amounts of cash
    on hand, we may seek to issue debt or equity securities or
    obtain a credit facility. Any issuance of equity or
    equity-linked securities could cause dilution for our
    shareholders. Any incurrence of indebtedness could increase our
    debt service obligations and cause us to be subject to
    restrictive operating and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    90
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    finance covenants. It is possible that, when we need additional
    cash resources, financing will only be available to us in
    amounts or on terms that would not be acceptable to us or
    financing will not be available at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Contractual
    Obligations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our contractual obligations at
    December&#160;31, 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom">
    <B>Contractual Obligations</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Less Than<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>More Than<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">1&#160;Year</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">1-3&#160;Year</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">3-5&#160;Year</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">5&#160;Years</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Total</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Short-term debt obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term debt obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91,960
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Capital lease obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,562
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,392
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating lease obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,547
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Purchase obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    115,919
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    115,919
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,343
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,385
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,536
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,264
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our short- and long-term debt obligations as of
    December&#160;31, 2008 represent bank borrowings obtained by our
    subsidiary Shanghai Medstar. All such borrowings were entered
    into with the Agricultural Bank of China and are secured by
    medical equipment under capital lease. Our short-term bank
    borrowing outstanding as of December&#160;31, 2008 had a
    weighted average interest rate of 6.66% per annum. Our long-term
    bank borrowing outstanding as of December&#160;31, 2008 had a
    weighted average interest rate of 7.47% per annum.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of September&#160;30, 2009, we had RMB30.0&#160;million
    (US$4.4&#160;million) in short-term borrowings outstanding and
    RMB149.8&#160;million (US$21.9&#160;million) in long-term
    borrowings outstanding, including the current portion of such
    long-term borrowings outstanding. Our short-term borrowing bore
    a weighted average interest of 5.07% per annum and our long-term
    borrowings bore a weighted average interest of 5.18% per annum.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shanghai Medstar entered into three additional long-term
    borrowing arrangements with the Agricultural Bank of China with
    a total amount of RMB53.8&#160;million (US$7.9&#160;million),
    all with a term to maturity of three years. These long-term
    borrowing arrangements each has a variable annual interest rate
    equal to 90% of the benchmark lending rate of the People&#146;s
    Bank of China adjusted every three months. Shanghai Medstar is
    required to make monthly payments beginning in October 2009 in
    an amount equal to RMB170,000 (US$24,900) and a final payment of
    RMB50,000 (US$7,300) related to one of the borrowings and
    monthly payments beginning in November 2009 in an amount equal
    to RMB1.2&#160;million (US$0.2&#160;million) and a final payment
    of RMB0.4 million (US$0.1&#160;million) related to another
    borrowing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shanghai Medstar also entered into a short-term loan agreement
    in June 2009 with HSBC Bank (China) Company Limited for
    RMB15.0&#160;million (US$2.2&#160;million) that matures in June
    2010 bearing interest at a rate of 5.16%, secured by account
    receivables of Shanghai Medstar and guaranteed by Aohua Medical.
    This borrowing contains restrictive covenants requiring the
    maintenance of tangible net worth of RMB400.0&#160;million and
    RMB180.0&#160;million by China Medstar and Aohua Medical,
    respectively, and a total liability to tangible net worth ratio
    of 0.5 times and 0.36 times at all time for China Medstar and
    Aohua Medical, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aohua Medical has entered into a long-term loan agreement in
    January 2009 with China Construction Bank, Shenzhen Branch for
    RMB20.0&#160;million (US$2.9&#160;million) that matures in
    January 2012. This long-term borrowing has a variable annual
    interest rate equal to 110% of the benchmark lending rate of the
    People&#146;s Bank of China, adjusted every 12&#160;months,
    secured by accounts receivable of Aohua Medical and Aohua
    Leasing and guaranteed by Aohua Leasing. Aohua Medical is
    required to make monthly repayments as to the principal of the
    borrowing beginning on the fourth month after the loan is
    obtained.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aohua Medical obtained a bank loan facility in the principal
    amount of RMB20.0&#160;million (US$2.9&#160;million) from China
    Merchant Bank Company Limited in September 2009 that expires in
    September 2010. This bank loan facility is guaranteed by Aohua
    Leasing. Interest rate for this bank loan facility is to be
    determined in accordance
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    91
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    with the specific loan agreement entered into every time the
    facility is drawn down. As of September&#160;30, 2009, Aohua
    Medical had drawn down RMB4.0&#160;million (US$0.6&#160;million)
    of this facility.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aohua Leasing entered into a RMB100.0&#160;million
    (US$14.6&#160;million) banking facility with China Construction
    Bank in August 2009 that matures in August 2012. This banking
    facility bears interest rate equal to a floating rate of the
    People&#146;s Bank of China&#146;s benchmark lending rate
    adjusted every twelve months, which was 5.4% in August 2009. We
    expect to use this banking facility for the purchase of medical
    equipment in the future and any amount drawn under the facility
    will be secured by the respective medical equipment to be
    purchased and accounts receivable of Aohua Leasing, as well as
    guaranteed by Aohua Medical and Shanghai Medstar. Aohua Leasing
    is required under the facility agreement to make quarterly
    repayments of the principal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aohua Leasing obtained a trade financing facility in the
    principal amount of RMB20.0&#160;million (US$2.9&#160;million)
    from China Construction Bank in August 2009 that expires in
    2010. Under this trade financing facility, Aohua Leasing is
    required to pay a management fee to China Construction Bank in
    an amount equal to 5.5% of the total principal amount under this
    facility. This trade financing facility is secured by accounts
    receivable of Aohua Leasing and guaranteed by Aohua Medical and
    Shanghai Medstar.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect to obtain bank loans of approximately
    RMB90.0&#160;million (US$13.2&#160;million) in 2010 to fund the
    development of the Chang&#146;an CMS International Cancer
    Center. We also expect to obtain bank loans of approximately
    RMB100.0&#160;million (US$14.6&#160;million) in 2010 to fund the
    development of the Beijing Proton Medical Center.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the nine months ended September&#160;30, 2009, we entered
    into two non-cancellable corporate office operating leases with
    a lease term of two and three years, respectively. As of
    September&#160;30, 2009, our operating lease obligation for the
    remainder of 2009, 2010, 2011 and 2012 was RMB1.3 million
    (US$0.2 million), RMB5.1 million (US$0.8 million), RMB4.8
    million (US$0.7 million) and RMB2.3 million (US$0.3 million),
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of September&#160;30, 2009, we had purchase obligation for
    certain medical equipment that amounted to RMB102.7 million
    (US$15.0 million), which are all scheduled to be paid within one
    year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Off-Balance
    Sheet Arrangements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not engage in trading activities involving non-exchange
    traded contracts or interest rate swap transactions or foreign
    currency forward contracts. In the ordinary course of our
    business, we do not enter into transactions involving, or
    otherwise form relationships with, unconsolidated entities or
    financials partnerships that are established for the purpose of
    facilitating off-balance sheet arrangements or other
    contractually narrow or limited purposes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Inflation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In recent years, China has not experienced significant
    inflation, and thus inflation has not had a material impact on
    our results of operations. According to the National Bureau of
    Statistics of China, the change in China&#146;s Consumer Price
    Index was 1.5%, 4.8% and 5.9% in the years 2006, 2007 and 2008,
    respectively. If inflation continues to rise, it may materially
    and adversely affect our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Quantitative
    and Qualitative Disclosure about Market Risk</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Foreign
    Exchange Risk</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All of our revenues and substantially all of our expenditures
    are denominated in Renminbi. However, the price of medical
    equipment that we purchase from foreign manufacturers is
    denominated in U.S.&#160;dollars. We pay for such equipment in
    Renminbi through importers at a pre-determined exchange rate
    that is typically agreed to at the time of purchase that will be
    adjusted to a certain extent if there is significant fluctuation
    as to the exchange rate. As a result, fluctuations in the
    exchange rate between the U.S.&#160;dollar and the Renminbi will
    affect the cost of such medical equipment to us and will affect
    our results of operation and financial condition. Such
    fluctuations will also affect us with respect to the translation
    of the net proceeds that we will receive from this offering into
    Renminbi. The Renminbi&#146;s exchange rate with the
    U.S.&#160;dollar and other currencies is affected by, among
    other things, changes in
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    92
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China&#146;s political and economic conditions. See &#147;Risk
    Factors&#160;&#151; Risks Related to Doing Business in
    China&#160;&#151; Fluctuations in the value of the Renminbi may
    have a material adverse effect on your investment.&#148; Any
    significant revaluation of the Renminbi may materially and
    adversely affect our cash flows, revenues, earnings and
    financial position, and the value of, and any dividends payable
    on, our ADSs in U.S.&#160;dollars. Based on the amount of our
    cash denominated in U.S.&#160;dollar as of September&#160;30,
    2009, a 10% change in the exchange rates between the Renminbi
    and the U.S.&#160;dollar would result in an increase or decrease
    of RMB24.3&#160;million (US$3.6&#160;million) in our total cash
    position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The functional currency of our company and our subsidiaries,
    including Ascendium, CMS Holdings, OMS, Cyber Medical and China
    Medstar, is the U.S.&#160;Dollar. Our PRC subsidiaries have
    determined their functional currencies to be the Renminbi based
    on the criteria of Statement of Financial Accounting Standards
    No.&#160;52, &#147;Foreign Currency Translation,&#148; or
    SFAS&#160;52. We use the Renminbi as our reporting currency. We
    use the monthly average exchange rate for the year and the
    exchange rate at the balance sheet date to translate the
    operating results and financial position of our PRC
    subsidiaries, respectively. Translation differences are recorded
    in accumulated other comprehensive income, a component of
    shareholders&#146; equity. Transactions denominated in foreign
    currencies are remeasured into our functional currency at the
    exchange rates prevailing on the transaction dates. Foreign
    currency denominated financial assets and liabilities are
    remeasured at the balance sheet date exchange rate. Exchange
    gains and losses are included in the consolidated statements of
    income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Interest
    Rate Risk</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our exposure to interest rate risk relates to interest expenses
    incurred by our short-term and long-term bank borrowings and
    interest income on our interest-bearing bank deposits. We have
    not used any derivative financial instruments or engaged in any
    interest rate hedging activities to manage our interest rate
    risk exposure. Our future interest expense on our short-term and
    long-term borrowings may increase or decrease due to changes in
    market interest rates. During 2008, our short-term and long-term
    bank borrowings, all of which were denominated in Renminbi, had
    a weighted average interest rate of 6.66% per annum and 7.47%
    per annum, respectively. Our future interest income on our
    interest-bearing cash and pledged deposit balances may increase
    or decrease due to changes in market interest conditions. We
    monitor interest rates in conjunction with our cash requirements
    to determine the appropriate level of bank borrowings relative
    to other sources of funds. Based on our outstanding borrowings
    during the six months ended September&#160;30, 2009, a 10%
    change in the interest rates would result in an increase or
    decrease of RMB0.5&#160;million (US$0.1&#160;million) of our
    total amount of interest expense for the nine months ended
    September&#160;30, 2009. Based on our outstanding interest
    earning instruments during the nine months ended
    September&#160;30, 2009, a 10% change in the interest rates
    would result in an increase or decrease of RMB 82,000
    (US$12,000) in our total amount of interest income for the nine
    months ended September&#160;30, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There have been no developments to recently issued accounting
    standards, including the expected dates of adoption and
    estimated effects on the Group&#146;s consolidated financial
    statements, from those disclosed in the Group&#146;s
    consolidated financial statements for the year ended
    December&#160;31, 2008, except for the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In April 2009, the Financial Accounting Standards Board, or
    FASB, issued Accounting Standards Codification
    <FONT style="white-space: nowrap">805-20,</FONT>
    &#147;Accounting for Assets Acquired and Liabilities Assumed in
    a Business Combination That Arise from Contingencies,&#148; or
    ASC <FONT style="white-space: nowrap">805-20,</FONT>
    to amend SFAS 141 (revised 2007)&#160;&#147;Business
    Combinations.&#148; ASC
    <FONT style="white-space: nowrap">805-20</FONT>
    addresses the initial recognition, measurement and subsequent
    accounting for assets and liabilities arising from contingencies
    in a business combination, and requires that such assets
    acquired or liabilities assumed be initially recognized at fair
    value at the acquisition date if fair value can be determined
    during the measurement period. If the acquisition-date fair
    value cannot be determined, the asset acquired or liability
    assumed arising from a contingency is recognized only if certain
    criteria are met. ASC
    <FONT style="white-space: nowrap">805-20</FONT> also
    requires that a systematic and rational basis for subsequently
    measuring and accounting for the assets or liabilities be
    developed depending on their nature. The Company does not
    anticipate that the adoption of this statement will have a
    material impact on its consolidated financial statements, absent
    any material business combinations.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2009, the FASB issued SFAS&#160;No.&#160;166,
    &#147;Accounting for Transfers of Financial Assets&#160;&#151;
    an amendment of FASB Statement No. 140,&#148; or SFAS&#160;166.
    SFAS&#160;166 seeks to improve the relevance,
</TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    93
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    representational faithfulness, and comparability of the
    information that a reporting entity provides in its financial
    statements about a transfer of financial assets; the effects of
    a transfer on its financial position, financial performance, and
    cash flows; and a transferor&#146;s continuing involvement, if
    any, in transferred financial assets. Specifically,
    SFAS&#160;166 eliminates the concept of a qualifying
    special-purpose entity, creates more stringent conditions for
    reporting a transfer of a portion of a financial asset as a
    sale, clarifies other sale-accounting criteria, and changes the
    initial measurement of a transferor&#146;s interest in
    transferred financial assets. The Company does not anticipate
    that the adoption of this statement will have a material impact
    on its consolidated financial statements.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2009, the FASB issued SFAS&#160;No.&#160;167,
    &#147;Amendments to FASB Interpretation No.&#160;46(R),&#148; or
    SFAS&#160;167. SFAS&#160;167 amends FASB Interpretation
    No.&#160;46(R), &#147;Variable Interest Entities&#148; for
    determining whether an entity is a variable interest entity, or
    VIE, and requires an enterprise to perform an analysis to
    determine whether the enterprise&#146;s variable interest or
    interests give it a controlling financial interest in a VIE.
    Under SFAS&#160;167, an enterprise has a controlling financial
    interest when it has a)&#160;the power to direct the activities
    of a VIE that most significantly impact the entity&#146;s
    economic performance and b)&#160;the obligation to absorb losses
    of the entity or the right to receive benefits from the entity
    that could potentially be significant to the VIE. SFAS 167 also
    requires an enterprise to assess whether it has an implicit
    financial responsibility to ensure that a VIE operates as
    designed when determining whether it has power to direct the
    activities of the VIE that most significantly impact the
    entity&#146;s economic performance. SFAS&#160;167 also requires
    ongoing assessments of whether an enterprise is the primary
    beneficiary of a VIE, requires enhanced disclosures and
    eliminates the scope exclusion for qualifying special-purpose
    entities. The Company is currently evaluating the impact the
    adoption of SFAS&#160;167 will have on its consolidated
    financial statements.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2009, the FASB issued Statement of Financial Accounting
    Standard, or SFAS, No.&#160;168, The FASB Accounting Standards
    Codification<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    and the Hierarchy of Generally Accepted Accounting Principles, a
    replacement of FASB Statement No.&#160;162. This statement
    modifies the Generally Accepted Accounting Principles, or GAAP,
    hierarchy by establishing only two levels of GAAP, authoritative
    and nonauthoritative accounting literature. Effective July 2009,
    the FASB Accounting Standards
    Codification<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>,

    or ASC, also known collectively as the &#147;Codification,&#148;
    is considered the single source of authoritative
    U.S.&#160;accounting and reporting standards, except for
    additional authoritative rules and interpretive releases issued
    by the SEC. Nonauthoritative guidance and literature would
    include, among other things, FASB Concepts Statements, American
    Institute of Certified Public Accountants Issue Papers and
    Technical Practice Aids and accounting textbooks. The
    Codification was developed to organize U.S.&#160;GAAP
    pronouncements by topic so that users can more easily access
    authoritative accounting guidance. It is organized by topic,
    subtopic, section, and paragraph, each of which is identified by
    a numerical designation. This statement applies beginning in
    third quarter 2009. All accounting references have been updated,
    and therefore U.S.&#160;GAAP standards have been replaced with
    ASC references. This standard had no impact on the
    Company&#146;s financial position, results of operations or cash
    flows.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In August 2009, the FASB issued Accounting Standards Update
    <FONT style="white-space: nowrap">No.&#160;2009-5,</FONT>
    &#147;Measuring Liabilities at Fair Value,&#148; or ASU
    <FONT style="white-space: nowrap">2009-05.</FONT> ASU
    <FONT style="white-space: nowrap">2009-05</FONT>
    amends Accounting Standards Codification Topic 820, &#147;Fair
    Value Measurements.&#148; Specifically, ASU
    <FONT style="white-space: nowrap">2009-05</FONT>
    provides clarification that in circumstances in which a quoted
    price in an active market for the identical liability is not
    available, a reporting entity is required to measure fair value
    using one or more of the following methods: 1)&#160;a valuation
    technique that uses a)&#160;the quoted price of the identical
    liability when traded as an asset or b)&#160;quoted prices for
    similar liabilities or similar liabilities when traded as assets
    <FONT style="white-space: nowrap">and/or</FONT>
    2)&#160;a valuation technique that is consistent with the
    principles of Topic 820 of the Accounting Standards Codification
    (e.g. an income approach or market approach). ASU
    <FONT style="white-space: nowrap">2009-05</FONT> also
    clarifies that when estimating the fair value of a liability, a
    reporting entity is not required to adjust to include inputs
    relating to the existence of transfer restrictions on that
    liability. The Company does not anticipate that the adoption of
    this statement will have a material impact on its consolidated
    financial statements.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    94
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In September 2009, the Emerging Issues Task Force, or EITF,
    reached final consensus on ASC
    <FONT style="white-space: nowrap">605-25,</FONT>
    &#147;Revenue Arrangements with Multiple Deliverables.&#148; ASC
    <FONT style="white-space: nowrap">605-25</FONT>
    addresses how to determine whether an arrangement involving
    multiple deliverables contains more than one unit of accounting,
    and how the arrangement consideration should be allocated among
    the separate units of accounting.
    <FONT style="white-space: nowrap">EITF&#160;08-1</FONT>
    may be applied retrospectively or prospectively for new or
    materially modified arrangements and early adoption is
    permitted. The Company does not anticipate that the adoption of
    this statement will have a material impact on its consolidated
    financial statements.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    95
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='113'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">OUR
    INDUSTRY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cancer was the leading cause of death in China in 2008 according
    to the MOH. Approximately 3.5&#160;million patients were
    diagnosed with cancer in 2008 in China, according to a
    commissioned report by Frost&#160;&#038; Sullivan.
    Frost&#160;&#038; Sullivan also estimated that the cancer
    radiotherapy and diagnostic imaging market in China was
    RMB16.6&#160;billion (US$2.4&#160;billion) in 2008 and is
    expected to grow to RMB68.3&#160;billion (US$10.0&#160;billion)
    in 2015, representing a CAGR of 22.4%. Among the factors
    contributing to this growth rate are significant projected
    growth in the number of new cancer cases due to the continued
    aging and urbanization of the Chinese population, increased
    affordability of cancer diagnosis and treatment as a result of
    rising disposable income and increased government expenditure on
    healthcare and growing awareness and adoption of advanced cancer
    diagnosis and treatment modalities by Chinese patients and
    physicians.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cancer in
    China</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cancer was the leading cause of death in China in 2008. Based on
    MOH data, cancer accounted for 2.1&#160;million deaths, or 26.2%
    of total deaths in China in 2008. There were approximately
    3.5&#160;million patients diagnosed with cancer in China in
    2008, according to a report by Frost&#160;&#038; Sullivan.
    Frost&#160;&#038; Sullivan further estimates that new cancer
    cases will increase to approximately 4.1&#160;million in China
    in 2015, representing CAGR of 2.6%, compared to an estimated
    CAGR of 1.5% for the United States over the same period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to a survey conducted by the MOH in 2008, the increase
    in cancer cases in China is primarily attributable to
    demographic changes and urbanization, since elderly and urban
    populations exhibit higher rates of cancer compared to the
    overall population. With respect to demographic changes,
    China&#146;s population increased by 9.6% from approximately
    1.2&#160;billion in 1995 to approximately 1.3&#160;billion in
    2008, while the number of individuals over 65&#160;years old
    increased by 46.8% from 75.1&#160;million to 110.2&#160;million
    over the same period. In contrast, according to United States
    Census Bureau, the U.S.&#160;population increased by 14.1% from
    266.6&#160;million in 1995 to 304.1&#160;million in 2008, while
    the number of individuals over 65&#160;years old increased by
    15.2% from 33.8&#160;million to 38.9&#160;million over the same
    period. Additionally, China&#146;s urban population increased by
    72.5% from 351.7&#160;million in 1995 to 606.7&#160;million in
    2008. According to the MOH, tobacco usage and environmental
    pollution have also contributed to higher rates of cancer for
    China&#146;s urban residents. All of these factors suggest a
    significant increase in potential demand for cancer diagnosis
    and treatment in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cancer
    Diagnosis and Treatment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Modern cancer treatments rely heavily on the utilization of
    advanced diagnostic imaging technologies such as computerized
    tomography, or CT, magnetic resonance imaging, or MRI and
    positron emission tomography, or PET. Principal cancer
    treatments include various types of radiotherapy, chemotherapy
    and surgery, which may be used alone or in combination with each
    other. With respect to radiotherapy, there are several different
    treatment options, including gamma knife systems and linear
    accelerators, as well as the more advanced proton therapy
    systems. The choice of cancer treatment options depends upon the
    location of the tumor in the body, the type of the tumor and the
    stage of the disease, as well as the general state of health of
    the patient. The WHO reported in its 2008 World Cancer Report
    that a little over 50% of all patients who develop cancer will
    require some type of radiotherapy during their illness.
    According to a report by Frost&#160;&#038; Sullivan, the
    percentage of cancer patients who underwent surgery,
    chemotherapy and radiotherapy in China in 2008 was approximately
    74.0%, 70.3% and 32.6%, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Radiotherapy (also called &#147;radiation therapy&#148; or
    &#147;radiation treatment&#148;) utilizes focused doses of
    intense radiation to kill cancer cells and shrink tumors.
    Radiotherapy can be used to treat almost every type of malignant
    solid tumor as well as benign tumors. Advances in different
    imaging modalities (e.g., PET-CT) and the integrated use of
    these modalities with radiotherapy are expected to enhance the
    precision of radiotherapy treatments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Provision
    of Healthcare Services in China</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Healthcare services in China are provided primarily at
    hospitals. Patients visit the hospital for both in-patient and
    most out-patient care. Physicians are typically employed by
    hospitals and work on the hospital premises. According to the
    MOH and the general logistics department of the PLA, at the end
    of 2008, there were approximately 19,800 hospitals in China,
    including approximately 115 specialty cancer hospitals.
    Approximately 80% of hospitals in China
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    96
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    are owned by the government, government agencies, government
    controlled corporations or the military. Such hospitals
    (including military hospitals) typically serve the general
    public. While these hospitals are owned in some way by the
    government, they receive little direct government funding and
    are individually financed. These government hospitals also
    operate largely independently of each other and generally do not
    operate as groups of hospitals under common control. Ownership
    of privately-owned hospitals in China is also fragmented, with a
    lack of dominant groups of hospitals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China has a relatively underdeveloped medical infrastructure,
    which has resulted in significant unmet demand for medical
    services in China. According to the WHO, there were 22 hospital
    beds per 10,000&#160;people in China in 2008 versus 31, 39, 86
    and 140 hospital beds per 10,000 people in the United States,
    the United Kingdom, Korea and Japan, respectively. The average
    occupancy rate for China&#146;s hospitals in 2008 was 74.6%,
    while the average occupancy rate for China&#146;s specialty
    cancer hospitals during that same period was a much higher
    104.1%, according to the MOH.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The largest portion of healthcare expenses in China is funded by
    private individuals. The MOH reported that in 2007, self payment
    accounted for 45.2% of China&#146;s total medical expenses,
    whereas payment by public medical insurance schemes, commercial
    insurance plans and employers accounted for another 34.5%, and
    the direct payment by the government accounted for the remaining
    20.4%. In China, most patients currently pay medical expenses
    out-of-pocket prior to receiving medical services and later seek
    insurance reimbursement, to the extent, if any, that they are
    covered by medical insurance schemes. The up-front collection of
    medical fees, whether or not the patient is insured, together
    with China&#146;s lack of emergency medical treatment laws such
    as those in the United States, which require the treatment of
    the uninsured, results in very low bad debt and charity care
    expenditures for hospitals and other healthcare service
    providers in China. Due to cultural factors, the high percentage
    of out-of-pocket expenses and the need to pay for medical
    services upfront, family members of Chinese patients frequently
    contribute to the payment of healthcare expenses, particularly
    in the case of non-discretionary healthcare expenses, such as
    the diagnosis and treatment of cancer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611a4h0361104.gif" alt="PIE CHART">
</DIV>



<DIV align="left" style="margin-left: 21%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 8pt">Source: MOH
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Radiotherapy
    and Diagnostic Imaging in China</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Chinese radiotherapy and diagnostic imaging market has grown
    steadily over the years. According to a report by
    Frost&#160;&#038; Sullivan, there were approximately
    1,187&#160;linear accelerators, 159 head gamma knife systems, 86
    body gamma knife systems, 122 PET-CT scanners and 2,260 MRI
    scanners installed across the country in 2008. CAGRs of such
    installed equipment were 16.4%, 18.9%, 16.0%, 16.9% and 22.6%
    from 2003 to 2008, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    97
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611a4h0361105.gif" alt="PIE CHART">
</DIV>



<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 8pt">Source: Frost&#160;&#038; Sullivan,
    2008
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Despite this high level of growth, the number of units of
    radiotherapy and diagnostic imaging equipment per capita in
    China is significantly lower than in developed countries. The
    Frost&#160;&#038; Sullivan report estimates that at the end of
    2008, China had only 0.7 linear accelerators per million people,
    compared to 9.5 in the United States, 6.6 in Japan, 5.6 in
    France and 3.0 in the United Kingdom during the same period. The
    relatively low penetration of radiotherapy equipment in China
    contributes to the low rate of treatment using radiotherapy
    received by cancer patients in China. We also believe that a
    generally low level of education amongst Chinese physicians
    about advanced radiotherapy is a key contributor to the
    relatively low rate of usage of radiotherapy for the treatment
    of cancer patients in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611a4h0361106.gif" alt="PIE CHART">
</DIV>



<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 8pt">Source: Frost&#160;&#038; Sullivan,
    2008
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The vast majority of radiotherapy and diagnostic imaging
    services are performed in hospitals. Hospitals are motivated to
    offer high-end services such as radiotherapy and diagnostic
    imaging services to attract patients and increase hospital
    revenues. The challenge, however, is that many hospitals in
    China cannot fund expensive equipment purchases due to limited
    operating cash flows, inability to raise equity funding, limited
    access to debt financing and the absence of vendor financing.
    Hospitals in China generally also lack experienced radiologists
    and technicians and management experience in operating
    radiotherapy and diagnostic imaging centers.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    98
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    While most of the expenses for radiotherapy and diagnostic
    imaging services are paid up-front by patients, some
    reimbursement is available to patients through
    government-directed insurance schemes. We believe that
    radiotherapy modalities including head gamma knife systems, body
    gamma knife systems and linear accelerators are currently
    covered by most government-directed medical insurance schemes in
    China, but reimbursement rates differ depending on geographical
    locations. MRI scans are commonly covered by various
    government-directed medical insurance schemes in China, while
    PET-CT scans are generally not covered by such schemes. For more
    information, see &#147;Regulation of Our Industry&#160;&#151;
    Medical Insurance Coverage.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to a report by Frost&#160;&#038; Sullivan, the China
    cancer radiotherapy and diagnostic imaging market is expected to
    continue to grow. It is estimated that the linear accelerator
    market will increase from RMB4.2&#160;billion
    (US$612.7&#160;million) in 2008 to RMB 17.9&#160;billion
    (US$2.6&#160;billion) in 2015, representing a CAGR of 23.0%. The
    gamma knife systems market is expected to grow from
    RMB1.3&#160;billion (US$194.9&#160;million) in 2008 to
    RMB6.7&#160;billion (US$977.6&#160;million) in 2015,
    representing a CAGR of 25.9%. The diagnostic imaging market,
    primarily consisting of MRI, PET-CT and CT, is expected to grow
    from RMB10.7&#160;billion (US$1.6&#160;billion) in 2008 to
    RMB23.9&#160;billion (US$3.5&#160;billion) in 2015, representing
    a CAGR of 12.1%. The following are the primary factors
    contributing to the growing demand for cancer radiotherapy and
    diagnostic imaging services:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <B>Increasing cancer incidence rate:</B> The cancer incidence
    rate in China has grown from approximately 0.216% in 2003 to
    approximately 0.260% in 2008, an increase of 20.4%, according to
    a report by Frost&#160;&#038; Sullivan. It is expected that
    demographic changes and urbanization will lead to further
    increases in the number of cancer cases in China.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <B>Increasing physician adoption of advanced diagnostic imaging
    equipment: </B>With the modernization of medical care in China,
    more physicians are expected to utilize more advanced diagnostic
    imaging equipment, such as MRI and PET-CT.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <B>Increasing percentage of cancer patients treated with
    radiotherapy:</B> The percentage of cancer patients treated with
    radiotherapy is expected to increase due to improving awareness
    of radiotherapy among the doctors and patients, and increased
    availability of radiotherapy and diagnostic imaging equipment.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <B>Increasing affordability and potentially increased
    accessibility:</B> China&#146;s rising disposable income and
    increasing government expenditure on healthcare are also
    expected to stimulate the overall demand for radiotherapy and
    diagnostic imaging services. In addition, China recently
    approved a new round of healthcare reforms that encourage the
    investment of private capital in non-profit hospitals, which may
    potentially increase the accessibility of radiotherapy and
    diagnostic imaging services to patients.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    99
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='114'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">BUSINESS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We operate the largest network of radiotherapy and diagnostic
    imaging centers in China in terms of revenue and the total
    number of centers in operation in 2008, according to a report by
    Frost&#160;&#038; Sullivan commissioned by us that compared our
    pro forma revenues against the revenues of our competitors in
    2008 and our number of centers and units of equipment against
    those of our competitors as of the end of 2008. As of
    September&#160;30, 2009, our network comprised 83&#160;centers
    based in 55&#160;hospitals, spanning 36&#160;cities across
    21&#160;provinces and administrative regions in China. These
    hospitals are substantially comprised of 3A hospitals, the
    highest ranked hospitals by quality and size in China as
    determined in accordance with the standards of the MOH. Cancer
    was the leading cause of death in China in 2008 according to the
    MOH, and there is a relatively low penetration of radiotherapy
    and diagnostic imaging equipment compared to developed
    countries. We believe that our leading network and our
    experience and expertise uniquely position us to address the
    underserved market in China for radiotherapy and diagnostic
    imaging services.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Most of the centers in our network are established through
    long-term lease and management services arrangements entered
    into with our hospital partners. Under these arrangements, we
    receive a contracted percentage of each center&#146;s revenue
    net of specified operating expenses. Each center is located on
    the premises of our hospital partners and is typically equipped
    with a primary unit of advanced radiotherapy or diagnostic
    imaging equipment, such as a linear accelerator, head gamma
    knife system, body gamma knife system, PET-CT scanner or MRI
    scanner. We provide clinical support services to doctors who
    work in the centers in our network, which include developing
    treatment protocols for doctors and organizing joint diagnosis
    between doctors in our network and clinical research. In
    addition, we help recruit and determine the compensation of
    doctors and other medical personnel in our network and are
    typically in charge of most of the non-clinical aspects of the
    centers&#146; daily operations, including marketing, training
    and administrative duties. Our hospital partners are responsible
    for the centers&#146; clinical activities, the medical decisions
    made by doctors, and the employment of the doctors in accordance
    with regulations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that our success is largely due to the high quality
    clinical care provided at our network of centers and our
    market-oriented management culture and practices. Many of the
    doctors who work in our network have extensive clinical
    experience in radiotherapy, some of whom are recognized as
    leading experts in radiation oncology in China. We enhance the
    quality of clinical care in our network through established
    training of, and on-going clinical education for, doctors in our
    network. We believe that our market-oriented management culture
    and practices allow us to manage centers more efficiently and
    offer more consistent and better patient services than our
    competitors. We believe that our success has given us a strong
    reputation within the medical community, which in turn gives us
    a competitive advantage in gaining patient referrals and
    establishing new centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To complement our organic growth, we have also selectively
    acquired businesses to expand our network. In July 2008, we
    acquired China Medstar, a company then publicly listed on the
    AIM, for approximately &#163;17.1&#160;million or approximately
    RMB238.7&#160;million (US$35.0&#160;million). At the time of the
    acquisition, China Medstar jointly managed 23 centers with its
    hospital partners across 14&#160;cities in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To further enhance our reputation and to employ high quality
    doctors, we plan to establish and operate specialty cancer
    hospitals in China. We intend for our specialty cancer hospitals
    to be centers of excellence. Our first specialty cancer
    hospital, the Chang&#146;an CMS International Cancer Center, in
    Xi&#146;an, Shaanxi Province, is expected to commence operation
    in early 2010. We are also in the process of establishing the
    Beijing Proton Medical Center, another specialty cancer
    hospital, which is expected to commence operation in 2012. We
    expect that the Beijing Proton Medical Center will be the first
    proton beam therapy treatment center in China equipped with a
    proton beam therapy system licensed for clinical use.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business has grown significantly in recent years through
    development of new centers, increases in the number of patient
    cases in our network and acquisitions. We have increased the
    number of centers in our network from 41 at the end of 2007 to
    72 at the end of 2008 and to 83 as of September&#160;30, 2009.
    Our total net revenues were RMB67.4&#160;million,
    RMB14.0&#160;million and RMB171.8&#160;million
    (US$25.2&#160;million) for the period from January&#160;1, 2007
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    100
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    to October&#160;30, 2007, the period from September&#160;10,
    2007 to December&#160;31, 2007 and for the year ended
    December&#160;31, 2008. Our total net revenues increased to
    RMB205.7&#160;million (US$30.1&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB102.0&#160;million for the
    same period in 2008, due primarily to an increase in the number
    of centers in our network, including centers added to our
    network as a result of our acquisition of China Medstar, and an
    increase in the number of patient cases in existing centers. For
    periods prior to October&#160;30, 2007, our predecessor is
    deemed the reporting entity for financial reporting purposes as
    a result of the OMS reorganization. We report the financial
    statements of our successor entity from September&#160;10, 2007,
    the date of inception of our successor entity. For additional
    information relating to our history and reorganization and our
    financial presentation, see &#147;Our History and Corporate
    Structure&#148; and &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Market
    Opportunities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed in the &#147;Our Industry&#148; section of this
    prospectus, the radiotherapy and diagnostic imaging market in
    China has several favorable characteristics. The market is
    expected to experience significant growth due to an increasing
    incidence rate of cancer and increasing adoption and
    affordability of advanced radiotherapy and diagnostic imaging
    technologies. Moreover, most hospitals lack the financial
    resources to purchase, or the expertise to operate, advanced
    radiotherapy and diagnostic imaging equipment. These
    deficiencies, together with the generally low level of awareness
    amongst doctors in China about the efficacy of advanced
    radiotherapy, has resulted in a relatively low usage rate of
    radiotherapy for the treatment of cancer patients in China. We
    believe that our ability to provide the necessary equipment and
    expertise to hospitals in China to establish and jointly manage
    radiotherapy centers will allow us to benefit from these
    positive market dynamics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Competitive
    Strengths</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the following competitive strengths have, and
    will continue to, uniquely position us to capitalize on growth
    opportunities in the cancer treatment market in China:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Leading
    Market Position and Successful Track Record</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to a report by Frost&#160;&#038; Sullivan that
    compared our pro forma revenues against the revenues of our
    competitors in 2008 and our number of centers and units of
    equipment against those of our competitors as of the end of
    2008, we operate the largest network of radiotherapy and
    diagnostic imaging centers in China in terms of revenues and the
    number of centers in operation in 2008. As of September&#160;30,
    2009, our network comprised 83&#160;centers based in
    55&#160;hospitals, spanning 36&#160;cities across
    21&#160;provinces and administrative region in China. Our
    network includes 73 radiotherapy and diagnostic imaging centers
    and 10&#160;centers that provide other treatment and diagnostic
    services, such as electroencephalography for the diagnosis of
    epilepsy, thermotherapy to increase the efficacy of and for pain
    relief after radiotherapy and chemotherapy, high intensity
    focused ultrasound therapy for the treatment of cancer,
    stereotactic radiofrequency ablation for the treatment of
    Parkinson&#146;s Disease and refraction and tonometry for the
    diagnosis of ophthalmic conditions. According to a report by
    Frost &#038; Sullivan, we were the first company to have
    established such an extensive network of centers across China.
    Our first center was established in 1997, and more than half of
    the centers in our network have been in operation for over five
    years. The doctors in our network have performed over 48,000
    radiotherapy treatments and over 100,000 diagnostic imaging
    scans since the beginning of 2007. We believe that we have a
    strong reputation within the medical community in China, due to
    the large number of cancer patients treated in our network and
    the extensive clinical experience of the doctors in our network
    of centers. We believe that our market leading position,
    successful track record and the strong reputation of centers in
    our network provide us with a significant advantage relative to
    our competitors in establishing new centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Doctors
    with Extensive Cancer Treatment Experience Developed and
    Supported by Our Network</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are over 240&#160;doctors, including radiation oncologists
    and neurosurgeons, who work in our network, some of whom are
    leading experts in their respective fields in China. We provide
    training, ongoing clinical education, including regularly
    scheduled network-wide clinical education conferences and
    seminars, where medical personnel from our network of centers
    and outside medical experts in China are invited to share their
    clinical experience. These efforts enable the doctors in our
    network to increase their clinical knowledge. We also
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    101
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    organize and sponsor clinical research conducted by doctors in
    our network. The clinical expertise of the doctors in our
    network is supplemented by their ability to consult with each
    other and thereby enhancing the clinical care they provide to
    their patients.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Market-oriented
    Management of Centers</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We bring a market-oriented management culture and practices to
    the operation of our centers, driven by patient needs and market
    conditions. As a result, we believe that the centers in our
    network are run more efficiently and provide better patient
    services as compared to other public hospitals. Such
    market-oriented management practices include staffing most
    centers in our network with dedicated marketing professionals
    who promote our services to potential referring doctors. In
    addition, the compensation for the staff in each center,
    including doctors, is partially based on such center&#146;s
    operating performance whereby the staff in each center typically
    receives bonuses based on the monthly revenue generated by such
    center, the number of patients treated or received diagnostic
    imaging services in a given month, the annual profit target of
    the center and other performance metrics as determined by us,
    such as staff&#146;s compliance with the operating procedures of
    the centers, the quality of treatments and services provided,
    the staff&#146;s research activities conducted at the centers
    and the timely maintenance of records. Our market-oriented
    management practices also, unlike most other public hospitals in
    China, focus on providing high quality patient services, which
    we believe is a key component in establishing a strong
    reputation as to our network of centers and a key factor in
    doctors&#146; decisions to refer patients to centers in our
    network.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Successful
    Track Record of New Center Development and
    Acquisitions</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have grown our business through development of new centers
    and through selective acquisitions of businesses and assets from
    third parties. Such development and acquisitions are subject to
    an extensive internal evaluation and approval process that
    involves a team of dedicated business development professionals,
    a team of project evaluation professionals and our senior
    management. In 2008, we added 32 new centers under lease and
    management services arrangements of which 25 were added through
    acquisitions. Our acquisitions in 2008 include China Medstar and
    its network of 23 centers located in 14&#160;cities across China
    which we have we successfully integrated into our network. This
    acquisition significantly expanded our network of centers,
    broadened our service offerings by significantly increasing the
    number of centers in our network that provide treatments through
    the use of linear accelerators and diagnostic imaging services
    using MRI scanners, and strengthened our management team. During
    the nine months ended September&#160;30, 2009, we added 19 new
    centers to our network under lease and management arrangements,
    five of which were converted in August 2009 from six centers
    that were previously managed under service-only agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Strong
    and Experienced Management Team</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are led by a strong management team of experienced
    professionals with complementary skill sets. Several of our
    senior executives have experience as senior managers of
    companies publicly listed on the stock exchanges in China, on
    the AIM and on the NYSE. Two members of our senior management
    team founded one of the first companies in China engaged in
    developing and providing management services to radiotherapy and
    diagnostic imaging centers and both have more than 10&#160;years
    of experience in establishing and managing such centers. Our
    senior management team is supported by a team of experienced
    professionals who have worked for many years in the radiotherapy
    market in China, including several former doctors who bring to
    our network clinical experience and strong relationships with
    directors and senior managers of hospitals around China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Business
    Strategies</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to further strengthen our leading position in the
    radiotherapy and diagnostic imaging market in China by pursuing
    the following strategies:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Continue
    to Develop New Radiotherapy and Diagnostic Imaging
    Centers</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that there are significant opportunities to grow our
    business through the continued expansion of our network of
    radiotherapy and diagnostic imaging centers. We have a dedicated
    business development team that is primarily responsible for
    identifying, evaluating, and negotiating opportunities to
    develop new centers with new
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    102
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    hospital partners. As of September&#160;30, 2009, we have
    entered into agreements to establish additional 30 new centers
    in China, and we expect five of these centers to commence
    operation by the end of 2009. We plan to increase the number of
    centers in our nationwide network of centers in China to at
    least 200 over the next three years.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Increase
    Marketing Efforts to Drive Growth in Patient Cases at Our
    Existing Centers</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We plan to continue our center-based marketing efforts to
    increase the number of patients diagnosed and treated in our
    network of centers. Most centers in our network are staffed with
    dedicated marketing personnel employed by us and responsible for
    promoting the radiotherapy and diagnostic imaging services
    offered at the centers to both referring doctors and patients.
    These marketing personnel help to educate referring doctors and
    patients on the types of cancer that are suitable for
    radiotherapy and the benefits of radiotherapy. At the corporate
    level, we support the center-based marketing efforts by
    arranging for radiotherapy experts to participate in academic
    conferences and seminars hosted by different centers in our
    network for referring doctors as well as helping the individual
    centers prepare relevant marketing materials. We plan to
    increase center-based marketing efforts to enhance the awareness
    and understanding of cancer diagnosis and treatment and thus
    increase the patient cases at our centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Establish
    Specialty Cancer Hospitals</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are in the process of establishing specialty cancer hospitals
    in China that will be majority owned by us. We intend for our
    specialty cancer hospitals to be our centers of excellence that
    will focus on providing radiotherapy services as well as
    diagnostic imaging services, chemotherapy and surgery in order
    to provide a comprehensive treatment program for cancer
    patients. We believe that establishing specialty cancer
    hospitals will allow us to further strengthen our reputation
    amongst patients and within the medical community in China and
    develop our corporate brand. We have established a dedicated
    hospital investment team focused on identifying and evaluating
    potential opportunities to develop additional specialty cancer
    hospitals. Our first two specialty cancer hospitals, the
    Chang&#146;an CMS International Cancer Center and the Beijing
    Proton Medical Center, are expected to be operational in early
    2010 and in 2012, respectively. We also plan to establish
    additional specialty cancer hospitals in key cities across China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Introduce
    Advanced Cancer Treatment Options and Diagnostic Technology in
    Our Network</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to introduce the most technologically advanced medical
    equipment in China to enhance the quality of treatment available
    to patients. For example, our Beijing Proton Medical Center is
    expected to be the first proton beam therapy system in China
    licensed for clinical use. We believe that introducing such
    technology will allow us to offer cancer patients some of the
    most advanced medical care available in China, attract
    additional patients and strengthen our leadership position and
    reputation in the radiotherapy market in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Complement
    Our Development of New Centers with Selected
    Acquisitions</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to selectively pursue strategic acquisitions that will
    complement our efforts to develop new centers. Given the
    fragmentation of the industry in which we operate, there are a
    large number of
    <FONT style="white-space: nowrap">stand-alone</FONT>
    centers and companies that manage small networks of centers that
    we believe may be attractive acquisition targets. We intend to
    acquire the businesses or assets of existing centers that are
    based in leading hospitals located in densely populated cities
    in China. We believe that our past acquisition experience will
    aid us in identifying potential opportunities in the future and
    successfully integrate newly acquired businesses or assets into
    our existing network.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Network of Centers and Specialty Cancer Hospitals</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of September&#160;30, 2009, we operated an extensive network
    of 83&#160;centers based in 55 hospitals, spanning
    36&#160;cities across 21&#160;provinces and administrative
    regions in China. These hospitals are substantially comprised of
    3A&#160;hospitals, the highest ranked hospitals by quality and
    size in China as determined in accordance with the standards of
    the MOH. Our network includes 73 radiotherapy and diagnostic
    imaging centers and 10 centers that provide other treatment and
    diagnostic services, such as electroencephalography for the
    diagnosis of epilepsy, thermotherapy to increase the efficacy of
    and for pain relief after radiotherapy and chemotherapy, high
    intensity focused ultrasound therapy for the treatment of
    cancer, stereotactic radiofrequency ablation for the treatment
    of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    103
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Parkinson&#146;s Disease and refraction and tonometry for the
    diagnosis of ophthalmic conditions. Each center is typically
    equipped with a primary unit of medical equipment, such as a
    linear accelerator, head gamma knife system, body gamma knife
    system, PET-CT scanner or MRI scanner. Each center is located on
    the premises of our hospital partners with the facilities of the
    centers provided by the hospitals. Each center is usually
    comprised of a treatment area, a patient preparation and
    observation room, working areas for the center&#146;s doctors
    and other personnel and a waiting and reception area.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to our network of centers, we plan to establish and
    operate specialty cancer hospitals that will be majority owned
    by us. We are currently in the process of establishing two such
    hospitals, the Chang&#146;an CMS International Cancer Center in
    Xi&#146;an, Shaanxi Province and the Beijing Proton Medical
    Center in Beijing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following chart illustrates our network of centers as of
    September&#160;30, 2009:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611a4h0361111.gif" alt="(MAPS)">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 8pt">Note: Bracketed numbers indicate
    the number of centers in cities with more than one center.
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    Arrangements with Hospital Partners</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Lease and Management Services Arrangements.</I>&#160;&#160;As
    of September&#160;30, 2009, we had 81&#160;centers that were
    established under lease and management services arrangements. We
    typically establish such centers with civilian hospitals by
    entering into a lease agreement and a management agreement.
    Centers at military hospitals, which are regulated by the
    military but most of which are otherwise the same as other
    government-owned hospitals open to the public, are typically
    established under a cooperation agreement. The reason for the
    two different contractual structures is to comply with the
    different regulations governing civilian and military hospitals
    in China. See &#147;Regulations of Our Industry&#160;&#151;
    Regulation of Medical Institutions&#160;&#151; Restrictions on
    Cooperation Agreements.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under these lease and management services arrangements, we are
    responsible for purchasing the medical equipment used in the
    centers. We lease this medical equipment to the hospitals for a
    fixed period of time and establish and manage the centers in
    conjunction with our hospital partners. These arrangements are
    typically long-term in nature, ranging from six to
    20&#160;years. We receive from the hospital a contracted
    percentage of each center&#146;s
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    104
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    revenue net of specified operating expenses. Such contracted
    percentage typically ranges from 50% to 90% and are typically
    adjusted based on a declining scale over the term of the
    arrangement but in some instances, are fixed for the duration of
    the arrangement. The specified operating expenses of centers
    typically include variable expenses such as the salaries and
    benefits of the medical and other personnel at the center, the
    cost of medical consumables, marketing expenses, training
    expenses, utility expenses and routine equipment repair and
    maintenance expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Typically, these lease and management services arrangements may
    be terminated upon the mutual agreement of the parties if the
    centers experience an operating loss for a specified period of
    time or fail to achieve certain operating targets. In addition,
    the arrangements typically can be terminated upon the default or
    failure by either party to perform its respective obligations
    under the arrangement. In the event of termination, most
    arrangements call for the parties to reach a mutual agreement as
    to the resolution of the remaining obligations of the parties or
    the division of assets that have been acquired for the centers.
    Under certain of these arrangements, our hospital partners are
    required to compensate us based on the average contracted
    percentage for an agreed upon period of time if we are not
    responsible for the early termination. Since the beginning of
    2007, we have terminated the agreements of five&#160;centers in
    our network with our hospital partners primarily due to the
    unsatisfactory performances of the centers located in these
    hospitals. Excluding acquired centers, as of September&#160;30,
    2009, we entered into agreements with hospital partners to
    establish 49 new centers since the beginning of 2007 all of
    which remain in force. 19 of such centers are already in
    operation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Service-Only Arrangements.</I>&#160;&#160;From time to time,
    we provide management services to radiotherapy and diagnostic
    imaging centers under service-only agreements. As of
    September&#160;30, 2009, we had such agreements for two centers.
    Unlike the centers established under lease and management
    services arrangements, we do not purchase and lease to the
    hospitals the medical equipment used at the centers established
    under service-only agreements. Rather, we only manage such
    centers in exchange for a management fee typically consisting of
    a contracted percentage of the revenue net of specified
    operating expenses of the center. In addition, as compared to
    our lease and management services arrangements, the terms of the
    service-only agreements are typically shorter. We enter into
    such service-only agreements on a strategic basis to expand the
    coverage of our network. We will continue from time to time
    enter into additional strategic service-only agreements with
    other hospitals in the future. As part of our arrangement to
    establish our first speciality cancer hospital, Chang&#146;an
    CMS International Cancer Center, we entered into service-only
    agreements in 2008 to provide management services to a general
    hospital in Xi&#146;an, Chang&#146;an Hospital, and six
    radiotherapy and diagnostic imaging centers located in such
    hospitals.  We receive a management fee from the Chang&#146;an
    Hospital that is equal to a percentage of its total revenues.
    For additional information, see &#147;&#151;&#160;Specialty
    Cancer Hospitals.&#148; In August 2009, we purchased from
    Chang&#146;an Hospital the six units of radiotherapy and
    diagnostic imaging equipment that were located at the six
    centers that we managed under service-only agreements with
    Chang&#146;an Hospital. The total agreed upon consideration for
    such equipment was approximately RMB72.7&#160;million
    (US$10.6&#160;million), of which RMB50.0&#160;million
    (US$7.3&#160;million) was paid as of September&#160;30, 2009. We
    paid an additional RMB20.0&#160;million (US$2.9&#160;million) of
    the consideration in October 2009 and we expect to pay the
    remaining RMB2.7&#160;million (US$0.5&#160;million) before the
    end of 2009. We subsequently entered into a long-term lease and
    management services arrangement with Chang&#146;an Hospital
    pursuant to which we leased these six units of equipment to
    Chang&#146;an Hospital. Two of the six units of equipment were
    combined into one center and we provide lease and management
    services to the five centers in which these six units of
    equipment are located.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Specialty
    Cancer Hospitals</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are currently in the process of establishing specialty cancer
    hospitals that will focus on providing radiotherapy services as
    well as diagnostic imaging services, chemotherapy and surgery.
    We intend for these specialty cancer hospitals to provide a
    complete and coordinated treatment program for cancer patients.
    We intend for these hospitals to be centers of excellence in our
    network providing cancer treatments to patients using the latest
    radiotherapy technology in China. Typically, in China the
    various specialist doctors such as surgeons, radiation
    oncologists or medical oncologists who provide care to a given
    cancer patient do not collaborate. We believe that the quality
    of cancer treatment will be greatly improved at our specialty
    cancer hospitals, because we will employ and manage the various
    specialist doctors directly and thereby promote the appropriate
    coordination of their services for the benefit of cancer
    patients. We believe that these hospitals will play an important
    role in further strengthening our
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    105
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    reputation as the leading provider of radiotherapy services in
    China and developing our corporate brand. These specialty cancer
    hospitals will be majority owned and operated by us. We will
    purchase all of the medical equipment for these hospitals and
    will employ and manage all of the personnel, including doctors,
    nurses, medical technicians and administrative personnel. The
    specialty cancer hospitals will be licensed as for-profit
    hospitals in China and will be subject to the relevant PRC laws
    and regulations and permits requirements. As for-profit
    hospitals, the medical service fees of our specialty cancer
    hospitals will not be subject to price controls but will be
    subject to certain taxes not applicable to non-profit hospitals.
    We plan to fund the development of our specialty cancer
    hospitals with proceeds raised from this offering and with bank
    loans.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Chang&#146;an CMS International Cancer
    Center.</I>&#160;&#160;We have entered into a framework
    agreement and a supplemental agreement with Chang&#146;an
    Hospital, a private hospital serving the northeastern region of
    China, and Xi&#146;an Century Friendship Medical Technology
    R&#038;D Co., Ltd., or Xi&#146;an Century Friendship, a
    subsidiary of Chang&#146;an Hospital, to establish a specialty
    cancer hospital, the Chang&#146;an CMS International Cancer
    Center, in Xi&#146;an, Shaanxi Province. Chang&#146;an Hospital
    is controlled by Chang&#146;an Information Industry (Group) Co.,
    Ltd., or Chang&#146;an Information Industry, a China-based
    conglomerate engaged in information technology, real estate and
    the medical industries. The Chang&#146;an CMS International
    Cancer Center is expected to have a gross floor area of
    approximately 12,000&#160;square meters with over 300 licensed
    patient beds. The Chang&#146;an CMS International Cancer Center
    is expected to provide treatments for a wide range of tumor
    types using a variety of radiotherapy equipment as well as
    chemotherapy and surgery. Due to the treatment methods used,
    many patients visiting the Chang&#146;an CMS International
    Cancer Center are expected to require hospitalization.
    Initially, the hospital will have a MM50 intensity-modulated
    radiation therapy system, a Novalis intensity-modulated
    radiation therapy system and PET-CT, MRI and CT scanners. We
    expect the hospital to initially employ about
    500&#160;employees, including over 300&#160;doctors and other
    medical professionals. We expect the Chang&#146;an CMS
    International Cancer Center to be operational in early 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the framework agreement, Xi&#146;an Century Friendship
    will establish a wholly owned subsidiary to be tentatively named
    &#147;Chang&#146;an Huaxiang Medical Services Co., Ltd.&#148; or
    &#147;Chang&#146;an CMS Medical Services Co., Ltd.&#148; and
    will transfer all land and properties in connection with
    establishing the specialty cancer hospital to such subsidiary.
    Thereafter, such subsidiary will change its name to the
    Chang&#146;an CMS International Cancer Center. The framework
    agreement contemplates that we will acquire equity interest in
    Chang&#146;an CMS International Cancer Center for a
    consideration of RMB34.8&#160;million (US$5.1&#160;million).
    However, prior to the purchase of such equity interest, the
    Chang&#146;an CMS International Cancer Center must first be
    established and a subsequent share transfer agreement will need
    to be entered into. Chang&#146;an CMS International Cancer
    Center will then increase its registered capital and we and
    Xi&#146;an Century Friendship will contribute other properties,
    such as equipment, land or cash, to subscribe for such increased
    capital. As a result, we will own approximately 52.0% and
    Xi&#146;an Century Friendship will own approximately 48.0% of
    the equity interest in Chang&#146;an CMS International Cancer
    Center. We are required under the framework agreement to pay a
    deposit of RMB15.0&#160;million (US$2.2&#160;million) to
    Xi&#146;an Century Friendship. Such deposit can be later
    converted as contribution to subscribe for the additional
    increase in registered capital in Chang&#146;an CMS
    International Cancer Center. A supplemental agreement to the
    framework agreement was subsequently entered into where
    Xi&#146;an Century Friendship transferred its rights and
    obligations under the framework agreement and any other
    agreements contemplated under the framework agreement to its
    subsidiary that will be tentatively named &#147;Xi&#146;an
    Wanjie Huaxiang Medical Investment Co., Ltd.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of September&#160;30, 2009, we paid RMB18.0&#160;million
    (US$2.6&#160;million) towards the establishment of the
    Chang&#146;an CMS International Cancer Center. We and the other
    parties to the agreements are currently in the process of
    applying for the relevant permits and licenses in order to
    establish the Chang&#146;an CMS International Cancer Center as
    an independent for-profit hospital in the PRC. Total development
    costs for the completion of the Chang&#146;an CMS International
    Cancer Center are expected to be approximately
    RMB250.0&#160;million (US$36.6&#160;million). We plan to fund
    the development of the Chang&#146;an CMS International Cancer
    Center with proceeds raised from this offering and with bank
    loans. We expect to obtain bank loans of approximately
    RMB90.0&#160;million (US$13.2&#160;million) in 2010 to fund the
    hospital&#146;s development.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Beijing Proton Medical Center.</I>&#160;&#160;We have also
    entered into a framework agreement with Chang&#146;an
    Information Industry to establish the Beijing Proton Medical
    Center. The Beijing Proton Medical Center will
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    106
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    allow us to bring the latest in radiotherapy treatment
    technology to China and increase the radiotherapy treatment
    options available to cancer patients. The Beijing Proton Medical
    Center is expected to be operational in 2012 and is expected to
    be the first proton beam therapy system in China licensed for
    clinical use. The Beijing Proton Medical Center is expected to
    have a gross floor area of approximately 12,700&#160;square
    meters and have 50 licensed patient beds. The Beijing Proton
    Medical Center will primarily offer treatments using a proton
    beam therapy system, which treatments are designed to be
    non-invasive and usually do not require hospitalization. As a
    result, the Beijing Proton Medical Center will not require the
    use of as many patient beds as the Chang&#146;an CMS
    International Cancer Center. In addition, the proton beam
    therapy system occupies a much larger installation area than the
    radiotherapy and diagnostic imaging equipment that is to be used
    in the Chang&#146;an CMS International Cancer Center, which
    reduced physical areas for licensed beds that can be made
    available in the Beijing Proton Medical Center.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The framework agreement contemplates that we are to invest
    equity capital to the Beijing Proton Medical Center project that
    was previously invested and developed by Chang&#146;an
    Information Industry, Hong Kong Jian Chang Group Ltd. and
    China-Japan Friendship Hospital. We will then obtain
    approximately 93.0% of the equity interest in Beijing Century
    Friendship Science&#160;&#038; Technology Development Co., Ltd.,
    or Beijing Century Friendship, which will in turn own
    approximately 55.0% of the Beijing Proton Medical Center. The
    remaining approximately 7.0% of the equity interest in Beijing
    Century Friendship will be owned by Xi&#146;an Wanjie Changxin
    Medical Development Co., Ltd., or Xi&#146;an Wanjie Changxin, a
    subsidiary of Chang&#146;an Information Industry. As a result,
    we will ultimately own approximately 51.2% of the Beijing Proton
    Medical Center, with the remaining equity interest owned by
    Xi&#146;an Wanjie Changxin, Hong Kong Jian Chang Group Ltd. and
    China-Japan Friendship Hospital.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The framework agreement provides that it will only become
    effective upon our payment of RMB10.0&#160;million
    (US$1.5&#160;million) in deposit to Chang&#146;an Information
    Industry. As of the date of this prospectus, we have not made
    such deposits.  However, we have, as of September&#160;30, 2009,
    provided Beijing Century Friendship with interest-free loans of
    RMB14.6&#160;million (US$2.1&#160;million) for working capital
    purposes towards establishing the Beijing Proton Medical Center.
    All outstanding amounts of such loans are expected to be repaid
    before the end 2009. We are currently waiting for the relevant
    permits and approvals to be obtained by the other shareholders
    to the Beijing Proton Medical Center. We plan to enter into
    additional definitive agreements as to the establishment of the
    Beijing Proton Medical Center after the relevant permits and
    approvals are obtained. Total development costs for the
    completion of Beijing Proton Medical Center are expected to be
    approximately RMB500.0&#160;million (US$73.2&#160;million) to
    RMB600.0&#160;million (US$87.9&#160;million). We plan to fund
    the development of the Beijing Proton Medical Center with
    proceeds raised from this offering and with bank loans. We
    expect to obtain bank loans of approximately
    RMB100.0&#160;million (US$14.6&#160;million) in 2010 to fund the
    hospital&#146;s development.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Business Arrangements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have, from time to time, purchased medical equipment from
    manufacturers or distributors for re-sale to hospitals, and have
    contractual relationships with certain equipment manufacturers,
    acted as a distributor of such manufacturer&#146;s equipment in
    selling medical equipment to hospitals. Although we may continue
    these activities on a limited basis in the future, we do not
    expect these activities to represent an important part of our
    business going forward.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Service
    Offerings in Our Network</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each of the centers in our network is typically equipped with a
    primary unit of medical equipment, such as a linear accelerator,
    head gamma knife system, body gamma knife system,
    <FONT style="white-space: nowrap">PET-CT</FONT>
    scanner or MRI scanner. Set forth below is a summary of the
    principal treatment and diagnostic imaging modalities provided
    at our centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Linear
    Accelerators External Beam Radiotherapy</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of September&#160;30, 2009, we owned 15&#160;linear
    accelerators and one MM50 intensity-modulated radiation therapy
    system. Linear accelerators use microwave technology to deliver
    a high-energy x-ray beam directed at the tumor. Linear
    accelerators can be used to treat tumors in the brain or
    elsewhere in the body. A typical course of treatment given to a
    patient ranges from 20 to 40 daily sessions and with each
    session lasting for 10 to 20 minutes. Since linear accelerators
    move during treatment, they are not as precise as gamma knife
    systems. However, linear
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    107
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    accelerators are capable of treating larger tumors. Linear
    accelerators can also be integrated with specialized computer
    software and advanced imaging and detection equipment to provide
    more effective and advanced treatments. Such advanced treatments
    include three-dimensional conformal radiation therapy, which
    uses imaging equipment to create detailed, three-dimensional
    representations of the tumor and surrounding organs. The
    radiation beam can then be shaped to match the patient&#146;s
    tumor, thereby reducing the radiation damage to healthy tissues.
    In general, such advanced modalities increase the medical
    service fees that can be charged as compared to the maximum
    medical service fees that can be charged for treatments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Gamma
    Knife Radiosurgery</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A gamma knife is used in radiosurgery for the treatment of
    tumors and other abnormal growths. A gamma knife uses multiple
    radiation sources, which differentiates it from traditional
    radiotherapy where only a single radiation source is used. These
    radioactive sources, which are typically cobalt-60, a
    radioactive isotope, emit gamma rays that are passed through a
    collimator unit to produce a highly-focused beam of radiation.
    The individual beams then converge to deliver an extremely
    concentrated dose of radiation to locations within the patient
    that are identified using imaging guidance systems, such as
    PET-CT or MRI scanners. The intense radiation produced by a
    gamma knife at a precise target point destroys tumor cells,
    while minimizing damage to the surrounding healthy tissues. The
    treatment procedure is minimally or non-invasive and may be used
    as a primary or supplementary treatment option for cancer
    patients. The treatment requires no general anesthesia and
    provides an alternative treatment option to patients who may not
    be good candidates for surgery. In addition, the gamma knife
    procedure usually involves shorter patient hospitalization, is
    more cost effective than surgery and avoids many of the
    potential risks and complications that are associated with other
    treatment options. Our network of centers currently operates two
    types of gamma knife systems, head gamma knife systems and body
    gamma knife systems. As of September&#160;30, 2009, we owned 26
    gamma knife systems, including 16 head gamma knife systems and
    10 body gamma knife systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Head Gamma Knife Systems.</I>&#160;&#160;Head gamma knife
    systems are primarily used for the treatment of brain tumors.
    The treatment is typically completed in one 10 to 30 minute
    session rather than in multiple daily sessions spanning several
    weeks during which time small doses of radiation are given at
    each session. Head gamma knife systems can also be used to treat
    other conditions, such as certain types of brain lesions,
    trigeminal neuralgia (facial pain) and arteriovenous
    malformations (abnormal connection between veins and arteries).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Body Gamma Knife Systems.</I>&#160;&#160;Body gamma knife
    systems are used for the treatment of tumors located in the body
    but outside of the brain. Treatments using the body gamma knife
    are provided over a course of multiple sessions spanning several
    weeks. The radiation that converges from the individual beams is
    less concentrated than in head gamma knife systems due to the
    difficulty of fixing and restricting the movement of the body.
    This is a widely used technology in China that was developed
    domestically and approved by the PRC State Food and Drug
    Administration, or the SFDA. However, the body gamma knife
    system has not been broadly introduced and widely adopted
    outside of China. We believe this is because the Chinese
    manufacturers of body gamma knife system have determined that
    the time and cost of gaining approval for use of the body gamma
    knife system in countries other than China are likely
    commercially prohibitive. In addition, potential gamma knife
    system manufacturers outside of China may not have historically
    viewed clinical studies conducted by users of body gamma knife
    systems in China as sufficiently convincing for them to try to
    develop such systems outside of China. As a result, we believe
    that the international medical community has not yet had the
    opportunity to develop a large quantity of peer-reviewed
    literature that supports the safe and effective use of body
    gamma knife system and to adopt such technology outside of China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Proton
    Beam Therapy</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Proton beam therapy is a form of external beam radiotherapy that
    uses beams of protons rather than the x-ray beams used by linear
    accelerators. The advantages of proton beam therapy compared to
    other types of external beam radiotherapy is that a proton
    beam&#146;s signature energy distribution curve, known as the
    &#147;Bragg peak,&#148; allows for greater accuracy in targeting
    tumor cells so that healthy tissue is exposed to a smaller
    dosage. Proton beam therapy can focus cell damage caused by the
    proton beam at the precise depth of the tissue where the tumor
    is situated, while tissues located before the Bragg peak receive
    a reduced dose and tissues situated after the peak receive none.
    These
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    108
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    advantages make proton beam therapy a preferred option for
    treating certain types of cancers where conventional
    radiotherapy would damage surrounding tissues to an unacceptable
    level, such as tumors near optical nerves, the spinal cord or
    central nervous system and in the head and neck area, as well as
    prostate cancer and cancer in pediatric cases. Proton beam
    therapy is not a widely utilized treatment modality, with only
    approximately 30 proton beam therapy treatment centers in
    operation or under construction worldwide. We plan to enter into
    the proton therapy market with the construction of our Beijing
    Proton Medical Center. See &#147;&#151;&#160;Our Network of
    Centers and Specialty Cancer Hospitals&#160;&#151; Specialty
    Cancer Hospitals.&#148;
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Diagnostic
    Imaging</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our network of centers employs a wide range of diagnostic
    imaging equipment. Such equipment includes some of the most
    advanced diagnostic imaging technology available in China,
    including PET-CT scanners. A PET-CT scanner is a device that
    combines a positron emission tomography, or PET, scanner and a
    computed tomography, or CT, scanner in one unit. PET-CT scanners
    allow the functional imaging obtained by PET scanning, which
    depicts the spatial distribution of metabolic or biochemical
    activities in the body, to be more precisely aligned or
    correlated with the anatomic imaging obtained by a CT scanner.
    Other diagnostic imaging services offered in our centers include
    MRI, CT and ECT. MRI scanners use a powerful magnetic field,
    radio frequency pulses and computers to produce detailed
    pictures of organs, soft tissues, bone and virtually all other
    internal body structures. MRI technology, which does not involve
    radiation, is typically able to provide a much greater level of
    contrast between the different soft tissues of the body than CT,
    making it especially useful in neurological or oncological
    imaging. As of September&#160;30, 2009, we owned seven PET-CT
    scanners and 16&#160;MRI scanners.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Other
    Treatment and Diagnostic Modalities</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our network also includes centers that provide other treatments
    and diagnostic services through the use of other types of
    medical equipment. Such equipment currently includes
    electroencephalography for the diagnosis of epilepsy,
    thermotherapy to increase the efficacy of and for pain relief
    after radiotherapy and chemotherapy, high intensity focused
    ultrasound therapy for the treatment of cancer, stereotactic
    radiofrequency ablation for the treatment of Parkinson&#146;s
    Disease and refraction and tonometry for the diagnosis of
    ophthalmic conditions. In 2008 and for the nine months ended
    September&#160;30, 2009, revenues derived from centers that
    provide such other services were approximately 2.9% and 2.5%,
    respectively, of our total net revenues.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Medical
    Equipment Procurement</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The medical equipment used in our network of centers is highly
    complex and there are usually a limited number of manufacturers
    worldwide that produce such equipment. We typically purchase the
    medical equipment used in our network directly from domestic
    manufacturers and through importers from overseas manufacturers.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with the relevant PRC laws and regulations, the
    procurement, installation and operation of Class&#160;A or
    Class&#160;B large medical equipment by hospitals in China are
    subject to procurement quotas or procurement planning and a
    large medical equipment procurement license must be obtained
    prior to the purchase of such medical equipment. For medical
    equipment classified as Class&#160;A large medical equipment,
    which includes gamma knife systems, proton beam therapy systems
    and PET-CT scanners, quotas are set by the MOH and the NDRC and
    large medical equipment procurement licenses are issued by the
    MOH. For medical equipment classified as Class&#160;B large
    medical equipment, which includes linear accelerators and MRI
    and CT scanners, procurement planning and approval is conducted
    by the relevant provincial healthcare administrative authorities
    with ratification by the MOH and the large medical equipment
    procurement licenses are issued by the relevant provincial
    healthcare administrative authorities. A large medical equipment
    procurement license is not required for medical equipment that
    is not classified as either Class&#160;A or Class&#160;B large
    medical equipment. These rules concerning procurement of large
    medical equipment apply to all public and private medical
    institutions in China, whether non-profit or for-profit, except
    for military hospitals in China, which have a separate
    procurement system. See &#147;Regulation of Our
    Industry&#160;&#151; Regulation of Medical
    Institutions&#160;&#151; Large Medical Equipment Procurement
    License.&#148;
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Once non-profit hospitals have obtained large medical equipment
    procurement licenses, the purchase of medical equipment for such
    hospitals is conducted through a collective tender process. The
    tender process is centralized in accordance with relevant PRC
    laws and regulations and is supervised by the MOH for
    Class&#160;A large medical equipment. For Class&#160;B large
    medical equipment, the tender process is supervised by the
    relevant
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    109
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    provincial heath administrative authorities. Equipment purchases
    by military hospitals are also conducted through a centralized
    collective tender process supervised by the general logistics
    department of the PLA. The government or military authority will
    appoint an agent to manage the tender process who must be
    certified by the government and qualified to conduct the tender
    process. The agent publicizes information relevant to the tender
    process, such as the type of equipment requested by the hospital
    and the desired commercial terms. The manufacturers will prepare
    the tender document according to the agent&#146;s requirement
    and submit their bids to the agent on or before the specified
    date. The agent will then consult with industry experts in
    evaluating each bid and the industry experts will make a
    determination on the winning manufacturer. When the tender
    process is complete, the results are publicly announced and an
    import permit is issued for the equipment of the winning
    manufacturer. We then begin negotiations with such manufacturer
    or its importer on the purchase price and the purchasing terms
    for the equipment based on the general commercial terms
    submitted by such manufacturer in the tender process.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Operation
    of Radiotherapy and Diagnostic Imaging Centers in Our
    Network</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a brief summary of the various aspects of the
    operations of the radiotherapy and diagnostic imaging centers in
    our network.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Management
    Structure</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We manage each of the radiotherapy and diagnostic centers
    jointly with our hospital partners. Our hospital partners
    appoint a medical director to each center and are responsible
    for the centers&#146; clinical activities, the medical decisions
    made by doctors, and the employment of doctors in accordance
    with the licencing regulations. We provide clinical support to
    doctors, including developing treatment protocols for doctors
    and organizing joint diagnosis between doctors in our network
    and clinical research. We appoint either an operations director
    or a project manager to each center. Such director or manager
    provides most of the non-clinical aspects of the centers&#146;
    day-to-day operations, which include marketing, providing
    training and clinical education to doctors and other medical
    personnel in the centers and other general administrative duties
    such as arranging for the repair and maintenance of medical
    equipment. Budgets for each center are established annually
    based on discussions between our hospital partners and us. Costs
    incurred at the centers usually require approval of both our
    hospital partners and us. As a matter of practice, certain major
    expenditures of the center are subject to further approval by
    our hospital partners&#146; management and our management.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have established operating procedures and a comprehensive
    quality assurance program to ensure that our centers operate
    efficiently and provide consistent and high quality services.
    The operating procedures cover the use and maintenance of the
    medical equipment and interactions with patients, from initial
    patient appointment and registration to post-treatment
    <FONT style="white-space: nowrap">follow-up.</FONT>
    The operations director or project manager of each center is
    primarily responsible for ensuring the adherence to our
    operating procedures and comprehensive quality assurance program.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    At the corporate level, we have established a dedicated
    operations department to supervise and provide support to ensure
    the effective operation of each center. We actively monitor the
    activities of each center and conduct scheduled annual
    evaluations for all centers. These evaluations focus on whether
    the applicable procedures are followed and whether our operating
    personnel are performing at the expected level. In addition to
    the scheduled annual review, we also conduct unscheduled
    evaluations for certain randomly selected centers. The results
    of these evaluations are used to help determine the compensation
    received by our operations directors or project managers and our
    other employees at the centers. We receive weekly reports on the
    operating activities for each center, which help us identify
    opportunities for continued improvement with regards to various
    aspects of each center&#146;s operations. We also have a risk
    management department that helps to ensure that we meet
    applicable PRC laws and regulations and compliance standards for
    the operation of our business. We have also adopted a code of
    ethics.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For our specialty cancer hospitals Chang&#146;an CMS
    International Cancer Center and Beijing Proton Medical Center,
    we will have full operating control over all clinical and
    non-clinical aspects of such hospitals&#146; operation,
    including direct supervision over medical decisions made by
    doctors.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Staffing</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the operations director or project manager
    appointed by us to each center, we also typically staff each
    center with dedicated marketing and accounting personnel. Our
    hospital partners appoint medical directors to the centers and,
    except in very limited cases, they also assign all of the
    doctors and other medical personnel to the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    110
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    centers. However, we also help our hospital partners to recruit
    many of the doctors or medical personnel providing services at
    the center. We provide feedback to our hospital partners as to
    the suitability and performance of the doctors and other medical
    personnel at each center, and work with our hospital partners to
    ensure that each center is staffed with the most qualified and
    suitable personnel. In addition, we help our hospital partners
    to determine the compensation of doctors and other medical
    personnel providing services in our network of centers. We also,
    on a very limited basis, enter into employment agreements with
    doctors to work at centers in our network after consulting with
    our hospital partners where such centers are based.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are currently in the process of establishing specialty cancer
    hospitals. We will be responsible for employing and managing all
    personnel of these specialty cancer hospitals, including doctors
    and other medical personnel.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Medical
    Affairs</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have a medical affairs department to support the training,
    clinical education and clinical research activities of our
    network of centers. Prior to setting up a new center, we arrange
    training for the medical professionals of such new center at
    certain established centers in our network designated as
    training centers. This provides the medical professionals of
    such new center with the opportunity to gain hands-on clinical
    experience in advanced radiotherapy treatment and diagnostic
    imaging technologies and to benefit from the considerable
    clinical knowledge of the doctors and other medical personnel at
    the designated training centers. The doctors at the designated
    training centers will evaluate the performance of the medical
    professionals of the new center and ensure that they can provide
    high quality clinical care. In addition, we also arrange
    training for the medical staff with the medical equipment
    manufacturers. We also periodically provide
    <FONT style="white-space: nowrap">follow-up</FONT>
    training at selected centers and host academic conferences and
    semi-annual academic seminars where doctors and other medical
    personnel from our network of centers and medical experts in
    China are invited to share their knowledge and clinical
    experience. From time to time, we invite experts from
    professional or academic institutions, such as the Oncology
    Hospital of the Chinese Academy of Medical Science, to give
    lectures and provide guidance as to the latest developments and
    trends in radiotherapy treatments.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that a well-managed clinical research program
    enhances the reputation of doctors in our network, which in turn
    enhances the reputation of our network of centers. We maintain a
    database of radiotherapy treatments. This collection of data can
    be used, upon approval by us and our hospital partners, to
    conduct cross-center clinical research and statistical analysis
    to determine the efficacy and potential of treatment methods
    offered in our network. We actively organize, encourage and
    assist doctors in our network to engage in clinical research and
    to publish their results. We assist in coordinating the clinical
    research efforts between different radiotherapy and diagnostic
    imaging centers in our network, which is critical for certain
    research initiatives that require a significant amount of
    clinical data that would be difficult for one center to collect.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Doctors in China have historically had very limited
    opportunities for discussions or consultations with doctors
    outside of their own hospital. Our network offers doctors the
    opportunity to consult with each other on challenging cases and
    treatments. In addition, we have developed treatment protocols
    that are introduced to each center and can be followed by
    doctors in our network of centers. We also evaluate the clinical
    activities of each center as part of our annual evaluations to
    ensure that high quality treatments or services are provided to
    patients. We also publish an internal quarterly magazine titled
    &#147;Stereotactic Radiosurgery&#148; that highlights the
    different clinical cases being treated in our centers and the
    latest developments in radiosurgery treatment. We further assist
    in the publication of other literature related to radiosurgery.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Marketing</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Marketing efforts for each center in our network are primarily
    initiated and implemented by the marketing personnel or the
    operations director or project manager situated at each center
    with the support of our headquarters. Each center&#146;s
    marketing efforts are directed at other doctors in the hospital
    where the center is based and at other local hospitals. These
    marketing efforts are focused on informing such doctors of the
    applicability and benefits of radiotherapy and the expertise and
    experience of the doctors at the centers. We also create and
    distribute educational materials and brochures and engage in
    consumer advertising and educational campaigns through
    television, magazines and electronic media.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each center is required to report its marketing activities to
    us, and we closely monitor such activities and give approval for
    major marketing initiatives. We also oversee the budget for
    marketing activities at the centers. We
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    111
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    assist the centers by providing relevant content for marketing
    materials and help to coordinate with leading experts in the
    medical community to attend conferences or seminars hosted by
    the centers. As our network of centers continues to expand and
    as we begin operating our specialty cancer hospitals, we plan to
    begin centralizing certain of the marketing and advertising
    efforts.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounting
    and Payment Collection</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our hospital partners are responsible for patient billing and
    fee collections and for delivering to us our contracted
    percentage of medical fees based on our arrangements with them.
    We typically appoint accounting personnel to each of our centers
    who are in charge of keeping books and records as to the
    revenues and expenses of the center. We reconcile the accounting
    records for each center in our network with our hospital
    partners periodically. After the revenue net of specified
    operating expenses of a center is agreed upon between us and our
    hospital partner, we will bill our hospital partner for our
    portion of the revenue determined based on our contracted
    percentage. Our hospital partners will then go through their
    internal approval process, which usually takes about
    45&#160;days from the time of billing before making payments to
    us. We have implemented accounting procedures at each of the
    centers in our network, and perform periodic reviews to ensure
    that such activities are properly conducted. For our specialty
    cancer hospitals, we will be responsible for patient billing and
    fee collection.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Medical
    Equipment Maintenance and Repair</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Equipment maintenance and repair are typically carried out by
    the equipment manufacturers or third party service companies.
    The manufacturers typically provide equipment warranties for a
    period of one year. After the warranty period expires, we
    typically enter into service agreements with the manufacturers
    or third party service companies to provide periodic maintenance
    and repair services. We have also established a dedicated
    engineering team that is responsible for the general preventive
    maintenance of medical equipment used in our network of centers.
    Our engineering team serves as an initial point of contact when
    problems are encountered and coordinates with equipment
    manufacturers or a third party service company to ensure that
    problems are resolved in a timely manner whenever they arise.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pricing
    of Medical Service</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Medical service fees generated through the use of both
    Class&#160;A and Class&#160;B large medical equipment at
    non-profit civilian hospitals and military hospitals are subject
    to the pricing guidance of the relevant provincial or regional
    price control authorities and healthcare administrative
    authorities. The pricing guidance sets forth the range of
    medical service fees that can be charged by non-profit civilian
    medical institutions and military hospitals. See &#147;Risk
    Factors&#160;&#151; Risks Related to Our Industry&#160;&#151;
    Pricing for the services provided by our network of centers may
    be adversely affected by reductions in treatment and examination
    fees set by the Chinese government&#148;&#160;and
    &#147;Regulation of Our Industry&#160;&#151; Pricing of Medical
    Services.&#148; The relevant price control authorities and
    healthcare administrative authorities provide notices to
    hospitals, which in turn provide immediate notices to us, as to
    any change in the pricing ceiling for medical services. The
    timing between when notices are provided by the relevant price
    control authorities and healthcare administrative authorities
    and the effective date of such pricing change varies in
    different cities and regions as well as the relevant medical
    services in question, but typically ranges from one to three
    months. For-profit hospitals or centers based in for-profit
    hospitals in China, such as our planned specialty cancer
    hospitals, are not subject to such pricing restrictions and are
    entitled to set medical service fees based on their cost
    structures, market demand and other factors.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Business
    Development</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have a business development team responsible for pursuing
    opportunities to develop centers with hospitals and a hospital
    investment team responsible for pursuing opportunities to
    establish specialty cancer hospitals. When examining potential
    opportunities, we take into account factors that include:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    population density, demographics and the level of economic
    development of the regions or cities in which such new centers
    would be located;&#160;and
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the reputation of the potential hospital partner and its
    doctors, nurses and other personnel and the number of licensed
    patient beds and patient volume.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After each potential opportunity is identified and evaluated by
    the business development team or the hospital investment team,
    as applicable, the opportunity is presented to our investment
    evaluation committee for review. Our
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    112
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    investment evaluation committee is comprised of several of our
    senior executives and members of our board of directors, and
    includes Mr.&#160;Steve Sun, the chairman of the committee,
    Mr.&#160;Jing Zhang, Dr.&#160;Zheng Cheng, Mr.&#160;Yaw Kong Yap
    and Ms. Elaine Zong. New projects need to be approved by a
    super-majority approval of our investment evaluation committee
    and by our chief executive officer.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employees</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our employees consist of all personnel that work in our
    headquarters and our regional offices and certain personnel that
    work in our network of centers. Our employees in our network are
    generally the operations directors or project managers and the
    marketing, accounting or administrative personnel of the
    centers. We had 57, 58, 130 and 150&#160;employees as of
    December&#160;31, 2006, 2007 and 2008 and September&#160;30,
    2009, respectively. The following table set forth certain
    information about our employees by function as of the period
    indicated:
</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="66%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="17%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As of September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Employees</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Administration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18.7
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Financial control
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Marketing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Business development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Medical development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into employment agreements with each of our
    employees. We may terminate the employment of any of our
    employees in the event that such employee&#146;s actions have
    resulted in material and demonstrable harm to our interests or
    if the employee has not performed as expected. An employee may
    typically terminate his or her employment at any time for any
    material breach of the employment agreement by us. The employee
    may also terminate the employment agreement at any time without
    cause upon 30&#160;days prior notice. Each of our employees who
    have access to sensitive and confidential information has also
    entered into a non-disclosure and confidentiality agreement with
    us. For information as to employment agreements with our
    executive officers, see &#147;Management&#160;&#151; Employment
    Agreements.&#148; We are required under PRC law to make
    contributions to our employee benefit plans based on specified
    percentages of the salaries, bonuses, housing allowances and
    certain other allowances of our employees, up to a maximum
    amount specified by the respective local government authorities.
    The total amount of the contributions that we made to employee
    benefit plans in 2007, 2008 and for the nine months ended
    September&#160;30, 2009 was RMB0.2&#160;million,
    RMB0.9&#160;million (US$0.1&#160;million) and
    RMB1.7&#160;million (US$0.3&#160;million), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our success depends to a significant extent upon, among other
    factors, our ability to attract, retain and motivate qualified
    personnel. Many of our employees have extensive industry
    experience, and we place a strong emphasis on continuously
    improving our employees&#146; expertise by providing periodic
    training to enhance their skills and knowledge. Our employees
    are not covered by any collective bargaining agreement. We
    believe that we have a good relationship with our employees. All
    of our employees are based in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with applicable PRC laws and regulations, the MOH
    oversees the activities of doctors in China. The relevant local
    healthcare administrative authorities above the county level are
    responsible for the supervision of doctors located in their
    regions. Doctors in China are regulated by a registration system
    and each doctor may only practice medicine in the sole medical
    institution where such doctor is registered. Doctors are not
    permitted to be registered in more than one medical institution.
    However, doctors may, upon the approval of the medical
    institution with which they are registered, enter into
    consulting agreements with third parties to engage in medical
    practice for another institution. We enter into such consulting
    contracts with doctors from time to time to provide expert
    assistance and consultation to our company and our network of
    centers. In very limited cases, we enter into employment
    agreements with doctors to work at centers in our network after
    consulting with our hospital partners where such centers are
    based. These doctors register their practice with the hospitals
    in accordance with applicable PRC laws and regulations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    113
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Competition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The radiotherapy and diagnostic imaging market in China is
    fragmented and the competition is intense. The centers in our
    network compete primarily on a regional or local basis with
    government-owned and private hospitals that offer radiotherapy
    and diagnostic imaging services either directly or in
    conjunction with third parties, such as China Renji Medical
    Group Ltd. and Jiancheng Investment Co. In addition, since
    hospitals typically establish radiotherapy and diagnostic
    imaging centers located on their premises through long term
    lease and management services arrangements with us or our
    competitors, in a given locality over a given period there may
    only be a limited number of top-tier hospitals who have not yet
    entered into long-term arrangements with us or other companies
    like us with whom we are still able to enter into new
    arrangements. In addition, quotas as to the number and type of
    certain medical equipment that can be purchased by us or our
    hospital partners, such as head gamma knife systems of PET-CT
    scanners, further limit the number of top-tier hospitals that we
    or our competitors can enter into arrangements with in a given
    period. We primarily compete with our competitors on the range
    of the option of services provided by us and our competitors,
    the reputation of centers in our network among doctors and
    patients in China and level of patient service and satisfaction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, we also compete with those who offer other types of
    available treatment methods that we do not offer, such as
    chemotherapy, surgery, different forms of radiotherapy that we
    do not currently offer, other alternative treatment methods
    commercialized in recent years and certain treatments that are
    currently in the experimental stage. These treatments may be
    more effective or less costly, or both, compared to the
    treatment methods that our centers provide.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Environmental
    Matters</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The MOH enacted the <I>Administrative Measures on Medical Wastes
    Management of Medical Institutions </I>in 2003, which sets forth
    the management of and criteria for the disposal of medical waste
    generated in the operation of medical institutions. As the
    supervising authority, the environmental protection authority at
    the county or higher levels is responsible for environmental
    inspections of hospitals within their jurisdictions. The MOH and
    the environmental protection authorities have also promulgated a
    series of specific regulations on the disposal of dangerous
    medical waste and the requirements of vehicles used to transport
    medical wastes. In addition, certain of the medical equipment
    used in our network of centers, such as gamma knife systems, use
    radioactive sources. In accordance with the <I>Regulation on
    Radioisotope and Radiation Equipment Safety and Protection
    </I>promulgated by the PRC State Council in 2005, these
    radioactive sources should be returned to the manufacturer of
    such radioactive materials or sent to dedicated radioactive
    waste disposal units appointed by the MEP. Radioactive materials
    are generally obtained from, and returned to, the medical
    equipment manufacturers or other third parties, which then have
    the ultimate responsibility for their proper disposal. However,
    as all centers in our network are located on the premises of our
    hospital partners, we do not directly oversee the disposal of
    certain medical waste generated in the centers. The failure of
    any of our hospital partners to dispose of such waste in
    accordance with PRC laws and regulations may have an adverse
    effect on the operation of centers in our network. See
    &#147;Risk Factors&#160;&#151; Risks Related to Our
    Company&#160;&#151; Most of our radiotherapy and diagnostic
    imaging equipment contains radioactive materials or emits
    radiation during operation.&#148; For our specialty cancer
    hospitals, we will be responsible for the disposal of the
    medical waste generated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Insurance</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We maintain property insurance on many of the medical equipment
    used in our network of centers to protect against loss in the
    event of fire, earthquake, flood and a wide range of natural
    disasters. We do not typically maintain any professional
    malpractice liability insurance since we do not employ the
    doctors and other medical personnel providing services in the
    centers, except in very limited cases and the centers are
    located on the premises of our hospital partners. Accordingly,
    we are not directly responsible for any incidents that occur in
    the course of providing treatment. However, as certain
    agreements entered into with our hospital partners require us to
    share in the expenses related to medical disputes and for such
    expenses to be included as the expenses of the centers, we have
    obtained malpractice liability insurance for a limited number of
    centers. We do not maintain product liability insurance for the
    medical equipment. We do not maintain real property insurance on
    the centers as this is the responsibility of our hospital
    partners. We do not maintain business interruption insurance or
    key employee insurance for our executive offices as we believe
    it is not the normal industry practice in China to maintain such
    insurance. We consider our current insurance coverage to be
    adequate. However, uninsured damage to any of the medical
    equipment in our
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    114
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    network of centers or inadequate insurance carried by our
    partner hospitals as to their respective centers could result in
    significant disruption to the operation of centers in our
    network and result in a material adverse effect to our business,
    financial condition and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into framework agreements to establish specialty
    cancer hospitals that are to be majority-owned by us. We will
    employ all of the personnel of such hospitals, including
    doctors, nurses and medical technicians. As a result, we plan to
    obtain professional malpractice liability insurance for such
    specialty cancer hospitals. However, there can be no assurance
    that such insurance will be available at a reasonable price or
    that we will be able to maintain adequate levels of professional
    and general liability insurance coverage.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Facilities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our principal headquarters are located at 18/F, Tower A, Global
    Trade Center, 36 North Third Ring Road East, Dongcheng District,
    Beijing, 100013. We occupy and use this office space with a
    gross floor area of approximately 624&#160;square meters,
    pursuant to a lease agreement entered into on December&#160;27,
    2006 and expiring on February&#160;8, 2010. We also entered into
    lease agreements on March&#160;25, 2009 for a period of three
    years for additional office space located in the same building
    with an aggregate gross floor area of approximately
    1,931&#160;square meters. The following table sets forth our
    other leased properties as of the date of this prospectus:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="31%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Location</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Size (in square
    meters)</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Expiration Date</FONT></B>
</DIV>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Beijing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    286
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    July 2010
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Shanghai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    16
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    November 2009
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Shanghai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    34
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    May 2010
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Shanghai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    195
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    January 2011
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Shenzhen
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    522
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="bottom">
    November 2012
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The centers in our network typically have gross floor area
    ranging from approximately 100 to 400&#160;square meters
    depending on the services provided at the center. We also
    currently provide management services to a general hospital in
    Xi&#146;an, Chang&#146;an Hospital, that has a gross floor area
    of approximately 12,000&#160;square meters. We have entered into
    agreements to establish and operate two specialty cancer
    hospitals that are to be majority owned by us. The Chang&#146;an
    CMS International Cancer Center has a planned gross floor area
    of approximately 12,000&#160;square meters and the Beijing
    Proton Medical Center has a planned gross floor area of
    approximately 12,700&#160;square meters. We expect the land use
    rights for properties occupied by our specialty cancer hospitals
    to be owned by our specialty cancer hospitals. For additional
    information on our centers and specialty cancer hospitals,
    please see &#147;&#160;&#151; Our Network of Centers and
    Specialty Cancer Hospitals.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Intellectual
    Property</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have applied to the PRC Trademark Office of the State
    Administration for Industry and Commerce for the registration of
    our trademark &#147;Medstar&#148; to protect our corporate name.
    We also own the rights to 146 domain names that we use in
    connection with the operation of our business. Many of the
    domain names that we own include domain names in Chinese that
    contain relevant key words associated with various types of
    cancer, radiotherapy, gamma knife systems, linear accelerators
    or other medical equipment used or treatments and services
    provided in our network. We believe that such domain names
    provide us with the opportunity to enhance our marketing efforts
    for the treatments and services provided in our network and
    enhance patients&#146; knowledge as to cancers, the benefits of
    radiotherapy and the various treatment options that are
    available. Other than the use of our trademark and domain names,
    our business generally is not directly dependent upon any
    patents, licensed technology or other intellectual property.
    However, we cannot be certain that the equipment manufacturers
    from whom we purchase equipment have all requisite third-party
    consents and licenses for the intellectual property used in the
    equipment they manufacture. As a result, those equipment
    manufacturers may be exposed to risks associated with
    intellectual property infringement and misappropriation claims
    by third parties which, in turn, may subject us to claims that
    the equipment we have purchased infringes the intellectual
    property rights of third parties. See &#147;Risk
    Factors&#160;&#151; Risk Related to Our Company&#160;&#151; We
    may fail to protect our intellectual property rights or we may
    be exposed to misappropriation and infringement claims by third
    parties, either of which may have a material adverse effect as
    to our business.&#148; As we begin to operate specialty cancer
    hospitals under our own brand name in the future and as our
    brand name gains more recognition among the general public, we
    will work to increase, maintain and enforce our
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    115
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    rights in our trademark portfolio, the protection of which is
    important to our reputation and branding strategy and the
    continued growth of our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Legal and
    Administrative Proceedings</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;4, 2009, we received a notice that a legal
    proceeding was initiated against us that alleges a gamma knife
    system currently in use in certain centers in our network was
    previously found to infringe upon the patent of a third party.
    This claim relates to a patent used in the head gamma knife
    system manufactured by one of our equipment manufacturers, Our
    Medical New Technology. A previous legal proceeding involving
    such patent was initiated in June 2000 against Our Medical New
    Technology, its related parties and our subsidiary, AMS. The
    relevant PRC court determined in 2004 that all head gamma knife
    systems manufactured by Our Medical New Technology after the
    patent owner began to contest the use of such patent on
    December&#160;23, 1999 were manufactured without the requisite
    consent to use the patent in question. The relevant PRC court
    also ordered the use of such equipment to cease. We are
    currently assessing the validity and the potential impact of the
    claim filed against us. Based on our current assessment, we have
    identified one head gamma knife system in one of the centers in
    our network that may be subject to such claim. Revenue derived
    from such center represented approximately 1.5% and 1.0% of our
    total net revenues in 2008 and for the nine months ended
    September&#160;30, 2009, respectively. Our Medical New
    Technology, the manufacturer of the head gamma knife system that
    may be subject to this claim, has agreed to indemnify us for any
    damages or losses that we may incur from any intellectual
    property infringement by such system. We are also continuing to
    assess whether there is any other medical equipment in our
    network that might be subject to this claim. We do not currently
    believe that this claim would result in a material adverse
    effect on our business, financial condition or results of
    operations.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are not currently involved in any other material litigation,
    arbitration or administrative proceedings. However, we may from
    time to time become a party to various other litigation,
    arbitration or administrative proceedings arising in the
    ordinary course of our business.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
  <!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    116
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='115'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">REGULATION&#160;OF
    OUR INDUSTRY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">General
    Regulatory Environment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China&#146;s healthcare industry is regulated by various
    government agencies, including the Ministry of Health, or MOH.
    The MOH has branch offices across China that oversee the
    healthcare industry at the provincial and county levels, which
    branch offices, together with the MOH, we refer to as the
    healthcare administrative authorities. The healthcare
    administrative authorities and other government agencies, such
    as the National Development and Reform Commission, or NDRC, the
    State Food and Drug Administration, or SFDA, the Ministry of
    Environmental Protection, or MEP, and the Ministry of Commerce,
    or MOFCOM, have promulgated rules and regulations relating to
    the procurement of large medical equipment, the pricing of
    medical services, the operation of radiotherapy equipment, the
    licensing and operation of medical institutions and the
    licensing of medical staff.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Permits
    Required by Our Company</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Medical
    Equipment Operating Enterprise Permits</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The SFDA categorizes medical equipment into three classes
    according to the level of control by the government authorities
    that, in the judgment of the SFDA, is required for their safe
    and effective operation. Class&#160;I medical equipment are
    those medical equipment that require only an ordinary level of
    control in order to ensure their safe and effective operation.
    Class&#160;II medical equipment are those medical equipment that
    require a heightened level of control in order to ensure their
    safe and effective operation. Class&#160;III medical equipment
    are those medical equipment that are used to support or maintain
    human life, are implanted into the human body or otherwise pose
    a potential danger to the human body. Class&#160;III medical
    equipment require strict control in order to ensure their safe
    and effective operation. In order to ensure an adequate level of
    control in the operation of Class&#160;II and Class&#160;III
    medical equipment, enterprises that engage in the operation of
    such equipment, which include gamma knife systems, linear
    accelerators, MRI systems and
    <FONT style="white-space: nowrap">PET-CT</FONT>
    systems, must each obtain a medical equipment operating
    enterprise permit from the relevant provincial drug supervision
    and administration agency. As a result, our subsidiaries
    Shanghai Medstar, Aohua Medical, Xing Heng Feng Medical and
    Aohua Leasing must each obtain a medical equipment operating
    enterprise permit from the relevant provincial drug supervision
    and administration agency pursuant to the <I>Medical Equipment
    Supervision and Administration Regulation</I> effective as of
    April&#160;1, 2000. Each such permit is valid for a term of five
    years and, prior to expiration, must be reviewed by and an
    extension of its term must be obtained from the relevant
    authorities. All of our aforementioned subsidiaries have
    received a medical equipment operating enterprise permit.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Radiation
    Safety Permits</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As organizations that produce, sell or use radioactive materials
    or devices in the PRC, our subsidiaries Shanghai Medstar, Aohua
    Medical and Aohua Leasing are required to obtain radiation
    safety permits from the relevant national or provincial
    environmental protection authorities pursuant to the
    <I>Regulation on Radioisotope and Radiation Equipment Safety and
    Protection </I>issued on September&#160;14, 2005 by the PRC
    State Council and the <I>Rules on Radioisotopes and Radiation
    Device Safety Permit </I>issued on January&#160;18, 2006 by the
    State Environmental Protection Administration (now the MEP) and
    amended on December&#160;6, 2008 by the MEP. Each such radiation
    safety permit is valid for a term of five years and, prior to
    expiration, must be reviewed by and an extension of its term
    must be obtained from the relevant authorities. All of our
    forementioned subsidiaries have received a radiation safety
    permit.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any organization that is subject to radiation safety permitting
    requirements is required to strictly observe state regulations
    regarding individual radiation dosage monitoring and health
    administration, conduct individual dosage monitoring and
    occupational health examinations for its staff that are directly
    involved in the production, sale or use of radioactive materials
    or devices and maintain individual dosage files and occupational
    health files. Any used radioactive source materials must be
    returned to the manufacturer or the original exporter of the
    equipment. If return to the manufacturer or the original
    exporter is not possible, the used radioactive materials must be
    delivered to a qualified radioactive waste consolidation and
    storage unit for storage.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    117
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Leasing
    Company Permit</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As foreign-invested companies engaged in the leasing or
    financial leasing business, certain of our subsidiaries must
    obtain a Foreign-invested Enterprise Approval Certificate from
    the MOFCOM or its competent local branch. Each such certificate
    will specify the permitted business scope of the
    foreign-invested company as either leasing or financial leasing.
    Foreign-invested leasing companies, such as our subsidiary,
    Aohua Medical, are permitted to operate their businesses for no
    more than 30&#160;years after obtaining such certificates, after
    which time they are required to apply for and obtain an
    extension of the term of their certificate. Foreign-invested
    leasing companies are also required to observe the rules for the
    registered capital and total investment provided in the
    <I>Company Law </I>issued by the Standing Committee of National
    People&#146;s Congress of the PRC on December&#160;29, 1993, as
    amended from time to time, and other relevant regulations.
    Foreign-invested financial leasing companies, such as our
    subsidiaries Aohua Leasing and Shanghai Medstar are, in addition
    to the aforementioned requirements for foreign-invested leasing
    companies, subject to the additional requirements of maintaining
    a registered capital level of at least US$10&#160;million,
    having qualified professionals and having senior managers with
    professional qualifications and with no less than 3&#160;years
    of management experience. Our subsidiaries Aohua Leasing and
    Shanghai Medstar have each obtained a foreign-invested financial
    leasing company permit and our subsidiary Aohua Medical has
    obtained a foreign-invested leasing company permit.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Regulation
    of Medical Institutions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Distinction
    between For-Profit and Non-Profit Medical
    Institutions</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Medical institutions in China can be divided into three main
    categories: public non-profit medical institutions, private
    non-profit medical institutions and for-profit medical
    institutions. Medical institutions falling under each category
    have differing registered business purposes and governing
    financial, tax, pricing and accounting standards than medical
    institutions falling under one of the other categories. Public
    non-profit medical institutions, including those owned by the
    government and military hospitals, are set up and operated to
    provide a public service and are eligible for financial
    subsidies from the government. In contrast, private non-profit
    medical institutions are not eligible for government financial
    subsidies. Both public and private non-profit medical
    institutions are required to set their medical service fees
    within a range stipulated by the relevant governmental price
    control authorities, to implement financial and accounting
    systems in accordance with standards promulgated by government
    authorities and to retain any profits for the continued
    development of such institutions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For-profit medical institutions are permitted to set prices for
    their medical services in accordance with the market, to
    implement financial and accounting systems in accordance with
    market practice for business enterprises and to distribute
    profits to their shareholders. Like private non-profit medical
    institutions, for-profit medical institutions are not entitled
    to government financial subsidies. The specialty cancer
    hospitals that we plan to develop will be established as
    for-profit medical institutions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Medical
    Institution Practicing License</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the <I>Regulation on Medical Institution </I>issued
    on February&#160;26, 1994 by the PRC State Council, any
    organization or individual that intends to establish a medical
    institution must obtain a medical institution practicing license
    from the relevant healthcare administrative authorities. In
    determining whether to approve any application, the relevant
    healthcare administrative authorities are to consider whether
    the proposed medical institution comports with the population,
    medical resources, medical needs and geographic distribution of
    existing medical institutions in the regions for which such
    authorities are responsible as well as whether the proposed
    medical institution meets the basic medical standards set by the
    MOH. The independent specialty cancer hospitals that we intend
    to establish would each need to obtain such a medical
    institution practicing license.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Large
    Medical Equipment Procurement License</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The procurement, installation and operation in China of large
    medical equipment, which is defined as any medical equipment
    valued at over RMB5.0&#160;million or listed in the medical
    equipment administration catalogue of the MOH, is regulated by
    the <I>Rules on Procurement and Use of Large Medical
    Equipment</I> issued on December&#160;31, 2004 by the MOH, the
    NDRC and the Ministry of Finance, which became effective on
    March&#160;1, 2005. Pursuant to these rules, quotas for large
    medical equipment are set by the MOH and the NDRC or the
    relevant provincial
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    118
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    healthcare administrative authorities, and hospitals must obtain
    a large medical equipment procurement license prior to the
    procurement of any such equipment that is covered by the rules
    on procurement. For large medical equipment classified as
    Class&#160;A large medical equipment, which includes gamma knife
    systems, proton beam therapy systems and PET-CT scanners, quotas
    are set by the MOH and the NDRC and large medical equipment
    procurement licenses are issued by the MOH. For large medical
    equipment classified as Class&#160;B large medical equipment,
    which includes linear accelerators and MRI and CT scanners,
    procurement planning and approval is conducted by the relevant
    provincial healthcare administrative authorities with
    ratification by the MOH and the large medical equipment
    procurement licenses are issued by the relevant provincial
    healthcare administrative authorities. However, many provincial
    administrative authorities do not provide the general public
    with information on their procurement planning and quotas for
    Class&#160;B large medical equipment procurement licenses, if
    any. A large medical equipment procurement license is not
    required for medical equipment that is not classified as either
    Class&#160;A or Class&#160;B large medical equipment. These
    rules concerning procurement of large medical equipment apply to
    all public and private medical institutions in China, whether
    non-profit or for-profit, except for military hospitals which
    have a separate procurement system. See &#147;&#160;&#151;
    Regulation of Military Hospitals.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with the
    <I><FONT style="white-space: nowrap">2008-2010</FONT>
    National PET-CT Procurement Plan </I>issued on May&#160;13, 2008
    by the MOH and the NDRC, the total number of PET-CT large
    medical equipment procurement licenses issued in China cannot
    exceed 38 from the date of the plan through the end of 2010. In
    accordance with the <I>National Gamma Ray Stereotactic Head
    Radiosurgery System Procurement Plan </I>issued on
    March&#160;20, 2007 by the MOH and the NDRC, from the date of
    the plan through the end of 2010, the total number of large
    medical equipment procurement licenses issued for head gamma
    knife systems cannot exceed 60 nationwide. Procurement
    applications for head gamma knife equipment must be filed with
    the relevant provincial healthcare administrative authorities
    along with a feasibility report, which must be reviewed by such
    provincial authorities before it is submitted to the MOH for
    approval. There is currently no guidance as to the total number
    of large medical equipment procurement licenses that may be
    issued for other types of medical equipment that the centers in
    our network operate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    With respect to any Class A or Class B large medical equipment
    purchased before the <I>Rules on Procurement and Use of Large
    Medical Equipment </I>came into effect on March&#160;1, 2005,
    the medical institution that houses such equipment must apply to
    the MOH or the relevant provincial healthcare administrative
    authorities for a large medical equipment procurement license
    for such equipment. If such medical institution is unable to
    obtain a procurement license as a result of a lack of
    procurement quotas for such medical equipment allocated to the
    region in which the medical institution is located, an interim
    procurement permit for large medical equipment is required to be
    obtained in lieu thereof. Moreover, any medical institution
    holding an interim permit must pay taxes on income derived from
    the use of the equipment covered by the interim permit and, upon
    the expiration of the useful life of such medical equipment, the
    medical institution must dispose of such equipment and is not
    permitted to replace it with a newer model. Some of our medical
    equipment have not yet received a large medical equipment
    procurement license or an interim permit. For more information,
    see &#147;Risk Factors&#160;&#151; Risks Related to Our
    Industry&#160;&#151; Certain of our hospital partners have not
    received large medical equipment procurement licenses or interim
    procurement permits for some of the medical equipment in our
    network of centers which could result in fines or the suspension
    from use of such medical equipment.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Radiotherapy
    Permit</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Medical institutions that engage in radiotherapy are governed by
    the <I>Regulatory Rules on Radiotherapy </I>issued on
    January&#160;24, 2006 by the MOH and are required to obtain a
    radiotherapy permit from the relevant healthcare administrative
    authorities. These rules require such medical institutions to
    possess qualifications sufficient for radiotherapy work, which
    include having adequate facilities for housing radiotherapy
    equipment as well as having qualified, properly trained
    personnel. Medical institutions that operate medical equipment
    containing radioactive materials are also required to obtain a
    radiation safety permit. See &#147;&#160;&#151; Permits Required
    by Our Company&#160;&#151; Radiation Safety Permits.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Radiation
    Worker Permit</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Medical institutions that engage in the operation of medical
    equipment that contains radioactive materials or emits radiation
    during operation are required to obtain a radiation worker
    permit from the competent healthcare administrative authorities
    for each medical technician who operates such equipment.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    119
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Regulation
    of Military Hospitals</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The procurement, installation and operation of large medical
    equipment by medical institutions of the PLA is regulated by the
    healthcare administrative authority of the general logistics
    department of the PLA with reference to the <I>Rules on
    Procurement and Use of Large Medical Equipment</I>. The general
    logistic department of the PLA issues a large equipment
    application permit to those military hospitals approved for
    procurement. The procurement planning records and annual reviews
    are provided to the MOH for its records.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Restrictions
    on Cooperation Agreements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since the effectiveness in September 2000 of the
    <I>Implementation Opinions on the Management by Classification
    of Urban Medical Institutions </I>by the MOH, the State
    Administration of Traditional Chinese Medicine, the Ministry of
    Finance and the NDRC, non-profit medical institutions other than
    military hospitals have been prohibited from entering into new
    cooperation agreements or continuing to operate under existing
    cooperation agreements with third parties pursuant to which the
    parties jointly invest in or cooperate to set up for-profit
    centers or units that are not independent legal entities.
    However, according to the <I>Opinions on Certain Issues
    Regarding Management by Classification of Urban Medical
    Institutions </I>issued on July&#160;20, 2001 by the MOH, the
    State Administration of Traditional Chinese Medicine, the
    Ministry of Finance and the NDRC, a non-profit medical
    institution that lacks sufficient funds to purchase medical
    equipment outright may enter into a leasing agreement pursuant
    to which the medical institution leases medical equipment at
    market rates. In response to this regulatory change, we have
    replaced the majority of our cooperation agreements with
    non-profit civilian hospitals with leasing and management
    agreements. See &#147;Risk Factors&#160;&#151; Risks Related to
    Our Company&#160;&#151; We may not be successful in negotiating
    the conversion of a few of our cooperation agreements with our
    partner hospitals into lease and management arrangements due to
    regulatory changes.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Regulation
    of Proton Treatment Centers</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the <I>Administrative Measures on Clinical
    Application of Medical Technology</I>, effective as of
    May&#160;1, 2009, medical institutions must apply to the MOH for
    approval before utilizing certain medical technologies. On
    November&#160;13, 2009, the MOH issued the <I>Trial
    Administrative Rules on Proton and Heavy Ion Radiotherapy
    Technologies</I>, which provide the guidelines for government
    authorities to review and approve applications of medical
    institutions for clinical use of proton and heavy ion
    radiotherapy technologies. Furthermore, these rules set out the
    minimum requirements for medical institutions and their medical
    staff to provide proton and heavy ion radiotherapy. Such
    requirements include, among other things, that medical
    institutions that are eligible for providing proton and heavy
    ion radiotherapy must (i)&#160;be 3A hospitals; (ii)&#160;have a
    radiotherapy department with 10 or more years of radiotherapy
    experience and 30 or more inpatient beds; (iii)&#160;have a
    diagnostic imaging department with five or more years of
    diagnostic imaging experience and equipped with diagnostic
    imaging equipment such as MRI, CT and PET-CT; and (iv)&#160;have
    at least two staff doctors possessing technical competence in
    the clinical application of proton and heavy ion radiotherapy
    technologies. Our Beijing Proton Medical Center has already
    received preliminary approval from the MOH prior to the
    promulgation of these new rules. These rules will apply to any
    proton or heavy ion radiotherapy treatment centers that we or
    our hospital partners may build and operate in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    of Doctors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Doctors in China must obtain a doctor practitioner or assistant
    doctor practitioner license in accordance with the <I>Law on
    Medical Practitioners</I>, effective as of May&#160;1, 1999, and
    the <I>Interim Measures for Registration of Medical
    Practitioners</I>, effective as of July&#160;16, 1999.
    Currently, each doctor is required to practice in the medical
    institution specified in such doctor&#146;s registration. If a
    doctor intends to change such doctor&#146;s practice location,
    including but not limited to moving to or from a non-profit
    medical institution or to or from a for-profit medical
    institution, practice classification, practice scope or other
    registered matters, such doctor is required to apply for such
    change with the competent healthcare administrative authorities.
    However, with the approval of the medical institution with which
    a doctor is affiliated, such doctor may, within such
    doctor&#146;s scope of practice, undertake outside
    consultations, including diagnostic and treatment activities,
    for patients of another medical institution.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    120
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pricing
    of Medical Services</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the <I>Opinion Concerning the Reform of Medical
    Service Pricing Management </I>issued by the NDRC and the MOH on
    July&#160;20, 2000, medical services fees generated through the
    use of both Class&#160;A and Class&#160;B large medical
    equipment at non-profit medical institutions and military
    hospitals are subject to the pricing guidelines of the relevant
    provincial or regional price control authorities and healthcare
    administrative authorities. The pricing guidance sets forth the
    range of medical services fees that can be charged by non-profit
    medical institutions and military hospitals. For-profit medical
    institutions are not subject to such pricing restrictions and
    are entitled to set medical services fees based on their cost
    structures, market demand and other factors. According to the
    <I>Implementation Plan for the Recent Priorities of the Health
    Care System Reform
    <FONT style="white-space: nowrap">(2009-2011)</FONT></I>,
    which was issued by the State Council on March&#160;18, 2009,
    the Chinese government is aiming to reduce the examination fees
    for large medical equipment. In addition, according to the
    <I>Opinion on the Reform of Pharmaceuticals and Healthcare
    Service Pricing Structures </I>issued on November&#160;9, 2009
    by the NDRC, the MOH and the MHRSS, the Chinese government is
    also aiming to reduce the treatment fees for large medical
    equipment. See &#147;Risk Factors&#160;&#151; Pricing for the
    services provided by our network of centers may be adversely
    affected by reductions in treatment and examination fees set by
    the Chinese government.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Medical
    Insurance Coverage</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China has a complex medical insurance system that is currently
    undergoing reform. Typically, those covered by medical insurance
    must pay for medical services out of their own pocket at the
    time services are rendered and must then seek reimbursement from
    the relevant insurer. For public servants and others covered by
    the <I>1989 Administrative Measure on State Provision of
    Healthcare </I>and the <I>1997 Circular on Reimbursement
    Coverage of Large Medical Equipment under State Provision of
    Healthcare</I>, the PRC government currently either fully or
    partially reimburses medical expenses for certain approved
    cancer diagnosis and radiotherapy treatment services, including
    treatments utilizing linear accelerators and diagnostic imaging
    services utilizing CT and MRI scanners. However, gamma knife
    treatments and PET scans are currently not eligible for
    reimbursement under this plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Urban residents in China that are not covered by the <I>1989
    Administrative Measure on State Provision of Healthcare </I>and
    the <I>1997 Circular on Reimbursement Coverage of Large Medical
    Equipment under State Provision of Healthcare </I>are covered by
    one of two nationwide public medical insurance schemes, which
    are the <I>Urban Employees Basic Medical Insurance Program
    </I>and the <I>Urban Residents Basic Medical Insurance
    Program</I>. Rural residents in China are covered under a new
    <I>Rural Cooperative Medical Program </I>launched in 2003. The
    <I>Urban Employees Basic Medical Insurance Program</I>, which
    covers employed urban residents, partially reimburses urban
    workers for treatments utilizing linear accelerators and gamma
    knife systems and diagnostic imaging services utilizing CT and
    MRI scanners, with reimbursement levels varying from province to
    province. However, diagnostic imaging services utilizing PET and
    PET-CT scans are currently not reimbursable under the <I>Urban
    Employees Basic Medical Insurance Program</I>. For urban
    non-workers who are covered by the <I>Urban Residents Basic
    Medical Insurance Program</I> and rural residents who are
    covered by the new <I>Rural Cooperative Medical Program</I>, the
    types of cancer diagnosis and radiotherapy treatments that are
    covered are generally set with reference to the policy for urban
    employees in the same region of the country. However, the
    reimbursement levels for covered medical expenses for urban
    non-workers and rural residents, which vary widely from region
    to region and treatment to treatment, are generally lower than
    those for urban employees in the same region. Currently no
    reimbursement is
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    121
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    available for proton beam therapy treatments. The table below
    summarizes certain key aspects of these three medical insurance
    programs:
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="26%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="22%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="22%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="22%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Urban Employees Basic Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Urban Residents Basic Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Insurance Program</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Insurance Program</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Rural Cooperative Medical Program</B>
</DIV>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    Launch Time
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    1998
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    2003
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    Participants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Urban employees
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Urban non-employees
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Rural residents
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    Participation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Mandatory
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Voluntary
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Voluntary
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    Number of People covered<BR>
    in 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Approximately 200.0&#160;million (33.0% of China&#146;s urban
    population)
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Approximately 118.3&#160;million (19.5% of China&#146;s urban
    population)
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Approximately 815&#160;million (91.5% of China&#146;s rural
    population)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    Total reimbursement<BR>
    amount in 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    RMB208.4&#160;billion
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    N/A
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    RMB66.2&#160;billion
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    Funding
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
<DIV style="text-indent: -3pt; margin-left: 3pt;">
Employers and employees:<BR>&#149;&#160;&#160;&#160;employer contributes approximately 6% of each employee&#146;s total salary; and<BR>
</DIV>
<DIV style="text-indent: -3pt; margin-left: 3pt;">
&#149;&#160;&#160;&#160;employee contributes approximately 2% of such employee&#146;s total salary.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
<DIV style="text-indent: -3pt; margin-left: 3pt;">
Households and the government:<BR>&#149;&#160;&#160;&#160;monthly premium are paid by each household; and<BR>
</DIV>
<DIV style="text-indent: -3pt; margin-left: 3pt;">
&#149;&#160;&#160;&#160;government subsidizes no less than RMB80&#160;per person annually and RMB40&#160;per person annually for the mid/western regions of China, with greater subsidies provided to low-income families and disabled persons.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
<DIV style="text-indent: -3pt; margin-left: 3pt;">
Individuals and the government:<BR>&#149;&#160;&#160;&#160;individual pays no less than RMB20 per year and local government subsidizes no less than RMB40 per person annually; and<BR>
</DIV>
<DIV style="text-indent: -3pt; margin-left: 3pt;">
&#149;&#160;&#160;&#160;government subsidizes RMB40 per person annually for the middle and western regions of the country and a smaller amount for the eastern region.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    General Reimbursement Policy
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
<DIV style="text-indent: -3pt; margin-left: 3pt;">
Reimbursement comes from two sources&#160;&#151; individual&#146;s reimbursement account and the social medical expense pool:<BR>&#149;&#160;&#160;&#160;All of the employee&#146;s contribution and 30% of the employer&#146;s contribution are allocated to the individual&#146;s reimbursement account; the reimbursement cap from the individual account is the balance of that account; and<BR>
</DIV>
<DIV style="text-indent: -3pt; margin-left: 3pt;">
&#149;&#160;&#160;&#160;The remaining 70% of the employers&#146; contribution is aggregated into a social medical expense pool; the reimbursement cap from the social medical expense pool for an individual participant in a calendar year is around four times the regional average annual salary.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    There is no specific requirement or guidance from the central
    government. Reimbursement policy is separately determined by
    local governments.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    The central government suggests that, beginning in the second
    half of 2009, the reimbursement cap for all regions should be no
    less than six times the average annual per capita net  income of
    rural residents in the region.
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    Examples of Local Reimbursement Policy
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <U>Shanghai:</U> reimbursement cap from the social medical
    expense pool for an individual participant in a calendar year is
    approximately four times the average annual salary in Shanghai
    from the previous year.<BR>
    <U>Inner Mongolia:</U> reimbursement cap from the social medical
    expense pool for an individual participant in a calendar year is
    RMB25,000.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <U>Jiangsu Province:</U> approximately 50% to 60% of medical
    expense can be reimbursed by the program.<BR>
    <U>Sichuan Province:</U> approximately 60% (and not less than
    50%) of medical expense can be reimbursed by the program.<BR>
    <U>Guangdong Province:</U> approximately 40% to 60% of medical
    expense can be reimbursed by the program; maximum reimbursement
    amount is approximately two times the average annual salary in
    Guangdong province from the previous year.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <U>Guangdong Province:</U> maximum reimbursement amount is
    approximately RMB50,000&#160;per person per year.<BR>
    <U>Hubei Province:</U> maximum reimbursement amount for
    hospitalization is approximately RMB30,000 per person per
    year.<BR>
    <U>Anhui Province:</U> maximum reimbursement amount for
    hospitalization is approximately RMB30,000 per person per year.
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 3pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    Sources: </TD>
    <TD align="left">
    MOH, MHRSS, National Bureau of Statistics, and various other
    central and local PRC government websites.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    122
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Foreign
    Exchange Control and Administration</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the <I>Foreign Exchange Administration Regulation
    </I>promulgated on January&#160;29, 1996, as amended on
    January&#160;14, 1997 and August&#160;5, 2008, and various
    regulations issued by the SAFE and other relevant PRC government
    authorities, the Renminbi is freely convertible only with
    respect to current account items, such as trade-related receipts
    and payments, interest and dividends. Capital account items,
    such as direct equity investments, loans and repatriations of
    investments, require the prior approval of the SAFE or its local
    branches for conversion of Renminbi into foreign currency, such
    as U.S.&#160;dollars, and remittance of the foreign currency
    outside the PRC. Payments for transactions that take place
    within the PRC must be made in Renminbi. Foreign exchange
    transactions under the capital account are still subject to
    limitations and require approvals from, or registration with,
    the SAFE and other relevant PRC governmental authorities, or
    their competent local branches.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;29, 2008, the SAFE promulgated SAFE Circular
    No.&#160;142, a notice regulating the conversion by a
    foreign-invested company of foreign currency into Renminbi by
    restricting how converted Renminbi may be used. This notice
    requires that Renminbi converted from the foreign
    currency-denominated capital of a foreign-invested company only
    be used for purposes within the business scope approved by the
    applicable governmental authority and may not be used for equity
    investments within the PRC unless specifically provided for
    otherwise in its business scope. In addition, the SAFE
    strengthened its oversight of the flow and use of Renminbi funds
    converted from the foreign currency-denominated capital of a
    foreign-invested company. The use of such Renminbi may not be
    changed without SAFE&#146;s approval and may not be used to
    repay Renminbi loans if the proceeds of such loans have not yet
    been used for purposes within the company&#146;s approved
    business scope. Violations of SAFE Circular No.&#160;142 may
    result in severe penalties, including substantial fines as set
    forth in the <I>Foreign Exchange Administration Regulation</I>.
    As a result, SAFE Circular No.&#160;142 may significantly limit
    our ability to transfer the net proceeds from this offering to
    our PRC subsidiaries, which may adversely affect the continued
    growth of our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to SAFE Circular No.&#160;75, (i)&#160;a PRC resident
    must register with the local SAFE branch before establishing or
    controlling an overseas special purpose vehicle, or SPV, for the
    purpose of obtaining overseas equity financing using the assets
    of or equity interests in a domestic enterprise; (ii)&#160;when
    a PRC resident contributes the assets of or its equity interests
    in a domestic enterprise into an SPV, or engages in overseas
    financing after contributing assets or equity interests into an
    SPV, such PRC resident must register his or her interest in the
    SPV and any subsequent change thereto with the local SAFE
    branch; and (iii)&#160;when the SPV experiences a material
    event, such as a change in share capital, merger or acquisition,
    share transfer or exchange, spin-off or long-term equity or debt
    investment, the PRC resident must, within 30&#160;days after the
    occurrence of such event, register such event with the local
    SAFE branch. On May&#160;29, 2007, the SAFE issued guidance to
    its local branches for the implementation of the SAFE Circular
    No.&#160;75, which guidance provides for more standardized,
    specific and stringent supervision regarding such registration
    requirements and requires PRC residents holding any equity
    interests or options in SPVs, directly or indirectly,
    controlling or nominal, to register with the SAFE.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Currently, several of our shareholders who are residents in the
    PRC and are subject to the above registration or amendment of
    registration requirements, have applied to SAFE&#146;s local
    branches to make the required SAFE registration with respect to
    their investments in our company. Because of the current
    suspension of acceptance of such registrations by the SAFE
    authorities due to reportedly forthcoming new SAFE regulations,
    such shareholders&#146; applications are still pending. We
    cannot assure you that these shareholders&#146; pending
    applications will eventually be approved by the authorities. See
    &#147;Risk Factors&#160;&#151; Risks Related to Doing Business
    in China&#160;&#151; Recent PRC regulations, particularly SAFE
    Circular No.&#160;75 relating to acquisitions of PRC companies
    by foreign entities, may limit our ability to acquire PRC
    companies and adversely affect the implementation of our
    strategy as well as our business and prospects.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Dividend
    Distributions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the <I>Foreign Exchange Administration Regulation
    </I>promulgated in 1996, as amended in 1997 and 2008, and
    various regulations issued by the SAFE and other relevant PRC
    government authorities, the PRC government imposes restrictions
    on the convertibility of Renminbi into foreign currencies and,
    in certain cases, on the remittance of currency out of China.
    Our PRC subsidiaries are regulated under the <I>Foreign
    Investment Enterprise Law</I>, which was issued on
    April&#160;12, 1986 and amended on October&#160;31, 2000, the
    <I>Implementation Rules of the Foreign Investment Enterprise
    Law</I>, which was issued on October&#160;28, 1990 and amended
    on April&#160;12, 2001, and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    123
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    the newly revised <I>PRC Company Law</I>, which became effective
    as of January&#160;1, 2006. Pursuant to these regulations, each
    of our PRC subsidiaries must allocate at least 10.0% of its
    after-tax profits to a statutory common reserve fund. When the
    accumulated amount of the statutory common reserve fund exceeds
    50.0% of the registered capital of such subsidiary, no further
    allocation is required. Funds allocated to a statutory common
    reserve fund may not be distributed to equity owners as cash
    dividends. Furthermore, each of our PRC subsidiaries may
    allocate a portion of its after-tax profits, as determined by
    such subsidiary&#146;s ultimate decision-making body, to its
    staff welfare and bonus funds, which allocated portion may not
    be distributed as cash dividends.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Regulations
    Relating to Employee Share Options</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the <I>Administration Measure for Individual Foreign
    Exchange</I> issued in December 2006 and the <I>Implementation
    Rules of Administration Measure for Individual Foreign
    Exchange</I>, issued in January 2007 by the SAFE, all foreign
    exchange matters relating to employee stock award plans or stock
    option plans for PRC residents may only be transacted upon the
    approval of the SAFE or its authorized branch. On March&#160;28,
    2007, the SAFE promulgated the <I>Application Procedure of
    Foreign Exchange Administration for Domestic Individuals
    Participating in Employee Stock Award Plan or Stock Option Plan
    of Overseas-Listed Company</I>, or the Stock Option Rule. Under
    the Stock Option Rule, PRC citizens who participate in employee
    stock award and share option plans of an overseas
    publicly-listed company must register with the SAFE and complete
    certain related procedures. These procedures must be conducted
    by a PRC agent designated by the subsidiary of such overseas
    publicly-listed company with which the PRC citizens affiliate.
    The PRC agent may be a subsidiary of such overseas
    publicly-listed company, any such PRC subsidiary&#146;s trade
    union having legal person status, a trust and investment company
    or other financial institution qualified to act as a custodian
    of assets. Such participant&#146;s foreign exchange income
    received from the sale of shares or dividends distributed by the
    overseas publicly-listed company must first be remitted into a
    collective foreign exchange account opened and managed by the
    PRC agent prior to any distribution of such income to such
    participants in a foreign currency or in Renminbi.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to Circular No.&#160;106, employee stock award plans of
    SPVs and employee share option plans of SPVs must be filed with
    the SAFE while applying for the registration for the
    establishment of the SPVs. After employees exercise their
    options, they must apply for an amendment to the registration
    for the SPV with the SAFE. We intend to comply with these
    regulations and to ask our PRC optionees to comply with these
    regulations. However, as these rules have only been recently
    promulgated, it is currently unclear how these rules will be
    interpreted and implemented. If the applicable authorities
    determine that we or our PRC optionees have failed to comply
    with these regulations, we or our PRC optionees may be subject
    to fines and legal sanctions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Provisions
    Regarding Mergers and Acquisitions of Domestic Enterprises by
    Foreign Investors and Overseas Listings</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;8, 2006, six PRC regulatory agencies, including
    the PRC Ministry of Commerce, the State Assets Supervision and
    Administration Commission, the State Administration for
    Taxation, the State Administration for Industry and Commerce,
    the CSRC and the SAFE, jointly issued the <I>Regulations on
    Mergers and Acquisitions of Domestic Enterprises by Foreign
    Investors</I>, or the M&#038;A Rule, which became effective on
    September&#160;8, 2006. The M&#038;A Rule, among other things,
    includes provisions that require any offshore special purpose
    vehicle, or SPV, formed for the purpose of an overseas listing
    of equity interests in a PRC company that is controlled directly
    or indirectly by one or more PRC companies or individuals, to
    obtain the approval of the CSRC prior to the listing and trading
    of such SPV&#146;s securities on an overseas stock exchange. The
    application of the M&#038;A Rule is currently unclear. However,
    our PRC counsel, Jingtian&#160;&#038; Gongcheng Attorneys At
    Law, has advised us that based on its understanding of the
    current PRC laws, rules and regulations and the M&#038;A Rule,
    the M&#038;A Rule does not require that we obtain prior CSRC
    approval for the listing and trading of our ADSs on the NYSE,
    because our acquisition of the equity interest in our PRC
    subsidiaries is not subject to the M&#038;A Rule due to the fact
    that Aohua Medical and Shanghai Medstar were already
    foreign-invested enterprises before September&#160;8, 2006, the
    effective date of the M&#038;A Rule. Jingtian&#160;&#038;
    Gongcheng Attorneys At Law has further advised us that their
    opinions summarized above are subject to the timing and content
    of any new laws, rules and regulations or clear implementations
    and interpretations from the CSRC in any form relating to the
    M&#038;A Rule.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    124
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Regulation
    of Loans between a Foreign Company and its Chinese
    Subsidiary</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A loan made by foreign investors as shareholders in a
    foreign-invested enterprise is considered to be foreign debt in
    China and is subject to several Chinese laws and regulations,
    including the <I>Foreign Exchange Administration Regulation of
    1996 </I>and its amendments of 1997 and 2008, the <I>Interim
    Measures on Foreign Debts Administration of 2003</I>, or the
    Interim Measures, the <I>Statistical Monitoring of Foreign Debts
    Tentative Provisions of 1987 </I>and its implementing rules of
    1998, the <I>Administration Provisions on the Settlement, Sale
    and Payment of Foreign Exchange of 1996</I>, and the <I>Notice
    of the SAFE on Issues Related to Perfection of Foreign Debts
    Administration</I>, dated October&#160;21, 2005.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under these rules and regulations, a shareholder loan in the
    form of foreign debt made to a Chinese entity does not require
    the prior approval of the SAFE. However, such foreign debt must
    be registered with and recorded by the SAFE or its local branch
    in accordance with relevant PRC laws and regulations. Our PRC
    subsidiaries can legally borrow foreign exchange loans up to
    their respective borrowing limits, which is defined as the
    difference between the amount of their respective &#147;total
    investment&#148; and &#147;registered capital&#148; as approved
    by the MOFCOM, or its local counterparts. Interest payments, if
    any, on the loans are subject to a 10% withholding tax unless
    any such foreign shareholder&#146;s jurisdiction of
    incorporation has a tax treaty with China that provides for a
    different withholding arrangement. Pursuant to Article&#160;18
    of the Interim Measures, if the amount of foreign exchange debt
    of our PRC subsidiaries exceeds their respective borrowing
    limits, we are required to apply to the relevant Chinese
    authorities to increase the total investment amount and
    registered capital to allow the excess foreign exchange debt to
    be registered with the SAFE.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Taxation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For a discussion of applicable PRC tax regulations, see
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations&#160;&#151; Taxation.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Regulation
    on Employment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On June&#160;29, 2007, the National People&#146;s Congress
    promulgated the <I>Labor Contract Law of PRC</I>, or the Labor
    Law, which became effective as of January&#160;1, 2008. On
    September&#160;18, 2008, the PRC State Council issued the <I>PRC
    Labor Contract Law Implementation Rules</I>, which became
    effective as of the date of issuance. The Labor Law and its
    implementation rules are intended to give employees long-term
    job security by, among other things, requiring employers to
    enter into written contracts with their employees and
    restricting the use of temporary workers. The Labor Law and its
    implementation rules impose greater liabilities on employers,
    require certain terminations to be based upon seniority rather
    than merit and significantly affect the cost of an
    employer&#146;s decision to reduce its workforce. Employment
    contracts lawfully entered into prior to the implementation of
    the Labor Law and continuing after the date of its
    implementation remain legally binding and the parties to such
    contracts are required to continue to perform their respective
    obligations thereunder. However, employment relationships
    established prior to the implementation of the Labor Law without
    a written employment agreement were required to be memorialized
    by a written employment agreement that satisfies the
    requirements of the Labor Law within one month after it became
    effective on January&#160;1, 2008.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    125
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='116'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANAGEMENT</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Directors
    and Executive Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information regarding our
    directors and executive officers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="31%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="59%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Name</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Age</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Position/Title</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director, chief executive officer and president
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Co-chairman of the board of directors and chief operating officer
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Steve Sun
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Co-chairman of the board of directors and chief financial officer
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Jing Zhang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and executive president
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yaw Kong Yap
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and financial controller
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shirley Chen
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Feng Xiao
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine Zong
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Wai Hong Ku
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Denny Lee*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Independent director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Boxun Zhang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Corporate vice president
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;Denny Lee has accepted our
    appointment to be an independent director of our company,
    effective upon the commencement of trading of our ADSs on the
    NYSE.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Dr.&#160;Jianyu Yang </I>has served as a director of our
    company and our chief executive officer and president since
    2007. Prior to joining our company, Dr.&#160;Yang served as
    chief executive officer of Eguard Resource Development Co.,
    Ltd., a PRC company listed on the Shenzhen Stock Exchange in
    China principally engaged in the provision of comprehensive
    solutions in recycling, re-use of solid wastes and wastewater
    since 2003, vice president of Beijing Sound Environmental Group
    Co. Ltd. from 2002 to 2003, assistant to the general manager of
    Xiangcai Securities Co., Ltd. from 2000 to 2002, and senior
    economist at China Agricultural Bank from 1999 to 2000.
    Dr.&#160;Yang received a doctorate degree in economics from
    Liaoning University in 1999 in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Dr.&#160;Zheng Cheng </I>has served as co-chairman of our
    board of directors and our chief operating officer since 2008.
    Dr.&#160;Cheng was a co-founder of China Medstar. Prior to
    founding China Medstar in 1996, Dr.&#160;Cheng served as
    division chief of steel products of China National Defense
    Military Material General Company from 1992 to 1996 and military
    physician in the Department of Cerebral Surgery of the Beijing
    Air Force General Hospital from 1986 to 1992 and in the
    No.&#160;1 Field Clinic of Yunnan Laoshan Frontier in 1986.
    Dr.&#160;Cheng received his bachelor&#146;s degree in clinical
    neurosurgery from the First Military Medical University of the
    People&#146;s Liberation Army of China in 1986. Dr.&#160;Cheng
    is a qualified clinical surgeon in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Steve Sun </I>has served as co-chairman of our board
    of directors since 2008 and our chief financial officer since
    2009. Mr.&#160;Sun was a director and the president of Aohua
    Medical from 2006 to 2008. Prior to joining our company,
    Mr.&#160;Sun served as the chief operating officer of
    Sunshine100 Real Estate Group, a Beijing-based real estate
    company, from 2004 to 2005 and executive vice president of AE
    Capital Markets Inc., a New York-based investment bank, from
    1997 to 2000. Mr.&#160;Sun received a master&#146;s degree in
    business management from the University of Chicago in 1996, a
    master&#146;s degree in operational research from Xidian
    University in 1985 and a bachelor&#146;s degree in mathematics
    from Heilongjiang University in 1983.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Jing Zhang </I>has served as a director of our
    company and our executive president since 2008. Mr.&#160;Zhang
    was a co-founder of China Medstar. Prior to founding China
    Medstar in 1996, Mr.&#160;Zhang was in charge of research and
    development at the Institute of Chemistry of Beijing Timber
    General Co., Ltd. from 1987 to 1996. Mr.&#160;Zhang received a
    bachelor&#146;s degree in polymer chemistry from the Beijing
    Institute of Chemical Technology in 1987.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Yaw Kong Yap </I>has served as a director of our
    company and our financial controller since 2008. Mr.&#160;Yap
    joined China Medstar in 2005 and served as its chief financial
    officer prior to our acquisition of China Medstar. Prior to
    joining China Medstar, Mr.&#160;Yap served as the chief
    executive officer of Advanced Produce Centre Development Pte,
    Ltd., a Singapore real estate company, from 2003 to 2005, the
    chief financial officer of Global Fruits Pte Limited from 1999
    to 2003, the regional financial controller of America Air
    Filtration Asia from 1996 to 1998 and the financial controller
    of Chevalier International (USA) Ltd. from 1991 to 1996.
    Mr.&#160;Yap received a bachelor&#146;s
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    126
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    degree from Indiana University of Pennsylvania in the United
    States in 1990. Mr.&#160;Yap was a Certified Public Accountant
    in the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Ms.&#160;Shirley Chen </I>has served as a director of our
    company since 2007. Ms.&#160;Chen is also currently a managing
    director of China International Capital Corporation Limited, or
    CICC, and head of private equity and chief executive officer of
    CICC Investment Group Company Limited, an affiliate of CICC.
    Ms.&#160;Chen joined CICC in 2003 and was a managing director of
    its Investment Banking Department. Prior to joining CICC, she
    was a director of Credit Suisse First Boston and worked in its
    Investment Banking Division in New York and Hong Kong from 1995
    to 2002. Ms.&#160;Chen received an M.B.A. degree from Yale
    University&#146;s School of Management, a master of law degree
    in International Economic Law from Wuhan University and a
    bachelor of law degree in International Law from Wuhan
    University in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Feng Xiao </I>has served as a director of our
    company since 2008. Mr.&#160;Xiao is also currently a managing
    director of the Carlyle Group, focusing on growth capital
    investments in China. Mr.&#160;Xiao had served as a vice
    president at CICC from 2000 to 2005, where he had been involved
    in the restructuring and listing of a number of leading Chinese
    companies, and worked at as a lawyer and a registered trademark
    agent at China Patent Agent (HK) Limited from 1995 to 1998.
    Mr.&#160;Xiao received an M.B.A. degree from the China Europe
    International Business School in 1999 and a bachelor&#146;s
    degree in both computer science and English from Tsinghua
    University in 1995. Mr.&#160;Xiao also holds a lawyer&#146;s
    qualification certificate in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Ms.&#160;Elaine Zong </I>has served as a director of our
    company since 2008. Ms.&#160;Zong is also currently a managing
    director of C.V. Starr Investment Advisors (Asia) Limited,
    focusing on private equity investments in China. Ms.&#160;Zong
    served as senior vice president at Deutsche Bank from 2005 to
    2006, as vice president at Merrill Lynch from 2001 to 2003, and
    as an associate in the investment banking division of
    J.P.&#160;Morgan from 1998 to 2001. Ms.&#160;Zong received an
    M.B.A. degree from the University of Chicago in the United
    States in 1998 and a bachelor&#146;s degree in economics from
    Fudan University of China in 1992. Ms.&#160;Zong is a Chartered
    Financial Analyst.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Wai Hong Ku </I>has served as a director of our
    company since 2005. Mr.&#160;Ku is also currently a member of
    the board of directors and the general manager of Yanli Paper
    (China) Limited. Mr.&#160;Ku was the general manager of Fengjia
    Industries Co., Ltd. from 1992 to 1995 and was a project
    planning manager and the general manager of Zhong Fa Development
    Company of Addi Lee&#160;&#038; Partners Limited from 1979 to
    1992, responsible for the development of hotels and other
    properties.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Denny Lee</I> will become an independent
    non-executive director of our company upon the commencement of
    trading of our ADSs on the NYSE. Mr.&#160;Lee is currently a
    non-executive director of Netease.com, Inc., a company listed on
    the Nasdaq Global Select Market, and an independent director and
    chairman of the audit committee of three NYSE listed companies,
    New Oriental Education &#038; Technology Group Inc., Acorn
    International, Inc. and Gushan Environmental Energy Limited.
    Previously, Mr.&#160;Lee was the chief financial officer of
    Netease.com until June 2007 and the financial controller of
    Netease.com from November 2001 to April 2002. Prior to joining
    Netease.com in 2001, Mr.&#160;Lee worked in the Hong Kong office
    of KPMG for more than ten years. Mr.&#160;Lee graduated from the
    Hong Kong Polytechnic University majoring in accounting and is a
    member of The Hong Kong Institute of Certified Public
    Accountants and The Chartered Association of Certified
    Accountants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Boxun Zhang </I>has served as corporate vice
    president of our company since August 2009. Prior to joining our
    company, from 2006 to August 2009, Mr.&#160;Zhang served as the
    director of financial and business analysis, financial
    controller and investment controller of Suntech Power Holdings
    Co., Ltd, a Cayman Islands company listed on the NYSE
    principally engaged in the design, manufacture and sale of solar
    energy products. Mr.&#160;Zhang previously worked for the
    investment bank department of Credit Suisse from 2004 to 2005
    and was a senior auditor for PricewaterhouseCooper from 1998 to
    2002. Mr.&#160;Zhang received his MBA degree from Cass Business
    School in the United Kingdom in 2004 and a bachelor&#146;s
    degree in accounting and auditing from Wuhan University in China
    in 1998.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The address of our directors and executive officers is Concord
    Medical Services Holdings Limited, 18/F, Tower A, Global Trade
    Center, 36 North Third Ring Road East, Dongcheng District,
    Beijing, People&#146;s Republic of China, 100013.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    127
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Duties of
    Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under Cayman Islands law, our directors have a fiduciary duty to
    act honestly, in good faith and with a view to our best
    interests. Our directors also have a duty to exercise the skill
    they actually possess and such care and diligence that a
    reasonably prudent person would exercise in comparable
    circumstances. In fulfilling their duty of care to us, our
    directors must ensure compliance with our memorandum and
    articles of association, as amended and restated from time to
    time. A shareholder has the right to seek damages if a duty owed
    by our directors is breached.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The functions and powers of our board of directors include,
    among others:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    convening shareholders&#146; annual general meetings and
    reporting its work to shareholders at such meetings;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    declaring dividends and distributions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    appointing officers and determining the term of office of
    officers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    exercising the borrowing powers of our company and mortgaging
    the property of our company; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approving the transfer of shares of our company, including
    registering such shares in our share register.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board of
    Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon the completion of this offering, we expect that our board
    of directors will have 10&#160;directors, consisting of one
    independent director. Our board of directors will establish an
    audit committee and a compensation committee upon the completion
    of this offering. We currently do not plan to establish a
    nominating committee. We have adopted a charter for each of the
    audit and compensation committees, which will become effective
    immediately upon the completion of this offering. Each
    committee&#146;s members and functions are described below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Audit
    Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our audit committee will initially consist of Mr.&#160;Denny
    Lee, Mr.&#160;Feng Xiao and Mr.&#160;Wai Hong Ku. Mr.&#160;Denny
    Lee will be the chairman of our audit committee and meets the
    criteria of an audit committee financial expert as set forth
    under the applicable rules of the SEC. Our board of directors
    has determined that Mr.&#160;Denny Lee satisfies the
    requirements for an &#147;independent director&#148; within the
    meaning of Section&#160;303A of the NYSE Listed Company Manual
    and will meet the criteria for independence set forth in
    <FONT style="white-space: nowrap">Rule&#160;10A-3</FONT>
    of the Exchange Act. Our board of directors has also determined
    that the simultaneous service by Mr.&#160;Denny Lee on the audit
    committee of three other public companies would not impair his
    ability to effectively serve on our audit committee. Our audit
    committee will consist of two independent directors within
    90&#160;days of our initial public offering and solely of
    independent directors within one year of our initial public
    offering. The audit committee oversees our accounting and
    financial reporting processes and the audits of the financial
    statements of our company. The audit committee is responsible
    for, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    selecting our independent registered public accounting firm and
    pre-approving all auditing and non-auditing services permitted
    to be performed by our independent registered public accounting
    firm;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing with our independent registered public accounting firm
    any audit problems or difficulties and management&#146;s
    response;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and approving all proposed related-party transactions,
    as defined in Item&#160;404 of
    <FONT style="white-space: nowrap">Regulation&#160;S-K</FONT>
    under the Securities Act;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    discussing the annual audited financial statements with
    management and our independent registered public accounting firm;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing major issues as to the adequacy of our internal
    controls and any special audit steps adopted in light of
    significant control deficiencies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    annually reviewing and reassessing the adequacy of our audit
    committee charter;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    such other matters that are specifically delegated to our audit
    committee by our board of directors from time to time;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    128
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    meeting separately and periodically with management and our
    internal auditor and independent registered public accounting
    firm;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reporting regularly to the full board of directors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our compensation committee will initially consist of
    Ms.&#160;Shirley Chen and Mr.&#160;Feng Xiao. Ms.&#160;Shirley
    Chen will be the chairperson of our compensation committee. Our
    compensation committee assists the board in reviewing and
    approving the compensation structure of our directors and
    executive officers, including all forms of compensation to be
    provided to our directors and executive officers. Members of the
    compensation committee are not prohibited from direct
    involvement in determining their own compensation. Our chief
    executive officer may not be present at any committee meeting
    during which his compensation is deliberated. The compensation
    committee is responsible for, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approving and overseeing the compensation package for our
    executive officers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and making recommendations to the board with respect
    to the compensation of our directors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and approving corporate goals and objectives relevant
    to the compensation of our chief executive officer, evaluating
    the performance of our chief executive officer in light of those
    goals and objectives, and setting the compensation level of our
    chief executive officer based on such evaluation;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing periodically and making recommendations to the board
    regarding any long-term incentive compensation or equity plans,
    programs or similar arrangements, annual bonuses, employee
    pension and welfare benefit plans.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Interested
    Transactions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A director may vote in respect of any contract or transaction in
    which he or she is interested, provided that the nature of the
    interest of any directors in such contract or transaction is
    disclosed by him or her at or prior to its consideration and any
    vote on that matter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Remuneration
    and Borrowing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The directors may determine remuneration to be paid to the
    directors. The compensation committee assists the directors in
    reviewing and approving the compensation structure for the
    directors. The directors may exercise all the powers of the
    company to borrow money and to mortgage or charge its
    undertaking, property and uncalled capital, and to issue
    debentures or other securities whether outright or as security
    for any debt obligations of our company or of any third party.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Qualification</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There is no shareholding qualification for directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Terms of
    Directors and Executive Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive officers are elected by and serve at the
    discretion of the board of directors. Our directors are not
    subject to a term of office and hold office until such time as
    they resign or are removed from office without cause by special
    resolution or the unanimous written resolution of all
    shareholders or with cause by ordinary resolution or the
    unanimous written resolutions of all shareholders. A director
    will be removed from office automatically if, among other
    things, the director (i)&#160;becomes bankrupt or makes any
    arrangement or composition with his creditors or (ii)&#160;dies
    or is found by our company to be or becomes of unsound mind. We
    have not entered into any service agreements with our directors
    that provide for any type of compensation upon termination.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employment
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into employment agreements with all of our
    executive officers. Under these agreements, each of our
    executive officers is employed for a non-fixed period of time.
    These employment agreements can be terminated in accordance with
    the <I>Labor Contract Law of the PRC </I>and other relevant
    regulations. Under the Labor Contract Law, we can terminate
    without any prior notice the employment agreement with any of
    our executive officers in the event that
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    129
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    such officer&#146;s actions have resulted in material and
    demonstrable harm to our interest. Under certain circumstances,
    including where the officer has not performed as expected and,
    upon internal reassignment or training, still fails to be
    qualified for the job, we may also terminate the employment
    agreement with any of our executive officers upon providing 30
    days notice or paying one month in severance. Our executive
    officer may typically terminate his or her employment at any
    time if we fail to provide labor protection or work conditions
    as stipulated in the employment agreement. The executive
    officers may also terminate the employment agreement at any time
    without cause upon 30 days notice. Usually, if we terminate the
    employment agreement of any of our executive officers, we have
    to pay them certain severance pay in proportion to their working
    years with us, except where such officer&#146;s actions have
    resulted in material and demonstrable harm to our interests,
    among other circumstances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each executive officer has agreed to hold, both during and
    subsequent to the terms of his or her agreement, in confidence
    and not to use, except in pursuance of his or her duties in
    connection with the employment, any of our confidential
    information, technological secrets, commercial secrets and
    know-how. Each of our executive officers has entered into a
    confidentiality agreement with us. Our executive officers have
    also agreed to disclose to us all inventions, designs and
    techniques resulted from work performed by them, and to assign
    us all right, title and interest of such inventions, designs and
    techniques.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    of Directors and Executive Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2008, the aggregate cash compensation to all of our directors
    and our executive officers was RMB1.2&#160;million
    (US$0.2&#160;million). For share-based compensation, see
    &#147;&#160;&#151; Share Incentive Plans.&#148; The total amount
    accrued in 2008 for pension, retirement or other similar
    benefits to our directors and our executive officers was
    approximately RMB240,000 (US$35,000).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Share
    Incentive Plans</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">OMS
    Share Option Plan</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2007, OMS, the predecessor of our company,
    adopted a share option plan, or the OMS option plan, pursuant to
    which OMS granted to three of its executive directors,
    Mr.&#160;Haifeng Liu, Mr.&#160;Jianyu Yang and Mr.&#160;Steve
    Sun, or the OMS grantees, options to purchase a total of up to
    25,000,000 ordinary shares, or the OMS share options, to
    purchase the ordinary shares of OMS at an exercise price of
    US$0.80 per share, which the board of OMS determined to become
    vested upon the satisfaction of a number of performance
    conditions that related to the completion of the OMS
    reorganization, achievement of net profit target of OMS, and the
    raising of new financing. The OMS share options were exercisable
    from the date of completion of the 2007 audited consolidated
    financial statements of OMS to December&#160;31, 2008 and were
    transferrable to any individuals designated by the OMS grantees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;18, 2008, the board of directors of OMS
    contemplated that the OMS grantees had achieved certain
    performance conditions outlined in the OMS option plan. However,
    as the capital structure of our company had changed at that time
    such that we had replaced OMS as the ultimate holding company of
    our subsidiaries, the board of directors of OMS resolved that
    the OMS option plan would be settled in vested options to
    purchase 21,184,600 ordinary shares to purchase shares of our
    company, with each option having an exercise price of US$0.79
    exercisable before December&#160;31, 2008. On the same day, two
    of the OMS grantees, Mr.&#160;Jianyu Yang and Mr.&#160;Steve
    Sun, exercised their respective options to purchase an aggregate
    of 6,355,400&#160;ordinary shares of our company, with total
    proceeds from such exercise received by us amounting to
    approximately RMB34.4&#160;million (US$5.0&#160;million). We
    recorded share-based compensation expense of approximately
    RMB49.5&#160;million in 2007 related to these options granted,
    which was recorded in general and administrative expenses. The
    third OMS grantee, Mr.&#160;Haifeng Liu, sold all of his vested
    options to purchase 14,829,200 ordinary shares of our company to
    three former directors of China Medstar who are now our
    directors and executive officers as employment incentive for
    such directors. The three executive directors subsequently
    exercised the vested options with total proceeds from such
    exercise received by us amounting to approximately
    US$11.7&#160;million. Given the transfer of the OMS share
    options to the three directors was provided as an employment
    incentive, we recorded additional share-based compensation
    expense of approximately RMB4.2&#160;million
    (US$0.6&#160;million) in 2008, which was recorded in general and
    administrative expenses.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    130
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">2008&#160;Share
    Incentive Plan</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The 2008&#160;share incentive plan was adopted by our
    shareholders on October&#160;16, 2008 and amended on
    November&#160;17, 2009 to increase the number of ordinary shares
    available for grant under the plan. Our share incentive plan
    provides for the grant of options, share appreciation rights, or
    other share-based awards, referred to as &#147;awards.&#148; The
    purpose of the plan is to aid us in recruiting and retaining key
    employees, directors or consultants and to motivate such persons
    to exert their best efforts on behalf of our company by
    providing incentives through the granting of awards. Our board
    of directors believes that our company will benefit from the
    added interest that such persons will have in the welfare of the
    company as a result of their proprietary interest in the
    company&#146;s success.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Termination of Awards.</I>&#160;Options have specified terms
    set forth in a share option agreement. If the recipient&#146;s
    employment with the company is terminated for any reason, the
    recipient&#146;s vested options shall remain exercisable subject
    to the provisions of the plan and the option agreement and the
    recipient&#146;s unvested options shall terminate without
    consideration. If the options are not exercised or purchased by
    the last day of the exercise period, they will terminate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Administration.</I>&#160;Our 2008&#160;share incentive plan
    is currently administered by our board of directors and, after
    this offering, will be administered by the compensation
    committee of our board of directors. Our board of directors or
    the compensation committee is authorized to interpret the plan,
    to establish, amend and rescind any rules and regulations
    relating to the plan, and to make any other determinations that
    it deems necessary or desirable for the administration of the
    plan. Our board of directors or the compensation committee will
    determine the provisions, terms and conditions of each award
    consistent with the provisions of the plan, including, but not
    limited to, the exercise price for an option, vesting schedule,
    forfeiture provisions, form of payment of exercise price and
    other applicable terms.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Option Exercise.</I>&#160;The term of options granted under
    the 2008&#160;share incentive plan may not exceed eight years
    from the date of grant. The consideration to be paid for our
    ordinary shares upon exercise of an option or purchase of shares
    underlying the option may include cash, check or other
    cash-equivalent, consideration received by us in a cashless
    exercise and, to the extent permitted by our board of directors
    or the compensation committee and subject to the provisions of
    the option agreement, ordinary shares or a combination of
    ordinary shares and cash or cash-equivalent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Change in Control.</I>&#160;If a third-party acquires us
    through the purchase of all or substantially all of our assets,
    a merger or other business combination or if during any two
    consecutive year period individuals who at the beginning of such
    period constituted the board of directors cease for any reason
    to constitute a majority of our board of directors, then, if so
    determined by our board of directors or the compensation
    committee with respect to the applicable award agreement or
    otherwise, any outstanding awards that are unexercisable or
    otherwise unvested or subject to lapse restrictions will
    automatically be deemed exercisable or otherwise vested or no
    longer subject to lapse restrictions, as the case may be, as of
    immediately prior to such change in control. Our board of
    directors or the compensation committee may also, in its sole
    discretion, decide to cancel such awards for fair value, provide
    for the issuance of substitute awards that will substantially
    preserve the otherwise applicable terms of any affected awards
    previously granted, or provide that affected options will be
    exercisable for a period of at least 15&#160;days prior to the
    change in control but not thereafter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Amendment and Termination of Plan.</I>&#160;Our board of
    directors may at any time amend, alter or discontinue our
    2008&#160;share incentive plan. Amendments or alterations to our
    2008&#160;share incentive plan are subject to shareholder
    approval if they increase the total number of shares reserved
    for the purposes of the plan or change the maximum number of
    shares for which awards may be granted to any participant. Any
    amendment, alteration or termination of our 2008&#160;share
    incentive plan must not adversely affect awards already granted
    without written consent of the recipient of such awards. Unless
    terminated earlier, our 2008&#160;share incentive plan will
    continue in effect for a term of ten years from the date of its
    adoption.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    131
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our board of directors and shareholders authorized the issuance
    of up to 4,765,800 ordinary shares upon exercise of awards
    granted under our 2008&#160;share incentive plan. On
    November&#160;27, 2009, we granted options to purchase an
    aggregate of 4,765,800&#160;ordinary shares, of which options to
    purchase an aggregate of 1,716,500&#160;ordinary shares were
    granted to our executive officers and directors, including
    288,700&#160;ordinary shares to Mr.&#160;Jianyu Yang,
    288,700&#160;ordinary shares to Mr.&#160;Zheng Cheng,
    264,400&#160;ordinary shares to Mr.&#160;Steve Sun,
    250,000&#160;ordinary shares to Mr.&#160;Jing Zhang,
    230,000&#160;ordinary shares to Mr.&#160;Yaw Kong Yap,
    264,400&#160;ordinary shares to Mr.&#160;Boxun Zhang and
    130,300&#160;ordinary shares to Mr.&#160;Denny Lee, and the
    remainder to other employees. Such options have an exercise
    price equal to the initial public offering price per ordinary
    share in this offering, are subject to a four-year vesting
    schedule with 25% vesting on each of the first, second, third
    and fourth anniversary of the grant date, and will terminate no
    later than eight years from their grant date.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    132
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='117'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PRINCIPAL
    AND SELLING SHAREHOLDERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information with respect to the
    beneficial ownership of our ordinary shares, as of the date of
    this prospectus, assuming the conversion of all outstanding
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares into ordinary shares, by:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each of our directors and executive officers;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each person known to us to own beneficially more than 5.0% of
    our ordinary shares; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each other selling shareholders.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Beneficial ownership is determined in accordance with rules and
    regulations of the SEC. In computing the number of shares
    beneficially owned by a person or the percentage ownership of
    that person, we have included shares that the person has the
    right to acquire within 60&#160;days of this offering, including
    through the exercise of any option, warrant or other right or
    the conversion of any other security. These shares, however, are
    not included in the computation of the percentage ownership of
    any other person. The calculation of the number of shares also
    assumes the conversion of all of our Series&#160;A and
    Series&#160;B contingently redeemable convertible preferred
    shares into our ordinary shares upon the completion of this
    offering. Percentage of beneficial ownership of each listed
    person prior to this offering is based on 111,455,500 ordinary
    shares outstanding as of the date of this prospectus, including
    41,027,400 ordinary shares convertible from our outstanding
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares. Percentage of beneficial ownership
    of each listed person after the offering is based on 147,455,500
    ordinary shares outstanding immediately after the closing of
    this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table below assumes the exercise in full of the
    underwriters&#146; option to purchase up to an additional
    1,800,000 ADSs to be sold by the selling shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="48%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Ordinary Shares Beneficially<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Ordinary Shares Being Sold<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Ordinary Shares Beneficially<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Owned Prior to This Offering</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>in This Offering</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Owned After This Offering</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Number</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">%</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Number</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">%</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Number</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">%</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Directors and Executive Officers:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Jianyu
    Yang<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,065,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,065,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Zheng
    Cheng<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,319,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,319,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Steve
    Sun<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,065,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,065,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Jing
    Zhang<SUP style="font-size: 85%; vertical-align: top">(4)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,979,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,979,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yaw Kong
    Yap<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shirley
    Chen<SUP style="font-size: 85%; vertical-align: top">(6)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,533,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,533,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Feng
    Xiao<SUP style="font-size: 85%; vertical-align: top">(7)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,172,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,172,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine
    Zong<SUP style="font-size: 85%; vertical-align: top">(8)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,418,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,418,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Wai Hong
    Ku<SUP style="font-size: 85%; vertical-align: top">(9)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,889,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,889,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Boxun
    Zhang<SUP style="font-size: 85%; vertical-align: top">(10)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All directors and executive officers as a group
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,240,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,240,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Principal and Selling Shareholders:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Carlyle
    Entities<SUP style="font-size: 85%; vertical-align: top">(11)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,172,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,172,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Notable Enterprise
    Limited<SUP style="font-size: 85%; vertical-align: top">(12)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,321,300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,321,300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Starr Investments Cayman II,
    Inc.<SUP style="font-size: 85%; vertical-align: top">(13)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,418,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,418,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Grand Best Group
    Limited<SUP style="font-size: 85%; vertical-align: top">(14)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,215,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,015,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CZY Investments
    Limited<SUP style="font-size: 85%; vertical-align: top">(15)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,319,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,319,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CICC Sun Company
    Limited<SUP style="font-size: 85%; vertical-align: top">(16)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,177,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,177,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sino Prime Investments
    Limited<SUP style="font-size: 85%; vertical-align: top">(17)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    750,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    ATL International Group
    Limited<SUP style="font-size: 85%; vertical-align: top">(18)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    450,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Beneficially owns less than 1.0% of
    our outstanding ordinary shares.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    133
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 4,065,800 ordinary
    shares held by Daketala International Investment Holdings Ltd.,
    a limited liability company organized under the laws of the
    British Virgin Islands wholly owned by Dr.&#160;Yang. 2,910,800
    of the ordinary shares held by Daketala International Investment
    Holdings Ltd. have been pledged to certain of our shareholders
    in connection with the issuance of our Series&#160;B
    contingently redeemable convertible preferred shares on
    October&#160;20, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 7,319,900 ordinary
    shares held by CZY Investment Ltd., a limited liability company
    organized under the laws of the British Virgin Islands wholly
    owned by Mr.&#160;Cheng. 5,232,200 of the ordinary shares held
    by CZY Investment Ltd. have been pledged to certain of our
    shareholders in connection with the issuance of our
    Series&#160;B contingently redeemable convertible preferred
    shares on October&#160;20, 2008. In addition, 2,087,700 of the
    ordinary shares held by CZY Investment Ltd. have been pledged to
    certain of our shareholders as security for a loan.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 4,065,800 ordinary
    shares held by Dragon Image Investment Ltd., a limited liability
    company organized under the laws of the British Virgin Islands
    wholly owned by Mr.&#160;Sun. 3,193,800 of the ordinary shares
    held by Dragon Image Investment Ltd. have been pledged to
    certain of our shareholders in connection with the issuance of
    our Series&#160;B contingently redeemable convertible preferred
    shares on October&#160;20, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 2,979,900 ordinary
    shares held by Thousand Ocean Group Limited, a limited liability
    company organized under the laws of the British Virgin Islands
    wholly owned by Mr.&#160;Zhang. 1,675,000 of the ordinary shares
    held by Thousand Ocean Group Limited have been pledged to
    certain of our shareholders in connection with the issuance of
    our Series&#160;B contingently redeemable convertible preferred
    shares on October&#160;20, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents ordinary shares held by
    Top Mount Group Limited, a limited liability company organized
    under the laws of the British Virgin Islands wholly owned by
    Mr.&#160;Yap. Certain portion of the ordinary shares held by Top
    Mount Group Limited have been pledged to certain of our
    shareholders in connection with the issuance of our
    Series&#160;B contingently redeemable convertible preferred
    shares on October&#160;20, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 6,616,900 and 323,200
    ordinary shares held by CICC Sun Company Limited and Perfect Key
    Holdings Limited, respectively, issuable upon conversion of all
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares held by such shareholders and
    560,300 and 33,400 ordinary shares, respectively, held by such
    shareholders. For a description of the beneficial ownership of
    our ordinary shares by CICC Sun Company Limited, see Note 16
    below. Ms.&#160;Shirley Chen disclaims beneficial ownership of
    our ordinary shares held by CICC Sun Company Limited except to
    the extent of her pecuniary interest in these shares. Perfect
    Key Holdings Limited is a limited liability company organized
    under the laws of the British Virgin Islands in which
    Ms.&#160;Shirley Chen holds 47.4% beneficial ownership.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 23,085,700 and 920,600
    ordinary shares held by Carlyle Asia Growth Partners III, L.P.
    and CAGP III Co-Investment, L.P., respectively, issuable upon
    conversion of all Series&#160;A and Series&#160;B contingently
    redeemable convertible preferred shares held by such
    shareholders and 2,083,300 and 83,100 ordinary shares,
    respectively, held by such shareholders. Carlyle Asia Growth
    Partners III, L.P. and CAGP III Co-Investment, L.P. are
    collectively referred to in this prospectus as the Carlyle
    Entities. For a description of the beneficial ownership of our
    ordinary shares by the Carlyle Entities, see Note&#160;11 below.
    Mr.&#160;Feng Xiao disclaims beneficial ownership of our
    ordinary shares held by the Carlyle Entities, except to the
    extent of his pecuniary interest in these shares.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 9,722,200 ordinary
    shares issuable upon conversion of all Series B contingently
    redeemable convertible preferred shares held by Starr
    Investments Cayman II, Inc. and 695,800 ordinary shares held by
    such shareholder. For a description of the beneficial ownership
    of our ordinary shares by Starr Investments Cayman II, Inc., see
    Note&#160;12 below. Ms.&#160;Elaine Zong disclaims beneficial
    ownership of our ordinary shares held by Starr Investments
    Cayman II, Inc. except to the extent of her pecuniary interest
    in these shares.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(9)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 2,889,500 ordinary
    shares held by Grand Best Group Limited, a limited liability
    company organized under the laws of the British Virgin Islands.
    For a description of the beneficial ownership of our ordinary
    shares held by Grand Best Group Limited, see Note&#160;14 below.
    Mr.&#160;Ku owns 31.4% of the equity interest in Grand Best
    Group Limited.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(10)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents ordinary shares held by
    Triumph Concept Investment Limited, a limited liability company
    organized under the laws of the British Virgin Islands wholly
    owned by Mr.&#160;Zhang.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(11)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 23,085,700 and 920,600
    ordinary shares held by Carlyle Asia Growth Partners III, L.P.
    and CAGP III Co-Investment, L.P., respectively, issuable upon
    conversion of all Series&#160;A and Series&#160;B contingently
    redeemable convertible preferred shares held by such
    shareholders and 2,083,300 and 83,100 ordinary shares,
    respectively, held by such shareholders. The general partner of
    each Carlyle Entity is CAGP General Partner, L.P., which is in
    turn managed by its general partner, CAGP Ltd. The directors of
    CAGP Ltd. are Mr.&#160;William E. Conway, Jr., Mr.&#160;Daniel
    A. D&#146;Aniello, Mr.&#160;David Rubenstein, Mr.&#160;Jeffery
    Ferguson and Mr.&#160;Curtis L. Buser. The address of the
    Carlyle Entities is Walker House, PO&#160;Box&#160;908GT, Mary
    Street, George Town, Grand Cayman, Cayman Islands.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(12)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Notable Enterprise Limited is a
    limited liability company organized under the laws of the
    British Virgin Islands wholly owned by Ms.&#160;Bona Lau.
    Ms.&#160;Lau is the daughter of Mr.&#160;Haifeng Liu, the
    chairman of Aohua Medical from December 2005 to December 2007
    and our director until July 2009. Prior to serving as chairman
    of Aohua Medical, Mr.&#160;Liu was detained in March 2004 by the
    authorities of Luoyang city, Henan Province, for alleged
    misappropriation of funds while serving as chairman of a company
    unrelated to Aohua Medical or us. Mr.&#160;Liu was released in
    June 2005 by the local prosecutor without an indictment due to
    insufficient evidence. Notable Enterprise Limited was originally
    owned by Mr.&#160;Liu, who irrevocably transferred all of his
    interest in Notable Enterprise Limited to Ms.&#160;Lau in
    November 2007 for consideration not significantly lower than the
    then fair market value. At the time of the transfer, Notable
    Enterprise Limited indirectly held a 44.2% equity interest in
    OMS. The address of Notable Enterprise Limited is
    P.O.&#160;Box&#160;957, Offshore Incorporations Centre, Road
    Town, Tortola, British Virgin Islands. 134,478 of the ordinary
    shares held by Notable Enterprise Limited have been pledged to
    certain of our shareholders in connection with the issuance of
    our Series&#160;B contingently redeemable convertible preferred
    shares on October&#160;20, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(13)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 9,722,200 ordinary
    shares issuable upon conversion of all Series B contingently
    redeemable convertible preferred shares held by Starr
    Investments Cayman II, Inc. and 695,800 ordinary shares held by
    such shareholder. Starr Investments Cayman II, Inc. is
    ultimately controlled by Starr International Company, Inc. whose
    voting shareholders (none of whom control 10% or more
    individually) are Mr.&#160;Maurice R. Greenberg, Mr.&#160;Edward
    E. Matthews, Mr.&#160;Howard I. Smith, Mr.&#160;John J. Roberts,
    Mr.&#160;Houghton Freeman, Mr.&#160;Joseph C. H. Johnson,
    Mr.&#160;Cesar Zalamea, Mr.&#160;Peter Hammer, Mr.&#160;Michael
    Morrison, Mr.&#160;Bertil P. Lundqvist and Ms.&#160;Florence
    Davis. The address of Starr Investments Cayman II, Inc. is
    Avalon Management Limited, Landmark Square, 64 Earth Close, West
    Bay Beach, Grand Cayman, KY1-1107, Cayman Islands
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    134
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(14)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Grand Best Group Limited is a
    limited liability company organized under the laws of the
    British Virgin Islands. The shareholders of Grand Best Group
    Limited are Ku Wai Hong, Ever Bounteous Group Limited, Iu Kong,
    Cheng Mai Yue, Wang Rong Kang, Brave Faith Development Limited,
    Echolac Company Limited and Huang Pei Lin. The address of Grand
    Best Group Limited is Portcullis TrustNet Chambers, P.O.
    Box&#160;3444, Road Town, Tortola, British Virgin Islands.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(15)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">CZY Investments Limited is a
    limited liability company organized under the laws of the
    British Virgin Islands wholly owned by Dr.&#160;Zheng Cheng. The
    address of CZY Investments Limited is P.O.&#160;Box&#160;957,
    Offshore Incorporations Centre, Road Town, Tortola, British
    Virgin Islands.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(16)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 6,616,900 ordinary
    shares issuable upon conversion of all Series A and
    Series&#160;B contingently redeemable convertible preferred
    shares held by CICC Sun Company Limited and 560,300 ordinary
    shares held by such shareholder. CICC Sun Company Limited is
    wholly owned by China International Capital Corporation Limited,
    one of our underwriters, in which Morgan Stanley, another
    underwriter to this offering, beneficially owns 34.0% of its
    equity interest. China International Capital Corporation Limited
    has ultimate investment and voting power over the shares held by
    CICC Sun Company Limited. The address of CICC Sun Company
    Limited is 2/F., Abbott Building, Road Town, Tortola, British
    Virgin Islands.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(17)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Sino Prime Investments Limited is a
    limited liability company organized under the laws of the
    British Virgin Islands. The shareholder of Sino Prime
    Investments Limited is Sirong Tian. The address of Sino Prime
    Investments Limited is Palm Grove House, P.O.&#160;Box&#160;438,
    Road Town, Tortola, British Virgin Islands.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(18)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">ATL International Group Limited is
    a limited liability company organized under the laws of the
    British Virgin Islands. The shareholders of ATL International
    Group Limited are Huaying Shang and Qiushi Ren. The address of
    ATL International Group Limited is P.O.&#160;Box&#160;957,
    Offshore Incorporations Centre, Road Town, Tortola, British
    Virgin Islands.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each selling shareholder named above acquired its shares in
    offerings which were exempted from registration under the
    Securities Act because they involved either private placements
    or offshore sales to
    <FONT style="white-space: nowrap">non-U.S.&#160;persons.</FONT>
    As of the date of this prospectus, none of our outstanding
    ordinary shares is held by record holders in the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Two of our shareholders, namely CICC Sun Company Limited and
    Perfect Key Holdings Limited, have informed us that they are
    affiliated with registered broker-dealers or are in the business
    of underwriting securities. Neither of these shareholders were
    affiliated or otherwise related to us prior to their purchase of
    our Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares. These shareholders purchased our
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares directly from us in their ordinary
    course of business and, at the time of the purchase, neither of
    these shareholders had agreements or understandings, directly or
    indirectly, with any person to distribute our Series&#160;A and
    Series&#160;B contingently redeemable convertible preferred
    shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    None of our shareholders will have different voting rights from
    other shareholders after the closing of this offering. We are
    not aware of any arrangement that may, at a subsequent date,
    result in a change of control of our company.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    135
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='118'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RELATED
    PARTY TRANSACTIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Non-Interest
    Bearing Borrowings from Related Parties</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We borrowed RMB38.7&#160;million from Shenzhen Hai Ji Tai
    Technology Co., Ltd., or Hai Ji Tai, in 2007 for working capital
    purposes. Hai Ji Tai is wholly-owned by Mr.&#160;Haifeng Liu who
    was the chairman of Aohua Medical from December 2005 to December
    2007 and our director until July 2009. This borrowing was repaid
    in full in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We borrowed RMB4.0&#160;million in 2007 from Mr.&#160;Haifeng
    Liu for working capital purposes. We repaid RMB2.0&#160;million
    of such borrowing in 2008 and the remaining balance of
    RMB2.0&#160;million (US$0.3&#160;million) in full in August 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We borrowed RMB1.0&#160;million and RMB4.0&#160;million from
    Dr.&#160;Jianyu Yang, our director, chief executive officer and
    president, in 2007 and 2008, respectively, for working capital
    purposes. These borrowings were repaid in full in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China Medstar has, in connection with payments of certain
    professional fees related to a private placement transaction in
    2004, borrowed from Beijing Medstar Hi-Tech Investment Co.,
    Ltd., a company majority owned by Dr.&#160;Zheng Cheng, our
    co-chairman and chief operating officer. As of
    September&#160;30, 2009, the remaining balance was
    RMB0.2&#160;million (US$28,000). In addition, in connection with
    payment of certain fees related to China Medstar&#146;s initial
    public offering on the AIM, China Medstar has borrowed from
    Dr.&#160;Zheng Cheng. As of September&#160;30, 2009, the
    remaining balance was RMB1.4&#160;million (US$0.2&#160;million).
    Furthermore, in connection with certain administrative expenses
    related to China Medstar in 2006 and 2007, China Medstar
    borrowed from Mr.&#160;Yaw Kong Yap, our director and financial
    controller. As of September&#160;30, 2009, the remaining balance
    was RMB60,000 (US$9,000). These loans are unsecured,
    interest-free and repayable on demand and are all based on oral
    agreements between the parties. We expect to repay all such
    borrowings by the end of 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Medical
    Equipment Sale and Purchase Agreement</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;31, 2007, we entered into a long-term sale and
    purchase agreement with Our Medical New Technology under which
    we agreed to purchase gamma knife systems at agreed upon prices
    and Our Medical New Technology also agreed to provide to us
    relevant maintenance and repair services and training. Our
    Medical New Technology is controlled by Mr.&#160;Haifeng Liu,
    who was a director of our company until July 2009. We made
    deposits of RMB11.5&#160;million, RMB0.7&#160;million,
    RMB1.7&#160;million (US$0.3&#160;million) and
    RMB11.4&#160;million (US$1.7&#160;million) to Our New Medical
    Technology under this agreement for the period from
    January&#160;1, 2007 to October&#160;30, 2007, the period from
    September&#160;10, 2007 to December&#160;31, 2007, in 2008 and
    for the nine months ended September&#160;30, 2009, respectively.
    Deposits held by Our New Medical Technology as of
    December&#160;31, 2007 and 2008 and September&#160;30, 2009 were
    RMB15.9&#160;million, RMB17.6&#160;million (US$2.6&#160;million)
    and RMB16.4&#160;million (US$2.4&#160;million). In addition,
    RMB12.7&#160;million (US$1.9&#160;million) of the deposits paid
    to Our New Medical Technology were used for the purchase of
    radioactive source material used in our medical equipment during
    the nine months ended September 30, 2009.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Reorganization
    and Private Placement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See &#147;Our History and Corporate Structure&#148; and
    &#147;Description of Share Capital&#160;&#151; History of
    Securities Issuances&#160;&#151; Convertible Loan and Preferred
    Shares.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Shareholders&#146;
    Agreement</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the issuance of our Series&#160;B
    contingently redeemable convertible preferred shares, we entered
    into an Amended and Restated Shareholders&#146; Agreement dated
    as of October&#160;20, 2008, which was subsequently amended on
    November&#160;17, 2009 and on December&#160;7, 2009, by and
    among us, the Carlyle Entities, Starr Investments Cayman II,
    Inc., CICC Sun Company Limited and certain of our other
    shareholders and other parties named therein. Under this
    shareholders&#146; agreement, our board of directors shall
    consist of up to eleven directors, out of which one of such
    director shall be designated by the Carlyle Entities, another
    shall be designated by CICC Sun Company Limited and another
    shall be designated by Starr Investments Cayman II, Inc. Prior
    to the completion of this offering, our existing shareholders
    are prohibited from transferring their shares without the prior
    consent of each of the Carlyle Entities, Starr Investments
    Cayman II, Inc. and CICC Sun Company Limited. These
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    136
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     parties and our other existing shareholders hold certain rights
    of first refusal with respect to any such proposed transfers. In
    addition, the Carlyle Entities, Starr Investments Cayman II,
    Inc. and CICC Sun Company Limited have certain co-sale rights
    with respect to any proposed share transfers by any of our other
    existing shareholders. We have also granted under this
    shareholders&#146; agreement certain registration rights to the
    Carlyle Entities, Starr Investments Cayman II, Inc. and CICC Sun
    Company Limited. No later than 181&#160;days after this initial
    public offering or the expiration of the lock-up agreements
    entered into in connection with this public offering, whichever
    date is later, we shall file a shelf registration statement with
    the SEC covering the resale of all of our registrable securities
    held by the Carlyle Entities, Starr Investments Cayman&#160;II,
    Inc., CICC Sun Company Limited and Perfect Key Holdings Limited.
    We shall use our best efforts to cause such shelf registration
    statement to become effective on or prior to the 90th day
    following the filing of the shelf registration statement and to
    keep such shelf registration statement in effect until all of
    the registrable securities held by each of the Carlyle Entities,
    Starr Investments Cayman&#160;II, Inc., CICC Sun Company Limited
    and Perfect Key Holdings Limited have been resold. See
    &#147;Description of Share Capital&#160;&#151; Registration
    Rights.&#148; Except for the registration rights, all other
    shareholders&#146; rights under the shareholders agreement will
    automatically terminate upon the completion of this offering.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Share
    Incentives</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For a discussion of the share option plan adopted in 2007 by
    OMS, our predecessor, and our 2008&#160;share incentive plan,
    see &#147;Management&#160;&#151; Share Incentive Plans.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    137
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='130'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DESCRIPTION
    OF SHARE CAPITAL</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are a Cayman Islands exempted company with limited liability
    and our affairs are governed by our memorandum and articles of
    association, as amended and restated from time to time, and the
    Companies Law (as amended) of the Cayman Islands, which is
    referred to as the Companies Law below. Our registered office is
    in the Cayman Islands is at Scotia Centre, 4th&#160;Floor,
    P.O.&#160;Box&#160;2804, George Town, Grand Cayman, Cayman
    Islands
    <FONT style="white-space: nowrap">KY1-1112.</FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2009, we effected a share split whereby all
    of our issued and outstanding 704,281 ordinary shares of a par
    value of US$0.01 per share were split into 70,428,100 ordinary
    shares of US$0.0001 par value per share and the number of our
    authorized ordinary shares was increased from 4,500,000 to
    450,000,000. As of September&#160;30, 2009 and after
    retroactively giving effect to the
    <FONT style="white-space: nowrap">1-for-100</FONT>
    share split, our authorized share capital consists of
    450,500,000&#160;shares, comprised of (i)&#160;450,000,000
    ordinary shares, each with a par value of US$0.0001, of which
    70,428,100 such shares are issued and outstanding;
    (ii)&#160;200,000 Series&#160;A contingently redeemable
    convertible preferred shares authorized, each with a par value
    of US$0.01, of which 176,942 such shares are issued and
    outstanding; and (iii)&#160;300,000 Series&#160;B contingently
    redeemable convertible preferred shares authorized, each with a
    par value of US$0.01, of which 233,332 such shares are issued
    and outstanding. As of the date hereof, our authorized share
    capital consists of 450,500,000&#160;shares, comprised of
    (i)&#160;450,000,000 ordinary shares, each with a par value of
    US$0.0001, of which 70,428,100&#160;such shares are issued and
    outstanding; (ii)&#160;200,000 Series&#160;A contingently
    redeemable convertible preferred shares authorized, each with a
    par value of US$0.01, of which 176,942&#160;such shares are
    issued and outstanding; and (iii)&#160;300,000 Series&#160;B
    contingently redeemable convertible preferred shares authorized,
    each with a par value of US$0.01, of which 233,332&#160;such
    shares are issued and outstanding. Upon completion of this
    offering, all of our issued and outstanding Series&#160;A and
    Series&#160;B contingently redeemable convertible preferred
    shares will automatically convert into ordinary shares, at a
    <FONT style="white-space: nowrap">1-for-100</FONT>
    conversion rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, we will adopt our third
    amended and restated memorandum and articles of association,
    which will replace the current memorandum and articles of
    association in its entirety and our authorized share capital
    will consist of 500,000,000 ordinary shares, each with a par
    value of US$0.0001. The following are summaries of material
    provisions of our third amended and restated memorandum and
    articles of association and the Companies Law insofar as they
    relate to the material terms of our ordinary shares that we
    expect will become effective upon the closing of this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Ordinary
    Shares</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">General</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All of our outstanding ordinary shares are fully paid and
    non-assessable. Certificates representing the ordinary shares
    are issued in registered form. Our shareholders who are
    non-residents of the Cayman Islands may freely hold and transfer
    their ordinary shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Dividends</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The holders of our ordinary shares are entitled to such
    dividends as may be declared by our board of directors subject
    to the Companies Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Voting
    Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each holder of ordinary shares is entitled to one vote on all
    matters upon which the ordinary shares are entitled to vote.
    Each holder is entitled to have one vote for each share
    registered in his name on the register of members. Voting at any
    meeting of shareholders is by show of hands unless a poll is
    demanded by the chairman of our board of directors or by any
    shareholder present in person or by proxy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A quorum is required for a meeting of shareholders. Shareholders
    who hold at least one-third of our ordinary shares at the
    meeting present in person or by proxy or, if a corporation or
    other non-natural person, by its duly authorized representative
    constitutes a quorum. Shareholders&#146; meetings are held
    annually and may be convened by our board of directors on its
    own initiative or upon a request to the directors by
    shareholders holding in the aggregate
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    138
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    at least ten percent of our ordinary shares. At least seven days
    advanced notice is required prior to convening our annual
    general meeting and other shareholders meetings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An ordinary resolution of the shareholders requires the
    affirmative vote of a simple majority of the votes attaching to
    the ordinary shares cast in a general meeting to pass. A special
    resolution requires the affirmative vote of not less than
    two-thirds of the votes cast attaching to the ordinary shares to
    pass.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Transfer
    of Ordinary Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the restrictions of our articles of association, as
    applicable, any of our shareholders may transfer all or any of
    such shareholder&#146;s ordinary shares by an instrument of
    transfer in the usual or common form or any other form approved
    by our board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our board of directors may, in its absolute discretion, decline
    to register any transfer of any ordinary share which is not
    fully paid up or on which we have a lien. Our directors may also
    decline to register any transfer of any ordinary share unless:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the instrument of transfer is lodged with us, accompanied by the
    certificate for the ordinary shares to which it relates and such
    other evidence as our board of directors may reasonably require
    to show the right of the transferor to make the transfer;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the instrument of transfer is in respect of only one class of
    ordinary shares;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the instrument of transfer is properly stamped, if required;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in the case of a transfer to joint holders, the number of joint
    holders to whom the ordinary share is to be transferred does not
    exceed four; or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the ordinary shares transferred are free of any lien in favor of
    us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If our directors refuse to register a transfer they shall,
    within two months after the date on which the instrument of
    transfer was lodged, send notice of such refusal to both the
    transferor and transferee. The registration of transfers may, on
    14&#160;days&#146; notice, given by advertisement in one or more
    newspapers or by electronic means, be suspended and the register
    closed at such times and for such periods as our board of
    directors may from time to time determine, provided, however,
    that the registration of transfers shall not be suspended nor
    the register closed for more than 30&#160;days in any year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Liquidation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On a return of capital in connection with the winding up of the
    company or otherwise (other than in connection with conversion,
    redemption or purchase of ordinary shares), assets available for
    distribution to the holders of ordinary shares shall be
    distributed among them on a pro rata basis. If our assets
    available for distribution are insufficient to repay all of the
    <FONT style="white-space: nowrap">paid-up</FONT>
    capital, the assets will be distributed so that the losses are
    borne by our shareholders proportionately.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Calls
    on Ordinary Shares and Forfeiture of Ordinary
    Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our board of directors may from time to time call upon
    shareholders for any amounts unpaid on their ordinary shares in
    a notice served to such shareholders at least 14&#160;days prior
    to the specified time of payment. Ordinary shares that have been
    called upon and remain unpaid are subject to forfeiture.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Redemption
    of Ordinary Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the provisions of the Companies Law, we may under the
    terms of our third amended and restated memorandum and articles
    of association to be adopted upon the completion of this
    offering:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    issue ordinary shares on terms that they are to be redeemed or
    are liable to be redeemed at our option or at the option of the
    shareholders, on such terms and in such manner as we may, before
    the issue of such ordinary shares, determine;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    purchase our own ordinary shares (including any redeemable
    shares) on such terms and in such manner as we may determine and
    agree with our shareholders; and
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    139
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    make a payment in respect of the redemption or purchase of our
    own ordinary shares in any manner authorized by the Companies
    Law, including out of our capital, profits or the proceeds of a
    fresh issue of ordinary shares.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Variations
    of Rights of Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All or any of the special rights attached to any class of shares
    may, subject to the provisions of the Companies Law, be varied
    either with the unanimous written consent of the holders of the
    issued shares of that class or with the sanction of a special
    resolution passed at a general meeting of the holders of the
    shares of that class.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Inspection
    of Books and Records</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of our ordinary shares have no general right under
    Cayman Islands law to inspect or obtain copies of our list of
    shareholders or our corporate records. However, we will provide
    our shareholders with annual audited financial statements. See
    &#147;Where You Can Find Additional Information.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Changes
    in Capital</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may from time to time by ordinary resolutions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    increase the share capital by such sum, to be divided into
    shares of such classes and amount, as the resolution shall
    prescribe;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    consolidate and divide all or any of our share capital into
    shares of a larger amount than our existing shares;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    convert all or any of our paid up shares into stock and
    reconvert that stock into paid up shares of any denomination;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    sub-divide our existing shares, or any of them into shares of a
    smaller amount that is fixed by the third amended and restated
    memorandum and articles of association; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cancel any shares that, at the date of the passing of the
    resolution, have not been taken or agreed to be taken by any
    person and diminish the amount of our share capital by the
    amount of the shares so cancelled.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the Companies Law and our third amended and restated
    memorandum and articles of association with respect to matters
    to be dealt with by ordinary resolution, we may, by special
    resolution, reduce our share capital and any capital redemption
    reserve in any manner authorized by law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Issuance
    of Additional Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our third amended and restated memorandum of association
    authorizes our board of directors to issue additional ordinary
    shares from time to time as our board of directors shall
    determine, to the extent there are available authorized but
    unissued shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our third amended and restated memorandum of association
    authorizes our board of directors to establish from time to time
    one or more series of preferred shares and to determine, with
    respect to any series of preferred shares, the terms and rights
    of that series, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the designation of the series;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the number of shares of the series;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the dividend rights, dividend rates, conversion rights, voting
    rights; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the rights and terms of redemption and liquidation preferences.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our board of directors may issue preferred shares without action
    by our shareholders to the extent there are available authorized
    but unissued preferred shares. In addition, the issuance of
    preferred shares may be used as an anti-takeover device without
    further action on the part of the shareholders. Issuance of
    these shares may dilute the voting power of holders of ordinary
    shares.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    140
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Actions
    Requiring the Approval of a Supermajority of Our Board of
    Directors</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Actions require the approval of a supermajority of at least
    two-thirds of our board of directors, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the appointment or removal of either our chief executive officer
    or chief financial officer;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any anti-takeover action in response to a takeover attempt;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any merger resulting in our shareholders immediately prior to
    such merger holding less than a majority of the voting power of
    the outstanding share capital of the surviving business entity;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the sale or transfer of all or substantially all of our assets;
    and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any change in the number of directors on our board of directors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Exempted
    Company</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are an exempted company with limited liability under the
    Companies Law. The Companies Law distinguishes between ordinary
    resident companies and exempted companies. Any company that is
    registered in the Cayman Islands but conducts business mainly
    outside of the Cayman Islands may apply to be registered as an
    exempted company. The requirements for an exempted company are
    essentially the same as for an ordinary company except for the
    exemptions and privileges listed below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company does not have to file an annual return of
    its shareholders with the Registrar of Companies;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company&#146;s register of members is not open to
    inspection;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company does not have to hold an annual general
    meeting;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company may issue negotiable or bearer shares or
    shares with no par value;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company may obtain an undertaking against the
    imposition of any future taxation (such undertakings are usually
    given for 20&#160;years in the first instance);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company may register by way of continuation in
    another jurisdiction and be deregistered in the Cayman Islands;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company may register as a limited duration company;
    and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company may register as a segregated portfolio
    company.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#147;Limited liability&#148; means that the liability of each
    shareholder is limited to the amount unpaid by the shareholder
    on the shares of the company. We are subject to reporting and
    other informational requirements of the Exchange Act, as
    applicable to foreign private issuers. We currently intend to
    comply with NYSE rules, in lieu of following home country
    practice after the closing of our initial public offering. NYSE
    rules require that every company traded on the NYSE hold an
    annual general meeting of shareholders. In addition, our third
    amended and restated articles of association, which, upon
    receiving the requisite shareholder approval, are expected to
    become effective immediately upon the closing of this offering,
    will allow directors or shareholders to call special shareholder
    meetings pursuant to the procedures set forth in such articles.
    We believe that the differences with respect to our being a
    Cayman Islands exempted company as opposed to a Delaware
    corporation do not pose additional material risks to investors,
    other than the risks described under &#147;Risk
    Factors&#160;&#151; Risks Related to This Offering.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Differences
    in Corporate Law</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Companies Law is modeled after that of English law but does
    not follow many recent English law statutory enactments. In
    addition, the Companies Law differs from laws applicable to
    United States corporations and their shareholders. Set forth
    below is a summary of the significant differences between the
    provisions of the Companies Law applicable to us and the laws
    applicable to companies incorporated in the United States and
    their shareholders.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    141
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Mergers
    and Similar Arrangements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Companies Law permits mergers and consolidations between
    Cayman Islands companies and between Cayman Islands companies
    and non-Cayman Islands companies. For these purposes,
    (a)&#160;&#147;merger&#148; means the merging of two or more
    constituent companies and the vesting of their undertaking,
    property and liabilities in one of such companies as the
    surviving company and (b)&#160;a &#147;consolidation&#148; means
    the combination of two or more constituent companies into a
    consolidated company and the vesting of the undertaking,
    property and liabilities of such companies to the consolidated
    company. In order to effect such a merger or consolidation, the
    directors of each constituent company must approve a written
    plan of merger or consolidation, which must then be authorized
    by either (i)&#160;a special resolution of the shareholders of
    each constituent company voting together as one class if the
    shares to be issued to each shareholder in the consolidated or
    surviving company will have the same rights and economic value
    as the shares held in the relevant constituent company or
    (ii)&#160;a shareholder resolution of each constituent company
    passed by a majority in number representing 75% in value of the
    shareholders voting together as one class. The plan of merger or
    consolidation must be filed with the Registrar of Companies
    together with a declaration as to the solvency of the
    consolidated or surviving company, a list of the assets and
    liabilities of each constituent company and an undertaking that
    a copy of the certificate of merger or consolidation will be
    given to the members and creditors of each constituent company
    and published in the Cayman Islands Gazette. Dissenting
    shareholders have the right to be paid the fair value of their
    shares (which, if not agreed between the parties, will be
    determined by the Cayman Islands court) if they follow the
    required procedures, subject to certain exceptions. Court
    approval is not required for a merger or consolidation which is
    effected in compliance with these statutory procedures.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, there are statutory provisions that facilitate the
    reconstruction and amalgamation of companies, provided that the
    arrangement is approved by a majority in number of each class of
    shareholders and creditors with whom the arrangement is to be
    made, and who must in addition represent three-fourths in value
    of each such class of shareholders or creditors, as the case may
    be, that are present and voting either in person or by proxy at
    a meeting, or meetings, convened for that purpose. The convening
    of the meetings and subsequently the arrangement must be
    sanctioned by the Grand Court of the Cayman Islands. While a
    dissenting shareholder has the right to express to the court the
    view that the transaction ought not be approved, the court can
    be expected to approve the arrangement if it determines that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the statutory provisions as to the dual majority vote have been
    met;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the shareholders have been fairly represented at the meeting in
    question;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the arrangement is such that a businessman would reasonably
    approve; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the arrangement is not one that would more properly be
    sanctioned under some other provision of the Companies Law.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    When a take-over offer is made and accepted by holders of 90.0%
    of the shares (within four months after the making of the
    offer), the offeror may, within a two month period, require the
    holders of the remaining shares to transfer such shares on the
    terms of the offer. An objection can be made to the Grand Court
    of the Cayman Islands, but this is unlikely to succeed unless
    there is evidence of fraud, bad faith or collusion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the arrangement and reconstruction is approved, the
    dissenting shareholder would have no rights comparable to
    appraisal rights, which would otherwise ordinarily be available
    to dissenting shareholders of United States corporations,
    providing rights to receive payment in cash for the judicially
    determined value of the shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Shareholders&#146;
    Suits</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are not aware of any reported class action or derivative
    action having been brought in a Cayman Islands court. In
    principle, we will normally be the proper plaintiff and a
    derivative action may not be brought by a minority shareholder.
    However, based on English authorities, which would in all
    likelihood be of persuasive authority in the Cayman Islands,
    there are exceptions to the foregoing principle, including when:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a company acts or proposes to act illegally or ultra vires;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    142
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the act complained of, although not ultra vires, could be duly
    effected if authorized by a special or ordinary resolution that
    has not been obtained; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    those who control the company are perpetrating a &#147;fraud on
    the minority.&#148;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Indemnification
    of Directors and Executive Officers and Limitation of
    Liability</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cayman Islands law does not limit the extent to which a
    company&#146;s articles of association may provide for
    indemnification of officers and directors, except to the extent
    any such provision may be held by the Cayman Islands courts to
    be contrary to public policy, such as a provision purporting to
    provide indemnification against civil fraud or the consequences
    of committing a crime. Our third amended and restated memorandum
    and articles of association permit indemnification of officers
    and directors against all actions, proceedings, costs, charges,
    expenses, losses, damages or liabilities incurred or sustained
    in their capacities as such unless such losses or damages arise
    from dishonesty, fraud or default of such directors or officers.
    This standard of conduct is generally the same as permitted
    under the Delaware General Corporation Law for a Delaware
    corporation. In addition, we have entered into indemnification
    agreements with our directors and senior executive officers that
    provide such persons with additional indemnification beyond that
    provided in our third amended and restated memorandum and
    articles of association.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Insofar as indemnification for liabilities arising under the
    Securities Act may be permitted to our directors, officers or
    persons controlling us under the foregoing provisions, we have
    been informed that in the opinion of the SEC such
    indemnification is against public policy as expressed in the
    Securities Act and is therefore unenforceable as a matter of
    United States law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Anti-takeover
    Provisions in Our Third Amended and Restated Memorandum and
    Articles of Association</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Some provisions of our third amended and restated memorandum and
    articles of association may discourage, delay or prevent a
    change in control of our company or management that shareholders
    may consider favorable, including provisions that authorize our
    board of directors to issue preferred shares in one or more
    series and to designate the price, rights, preferences,
    privileges and restrictions of such preferred shares without any
    further vote or action by our shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, under Cayman Islands law, our directors may only
    exercise the rights and powers granted to them under our third
    amended and restated memorandum and articles of association, as
    amended and restated from time to time, for what they believe in
    good faith to be in the best interests of our company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Directors&#146;
    Fiduciary Duties</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under Delaware corporate law, a director of a Delaware
    corporation has a fiduciary duty to the corporation and its
    shareholders. This duty has two components: the duty of care and
    the duty of loyalty. The duty of care requires that a director
    act in good faith, with the care that an ordinarily prudent
    person would exercise under similar circumstances. Under this
    duty, a director must inform himself of, and disclose to
    shareholders, all material information reasonably available
    regarding a significant transaction. The duty of loyalty
    requires that a director act in a manner he reasonably believes
    to be in the best interests of the corporation. He must not use
    his corporate position for personal gain or advantage. This duty
    prohibits self-dealing by a director and mandates that the best
    interest of the corporation and its shareholders take precedence
    over any interest possessed by a director, officer or
    controlling shareholder and not shared by the shareholders
    generally. In general, actions of a director are presumed to
    have been made on an informed basis, in good faith and in the
    honest belief that the action taken was in the best interests of
    the corporation. However, this presumption may be rebutted by
    evidence of a breach of one of the fiduciary duties. Should such
    evidence be presented concerning a transaction by a director, a
    director must prove the procedural fairness of the transaction,
    and that the transaction was of fair value to the corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a matter of Cayman Islands law, a director of a Cayman
    Islands company is in the position of a fiduciary with respect
    to the company and, therefore, he owes the following duties to
    the company&#160;&#151; a duty to act bona fide in the best
    interests of the company, a duty not to make a profit based on
    his position as director (unless the company permits him to do
    so) and a duty not to put himself in a position where the
    interests of the company conflict with his personal interest or
    his duty to a third party. A director of a Cayman Islands
    company owes to the company a duty to
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    143
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    act with skill and care. It was previously thought that a
    director need not exhibit in the performance of his duties a
    greater degree of skill than may reasonably be expected from a
    person of his knowledge and experience. However, English and
    Commonwealth courts have moved away from this subjective
    standard and towards an objective, reasonable director standard
    with regard to the required skill and care and these
    authorities, objective approach is likely to be followed in the
    Cayman Islands.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Shareholder
    Action by Written Consent</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, a corporation may
    eliminate the right of shareholders to act by written consent
    through amendment to its certificate of incorporation. Cayman
    Islands law and our third amended and restated articles of
    association provide that shareholders may approve corporate
    matters by way of a unanimous written resolution signed by or on
    behalf of each shareholder who would have been entitled to vote
    on such matter at a general meeting without a meeting being held.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Shareholder
    Proposals</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, a shareholder has
    the right to put any proposal before the shareholders at the
    annual meeting, provided that such shareholder complies with the
    notice provisions in the governing documents. A special meeting
    may be called by the board of directors or any other person
    authorized to do so in the governing documents, but shareholders
    may be precluded from calling special meetings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cayman Islands law and our third amended and restated articles
    of association allow our shareholders holding not less than
    10.0% of the paid up voting share capital of the Company to
    require the company to call a shareholder&#146;s meeting. As an
    exempted Cayman Islands company, we are not obliged by law to
    call shareholders&#146; annual general meetings. However, our
    third amended and restated articles of association require us to
    call such meetings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Cumulative
    Voting</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, cumulative voting
    for elections of directors is not permitted unless the
    corporation&#146;s certificate of incorporation specifically
    provides for it. Cumulative voting potentially facilitates the
    representation of minority shareholders on a board of directors
    since it permits a minority shareholder to cast all the votes to
    which such shareholder is entitled on a single director, which
    increases such shareholder&#146;s voting power with respect to
    electing such director. There are no prohibitions in relation to
    cumulative voting under the laws of the Cayman Islands, but our
    third amended and restated articles of association do not
    provide for cumulative voting. As a result, our shareholders are
    not afforded any less protections or rights on this issue than
    shareholders of a Delaware corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Removal
    of Directors</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, a director of a
    corporation with a classified board may be removed only for
    cause with the approval of a majority of the outstanding shares
    entitled to vote, unless the certificate of incorporation
    provides otherwise. Under our third amended and restated
    articles of association, directors can be removed without cause,
    but only by the vote of holders of two-thirds of our shares,
    cast at a general meeting, or by the unanimous written
    resolution of all shareholders, or with cause, by the ordinary
    resolution or the unanimous written resolution of all
    shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Transactions
    with Interested Shareholders</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Delaware General Corporation Law contains a business
    combination statute applicable to Delaware public corporations
    whereby, unless the corporation has specifically elected not to
    be governed by such statute by amendment to its certificate of
    incorporation, it is prohibited from engaging in certain
    business combinations with an &#147;interested shareholder&#148;
    for three years following the date that such person becomes an
    interested shareholder. An interested shareholder generally is a
    person or a group who or which owns or has owned 15.0% or more
    of the target&#146;s outstanding voting stock within the past
    three years. This has the effect of limiting the ability of a
    potential acquirer to make a two-tiered bid for the target in
    which all shareholders would not be treated equally. The statute
    does not apply if, among other things, prior to the date on
    which such shareholder becomes an interested shareholder, the
    board of directors approves either the business combination or
    the transaction which resulted in the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    144
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    person becoming an interested shareholder. This encourages any
    potential acquirer of a Delaware public corporation to negotiate
    the terms of any acquisition transaction with the target&#146;s
    board of directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cayman Islands law has no comparable statute. As a result, we
    cannot avail ourselves of the types of protections afforded by
    the Delaware business combination statute. However, although
    Cayman Islands law does not regulate transactions between a
    company and its significant shareholders, it does provide that
    such transactions must be entered into bona fide in the best
    interests of the company and not with the effect of constituting
    a fraud on the minority shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Dissolution;
    Winding up</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, unless the board of
    directors approves the proposal to dissolve, dissolution must be
    approved by shareholders holding 100% of the total voting power
    of the corporation. Only if the dissolution is initiated by the
    board of directors may it be approved by a simple majority of
    the corporation&#146;s outstanding shares. Delaware law allows a
    Delaware corporation to include in its certificate of
    incorporation a supermajority voting requirement in connection
    with dissolutions initiated by the board. Under the Companies
    Law of the Cayman Islands and our third amended and restated
    articles of association, our company may be dissolved,
    liquidated or wound up by the vote of holders of two-thirds of
    our shares voting at a meeting or the unanimous written
    resolution of all shareholders or by an ordinary resolution on
    the basis that we are unable to pay our debts as they fall due.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Variation
    of Rights of Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, a corporation may
    vary the rights of a class of shares with the approval of a
    majority of the outstanding shares of such class, unless the
    certificate of incorporation provides otherwise. Under Cayman
    Islands law and our third amended and restated articles of
    association, if our share capital is divided into more than one
    class of shares, we may vary the rights attached to any class
    only with the vote at a class meeting of holders of two-thirds
    of the shares of such class or unanimous written resolution of
    all shareholders of that class.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Amendment
    of Governing Documents</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, a corporation&#146;s
    governing documents may be amended with the approval of a
    majority of the outstanding shares entitled to vote, unless the
    certificate of incorporation provides otherwise. As permitted by
    Cayman Islands law, our third amended and restated memorandum
    and articles of association may only be amended with a special
    resolution at a meeting or the unanimous written resolution of
    all shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Rights
    of Non-resident or Foreign Shareholders</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are no limitations imposed by our third amended and
    restated memorandum and articles of association on the rights of
    non-resident or foreign shareholders to hold or exercise voting
    rights on our shares. In addition, there are no provisions in
    our third amended and restated memorandum and articles of
    association governing the ownership threshold above which
    shareholder ownership must be disclosed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">History
    of Securities Issuances</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a summary of our securities issuances since our
    inception in November 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Ordinary
    Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March&#160;8, 2008, we issued a total of 49,999,900 ordinary
    shares to certain of our officers, directors and other minority
    shareholders in connection with our incorporation for an
    aggregate subscription amount of US$4,999.99.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;18, 2008, we issued a total of 21,184,600
    ordinary shares to certain of our officers in connection with
    the exercise of share options for an aggregate subscription
    amount of US$16,735,834.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2009, we effected a share split whereby all
    of our issued and outstanding 704,281 ordinary shares of a par
    value of US$0.01 per share were split into 70,428,100 ordinary
    shares of US$0.0001 par value per share and the number of our
    authorized ordinary shares was increased from 4,500,000 to
    450,000,000.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    145
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Convertible
    Loan and Preferred Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;16, 2007, pursuant to the Convertible Loan
    Agreement dated as of November&#160;16, 2007, our predecessor,
    OMS, issued two convertible loan promissory notes to the Carlyle
    Entities for total consideration of US$5.0&#160;million. The
    proceeds from the issuance of the convertible loan promissory
    notes were primarily used to fund the growth of OMS. On
    April&#160;3, 2008, pursuant to the Series&#160;A Preferred
    Shares Subscription Agreement dated as of February&#160;5, 2008,
    as amended on April&#160;2, 2008 and on October&#160;20, 2008,
    we issued a total of 81,952 Series&#160;A contingently
    redeemable convertible preferred shares to the Carlyle Entities
    and CICC Sun Company Limited for total consideration of
    US$10.0&#160;million and the conversion of the two convertible
    loan promissory notes issued to the Carlyle Entities by OMS on
    November&#160;16, 2007 plus accrued interest. The proceeds from
    the issuance of Series&#160;A contingently redeemable
    convertible preferred shares were primarily used to fund our
    growth. Also, on June&#160;18, 2008, we re-designated 756,500
    ordinary shares as 7,565 Series&#160;A contingently redeemable
    convertible preferred shares, which were transferred by Notable
    Enterprise Limited, a British Virgin Islands company controlled
    by Ms.&#160;Bona Lau, to the CICC Sun Company Limited as part of
    the issuance of our Series&#160;A contingently redeemable
    convertible preferred shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;10, 2008, pursuant to the Convertible Loan
    Agreement dated as of April&#160;10, 2008, we issued two
    convertible loan promissory notes to the Carlyle Entities for
    total consideration of US$20.0&#160;million. On July&#160;30,
    2008, we issued a total of 87,425 Series&#160;A contingently
    redeemable convertible preferred shares to the Carlyle Entities
    as a result of the conversion of the convertible loan promissory
    notes issued by us on April&#160;10, 2008 plus accrued interest.
    The proceeds from the issuance of the convertible loan
    promissory notes were primarily used to fund our growth.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;20, 2008, pursuant to the Series&#160;B
    Preferred Shares Subscription Agreement, dated as of
    October&#160;10, 2008, as amended on October&#160;20, 2008, we
    issued a total of 233,332 Series&#160;B contingently redeemable
    convertible preferred shares to the Carlyle Entities, Starr
    Investments Cayman II, Inc. and CICC Sun Company Limited for
    total consideration of US$60&#160;million. The proceeds from the
    issuance of Series&#160;B contingently redeemable convertible
    preferred shares were primarily used to fund our growth.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the issuance of our Series&#160;B
    contingently redeemable convertible preferred shares, certain of
    our directors and principal shareholders have entered into an
    agreement to provide each of CICC Sun Company Limited, Carlyle
    Asia Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc., or the preferred
    shareholders, with a right to adjust their shareholding in our
    company based on our results of operations in 2008 and 2009.
    This performance adjustment provision specifies that in the
    event our results of operations are less than certain predefined
    amounts, these directors and principal shareholders will
    transfer a certain portion of their ordinary shares in our
    company to the preferred shareholders. As security for this
    performance adjustment provision, these directors or principal
    shareholders have pledged a certain percentage of their ordinary
    shares in our company to the preferred shareholders. The pledged
    shares will be released after our results of operations for 2009
    are determined or upon the occurrence of this offering. On
    November&#160;6, 2009, pursuant to the share charge agreements,
    certain of our directors or principal shareholders have
    transferred an aggregate of 3,493,000 ordinary shares to the
    preferred shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our directors or principal shareholders have also entered into
    share charge agreements that pledge a certain portion of their
    ordinary shares to the preferred shareholders against the
    occurrence of any dispute or litigation in connection with any
    acquisition by us or our subsidiaries which had been consummated
    prior to the closing of our issuance of Series&#160;B
    contingently redeemable convertible preferred shares. These
    share charge agreements will terminate on November&#160;10, 2014
    or upon the occurrence of certain other conditions specified in
    the relevant share charge agreement. See &#147;Principal and
    Selling Shareholders&#148; for additional information as to the
    ordinary shares pledged by our directors or principal
    shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Share
    Options</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2007, OMS, the predecessor of our company,
    adopted a share option plan, or the OMS option plan, pursuant to
    which OMS granted to three of its executive directors,
    Mr.&#160;Haifeng Liu, Mr.&#160;Jianyu Yang and Mr.&#160;Steve
    Sun, or the OMS grantees, options to purchase a total of up to
    25,000,000 ordinary shares, or the OMS share options, to
    purchase the ordinary shares of OMS at an exercise price of
    US$0.80 per share, which the board of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    146
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    OMS determined to become vested upon the satisfaction of a
    number of performance conditions that related to the completion
    of the OMS reorganization, achievement of net profit target of
    OMS, and the raising of new financing. The OMS share options
    were exercisable from the date of completion of the 2007 audited
    consolidated financial statements of OMS to December&#160;31,
    2008 and were transferrable to any individuals designated by the
    OMS grantees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;18, 2008, the board of directors of OMS
    contemplated that the OMS grantees had achieved certain
    performance conditions outlined in the OMS option plan. However,
    as the capital structure of our company had changed at that time
    such that we had replaced OMS as the ultimate holding company of
    our subsidiaries, the board of directors of OMS resolved that
    the OMS option plan would be settled in vested options to
    purchase 21,184,600 ordinary shares to purchase shares of our
    company, with each option having an exercise price of US$0.79
    exercisable before December&#160;31, 2008. On the same day, two
    of the OMS grantees, Mr.&#160;Jianyu Yang and Mr.&#160;Steve
    Sun, exercised their respective options to purchase an aggregate
    of 6,355,400&#160;ordinary shares of our company, with total
    proceeds from such exercise received by us amounting to
    approximately RMB34.4&#160;million (US$5.0&#160;million). We
    recorded share-based compensation expense of approximately
    RMB49.5&#160;million in 2007 related to these options granted,
    which was recorded in general and administrative expenses. The
    third OMS grantee, Mr.&#160;Haifeng Liu, sold all of his vested
    options to purchase 14,829,200 ordinary shares of our company to
    three former directors of China Medstar who are now our
    directors and executive officers as employment incentive for
    such directors. The three executive directors subsequently
    exercised the vested options with total proceeds from such
    exercise received by us amounting to approximately
    US$11.7&#160;million. Given the transfer of the OMS share
    options to the three directors was provided as an employment
    incentive, we recorded additional share-based compensation
    expense of approximately RMB4.2&#160;million
    (US$0.6&#160;million) in 2008, which was recorded in general and
    administrative expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have adopted a 2008&#160;share incentive plan on
    October&#160;16, 2008, which was subsequently amended on
    November&#160;17, 2009 to increase the number of ordinary shares
    that may be granted under the plan to 4,765,800. On
    November&#160;27, 2009, we granted options to purchase an
    aggregate of 4,765,800&#160;ordinary shares, of which options to
    purchase an aggregate of 1,716,500&#160;ordinary shares were
    granted to our executive officers and directors, and the
    remainder to other employees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For additional information as to the issuance of our share
    options, see &#147;Management&#160;&#151; Share Incentive
    Plans.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our current shareholder agreement entered into on
    October&#160;20, 2008 and as amended on November&#160;17, 2009
    and on December&#160;7, 2009, we have granted the Carlyle
    Entities, Starr Investments Cayman II, Inc., CICC Sun Company
    Limited and Perfect Key Holdings Limited certain registration
    rights. No later than 181&#160;days after this initial public
    offering or the expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements entered into in connection with this public offering,
    whichever date is later, we shall file a shelf registration
    statement with the SEC covering the resale of all of our
    registrable securities held by the Carlyle Entities, Starr
    Investments Cayman II, Inc., CICC Sun Company Limited and
    Perfect Key Holdings Limited. We shall use our best efforts to
    cause such shelf registration statement to become effective on
    or prior to the 90th&#160;day following the filing of the shelf
    registration statement and to keep such shelf registration
    statement in effect until all of the registrable securities held
    by each of the Carlyle Entities, Starr Investments Cayman II,
    Inc., CICC Sun Company Limited and Perfect Key Holdings Limited
    have been resold. We shall pay all registration expenses
    incurred in connection with the foregoing.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
  <!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    147
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='119'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DESCRIPTION
    OF AMERICAN DEPOSITARY SHARES</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">American
    Depositary Receipts</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    JPMorgan Chase Bank, N.A., as depositary will issue the ADSs
    which you will be entitled to receive in this offering. Each ADS
    will represent an ownership interest in three ordinary shares
    which we will deposit with the custodian, as agent of the
    depositary, under the deposit agreement among ourselves, the
    depositary and yourself as an ADR holder. In the future, each
    ADS will also represent any securities, cash or other property
    deposited with the depositary but which they have not
    distributed directly to you. Unless specifically requested by
    you, all ADSs will be issued on the books of our depositary in
    book-entry form and periodic statements will be mailed to you
    which reflect your ownership interest in such ADSs. In our
    description, references to American depositary receipts or ADRs
    shall include the statements you will receive which reflect your
    ownership of ADSs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary&#146;s office is located at 4 New York Plaza, New
    York, NY 10004.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You may hold ADSs either directly or indirectly through your
    broker or other financial institution. If you hold ADSs
    directly, by having an ADS registered in your name on the books
    of the depositary, you are an ADR holder. This description
    assumes that you hold your ADSs directly. If you hold the ADSs
    through your broker or financial institution nominee, you must
    rely on the procedures of such broker or financial institution
    to assert the rights of an ADR holder described in this section.
    You should consult with your broker or financial institution to
    find out what those procedures are.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As an ADR holder, we will not treat you as a shareholder of ours
    and you will not have any shareholder rights. Cayman Island law
    governs shareholder rights. Because the depositary or its
    nominee will be the shareholder of record for the shares
    represented by all outstanding ADSs, shareholder rights rest
    with such record holder. Your rights are those of an ADR holder.
    Such rights derive from the terms of the deposit agreement to be
    entered into among us, the depositary and all registered holders
    from time to time of ADSs issued under the deposit agreement.
    The obligations of the depositary and its agents are also set
    out in the deposit agreement. Because the depositary or its
    nominee will actually be the registered owner of the ordinary
    shares, you must rely on it to exercise the rights of a
    shareholder on your behalf. The deposit agreement and the ADSs
    are governed by laws of the State of New&#160;York.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a summary of the material terms of the deposit
    agreement. Because it is a summary, it does not contain all the
    information that may be important to you. For more complete
    information, you should read the entire deposit agreement and
    the form of ADR which contains the terms of your ADSs. You can
    read a copy of the deposit agreement which is filed as an
    exhibit to the registration statement of which this prospectus
    forms a part. You may also obtain a copy of the deposit
    agreement at the SEC&#146;s Public Reference Room which is
    located at 100&#160;F&#160;Street, NE, Washington, DC 20549. You
    may obtain information on the operation of the Public Reference
    Room by calling the SEC at
    <FONT style="white-space: nowrap">1-800-732-0330.</FONT>
    You may also find the registration statement and the attached
    deposit agreement on the SEC&#146;s website at
    <FONT style="white-space: nowrap">http://www.sec.gov.</FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Share
    Dividends and Other Distributions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">How
    will I receive dividends and other distributions on the shares
    underlying my ADSs?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may make various types of distributions with respect to our
    securities. The depositary has agreed that, to the extent
    practicable, it will pay to you the cash dividends or other
    distributions it or the custodian receives on shares or other
    deposited securities, after converting any cash received into
    U.S.&#160;dollars and, in all cases, making any necessary
    deductions provided for in the deposit agreement. You will
    receive these distributions in proportion to the number of
    underlying securities that your ADSs represent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Except as stated below, the depositary will deliver such
    distributions to ADR holders in proportion to their interests in
    the following manner:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Cash.</I>&#160;&#160;The depositary will distribute any
    U.S.&#160;dollars available to it resulting from a cash dividend
    or other cash distribution or the net proceeds of sales of any
    other distribution or portion thereof (to the extent
    applicable), on an averaged or other practicable basis, subject
    to (i)&#160;appropriate adjustments for taxes withheld,
    (ii)&#160;such distribution being impermissible or impracticable
    with respect to certain registered ADR holders, and
    (iii)&#160;deduction of the depositary&#146;s expenses in
    (1)&#160;converting any foreign currency to U.S.&#160;dollars to
    the extent that it determines that such
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    148
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    conversion may be made on a reasonable basis,
    (2)&#160;transferring foreign currency or U.S.&#160;dollars to
    the United States by such means as the depositary may determine
    to the extent that it determines that such transfer may be made
    on a reasonable basis, (3)&#160;obtaining any approval or
    license of any governmental authority required for such
    conversion or transfer, which is obtainable at a reasonable cost
    and within a reasonable time and (4)&#160;making any sale by
    public or private means in any commercially reasonable manner.
    <I>If exchange rates fluctuate during a time when the depositary
    cannot convert a foreign currency, you may lose some or all of
    the value of the distribution.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Shares.</I>&#160;&#160;In the case of a distribution in
    shares, the depositary will issue additional ADRs to evidence
    the number of ADSs representing such shares. Only whole ADSs
    will be issued. Any shares which would result in fractional ADSs
    will be sold and the net proceeds will be distributed in the
    same manner as cash to the ADR holders entitled thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Rights to receive additional shares.</I>&#160;&#160;In the
    case of a distribution of rights to subscribe for additional
    shares or other rights, if we provide evidence satisfactory to
    the depositary that it may lawfully distribute such rights, the
    depositary will distribute warrants or other instruments in the
    discretion of the depositary representing such rights. However,
    if we do not furnish such evidence, the depositary may:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    sell such rights if practicable and distribute the net proceeds
    in the same manner as cash to the ADR holders entitled
    thereto;&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if it is not practicable to sell such rights, do nothing and
    allow such rights to lapse, in which case ADR holders will
    receive nothing.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have no obligation to file a registration statement under the
    Securities Act in order to make any rights available to ADR
    holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Distributions.</I>&#160;&#160;In the case of a
    distribution of securities or property other than those
    described above, the depositary may either (i)&#160;distribute
    such securities or property in any manner it deems equitable and
    practicable or (ii)&#160;to the extent the depositary deems
    distribution of such securities or property not to be equitable
    and practicable, sell such securities or property and distribute
    any net proceeds in the same way it distributes cash.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the depositary determines that any distribution described
    above is not practicable with respect to any specific registered
    ADR holder, the depositary may choose any method of distribution
    that it deems practicable for such ADR holder, including the
    distribution of foreign currency, securities or property, or it
    may retain such items, without paying interest on or investing
    them, on behalf of the ADR holder as deposited securities, in
    which case the ADSs will also represent the retained items.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any U.S.&#160;dollars will be distributed by checks drawn on a
    bank in the United States for whole dollars and cents.
    Fractional cents will be withheld without liability and dealt
    with by the depositary in accordance with its then current
    practices.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The depositary is not responsible if it decides that it is
    unlawful or impractical to make a distribution available to any
    ADR holders.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>There can be no assurance that the depositary will be able to
    convert any currency at a specified exchange rate or sell any
    property, rights, shares or other securities at a specified
    price, nor that any of such transactions can be completed within
    a specified time period.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Deposit,
    Withdrawal and Cancellation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">How
    does the depositary issue ADSs?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary will issue ADSs if you or your broker deposit
    shares or evidence of rights to receive shares with the
    custodian and pay the fees and expenses owing to the depositary
    in connection with such issuance. In the case of the ADSs to be
    issued under this prospectus, we will arrange with the
    underwriters named herein to deposit such shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shares deposited in the future with the custodian must be
    accompanied by certain delivery documentation, including
    instruments showing that such shares have been properly
    transferred or endorsed to the person on whose behalf the
    deposit is being made.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    149
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The custodian will hold all deposited shares (including those
    being deposited by or on our behalf in connection with this
    offering) for the account of the depositary. ADR holders thus
    have no direct ownership interest in the shares and only have
    such rights as are contained in the deposit agreement. The
    custodian will also hold any additional securities, property and
    cash received on or in substitution for the deposited shares.
    The deposited shares and any such additional items are referred
    to as &#147;deposited securities&#148;.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon each deposit of shares, receipt of related delivery
    documentation and compliance with the other provisions of the
    deposit agreement, including the payment of the fees and charges
    of the depositary and any taxes or other fees or charges owing,
    the depositary will issue an ADR or ADRs in the name or upon the
    order of the person entitled thereto evidencing the number of
    ADSs to which such person is entitled. All of the ADSs issued
    will, unless specifically requested to the contrary, be part of
    the depositary&#146;s direct registration system, and a
    registered holder will receive periodic statements from the
    depositary which will show the number of ADSs registered in such
    holder&#146;s name. An ADR holder can request that the ADSs not
    be held through the depositary&#146;s direct registration system
    and that a certificated ADR be issued.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">How do
    ADR holders cancel an ADS and obtain deposited
    securities?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    When you turn in your ADR certificate at the depositary&#146;s
    office, or when you provide proper instructions and
    documentation in the case of direct registration ADSs, the
    depositary will, upon payment of certain applicable fees,
    charges and taxes, deliver the underlying shares to you or upon
    your written order. In the case of certificated ADSs, delivery
    will be made at the custodian&#146;s office. At your risk,
    expense and request, the depositary may deliver deposited
    securities at such other place as you may request.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary may only restrict the withdrawal of deposited
    securities in connection with:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    temporary delays caused by closing our transfer books or those
    of the depositary or the deposit of shares in connection with
    voting at a shareholders&#146; meeting, or the payment of
    dividends;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the payment of fees, taxes and similar charges;&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    compliance with any U.S.&#160;or foreign laws or governmental
    regulations relating to the ADRs or to the withdrawal of
    deposited securities.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This right of withdrawal may not be limited by any other
    provision of the deposit agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Record
    Dates</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary may, after consultation with us if practicable,
    fix record dates for the determination of the registered ADR
    holders who will be entitled (or obligated, as the case may be):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to receive any distribution on or in respect of shares,
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to give instructions for the exercise of voting rights at a
    meeting of holders of shares,
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to pay the fee assessed by the depositary for administration of
    the ADR program and for any expenses as provided for in the
    ADR,&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to receive any notice or to act in respect of other matters all
    subject to the provisions of the deposit agreement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">How do
    I vote?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you are an ADR holder and the depositary asks you to provide
    it with voting instructions, you may instruct the depositary how
    to exercise the voting rights for the shares which underlie your
    ADSs. As soon as practicable after receiving notice of any
    meeting or solicitation of consents or proxies from us, the
    depositary will distribute to the registered ADR holders a
    notice stating such information as is contained in the voting
    materials received by the depositary and describing how you may
    instruct the depositary to exercise the voting rights for the
    shares which underlie your ADSs, including instructions for
    giving a discretionary proxy to a person designated by us. For
    instructions to be valid, the depositary must receive them in
    the manner and on or before the date specified. The
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    150
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    depositary will try, as far as is practical, subject to the
    provisions of and governing the underlying shares or other
    deposited securities, to vote or to have its agents vote the
    shares or other deposited securities as you instruct.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary will only vote or attempt to vote as you
    instruct. The depositary will not itself exercise any voting
    discretion. Furthermore, neither the depositary nor its agents
    are responsible for any failure to carry out any voting
    instructions, for the manner in which any vote is cast or for
    the effect of any vote.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There is no guarantee that you will receive voting materials in
    time to instruct the depositary to vote and it is possible that
    you, or persons who hold their ADSs through brokers, dealers or
    other third parties, will not have the opportunity to exercise a
    right to vote.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Reports
    and Other Communications</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Will
    ADR holders be able to view our reports?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary will make available for inspection by ADR holders
    at the offices of the depositary and the custodian the deposit
    agreement, the provisions of or governing deposited securities,
    and any written communications from us which are both received
    by the custodian or its nominee as a holder of deposited
    securities and made generally available to the holders of
    deposited securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additionally, if we make any written communications generally
    available to holders of our shares, and we furnish copies
    thereof (or English translations or summaries) to the
    depositary, it will distribute the same to registered ADR
    holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Fees and
    Expenses</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">What
    fees and expenses will I be responsible for
    paying?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary may charge each person to whom ADSs are issued,
    including, without limitation, issuances against deposits of
    shares, issuances in respect of share distributions, rights and
    other distributions, issuances pursuant to a stock dividend or
    stock split declared by us or issuances pursuant to a merger,
    exchange of securities or any other transaction or event
    affecting the ADSs or deposited securities, and each person
    surrendering ADSs for withdrawal of deposited securities or
    whose ADRs are cancelled or reduced for any other reason, $5.00
    for each 100 ADSs (or any portion thereof) issued, delivered,
    reduced, cancelled or surrendered, as the case may be. The
    depositary may sell (by public or private sale) sufficient
    securities and property received in respect of a share
    distribution, rights
    <FONT style="white-space: nowrap">and/or</FONT> other
    distribution prior to such deposit to pay such charge.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following additional charges shall be incurred by the ADR
    holders, by any party depositing or withdrawing shares or by any
    party surrendering ADSs or to whom ADSs are issued (including,
    without limitation, issuance pursuant to a stock dividend or
    stock split declared by us or an exchange of stock regarding the
    ADRs or the deposited securities or a distribution of ADSs),
    whichever is applicable:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee of up to US$1.50 per ADR or ADRs for transfers of
    certificated or direct registration ADRs;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee of up to US$0.05 per ADS for any cash distribution made
    pursuant to the deposit agreement;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee of up to US$0.05 per ADS per calendar year (or portion
    thereof) for services performed by the depositary in
    administering the ADRs (which fee may be charged on a periodic
    basis during each calendar year and shall be assessed against
    holders of ADRs as of the record date or record dates set by the
    depositary during each calendar year and shall be payable in the
    manner described in the next succeeding provision);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement of such fees, charges and expenses as are incurred
    by the depositary
    <FONT style="white-space: nowrap">and/or</FONT> any
    of the depositary&#146;s agents (including, without limitation,
    the custodian and expenses incurred on behalf of holders in
    connection with compliance with foreign exchange control
    regulations or any law or regulation relating to foreign
    investment) in connection with the servicing of the shares or
    other deposited securities, the delivery of deposited securities
    or otherwise in connection with the depositary&#146;s or its
    custodian&#146;s compliance with applicable law, rule or
    regulation (which charge shall be assessed on a proportionate
    basis against holders as of the record date or dates set by the
    depositary and shall be payable at the sole discretion of the
    depositary by billing such holders or by deducting such charge
    from one or more cash dividends or other cash distributions);
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    151
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee for the distribution of securities (or the sale of
    securities in connection with a distribution), such fee being in
    an amount equal to the fee for the execution and delivery of
    ADSs which would have been charged as a result of the deposit of
    such securities (treating all such securities as if they were
    shares) but which securities or the net cash proceeds from the
    sale thereof are instead distributed by the depositary to those
    holders entitled thereto;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    stock transfer or other taxes and other governmental charges;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cable, telex and facsimile transmission and delivery charges
    incurred at your request in connection with the deposit or
    delivery of shares;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfer or registration fees for the registration of transfer
    of deposited securities on any applicable register in connection
    with the deposit or withdrawal of deposited securities;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    expenses of the depositary in connection with the conversion of
    foreign currency into U.S.&#160;dollars.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will pay all other charges and expenses of the depositary and
    any agent of the depositary (except the custodian) pursuant to
    agreements from time to time between us and the depositary. The
    charges described above may be amended from time to time by
    agreement between us and the depositary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our depositary has agreed to reimburse us for certain expenses
    we incur that are related to establishment and maintenance of
    the ADR program, including investor relations expenses and
    exchange application and listing fees. Neither the depositary
    nor we can determine the exact amount to be made available to us
    because (i)&#160;the number of ADSs that will be issued and
    outstanding, (ii)&#160;the level of fees to be charged to
    holders of ADSs and (iii)&#160;our reimbursable expenses related
    to the ADR program are not known at this time. The depositary
    collects its fees for issuance and cancellation of ADSs directly
    from investors depositing shares or surrendering ADSs for the
    purpose of withdrawal or from intermediaries acting for them.
    The depositary collects fees for making distributions to
    investors by deducting those fees from the amounts distributed
    or by selling a portion of distributable property to pay the
    fees. The depositary may collect its annual fee for depositary
    services by deduction from cash distributions, or by directly
    billing investors, or by charging the book-entry system accounts
    of participants acting for them. The depositary may generally
    refuse to provide services to any holder until the fees and
    expenses owing by such holder for those services or otherwise
    are paid.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Payment
    of Taxes</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    ADR holders must pay any tax or other governmental charge
    payable by the custodian or the depositary on any ADS or ADR,
    deposited security or distribution. If an ADR holder owes any
    tax or other governmental charge, the depositary may
    (i)&#160;deduct the amount thereof from any cash distributions,
    or (ii)&#160;sell deposited securities (by public or private
    sale) and deduct the amount owing from the net proceeds of such
    sale. In either case the ADR holder remains liable for any
    shortfall. Additionally, if any tax or governmental charge is
    unpaid, the depositary may also refuse to effect any
    registration, registration of transfer,
    <FONT style="white-space: nowrap">split-up</FONT> or
    combination of deposited securities or withdrawal of deposited
    securities until such payment is made. If any tax or
    governmental charge is required to be withheld on any cash
    distribution, the depositary may deduct the amount required to
    be withheld from any cash distribution or, in the case of a
    non-cash distribution, sell the distributed property or
    securities (by public or private sale) to pay such taxes and
    distribute any remaining net proceeds to the ADR holders
    entitled thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    By holding an ADR or an interest therein, you will be agreeing
    to indemnify us, the depositary, its custodian and any of our or
    their respective directors, employees, agents and affiliates
    against, and hold each of them harmless from, any claims by any
    governmental authority with respect to taxes, additions to tax,
    penalties or interest arising out of any refund of taxes,
    reduced rate of withholding at source or other tax benefit
    obtained.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Reclassifications,
    Recapitalizations and Mergers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we take certain actions that affect the deposited securities,
    including (i)&#160;any change in par value,
    <FONT style="white-space: nowrap">split-up,</FONT>
    consolidation, cancellation or other reclassification of
    deposited securities or (ii)&#160;any distributions not made to
    holders of ADRs or (iii)&#160;any recapitalization,
    reorganization, merger, consolidation, liquidation,
    receivership, bankruptcy or sale of all or substantially all of
    our assets, then the depositary may choose to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (1)&#160;amend the form of ADR;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    152
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (2)&#160;distribute additional or amended ADRs;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (3)&#160;distribute cash, securities or other property it has
    received in connection with such actions;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (4)&#160;sell any securities or property received and distribute
    the proceeds as cash;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (5)&#160;none of the above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the depositary does not choose any of the above options, any
    of the cash, securities or other property it receives will
    constitute part of the deposited securities and each ADS will
    then represent a proportionate interest in such property.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Amendment
    and Termination</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">How
    may the deposit agreement be amended?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may agree with the depositary to amend the deposit agreement
    and the ADSs without your consent for any reason. ADR holders
    must be given at least 30&#160;days notice of any amendment that
    imposes or increases any fees or charges (other than stock
    transfer or other taxes and other governmental charges, transfer
    or registration fees, cable, telex or facsimile transmission
    costs, delivery costs or other such expenses), or otherwise
    prejudices any substantial existing right of ADR holders. Such
    notice need not describe in detail the specific amendments
    effectuated thereby, but must give ADR holders a means to access
    the text of such amendment. If an ADR holder continues to hold
    an ADR or ADRs after being so notified, such ADR holder is
    deemed to agree to such amendment and to be bound by the deposit
    agreement as so amended. Notwithstanding the foregoing, if any
    governmental body or regulatory body should adopt new laws,
    rules or regulations which would require amendment or supplement
    of the deposit agreement or the form of ADR to ensure compliance
    therewith, we and the depositary may amend or supplement the
    deposit agreement and the ADR at any time in accordance with
    such changed laws, rules or regulations, which amendment or
    supplement may take effect before a notice is given or within
    any other period of time as required for compliance. No
    amendment, however, will impair your right to surrender your
    ADSs and receive the underlying securities, except in order to
    comply with mandatory provisions of applicable law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">How
    may the deposit agreement be terminated?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary may, and shall at our written direction,
    terminate the deposit agreement and the ADRs by mailing notice
    of such termination to the registered holders of ADRs at least
    30&#160;days prior to the date fixed in such notice for such
    termination; provided, however, if the depositary shall have
    (i)&#160;resigned as depositary under the deposit agreement,
    notice of such termination by the depositary shall not be
    provided to registered holders unless a successor depositary
    shall not be operating under the deposit agreement within
    45&#160;days of the date of such resignation, and (ii)&#160;been
    removed as depositary under the deposit agreement, notice of
    such termination by the depositary shall not be provided to
    registered holders of ADRs unless a successor depositary shall
    not be operating under the deposit agreement on the
    90th&#160;day after our notice of removal was first provided to
    the depositary. After termination, the depositary&#146;s only
    responsibility will be (i)&#160;to deliver deposited securities
    to ADR holders who surrender their ADRs, and (ii)&#160;to hold
    or sell distributions received on deposited securities. As soon
    as practicable after the expiration of six months from the
    termination date, the depositary will sell the deposited
    securities which remain and hold the net proceeds of such sales
    (as long as it may lawfully do so), without liability for
    interest, in trust for the ADR holders who have not yet
    surrendered their ADRs. After making such sale, the depositary
    shall have no obligations except to account for such proceeds
    and other cash.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    153
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Limitations
    on Obligations and Liability to ADR Holders</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Limits
    on our obligations and the obligations of the depositary; limits
    on liability to ADR holders and holders of ADSs</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to the issue, registration, registration of transfer,
    <FONT style="white-space: nowrap">split-up,</FONT>
    combination, or cancellation of any ADRs, or the delivery of any
    distribution in respect thereof, and from time to time, we or
    the depositary or its custodian may require:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    payment with respect thereto of (i)&#160;any stock transfer or
    other tax or other governmental charge, (ii)&#160;any stock
    transfer or registration fees in effect for the registration of
    transfers of shares or other deposited securities upon any
    applicable register and (iii)&#160;any applicable fees and
    expenses described in the deposit agreement;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the production of proof satisfactory to it of (i)&#160;the
    identity of any signatory and genuineness of any signature and
    (ii)&#160;such other information, including without limitation,
    information as to citizenship, residence, exchange control
    approval, beneficial ownership of any securities, compliance
    with applicable law, regulations, provisions of or governing
    deposited securities and terms of the deposit agreement and the
    ADRs, as it may deem necessary or proper;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    compliance with such regulations as the depositary may establish
    consistent with the deposit agreement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The issuance of ADRs, the acceptance of deposits of shares, the
    registration, registration of transfer,
    <FONT style="white-space: nowrap">split-up</FONT> or
    combination of ADRs or the withdrawal of shares, may be
    suspended, generally or in particular instances, when the ADR
    register or any register for deposited securities is closed or
    when any such action is deemed advisable by the depositary;
    provided that the ability to withdrawal shares may only be
    limited under the following circumstances: (i)&#160;temporary
    delays caused by closing transfer books of the depositary or our
    transfer books or the deposit of shares in connection with
    voting at a shareholders&#146; meeting, or the payment of
    dividends, (ii)&#160;the payment of fees, taxes, and similar
    charges, and (iii)&#160;compliance with any laws or governmental
    regulations relating to ADRs or to the withdrawal of deposited
    securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The deposit agreement expressly limits the obligations and
    liability of the depositary, ourselves and our respective
    agents. Neither we nor the depositary nor any such agent will be
    liable if:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any present or future law, rule, regulation, fiat, order or
    decree of the United States, the Cayman Islands, The
    People&#146;s Republic of China (including the Hong Kong Special
    Administrative Region, the People&#146;s Republic of China) or
    any other country, or of any governmental or regulatory
    authority or securities exchange or market or automated
    quotation system, the provisions of or governing any deposited
    securities, any present or future provision of our charter, any
    act of God, war, terrorism or other circumstance beyond our, the
    depositary&#146;s or our respective agents&#146; control shall
    prevent, delay or subject to any civil or criminal penalty any
    act which the deposit agreement or the ADRs provide shall be
    done or performed by us, the depositary or our respective agents
    (including, without limitation, voting);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    it exercises or fails to exercise discretion under the deposit
    agreement or the ADR;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    it performs its obligations under the deposit agreement and ADRs
    without gross negligence or bad faith;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    it takes any action or refrains from taking any action in
    reliance upon the advice of or information from legal counsel,
    accountants, any person presenting shares for deposit, any
    registered holder of ADRs, or any other person believed by it to
    be competent to give such advice or information;&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    it relies upon any written notice, request, direction or other
    document believed by it to be genuine and to have been signed or
    presented by the proper party or parties.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Neither the depositary nor its agents have any obligation to
    appear in, prosecute or defend any action, suit or other
    proceeding in respect of any deposited securities or the ADRs.
    We and our agents shall only be obligated to appear in,
    prosecute or defend any action, suit or other proceeding in
    respect of any deposited securities or the ADRs, which in our
    opinion may involve us in expense or liability, if indemnity
    satisfactory to us against all expense (including fees and
    disbursements of counsel) and liability is furnished as often as
    may be required. The depositary and its agents may fully respond
    to any and all demands or requests for information maintained by
    or on its behalf in
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    154
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    connection with the deposit agreement, any registered holder or
    holders of ADRs, any ADRs or otherwise related to the deposit
    agreement or ADRs to the extent such information is requested or
    required by or pursuant to any lawful authority, including
    without limitation laws, rules, regulations, administrative or
    judicial process, banking, securities or other regulators. The
    depositary shall not be liable for the acts or omissions made by
    any securities depository, clearing agency or settlement system
    in connection with or arising out of book-entry settlement of
    deposited securities or otherwise. Furthermore, the depositary
    shall not be responsible for, and shall incur no liability in
    connection with or arising from, the insolvency of any custodian
    that is not a branch or affiliate of JPMorgan Chase Bank, N.A.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additionally, none of us, the depositary or the custodian shall
    be liable for the failure by any registered holder of ADRs or
    beneficial owner therein to obtain the benefits of credits on
    the basis of
    <FONT style="white-space: nowrap">non-U.S.&#160;tax</FONT>
    paid against such holder&#146;s or beneficial owner&#146;s
    income tax liability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Neither we nor the depositary shall incur any liability for any
    tax consequences that may be incurred by holders or beneficial
    owners on account of their ownership of ADRs or ADSs. Neither
    the depositary nor its agents will be responsible for any
    failure to carry out any instructions to vote any of the
    deposited securities, for the manner in which any such vote is
    cast or for the effect of any such vote. Neither the depositary
    nor any of its agents shall be liable to registered holders of
    ADRs or beneficial owners of interests in ADSs for any indirect,
    special, punitive or consequential damages (including, without
    limitation, lost profits) of any form incurred by any person or
    entity, whether or not foreseeable and regardless of the type of
    action in which such a claim may be brought.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary may own and deal in any class of our securities
    and in ADSs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Disclosure
    of Interest in ADSs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To the extent that the provisions of or governing any deposited
    securities may require disclosure of or impose limits on
    beneficial or other ownership of deposited securities, other
    shares and other securities and may provide for blocking
    transfer, voting or other rights to enforce such disclosure or
    limits, you agree to comply with all such disclosure
    requirements and ownership limitations and to comply with any
    reasonable instructions we may provide in respect thereof. We
    reserve the right to instruct you to deliver your ADSs for
    cancellation and withdrawal of the deposited securities so as to
    permit us to deal with you directly as a holder of shares and,
    by holding an ADS or an interest therein, you will be agreeing
    to comply with such instructions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Books of
    Depositary</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary or its agent will maintain a register for the
    registration, registration of transfer, combination and
    <FONT style="white-space: nowrap">split-up</FONT> of
    ADRs, which register shall include the depositary&#146;s direct
    registration system. Registered holders of ADRs may inspect such
    records at the depositary&#146;s office at all reasonable times,
    but solely for the purpose of communicating with other holders
    in the interest of the business of our company or a matter
    relating to the deposit agreement. Such register may be closed
    from time to time, when deemed expedient by the depositary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary will maintain facilities for the delivery and
    receipt of ADRs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pre-release
    of ADSs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In its capacity as depositary, the depositary shall not lend
    shares or ADSs; provided, however, that the depositary may
    (i)&#160;issue ADSs prior to the receipt of shares and
    (ii)&#160;deliver shares prior to the receipt of ADSs for
    withdrawal of deposited securities, including ADSs which were
    issued under (i)&#160;above but for which shares may not have
    been received (each such transaction a &#147;pre-release&#148;).
    The depositary may receive ADSs in lieu of shares under
    (i)&#160;above (which ADSs will promptly be canceled by the
    depositary upon receipt by the depositary) and receive shares in
    lieu of ADSs under (ii)&#160;above. Each such pre-release will
    be subject to a written agreement whereby the person or entity
    (the &#147;applicant&#148;) to whom ADSs or shares are to be
    delivered (a)&#160;represents that at the time of the
    pre-release the applicant or its customer owns the shares or
    ADSs that are to be delivered by the applicant under such
    pre-release, (b)&#160;agrees to indicate the depositary as owner
    of such shares or ADSs in its records and to hold such shares or
    ADSs in trust for the depositary until such shares or ADSs are
    delivered to the depositary or the custodian,
    (c)&#160;unconditionally guarantees to deliver to the depositary
    or the custodian, as applicable, such shares or ADSs, and
    (d)&#160;agrees to any additional restrictions or requirements
    that the depositary deems appropriate. Each such pre-release
    will be at all times fully collateralized with cash,
    U.S.&#160;government securities or such other collateral as the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    155
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    depositary deems appropriate, terminable by the depositary on
    not more than five (5)&#160;business days&#146; notice and
    subject to such further indemnities and credit regulations as
    the depositary deems appropriate. The depositary will normally
    limit the number of ADSs and shares involved in such pre-release
    at any one time to thirty percent (30%) of the ADSs outstanding
    (without giving effect to ADSs outstanding under
    (i)&#160;above), provided, however, that the depositary reserves
    the right to change or disregard such limit from time to time as
    it deems appropriate. The depositary may also set limits with
    respect to the number of ADSs and shares involved in pre-release
    with any one person on a
    <FONT style="white-space: nowrap">case-by-case</FONT>
    basis as it deems appropriate. The depositary may retain for its
    own account any compensation received by it in conjunction with
    the foregoing. Collateral provided pursuant to (b)&#160;above,
    but not the earnings thereon, shall be held for the benefit of
    the registered holders of ADRs (other than the applicant).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Appointment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the deposit agreement, each registered holder of ADRs and
    each person holding an interest in ADSs, upon acceptance of any
    ADSs (or any interest therein) issued in accordance with the
    terms and conditions of the deposit agreement will be deemed for
    all purposes to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    be a party to and bound by the terms of the deposit agreement
    and the applicable ADR or ADRs,&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    appoint the depositary its attorney-in-fact, with full power to
    delegate, to act on its behalf and to take any and all actions
    contemplated in the deposit agreement and the applicable ADR or
    ADRs, to adopt any and all procedures necessary to comply with
    applicable laws and to take such action as the depositary in its
    sole discretion may deem necessary or appropriate to carry out
    the purposes of the deposit agreement and the applicable ADR and
    ADRs, the taking of such actions to be the conclusive
    determinant of the necessity and appropriateness thereof.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Governing
    Law</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The deposit agreement and the ADRs shall be governed by and
    construed in accordance with the laws of the State of New York.
    In the deposit agreement, we have submitted to the jurisdiction
    of the courts of the State of New York and appointed an agent
    for service of process on our behalf.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    156
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='120'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SHARES
    ELIGIBLE FOR FUTURE SALE</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, assuming no exercise of the
    underwriters&#146; option to purchase additional ADSs, we will
    have 12,000,000 outstanding ADSs representing approximately
    24.4% of our ordinary shares in issue. All of the ADSs sold in
    this offering will be freely transferable by persons other than
    our &#147;affiliates&#148; without restriction or further
    registration under the Securities Act. Sales of substantial
    amounts of our ADSs in the public market could adversely affect
    prevailing market prices of our ADSs. Prior to this offering,
    there has been no public market for our ordinary shares or the
    ADSs, and although we have received approval to list the ADSs on
    the NYSE, we cannot assure you that a regular trading market
    will develop in the ADSs. We do not expect that a trading market
    will develop for our ordinary shares not represented by the ADSs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times"><FONT style="white-space: nowrap">Lock-up</FONT>
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our directors, executive officers and all existing shareholders
    have signed
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements under which they have agreed, subject to certain
    exceptions, not to transfer or dispose of, directly or
    indirectly, any of our ordinary shares, in the form of ADSs or
    otherwise, or any securities convertible into or exchangeable or
    exercisable for our ordinary shares, in the form of ADSs or
    otherwise, for a period of 180&#160;days after the date of this
    prospectus. The
    <FONT style="white-space: nowrap">180-day</FONT>
    <FONT style="white-space: nowrap">lock-up</FONT>
    period may be extended under certain circumstances described in
    &#147;Underwriting.&#148; After the expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    period, the ordinary shares or ADSs held by our directors,
    executive officers or existing shareholders may be sold subject
    to the restrictions under Rule&#160;144 under the Securities
    Act, or Rule&#160;144, or by means of registered public
    offerings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Rule&#160;144</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;144 as currently in effect, a person
    who has beneficially owned our restricted securities for at
    least six months is entitled to sell the restricted securities
    without registration under the Securities Act, subject to
    certain restrictions. Persons who are our affiliates (including
    persons beneficially owning 10.0% or more of our outstanding
    shares) may sell within any three-month period a number of
    restricted securities that does not exceed the greater of the
    following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    1.0% of the number of our ordinary shares then outstanding, in
    the form of ADSs or otherwise, which will equal approximately
    1,474,555&#160;ordinary shares immediately after this
    offering;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the average weekly trading volume of our ADSs on the NYSE during
    the four calendar weeks preceding the date on which notice of
    the sale is filed with the SEC.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Such sales are also subject to manner-of-sale provisions, notice
    requirements and the availability of current public information
    about us. The manner-of-sale provisions require the securities
    to be sold either in &#147;brokers&#146; transactions&#148; as
    such term is defined under the Securities Act, through
    transactions directly with a market maker as such term is
    defined under the Exchange Act or through a riskless principal
    transactions as described in Rule&#160;144. In addition, the
    manner-of-sale provisions require the person selling the
    securities not to solicit or arrange for the solicitation of
    orders to buy the securities in anticipation of or in connection
    with such transaction or make any payment in connection with the
    offer or sale of the securities to any person other than the
    broker or dealer who executes the order to sell the securities.
    If the amount of securities to be sold in reliance upon
    Rule&#160;144 during any period of three months exceeds
    5,000&#160;shares or other units or has an aggregate sale price
    in excess of US$50,000, three copies of a notice on
    Form&#160;144 should be filed with the SEC. If such securities
    are admitted to trading on any national securities exchange, one
    copy of such notice also shall be transmitted to the principal
    exchange on which such securities are admitted. The
    Form&#160;144 should be signed by the person for whose account
    the securities are to be sold and should be transmitted for
    filing concurrently with either the placing with a broker of an
    order to execute a sale of securities or the execution directly
    with a market maker of such a sale.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Persons who are not our affiliates and have beneficially owned
    our restricted securities for more than six months but not more
    than one year may sell the restricted securities without
    registration under the Securities Act subject to the
    availability of current public information about us. Persons who
    are not our affiliates and have beneficially owned our
    restricted securities for more than one year may freely sell the
    restricted securities without registration under the Securities
    Act.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    157
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Rule&#160;701</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Beginning 90&#160;days after the date of this prospectus,
    persons other than affiliates who purchased ordinary shares
    under a written compensatory plan or contract may be entitled to
    sell such shares in the United States in reliance on
    Rule&#160;701 under the Securities Act, or Rule&#160;701.
    Rule&#160;701 permits affiliates to sell their shares satisfying
    the requirements of Rule&#160;701 under Rule&#160;144 without
    complying with the holding period requirements of Rule&#160;144.
    Rule&#160;701 further provides that non-affiliates may sell
    these shares in reliance on Rule&#160;144 subject only to its
    manner-of-sale requirements. However, these shares would remain
    subject to
    <FONT style="white-space: nowrap">lock-up</FONT>
    arrangements and would only become eligible for sale when the
    <FONT style="white-space: nowrap">lock-up</FONT>
    period expires.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, certain holders of our
    ordinary shares, or their transferees will be entitled to
    request that we register their shares under the Securities Act,
    following the expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements described above. See &#147;Description of Share
    Capital&#160;&#151; Registration Rights.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    158
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='121'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">TAXATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The following are the material Cayman Islands, People&#146;s
    Republic of China and United States federal income tax
    consequences of an investment in our ADSs or ordinary shares is
    based upon laws and relevant interpretations thereof in effect
    as of the date of this prospectus, all of which are subject to
    change or different interpretations, possibly with retroactive
    effect. This summary does not deal with all possible tax
    consequences relating to an investment in our ADSs or ordinary
    shares, such as the tax consequences under U.S.&#160;state,
    local and other tax laws, or tax laws of jurisdictions other
    than the Cayman Islands, the People&#146;s Republic of China and
    the United States. To the extent the discussion relates to
    matters of Cayman Islands tax law, it constitutes the opinion of
    Walkers, our Cayman Islands counsel.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cayman
    Islands Taxation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Cayman Islands currently levy no taxes on individuals or
    corporations based upon profits, income, gains or appreciation,
    and there is no taxation in the nature of inheritance tax or
    estate duty. No Cayman Islands stamp duty will be payable unless
    an instrument is executed in, brought to, or produced before a
    court of the Cayman Islands. The Cayman Islands are not parties
    to any double tax treaties. There are no exchange control
    regulations or currency restrictions in the Cayman Islands.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">People&#146;s
    Republic of China Taxation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The PRC Enterprise Income Tax Law, or the EIT Law, and the
    implementation regulations for the EIT Law issued by the PRC
    State Council, became effective as of January&#160;1, 2008. The
    new EIT law and its implementation regulation impose a single
    uniform income tax rate of 25% on all Chinese enterprises,
    including foreign-invested enterprises, and levies a withholding
    tax rate of 10% on dividends payable by Chinese subsidiaries to
    their non-PRC enterprise shareholders except with respect to any
    such non-PRC enterprise shareholder whose jurisdiction of
    incorporation has a tax treaty with China that provides for a
    different withholding agreement. The EIT Law provides that
    enterprises established outside of China whose &#147;de facto
    management bodies&#148; are located in China are considered
    &#147;resident enterprises&#148; and are generally subject to
    the uniform 25% enterprise income tax rate on their worldwide
    income. Under the implementation regulations for the EIT Law
    issued by the PRC State Council, a &#147;de facto management
    body&#148; is defined as a body that has material and overall
    management and control over the manufacturing and business
    operations, personnel and human resources, finances and treasury
    and assets of an enterprise. On April&#160;22, 2009, the State
    Administration of Taxation promulgated a circular which sets out
    criteria for determining whether &#147;de facto management
    bodies&#148; are located in China for overseas incorporated,
    domestically controlled enterprises. However, as this circular
    only applies to enterprises incorporated under the laws of
    foreign countries or regions that are controlled by PRC
    enterprises or groups of PRC enterprises, it remains unclear how
    the tax authorities will determine the location of &#147;de
    facto management bodies&#148; for overseas incorporated
    enterprises that are controlled by individual PRC residents like
    us and some of our subsidiaries. Therefore, although
    substantially all of our operational management is currently
    based in the PRC, it is unclear whether PRC tax authorities
    would require (or permit) us to be treated as a PRC resident
    enterprise. We do not currently consider our company to be a PRC
    resident enterprise. However, if the Chinese tax authorities
    disagree with our assessment and determine that we are a PRC
    resident enterprise, we may be subject to a 25% enterprise
    income tax on our global income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the EIT Law and implementation regulations issued by the
    State Council, a 10% PRC income tax is applicable to dividends
    payable to investors that are &#147;non-resident
    enterprises,&#148; which do not have an establishment or place
    of business in the PRC, or which have such establishment or
    place of business but the relevant income is not effectively
    connected with the establishment or place of business, to the
    extent such dividends have their sources within the PRC.
    Furthermore, a circular issued by the Ministry of Finance and
    the State Administration of Taxation on February&#160;22, 2008
    stipulates that undistributed earnings generated prior to
    January&#160;1, 2008 are exempt from enterprise income tax. We
    are a holding company incorporated in the Cayman Islands, which
    indirectly holds, through Ascendium, Cyber Medical and OMS, our
    equity interests in our PRC subsidiaries. Our business
    operations are principally conducted through PRC subsidiaries.
    Thus, dividends for earnings accumulated beginning on
    January&#160;1, 2008 payable to us by our subsidiaries in China,
    if any, will be subject to the 10% income tax if we are
    considered as &#147;non-resident enterprises&#148; under the EIT
    Law. Under the EIT law, the Notice 112, which was issued on
    January&#160;29, 2008 and the Double Taxation Arrangement (Hong
    Kong), which became effective on December&#160;8, 2006,
    dividends from our PRC subsidiaries paid to us through our Hong
    Kong subsidiary may be subject to a 10%
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    159
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    withholding tax or a 5% withholding tax if our Hong Kong
    subsidiary can be considered as a &#147;beneficial owner&#148;
    and entitled to treaty benefits under the Double Taxation
    Arrangement (Hong Kong). Under the existing implementation rules
    of the EIT Law, it is unclear what will constitute income
    derived from sources within the PRC. Accordingly dividends paid
    by us to our non-PRC resident enterprise ADS holders and
    ordinary shareholders may be deemed to be derived from sources
    within the PRC and, therefore, be subject to the 10% PRC income
    tax.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Similarly, any gain realized on the transfer of our ADSs or
    ordinary shares by our non-PRC resident enterprise ADS holders
    and ordinary shareholders may also be subject to the 10% PRC
    income tax if such gain is regarded as income derived from
    sources within the PRC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">United
    States Federal Income Taxation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following discussion describes the material United States
    federal income tax consequences of the ownership of our ordinary
    shares and ADSs as of the date hereof. The discussion is
    applicable to United States Holders (as defined below) who hold
    our ordinary shares or ADSs as capital assets. As used herein,
    the term &#147;United States Holder&#148; means a holder of an
    ordinary share or ADS that is for United States federal income
    tax purposes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an individual citizen or resident of the United States;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a corporation (or other entity treated as a corporation for
    United States federal income tax purposes) created or organized
    in or under the laws of the United States, any state thereof or
    the District of Columbia;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an estate the income of which is subject to United States
    federal income taxation regardless of its source;&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a trust if it (1)&#160;is subject to the primary supervision of
    a court within the United States and one or more United States
    persons have the authority to control all substantial decisions
    of the trust or (2)&#160;has a valid election in effect under
    applicable United States Treasury regulations to be treated as a
    United States person.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This discussion does not represent a detailed description of the
    United States federal income tax consequences applicable to you
    if you are subject to special treatment under the United States
    federal income tax laws, including if you are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a dealer in securities or currencies;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a financial institution;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a regulated investment company;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a real estate investment trust;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an insurance company;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a tax exempt organization;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a person holding our ordinary shares or ADSs as part of a
    hedging, integrated or conversion transaction, a constructive
    sale or a straddle;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a trader in securities that has elected the mark-to-market
    method of accounting for your securities;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a person liable for alternative minimum tax;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a person who owns or is deemed to own more than 10% of our
    voting stock;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a partnership or other pass-through entity for United States
    federal income tax purposes;&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a person whose &#147;functional currency&#148; is not the United
    States dollar.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The discussion below is based upon the provisions of the
    Internal Revenue Code of 1986, as amended (the
    &#147;Code&#148;), and regulations, rulings and judicial
    decisions thereunder as of the date hereof, and such authorities
    may be replaced, revoked or modified so as to result in United
    States federal income tax consequences different from those
    discussed below. In addition, this discussion is based, in part,
    upon representations made by the depositary to us and assumes
    that the deposit agreement, and all other related agreements,
    will be performed in accordance with their terms.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    160
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If a partnership holds ordinary shares or ADSs, the tax
    treatment of a partner will generally depend upon the status of
    the partner and the activities of the partnership. If you are a
    partner of a partnership holding our ordinary shares or ADSs,
    you should consult your tax advisors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This discussion does not contain a detailed description of all
    the United States federal income tax consequences to you in
    light of your particular circumstances and does not address the
    effects of any state, local or
    <FONT style="white-space: nowrap">non-United</FONT>
    States tax laws. <B>If you are considering the purchase,
    ownership or disposition of our ordinary shares or ADSs, you
    should consult your own tax advisors concerning the United
    States federal income tax consequences to you in light of your
    particular situation as well as any consequences arising under
    the laws of any other taxing jurisdiction.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The United States Treasury has expressed concerns that
    intermediaries in the chain of ownership between the holder of
    an ADS and the issuer of the security underlying the ADS may be
    taking actions that are inconsistent with the claiming of
    foreign tax credits for United States holders of ADSs. Such
    actions would also be inconsistent with the claiming of the
    reduced rate of tax described below, applicable to dividends
    received by certain non-corporate holders. Accordingly, the
    analysis of the creditability of PRC taxes, if any, and the
    availability of the reduced tax rate for dividends received by
    certain non-corporate holders, each described below, could be
    affected by actions taken by intermediaries in the chain of
    ownership between the holder of an ADS and our company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">ADSs</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you hold ADSs, for United States federal income tax purposes,
    you generally will be treated as the owner of the underlying
    ordinary shares that are represented by such ADSs. Accordingly,
    deposits or withdrawals of ordinary shares for ADSs will not be
    subject to United States federal income tax.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Taxation
    of Dividends</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the discussion under &#147;&#151; Passive Foreign
    Investment Company&#148; below, the gross amount of
    distributions on the ADSs or ordinary shares (including amounts
    withheld to reflect PRC withholding taxes) will be taxable as
    dividends, to the extent paid out of our current or accumulated
    earnings and profits as determined under United States federal
    income tax principles. Such income will be includable in your
    gross income as ordinary income on the day actually or
    constructively received by you, in the case of the ordinary
    shares, or by the depositary, in the case of ADSs. Such
    dividends will not be eligible for the dividends-received
    deduction allowed to corporations under the Code. To the extent
    that the amount of the distribution exceeds our current and
    accumulated earnings and profits for a taxable year, as
    determined under United States federal income tax principles, it
    will be treated first as a tax-free return of your tax basis in
    your ADSs or ordinary shares, and to the extent the amount of
    the distribution exceeds your tax basis, the excess will be
    taxed as capital gain. We do not expect to keep earnings and
    profits in accordance with United States federal income tax
    principles. Therefore, you should expect that a distribution
    will be treated as a dividend (as discussed above).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    With respect to non-corporate United States Holders, certain
    dividends received in taxable years beginning before
    January&#160;1, 2011 from a qualified foreign corporation may be
    subject to reduced rates of taxation. A foreign corporation is
    treated as a qualified foreign corporation with respect to
    dividends received from that corporation on shares (or ADSs
    backed by such shares) that are readily tradable on an
    established securities market in the United States. Based on
    United States Treasury Department guidance, we expect that our
    ADSs (which we have received approval to list on the NYSE), but
    not our ordinary shares, will be readily tradable on an
    established securities market in the United States. Thus, we
    believe that dividends we pay on our Shares that are represented
    by ADSs, but not on our ordinary shares that are not so
    represented, will meet such conditions required for the reduced
    tax rates. There can be no assurance that our ADSs will be
    considered readily tradable on an established securities market
    in later years. A qualified foreign corporation also includes a
    foreign corporation that is eligible for the benefits of certain
    income tax treaties with the United States. In the event that we
    are deemed to be a PRC &#147;resident enterprise&#148; under PRC
    tax law (see discussion under &#147;Taxation&#160;&#151;
    People&#146;s Republic of China Taxation&#148;), we may be
    eligible for the benefits of the income tax treaty between the
    United States and the PRC and, if we are eligible for such
    benefits, dividends we pay on our ordinary shares, regardless of
    whether such ordinary shares are represented by ADSs, would be
    subject to the reduced rates of taxation. Non-corporate United
    States Holders that do not meet a minimum holding period
    requirement during which they are not protected from the risk of
    loss or that elect to treat
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    161
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    the dividend income as &#147;investment income&#148; pursuant to
    Section&#160;163(d)(4) of the Code will not be eligible for the
    reduced rates of taxation regardless of our status as a
    qualified foreign corporation. In addition, the rate reduction
    will not apply to dividends if the recipient of a dividend is
    obligated to make related payments with respect to positions in
    substantially similar or related property. This disallowance
    applies even if the minimum holding period has been met.
    Moreover, non-corporate United States Holders will not be
    eligible for reduced rates of taxation on any dividends received
    from us in taxable years beginning prior to January&#160;1, 2011
    if we are a PFIC in the taxable year in which such dividends are
    paid or in the preceding taxable year. You should consult your
    own tax advisors regarding the application of these rules given
    your particular circumstances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event that we are deemed to be a PRC &#147;resident
    enterprise&#148; under PRC tax law, you may be subject to PRC
    withholding taxes on dividends paid to you with respect to the
    ADSs or ordinary shares (see discussion under
    &#147;Taxation&#160;&#151; People&#146;s Republic of China
    Taxation&#148;). However, you may be able to obtain a reduced
    rate of PRC withholding taxes under the treaty between the
    United States and the PRC if certain requirements are met. In
    addition, subject to certain conditions and limitations, PRC
    withholding taxes on dividends may be treated as foreign taxes
    eligible for credit against your United States federal income
    tax liability. For purposes of calculating the foreign tax
    credit, dividends paid on the ADSs or ordinary shares will be
    treated as foreign-source income and will generally constitute
    passive category income. Furthermore, in certain circumstances,
    if you have held the ADSs or ordinary shares for less than a
    specified minimum period during which you are not protected from
    risk of loss, or are obligated to make payments related to the
    dividends, you will not be allowed a foreign tax credit for any
    PRC withholding taxes imposed on dividends paid on the ADSs or
    ordinary shares. The rules governing the foreign tax credit are
    complex. You are urged to consult your tax advisors regarding
    the availability of the foreign tax credit under your particular
    circumstances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Passive
    Foreign Investment Company</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Based on the projected composition of our income and valuation
    of our assets, including goodwill, we do not expect to be a
    passive foreign investment company, or a PFIC, for United States
    federal income tax purposes for our current taxable year ending
    December&#160;31, 2009, and we do not expect to become one in
    the future, although there can be no assurance in this regard.
    If we are a PFIC for any taxable year during which you hold our
    ADSs or ordinary shares, you will be subject to special tax
    rules discussed below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, we will be a PFIC for any taxable year in which:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at least 75% of our gross income is passive income;&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at least 50% of the value of our assets (based on an average of
    the quarterly values) is attributable to assets that produce or
    are held for the production of passive income.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For this purpose, passive income generally includes dividends,
    interest, royalties and rents (other than royalties and rents
    derived in the active conduct of a trade or business and not
    derived from a related person). If we own at least 25% (by
    value) of the stock of another corporation, we will be treated
    for purposes of the PFIC tests, as owning our proportionate
    share of the other corporation&#146;s assets and receiving our
    proportionate share of the other corporation&#146;s income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The determination of whether we are a PFIC is made annually.
    Accordingly, it is possible that we may become a PFIC in the
    current or any future taxable year due to changes in our asset
    or income composition. Because we have valued our goodwill based
    on the market value of our equity, a decrease in the price of
    our ADSs or ordinary shares may result in our becoming a PFIC.
    In addition, the composition of our income and assets will be
    affected by how, and how quickly, we spend the cash we raise in
    this offering. If we are a PFIC for any taxable year during
    which you hold our ADSs or ordinary shares, you will be subject
    to special tax rules discussed below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we are a PFIC for any taxable year during which you hold our
    ADSs or ordinary shares, you will be subject to special tax
    rules with respect to any &#147;excess distribution&#148;
    received and any gain realized from a sale or other disposition,
    including a pledge, of ADSs or ordinary shares. Distributions
    received in a taxable year that are greater than 125% of the
    average annual distributions received during the shorter of the
    three preceding taxable years or
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    162
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    your holding period for the ADSs or ordinary shares will be
    treated as excess distributions. Under these special tax rules:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the excess distribution or gain will be allocated ratably over
    your holding period for the ADSs or ordinary shares;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the amount allocated to the current taxable year, and any
    taxable year prior to the first taxable year in which we were a
    PFIC, will be treated as ordinary income;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the amount allocated to each other year will be subject to tax
    at the highest tax rate in effect for that year and the interest
    charge generally applicable to underpayments of tax will be
    imposed on the resulting tax attributable to each such year.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, non-corporate United States Holders will not be
    eligible for reduced rates of taxation on any dividends received
    from us in taxable years beginning prior to January&#160;1, 2011
    if we are a PFIC in the taxable year in which such dividends are
    paid or in the preceding taxable year. You will be required to
    file Internal Revenue Service Form&#160;8621 if you hold our
    ADSs or ordinary shares in any year in which we are classified
    as a PFIC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we are a PFIC for any taxable year during which you hold our
    ADSs or ordinary shares and any of our
    <FONT style="white-space: nowrap">non-United</FONT>
    States subsidiaries is also a PFIC, a United States Holder would
    be treated as owning a proportionate amount (by value) of the
    shares of the lower-tier&#160;PFIC for purposes of the
    application of these rules. You are urged to consult your tax
    advisors about the application of the PFIC rules to any of our
    subsidiaries.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In certain circumstances, in lieu of being subject to the excess
    distribution rules discussed above, you may make an election to
    include gain on the stock of a PFIC as ordinary income under a
    mark-to-market method, provided that such stock is regularly
    traded on a qualified exchange. Under current law, the
    mark-to-market election may be available to holders of ADSs
    because we have received approval to list the ADSs on the NYSE,
    which constitutes a qualified exchange, although there can be no
    assurance that the ADSs will be &#147;regularly traded&#148; for
    purposes of the mark-to-market election. It should be noted that
    we have received approval to list only the ADSs, and not the
    ordinary shares, on the NYSE. Consequently, if you are a holder
    of ordinary shares that are not represented by ADSs, you
    generally will not be eligible to make a mark-to-market
    election. If you make an effective mark-to-market election, you
    will include in each year as ordinary income the excess of the
    fair market value of your ADSs at the end of the year over your
    adjusted tax basis in the ADSs. You will be entitled to deduct
    as an ordinary loss each year the excess of your adjusted tax
    basis in the ADSs over their fair market value at the end of the
    year, but only to the extent of the net amount previously
    included in income as a result of the mark-to-market election.
    If you make an effective mark-to-market election, any gain you
    recognize upon the sale or other disposition of ADSs will be
    treated as ordinary income and any loss will be treated as
    ordinary loss, but only to the extent of the net amount
    previously included in income as a result of the mark-to-market
    election.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Your adjusted tax basis in the ADSs will be increased by the
    amount of any income inclusion and decreased by the amount of
    any deductions under the mark-to-market rules. If you make a
    mark-to-market election it will be effective for the taxable
    year for which the election is made and all subsequent taxable
    years unless the ADSs are no longer regularly traded on a
    qualified exchange or the Internal Revenue Service consents to
    the revocation of the election. You are urged to consult your
    tax advisors about the availability of the mark-to-market
    election and whether making the election would be advisable in
    your particular circumstances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Alternatively, you can sometimes avoid the rules described above
    by electing to treat us as a &#147;qualified electing fund&#148;
    under Section&#160;1295 of the Code. However, this option is not
    available to you because we do not intend to comply with the
    requirements necessary to permit you to make this election. You
    are urged to consult your tax advisors concerning the United
    States federal income tax consequences of holding ADSs or
    ordinary shares if we are considered a PFIC in any taxable year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Taxation
    of Capital Gains</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For United States federal income tax purposes and subject to the
    discussion under &#147;&#160;&#151; Passive Foreign Investment
    Company&#148; above, you will recognize taxable gain or loss on
    any sale or exchange of ADSs or ordinary shares in an amount
    equal to the difference between the amount realized for the ADSs
    or ordinary shares and your tax basis in the ADSs or ordinary
    shares. Such gain or loss will generally be capital gain or
    loss. Capital gains of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    163
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    non-corporate United States Holders derived with respect to
    capital assets held for more than one year are eligible for
    reduced rates of taxation. The deductibility of capital losses
    is subject to limitations. Any gain or loss recognized by you
    will generally be treated as United States source gain or loss.
    However, in the event that we are deemed to be a PRC
    &#147;resident enterprise&#148; under PRC tax law, we may be
    eligible for the benefits of the income tax treaty between the
    United States and the PRC. Under that treaty, if any PRC tax was
    to be imposed on any gain from the disposition of the ADSs or
    ordinary shares, the gain may be treated as PRC-source income.
    You are urged to consult your tax advisors regarding the tax
    consequences if a foreign tax is imposed on gain on a
    disposition of our ADSs or ordinary shares, including the
    availability of the foreign tax credit under your particular
    circumstances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Information
    Reporting and Backup Withholding</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, information reporting will apply to dividends in
    respect of our ADSs or ordinary shares and to the proceeds from
    the sale, exchange or redemption of our ADSs or ordinary shares
    that are paid to you within the United States (and in certain
    cases, outside the United States), unless you are an exempt
    recipient such as a corporation. A backup withholding tax may
    apply to such payments if you fail to provide a taxpayer
    identification number or certification of other exempt status or
    fail to report in full dividend and interest income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any amounts withheld under the backup withholding rules will be
    allowed as a refund or a credit against your United States
    federal income tax liability provided the required information
    is furnished to the Internal Revenue Service.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    164
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='122'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">UNDERWRITING</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the terms and subject to the conditions contained in an
    underwriting agreement dated the date of this prospectus, the
    underwriters named below have severally agreed to purchase, and
    we and the selling shareholders have agreed to sell to them,
    severally, the number of ADSs indicated below:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Name</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">ADSs</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Morgan Stanley&#160;&#038; Co. International plc
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    J.P. Morgan Securities Inc.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    China International Capital Corporation Hong Kong Securities
    Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 50pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters are collectively referred to as the
    &#147;underwriters.&#148; The underwriters are offering the ADSs
    subject to their acceptance of the ADSs from us and the selling
    shareholders and subject to prior sale. The underwriting
    agreement provides that the obligations of the several
    underwriters to pay for and accept delivery of the ADSs offered
    by this prospectus are subject to the approval of certain legal
    matters by their counsel and to certain other conditions,
    including the absence of any material adverse change in our
    business and the receipt of certain certificates, opinions and
    letters from us, our counsel and the independent accountants.
    The underwriters are obligated, severally and not jointly, to
    take and pay for all of the ADSs offered by this prospectus if
    any such ADSs are taken. The underwriters are not required,
    however, to take or pay for the ADSs covered by the
    underwriters&#146; over-allotment option described below. Morgan
    Stanley&#160;&#038; Co. International plc and China
    International Capital Corporation Hong Kong Securities Limited
    will offer the ADSs in the United States through their
    registered broker-dealers in the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters initially propose to offer part of the ADSs
    directly to the public at the initial public offering price
    listed on the cover page of this prospectus and part to certain
    dealers at a price that represents a concession not in excess of
    US$&#160;&#160;  per ADS under the initial public offering
    price. After the initial offering of the ADSs, the offering
    price and other selling terms may from time to time be varied by
    the underwriters.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The selling shareholders have granted to the underwriters an
    option, exercisable for 30&#160;days from the date of this
    prospectus, to purchase up to an aggregate of
    1,800,000&#160;additional ADSs at the public offering price set
    forth on the cover of this prospectus less underwriting
    discounts and commissions. The underwriters may exercise this
    option solely for the purpose of covering over-allotments, if
    any, made in connection with the offering of the ADSs offered by
    this prospectus. To the extent the option is exercised, each
    underwriter will become obligated, subject to certain
    conditions, to purchase about the same percentage of the
    additional ADSs as the number listed next to the
    underwriter&#146;s name in the preceding table bears to the
    total number of ADSs listed in the preceding table. If the
    underwriters&#146; option is exercised in full, the total price
    to the public would be US$&#160;&#160; and the total
    underwriters&#146; discounts and commissions would be
    US$&#160;&#160;. We will not receive any of the proceeds from
    the sale of the ADSs by the selling shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table below shows the per ADS and total underwriting
    discounts and commissions that we and the selling shareholders
    will pay to the underwriters. The underwriting discounts and
    commissions are determined by negotiations among us, the selling
    shareholders and the underwriters and are a percentage of the
    offering price to the public. Among the factors considered in
    determining the discounts and commissions are the size of the
    offering, the nature of the security to be offered and the
    discounts and commissions charged in comparable transactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These amounts are shown assuming both no exercise and full
    exercise of the underwriters&#146; option to purchase additional
    ADSs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="60%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="7%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="7%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Underwriting Discounts and
    Commissions</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">No Exercise</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Full Exercise</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Per ADS
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total by us
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total by the selling shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    165
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters have informed us that they do not intend sales
    to discretionary accounts to exceed five&#160;percent of the
    total number of ADSs offered by them.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The total expenses of the offering payable by us, excluding
    underwriting discounts and commissions, will be approximately
    US$3.3&#160;million. Expenses include the SEC and the Financial
    Industry Regulatory Authority, or FINRA, filing fees, the NYSE
    listing fee, and printing, legal, accounting and miscellaneous
    expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have received approval to list the ADSs on the NYSE under the
    symbol &#147;CCM.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have agreed that, without the prior written consent of the
    underwriters, we will not, during the period ending
    180&#160;days after the date of this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    offer, pledge, sell, contract to sell, sell any option or
    contract to purchase, purchase any option or contract to sell,
    grant any option, right or warrant to purchase, lend or
    otherwise transfer or dispose of, directly or indirectly, any
    ordinary shares or ADSs or any securities convertible into or
    exercisable or exchangeable for ordinary shares or ADSs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into any swap or other arrangement that transfers to
    another, in whole or in part, any of the economic consequences
    of ownership of the ordinary shares or ADSs;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    file any registration statement with the SEC relating to the
    offering of any ordinary shares, ADSs or any securities
    convertible into or exercisable or exchangeable for ordinary
    shares or ADSs (other than a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8).</FONT>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    whether any such transaction described above is to be settled by
    delivery of ordinary shares, ADSs, or such other securities, in
    cash or otherwise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The restrictions described in the immediately preceding
    paragraph do not apply to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    ADSs to be sold by us to the underwriters in the offering;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transactions by the selling shareholders relating to ordinary
    shares, ADSs or other securities acquired in open market
    transactions after the completion of the offering, provided that
    no filing under Section 16(a) of the Exchange Act shall be
    required or shall be voluntarily made in connection with
    subsequent sales of ordinary shares, ADSs or other securities
    acquired in such open market transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the issuance by us of ordinary shares issuable upon the exercise
    of an option or warrant or the conversion of any outstanding
    securities, provided that such recipients shall agree in writing
    to be subject to the restrictions described above;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the grant or issuance by us of options, shares, restricted
    shares, restricted share units, share appreciation rights,
    performance units or performance shares under our equity plans
    and the shares or other securities issued upon exercise or
    conversion of any of the foregoing, provided that such
    recipients shall agree in writing to be subject to the
    restrictions described above.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each of our directors, executive officers and existing
    shareholders has agreed that, without the prior written consent
    of the underwriters, such director, officer, or shareholder will
    not, during the period ending 180&#160;days after the date of
    this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    offer, pledge, sell, contract to sell, sell any option or
    contract to purchase, purchase any option or contract to sell,
    grant any option, right or warrant to purchase, lend or
    otherwise transfer or dispose of, directly or indirectly, any
    ordinary shares or ADSs or any securities convertible into or
    exercisable or exchangeable for ordinary shares or ADSs; or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into any swap or other arrangement that transfers to
    another, in whole or in part, any of the economic consequences
    of ownership of the ordinary shares or ADSs.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    whether any such transaction described above is to be settled by
    delivery of ordinary shares, ADSs, or such other securities, in
    cash or otherwise.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    166
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The restrictions described in the immediately preceding
    paragraph generally do not apply to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the ordinary shares as represented by the ADSs to be sold in
    this offering;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transactions relating to ordinary shares, ADSs or other
    securities acquired in open market transactions after the
    completion of the offering, provided that no filing under
    Section&#160;16(a) of the Exchange Act will be required or will
    be voluntarily made in connection with subsequent sales of
    ordinary shares, ADSs or other securities acquired in such open
    market transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the exercise of rights to acquire ordinary shares, ADSs or other
    securities of our company issued pursuant to any of our share
    option or similar equity incentive or compensation plan for the
    issuance of share options or equity grants, provided that, in
    each case, such plan is in effect as of the date of and
    disclosed in the prospectus, and that any subsequent sale,
    transfer or disposition of any securities issued upon exercise
    of such equity incentive grants should be subject to the
    restrictions described above;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers of our ordinary shares or ADSs to shareholders who are
    our existing shareholders prior to the offering or partners,
    members, stockholders or affiliates (as defined in
    <FONT style="white-space: nowrap">Rule&#160;12b-2</FONT>
    of the Exchange Act) of such existing shareholders, provided
    that each transferee should agree in writing to be subject to
    the restrictions described above, and that no filing under
    Section&#160;16(a) of the Exchange Act reporting a reduction in
    beneficial ownership of ordinary shares or ADSs will be required
    or will be voluntarily made during the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers of our ordinary shares, ADSs or any security
    convertible into our ordinary shares or ADSs (i)&#160;to an
    immediate family member or a trust formed for the benefit of an
    immediate family member, (ii)&#160;as a bona fide gift or
    (iii)&#160;through will or intestacy, provided that each
    transferee or donee should agree in writing to be subject to the
    restrictions described above, and that no filing under
    Section&#160;16(a) of the Exchange Act reporting a reduction in
    beneficial ownership of our ordinary shares or ADSs will be
    required or will be voluntarily made during the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers or distributions of our ordinary shares, ADSs or any
    security convertible into our ordinary shares or ADSs to
    partners, members, stockholders or affiliates, provided that
    each transferee or distributee should agree in writing to be
    subject to the restrictions described above, and that no filing
    under Section&#160;16(a) of the Exchange Act reporting a
    reduction in beneficial ownership of our ordinary shares or ADSs
    should be required or should be voluntarily made during the
    applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the establishment of a trading plan pursuant to
    <FONT style="white-space: nowrap">Rule&#160;10b5-1</FONT>
    under the Exchange Act for the sale of our ordinary shares or
    ADSs, provided that such plan does not provide for the transfer
    of our ordinary shares or ADSs during the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The foregoing
    <FONT style="white-space: nowrap">lock-up</FONT>
    period will be extended under certain circumstances. If
    (1)&#160;during the last 17&#160;days of the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period, we issue an earnings release or material news or a
    material event relating to us occurs; or (2)&#160;prior to the
    expiration of the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period, we announce that we will release earnings results during
    the <FONT style="white-space: nowrap">16-day</FONT>
    period beginning on the last day of the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period, the
    <FONT style="white-space: nowrap">lock-up</FONT> will
    continue to apply until the expiration of the
    <FONT style="white-space: nowrap">18-day</FONT>
    period beginning on the issuance of the earnings release or the
    occurrence of the material news or material event unless the
    extension is waived in writing by the underwriters.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To facilitate this offering of the ADSs, the underwriters may
    engage in transactions that stabilize, maintain or otherwise
    affect the price of the ADSs. Specifically, the underwriters may
    sell more ADSs than they are obligated to purchase under the
    underwriting agreement, creating a short position. A short sale
    is covered if the short position is no greater than the number
    of ADSs available for purchase by the underwriters under the
    over- allotment option. The underwriters can close out a covered
    short sale by exercising the over-allotment option or purchasing
    ADSs in the open market. In determining the source of ADSs to
    close out a covered short sale, the underwriters will consider,
    among other things, the open market price of ADSs compared to
    the price available under the over-allotment option. The
    underwriters may also sell ADSs in excess of the over-allotment
    option, creating a naked short position. The underwriters must
    close out any naked short position by purchasing ADSs in the
    open market. A naked short position is more likely to be created
    if the underwriters are concerned that there may be downward
    pressure on the price of the ADSs in the open market after
    pricing that could adversely affect investors who purchase in
    this
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    167
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    offering. In addition, to stabilize the price of the ADSs, the
    underwriters may bid for, and purchase, ADSs in the open market.
    Finally, the underwriting syndicate may reclaim selling
    concessions allowed to an underwriter or a dealer for
    distributing the ADSs in this offering, if the syndicate
    repurchases previously distributed ADSs to cover syndicate short
    positions or to stabilize the price of the ADSs. Any of these
    activities may stabilize or maintain the market price of the
    ADSs above independent market levels. The underwriters are not
    required to engage in these activities, and may end any of these
    activities at any time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    From time to time, the underwriters may have provided, and may
    continue to provide, investment banking and other financial
    advisory services to us, our officers or our directors for which
    they have received or will receive customary fees and
    commissions. The CICC Sun Company Limited, which is a major
    shareholder of our company, is an affiliate of China
    International Capital Corporation Hong Kong Securities Limited,
    one of the underwriters for this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and the selling shareholders have agreed to indemnify the
    underwriters against certain liabilities, including liabilities
    under the Securities Act and liabilities incurred in connection
    with the directed share program referred to below. If we or the
    selling shareholders are unable to provide this indemnification,
    we and the selling shareholders will contribute to payments that
    the underwriters may be required to make for these liabilities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    At our request, the underwriters have reserved for sale, at the
    initial public offering price, up to 600,000&#160;ADSs offered
    by this prospectus to our directors, officers, employees,
    business associates and related persons. We will pay all fees
    and disbursements of counsel incurred by the underwriters in
    connection with offering the ADSs to such persons. Any sales to
    these persons will be made by Morgan Stanley&#160;&#038; Co.
    International plc through a directed share program. The number
    of ADSs available for sale to the general public will be reduced
    to the extent such persons purchase such reserved ADSs. Any
    reserved ADSs not so purchased will be offered by the
    underwriters to the general public on the same basis as the
    other ADSs offered by this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The address of Morgan Stanley&#160;&#038; Co. International plc
    is 25 Cabot Square, Canary Wharf, London E14 4QA, United
    Kingdom. The address of J.P.&#160;Morgan Securities Inc. is 383
    Madison Avenue, New York, New York 10179, United States of
    America. The address of China International Capital Corporation
    Hong Kong Securities Limited is 29th&#160;Floor, One
    International Finance Center, 1 Harbour View Street, Central,
    Hong Kong, People&#146;s Republic of China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Electronic
    Offer, Sale and Distribution of ADSs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A prospectus in electronic format may be made available on the
    websites maintained by one or more of the underwriters. The
    underwriters may agree to allocate a number of ADSs to
    underwriters for sale to their online brokerage account holders.
    Internet distributions will be allocated by the underwriters
    that may make Internet distributions on the same basis as other
    allocations. In addition, ADSs may be sold by the underwriters
    to securities dealers who resell ADSs to online brokerage
    account holders. Other than the prospectus in electronic format,
    the information on any underwriter&#146;s or selling group
    member&#146;s website and any information contained in any other
    website maintained by any underwriter or selling group member is
    not part of the prospectus or the registration statement of
    which this prospectus forms a part, has not been approved
    <FONT style="white-space: nowrap">and/or</FONT>
    endorsed by us or any underwriter or selling group member in its
    capacity as underwriter or selling group member and should not
    be relied upon by investors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pricing
    of the Offering</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, there has been no public market for the
    ordinary shares or ADSs. The initial public offering price is
    determined by negotiations between us and the underwriters.
    Among the factors considered in determining the initial public
    offering price are our future prospects and those of our
    industry in general, our sales, earnings, certain other
    financial and operating information in recent periods, the
    price-earnings ratios, price-sales ratios and market prices of
    securities and certain financial and operating information of
    companies engaged in activities similar to ours.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Selling
    Restrictions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No action has been taken in any jurisdiction (except in the
    United States) that would permit a public offering of the ADSs,
    or the possession, circulation or distribution of this
    prospectus or any other material relating to us or the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    168
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    ADSs in any jurisdiction where action for that purpose is
    required. Accordingly, the ADSs may not be offered or sold,
    directly or indirectly, and neither this prospectus nor any
    other offering material or advertisements in connection with the
    ADSs may be distributed or published, in or from any country or
    jurisdiction except in compliance with any applicable rules and
    regulations of any such country or jurisdiction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>European Economic Area.</I>&#160;&#160;In relation to each
    Member State of the European Economic Area which has implemented
    the Prospectus Directive, or a Relevant Member State, from and
    including the date on which the Prospectus Directive is
    implemented in that Relevant Member State, or the Relevant
    Implementation Date, an offer of the ADSs to the public may not
    be made in that Relevant Member State prior to the publication
    of a prospectus in relation to the ADSs which has been approved
    by the competent authority in that Relevant Member State or,
    where appropriate, approved in another Relevant Member State and
    the competent authority in that Relevant Member State has been
    notified, all in accordance with the Prospectus Directive,
    except that it may, with effect from and including the Relevant
    Implementation Date, make an offer of the ADS to the public in
    that Relevant Member State at any time,
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="3%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (a)&#160;
</TD>
    <TD align="left">
    to legal entities which are authorized or regulated to operate
    in the financial markets or, if not so authorized or regulated,
    whose corporate purpose is solely to invest in securities;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (b)&#160;
</TD>
    <TD align="left">
    to any legal entity which has two or more of (1)&#160;an average
    of at least 250&#160;employees during the last financial year;
    (2)&#160;a total balance sheet of more than &#128;43,000,000 and
    (3)&#160;an annual net turnover of more than &#128;50,000,000,
    as shown in its last annual or consolidated accounts;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="3%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (c)&#160;
</TD>
    <TD align="left">
    to fewer than 100 natural or legal persons (other than qualified
    investors as defined in the Prospectus Directive;&#160;or
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (d)&#160;
</TD>
    <TD align="left">
    in any other circumstances which do not require the publication
    by the company of a prospectus pursuant to Article&#160;3 of the
    Prospectus Directive;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    provided that no such offer of ADSs shall result in a
    requirement for the publication by the company of a prospectus
    pursuant to Article&#160;3 of the Prospectus Directive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For purposes of the above provision, the expression &#147;an
    offer of ADSs to the public&#148; in relation to any ADSs in any
    Relevant Member State means the communication in any form and by
    any means of sufficient information on the terms of the offer
    and the ADSs to be offered so as to enable an investor to decide
    to purchase or subscribe the ADSs, as the same may be varied in
    that Member State by any measure implementing the Prospectus
    Directive in that Member State, and the expression
    &#147;Prospectus Directive&#148; means Directive
    <FONT style="white-space: nowrap">2003/71/EC</FONT>
    and includes any relevant implementing measure in each Relevant
    Member State.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>United Kingdom.</I>&#160;&#160;An offer of the ADSs may not
    be made to the public in the United Kingdom within the meaning
    of Section&#160;102B of the Financial Services and Markets Act
    2000, as amended, or the FSMA, except to legal entities which
    are authorized or regulated to operate in the financial markets
    or, if not so authorized or regulated, whose corporate purpose
    is solely to invest in securities or otherwise in circumstances
    which do not require the publication by the company of a
    prospectus pursuant to the Prospectus Rules of the Financial
    Services Authority, or the FSA.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An invitation or inducement to engage in investment activity
    (within the meaning of Section&#160;21 of FSMA) may only be
    communicated to persons who have professional experience in
    matters relating to investments falling within
    Article&#160;19(5) of the Financial Services and Markets Act
    2000 (Financial Promotion) Order 2005 or in circumstances in
    which Section&#160;21 of FSMA does not apply to the company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All applicable provisions of the FSMA with respect to anything
    done by the underwriters in relation to the ADSs must be
    complied with in, from or otherwise involving the United Kingdom.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Japan.</I>&#160;&#160;The underwriters will not offer or sell
    any of our ADSs directly or indirectly in Japan or to, or for
    the benefit of any Japanese person or to others, for re-offering
    or re-sale directly or indirectly in Japan or to any Japanese
    person, except, in each case, pursuant to an exemption from the
    registration requirements of, and otherwise in compliance with,
    the Securities and Exchange Law of Japan and any other
    applicable laws and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    169
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    regulations of Japan. For purposes of this paragraph,
    &#147;Japanese person&#148; means any person resident in Japan,
    including any corporation or other entity organized under the
    laws of Japan.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Hong Kong.</I>&#160;&#160;Our ADSs may not be offered or sold
    in Hong Kong, by means of any document, other than (a)&#160;to
    &#147;professional investors&#148; as defined in the Securities
    and Futures Ordinance (Cap. 571)&#160;of Hong Kong and any rules
    made under that Ordinance or (b)&#160;in other circumstances
    which do not result in the document being a
    &#147;prospectus&#148; as defined in the Companies Ordinance
    (Cap. 32)&#160;of Hong Kong or which do not constitute an offer
    to the public within the meaning of that Ordinance. No
    advertisement, invitation or document relating to our ADSs may
    be issued, whether in Hong Kong or elsewhere, which is directed
    at, or the contents of which are likely to be read by, the
    public in Hong Kong (except if permitted to do so under the laws
    of Hong Kong) other than with respect to our ADSs which are or
    are intended to be disposed of only to persons outside Hong Kong
    or only to &#147;professional investors&#148; as defined in the
    Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong)
    or any rules made under that Ordinance. The contents of this
    prospectus have not been reviewed by any regulatory authority in
    Hong Kong. You are advised to exercise caution in relation to
    the offer. If you are in any doubt about any of the contents of
    this prospectus, you should obtain independent professional
    advice.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Singapore.</I>&#160;&#160;This prospectus has not been
    registered as a prospectus with the Monetary Authority of
    Singapore. Accordingly, this prospectus and any other document
    or material in connection with the offer or sale, or invitation
    for subscription or purchase, of the ADSs may not be circulated
    or distributed, nor may the ADSs be offered or sold, or be made
    the subject of an invitation for subscription or purchase,
    whether directly or indirectly, to persons in Singapore other
    than (i)&#160;to an institutional investor under
    Section&#160;274 of the Securities and Futures Act,
    Chapter&#160;289 of Singapore, or the SFA; (ii)&#160;to a
    relevant person, or any person pursuant to Section&#160;275(1A),
    and in accordance with the conditions, specified in
    Section&#160;275 of the SFA; or (iii)&#160;otherwise pursuant
    to, and in accordance with the conditions of, any other
    applicable provision of the SFA.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Where the ADSs are subscribed or purchased under
    Section&#160;275 by a relevant person which is:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="3%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (a)&#160;
</TD>
    <TD align="left">
    a corporation (which is not an accredited investor) the sole
    business of which is to hold investments and the entire share
    capital of which is owned by one or more individuals, each of
    whom is an accredited investor;&#160;or
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (b)&#160;
</TD>
    <TD align="left">
    a trust (where the trustee is not an accredited investor) whose
    sole purpose is to hold investments and each beneficiary is an
    accredited investor,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    shares, debentures and units of shares and debentures of that
    corporation or the beneficiaries&#146; rights and interest in
    that trust shall not be transferable for six&#160;months after
    that corporation or that trust has acquired the ADSs under
    Section&#160;275 except:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (1)&#160;
</TD>
    <TD align="left">
    to an institutional investor (for corporations, under 274 of the
    SFA) or to a relevant person defined in Section&#160;275(2) of
    the SFA, or to any person pursuant to an offer that is made on
    terms that such shares, debentures and units of shares and
    debentures of that corporation or such rights and interest in
    that trust are acquired at a consideration of not less than
    S$200,000 (or its equivalent in a foreign currency) for each
    transaction, whether such amount is to be paid for in cash or by
    exchange of securities or other assets, and further for
    corporations, in accordance with the conditions specified in
    Section&#160;275 of the SFA;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (2)&#160;
</TD>
    <TD align="left">
    where no consideration is or will be given for the
    transfer;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (3)&#160;
</TD>
    <TD align="left">
    where the transfer is by operation of law.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Cayman Islands.</I>&#160;&#160;This prospectus does not
    constitute a public offer of the ADSs or ordinary shares,
    whether by way of sale or subscription, in the Cayman Islands.
    Each underwriter has represented and agreed that it has not
    offered or sold, and will not offer or sell, directly or
    indirectly, any ADSs or ordinary shares to any member of the
    public in the Cayman Islands.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>People&#146;s Republic of China.</I>&#160;&#160;This
    prospectus may not be circulated or distributed in the PRC and
    the ADSs may not be offered or sold, and will not offer or sell
    to any person for re-offering or resale directly or indirectly
    to any resident of the PRC except pursuant to applicable laws
    and regulations of the PRC. For the purpose of this paragraph,
    PRC does not include Taiwan and the special administrative
    regions of Hong Kong and Macau.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    170
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='123'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXPENSES
    RELATED TO THIS OFFERING</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Set forth below is an itemization of the total expenses,
    excluding underwriting discount, which are expected to be
    incurred in connection with the offer and sale of the ADSs by us
    and the selling shareholders. With the exception of the SEC
    registration fee and the Financial Industry Regulatory Authority
    Inc. filing fee, all amounts are estimates.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="84%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    SEC registration fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    8,855
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    NYSE listing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Financial Industry Regulatory Authority Inc. filing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Printing and engraving expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    350,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Legal fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,400,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounting fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    675,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Miscellaneous
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    729,775
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    3,280,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    171
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='124'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">LEGAL
    MATTERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain other legal matters as to the United States federal and
    New York law in connection with this offering will be passed
    upon for us by Simpson Thacher&#160;&#038; Bartlett LLP. Certain
    legal matters as to the United States federal and New York law
    in connection with this offering will be passed upon for the
    underwriters by O&#146;Melveny&#160;&#038; Myers LLP. The
    validity of the ordinary shares represented by the ADSs offered
    in this offering and certain other legal matters as to Cayman
    Islands law will be passed upon for us by Walkers. Legal matters
    as to PRC law will be passed upon for us by Jingtian&#160;&#038;
    Gongcheng Attorneys At Law and for the underwriters by
    Commerce&#160;&#038; Finance Law Offices. Simpson
    Thacher&#160;&#038; Bartlett LLP may rely upon Walkers with
    respect to matters governed by Cayman Islands law and
    Jingtian&#160;&#038; Gongcheng Attorneys At Law with respect to
    matters governed by PRC law. O&#146;Melveny&#160;&#038; Myers
    LLP may rely upon Commerce&#160;&#038; Finance Law Offices with
    respect to matters governed by PRC law.
</DIV>

<A name='125'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXPERTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The consolidated financial statements of Concord Medical
    Services Holdings Limited (successor company) at
    December&#160;31, 2007 and 2008, for the period from
    September&#160;10, 2007 to December&#160;31, 2007 and for the
    year ended December&#160;31, 2008, Our Medical Services Limited
    and its subsidiaries (predecessor company) for the period from
    January&#160;1, 2007 to October&#160;30, 2007, and China Medstar
    Limited as of December&#160;31, 2007 and July&#160;31, 2008 and
    for the year and the seven months period then ended, appearing
    in this Prospectus and Registration Statement have been audited
    by Ernst&#160;&#038; Young Hua Ming, an independent registered
    public accounting firm, as set forth in their reports thereon
    appearing elsewhere herein, and are included in reliance upon
    such reports given on the authority of such firm as experts in
    accounting and auditing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The offices of Ernst&#160;&#038; Young Hua Ming are located at
    21/F China Resources Building, No.&#160;5001 Shennan Dong Road,
    Shenzhen 518001, China.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    172
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='126'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">WHERE YOU
    CAN FIND ADDITIONAL INFORMATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have filed with the SEC a registration statement on
    <FONT style="white-space: nowrap">Form&#160;F-1,</FONT>
    including relevant exhibits and schedules under the Securities
    Act with respect to underlying ordinary shares represented by
    the ADSs, to be sold in this offering. We have also filed with
    the SEC a related registration statement on F-6 to register the
    ADSs. This prospectus, which constitutes a part of the
    registration statement, does not contain all of the information
    contained in the registration statement. You should read the
    registration statement and its exhibits and schedules for
    further information with respect to us and our ADSs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Immediately upon completion of this offering, we will become
    subject to periodic reporting and other informational
    requirements of the Exchange Act as applicable to foreign
    private issuers. Accordingly, we will be required to file
    reports, including annual reports on
    <FONT style="white-space: nowrap">Form&#160;20-F,</FONT>
    and other information with the SEC. All information filed with
    the SEC can be inspected and copied at the public reference
    facilities maintained by the SEC at 100&#160;F&#160;Street,
    N.E., Washington,&#160;D.C. 20549. You can request copies of
    these documents upon payment of a duplicating fee, by writing to
    the SEC. Please call the SEC at
    <FONT style="white-space: nowrap">1-800-SEC-0330</FONT>
    for further information on the operation of the public reference
    rooms. Additional information may also be obtained over the
    Internet at the SEC&#146;s website at www.sec.gov.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a foreign private issuer, we are exempt under the Exchange
    Act from, among other things, the rules prescribing the
    furnishing and content of proxy statements, and our executive
    officers, directors and principal shareholders are exempt from
    the reporting and short-swing profit recovery provisions
    contained in Section&#160;16 of the Exchange Act. In addition,
    we will not be required under the Exchange Act to file periodic
    reports and financial statements with the SEC as frequently or
    as promptly as U.S.&#160;companies whose securities are
    registered under the Exchange Act. However, we intend to furnish
    the depositary with our annual reports, which will include a
    review of operations and annual audited consolidated financial
    statements prepared in conformity with U.S.&#160;GAAP, and all
    notices of shareholders&#146; meeting and other reports and
    communications that are made generally available to our
    shareholders. The depositary will make such notices, reports and
    communications available to holders of ADSs and, upon our
    written request, will mail to all record holders of ADSs the
    information contained in any notice of a shareholders&#146;
    meeting received by the depositary from us.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    173
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<A name='127'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INDEX TO
    CONSOLIDATED FINANCIAL STATEMENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="91%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Page</FONT></B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <U>Audited Consolidated Financial Statements</U>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#301'>Report of Independent Registered Public
    Accounting Firm</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-2
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#302'>Consolidated Balance Sheets as of
    December&#160;31, 2007 and 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-3
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#303'>Consolidated Statements of Operations for the
    period from January&#160;1, 2007 to October&#160;30, 2007 for
    Our Medical Services Limited and its subsidiaries
    (predecessor)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#303'>Consolidated Statements of Operations for the
    period from September&#160;10, 2007 to December&#160;31, 2007
    and for the year ended December&#160;31, 2008 for Concord
    Medical Services Holdings Limited (successor)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#305'>Consolidated Statements of Cash Flows for the
    period from January&#160;1, 2007 to October&#160;30, 2007 for
    Our Medical Services Limited and its subsidiaries
    (predecessor)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-7
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#305'>Consolidated Statements of Cash Flows for the
    period from September&#160;10, 2007 to December&#160;31, 2007
    and for the year ended December&#160;31, 2008 for Concord
    Medical Services Holdings Limited (successor)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-7
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#304'>Consolidated Statements of Changes in
    Shareholders&#146; Equity for the period from January&#160;1,
    2007 to October&#160;30, 2007 for Our Medical Services Limited
    and its subsidiaries (predecessor)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-9
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#304'>Consolidated Statements of Changes in
    Shareholders&#146; Equity for the period from September&#160;10,
    2007 to December&#160;31, 2007 and for the year ended
    December&#160;31, 2008 for Concord Medical Services Holdings
    Limited (successor)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-9
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#306'>Notes to the Consolidated Financial Statements
    for the years ended December&#160;31, 2007 and 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-10
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <U>Unaudited Condensed Consolidated Financial Statements</U>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#307'>Unaudited Condensed Consolidated Balance Sheets
    as at December 31, 2008 and September&#160;30, 2009</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-53
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#308'>Unaudited Condensed Consolidated Statements of
    Operations for the nine months ended September&#160;30, 2008 and
    2009</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-55
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#309'>Unaudited Condensed Consolidated Statements of
    Cash Flows for the nine months ended September&#160;30, 2008 and
    2009</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-57
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#310'>Unaudited Condensed Consolidated Statements of
    Changes in Shareholders&#146; Equity for the year ended
    December&#160;31, 2008 and the nine months ended
    September&#160;30, 2008 and 2009</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-59
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#311'>Notes to Unaudited Condensed Consolidated
    Financial Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-60
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='301'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">REPORT OF
    INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To the Shareholders and the Board of Directors of
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Concord Medical Services Holdings Limited (successor company)
    and Our Medical Services Limited (predecessor company):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have audited the accompanying consolidated balance sheets of
    Concord Medical Services Holdings Limited (the
    &#147;Company&#148;) and its subsidiaries (together, the
    &#147;Group&#148;) as of December&#160;31, 2007 and 2008, and
    the related consolidated statements of operations, cash flows
    and changes in shareholders&#146; equity for the period from
    September&#160;10, 2007 to December&#160;31, 2007 and for the
    year ended December&#160;31, 2008. We have also audited the
    consolidated statements of operations, cash flows, and changes
    in shareholders&#146; equity of Our Medical Services Limited and
    its subsidiaries (predecessor company) for the period from
    January&#160;1, 2007 to October&#160;30, 2007. These
    consolidated financial statements are the responsibility of the
    Company&#146;s management. Our responsibility is to express an
    opinion on these financial statements based on our audits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We conducted our audits in accordance with the standards of the
    Public Company Accounting Oversight Board (United States). Those
    standards require that we plan and perform the audit to obtain
    reasonable assurance about whether the financial statements are
    free of material misstatement. We were not engaged to perform an
    audit of the Group&#146;s internal control over financial
    reporting. Our audits included consideration of internal control
    over financial reporting as a basis for designing audit
    procedures that are appropriate in the circumstances, but not
    for the purpose of expressing an opinion on the effectiveness of
    the Group&#146;s internal control over financial reporting.
    Accordingly, we express no such opinion. An audit also includes
    examining, on a test basis, evidence supporting the amounts and
    disclosures in the financial statements, assessing the
    accounting principles used and significant estimates made by
    management, and evaluating the overall financial statement
    presentation. We believe that our audits provide a reasonable
    basis for our opinion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In our opinion, such consolidated financial statements of the
    successor company referred to above present fairly, in all
    material respects, the financial position of Concord Medical
    Services Holdings Limited and its subsidiaries as of
    December&#160;31, 2007 and 2008 and the results of their
    operations and cash flows for the period from September&#160;10,
    2007 to December&#160;31, 2007 and for the year ended
    December&#160;31, 2008 in conformity with U.S.&#160;generally
    accepted accounting principles. Further, in our opinion, the
    predecessor company&#146;s financial statements referred to
    above present fairly, in all material respects, the results of
    operations and cash flows of Our Medical Services Limited and
    its subsidiaries for the period from January&#160;1, 2007 to
    October&#160;30, 2007 in conformity with U.S.&#160;generally
    accepted accounting principles.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Ernst&#160;&#038;
    Young Hua Ming</DIV>
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shenzhen, the People&#146;s Republic of China
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    October&#160;16, 2009
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    except for Note&#160;26, as to which the date is,
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    November&#160;17, 2009
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<A name='302'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    BALANCE SHEETS</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    </A><B>(Amounts in thousands of Renminbi (&#147;RMB&#148;) and
    US dollar (&#147;US$&#148;) except for number of shares)</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro Forma as at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Note</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(unaudited)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(Note 2)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="25" align="center" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>ASSETS</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Current Assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    343,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accounts receivable (net of allowance of RMB3,808, RMB3,830
    (US$561), for 2007 and 2008, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Prepayment and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,132
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,566
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred tax assets, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,201
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,649
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total Current Assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,135
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    492,978
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72,219
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Non-current assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Property, plant and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    349,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4, 8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Acquired intangible assets, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    181,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deposits for non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9, 20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,540
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,445
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,530
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543,023
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="25">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="25" align="center" valign="bottom">
    <B>LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Current Liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Short-term bank borrowing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,047
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term bank borrowings, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,836
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,741
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accrual for purchase of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,881
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    276
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Obligations under capital leases, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,979
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Income tax payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,033
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,041
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,496
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred revenue, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Payable for acquisition of a subsidiary and business components
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,104
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Dividends payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,788
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Amounts due to related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total current liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,372
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190,533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    BALANCE SHEETS&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>(Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;) except for number of shares)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro Forma as at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Note</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(unaudited)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(Note 2)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Non-Current Liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term bank borrowings, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred revenue, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,524
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,314
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    925
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Obligations under capitalized leases, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,631
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,707
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Lease deposit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    471
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,941
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    148,145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    283,916
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Commitments and contingencies</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;A contingently redeemable convertible preferred
    shares (par value of US$0.01 per share; Authorized&#160;&#151;
    nil and 200,000&#160;shares as at December&#160;31, 2007 and
    2008, respectively; Issued and outstanding&#160;&#151; nil and
    176,942&#160;shares as at December&#160;31, 2007 and 2008,
    respectively; pro forma nil (unaudited). As at December&#160;31,
    2008, aggregate liquidation preference and redemption amounts
    were US$54,573 and US$38,147, respectively (2007-nil))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;B contingently redeemable convertible preferred
    shares (par value of US$0.01 per share; Authorized&#160;&#151;
    nil and 300,000&#160;shares as at December&#160;31, 2007 and
    2008, respectively; Issued and outstanding&#160;&#151; nil and
    233,332&#160;shares as at December&#160;31, 2007 and 2008,
    respectively; pro forma nil (unaudited). As at December&#160;31,
    2008, aggregate liquidation preference and redemption amounts
    were US$90,583 and US$61,390, respectively (2007-nil))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Shareholders&#146; Equity:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Ordinary shares (par value of US$0.0001 per share at
    December&#160;31, 2007 and 2008; Authorized&#160;&#151;
    450,000,000&#160;shares at December&#160;31, 2007 and 2008;
    Issued and outstanding&#160;&#151; 50,000,000 and
    70,428,100&#160;shares at December&#160;31, 2007 and 2008,
    respectively, 111,455,500&#160;shares for pro forma (unaudited))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    443,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,778,581
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    260,552
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accumulated other comprehensive (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,822
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (560
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,822
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (560
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (544,363
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (79,746
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (544,363
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (79,746
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total shareholders&#146; equity</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,230,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    180,258
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total liabilities and shareholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543,023
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<A name='303'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF OPERATIONS</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    </A><B>(Amounts in thousands of Renminbi (&#147;RMB&#148;) and
    US dollar (&#147;US$&#148;),</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>except for number of shares and per share data)</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Notes</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>October&#160;30, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Predecessor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Revenues, Net of Business Tax, Value-Added Tax and Related
    Surcharges:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,716
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,422
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Cost of Revenues:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,396
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,046
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,669
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,003
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,416
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,914
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,597
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,680
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Gross profit</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Operating Expenses:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,601
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (757
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (805
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,467
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (57,171
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,764
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Operating income (loss)</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,938
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (47,859
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest expense (including related party amounts of RMB8, RMB96
    and RMB2,991 (US$438) for the period from January&#160;1 to
    October&#160;30, 2007 (predecessor), September&#160;10 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor), respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (954
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (279
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,455
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,092
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (341
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (325
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    (Loss) gain from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Income (loss) before income taxes</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Income tax (expense) benefit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,418
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Net income (loss)</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF OPERATIONS&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>(Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;),</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>except for number of shares and per share data)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Notes</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>October&#160;30, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Predecessor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,343
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (39,604
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (44,646
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Net income (loss) attributable to ordinary shareholders</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (496,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72,667
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Income (loss) per share</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.97
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.26
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Weighted Average Number of Ordinary Shares Outstanding:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Basic and diluted shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Pro forma loss per share</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Basic and diluted on an as converted basis (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4.76
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.70
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Weighted average number of ordinary shares outstanding used
    in computation of:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Pro forma basic and diluted on an as converted basis (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98,508,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98,508,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<A name='305'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF CASH FLOWS</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    </A><B>(Amounts in thousands of Renminbi (&#147;RMB&#148;) and
    US dollar (&#147;US$&#148;))</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="17%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">December 31, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">December&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    CASH FLOWS FROM OPERATING ACTIVITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Adjustments to reconcile net income (loss) to net cash generated
    from operating activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    617
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Imputed interest on amounts due to related parties (note&#160;20)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    438
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Depreciation of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,906
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,629
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Amortization of acquired intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,002
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,497
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Loss (gain) on disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,555
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (658
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (96
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Deferred tax expense (benefit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,472
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,608
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,080
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (744
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    341
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    464
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    131
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Changes in operating assets and liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Increase in accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,416
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,771
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,283
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,825
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Increase (decrease) in prepayments and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,782
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,043
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,376
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Increase in deposits for non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (280
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (621
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (91
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Decrease in accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,221
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,962
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Increase (decrease) in accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,095
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,049
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,709
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,008
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Decrease in deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,666
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (244
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Decrease in lease deposit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Increase in income tax payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,605
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    962
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,265
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    771
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,774
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    CASH FLOWS FROM INVESTING ACTIVITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Payment under arrangement with Chang&#146;an Hospital
    (note&#160;25)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,821
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,050
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Acquisitions, net of cash acquired (note&#160;4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (231,481
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (33,911
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Acquisition of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (43,398
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,466
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31,575
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,625
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Deposits for the purchase of non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,031
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,573
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (95,110
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,933
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Proceeds from disposal of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,977
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,598
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,616
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    383
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net cash used in investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (50,452
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30,441
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (376,371
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (55,136
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF CASH FLOWS&#160;&#151; (Continued)</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>(Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;))</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="17%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">December 31, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">December&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    CASH FLOWS FROM FINANCING ACTIVITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Proceeds from issuance of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Proceeds from issuance of Series&#160;A contingently redeemable
    convertible preferred shares (net of paid issuance costs of
    RMB2,449)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,913
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Proceeds from issuance of Series&#160;B contingently redeemable
    convertible preferred shares (net of paid issuance costs of
    RMB5,664)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    405,331
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59,379
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Proceeds from short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,047
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Proceeds from long-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,093
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Repayment of obligations under capitalized leases
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (786
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,698
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,525
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (809
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Repayment of long-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (37,890
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,551
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Repayment of short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,500
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,150
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Proceeds from exercise of share options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Increase (decrease) in amounts due to related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,806
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (41,700
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,109
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    649,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95,147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,698
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (834
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net increase in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    314,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cash at beginning of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cash at end of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Supplemental schedule of cash flows information:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Income tax paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (737
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,688
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,712
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (946
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (184
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,538
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (518
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Supplemental schedule of non-cash activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Acquisition of property, plant and equipment and other
    intangible assets through utilization of deposits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,961
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,601
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,413
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Acquisition of property, plant and equipment under capitalized
    lease
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Conversion of convertible notes into Series&#160;A contingently
    redeemable convertible preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,795
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='304'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#146;
    EQUITY<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="42%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Retained<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Earnings<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ordinary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ordinary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid-in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Comprehensive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Cumulative<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shareholders&#146;<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Income(loss)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Equity</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Predecessor&#160;&#151; Our Medical Services, Limited</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    RMB
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    RMB
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    RMB
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    RMB
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    RMB
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Balance as of January&#160;1, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,779
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    134,264
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Imputed interest on related parties&#146; loan (note&#160;20)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Balance as of October&#160;30, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,787
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    107,874
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    153,702
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Successor&#160;&#151; Concord Medical Services Holdings,
    Limited</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Reorganization (note&#160;1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    347,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (107,874
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    239,733
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,179
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Imputed interest on related parties&#146; loan (note&#160;20)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Balance as of December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    443,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Imputed interest on related parties&#146; loan (note&#160;20)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Exercise of share options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,184,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Redesignation of 756,500 ordinary shares to Series&#160;A
    contingently redeemable convertible preferred shares
    (note&#160;15)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (756,500
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Recognition of beneficial conversion feature upon issuance of
    Series&#160;A contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,317
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,317
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Recognition of beneficial conversion feature upon issuance of
    Series&#160;B contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    295,019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    295,019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares (note&#160;14)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,343
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,343
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares (note&#160;14)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Balance as of December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,822
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (544,363
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Balance as of December&#160;31, 2008, in US$
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (560
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (79,746
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='306'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ORGANIZATION
    AND BASIS OF PRESENTATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying consolidated financial statements include the
    financial statements of Concord Medical Services Holdings
    Limited (the &#147;Company&#148;) and its subsidiaries,
    including Ascendium Group Limited (&#147;Ascendium&#148;), China
    Medical Services Holdings Limited (&#147;CMS Holdings&#148;),
    Our Medical Services Limited (&#147;OMS&#148;), China Medstar
    Pte Limited (&#147;China Medstar&#148;), Cyber Medical Networks
    Limited (&#147;Cyber&#148;), CMS Hospital Management Co., Ltd.
    (&#147;CHM&#148;), Shenzhen Aohua Medical Services Co., Ltd
    (&#147;AMS&#148;), Shenzhen Aohua Medical Leasing&#160;&#038;
    Services Limited (&#147;AML&#148;), Medstar (Shanghai) Leasing
    Co., Ltd. (&#147;MSC&#148;) and Beijing Xing Heng Feng Medical
    Technology Co., Ltd. (&#147;XHF&#148;). The Company and its
    subsidiaries are collectively referred to as the
    &#147;Group&#148;.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group is principally engaged in the leasing of radiotherapy
    and diagnostic imaging equipment and the provision of management
    services to hospitals located in the People&#146;s Republic of
    China (&#147;PRC&#148;). The Group develops and operates its
    business through its subsidiaries. Details of the Company&#146;s
    subsidiaries as of December&#160;31, 2008 are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="19%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="31%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Percentage of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Date of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Place of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ownership by the<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Company</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Establishment</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Establishment</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Company</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Principal Activities</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ascendium
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    September 10, 2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    BVI
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Investment Holding
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    OMS
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    August 22, 1996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    BVI
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Investment Holding
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    China Medstar
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    August 8, 2003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Singapore
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Investment Holding
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cyber
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    May 26, 2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Hong Kong
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Investment Holding
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CMS Holdings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    July 18, 2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Hong Kong
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Investment Holding
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    AMS
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    July 23, 1997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    PRC
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Leasing of medical equipment and<BR>
    &#160;&#160;provision of management services
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    AML
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    February 21, 2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    PRC
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Leasing of medical equipment and<BR>
    &#160;&#160;provision of management services
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    MSC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    March 21, 2003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    PRC
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Leasing and sales of medical<BR>
    equipment, provision of<BR>
    management services
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CHM
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    July 23, 2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    PRC
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Provision of management services
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    XHF
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    July 26, 2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    PRC
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Provision of management services
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to October&#160;30, 2007, OMS was owned by a group of
    individuals (the &#147;OMS Individual Shareholders&#148;)
    through two intermediate investment holding companies
    (&#147;IIHC&#148;), there was no ultimate controlling
    shareholder of OMS in accordance with EITF Issue
    <FONT style="white-space: nowrap">No.&#160;02-5,</FONT>
    &#147;Definition of &#145;Common Control&#146; in Relation to
    FASB Statement No.&#160;141&#148; (&#147;SFAS&#160;141&#148;).
    OMS together with AMS, OMS&#146; wholly owned subsidiary, were
    the predecessors of the Group and operated the business of the
    Group prior to the reorganization on October&#160;30, 2007 (the
    &#147;Reorganization&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ascendium is a limited liability company that was incorporated
    in the British Virgin Islands (the &#147;BVI&#148;) on
    September&#160;10, 2007. The Reorganization agreement provided
    that Ascendium (a shell company owned by a nominee shareholder
    prior to the Reorganization), upon completion of the
    Reorganization, be owned by a group of individuals
    (&#147;Ascendium&#146;s shareholders&#148;), who as a group are
    substantively different than the shareholders of the IIHC (IIHC
    directly owned 100% of OMS prior to October&#160;30, 2007). In
    accordance with the Reorganization agreement, Ascendium&#146;s
    shareholders acquired 100% ownership in OMS in exchange for
    issuing Ascendium shares to a portion of the IIHC shareholders.
    The agreement also provided for the settlement of certain
    unspecified obligations amongst the IIHC shareholders and IIHC.
    The majority of Ascendium&#146;s shareholdings was acquired by a
    number of indirect shareholders of OMS, however because there
    was no controlling shareholder and the differences in
    shareholders is substantive, Ascendium accounted for the
    acquisition of 100% of OMS. The aggregate
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    purchase price for the acquisition on October&#160;30, 2007 was
    determined to be RMB393,435 (US$57,636), which represents the
    fair value of the Ascendium shares issued as consideration. The
    following table presents the allocation of the purchase price to
    the estimated fair values of the assets acquired and liabilities
    assumed, which were determined by the Group with the assistance
    of American Appraisal China (&#147;American Appraisal&#148;)
    Limited, an independent valuation firm. The total purchase price
    was allocated to OMS&#146;s tangible and identifiable intangible
    assets and liabilities based on their estimated fair values as
    of October&#160;30, 2007 as set forth below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,253
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,458
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,786
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,879
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other intangible assets- customer relationships and operating
    leases
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    132,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,337
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit for property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,753
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,035
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (58,792
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,612
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,104
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Liabilities assumed
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (92,584
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,563
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total consideration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    393,435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company was incorporated under the law of the Cayman Islands
    on November&#160;27, 2007. On March&#160;7, 2008, all the then
    existing shareholders of Ascendium exchanged their respective
    shares of Ascendium for shares of the Company at a ratio of
    10&#160;shares in the Company in return for each share in
    Ascendium. As a result, Ascendium became the wholly-owned
    subsidiary of the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, the Group acquired 100% of the equity
    interest in China Medstar. On October&#160;28, 2008, the Group
    consummated 100% of the equity interest in XHF. The acquisitions
    were accounted for using the purchase method of accounting
    pursuant to Statement of Financial Accounting Standards (the
    &#147;SFAS&#148;) No.&#160;141 &#147;Business Combinations&#148;
    (&#147;SFAS&#160;141&#148;). The acquired assets and liabilities
    of China Medstar and XHF were recorded at estimated fair values
    on their respective acquisition dates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shenzhen Aohua Medical Services (&#147;AMS&#148;) was
    incorporated by OMS on July&#160;23, 1997 and OMS contributed
    RMB4.8&#160;million representing 90% equity interest in AMS.
    Since the incorporation of AMS, 10% of its equity interest was
    held by two third party nominees who acted as the custodians of
    such equity interest. The two nominees did not maintain their
    required capital contributions at any time subsequent to the
    incorporation of AMS. In December 2007, the Group entered into
    an agreement with the two nominees to obtain title of their 10%
    equity interest. The two nominees agreed to complete all legal
    procedures required to effect legal transfer of the shares to
    OMS in return for a fee of RMB 4.2&#160;million. The transfer of
    the 10% equity interest in AMS was on June&#160;10, 2009 upon
    approval by the Shenzhen Industrial and Commercial
    Administration Bureau, and the Group paid the Minority
    Shareholders the 4.2&#160;million fee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Due to the two nominees failure to complete their capital
    injection obligations as required by PRC Company Law, it is in
    the Company&#146;s view that the two nominees never possessed
    any ordinary shareholding rights, including dividend or voting
    rights. Consequently, OMS effectively controlled 100% of the
    equity of AMS prior to the legal reacquisition of shares
    subsequent to December&#160;31, 2008. As such, the Group&#146;s
    consolidated financial statements do not present a minority
    interest for the financial statement periods presented.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    OF SIGNIFICANT ACCOUNTING POLICIES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Basis
    of presentation and use of estimates</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying consolidated financial statements have been
    prepared in accordance with United States generally accepted
    accounting principles (&#147;U.S.&#160;GAAP&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The preparation of consolidated financial statements in
    conformity with U.S.&#160;GAAP requires management to make
    estimates and assumptions that affect the reported amounts of
    assets and liabilities, disclosures of contingent assets and
    liabilities at the balance sheet dates and the reported amounts
    of revenues and expenses during the reporting periods.
    Significant estimates and assumptions reflected in the
    Company&#146;s financial statements include, but are not limited
    to, purchase price allocation, revenue recognition, allowance
    for doubtful accounts, useful lives of property, plant and
    equipment and acquired intangible assets, realization of
    deferred tax assets, share-based compensation expense, and the
    valuation of the Company&#146;s acquired tangible and intangible
    assets&#160;and liabilities and ordinary shares, Series&#160;A
    and B contingently redeemable convertible preferred shares and
    convertible notes. Actual results could materially differ from
    those estimates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Predecessor financial information is presented on the
    historical basis of accounting compared to the Successor
    financial information, which reflects the fair value of the net
    assets acquired on the date of the Reorganization rather than
    their historical cost.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The financial position, results of operations, statement of cash
    flows and related disclosures for periods prior to
    October&#160;30, 2007, the effective date of the Reorganization
    are presented as those of the &#147;Predecessor&#148;. The
    financial position, results of operations, statement of cash
    flows and related disclosures subsequent to October&#160;30,
    2007 (September&#160;10, 2007&#160;&#151; December&#160;31,
    2007)&#160;are presented as those of the &#147;Successor&#148;,
    which was a shell company prior to October&#160;30, 2007. The
    consolidated financial statements of the Successor as of
    December&#160;31, 2007 and for the period from
    September&#160;10, 2007 reflect the new basis of accounting in
    accordance with SFAS&#160;141. Accordingly, the fair value of
    net assets as of October&#160;30, 2007 have been recorded in the
    financial statements for the period commencing on
    September&#160;10, 2007. The consolidated financial statements
    of the Predecessor are presented using the Company&#146;s
    historic basis of accounting. Therefore, the results of the
    Successor are not comparable to the results of the Predecessor
    due to the difference in the new basis of presentation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Principles
    of Consolidation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The consolidated financial statements of the group include the
    financial statements of the Company and its subsidiaries. All
    transactions and balances between the Company and its
    subsidiaries have been eliminated upon consolidation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Foreign
    Currency Translation and Transactions</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s PRC subsidiaries determine their functional
    currencies to be the Chinese Renminbi (&#147;RMB&#148;) based on
    the criteria of SFAS&#160;52, &#147;Foreign Currency
    Translation&#148;. The Company uses the RMB as its reporting
    currency. The Company uses the monthly average exchange rate for
    the year and the exchange rate at the balance sheet date to
    translate the operating results and financial position,
    respectively. Translation differences are recorded in
    accumulated other comprehensive income, a component of
    shareholders&#146; equity. Functional currency of the Company
    and its subsidiaries, Ascendium, CMS Holdings, OMS, Cyber and
    China Medstar, is the United States dollar (&#147;US$&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Transactions denominated in foreign currencies are remeasured
    into the functional currency at the exchange rates prevailing on
    the transaction dates. Foreign currency denominated financial
    assets and liabilities are remeasured at the exchange rates
    prevailing at the balance sheet date. Exchange gains and losses
    are included in the consolidated statements of operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Convenience
    translation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amounts in U.S.&#160;dollars (&#147;US$&#148;) are presented for
    the convenience of the reader and are translated at the noon
    buying rate of RMB6.8262 to US$1.00 on September&#160;30, 2009
    in the City of New York for cable transfers of RMB as certified
    for customs purposes by the Federal Reserve Bank of New York. No
    representation is made that the RMB amounts could have been, or
    could be, converted into US$ at such rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Cash</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cash consists of cash deposits, which are unrestricted as to
    withdrawal and use.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounts
    receivable and allowance for doubtful accounts</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group considers many factors in assessing the collectability
    of its receivables due from its customers, such as, the age of
    the amounts due, the customer&#146;s payment history and
    credit-worthiness. An allowance for doubtful accounts is
    recorded in the period in which uncollectability is determined
    to be probable. Accounts receivable balances are written off
    after all collection efforts have been exhausted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Leases</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with SFAS&#160;13 &#147;Accounting for
    Leases&#148; (&#147;SFAS&#160;13&#148;), leases for a lessee are
    classified at the inception date as either a capital lease or an
    operating lease. The Company assesses a lease to be a capital
    lease if any of the following conditions exist:
    a)&#160;ownership is transferred to the lessee by the end of the
    lease term, b)&#160;there is a bargain purchase option,
    c)&#160;the lease term is at least 75% of the property&#146;s
    estimated remaining economic life or d)&#160;the present value
    of the minimum lease payments at the beginning of the lease term
    is 90% or more of the fair value of the leased property to the
    lessor at the inception date. A capital lease is accounted for
    as if there was an acquisition of an asset and an incurrence of
    an obligation at the inception of the lease. The capitalized
    lease obligation reflects the present value of future rental
    payments, discounted at the appropriate interest rates. The cost
    of the asset is amortized over the lease term. However, if
    ownership is transferred at the end of the lease term, the cost
    of the asset is amortized as set out below under property, plant
    and equipment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Property,
    Plant and Equipment, net</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property, plant and equipment are stated at cost and are
    depreciated using the straight-line method over the estimated
    useful lives of the assets, as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="35%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="20%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Category</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Estimated useful life</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Estimated residual
    value</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Medical equipment*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Shorter of customer contract or 6-20&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Electronic and office equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5 years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5-10
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Motor vehicles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5 years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5-10
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    shorter of lease term or 5&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=468 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">*&#160;
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The cost of the asset is amortized
    over the lease term. However, if ownership is transferred at the
    end of the lease term, the cost of the asset is amortized over
    the shorter of customer contract or the useful life of the asset
    which ranges from 6-20&#160;years.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Repair and maintenance costs are charged to expense as incurred,
    whereas the cost of renewals and betterments that extends the
    useful lives of property, plant and equipment are capitalized as
    additions to the related assets. Retirements, sales and
    disposals of assets are recorded by removing the cost and
    accumulated depreciation from the asset and accumulated
    depreciation accounts with any resulting gain or loss reflected
    in the consolidated statements of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost incurred in constructing new facilities, including progress
    payment, interest and other costs relating to the construction
    are capitalized and transferred to fixed assets on completion.
    Total interest costs incurred and capitalized
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    during the period from January 1 to October&#160;30, 2007
    (predecessor), the period from September&#160;10, 2007 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor) amounted to approximately
    nil, nil and RMB2,179 (US$319), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Goodwill</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Goodwill represents the excess of the purchase price over the
    estimated fair value of net tangible and identifiable intangible
    assets acquired. The Company&#146;s goodwill and acquisition
    related intangible assets outstanding at December&#160;31, 2007
    and 2008 were related to the Company&#146;s Reorganization, and
    acquisition of China Medstar, XHF and other businesses (see
    notes&#160;1 and 4). In accordance with the provisions of
    Statement of Financial Accounting Standards (SFAS) No.&#160;142,
    <I>Goodwill and Other Intangible Assets </I>(SFAS&#160;142),
    goodwill amounts are not amortized, but rather are tested for
    impairment at least annually or more frequently if there are
    indicators of impairment present. An impairment loss must be
    measured if the sum of the expected future undiscounted cash
    flows from the use and eventual disposition of the asset is less
    than the net book value of the asset. The amount of the
    impairment loss will generally be measured as the difference
    between the net book value of the asset and their estimated fair
    value. The Company determined it has one reporting unit in which
    all goodwill was tested for impairment at each reporting period
    end resulting in no impairment charges.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Acquired
    Intangible Assets, net</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acquired intangible assets relate to customer relationships and
    operating leases that are not considered to have an indefinite
    useful life. These intangible assets are amortized on a straight
    line basis over the economic life. The customer relationship
    assets relate to the ability to sell existing and future
    versions of products to existing customers and has been
    estimated using the income method. Operating leases relate to
    favorable operating lease terms based on market conditions that
    existed on the date of acquisition and are amortized over the
    term of the leases.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Impairment
    of Long-Lived Assets and Acquired Intangibles</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group evaluates its long-lived assets or asset group
    including acquired intangibles with finite lives for impairment
    whenever events or changes in circumstances (such as a
    significant adverse change to market conditions that will impact
    the future use of the assets) indicate that the carrying amount
    of a group of long-lived assets may not be fully recoverable.
    When these events occur, the Group evaluates the impairment by
    comparing the carrying amount of the assets to future
    undiscounted cash flows expected to result from the use of the
    assets and their eventual disposition. If the sum of the
    expected undiscounted cash flows is less than the carrying
    amount of the assets, the Group recognizes an impairment loss
    based on the excess of the carrying amount of the asset group
    over its fair value, generally based upon discounted cash flows.
    No such impairment charge was recognized for any of the periods
    presented.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fair
    Value of Financial Instruments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The carrying amounts of the Group&#146;s financial instruments,
    including cash, accounts receivable, accounts payable and
    accrued expenses and other liabilities approximate fair value
    because of their short maturities. The carrying amounts of the
    Group&#146;s short-term and long-term bank borrowings bear
    interest at floating rates and therefore approximate the fair
    value of these obligations based upon management&#146;s best
    estimates of interest rates that would be available for similar
    debt obligations at December&#160;31, 2007 and 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Revenue
    Recognition</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The majority of the Group&#146;s revenues are derived directly
    from hospitals that enter into medical equipment lease and
    management service arrangements with the Company. A lease and
    management service arrangement will typically include the
    purchase and installation of diagnostic imaging
    <FONT style="white-space: nowrap">and/or</FONT>
    radiation oncology system (&#147;medical equipment&#148;) at the
    hospital, and the full-time deployment of a qualified system
    technician that is responsible for certain management services
    related to the radiotherapy or diagnostic services being
    performed the hospital centers&#146;
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    doctors to their patients. To a lesser extent, revenues are
    generated from stand-alone management service arrangements where
    a hospital has previously acquired the equipment from the
    Company or through another vendor or sale of medical equipment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenues arising from sales of medical equipment and services
    are recognized when there is persuasive evidence of an
    arrangement, the fee is fixed or determinable, collectability is
    reasonably assured and the delivery of the medical equipment or
    services has occurred. When the fees associated with an
    arrangement containing extended payment terms are not considered
    to be fixed or determinable at the outset of arrangement,
    revenue is recognized as payments become due, and all of the
    other criteria above have been met.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group is subject to approximately 5% business tax and
    related surcharges on the revenue earned from provision of
    leasing and management services. The Group has recognized
    revenues net of these business taxes and other surcharges. Such
    business tax and related surcharges for the period from
    January&#160;1, 2007 to October&#160;30, 2007 (predecessor),
    September&#160;10, 2007 to December&#160;31, 2007 (successor)
    and the year ended December&#160;31, 2008 (successor) are
    approximately RMB428, RMB208 and RMB4,500 (US$659),
    respectively. In the event that revenue recognition is deferred
    to a later period, the related business tax and other surcharges
    and fees are also deferred and will be recognized only upon
    recognition of the deferred revenue.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Lease and
    management services</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group enters into both leases and management service
    arrangements with independent hospitals consisting of terms that
    range from 6 to 20&#160;years. Pursuant to these arrangements,
    the Group receives a percentage of the net profit (&#147;profit
    share&#148; as defined in the arrangement) of the hospital unit
    that delivers the diagnostic imaging
    <FONT style="white-space: nowrap">and/or</FONT>
    radiation oncology services determined in accordance with the
    terms of the arrangement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to
    <FONT style="white-space: nowrap">EITF&#160;01-8,</FONT>
    &#147;Determining Whether an Arrangement Contains a Lease&#148;
    <FONT style="white-space: nowrap">(&#147;EITF&#160;01-8&#148;)</FONT>
    the Group determined that the Lease and management service
    arrangements contain a lease of medical equipment. The hospital
    has the ability and right to operate the medical equipment while
    obtaining more than a minor amount of the output. The
    arrangement also contains a non-lease deliverable being the
    management service element. The arrangement consideration should
    be allocated between the lease element and the non-lease
    deliverables on a relative fair value basis, however because all
    of the consideration is earned through the contingent rent
    feature discussed below, there is no impact of such allocation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    SFAS&#160;13, &#147;Accounting for Leases&#148;
    (&#147;SFAS&#160;13&#148;) is applied to the lease elements of
    the arrangement and U.S.&#160;Securities and Exchange Commission
    (&#147;SEC&#148;) Staff Accounting Bulletin&#160;No.&#160;104
    (&#147;SAB&#160;104&#148;) is applied to other elements of the
    arrangement not within the scope of SFAS&#160;13.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The lease rentals and management service receivable under the
    lease arrangement are based entirely on a profit share formula
    (&#147;contingent rent feature&#148;). The profitability of the
    business unit is not only dependent on the medical equipment
    placed at the hospital, but also the hospital&#146;s ability to
    manage the costs and appoint doctors and clinical staff to
    operate the equipment. Certain of the lease and management
    service arrangements may include a transfer of ownership or
    bargain purchase option at the end of the lease term. Due to the
    length of the lease term, the collectability of these minimum
    lease payments are not considered reasonably predictable and
    there are also important uncertainties regarding the future
    costs to be incurred by the Group relating to the arrangement.
    Given these uncertainties, the Group accounts for all of these
    lease arrangements as operating leases.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As the collectability of the minimum lease rental is not
    considered predictable, and the remaining rental is considered
    contingent, the Group recognizes revenue when a lease payment
    under the arrangement become fixed, i.e. when the profit share
    under the arrangement is determined and agreed upon by both
    parties to the agreement. Similarly, for the service element of
    the arrangement, revenue is only considered determinable at the
    time a payment under the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    arrangement becomes fixed, i.e. when the profit share under the
    arrangement is determined and agreed upon by both parties.
    Revenue is recognized when it is determined that the basic
    criteria, referred to above, have also been met.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Management
    Services</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group provides stand-alone management services to certain
    hospitals which are already in possession of radiotherapy and
    diagnostic equipment. The fee for the management service
    arrangement is either based on a contracted percentage of
    monthly revenue generated by the specified hospital unit
    (&#147;revenue share&#148;) or in limited instances on a fixed
    monthly fee. The consideration that is based on a contracted
    percentage of revenue is recognized when the monthly fees under
    the arrangement become due, i.e. when the revenue share under
    the arrangement is determined and agreed upon by both parties to
    the agreement. Fixed monthly fees are recognized ratably over
    the service term.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Medical
    equipment sales</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the application of Emerging Issues Task Force
    Consensus
    <FONT style="white-space: nowrap">99-19,</FONT>
    &#147;Reporting Revenue Gross as Principal versus Net as an
    Agent&#148;
    <FONT style="white-space: nowrap">(&#147;EITF&#160;99-19&#148;),</FONT>
    the Group records revenue related to medical equipment sales on
    a net basis when the equipment is delivered to the customer and
    the sales price is determinable. During the periods from January
    1 to October&#160;30, 2007 (predecessor), September 10 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor), the Company had medical
    equipment sales, of nil, nil and RMB 1,725, net of 17%
    value-added tax of approximately nil, nil and RMB863 (US$126)
    taxes, respectively. Revenue derived from medical equipment
    sales is recorded under &#147;Other&#148; in the consolidated
    statements of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cost
    relating to lease and management service arrangement</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The cost of medical equipment that is leased under an operating
    lease is included in property, plant and equipment in the
    balance sheet. The medical equipment is depreciated using the
    Group&#146;s depreciation policy. The costs of the management
    service component is recognized as an expense as incurred.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cost of
    management services</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Costs of management services mainly include the labor costs of
    technicians and management staff.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cost of
    equipment sales</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost of equipment sales, recorded net against the related
    revenue, include the cost of the equipment purchased and other
    direct costs involved in the equipment sales.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Income
    Taxes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group follows the liability method of accounting for income
    taxes. Under this method, deferred tax assets and liabilities
    are determined based on the difference between the financial
    reporting and tax bases of assets and liabilities using enacted
    tax rates that will be in effect in the period in which the
    differences are expected to reverse. The Group records a
    valuation allowance to offset deferred tax assets if based on
    the weight of available evidence, it is more-likely-than-not
    that some portion, or all, of the deferred tax assets will not
    be realized. The effect on deferred taxes of a change in tax
    rate is recognized in tax expense in the period that includes
    the enactment date of the change in tax rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;1, 2007, the Group adopted FASB Interpretation
    No.&#160;48, &#147;Accounting for Uncertainty in Income
    Taxes&#160;&#151; an interpretation of FASB Statement
    No.&#160;109&#148; (&#147;FIN&#160;48&#148;), which clarifies
    the accounting and disclosure for uncertainty in income taxes.
    Interest and penalties arising from underpayment of income taxes
    shall be computed in accordance with the related PRC tax law.
    The amount of interest expense is computed by applying the
    applicable statutory rate of interest to the difference between
    the tax position recognized and the amount previously taken or
    expected to be taken in a tax return. Interest and penalties
    recognized in accordance with FIN&#160;48 is classified in the
    financial statements as income tax expense.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with the provisions of FIN&#160;48, the Group
    recognizes in its financial statements the impact of a tax
    position if a tax return position or future tax position is
    &#147;more likely than not&#148; to prevail based on the facts
    and technical merits of the position. Tax positions that meet
    the &#147;more likely than not&#148; recognition threshold are
    measured at the largest amount of tax benefit that has a greater
    than fifty percent likelihood of being realized upon settlement.
    The Group&#146;s estimated liability for unrecognized tax
    benefits which is included in the &#147;accrued expenses and
    other liabilities&#148; account is periodically assessed for
    adequacy and may be affected by changing interpretations of
    laws, rulings by tax authorities, changes
    <FONT style="white-space: nowrap">and/or</FONT>
    developments with respect to tax audits, and expiration of the
    statute of limitations. The outcome for a particular audit
    cannot be determined with certainty prior to the conclusion of
    the audit and, in some cases, appeal or litigation process. The
    actual benefits ultimately realized may differ from the
    Group&#146;s estimates. As each audit is concluded, adjustments,
    if any, are recorded in the Group&#146;s financial statements.
    Additionally, in future periods, changes in facts,
    circumstances, and new information may require the Group to
    adjust the recognition and measurement estimates with regard to
    individual tax positions. Changes in recognition and measurement
    estimates are recognized in the period in which the changes
    occur.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Share-based
    compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group&#146;s employees participate in the Company&#146;s
    share-based scheme which is more fully discussed in
    note&#160;19. Share-based awards granted to employees are
    accounted for under SFAS&#160;No.&#160;123(R) &#147;Share-Based
    Payment&#148; (&#147;SFAS&#160;123(R)&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with SFAS&#160;123(R), all grants of share-based
    awards to employees are recognized in the financial statements
    based on their grant date fair values which are calculated using
    an option pricing model. The Group has elected to recognize
    compensation expense using the straight-line method for all
    share options granted with graded vesting based on service
    conditions. For share-based awards whose vesting is contingent
    on performance conditions, their fair value is estimated on the
    date of grant using an option pricing model. To the extent the
    required vesting conditions are not met resulting in the
    forfeiture of the share-based awards, previously recognized
    compensation expense relating to those awards are reversed.
    SFAS&#160;123(R) requires forfeitures to be estimated at the
    time of grant and revised, if necessary, in subsequent period if
    actual forfeitures differ from initial estimates. Share-based
    compensation expense was recorded net of estimated forfeitures
    such that expense was recorded only for those share-based awards
    that are expected to vest.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Income
    (loss) per Share</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Income (loss) per share is computed in accordance with
    SFAS&#160;No.&#160;128, &#147;Earnings per Share&#148;. Basic
    income (loss) per ordinary share is computed by dividing income
    (loss) attributable to holders of ordinary shares by the
    weighted average number of ordinary shares outstanding during
    the period. Diluted income (loss) per ordinary share reflects
    the potential dilution that could occur if securities or other
    contracts to issue ordinary shares were exercised or converted
    into ordinary shares. Ordinary shares issuable upon the
    conversion of the contingently redeemable convertible preferred
    shares are included in the computation of diluted income (loss)
    per ordinary share on an &#147;if-converted&#148; basis when the
    impact is dilutive. The dilutive effect of outstanding
    share-based awards is reflected in the diluted income (loss) per
    share by application of the treasury stock method.
    Two-Class&#160;Method prescribed under
    <FONT style="white-space: nowrap">EITF&#160;03-6,</FONT>
    Participating Securities and the Two-Class&#160;Method under
    FASB Statement No.&#160;128, is used to calculate income (loss)
    per share data for preferred shares that are participating
    securities in the event the Group has reportable net income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Unaudited
    Pro Forma Shareholders&#146; Equity</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If an initial public offering is completed, all of the
    Series&#160;A and Series B contingently redeemable convertible
    preferred shares outstanding will automatically convert into
    ordinary shares and all accrued but unpaid 5% fixed dividend
    attributable to preferred share holders will be paid
    immediately. Unaudited pro forma shareholders&#146; equity as of
    December&#160;31, 2008, as adjusted for the assumed conversion
    of the contingently redeemable convertible preferred shares and
    payment of the accrued but unpaid fixed dividend attributable to
    preferred shareholders, is set forth on the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    consolidated balance sheets. Unaudited pro forma income (loss)
    per share for year ended December&#160;31, 2008, as adjusted for
    the assumed conversion of the contingently redeemable
    convertible preferred shares as of January&#160;1, 2008, is set
    forth on the consolidated statements of operations (see
    note&#160;24).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Comprehensive
    Income</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Comprehensive income is defined to include all changes in equity
    except those resulting from investments by owners and
    distributions to owners. Among other disclosures,
    SFAS&#160;No.&#160;130 &#147;Reporting Comprehensive
    Income&#148; requires that all items that are required to be
    recognized under current accounting standards as components of
    comprehensive income be reported in a financial statement that
    is displayed with the same prominence as other financial
    statements. During the periods presented, the Group&#146;s
    comprehensive income includes net income and foreign currency
    translation adjustments and is presented in the statement of
    changes in shareholders&#146; equity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;4, 2007 the FASB issued SFAS&#160;No.&#160;141
    (Revised 2007), &#147;Business Combinations&#148;
    (SFAS&#160;141(R)). This Statement will apply to all
    transactions in which an entity obtains control of one or more
    other businesses. In general, SFAS&#160;No.&#160;141(R) requires
    the acquiring entity in a business combination to recognize the
    fair value of all the assets acquired and liabilities assumed in
    the transaction; establishes the acquisition date as the fair
    value measurement point; and modifies the disclosure
    requirements. Additionally, it changes the accounting treatment
    for transaction costs, acquired contingent arrangements,
    in-process research and development, restructuring costs,
    changes in deferred tax asset valuation allowances as a result
    of business combination, and changes in income tax uncertainties
    after the acquisition date. SFAS&#160;141(R) applies
    prospectively to business combinations for which the acquisition
    date is on or after the beginning of the first annual reporting
    period beginning on or after December&#160;15, 2008. Earlier
    adoption is prohibited. However, accounting for changes in
    valuation allowances for acquired deferred tax assets and the
    resolution of uncertain tax positions for prior business
    combinations will impact tax expense instead of impacting
    goodwill. The Group is currently assessing the impact, if any,
    that the adoption of SFAS&#160;141(R) will have on its
    consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;4, 2007 the FASB issued SFAS&#160;No.&#160;160,
    &#147;Non-controlling Interests in Consolidated Financial
    Statements&#160;&#151; An Amendment of ARB No. 51&#148;
    (&#147;SFAS&#160;160&#148;). SFAS&#160;160 establishes new
    accounting and reporting standards for the non-controlling
    interest in a subsidiary and for the deconsolidation of a
    subsidiary. Specifically, this statement requires the
    recognition of a non-controlling interest (minority interest) as
    equity in the consolidated financial statements and separate
    from the parent&#146;s equity. The amount of net income
    attributable to the non-controlling interest will be included in
    consolidated net income on the face of the statement of
    operations. SFAS&#160;160 clarifies that changes in a
    parent&#146;s ownership interest in a subsidiary that do not
    result in deconsolidation are equity transactions if the parent
    retains its controlling financial interest. In addition, this
    statement requires that a parent recognize a gain or loss in net
    income when a subsidiary is deconsolidated. Such gain or loss
    will be measured using the fair value of the non-controlling
    equity investment on the deconsolidation date. SFAS&#160;160
    also includes expanded disclosure requirements regarding the
    interests of the parent and its non-controlling interest.
    SFAS&#160;160 is effective for fiscal years, and interim periods
    within those fiscal years, beginning on or after
    December&#160;15, 2008 and will be applied prospectively with
    the exception of the presentation and disclosure requirements,
    which must be applied retrospectively for all periods presented.
    Earlier adoption is prohibited. The Company is currently
    assessing the impact, if any, the adoption of SFAS&#160;160 will
    have on its consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2008, the FASB issued SFAS&#160;No.&#160;161,
    &#147;Disclosures About Derivative Instruments and Hedging
    Activities&#148;, an amendment of FASB Statement No.&#160;133
    (&#147;SFAS&#160;161&#148;). SFAS&#160;161 requires enhanced
    disclosures to help investors better understand the effect of an
    entity&#146;s derivative instruments and related hedging
    activities on its financial position, financial performance, and
    cash flows. SFAS&#160;161 is effective for financial statements
    issued for fiscal years
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    and interim periods beginning after November&#160;15, 2008, with
    early application encouraged. The Group is currently assessing
    the impact, if any, that the adoption of SFAS&#160;No.&#160;161
    will have on its consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2008, the FASB issued FASB Staff Position
    <FONT style="white-space: nowrap">No.&#160;FAS&#160;142-3,</FONT>
    Determination of the Useful Life of Intangible Assets (&#147;FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3&#148;).</FONT>
    FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3</FONT>
    amends the factors that should be considered in developing
    renewal or extension assumptions used to determine the useful
    life of a recognized intangible asset under FASB Statement
    No.&#160;142, &#147;Goodwill and Other Intangible Assets,&#148;
    and requires enhanced disclosures relating to: (a)&#160;the
    entity&#146;s accounting policy on the treatment of costs
    incurred to renew or extend the term of a recognized intangible
    asset; (b)&#160;in the period of acquisition or renewal, the
    weighted-average period prior to the next renewal or extension
    (both explicit and implicit), by major intangible asset class;
    and (c)&#160;for an entity that capitalizes renewal or extension
    costs, the total amount of costs incurred in the period to renew
    or extend the term of a recognized intangible asset for each
    period for which a statement of financial position is presented,
    by major intangible asset class. FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3</FONT>
    must be applied prospectively to all intangible assets acquired
    as of and subsequent to fiscal years beginning after
    December&#160;15, 2008, and interim periods within those fiscal
    years. Early adoption is prohibited. The Group is currently
    evaluating the impact that FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3</FONT>
    will have on the consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2009, the FASB issued SFAS&#160;No.&#160;168, &#147;The
    FASB Accounting Standards
    Codification<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    and the Hierarchy of Generally Accepted Accounting
    Principles&#160;&#151; a replacement of FASB Statement
    No.&#160;162.&#148; The FASB Accounting Standards
    Codification<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    (Codification) will become the source of authoritative United
    States GAAP recognized by the FASB to be applied by
    nongovernmental entities. This Statement and the Codification
    will not change GAAP. This Statement is effective for interim
    and annual periods ending after September&#160;15, 2009. The
    Codification will not change GAAP and therefore should not
    impact the Group&#146;s consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2009, the FASB issued Staff Position
    <FONT style="white-space: nowrap">No.&#160;FAS&#160;157-4,</FONT>
    Determining Fair Value When the Volume and Level of Activity for
    the Asset or Liability Have Significantly Decreased and
    Identifying Transactions That Are Not Orderly (&#147;FSP
    <FONT style="white-space: nowrap">FAS&#160;157-4&#148;).</FONT>
    FSP
    <FONT style="white-space: nowrap">FAS&#160;157-4</FONT>
    relates to determining fair values when there is no active
    market or where the price inputs being used represent distressed
    sales. It reaffirms what SFAS&#160;No.&#160;157&#160;states is
    the objective of fair value measurement&#160;&#151; to reflect
    how much an asset would be sold for in an orderly transaction
    (as opposed to a distressed or forced transaction) at the date
    of the financial statements under current market conditions.
    Specifically, it reaffirms the need to use judgment to ascertain
    if a formerly active market has become inactive and in
    determining fair values when markets have become inactive. This
    guidance is effective for interim and annual periods ending
    after June&#160;15, 2009, but entities may early adopt this
    guidance for the interim and annual periods ending after
    March&#160;15, 2009. The Group is currently evaluating the
    impact that FSP
    <FONT style="white-space: nowrap">FAS&#160;157-4</FONT>
    will have on the consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In May 2009, the FASB issued SFAS&#160;No.&#160;165
    &#147;Subsequent Events&#148; (&#147;SFAS 165&#148;).
    SFAS&#160;165 names the two types of subsequent events either as
    recognized subsequent events or non-recognized subsequent events
    and modifies the definition of subsequent events as events or
    transactions that occur after the balance sheet date, but before
    the financial statements are issued. The statement also requires
    entities to disclose the date through which an entity has
    evaluated subsequent events and the basis for that date.
    SFAS&#160;165 is effective on a prospective basis for interim or
    annual financial periods ending after June&#160;15, 2009. The
    Company does not believe that the application of SFAS&#160;165
    will have a material impact on the Company&#146;s consolidated
    financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">3.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">CONCENTRATION
    OF RISKS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concentration
    of credit risk</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Assets that potentially subject the Group to significant
    concentration of credit risk primarily consist of cash and
    accounts receivable. As of December&#160;31, 2008, substantially
    all of the Group&#146;s cash was deposited in financial
    institutions located in the PRC and in Hong Kong, which
    management believes are of high credit quality. Accounts
    receivable are typically unsecured and are derived from revenue
    earned from hospitals in the PRC. The risk with respect to
    accounts receivable is mitigated by credit evaluations the Group
    performs on its customers and its ongoing
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    monitoring of outstanding balances. As of December&#160;31, 2007
    and 2008, the Company had deposits with and receivables due from
    one of its customers (see note&#160;9).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concentration
    of customers</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group currently generates a substantial portion of its
    revenue from a limited number of customers. As a percentage of
    revenues, the top five customers accounted for 62% for the
    period from January&#160;1, 2007 to October&#160;30, 2007
    (predecessor), 65% for the period from September&#160;10, 2007
    to December&#160;31, 2007 (successor) and 38% for the year ended
    December&#160;31, 2008 (successor). The loss of revenue from any
    of these customers would have a significant negative impact on
    the Group&#146;s business. However, arrangements with customers
    are mostly long-term in nature. Due to the Group&#146;s
    dependence on a limited number of customers and the contingent
    fees received based on variables the Group does not control, any
    negative events with respect to the Group&#146;s customers may
    cause material fluctuations or declines in the Group&#146;
    revenue and have a material adverse effect on the Group&#146;s
    financial condition and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concentration
    of suppliers</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A significant portion of the Group&#146;s medical equipment are
    sourced from its three largest suppliers who collectively
    accounted for 100% of the total medical equipment purchases of
    the Group for the period from January&#160;1, 2007 to
    October&#160;30, 2007 (predecessor), 100%&#160;for the period
    from September&#160;10, 2007 to December&#160;31, 2007
    (successor) and 96% of the total medical equipment purchases of
    the Group for the year ended December&#160;31, 2008 (successor).
    Failure to develop or maintain the relationships with these
    suppliers may cause the Group to identify other suppliers in
    order to expand its business with new hospitals. Any disruption
    in the supply of the medical equipment to the Group may
    adversely affect the Group&#146;s business, financial condition
    and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Current
    vulnerability due to certain other concentrations</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group&#146;s operations may be adversely affected by
    significant political, economic and social uncertainties in the
    PRC. Although the PRC government has been pursuing economic
    reform policies for more than 20&#160;years, no assurance can be
    given that the PRC government will continue to pursue such
    policies or that such policies may not be significantly altered,
    especially in the event of a change in leadership, social or
    political disruption or unforeseen circumstances affecting the
    PRC&#146;s political, economic and social conditions. There is
    also no guarantee that the PRC government&#146;s pursuit of
    economic reforms will be consistent or effective.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group transacts all of its business in RMB, which is not
    freely convertible into foreign currencies. On January&#160;1,
    1994, the PRC government abolished the dual rate system and
    introduced a single rate of exchange as quoted daily by the
    People&#146;s Bank of China (the &#147;PBOC&#148;). However, the
    unification of the exchange rates does not imply that the RMB
    may be readily convertible into United States dollars or other
    foreign currencies. All foreign exchange transactions continue
    to take place either through the PBOC or other banks authorized
    to buy and sell foreign currencies at the exchange rates quoted
    by the PBOC. Approval of foreign currency payments by the PBOC
    or other institutions requires submitting a payment application
    form together with suppliers&#146; invoices, shipping documents
    and signed contracts.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additionally, the value of the RMB is subject to changes in
    central government policies and international economic and
    political developments affecting supply and demand in the PRC
    foreign exchange trading system market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A medical-related business is subject to significant
    restrictions under current PRC laws and regulations. Currently,
    the Group conducts its operations in China through contractual
    arrangements entered into with hospitals in the PRC. The
    relevant regulatory authorities may find the current contractual
    arrangements and businesses to be in violation of any existing
    or future PRC laws or regulations. If so, the relevant
    regulatory authorities would have broad discretion in dealing
    with such violations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">4.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ACQUISITIONS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Acquisition
    of China Medstar</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China Medstar was a publicly listed company on the Alternative
    Investment Market (the &#147;AIM&#148;) of the London Stock
    Exchange in the United Kingdom. Consistent with the
    Company&#146;s business, MSC, the wholly-owned subsidiary of
    China Medstar, was also principally engaged in leasing of
    medical equipment to hospitals and provision of management
    services in the PRC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In July 2008, the Group acquired China Medstar for cash
    consideration of &#163;17.1&#160;million, (US$34,975) or
    62&#160;pence per share in exchange for 100% of Medstar&#146;s
    issued and outstanding share capital. On July&#160;31, 2008, the
    Company completed the acquisition of China Medstar at which
    China Medstar became a 100% owned subsidiary of the Group. The
    acquisition of China Medstar was designed to complement the
    Group&#146;s existing network of treatment and diagnostic lease
    and management service arrangements. The results of China
    Medstar&#146;s operations have been included in the
    Company&#146;s consolidated financial statements commencing
    August&#160;1, 2008, the acquisition date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The purchase price allocation for the acquisition is primarily
    based on valuations determined by the Group with the assistance
    of American Appraisal. The consideration paid by the Company was
    more than the fair value of the net identifiable assets which
    led to the realization of goodwill. The purchase price was
    allocated to net assets acquired at fair value as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="82%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,210
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,107
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term receivables
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,397
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,377
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    217,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,931
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other intangible assets- customer relationships and operating
    lease
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,380
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit for property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,505
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,089
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,529
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,835
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Liabilities assumed
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (233,323
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34,180
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total consideration paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    238,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company, with the assistance of American Appraisal,
    determined the fair value of the acquired customer relationships
    and operating lease agreements (acquired intangibles) to be
    approximately RMB52,380 (US$7,673). The Company amortizes
    acquisition related intangible assets on a straight line basis
    over the economic life.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following unaudited pro forma consolidated financial
    information reflects the Group&#146;s consolidated results of
    operations for the period from September&#160;10, 2007 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor) as if the acquisition of
    China Medstar had occurred September&#160;10, 2007 and
    January&#160;1, 2008, respectively. These unaudited pro forma
    results have been prepared for information purposes only and do
    not purport to be indicative of what the Company&#146;s
    consolidated results of operations would have been had the
    acquisition of China Medstar actually taken place on
    September&#160;10, 2007 and January&#160;1, 2008, respectively,
    and may not be indicative of future results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenues, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,392
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    234,662
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,377
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,638
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,620
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss attributable to ordinary shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,610
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (603,628
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (88,428
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per common share&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.91
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10.50
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Acquisition
    of XHF</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    XHF was established in Beijing, the PRC on July&#160;27, 2007 as
    a limited liability company. The registered and paid-in capital
    of XHF amounted to RMB10,000 (US$1,465). Similarly, XHF is
    principally engaged in the provision of leasing of medical
    equipment and management services. On October&#160;28, 2008, the
    Group consummated 100% of the equity interest of XHF for cash
    consideration of approximately RMB34,979 (US$5,124). As at
    December&#160;31, 2008, RMB18,016 (US$2,639) was recorded in
    &#147;Payable for acquisition of a subsidiary and business
    components&#148; which was paid in first half of 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company, with the assistance of American Appraisal,
    determined the fair value of the acquired customer relationships
    to be approximately RMB18,000 (US$2,637). The Company amortizes
    acquisition related intangible assets on a straight basis over
    the economic life.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unaudited pro forma consolidated financial information has not
    been provided due to the overall insignificance of the
    acquisition relative to the Company&#146;s results of operations
    and financial condition for the year ended December&#160;31,
    2008. The results of XHF&#146;s operations have been included in
    the Company&#146;s consolidated financial statements since
    October&#160;28, 2008, the acquisition date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The purchase price allocation for the acquisition is primarily
    based on valuations determined by the Group with the assistance
    of American Appraisal. The purchase price was allocated to net
    assets acquired at estimated fair value as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="84%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,906
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,598
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,680
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,239
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other intangible assets&#160;&#151; customer contracts and
    customer relationships
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Liabilities assumed
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,895
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,207
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total cash consideration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,979
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,124
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Other
    acquisitions</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to expand the Group&#146;s network in cancer
    radiotherapy and diagnosis, on March&#160;31, 2008, the Group
    acquired certain medical equipment located in Tianjin People
    Liberation Army 272 Hospital and the related business
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    F-22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    from a third party for cash consideration of RMB14,000
    (US$2,051). As at December&#160;31, 2008, the Company had RMB
    10,000 (US$1,465) recorded in &#147;Payable for acquisition of a
    subsidiary and business components&#148; relating to these
    acquisitions. On August&#160;31, 2008, the Group acquired
    certain medical equipment located in People Liberation Army 254
    Hospital and the related business from another third party for
    cash consideration of RMB3,980 (US$583). These acquired assets
    and activities were considered to constitute businesses in
    accordance with
    <FONT style="white-space: nowrap">EITF&#160;98-3</FONT>
    &#147;Determining Whether a Nonmonetary Transaction Involves
    Receipt of Productive Assets or of a Business&#148;.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company, with the assistance of American Appraisal,
    determined the estimated fair value of the goodwill and
    intangible assets to be approximately RMB8,766 (US$1,284) and
    RMB1,957 (US$287), respectively. The Company amortizes
    acquisition related intangible assets based on the benefits
    expected to be realized, considering the related cash flows over
    the life of each relationship, up to a period of 12&#160;years.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">5.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ACCOUNTS
    RECEIVABLE</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,818
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96,602
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,152
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Allowance for doubtful accounts
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,808
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,830
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (561
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounts receivable, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Movement in allowance for doubtful accounts:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance at beginning of the period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,528
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,808
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Provisions
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,280
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance at end of the period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,808
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,830
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    561
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">6.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">PREPAYMENT
    AND OTHER CURRENT ASSETS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prepayment and other current assets consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposits to a hospital*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,197
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Prepayments to suppliers**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,953
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,458
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Advance to the hospitals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,217
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred cost
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,005
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,026
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Others
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,915
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,040
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,325
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,132
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,566
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=468 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">*&#160;
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amount represents an
    interest-free cash deposit paid to a customer hospital pursuant
    to the management service contract to which the deposit is
    repayable at the termination of the service contract (see
    note&#160;25.)
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">**
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amount represents interest-free
    non-refundable partial payments to suppliers associated with
    contracts the Group enters into for the future scheduled
    delivery of medical equipment for sales. The remaining
    contractual obligations associated with these purchase contracts
    are approximately RMB4,200 (US$615) which is included in the
    amount disclosed as Purchase Commitments at note&#160;22. The
    risk of loss arising from non-performance by or bankruptcy of
    the suppliers is assessed prior to ordering the equipment. To
    date, the Group has not experienced any loss on advances to
    suppliers.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">7.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">PROPERTY,
    PLANT AND EQUIPMENT, NET</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property, plant and equipment consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Medical equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    299,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,816
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Electronic and office equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,186
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Motor vehicles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvement and building improvement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    113
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    173
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Construction in progress
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,702
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    367,384
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,819
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: Accumulated depreciation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (999
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,263
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,675
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    349,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Depreciation expenses were approximately RMB17,906, RMB1,084 and
    RMB17,629 (US$2,583) for the period from January&#160;1, 2007 to
    October&#160;30, 2007 (predecessor), September&#160;10, 2007 to
    December&#160;31, 2007 (successor) and for the year ended
    December&#160;31, 2008 (successor), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As at December&#160;31, 2008, certain of the Group&#146;s
    property, plant and equipment with a net book value of
    approximately RMB81,595 (US$11,953) (2007: Nil) were pledged as
    security for bank borrowings of RMB112,760 (US$16,519) (2007:
    Nil).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As at December&#160;31, 2008, the Company held equipment under
    operating lease contracts with customers with an original cost
    of RMB299,100 (US$43,816) and accumulated depreciation of
    RMB17,705 (US$2,594). As at December&#160;31, 2007, the Company
    held equipment under operating lease contracts with customers
    with an original cost of RMB54,225 and accumulated depreciation
    of RMB939.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">8.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">OTHER
    INTANGIBLE ASSETS AND GOODWILL</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Goodwill is comprised of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="46%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30,</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance at beginning of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill recognized upon Reorganization (note&#160;1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill recognized upon acquisition of China Medstar
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,107
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill recognized upon acquisition of XHF (note&#160;4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,906
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,598
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill recognized in other business acquisitions (note&#160;4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,766
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance at end of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No impairment loss was recognized in any of the periods
    presented.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acquired intangible assets consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Customer relationship intangibles&#160;&#151; OMS (note&#160;1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,872
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating lease intangibles&#160;&#151; OMS (note&#160;1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,465
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Customer relationship intangibles&#160;&#151; China Medstar and
    other acquisitions (note&#160;4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,259
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating lease intangibles&#160;&#151; China Medstar and other
    acquisitions (note&#160;4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: Accumulated amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,499
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,296
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    181,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acquired intangible amortization expenses were approximately
    nil, RMB2,002 and RMB20,894 (US$3,061) for the period from
    January&#160;1, 2007 to October&#160;30, 2007 (predecessor),
    September&#160;10, 2007 to December&#160;31, 2007 (successor)
    and for the year ended December&#160;31, 2008 (successor),
    respectively. The estimated annual amortization expenses for the
    above intangible assets for each of the five succeeding years
    are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="82%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amortization</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,881
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,815
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,390
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2012
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,390
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2013
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,862
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,763
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,454
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,352
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">9.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">DEPOSITS
    FOR NON-CURRENT ASSETS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Deposits for non-current assets consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit for purchase of property, plant and equipment *
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    128,749
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,861
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit held by a related party **
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,904
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,630
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other ***
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=468 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">*&#160;
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents interest-free
    non-refundable partial payments to suppliers associated with
    contracts the Company enters into for the future scheduled
    delivery of medical equipment to customers. The remaining
    contractual obligations associated with these purchase contracts
    are approximately RMB50,220 (US$7,357) which is included in the
    amount disclosed as Purchase Commitments in Note&#160;22. The
    risk of loss arising from non-performance by or bankruptcy of
    the suppliers is assessed prior to ordering the equipment. To
    date, the Group has not experienced any loss on deposit to
    suppliers.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">**
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">On October&#160;31, 2007, the Group
    entered into a long-term sale and purchase agreement with Our
    Medical, under which the Group agreed to purchase gamma knife
    systems at agreed upon prices and Our Medical also agreed to
    provide the Group relevant maintenance and repair services and
    training. Our Medical is controlled by an individual who was a
    director of the Group until July 2009.
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">***
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The Group has entered into two
    distinct framework agreements with Chang&#146;an Hospital Co.
    Ltd. (&#147;Chang&#146;an&#148;) towards the development and
    construction of the following two medical facilities:
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    On December&#160;18, 2007, the Group entered into a framework
    agreement to build a proton treatment center in Beijing,
    pursuant to which the Group paid deposits to a subsidiary of
    Chang&#146;an Information Industry (Group) Co., Ltd.,
    (&#147;Chang&#146;an Information&#148;) to be used towards the
    construction of the proton treatment center (&#147;Beijing
    Proton Medical Center&#148;). Total deposits paid as of
    December&#160;31, 2008 pursuant to this arrangement amounted to
    RMB3,821 (US$560).
</TD>
</TR>





<TR valign="top" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    On July&#160;1, 2008, the Group entered into a framework
    agreement with Chang&#146;an to build a cancer center in
    northwest China, the Chang&#146;an CMS International Cancer
    Center (&#147;CCICC&#148;) pursuant to which the Group paid
    security deposits to Chang&#146;an totaling RMB17,000
    (US$2,490), which were been recorded as a non-current deposit as
    of December&#160;31, 2008. (See note&#160;25.)
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">10.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">BANK
    BORROWINGS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="9%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="8" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,760
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Comprised of:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Short-term
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,047
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Long-term, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,836
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,640
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,883
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Long-term, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,760
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All bank borrowings were originally obtained by MSC and assumed
    by the Company and are from financial institutions in the PRC
    and are secured by equipment with a net carrying value of
    RMB81,595 (US$11,953) (2007: Nil). As at December&#160;31, 2008,
    the Company had RMB39,840 (US$5,836) due within one year and
    RMB52,120 (US$7,636) due between one and two years. These
    arrangements do not have any financial reporting or
    administrative covenants restricting the Company&#146;s
    operating, investing and financing activities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The short-term bank borrowing outstanding at December&#160;31,
    2008 bore weighted average interest at 6.66% per annum, and was
    denominated in RMB. The long-term bank borrowings outstanding at
    December&#160;31, 2008 bore weighted average interest at 7.47%
    per annum and were denominated in RMB.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">11.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ACCRUED
    EXPENSES AND OTHER LIABILITIES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The components of accrued expenses and other liabilities are as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accrued expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    553
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Salary and welfare payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,152
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Business and other taxes payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,879
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,368
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Unrecognized tax benefit and related interest and penalty
    (note&#160;17)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,509
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other accruals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,942
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,174
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    905
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,979
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">12.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">OBLIGATIONS
    UNDER CAPITAL LEASES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has three capital lease obligations with three
    independent financing companies, collateralized by the
    respective medical equipment with an aggregate net book value of
    approximately RMB 31,610 (US$4,631) as at December&#160;31,
    2008. These obligations have stated interest rates ranging
    between 6.3% and 12.53%, are payable in 3 to 56&#160;monthly
    installments, and mature between March 2009 and August 2013.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Future minimum lease payments, together with the present value
    of the net minimum lease payments under capital leases, at
    December&#160;31, 2008, are summarized as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Minimum Lease Payments</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    745
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,781
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    554
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,781
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    554
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2012
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,781
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    554
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2013
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,611
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total capital lease payments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: imputed interest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (537
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,252
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,719
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (545
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,707
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    At December&#160;31, 2008, the Company held equipment under
    capital lease contracts with an original cost of RMB39,799
    (US$5,830) and accumulated depreciation of RMB8,739 (US$1,280).
    At December&#160;31, 2007, the Company held equipment under
    capitalized lease contracts with an original cost of RMB23,675
    (US$3,468) and accumulated depreciation of RMB6,959 (US$1,019).
    The depreciation and amortization expenses of medical equipment
    under capital leases are included in cost of
    revenues&#160;&#151; depreciation and amortization expenses
    lease and management services.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">13.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">CONVERTIBLE
    NOTES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Tranche&#160;A
    Convertible Notes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2007, OMS issued notes convertible into
    Series&#160;A contingently redeemable convertible preferred
    shares (the &#147;Series&#160;A Preferred Shares&#148;) with a
    principal amount of US$5,000 (the &#147;Tranche&#160;A
    Convertible Notes&#148;) to Carlyle Asia Growth Partners III,
    L.P. (hereafter, &#147;Carlyle Asia&#148;) and CAGP III
    Co-Investment, L.P. (&#147;CAGP&#148;, an affiliate of Carlyle
    Asia, together with Carlyle Asia, &#147;Carlyle&#148;) for cash
    consideration of US$5,000. The Tranche&#160;A Convertible Notes
    bear compound interest on the principal amount at a rate of 10%
    per annum. The maturity date of the Tranche&#160;A Convertible
    Notes is December&#160;31, 2008, provided they are not
    previously converted into Series A Preferred Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Automatic
    Conversion</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Tranche&#160;A Convertible Notes, including any accrued and
    unpaid interest, are automatically convertible upon the issuance
    of Series&#160;A Preferred Shares at a conversion price that is
    not fixed until the issuance date of Series&#160;A Preferred
    Shares; the conversion price will be the then subscription price
    of the Series&#160;A Preferred Shares. On April&#160;10, 2008,
    the Company issued a tranche of Series&#160;A Preferred Shares
    at US$188 per share. Concurrently, the conversion price of the
    Tranche&#160;A Convertible Notes was renegotiated and modified
    to a conversion price of US$179 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;10, 2008, the total principal and accrued and
    unpaid interest of the Tranche&#160;A Convertible Notes
    amounting to US$5,172 was converted into 28,882 Series&#160;A
    Preferred Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Tranche&#160;B
    Convertible Notes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;2, 2008, the Company issued notes convertible into
    Series&#160;A Preferred Shares (&#147;Tranche&#160;B Convertible
    Notes&#148;) to Carlyle with a principal amount of US$20,000.
    The Tranche&#160;B Convertible Notes bear compound interest on
    the principal amount at a rate of 9% per annum. The maturity
    date of the Tranche&#160;B Convertible Notes is
    December&#160;31, 2009, provided they are not previously
    converted into Series&#160;A Preference Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Conversion</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Carlyle shall have the right, at its sole option, to convert the
    Tranche&#160;B Convertible Notes into Series&#160;A Preferred
    Shares at any time starting from the closing of the subscription
    of the Series&#160;A Preferred Shares on April&#160;10, 2008 to
    August&#160;30, 2008 at an initial conversion price of $235 per
    share. If an initial public offering (&#147;IPO&#148;) of the
    Company occurs after August&#160;31, 2008, all the principal and
    accrued and unpaid interest shall be automatically converted
    into a number of Series&#160;A Preferred Shares at a conversion
    price that is not fixed, calculated according to a formula based
    on the Group&#146;s 2008&#160;net income as disclosed in the IPO.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, Carlyle exercised its conversion right
    and the total principal and accrued and unpaid interest of the
    Tranche&#160;B Convertible Notes amounting to US$20,547 was
    converted into 87,425 Series&#160;A Preferred Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Accounting
    for the Tranche&#160;A and Tranche&#160;B Convertible
    Notes</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Tranche&#160;A and Tranche&#160;B Convertible Notes
    (collectively the &#147;Convertible Notes&#148;) were accounted
    for in accordance with SFAS&#160;150, &#147;Accounting for
    Certain Financial Instruments with Characteristics of both
    Liabilities and Equity&#148; (&#147;SFAS&#160;150&#148;) as a
    liability recorded at fair value, because the Convertible Notes
    are convertible into Series&#160;A Preferred Shares, which are
    redeemable instruments.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The movement of Convertible Notes presented on the consolidated
    balance sheets is as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as at September&#160;10, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Issuance of Tranche&#160;A Convertible Notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Fair value loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    341
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign exchange translation gain
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as at December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Issuance of Tranche&#160;B Convertible Notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Fair value loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    464
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign exchange translation gain
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,476
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion to Series&#160;A Preferred Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (176,082
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as at December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as at December&#160;31, 2008 in US$
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">14.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">CONTINGENTLY
    REDEEMABLE CONVERTIBLE PREFERRED SHARES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2008, OMS issued an aggregate of 53,070 Series&#160;A
    contingently redeemable convertible preferred shares
    (&#147;Series&#160;A Preferred Shares&#148;) to Carlyle and CICC
    Sun Company Limited (&#147;CICC&#148;) for total cash proceeds
    of US$10,000, each investor subscribing for US$5,000. As
    discussed in note 13, the aggregate principal and accrued and
    unpaid interest relating to the Tranche&#160;A Convertible Notes
    were converted into 28,882 Series&#160;A Preferred Shares on
    April&#160;10, 2008 and all the principal and accrued and unpaid
    interest relating to the Tranche&#160;B Convertible Notes were
    converted into 87,425 Series&#160;A Preferred Shares on
    July&#160;31, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Concurrent with the issuance of the Series&#160;A Preferred
    Shares, one of the Company&#146;s major shareholders transferred
    additional Series&#160;A Preferred Shares to CICC in return for
    services rendered relating to the placement of Series&#160;A
    Preferred Shares and the Tranche&#160;B Convertible Notes. The
    total additional shares to be transferred represented 1.3% of
    the then if-converted outstanding ordinary shares. This transfer
    agreement was settled on June&#160;18, 2008. The Company agreed
    that a relative of a director of the Company shall transfer
    756,500 of her own holdings of the Company&#146;s ordinary
    shares, which were redesignated as Series&#160;A Preferred
    Shares, and issued to CICC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In October 2008, the Company issued an aggregate of 233,332
    Series&#160;B contingently redeemable convertible preferred
    shares (the &#147;Series&#160;B Preferred Shares&#148;) to
    Carlyle, Starr Investments Cayman II, Inc. (&#147;Starr&#148;),
    and CICC for cash consideration of US$25,000, US$25,000 and
    US$10,000, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The key terms of the Series&#160;A Preferred Shares and the
    Series&#160;B Preferred Shares (collectively the &#147;Preferred
    Shares&#148;) summarized below are defined in the Amended and
    Restated Shareholders&#146; Agreement and the Company&#146;s
    Second Amended and Restated Memorandum and Articles of
    Association adopted by special resolution passed on
    October&#160;20, 2008, signed among the Company, Carlyle, Starr
    and CICC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Voting
    rights</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The holder of each Preferred Share shall be entitled to the
    number of votes equal to the number of ordinary shares into
    which such Preferred Share could be converted.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Dividends</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A qualified initial public offering (&#147;QIPO&#148;) is
    defined as a firm-commitment underwritten IPO led by the Board,
    yielding a valuation of the Company of not less than US$450,000
    immediately prior to the consummation of such IPO, or any other
    IPO approved by holders of at least 70% of the then outstanding
    Series&#160;B Preferred Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each holder of Preferred Shares shall be entitled to receive a
    dividend on an annual basis, in respect of each Preferred Share,
    of an amount equal to the higher of: (a)&#160;the product of the
    number of ordinary shares into which such Preferred Share may
    then be converted multiplied by the dividend per ordinary share
    declared on the ordinary shares; or (b)&#160;the product of the
    original issuance price of each Preferred Share multiplied by
    5%. Dividends are payable annually on April 30 in the following
    financial year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Liquidation
    Preference</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of any liquidation, dissolution or winding up of
    the Company, each holder of Preferred Shares shall be entitled
    to receive, prior to and in preference to any distribution of
    any of the assets or surplus funds of the Company to the holders
    of the ordinary shares, the amount equal to the sum of 150%
    times the original price of each Preferred Share plus all
    accrued but unpaid dividends thereon and all interest accrued on
    such unpaid dividends, taking into account adjustments for share
    splits, share dividends, recapitalizations, share consolidations
    and other capital reorganizations (&#147;Liquidation
    Preference&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Conversion</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each Preferred Share shall be convertible, at the option of the
    holder at any time into a number of fully paid and
    non-assessable ordinary shares at an initial conversion ratio of
    1:100 (the &#147;Conversion Ratio&#148;), subject to adjustments
    for anti-dilution, as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;if there was a share split or reverse share split, the
    conversion price should be adjusted proportionally;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;if new equity or equity-linked securities (either
    ordinary or preferred shares, but not including securities
    issued to employees pursuant to employee benefit plans) were
    subsequently issued at a lower price than the then-Conversion
    Price of any class of Preferred Shares, the Conversion Price of
    such Preferred Shares shall be adjusted to the price of the
    newly issued shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All Preferred Shares outstanding immediately prior to the
    closing of the QIPO shall, on and with effect from the closing
    of the qualified initial public offering, be automatically
    converted into ordinary shares at the then Conversion Ratio.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Redemption</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon the occurrence of any Put Trigger Event as defined below,
    each holder of Preferred Shares shall have the right to require
    the Company to purchase all the Preferred Shares held by the
    Preferred Shareholders at a rate of return of 12.5%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#147;Put Trigger Event&#148; means any of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;the Company has not completed a qualified initial
    public offering by the third anniversary of the closing date of
    the subscription of the Series&#160;B Preferred Shares;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;any of certain key directors has resigned from the
    Company and its subsidiaries, which resignation, in the sole
    determination of a majority of the Investors, has resulted in or
    would be likely to result in, a material adverse effect;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iii)&#160;the Company or any of its Subsidiaries has breached
    or failed to be in compliance with any applicable laws that has
    had or would be reasonably likely to have, a material adverse
    effect.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Earning
    adjustments</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the Group&#146;s 2008 adjusted net income (pro forma adjusted
    net income including 2008&#160;net income of China Medstar for
    the whole year) falls below US$21,430 or if the Group&#146;s
    2009 adjusted net income falls below US$34,000, the controlling
    shareholders shall transfer a number of ordinary shares and cash
    to the Series&#160;A Preferred shareholders and Series B
    preferred shareholders, to a maximum of approximately
    198,200,000 ordinary shares as well as pay cash to the Preferred
    shareholders to a maximum of US$18,000. The Company has no legal
    obligation to indemnify the controlling shareholders for such
    cash payment. The above earnings adjustments automatically
    terminate upon occurrence of a qualified IPO.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Accounting
    for the contingently redeemable convertible preferred
    shares</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Preferred Shares have been classified as mezzanine equity
    because their redemption is contingent on certain events which
    are not within the control of the Company. The Preferred Shares
    are not currently redeemable because none of the Put Trigger
    Events have occurred and, to date, the Company has determined
    that they are not probable of occurring. The initial carrying
    value of the preferred shares is accreted using the effective
    interest method to the redemption amount over the earliest
    redemption date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The initial carrying values of the Preferred Shares is the
    issuance price at their respective issuance dates less the
    attributable issuance costs. The Company evaluated the Preferred
    Shares to determine if there were any embedded derivatives
    requiring bifurcation and to determine if there was any
    beneficial conversion feature. The Company determined that the
    conversion option of the Preference Shares did not qualify for
    the scope exception of SFAS&#160;133 paragraph&#160;11(a)
    because the conversion price may be adjusted if the
    Company&#146;s ordinary or preference shares are subsequently
    issued at a lower price than the original conversion price.
    However, the conversion option of the Preferred Shares did not
    qualify for derivative accounting because the Preferred Shares
    are not readily convertible into cash as there is not a market
    mechanism in place for trading its shares. The redemption option
    of the Preferred Shares did not qualify for derivative
    accounting because the option was not considered to require a
    principal repayment involving a substantial premium or discount.
    The liquidation preference of the Series&#160;A Preferred Shares
    that may be triggered if the Company is placed in liquidation,
    dissolution or winding up was evaluated to be an embedded
    derivative to be bifurcated. As at December&#160;31, 2008, the
    Company has assessed the value of this embedded derivative to be
    insignificant and will continually assess the value of this
    embedded derivative at each balance sheet date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A beneficial conversion feature exists when the effective
    conversion price of the Preferred Shares is lower than the fair
    value of the ordinary shares at April&#160;2, 2009 and
    July&#160;31, 2009 for the Series&#160;A Preferred Shares and
    October&#160;17, 2008 for the Series&#160;B Preferred Shares.
    The intrinsic value of the beneficial conversion feature is
    allocated from the carrying value of the Preferred Shares as a
    contribution to additional
    <FONT style="white-space: nowrap">paid-in-capital.</FONT>
    Since the conversion price of the Preferred Shares is subject to
    additional Preferred Shares from the Earnings Adjustments, the
    effective conversion price used to calculate the beneficial
    conversion feature is determined at the commitment date as the
    most favorable conversion price that would be in effect at the
    conversion date, assuming there are no changes to the current
    circumstances except for the passage of time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company determined the fair value of ordinary shares based
    on valuations performed with assistance from American Appraisal.
    In accordance with
    <FONT style="white-space: nowrap">EITF&#160;98-5,</FONT>
    Accounting for Convertible Securities with Beneficial Conversion
    Features or Contingently Adjustable Conversion Ratios
    <FONT style="white-space: nowrap">(&#147;EITF&#160;98-5&#148;),</FONT>
    if the intrinsic value of the beneficial conversion feature is
    greater than the proceeds allocated to the Preferred Shares, the
    amount of discount assigned to the beneficial conversion feature
    is limited to the amount of the proceeds allocated to the
    Preferred Shares. The cumulative preferred dividends were
    recorded as a reduction of income available to ordinary
    shareholders. The discount resulting from the beneficial
    conversion feature to the Preferred Shares is then accreted to
    the earliest conversion date. For the year ended
    December&#160;31, 2008, total beneficial conversion feature
    recorded for the Series&#160;A
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    and Series&#160;B Preferred Shares was RMB253,317 (US$37,110)
    and RMB295,019 (US$43,219), respectively, which was immediately
    accreted at the issuance date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An accretion charge to increase the carrying value of the
    Preferred Shares to their expected redemption amount is recorded
    as a reduction to retained earnings from the date of issuance to
    the earliest redemption date of the Preferred Shares using the
    effective interest method. For the year ended December&#160;31,
    2008, accretion recorded to the expected redemption amount for
    the Series&#160;A and Series&#160;B Preferred Shares amounted to
    RMB17,026 (US$2,494) and RMB9,744 (US$1,427), of which RMB6,801
    (US$996) and RMB3,987 (US$584) was recorded as dividends
    payable, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The balance and changes in balance of the Series&#160;A
    Preferred Shares and Series&#160;B Preferred Shares are as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="71%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Series A<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Series B<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mezzanine equity&#160;&#151; Balance as at December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of Convertible Notes into Series&#160;A Preferred
    Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Issuance of Series&#160;A Preferred Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: Series&#160;A Preferred Shares issuance costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,964
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,964
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Issuance of Series&#160;B Preferred Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,021
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,021
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: Series&#160;B Preferred Shares issuance costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,677
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,677
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Redesignation of 756,500 ordinary shares to Series&#160;A
    Preferred Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Allocation of proceeds to beneficial conversion feature
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (253,317
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (295,019
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (548,336
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion of beneficial conversion feature
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,317
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    295,019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    548,336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion of 5% fixed dividend
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,987
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,788
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion to the redemption amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    261,159
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    415,088
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    676,247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mezzanine equity&#160;&#151; Balance as at December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    665,459
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mezzanine equity&#160;&#151; Balance as at December&#160;31,
    2008, in US$
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    97,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend payable&#160;&#151; Balance as at December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,987
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,788
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend payable&#160;&#151; Balance at the end of
    December&#160;31, 2008, in US$
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">15.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SHAREHOLDERS&#146;
    EQUITY</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Share
    exchange</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All share and per share data before March&#160;7, 2008 are
    presented to give retroactive effect to the share exchange
    between Ascendium and the Company at a rate of 10&#160;shares in
    the Company to 1&#160;share in Ascendium which included all
    shares of OMS exchanged into shares of Ascendium at a rate of 1
    to 1 on November&#160;8, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Redesignation
    of 756,500 ordinary shares</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On June&#160;18, 2008, the Company redesignated 756,500 ordinary
    shares held by a relative of a director of the Company into
    7,565 Series&#160;A Preferred Shares which were issued to CICC
    as consideration for services related to the Series&#160;A
    Preferred Shares subscription and issuance of the Tranche&#160;B
    Convertible Notes. The aggregate fair value of the 7,565
    Series&#160;A Preferred Shares issued to CICC of RMB8,734
    (US$1,279) was considered issuance costs and was allocated on a
    pro rata basis between the US$10&#160;million subscription
    amount of the Series&#160;A Preferred Shares and the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    US$20&#160;million subscription amount of the Tranche&#160;B
    Convertible Notes, respectively. The issuance costs related to
    the Series&#160;A Preferred Shares of RMB2,911 (US$426) were
    charged against the gross proceeds of the offering. The debt
    issuance costs related to the Tranche&#160;B Convertible Notes
    are amortized into interest expense over the term of the loan
    until maturity on December&#160;31, 2009. Total interest expense
    recorded was RMB895 (US$131). On July&#160;31, 2008, when the
    Tranche&#160;B Convertible Notes were converted into
    Series&#160;A Preferred Shares, the unamortized balance of the
    debt issuance costs was charged against the conversion amount of
    the Series&#160;A Preferred Shares. The fair value of the 7,565
    Series&#160;A Preferred Shares issued to CICC was determined
    with assistance from American Appraisal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">16.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">RESTRICTED
    NET ASSETS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s ability to pay dividends is primarily
    dependent on the Company receiving distributions of funds from
    its subsidiaries. Relevant PRC statutory laws and regulations
    permit payments of dividends by the Group&#146;s PRC
    subsidiaries only out of their retained earnings, if any, as
    determined in accordance with PRC accounting standards and
    regulations. The results of operations reflected in the
    financial statements prepared in accordance with U.S.&#160;GAAP
    differ from those reflected in the statutory financial
    statements of the Company&#146;s subsidiaries.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with the PRC Regulations on Enterprises with
    Foreign Investment and their articles of association, a foreign
    invested enterprise established in the PRC is required to
    provide certain statutory reserves, namely general reserve fund,
    the enterprise expansion fund and staff welfare and bonus fund
    which are appropriated from net profit as reported in the
    enterprise&#146;s PRC statutory accounts. A foreign invested
    enterprise is required to allocate at least 10% of its annual
    after-tax profit to the general reserve until such reserve has
    reached 50% of its respective registered capital based on the
    enterprise&#146;s PRC statutory accounts. Appropriations to the
    enterprise expansion fund and staff welfare and bonus fund are
    at the discretion of the board of directors for all foreign
    invested enterprises. The aforementioned reserves can only be
    used for specific purposes and are not distributable as cash
    dividends. MSC, CHM, AMS, XHF and AML were established as a
    foreign invested enterprise and therefore are subject to the
    above mandated restrictions on distributable profits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of these PRC laws and regulations that require
    annual appropriations of 10% of after-tax income to be set aside
    prior to payment of dividends as general reserve fund, the
    Company&#146;s PRC subsidiaries are restricted in their ability
    to transfer a portion of their net assets to the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amounts restricted include paid-in capital, statutory reserve
    funds and net assets of the Company&#146;s PRC subsidiaries, as
    determined pursuant to PRC generally accepted accounting
    principles, totaling approximately RMB680,476 (US$99,686) as of
    December&#160;31, 2008; therefore in accordance with
    Rules&#160;504 and 4.08 (e) (3)&#160;of
    <FONT style="white-space: nowrap">Regulation&#160;S-X,</FONT>
    the condensed parent company only financial statements as of
    December&#160;31, 2008 and 2007 and for each of the two years in
    the period ended December&#160;31, 2008 are disclosed in
    note&#160;28.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">17.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">TAXATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Enterprise
    income tax:</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cayman
    Islands</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the current laws of the Cayman Islands, the Company is not
    subject to tax on income or capital gains. In addition, upon
    payments of dividends by the Company to its shareholders, no
    Cayman Islands withholding tax will be imposed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">British
    Virgin Islands</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the current laws of the British Virgin Islands, Ascendium
    and OMS are not subject to tax on income or capital gains. In
    addition, upon payments of dividends by these companies to their
    shareholders, no British Virgin Islands withholding tax will be
    imposed.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Hong
    Kong</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    CMS Holdings and Cyber are incorporated in Hong Kong and do not
    conduct any substantive operations of their own.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No provision for Hong Kong profits tax has been made in the
    financial statements as the Company has no assessable profits
    for the year ended December&#160;31, 2008. In addition, upon
    payment of dividends by CMS Holdings and Cyber to their
    shareholder, no Hong Kong withholding tax will be imposed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Singapore</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China Medstar is incorporated in Singapore and does not conduct
    any substantive operations of its own.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No provision for Singapore profits tax has been made in the
    financial statements as the Company has no assessable profits
    for the year ended December&#160;31, 2008. In addition, upon
    payments of dividends by China Medstar to its shareholder, no
    Singapore withholding tax will be imposed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">China</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to January&#160;1, 2008, PRC enterprise income tax,
    &#147;EIT&#148;, was generally assessed at the rate of 33% of
    taxable income. However, as foreign enterprises located in the
    Shenzhen Special Economic Zone or Pudong New District of
    Shanghai, AMS and MSC are entitled to preferential EIT rate of
    15%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2007, a new enterprise income tax law (the &#147;New
    EIT Law&#148;) in the PRC was enacted which was effective on
    January&#160;1, 2008. The New EIT Law applies a uniform 25% EIT
    rate to both foreign invested enterprises and domestic
    enterprises. The new law provides a five-year transition period
    from its effective date for those enterprises which were
    established before the promulgation date of the new tax law and
    which were entitled to a preferential tax treatment such as a
    reduced tax rate or a tax holiday. Based on the transitional
    rule, certain categories of enterprises, including the foreign
    invested enterprise located in Shenzhen Special Economic Zone
    and Pudong New District, which previously enjoyed a preferential
    tax rate of 15% are eligible for a five-year transition period
    during which the income tax rate will be gradually increased to
    the unified rate of 25%. Specifically, the applicable rates for
    AMS and MSC would be 18%, 20%, 22%, 24% and 25% for 2008, 2009,
    2010, 2011, 2012 and thereafter, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    AMS and MSC have accounted for their current and deferred income
    tax based on the five-year transitional tax rates, as applicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dividends paid by PRC subsidiaries of the Group out of the
    profits earned after December&#160;31, 2007 to non-PRC tax
    resident investors would be subject to PRC withholding tax. The
    withholding tax would be 10%, unless a foreign investor&#146;s
    tax jurisdiction has a tax treaty with China that provides for a
    lower withholding tax rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Income (loss) before income taxes consists of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="39%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="19%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non&#160;&#151; PRC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54,205
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (928
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    PRC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,697
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    108,739
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The current and deferred components of the income tax
    expense/(benefit) appearing in the consolidated statements of
    operations are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="39%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="19%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="7%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current tax expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,542
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,426
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,159
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax expense (benefit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,472
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,608
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,060
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (741
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (182
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,335
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,418
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A reconciliation of the differences between the statutory tax
    rate and the effective tax rate for EIT is as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="39%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="19%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income (loss) before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax computed at applicable tax rates (33% or 25%)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,367
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,007
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,601
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effect of different tax rates in different jurisdictions
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,887
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,548
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    227
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-deductible expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    234
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,181
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    173
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effect of preferential tax rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,328
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,057
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,684
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,272
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effect of tax rate changes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,248
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (378
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (55
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest and penalty on unrecognized tax benefits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    812
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    186
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,067
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (182
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,335
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,418
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Reconciliation of accrued unrecognized tax benefits is as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="19%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Years Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance&#160;&#151; beginning
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,552
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,941
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    471
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Additions based on tax positions related to the current year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,393
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Addition arising from business acquisitions
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance&#160;&#151; end
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,941
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,905
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,890
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group has recorded an unrecognized tax benefit of
    approximately RMB3,218 and RMB12,905 (US$1,890) in 2007 and
    2008, respectively, which is included in the account of
    &#147;accrued expenses and other liabilities&#148;. In 2007 and
    2008, RMB2,821 and RMB10,064 (US$1,474), respectively, would
    impact the effective tax rate, if recognized in
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    connection with the normal tax return preparation. Included in
    the balance at December&#160;31, 2007 and 2008 are approximately
    RMB397 and RMB2,841 (US$416), respectively, of tax positions for
    which the ultimate deductibility is highly certain but for which
    there is uncertainty about the timing of such deductibility.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    It is possible that the amount of unrecognized tax benefits will
    change in the next twelve months. However, an estimate of the
    range of the possible change cannot be made at this time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the period from January 1 to October&#160;30, 2007
    (predecessor), the period September 10 to December&#160;31, 2007
    (successor) and the year ended December&#160;31, 2008
    (successor), the Company recognized approximately RMB812, RMB186
    and RMB4,067 (US$595) in income tax expenses for interest and
    penalties related to uncertain tax positions. The Company
    accrued interest and penalties of approximately RMB1,774 and
    RMB7,604 (US$1,114), including approximately RMB1,762 (US$258)
    assumed in the acquisition of China Medstar, at
    December&#160;31, 2007, and 2008, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate amount and per share effect of the tax holidays
    are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="19%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Years Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="15" nowrap align="center" valign="bottom">
    <B>(amounts in thousands except for the per share data)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    The aggregate amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,676
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,488
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,684
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,272
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    The aggregate effect on basic and diluted earnings per share:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    -Basic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.03
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.02
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    -Diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.03
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.02
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The components of deferred taxes are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="63%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB(&#146;000)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB(&#146;000)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$(&#146;000)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accrued expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    516
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    685
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    146
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    380
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,201
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    570
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax liability, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred cost
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,240
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (182
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, current portion, net*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,201
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,649
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    552
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,044
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenue, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,841
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    270
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    530
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    87
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,155
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,245
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred cost
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,240
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,523
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (223
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29,945
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (44,750
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,556
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,735
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,400
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (53,920
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (67,673
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,914
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion, net **
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax liabilities, non-current portion, net **
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,765
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,078
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,941
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=468 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">As at December&#160;31, 2007 and
    2008, deferred tax assets, current portion of approximately nil
    and RMB1,240 (US$182) have been offset against deferred tax
    liabilities, current portion relating to a particular tax-paying
    component of an enterprise and within a particular tax
    jurisdiction, respectively.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">**
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">As at December&#160;31, 2007 and
    2008, deferred tax assets, non-current portion of approximately
    RMB38,155 and RMB47,595 (US$6,972) have been offset against
    deferred tax liabilities, non-current portion relating to a
    particular tax-paying component of an enterprise and within a
    particular tax jurisdiction, respectively.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aggregate undistributed earnings of the Company&#146;s
    subsidiaries located in the PRC that are available for
    distribution at December&#160;31, 2008 are considered to be
    indefinitely reinvested under Accounting Principles Board
    Opinion No.&#160;23 &#147;Accounting for Income
    Taxes&#160;&#151; Special Areas&#148; and accordingly, no
    provision has been made for taxes that would be payable upon the
    distribution of those amounts to any entity within the Group
    outside the PRC. Unrecognized deferred tax liabilities for
    temporary differences related to investments in foreign
    subsidiaries were not recorded because the determination of that
    amount is not practicable.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group does not have any present plan to pay any cash
    dividends on its ordinary shares in the foreseeable future. It
    intends to retain most of its available funds and any future
    earnings for use in the operation and expansion of its business.
    As of December&#160;31, 2008, the Group has not declared any
    dividends.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Business
    taxes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally revenue earned from the provision of leasing and
    management services is subject to 5% business tax regulations
    promulgated by the State Council of the PRC. Guoshuihan [1999]
    No.&#160;3402 issued by State Administration of Tax (the
    &#147;SAT&#148;) provided for an exemption to allow certain
    qualified profit sharing cooperation arrangements under existing
    PRC tax regulation to be exempt from paying business taxes. One
    of the Group&#146;s subsidiaries has not recorded any business
    taxes on certain of its leasing and management services on the
    basis that revenue generated from these exceptional profit
    sharing cooperation arrangements with hospitals are exempt from
    business taxes. Based on the above, management believes that it
    is not probable the SAT will challenge this subsidiary&#146;s
    business tax exemption status for those exceptional profit
    sharing cooperation arrangements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">18.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Income</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;21, 2008, the Company was awarded a settlement
    from the Intermediate Court of Shenzhen city, Guangdong Province
    in the amount of RMB7,734 (US$1,133) for the reimbursement of
    amounts that were misappropriated by employees. These activities
    occurred during fiscal 2005 or before and were discovered in
    July 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">19.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Employee
    Share Options</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">OMS
    Share Options</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2007, OMS, the predecessor of Ascendium and
    the Company, adopted a share option plan pursuant to which OMS
    granted three executive directors (&#147;Grantees&#148;)
    25,000,000 options in aggregate (&#147;OMS Share Options&#148;)
    to purchase ordinary shares of OMS at an exercise price of
    US$0.80 per share. The OMS Share Options vest upon the
    achievement of certain performance conditions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The OMS Share Options are exercisable from the date they vest
    until their expiry on December&#160;31, 2008 and are
    transferrable to any individuals designated by Grantees. As at
    December&#160;31, 2007, the OMS Share Options vested because all
    performance conditions had been met. The aggregate fair value of
    the options on the grant date of November&#160;17, 2007 was
    RMB49,526 (US$7,255), which was recorded as compensation expense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In August 2008, Concord agreed to issue 21,184,600 vested
    options (&#147;Concord Options&#148;) with an exercise price of
    US$0.79 per share to the Grantees in exchange for their vested
    OMS Share Options. Since the fair value of the Concord Options
    RMB36,207 (US$5,304) was less than the fair value of the OMS
    Share Options RMB45,970 (US$6,734), the difference of RMB9,763
    (US$1,430) has been credited to Additional Paid-In Capital.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Of the 21,184,600 vested Concord Options issued, 6,355,400
    Concord Options were exercised immediately resulting in total
    proceeds of RMB34,382 (US$5,037) being paid to the Company. The
    remaining 14,829,200 vested Concord Options, which were held by
    a significant shareholder of Concord, were sold to three
    directors of Concord for an amount which was less than the fair
    value of the Concord Options (the &#147;Concord Options
    Transfer&#148;). The difference represented a benefit that the
    shareholder conveyed to the three directors to compensate them
    for assuming directorship roles with the Company. The three
    directors signed employment contracts with the Company but the
    contractual terms did not contain a required service period. At
    the date of the Concord Options Transfer, the fair value of the
    Concord Options (RMB25,460 (US$3,730)) calculated using an
    option pricing model exceeded the consideration paid by the
    directors (RMB21,245 (US$3,112)) with the difference of RMB4,215
    (US$617) being recognized immediately as compensation expense
    since the options had vested. An offsetting credit was
    recognized in Additional Paid-In Capital to reflect the
    contribution made by the shareholder for providing a benefit to
    directors of the Company in accordance
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    with SAB&#160;Topic 5T <I>&#147;Accounting for Expenses or
    Liabilities Paid by Principal Stockholder(s)&#148;</I>. The
    three directors immediately exercised the 14,829,200 Concord
    Options and paid total proceeds of US$11,715 (RMB79,662) in
    aggregate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company calculated the estimated grant date fair value of
    the share-based awards in 2007 and 2008 using a Binomial-Lattice
    Model based on the following weighted average assumptions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="53%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>November&#160;17,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>August&#160;18,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>August&#160;18,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2008<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2008<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">OMS Options</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">OMS Options</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Concord Options</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.17
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.94
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.94
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility range
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38.34
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39.53
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39.53
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sub optimal early exercise factor
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.5 times
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.5 times
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.5 times
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The volatility assumption was estimated based on the price
    volatility of ordinary shares of comparable companies in the
    health care industry. The sub optimal early exercise factor was
    estimated based on the vesting and contractual terms of the
    awards and management&#146;s expectation of exercise behavior of
    the grantees. The risk-free rate was based on the market yield
    of China Sovereign Bonds denominated in US$ with maturity terms
    equal to the expected term of the option awards. Forfeitures
    were estimated based on historical experience. The fair value of
    the ordinary shares, at the option grant dates, was determined
    with assistance from an independent valuation firm, American
    Appraisal. The weighted-average grant-date fair value of stock
    options granted during the period from September 10 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor) were RMB1.29 (US$0.19) and
    RMB1.71 (US$0.25) per share, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No compensation expense was recorded by the predecessor entity
    for the period from January 1 to October&#160;30, 2007 since no
    share-based awards were issued. Total share-based compensation
    expense of RMB49,526 and RMB4,215 was recognized in the period
    from September 10 to December&#160;31, 2007 (successor) and in
    the year ended December&#160;31, 2008 (successor), respectively,
    in general and administrative expenses.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table summarizes employee share-based awards
    activities during the period from January 1 to October&#160;30,
    2007 (predecessor), September 10 to December&#160;31, 2007
    (successor) and the year ended December&#160;31, 2008
    (successor):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="26%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-size: 9pt">Share Options Granted to<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Weighted-Average<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Weighted-Average<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Contractual<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Aggregate Intrinsic<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Employees</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercise Price</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant-date Fair Value</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Term (Years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Value</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding, January&#160;1, 2007 and October&#160;30, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Granted&#160;&#151; OMS Options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.09
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding, December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expiration of OMS Options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,000,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Grant of Concord Options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,184,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exercised of Concord Options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,184,600
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    10,793
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding, December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate intrinsic value is calculated as the difference
    between the exercise price of the underlying awards and the fair
    value of the Company&#146;s shares that would have been received
    by the option holders if all in-the-money options had been
    exercised on December&#160;31, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concord
    2008&#160;Share Incentive Plan</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;16, 2008, the Board of Directors adopted the
    2008&#160;Share Incentive Plan (&#147;The 2008&#160;Share
    Incentive Plan&#148;). The 2008&#160;Share Incentive Plan
    provides for the granting of options, share appreciation rights,
    or other share-based awards to key employees, directors or
    consultants. The total number of Concord ordinary shares that
    may be issued under the 2008&#160;Share Incentive Plan is up to
    1,321,800 ordinary shares. As of December&#160;31, 2008, no
    awards have been granted under the 2008&#160;Share Incentive
    Plan.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">20.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">RELATED
    PARTY TRANSACTIONS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;Related parties
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Name of Related
    Parties</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Relationship with the
    Group</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A relative of a shareholder of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and shareholder of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and shareholder of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Yaw Kong Yap
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and shareholder of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shenzhen Hai Ji Tai Technology Co., Ltd. (&#147;Haijitai&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company owned by Mr. Haifeng Liu
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Beijing Medstar Hi-Tech Investment Co., Ltd. (&#147;Beijing
    Medstar&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company under the control of Mr. Zheng Cheng
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Our Medical New Technology Co, Ltd (&#147;Our Medical&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company under the control of Mr. Haifeng Liu
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;The Group had the following related party transactions
    for the years ended December&#160;31, 2007 and 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="41%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="17%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Short-term interest-free loans borrowed from:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Haijitai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    586
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Repayment of interest-free loans borrowed from:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Haijitai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,669
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    732
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-current deposits made to:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Our Medical
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,521
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    706
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,726
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Imputed interest, calculated using incremental borrowing rates
    ranging from 6.57% to 7.48%, amounting to approximately RMB8,
    RMB96, and RMB2,991 (US$438) for the period from January 1 to
    October&#160;30, 2007 (predecessor), September 10 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor), respectively, were recorded
    with an offsetting credit to Additional Paid-in Capital.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;The Group had the following related party balances at
    the end of the period:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amount due to related parties:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Haijitai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Beijing Medstar
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,351
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Yaw Kong Yap
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposits held by a related party:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Our Medical
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,904
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,630
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All balances with the related parties as of December&#160;31,
    2007 and 2008 were unsecured, interest-free and have no fixed
    terms of repayment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">21.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">EMPLOYEE
    DEFINED CONTRIBUTION PLAN</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Full time employees of the Group in the PRC participate in a
    government mandated defined contribution plan, pursuant to which
    certain pension benefits, medical care, employee housing fund
    and other welfare benefits are provided to employees. Chinese
    labor regulations require that the PRC subsidiaries of the Group
    make contributions to the government for these benefits based on
    certain percentages of the employees&#146; salaries. The Group
    has no legal obligation for the benefits beyond the
    contributions made. The total amounts for such employee
    benefits, which were expensed as incurred, were approximately
    RMB208, RMB35 and RMB938 (US$137) for the period from January 1
    to October&#160;30, 2007 (predecessor), September 10 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Obligations for contributions to defined contribution retirement
    plans for full-time employees in Singapore are recognized as
    expense in the statements of operations as incurred. The total
    amounts for such employee benefits, who is also a Director of
    the Company, were approximately nil, nil and RMB14 (US$2) for
    the period from January&#160;1, 2007 to October&#160;30, 2007
    (predecessor), the period from September 10 to December&#160;31,
    2007 (successor) and the year ended December&#160;31, 2008
    (successor), respectively.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-42
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">22.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">COMMITMENTS
    AND CONTINGENCIES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Operating
    lease commitments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Future minimum payments under non-cancelable operating leases
    with initial terms in excess of one year consist of the
    following at December&#160;31, 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    396
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,512
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2012
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,547
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Payments under operating leases are expensed on a straight-line
    basis over the periods of their respective leases. The terms of
    the leases do not contain material rent escalation clauses or
    contingent rents. For the years ended December&#160;31, 2007 and
    2008, total rental expenses for all operating leases amounted to
    approximately RMB711 and RMB2,620 (US$384), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Purchase
    commitments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group has commitments to purchase certain medical equipment
    of approximately RMB115,919 (US$16,981) at of December&#160;31,
    2008, which are scheduled to be paid in one year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Income
    taxes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2008, the Group has recognized
    approximately RMB20,509 (US$3,004) as an accrual for
    unrecognized tax benefits (note&#160;17). The final outcome of
    the tax uncertainty is dependent upon various matters including
    tax examinations, interpretation of tax laws or expiration of
    status of limitation. However, due to the uncertainties
    associated with the status of examinations, including the
    protocols of finalizing audits by the relevant tax authorities,
    there is a high degree of uncertainty regarding the future cash
    outflows associated with these tax uncertainties. As of
    December&#160;31, 2008, the Group classified the RMB20,509
    (US$3,004) accrual as a current liability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">23.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SEGMENT
    REPORTING</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with SFAS&#160;No.&#160;131, &#147;Disclosures
    About Segments of an Enterprise and Related Information&#148;,
    the Group chief operating decision maker has been identified as
    the chief executive officer, who reviews consolidated results
    when making decisions about allocating resources and assessing
    performance of the Group; hence, the Group has only one
    reportable segment. The Group operates and manages its business
    as a single segment that includes primarily lease rental,
    management services and equipment sales.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Lease and management services accounted for 94%, 93% and 90% of
    the Group&#146;s net revenue for the period from January 1 to
    October&#160;30, 2007 (predecessor), September 10 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor), respectively. Any
    significant reduction in sales from this service could have a
    substantial negative impact on the Group&#146;s results of
    operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Hospital A represented the largest customer of the Group which
    individually accounted for approximately RMB23,191 (US$3,397) or
    more than 10% of the Group&#146;s consolidated revenues for the
    years ended December&#160;31, 2008. Hospital A, Hospital B and
    Hospital C represented the largest customers of the Group
    accounting for RMB3,387, RMB1,683 and RMB1,911, respectively,
    each of which is more than 10% of the Group&#146;s consolidated
    revenues for the period from September 10 to December&#160;31,
    2007 (successor). Hospital&#160;A, Hospital&#160;C and
    Hospital&#160;D represented the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-43
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    largest customers of the Group accounting for RMB14,641,
    RMB8,062 and RMB7,767 or more than 10% of the Group&#146;s
    consolidated revenues for the period from January 1 to
    October&#160;30, 2007 (predecessor).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Geographic disclosures:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As the Group primarily generates its revenues from customers in
    the PRC, no geographical segments are presented. All of the
    Group&#146;s long-lived assets are located in the PRC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">24.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">INCOME
    (LOSS) PER SHARE</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Basic and diluted loss per share for each of the periods
    presented is calculated as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="18%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">December&#160;31,</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="15" nowrap align="center" valign="bottom">
    <B>(amounts in thousands except for the number of shares and per
    share data)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Numerator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income (loss) attributable to ordinary shareholders used in
    calculating loss per ordinary share&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (496,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72,667
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Denominator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average number of ordinary shares outstanding used in
    calculating basic and diluted loss per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Basic and diluted income (loss) per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.97
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.26
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the period from September&#160;10 to December&#160;31, 2007
    (successor), the diluted income (loss) per share is the same as
    basic loss per share because the if-converted method would not
    be applied as the effect of the convertible notes would be
    anti-dilutive. The share options should not be included in the
    calculation of diluted income (loss) per share because the
    company incurred a net loss and, therefore, the effect would be
    anti-dilutive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2008, the basic loss per share was calculated using the two
    class method because the Preferred Shares were participating
    securities. The losses were not allocated to holders of the
    Preferred Shares because they are not obligated to fund the
    losses of the Group and the contractual principal and mandatory
    redemption amount of Preferred Shares are not reduced as a
    result of losses incurred by the Group. Diluted loss per share
    is the same as basic loss per share because the effects of the
    Preferred Shares were anti-dilutive when computed on an &#147;if
    converted&#148; basis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2008, the Company issued Series&#160;A and Series&#160;B
    contingently redeemable convertible preferred shares (see
    note&#160;14). Each Preferred Share shall be convertible, at the
    option of the holder thereof, at any time after the closing of
    the subscription, into a number of fully paid and non-assessable
    ordinary Shares at a ratio 1:100 and is subject to adjustment
    pursuant to anti-dilution provisions. One hundred per cent of
    each class of the Preferred Shares which are outstanding
    immediately prior to the closing of the qualified initial public
    offering shall, on and with effect from the closing of the
    qualified initial public offering, be automatically converted
    into ordinary shares. Assuming the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-44
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    conversion had occurred &#147;on a hypothetical&#148; basis on
    January&#160;1, 2008, the pro-forma basic and diluted loss per
    share for the year ended December&#160;31, 2008 is calculated as
    follows (unaudited):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(pro forma)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB (unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Numerator</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss attributable to ordinary shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (496,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma adjustments:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;A contingently redeemable convertible preferred
    shares&#160;&#151; accretion to redemption amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,026
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;B contingently redeemable convertible preferred
    shares&#160;&#151; accretion to redemption amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss for pro forma basic and diluted loss per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (469,267
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Denominator</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average number of ordinary shares outstanding used in
    calculating basic loss per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of Series&#160;A preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,694,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of Series&#160;B preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,333,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average number of ordinary shares outstanding used in
    calculating basic and diluted loss per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98,508,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma loss per share&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4.76
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma loss per share&#160;&#151; basic and diluted (in US$)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.70
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">25.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ARRANGEMENT
    WITH CHANG&#146;AN HOSPITAL CO., LTD.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group has entered into the following agreements with
    Chang&#146;an Hospital Co., Ltd. (&#147;Chang&#146;an&#148;), a
    general hospital located in Xi&#146;an in Shaanxi province in
    the PRC, which is also a significant customer of the Group, and
    certain of its affiliated entities, including the controlling
    parent of Chang&#146;an, Chang&#146;an Information Industry
    (Group) Co., Ltd., (&#147;Chang&#146;an Information&#148;), a
    China-based conglomerate engaged in information technology, real
    estate and the medical industries; a subsidiary of
    Chang&#146;an, Xi&#146;an Century Friendship Medical Technology
    R&#038;D Co., Ltd. (&#147;Xi&#146;an&#148;), and another
    subsidiary controlled by Chang&#146;an Information, Beijing
    Century Friendship Science&#160;&#038; Technology Development
    Co., Ltd., (&#147;Beijing Century&#148;):
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Management
    agreements to provide stand-alone management
    services</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group entered into a Medical Equipment Entrusted Management
    Agreement on March&#160;1, 2007 with Xi&#146;an and
    Chang&#146;an to provide management services with respect to
    radiotherapy and diagnostic equipment owned by Xi&#146;an
    located in the oncology center of Chang&#146;an. Commencing
    January&#160;1, 2010 or an agreed upon earlier date, Concord has
    the option to purchase the radiotherapy and diagnostic equipment
    owned by Xi&#146;an at fair value if the Chang&#146;an oncology
    center&#146;s annualized revenues achieves a certain targeted
    level. Total management services revenue recognized under this
    contract was RMB8,000 (US$1,172) for year ended
    December&#160;31, 2008. Accounts receivable related to this
    contract as at December&#160;31, 2008 was RMB4,000 (US$586). On
    August&#160;25, 2009, the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-45
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Group exercised its option under the Medical Equipment Entrusted
    Management Agreement and converted the stand-alone management
    services arrangement into a lease and service arrangement. (See
    note 26.)
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;1, 2008, the Company signed an Entrusted
    Management Contract with Xi&#146;an and Chang&#146;an to provide
    general administrative management services to Chang&#146;an.
    Under this arrangement, the Group earns a certain percentage of
    total monthly revenues of Chang&#146;an Hospital. In accordance
    with the contract, the Group paid a performance guarantee
    deposit of RMB15,000 (US$2,197) to a related party of
    Xi&#146;an, which is refundable 15&#160;days after the
    cancellation or expiration of the contract (January&#160;15,
    2010). Total revenue recognized during the year ended
    December&#160;31, 2008 under this contract was RMB2,000 (US$293)
    and the ending accounts receivable relating to this contract as
    at December&#160;31, 2008 was nil.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Beijing
    Proton Medical Center</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;18, 2007, the Group entered into a framework
    agreement with Chang&#146;an Information to build a Beijing
    Proton Medical Center (&#147;Proton Center&#148;). The Proton
    Center will initially be established by Chang&#146;an
    Information with a total registered capital of RMB100,000. The
    parties agreed that after certain capital injections from the
    Group, the Company will hold a 51.2% interest in the Proton
    Center, while Jian Chang Group Limited, a related party of
    Chang&#146;an, will hold 28.8% and China-Japan Friendship
    Hospital, a state-owned hospital, will hold 20.0%. Once the
    Proton Center commences operations, the Group shall own a 51.2%
    controlling interest in the Proton Center and will consolidate
    the operating results and financial position within the Group.
    Additional contractual arrangements will be entered into by the
    Group once all relevant permits and approvals are obtained. In
    order for this framework agreement to become effective, the
    Group is required to pay a deposit of RMB10,000 (US$1,465); this
    deposit was not paid as of December&#160;31, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To assist with this project, the Group has made deposits to
    Beijing Century in the amount of RMB3,821 (US$560) as of
    December&#160;31, 2008 towards certain setup and construction
    costs. All of the deposits are guaranteed by Chang&#146;an
    Information and are due back to the Group by December&#160;31,
    2009.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Chang&#146;an
    CMS International Cancer Center</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;1, 2008, the Group entered into a framework
    agreement with Xi&#146;an to build a cancer center in northwest
    China, to be called Chang&#146;an CMS International Cancer
    Center (&#147;CCICC&#148;). Although the CCICC will initially be
    established by Xi&#146;an, the parties agreed that after certain
    initial capital injections estimated at RMB34,800 (US$5,098)
    from the Group, the Company shall hold a controlling interest of
    52% in the CCICC, while Xi&#146;an will hold a non-controlling
    interest of 48%. Similarly, the Group anticipates having to
    consolidate the operating results and financial position of the
    CCICC when the Group obtains a controlling interest. As of
    December&#160;31, 2008, Xi&#146;an is waiting for all relevant
    permits and approvals to be obtained prior to the legal
    establishment of the CCICC, upon which, additional contractual
    arrangements will be entered into by the Group. As of
    December&#160;31, 2008, the Group paid a deposit of RMB15,000
    (US$2,197) to a related party of Xi&#146;an in accordance with
    the framework agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are no other obligations under the current framework
    agreement and the agreement does not specify a contractual
    completion date for the deposit to be repaid to the Group. If
    the CCICC is established, the RMB15,000 deposit will be applied
    against future capital injections beyond the initial capital
    investment estimate of RMB34,800. The Group has also paid
    deposits to Xi&#146;an to be used towards setup and construction
    costs of the CCICC amounting to RMB2,000 (US$293) as of
    December&#160;31, 2008.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-46
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group had the following transactions with Chang&#146;an and
    its affiliated companies for the six months ended
    December&#160;31, 2007 and 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="79%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For The Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Management services revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Medical Equipment Entrusted Management Agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,172
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entrusted Management Contract
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total management services revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,465
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounts receivable due from Chang&#146;an
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    586
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group had the following deposits on loan with Chang&#146;an
    and its affiliated companies as at December&#160;31, 2007 and
    2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="79%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="8" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current&#160;&#151; Entrusted Management Contract
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,197
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-current&#160;&#151; Proton Center and CCICC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">26.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SUBSEQUENT
    EVENTS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subsequent to the year end, the Group made aggregate deposits in
    the amounts of RMB1,000 (US$146) and RMB10,800 (US$1,582) to
    Chang&#146;an and its affiliated companies towards the setup of
    the CCICC and Proton Center, respectively. These deposits are
    due to be repaid back to the Group by December&#160;31, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January and May 2009, the Group entered into two
    non-cancellable corporate office operating leases with a lease
    term of two to three years. These leases have no renewal
    options, material rent escalation clauses or contingent rents.
    Upon termination of the leases, they are renewable at fair value
    upon negotiation with the lessor.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January and June 2009, the Group entered into two new bank
    borrowings with PRC financial institutions with an aggregate
    principal amount of RMB35,000 (US$5,127). The weighted average
    interest rate of these two new bank borrowings was 5.59%. Both
    bank financing arrangements are secured by certain accounts
    receivable pledged to the bank and restricted cash deposited
    with each of the respective financial institutions. One of these
    new borrowing arrangements were entered into by a subsidiary of
    the Group, MSC, which requires MSC and AMS, another subsidiary
    of the Group, in accordance with PRC GAAP, to maintain a
    financial reporting covenant of tangible net worth of at least
    RMB400,000 and RMB180,000 and total gearing ratio of less than
    0.5 and 0.36, respectively. Tangible net worth is calculated as
    the sum of issued share capital and reserves less goodwill and
    intangible assets and any amount due from shareholders and the
    total gearing ratio is calculated as the ratio of total
    liabilities to tangible net worth.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In August 2009, the Group obtained a RMB100,000 (US$14,649)
    banking facility with a financial institution in the PRC for a
    term of 3&#160;years. The facility bears interest at a floating
    rate of the PBOC benchmark lending rate which was 5.4% in August
    2009 when the banking facility was obtained. Proceeds of this
    facility will be used towards future purchases of equipment and
    any drawdowns of the facility will be secured by those
    respective equipment. As at October&#160;16, 2009, the Group had
    drawn down RMB54,980 (US$8,054) of this facility.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-47
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In August 2009, the Group exercised its option in the Medical
    Equipment Entrusted Management Agreement and entered into an
    Equipment Purchase Agreement with Xi&#146;an and Chang&#146;an
    to acquire certain radiotherapy and diagnostic equipment owned
    by Xi&#146;an for total proceeds of RMB72,716 (US$10,652) to be
    paid in cash. Upon exercise, the Group converted the stand-alone
    management services arrangement into a lease and service
    agreement with Xi&#146;an and Chang&#146;an. This new lease and
    management service agreement provides the Group with a
    percentage of net profit generated by the oncology center.
    Commencing September 2009, the Group will record all revenue
    associated with this arrangement within lease and management
    services. (See note&#160;25 for amounts previously recorded as
    management services.)
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2009, the Company&#146;s Board of Directors
    approved the following resolutions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To distribute an interim dividend to the holders of the ordinary
    shares as at November&#160;17, 2009 in the sum of
    (i)&#160;US$2,391,534 to the holders of the ordinary shares; and
    (ii)&#160;US$1,590,676 to the holders of the Series&#160;A and B
    Preferred Shares, such dividend to be payable in cash on or
    about November&#160;27, 2009.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To amend the Articles of Association in conjunction with the
    Company&#146;s initial public offering, to reflect
    <FONT style="white-space: nowrap">1-for-100</FONT>
    share split of the Company&#146;s ordinary shares whereby each
    ordinary share of the Company is subdivided into 100&#160;shares
    at a par value of US$0.0001. All shares and per share amounts
    presented in the accompanying consolidated financial statements
    have been revised on a retroactive basis to reflect the effect
    of the share split. The par value per ordinary share has been
    retroactively revised as if it had been adjusted in proportion
    to the
    <FONT style="white-space: nowrap">1-for-100</FONT>
    share split.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To amend the Company&#146;s 2008&#160;Share Incentive Plan, to
    increase the total number of ordinary shares that may be issued
    under the 2008&#160;Share Incentive Plan from 1,321,800 ordinary
    shares to 4,765,800 ordinary shares.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">27.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Events
    Subsequent to the Date of the Report of Independent Auditors
    (Unaudited)</FONT></B>
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;27, 2009, the board of directors approved a
    grant of options to its directors and employees to purchase an
    aggregate of 4,765,800&#160;ordinary shares under its 2008 share
    incentive plan. The stock options will have an exercise price
    equal to the Company&#146;s initial public offering price, a
    contractual life of eight years and will vest ratably over four
    years. The measurement date will occur once the exercise price
    is established, at which time the Company will estimate the fair
    value of these share-based payment awards and recognize
    compensation cost over each employee&#146;s respective requisite
    service period which closely approximates the vesting period of
    the awards.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;4, 2009, the Company received a formal
    plaintiff&#146;s claim alleging that certain of the Group&#146;s
    centers gamma knife systems were infringing third-party owned
    patents. This claim relates to a patent used in the head gamma
    knife system manufactured by one of the Company&#146;s equipment
    manufacturers, Our Medical New Technology Co., Ltd., or Our
    Medical, which is a related party of the Group. A previous legal
    proceeding involving the same such patent was initiated in June
    2000 against Our Medical, its related parties, and AMS, a
    subsidiary of the Group, whereby the relevant PRC court also
    ordered the use of such equipment to cease. The Company is
    currently assessing the validity of the claim and has received a
    written indemnification from Our Medical for any damages or
    losses incurred from any intellectual property infringement by
    such system. The Company has identified one head gamma knife
    system operating in one of the centers that could be subject to
    such claim, representing approximately 1.5% and 1.0% of the
    Group&#146;s total net revenues in 2008 and for the nine months
    ended September 30, 2009, respectively. Based on the early
    stages of this legal claim, the Group has determined that it is
    not probable that a loss will result from this contingency nor
    could an amount of the loss contingency be reasonably estimated.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-48
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">28.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">PARENT
    COMPANY ONLY CONDENSED FINANCIAL INFORMATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Condensed
    balance sheet</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>ASSETS</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Current Assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    274,515
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Amount due from subsidiary
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total current assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    441,655
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    64,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Non-Current Assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Investment in subsidiaries
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    395,208
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    763,010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111,777
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Deposit for non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,746
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    431,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,242,411
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
    <B>LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Current Liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    78
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Amounts due to subsidiaries
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Dividend payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,788
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total current liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,932
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,748
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Non-Current Liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Convertible loan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,932
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,748
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-49
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Commitments and Contingencies</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Series&#160;A contingently redeemable convertible preferred
    shares (par value of US$0.01 per share; Authorized&#160;&#151;
    nil and 200,000&#160;shares as at December&#160;31, 2007 and
    2008, respectively; Issued and outstanding&#160;&#151; nil and
    176,942&#160;shares as at December&#160;31, 2007 and 2008,
    respectively. As at December&#160;31, 2008, aggregate
    liquidation preference and redemption amounts were US$54,573 and
    US$38,147, respectively (2007-nil))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Series&#160;B contingently redeemable convertible preferred
    shares (par value of US$0.01 per share; Authorized&#160;&#151;
    nil and 300,000&#160;shares as at December&#160;31, 2007 and
    2008, respectively; Issued and outstanding&#160;&#151; nil and
    233,332&#160;shares as at December&#160;31, 2007 and 2008,
    respectively. As at December&#160;31, 2008, aggregate
    liquidation preference and redemption amounts were US$90,583 and
    US$61,390, respectively (2007-nil))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Shareholders&#146; Equity:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Ordinary shares (par value of US$0.0001 per share as at
    December&#160;31, 2007 and 2008, respectively;
    Authorized&#160;&#151; 450,000,000&#160;shares as at
    December&#160;31, 2007 and 2008; Issued and
    outstanding&#160;&#151; 50,000,000 and 70,428,100&#160;shares as
    at December&#160;31, 2007 and 2008, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    443,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated other comprehensive income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,822
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (560
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Retained earnings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (544,363
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (79,746
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total shareholders&#146; equity</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total liabilities, preferred shares and shareholders&#146;
    equity</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    431,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,242,411
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    F-50
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Condensed
    statements of operations</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="58%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="18%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Years Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (53,862
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,593
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (673
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Operating loss</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (53,862
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,593
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (673
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Equity in profit of subsidiaries
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,877
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,413
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (895
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (131
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Change in fair value of convertible note
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (341
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (74
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Net (loss) income</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,343
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (39,604
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (44,646
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Net loss attributable to ordinary shareholders</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (496,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72,667
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-51
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Condensed
    statements of cash flows</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>For the Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net cash used in investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (448,224
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (65,662
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    727,849
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,636
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (826
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net increase in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    274,515
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash at beginning of the year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash at end of the year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    274,515
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Supplemental schedule of non-cash activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of convertible notes into Series&#160;A contingently
    redeemable convertible preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,795
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Proceeds from convertible notes paid directly to a subsidiary of
    the Company
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Basis of
    Presentation</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the presentation of the parent company only condensed
    financial information, the Company records its investment in
    subsidiaries under the equity method of accounting as prescribed
    in APB opinion No.&#160;18, &#147;The Equity Method of
    Accounting for Investments in Common Stock&#148;. Such
    investment is presented on the balance sheet as &#147;Investment
    in Subsidiaries&#148; and the subsidiaries profit or loss as
    &#147;Equity in profit or loss of subsidiaries&#148; on the
    statement of income. The parent company only financial
    statements should be read in conjunction with the Company&#146;s
    consolidated financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-52
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='307'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">UNAUDITED
    CONDENSED CONSOLIDATED BALANCE SHEETS<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and US dollar
    (&#147;US$&#148;) except for number of shares)</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="51%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro Forma as at</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Note</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008*</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="25" align="center" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>ASSETS</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    285,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    250,276
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,664
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Restricted cash, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounts receivable (net of allowance of RMB3,830 (US$561) as of
    December&#160;31, 2008 and September&#160;30, 2009)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    119,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Prepayment and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,566
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,869
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,331
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,649
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    407
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total current assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    492,978
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    466,487
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Non-Current Assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Restricted cash, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property, plant and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    349,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,661
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acquired intangible assets, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    181,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,450
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposits for non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147,851
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,659
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,648
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,445
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,782
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,578
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred initial public offering expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,207
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,642
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,673,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="25">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="25" align="center" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>LIABILITIES AND SHAREHOLDERS&#146;&#160;EQUITY</B>
</DIV>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Current Liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Short-term bank borrowing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term bank borrowings, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,741
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accrual for purchase of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,881
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,839
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,785
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Obligations under capital leases, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    525
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,221
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,041
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,864
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,349
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred revenue, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,962
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Payable for acquisition of business components
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    952
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividends payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,788
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,428
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amounts due to related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total current liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190,533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    238,060
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,874
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-53
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="45%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As at<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro Forma as at September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Note</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008*</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Non-Current Liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term bank borrowings, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred revenue, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,314
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,470
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Obligations under capitalized leases, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Lease deposit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,665
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    283,916
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    378,619
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,465
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Commitments and Contingencies</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;A contingently redeemable convertible preferred
    shares (par value of US$0.01 per share; Authorized&#160;&#151;
    200,000&#160;shares as at December&#160;31, 2008 and
    September&#160;30, 2009; Issued and outstanding&#160;&#151;
    176,942&#160;shares as at December&#160;31, 2008 and
    September&#160;30, 2009; pro forma nil (unaudited))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    269,017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;B contingently redeemable convertible preferred
    shares (par value of US$0.01 per share; Authorized&#160;&#151;
    300,000&#160;shares as at December&#160;31, 2008 and
    September&#160;30, 2009; Issued and outstanding&#160;&#151;
    233,332&#160;shares as at December&#160;31, 2008 and
    September&#160;30, 2009; pro forma nil (unaudited))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    434,036
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Shareholders&#146; Equity:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Ordinary shares (par value of US$0.0001 per share at
    December&#160;31, 2008 and September&#160;30, 2009;
    Authorized&#160;&#151; 450,000,000&#160;shares at
    December&#160;31, 2008 and September&#160;30, 2009; Issued and
    outstanding&#160;&#151; 70,428,100&#160;shares at
    December&#160;31, 2008 and September&#160;30, 2009,
    111,455,500&#160;shares for pro forma)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,816,229
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    266,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,822
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (592
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (592
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (544,363
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (517,640
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75,831
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (517,640
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75,831
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total shareholders&#146; equity</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    591,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,294,635
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    189,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total liabilities and shareholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,673,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=468 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">*&#160;
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amounts for the year ended
    December&#160;31, 2008 were derived from the December&#160;31,
    2008 audited consolidated financial statements.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-54
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='308'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;),<BR>
    except for number of shares and per share data)</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Note</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Revenues, Net of Business Tax, Value-Added Tax and Related
    Surcharges:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,092
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    205,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Cost of Revenues:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (42,144
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,174
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,388
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,987
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,361
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (62,541
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,162
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Gross profit</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,632
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143,116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Operating Expenses:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,275
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,463
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (654
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,468
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,687
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,884
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Operating Income</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest expense (including related party amounts of RMB2,425
    and RMB 54 (US$8) for the nine months ended September&#160;30,
    2008 and 2009, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,293
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,880
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (715
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (218
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gain from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    392
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    823
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Income before income taxes</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,627
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,691
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,611
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,734
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,770
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Net income</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-55
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;),<BR>
    except for number of shares and per share data)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Note</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>USD <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (262,286
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,851
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (38,383
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,623
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Net (loss) income attributable to ordinary shareholders</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (222,270
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,914
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Income (loss) per share</B> Basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.06
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Weighted Average Number of Ordinary Shares Outstanding:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Basic and diluted shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,621,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Pro forma income per share</B> Basic and diluted on an as
    converted basis
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Weighted Average Number of Ordinary Shares Outstanding Used
    in Computation of:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma basic and diluted on an as converted basis
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111,455,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111,455,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes to unaudited condensed consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-56
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='309'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">UNAUDITED
    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and US dollar
    (&#147;US$&#148;))</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="62%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>CASH FLOWS FROM OPERATING ACTIVITIES</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Adjustments to reconcile net income to net cash generated from
    operating activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Imputed interest on amounts due to related parties (note&#160;10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,425
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Depreciation of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,413
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Amortization of acquired intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,987
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Gain on disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (392
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred tax benefit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,830
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (295
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    464
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Changes in operating assets and liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,623
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26,355
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,861
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in prepayments and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (49,570
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,828
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,586
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in other non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (500
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,035
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (152
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase (decrease) in accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,057
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,543
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (812
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase (decrease) in deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Decrease in lease deposit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    (Decrease) increase in income tax payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (121
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,823
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,308
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>CASH FLOWS FROM INVESTING ACTIVITIES</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Purchase of subsidiaries, net of cash acquired
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (219,163
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,534
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,155
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deposits with Chang&#146;an Hospital and its affiliated
    companies (note&#160;15)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (300
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,800
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,729
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Acquisition of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,439
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (74,033
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,845
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deposits for the purchase of non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (71,406
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (116,059
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from disposal of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,616
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net cash used in investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (300,692
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (223,426
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32,731
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-57
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">UNAUDITED
    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS&#160;&#151;
    (Continued)<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and US dollar
    (&#147;US$&#148;))</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="62%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>CASH FLOWS FROM FINANCING ACTIVITIES</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from issuance of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from issuance of Series&#160;A contingently redeemable
    convertible preferred shares (net of paid issuance costs of
    RMB2,449)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Payment of issuance cost of convertible shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (529
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (77
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Payment of deferred initial public offering costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,355
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (491
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,783
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from long-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    128,780
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Repayment of obligations under capitalized leases
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,703
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,074
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (450
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Repayment of long-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,260
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (70,948
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,393
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Repayment of short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,800
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,436
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in amounts due to related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (293
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,245
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,061
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from exercise of share options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,458
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    278,407
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,448
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,949
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (191
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net decrease in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (864
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68,288
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,004
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash at beginning of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash at end of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    285,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Supplemental schedule of cash flows information:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,787
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,045
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,771
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (699
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Supplemental schedule of non-cash activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acquisition of property, plant and equipment included in accrual
    for purchase of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,777
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acquisition of property, plant and equipment through utilization
    of deposits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,712
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    152,181
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of convertible notes into Series&#160;A contingently
    redeemable convertible preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-58
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='310'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF<BR>
    CHANGES IN SHAREHOLDERS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;))</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="44%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Retained<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Earnings<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ordinary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ordinary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid-in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Comprehensive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Cumulative<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shareholders&#146;<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Income(loss)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Equity</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    443,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,810
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,810
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,206
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Imputed interest on related parties&#146; loan (note&#160;10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,425
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,425
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Exercise of share options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,184,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Redesignation of 756,500 ordinary shares to Series&#160;A
    contingently redeemable convertible preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (756,500
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Recognition of beneficial conversion feature upon issuance of
    Series&#160;A contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,317
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,317
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares (note&#160;6)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (262,286
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (262,286
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of September&#160;30, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    817,565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,596
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    541,361
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,841
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,841
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,894
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Imputed interest on related parties&#146; loan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    566
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    566
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Recognition of beneficial conversion feature upon issuance of
    Series&#160;B contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    295,019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    295,019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,057
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,057
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,822
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (544,363
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (215
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (215
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,742
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Imputed interest on related parties&#146; loan (note&#160;10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares (note&#160;6)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,851
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,851
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares (note&#160;6)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (38,383
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (38,383
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of September&#160;30, 2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (517,640
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    591,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of September&#160;30, 2009, in US$
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (590
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75,831
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86,664
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-59
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='311'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    OF SIGNIFICANT ACCOUNTING POLICIES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Basis
    of Presentation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying unaudited condensed consolidated financial
    statements include the financial statements of Concord Medical
    Services Holdings Limited (the &#147;Company&#148;) and its
    subsidiaries (the &#147;Group&#148;). These unaudited condensed
    consolidated financial statements of the Group have been
    prepared in accordance with U.S.&#160;generally accepted
    accounting principles (&#147;U.S.&#160;GAAP&#148;) for interim
    financial information using accounting policies that are
    consistent with those used in the preparation of the
    Group&#146;s audited consolidated financial statements for the
    year ended December&#160;31, 2008. Accordingly, these unaudited
    condensed consolidated financial statements do not include all
    of the information and footnotes required by U.S.&#160;GAAP for
    complete financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the opinion of management, the accompanying unaudited
    condensed consolidated financial statements contain all normal
    recurring adjustments necessary to present fairly the financial
    position, operating results and cash flows of the Group for each
    of the periods presented. The results of operations for the nine
    months ended September&#160;30, 2009 are not necessarily
    indicative of results to be expected for any other interim
    period or for the year ending December&#160;31, 2009. The
    consolidated balance sheet as of December&#160;31, 2008 was
    derived from the audited consolidated financial statements at
    that date but does not include all of the disclosures required
    by U.S.&#160;GAAP for complete financial statements. These
    unaudited condensed consolidated financial statements should be
    read in conjunction with the Group&#146;s consolidated financial
    statements for the year ended December&#160;31, 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Principles
    of Consolidation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The condensed consolidated financial statements of the Group
    include the financial statements of the Company and its
    subsidiaries. All transactions and balances between the Company
    and its subsidiaries have been eliminated upon consolidation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Convenience
    Translation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amounts in U.S.&#160;dollars (&#147;US$&#148;) are presented for
    the convenience of the reader and are translated at the noon
    buying rate of RMB6.8262 to US$1.00 on September&#160;30, 2009
    in the City of New York for cable transfers of RMB as certified
    for customs purposes by the Federal Reserve Bank of New York. No
    representation is made that the RMB amounts could have been, or
    could be, converted into US$ at such rate.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Restricted
    Cash</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Short-term and Long-term restricted cash represents cash
    collateral deposits required to be maintained pursuant to
    certain contractual financing arrangements the Group entered
    into with certain financial institutions (see note&#160;5.)
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Deferred
    Initial Public Offering Expenses</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Deferred initial public offering expenses represent incremental
    costs incurred by the Group directly attributable to the
    Company&#146;s initial public offering. The deferred initial
    public offering costs will be charged against the gross proceeds
    of such offering.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-60
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There have been no developments to recently issued accounting
    standards, including the expected dates of adoption and
    estimated effects on the Group&#146;s consolidated financial
    statements, from those disclosed in the Group&#146;s
    consolidated financial statements for the year ended
    December&#160;31, 2008, except for the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In April 2009, the Financial Accounting Standards Board
    (&#147;FASB&#148;) issued Accounting Standards Codification
    (&#147;ASC&#148;)
    <FONT style="white-space: nowrap">805-20,</FONT>
    &#147;Accounting for Assets Acquired and Liabilities Assumed in
    a Business Combination That Arise from Contingencies&#148; to
    amend SFAS 141 (revised 2007)&#160;&#147;Business
    Combinations.&#148; ASC
    <FONT style="white-space: nowrap">805-20</FONT>
    addresses the initial recognition, measurement and subsequent
    accounting for assets and liabilities arising from contingencies
    in a business combination, and requires that such assets
    acquired or liabilities assumed be initially recognized at fair
    value at the acquisition date if fair value can be determined
    during the measurement period. If the acquisition-date fair
    value cannot be determined, the asset acquired or liability
    assumed arising from a contingency is recognized only if certain
    criteria are met. ASC
    <FONT style="white-space: nowrap">805-20</FONT> also
    requires that a systematic and rational basis for subsequently
    measuring and accounting for the assets or liabilities be
    developed depending on their nature. The Company does not
    anticipate that the adoption of this statement will have a
    material impact on its consolidated financial statements, absent
    any material business combinations.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2009, the FASB issued SFAS&#160;No.&#160;166,
    &#147;Accounting for Transfers of Financial Assets&#160;&#151;
    an amendment of FASB Statement No. 140&#148;
    (&#147;SFAS&#160;166&#148;). SFAS&#160;166 seeks to improve the
    relevance, representational faithfulness, and comparability of
    the information that a reporting entity provides in its
    financial statements about a transfer of financial assets; the
    effects of a transfer on its financial position, financial
    performance, and cash flows; and a transferor&#146;s continuing
    involvement, if any, in transferred financial assets.
    Specifically, SFAS&#160;166 eliminates the concept of a
    qualifying special-purpose entity, creates more stringent
    conditions for reporting a transfer of a portion of a financial
    asset as a sale, clarifies other sale-accounting criteria, and
    changes the initial measurement of a transferor&#146;s interest
    in transferred financial assets. The Company does not anticipate
    that the adoption of this statement will have a material impact
    on its consolidated financial statements.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2009, the FASB issued SFAS&#160;No.&#160;167,
    &#147;Amendments to FASB Interpretation No.&#160;46(R)&#148;
    (&#147;SFAS&#160;167&#148;). SFAS&#160;167 amends FASB
    Interpretation No.&#160;46(R), &#147;Variable Interest
    Entities&#148; for determining whether an entity is a variable
    interest entity (&#147;VIE&#148;) and requires an enterprise to
    perform an analysis to determine whether the enterprise&#146;s
    variable interest or interests give it a controlling financial
    interest in a VIE. Under SFAS&#160;167, an enterprise has a
    controlling financial interest when it has a)&#160;the power to
    direct the activities of a VIE that most significantly impact
    the entity&#146;s economic performance and b)&#160;the
    obligation to absorb losses of the entity or the right to
    receive benefits from the entity that could potentially be
    significant to the VIE. SFAS 167 also requires an enterprise to
    assess whether it has an implicit financial responsibility to
    ensure that a VIE operates as designed when determining whether
    it has power to direct the activities of the VIE that most
    significantly impact the entity&#146;s economic performance.
    SFAS&#160;167 also requires ongoing assessments of whether an
    enterprise is the primary beneficiary of a VIE, requires
    enhanced disclosures and eliminates the scope exclusion for
    qualifying special-purpose entities. The Company is currently
    evaluating the impact the adoption of SFAS&#160;167 will have on
    its consolidated financial statements.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2009, the FASB issued
    <FONT style="white-space: nowrap">ASC&#160;105-10,</FONT>
    &#147;Generally Accepted Accounting Principles,&#148; previously
    referenced as FASB Statement No.&#160;168, The FASB Accounting
    Standards
    Codification<SUP style="font-size: 85%; vertical-align: top">TM</SUP>

    and the Hierarchy of Generally Accepted Accounting Principles, a
    replacement of FASB Statement No.&#160;162. This statement
    modifies the Generally Accepted Accounting Principles
    (&#147;GAAP&#148;) hierarchy by establishing only two levels of
    GAAP, authoritative and nonauthoritative accounting literature.
    Effective July 2009, the FASB Accounting Standards
    Codification<SUP style="font-size: 85%; vertical-align: top">TM</SUP>

    (&#147;ASC&#148;), also known collectively as the
    &#147;Codification,&#148; is considered
</TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-61
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    the single source of authoritative U.S.&#160;accounting and
    reporting standards, except for additional authoritative rules
    and interpretive releases issued by the SEC. Nonauthoritative
    guidance and literature would include, among other things, FASB
    Concepts Statements, American Institute of Certified Public
    Accountants Issue Papers and Technical Practice Aids and
    accounting textbooks. The Codification was developed to organize
    U.S.&#160;GAAP pronouncements by topic so that users can more
    easily access authoritative accounting guidance. It is organized
    by topic, subtopic, section, and paragraph, each of which is
    identified by a numerical designation. This statement applies
    beginning in third quarter 2009. All accounting references have
    been updated, and therefore U.S.&#160;GAAP standards have been
    replaced with ASC references. This standard had no impact on the
    Company&#146;s financial position, results of operations or cash
    flows.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In August 2009, the FASB issued Accounting Standards Update
    <FONT style="white-space: nowrap">No.&#160;2009-5,</FONT>
    &#147;Measuring Liabilities at Fair Value&#148; (&#147;ASU
    <FONT style="white-space: nowrap">2009-05&#148;).</FONT>
    ASU <FONT style="white-space: nowrap">2009-05</FONT>
    amends Accounting Standards Codification Topic 820, &#147;Fair
    Value Measurements.&#148; Specifically, ASU
    <FONT style="white-space: nowrap">2009-05</FONT>
    provides clarification that in circumstances in which a quoted
    price in an active market for the identical liability is not
    available, a reporting entity is required to measure fair value
    using one or more of the following methods: 1)&#160;a valuation
    technique that uses a)&#160;the quoted price of the identical
    liability when traded as an asset or b)&#160;quoted prices for
    similar liabilities or similar liabilities when traded as assets
    <FONT style="white-space: nowrap">and/or</FONT>
    2)&#160;a valuation technique that is consistent with the
    principles of Topic 820 of the Accounting Standards Codification
    (e.g. an income approach or market approach). ASU
    <FONT style="white-space: nowrap">2009-05</FONT> also
    clarifies that when estimating the fair value of a liability, a
    reporting entity is not required to adjust to include inputs
    relating to the existence of transfer restrictions on that
    liability. The Company does not anticipate that the adoption of
    this statement will have a material impact on its consolidated
    financial statements.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In September 2009, the Emerging Issues Task Force (EITF) reached
    final consensus on ASC
    <FONT style="white-space: nowrap">605-25,</FONT>
    &#147;Revenue Arrangements with Multiple Deliverables.&#148; ASC
    <FONT style="white-space: nowrap">605-25</FONT>
    addresses how to determine whether an arrangement involving
    multiple deliverables contains more than one unit of accounting,
    and how the arrangement consideration should be allocated among
    the separate units of accounting.
    <FONT style="white-space: nowrap">EITF&#160;08-1</FONT>
    may be applied retrospectively or prospectively for new or
    materially modified arrangements and early adoption is
    permitted. The Company does not anticipate that the adoption of
    this statement will have a material impact on its consolidated
    financial statements.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">BUSINESS
    COMBINATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, the Company completed the acquisition of
    China Medstar at which time China Medstar became a 100% owned
    subsidiary of the Group. The results of China Medstar&#146;s
    operations have been included in the Company&#146;s consolidated
    financial statements commencing August&#160;1, 2008, the
    acquisition date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following unaudited pro forma condensed consolidated
    financial information reflects the Group&#146;s condensed
    consolidated results of operations for the period from
    January&#160;1, 2008 to September&#160;30, 2008 (successor) as
    if the acquisition of China Medstar had occurred on
    January&#160;1, 2008. The unaudited pro forma results have been
    prepared for information purposes only and do not purport to be
    indicative of what the Company&#146;s condensed consolidated
    results of operations would have been had the acquisition of
    China Medstar actually taken place on January&#160;1, 2008, and
    may not be indicative of future results of operations. Due to
    the overall insignificance of the acquisitions and their
    respective
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-62
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    results of operations individually and in the aggregate of XHF
    and other entities for the year ended December&#160;31, 2008,
    unaudited pro forma consolidated financial information has not
    been provided.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenues, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    164,867
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,152
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,573
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,899
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss attributable to ordinary shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194,274
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,460
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per common share&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.20
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.47
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">3.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">PROPERTY,
    PLANT AND EQUIPMENT, NET</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property, plant and equipment consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="60%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">September 30, 2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Medical equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    299,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    524,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Electronic and office equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,154
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Motor vehicles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvement and building improvement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,552
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Construction in progress
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,883
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,702
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    367,384
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    609,623
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89,307
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: Accumulated depreciation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,263
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52,190
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,646
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    349,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,661
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Depreciation expenses were approximately RMB9,413 and RMB35,101
    (US$5,142) for nine months ended September&#160;30, 2008 and
    2009, respectively. As at December&#160;31, 2008 and
    September&#160;30, 2009, certain of the Group&#146;s property,
    plant and equipment were pledged as security for bank borrowings
    (see note&#160;5.) As at December&#160;31, 2008 and
    September&#160;30, 2009, the Company held equipment under
    operating lease contracts with customers with an original cost
    of RMB299,100 and RMB241,414 (US$35,366) and accumulated
    depreciation of RMB17,705 and RMB23,786 (US$3,485), respectively.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-63
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">4.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">DEPOSITS
    FOR NON-CURRENT ASSETS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Deposits for non-current assets consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">September&#160;30,
    2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit for purchase of property, plant and equipment*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    128,749
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98,822
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit held by a related party **
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,630
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,420
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,405
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other ***
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,609
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,777
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147,851
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,659
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=468 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">*&#160;
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents interest-free
    non-refundable partial payments to suppliers associated with
    contracts the Group enters into for the future scheduled
    delivery of medical equipment to customers. As at
    September&#160;30, 2009, the remaining contractual obligations
    associated with these purchase contracts are approximately
    RMB102,688 (US$15,043) which is included in the amount disclosed
    as Purchase commitments in note&#160;12. The risk of loss
    arising from non-performance by or bankruptcy of the suppliers
    is assessed prior to ordering the equipment. To date, the Group
    has not experienced any loss on deposit to suppliers.
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">**
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">On October&#160;31, 2008, the Group
    entered into a long-term sale and purchase agreement with Our
    Medical New Technology, under which the Group agreed to purchase
    gamma knife systems at agreed upon prices and Our Medical New
    Technology also agreed to provide the Group relevant maintenance
    and repair services and training. Our Medical New Technology is
    controlled by an individual who is a relative of a shareholder
    of the company. (See note&#160;10.)
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">***
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The Group has entered into two
    distinct framework agreements with Chang&#146;an Hospital Co.
    Ltd. (&#147;Chang&#146;an&#148;) and Chang&#146;an Information
    Industry (Group) Co., Ltd., (&#147;Chang&#146;an
    Information&#148;) towards the development and construction of
    the following two medical facilities:
    </FONT></TD>
</TR>

</TABLE>



<DIV align="left" style="margin-left: 3%; margin-right: 0%; text-indent: 0%; font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;18, 2007, the Group entered into a framework
    agreement to build a proton treatment center in Beijing,
    pursuant to which the Group paid deposits to a subsidiary of
    Chang&#146;an Information to be used towards the construction of
    the proton treatment center (&#147;Beijing Proton Medical
    Center&#148;). Total deposits paid as of December&#160;31, 2008
    and September&#160;30, 2009 pursuant to this arrangement
    amounted to RMB3,821 and RMB14,615 (US$2,141), respectively.
</DIV>



<DIV align="left" style="margin-left: 3%; margin-right: 0%; text-indent: 0%; font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;1, 2008, the Group entered into a framework
    agreement with Chang&#146;an to build a cancer center in
    northwest China, the Chang&#146;an CMS International Cancer
    Center (&#147;CCICC&#148;) pursuant to which the Group paid
    deposits to Chang&#146;an totaling RMB17,000 and RMB18,000
    (US$2,635), which have been recorded as a non-current deposit as
    of December&#160;31, 2008 and September&#160;30, 2009,
    respectively. (See note 15.)
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">5.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">BANK
    BORROWINGS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">September&#160;30,
    2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,760
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    179,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Comprised of:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Short-term
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Long-term, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,640
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    74,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,970
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,760
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    179,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All bank borrowings at December&#160;31, 2008 and
    September&#160;30, 2009 are obtained from financial institutions
    in the PRC and are secured by equipment with a net book value of
    RMB81,595 and RMB217,646 (US$31,884), accounts receivable with
    carrying value of nil and RMB10,131 (US$1,484), and restricted
    cash with carrying value of nil and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-64
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    RMB7,245 (US$1,062), respectively. Restricted cash is classified
    as current and non-current in the amounts of RMB2,012 (US$295)
    and RMB5,233 (US$767), respectively, based on the classification
    of the underlying financing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As at December&#160;31, 2008 and September&#160;30, 2009, the
    short-term bank borrowing bore a weighted average interest of
    6.66% and 5.07% per annum, and the long-term bank borrowings
    bore weighted average interest of 7.47% and 5.18% per annum,
    respectively. All borrowings are denominated in RMB.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group entered into four new bank borrowings with PRC
    financial institutions during the nine months ended
    September&#160;30, 2009 with an aggregate principal amount of
    RMB155,000, of which RMB93,980 (US$13,768) was drawn down as at
    September&#160;30, 2009. The weighted average interest rate of
    these four new bank borrowings was 5.47%. The three bank
    financing arrangements are secured by certain accounts
    receivable and restricted cash deposited with each of the
    respective financial institutions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    One of these new borrowing arrangements were entered into by a
    subsidiary of the Group, MSC, which requires MSC and AMS,
    another subsidiary of the Group, in accordance with PRC GAAP, to
    maintain a financial reporting covenant of tangible net worth of
    at least RMB400,000 and RMB180,000 and total gearing ratio of
    less than 0.5 and 0.36, respectively. Tangible net worth is
    calculated as the sum of issued share capital and reserves less
    goodwill and intangible assets and any amount due from
    shareholders and the total gearing ratio is calculated as the
    ratio of total liabilities to tangible net worth. The Group was
    in compliance of these financial covenants as of
    September&#160;30, 2009. The remaining bank borrowings do not
    have any financial reporting or administrative covenants
    restricting the Company&#146;s operating, investing and
    financing activities.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">6.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">CONTINGENTLY
    REDEEMABLE CONVERTIBLE PREFERRED SHARES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Background</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2007, OMS, a subsidiary of the Group,
    issued notes convertible into Series&#160;A contingently
    redeemable convertible preferred shares (the &#147;Series&#160;A
    Preferred Shares&#148;) with a principal amount of US$5,000 (the
    &#147;Tranche&#160;A Convertible Notes&#148;) to Carlyle Asia
    Growth Partners III, L.P. (hereafter, &#147;Carlyle Asia&#148;)
    and CAGP III Co- Investment, L.P. (an affiliate of Carlyle Asia,
    together with Carlyle Asia, &#147;Carlyle&#148;) for cash
    consideration of US$5,000. On April&#160;10, 2008, the total
    principal and accrued and unpaid interest of the Tranche&#160;A
    Convertible Notes amounting to US$5,171 were converted into
    28,882 Series&#160;A Preferred Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;2, 2008, the Company issued notes convertible into
    Series&#160;A Preferred Shares (&#147;Tranche&#160;B Convertible
    Notes&#148;) at the holder&#146;s option to Carlyle with a
    principal amount of US$20,000. On July&#160;31, 2008, Carlyle
    exercised its conversion right and the total principal and
    accrued and unpaid interest of the Tranche&#160;B Convertible
    Notes amounting to US$20,547 was converted into 87,425
    Series&#160;A Preferred Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;10, 2008, OMS issued an aggregate of 53,070
    Series&#160;A Preferred Shares to Carlyle and CICC Sun Company
    Limited (&#147;CICC&#148;) for total cash proceeds of US$10,000.
    On June&#160;18, 2008, the Company agreed that a relative of a
    director of the Company shall transfer 756,500 of her own
    holdings of the Company&#146;s ordinary shares, which were
    redesignated as 7,565 Series&#160;A Preferred Shares, and issued
    to CICC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;20, 2008, the Company issued an aggregate of
    233,332 Series&#160;B contingently redeemable convertible
    preferred shares (the &#147;Series&#160;B Preferred
    Shares&#148;) to Carlyle, Starr Investments Cayman II, Inc.
    (&#147;Starr&#148;), and CICC for cash consideration of
    US$25,000, US$25,000 and US$10,000, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounting
    for the contingently redeemable convertible preferred
    shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Preferred Shares have been classified as mezzanine equity
    recorded at the subscription amount, less issuance costs, and is
    accreted to the redemption amount using the effective interest
    method. The redemption amount for the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-65
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Preferred Shares provides the shareholder with a 12.5%
    compounded annual return on the original subscription price or
    converted value, of which 5% is payable as a fixed dividend. For
    the nine months ended September&#160;30, 2008 and 2009, the
    Group recorded accretion related to its Series&#160;A Preferred
    Shares in the amount of RMB8,969 and RMB23,851 (US$3,494), of
    which RMB3,655 and RMB9,192 (US$1,347) were recorded as
    dividends payable, respectively. Similarly, for the nine months
    ended September&#160;30, 2009, the Group recorded accretion
    expense for its Series&#160;B Preferred Shares in the amount of
    RMB38,383 (US$5,623), of which RMB15,448 (US$2,263) was recorded
    as dividends payable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A beneficial conversion feature exists when the effective
    conversion price of the Preferred Shares is lower than the fair
    value of the ordinary shares on their issuance date. The
    effective conversion price of the Series&#160;A Preferred
    Shares, after considering the impact of all adjustments to the
    conversion price, was lower than the average estimated fair
    value of US$0.95 per ordinary share. The allocation of the
    beneficial conversion feature is recorded to additional paid-in
    capital. Because the Preferred Shares do not have a stated
    redemption date, the beneficial conversion feature is accreted
    to the earliest conversion date, which was upon issuance. For
    the nine months ended September&#160;30, 2008, the aggregate
    beneficial conversion feature in relation to the April 2008 and
    June 2008 issuances of Series&#160;A Preferred Shares amounted
    to RMB253,317 (US$37,110).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon the occurrence of a Put Trigger Event, each holder of
    Preferred Shares shall have the right to require the Company to
    purchase all the Preferred Shares held by the Preferred
    Shareholders at a rate of return of 12.5%. A Put Trigger Event
    means any of the non-completion of a qualified initial public
    offering by the third anniversary of the closing date of the
    subscription of the Preferred Shares, the resignation of certain
    key directors of the Company and its subsidiaries which would
    likely to result in a material adverse effect, or the breach or
    failure to comply with any applicable laws that has had or would
    be reasonably likely to have, a material adverse effect. As at
    December&#160;31, 2008 and September&#160;30, 2009, the
    Series&#160;A Preferred Shares redemption amounts were US$38,147
    and US$41,638, and similarly, the Series&#160;B Preferred Shares
    redemption amounts were US$61,390 and US$67,008, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the case of liquidation, dissolution or winding up of the
    Company, each holder of Preferred Shares shall be entitled to
    receive, prior to and in preference to any distribution of any
    of the assets or surplus of funds of the Company to the holders
    of the ordinary shares, the amount equal to the sum of 150%
    times the original price of each Preferred share plus all
    accrued but unpaid dividends thereon. As at December&#160;31,
    2008 and September&#160;30, 2009, aggregate liquidation
    preference amounts for the Series&#160;A Preferred Shares were
    US$54,573 and US$55,471, respectively, and similarly, the
    aggregate liquidation preference amounts for the Series&#160;B
    Preferred Shares were US$90,583 and US$92,846, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">7.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">RESTRICTED
    NET ASSETS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with the PRC Regulations on Enterprises with
    Foreign Investment and their articles of association, a foreign
    invested enterprise established in the PRC is required to
    provide certain statutory reserves, namely general reserve fund,
    the enterprise expansion fund and staff welfare and bonus fund
    which are appropriated from net profit as reported in the
    enterprise&#146;s PRC statutory accounts. A foreign invested
    enterprise is required to allocate at least 10% of its annual
    after-tax profit to the general reserve until such reserve has
    reached 50% of its respective registered capital based on the
    enterprise&#146;s PRC statutory accounts. Appropriations to the
    enterprise expansion fund and staff welfare and bonus fund are
    at the discretion of the board of directors for all foreign
    invested enterprises.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of these PRC laws and regulations that require
    annual appropriations of 10% of after-tax income to be set aside
    prior to payment of dividends as general reserve fund, the
    Company&#146;s PRC subsidiaries are restricted in their ability
    to transfer a portion of their net assets to the Company.
    Amounts restricted include paid-in capital, statutory reserve
    funds and net assets of the Company&#146;s PRC subsidiaries, as
    determined pursuant to PRC generally accepted
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-66
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    accounting principles, totaling approximately RMB680,476 and
    RMB912,850 (US$133,727) as of December&#160;31, 2008 and
    September&#160;30, 2009, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">8.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">TAXATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the nine months ended September&#160;30, 2009, the Group
    has no additional unrecognized tax benefits relating to
    uncertain tax positions except for accruing interests related to
    unsolved previous year unrecognized tax benefits. Also, the
    Group does not expect that the amount of unrecognized tax
    benefits will increase significantly within the next
    12&#160;months.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2008 and September&#160;30, 2009, the
    Group has recognized approximately RMB20,509 and RMB21,647
    (US$3,171) as an accrual for unrecognized tax benefits,
    respectively. The final outcome of the tax uncertainty is
    dependent upon various matters including tax examinations,
    interpretation of tax laws or expiration of status of
    limitation. However, due to the uncertainties associated with
    the status of examinations, including the protocols of
    finalizing audits by the relevant tax authorities, there is a
    high degree of uncertainty regarding the future cash outflows
    associated with these tax uncertainties. As of
    September&#160;30, 2009, the Group classified the RMB21,647
    (US$3,171) accrual as a current liability.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">9.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">EMPLOYEE
    SHARE OPTIONS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;16, 2008, the Board of Directors adopted the
    2008&#160;Share Incentive Plan (&#147;The 2008&#160;Share
    Incentive Plan&#148;). The 2008&#160;Share Incentive Plan
    provides for the granting of options, share appreciation rights,
    or other share-based awards to key employees, directors or
    consultants. The total number of the ordinary shares of the
    Company that may be issued under the 2008&#160;Share Incentive
    Plan is up to 1,321,800. As of September&#160;30, 2009, no
    awards have been granted under the 2008&#160;Share Incentive
    Plan.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">10.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">RELATED
    PARTY TRANSACTIONS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    a)&#160;&#160;Related parties
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Name of Related
    Parties</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Relationship with the
    Group</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A relative of shareholder of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and shareholder of the Company
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and shareholder of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Yaw Kong Yap
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and shareholder of the Company
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shenzhen Hai Ji Tai Technology Co., Ltd. (&#147;Haijitai&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company owned by Mr. Haifeng Liu
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Beijing Medstar Hi-Tech Investment Co., Ltd. (&#147;Beijing
    Medstar&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company under the control of Mr. Zheng Cheng
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Our Medical New Technology Co., Ltd
    (&#147;Our&#160;Medical&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company under the control of Mr. Haifeng Liu
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-67
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    b)&#160;&#160;
</TD>
    <TD align="left">
    The Group had the following related party transactions for the
    nine months ended September&#160;30, 2008 and 2009:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Short-term interest-free loans borrowed from:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Repayment of interest-free loans borrowed from:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Haijitai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-current deposits made to:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Our Medical
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,442
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,676
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Purchase of radioactive material source through utilization of
    non-current deposits from :
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Our Medical
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Imputed interest, calculated using incremental borrowing rates
    ranging from 6.57% to 7.48%, amounting to approximately
    RMB2,425, and RMB54 (US$8)for the nine months ended
    September&#160;30, 2008 and 2009 respectively, were recorded
    with an offsetting credit to Additional Paid-in Capital.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    c)&#160;&#160;The Group had the following related party balances:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="51%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="17%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">September&#160;30,
    2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amount due to related parties:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Beijing Medstar
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mr. Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,351
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,351
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mr. Yaw Kong Yap
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposits held by a related party:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Our Medical
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,630
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,420
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,405
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All balances with the related parties as of December&#160;31,
    2008 and September&#160;30, 2009 were unsecured, interest-free
    and have no fixed terms of repayment.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">11.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">EMPLOYEE
    DEFINED CONTRIBUTION PLAN</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Full time employees of the Group in the PRC participate in a
    government mandated defined contribution plan, pursuant to which
    certain pension benefits, medical care, employee housing fund
    and other welfare benefits are provided to employees. Chinese
    labor regulations require that the PRC subsidiaries of the Group
    make contributions to
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-68
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    the government for these benefits based on certain percentages
    of the employees&#146; salaries. The Group has no legal
    obligation for the benefits beyond the contributions made. The
    total amounts for such employee benefits, which were expensed as
    incurred, were approximately RMB480 and RMB1,694 (US$248) for
    the nine months ended September&#160;30, 2008 and 2009,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Obligations for contributions to defined contribution retirement
    plans for full-time employees in Singapore are recognized as
    expense in the statements of operations as incurred. The total
    amounts for such employee benefits, who is also a Director of
    the Company, were approximately RMB15 and RMB40 (US$6) for the
    nine months ended September&#160;30, 2008 and 2009, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">12.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">COMMITMENTS
    AND CONTINGENCIES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Operating
    lease commitments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the nine months ended September&#160;30, 2009, the Group
    entered into two non-cancellable corporate office operating
    leases with a lease term of two and three years, respectively.
    These leases have no renewal options, material rent escalation
    clauses or contingent rents. Upon termination of the leases,
    they are renewable at fair value upon negotiation with the
    lessor.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Future minimum payments under non-cancelable operating leases
    with initial terms in excess of one year consist of the
    following at September&#160;30, 2009:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="84%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Three months ended December&#160;31,
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Year ended December&#160;31,
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,148
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    754
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,763
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    698
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2012
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,305
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,552
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,986
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Payments under operating leases are expensed on a straight-line
    basis over the periods of their respective leases. For the nine
    months ended September&#160;30, 2008 and 2009, total rental
    expenses for all operating leases amounted to approximately
    RMB1,581 and RMB3,830 (US$561), respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Purchase
    commitments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group has commitments to purchase certain medical equipment
    of approximately RMB102,688 (US$15,043) as of September&#160;30,
    2009, which are scheduled to be paid within one year.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">13.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SEGMENT
    REPORTING</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group&#146;s chief operating decision maker operates,
    evaluates performance, allocates resources, and manages its
    business as a single segment which includes primarily lease,
    management services and equipment sales.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Lease and management services accounted for approximately 90%
    and 90% of the Group&#146;s net revenue for the nine months
    ended September&#160;30, 2008 and 2009, respectively. Any
    significant reduction in sales from this service could have a
    substantial negative impact on the Group&#146;s results of
    operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-69
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Hospital A and Hospital B represented the two largest customers
    of the Group accounting for approximately RMB21,988 (US$3,221)
    and RMB20,861 (US$3,056), respectively, each of which is more
    than 10% of the Group&#146;s consolidated revenues for nine
    months ended September&#160;30, 2009. Hospital A represented the
    largest customer of the Group accounting for approximately
    RMB14,644 of revenues, which is greater than 10% of the
    Group&#146;s consolidated revenues for the nine months ended
    September&#160;30, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Geographic disclosures:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As the Group primarily generates its revenues from customers in
    the PRC, no geographical segments are presented. All of the
    Group&#146;s long-lived assets are located in the PRC.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">14.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">(LOSS)
    INCOME PER SHARE (UNAUDITED)</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Basic and diluted (loss) income per share for each of the
    periods presented is calculated as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom">
    <B>(amounts in thousands except for the number of shares and per
    share data)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Numerator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -20pt; margin-left: 20pt">
    Net (loss) income attributable to ordinary shareholders used in
    calculating loss per ordinary share&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (222,270
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,914
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Denominator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -20pt; margin-left: 20pt">
    Weighted average number of ordinary shares outstanding used in
    calculating basic and diluted loss per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,621,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Basic and diluted (loss) income per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.06
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the nine months ended September&#160;30, 2008, the diluted
    loss per share is the same as basic loss per share because the
    if-converted method would not be applied as the effect of the
    convertible notes would be anti-dilutive. The share options
    should not be included in the calculation of diluted loss per
    share because the company incurred a net loss and, therefore,
    the effect would be anti-dilutive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the nine months ended September&#160;30, 2009, the basic
    income per share was calculated using the two class method
    because the Preferred Shares were participating securities.
    Diluted income per share is the same as basic income per share
    because the effects of the Preferred Shares were anti-dilutive
    when computed on an &#147;if converted&#148; basis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2008, the Company issued Series&#160;A and Series&#160;B
    contingently redeemable convertible preferred shares. Each
    Preferred Share shall be convertible, at the option of the
    holder thereof, at any time after the closing of the
    subscription, into a number of fully paid and non-assessable
    ordinary shares at a ratio 1:100 and is subject to adjustment
    pursuant to anti-dilution provisions. One hundred percent of
    each class of the Preferred Shares which are outstanding
    immediately prior to the closing of the qualified initial public
    offering shall, on and with effect from the closing of the
    qualified initial public offering, be automatically converted
    into ordinary shares. Assuming the conversion had occurred
    &#147;on a
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-70
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    hypothetical&#148; basis on January&#160;1, 2009, the pro-forma
    basic and diluted loss per share for the nine months ended
    September&#160;30, 2009 is calculated as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="82%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>For the Nine<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Months Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(pro forma) <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(amounts in <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>thousands except <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>for the number of <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>shares and per <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>share data)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Numerator</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income attributable to ordinary shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma adjustments:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;A contingently redeemable convertible preferred
    shares&#160;&#151; accretion to redemption amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,851
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;B contingently redeemable convertible preferred
    shares&#160;&#151; accretion to redemption amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,383
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income for pro forma basic and diluted income per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Denominator</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average number of ordinary shares outstanding used in
    calculating basic income per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of Series&#160;A preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,694,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of Series&#160;B preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,333,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average number of ordinary shares outstanding used in
    calculating basic and diluted income per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111,455,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma income per share&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma income per share&#160;&#151; basic and diluted (in US$)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">15.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ARRANGEMENT
    WITH CHANG&#146;AN HOSPITAL CO., LTD.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group has entered into the following agreements with
    Chang&#146;an Hospital Co., Ltd. (&#147;Chang&#146;an&#148;), a
    general hospital located in Xi&#146;an in Shaanxi province in
    the PRC, which is also a significant customer of the Group, and
    certain of its related parties, including the controlling parent
    of Chang&#146;an, Chang&#146;an Information Industry (Group)
    Co., Ltd., (&#147;Chang&#146;an Information&#148;), a
    China-based conglomerate engaged in information technology, real
    estate and the medical industries; a subsidiary of
    Chang&#146;an, Xi&#146;an Century Friendship Medical Technology
    R&#038;D Co., Ltd.
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-71
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (&#147;Xi&#146;an&#148;), and another subsidiary controlled by
    Chang&#146;an Information, Beijing Century Friendship
    Science&#160;&#038; Technology Development Co., Ltd.,
    (&#147;Beijing Century&#148;):
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Management
    agreements to provide stand-alone management
    services</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group entered into a Medical Equipment Entrusted Management
    Agreement on March&#160;1, 2007 with Xi&#146;an and
    Chang&#146;an to provide management services with respect to
    radiotherapy and diagnostic equipment owned by Xi&#146;an
    located in the oncology center of Chang&#146;an. Commencing
    January&#160;1, 2010 or an agreed upon earlier date, Concord has
    the option to purchase the radiotherapy and diagnostic equipment
    owned by Xi&#146;an at fair value if the Chang&#146;an oncology
    center&#146;s annualized revenues achieves a certain targeted
    level. Total management services revenue recognized under this
    contract was RMB6,135 and RMB10,921 (US$1,600) for the nine
    months ended September&#160;30, 2008 and 2009, respectively.
    Accounts receivable related to this contract as at
    December&#160;31, 2008 and September&#160;30, 2009 was RMB4,000
    and RMB10,921 (US$1,600), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;25, 2009, the Group entered into an Equipment
    Purchase Agreement with Xi&#146;an and Chang&#146;an to acquire
    the radiotherapy and diagnostic equipment for a total cash
    consideration of RMB72,716 (US$10,646), of which RMB50,000
    (US$7,325) was paid in September 2009. Concurrently, the Group
    also converted the stand-alone management services arrangement
    into a lease and management service agreement, which provides
    the Group with a percentage of net profit generated by
    Chang&#146;an&#146;s oncology center. Commencing September 2009,
    the Group records all revenue associated with this arrangement
    as lease and management services revenue. The depreciation
    expense of the associated equipment is recorded as lease and
    management services cost of revenues. Total lease and management
    service revenue recognized under this lease and management
    service agreement was RMB2,036 (US$298) for the nine months
    ended September&#160;30, 2009. Accounts receivable related to
    this contract as at September&#160;30, 2009 was RMB2,036
    (US$298).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;1, 2008, the Company signed an Entrusted
    Management Contract with Xi&#146;an and Chang&#146;an to provide
    general administrative management services to Chang&#146;an.
    Under this arrangement, the Group earns a certain percentage of
    total monthly revenues of Chang&#146;an Hospital. In accordance
    with the contract, the Group paid a performance guarantee
    deposit of RMB15,000 (US$2,197) to a related party of
    Xi&#146;an, which is refundable 15&#160;days after the
    cancellation or expiration of the contract (January&#160;15,
    2010). Total revenue recognized during the nine months ended
    September&#160;30, 2009 under this contract was RMB9,024
    (US$1,322). Accounts receivable related to this contract as at
    September&#160;30, 2009 was RMB9,024 (US$1,322).
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Beijing
    Proton Medical Center</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;18, 2007, the Group entered into a framework
    agreement with Chang&#146;an Information to build a Beijing
    Proton Medical Center (&#147;Proton Center&#148;). The Proton
    Center will initially be established by Chang&#146;an
    Information with a total registered capital of RMB100,000. The
    parties agreed that after certain capital injections from the
    Group are made for purposes of financing the construction and
    center development costs, the Company will hold a 51.2% interest
    in the Proton Center, while Jian Chang Group Limited, a related
    party of Chang&#146;an, will hold 28.8% and China-Japan
    Friendship Hospital, a state-owned hospital, will hold 20.0%.
    Once the Proton Center commences operations, the Group shall own
    a 51.2% controlling interest in the Proton Center and will
    consolidate the operating results and financial position within
    the Group. Additional contractual arrangements will be entered
    into by the Group once all relevant permits and approvals are
    obtained. In order for this framework agreement to become
    effective, the Group is required to pay a deposit of RMB10,000
    (US$1,465); this deposit was not paid as of December&#160;31,
    2008 and September&#160;30, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To assist with the project, the Group has made deposits to
    Beijing Century in the amounts of RMB3,821 and RMB14,615
    (US$2,141) as of December&#160;31, 2008 and September&#160;30,
    2009, respectively, towards certain setup and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-72
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    construction costs of the Proton Center; these deposits are due
    back to the Group by December&#160;31, 2009. All of the deposits
    are guaranteed by Chang&#146;an Information.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Chang&#146;an
    CMS International Cancer Center</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;1, 2008, the Group entered into a framework
    agreement with Xi&#146;an to build a cancer center in northwest
    China, to be called Chang&#146;an CMS International Cancer
    Center (&#147;CCICC&#148;). Although the CCICC will initially be
    established by Xi&#146;an, the parties agreed that after certain
    initial capital injections estimated at RMB34,800 (US$5,098)
    from the Group are made, the Company shall hold a controlling
    interest of 52% in the CCICC, while Xi&#146;an will hold a
    non-controlling interest of 48%. Similarly, the Group
    anticipates having to consolidate the operating results and
    financial position of the CCICC when the Group obtains a
    controlling interest. As of September&#160;30, 2009, Xi&#146;an
    is waiting for all relevant permits and approvals to be obtained
    prior to the legal establishment the CCICC, upon which,
    additional contractual arrangements will be entered into by the
    Group. As of December&#160;31, 2008 and September&#160;30, 2009,
    the Group paid a deposit of RMB15,000 (US$2,197) to a related
    party of Xi&#146;an in accordance with the framework agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are no other obligations under the current framework
    agreement and the agreement does not specify a contractual
    completion date for the deposit to be repaid to the Group. If
    the CCICC is established, the RMB15,000 deposit will be applied
    against future capital injections beyond the initial capital
    investment estimate of RMB34,800. The Group has also paid
    deposits to Xi&#146;an to be used towards setup and construction
    costs of the CCICC amounting to RMB2,000 and RMB3,000 (US$439)
    as of December&#160;31, 2008 and September&#160;30, 2009,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group had the following transactions with Chang&#146;an and
    its affiliated companies for the nine months ended
    September&#160;30, 2008 and 2009:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="62%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Management services revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Medical Equipment Entrusted Management Agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,135
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,921
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entrusted Management Contract
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,024
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,322
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lease and management service revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,036
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    298
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,135
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,981
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,220
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounts receivable due from Chang&#146;an
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,981
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,220
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group had the following deposits on loan with Chang&#146;an
    and its affiliated companies as at December&#160;31, 2008 and
    September&#160;30, 2009:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="54%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December 31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current&#160;&#151; Entrusted Management Contract
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,197
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-current&#160;&#151; Proton Center and CCICC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,778
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-73
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS&#160;&#151; (Continued)<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">16.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SUBSEQUENT
    EVENTS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with ASC subtopic
    <FONT style="white-space: nowrap">855-10</FONT>
    <FONT style="white-space: nowrap">(&#147;ASC&#160;855-10&#148;),</FONT>
    <I>Subsequent Events: Overall </I>(Pre-Codification:
    SFAS&#160;165), the Company evaluated subsequent events through
    December&#160;7, 2009, which was the date that the consolidated
    interim financial statements were available to be issued. The
    Company had the following significant subsequent events:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2009, the Company&#146;s Board of Directors
    approved the following resolutions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To distribute an interim dividend to the holders of the ordinary
    shares as at November&#160;17, 2009 in the sum of
    (i)&#160;US$2,391,534 to the holders of the ordinary shares; and
    (ii)&#160;US$1,590,676 to the holders of the Series&#160;A and B
    Preferred Shares, such dividend to be payable in cash on or
    about November&#160;27, 2009.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To amend the Articles of Association in conjunction with the
    Company&#146;s initial public offering, to reflect a 1-for-100
    share split of the Company&#146;s ordinary shares whereby each
    ordinary share of the Company is subdivided into 100&#160;shares
    at a par value of US$0.0001. All shares and per share amounts
    presented in the accompanying consolidated financial statements
    have been revised on a retroactive basis to reflect the effect
    of the share split. The par value per ordinary share has been
    retroactively revised as if it had been adjusted in proportion
    to the
    <FONT style="white-space: nowrap">1-for-100</FONT>
    share split.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To amend the Company&#146;s 2008&#160;Share Incentive Plan, to
    increase the total number of ordinary shares that may be issued
    under the 2008 Incentive Plan from 1,321,800 ordinary shares to
    4,765,800 ordinary shares
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;27, 2009, the board of directors approved a
    grant of options to its directors and employees to purchase an
    aggregate of 4,765,800&#160;ordinary shares under its 2008 share
    incentive plan. The stock options will have an exercise price
    equal to the Company&#146;s initial public offering price, a
    contractual life of eight years and will vest ratably over four
    years. The measurement date will occur once the exercise price
    is established, at which time the Company will estimate the fair
    value of these share-based payment awards and recognize
    compensation cost over each employee&#146;s respective requisite
    service period which closely approximates the vesting period of
    the awards.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;4, 2009, the Company received a formal
    plaintiff&#146;s claim alleging that certain of the Group&#146;s
    centers gamma knife systems were infringing third-party owned
    patents. This claim relates to a patent used in the head gamma
    knife system manufactured by one of the Company&#146;s equipment
    manufacturers, Our Medical New Technology Co., Ltd., or Our
    Medical, which is a related party of the Group. A previous legal
    proceeding involving the same such patent was initiated in June
    2000 against Our Medical, its related parties, and AMS, a
    subsidiary of the Group, whereby the relevant PRC court also
    ordered the use of such equipment to cease. The Company is
    currently assessing the validity of the claim and has received a
    written indemnification from Our Medical for any damages or
    losses incurred from any intellectual property infringement by
    such system. The Company has identified one head gamma knife
    system operating in one of the centers that could be subject to
    such claim, representing approximately 1.5% and 1.0% of the
    Group&#146;s total net revenues in 2008 and for the nine months
    ended September 30, 2009, respectively. Based on the early
    stages of this legal claim, the Group has determined that it is
    not probable that a loss will result from this contingency nor
    could an amount of the loss contingency be reasonably estimated.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
  <!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-74
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times"> CHINA
    MEDSTAR PTE. LIMITED</FONT></B>
</DIV>

<A name='128'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INDEX TO
    CONSOLIDATED FINANCIAL STATEMENTS</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="91%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Page</FONT></B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#312'>Report of Independent Registered Public
    Accounting Firm</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-76
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#313'>Consolidated Balance Sheets as of
    December&#160;31, 2007 and as of July&#160;31, 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-77
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#314'>Consolidated Statements of Operations for the
    year ended December&#160;31, 2007 and the seven month period
    ended July&#160;31, 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-79
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#315'>Consolidated Statements of Cash Flows for the
    year ended December&#160;31, 2007 and the seven month period
    ended July&#160;31, 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-80
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#316'>Consolidated Statements of Changes in
    Shareholders&#146; Equity for the year ended December&#160;31,
    2007 and the seven month period ended July&#160;31, 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-82
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#317'>Notes to the Consolidated Financial Statements
    for the year ended December&#160;31, 2007 and the seven month
    period ended July&#160;31, 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-83
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-75
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='312'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">REPORT OF
    INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors and Shareholders of
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China Medstar Limited
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have audited the accompanying consolidated balance sheets of
    China Medstar Limited (the &#147;Company&#148;) and its
    subsidiaries (together, the &#147;Group&#148;) as of
    December&#160;31, 2007 and July&#160;31, 2008, and the related
    consolidated statements of operations, cash flows and changes in
    shareholders&#146; equity for the year and the seven months
    period then ended. These financial statements are the
    responsibility of the Company&#146;s management. Our
    responsibility is to express an opinion on these financial
    statements based on our audits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We conducted our audits in accordance with the standards of the
    Public Company Accounting Oversight Board (United States). Those
    standards require that we plan and perform the audit to obtain
    reasonable assurance about whether the financial statements are
    free of material misstatement. We were not engaged to perform an
    audit of the Group&#146;s internal control over financial
    reporting. Our audits included consideration of internal control
    over financial reporting as a basis for designing audit
    procedures that are appropriate in the circumstances, but not
    for the purpose of expressing an opinion on the effectiveness of
    the Group&#146;s internal control over financial reporting.
    Accordingly, we express no such opinion. An audit also includes
    examining, on a test basis, evidence supporting the amounts and
    disclosures in the financial statements, assessing the
    accounting principles used and significant estimates made by
    management, and evaluating the overall financial statement
    presentation. We believe that our audits provide a reasonable
    basis for our opinion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In our opinion, the financial statements referred to above
    present fairly, in all material respects, the consolidated
    financial position of the Group at December&#160;31, 2007 and
    July&#160;31, 2008 and the consolidated results of their
    operations and their cash flows for the year and the seven
    months period then ended in conformity with U.S.&#160;generally
    accepted accounting principles.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Ernst&#160;&#038;
    Young Hua Ming</DIV>
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shenzhen, the People&#146;s Republic of China
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    September&#160;3, 2009
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-76
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">


    <A name='313'><B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    BALANCE SHEETS</A><BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and U.S. Dollars
    (&#147;US$&#148;))</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="41%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As at<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at July&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Notes</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="17" align="center" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>ASSETS</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Current assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,926
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,869
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,285
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Prepayment and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,780
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,095
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred tax assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Current assets held for sale
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total current assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,212
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Non-current assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Property, plant and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    216,918
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    284,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,707
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deposits for property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,505
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred tax assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Non-current assets held for sale
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,229
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,059
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    347,306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460,012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-77
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    BALANCE SHEETS&#160;&#151; (Continued)<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and U.S. Dollars
    (&#147;US$&#148;) except for number of shares)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As at<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at July&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Notes</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="17" align="center" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Current liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Long-term bank borrowings, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,623
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,320
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,830
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,733
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,238
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accrual for purchase of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,259
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,825
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Income tax payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,605
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    694
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenue, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    737
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,622
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Current liabilities of discontinued operation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Amounts due to related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,881
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,033
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total current liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    123,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,124
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Non-current liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Long-term bank borrowings, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    103,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,099
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenue, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,683
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,344
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    490
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Lease deposits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,118
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,185
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    149,504
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    233,323
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,180
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Commitments and contingencies</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Minority interests</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,179
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Shareholders&#146; equity:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Share capital (Issued and outstanding&#160;&#151;
    27,564,138&#160;shares as at December&#160;31, 2007 and
    July&#160;31, 2008; nil par value)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,979
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,237
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,962
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (929
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (682
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Retained earnings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,112
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total shareholders&#146; equity</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    195,623
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    226,689
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total liabilities and shareholders&#146; equity</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    347,306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460,012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-78
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">


    <A name='314'><B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF OPERATIONS<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    </A><B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and U.S. Dollars
    (&#147;US$&#148;))</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Seven Month Period Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Notes</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">July&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Revenues, net of business tax, value-added tax and related
    surcharge:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,357
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,745
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,141
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,169
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,148
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,873
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,210
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Cost of revenues:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,484
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,806
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,169
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Others
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,781
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,265
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,178
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Gross profit</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,186
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Operating expenses:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,911
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,581
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (232
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,224
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,340
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,221
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Operating profit</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,579
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    351
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,204
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,585
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (233
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loss from disposal of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (400
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (49
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (230
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (200
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Income from continuing operations before income taxes</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Income tax expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (922
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,445
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,237
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Income from continuing operations</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,822
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,655
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Discontinued operations:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loss from discontinued operations, net of taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (193
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (683
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Gain on disposal of discontinued operations, net of taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    164
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>(Loss) gain from discontinued operations</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (193
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    439
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    64
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Net income</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,629
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,115
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying notes are an integral part of the consolidated
    financial statements
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-79
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">


    <A name='315'><B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF CASH FLOWS</A><BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and U.S. Dollars
    (&#147;US$&#148;))</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Seven Month Period Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">July&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    CASH FLOWS FROM OPERATING ACTIVITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,629
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,115
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Add/less: net loss (income) from discontinued operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    193
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (439
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (64
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Income from continuing operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,822
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,655
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Adjustments to reconcile income from continuing operations to
    net cash generated from operating activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,725
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    399
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,180
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Loss on disposal of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Deferred tax (benefit) expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,776
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Changes in operating assets and liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Increase in accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,196
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,694
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,204
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Increase in prepayment and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (803
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,083
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (159
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Decrease in other non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,613
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,205
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    (Decrease) increase in accounts payable and note payables
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,803
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,506
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Increase in accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    270
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,964
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    (Decrease) increase in deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (826
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Increase in amounts due to related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    188
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Increase in long term lessee deposits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    117
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    156
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    (Decrease) increase in income tax payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (762
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net cash generated from operating activities from continuing
    operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,953
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,033
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net cash used in operating activities from discontinued
    operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,684
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    413
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,425
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    CASH FLOWS FROM INVESTING ACTIVITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Acquisition of property, plant and equipment, net of related
    payables
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,661
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26,351
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,860
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Deposits for the purchase of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (81,637
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72,713
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,652
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Proceeds from disposal of fixed assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    158
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net cash used in investing activities from continuing operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (101,140
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (99,064
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,512
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net cash used in investing activities from discontinued
    operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (317
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (77
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net cash used in investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (101,457
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (99,141
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,523
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-80
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF CASH FLOWS&#160;&#151; (Continued)<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and U.S. Dollars
    (&#147;US$&#148;))</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Seven Month Period<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>January&#160;1 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">July&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CASH FLOWS FROM FINANCING ACTIVITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Decrease in restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from long-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    135,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,780
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loans from Ascendium and other unrelated parties (note&#160;7)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loans from related party
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,274
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,798
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Repayment of long-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (103,985
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (33,613
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,924
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Repayment of short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,222
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net cash used in financing activities from continuing operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,441
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,510
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net cash generated from financing activities from discontinued
    operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,350
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,343
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,441
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,510
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,384
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net decrease in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,461
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,342
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (929
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash at beginning of the year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,387
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,926
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,798
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash at end of the year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,926
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,869
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Supplemental schedule of cash flow information:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,502
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,979
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (876
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,204
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,585
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (232
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Supplemental schedule of non-cash activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acquisition of property, plant and equipment included in accrued
    expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,403
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acquisition of property, plant and equipment and other
    intangible assets through utilization of deposits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,809
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-81
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">


    <A name='316'><B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; EQUITY</A><BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and U.S. Dollars
    (&#147;US$&#148;) except for number of shares)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ordinary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Share<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid-In<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Comprehensive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Retained<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shareholders&#146;<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Income (Loss)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Earnings</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Equity</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of January&#160;1, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,564,138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (353
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,129
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    181,041
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,629
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,629
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (576
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (576
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Share-based compensation (note&#160;10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,564,138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,237
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (929
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    195,623
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,341
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Share-based compensation (note&#160;10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,725
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,725
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of July&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,564,138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,962
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (682
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    226,689
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of July&#160;31, 2008, in US$
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,979
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,112
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-82
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

    <A name='317'><B>NOTES TO THE CONSOLIDATED FINANCIAL
    STATEMENTS</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    </A><B>(Amounts in thousands of Renminbi (&#147;RMB&#148;), and
    U.S.&#160;Dollars (&#147;US$&#148;) except for number of
    shares)</B>
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ORGANIZATION
    AND BASIS OF PRESENTATION</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying consolidated financial statements include the
    financial statements of China Medstar Limited (the
    &#147;Company&#148;, or &#147;China Medstar&#148;) and its
    subsidiaries, Medstar (Shanghai) Leasing Co., Ltd. (formerly
    Shanghai Medstar Investment Management Limited Company,
    &#147;MSC&#148;) and Medstar (Beijing) International Anti-Aging
    Health Bio-tech Inc. (&#147;Anti-Aging&#148;). The Company and
    its subsidiaries are collectively referred to as the
    &#147;Group&#148;.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company was incorporated in the Republic of Singapore on
    August&#160;7, 2003 as an investment holding company. In
    November 2006, the Company completed an initial public offering
    and became a listed company with its shares trading in
    Alternative Investment Market (the &#147;AIM&#148;) of the
    London Stock Exchange in United Kingdom.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, Ascendium Group Limited
    (&#147;Ascendium&#148;) acquired the Company for cash
    consideration of &#163;17.1&#160;million, (RMB238,747 or
    US$34,975) or 62 pence per share in exchange for 100% of the
    Company&#146;s issued and outstanding share capital. Immediately
    prior to the acquisition, China Medstar delisted its ordinary
    shares from trading on the AIM and converted from being public
    limited company to a private limited company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group is principally engaged in the leasing of radiotherapy
    and diagnostic imaging equipment and the provision of management
    services to hospitals located in the People&#146;s Republic of
    China (&#147;PRC&#148;). The Group develops and operates its
    business through its subsidiaries. Details of the Company&#146;s
    subsidiaries as of December&#160;31, 2007 and July&#160;31, 2008
    are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="17%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="17%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="26%">&nbsp;</TD>	<!-- colindex=06 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percentage of Ownership by the Company</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Date of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Place of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Company</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Establishment</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Establishment</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Principal Activities</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    MSC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    March 21, 2003
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    PRC
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    100%
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    100%
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Leasing and sales of medical equipment, provision of<BR>
    management services
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Anti-Aging
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    September&#160;29,&#160;2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    PRC
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    53%
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    &#151;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Provision of technology and consultancy services
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;30, 2008, the Group entered into an agreement to
    sell its 53% interest in Anti-Aging. Accordingly, the disposal
    was accounted for as a discontinued operation (See note&#160;9).
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    OF SIGNIFICANT ACCOUNTING POLICIES</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Basis
    of presentation and use of estimates</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying consolidated financial statements have been
    prepared in accordance with United States generally accepted
    accounting principles (&#147;U.S.&#160;GAAP&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The preparation of consolidated financial statements in
    conformity with U.S.&#160;GAAP requires management to make
    estimates and assumptions that affect the reported amounts of
    assets and liabilities, disclosures of contingent assets and
    liabilities at the balance sheet dates and the reported amounts
    of revenues and expenses during the reporting periods.
    Significant estimates and assumptions reflected in the
    Company&#146;s financial statements include, but are not limited
    to, revenue recognition, allowance for doubtful accounts, useful
    lives of property, plant and equipment, realization of deferred
    tax assets and share-based compensation expenses. Actual results
    could materially differ from those estimates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Principles
    of Consolidation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The consolidated financial statements include the financial
    statements of the Company and its subsidiaries. All transactions
    and balances between the Company and its subsidiaries have been
    eliminated upon consolidation.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-83
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Foreign
    Currency Translation and Transactions</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s PRC subsidiaries determine their functional
    currencies to be the Chinese Renminbi (&#147;RMB&#148;) based on
    the criteria of SFAS&#160;52, &#147;Foreign Currency
    Translation&#148;. The Company uses the RMB as its reporting
    currency. The Company uses the monthly average exchange rate for
    the year and the exchange rate at the balance sheet date to
    translate the operating results and financial position,
    respectively. Translation differences are recorded in
    accumulated other comprehensive income, a component of
    shareholders&#146; equity. Functional currency of the Company is
    United States dollars (&#147;US$&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Transactions denominated in foreign currencies are remeasured
    into the functional currency at the exchange rates prevailing on
    the transaction dates. Foreign currency denominated financial
    assets and liabilities are remeasured at the exchange rates
    prevailing at the balance sheet date. Exchange gains and losses
    are included in the consolidated statements of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Convenience
    translation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amounts in US$ are presented for the convenience of the reader
    and are translated at the noon buying rate of RMB6.8262 to
    US$1.00 on September&#160;30, 2009 in the City of New York for
    cable transfers of RMB as certified for customs purposes by the
    Federal Reserve Bank of New York. No representation is made that
    the RMB amounts could have been, or could be, converted into US$
    at such rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Cash</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cash consists of cash on hand and bank deposits, which are
    unrestricted as to withdrawal and use.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounts
    receivable and allowance for doubtful accounts</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group considers many factors in assessing the collectability
    of its receivables due from its customers, such as, the aging of
    the amounts due, the customer&#146;s payment history and
    credit-worthiness. An allowance for doubtful accounts is
    recorded in the period in which uncollectability is determined
    to be probable. Accounts receivable balances are written off
    after all collection efforts have been exhausted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Leases</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with SFAS&#160;13 &#147;Accounting for
    Leases&#148; (&#147;SFAS&#160;13&#148;), leases for a lessee are
    classified at the inception date as either a capital lease or an
    operating lease. The Company assesses a lease to be a capital
    lease if any of the following conditions exists:
    a)&#160;ownership is transferred to the lessee by the end of the
    lease term, b)&#160;there is a bargain purchase option,
    c)&#160;the lease term is at least 75% of the property&#146;s
    estimated remaining economic life or d)&#160;the present value
    of the minimum lease payments at the beginning of the lease term
    is 90% or more of the fair value of the leased property to the
    lessor at the inception date. A capital lease is accounted for
    as if there was an acquisition of an asset and an incurrence of
    an obligation at the inception of the lease. The capitalized
    lease obligation reflects the present value of future rental
    payments, discounted at the appropriate interest rates. The cost
    of the asset is amortized over the lease term. However, if
    ownership is transferred at the end of the lease term, the cost
    of the asset is amortized as set out below under property, plant
    and equipment.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-84
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Property,
    Plant and Equipment, net</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property, plant and equipment are stated at cost and are
    depreciated using the straight-line method over the estimated
    useful lives of the assets, as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="37%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=align1 -->
    <TD width="10%" align="left">&nbsp;</TD>	<!-- colindex=03 type=align2 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Category</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Estimated Useful Life</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="4" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Estimated Residual
    Value</FONT></B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Medical equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Shorter of customer contract or 6-12&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    &#151;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Electronic and office equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    5&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5-10
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Shorter of lease term or 5&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    &#151;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    The cost of the asset is amortized over the lease term. However,
    if ownership is transferred at the end of the lease term, the
    cost of the asset is amortized over the shorter of customer
    contract or 6-12&#160;years.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Repair and maintenance costs are charged to expense as incurred,
    whereas the cost of renewals and betterment that extends the
    useful lives of property, plant and equipment are capitalized as
    additions to the related assets. Retirements, sales and
    disposals of assets are recorded by removing the cost and
    accumulated depreciation from the asset and accumulated
    depreciation accounts with any resulting gain or loss reflected
    in the consolidated statements of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost incurred in constructing new facilities, including progress
    payment, interest and other costs relating to the construction
    are capitalized and transferred to fixed assets on completion.
    Total interest costs incurred and capitalized during the year
    ended December&#160;31, 2007 and the period from January 1 to
    July&#160;31, 2008 amounted to approximately RMB 1,235 and
    RMB4,489 (US$658), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Impairment
    of Long-Lived Assets</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group evaluates its long-lived assets or asset group for
    impairment whenever events or changes in circumstances (such as
    a significant adverse change to market conditions that will
    impact the future use of the assets) indicate that the carrying
    amount of a group of long-lived assets may not be fully
    recoverable. When these events occur, the Group evaluates the
    impairment by comparing the carrying amount of the assets to
    future undiscounted net cash flows expected to result from the
    use of the assets and their eventual disposition. If the sum of
    the expected undiscounted cash flows is less than the carrying
    amount of the assets, the Group recognizes an impairment loss
    based on the excess of the carrying amount of the asset group
    over its fair value, generally based upon discounted cash flows.
    No such impairment charge was recognized for any of the periods
    presented.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fair
    Value of Financial Instruments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The carrying amounts of the Group&#146;s financial instruments,
    including cash, accounts receivable, accounts payable, accrued
    and other liabilities, and amounts due to related parties
    approximate fair value because of their short maturities. The
    carrying amounts of the Group&#146;s short-term and long-term
    bank borrowings bear interest at floating rates and therefore
    approximate the fair value of these obligations based upon
    management&#146;s best estimates of interest rates that would be
    available for similar debt obligations at December&#160;31, 2007
    and 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Revenue
    Recognition</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The majority of the Group&#146;s revenues are derived directly
    from hospitals that enter into medical equipment lease and
    management service arrangements with the Company. A lease and
    management service arrangement will typically include the
    purchase and installation of diagnostic imaging
    <FONT style="white-space: nowrap">and/or</FONT>
    radiation oncology system (&#147;medical equipment&#148;) at the
    hospital, and the full-time deployment of a qualified system
    technician that is responsible for certain management services
    of managing radiotherapy or diagnostic services such that the
    hospital and doctors can provide specialized services to their
    patients. To a lesser extent, revenues are generated from
    stand-alone management service arrangements where the hospital
    has previously acquired the equipment from the Company or
    through another vendor or sale of medical equipment.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-85
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenues arising from sales of medical equipment and services
    are recognized when there is persuasive evidence of an
    arrangement, the fee is fixed or determinable, collectability is
    reasonably assured and the delivery of the medical equipment or
    services has occurred. When the fees associated with an
    arrangement containing extended payment terms are not considered
    to be fixed or determinable at the outset of arrangement,
    revenue is recognized as payments become due, and all of the
    other criteria above have been met.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group is subject to approximately 5% business tax and
    related surcharges on the revenue earned from provision of
    leasing and management services. The Group has recognized
    revenues net of these business taxes and other surcharges. Such
    business tax and related surcharges for the year ended
    December&#160;31, 2007 and the seven month period ended
    July&#160;31, 2008 are approximately RMB3,763, RMB2,856
    (US$418), respectively. In the event that revenue recognition is
    deferred to a later period, the related business tax and other
    surcharges and fees is also deferred and will be recognized only
    upon recognition of the deferred revenue.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Lease and
    management services</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group enters into a lease and management service
    arrangements with independent hospitals with terms ranging from
    6 to 20&#160;years, pursuant to which the Group receives a
    percentage of the net profit (&#147;profit share&#148; as
    defined in the arrangement) of the hospital unit that delivers
    the diagnostic imaging
    <FONT style="white-space: nowrap">and/or</FONT>
    radiation oncology services determined in accordance with the
    terms of the arrangement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to
    <FONT style="white-space: nowrap">EITF&#160;01-8,</FONT>
    &#147;Determining Whether an Arrangement Contains a Lease&#148;
    <FONT style="white-space: nowrap">(&#147;EITF&#160;01-8&#148;)</FONT>
    the Group determined that the Lease and management service
    arrangements contain a lease of medical equipment. The hospital
    has ability and right to operate the medical equipment while
    obtaining more than a minor amount of the output. The
    arrangement also contains a non-lease deliverable being the
    management service element. The arrangement consideration should
    be allocated between the lease element and the non-lease
    deliverables on a relative fair value basis, however because all
    of the consideration is earned through the contingent rent
    feature discussed below, there is no impact of such allocation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    SFAS&#160;13, &#147;Accounting for Leases&#148;
    (&#147;SFAS&#160;13&#148;) is applied to the lease elements of
    the arrangement and U.S.&#160;Securities and Exchange Commission
    (&#147;SEC&#148;) Staff Accounting Bulletin&#160;No. 104
    (&#147;SAB&#160;104&#148;) is applied to other elements of the
    arrangement not within the scope of SFAS 13.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The lease element of rentals and management service receivable
    under the lease arrangement are based purely on a profit share
    formula (&#147;contingent rent feature&#148;). The profitability
    of the business unit is not only dependent on the medical
    equipment placed at the hospital, but also the hospital&#146;s
    ability to manage the costs and appoint doctors and clinical
    staff to operate the equipment. Certain of the lease and
    management service arrangements may include a transfer of
    ownership or bargain purchase option at the end of the lease
    term. Due to the length of the lease term, the collectibility of
    these minimum lease payments are not considered predictable and
    there are important uncertainties regarding the future costs to
    be incurred by the Group relating to the arrangement. Therefore,
    the lessor&#146;s additional criteria for capital lease
    classification in SFAS&#160;13&#160;par. 8 (a)&#160;and
    (b)&#160;was not met even if any of the SFAS&#160;13&#160;par. 7
    criteria for capital leases are met. Consequently, the Group
    accounts for all lease arrangements as operating leases.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As the collectability of the minimum lease rental is not
    considered predictable, and the remaining rental is considered
    contingent, the Group recognizes revenue when the lease payments
    under the arrangement become due, i.e. when the profit share
    under the arrangement is determined and agreed upon by both
    parties to the agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the service element of the arrangement, as discussed above,
    revenue is only considered determinable at the time the
    consideration under the arrangement becomes known, i.e. when the
    profit share under the arrangement is determined and agreed upon
    by both parties. Revenue is recognized when determined if all
    other basic criteria have also been met.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenue derived from the lease and management service
    arrangement is recorded under &#147;Lease and management
    service&#148; in the consolidated statements of operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-86
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Management
    Services</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group provides stand-alone management services to certain
    hospitals which are already in possession of radiotherapy and
    diagnostic equipment. The fee for the management service
    arrangement is either based on a contracted percentage of
    monthly revenue generated by the specified hospital unit
    (&#147;revenue share&#148;) or in limited instances on a fixed
    monthly fee. The consideration that is based on a contracted
    percentage of revenue is recognized when the monthly fees under
    the arrangement become due, i.e. when the revenue share under
    the arrangement is determined and agreed upon by both parties to
    the agreement. Fixed monthly fees are recognized ratably over
    the service term. Revenue derived from stand-alone management
    services is recorded under &#147;Management Service&#148; in the
    consolidated statements of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Medical
    equipment sales</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the application of Emerging Issues Task Force
    Consensus
    <FONT style="white-space: nowrap">99-19,</FONT>
    &#147;Reporting Revenue Gross as Principal versus Net as an
    Agent&#148;
    <FONT style="white-space: nowrap">(&#147;EITF&#160;99-19&#148;),</FONT>
    the Group records revenue related to medical equipment sales on
    a net basis when the equipment is delivered to the customer and
    the sales price is determinable. During the year ended
    December&#160;31, 2007 and the seven month period ended
    July&#160;31, 2008, the Company had medical equipment sales, of
    RMB3,094, RMB6,148 (US$901), net of 17% value-added tax of
    approximately RMB1,865, RMB6,150 (US$901), respectively. Revenue
    derived from medical equipment sales is recorded under
    &#147;Other, net&#148; in the consolidated statements of
    operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cost
    relating to lease and management service arrangement</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The cost of medical equipment that is leased under an operating
    lease is included in property, plant and equipment in the
    balance sheet. The medical equipment is depreciated using the
    Group&#146;s depreciation policy. In determining the
    Group&#146;s normal depreciation policy, the planned use of the
    asset, the lease term and its related useful life is taken into
    account. The costs of the management service component is
    recognized as an expense as incurred.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cost of
    management services</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Costs of management services mainly include the labor costs of
    technicians and management staff.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cost of
    equipment sales</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost of equipment sales, recorded net against the related
    revenue, include the cost of the equipment purchased and other
    direct costs involved in the equipment sales.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Income
    Taxes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group follows the liability method of accounting for income
    taxes. Under this method, deferred tax assets and liabilities
    are determined based on the difference between the financial
    reporting and tax bases of assets and liabilities using enacted
    tax rates that will be in effect in the period in which the
    differences are expected to reverse. The Group records a
    valuation allowance to offset deferred tax assets if based on
    the weight of available evidence, it is more-likely-than-not
    that some portion, or all, of the deferred tax assets will not
    be realized. The effect on deferred taxes of a change in tax
    rate is recognized in tax expense in the period that includes
    the enactment date of the change in tax rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;1, 2007, the Group adopted FASB Interpretation
    No.&#160;48, &#147;Accounting for Uncertainty in Income
    Taxes&#160;&#151; an interpretation of FASB Statement
    No.&#160;109&#148; (&#147;FIN&#160;48&#148;), which clarifies
    the accounting and disclosure for uncertainty in income taxes.
    Interest and penalties arising from underpayment of income taxes
    shall be computed in accordance with the related PRC tax law.
    The amount of interest expense is computed by applying the
    applicable statutory rate of interest to the difference between
    the tax position recognized and the amount previously taken or
    expected to be taken in a tax return. Interest and penalties
    recognized in accordance with FIN&#160;48 is classified in the
    financial statements as income tax expense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with the provisions of FIN&#160;48, the Group
    recognizes in its financial statements the impact of a tax
    position if a tax return position or future tax position is
    &#147;more likely than not&#148; to prevail based on the facts
    and technical
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-87
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    merits of the position. Tax positions that meet the &#147;more
    likely than not&#148; recognition threshold are measured at the
    largest amount of tax benefit that has a greater than fifty
    percent likelihood of being realized upon settlement. The
    Group&#146;s estimated liability for unrecognized tax benefits
    which is included in the &#147;accrued expenses and other
    liabilities&#148; account is periodically assessed for adequacy
    and may be affected by changing interpretations of laws, rulings
    by tax authorities, changes
    <FONT style="white-space: nowrap">and/or</FONT>
    developments with respect to tax audits, and expiration of the
    statute of limitations. The outcome for a particular audit
    cannot be determined with certainty prior to the conclusion of
    the audit and, in some cases, appeal or litigation process. The
    actual benefits ultimately realized may differ from the
    Group&#146;s estimates. As each audit is concluded, adjustments,
    if any, are recorded in the Group&#146;s financial statements.
    Additionally, in future periods, changes in facts,
    circumstances, and new information may require the Group to
    adjust the recognition and measurement estimates with regard to
    individual tax positions. Changes in recognition and measurement
    estimates are recognized in the period in which the changes
    occur.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Share-based
    compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s employees and non-employees participate in
    the Company&#146;s share-based scheme which is more fully
    discussed in note&#160;10. Share-based awards granted to
    employees are accounted for under SFAS&#160;No.&#160;123(R)
    &#147;Share-Based Payment&#148; (&#147;SFAS&#160;123(R)&#148;).
    Share-based awards granted to employees and non-employees are
    accounted for under SFAS&#160;No.&#160;123(R) &#147;Share-Based
    Payment&#148; (&#147;SFAS&#160;123(R)&#148;) and EITF Issue
    <FONT style="white-space: nowrap">No.&#160;96-18</FONT>
    &#147;Accounting for Equity Instruments That Are Issued to Other
    Than Employees for Acquiring, or in Conjunction with Selling,
    Goods or Services&#148;
    <FONT style="white-space: nowrap">(&#147;EITF&#160;96-18&#148;),</FONT>
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with SFAS&#160;123(R), all grants of share-based
    awards to employees are recognized in the financial statements
    based on their grant date fair values which are calculated using
    an option pricing model. The Group has elected to recognize
    compensation expense using the straight-line method for all
    share options granted with graded vesting based on service
    conditions. To the extent the required vesting conditions are
    not met resulting in the forfeiture of the share-based awards,
    previously recognized compensation expense relating to those
    awards are reversed. SFAS&#160;123(R) requires forfeitures to be
    estimated at the time of grant and revised, if necessary, in
    subsequent period if actual forfeitures differ from initial
    estimates. Share-based compensation expense was recorded net of
    estimated forfeitures such that expense was recorded only for
    those share-based awards that are expected to vest.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with
    <FONT style="white-space: nowrap">EITF&#160;96-18,</FONT>
    grants of share-based awards to non-employees are measured at
    fair value at the earlier of the performance commitment date and
    the date when performance is complete.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Comprehensive
    Income</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Comprehensive income is defined to include all changes in equity
    except those resulting from investments by owners and
    distributions to owners. Among other disclosures,
    SFAS&#160;No.&#160;130, &#147;Reporting Comprehensive
    Income&#148;, requires that all items that are required to be
    recognized under current accounting standards as components of
    comprehensive income be reported in a financial statement that
    is displayed with the same prominence as other financial
    statements. During the periods presented, the Company&#146;s
    comprehensive income represents its net income and foreign
    currency translation adjustments and is presented in the
    statement of changes in shareholders&#146; equity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;4, 2007 the FASB issued SFAS&#160;No.&#160;141
    (Revised 2007), &#147;Business Combinations&#148;
    (SFAS&#160;141(R)). This Statement will apply to all
    transactions in which an entity obtains control of one or more
    other businesses. In general, SFAS&#160;No.&#160;141(R) requires
    the acquiring entity in a business combination to recognize the
    fair value of all the assets acquired and liabilities assumed in
    the transaction; establishes the acquisition date as the fair
    value measurement point; and modifies the disclosure
    requirements. Additionally, it changes the accounting treatment
    for transaction costs, acquired contingent arrangements,
    in-process research and development, restructuring costs,
    changes in deferred tax asset valuation allowances as a result
    of business combination, and changes in income tax uncertainties
    after the acquisition date. SFAS&#160;141(R) applies
    prospectively to business combinations for which the acquisition
    date is on or after the beginning of the first annual reporting
    period beginning on or after December&#160;15,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-88
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2008. Earlier adoption is prohibited. However, accounting for
    changes in valuation allowances for acquired deferred tax assets
    and the resolution of uncertain tax positions for prior business
    combinations will impact tax expense instead of impacting
    goodwill. The Company is currently assessing the impact, if any,
    that the adoption of SFAS&#160;141(R) will have on its financial
    statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;4, 2007 the FASB issued SFAS&#160;No.&#160;160,
    &#147;Non-controlling Interests in Consolidated Financial
    Statements&#160;&#151; An Amendment of ARB No.&#160;51&#148;
    (&#147;SFAS&#160;160&#148;). SFAS&#160;160 establishes new
    accounting and reporting standards for the non-controlling
    interest in a subsidiary and for the deconsolidation of a
    subsidiary. Specifically, this statement requires the
    recognition of a non-controlling interest (minority interest) as
    equity in the consolidated financial statements and separate
    from the parent&#146;s equity. The amount of net income
    attributable to the non-controlling interest will be included in
    consolidated net income on the face of the statement of
    operations. SFAS&#160;160 clarifies that changes in a
    parent&#146;s ownership interest in a subsidiary that do not
    result in deconsolidation are equity transactions if the parent
    retains its controlling financial interest. In addition, this
    statement requires that a parent recognize a gain or loss in net
    income when a subsidiary is deconsolidated. Such gain or loss
    will be measured using the fair value of the non-controlling
    equity investment on the deconsolidation date. SFAS&#160;160
    also includes expanded disclosure requirements regarding the
    interests of the parent and its non-controlling interest.
    SFAS&#160;160 is effective for fiscal years, and interim periods
    within those fiscal years, beginning on or after
    December&#160;15, 2008 and will be applied prospectively with
    the exception of the presentation and disclosure requirements,
    which must be applied retrospectively for all periods presented.
    Earlier adoption is prohibited. The Company is currently
    assessing the impact, if any, that the adoption of SFAS&#160;160
    will have on its financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2008, the FASB issued FASB Staff Position
    <FONT style="white-space: nowrap">No.&#160;FAS&#160;142-3,</FONT>
    Determination of the Useful Life of Intangible Assets (&#147;FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3&#148;).</FONT>
    FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3</FONT>
    amends the factors that should be considered in developing
    renewal or extension assumptions used to determine the useful
    life of a recognized intangible asset under FASB Statement
    No.&#160;142, &#147;Goodwill and Other Intangible Assets,&#148;
    and requires enhanced disclosures relating to: (a)&#160;the
    entity&#146;s accounting policy on the treatment of costs
    incurred to renew or extend the term of a recognized intangible
    asset; (b)&#160;in the period of acquisition or renewal, the
    weighted-average period prior to the next renewal or extension
    (both explicit and implicit), by major intangible asset class;
    and (c)&#160;for an entity that capitalizes renewal or extension
    costs, the total amount of costs incurred in the period to renew
    or extend the term of a recognized intangible asset for each
    period for which a statement of financial position is presented,
    by major intangible asset class. FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3</FONT>
    must be applied prospectively to all intangible assets acquired
    as of and subsequent to fiscal years beginning after
    December&#160;15, 2008, and interim periods within those fiscal
    years. Early adoption is prohibited. The Group is currently
    evaluating the impact that FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3</FONT>
    will have on the consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In May 2009, the FASB issued SFAS&#160;No.&#160;165
    &#147;Subsequent Events&#148; (&#147;SFAS&#160;165&#148;).
    SFAS&#160;165 names the two types of subsequent events either as
    recognized subsequent events or non-recognized subsequent events
    and modifies the definition of subsequent events as events or
    transactions that occur after the balance sheet date, but before
    the financial statements are issued. The statement also requires
    entities to disclose the date through which an entity has
    evaluated subsequent events and the basis for that date.
    SFAS&#160;165 is effective on a prospective basis for interim or
    annual financial periods ending after June&#160;15, 2009. The
    Company does not believe that the application of SFAS&#160;165
    will have a significant impact on its financial position and
    results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2009, the FASB issued SFAS&#160;No.&#160;168, &#147;The
    FASB Accounting Standards
    Codification<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    and the Hierarchy of Generally Accepted Accounting
    Principles&#160;&#151; a replacement of FASB Statement
    No.&#160;162.&#148; The FASB Accounting Standards
    Codification<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    (Codification) will become the source of authoritative United
    States GAAP recognized by the FASB to be applied by
    nongovernmental entities. This Statement and the Codification
    will not change GAAP. This Statement is effective for interim
    and annual periods ending after September&#160;15, 2009. The
    Codification will not change GAAP and therefore should not
    impact the Company&#146;s consolidated financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-89
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">3.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">CONCENTRATION
    OF RISKS</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concentration
    of Credit Risk</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Assets that potentially subject the Group to significant
    concentration of credit risk primarily consist of cash and
    accounts receivable. As of July&#160;31, 2008, substantially all
    of the Group&#146;s cash were deposited in financial
    institutions located in the PRC and in Singapore, which
    management believes are of high credit quality. Accounts
    receivable are typically unsecured and are derived from revenue
    earned from customers in the PRC. The risk with respect to
    accounts receivable is mitigated by credit evaluations the Group
    performs on its customers and its ongoing monitoring process of
    outstanding balances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concentration
    of Customers</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group currently generates a substantial portion of its
    revenue from a limited number of customers. As a percentage of
    revenues, the top five customers accounted for 58% for the year
    ended December&#160;31, 2007 and 52% for the period from January
    1 to July&#160;31, 2008. The loss of revenue from any of these
    customers would have a significant negative impact on the
    Group&#146;s business. However arrangements with customers are
    mostly long-term in nature. Due to the Group&#146;s dependence
    on a limited number of customers and the contingent fees based
    on variables the Group does not control of certain contracts,
    any negative events with respect to the Group&#146;s customers
    may cause material fluctuations or declines in the Group&#146;s
    revenue and have a material adverse effect on the Group&#146;s
    financial condition and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concentration
    of Suppliers</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A significant portion of the Group&#146;s medical equipment are
    sourced from its three largest suppliers who collectively
    accounted for 100% of the total medical equipment purchases of
    the Group for the year ended December&#160;31, 2007 and 96% of
    the total medical equipment purchases of the Group for the
    period from January 1 to July&#160;31, 2008. Failure to develop
    or maintain the relationships with these suppliers may cause the
    Group to be unable to expand its business with new hospitals.
    Any disruption in the supply of the medical equipment to the
    Group may adversely affect the Group&#146;s business, financial
    condition and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Current
    vulnerability due to certain other concentrations</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group&#146;s operations may be adversely affected by
    significant political, economic and social uncertainties in the
    PRC. Although the PRC government has been pursuing economic
    reform policies for more than 20&#160;years, no assurance can be
    given that the PRC government will continue to pursue such
    policies or that such policies may not be significantly altered,
    especially in the event of a change in leadership, social or
    political disruption or unforeseen circumstances affecting the
    PRC&#146;s political, economic and social conditions. There is
    also no guarantee that the PRC government&#146;s pursuit of
    economic reforms will be consistent or effective.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group transacts all of its business in RMB, which is not
    freely convertible into foreign currencies. On January&#160;1,
    1994, the PRC government abolished the dual rate system and
    introduced a single rate of exchange as quoted daily by the
    People&#146;s Bank of China (the &#147;PBOC&#148;). However, the
    unification of the exchange rates does not imply that the RMB
    may be readily convertible into United States dollars or other
    foreign currencies. All foreign exchange transactions continue
    to take place either through the PBOC or other banks authorized
    to buy and sell foreign currencies at the exchange rates quoted
    by the PBOC. Approval of foreign currency payments by the PBOC
    or other institutions requires submitting a payment application
    form together with suppliers&#146; invoices, shipping documents
    and signed contracts.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additionally, the value of the RMB is subject to changes in
    central government policies and international economic and
    political developments affecting supply and demand in the PRC
    foreign exchange trading system market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A medical-related business is subject to significant
    restrictions under current PRC laws and regulations. Currently,
    the Group conducts its operations in China through contractual
    arrangements entered into with
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-90
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    hospitals in the PRC. The relevant regulatory authorities may
    find the current contractual arrangements and businesses to be
    in violation of any existing or future PRC laws or regulations.
    If so, the relevant regulatory authorities would have broad
    discretion in dealing with such violations.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">4.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">PREPAYMENT
    AND OTHER CURRENT ASSETS</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prepayment and other current assets consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="66%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at July&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Advance to suppliers
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,564
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,564
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Receivable arising from disposal of a subsidiary (note&#160;9)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,950
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    432
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Others
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,216
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,963
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,780
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,095
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">5.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">PROPERTY,
    PLANT AND EQUIPMENT, NET</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property, plant and equipment consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at July&#160;31</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Medical equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    210,176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    286,581
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Electronic and office equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    448
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    448
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvement and building improvement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    528
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    528
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Construction in progress
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,718
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    284,637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    367,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,804
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: Accumulated depreciation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (67,719
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (82,576
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,097
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    216,918
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    284,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,707
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Depreciation expenses were approximately RMB23,180 and RMB14,857
    (US$2,176) for the year ended December&#160;31, 2007 and for the
    period from January 1 to July&#160;31, 2008, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As at July&#160;31, 2008, the Company held equipment under
    operating lease contracts with customers with an original cost
    of RMB286,581 (US$41,983) and accumulated depreciation of
    RMB82,254 (US$12,050). As at December&#160;31, 2007, the Company
    held equipment under operating lease contracts with customers
    with an original cost of RMB210,176 and accumulated depreciation
    of RMB67,490.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-91
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL,n -->
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">6.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">BANK
    BORROWINGS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at July&#160;31</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Short-term
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,623
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,320
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,830
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,123
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,820
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    103,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,099
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    123,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143,890
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,079
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All bank borrowings were obtained from financial institutions in
    the PRC and secured by the equipment under capital lease with
    net carrying value of RMB117,226 (US$17,173) (2007: RMB118,001).
    As at July&#160;31, 2008, the Company had RMB19,320 (US$2,830)
    and RMB103,070 (US$15,099) of long term facilities due within 1
    and 2&#160;years, respectively. These arrangements do not have
    any financial reporting or administrative covenants restricting
    the Company&#146;s operating, investing and financing activities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The short-term bank borrowing outstanding as of July&#160;31,
    2008 bore weighted average interest at 7.29% per annum, and was
    denominated in RMB. The long-term bank borrowings outstanding as
    of July&#160;31, 2008 bore weighted average interest at 7.48%
    per annum and were denominated in RMB.
</DIV>
<!-- XBRL,n -->
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">7.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ACCRUED
    EXPENSES AND OTHER LIABILITIES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The components of accrued expenses and other liabilities are as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As at December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>As at July&#160;31</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Unrecognized tax benefit and related interest and penalty
    (note&#160;8)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,692
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Loans from Ascendium and other unrelated parties*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Others
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,769
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,825
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amount represents interest-free
    loans borrowed from an unrelated party. Such loan is for working
    capital purpose and is repayable on demand. The balance was
    settled by the end of December&#160;31, 2008.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL,n -->
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">8.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">TAXATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Singapore</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company is incorporated in Singapore and does not conduct
    any substantive operations of its own. As the Company has no
    assessable profits for the year ended December&#160;31, 2007 and
    the period from January 1 to July&#160;31, 2008, no provision
    for tax has been made in the financial statements. In addition,
    upon payments of dividends by China Medstar to its shareholder,
    no Singapore withholding tax will be imposed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">China</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to January&#160;1, 2008, PRC enterprise income tax,
    &#147;EIT&#148;, was generally assessed at the rate of 33% of
    taxable income. However, as foreign enterprises located in
    Pudong New District of Shanghai, MSC is entitled to preferential
    EIT rate of 15%.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-92
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2007, a new enterprise income tax law (the &#147;New
    EIT Law&#148;) in the PRC was enacted which was effective on
    January&#160;1, 2008. The New EIT Law applies a uniform 25% EIT
    rate to both foreign invested enterprises and domestic
    enterprises. The new law provides a five-year transition period
    from its effective date for those enterprises which were
    established before the promulgation date of the new tax law and
    which were entitled to a preferential tax treatment such as a
    reduced tax rate or a tax holiday. Based on the transitional
    rule, certain categories of enterprises, including the foreign
    invested enterprise located in Pudong New District, which
    previously enjoyed a preferential tax rate of 15% are eligible
    for a five-year transition period during which the income tax
    rate will gradually be increased to the unified rate of 25%.
    Specifically, the applicable rates for MSC would be 18%, 20%,
    22%, 24% and 25% for 2008, 2009, 2010, 2011, 2012 and
    thereafter, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    MSC has accounted for their current and deferred income tax
    based on the five-year transitional tax rate, as applicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, the PRC tax authorities have up to five years to
    conduct examinations of the PRC entities&#146; tax filings.
    Accordingly, MSC&#146;s tax years from 2003 to 2008 remain
    subject to examination by the tax authorities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Income from continuing operations before income taxes consists
    of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Period From<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>January&#160;1 to July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-PRC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,175
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,392
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    PRC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,919
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,785
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The current and deferred components of the income tax expense
    (benefit) appearing in the consolidated statements of operations
    are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Period From<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>January&#160;1 to July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current tax expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,698
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,234
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax (benefit) expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,776
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    922
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,445
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,237
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A reconciliation of the differences between the statutory tax
    rate and the effective tax rate for EIT is as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Period From<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>January&#160;1 to July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income from continuing operations before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax computed at applicable tax rates (33% or 25%)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,322
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-deductible expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,285
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,572
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    230
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effect of preferential tax rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,431
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,009
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (441
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effect of tax rate changes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,137
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest and penalty on unrecognized tax benefits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    689
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    922
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,445
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,237
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-93
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Reconciliation of accrued unrecognized tax benefits is as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>Unrecognized Tax Benefits</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">RMB(&#146;000)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">US$(&#146;000)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance&#160;&#151; January&#160;1, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    175
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Additions based on tax positions related to the current year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance&#160;&#151; December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,619
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    237
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Additions based on tax positions related to the current period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    675
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    99
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance&#160;&#151; July&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2007 and July&#160;31, 2008, the Group
    has recognized a provision of RMB1,619 and RMB2,294 (US$336) for
    unrecognized tax benefits, of which RMB185 and RMB306 (US$45)
    would impact the effective tax rate, if ultimately recognized.
    Included in the balance at December&#160;31, 2007 and
    July&#160;31, 2008 are approximately RMB1,434 and RMB1,988
    (US$291), respectively, of tax positions for which the ultimate
    deductibility is highly certain but for which there is
    uncertainty about the timing of such deductibility. The Company
    had approximately RMB1,073 and RMB1,761 (US$258) for the payment
    of interest and penalty accrued at December&#160;31, 2007, and
    July&#160;31, 2008, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    It is possible that the amount of unrecognized tax benefits will
    change in the next twelve months. However, an estimate of the
    range of the possible change cannot be made at this time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Deferred taxes reflect the tax effects of temporary differences
    between the carrying amounts of assets and liabilities for
    financial reporting purposes and the amounts used for income tax
    purposes. The components of deferred taxes are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>As at July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    216
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, current portion, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,810
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred cost, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,664
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,198
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (175
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,174
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,642
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    680
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenue, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    320
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    272
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dividends paid by PRC subsidiaries of the Group out of the
    profits earned after December&#160;31, 2007 to non-PRC tax
    resident investors would be subject to PRC withholding tax. The
    withholding tax would be 10%, unless a foreign investor&#146;s
    tax jurisdiction has a tax treaty with China that provides for a
    lower withholding tax rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aggregate undistributed earnings of the Company&#146;s
    subsidiary located in the PRC that are available for
    distribution at July&#160;31, 2008 are considered to be
    indefinitely reinvested under Accounting Principles Board
    Opinion No.&#160;23 &#147;Accounting for Income
    Taxes&#160;&#151; Special Areas&#148; and accordingly, no
    provision has been made for taxes that would be payable upon the
    distribution of those amounts to any entity within the Group
    outside the PRC. Unrecognized deferred tax liabilities for
    temporary differences related to investments in foreign
    subsidiaries were not recorded because the determination of that
    amount is not practicable.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-94
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group does not have any present plan to pay any cash
    dividends on its ordinary shares in the foreseeable future. It
    intends to retain most of its available funds and any future
    earnings for use in the operation and expansion of its business.
    As of July&#160;31, 2008, the Group has not declared any
    dividends.
</DIV>
<!-- XBRL,n -->
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">9.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">DISCONTINUED
    OPERATIONS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;30, 2008, the Group entered into an agreement to
    sell all its 53% interest in Anti-Aging to an independent third
    party for RMB2,950 (US$432), which resulted in a gain on
    disposal of RMB1,122 (US$164), net of income tax expense of
    RMB54 (US$8). Accordingly, as of December&#160;31, 2007, the
    Company has accounted for Anti-Aging as discontinued operations.
    The assets and liabilities of Anti-Aging as at December&#160;31,
    2007 have been reclassified as assets held for sale and
    liabilities of discontinued operations, respectively, and the
    results of operations of Anti-Aging have been removed from the
    Company&#146;s results of continuing operations and cash flows
    for the year ended December&#160;31, 2007. Subsequent to the
    year end, RMB1,000 (US$146) was collected from the seller such
    that the outstanding receivable amount is RMB1,950 (US$286).
    Anti-Aging was established in September 2007 and thus did not
    generate any revenue in any of the periods presented.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The assets and liabilities of Anti-Aging reported as
    <FONT style="white-space: nowrap">held-for-sale</FONT>
    include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="86%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As at December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current assets held for sale
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,211
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Prepayment and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Current assets held for sale
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-current assets held for sale
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Property, plant and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL,n -->
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">10.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SHARE
    BASED COMPENSATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s 2006&#160;Share Option Plan (the
    &#147;Plan&#148;) was adopted on November&#160;24, 2006 and is
    administered by the Remuneration Committee (the
    &#147;Committee&#148;). Employees (including executive
    Directors) and non-executive Directors of the Company, employees
    of Group companies, subject to certain conditions, are eligible
    to participate in the Plan. Options granted from the Plan a
    maximum life of ten years from the date of grant. Options
    granted to employees cliff vest at the end of three years of
    continued employment.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-95
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table summarizes the activity of employee
    share-based awards granted in November 2006, for the year ended
    December&#160;31, 2007 and the period from January 1 to
    July&#160;31, 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="31%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=03 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=03 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=04 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=04 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=05 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=05 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=06 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=maindata -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=06 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Weighted Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-size: 9pt">Share Options<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Weighted-Average<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Grant-Date Fair<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Remaining<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Aggregated<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>granted to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Contractual Term<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Intrinsic Value<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>employees</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Number of Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(GB pound)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(GB pound)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(GB pound)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding, January&#160;1, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    872,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.78
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.36
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding, January&#160;1, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    872,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.78
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.36
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cancellation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (872,853
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.78
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.36
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.3
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding, July&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company also granted 1,240,386 options to two non-employees
    with exercise prices ranging from GBP0.78 to GBP1.97 on
    November&#160;27, 2006. The options had expiring terms ranging
    from 3 to 4&#160;years. The vesting of the options was subject
    to the successful completion of the Company&#146;s initial
    public offering which was completed on November&#160;30, 2006.
    The options were issued to these two non-employees as
    compensation for services which relate directly to the
    Company&#146;s initial public offering. Accordingly, the fair
    value of the options, representing a share issuance cost,
    results in an offsetting amount being recognized in
    shareholders&#146; equity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to Ascendium&#146;s acquisition of the Company, all
    employee and non-employee holders of share options under the
    Plan voluntarily waived their rights related to each of their
    respective share options and did not receive any compensation in
    return. The waiver from the option holders has been accounted
    for as a cancellation of stock options and thus all unrecognized
    share-based compensation cost relating to unvested stock options
    amounting to approximately RMB 2,248 (US$329) was immediately
    recognized to expense on the date of the waiver.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The fair value of each option award to employees was estimated
    using the Black&#160;&#151; Scholes Option Pricing Model by
    management of the Company. The volatility assumption was
    estimated based on the Company&#146;s historical price
    volatility of the Company&#146;s shares and therefore did not
    have data to calculate expected volatility of the price of the
    underlying ordinary shares over the expected term of the option.
    The expected term was estimated based on the vesting terms,
    contractual terms and management&#146;s expectation of exercise
    behavior of the option grantees. The risk-free rate was based on
    the market yield of UK Guilt Stock with maturity terms equal to
    the expected term of the option awards. Forfeitures were
    estimated based on historical experience. The grant date fair
    value of the share options granted in the last year in which
    options were granted (the year ended December&#160;31,
    2006)&#160;is as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.7
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Nil
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility range
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.5&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Total share-based compensation expense of RMB1,529 and RMB2,725
    (US$399) recognized in the year ended December&#160;31, 2007 and
    the period from January 1 to July&#160;31, 2008, respectively,
    were recorded in general and administrative expenses.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-96
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL,n -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">11.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">RELATED
    PARTY TRANSACTIONS</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    a)&#160;Related parties
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Name of related
    parties</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Relationship with the
    Group</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Yap Yaw Kong
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director of the Company
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Beijing Medstar Hi-Tech Investment Co., Ltd. (&#147;Beijing
    Medstar&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company under the control of a director of the Company
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    b)&#160;The Group had the following related party balances at
    the end of the period:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>As at July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amount due to related parties:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Beijing Medstar
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Yap Yaw Kong
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    220
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ascendium
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,274
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,798
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,881
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,033
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All amounts due to related parties as of December&#160;31, 2007
    and July&#160;31, 2008 were unsecured, interest-free and have no
    fixed terms of repayment.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">12.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">EMPLOYEE
    DEFINED CONTRIBUTION PLAN</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Full time employees of the Group in the PRC participate in a
    government mandated defined contribution plan, pursuant to which
    certain pension benefits, medical care, employee housing fund
    and other welfare benefits are provided to employees. Chinese
    labor regulations require that the PRC subsidiaries of the Group
    make contributions to the government for these benefits based on
    certain percentages of the employees&#146; salaries. The Group
    has no legal obligation for the benefits beyond the
    contributions made. The total amounts for such employee
    benefits, which were expensed as incurred, were approximately
    RMB1,103 and RMB637 (US$93) for the year ended December&#160;31,
    2007 and the period from January 1 to July&#160;31, 2008,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Obligations for contributions to defined contribution retirement
    plans for full-time employees in Singapore are recognized as
    expenses in the income statement as incurred. The total amounts
    for such employee benefits were approximately RMB42 and RMB55
    (US$8) for the year ended December&#160;31, 2007 and the period
    from January 1 to July&#160;31, 2008, respectively.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">13.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">COMMITMENTS
    AND CONTINGENCIES</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Operating
    lease commitments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Future minimum payments under non-cancelable operating leases
    with initial terms in excess of one year consist of the
    following at July&#160;31, 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Period from August 1 to December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,322
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-97
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Payments under operating leases are expensed on a straight-line
    basis over the periods of their respective leases. The terms of
    the leases do not contain material rent escalation or contingent
    rents. For the year ended December&#160;31, 2007 and the period
    from January 1 to July&#160;31, 2008, total rental expenses for
    all operating leases amounted for approximately RMB1,919 and
    RMB1,147 (US$168), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Purchase
    commitments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group has commitments to purchase certain medical equipment
    of approximately RMB37,916 (US$5,554), which are scheduled to be
    paid within one year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Income
    taxes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of July&#160;31, 2008, the Group has recognized approximately
    RMB4,056 (US$594) accrual for unrecognized tax benefits and
    related interest and penalty (note&#160;8). The final outcome of
    the tax uncertainty is dependent upon various matters including
    tax examinations, interpretation of tax laws or expiration of
    status of limitation. However, due to the uncertainties
    associated with the status of examinations, including the
    protocols of finalizing audits by the relevant tax authorities,
    there is a high degree of uncertainty regarding the future cash
    outflows associated with these tax uncertainties. As of
    July&#160;31, 2008, the Group classified the RMB4,056 (US$594)
    accrual as a current liability.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-98
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='129'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INDEX TO
    UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF
    OPERATIONS</FONT></B>
</DIV>
</A><DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="95%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Page</FONT></B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#403'>Introduction to Unaudited Pro Forma Condensed
    Combined Financial Information</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    P-2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#401'>Unaudited Pro Forma Condensed Combined Statement
    of Operations for the year ended December&#160;31, 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    P-3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#402'>Notes to the Unaudited Pro Forma Condensed
    Combined Financial Information </A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    P-4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    P-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='403'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">UNAUDITED
    PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, the Group acquired China Medstar Pte.
    Ltd. (&#147;China Medstar&#148;) for cash consideration of
    approximately &#163;17.1&#160;million or 62&#160;pence per share
    in exchange for 100% of China Medstar&#146;s issued and
    outstanding share capital. The following unaudited pro forma
    condensed consolidated statement of operations gives effect to
    the acquisition of China Medstar, accounted for under the
    purchase method in accordance with SFAS No.&#160;141
    &#147;Business Combinations&#148; (&#147;SFAS&#160;141&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following unaudited pro forma condensed combined statement
    of operations for the year ended December&#160;31, 2008 assumes
    that the acquisition of China Medstar was consummated on
    January&#160;1, 2008. The historical results of the Company and
    China Medstar were derived from the consolidated statements of
    operations for the year ended December&#160;31, 2008,
    respectively, included elsewhere in this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The pro forma information is presented solely for informational
    purposes and is not necessarily indicative of the combined
    results of operations that might have been achieved for the
    periods indicated, nor is it necessarily indicative of the
    future results of the combined company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The pro forma adjustments are based upon available information
    and certain assumptions we believe are reasonable under the
    circumstances. The unaudited pro forma condensed combined
    statement of operations should be read in conjunction with the
    accompanying notes and assumptions and the historical financial
    statements of the Company and China Medstar.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    P-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='401'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Unaudited
    Pro Forma Condensed Combined Statement of Operations<BR>
    for the Year Ended December&#160;31, 2008<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) except for
    number of shares)</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="42%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>China Medstar</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Adjustment</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Notes</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>For the seven<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>month period<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>ended July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Revenue, net of business tax, value-added tax and related
    surcharges:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,745
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    203,806
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,148
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,873
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    234,662
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Cost of revenue:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,046
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,806
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34,228
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,743
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26,240
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (117
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total cost of sales
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,597
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (60,585
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Gross profit</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Operating expenses:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,581
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,078
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,340
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (27,209
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Operating income</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    139,790
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,455
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,585
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,040
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (325
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (230
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Loss from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (658
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    462
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other income (expense)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (200
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,534
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Income before income taxes</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138,385
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Income tax expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,445
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31,759
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Net income from continuing operations</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,655
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Pro forma income per share from continuing operations</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Weighted average number of ordinary shares outstanding:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    P-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='402'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Note&#160;1</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate purchase price of approximately
    &#163;17.1&#160;million (RMB238,747 or US$34,975) for the
    purchase of China Medstar is comprised of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="82%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,210
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,107
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,397
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,377
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    217,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,931
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other intangible assets- customer relationships
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    and operating leases
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,380
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit for property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,505
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,089
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,529
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,835
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Liabilities assumed
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (233,323
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34,180
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total consideration paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    238,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The preliminary purchase price allocation and preliminary
    intangible asset valuations described above were based on
    valuation work determined by the Company with the assistance of
    American Appraisal China Limited, an independent valuation firm.
    The valuation report utilizes and considers generally accepted
    valuation methodologies such as the income, market, cost and
    actual transaction of shares approach. We have incorporated
    certain assumptions which include projected cash flows and
    replacement costs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This adjustment of RMB5,743 reflects an additional seven full
    months of amortization of the acquired intangibles recorded as a
    result of our acquisition of China Medstar on July&#160;31, 2008
    as if the acquisition had been consummated on January&#160;1,
    2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This adjustment of RMB 5,624 reflects an additional reduction in
    depreciation expense as if the acquisition had been consummated
    on January&#160;1, 2008 related to medical equipment because the
    assigned estimated fair values are lower than the net book
    values as at the acquisition date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Note&#160;2</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Reflects the adjustment to income tax expense based on the pro
    forma adjusting entries to depreciation expense and amortization
    expense discussed above.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    P-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611a4h0361108.gif" alt="(CMS LOGO)">
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PART&#160;II</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INFORMATION
    NOT REQUIRED IN PROSPECTUS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ITEM&#160;6&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">INDEMNIFICATION
    OF DIRECTORS AND OFFICERS</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cayman Islands law does not limit the extent to which a
    company&#146;s articles of association may provide for
    indemnification of officers and directors, except to the extent
    any such provision may be held by the Cayman Islands courts to
    be contrary to public policy, such as to provide indemnification
    against civil fraud or the consequences of committing a crime.
    Our third amended and restated memorandum and articles of
    association, which will become effective upon the closing of
    this offering, will provide for indemnification of officers and
    directors for losses, damages, costs and expenses incurred in
    their capacities as such, except through their own dishonesty,
    fraud or default.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the form of indemnification agreements filed as
    Exhibit&#160;10.2 to this registration statement, we will agree
    to indemnify our directors and executive officers against
    certain liabilities and expenses incurred by such persons in
    connection with claims made by reason of their being such a
    director or executive officer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The form of underwriting agreement to be filed as
    Exhibit&#160;1.1 to this registration statement will also
    provide for indemnification of us and our officers and directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Insofar as indemnification for liabilities arising under the
    Securities Act may be permitted to directors, officers or
    persons controlling us under the foregoing provisions, we have
    been informed that in the opinion of the SEC such
    indemnification is against public policy as expressed in the
    Securities Act and is therefore unenforceable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ITEM&#160;7&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">RECENT
    SALES OF UNREGISTERED SECURITIES</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the past three years, we have issued the following
    securities (including options to acquire our ordinary shares).
    We believe that each of the following issuances was exempt from
    registration under the Securities Act in reliance on
    Regulation&#160;S under the Securities Act or under
    Section&#160;4(2) of the Securities Act regarding transactions
    not involving a public offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="33%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="12%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Underwriting<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Date of Sale or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="right" valign="bottom">
    <B>Consideration in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Discount and<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Purchaser</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Issuance</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number of Securities</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="right" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">U.S. dollars</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Commission</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Certain director of the registrant
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    November&#160;27,&#160;2007
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    1 ordinary share*
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.05
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Notable Enterprise Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    March 8, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    225,000 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Dragon Image Investment Ltd.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    March 8, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    37,500 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Daketala International Investment Holdings Ltd.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    March 8, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    37,500 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Certain directors of the registrant and other minority
    shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    March 8, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    199,999 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,999.99
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Carlyle Asia Growth Partners III, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 3, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    53,292 Series A contingently redeemable convertible preferred
    shares<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,808,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CAGP III Co-Investment, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 3, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    2,125 Series A contingently redeemable convertible preferred
    shares<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    191,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CICC Sun Company Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 3, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    26,535 Series A contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Carlyle Asia Growth Partners III, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 10, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    convertible loan promissory
    note<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,233,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CAGP III Co-Investment, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 10, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    convertible loan promissory
    note<SUP style="font-size: 85%; vertical-align: top">(4)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    767,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CZY Investments Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    109,736 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,669,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Daketala International Investment Holdings Ltd.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    47,030 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,715,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Thousand Ocean Group Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    32,624 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,577,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Dragon Image Investment Ltd.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    16,524 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,305,396
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Top Mount Group Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    5,932 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    468,628
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="33%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="12%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Underwriting<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Date of Sale or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="right" valign="bottom">
    <B>Consideration in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Discount and<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Purchaser</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Issuance</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number of Securities</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="right" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">U.S. dollars</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Commission</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Carlyle Asia Growth Partners III, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    October 20, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    93,493 Series B contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    24,041,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CAGP III Co-Investment, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    October 20, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    3,728 Series B contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    958,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CICC Sun Company Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    October 20, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    38,889 Series B contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Starr Investments Cayman II, Inc.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    October 20, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    97,222 Series B contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Directors, Officers and Employees of the Registrant
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    November&#160;27, 2009
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    Option to purchase 4,765,800 ordinary shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Nil
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Issued in connection with a share
    swap with Ascendium Group Limited as part of the reorganization
    to establish Concord Medical Services Holdings Limited as our
    ultimate holding company.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The numbers of Series&#160;A
    contingently redeemable convertible preferred shares issued to
    Carlyle Asia Growth Partners III, L.P. and CAGP III
    Co-Investment, L.P. on April&#160;3, 2008 also include
    Series&#160;A contingently redeemable convertible preferred
    shares issued as a result of the conversion of two convertible
    loan promissory notes issued on November&#160;16, 2007 by our
    predecessor, Our Medical Services, Ltd., or OMS, plus accrued
    interest. OMS received consideration for the issuance of such
    convertible loan promissory notes in the amount of $4,808,250
    and $191,750 from Carlyle Asia Growth Partners III, L.P. and
    CAGP III Co-Investment, L.P., respectively.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The convertible loan promissory
    note was converted into 84,072 of our Series&#160;A contingently
    redeemable convertible preferred shares on July&#160;30, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The convertible loan promissory
    note was converted into 3,353 of our Series&#160;A contingently
    redeemable convertible preferred shares on July&#160;30, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Issued as settlement for the share
    options issued to certain of our directors under the share
    option plan adopted by our predecessor company, Our Medical
    Services Limited, on November&#160;17, 2007.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Does not take into account the
    share split effective on November&#160;17, 2009 whereby all of
    our issued and outstanding 704,281 ordinary shares of a par
    value of US$0.01 per share were split into 70,428,100 ordinary
    shares of US$0.0001 par value per share and the number of our
    authorized ordinary shares was increased from 4,500,000 to
    450,000,000.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ITEM&#160;8&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">EXHIBITS&#160;AND
    FINANCIAL STATEMENT SCHEDULES</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See Exhibit&#160;Index beginning on
    <FONT style="white-space: nowrap">page&#160;II-6</FONT>
    of this registration statement.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial
    Statement Schedules
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Schedules have been omitted because the information required to
    be set forth therein is not applicable or is shown in our
    consolidated financial statements or the notes thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ITEM&#160;9&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">UNDERTAKINGS</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes to provide to the
    underwriter at the closing specified in the underwriting
    agreements, certificates in such denominations and registered in
    such names as required by the underwriter to permit prompt
    delivery to each purchaser.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Insofar as indemnification for liabilities arising under the
    Securities Act may be permitted to directors, officers and
    controlling persons of the registrant under the provisions
    described in Item&#160;6, or otherwise, the registrant has been
    advised that in the opinion of the SEC such indemnification is
    against public policy as expressed in the Securities Act and is
    therefore unenforceable. In the event that a claim for
    indemnification against such liabilities (other than the payment
    by the registrant of expenses incurred or paid by a director,
    officer or controlling person of the registrant in the
    successful defense of any action, suit or proceeding) is
    asserted by such director, officer or controlling person in
    connection with the securities being registered, the registrant
    will, unless in the opinion of its counsel the matter has been
    settled by controlling precedent, submit to a court of
    appropriate jurisdiction the question whether such
    indemnification by it is against public policy as expressed in
    the Securities Act and will be governed by the final
    adjudication of such issue.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    II-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes that:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (1)&#160;For purposes of determining any liability under the
    Securities Act, the information omitted from the form of
    prospectus filed as part of this registration statement in
    reliance upon Rule&#160;430A and contained in a form of
    prospectus filed by the registrant under Rule&#160;424(b)(1) or
    (4)&#160;or 497(h) under the Securities Act shall be deemed to
    be part of this registration statement as of the time it was
    declared effective.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (2)&#160;For the purpose of determining any liability under the
    Securities Act, each post-effective amendment that contains a
    form of prospectus shall be deemed to be a new registration
    statement relating to the securities offered therein, and the
    offering of such securities at that time shall be deemed to be
    the initial bona fide offering thereof.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (3)&#160;For the purpose of determining liability under the
    Securities Act of 1933 to any purchaser, each prospectus filed
    pursuant to Rule&#160;424(b) as part of a registration statement
    relating to an offering, other than registration statements
    relying on Rule&#160;430B or other than prospectuses filed in
    reliance on Rule&#160;430A, shall be deemed to be part of and
    included in the registration statement as of the date it is
    first used after effectiveness, provided, however, that no
    statement made in a registration statement or prospectus that is
    part of the registration statement or made in a document
    incorporated or deemed incorporated by reference into the
    registration statement or prospectus that is part of the
    registration statement will, as to a purchaser with a time of
    contract of sale prior to such first use, supersede or modify
    any statement that was made in the registration statement or
    prospectus that was part of the registration statement or made
    in any such document immediately prior to such date of first use.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (4)&#160;For the purpose of determining liability of the
    registrant under the Securities Act of 1933 to any purchaser in
    the initial distribution of the securities, the undersigned
    registrant undertakes that in a primary offering of securities
    of the undersigned registrant pursuant to this registration
    statement, regardless of the underwriting method used to sell
    the securities to the purchaser, if the securities are offered
    or sold to such purchaser by means of any of the following
    communications, the undersigned registrant will be a seller to
    the purchaser and will be considered to offer or sell such
    securities to such purchaser:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;Any preliminary prospectus or prospectus of the
    undersigned registrant relating to the offering required to be
    filed pursuant to Rule 424;
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;Any free writing prospectus relating to the offering
    prepared by or on behalf of the undersigned registrant or used
    or referred to by the undersigned registrant;
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iii)&#160;The portion of any other free writing prospectus
    relating to the offering containing material information about
    the undersigned registrant or its securities provided by or on
    behalf of the undersigned registrant;&#160;and
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iv)&#160;Any other communication that is an offer in the
    offering made by the undersigned registrant to the purchaser.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SIGNATURES</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act, the
    registrant certifies that it has reasonable grounds to believe
    that it meets all of the requirements for filing on
    <FONT style="white-space: nowrap">Form&#160;F-1</FONT>
    and has duly caused this registration statement to be signed on
    its behalf by the undersigned, thereunto duly authorized, in the
    City of Beijing, People&#146;s Republic of China, on
    December&#160;7, 2009.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 38%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="38%"></TD>
    <TD width="4%"></TD>
    <TD width="58%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Jianyu
    Yang</FONT></DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 42%; width: 48%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=222 -->

<DIV align="left" style="margin-left: 42%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Name:&#160;&#160;&#160;&#160;&#160;Jianyu Yang
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="42%"></TD>
    <TD width="7%"></TD>
    <TD width="51%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Director, Chief Executive Officer and President
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, this
    registration statement has been signed by the following persons
    in the capacities indicated on December&#160;7, 2009.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="9%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="35%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="52%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Signature</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Title</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 12pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Jianyu
    Yang</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Jianyu Yang
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Director, Chief Executive Officer and President<BR>
    (principal executive officer)
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Zheng Cheng
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Co-Chairman and Chief Operating Officer
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Steve Sun
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Co-Chairman and Chief Financial Officer<BR>
    (principal financial and accounting officer)
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Jing Zhang
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Director and Executive President
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Yaw Kong Yap
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Director and Financial Controller
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Shirley Chen
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Feng Xiao
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Elaine Zong
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Wai Hong Ku
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -23pt; margin-left: 23pt">
    * By:
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Jianyu
    Yang</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Jianyu
    Yang<BR>
    Attorney-in-fact
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SIGNATURE
    OF AUTHORIZED U.S. REPRESENTATIVE</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Securities Act of 1933, the undersigned, the duly
    authorized representative in the United States of Concord
    Medical Services Holdings Limited, has signed this registration
    statement or amendment thereto in Newark, Delaware, on
    December&#160;7, 2009.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Authorized U.S. Representative
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    PUGLISI &#038; ASSOCIATES
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Donald
    J. Puglisi</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Name:&#160;&#160;&#160;&#160;&#160;Donald J. Puglisi
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="8%"></TD>
    <TD width="43%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Managing Director
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXHIBIT&#160;INDEX</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Exhibit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Description of
    Document</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Underwriting Agreement
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated Memorandum and Articles of
    Association of the Registrant, as currently in effect
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Secretary&#146;s Certificate of the Registrant dated as of
    November&#160;17, 2009 as to the Amendment to the Second Amended
    and Restated Memorandum and Articles of Association of the
    Registrant
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.3*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Third Amended and Restated Memorandum and Articles of
    Association of the Registrant
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Registrant&#146;s American Depository Receipt (included
    in Exhibit&#160;4.3)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Specimen Certificate for Ordinary Shares of the Registrant
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.3
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Deposit Agreement among the Registrant, the Depositary
    and Owners and Beneficial Owners of the American Depository
    Shares issued thereunder
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.4*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;A Preferred Shares Subscription Agreement, dated as
    of February&#160;5, 2008, as amended on April&#160;2, 2008 and
    on October&#160;20, 2008, among CICC Sun Company Limited,
    Carlyle Asia Growth Partners III, L.P., CAGP III Co-Investment,
    L.P., Liu Haifeng, Steve Sun, Yang Jianyu, Bona Liu, Our Medical
    Services, Ltd., Ascendium Group Limited, Shenzhen Aohua Medical
    Services Co., Ltd. and Concord Medical Services Holdings Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.5*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;1 to Series&#160;A Preferred Shares
    Subscription Agreement, dated as of April&#160;2, 2008, among
    CICC Sun Company Limited, Carlyle Asia Growth Partners III,
    L.P., CAGP III Co-Investment, L.P., Liu Haifeng, Steve Sun, Yang
    Jianyu, Bona Liu, Our Medical Services, Ltd., Ascendium Group
    Limited, Shenzhen Aohua Medical Services Co., Ltd. and Concord
    Medical Services Holdings Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.6*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;2 to Series&#160;A Preferred Shares
    Subscription Agreement, dated as of October&#160;20, 2008, among
    CICC Sun Company Limited, Carlyle Asia Growth Partners III,
    L.P., CAGP III Co-Investment, L.P., Liu Haifeng, Steve Sun, Yang
    Jianyu, Bona Liu, Our Medical Services, Ltd., Ascendium Group
    Limited, Shenzhen Aohua Medical Services Co., Ltd. and Concord
    Medical Services Holdings Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.7*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;B Preferred Shares Subscription Agreement, dated as
    of October&#160;10, 2008, as amended on October&#160;20, 2008,
    among CICC Sun Company Limited, Carlyle Asia Growth Partners
    III, L.P., CAGP III Co-Investment, L.P., Starr Investments
    Cayman II, Inc., Concord Medical Services Holdings Limited and
    other persons named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.8*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment to Series&#160;B Preferred Shares Subscription
    Agreement, dated as of October&#160;20, 2008, among CICC Sun
    Company Limited, Carlyle Asia Growth Partners III, L.P., CAGP
    III Co-Investment, L.P., Starr Investments Cayman II, Inc.,
    Concord Medical Services Holdings Limited and other persons
    named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.9*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Shareholders Agreement, dated as of
    October&#160;20, 2008, among Concord Medical Services Holdings
    Limited, Carlyle Asia Growth Partners III, L.P., CAGP III
    Co-Investment, CICC Sun Company Limited, Perfect Key Holdings
    Limited, Starr Investments Cayman II, Inc. and certain other
    persons named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.10*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by CZY Investments
    Limited in favor of CICC Sun Company Limited, Carlyle Asia
    Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.11*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Daketala
    International Investment Holdings Ltd. in favor of CICC Sun
    Company Limited, Carlyle Asia Growth Partners III, L.P., CAGP
    III Co-Investment, L.P. and Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.12*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Dragon Image
    Investment Ltd. in favor of CICC Sun Company Limited, Carlyle
    Asia Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.13*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Notable
    Enterprise Limited in favor of CICC Sun Company Limited, Carlyle
    Asia Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.14*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Thousand Ocean
    Group Limited in favor of CICC Sun Company Limited, Carlyle Asia
    Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Exhibit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Description of
    Document</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.15*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Top Mount Group
    Limited in favor of CICC Sun Company Limited, Carlyle Asia
    Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.16*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Deed of Amendment, dated as of September&#160;14, 2009, among
    CICC Sun Company Limited, Carlyle Asia Growth Partners III,
    L.P., CAGP III Co-Investment, L.P., Starr Investments Cayman II,
    Inc. and Notable Enterprise Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.17*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Deed of Partial Release, dated as of September&#160;14, 2009, by
    CICC Sun Company Limited, Carlyle Asia Growth Partners III,
    L.P., CAGP III Co-Investment, L.P. and Starr Investments Cayman
    II, Inc. in favor of CZY Investment Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.18*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment to Amended and Restated Shareholders Agreement, dated
    as of November&#160;17, 2009, among Concord Medical Services
    Holdings Limited, Carlyle Asia Growth Partners&#160;III, L.P.,
    CAGP&#160;III Co-Investment, CICC Sun Company Limited, Perfect
    Key Holdings Limited, Starr Investments Cayman II, Inc. and
    certain other persons named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.19
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;2 to Amended and Restated Shareholders
    Agreement, dated as of December&#160;7, 2009, among Concord
    Medical Services Holdings Limited, Carlyle Asia Growth
    Partners&#160;III, L.P., CAGP&#160;III Co-Investment, CICC Sun
    Company Limited, Perfect Key Holdings Limited, Starr Investments
    Cayman&#160;II, Inc. and certain other persons named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    5.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Walkers regarding the validity of the ordinary shares
    being registered
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    8.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Walkers regarding certain Cayman Islands tax matters
    (included in Exhibit&#160;5.1)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    8.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Simpson Thacher&#160;&#038; Bartlett LLP regarding
    certain U.S. tax matters
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2008&#160;Share Incentive Plan adopted as of October&#160;16,
    2008
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Indemnification Agreement with the Registrant&#146;s
    directors and officers
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.3*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Medical Equipment Lease Agreement
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.4*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Equipment Management Services Agreement
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.5*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Service-only Management Agreement
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.6*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Summary of the Oral Agreement entered into between China Medstar
    Pte. Ltd. and Beijing Medstar Hi-Tech Investment Co., Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.7*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Summary of the Oral Agreement entered into between China Medstar
    Pte. Ltd. and Cheng Zheng
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.8*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Summary of the Oral Agreement entered into between China Medstar
    Pte. Ltd. and Yaw Kong Yap
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.9*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Medical Equipment Lease Agreement, dated as of
    August 25, 2009, by and between Medstar (Shanghai) Leasing Co.,
    Ltd. and Chang&#146;an Hospital Co., Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.10*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Service-Only Management Agreement, dated as of
    August 1, 2008, among CMS Hospital Management Co., Ltd.,
    Xi&#146;an Wanjiechangxin Medical Services Company Limited and
    Chang&#146;an Hospital Co., Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.11*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Agreement Concerning the Establishment of the
    Aohai Radiotherapy Treatment and Diagnosis Research Center,
    dated as of September 19, 1995, by and between the Chinese
    People&#146;s Liberation Army Navy General Hospital and Beijing
    Our Medical Equipment Development Company, which transferred its
    interest in the agreement to Shenzhen Aohua Medical Services
    Co., Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.12*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement Concerning the Development
    of the Aohai Radiotherapy Treatment and Diagnosis Research
    Center, dated as of March 18, 1999, by and between Shenzhen
    Aohua Medical Services Co., Ltd. and the Chinese People&#146;s
    Liberation Army Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.13*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement Concerning the Development
    of the Aohai Radiotherapy Treatment and Diagnosis Research
    Center, dated as of September 27, 2003, by and between Shenzhen
    Aohua Medical Services Co., Ltd. and the Chinese People&#146;s
    Liberation Army Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.14*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Medical Equipment Lease Agreement, dated as of
    September 29, 2006, by and between Shanghai Medstar Investment
    Management Co., Ltd., the predecessor of Medstar (Shanghai)
    Leasing Co., Ltd., and the Chinese People&#146;s Liberation Army
    Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.15*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement Concerning the Development
    of the Aohai Radiotherapy Treatment and Diagnosis Research
    Center, dated as of July 8, 2009, by and between Shenzhen Aohua
    Medical Services Co., Ltd. and the Chinese People&#146;s
    Liberation Army Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.16*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement to the Service-only
    Management Agreement, dated as of August 1, 2008, among
    Xi&#146;an Wanjiechangxin Medical Services Company Limited,
    Chang&#146;an Hospital Co., Ltd. and CMS Hospital Management
    Co., Ltd.
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Exhibit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Description of
    Document</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.17*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Agreement Regarding the Transfer of Equity in
    Aohai Radiotherapy Treatment and Diagnosis Research Center,
    dated as of May 5, 1997, among Beijing Our Medical Equipment
    Development Company, Shenzhen Aohua Medical Services Co., Ltd.
    and the Chinese People&#146;s Liberation Army Navy General
    Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.18*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement to the Supplemental
    Agreement Concerning the Development of the Aohai Radiotherapy
    Treatment and Diagnosis Research Center, dated as of September
    15, 2004, by and between Shenzhen Aohua Medical Services Co.,
    Ltd. and the Chinese People&#146;s Liberation Army Navy General
    Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.19*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement to the Cooperation
    Contract Concerning the Aohai Radiotherapy Treatment and
    Diagnosis Research Center, dated as of August 16, 2003, by and
    between Shenzhen Aohua Medical Services Co., Ltd. and the
    Chinese People&#146;s Liberation Army Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.20*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment to 2008 Share Incentive Plan adopted as of
    November&#160;17, 2009
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.21
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Strategic Cooperative Agreement, dated as of
    November&#160;17, 2009, between China Construction Bank
    Corporation, Shenzhen Branch and China Medical Services Holdings
    Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    21.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Subsidiaries of the Registrant
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Independent Registered Public Accounting Firm
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Walkers (included in Exhibit&#160;5.1)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.3*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Simpson Thacher&#160;&#038; Bartlett LLP (included in
    Exhibit&#160;8.2)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.4*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Jingtian&#160;&#038; Gongcheng Attorneys At Law
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.5*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Frost &#038; Sullivan
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    24.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Powers of Attorney (included on the signature page in
    Part&#160;II of this registration statement)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    99.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Code of Business Conduct and Ethics
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    99.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Opinion of Jingtian &#038; Gongcheng Attorneys At Law
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    Previously filed.</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    &#134; </TD>
    <TD></TD>
    <TD valign="bottom">
    Portions of this document have been omitted pursuant to a
    confidential treatment request and the omitted information has
    been filed separately with the Securities and Exchange
    Commission.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-8
</DIV><!-- END PAGE WIDTH -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>h03611a4exv1w1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv1w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;1.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Concord Medical Services Holdings Limited</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>&#091;12,000,000&#093; American Depositary Shares<BR>
Representing<BR>
Three Ordinary Shares, Par Value U.S.$0.0001 Per Ordinary Share</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>UNDERWRITING AGREEMENT</B>

</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">December &#091;<B>&#149;</B>&#093;, 2009
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Morgan Stanley &#038; Co. International plc<BR>
J.P. Morgan Securities Inc.<BR>
China International Capital Corporation Hong Kong Securities Limited,<BR>
as Representatives of the several Underwriters named in Schedule&nbsp;II hereto

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">c/o</TD>
    <TD>&nbsp;</TD>
    <TD>Morgan Stanley &#038; Co. International plc<BR>
25 Cabot Square, Canary Wharf<BR>
London E14 4QA<BR>
United Kingdom<BR><BR>
and<BR><BR>
J.P. Morgan Securities Inc.<BR>
383 Madison Avenue, Floor 4<BR>
New York, New York 10179</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concord Medical Services Holdings Limited, an exempted company incorporated in the Cayman
Islands with limited liability (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several
Underwriters named in Schedule&nbsp;II hereto (the &#147;<B>Underwriters</B>&#148;) &#091;12,000,000&#093; American Depository
Shares (the &#147;<B>ADSs</B>&#148;), each ADS representing three ordinary shares of the Company, par value
U.S.$0.0001 per share (the &#147;<B>Ordinary Shares</B>&#148;) (such &#091;12,000,000&#093; ADSs being hereinafter referred to
as the &#147;<B>Firm Shares</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain shareholders of the Company (the &#147;<B>Selling Shareholders</B>&#148;) named in Schedule&nbsp;I hereto
severally propose to sell to the several Underwriters, an aggregate of &#091;1,800,000&#093; additional ADSs
(the &#147;<B>Additional Shares</B>&#148;), each Selling Shareholder selling up to the amount set forth opposite
such Selling Shareholder&#146;s name in Schedule&nbsp;I hereto, in each case, if and to the extent that you,
as Representatives, shall have determined to exercise, on behalf of the Underwriters, the right to
purchase such Additional Shares granted to the Underwriters in Section&nbsp;3 hereof. The Firm Shares
and the Additional Shares to be outstanding after giving effect to the sales contemplated hereby,
in each case including the underlying Ordinary Shares, are hereinafter collectively referred to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">as the &#147;<B>Shares</B>.&#148; The Company and the Selling Shareholders are hereinafter sometimes
collectively referred to as the &#147;<B>Sellers</B>.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Shares purchased by the Underwriters will be evidenced by American depository receipts
(&#147;<B>ADRs</B>&#148;) to be issued pursuant to a deposit agreement dated as of December &#091;<B>&#149;</B>&#093;, 2009 (the &#147;<B>Deposit
Agreement</B>&#148;) to be entered into among the Company, JPMorgan Chase Bank, N.A., as depositary (the
&#147;<B>Depositary</B>&#148;), and the holders and beneficial owners from time to time of the ADRs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is understood by all the parties that the Underwriters are offering the ADSs in the United
States and internationally outside of the People&#146;s Republic of China (the &#147;<B>PRC</B>&#148;), which, for
purposes of this Agreement only, excludes Taiwan, The Hong Kong Special Administrative Region and
The Macau Special Administrative Region.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has filed with the U.S. Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a
registration statement on Form&nbsp;F-1 (No.&nbsp;333-163155), including a prospectus, relating to the
Shares. The registration statement as amended at the time it becomes effective, including the
information (if any) deemed to be part of the registration statement at the time of effectiveness
pursuant to Rule&nbsp;430A under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), is
hereinafter referred to as the &#147;<B>Registration Statement</B>&#148;; the prospectus in the form first used to
confirm sales of Shares (or in the form first made available to the Underwriters by the Company to
meet requests of purchasers pursuant to Rule&nbsp;173 under the Securities Act) is hereinafter referred
to as the &#147;<B>Prospectus.</B>&#148; If the Company has filed an abbreviated registration statement to register
additional Ordinary Shares pursuant to Rule&nbsp;462(b) under the Securities Act (the &#147;<B>Rule&nbsp;462
Registration Statement</B>&#148;), then any reference herein to the term &#147;<B>Registration Statement</B>&#148; shall be
deemed to include such Rule&nbsp;462 Registration Statement. The Company has filed with the Commission
a registration statement on Form&nbsp;F-6 (No.&nbsp;333-&#091;<B>&#149;</B>&#093;) relating to the ADSs (such registration
statement on Form F-6, including all exhibits thereto, as amended at the time such registration
becomes effective, is hereinafter referred to as the &#147;<B>ADS Registration Statement</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule
405 under the Securities Act, &#147;<B>Time of Sale Prospectus</B>&#148; means the preliminary prospectus together
with the free writing prospectuses, if any, each identified in Schedule&nbsp;III hereto, and &#147;<B>broadly
available road show</B>&#148; means a &#147;bona fide electronic road show&#148; as defined in Rule&nbsp;433(h)(5) under
the Securities Act that has been made available without restriction to any person. As used herein,
the terms &#147;Registration Statement,&#148; &#147;preliminary prospectus,&#148; &#147;Time of Sale Prospectus&#148; and
&#147;Prospectus&#148; shall include the documents, if any, incorporated by reference therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Morgan Stanley &#038; Co. International plc (&#147;<B>Morgan Stanley</B>&#148;) has agreed to reserve &#091;600,000&#093;
Shares to be purchased by it under this Agreement for sale to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Company&#146;s directors, officers, employees and business associates and other parties related
to the Company (collectively, &#147;<B>Participants</B>&#148;), as set forth in the Prospectus under the heading
&#147;Underwriting&#148; (the &#147;<B>Directed Share Program</B>&#148;). The &#091;600,000&#093; Shares to be sold by Morgan Stanley
and its affiliates pursuant to the Directed Share Program are referred to hereinafter as the
&#147;<B>Directed Shares</B>&#148;. Any Directed Shares not orally confirmed for purchase by any Participant by the
end of the business day on which this Agreement is executed will be offered to the public by the
Underwriters as set forth in the Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>1.&nbsp;Representations and Warranties of the Company. </I>The Company represents and warrants to and
agrees with each of the Underwriters that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(a)&nbsp;</I>The Registration Statement and the ADS Registration Statement have become effective; no
stop order suspending the effectiveness of the Registration Statement or the ADS Registration
Statement is in effect; and no proceedings for such purpose are pending before or, to the knowledge
of the Company, threatened by the Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>(i)&nbsp;Each of the Registration Statement and the ADS Registration Statement, when it became
effective, did not contain and, as amended or supplemented, if applicable, will not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading, (ii)&nbsp;the Registration Statement, the
Prospectus and the ADS Registration Statement comply and, as amended or supplemented, if
applicable, will comply in all material respects with the Securities Act and the applicable rules
and regulations of the Commission thereunder, (iii)&nbsp;the Time of Sale Prospectus does not, and at
the time of each sale of the Shares in connection with the offering when the Prospectus is not yet
available to prospective purchasers and at the Closing Date (as defined in Section&nbsp;6), the Time of
Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain
any untrue statement of a material fact or omit to state a material fact necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading,
(iv)&nbsp;each broadly available road show, if any, when considered together with the Time of Sale
Prospectus, does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading, and (v)&nbsp;the Prospectus does not contain and, as amended or supplemented,
if applicable, will not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading, except that the representations and warranties set forth in this
paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale
Prospectus or the Prospectus based upon information relating to any Underwriter furnished to the
Company in writing by such Underwriter through you expressly for use therein.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 3 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>The Company is not an &#147;ineligible issuer&#148; in connection with the offering pursuant to
Rules&nbsp;164, 405 and 433 under the Securities Act. Any free writing prospectus that the Company is
required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with
the Commission in accordance with the requirements of the Securities Act and the applicable rules
and regulations of the Commission thereunder. Each free writing prospectus that the Company has
filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was
prepared by or on behalf of or used or referred to by the Company complies or will comply in all
material respects with the requirements of the Securities Act and the applicable rules and
regulations of the Commission thereunder. Except for the free writing prospectuses, if any,
identified in Schedule&nbsp;III hereto, and electronic road shows, if any, each furnished to you before
first use, the Company has not prepared, used or referred to, and will not, without your prior
consent, prepare, use or refer to, any free writing prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>The Company has been duly organized, is validly existing as an exempted company in good
standing under the laws of the Cayman Islands, has the corporate power and authority to own its
property and to conduct its business as described in the Time of Sale Prospectus and is duly
qualified to transact business and is in good standing in each jurisdiction in which the conduct of
its business or its ownership or leasing of property requires such qualification, except to the
extent that the failure to be so qualified or be in good standing would not have a material adverse
effect on the Company and its subsidiaries, taken as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>The Company does not own or control, directly or indirectly, any corporation, association
or entity other than as set forth in the Time of Sale Prospectus. Each subsidiary of the Company
has been duly organized, is validly existing as a corporation in good standing under the laws of
the jurisdiction of its incorporation, has the corporate power and authority to own its property
and to conduct its business as described in the Time of Sale Prospectus and is duly qualified to
transact business and is in good standing in each jurisdiction in which the conduct of its business
or its ownership or leasing of property requires such qualification, except to the extent that the
failure to be so qualified or be in good standing would not have a material adverse effect on the
Company and its subsidiaries, taken as a whole; all of the issued shares of capital stock of each
subsidiary of the Company have been duly and validly authorized and issued, are fully paid and
non-assessable and are owned directly by the Company, free and clear of all liens, encumbrances,
equities or claims.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(f)&nbsp;</I>This Agreement has been duly authorized, executed and delivered by the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(g)&nbsp;</I>The authorized share capital of the Company conforms in all material respects as to legal
matters to the description thereof contained in each of the Time of Sale Prospectus and the
Prospectus.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 4 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(h)&nbsp;</I>The outstanding Ordinary Shares and all other outstanding shares of the Company prior to
the issuance of the Shares have been duly authorized and are validly issued, fully paid and
non-assessable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(i)&nbsp;</I>The Shares have been duly authorized and, when issued and delivered in accordance with the
terms of this Agreement and the Deposit Agreement, as the case may be, will be validly issued,
fully paid and non-assessable, and the issuance of such Shares will not be subject to any
preemptive or similar rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(j)&nbsp;</I>The Shares to be sold by the Company, when issued and delivered against payment heretofore
pursuant to this Agreement, will not be subject to any security interest, other encumbrance or
adverse claims, and will have been issued in compliance with all U.S. federal, state and foreign
securities laws and will not have been issued in violation of any preemptive right, resale right,
right of first refusal or similar right; upon payment of the purchase price in accordance with this
Agreement on the Closing Date, the Depositary or its nominee, as the registered holder of the
Ordinary Shares represented by the ADSs, will be, subject to the terms of the Deposit Agreement,
entitled to all the rights of a shareholder conferred by the Memorandum and Articles of Association
of the Company, as amended from time to time (the &#147;<B>Memorandum and Articles of Association</B>&#148;); except
as disclosed in the Time of Sale Prospectus and subject to the terms and provisions of the Deposit
Agreement, there are no restrictions on transfers of Ordinary Shares represented by the ADSs or the
ADSs under the laws of the Cayman Islands, the PRC or the United States, as the case may be; the
Ordinary Shares represented by the Shares may be freely deposited by the Company with the
Depositary or its nominee against issuance of ADRs evidencing the ADSs as contemplated by the
Deposit Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(k)&nbsp;</I>The execution and delivery by the Company of, and the performance by the Company of its
obligations under, this Agreement and the Deposit Agreement will not contravene any provision of
applicable law or the Memorandum and Articles of Association or any other organizational documents
of the Company or any agreement or other instrument binding upon the Company or any of its
subsidiaries that is material to the Company and its subsidiaries, taken as a whole, or any
judgment, order or decree of any governmental body, agency or court having jurisdiction over the
Company or any subsidiary, and no consent, approval, authorization or order of, or qualification
with (&#147;<B>Governmental Authorization</B>&#148;), any governmental body or agency (&#147;<B>Governmental Agency</B>&#148;) is
required for the performance by the Company of its obligations under this Agreement of the Deposit
Agreement in connection with the offer, issuance and sale of the Shares by the Company and the
deposit of the Ordinary Shares with the Depositary against issuance of ADRs evidencing the ADSs,
except such as may be required by the securities or Blue Sky laws of the various states in
connection with the offer and sale of the Shares.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 5 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(l)&nbsp;</I>Neither the Company nor any of its subsidiaries is in violation of its respective
organizational documents or in default (or with the giving of notice or lapse of time would be in
default) under any existing obligation, agreement, covenant or condition contained in any
indenture, loan agreement, mortgage, lease or other agreement or instrument to which any of them is
a party or by which any of them is bound or to which any of the properties of any of them is
subject, other than violations or defaults that would not have a material adverse effect on the
Company and its subsidiaries, taken as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(m)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus under the headings &#147;Risk
Factors&#150;Certain of our hospital partners have not received large medical equipment procurement
licenses or interim procurement permits for some of the medical equipment in our network or centers
which could result in fines or the suspension from use of such medical equipment&#148; and
&#147;Regulation&#150;Regulation of Medical Institutions&#150;Large Medical Procurement License,&#148; neither the
Company nor any of its subsidiaries is (i)&nbsp;in breach of or in default under any laws, regulations,
rules, orders, decrees, guidelines or notices of the PRC, the Cayman Islands or any other
jurisdiction where it is incorporated or operates, or (ii)&nbsp;in breach of or in default under any
Governmental Authorization of any Governmental Agency in the PRC, the Cayman Islands or any other
jurisdiction where it was incorporated or operates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(n)&nbsp;</I>There has not occurred any material adverse change, or any development involving a
prospective material adverse change, in the condition, financial or otherwise, or in the earnings,
business or operations of the Company and its subsidiaries, taken as a whole, from that set forth
in the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(o)&nbsp;</I>There are no legal or governmental proceedings pending or, to the knowledge of the
Company, threatened to which the Company, any of its subsidiaries or any of its or their officers
and directors is a party or to which any of the properties of the Company or any of its
subsidiaries is subject (i)&nbsp;other than proceedings accurately described in all material respects in
the Time of Sale Prospectus and proceedings that would not have a material adverse effect on the
Company and its subsidiaries, taken as a whole, or on the power or ability of the Company to
perform its obligations under this Agreement or to consummate the transactions contemplated by the
Time of Sale Prospectus, or (ii)&nbsp;that are required to be described in the Registration Statement or
the Prospectus and are not so described; and there are no statutes, regulations, contracts or other
documents that are required to be described in the Registration Statement or the Prospectus or to
be filed as exhibits to the Registration Statement that are not described or filed as required.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(p)&nbsp;</I>Each preliminary prospectus filed as part of the registration statement as originally
filed or as part of any amendment thereto, or filed pursuant to Rule&nbsp;424 under the Securities Act,
complied when so filed in all material
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 6 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">respects with the Securities Act and the applicable rules and regulations of the Commission
thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(q)&nbsp;</I>The Company is not, and after giving effect to the offering and sale of the Shares and the
application of the proceeds thereof as described in the Prospectus will not be, required to
register as an &#147;investment company&#148; as such term is defined in the Investment Company Act of 1940,
as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(r)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus: (a)(i)&nbsp;neither the Company nor any of
its subsidiaries is in violation of, or has any liability under, any local, domestic or foreign
statute, law, rule, regulation, ordinance, code, other requirement or rule of law (including common
law), or decision or order of any domestic or foreign governmental agency, governmental body or
court, relating to pollution, to the use, handling, transportation, treatment, storage, discharge,
disposal or release of Hazardous Substances (as defined below), to the protection or restoration of
the environment or natural resources (including biota), to health and safety including as such
relates to exposure to Hazardous Substances, and to natural resource damages (collectively,
&#147;<B>Environmental Laws</B>&#148;), (ii)&nbsp;neither the Company nor any of its subsidiaries is conducting or
funding any investigation, remediation, remedial action or monitoring of actual or suspected
Hazardous Substances in the environment, (iii)&nbsp;neither the Company nor any of its subsidiaries is
liable or allegedly liable for any release or, to the knowledge of the Company, threatened release
of Hazardous Substances, including at any off-site treatment, storage or disposal site,
(iv)&nbsp;neither the Company nor any of its subsidiaries is subject to any claim by any Governmental
Agency or person relating to Environmental Laws or Hazardous Substances, and (v)&nbsp;the Company and
its subsidiaries have received and are in compliance with all, and have no liability under any,
permits, licenses, authorizations, identification numbers or other approvals required under
applicable Environmental Laws to conduct their respective businesses; (b)&nbsp;the Company is not aware
of any facts or circumstances that would reasonably be expected to result in a violation of,
liability under, or claim pursuant to any Environmental Law that would have a material adverse
effect on the Company and its subsidiaries, taken as a whole; (c)&nbsp;to the Company&#146;s knowledge, there
are no requirements proposed for adoption or implementation under any Environmental Law that would
reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken
as a whole; and (d)&nbsp;in the ordinary course of its business, the Company periodically evaluates the
effect, including associated costs and liabilities, of Environmental Laws on the business,
properties, results of operations and financial condition of it and its subsidiaries, and, on the
basis of such evaluation, the Company has reasonably concluded that such Environmental Laws will
not have a material adverse effect on the Company and its subsidiaries, taken as a whole. For
purposes of this Agreement, &#147;<B>Hazardous Substances</B>&#148; means (A)&nbsp;radioactive materials and medical
waste and (B)&nbsp;any other chemical, material or substance defined or regulated as toxic or hazardous
or as a pollutant, biohazard, contaminant or waste under Environmental Laws.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 7 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(s)&nbsp;</I>There are no contracts, agreements or understandings between the Company and any person
granting such person the right to require the Company to file a registration statement under the
Securities Act with respect to any securities of the Company or to require the Company to include
such securities with the Shares registered pursuant to the Registration Statement other than
contracts, agreements or understandings accurately described in all material respects in the Time
of Sale Prospectus, and any person to whom the Company has granted such rights has agreed not to
exercise such rights until after the expiration of the 180-day restricted period referred to in
Section&nbsp;3.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(t)&nbsp;</I>Neither the Company nor any of its subsidiaries or affiliates, nor any director, officer,
or employee, nor, to the knowledge of the Company, any agent or representative of the Company or of
any of its subsidiaries or affiliates, has taken or will take any action in furtherance of an
offer, payment, promise to pay, or authorization or approval of the payment or giving of money,
property, gifts or anything else of value, directly or indirectly, to any &#147;government official&#148;
(including any officer or employee of a government or government-owned or controlled entity or of a
public international organization, or any person acting in an official capacity for or on behalf of
any of the foregoing, or any political party or party official or candidate for political office)
to influence official action or secure an improper advantage; and the Company and its subsidiaries
and affiliates have conducted their businesses in compliance with all applicable anti-corruption
laws and have instituted and maintain and will continue to maintain policies and procedures
designed to promote and achieve compliance with such laws and with the representation and warranty
contained herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(u)&nbsp;</I>The operations of the Company and its subsidiaries are and have been conducted at all
times in material compliance with all applicable financial recordkeeping and reporting
requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and
Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism
Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions
where the Company and its subsidiaries conduct business, the rules and regulations thereunder and
any related or similar rules, regulations or guidelines, issued, administered or enforced by any
governmental agency (collectively, the &#147;<B>Anti-Money Laundering Laws</B>&#148;), and no action, suit or
proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is
pending or, to the knowledge of the Company, threatened.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(v)&nbsp;</I>(i)&nbsp;The Company represents that neither the Company nor any of its subsidiaries
(collectively, the &#147;<B>Entity</B>&#148;) or, to the knowledge of the Company after due inquiry, any director,
officer, employee, agent, affiliate or representative of the Entity, is an individual or entity
(&#147;<B>Person</B>&#148;) that is, or is owned or controlled by a Person that is:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 8 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) the subject of any sanctions administered or enforced by the U.S.
Department of Treasury&#146;s Office of Foreign Assets Control (&#147;<B>OFAC</B>&#148;) or other
relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;), nor
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) located, organized or resident in a country or territory that is the
subject of Sanctions (including, without limitation, Burma/Myanmar, Cuba, Iran,
North Korea, Sudan and Syria).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;The Entity represents and covenants that it will not, directly or indirectly, use the
proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any
subsidiary, joint venture partner or other Person:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) to fund or facilitate any activities or business of or with any Person
or in any country or territory that, at the time of such funding or facilitation,
is the subject of Sanctions; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) in any other manner that will result in a violation of Sanctions by any
Person (including any Person participating in the offering, whether as
underwriter, advisor, investor or otherwise).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;The Entity represents and covenants that it has not knowingly engaged in, is not now
knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in
any country or territory, that at the time of the dealing or transaction is or was the subject of
Sanctions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w)&nbsp;Subsequent to the respective dates as of which information is given in each of the
Registration Statement, the Time of Sale Prospectus and the Prospectus, (i)&nbsp;the Company and its
subsidiaries have not incurred any material liability or obligation, direct or contingent, nor
entered into any material transaction; (ii)&nbsp;the Company has not purchased any of its outstanding
shares, nor declared, paid or otherwise made any dividend or distribution of any kind on its shares
other than ordinary and customary dividends, and (iii)there has not been any material change in the
share capital, short-term debt or long-term debt of the Company and its subsidiaries, except in
each case as described in each of the Registration Statement, the Time of Sale Prospectus and the
Prospectus, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(x)&nbsp;</I>The Company and its subsidiaries have good and marketable title in fee simple to all real
property and good and marketable title to all personal property owned by them which is material to
the business of the Company and its subsidiaries, in each case free and clear of all liens,
encumbrances and defects except such as are described in the Time of Sale Prospectus or such as do
not materially affect the value of such property and do not interfere with the use made and
proposed to be made of such property by the Company and its subsidiaries; and any real property and
buildings held under lease by the Company and its subsidiaries are held by them under valid,
subsisting and enforceable leases with
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 9 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">such exceptions as are not material and do not interfere with the use made and proposed to be
made of such property and buildings by the Company and its subsidiaries, in each case except as
described in the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(y)&nbsp;</I>The Company and its subsidiaries own or possess, or can acquire on reasonable terms, all
material patents, patent rights, licenses, inventions, copyrights, trademarks service marks, trade
names, domain names, know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures) and other intellectual property and
similar rights, including registrations and applications for registration thereof, currently
employed by them in connection with the business now operated by them, and neither the Company nor
any of its subsidiaries has received any notice of infringement of or conflict with asserted rights
of others with respect to any of the foregoing which, singly or in the aggregate, if the subject of
an unfavorable decision, ruling or finding, would have a material adverse effect on the Company and
its subsidiaries, taken as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(z)&nbsp;</I>No material labor dispute with the employees of the Company or any of its subsidiaries
exists, except as described in the Time of Sale Prospectus, or, to the knowledge of the Company, is
imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by
the employees of any of its principal suppliers, manufacturers or contractors that could have a
material adverse effect on the Company and its subsidiaries, taken as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(aa)&nbsp;</I>The Company and each of its subsidiaries are insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as are prudent and customary in
the businesses in which they are engaged; neither the Company nor any of its subsidiaries has been
refused any insurance coverage applied for; and neither the Company nor any of its subsidiaries has
any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a material adverse effect on the Company and
its subsidiaries, taken as a whole, except as described in the Time of Sale Prospectus. The
Company has obtained directors&#146; and officers&#146; insurance in such amounts and scope of coverage as is
customary in connection with an initial public offering of a PRC-based company in the United States
and listing on a U.S. stock exchange, including, without limitation, coverage for liabilities or
losses arising under the Securities Act, the Exchange Act and the applicable rules and regulations
of the Commission thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(bb)&nbsp;</I>The Company and its subsidiaries possess all certificates, licenses, franchises,
authorizations and permits necessary to conduct their respective businesses, and neither the
Company nor any of its subsidiaries has received any notice of proceedings relating to the
revocation or modification of any such certificate, license, franchise, authorization or permit
which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding,
would have
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 10 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">a material adverse effect on the Company and its subsidiaries, taken as a whole, except as
described in the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(cc)&nbsp;</I>Except as described in the Time of Sale Prospectus, the Company, its subsidiaries and the
Company&#146;s Board of Directors (the &#147;<B>Board</B>&#148;) are in compliance with the Sarbanes-Oxley Act of 2002
(the &#147;<B>Sarbanes-Oxley Act</B>&#148;) to the extent applicable and all applicable rules (the &#147;<B>Exchange Rules</B>&#148;)
of the New York Stock Exchange (the &#147;<B>NYSE</B>&#148;); the Company and its subsidiaries maintain a system of
internal controls, including, but not limited to, disclosure controls and procedures, internal
controls over accounting matters and financial reporting, an internal audit function and legal and
regulatory compliance controls (collectively, &#147;<B>Internal Controls</B>&#148;) sufficient to provide reasonable
assurance that (i)transactions are executed in accordance with management&#146;s general or specific
authorizations, (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial
statements in conformity with U.S. generally accepted accounting principles (&#147;<B>U.S. GAAP</B>&#148;) and to
maintain asset accountability, (iii)&nbsp;access to assets is permitted only in accordance with
management&#146;s general or specific authorization, and (iv)&nbsp;the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences and (v)&nbsp;the Company has made and kept books, records and accounts which,
in reasonable detail, accurately and fairly reflect in all material respects the transactions and
dispositions of the Company and its subsidiaries. The Internal Controls, upon consummation of the
offering of the Shares will be, overseen by the Audit Committee (the &#147;<B>Audit Committee</B>&#148;) of the
Board in accordance with Exchange Rules. Except as disclosed in the Time of Sale Prospectus, the
Company has not publicly disclosed or reported to the Audit Committee or the Board, and the Company
does not reasonably expect to publicly disclose or report to the Audit Committee or the Board, a
significant deficiency, material weakness, change in Internal Controls or fraud involving
management or other employees who have a significant role in Internal Controls (each, an &#147;<B>Internal
Control Event</B>&#148;), any violation of, or failure to comply with, the Securities Laws, or any matter
which, if determined adversely, would have a material adverse effect on the Company and its
subsidiaries, taken as a whole. Each of the Company&#146;s independent directors meets the U.S.
criteria for &#147;independence&#148; under the Sarbanes-Oxley Act and the Exchange Rules.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(dd)&nbsp;Except as described in the Time of Sale Prospectus, the Company has not sold, issued or
distributed any Ordinary Shares during the six-month period preceding the date hereof, including
any sales pursuant to Rule&nbsp;144A under, or Regulation&nbsp;D or S of, the Securities Act, other than
shares issued pursuant to employee benefit plans, qualified stock option plans or other employee
compensation plans or pursuant to outstanding options, rights or warrants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ee)&nbsp;The Registration Statement, the Prospectus, the Time of Sale Prospectus and any
preliminary prospectus comply, and any amendments or supplements thereto will comply, with any
applicable laws or regulations of
foreign jurisdictions in which the Prospectus, the Time of Sale Prospectus or any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 11 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">preliminary
prospectus, as amended or supplemented, if applicable, are distributed in connection with the
Directed Share Program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ff)&nbsp;</I>No consent, approval, authorization or order of, or qualification with, any governmental
body or agency, other than those obtained, is required in connection with the offering of the
Directed Shares in any jurisdiction where the Directed Shares are being offered.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(gg)&nbsp;</I>The Company has not offered, or caused Morgan Stanley to offer, Shares to any person
pursuant to the Directed Share Program with the specific intent to unlawfully influence (i)&nbsp;a
customer or supplier of the Company to alter the customer&#146;s or supplier&#146;s level or type of business
with the Company, or (ii)&nbsp;a trade journalist or publication to write or publish favorable
information about the Company or its products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(hh)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus, there are no contracts, agreements or
understandings between the Company or any of its subsidiaries and any person that would give rise
to a valid claim against the Company or any of its subsidiaries or any Underwriter for a brokerage
commission, finder&#146;s fee or other like payment in connection with this offering.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ii)&nbsp;</I>The Shares have been approved for listing on the NYSE, subject to notice of issuance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(jj)&nbsp;</I>The execution, delivery and performance of this Agreement and the Deposit Agreement and
the consummation of the transactions contemplated herein and therein, and the issuance and sale of
the Shares, including the deposit of the Ordinary Shares with the Depositary and the issuance of
the ADRs evidencing the ADSs and the listing of the Shares on the NYSE, do not and will not result
in a breach or violation of any of the terms and provisions of, or constitute a default under, or
result in the imposition of any lien, charge or encumbrance upon any property or assets of the
Company or any of its subsidiaries pursuant to, the organizational documents of the Company or any
of its subsidiaries, any statute, rule, regulation or order of any governmental agency or body or
any court, domestic or foreign, having jurisdiction over the Company or any of its subsidiaries or
any of their properties, or any agreement or instrument to which the Company or any of its
subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any
of the properties of the Company or any of its subsidiaries is subject.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(kk)&nbsp;</I>No Governmental Authorization is required for the validity, enforceability or
effectiveness of any agreement, indenture, loan agreement, mortgage, lease or other agreement or
instrument to which the Company or any of its subsidiaries is a party or by which any of them is
bound or to which any of the properties of any of them is subject (the &#147;<B>Company Contracts</B>&#148;), except
where such lack of Governmental Authorization would not have a material adverse
effect on the Company and its subsidiaries, taken as a whole; neither the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 12 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company nor any of
its subsidiaries has sent or received any communication regarding termination of, or intent not to
renew, any of the Company Contracts and no such termination or non-renewal has been threatened by
the Company or any of its subsidiaries or, to the knowledge of the Company, any other party to any
such contract or agreement other than termination or intent not to renew of such contract or
agreement that would not reasonably be expected to have a material adverse effect on the Company
and its subsidiaries, taken as a whole; and neither the Company or its subsidiaries nor, to the
knowledge of the Company, any other party to any Company Contracts is in violation or breach of any
PRC, Cayman Islands, national, provincial, municipal or other local law, regulation, statute, rule
or order, which violation or breach could invalidate, impair or result in any fine, penalty or
government sanction with regard to any Company Contracts, except as disclosed in the Time of Sale
Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ll)&nbsp;</I>The Deposit Agreement has been duly authorized, executed and delivered by the Company
and, assuming due authorization, execution and delivery by the Depositary, constitutes a legal,
valid and binding agreement of the Company enforceable against the Company in accordance with its
terms, except as enforcement thereof may be limited by bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and similar laws of general applicability relating to or affecting
creditors&#146; rights and to general principles of equity; upon due issuance by the Depositary of ADRs
evidencing ADSs against the deposit of the Ordinary Shares in respect thereof in accordance with
the Deposit Agreement, such ADRs will be duly and validly issued and the holders and beneficial
owners thereof will be entitled to the rights specified therein and in the Deposit Agreement; and
the Deposit Agreement and the ADRs conform in all material respects to the descriptions thereof
contained in the Prospectus and the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(mm)&nbsp;</I>The statements in the Time of Sale Prospectus under the headings Prospectus Summary&#150;Our
History and Corporate Structure,&#148; &#147;Risk Factors,&#148; &#147;Dividend Policy,&#148; &#147;Enforcement of Civil
Liabilities,&#148; &#147;Our History and Corporate Structure,&#148; &#147;Business,&#148; &#147;Regulation of Our Industry,&#148;
&#147;Management,&#148; &#147;Related Party Transactions,&#148; &#147;Description of Share Capital,&#148; &#147;Description of
American Depositary Shares,&#148; &#147;Share Eligible for Future Sale,&#148; &#147;Taxation&#148; and &#147;Underwriting&#148;
insofar as such statements summarize legal matters, agreements, documents or proceedings discussed
therein, are accurate and fair summaries in all material respects of such legal matters,
agreements, documents or proceedings and include the information required to be included therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(nn)&nbsp;</I>The Company has not taken, directly or indirectly, any action that is designed to or that
has constituted or that would reasonably be expected to cause or result in the stabilization or
manipulation of the price of any security of the Company to facilitate the sale or resale of the
Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(oo)&nbsp;</I>Any third-party statistical and market-related data included in the Registration
Statement, the Prospectus or the Time of Sale Prospectus are based
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 13 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">on or derived from sources that
the Company believes to be reliable and accurate, and relevant third-party consents for such data
to be included therein have been duly obtained and have not been revoked.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(pp)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus, neither the Company&#146;s independent
auditors nor its internal auditors have recommended that the Board review or investigate, (i)
adding to, deleting, changing the application of, or changing the Company&#146;s disclosure with respect
to, any of the Company&#146;s material accounting policies, (ii)&nbsp;any matter which could result in a
restatement of the Company&#146;s financial statements for any annual or interim period during the
current or prior three fiscal years, or (iii)&nbsp;any Internal Control Event.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(qq)&nbsp;</I>The section entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations&#148; in the Time of Sale Prospectus accurately and fully describes (i)&nbsp;accounting
policies that the Company believes are the most important in the portrayal of the financial
condition and results of operations of the Company and its subsidiaries and that require
management&#146;s most difficult, subjective or complex judgments (&#147;<B>Critical Accounting Policies</B>&#148;),
(ii)&nbsp;judgments and uncertainties affecting the application of Critical Accounting Policies, and
(iii)&nbsp;the likelihood that materially different amounts would be reported under different conditions
or using different assumptions and an explanation thereof; and the Board and the Company&#146;s
management have reviewed and agreed with the selection, application and disclosure of the Critical
Accounting Policies as described in the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(rr)&nbsp;</I>The financial statements included in the Registration Statement, the Prospectus and the
Time of Sale Prospectus comply as to form in all material respects with the requirements of the
Securities Act and the rules and regulations of the Commission thereunder and present fairly the
financial position of the Company and its consolidated subsidiaries as of the dates shown and their
results of operations, shareholders equity and cash flows for the periods shown, and such financial
statements have been prepared in conformity with U.S. GAAP applied on a consistent basis; the
schedules included in the Registration Statement present fairly the information required to be
stated therein; and the selected financial data and the summary financial information included in
the Registration Statement, the Prospectus and the Time of Sale Prospectus present fairly the
information shown therein and have been compiled on a basis consistent with that of the audited
financial statements included in the Registration Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ss)&nbsp;</I>Ernst &#038; Young Hua Ming, who has expressed an opinion on the financial statements of the
Company included in the Registration Statement, the Prospectus and the Time of Sale Prospectus
based on its audits, is an independent public accounting firm as required by the Securities Act and
the rules and regulations of the Commission thereunder and is registered with, and is
independent in accordance with the requirements of, the Public Company Accounting Oversight
Board.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 14 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(tt)&nbsp;</I>The Company was not a &#147;passive foreign investment company&#148; (&#147;<B>PFIC</B>&#148;) as defined in Section
1297 of the U.S. Internal Revenue Code of 1986, as amended, for its most recently completed taxable
year and, based on the Company&#146;s current projected income, assets and activities, the Company does
not expect to be classified as a PFIC for 2009 or any subsequent taxable year.<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(uu)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus, under current laws and regulations of
the Cayman Islands, Hong Kong, the PRC and any political subdivision thereof, all dividends and
other distributions declared and payable on the Shares may be paid by the Company to the holder
thereof in U.S. dollars that may be converted into foreign currency and freely transferred out of
the Cayman Islands, Hong Kong or the PRC and all such payments made to holders thereof or therein
who are non-residents of the Cayman Islands, Hong Kong or the PRC will not be subject to income,
withholding or other taxes under laws and regulations of the Cayman Islands, Hong Kong, the PRC or
any political subdivision or taxing authority thereof or therein and will otherwise be free and
clear of any other tax, duty, withholding or deduction in the Cayman Islands, Hong Kong, the PRC or
any political subdivision or taxing authority thereof or therein and without the necessity of
obtaining any Governmental Authorization in the Cayman Islands, Hong Kong, the PRC or any political
subdivision or taxing authority thereof or therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(vv)&nbsp;</I>There are no material relationships or transactions within the past three years between
the Company or any of its subsidiaries on the one hand and their respective affiliates, directors
or officers or 10% or greater shareholders, or any affiliates or members of the immediate families
of such persons, on the other hand that are not disclosed in the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ww)&nbsp;</I>Except as set forth in the Time of Sale Prospectus, there are no affiliations or
associations between any member of the Financial Industry Regulatory Authority, Inc. (&#147;<B>FINRA</B>&#148;) and
the Company or any of its subsidiaries or between any member of FINRA, any of the officers or
directors of the Company, or holders of 5% or greater of the securities of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(xx)&nbsp;</I>The Company is a &#147;foreign private issuer&#148; within the meaning of Rule&nbsp;405 under the
Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(yy)&nbsp;</I>The Company and its subsidiaries have filed all Cayman Islands, Hong Kong, PRC and other
tax returns, if any, that are required to be filed or have requested extensions thereof (except in
any case in which the failure to file would not, individually or in the aggregate, have a material
adverse effect on the Company and its subsidiaries, taken as a whole; except as set forth in the
Time of Sale Prospectus, the Company and its subsidiaries have paid all taxes (including any
assessments, fines or penalties) required to be paid by them, except for any
such taxes, assessments, fines or penalties currently being contested in good faith as would
not, individually or in the aggregate, have a material adverse effect on the Company and its
subsidiaries, taken as a whole; neither the Company nor any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 15 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of its subsidiaries has received a
notice of deficiency with respect to the Company or any of its subsidiaries, except for such
notices the effect of which would not have a material adverse effect on the Company and its
subsidiaries, taken as a whole; and the provisions included in the audited consolidated financial
statements contained in the Prospectus and the Time of Sale Prospectus are in conformity with U.S.
GAAP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(zz)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus, no transaction, stamp, capital or
other issuance, registration, transaction, transfer or withholding taxes or duties are payable in
the PRC, Hong Kong and the Cayman Islands by or on behalf of the Underwriters to any PRC, Hong Kong
or Cayman Islands taxing authority in connection with (i)&nbsp;the issuance, sale and delivery of the
Ordinary Shares represented by the Shares by the Company and the Selling Shareholders, the issuance
of the Shares by the Depositary, and the delivery of the Shares to or for the account of the
Underwriters, (ii)&nbsp;the purchase from the Company and the initial sale and delivery by the
Underwriters of the Shares to purchasers thereof, (iii)&nbsp;the deposit of the Ordinary Shares with the
Depositary and the Custodian (as defined in the Deposit Agreement) and the issuance and delivery of
the ADRs evidencing the ADSs, or (iv)&nbsp;the execution and delivery of this Agreement or the Deposit
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(aaa) </I>This Agreement and the Deposit Agreement are in proper form under the laws of the Cayman
Islands for the enforcement thereof against the Company in accordance with the laws of the Cayman
Islands and to ensure the legality, validity, enforceability or admissibility into evidence in the
Cayman Islands of this Agreement and the Deposit Agreement; it is not necessary that this
Agreement, the Deposit Agreement or any other document be filed or recorded with any Governmental
Authority in the Cayman Islands or that any Cayman Islands stamp duty or similar tax be paid on or
in respect of this Agreement, the Deposit Agreement or any other document to be furnished hereunder
or thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(bbb) </I>The choice of laws of the State of New York as the governing law of this Agreement and
the Deposit Agreement is a valid choice of law under the laws of the Cayman Islands and the PRC and
will be honored by courts in the Cayman Islands and, to the extent permitted under the PRC civil
law and rules of civil procedures, will be honored by the courts in the PRC. The Company has the
power to submit, and pursuant to Section&nbsp;17 of this Agreement and Section&nbsp;19 of the Deposit
Agreement, has legally, validly, effectively and irrevocably submitted, to the personal
jurisdiction of each U.S. federal court and New York state court located in the Borough of
Manhattan, in The City of New York, New York, U.S.A. (each, a &#147;<B>New York Court</B>&#148;), and the Company
has the power to designate, appoint and authorize, and pursuant to Section&nbsp;17 of this Agreement and
Section&nbsp;19 of the Deposit Agreement, has legally, validly, effectively and
irrevocably designated, appointed and authorized an agent for service of process in any action
arising out of or relating to this Agreement, the Deposit Agreement or the Shares in any New York
Court, and service of process effected on such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 16 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">authorized agent will be effective to confer valid
personal jurisdiction over the Company as provided in Section&nbsp;17 hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ccc)&nbsp;</I>Neither the Company, nor any of its subsidiaries nor any of their respective properties,
assets or revenues has any right of immunity under Cayman Islands, PRC, Hong Kong or New York law,
from any legal action, suit or proceeding, from the giving of any relief in any such legal action,
suit or proceeding, from set-off or counterclaim, from the jurisdiction of any Cayman Islands, PRC,
Hong Kong, New York or U.S. federal court, from service of process, attachment upon or prior to
judgment, or attachment in aid of execution of judgment, or from execution of a judgment, or other
legal process or proceeding for the giving of any relief or for the enforcement of a judgment, in
any such court, with respect to its obligations, liabilities or any other matter under or arising
out of or in connection with this Agreement or the Deposit Agreement, and, to the extent that the
Company, or any of its subsidiaries or any of their respective properties, assets or revenues may
have or may hereafter become entitled to any such right of immunity in any such court in which
proceedings may at any time be commenced, each of the Company and its subsidiaries waives or will
waive such right to the extent permitted by law and has consented to such relief.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ddd) </I>Any final judgment for a fixed sum of money rendered by a New York Court having
jurisdiction under its own domestic laws in respect of any suit, action or proceeding against the
Company based upon this Agreement and the Deposit Agreement would be recognized and enforced
against the Company by Cayman Islands courts without re-examining the merits of the case under the
common law doctrine of obligation; <I>provided </I>that (i)&nbsp;adequate service of process has been effected
and the defendant has had a reasonable opportunity to be heard, (ii)&nbsp;such judgments or the
enforcement thereof are not contrary to the law, public policy, security or sovereignty of the
Cayman Islands, (iii)&nbsp;such judgments were not obtained by fraudulent means and do not conflict with
any other valid judgment in the same matter between the same parties, and (iv)&nbsp;an action between
the same parties in the same matter is not pending in any Cayman Islands court at the time the
lawsuit is instituted in the foreign court; it is not necessary that this Agreement, the Deposit
Agreement, the Prospectus or any other document be filed or recorded with any court or other
authority in the Cayman Islands or the PRC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(eee) </I>No holder of any of the Shares after the consummation of the transactions contemplated
by this Agreement and the Deposit Agreement is or will be subject to any personal liability in
respect of any liability of the Company solely by virtue of its holding of the Shares, and, except
as set forth in the Time of Sale Prospectus, there are no limitations on the rights of holders of
the Ordinary Shares or the ADSs to hold or vote their securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(fff) </I>Under the laws of the Cayman Islands, each holder of ADRs evidencing ADSs issued
pursuant to the Deposit Agreement shall be entitled,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 17 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">subject to the terms and provisions of the
Deposit Agreement, to seek enforcement of its rights through the Depositary or its nominee
registered as representative of the holders of the ADRs in a direct suit, action or proceeding
against the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ggg) </I>The Company has not distributed, directly or indirectly, and, prior to the later to
occur of any delivery date and completion of the distribution of the Shares, will not distribute
any offering material in connection with the offering and sale of the Shares other than any
Prospectus or Time of Sale Prospectus to which the Representatives have consented in accordance
with this Agreement and any free writing prospectus set forth on Schedule&nbsp;III hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(hhh) </I>Except as set forth in the Time of Sale Prospectus, none of the Company or any of its
subsidiaries is engaged in any trading activities involving credit default swaps, commodity
contracts or other trading contracts which are not currently traded on a securities or commodities
exchange and for which the market value cannot be determined.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(iii)&nbsp;</I>The Company has taken all reasonable steps to comply with, and has used reasonable
efforts to cause all of the Company&#146;s shareholders who are PRC residents or PRC citizens to comply
with, any applicable rules and regulations of the State Administration of Foreign Exchange (the
&#147;<B>SAFE Rules and Regulations</B>&#148;), including without limitation, requesting that each shareholder named
in the Company&#146;s share register that is, or is directly or indirectly owned or controlled by, a PRC
resident or PRC citizen to complete any registration and other procedures required under applicable
SAFE Rules and Regulations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(jjj) </I>The Company is aware of, and has been advised as to, the content of the Rules on Mergers
and Acquisitions of Domestic Enterprises by Foreign Investors jointly promulgated by the Ministry
of Commerce, the State Assets Supervision and Administration Commission, the State Tax
Administration, the State Administration of Industry and Commerce, the China Securities Regulatory
Commission (&#147;<B>CSRC</B>&#148;) and the State Administration of Foreign Exchange of the PRC on August&nbsp;8, 2006
(the &#147;<B>M&#038;A Rules</B>&#148;), in particular the relevant provisions thereof which purport to require offshore
special purpose vehicles (&#147;<B>SPVs</B>&#148;) formed for listing purposes and controlled directly or indirectly
by PRC companies or individuals, to obtain the approval of the CSRC prior to the listing and
trading of their securities on any stock exchange located outside of the PRC; the Company has
received legal advice specifically with respect to the M&#038;A Rules from its PRC counsel and the
Company understands such legal advice; and the Company has fully communicated such legal advice
from its PRC counsel to each of its directors and officers that signed the Registration Statement
and each such director and officer has confirmed that he or she understands such legal advice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(kkk) </I>The issuance and sale of the ADSs, the listing and trading of the ADSs on the NYSE or
the consummation of the transactions contemplated by this
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 18 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Agreement and the Deposit Agreement is
not and will not be, as of the date hereof or at the Closing and an Option Closing Date, if any,
adversely affected by the M&#038;A Rules or any official clarifications, guidance, interpretations or
implementation rules in connection with or related to the M&#038;A Rules, including the guidance and
notices issued by the CSRC on September&nbsp;8, 2006 and September&nbsp;21, 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(lll) </I>Any certificate signed by an officer or director of the Company and delivered to the
Representatives or counsel for the Representatives as required or contemplated by Section 6(b)
hereof or the Deposit Agreement shall constitute a representation and warranty hereunder by the
Company, as to matters covered thereby or as excluded from or disclosed against therein, to each
Underwriter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>2.&nbsp;Representations and Warranties of the Selling Shareholders. </I>Each Selling Shareholder
represents and warrants to and agrees with each of the Underwriters that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(a)&nbsp;</I>Such Selling Shareholder, if an entity, has been duly organized and is validly existing
and in good standing as an entity in its jurisdiction of formation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>This Agreement has been duly authorized, executed and delivered by each Selling
Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>Such Selling Shareholder has, and on the Closing Date will have, valid and unencumbered
title to the Shares to be delivered by such Selling Shareholder on the Closing Date and full right,
power and authority to enter into this Agreement and to sell, assign, transfer and deliver the
Ordinary Shares underlying the Shares to be delivered by such Selling Shareholder on such Closing
Date hereunder; and upon the delivery of and payment for the Shares on the Closing Date hereunder
the several Underwriters will acquire valid and unencumbered title to the Shares to be delivered
by such Selling Shareholder on such Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>The Ordinary Shares represented by the Shares to be sold by such Selling Shareholder may
be freely deposited by such Selling Shareholder with the Depositary or with &#091;Jianyu Yang&#093; (the
&#147;Selling Shareholder Custodian&#148;) as agent for the Depositary in accordance with the Deposit
Agreement against the issuance of ADRs evidencing the Shares representing such Ordinary Shares so
deposited by such Selling Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>The execution and delivery by such Selling Shareholder of, and the performance by such
Selling Shareholder of its obligations under, this Agreement, the Custody Agreement signed by such
Selling Stockholder and the Company, as
custodian (in such capacity, the &#147;<B>Selling Shareholder Custodian</B>&#148;), relating to the deposit of
the Shares to be sold by such Selling Shareholder (the &#147;<B>Custody Agreement</B>&#148;), and the Power of
Attorney appointing certain individuals as such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 19 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Selling Shareholder&#146;s attorneys-in-fact to the
extent set forth therein, relating to the transactions contemplated hereby and by the Registration
Statement (the &#147;<B>Power of Attorney</B>&#148;) will not contravene any provision of applicable law, or the
organizational documents of such Selling Shareholder (if such Selling Shareholder is an entity), or
any agreement or other instrument binding upon such Selling Shareholder or any judgment, order or
decree of any governmental body, agency or court having jurisdiction over such Selling Shareholder,
and no Governmental Authorization of any Government Agency is required for the performance by such
Selling Shareholder of its obligations under this Agreement or the Custody Agreement or Power of
Attorney of such Selling Shareholder, except such as may be required by the securities or Blue Sky
laws of the various states in connection with the offer and sale of the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(f)&nbsp;</I>The Custody Agreement and the Power of Attorney have been duly authorized, executed and
delivered by such Selling Shareholder and are valid and binding agreements of such Selling
Shareholder enforceable in accordance with their terms, subject to bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating
to or affecting creditors&#146; rights and to general equity principles.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(g)&nbsp;</I>The statements in the sections entitled &#147;Principal and Selling Shareholders&#148; relating to
such Selling Shareholder in the Prospectus and the Time of Sale Prospectus did not and do not
include any untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not
misleading.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(h)&nbsp;</I>The sale of the Shares by such Selling Shareholder pursuant to this Agreement is not
prompted by any material information concerning the Company or any of its subsidiaries that is not
set forth the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(i)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus, there are no contracts, agreements or
understandings between the Selling Shareholder and any person that would give rise to a valid claim
against such Selling Shareholder or any Underwriter for a brokerage commission, finder&#146;s fee or
other like payment in connection with this offering.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(j)&nbsp;</I>Such Selling Shareholder has not taken, directly or indirectly, any action that is
designed to or that has constituted or that would reasonably be expected to cause or result in the
stabilization or manipulation of the price of any security of the Company to facilitate the sale or
resale of the Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(k)&nbsp;</I>Upon payment for the Shares sold by such Selling Shareholder under this Agreement and the
delivery by such Selling Shareholder to DTC (as
defined below) or its agent of the Shares in book entry form to a securities account
maintained by the Underwriters at DTC or its nominee, and payment therefor in accordance with this
Agreement, the Underwriters will acquire a
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 20 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">securities entitlement (within the meaning of Section
8-501 of the Uniform Commercial Code (the &#147;<B>UCC</B>&#148;)) with respect to such Shares, and no action based
on an &#147;adverse claim&#148; (as defined in UCC Section&nbsp;8-102) may be asserted against the Underwriters
with respect to such security entitlement if, at such time, the Underwriters do not have notice of
any adverse claim within the meaning of UCC Section&nbsp;8-105.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(l)&nbsp;</I>The questionnaire containing certain information regarding such Selling Shareholder and
the election form which sets forth the amount of Ordinary Shares such Selling Shareholder has
elected to sell in the offering of the Shares (the &#147;<B>Questionnaire and Election Form</B>&#148;), completed by
such Selling Shareholder and submitted to the Company on or before the date hereof does not and as
of the Closing Date will not contain any untrue statement of material fact nor does it omit to
state any material fact required to be stated therein or necessary to make the statements therein
not misleading and such Selling Shareholder&#146;s election to sell the number of Ordinary Shares
indicated in the Questionnaire and Election Form is valid and binding on such Selling Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(m)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus or the Questionnaire and Election Form,
such Selling Shareholder has no affiliations or associations with any member of the FINRA; and none
of the proceeds received by such Selling Shareholder from the sale of the Shares to be sold by such
Selling Shareholder hereunder will be paid to a member of the FINRA or any affiliate (or person
&#147;associated with,&#148; as such terms are used in the rules of the FINRA).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(n)&nbsp;</I>No transaction, stamp, capital or other issuance, registration, transaction, transfer or
withholding taxes or duties are payable by or on behalf of the Underwriters in connection with
(i)&nbsp;the sale and delivery of the Ordinary Shares represented by the Shares by such Selling
Shareholder, the issuance of such Shares by the Depositary, and the delivery of such Shares to or
for the account of the Underwriters, (ii)&nbsp;the purchase from such Selling Shareholder and the
initial sale and delivery by the Underwriters of the Shares to purchasers thereof, (iii)&nbsp;the
deposit by such Selling Shareholder of the Ordinary Shares with the Depositary and the Selling
Shareholder Custodian and the issuance and delivery of the ADRs evidencing the ADSs, or (iv)&nbsp;the
execution and delivery of this Agreement, the Power of Attorney and the Custody Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(o)&nbsp;</I>Such Selling Shareholder has not distributed and will not distribute, prior to the later
of the latest Closing Date and the completion of the Underwriters&#146; distribution of the Shares, any
offering material in connection with the offering and sale of the Shares by such Selling
Shareholders, including any free writing prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(p)&nbsp;</I>Other than as disclosed in the Time of Sale Prospectus, such Selling Shareholder does not
have any registration or other similar rights to have any equity or debt securities registered for
sale by the Company under the Registration Statement or included in the offering of the Shares.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 21 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(q)&nbsp;</I>Such Selling Shareholder does not have, or has waived prior to the date hereof, any
preemptive right, co-sale right or right of first refusal or other similar right to purchase any of
the Ordinary Shares that are to be sold by the Company or any other Selling Shareholder to the
Underwriters pursuant to this Agreement; and such Selling Shareholder does not own any warrants,
options or similar rights to acquire, and does not have any right or arrangement to acquire, any
capital shares, right, warrants, options or other securities from the Company, other than those
described in the Prospectus and the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(r)&nbsp;</I>The sale of the Ordinary Shares by such Selling Shareholder does not violate such Selling
Shareholder&#146;s internal policies regarding the sale of shares by its affiliates, if applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(s)&nbsp;</I>Such Selling Shareholder has no reason to believe that the representations and warranties
of the Company contained in Section&nbsp;1 are not true and correct, is familiar with the Registration
Statement, the Time of Sale Prospectus and the Prospectus and has no knowledge of any material
fact, condition or information not disclosed in the Time of Sale Prospectus or the Prospectus that
has had, or may have, a material adverse effect on the Company and its subsidiaries, taken as a
whole. Such Selling Shareholder is not prompted by any information concerning the Company or its
subsidiaries which is not set forth in the Time of Sale Prospectus to sell its Shares pursuant to
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(t)&nbsp;</I>(i)&nbsp;The Registration Statement, as it relates to such Selling Shareholder, when it became
effective, did not contain and, as amended or supplemented, if applicable, will not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading, (ii)&nbsp;the Time of Sale Prospectus, as it
relates to such Selling Shareholder, does not, and at the time of each sale of the Shares in
connection with the offering when the Prospectus is not yet available to prospective purchasers and
at the Closing Date (as defined in Section&nbsp;5), the Time of Sale Prospectus, as then amended or
supplemented by the Company, if applicable, as it relates to such Selling Shareholder, will not,
contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements therein, in the light of the circumstances under which they were made, not
misleading, (iii)&nbsp;each broadly available road show, if any, when considered together with the Time
of Sale Prospectus, as it relates to such Selling Shareholder, does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading and (iv)&nbsp;the
Prospectus, as it relates to such Selling Shareholder, does not contain and, as amended or
supplemented, if applicable, will not contain any untrue statement of
a material fact or omit to state a material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 22 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(u)&nbsp;</I>The choice of law set forth in Section&nbsp;17 hereof as the governing law of this Agreement is
a valid choice of law and will be recognized and given effect to in any action brought before a
court of competent jurisdiction in jurisdiction in which such Selling Shareholder is organized and
has its principal place of business if not a natural person or in the jurisdiction in which such
person resides if a natural person. The courts of any such jurisdiction will recognize as a valid
judgment, a final and conclusive judgment in personam obtained in U.S. courts against such Selling
Shareholder based upon this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(v)&nbsp;</I>Neither such Selling Shareholder nor its properties, assets or revenues has any right of
immunity under Cayman Islands, PRC, Hong Kong or New York law, from any legal action, suit or
proceeding, from the giving of any relief in any such legal action, suit or proceeding, from
set-off or counterclaim, from the jurisdiction of any Cayman Islands, PRC, Hong Kong, New York or
U.S. federal court, from service of process, attachment upon or prior to judgment, or attachment in
aid of execution of judgment, or from execution of a judgment, or other legal process or proceeding
for the giving of any relief or for the enforcement of a judgment, in any such court, with respect
to its obligations, liabilities or any other matter under or arising out of or in connection with
this Agreement, the Power of Attorney and the Custody Agreement, and, to the extent that such
Selling Shareholder or any of its properties, assets or revenues may have or may hereafter become
entitled to any such right of immunity in any such court in which proceedings may at any time be
commenced, such Selling Shareholder waives or will waive such right to the extent permitted by law
and has consented to such relief and enforcement as provided in Section&nbsp;17 hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(w)&nbsp;</I>Any Selling Shareholder Certificate (as defined below) signed by any officer or director
of such Selling Shareholder and delivered to the Representatives or counsel for the Representatives
as required or contemplated by this Agreement shall constitute a representation and warranty
hereunder by such Selling Shareholder, as to matters covered thereby, to each Underwriter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>3.&nbsp;Agreements to Sell and Purchase. </I>The Company hereby agrees to sell to the several
Underwriters, and each Underwriter, upon the basis of the representations and warranties herein
contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to
purchase from the Company at U.S.$&#091;<B>&#149;</B>&#093; per ADS (the &#147;<B>Purchase Price</B>&#148;) the respective number of Firm
Shares set forth in Schedule&nbsp;II hereto opposite the name of such Underwriter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On the basis of the representations and warranties contained in this Agreement, and subject to
its terms and conditions, the Selling Shareholders, severally and not jointly, hereby agree to sell
to the several Underwriters the
Additional Shares, and the Underwriters shall have the right to purchase, severally and not
jointly, up to an aggregate of &#091;1,800,000&#093; Additional Shares at the Purchase Price. You may
exercise this right on behalf of the Underwriters in whole or from time to time in part by giving
written notice to the Company and the Selling Shareholders not later than 30&nbsp;days after the date of
this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 23 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any exercise notice shall specify the number of Additional Shares to be purchased
by the Underwriters and the date on which such Shares are to be purchased. Each purchase date must
be at least one business day after the written notice is given and may not be earlier than the
closing date for the Firm Shares or later than ten business days after the date of such notice.
Additional Shares may be purchased as provided in Section&nbsp;5 hereof solely for the purpose of
covering over-allotments made in connection with the offering of the Firm Shares. On each day, if
any, that Additional Shares are to be purchased (an &#147;<B>Option Closing Date</B>&#148;), each Underwriter
agrees, severally and not jointly, to purchase from each Selling Shareholder the number of
Additional Shares (subject to such adjustments to eliminate fractional shares as you may determine)
that bears the same proportion to the total number of Additional Shares to be purchased from each
Selling Shareholder on such Option Closing Date as the number of Firm Shares set forth in
Schedule&nbsp;II hereto opposite the name of such Underwriter bears to the total number of Firm Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Seller hereby agrees that, without the prior written consent of the Representatives on
behalf of the Underwriters, it will not, during the period ending 180&nbsp;days after the date of the
Prospectus, (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or
otherwise transfer or dispose of, directly or indirectly, any Ordinary Shares, ADSs or any
securities convertible into or exercisable or exchangeable for Ordinary Shares or ADSs or (2)&nbsp;enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the
economic consequences of ownership of Ordinary Shares or ADSs, whether any such transaction
described in clause&nbsp;(1) or (2)&nbsp;above is to be settled by delivery of Ordinary Shares, ADSs or such
other securities, in cash or otherwise or (3)&nbsp;file any registration statement with the Commission
relating to the offering of any Ordinary Shares, ADSs or any securities convertible into or
exercisable or exchangeable for Ordinary Shares or ADSs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The restrictions contained in the preceding paragraph shall not apply to (a)the Shares to be
sold hereunder, (b)&nbsp;transactions relating to Ordinary Shares, ADSs or other securities acquired in
open market transactions after the completion of the offering of the Shares, <I>provided </I>that no
filing under Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;),
shall be required or shall be voluntarily made in connection with subsequent sales of Ordinary
Shares or other securities acquired in such open market transactions, (c)&nbsp;the exercise of any
rights to acquire Ordinary Shares, ADSs or other securities of the Company issued pursuant to any
share option or similar equity incentive or compensation plan of the Company for the issuance of
share options or equity grants that is in effect as of the date of and disclosed in the
Prospectus (it being understood that any subsequent sale, transfer or disposition of any
securities of the Company issued upon exercise of such options or grants shall be subject to the
restrictions set forth in this Section&nbsp;3), (d)&nbsp;transfers of Ordinary Shares or ADSs to shareholders
who are existing shareholders of the Company prior to the date of the Prospectus or partners,
members, stockholders or affiliates
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 24 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of such shareholders, (e)&nbsp;transfers of Ordinary Shares, ADSs or
any security convertible into Ordinary Shares or ADSs (i)&nbsp;to an immediate family member or a trust
formed for the benefit of an immediate family member, (ii)&nbsp;as a bona fide gift or (iii)&nbsp;through
will or intestacy, (f)&nbsp;transfers or distributions of Ordinary Shares, ADSs or any security
convertible into Ordinary Shares or ADSs to partners, members, stockholders or affiliates of any
Selling Shareholder, <I>provided </I>that in the case of any transfer or distribution pursuant to
clause&nbsp;(d), (e)&nbsp;or (f), (x)&nbsp;each transferee, donee or distributee shall enter into a written
agreement accepting the restrictions set forth in this Section&nbsp;3 and (y)&nbsp;no filing under
Section&nbsp;16(a) of the Exchange Act, reporting a reduction in beneficial ownership of Ordinary Shares
or ADSs, shall be required or shall be voluntarily made in respect of the transfer or distribution
during the 180-day restricted period, or (g)&nbsp;the establishment of a trading plan pursuant to Rule
10b5-1 under the Exchange Act for the transfer of Ordinary Shares or ADSs, <I>provided </I>that such plan
does not provide for the transfer of Ordinary Shares during the 180-day restricted period. In
addition, each Selling Shareholder, agrees that, without the prior written consent of the
Representatives on behalf of the Underwriters, it will not, during the period ending 180&nbsp;days after
the date of the Prospectus, make any demand for, or exercise any right with respect to, the
registration of any Ordinary Shares, ADSs or any security convertible into or exercisable or
exchangeable for Ordinary Shares or ADSs. Each Selling Shareholder consents to the entry of stop
transfer instructions with the Company&#146;s transfer agent and registrar against the transfer of any
Ordinary Shares held by such Selling Shareholder except in compliance with the foregoing
restrictions. Notwithstanding the foregoing, if (1)&nbsp;during the last 17&nbsp;days of the 180-day
restricted period the Company issues an earnings release or material news or a material event
relating to the Company occurs; or (2)&nbsp;prior to the expiration of the 180-day restricted period,
the Company announces that it will release earnings results during the 16-day period beginning on
the last day of the 180-day period, the restrictions imposed by this agreement shall continue to
apply until the expiration of the 18-day period beginning on the issuance of the earnings release
or the occurrence of the material news or material event, unless the Representatives waive, in
writing, such extension. The Company shall promptly notify the Representatives of any earnings
release, news or event that may give rise to an extension of the initial 180-day restricted period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>4.&nbsp;Terms of Public Offering</I>. The Company is advised by you that the Underwriters propose to
make a public offering of their respective portions of the Shares as soon after the Registration
Statement and this Agreement have become effective as in your judgment is advisable. The Company
is further advised by you that the Shares are to be offered to the public initially at U.S.$&#091;<B>&#149;</B>&#093; per
ADS (the &#147;<B>Public Offering Price</B>&#148;) and to certain dealers selected by you at a price that represents
a concession not in excess of U.S.$&#091;<B>&#149;</B>&#093; per ADS under the Public
Offering Price, and that any Underwriter may allow, and such dealers may reallow, a
concession, not in excess of U.S.$&#091;<B>&#149;</B>&#093; per ADS, to any Underwriter or to certain other dealers.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 25 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>5.&nbsp;Payment and Delivery. </I>Executed transfer forms for the Ordinary Shares represented by the
Shares to be sold by the Selling Shareholders hereunder have been placed in custody, for delivery
under this Agreement, under Custody Agreements made with the Selling Shareholder Custodian. Each
Selling Shareholder agrees that the Ordinary Shares represented by the transfer forms held in
custody for the Selling Shareholders under such Custody Agreements are subject to the interests of
the Underwriters hereunder, that the arrangements made by the Selling Shareholders for such custody
are to that extent irrevocable, and that the obligations of the Selling Shareholders hereunder
shall not be terminated by operation of law, whether by the death of any individual Selling
Shareholder or the occurrence of any other event, or in the case of a trust, by the death of any
trustee or trustees or the termination of such trust. If any individual Selling Shareholder or any
such trustee or trustees should die, or if any other such event should occur, or if any of such
trusts should terminate, before the delivery of the Shares hereunder, such Shares shall be
delivered by the Selling Shareholder Custodian in accordance with the terms and conditions of this
Agreement as if such death or other event or termination had not occurred, regardless of whether or
not the Selling Shareholder Custodian shall have received notice of such death or other event or
termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company will deliver the Firm Shares to or as instructed by the Representatives for the
accounts of the several Underwriters through the facilities of The Depository Trust Company (&#147;<B>DTC</B>&#148;)
in a form reasonably acceptable to the Representatives against payment of the purchase price in
Federal (same day) funds by official bank check or checks or wire transfer to an account at a bank
acceptable to the Representatives drawn to the order of &nbsp;the Company at the office of O&#146;Melveny &#038;
Myers LLP, Yin Tai Center, Office Tower, 37<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor, No.&nbsp;2 Jianguomenwai Avenue, Chao
Yang District, Beijing, 100022 PRC at 10:00&nbsp;a.m., New York time, on December &#091;<B>&#149;</B>&#093;, 2009, or at such
other time on the same or such other date, not later than December &#091;<FONT face="Wingdings" style="font-size: 8pt">&#108;</FONT>&#093;, 2009, as shall be
designated in writing by you. The time and date of such payment are hereinafter referred to as the
&#147;<B>First Closing Date</B>&#148; (the First Closing Date and each Option Closing Date, if any, being sometimes
referred to as a &#147;<B>Closing Date</B>&#148;). For purposes of Rule&nbsp;15c6-1 under the Exchange Act, the First
Closing Date (if later than the otherwise applicable settlement date) shall be the settlement date
for payment of funds and delivery of securities for all the Shares sold pursuant to the offering.
The ADRs evidencing the Firm Shares will be in definitive form, in such denominations and
registered in such names as the Representatives request. The ADRs will be made available for
checking and packaging at the above office or such other place designated by the Representatives at
least 24 hours prior to the First Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Selling Shareholder Custodian will deliver any Additional Shares to or as instructed by
the Representatives for the accounts of the several Underwriters through the facilities of DTC in a
form reasonably acceptable to the
Representatives against payment of the purchase price in Federal (same day) funds by wire
transfer to an account at a bank acceptable to the Representatives drawn to the order of the
Company for each Selling Shareholder at the office of O&#146;Melveny &#038; Myers LLP, Yin Tai Center, Office
Tower, 37<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor, No.&nbsp;2
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 26 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Jianguomenwai Avenue, Chao Yang District, Beijing, 100022 PRC
at 10:00&nbsp;a.m., New York time, on the date specified in the corresponding notice described in
Section&nbsp;3, or at such other time on the same or such other date, no later than January &#091;<FONT face="Wingdings" style="font-size: 8pt">&#108;</FONT>&#093;, 2009,
as shall be designated in writing by you. The ADRs evidencing the Additional Shares will be in
definitive form, in such denominations and registered in such names as the Representatives request.
The ADRs will be made available for checking and packaging at the above office or such other place
designated by the Representatives at least 24 hours prior to the Option Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Firm Shares and Additional Shares shall be registered in such names and in such
denominations as you shall request in writing not later than one full business day prior to the
Closing Date or the applicable Option Closing Date, as the case may be. The Firm Shares and
Additional Shares shall be delivered to you on the Closing Date or an Option Closing Date, as the
case may be, for the respective accounts of the several Underwriters, with any transfer taxes
payable in connection with the transfer of the Shares to the Underwriters duly paid, against
payment of the Purchase Price therefor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>6.&nbsp;Conditions to the Underwriters&#146; Obligations</I>. The obligations of the Company and the
Selling Shareholders to sell the Shares to the Underwriters and the several obligations of the
Underwriters to purchase and pay for the Shares on the Closing Date are subject to the condition
that the Registration Statement shall have become effective not later than 4:00 p.m. (New York City
time) on the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The several obligations of the Underwriters are subject to the following further conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(a)&nbsp;</I>Subsequent to the execution and delivery of this Agreement and prior to the Closing Date
there shall not have occurred any change, or any development involving a prospective change, in the
condition, financial or otherwise, or in the earnings, business or operations of the Company and
its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus as of the
date of this Agreement that, in your judgment, is material and adverse and that makes it, in your
judgment, impracticable to market the Shares on the terms and in the manner contemplated in the
Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>The Representatives shall have received on the Closing Date a certificate, dated the
Closing Date and signed by an executive officer of the Company (the &#147;<B>Company Certificate</B>&#148;), to the
effect set forth in Section&nbsp;6(a)(i) above and to the effect that the representations and warranties
of the Company contained in this Agreement are true and correct as of the Closing Date and that
the Company has complied with all of the agreements and satisfied all of the conditions on its
part to be performed or satisfied hereunder on or before the Closing Date.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 27 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The officer signing and delivering such certificate may rely upon the best of his or her
knowledge as to proceedings threatened.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>The Representatives shall have received a certificate, dated as of the Closing Date, of an
authorized representative of each Selling Shareholder (the &#147;<B>Selling Shareholder Certificate</B>&#148;) in
which such authorized representative shall state that the representations and warranties of such
Selling Shareholder in this Agreement are true and correct and the Selling Shareholders have
complied with all agreements and satisfied all conditions on their part to be performed or
satisfied hereunder at or prior to such Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>The Representatives shall have received on the Closing Date an opinion of Simpson Thacher
&#038; Bartlett LLP, U.S. counsel for the Company, dated the Closing Date, addressed to the
Representatives substantially in the form attached hereto as Annex A. In rendering such opinion,
Simpson Thacher &#038; Bartlett LLP may rely as to all matters governed by Cayman Islands law on the
opinion of Walkers referenced to below and all matters governed by PRC law upon the opinion of
Jingtian &#038; Gongcheng Attorneys at Law referenced to below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>The Representatives shall have received on the Closing Date an opinion of Walkers, Cayman
Islands counsel for the Company, dated as of the Closing Date, addressed to the Representatives
substantially in the form attached hereto as Annex B.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(f)&nbsp;</I>The Representatives shall have received on the Closing Date, an opinion of Jingtian &#038;
Gongcheng Attorneys at Law, PRC counsel for the Company, dated as of the Closing Date, addressed to
the Representatives substantially in the form attached hereto as Annex C.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(g)&nbsp;</I>The Representatives shall have received on the Closing Date, an opinion of &#091;<B>&#149;</B>&#093;, Hong Kong
counsel for the Company, dated as of the Closing Date, addressed to the Representatives
substantially in the form attached hereto as Annex D.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(h)&nbsp;</I>The Representatives shall have received on the Closing Date, an opinion of Walkers,
British Virgin Islands counsel for the Company, dated as of the Closing Date, addressed to the
Representatives substantially in the form attached hereto as Annex E.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(i)&nbsp;</I>The Representatives shall have received on the Closing Date an opinion of local counsel
for each Selling Shareholder, dated as of the Closing Date, addressed to the Representatives
substantially in the form attached hereto as Annex F.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(j)&nbsp;</I>The Representatives shall have received on the Closing Date an opinion of Paul, Hastings,
Janofsky &#038; Walker LLP, counsel to the Depositary, dated as of the Closing Date, addressed to the
Representatives substantially in the form attached hereto as Annex G.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 28 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(k)&nbsp;</I>The Representatives shall have received on the Closing Date an opinion of O&#146;Melveny &#038;
Myers LLP, U.S. counsel to the Underwriters, dated as of the Closing Date, with respect to such
matters as the Underwriters may require, and the Company and the Selling Shareholders shall have
furnished to such counsel such documents, as they request for the purpose of enabling them to pass
upon such matters. In rendering such opinion, O&#146;Melveny &#038; Myers LLP may rely as to all matters
governed by Cayman Islands law on the opinion of Walkers referenced to above and all matters
governed by PRC law upon the opinion of Commerce &#038; Finance Law Offices referenced to below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(l)&nbsp;</I>The Representatives shall have received on the Closing Date an opinion of Commerce &#038;
Finance Law Offices, PRC counsel to the Underwriters, dated as of the Closing Date, with respect to
such matters as the Underwriters may require, and the Company and the Selling Shareholders shall
have furnished to such counsel such documents, as they request for the purpose of enabling them to
pass upon such matters.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(m)&nbsp;</I>The Representatives shall have received, on each of the date hereof and the Closing Date,
a letter dated the date hereof or the Closing Date, as the case may be, in form and substance
satisfactory to the Underwriters, from Ernst &#038; Young Hua Ming, independent public accountants,
containing statements and information of the type ordinarily included in accountants&#146; &#147;comfort
letters&#148; to underwriters with respect to the financial statements and certain financial information
contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus; <I>provided</I>
that the letter delivered on the Closing Date shall use a &#147;cut-off date&#148; not earlier than three
days prior to the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(n)&nbsp;</I>The Representatives shall have received a certificate, dated as of the Closing Date,
signed by the Chief Financial Officer of the Company certifying as to, among other things, the
accuracy of certain financial and operating data relating to the Company included in the Time of
Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(o)&nbsp;</I>The &#147;lock-up&#148; agreements, each substantially in the form of Exhibit&nbsp;A hereto (the &#147;<B>Lock-Up
Agreements</B>&#148;), between you and certain shareholders, officers and directors of the Company relating
to sales and certain other dispositions of Ordinary Shares or certain other securities, delivered
to you on or before the date hereof, shall be in full force and effect on the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(p)&nbsp;</I>The Depositary shall have furnished or caused to be furnished to the Underwriters a
certificate satisfactory to the Underwriters of one of its authorized officers with respect to the
deposit with it of the Ordinary Shares represented by the Shares against issuance of the ADRs
evidencing the Shares,
the execution, issuance, countersignature and delivery of the ADRs evidencing the Shares
pursuant to the Deposit Agreement and such other matters related thereto as the Underwriters may
reasonably request.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 29 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(q)&nbsp;</I>The Company and the Depositary shall have executed and delivered the Deposit Agreement and
the Deposit Agreement shall be in full force and effect and the Company and the Depositary shall
have taken all action necessary to permit the deposit of the Ordinary Shares and the issuance of
the Shares in accordance with the Deposit Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(r)&nbsp;</I>The Custody Agreement shall have been executed by each of the Selling Shareholders or
Attorney-in-Fact on behalf of the Selling Shareholders on or prior to the date hereof and
certificates in negotiable form representing all of the Ordinary Shares to be sold by the Selling
Shareholders hereunder on the Closing Date shall have been placed in custody under the Custody
Agreement by each of the Selling Shareholders, duly executed and delivered by such Selling
Shareholders to the Custodian, on or prior to the date at least two business days prior to the
Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(s)&nbsp;</I>On or prior to the Closing Date, the Underwriters shall have received from the Custodian
U.S. Treasury Department Form W-9 or the applicable Form W-8 (or other applicable form or statement
specified by Treasury Department regulations in lieu thereof) properly completed and executed by
each Selling Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(t)&nbsp;</I>The Shares shall have been approved for listing on the NYSE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(u)&nbsp;</I>On or prior to the Closing Date, the Shares shall be eligible for clearance and settlement
through the facilities of DTC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(v)&nbsp;</I>No Prospectus or Time of Sale Prospectus or amendment or supplement to the Registration
Statement, the ADS Registration Statement or the Prospectus shall have been filed to which the
Representatives shall have objected in writing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(w)&nbsp;</I>The FINRA shall have confirmed that it has not raised any objection with respect to the
fairness and reasonableness of the underwriting terms and arrangements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The several obligations of the Underwriters to purchase Additional Shares hereunder are
subject to the delivery to you on the applicable Option Closing Date of such documents as you may
reasonably request with respect to the good standing of the Company, the due authorization and
issuance of the Additional Shares to be sold on such Option Closing Date and other matters related
to the issuance of such Additional Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>7.&nbsp;Covenants of the Company</I>. The Company covenants with each Underwriter as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(a)&nbsp;</I>To furnish to you, without charge, four signed copies of the Registration Statement
(including exhibits thereto) and for delivery to each other Underwriter a conformed copy of the
Registration Statement (without exhibits
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 30 -<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">thereto) and for delivery to each other Underwriter a conformed copy of the
Registration Statement (without exhibits thereto) and to furnish to you in New York City, without
charge, prior to 10:00&nbsp;a.m. New York City time on the business day next succeeding the date of this
Agreement and during the period mentioned in Section&nbsp;7(e) or 7(f) below, as many copies of the Time
of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the
Registration Statement as you may reasonably request.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>Before amending or supplementing the Registration Statement, the ADS Registration
Statement, the Prospectus or the Time of Sale Prospectus, to furnish to you a copy of each such
proposed amendment or supplement and not to file any such proposed amendment or supplement to which
you reasonably object, and to file with the Commission within the applicable period specified in
Rule&nbsp;424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>To furnish to you a copy of each proposed free writing prospectus to be prepared by or on
behalf of, used by, or referred to by the Company and not to use or refer to any proposed free
writing prospectus to which you reasonably object.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>Not to take any action that would result in an Underwriter or the Company being required
to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing
prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not
have been required to file thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time
when the Prospectus is not yet available to prospective purchasers and any event shall occur or
condition exist as a result of which it is necessary to amend or supplement the Time of Sale
Prospectus in order to make the statements therein, in the light of the circumstances, not
misleading, or if any event shall occur or condition exist as a result of which the Time of Sale
Prospectus conflicts with the information contained in the Registration Statement then on file, or
if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time
of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission
and furnish, at its own expense, to the Underwriters and to any dealer upon request, either
amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale
Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time
of Sale Prospectus is delivered to a prospective purchaser, be misleading or so that the Time of
Sale Prospectus, as amended or supplemented, will no longer conflict with the Registration
Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with
applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(f)&nbsp;</I>If, during such period after the first date of the public offering of the Shares as in the
opinion of counsel for the Underwriters the Prospectus (or in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 31 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">lieu thereof the notice referred to
in Rule 173(a) under the Securities Act) is required by law to be delivered in connection with
sales by an Underwriter or dealer, any event shall occur or condition exist as a result of which it
is necessary to amend or supplement the Prospectus in order to make the statements therein, in the
light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule
173(a) under the Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion
of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply
with applicable law, forthwith to prepare, file with the Commission and furnish, at its own
expense, to the Underwriters and to the dealers (whose names and addresses you will furnish to the
Company) to which Shares may have been sold by you on behalf of the Underwriters and to any other
dealers upon request, either amendments or supplements to the Prospectus so that the statements in
the Prospectus as so amended or supplemented will not, in the light of the circumstances when the
Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under the Securities Act) is
delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will
comply with applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(g)&nbsp;</I>To endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws
of such jurisdictions as you shall reasonably request.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(h)&nbsp;</I>To make generally available to the Company&#146;s security holders and to you as soon as
practicable an earning statement covering a period of at least twelve months beginning with the
first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy
the provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the
Commission thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;To comply with all applicable securities and other laws, rules and regulations in each
jurisdiction in which the Directed Shares are offered in connection with the Directed Share
Program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(j)&nbsp;</I>The Company will use the net proceeds received by it in connection with this offering in
the manner described in the &#147;Use of Proceeds&#148; section of the Time of Sale Prospectus and, except as
disclosed in the Time of Sale Prospectus, the Company does not intend to use any of the proceeds
from the sale of the Shares hereunder to repay any outstanding debt owed to any affiliate of any
Underwriter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(k)&nbsp;</I>The Company will not take, directly or indirectly, any action designed to or that would
constitute or that might reasonably be expected to cause or result in, stabilization or
manipulation of the price of any securities of the Company to facilitate the sale or resale of the
Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(l)&nbsp;</I>The Company will indemnify and hold harmless the Underwriters against any documentary,
stamp or similar issue tax, including any interest and penalties, on the creation, issue and sale
of the Shares and on the execution and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 32 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">delivery of this Agreement. All payments to be made by the
Company hereunder shall be made exclusive of Value Added Tax, Goods and Services Tax, Business Tax,
withholding tax and/or similar taxes (collectively, &#147;<B>Taxes</B>&#148;) and shall be made without withholding
or deduction for or on account of any present or future taxes, duties or governmental charges
whatsoever unless the Company is compelled by law to deduct or withhold such taxes, duties or
charges. In that event, the Company shall (i)&nbsp;pay such additional amounts as may be necessary in
order that the net amounts received after such withholding or deduction shall equal the amounts
that would have been received if no withholding or deduction had been made, and (ii)&nbsp;forward to the
Underwriters for their records an official receipt or a copy of the official receipt issued by the
taxing authority or other document evidencing payment of such taxes, duties or charges that the
Company was compelled by law to deduct or withhold and remit to the taxing authority to satisfy the
tax obligation of the Underwriters. The Company agrees that it shall be responsible for all Taxes
as well as all applicable compliance and regulatory obligations related to such Taxes which may
arise from or in connection with this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(m)&nbsp;</I>The Company will use its best efforts to maintain the listing of the Shares on the NYSE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(n)&nbsp;</I>The Company, during the period when a prospectus (or, in lieu thereof, the notice referred
to in Rule 173(a) under the Securities Act) is required to be delivered under the Securities Act in
connection with the offer or sale of the Shares, will file all reports and other documents required
to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the
Exchange Act and the applicable rules and regulations of the Commission thereunder within the time
periods required thereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(o)&nbsp;</I>The Company shall comply with the SAFE Rules and Regulations, and shall use reasonable
efforts to cause its shareholders and option holders that are, or that are directly or indirectly
owned or controlled by, PRC residents or PRC citizens, to comply with the SAFE Rules and
Regulations applicable to them in connection with the Company, including without limitation,
requesting each shareholder and option holder, that is, or is directly or indirectly owned or
controlled by, a PRC resident or PRC citizen to complete any registration and other procedures
required under applicable SAFE Rules and Regulations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(p)&nbsp;</I>The Company shall at all times maintain transfer restrictions (including the inclusion of
legends in share certificates, as may be required) with respect to the Company&#146;s Ordinary Shares
which are subject to transfer restrictions pursuant to this Agreement and the Lock-Up Agreements
and shall ensure compliance with such restrictions on transfer of restricted Ordinary Shares. The
Company shall retain all share certificates which are by their terms subject to
transfer restrictions until such time as such transfer restrictions are no longer applicable
to such securities.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 33 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(q)&nbsp;</I>The Company will deposit the Ordinary Shares with the custodian for the Depositary in
compliance with the provisions of the Deposit Agreement and instruct the Depositary at the Closing
Date to deliver the ADR evidencing the ADSs representing such Ordinary Shares to participant
accounts within DTC in accordance with the written instructions of each of the Underwriters.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(r)&nbsp;</I>The Company agrees (i)&nbsp;not to attempt to avoid any judgment obtained by it or denied to it
in a court of competent jurisdiction outside of the Cayman Islands; (ii)&nbsp;following the consummation
of the offering of the Shares, it will use its best efforts to obtain and maintain all approvals,
if any, required in the Cayman Islands to pay and remit outside the Cayman Islands all dividends
declared by the Company and payable on the Ordinary Shares; and (iii)&nbsp;it will use its best efforts
to obtain and maintain all approvals, if any, required in the Cayman Islands for the Company to
acquire sufficient foreign exchange for the payment of dividends and all other relevant purposes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(s)&nbsp;</I>The Company will use its best efforts to comply with Sarbanes-Oxley, and will use its best
efforts to cause the Company&#146;s directors and officers, in their capacities as such, to comply with
Sarbanes-Oxley.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(t)&nbsp;</I>The Company will not directly or indirectly use the proceeds of the sale of the Shares
hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint
venture partner or other person or entity, for the purpose of financing the activities of any
person currently subject to any U.S. sanctions administered by OFAC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(u)&nbsp;</I>The Company will comply with Rule 433(d) (without reliance on Rule&nbsp;164(b)) and Rule 433(g)
under the Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(v)&nbsp;</I>The Company will not, prior to the delivery of the Shares on the Closing Date, issue any
press release or other communication directly or indirectly and will hold no press conferences with
respect to the Company or any of its subsidiaries, the financial condition, results of operations,
business, properties, assets or liabilities of the Company or any of its subsidiaries, or the
offering or sale of the Shares, without the Underwriters&#146; prior consent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(w)&nbsp;</I>The Company will not, at any time at or after the execution of this Agreement, directly or
indirectly, offer or sell any Shares by means of any &#147;prospectus&#148; (within the meaning of the
Securities Act), or use any &#147;prospectus&#148; (within the meaning of the Securities Act) in connection
with the offer or sale of the Shares, in each case other than the then most recent prospectus
included in the Registration Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(x)&nbsp;</I>The Company will do and perform all things required to be done or performed under this
Agreement by the Company prior to the Closing Date and to satisfy all conditions precedent to the
delivery of the Shares.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 34 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>8.&nbsp;Covenants of Selling Shareholders</I>. Each of the Selling Shareholders, severally and not
jointly, covenants with each Underwriter as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(a)&nbsp;</I>Such Selling Shareholder will indemnify and hold harmless the Underwriters against any
documentary, stamp or similar issue tax, including any interest and penalties, on the creation,
issue and sale of the Shares by such Selling Shareholder and on the execution and delivery of this
Agreement. All payments to be made by each Selling Shareholder hereunder shall be made exclusive of
any Taxes and shall be made without withholding or deduction for or on account of any present or
future taxes, duties or governmental charges whatsoever unless such Selling Shareholder or the
Company is compelled by law to deduct or withhold such taxes, duties or charges. In that event, a
Selling Shareholder shall (i)&nbsp;pay such additional amounts as may be necessary in order that the net
amounts received after such withholding or deduction shall equal the amounts that would have been
received if no withholding or deduction had been made, and (ii)&nbsp;forward to the Underwriters for
their records an official receipt of a copy of the official receipt issued by the taxing authority
or other document evidencing payment of such taxes, duties or charges that such Selling Shareholder
was compelled by law to deduct or withhold and remit to the taxing authority to satisfy the tax
obligation of such Selling Shareholder. Such Selling Shareholder agrees that it shall be
responsible for all Taxes as well as all applicable compliance and regulatory obligations related
to such Taxes which may arise from or in connection with this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>Such Selling Shareholder agrees to procure delivery to the Representatives on or prior to
the Closing Date of a properly completed and executed U.S. Treasury Department Form W-9 or
applicable Form W-8 (or other applicable form or statement specified by Treasury Department
regulations in lieu thereof).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>The Shares to be sold by such Selling Shareholder hereunder are subject to the interest of
the Underwriters and the obligations of such Selling Shareholder hereunder shall not be terminated
by any act of such Selling Shareholder, by operation of law, by the death or incapacity of any
individual Selling Shareholder or, in the case of a trust, by the death or incapacity of any
executor or trustee or the termination of such trust, or the occurrence of any other event.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>To notify promptly the Company and the Representatives if, at any time prior to the date
on which the distribution of the Shares as contemplated herein and in the Registration Statement
and the Prospectus has been completed, as determined by the Representatives, such Selling
Shareholder has knowledge of
the occurrence of any event relating to such Selling Shareholder as a result of which the
Registration Statement and the Prospectus, in each case as then amended or supplemented, would
include an untrue statement of a material fact or omit to state any material fact necessary to make
the statements therein (except in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 35 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the case of the Registration Statement), in the light of the
circumstances under which they were made not misleading.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>Prior to the delivery of the Shares on the Closing Date, such Selling Shareholder will
deposit, or cause to be deposited on its behalf, Ordinary Shares with the Depositary in accordance
with the provisions of the Deposit Agreement and otherwise to comply with the Deposit Agreement so
that ADRs evidencing the ADSs will be executed (and, if applicable, countersigned) and issued by
the Depositary against receipt of the Ordinary Shares and delivered to the Underwriters.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(f)&nbsp;</I>Such Selling Shareholder will not (and will cause its affiliates not to) take, directly or
indirectly, any action which is designed to or which constitutes or which might reasonably be
expected to cause or result in stabilization or manipulation of the price of any securities of the
Company to facilitate the sale or resale of the Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(g)&nbsp;</I>Such Selling Shareholder will advise the Representatives promptly and, if requested by the
Representatives, confirm such advice in writing, so long as a prospectus is required by the
Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the
Securities Act or any similar rule) in connection with any sale of ADSs by the Selling Shareholder
hereunder, of (A)&nbsp;any material change in condition (financial or otherwise), results of operations,
business, general affairs, management, shareholders equity, properties or prospects of the Company
and its subsidiaries, which has come to the attention of such Selling Shareholder, (B)&nbsp;any change
in information contained in the Registration Statement, the Prospectus and the Time of Sale
Prospectus, if any, relating to such Selling Shareholder or (C)&nbsp;any new material information
relating to the Company or its subsidiaries or relating to any matter stated in the Registration
Statement, the Prospectus and the Time of Sale Prospectus, if any, which has come to the attention
of such Selling Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(h)&nbsp;</I>Such Selling Shareholder will cooperate to the extent necessary to cause the Registration
Statement or any post-effective amendment thereto to become effective at the earliest practical
time and to do and perform all things to be done and performed under this Agreement prior to the
Closing Date and to satisfy all conditions precedent of such Selling Shareholder to the delivery of
the Shares and the Shares to be sold by such Selling Shareholder pursuant to this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(i)&nbsp;</I>Such Selling Shareholder will not, directly or indirectly, use any of the proceeds it will
receive from the sale of the Shares contemplated hereby (A)&nbsp;to fund any operations in, to finance
any investments, projects or activities in, or to
make any payments to, any country, or to make any payments to, or finance any activities with,
any Person, targeted by the Sanctions, or (B)&nbsp;in any manner that is not in compliance with
applicable laws, rules and regulations of any Governmental Agency having jurisdiction over such
Selling Shareholder,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 36 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">including, without limitation, the requirement for PRC residents or citizens
to repatriate the net proceeds received by such Selling Shareholder into the PRC under the SAFE
Rules and Regulations and applicable regulations of the PRC Ministry of Commerce.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>9.&nbsp;Expenses</I>. Whether or not the transactions contemplated in this Agreement are consummated
or this Agreement is terminated, the Sellers agree to pay or cause to be paid all expenses incident
to the performance of their obligations under this Agreement, including: (i)&nbsp;the fees,
disbursements and expenses of the Company&#146;s counsel, the Company&#146;s accountants and counsel for the
Selling Shareholders in connection with the registration and delivery of the Shares under the
Securities Act and all other fees or expenses in connection with the preparation and filing of the
Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, the Prospectus,
any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company and
amendments and supplements to any of the foregoing, including all printing costs associated
therewith, and the mailing and delivering of copies thereof to the Underwriters and dealers, in the
quantities hereinabove specified, (ii)&nbsp;all costs and expenses related to the transfer and delivery
of the Shares to the Underwriters, including any transfer or other taxes payable thereon, (iii)&nbsp;the
cost of printing or producing any Blue Sky or Legal Investment memorandum in connection with the
offer and sale of the Shares under state securities laws and all expenses in connection with the
qualification of the Shares for offer and sale under state securities laws as provided in
Section&nbsp;8(g) hereof, including filing fees and the reasonable fees and disbursements of counsel
for the Underwriters in connection with such qualification and in connection with the Blue Sky or
Legal Investment memorandum, (iv)&nbsp;all filing fees and the reasonable fees and disbursements of
counsel to the Underwriters incurred in connection with the review and qualification of the
offering of the Shares by the FINRA, (v)&nbsp;all fees and expenses in connection with the preparation
and filing of the registration statement on Form 8-A relating to the Ordinary Shares and all costs
and expenses incident to listing the Shares on the NYSE, (vi)&nbsp;the cost of printing certificates
representing the Shares, (vii)&nbsp;the costs and charges of any transfer agent, registrar or
depositary, (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any
&#147;road show&#148; undertaken in connection with the marketing of the offering of the Shares, including,
without limitation, expenses associated with the preparation or dissemination of any electronic
road show, expenses associated with the production of road show slides and graphics, fees and
expenses of any consultants engaged in connection with the road show presentations with the prior
approval of the Company, travel and lodging expenses of the representatives and officers of the
Company and any such consultants, and one-half the cost of any aircraft chartered in connection
with the road show, (ix)&nbsp;the document production charges and expenses associated with printing this
Agreement, (x)&nbsp;all fees and
disbursements of counsel incurred by the Underwriters in connection with the Directed Share
Program and stamp duties, similar taxes or duties or other taxes, if any, incurred by the
Underwriters in connection with the Directed Share Program and (xi)&nbsp;all other costs and expenses
incident to the performance of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 37 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">obligations of the Company hereunder for which provision is not
otherwise made in this Section. It is understood, however, that except as provided in this
Section, Section&nbsp;11 entitled &#147;Indemnity and Contribution&#148;, Section&nbsp;12 entitled &#147;Directed Share
Program Indemnification&#148; and the last paragraph of Section&nbsp;14 below, the Underwriters will pay all
of their costs and expenses, including fees and disbursements of their counsel, stock transfer
taxes payable on resale of any of the Shares by them and any advertising expenses connected with
any offers they may make, which costs and expenses shall be apportioned among the Underwriters
based on the relative economic benefits received by the Underwriters under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this Section shall not supersede or otherwise affect any agreement that the
Sellers may otherwise have for the allocation of such expenses among themselves.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>10.&nbsp;Covenants of the Underwriters</I>. Each Underwriter severally covenants with the Company not
to take any action that would result in the Company being required to file with the Commission
under Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of
such Underwriter that otherwise would not be required to be filed by the Company thereunder, but
for the action of the Underwriter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>11.&nbsp;Indemnity and Contribution. </I>(a)&nbsp;The Company agrees to indemnify and hold harmless each
Underwriter, each person, if any, who controls any Underwriter within the meaning of either
Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, and each affiliate of any
Underwriter within the meaning of Rule&nbsp;405 under the Securities Act from and against any and all
losses, claims, damages and liabilities (including, without limitation, any legal or other expenses
reasonably incurred in connection with defending or investigating any such action or claim) caused
by any untrue statement or alleged untrue statement of a material fact contained in the
Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale
Prospectus, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act,
any Company information that the Company has filed, or is required to file, pursuant to Rule 433(d)
under the Securities Act, or the Prospectus or any amendment or supplement thereto, or caused by
any omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, except insofar as such losses, claims,
damages or liabilities are caused by any such untrue statement or omission or alleged untrue
statement or omission based upon information relating to any Underwriter furnished to the Company
in writing by such Underwriter through you expressly for use therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>The Selling Shareholders, severally and not jointly, agree to indemnify and hold harmless
each Underwriter, each person, if any, who controls any Underwriter within the meaning of either
Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, and each affiliate of any
Underwriter within the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 38 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">meaning of Rule&nbsp;405 under the Securities Act from and against any and all
losses, claims, damages and liabilities (including, without limitation, any legal or other expenses
reasonably incurred in connection with defending or investigating any such action or claim) caused
by any untrue statement or alleged untrue statement of a material fact contained in the
Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale
Prospectus, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act,
any Company information that the Company has filed, or is required to file, pursuant to Rule 433(d)
under the Securities Act, or the Prospectus or any amendment or supplement thereto, or caused by
any omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, but in any case only with reference to
information relating to such Selling Shareholder furnished in writing by or on behalf of such
Selling Shareholder expressly for use in the Registration Statement or any amendment thereof, any
preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus as defined
in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is
required to file, pursuant to Rule 433(d) of the Securities Act, or the Prospectus or any amendment
or supplement thereto. The liability of each Selling Shareholder under the indemnity agreement
contained in this paragraph shall be limited to the net proceeds received by it from the sale of
Additional Shares under this Agreement, if any.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the
Company, the Selling Shareholders, the directors of the Company, the officers of the Company who
sign the Registration Statement and each person, if any, who controls the Company or any Selling
Shareholder within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the
Exchange Act from and against any and all losses, claims, damages and liabilities (including,
without limitation, any legal or other expenses reasonably incurred in connection with defending or
investigating any such action or claim) caused by any untrue statement or alleged untrue statement
of a material fact contained in the Registration Statement or any amendment thereof, any
preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus as defined
in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is
required to file, pursuant to Rule 433(d) under the Securities Act, or the Prospectus (as amended
or supplemented if the Company shall have furnished any amendments or supplements thereto), or
caused by any omission or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, but only with reference to
information relating to such Underwriter furnished to the Company in writing by such Underwriter
through you expressly for use in the Registration Statement, any preliminary prospectus, the Time
of Sale Prospectus, any issuer free writing prospectus or the Prospectus or any amendment or
supplement
thereto, it being understood and agree that the only such information furnished by any
Underwriter consists of the following information in the Prospectus furnished on behalf of each
Underwriter: the paragraph relating to stabilization by the Underwriters appearing under the
caption &#147;Underwriting.&#148;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 39 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>In case any proceeding (including any governmental investigation) shall be instituted
involving any person in respect of which indemnity may be sought pursuant to Section&nbsp;11(a), 11(b)
or 11(c), such person (the &#147;<B>indemnified party</B>&#148;) shall promptly notify the person against whom such
indemnity may be sought (the &#147;<B>indemnifying party</B>&#148;) in writing and the indemnifying party, upon
request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified
party to represent the indemnified party and any others the indemnifying party may designate in
such proceeding and shall pay the fees and disbursements of such counsel related to such
proceeding. In any such proceeding, any indemnified party shall have the right to retain its own
counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified
party unless (i)&nbsp;the indemnifying party and the indemnified party shall have mutually agreed to the
retention of such counsel or (ii)&nbsp;the named parties to any such proceeding (including any impleaded
parties) include both the indemnifying party and the indemnified party and representation of both
parties by the same counsel would be inappropriate due to actual or potential differing interests
between them. It is understood that the indemnifying party shall not, in respect of the legal
expenses of any indemnified party in connection with any proceeding or related proceedings in the
same jurisdiction, be liable for (i)&nbsp;the fees and expenses of more than one separate firm (in
addition to any local counsel) for all Underwriters and all persons, if any, who control any
Underwriter within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the
Exchange Act or who are affiliates of any Underwriter within the meaning of Rule&nbsp;405 under the
Securities Act, (ii)&nbsp;the fees and expenses of more than one separate firm (in addition to any local
counsel) for the Company, its directors, its officers who sign the Registration Statement and each
person, if any, who controls the Company within the meaning of either such Section and (iii)&nbsp;the
fees and expenses of more than one separate firm (in addition to any local counsel) for all Selling
Shareholders and all persons, if any, who control any Selling Shareholder within the meaning of
either such Section, and that all such fees and expenses shall be reimbursed as they are incurred.
In the case of any such separate firm for the Underwriters and such control persons and affiliates
of any Underwriters, such firm shall be designated in writing by Morgan Stanley. In the case of
any such separate firm for the Company, and such directors, officers and control persons of the
Company, such firm shall be designated in writing by the Company. In the case of any such separate
firm for the Selling Shareholders and such control persons of any Selling Shareholders, such firm
shall be designated in writing by the persons named as attorneys-in-fact for the Selling
Shareholders under the Powers of Attorney. The indemnifying party shall not be liable for any
settlement of any proceeding effected without its written consent, but if settled with such consent
or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the
indemnified party from and against any loss or liability by
reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time
an indemnified party shall have requested an indemnifying party to reimburse the indemnified party
for fees and expenses of counsel as contemplated by the second and third sentences of this
paragraph, the indemnifying party agrees
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 40 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">that it shall be liable for any settlement of any
proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30
days after receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying
party shall not have reimbursed the indemnified party in accordance with such request prior to the
date of such settlement. No indemnifying party shall, without the prior written consent of the
indemnified party, effect any settlement of any pending or threatened proceeding in respect of
which any indemnified party is or could have been a party and indemnity could have been sought
hereunder by such indemnified party, unless such settlement includes an unconditional release of
such indemnified party from all liability on claims that are the subject matter of such proceeding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>To the extent the indemnification provided for in Section&nbsp;11(a), 12(b) or 12(c) is
unavailable to an indemnified party or insufficient in respect of any losses, claims, damages or
liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of
indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by
such indemnified party as a result of such losses, claims, damages or liabilities (i)&nbsp;in such
proportion as is appropriate to reflect the relative benefits received by the indemnifying party or
parties on the one hand and the indemnified party or parties on the other hand from the offering of
the Shares or (ii)&nbsp;if the allocation provided by Section&nbsp;11(d)(i) above is not permitted by
applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in Section&nbsp;11(d)(i) above but also the relative fault of the indemnifying party or
parties on the one hand and of the indemnified party or parties on the other hand in connection
with the statements or omissions that resulted in such losses, claims, damages or liabilities, as
well as any other relevant equitable considerations. The relative benefits received by the Sellers
on the one hand and the Underwriters on the other hand in connection with the offering of the
Shares shall be deemed to be in the same respective proportions as the net proceeds from the
offering of the Shares (before deducting expenses) received by each Seller and the total
underwriting discounts and commissions received by the Underwriters, in each case as set forth in
the table on the cover of the Prospectus, bear to the aggregate Public Offering Price of the
Shares. The relative fault of the Sellers on the one hand and the Underwriters on the other hand
shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a material fact relates
to information supplied by the Sellers or by the Underwriters and the parties&#146; relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission.
The Underwriters&#146; respective obligations to contribute pursuant to this Section&nbsp;11 are several in
proportion to the respective number of Shares they have purchased hereunder, and not joint. The
liability of each Selling Shareholder under the contribution agreement contained in this
paragraph is several and shall be limited to an amount equal to the net proceeds received by
each such Selling Shareholder under this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 41 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(f)&nbsp;</I>The Sellers and the Underwriters agree that it would not be just or equitable if
contribution pursuant to this Section&nbsp;11 were determined by <I>pro rata </I>allocation (even if the
Underwriters were treated as one entity for such purpose) or by any other method of allocation that
does not take account of the equitable considerations referred to in Section&nbsp;11(d). The amount
paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities
referred to in Section 11(d) shall be deemed to include, subject to the limitations set forth
above, any legal or other expenses reasonably incurred by such indemnified party in connection with
investigating or defending any such action or claim. Notwithstanding the provisions of this
Section&nbsp;11, no Underwriter shall be required to contribute any amount in excess of the amount by
which the total price at which the Shares underwritten by it and distributed to the public were
offered to the public exceeds the amount of any damages that such Underwriter has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission or alleged
omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of
the Securities Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. The remedies provided for in this Section&nbsp;11 are not exclusive and
shall not limit any rights or remedies which may otherwise be available to any indemnified party at
law or in equity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(g)&nbsp;</I>The indemnity and contribution provisions contained in this Section&nbsp;11 and the
representations, warranties and other statements of the Company and the Selling Shareholders
contained in this Agreement shall remain operative and in full force and effect regardless of (i)
any termination of this Agreement, (ii)&nbsp;any investigation made by or on behalf of any Underwriter,
any person controlling any Underwriter or any affiliate of any Underwriter, any Selling Shareholder
or any person controlling any Selling Shareholder, or the Company, its officers or directors or any
person controlling the Company and (iii)&nbsp;acceptance of and payment for any of the Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>12.&nbsp;Directed Share Program Indemnification. </I>(a)&nbsp;The Company agrees to indemnify and hold
harmless Morgan Stanley, each person, if any, who controls Morgan Stanley within the meaning of
either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act and each affiliate of
Morgan Stanley within the meaning of Rule&nbsp;405 of the Securities Act (&#147;<B>Morgan Stanley Entities</B>&#148;)
from and against any and all losses, claims, damages and liabilities (including, without
limitation, any legal or other expenses reasonably incurred in connection with defending or
investigating any such action or claim) (i)&nbsp;caused by any untrue statement or alleged untrue
statement of a material fact contained in any material prepared by or with the consent of the
Company for distribution to Participants in connection with the Directed Share Program or caused by
any omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading; (ii)&nbsp;caused by
the failure of any Participant to pay for and accept delivery of Directed Shares that the
Participant agreed to purchase; or (iii)&nbsp;related to, arising out of, or in connection with the
Directed Share Program, other than losses, claims, damages or liabilities (or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 42 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">expenses relating
thereto) that are finally judicially determined to have resulted from the bad faith or gross
negligence of Morgan Stanley Entities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>In case any proceeding (including any governmental investigation) shall be instituted
involving any Morgan Stanley Entity in respect of which indemnity may be sought pursuant to
Section&nbsp;12(a), the Morgan Stanley Entity seeking indemnity, shall promptly notify the Company in
writing and the Company, upon request of the Morgan Stanley Entity, shall retain counsel reasonably
satisfactory to the Morgan Stanley Entity to represent the Morgan Stanley Entity and any others the
Company may designate in such proceeding and shall pay the fees and disbursements of such counsel
related to such proceeding. In any such proceeding, any Morgan Stanley Entity shall have the right
to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of
such Morgan Stanley Entity unless (i)&nbsp;the Company shall have agreed to the retention of such
counsel or (ii)&nbsp;the named parties to any such proceeding (including any impleaded parties) include
both the Company and the Morgan Stanley Entity and representation of both parties by the same
counsel would be inappropriate due to actual or potential differing interests between them. The
Company shall not, in respect of the legal expenses of the Morgan Stanley Entities in connection
with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and
expenses of more than one separate firm (in addition to any local counsel) for all Morgan Stanley
Entities. Any such separate firm for the Morgan Stanley Entities shall be designated in writing by
Morgan Stanley. The Company shall not be liable for any settlement of any proceeding effected
without its written consent, but if settled with such consent or if there be a final judgment for
the plaintiff, the Company agrees to indemnify the Morgan Stanley Entities from and against any
loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing
sentence, if at any time a Morgan Stanley Entity shall have requested the Company to reimburse it
for fees and expenses of counsel as contemplated by the second and third sentences of this
paragraph, the Company agrees that it shall be liable for any settlement of any proceeding effected
without its written consent if (i)&nbsp;such settlement is entered into more than 30&nbsp;days after receipt
by the Company of the aforesaid request and (ii)&nbsp;the Company shall not have reimbursed the Morgan
Stanley Entity in accordance with such request prior to the date of such settlement. The Company
shall not, without the prior written consent of Morgan Stanley, effect any settlement of any
pending or threatened proceeding in respect of which any Morgan Stanley Entity is or could have
been a party and indemnity could have been sought hereunder by such Morgan Stanley Entity, unless
such settlement includes an unconditional release of the Morgan Stanley Entities from all liability
on claims that are the subject matter of such proceeding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>To the extent the indemnification provided for in Section&nbsp;12(a) is unavailable to a Morgan
Stanley Entity or insufficient in respect of any losses,
claims, damages or liabilities referred to therein, then the Company in lieu of indemnifying
the Morgan Stanley Entity thereunder, shall contribute to the amount paid or payable by the Morgan
Stanley Entity as a result of such losses,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 43 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">claims, damages or liabilities (i)&nbsp;in such proportion as
is appropriate to reflect the relative benefits received by the Company on the one hand and the
Morgan Stanley Entities on the other hand from the offering of the Directed Shares or (ii)&nbsp;if the
allocation provided by Section&nbsp;12(c)(i) above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in Section
12(c)(i) above but also the relative fault of the Company on the one hand and of the Morgan Stanley
Entities on the other hand in connection with any statements or omissions that resulted in such
losses, claims, damages or liabilities, as well as any other relevant equitable considerations.
The relative benefits received by the Company on the one hand and the Morgan Stanley Entities on
the other hand in connection with the offering of the Directed Shares shall be deemed to be in the
same respective proportions as the net proceeds from the offering of the Directed Shares (before
deducting expenses) and the total underwriting discounts and commissions received by the Morgan
Stanley Entities for the Directed Shares, bear to the aggregate Public Offering Price of the
Directed Shares. If the loss, claim, damage or liability is caused by an untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a material fact, the
relative fault of the Company on the one hand and the Morgan Stanley Entities on the other hand
shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement or the omission or alleged omission relates to information supplied by the Company or by
the Morgan Stanley Entities and the parties&#146; relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>The Company and the Morgan Stanley Entities agree that it would not be just or equitable
if contribution pursuant to this Section&nbsp;12 were determined by <I>pro rata </I>allocation (even if the
Morgan Stanley Entities were treated as one entity for such purpose) or by any other method of
allocation that does not take account of the equitable considerations referred to in Section&nbsp;12(c).
The amount paid or payable by the Morgan Stanley Entities as a result of the losses, claims,
damages and liabilities referred to in the immediately preceding paragraph shall be deemed to
include, subject to the limitations set forth above, any legal or other expenses reasonably
incurred by the Morgan Stanley Entities in connection with investigating or defending any such
action or claim. Notwithstanding the provisions of this Section&nbsp;12, no Morgan Stanley Entity shall
be required to contribute any amount in excess of the amount by which the total price at which the
Directed Shares distributed to the public were offered to the public exceeds the amount of any
damages that such Morgan Stanley Entity has otherwise been required to pay. The remedies provided
for in this Section&nbsp;12 are not exclusive and shall not limit any rights or remedies which may
otherwise be available to any indemnified party at law or in equity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>The indemnity and contribution provisions contained in this Section&nbsp;13 shall remain
operative and in full force and effect regardless of (i)&nbsp;any
termination of this Agreement, (ii)&nbsp;any investigation made by or on behalf of any Morgan
Stanley Entity or the Company, its officers or directors or any person
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 44 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">controlling the Company and
(iii)&nbsp;acceptance of and payment for any of the Directed Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>13.&nbsp;Termination</I>. The Underwriters may terminate this Agreement by notice given by you to the
Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i)
trading generally shall have been suspended or materially limited on, or by, as the case may be,
any of the NYSE, the American Stock Exchange or The NASDAQ Global Market, (ii)&nbsp;trading of any
securities of the Company shall have been suspended on any exchange or in any over-the-counter
market, (iii)&nbsp;a material disruption in securities settlement, payment or clearance services in the
United States or other relevant jurisdiction shall have occurred, (iv)&nbsp;any moratorium on commercial
banking activities shall have been declared by U.S. federal, New York State, Cayman Islands, PRC or
other relevant foreign country authorities or (v)&nbsp;there shall have occurred any outbreak or
escalation of hostilities, or any change in financial markets, currency exchange rates or controls
or any calamity or crisis that, in your judgment, is material and adverse and which, singly or
together with any other event specified in this clause&nbsp;(v), makes it, in your judgment,
impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms
and in the manner contemplated in the Time of Sale Prospectus or the Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>14.&nbsp;Effectiveness; Defaulting Underwriters</I>. This Agreement shall become effective upon the
execution and delivery hereof by the parties hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, on any Closing Date, any one or more of the Underwriters shall fail or refuse to purchase
Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number
of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to
purchase is not more than one-tenth of the aggregate number of the Shares to be purchased on such
date, the other Underwriters shall be obligated severally in the proportions that the number of
Firm Shares set forth opposite their respective names in Schedule&nbsp;II bears to the aggregate number
of Firm Shares set forth opposite the names of all such non-defaulting Underwriters, or in such
other proportions as you may specify, to purchase the Shares which such defaulting Underwriter or
Underwriters agreed but failed or refused to purchase on such date; <I>provided </I>that in no event shall
the number of Shares that any Underwriter has agreed to purchase pursuant to this Agreement be
increased pursuant to this Section&nbsp;14 by an amount in excess of one-ninth of such number of Shares
without the written consent of such Underwriter. If, on the Closing Date, any Underwriter or
Underwriters shall fail or refuse to purchase Firm Shares and the aggregate number of Firm Shares
with respect to which such default occurs is more than one-tenth of the aggregate number of Firm
Shares to be purchased on such date, and arrangements satisfactory to you and the Company for the
purchase of such Firm Shares are not made within 36 hours after such default, this Agreement shall
terminate without liability on the part of any non-defaulting Underwriter or the Company. In any
such case either you or the Company shall have the right to postpone the Closing Date, but in
no event for longer than seven days, in order that the required
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 45 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">changes, if any, in the
Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents
or arrangements may be effected. If, on an Option Closing Date, any Underwriter or Underwriters
shall fail or refuse to purchase Additional Shares and the aggregate number of Additional Shares
with respect to which such default occurs is more than one-tenth of the aggregate number of
Additional Shares to be purchased on such Option Closing Date, the non-defaulting Underwriters
shall have the option to (i)&nbsp;terminate their obligation hereunder to purchase the Additional Shares
to be sold on such Option Closing Date or (ii)&nbsp;purchase not less than the number of Additional
Shares that such non-defaulting Underwriters would have been obligated to purchase in the absence
of such default. Any action taken under this paragraph shall not relieve any defaulting
Underwriter from liability in respect of any default of such Underwriter under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Agreement shall be terminated by the Underwriters, or any of them, because of any
failure or refusal on the part of any Seller to comply with the terms or to fulfill any of the
conditions of this Agreement, or if for any reason any Seller shall be unable to perform its
obligations under this Agreement, the Sellers will reimburse the Underwriters or such Underwriters
as have so terminated this Agreement with respect to themselves, severally, for all out-of-pocket
expenses (including the fees and disbursements of their counsel) reasonably incurred by such
Underwriters in connection with this Agreement or the offering contemplated hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>15.&nbsp;Entire Agreement</I>. (a)&nbsp;This Agreement, together with any contemporaneous written
agreements and any prior written agreements (to the extent not superseded by this Agreement) that
relate to the offering of the Shares, represents the entire agreement between the Company, the
Selling Shareholders and the Underwriters with respect to the preparation of any preliminary
prospectus, the Time of Sale Prospectus, the Prospectus, the conduct of the offering, and the
purchase and sale of the Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>Each of the Company and the Selling Shareholders acknowledge that in connection with the
offering of the Shares: (i)&nbsp;the Underwriters have acted at arms length, are not agents of, and owe
no fiduciary duties to, the Company, the Selling Shareholders or any other person, (ii)&nbsp;the
Underwriters owe the Company and the Selling Shareholders only those duties and obligations set
forth in this Agreement and prior written agreements (to the extent not superseded by this
Agreement), if any, and (iii)&nbsp;the Underwriters may have interests that differ from those of the
Company and the Selling Shareholders. Each of the Company and the Selling Shareholders waive to
the full extent permitted by applicable law any claims it may have against the Underwriters arising
from an alleged breach of fiduciary duty in connection with the offering of the Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>16.&nbsp;Counterparts</I>. This Agreement may be signed in any number of counterparts, each of which
shall be an original, with the same effect as if the signatures thereto and hereto were upon the
same instrument.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 46 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>17.&nbsp;Applicable Law</I>. (a)&nbsp;This Agreement shall be governed by and construed in accordance with
the internal laws of the State of New York.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each of the parties hereto irrevocably (i)&nbsp;agrees that any legal suit, action or
proceeding against the Company or any Selling Shareholder brought by any Underwriter or by any
person who controls any Underwriter arising out of or based upon this Agreement or the transactions
contemplated hereby may be instituted in any New York Court, (ii)&nbsp;waives, to the fullest extent it
may effectively do so, any objection which it may now or hereafter have to the laying of venue of
any such proceeding and (iii)&nbsp;submits to the exclusive jurisdiction of such courts in any such
suit, action or proceeding. Each of the Company and the Selling Shareholders irrevocably waives,
to the fullest extent permitted by law, any immunity to jurisdiction to which it may otherwise be
entitled or become entitled (including sovereign immunity, immunity to pre-judgment attachment,
post-judgment attachment and execution) in any legal suit, action or proceeding against it arising
out of or based on this Agreement or the transactions contemplated hereby which is instituted in
any New York Court or in any competent court in the Cayman Islands. Each of the Company and the
Selling Shareholders has appointed National Registered Agents, Inc., located at 875 Avenue of the
Americas, Suite&nbsp;501, New York, New York 10001, as its authorized agent (the &#147;<B>Authorized Agent</B>&#148;)
upon whom process may be served in any such action arising out of or based on this Agreement or the
transactions contemplated hereby which may be instituted in any New York Court by any Underwriter
or by any person who controls any Underwriter, expressly consents to the jurisdiction of any such
court in respect of any such action, and waives, to the fullest extent permitted by law, any other
requirements of or objections to personal jurisdiction with respect thereto. Such appointment shall
be irrevocable. Each of the Company and the Selling Shareholders represents and warrants that the
Authorized Agent has agreed to act as such agent for service of process and agrees to take any and
all action, including the filing of any and all documents and instruments, which may be necessary
to continue such appointment in full force and effect as aforesaid. Service of process upon the
Authorized Agent and written notice of such service to the Company shall be deemed, in every
respect, effective service of process upon the Company and the Selling Shareholders as the case may
be.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>18.&nbsp;Judgment Currency</I>. In respect of any judgment or order given or made for any amount due
hereunder that is expressed and paid in a currency (the &#147;<B>judgment currency</B>&#148;) other than United
States dollars, the Company and the Selling Shareholders, as the case may be, will indemnify each
Underwriter against any loss incurred by such Underwriter as a result of any variation as between
(i)&nbsp;the rate of exchange at which the United States dollar amount is converted into the judgment
currency for the purpose of such judgment or order and (ii)&nbsp;the rate
of exchange at which an Underwriter is able to purchase United States dollars with the amount
of the judgment currency actually received by such Underwriter. The foregoing indemnity shall
constitute a separate and independent obligation of the Company and the Selling Shareholders and
shall continue in full force and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 47 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">effect notwithstanding any such judgment or order as aforesaid.
The term &#147;rate of exchange&#148; shall include any premiums and costs of exchange payable in connection
with the purchase of or conversion into United States dollars.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>19.&nbsp;Headings</I>. The headings of the sections of this Agreement have been inserted for
convenience of reference only and shall not be deemed a part of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>20.&nbsp;Notices</I>. All communications hereunder shall be in writing and effective only upon receipt
and if to the Underwriters shall be delivered, mailed or sent to you in care of Morgan
Stanley&nbsp;&#038;&nbsp;Co. International plc, 25 Cabot Square, Canary Wharf, London E14 4QA, United Kingdom and
J.P. Morgan Securities Inc., 383 Madison Avenue, Floor 4, New York, New York 10179; and if to the
Company shall be delivered, mailed or sent to Room&nbsp;2001-2002, 20-F, Tower A, Global Trade Center,
36 North Third Ring Road East, Dongcheng District, Beijing 100013, People&#146;s Republic of China.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signature pages follow.&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 48 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Very truly yours, <BR>
<BR>
CONCORD MEDICAL SERVICES<BR>
HOLDINGS LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signature Page to Underwriting Agreement&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">The Selling Shareholders named in <BR>Schedule&nbsp;I
hereto<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Jianyu Yang&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Attorney-in-fact for and on behalf <BR>
of the Selling Shareholders&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signature Page to Underwriting Agreement&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Accepted as of the date hereof:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Morgan Stanley &#038; Co. International plc<BR>
J.P. Morgan Securities Inc.<BR>
China International Capital Corporation Hong Kong Securities Limited

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Acting severally on behalf of themselves and<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the several Underwriters named in<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schedule&nbsp;II hereto

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Morgan Stanley &#038; Co. International plc

</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;J.P. Morgan Securities Inc.

</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<tr style="font-size:6pt"><td>&nbsp;</td></tr>

<TR>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 0px solid #000000" align="left">China International Capital Corporation <BR>
Hong Kong Securities Limited
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>



<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signature Page to Underwriting Agreement&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>SCHEDULE&nbsp;I</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Number of</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Additional Shares</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="LEFT" style="border-bottom: 1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Selling Shareholder</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>To Be Sold</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Notable Enterprise Limited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,000,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Grand Best Group Limited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">400,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Sino Prime Investments Limited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">250,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ATL International Group Limited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,800,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->I-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>SCHEDULE&nbsp;II</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Number of Firm</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Shares To Be</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="LEFT" style="border-bottom: 1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Underwriter</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Purchased</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Morgan Stanley &#038; Co. International plc</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">J.P. Morgan
Securities Inc.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">China International Capital Corporation
Hong Kong Securities Limited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->II-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>SCHEDULE III</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Time of Sale Prospectus</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Preliminary Prospectus issued November&nbsp;27, 2009</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Free writing prospectus filed by the Company with the Commission on December &#091;<B>&#149;</B>&#093;, 2009</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;Other free writing prospectuses filed by the Company under Rule 433(d) of the Securities
Act&#093;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Price to public: US$&#091;<B>&#149;</B>&#093; per ADS</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Underwriting discounts and commissions: US$&#091;<B>&#149;</B>&#093; per ADS</TD>
</TR>

</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->III-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT&nbsp;A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LOCK-UP LETTER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2009

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Morgan Stanley &#038; Co. International plc<BR>
J.P. Morgan Securities Inc.<BR>
China International Capital Corporation Hong Kong Securities Limited<BR>
c/o Morgan Stanley &#038; Co. International plc<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 Cabot Square, Canary Wharf<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;London E14 4QA<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;United Kingdom

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ladies and Gentlemen:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned understands that Morgan Stanley &#038; Co. International plc (&#147;<B>Morgan Stanley</B>&#148;),
J.P. Morgan Securities Inc. (<B>&#147;J.P. Morgan</B>&#148;) and China International Capital Corporation Hong Kong
(&#147;<B>CICC</B>&#148; and together with Morgan Stanley and J.P. Morgan, the &#147;<B>Representatives</B>&#148;) propose to enter
into an Underwriting Agreement (the &#147;<B>Underwriting Agreement</B>&#148;) with Concord Medical Services
Holdings Limited, an exempted company incorporated in the Cayman Islands with limited liability
(the &#147;<B>Company</B>&#148;) and certain shareholders of the Company, providing for the public offering (the
&#147;<B>Public Offering</B>&#148;) by the several underwriters listed in Schedule&nbsp;II to the Underwriting Agreement
(collectively, the &#147;<B>Underwriters</B>&#148;), of &#091;12,000,000&#093; American Depository Shares (the &#147;<B>ADSs</B>&#148;), each
ADS representing three ordinary shares of the Company at par value US$0.01 per share (the &#147;<B>Ordinary
Shares</B>&#148;), and not more than an additional &#091;1,800,000&#093; ADSs, if and to the extent that the
Representatives shall have determined to exercise the right to purchase such additional &#091;1,800,000&#093;
ADSs granted to the Underwriters pursuant to the Underwriting Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To induce the Underwriters that may participate in the Public Offering to continue their
efforts in connection with the Public Offering, the undersigned hereby agrees that, without the
prior written consent of the Representatives on behalf of the Underwriters, it will not, during the
period commencing on the date hereof and ending 180&nbsp;days after the date of the Public Offering (the
&#147;<B>Public Offering Date</B>&#148;) set forth in the final prospectus relating to the Public Offering (the
&#147;<B>Prospectus</B>&#148;), (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Exhibit A-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any
Ordinary Shares or ADSs or any securities convertible into or exercisable or exchangeable for
Ordinary Shares or ADSs or (2)&nbsp;enter into any swap or other arrangement that transfers to another,
in whole or in part, any of the economic consequences of ownership of the Ordinary Shares or ADSs,
whether any such transaction described in clause&nbsp;(1) or (2)&nbsp;above is to be settled by delivery of
Ordinary Shares, ADSs, or such other securities, in cash or otherwise. The foregoing sentence
shall not apply to (a)&nbsp;the Ordinary Shares as represented by the ADSs to be sold by the undersigned
pursuant to the Underwriting Agreement, if any, (b)&nbsp;transactions relating to Ordinary Shares, ADSs
or other securities acquired in open market transactions after the completion of the Public
Offering, <I>provided </I>that no filing under Section&nbsp;16(a) of the Securities Exchange Act of 1934, as
amended (the &#147;<B>Exchange Act</B>&#148;), shall be required or shall be voluntarily made in connection with
subsequent sales of Ordinary Shares, ADSs or other securities acquired in such open market
transactions, (c)&nbsp;the exercise of any of the undersigned&#146;s rights to acquire Ordinary Shares, ADSs
or other securities of the Company issued pursuant to any share option or similar equity incentive
or compensation plan of the Company for the issuance of share options or equity grants
(collectively, &#147;<B>Equity Incentive Grants</B>&#148;), <I>provided </I>that, in each case, such plan is in effect as
of the date of and disclosed in the Prospectus (it being understood that any subsequent sale,
transfer or disposition of any securities of the Company issued upon exercise of such Equity
Incentive Grants shall be subject to the restrictions set forth in this agreement), (d)&nbsp;transfers
of Ordinary Shares or ADSs to shareholders who are existing shareholders of the Company prior to
the Public Offering (the &#147;<B>Existing Shareholders</B>&#148;) or partners, members, stockholders or affiliates
(as defined in Rule&nbsp;12b-2 of the Exchange Act) of the Existing Shareholders, (e)&nbsp;transfers of
Ordinary Shares, ADSs or any security convertible into Ordinary Shares or ADSs (i)&nbsp;to an immediate
family member or a trust formed for the benefit of an immediate family member, (ii)&nbsp;as a bona fide
gift or (iii)&nbsp;through will or intestacy, (f)&nbsp;transfers or distributions of Ordinary Shares, ADSs or
any security convertible into Ordinary Shares or ADSs to partners, members, stockholders or
affiliates of the undersigned, <I>provided </I>that in the case of any transfer or distribution pursuant
to clauses (d),&nbsp;(e) or (f), (x)&nbsp;each transferee, donee or distributee shall sign and deliver a
lock-up letter substantially in the form of this agreement and (y)&nbsp;no filing under Section&nbsp;16(a) of
the Exchange Act reporting a reduction in beneficial ownership of Ordinary Shares or ADSs, shall be
required or shall be voluntarily made during the restricted period referred to in the foregoing
sentence, or (g)&nbsp;the establishment of a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act
for the transfer of Ordinary Shares or ADSs, <I>provided </I>that such plan does not provide for the
transfer of Ordinary Shares or ADSs during the restricted period. In addition, the undersigned
agrees that, without the prior written consent of the Representatives on behalf of the
Underwriters, it will not, during the period commencing on the
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Exhibit A-2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"> date hereof and ending 180&nbsp;days after the Public Offering Date, make any demand for or
exercise any right with respect to, the registration of any Ordinary Shares, ADSs or any security
convertible into or exercisable or exchangeable for Ordinary Shares or ADSs. The undersigned also
agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent
and registrar against the transfer of the undersigned&#146;s Ordinary Shares or ADSs except in
compliance with the foregoing restrictions. For purposes of this paragraph, &#147;immediate family&#148;
means the spouse, domestic partner, lineal descendants, father, mother, brother or sister of the
transferor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;during the last 17&nbsp;days of the restricted period the Company issues an earnings release or
material news or a material event relating to the Company occurs; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;prior to the expiration of the restricted period, the Company announces that it will
release earnings results during the 16-day period beginning on the last day of the restricted
period;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the restrictions imposed by this agreement shall continue to apply until the expiration of the
18-day period beginning on the issuance of the earnings release or the occurrence of the material
news or material event, unless the Representatives waive, in writing, such extension.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned shall not engage in any transaction that may be restricted by this agreement
during the 34-day period beginning on the last day of the initial restricted period unless the
undersigned requests and receives prior written confirmation from the Company or the
Representatives that the restrictions imposed by this agreement have expired.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned understands that the Company and the Underwriters are relying upon this
agreement in proceeding toward consummation of the Public Offering. The undersigned further
understands that this agreement is irrevocable and shall be binding upon the undersigned&#146;s heirs,
legal representatives, successors and assigns.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Exhibit A-3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether or not the Public Offering actually occurs depends on a number of factors, including
market conditions. Any Public Offering will only be made pursuant to an Underwriting Agreement,
the terms of which are subject to negotiation between the Company and the Underwriters.
Notwithstanding anything to the contrary contained herein, this agreement will terminate and the
undersigned will be released from all of its obligations hereunder on March&nbsp;31, 2010 if the Public
Offering Date shall not have occurred on or before such date.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Very truly yours,<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">(Name)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">(Address)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->Exhibit A-4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>ANNEX A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;FORM OF OPINION OF U.S. COUNSEL FOR THE COMPANY&#093;</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Annex A-1
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>ANNEX B</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;FORM OF OPINION OF CAYMAN COUNSEL FOR THE COMPANY&#093;</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Annex B-1
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>ANNEX C</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;FORM OF OPINION OF PRC COUNSEL FOR THE COMPANY&#093;</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Annex C-1
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>ANNEX D</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;FORM OF OPINION OF HONG KONG COUNSEL<BR>
FOR THE COMPANY&#093;</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Annex D-1
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>ANNEX E</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;FORM OF OPINION OF BRITISH VIRGIN ISLANDS COUNSEL<BR>
FOR THE COMPANY&#093;</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Annex E-1
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>ANNEX F</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;FORM OF OPINION OF LOCAL COUNSEL FOR<BR>
THE SELLING SHAREHOLDERS&#093;</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Annex F-1
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>ANNEX G</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;FORM OF OPINION OF DEPOSITARY&#146;S COUNSEL&#093;</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Annex G-1
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>3
<FILENAME>h03611a4exv4w3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w3</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit 4.3
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361170.gif" alt="(COVER PAGE)">
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Page</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" align="left">PARTIES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left">RECITALS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;1.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certain Definitions</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADR Register</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADRs; Direct Registration ADRs</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Custodian</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deliver, execute, issue et al.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delivery Order</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deposited Securities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Direct Registration System</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holder</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities Act of 1933</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities Exchange Act of 1934</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer Office</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Withdrawal Order</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ADRs</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Deposit of Shares</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Issue of ADRs</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Distributions on Deposited Securities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Withdrawal of Deposited Securities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Substitution of ADRs</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cancellation and Destruction of ADRs</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Custodian</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;10.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Co-Registrars and Co-Transfer Agents</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lists of Holders</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;12.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Depositary's Agents</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Successor Depositary</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;14.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Reports</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;15.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Additional Shares</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;16.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Indemnification</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;17.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notices</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;18.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Miscellaneous</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;19.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent to Jurisdiction</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left"><B>TESTIMONIUM</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left"><B>SIGNATURES</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&#150; i &#150;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="83%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Page</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left"><B>EXHIBIT A</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left"><B>FORM OF FACE OF ADR</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Introductory Paragraph</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(1)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Issuance of ADRs and Pre-Release of ADRs</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(2)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Withdrawal of Deposited Securities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(3)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Transfers of ADRs</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(4)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certain Limitations</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(5)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Taxes</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(6)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Disclosure of Interests</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(7)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Charges of Depositary</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(8)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Available Information</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(9)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Execution</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Signature of Depositary</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Address of Depositary&#146;s Office</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left"><B>FORM OF REVERSE OF ADR</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(10)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Distributions on Deposited Securities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(11)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Record Dates</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(12)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Voting of Deposited Securities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(13)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Changes Affecting Deposited Securities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(14)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Exoneration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(15)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Resignation and Removal of Depositary; the Custodian</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(16)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(17)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(18)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Appointment</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(19)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Waiver</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">A-14</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&#150; ii &#150;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DEPOSIT
AGREEMENT dated as of December&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2009 (the &#147;Deposit Agreement&#148;) among CONCORD MEDICAL
SERVICES HOLDINGS LIMITED and its successors (the &#147;Company&#148;), JPMORGAN CHASE BANK, N.A., as
depositary hereunder (the &#147;Depositary&#148;), and all holders from time to time of ADRs (defined below)
evidencing American Depositary Shares (&#147;ADSs&#148;) representing deposited Shares (defined below). The
Company hereby appoints the Depositary as depositary for the Deposited Securities and hereby
authorizes and directs the Depositary to act in accordance with the terms set forth in this Deposit
Agreement. All capitalized terms used herein have the meanings ascribed to them in Section&nbsp;1 or
elsewhere in this Deposit Agreement. The parties hereto agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Certain Definitions</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&#147;<U>ADR Register</U>&#148; is defined in paragraph (3)&nbsp;of the form of ADR.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&#147;<U>ADRs</U>&#148; mean the American Depositary Receipts executed and delivered hereunder.
ADRs may be either in physical certificated form or Direct Registration ADRs. ADRs in physical
certificated form, and the terms and conditions governing the Direct Registration ADRs (as
hereinafter defined), shall be substantially in the form of Exhibit&nbsp;A annexed hereto (the &#147;<U>form
of ADR</U>&#148;). The term &#147;<U>Direct Registration ADR</U>&#148; means an ADR, the ownership of which is
recorded on the Direct Registration System. References to &#147;ADRs&#148; shall include certificated ADRs
and Direct Registration ADRs, unless the context otherwise requires. The form of ADR is hereby
incorporated herein and made a part hereof; the provisions of the form of ADR shall be binding upon
the parties hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Subject to paragraph (13)&nbsp;of the form of ADR, each &#147;<U>ADS</U>&#148; evidenced by an ADR
represents the right to receive three (3)&nbsp;Shares and a pro rata share in any other Deposited
Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&#147;<U>Custodian</U>&#148; means the agent or agents of the Depositary (singly or collectively,
as the context requires) and any additional or substitute Custodian appointed pursuant to Section
9.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The terms &#147;d<U>eliver</U>&#148;, &#147;<U>execute</U>&#148;, &#147;<U>issue</U>&#148;, &#147;<U>register</U>&#148;,
&#147;<U>surrender</U>&#148;, &#147;<U>transfer</U>&#148; or &#147;<U>cancel</U>&#148;, when used with respect to Direct
Registration ADRs, shall refer to an entry or entries or an electronic transfer or transfers in the
Direct Registration System, and, when used with respect to ADRs in physical certificated form,
shall refer to the physical delivery, execution, issuance, registration, surrender, transfer or
cancellation of certificates representing the ADRs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&#147;<U>Delivery Order</U>&#148; is defined in Section&nbsp;3.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&#147;<U>Deposited Securities</U>&#148; as of any time means all Shares at such time
deposited under this Deposit Agreement and any and all other Shares, securities,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">property and
cash at such time held by the Depositary or the Custodian in respect or in lieu of such deposited
Shares and other Shares, securities, property and cash.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&#147;Direct Registration System&#148; means the system for the uncertificated registration
of ownership of securities established by The Depository Trust Company (&#147;DTC&#148;) and utilized by the
Depositary pursuant to which the Depositary may record the ownership of ADSs without the issuance
of a certificate, which ownership shall be evidenced by periodic statements issued by the
Depositary to the Holders entitled thereto. For purposes hereof, the Direct Registration System
shall include access to the Profile Modification System maintained by DTC which provides for
automated transfer of ownership between DTC and the Depositary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&#147;<U>Holder</U>&#148; means, in the case of ADRs in physical certificated form, the person or
persons in whose name an ADR is registered on the ADR Register, and in the case of Direct
Registration ADRs, the person or persons whose ownership is evidenced by periodic statements issued
by the Depositary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&#147;<U>Securities Act of 1933</U>&#148; means the United States Securities Act of 1933, as from
time to time amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&#147;<U>Securities Exchange Act of 1934</U>&#148; means the United States Securities Exchange Act
of 1934, as from time to time amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&#147;<U>Shares</U>&#148; mean the ordinary shares of the Company and shall include the rights to
receive Shares specified in paragraph (1)&nbsp;of the form of ADR.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;&#147;<U>Transfer Office</U>&#148; is defined in paragraph (3)&nbsp;of the form of ADR.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;&#147;<U>Withdrawal Order</U>&#148; is defined in Section&nbsp;6.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>ADRs</U>. (a)&nbsp;ADRs in certificated form shall be engraved, printed or otherwise
reproduced at the discretion of the Depositary in accordance with its customary practices in its
American depositary receipt business, or at the request of the Company typewritten and photocopied
on plain or safety paper, and shall be substantially in the form set forth in the form of ADR, with
such changes as may be required by the Depositary or the Company to comply with their obligations
hereunder, any applicable law, regulation or usage or to indicate any special limitations or
restrictions to which any particular ADRs are subject. ADRs may be issued in denominations of any
number of ADSs. ADRs in certificated form shall be executed by the Depositary by the manual or
facsimile signature of a duly authorized officer of the Depositary. ADRs in certificated form
bearing the facsimile signature of anyone who was at the time of execution a duly authorized
officer of the Depositary shall bind the Depositary, notwithstanding that such officer has ceased
to hold such office prior to the delivery of such ADRs.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Direct Registration ADRs</U>. Notwithstanding anything in this Deposit Agreement or
in the form of ADR to the contrary, ADSs shall be evidenced by Direct Registration ADRs, unless
certificated ADRs are specifically requested by the Holder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Holders shall be bound by the terms and conditions of this Deposit Agreement and
of the form of ADR, regardless of whether their ADRs are Direct Registration ADRs or certificated
ADRs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Deposit of Shares</U>. In connection with the deposit of Shares hereunder, the
Depositary or the Custodian may require the following in form satisfactory to it: (a)&nbsp;a written
order directing the Depositary to issue to, or upon the written order of, the person or persons
designated in such order a Direct Registration ADR or ADRs evidencing the number of ADSs
representing such deposited Shares (a &#147;Delivery Order&#148;); (b)&nbsp;proper endorsements or duly executed
instruments of transfer in respect of such deposited Shares; (c)&nbsp;instruments assigning to the
Depositary, the Custodian or a nominee of either any distribution on or in respect of such
deposited Shares or indemnity therefor; and (d)&nbsp;proxies entitling the Custodian to vote such
deposited Shares. As soon as practicable after the Custodian receives Deposited Securities
pursuant to any such deposit or pursuant to paragraph (10)&nbsp;or (13)&nbsp;of the form of ADR, the
Custodian shall present such Deposited Securities for registration of transfer into the name of the
Depositary, the Custodian or a nominee of either, to the extent such registration is practicable,
at the cost and expense of the person making such deposit (or for whose benefit such deposit is
made) and shall obtain evidence satisfactory to it of such registration. Deposited Securities
shall be held by the Custodian for the account and to the order of the Depositary at such place or
places and in such manner as the Depositary shall determine. Deposited Securities may be delivered
by the Custodian to any person only under the circumstances expressly contemplated in this Deposit
Agreement. To the extent that the provisions of or governing the Shares make delivery of
certificates therefor impracticable, Shares may be deposited hereunder by such delivery thereof as
the Depositary or the Custodian may reasonably accept, including, without limitation, by causing
them to be credited to an account maintained by the Custodian for such purpose with the Company or
an accredited intermediary, such as a bank, acting as a registrar for the Shares, together with
delivery of the documents, payments and Delivery Order referred to herein to the Custodian or the
Depositary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Issue of ADRs</U>. After any such deposit of Shares, the Custodian shall notify the
Depositary of such deposit and of the information contained in any related Delivery Order by
letter, first class airmail postage prepaid, or, at the request, risk and expense of the person
making the deposit, by cable, telex or facsimile transmission. After receiving such notice from
the Custodian, the Depositary, subject to this Deposit Agreement, shall properly issue at the
Transfer Office, to or upon the order of any person named in such notice, an ADR or ADRs registered
as requested and evidencing the aggregate ADSs to which such person is entitled.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Distributions on Deposited Securities</U>. To the extent that the Depositary
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">determines in its reasonable discretion that any distribution pursuant to paragraph (10)&nbsp;of the
form of ADR is not practicable with respect to any Holder, the Depositary may make such
distribution as it so deems practicable, including the distribution of foreign currency, securities
or property (or appropriate documents evidencing the right to receive foreign currency, securities
or property) or the retention thereof as Deposited Securities with respect to such Holder&#146;s ADRs
(without liability for interest thereon or the investment thereof).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Withdrawal of Deposited Securities</U>. In connection with any surrender of an
ADR for withdrawal of the Deposited Securities represented by the ADSs evidenced thereby, the
Depositary may require proper endorsement in blank of such ADR (or duly executed instruments of
transfer thereof in blank) and the Holder&#146;s written order directing the Depositary to cause the
Deposited Securities represented by the ADSs evidenced by such ADR to be withdrawn and delivered
to, or upon the written order of, any person designated in such order (a &#147;Withdrawal Order&#148;).
Directions from the Depositary to the Custodian to deliver Deposited Securities shall be given by
letter, first class airmail postage prepaid, or, at the request, risk and expense of the Holder, by
cable, telex or facsimile transmission. Delivery of Deposited Securities may be made by the
delivery of certificates (which, if required by law shall be properly endorsed or accompanied by
properly executed instruments of transfer or, if such certificates may be registered, registered in
the name of such Holder or as ordered by such Holder in any Withdrawal Order) or by such other
means as the Depositary may deem practicable, including, without limitation, by transfer of record
ownership thereof to an account designated in the Withdrawal Order maintained either by the Company
or an accredited intermediary, such as a bank, acting as a registrar for the Deposited Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Substitution of ADRs</U>. The Depositary shall execute and deliver a new Direct
Registration ADR in exchange and substitution for any mutilated certificated ADR upon cancellation
thereof or in lieu of and in substitution for such destroyed, lost or stolen certificated ADR,
unless the Depositary has notice that such ADR has been acquired by a bona fide purchaser, upon the
Holder thereof filing with the Depositary a request for such execution and delivery and a
sufficient indemnity bond and satisfying any other reasonable requirements imposed by the
Depositary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Cancellation and Destruction of ADRs</U>. All ADRs surrendered to the Depositary
shall be cancelled by the Depositary. The Depositary is authorized to destroy ADRs in certificated
form so cancelled in accordance with its customary practices. The Depositary agrees to maintain or
cause its agents to maintain records of all ADRs surrendered and Deposited Securities withdrawn
under Section&nbsp;6 hereof and paragraph (2)&nbsp;of the form of ADR, substitute ADRs delivered under
Section&nbsp;7 hereof, and canceled or destroyed ADRs under this Section&nbsp;8, in keeping with the
procedures ordinarily followed by stock transfer agents located in the City of New York or as
required by the laws or regulations governing the Depositary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>The Custodian</U>. Any Custodian in acting hereunder shall be subject to the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">directions of the Depositary and shall be responsible solely to it. The Depositary shall be
responsible for the compliance by the Custodian with any applicable provisions of this Deposit
Agreement to the extent such provisions are directly applicable to the Custodian. The Depositary
reserves the right to add, replace or remove a Custodian. The Depositary will give prompt notice
of any such action, which will be advance notice if practicable. Each Custodian so appointed
(other than JPMorgan Chase Bank, N.A.) shall give written notice to the Company and the Depositary
accepting such appointment and agreeing to be bound by the applicable terms hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any Custodian may resign from its duties hereunder by at least 30&nbsp;days written notice to the
Depositary. Upon receipt of such written notice, the Depositary will promptly inform the Company
of the resignation to the extent practicable. The Depositary may discharge any Custodian at any
time upon notice to the Custodian being discharged. Any Custodian ceasing to act hereunder as
Custodian shall deliver, upon the instruction of the Depositary, all Deposited Securities held by
it to a Custodian continuing to act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Co-Registrars and Co-Transfer Agents</U>. The Depositary may appoint and
remove (i)&nbsp;co-registrars to register ADRs and transfers, combinations and split-ups of ADRs and to
countersign ADRs in accordance with the terms of any such appointment and (ii)&nbsp;co-transfer agents
for the purpose of effecting transfers, combinations and split-ups of ADRs at designated transfer
offices in addition to the Transfer Office on behalf of the Depositary. Each co-registrar or
co-transfer agent (other than JPMorgan Chase Bank, N.A.) shall give notice in writing to the
Company and the Depositary accepting such appointment and agreeing to be bound by the applicable
terms of this Deposit Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Lists of Holders</U>. The Company shall have the right to inspect transfer records
of the Depositary and its agents and the ADR Register, take copies thereof and require the
Depositary and its agents to supply copies of such portions of such records as the Company may
request. The Depositary or its agent shall furnish to the Company promptly upon the written
request of the Company, a list of the names, addresses and holdings of ADSs by all Holders as of a
date within seven days of the Depositary&#146;s receipt of such request.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Depositary&#146;s Agents</U>. The Depositary may perform its obligations under this
Deposit Agreement through any agent appointed by it, provided that the Depositary shall notify the
Company of such appointment and shall remain responsible for the performance of such obligations as
if no agent were appointed, subject to paragraph (14)&nbsp;of the form of ADR.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Successor Depositary</U>. The Depositary may at any time resign as Depositary
hereunder by written notice of its election so to do delivered to the Company, such resignation to
take effect upon the appointment of a successor depositary and its acceptance of such appointment
as hereinafter provided. The Depositary may at any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">time be removed by the Company by providing no
less than 90&nbsp;days prior written notice of such removal to the Depositary, such removal to take
effect the later of (i)&nbsp;the 90<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day after such notice of removal is first provided and
(ii)&nbsp;the appointment of a successor depositary and its acceptance of such appointment as
hereinafter provided. Notwithstanding the foregoing, if upon the resignation or removal of the
Depositary a successor depositary is not appointed within the applicable 45-day period (in the case
of resignation) or 90-day period (in the case of removal) as specified in paragraph (17)&nbsp;of the
form of ADR, then the Depositary may elect to terminate this Deposit Agreement and the ADR and the
provisions of said paragraph (17)&nbsp;shall thereafter govern the Depositary&#146;s obligations hereunder.
In case at any time the Depositary acting hereunder shall resign or be removed, the Company shall
use its best efforts to appoint a successor depositary, which shall be a bank or trust company
having an office in the Borough of Manhattan, The City of New York. Every successor depositary
shall execute and deliver to its predecessor and to the Company an instrument in writing accepting
its appointment hereunder, and thereupon such successor depositary, without any further act or
deed, shall become fully vested with all the rights, powers, duties and obligations of its
predecessor. The predecessor depositary, only upon payment of all sums due to it and on the
written request of the Company, shall (i)&nbsp;execute and deliver an instrument transferring to such
successor all rights and powers of such predecessor hereunder (other than its rights to
indemnification and fees owing, each of which shall survive any such removal and/or resignation),
(ii)&nbsp;duly assign, transfer and deliver all right, title and interest to the Deposited Securities to
such successor, and (iii)&nbsp;deliver to such successor a list of the Holders of all outstanding ADRs.
Any such successor depositary shall promptly mail notice of its appointment to such Holders. Any
bank or trust company into or with which the Depositary may be merged or consolidated, or to which
the Depositary shall transfer substantially all its American depositary receipt business, shall be
the successor of the Depositary without the execution or filing of any document or any further act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<U>Reports</U>. On or before the first date on which the Company makes any
communication available to holders of Deposited Securities or any securities regulatory authority
or stock exchange, by publication or otherwise, the Company shall transmit to the Depositary a copy
thereof in English or with an English translation or summary. The Company has delivered to the
Depositary, the Custodian and any Transfer Office, a copy of all provisions of or governing the
Shares and any other Deposited Securities issued by the Company or any affiliate of the Company
and, promptly upon any change thereto, the Company shall deliver to the Depositary, the Custodian
and any Transfer Office, a copy (in English or with an English translation) of such provisions as
so changed. The Depositary and its agents may rely upon the Company&#146;s delivery thereof for all
purposes of this Deposit Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;<U>Additional Shares</U>. Neither the Company nor any company controlling, controlled
by or under common control with the Company shall issue additional Shares, rights to subscribe for
Shares, securities convertible into or exchangeable for Shares or rights to subscribe for any such
securities or shall deposit any Shares under this Deposit
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Agreement, except under circumstances
complying in all respects with the Securities Act of 1933. The Depositary will use reasonable
efforts to comply with written instructions of the Company not to accept for deposit hereunder any
Shares identified in such instructions at such times and under such circumstances as may reasonably
be specified in such instructions in order to facilitate the Company&#146;s compliance with securities
laws in the United States.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;<U>Indemnification</U>. The Company shall indemnify, defend and save harmless each of
the Depositary and its agents against any loss, liability or expense (including reasonable fees and
expenses of counsel) which may arise out of acts performed or omitted, in connection with the
provisions of this Deposit Agreement and of the ADRs, as the same may be amended, modified or
supplemented from time to time in accordance herewith by either the Depositary or its agents or
their respective directors, employees, agents and affiliates, except for any liability or expense
directly arising out of the negligence or willful misconduct of the Depositary or its agents acting
hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indemnities set forth in the preceding paragraph shall also apply to any liability or
expense which may arise out of any misstatement or alleged misstatement or omission or alleged
omission in any registration statement, proxy statement, prospectus (or placement memorandum), or
preliminary prospectus (or preliminary placement memorandum) relating to the offer or sale of ADSs,
except to the extent any such liability or expense arises out of (i)&nbsp;information relating to the
Depositary or its agents (other than the Company), as applicable, furnished in writing by the
Depositary and not changed or altered by the Company expressly for use in any of the foregoing
documents or (ii)&nbsp;if such information is provided, the failure to state a material fact necessary
to make the information provided not misleading.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provision of this Deposit Agreement or the ADRs to the
contrary, neither the Depositary nor any of its agents shall be liable for any indirect, special,
punitive or consequential damages (including, without limitation, lost profits) of any form
incurred by any person or entity, whether or not foreseeable and regardless of the type of action
in which such a claim may be brought.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The obligations set forth in this Section&nbsp;16 shall survive the termination of this Deposit
Agreement and the succession or substitution of any indemnified person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;<U>Notices</U>. Notice to any Holder shall be deemed given when first mailed, first
class postage prepaid, to the address of such Holder on the ADR Register or received by such
Holder. Failure to notify a Holder or any defect in the notification to
a Holder shall not affect the sufficiency of notification to other Holders or to the
beneficial owners of ADSs held by such other Holders. Notice to the Depositary or the Company
shall be deemed given when first received by it at the address or facsimile transmission number set
forth in (a)&nbsp;or (b), respectively, or at such other address or facsimile transmission number as
either may specify to the other by written notice:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>JPMorgan Chase Bank, N.A.<BR>
Four New York Plaza<BR>
New York, New York 10004<BR>
Attention: ADR Administration<BR>
Fax: (&#043;1) 212-623-0079</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Concord Medical Services Holdings Limited<BR>
18/F, Tower A, Global Trade Center<BR>
36 North Third Ring Road East<BR>
Dongcheng District<BR>
Beijing, 100013<BR>
People&#146;s Republic of China<BR>
Attention: Jianyu Yang<BR>
Fax: (&#043;86) 10 5959-5252</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;<U>Miscellaneous</U>. This Deposit Agreement is for the exclusive benefit of the
Company, the Depositary, the Holders, and their respective successors hereunder, and shall not give
any legal or equitable right, remedy or claim whatsoever to any other person. The Holders and
owners of ADRs from time to time shall be parties to this Deposit Agreement and shall be bound by
all of the provisions hereof. If any such provision is invalid, illegal or unenforceable in any
respect, the remaining provisions shall in no way be affected thereby. This Deposit Agreement may
be executed in any number of counterparts, each of which shall be deemed an original and all of
which shall constitute one instrument.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.&nbsp;<U>Consent to Jurisdiction</U>. The Company irrevocably agrees that any legal
suit, action or proceeding against the Company brought by the Depositary or any Holder, arising out
of or based upon this Deposit Agreement or the transactions contemplated hereby, may be instituted
in any state or federal court in New York, New York, and irrevocably waives any objection which it
may now or hereafter have to the laying of venue of any such proceeding, and irrevocably submits to
the non-exclusive jurisdiction of such courts in any such suit, action or proceeding. The Company
also irrevocably agrees that any legal suit, action or proceeding against the Depositary brought by
the Company, arising out of or based upon this Deposit Agreement or the transactions contemplated
hereby, may only be instituted in a state or federal court in New York, New York. The Company has
appointed National Registered Agents, Inc., 875 Avenue of the Americas, Suite&nbsp;501, New York, New
York, 10001 as its authorized agent (the &#147;Authorized Agent&#148;) upon which process may be
served in any such action arising out of or based on this Deposit Agreement or the
transactions contemplated hereby which may be instituted in any state or federal court in New York,
New York by the Depositary or any Holder, and waives any other requirements of or objections to
personal jurisdiction with respect thereto. The Company represents and warrants that the
Authorized Agent has agreed to act as said agent for service of process, and the Company agrees to
take any and all action, including the filing of any and all documents and instruments, that
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">may be
necessary to continue such appointment in full force and effect as aforesaid. Service of process
upon the Authorized Agent and written notice of such service to the Company shall be deemed, in
every respect, effective service of process upon the Company. If, for any reason, the Authorized
Agent named above or its successor shall no longer serve as agent of the Company to receive service
of process in New York, the Company shall promptly appoint a successor acceptable to the
Depositary, so as to serve and will promptly advise the Depositary thereof. In the event the
Company fails to continue such designation and appointment in full force and effect, the Company
hereby waives personal service of process upon it and consents that any such service of process may
be made by certified or registered mail, return receipt requested, directed to the Company at its
address last specified for notices hereunder, and service so made shall be deemed completed five
(5)&nbsp;days after the same shall have been so mailed. Notwithstanding the foregoing, any action
based on this Deposit Agreement may be instituted by the Depositary in any competent court in the
Cayman Islands or People&#146;s Republic of China.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent that the Company or any of its properties, assets or revenues may have or may
hereafter be entitled to, or have attributed to it, any right of immunity, on the grounds of
sovereignty or otherwise, from any legal action, suit or proceeding, from the giving of any relief
in any respect thereof, from setoff or counterclaim, from the jurisdiction of any court, from
service of process, from attachment upon or prior to judgment, from attachment in aid of execution
or judgment, or from execution of judgment, or other legal process or proceeding for the giving of
any relief or for the enforcement of any judgment, in any jurisdiction in which proceedings may at
any time be commenced, with respect to its obligations, liabilities or other matter under or
arising out of or in connection with the Shares or Deposited Securities, the ADSs, the ADRs or this
Deposit Agreement, the Company, to the fullest extent permitted by law, hereby irrevocably and
unconditionally waives, and agrees not to plead or claim, any such immunity and consents to such
relief and enforcement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EACH PARTY TO THIS DEPOSIT AGREEMENT (INCLUDING, FOR AVOIDANCE OF DOUBT, EACH HOLDER
AND BENEFICIAL OWNER AND/OR HOLDER OF INTERESTS IN ADRS) HEREBY IRREVOCABLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY SUIT, ACTION OR
PROCEEDING AGAINST THE DEPOSITARY AND/OR THE COMPANY DIRECTLY OR INDIRECTLY ARISING OUT OF OR
RELATING TO THE SHARES OR OTHER DEPOSITED SECURITIES, THE ADSs OR THE ADRs, THE DEPOSIT AGREEMENT
OR ANY TRANSACTION CONTEMPLATED HEREIN OR THEREIN, OR THE BREACH HEREOF OR THEREOF (WHETHER BASED ON CONTRACT,
TORT, COMMON LAW OR ANY OTHER THEORY).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, CONCORD MEDICAL SERVICES HOLDINGS LIMITED and JPMORGAN CHASE BANK, N.A.
have duly executed this Deposit Agreement as of the day and year first above set forth and all
holders of ADRs shall become parties hereto upon acceptance by them of ADRs issued in accordance
with the terms hereof.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CONCORD MEDICAL SERVICES HOLDINGS LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top" colspan="3">Name:&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top" colspan="3">Title:&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">JPMORGAN CHASE BANK, N.A.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top" colspan="3">Name:&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top" colspan="3">Title:&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT A<BR>
ANNEXED TO AND INCORPORATED IN<BR>
<U>DEPOSIT AGREEMENT</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;FORM OF FACE OF ADR&#093;

</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 60%; margin-top: 6pt">No. of ADSs:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Number

</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 60%; margin-top: 6pt">Each ADS represents<BR>
three (3)&nbsp;Shares
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 60%; margin-top: 6pt">CUSIP:
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">AMERICAN DEPOSITARY RECEIPT
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">evidencing

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">AMERICAN DEPOSITARY SHARES

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">representing

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">ORDINARY SHARES

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">of

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CONCORD MEDICAL SERVICES HOLDINGS LIMITED

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">(Incorporated under the laws of the Cayman Islands)

</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JPMORGAN CHASE BANK, N.A., a national banking association organized under the laws of the
United States of America, as depositary hereunder (the &#147;Depositary&#148;), hereby certifies that <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> is the registered owner (a &#147;Holder&#148;) of American Depositary Shares
(&#147;ADSs&#148;), each (subject to paragraph (13)) representing three (3)&nbsp;ordinary shares (including the
rights to receive Shares described in paragraph (1), &#147;Shares&#148; and, together with any other
securities, cash or property from time to time held by the Depositary in respect or in lieu of
deposited Shares, the &#147;Deposited Securities&#148;), of Concord Medical Services Holdings Limited, an
exempted limited liability company organized under the laws of the Cayman Islands (the &#147;Company&#148;),
deposited under the Deposit Agreement dated as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2009 (as amended from time to time, the
&#147;Deposit Agreement&#148;) among the Company, the Depositary and all Holders from time to time of
American Depositary Receipts issued thereunder (&#147;ADRs&#148;), each of whom by accepting an ADR becomes a
party thereto. The Deposit Agreement and this ADR (which includes the provisions set forth on the
reverse hereof) shall be governed by and construed in accordance with the laws of the
State of New
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">York.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;<U>Issuance of ADRs; Pre-Release</U>. This ADR is one of the ADRs issued under
the Deposit Agreement. Subject to paragraph (4), the Depositary may so issue ADRs for delivery at
the Transfer Office (defined in paragraph (3)) only against deposit of: (a)&nbsp;Shares in form
reasonably satisfactory to the Custodian; (b)&nbsp;rights to receive Shares from the Company or any
registrar, transfer agent, clearing agent or other entity recording Share ownership or
transactions; or, (c)&nbsp;in accordance with the next paragraph of this paragraph (1).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In its capacity as Depositary, the Depositary shall not lend Shares or ADSs; provided,
however, that the Depositary may (i)&nbsp;issue ADSs prior to the receipt of Shares and (ii)&nbsp;deliver
Shares prior to the receipt of ADSs for withdrawal of Deposited Securities, including ADSs which
were issued under (i)&nbsp;above but for which Shares may not have been received (each such transaction
a &#147;Pre-Release&#148;). The Depositary may receive ADSs in lieu of Shares under (i)&nbsp;above (which ADSs
will promptly be canceled by the Depositary upon receipt by the Depositary) and receive Shares in
lieu of ADSs under (ii)&nbsp;above. Each such Pre-Release will be subject to a written agreement whereby
the person or entity (the &#147;Applicant&#148;) to whom ADSs or Shares are to be delivered (a)&nbsp;represents
that at the time of the Pre-Release the Applicant or its customer owns the Shares or ADSs that are
to be delivered by the Applicant under such Pre-Release, (b)&nbsp;agrees to indicate the Depositary as
owner of such Shares or ADSs in its records and to hold such Shares or ADSs in trust for the
Depositary until such Shares or ADSs are delivered to the Depositary or the Custodian, (c)
unconditionally guarantees to deliver to the Depositary or the Custodian, as applicable, such
Shares or ADSs, and (d)&nbsp;agrees to any additional restrictions or requirements that the Depositary
deems appropriate. Each such Pre-Release will be at all times fully collateralized with cash, U.S.
government securities or such other collateral as the Depositary deems appropriate, terminable by
the Depositary on not more than five (5)&nbsp;business days&#146; notice and subject to such further
indemnities and credit regulations as the Depositary deems appropriate. The Depositary will
normally limit the number of ADSs and Shares involved in such Pre-Release at any one time to thirty
percent (30%) of the ADSs outstanding (without giving effect to ADSs outstanding under (i)&nbsp;above),
provided, however, that the Depositary reserves the right to change or disregard such limit from
time to time as it deems appropriate. The Depositary may also set limits with respect to the number
of ADSs and Shares involved in Pre-Release with any one person on a case-by-case basis as it deems
appropriate. The Depositary may retain for its own account any compensation received by it in
conjunction with the foregoing. Collateral provided pursuant to (b)&nbsp;above, but not the earnings
thereon, shall be held for the benefit of the Holders (other than the Applicant).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Every person depositing Shares under the Deposit Agreement represents and warrants that such
Shares are validly issued and outstanding, fully paid, nonassessable and free of pre-emptive
rights, that the person making such deposit is duly authorized so to do and that such Shares (A)
are not &#147;restricted securities&#148; as such term is defined
in Rule&nbsp;144 under the Securities Act of 1933 (&#147;Restricted Securities&#148;) unless at the time of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">deposit the requirements of paragraphs (c), (e), (f)&nbsp;and (h)&nbsp;of Rule&nbsp;144 shall not apply and such
Shares may be freely transferred and may otherwise be offered and sold freely in the United States
or (B)&nbsp;have been registered under the Securities Act of 1933. To the extent the person depositing
Shares is an affiliate of the Company as such term is defined in Rule&nbsp;144, the person also
represents and warrants that upon the sale of the ADSs, all of the provisions of Rule&nbsp;144 which
enable the Shares to be freely sold (in the form of ADSs) will be fully complied with and, as a
result thereof, all of the ADSs issued in respect of such Shares will not be on the sale thereof,
Restricted Securities. Such representations and warranties shall survive the deposit of Shares and
issuance of ADRs. The Depositary will not knowingly accept for deposit under the Deposit Agreement
any Shares required to be registered under the Securities Act of 1933 and not so registered; the
Depositary may refuse to accept for such deposit any Shares identified by the Company in order to
facilitate the Company&#146;s compliance with such Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;<U>Withdrawal of Deposited Securities</U>. Subject to paragraphs (4)&nbsp;and (5),
upon surrender of (i)&nbsp;a certificated ADR in form satisfactory to the Depositary at the Transfer
Office or (ii)&nbsp;proper instructions and documentation in the case of a Direct Registration ADR, the
Holder hereof is entitled to delivery at, or to the extent in dematerialized form from, the
Custodian&#146;s office of the Deposited Securities at the time represented by the ADSs evidenced by
this ADR, provided that the Depositary may deliver Shares prior to the receipt of ADSs for
withdrawal of Deposited Securities, including ADSs which were issued under (1)&nbsp;above but for which
Shares may not have been received (until such ADSs are actually deposited, &#147;Pre-released Shares&#148;)
only if all the conditions in (1)&nbsp;above related to such Pre-Release are satisfied). At the
request, risk and expense of the Holder hereof, the Depositary may deliver such Deposited
Securities at such other place as may have been requested by the Holder. Notwithstanding any other
provision of the Deposit Agreement or this ADR, the withdrawal of Deposited Securities may be
restricted only for the reasons set forth in General Instruction I.A.(1) of Form F-6 (as such
instructions may be amended from time to time) under the Securities Act of 1933.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;<U>Transfers of ADRs</U>. The Depositary or its agent will keep, at a designated
transfer office (the &#147;Transfer Office&#148;), (a)&nbsp;a register (the &#147;ADR Register&#148;) for the registration,
registration of transfer, combination and split-up of ADRs, and, in the case of Direct Registration
ADRs, shall include the Direct Registration System, which at all reasonable times will be open for
inspection by Holders and the Company for the purpose of communicating with Holders in the interest
of the business of the Company or a matter relating to the Deposit Agreement and (b)&nbsp;facilities for
the delivery and receipt of ADRs. The term ADR Register includes the Direct Registration System.
Title to this ADR (and to the Deposited Securities represented by the ADSs evidenced hereby), when
properly endorsed (in the case of ADRs in certificated form) or upon delivery to the Depositary of
proper instruments of transfer, is transferable by delivery with the same effect as in the case of
negotiable instruments under the laws of the State of New York; <U>provided</U> that the Depositary, notwithstanding any
notice to the contrary, may treat the person in whose name this ADR is registered on the ADR
Register as the absolute owner hereof for all purposes and neither the Depositary nor the Company
will
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">have any obligation or be subject to any liability under the Deposit Agreement to any holder
of an ADR, unless such holder is the Holder thereof. Subject to paragraphs (4)&nbsp;and (5), this ADR
is transferable on the ADR Register and may be split into other ADRs or combined with other ADRs
into one ADR, evidencing the aggregate number of ADSs surrendered for split-up or combination, by
the Holder hereof or by duly authorized attorney upon surrender of this ADR at the Transfer Office
properly endorsed (in the case of ADRs in certificated form) or upon delivery to the Depositary of
proper instruments of transfer and duly stamped as may be required by applicable law;
<U>provided</U> that the Depositary may close the ADR Register at any time or from time to time
when deemed expedient by it or when requested by the Company to the extent required by applicable
law; <U>provided</U> that the Depositary shall have no liability and shall be indemnified by the
Company in such event. At the request of a Holder, the Depositary shall, for the purpose of
substituting a certificated ADR with a Direct Registration ADR, or vice versa, execute and deliver
a certificated ADR or a Direct Registration ADR, as the case may be, for any authorized number of
ADSs requested, evidencing the same aggregate number of ADSs as those evidenced by the certificated
ADR or Direct Registration ADR, as the case may be, substituted.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;<U>Certain Limitations</U>. Prior to the issue, registration, registration of
transfer, split-up or combination of any ADR, the delivery of any distribution in respect thereof,
or, subject to the last sentence of paragraph (2), the withdrawal of any Deposited Securities, and
from time to time in the case of clause (b)(ii) of this paragraph (4), the Company, the Depositary
or the Custodian may require: (a)&nbsp;payment with respect thereto of (i)&nbsp;any stock transfer or other
tax or other governmental charge, (ii)&nbsp;any stock transfer or registration fees in effect for the
registration of transfers of Shares or other Deposited Securities upon any applicable register and
(iii)&nbsp;any applicable charges as provided in paragraph (7)&nbsp;of this ADR; (b)&nbsp;the production of proof
satisfactory to it of (i)&nbsp;the identity of any signatory and genuineness of any signature and (ii)
such other information, including without limitation, information as to citizenship, residence,
exchange control approval, beneficial ownership of any securities, compliance with applicable law,
regulations, provisions of or governing Deposited Securities and terms of the Deposit Agreement and
this ADR, as it may deem necessary or proper; and (c)&nbsp;compliance with such regulations as the
Depositary may establish consistent with the Deposit Agreement. The issuance of ADRs, the
acceptance of deposits of Shares, the registration, registration of transfer, split-up or
combination of ADRs or, subject to the last sentence of paragraph (2), the withdrawal of Deposited
Securities may be suspended, generally or in particular instances, when the ADR Register or any
register for Deposited Securities is closed or when any such action is deemed advisable by the
Depositary or when requested by the Company to the extent required by applicable law;
<U>provided</U> that the Depositary shall have no liability and shall be indemnified by
the Company in such event.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;<U>Taxes</U>. If any tax or other governmental charge shall become payable by or on
behalf of the Custodian or the Depositary with respect to this ADR, any Deposited Securities
represented by the ADSs evidenced hereby or any distribution thereon, such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">tax or other
governmental charge shall be paid by the Holder hereof to the Depositary. The Depositary may
refuse to effect any registration, registration of transfer, split-up or combination hereof or,
subject to the last sentence of paragraph (2), any withdrawal of such Deposited Securities until
such payment is made. The Depositary may also deduct from any distributions on or in respect of
Deposited Securities, or may sell by public or private sale for the account of the Holder hereof
any part or all of such Deposited Securities (after attempting by reasonable means to notify the
Holder hereof prior to such sale), and may apply such deduction or the proceeds of any such sale in
payment of such tax or other governmental charge, the Holder hereof remaining liable for any
deficiency, and shall reduce the number of ADSs evidenced hereby to reflect any such sales of
Shares. In connection with any distribution to Holders, the Company will remit to the appropriate
governmental authority or agency all amounts (if any) required to be withheld and owing to such
authority or agency by the Company; and the Depositary and the Custodian will remit to the
appropriate governmental authority or agency all amounts (if any) required to be withheld and owing
to such authority or agency by the Depositary or the Custodian. The Depositary will forward to the
Company such information from its records as the Company may reasonably request to enable the
Company to file any necessary reports with governmental authorities or agencies. If the Depositary
determines that any distribution in property other than cash (including Shares or rights) on
Deposited Securities is subject to any tax that the Depositary or the Custodian is obligated to
withhold, the Depositary may dispose of all or a portion of such property in such amounts and in
such manner as the Depositary deems necessary and practicable to pay such taxes, by public or
private sale, and the Depositary shall distribute the net proceeds of any such sale or the balance
of any such property after deduction of such taxes to the Holders entitled thereto. Each Holder of
an ADR or an interest therein agrees to indemnify the Depositary, the Company, the Custodian and
any of their respective directors, employees, agents and affiliates against, and hold each of them
harmless from, any claims by any governmental authority with respect to taxes, additions to tax,
penalties or interest arising out of any refund of taxes, reduced rate of withholding at source or
other tax benefit obtained.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;<U>Disclosure of Interests</U>. To the extent that the provisions of or governing
any Deposited Securities may require disclosure of or impose limits on beneficial or other
ownership of Deposited Securities, other Shares and other securities and may provide for blocking
transfer, voting or other rights to enforce such disclosure or limits, Holders and all persons
holding ADRs agree to comply with all such disclosure requirements and ownership limitations and to
comply with any reasonable Company instructions in respect thereof. The Depositary shall forward to
the Holders, upon the request of the Company, any written request for beneficial ownership
information from the Company to the Holders and shall promptly forward to the Company any responses
thereto received by the Depositary. The Company reserves the right to instruct Holders to deliver
their ADSs for cancellation and withdrawal of the Deposited Securities so as to permit the Company
to deal directly with the Holder thereof as a holder of Shares and Holders agree to comply with
such instructions. The Depositary agrees to cooperate with the Company in its efforts to inform
Holders of the Company&#146;s exercise of its rights
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">under this paragraph and agrees to consult with,
and provide reasonable assistance without risk, liability or expense on the part of the Depositary,
to the Company on the manner or manners in which it may enforce such rights with respect to any
Holder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)&nbsp;<U>Charges of Depositary</U>. The Depositary may charge, and collect from, (i)&nbsp;each
person to whom ADSs are issued, including, without limitation, issuances against deposits of
Shares, issuances in respect of Share Distributions, Rights and Other Distributions (as such terms
are defined in paragraph (10)), issuances pursuant to a stock dividend or stock split declared by
the Company, or issuances pursuant to a merger, exchange of securities or any other transaction or
event affecting the ADSs or the Deposited Securities, and (ii)&nbsp;each person surrendering ADSs for
withdrawal of Deposited Securities or whose ADSs are cancelled or reduced for any other reason,
U.S.$5.00 for each 100 ADSs (or portion thereof) issued, delivered, reduced, cancelled or
surrendered (as the case may be). The Depositary may sell (by public or private sale) sufficient
securities and property received in respect of Share Distributions, Rights and Other Distributions
prior to such deposit to pay such charge. The following additional charges shall be incurred by the
Holders, by any party depositing or withdrawing Shares or by any party surrendering ADSs, to whom
ADSs are issued (including, without limitation, issuance pursuant to a stock dividend or stock
split declared by the Company or an exchange of stock regarding the ADSs or the Deposited
Securities or a distribution of ADSs pursuant to paragraph (10)), whichever is applicable (i)&nbsp;to
the extent not prohibited by the rules of any stock exchange on which the ADSs are listed for
trading, a fee of U.S.$0.05 or less per ADS for any Cash distribution made pursuant to the Deposit
Agreement, (ii)&nbsp;a fee of U.S.$1.50 per ADR or ADRs for transfers made pursuant to paragraph (3)
hereof, (iii)&nbsp;a fee for the distribution or sale of securities pursuant to paragraph (10)&nbsp;hereof,
such fee being in an amount equal to the fee for the execution and delivery of ADSs referred to
above which would have been charged as a result of the deposit of such securities (for purposes of
this paragraph (7)&nbsp;treating all such securities as if they were Shares) but which securities or the
net cash proceeds from the sale thereof are instead distributed by the Depositary to Holders
entitled thereto, (iv)&nbsp;an aggregate fee of U.S.$0.05 per ADS per calendar year (or portion thereof)
for services performed by the Depositary in administering the ADRs (which fee may be charged on a
periodic basis during each calendar year and shall be assessed against Holders as of the record
date or record dates set by the Depositary during each calendar year and shall be payable at the
sole discretion of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Depositary by billing such Holders or by deducting such charge from one or
more cash dividends or other cash distributions), and (v)&nbsp;reimbursement of such fees, charges and
expenses as are incurred by the Depositary and/or any of the Depositary&#146;s agents (including, without limitation, the Custodian
and expenses incurred on behalf of Holders in connection with compliance with foreign exchange
control regulations or any law or regulation relating to foreign investment) in connection with the
servicing of the Shares or other Deposited Securities, the delivery of Deposited Securities or
otherwise in connection with the Depositary&#146;s or its Custodian&#146;s compliance with applicable law,
rule or regulation (which charge shall be assessed on a proportionate basis against Holders as of
the record date or dates set by the depositary and shall be payable at the sole discretion of the
Depositary by billing such Holders or by deducting such charge from one or more cash dividends or
other cash distributions). The Company will pay all other charges and expenses of the Depositary
and any agent of the Depositary (except the Custodian) pursuant to agreements from time to time
between the Company and the Depositary, except (i)&nbsp;stock transfer or other taxes and other
governmental charges (which are payable by Holders or persons depositing Shares), (ii)&nbsp;cable, telex
and facsimile transmission and delivery charges incurred at the request of persons depositing, or
Holders delivering Shares, ADRs or Deposited Securities (which are payable by such persons or
Holders), (iii)&nbsp;transfer or registration fees for the registration or transfer of Deposited
Securities on any applicable register in connection with the deposit or withdrawal of Deposited
Securities (which are payable by persons depositing Shares or Holders withdrawing Deposited
Securities; there are no such fees in respect of the Shares as of the date of the Deposit
Agreement), and (iv)&nbsp;expenses of the Depositary in connection with the conversion of foreign
currency into U.S. dollars (which are paid out of such foreign currency). Such charges may at any
time and from time to time be changed by agreement between the Company and the Depositary.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8)&nbsp;<U>Available Information</U>. The Deposit Agreement, the provisions of or governing
Deposited Securities and any written communications from the Company, which are both received by
the Custodian or its nominee as a holder of Deposited Securities and made generally available to
the holders of Deposited Securities, are available for inspection by Holders at the offices of the
Depositary and the Custodian and at the Transfer Office. The Depositary will distribute copies of
such communications (or English translations or summaries thereof) to Holders when furnished by the
Company. The Company is subject to the periodic reporting requirements of the Securities Exchange
Act of 1934 and accordingly files certain reports with the United States Securities and Exchange
Commission (the &#147;Commission&#148;). Such reports and other information may be inspected and copied at
public reference facilities maintained by the Commission located at the date hereof at 100 F
Street, NE, Washington, DC 20549.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9)&nbsp;<U>Execution</U>. This ADR shall not be valid for any purpose unless executed by the
Depositary by the manual or facsimile signature of a duly authorized officer of the Depositary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated:
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">JPMORGAN CHASE BANK, N.A., as Depositary<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD style="border-bottom: 0px solid #000000" align="left">By&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Authorized Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Depositary&#146;s office is located at 4 New York Plaza, New York, New York 10004.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;FORM OF REVERSE OF ADR&#093;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(10)&nbsp;<U>Distributions on Deposited Securities</U>. Subject to paragraphs (4)&nbsp;and (5), to
the extent practicable, the Depositary will distribute to each Holder entitled thereto on the
record date set by the Depositary therefor at such Holder&#146;s address shown on the ADR Register, in
proportion to the number of Deposited Securities (on which the following distributions on Deposited
Securities are received by the Custodian) represented by ADSs evidenced by such Holder&#146;s ADRs: (a)
<U>Cash</U>. Any U.S. dollars available to the Depositary resulting from a cash dividend or other
cash distribution or the net proceeds of sales of any other distribution or portion thereof
authorized in this paragraph (10) (&#147;Cash&#148;), on an averaged or other practicable basis, subject to
(i)&nbsp;appropriate adjustments for taxes withheld, (ii)&nbsp;such distribution being impermissible or
impracticable with respect to certain Holders, and (iii)&nbsp;deduction of the Depositary&#146;s expenses in
(1)&nbsp;converting any foreign currency to U.S. dollars by sale or in such other manner as the
Depositary may determine to the extent that it determines that such conversion may be made on a
reasonable basis, (2)&nbsp;transferring foreign currency or U.S. dollars to the United States by such
means as the Depositary may determine to the extent that it determines that such transfer may be
made on a reasonable basis, (3)&nbsp;obtaining any approval or license of any governmental authority
required for such conversion or transfer, which is obtainable at a reasonable cost and within a
reasonable time and (4)&nbsp;making any sale by public or private means in any commercially reasonable
manner. (b) <U>Shares</U>. (i)&nbsp;Additional ADRs evidencing whole ADSs representing any Shares
available to the Depositary resulting from a dividend or free distribution on Deposited Securities
consisting of Shares (a &#147;Share Distribution&#148;) and (ii)&nbsp;U.S. dollars available to it resulting from
the net proceeds of sales of Shares received in a Share Distribution, which Shares would give rise
to fractional ADSs if additional ADRs were issued therefor, as in the case of Cash. (c)
<U>Rights</U>. (i)&nbsp;Warrants or other instruments in the discretion of the Depositary representing
rights to acquire additional ADRs in respect of any rights to subscribe for additional Shares or
rights of any nature available to the Depositary as a result of a distribution on Deposited
Securities (&#147;Rights&#148;), to the extent that the Company timely furnishes to the Depositary evidence
satisfactory to the Depositary that the Depositary may lawfully distribute the same (the Company
has no obligation to so furnish such evidence), or (ii)&nbsp;to the extent the Company does not so
furnish such evidence and sales of Rights are practicable, any U.S. dollars available to the
Depositary from the net proceeds of sales of Rights as in the case of Cash, or (iii)&nbsp;to the extent
the Company does not so furnish such evidence and such sales cannot practicably be accomplished by
reason of the nontransferability of the Rights, limited markets therefor, their short duration or
otherwise, nothing (and any Rights may lapse). (d) <U>Other Distributions</U>. (i)&nbsp;Securities or
property available to the Depositary resulting from any distribution on Deposited Securities other
than Cash, Share Distributions and Rights (&#147;Other Distributions&#148;), by any means that the
Depositary may deem equitable and practicable, or (ii)&nbsp;to the extent the Depositary deems
distribution of such securities or property not to be equitable and practicable, any U.S. dollars
available to the Depositary from the net proceeds of sales of Other Distributions as in the case of
Cash. Such U.S. dollars available will be distributed by checks drawn on a bank in the United
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">States for whole dollars
and cents. Fractional cents will be withheld without liability and dealt with by the Depositary in
accordance with its then current practices.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(11)&nbsp;<U>Record Dates</U>. The Depositary may, after consultation with the Company if
practicable, fix a record date (which, to the extent applicable, shall be as near as practicable to
any corresponding record date set by the Company) for the determination of the Holders who shall be
responsible for the fee assessed by the Depositary for administration of the ADR program and for
any expenses provided for in paragraph (7)&nbsp;hereof as well as for the determination of the Holders
who shall be entitled to receive any distribution on or in respect of Deposited Securities, to give
instructions for the exercise of any voting rights, to receive any notice or to act in respect of
other matters and only such Holders shall be so entitled or obligated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(12)&nbsp;<U>Voting of Deposited Securities</U>. As soon as practicable after receipt from the
Company of notice of any meeting or solicitation of consents or proxies of holders of Shares or
other Deposited Securities, the Depositary shall distribute to Holders a notice stating (a)&nbsp;such
information as is contained in such notice and any solicitation materials, (b)&nbsp;that each Holder on
the record date set by the Depositary therefor will, subject to any applicable provisions of the
laws of the Cayman Islands, be entitled to instruct the Depositary as to the exercise of the voting
rights, if any, pertaining to the Deposited Securities represented by the ADSs evidenced by such
Holder&#146;s ADRs and (c)&nbsp;the manner in which such instructions may be given, including instructions to
give a discretionary proxy to a person designated by the Company. Upon receipt of instructions of
a Holder on such record date in the manner and on or before the date established by the Depositary
for such purpose, the Depositary shall endeavor insofar as practicable and permitted under the
provisions of or governing Deposited Securities to vote or cause to be voted the Deposited
Securities represented by the ADSs evidenced by such Holder&#146;s ADRs in accordance with such
instructions. The Depositary will not itself exercise any voting discretion in respect of any
Deposited Securities. There is no guarantee that Holders generally or any Holder in particular
will receive the notice described above with sufficient time to enable such Holder to return any
voting instructions to the Depositary in a timely manner.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(13)&nbsp;<U>Changes Affecting Deposited Securities</U>. Subject to paragraphs (4)&nbsp;and (5), the
Depositary may, in its discretion, amend this ADR or distribute additional or amended ADRs (with or
without calling this ADR for exchange) or cash, securities or property on the record date set by
the Depositary therefor to reflect any change in par value, split-up, consolidation, cancellation
or other reclassification of Deposited Securities, any Share Distribution or Other Distribution not
distributed to Holders or any cash, securities or property available to the Depositary in respect
of Deposited Securities from (and the Depositary is hereby authorized to surrender any Deposited
Securities to any person and, irrespective of whether such Deposited Securities are surrendered or
otherwise cancelled by operation of law, rule, regulation or otherwise, to sell by public or
private sale any property received in connection with) any recapitalization, reorganization, merger, consolidation, liquidation, receivership,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">bankruptcy
or sale of all or substantially all the assets of the Company, and to the extent the Depositary
does not so amend this ADR or make a distribution to Holders to reflect any of the foregoing, or
the net proceeds thereof, whatever cash, securities or property results from any of the foregoing
shall constitute Deposited Securities and each ADS evidenced by this ADR shall automatically
represent its pro rata interest in the Deposited Securities as then constituted.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(14)&nbsp;<U>Exoneration</U>. The Depositary, the Company, their agents and each of them shall:
(a)&nbsp;incur no liability (i)&nbsp;if any present or future law, rule, regulation , fiat, order or decree
of the United States, the Cayman Islands, The People&#146;s Republic of China (including the Hong Kong
Special Administrative Region, the People&#146;s Republic of China) or any other country, or of any
governmental or regulatory authority or any securities exchange or market or automated quotation
system, the provisions of or governing any Deposited Securities, any present or future provision of
the Company&#146;s charter, any act of God, war, terrorism or other circumstance beyond its control
shall prevent, delay or subject to any civil or criminal penalty any act which the Deposit
Agreement or this ADR provides shall be done or performed by it or them (including, without
limitation, voting pursuant to paragraph (12)&nbsp;hereof), or (ii)&nbsp;by reason of any exercise or failure
to exercise any discretion given it in the Deposit Agreement or this ADR; (b)&nbsp;assume no liability
except to perform its obligations to the extent they are specifically set forth in this ADR and the
Deposit Agreement without gross negligence or bad faith; (c)&nbsp;in the case of the Depositary and its
agents, be under no obligation to appear in, prosecute or defend any action, suit or other
proceeding in respect of any Deposited Securities or this ADR; (d)&nbsp;in the case of the Company and
its agents hereunder be under no obligation to appear in, prosecute or defend any action, suit or
other proceeding in respect of any Deposited Securities or this ADR, which in its opinion may
involve it in expense or liability, unless indemnity satisfactory to it against all expense
(including fees and disbursements of counsel) and liability be furnished as often as may be
required; or (e)&nbsp;not be liable for any action or inaction by it in reliance upon the advice of or
information from legal counsel, accountants, any person presenting Shares for deposit, any Holder,
or any other person believed by it to be competent to give such advice or information. The
Depositary shall not be liable for the acts or omissions made by any securities depository,
clearing agency or settlement system in connection with or arising out of book-entry settlement of
Deposited Securities or otherwise. The Depositary shall not be responsible for, and shall incur
no liability in connection with or arising from, the insolvency of any Custodian that is not a
branch or affiliate of JPMorgan Chase Bank, N.A. The Depositary, its agents and the Company may
rely and shall be protected in acting upon any written notice, request, direction or other document
believed by them to be genuine and to have been signed or presented by the proper party or parties.
The Depositary and its agents will not be responsible for any failure to carry out any
instructions to vote any of the Deposited Securities, for the manner in which any such vote is cast
or for the effect of any such vote. The Depositary and its agents may own and deal in any class of
securities of the Company and its affiliates and in ADRs. Notwithstanding anything to the contrary set forth in the Deposit Agreement or an ADR, the
Depositary and its agents may fully respond to any and all demands or requests for
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">information
maintained by or on its behalf in connection with the Deposit Agreement, any Holder or Holders, any
ADR or ADRs or otherwise related hereto or thereto to the extent such information is requested or
required by or pursuant to any lawful authority, including without limitation laws, rules,
regulations, administrative or judicial process, banking, securities or other regulators. None of
the Depositary, the Custodian or the Company shall be liable for the failure by any Holder or
beneficial owner to obtain the benefits of credits on the basis of non-U.S. tax paid against such
Holder&#146;s or beneficial owner&#146;s income tax liability. The Depositary and the Company shall not incur
any liability for any tax consequences that may be incurred by Holders and beneficial owners on
account of their ownership of the ADRs or ADSs. The Company has agreed to indemnify the Depositary
and its agents under certain circumstances. Neither the Depositary nor any of its agents shall be
liable to Holders or beneficial owners of interests in ADSs for any indirect, special, punitive or
consequential damages (including, without limitation, lost profits) of any form incurred by any
person or entity, whether or not foreseeable and regardless of the type of action in which such a
claim may be brought. No disclaimer of liability under the Securities Act of 1933 is intended by
any provision hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(15)&nbsp;<U>Resignation and Removal of Depositary; the Custodian</U>. The Depositary may resign
as Depositary by written notice of its election so to do delivered to the Company, such resignation
to take effect upon the appointment of a successor depositary and its acceptance of such
appointment as provided in the Deposit Agreement. The Depositary may at any time be removed by the
Company by no less than 90&nbsp;days prior written notice of such removal, to become effective upon the
later of (i)&nbsp;the 90th day after delivery of the notice to the Depositary and (ii)&nbsp;the appointment
of a successor depositary and its acceptance of such appointment as provided in the Deposit
Agreement. The Depositary may appoint substitute or additional Custodians and the term
&#147;<U>Custodian</U>&#148; refers to each Custodian or all Custodians as the context requires.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(16)&nbsp;<U>Amendment</U>. Subject to the last sentence of paragraph (2), the ADRs and the
Deposit Agreement may be amended by the Company and the Depositary, <U>provided</U> that any
amendment that imposes or increases any fees or charges (other than stock transfer or other taxes
and other governmental charges, transfer or registration fees, cable, telex or facsimile
transmission costs, delivery costs or other such expenses), or that shall otherwise prejudice any
substantial existing right of Holders, shall become effective 30&nbsp;days after notice of such
amendment shall have been given to the Holders. Every Holder of an ADR at the time any amendment
to the Deposit Agreement so becomes effective shall be deemed, by continuing to hold such ADR, to
consent and agree to such amendment and to be bound by the Deposit Agreement as amended thereby.
In no event shall any amendment impair the right of the Holder of any ADR to surrender such ADR and
receive the Deposited Securities represented thereby, except in order to comply with mandatory
provisions of applicable law. Any amendments or supplements which (i)&nbsp;are reasonably necessary (as agreed by
the Company and the Depositary) in order for (a)&nbsp;the ADSs to be registered on Form F-6 under the
Securities Act of 1933 or (b)&nbsp;the ADSs or Shares to be traded solely in electronic book-entry form
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and (ii)&nbsp;do not in either such case impose or increase any fees or charges to be borne by Holders,
shall be deemed not to prejudice any substantial rights of Holders. Notwithstanding the
foregoing, if any governmental body or regulatory body should adopt new laws, rules or regulations
which would require amendment or supplement of the Deposit Agreement or the form of ADR to ensure
compliance therewith, the Company and the Depositary may amend or supplement the Deposit Agreement
and the ADR at any time in accordance with such changed laws, rules or regulations. Such amendment
or supplement to the Deposit Agreement in such circumstances may become effective before a notice
of such amendment or supplement is given to Holders or within any other period of time as required
for compliance. Notice of any amendment to the Deposit Agreement or form of ADRs shall not need to
describe in detail the specific amendments effectuated thereby, and failure to describe the
specific amendments in any such notice shall not render such notice invalid, provided, however,
that, in each such case, the notice given to the Holders identifies a means for Holders to retrieve
or receive the text of such amendment (i.e., upon retrieval from the Securities and Exchange
Commission&#146;s, the Depositary&#146;s or the Company&#146;s website or upon request from the Depositary).<U>
</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(17)&nbsp;<U>Termination</U>. The Depositary may, and shall at the written direction of the
Company, terminate the Deposit Agreement and this ADR by mailing notice of such termination to the
Holders at least 30&nbsp;days prior to the date fixed in such notice for such termination; provided,
however, if the Depositary shall have (i)&nbsp;resigned as Depositary hereunder, notice of such
termination by the Depositary shall not be provided to Holders unless a successor depositary shall
not be operating hereunder within 45&nbsp;days of the date of such resignation, or (ii)&nbsp;been removed as
Depositary hereunder, notice of such termination by the Depositary shall not be provided to Holders
unless a successor depositary shall not be operating hereunder on the 90<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day after the
Company&#146;s notice of removal was first provided to the Depositary. After the date so fixed for
termination, the Depositary and its agents will perform no further acts under the Deposit Agreement
and this ADR, except to receive and hold (or sell) distributions on Deposited Securities and
deliver Deposited Securities being withdrawn. As soon as practicable after the expiration of six
months from the date so fixed for termination, the Depositary shall sell the Deposited Securities
and shall thereafter (as long as it may lawfully do so) hold in a segregated account the net
proceeds of such sales, together with any other cash then held by it under the Deposit Agreement,
without liability for interest, in trust for the <U>pro</U> <U>rata</U> benefit of the Holders of
ADRs not theretofore surrendered. After making such sale, the Depositary shall be discharged from
all obligations in respect of the Deposit Agreement and this ADR, except to account for such net
proceeds and other cash. After the date so fixed for termination, the Company shall be discharged
from all obligations under the Deposit Agreement except for its obligations to the Depositary and
its agents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(18)&nbsp;<U>Appointment.</U> Each Holder and each person holding an interest in ADSs, upon
acceptance of any ADSs (or any interest therein) issued in accordance with the terms and conditions
of the Deposit Agreement shall be deemed for all purposes to (a)&nbsp;be a party to and bound by the
terms of the Deposit Agreement and the applicable
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="h03611a4h0361171.gif" alt="(J.P.Morgan LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ADR(s), and (b)&nbsp;appoint the Depositary its
attorney-in-fact, with full power to delegate, to act on its behalf and to take any and all actions
contemplated in the Deposit Agreement and the applicable ADR(s), to adopt any and all procedures
necessary to comply with applicable law and to take such action as the Depositary in its sole
discretion may deem necessary or appropriate to carry out the purposes of the Deposit Agreement and
the applicable ADR(s), the taking of such actions to be the conclusive determinant of the necessity
and appropriateness thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(19)&nbsp;<U>Waiver</U>. EACH PARTY TO THE DEPOSIT AGREEMENT (INCLUDING, FOR
AVOIDANCE OF DOUBT, EACH HOLDER AND BENEFICIAL OWNER AND/OR HOLDER OF INTERESTS IN ADRS) HEREBY
IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A
TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING AGAINST THE DEPOSITARY AND/OR THE COMPANY DIRECTLY
OR INDIRECTLY ARISING OUT OF OR RELATING TO THE SHARES OR OTHER DEPOSITED SECURITIES, THE ADSs OR
THE ADRs, THE DEPOSIT AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREIN OR THEREIN, OR THE BREACH
HEREOF OR THEREOF (WHETHER BASED ON CONTRACT, TORT, COMMON LAW OR ANY OTHER THEORY).
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->A-13<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.19
<SEQUENCE>4
<FILENAME>h03611a4exv4w19.htm
<DESCRIPTION>EX-4.19
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w19</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 18pt">Exhibit 4.19
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENT NO. 2 TO AMENDED AND RESTATED SHAREHOLDERS&#146; AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMENDMENT NO. 2 TO AMENDED AND RESTATED SHAREHOLDERS&#146; AGREEMENT (this &#147;<B>Amendment</B>&#148;) dated as
of December&nbsp;7, 2009 (the &#147;<B>Amendment Date</B>&#148;) by and among (1)&nbsp;CICC Sun Company Limited, a company
incorporated under the laws of the British Virgin Islands (&#147;<B>CICC</B>&#148;), (2)&nbsp;Carlyle Asia Growth
Partners III, L.P., a limited partnership formed under the laws of the Cayman Islands (&#147;<B>CAGP</B>&#148;), (3)
CAGP III Co-Investment III, L.P. (&#147;<B>CAGP Co-Invest</B>&#148;, together with CAGP, &#147;<B>Carlyle</B>&#148;), (4)&nbsp;Starr
Investments Cayman II, Inc., a company incorporated under the laws of the Cayman Islands (&#147;<B>Starr</B>&#148;,
together with CICC and Carlyle, the &#147;<B>Investors</B>&#148;), (5)&nbsp;Concord Medical Services Holdings Limited, an
exempted company with limited liability organized and existing under the laws of the Cayman Islands
(the &#147;<B>Company</B>&#148;), and (6)&nbsp;the other parties set forth in the signature pages hereof.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>W I T N E S S E T H :</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the parties hereto entered into an Amended and Restated Shareholders&#146; Agreement dated
as of October&nbsp;20, 2008 in relation to the issuance by the Company to each of the Investors of
certain Series&nbsp;B convertible redeemable preferred shares, par value $0.01 per share, of the
Company, which was amended on Novmeber 17, 2009 (the &#147;<B>Agreement</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the parties hereto and thereto desire to amend the Agreement to reflect the changes
set forth herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, the parties hereto agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;1 </B><I>. Amendment. </I>The Agreement is amended by adding the following Section&nbsp;7.03(c):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;Section&nbsp;7.03. <I>Waiver; Amendment; Termination</I>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;This
Agreement (except for Article&nbsp;5, Section&nbsp;6.01, this Article&nbsp;7, and any applicable definitions in Article&nbsp;1) shall terminate and
be of no further force or effect immediately prior to the closing of a QPO.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;2 </B><I>. Effect of Amendment. </I>Except as amended by this Amendment, the Agreement shall
remain unchanged and in full force and effect. From and after the Amendment Date, each reference
to &#147;this Agreement,&#148; &#147;hereof,&#148; &#147;hereunder&#148; or words of like import, and all references to the
Agreement in any and all agreements, instruments, documents, notes, certificates and other writings
of every kind and nature shall be deemed to mean the Agreement as amended by this Amendment, except
as is otherwise expressly stated.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;3 </B><I>. General. </I>(a)&nbsp;This Amendment shall be binding on the successors and permitted
assigns of the parties hereto; (b)&nbsp;this Amendment shall be governed by and construed in accordance
with the laws of the State of New York, without regard to conflicts of law principles thereunder
and shall be subject to the jurisdiction of the courts in the State of New York; (c)&nbsp;this Amendment
may be executed in more than one counterpart, each of which shall be deemed an original and any
counterpart so executed shall be deemed to be one and the same instrument; (d)&nbsp;each party hereto
acknowledges that the parties hereto have participated jointly in the negotiation and drafting of
this Amendment, and in the event an ambiguity or question of intent or interpretation arises, this
Amendment shall be construed as if drafted jointly by the parties hereto and no presumption or
burden of proof shall arise favoring or disfavoring any party hereto by virtue of the authorship of
any of the provisions of this Amendment; (e)&nbsp;if any part of any provision of this Amendment shall
be invalid or unenforceable under applicable law, such part shall be ineffective to the extent of
such invalidity only, without in any way affecting the remaining parts of such provision or the
remaining provisions of this Amendment; and (f)&nbsp;each party hereto acknowledges that the remedies at
law of the other parties hereto for a breach or threatened breach of this Amendment would be
inadequate and, in recognition of this fact, any party hereto, without posting any bond, and in
addition to all other remedies that may be available, shall be entitled to obtain equitable relief
in the form of specific performance, a temporary restraining order, a temporary or permanent
injunction or any other equitable remedy that may then be available.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>&#091;The remainder of this page has been intentionally left blank&#093;</I>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned shareholders have executed this Agreement, in one or more counterparts, each of which
shall constitute an original and all of which when taken together shall constitute one instrument,
on December&nbsp;7, 2009.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Jianyu Yang
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Concord Medical Services Holdings Limited</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Bo Tao Shi
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Grand Best Group Limited</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Steve Sun
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Dragon Image Investment Ltd.</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Jianyu Yang
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Daketala International Investment Holdings Ltd.</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Sirong Tian
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Sino Prime Investments Limited</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Xiaogang Wang
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Latek Corporation</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Peipei Zhang
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Genius Aspect Investment Ltd.</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Wenqing Tan
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Star Rising Ltd.</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Homerun Technology Ltd.</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Wenqing Tan
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Sino First Holdings Ltd.</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Bona Lau
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Notable Enterprise Limited</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Zheng Cheng
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>CZY Investment Limited</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Jing Zhang
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Thousand Ocean Group Limited</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Yap Yaw Kong
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Top Mount Group Limited</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Boxun Zhang
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Triumph Concept Investment Limited</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>ATL International Group Limited</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Huang Jen-Fu, in his individual capacity</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Wang Jen-Wen, in his individual capacity</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Ni Shiao-Jane, in her individual capacity</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Daniel A. D&#146;Aniello
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Carlyle Asia Growth Partners III, L.P.</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Daniel A. D&#146;Aniello
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>CAGP III Co-Investment, L.P.</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Michael J. Horvath
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Starr Investments Cayman II, Inc.</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Shirley Chen
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>CICC Sun Company Limited</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD style="border-bottom: 1px solid #000000" align="left">/s/ Shirley Chen
&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>For and on behalf of</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left"><B>Perfect Key Holdings Limited</B>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>BEING ALL OF THE SHAREHOLDERS OF THE COMPANY</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>5
<FILENAME>h03611a4exv10w21.htm
<DESCRIPTION>EX-10.21
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w21</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;10.21
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>English Translation</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Strategic Cooperative Agreement</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>between</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>China Construction Bank Corporation<BR>
Shenzhen Branch</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>and</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>China Medical Services Holdings Limited</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 36pt"><B>16 November, 2009</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Party A: China Medical Services Holdings Limited<BR>
Address: No.&nbsp;3702, Rongchao Trade Center, Jintian Road, Futian District, Shenzhen<BR>
Legal Representative: YANG Jianyu</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Party B: China Construction Bank Corporation, Shenzhen Branch<BR>
Address: East Tower, Financial Center, Hongling South Road, Shenzhen<BR>
Person in Charge: TIAN Huiyu</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party A is Asia&#146;s largest, most professionally competent and longest-operating medical equipment
investment service provider and operator of relevant medical centers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party B is a major state-owned commercial bank with a nationwide branch network, a comprehensive
service system as well as a presence (through branches or representative offices) in the world&#146;s
major financial centers, which enjoys extensive experiences in servicing key engineering and
construction projects and large enterprise groups and possesses competitive edges in terms of
products, technology, talents, service philosophy, etc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In order to establish a sound bank-enterprise cooperative relationship and promote the mutual
development and long term partnership of the Parties, in keeping with the principle of &#147;equality
and mutual benefit, mutual support, honesty and creditworthiness&#148; , Party A and Party B, on the
basis of their existing successful cooperation, reach the following agreement upon full discussions
and covenant to strictly abide by each provision set out herein and duly fulfill their respective
obligations hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;I </B>The Parties mutually agree to establish between them a long-term strategic partnership.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party B will treat Party A as one of its most important clients, will fully support the development
of Party A, and will, to the extent permitted by the laws, regulations and financial policies of
the state and relevant rules of Party B, provide, on a priority basis, Party A and all of its
controlled subsidiaries with full financial services and full financial support.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party A will treat Party B as one of its most important long-term partners and will, where the
conditions are equal, retain, on a priority basis, Party B as its primary cooperation bank for its
financial operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;II </B>Subject to compliance with the <I>Guarantee Law, </I>the <I>General Provisions on Lending </I>and
other relevant laws, regulations and financial policies of the state as well as relevant lending
rules of Party B, Party B will actively support the business growth of Party A and will in the
forthcoming three years grant to Party A an indicative credit line of RMB1.5&nbsp;billion (subject to
business review and approval by Party B and satisfaction of relevant approval conditions of Party
B, with the specific rights and obligations to be
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">governed by relevant definitive agreements entered into by the Parties upon mutual discussions and mutual agreement), which may be disbursed
towards working capital loans, fixed-asset project loans, RMB bridge loans, onshore
guarantor-backed offshore affiliate loans, export buyer credit, pooled guarantees-backed loans, M&#038;A
loans, factoring, receivables pledge arrangements and other areas of business cooperation. The
Parties will equally strengthen their cooperation in the areas of import and export business, trade
finance, etc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;III </B>Party B will actively design a best possible management solution for the funds of Party
A, will ensure the security and timely transfer and disbursement of the funds of Party A, and will,
subject to compliance with the relevant laws, regulations and financial policies of the state and
relevant lending rules of Party B, procure the funds deposited by Party A with Party B to achieve
highest possible returns.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;III</B><SUP style="font-size: 85%; vertical-align: text-top"><B>1</B></SUP> Party B&#146;s Undertakings on Financial Service

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Credit Financing Service</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Conditions for Grant of Credit Facility</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In respect of RMB and foreign currency-denominated financing services under the aforesaid credit
facility, Party B undertakes to offer, where the conditions are equal, Party A and its subordinated
enterprises preferential conditions and rates within the pricing range stipulated by applicable
regulators.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Approval procedures for grant of credit facility</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">When Party A and its subordinated enterprises apply to Party B to draw on the credit facility
granted by Party B, Party B shall to the extent possible simplify its approval procedures and offer
the most convenient services.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Innovative financial service</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">To the extent permitted by applicable rules and regulations, Party B will carry out product
innovation and provide corresponding financial products in respect of its overall financial
services to the various projects of Party A and its controlled subsidiaries.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Fund settlement service</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">To the extent permitted by applicable rules and regulations, Party B will, in line with the
financial and fund settlement patterns of Party A, consider and develop, on a priority basis,
corresponding settlement methods and provide relevant financial settlement services to Party A so
as to meet Party A&#146;s needs for the management of its funds, finances, etc.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;IV </B>Party A&#146;s Undertakings on Business Cooperation

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Undertakings on grant of credit facility</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall maintain reasonable financial conditions and shall have sound operating
conditions and development prospects.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Article&nbsp;III was used twice in the original Chinese
version.</TD>
</TR>

</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">






<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon accepting a credit facility from Party B, Party A shall act in accordance with the
principle of &#147;fairness and reasonableness&#148; in accepting any credit facility from another bank so as
not to prejudice the rights of Party B.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall promptly provide Party B or its branches with material information as well as
basic information reflecting the changes in its operations and management.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall on a priority basis choose to open with Party B its sweeping accounts for IPO
proceeds, follow-on offerings and rights issues.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall use its best efforts to perform the obligations required to be performed by it in
the course of its existing and future business cooperation with Party B.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Where the conditions are equal, Party A and its subordinated enterprises and controlled
enterprises shall on a priority basis choose to open their accounts with Party B and shall utilize,
on a priority basis, the financial products and services of Party B, including:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To select Party B as one of their major RMB and foreign currency financing banks;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To select party B as one of their major RMB and foreign currency account-opening banks
(including the basic account, the capital funds account, the foreign debt account, the rent payment
account, the escrow account and the general settlement account) and settlement banks;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To select Party B as the &#147;main bank&#148; for their international settlement business (including
but not limited to L/C, remittance, profit repatriation, letter of guarantee and other non-trade
settlement businesses), as well as the major RMB settlement reporting bank for their cross-border
trading businesses;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To select Party B as one of the &#147;main banks&#148; for their co-branding card, credit card and
personal wealth management businesses;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To select Party B as one of the main handling banks for their cash management and drafts
operations as well as for the NRA accounts of Party B&#146;s <SUP style="font-size: 85%; vertical-align: text-top">2</SUP>offshore affiliates;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To select, in line with their business growth needs, Party B as the provider of financial
advisory service, public housing fund service, personal residential mortgage loans, corporate
annuity service, and other financial services and products provided by Party B; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To utilize other financial products not specified herein.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;V </B>Cooperation on Other Businesses

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cooperation on Cash Management</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party B will support the centralized management of the multi-level funds of Party A and enhance the
operating efficiency of such funds by utilizing its online banking services and other electronic
banking platforms and by providing entrusted loan facilities, legal person account overdraft
facilities and other services to Party A, all in accordance with the needs of Party A. Party B
will, by means of its own money products, provide corresponding services in respect of the RMB and
foreign currency receipts and
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>As shown in the original Chinese version.</TD>
</TR>

</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">






<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>disbursements of Party A and thereby procure the value maintenance
and appreciation of the relevant funds.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Consultancy and Advisory Service</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party B will provide Party A with financial advisory and foreign exchange management policy
consulting services.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B will fully tap into its strengths in the Bank-Customs-Connection system and the online
trade settlement system (E-TRADE) so as to satisfy Party A&#146;s business needs for fast customs
clearance, fast remittance, etc.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Other Services</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party B will design individualized financial products or a combination of such products based on
the needs of Party A.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;VI </B>Coordination and Communication

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">So long as the Parties shall maintain each other&#146;s trade secrets in confidence, Party A and Party B
shall strengthen their mutual communication and thereby facilitate the implementation of this
Strategic Cooperative Agreement. The Parties agree to timely circulate this Strategic Cooperative
Agreement to their respective subordinated entities, to each designate business cooperation contact
persons at different levels and to establish a regular coordination meeting system so as to resolve
issues arising during the course of implementation hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party A shall designate its Finance Department as the agreement implementation coordination
department which shall be responsible for the full implementation of this Agreement. Party B shall
designate the Corporate Business Department of its branch as the agreement implementation
coordination department which shall be responsible for the full implementation of this Agreement;
and the business office of such branch of Party B shall act as the main entity to provide the
specific services while other relevant sub-branches of Party B shall act as the auxiliary entity to
assist with the provision of such services.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;VII </B>Dispute Settlement

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any dispute arising out of the implementation of this Agreement upon its effectiveness shall be
resolved by Party A and Party B through friendly consultations based on the principle of &#147;equality,
mutual benefit, mutual understanding and mutual accommodation&#148;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;VIII </B>Effectiveness of Agreement

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Agreement shall become effective when it shall have been signed by the legal representatives
(or persons in charge) of the Parties or their authorized representatives and affixed with the
corporate seals of the Parties and shall remain valid for 2&nbsp;years. Upon expiry of such term, this
Agreement shall continue to be effective if so confirmed in writing by the Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;IX </B>This Agreement shall be made in four originals and Party A and Party B shall each hold
two copies thereof.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">(No operative text on this page)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>China Medical Services Holdings Limited</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>China Construction Bank Corporation Shenzhen Branch</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>(Corporate Seal)</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>(Corporate Seal)</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Legal Representative (or Authorized Representative)</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Legal Representative (or Authorized Representative)</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>(Signature)</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>(Signature)</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>17 November, 2009</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>17 November, 2009</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>h03611a4exv23w1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv23w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;23.1
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Consent of Independent Registered Public Accounting Firm
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We consent to the references to our firm under the caption &#147;Experts&#148; and to the use of our report
dated October&nbsp;16, 2009 (except Note 26, as to which the date is November&nbsp;17, 2009) in the
Registration Statement (Form F-1 No.&nbsp;333-163155) and the related Prospectus of Concord Medical
Services Holdings Limited for the registration of its ordinary shares. We also consent to the use
of our report dated September&nbsp;3, 2009 with respect to the consolidated financial statements of
China Medstar Limited also included in this Registration Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 24pt">/s/ Ernst &#038; Young Hua Ming<BR>
Shenzhen, the People&#146;s Republic of China<BR>
December&nbsp;7, 2009

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>h03611a4h0361100.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611a4h0361100.gif
M1TE&.#EA?0!B`,0?`(K(QT^LJL7DX\3CXXG'Q_'X^*?6U=3KZB&5EFRZN:?5
MU2.7E4"EHVNYN7O!P.+Q\=/JZC"<G5RQLN+R\7K`P%ZSL3&>G+;<W#^CI)C.
MSK;=W)G/SDVJJQ20CA*.C____R'Y!`$``!\`+`````!]`&(```7_X"<^!&>>
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MR,@`AHNDQ-J2P2$1B$[2J:)XZ\@`A%H4_T3YM:6`QS3G0DH<2?'3@`+-E!3,
MF4302Y!*1.HD6=*BFR^19F3;0N=GL'D&I1&U^6&C%B@TRE5Y]<%I3)V-UG`(
M570B2:H?,#KAV@(>J)@S4"+J698F-9,B_&FA,PDIW+8\YQ914*^@*+1NM0AJ
MH5;)XJX`XPK667@J7A%O6KKXPA>RE2M:)Q>I?/9R72?C/K#<"C)*@0$7"%P8
M0+NV[<Q:2-<T_8$4Z]Y;L/ZE^%*)[KM&^VZ![??I0Y+%DQP7.F"&EX2X[7I^
M3CR1U-+)6X16$AB)RM;0O1.T'%[$TLED:'@]%AW)])D>JM/P/5>X\X_I+??=
M;NU]M4=2_\%$G_]Z9A$X&B&"W3/?+O69-"!R#]8P'ASGR1=9=P*N!UZ&-,@%
M1WPU3&A+A19=2%T4Y244A8JKL#B:B_CI5\-J</!C`XVHV$C$??@4V,)U<+@S
MXX<+AM@@AD-*P<$>':;()(4,:I>C%"9N@<`U2WX&8FXX%DEB#3BQH5"8W#5)
M9D,$Q"GGG'3624!V^96!IQ8^LCFD;8`&*NB>7(BVAXXV6+6%DE((::@1[FSX
MJ!.(VM`8:G4X.JD'4"BZ*:5U=*D$F(U^NH6/0I@*:AF)5;%FJ:HJX1\/F-3Z
M0Y^--E*I#0K8ZBL,51(E[+#$%FOLL<@FJ^RRS#;K[+/01BOMM-16:^W_M=AF
MJ^VVW';K[;?@ABONN.26:^ZY(@B@[KH'4+3NN_#&*X`(`-1K[[WXUFO#`?"V
M*TF\(DR`+RH&=&#PP0!0=/#"##?<@0@.1VRP#0$P'$`G"S!\C0`,.Q#`QR"'
M+'+&##,@\LD@VR#QRA"OW##%%G=2\<+S<KSPS"[GG+/*.C/<<L\/UX"SP1=_
MD&^^0W<0```)6`STTR_7`/7$'T`-\\T_3^VTUE;7D*\%#">0;]8=,``O`SX+
M'7/57#/,K[SO:D#RP1;`;;<D2<_+\\%%MY#TU7R3W;8D`#2L`;)Y1[&VWVG3
MD'31;6\=N<YX,ZRWU%C/\'<-;[-+MLDGH[WP_P(H3]YSY30KGCGC"Z-B^;X,
M6Z"VZ3M[C2_8"XM]KP%D]RW"YND>#8#>K]LPM\&D_DY[[31,#?GJRK?>0N$.
M)\SVP9?34`'#AW>R/<.\$^M\[XXW;G3$UA?O-</6!VR`\$TSO(#P]-^[-]#/
M!ZZY^=0WG/["H`L9[VRFOP\4@'3+<]G]>I8_HI5/>O1"G^#\)SC&)2V!YIO>
M[<*&K_`M+GH'F\$$U+4!]DW0A!\0W<':1;T+8C"$@TC<`GWW`>#-@(`&^]_*
MK.<`AFV`@.^KU_<<YH#Z.6QI]HNA^IH'O1IF,%THS)GU"K:P"LSM`Q/8@`H;
MEH`ZQ(]]R;-=O>:5./^1D6]_$+QA%%.'0^M-8&5?C%@7`]:O@$DL``D('Q-S
MZ,34I>V#?80A#7#8`1T:K&8+:Q_NC@C'&?3/@2*@8L1HF+6$)>Z/3;1A"PAI
MR`X@$F$M&&+#7-B!!71O>A^4Y"CO9\G78;*`(*3:(->(O0^TL04E=)C)B!C&
M\S51`(ML8B4#><CK40V0FH1B(LGV23XJ4WX'&-H"'#"!*#Q2:38PP.-824Q/
M&C-HR'RB+6E9S%NVP&&\J]@"*L`[CX',`8Y<7!P[4``-`*`"`8`GYOAX2>F%
M,XV;)*<WS3G.CD4R>SU,XS7[-C1*<K.?,/RG(-6XS&\VLY`B.&##-A`%57;_
MP%^^+&#8)+%,B!XSD^+D)#,+ZDP7SI%SX$-EYMY8T3J4U)7^1"E`G^G,U]WR
MFG23`@I#"DD-+%&HH#0I.'4ZT8!6U*?+7%DO8]FWA49P8=4<Q$W]F%-8=M,&
M*K4H2S&ZLE-J;W0RU9\H@Z;5I.(THDR5)45!*=9;CFZH+3A`0A<&)JM^()AE
M,\!49[#56KX2DJQK*D\Q6M>H&FP!'KW8".\)V!5.\H1*`\`&0$I8MW(5KEY-
MYE@9"U50'NQP+P/J2"^;0I<YM+#%/&S9SI92@5XT80;39](.H-J#S9&U!=CB
M*O>)4:5B-F)@U=EMJU95'_:6L=\L8`'V.MP]%O>M0B<%6G)SMMP%D(J0%5!M
M`K)Z0AH*P(6O]:QANWJZ&A`R8LOE;`%BUS\+L+.7K*6!7K>87GYB=ZG:=:]R
)Q]J^&0@W!``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>h03611a4h03611146.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611a4h03611146.gif
M1TE&.#EAT`*J`^8``-'M^U5,4]J-/PN;FR08(+#9\HJMV?S[_D5';7B<SI*2
MLJJ7EW!03'1UDO3IU6N,C8IR<+K'V^#0L$LM+6JNM._^_S,O1V^)M\NXL]C;
M[>O;ULK(VKF[V,ZIF,W6ZZI=,[WG\&-88X>:S%=GD[JYRH1Z@S-);FIC9+FV
MNLC.YG=U>:JFJ,K'R>GIZ4`[5X]G4\>\R&EXJ)_)[-S9VH:$B(U7292ZY:FJ
MRIJ5F+:KJTU6A*2;J>;L]Y:'B:QG0I&IKV3#S:NJMWAJ=65`.VMW=W5E:MG+
MR;BLN-%Z+MC-VB9L>YR,E+NFE8>'FJJWV6EI=B^#=]_6S*NWN:FVRU"GJ%AS
MH\S6VOWXXOCNZ[:MR<5U1'E<5%.9I9;6WX,P*D^)D55F;L";D-C>]Z*KUJ!7
M0Z-]:NC>ZKZUJXF5F*[`XTAN3C6DH6%;A<7B^-;.YY^<P:21???O]V5X9=Z_
MHYREI'A[6.SW[VR@HIZUM)))5KM67`"AG&AG9;SEZV/(TNWX_B'Y!```````
M+`````#0`JH#``?_@'Z"@X2%AH>(B8J+C(V.CY"1DI.4E9:*0)F:FYR=FQ1`
MH**AHA2FIZBIJJNI=Z:N=["QL[2UMK>XM`]WN[V\O`_!PL/$Q<;'R,1$P<O-
M#T3-T-+3U-76U]A/1-I/W-U/?.#A?.3EYN?HZ>KK[.WN[_#Q\O/T]?&7^/GZ
M^_S]_O^4/`GD-*H@J5"D2K%:N`H6!5</'<:*&#&715R^=OW**&QCLH\@BSD;
M^:QD-&C/3J;$QI(EMVU$^,2<*;,F.7'B[.G<R;.GSY]`WP$<2K2HT:-()0T<
M""I34X,*$R9D2+75*XH3+VJMI9%KK(P;@84<^W'9,+,DTT9;V;)M-CE$_^2\
M[+:M9C<YX_(&W<NWK]^_\Y(*'DRXL&%'2SLU=<H8JL+'51=*O"IQ5L6M6L%^
M#=NK8S"Q9,F:-<FLM%JWJ-W*A,9-;LV9W<KA!$R[MNW;/`_KWLV[-[_$`I\V
M1N@XLG%4$"M7O(RY.=C.'D&'GJ[,-&FU*=FF3KT:IK>8X)ZXUHN[O/GSY7VK
M7\^^_2#@3(>7FFJ*_G&K#K'*VM\\<UC.'E$GX%FD77<=2@B>M%UJVM#DH$SB
MS>9:3NA5:.&%.KFGX88<'@6?)L(A1-R(!=5W7V3)/:0??_UY=<MS``XHFC'.
M&(C6-=HMV%)W<W$3CC8WG4,AAD06:20Y'2:IY/^2E7SX"6,D$@?9B:Q,IJ(L
MR[5X$8PQ%B.=C,B@59)UV*VEXW;=0>C:@S'E%=Z1<,9Y(9-TUFEG(4YZ(IQC
M4MI'I557KJAEBS`^!Z:,8J;%UJ)GHL:C=][8A=>0Y,EIZ:5[W:GIIATZN=@H
M49KHYY_(!:I?EH-:I%FAG1TZ8XV)'LAHHZ@UJ"8X#L869*68]NIK3YP&*ZQO
M>8H()50'S4>J9)2MR%RJ7>G2)6@!NEH=C63:J&".M%:SFER0U@4;.6T.2>FO
MZ*:;SK#LMCM8L<.%FNRR59JJG&6I8O1?C,!4:^TQL=IHTC39==O6HQ&^9E<Y
MY:KK\,/MN"OQQ`!YJIC_?'TJ2Z\J*6*9KW/\<O3O=+`:.#`UW!HLC39P]0@>
MD+-!+//,Y5!L\\V7P#MBJ"5NC)^*I^+[\8N_S&*H6/V.#'"!`F^;H,IOP:3P
M@^(TS"O-6%N*\]9<(Y;G8B(B*ZJ)/I<::%9H#QWM9JQ"I[1(2S<]\*Q03]/R
MRN'&!AZYNV;M-Z9=!RXXGO""*O:4/EMY;]I#LUUTR%^^?6W)35>3<MT-@IMP
MKE7+ELZY?X=NWN"D!VXQ01@K.V_95YW-8N/ZLNJOY&%F6Z8TEZO<FLNXVG2U
MZ,!C6/KP..ML.(D]LW[V*QXS#CN`7;8J/>TF*ZH2P75?`^[*:RH\V][F@![\
M__B`$6_^Q,6"O2?R&2L/].*O0QL[9R)3/QJ!L<**._;94_.:R^&0&H7$1[X"
MEN]\"!R6\<+&LU'12W%7VL^SU`:Y^E%O<F.2&X(*UC]J-$@:4UM8.2;D.0.:
MD#8)3"&G3O<D>8T-<0]LEO.>1[2C&>J"<-,@CCHX#2"Q9AO>B-#>"'C"(@9%
MA4BTTP+7ISKWR9!YSJ(AOT*&PZ51SGHC41`/MP>-$+YL5^,QHACYDL0R+BE]
M+3Q<^Y37L2A*T18VG-W;[D<@'3Y-B_U[3=YVAQ>]$'&,@+R'&0>YH26F;G5L
MM%<$445#+MW0,S@,F/560C<>PF0:7OQ1D-X4R$[FAO^0H&0/"T%TR!<ZD%1M
MG"$%:UC!*F(K?V,RT_XL*37O`%%<"^MC"3W)2WB$\I?$*AP#2R0E]RFN>?'[
MF&:HZ,KJU,B.LJ0E%]D$(5UMLI?8E`<PMZD;-)+2A<1T8BHE^$:C43%Z<XS;
M)/'(SKK]+V_><U/XLDE/='#SGH0Q)#A/B4I%(G."RGS<M)I9QRMJ*T&YTYW_
MJ,G)/OZQGMC$IT21,LIC-5!CB70=0/.UM@K2CZ`%U6$E.^A#`+YD'&V"J$KM
M.=&6#D6??()A#/.#-D8^;YEM@V0D"[3..R;48-/,9$YF0ZF'KM2$+DVJ/[QI
MT9@BLFSCM.D;96=!R='1.@+_J^1/::7'[]!%35<SZE%/J-2RZ@.F%Q6G/]W8
MR/_DE*`!$VDT+?G!+C(T9N`;*T3-RE=+5'28[,,HZZ):SHXZKE!RW"DT44;+
M6@*0)C'3ZTK[2EFE").)R>+GGX[)UK8B=GH@)4DLM36WQL:EKEYL:,S$*ED#
M5O:U7ALE9ILHTWYJ5&CE/"PS[:?.ROFTL>_T:@!U%=F^M1:0L$TN)BY;RMKV
MDZ:+Q&WC'#G0SU11DKX=*4D7.K6$!2F,QXVH<L=+./B`K:F!?6KB9)C,W-K0
MNB`51LE$.]>M-JJD\/2A<7\7WB*2][^"0&LX-4LESJ9MHQR%WGOARK2>(M2T
M0643_R?EV5_Q`GB\3`7L@,F64?@A&&2L?&1B7775TFB06_8]4U=O>1=O3&J_
MK*UPUBY,7@$'5JW0_:<4<3K0R%D5J[!T6CLQQ]U<^7&_,D8NC97[U]EFEL.#
M9>^';]KC^.9PG1R\XW97\QV4>C?&20[>DIG,W(L2^$0&)N=4W8K.I.UTO@?5
M;O\B'%QYDI"_81X?%_;,YS[[^<^`#K2@!TWH0AOZT(A.M*(7S>A&._K1C?X"
M%R1-Z4E;^@N8GO07'H!I3G<:TYO^=*A'S6E/FUK4H`YUJ3_M:2)\P=6P?K6L
M8TWK5V</+D0``S1TG>M>Z_K7OO:U',`P;#`8^]C(3K:RE__-[&8[V]@A@#88
MHAV":E/;VMC.MK:WS>T`A,#;X/[VML--;G&'V]S8]C:WLZWN<:_[W?".M[SG
M3>]ZV_O=`3!!OO>M;W[[6]_]!OB_!R[P@A/\X`9/.,(7KO"&,_SA#H\XQ"<N
M\8I3_.(2W[?&^QT`!`1@XQ_W^,=!'O"1<US?'A=XROV]\I*/_.,F<$$`9$[S
MF<-\X#77-\U=L',7Q/SG/@]ZS(,N\Z$7G><S'_K,>\[SIB^=Z4B/^M.=7O.F
M6_WJ5,>ZUK?.]:Y[G>L6P'K8OT[VLIO][&CW^M2U_O2V9]WF.X>[W*L^][K;
M_.,RQ_O(\W[WOK_\[X#GN][OGG?_P0L>\(A/O.(7S_C&._[QD(^\Y"=/^<I;
M_O*4/_S@^Z[YRA>>\9W'_.(-O_>7AW[S?M^\YFN>^M%'_O!TIWO=92_[UL]\
M"*5_O>M%S_O>^U[QL5_Z!%PP`0M8H/C'3SX!+$"`Y3?_^="/OO2GW_RH6]WM
M<<^Z]6?/_>![O_O@9SWM]<YZSN?>_*@//.)/__OVN__]\(^__.</?[Y__N_W
MM__@RS]__0/__/07@`)H>2XP!`5(?#,W?,57?-37@`[X@`2P>09(>!-X@`"8
M?X2W?P-H>O^'?XGG?Z%'>A[X@2.8>NRW@2B8@BJX@BS8@B[X@C#H@C*G@,:W
M@,S'?!"8_X,.F(&D]WGEQW\Q&(1".(1$6(1&>(1(F(1**'\]1X,,.`$Z&(74
M1X*-=X)+>(58F(5:N(5<V(61]VV(!X8C)X;F5FYFN&YG6&WJUF[BUH9KB&YG
M&(=BJ'C#EWP,R'Q0*(5Z&(&/9X5>^(>`&(B".(B`"(9S^'=E"(?HMHAO^(9N
MJ(:0N(CQEH;NQF[W!F_M1F[KQW,38(-0F(=[J(>$.(JD6(JF>(KQ=XAA^'&&
M>&YLZ(CN5F[6)HN6B(:7>(NXF(N6"&[X5X<+Z'S`&(HZB(K$6(S&>(R#2(:L
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M59F5`:F5'0F2/^F,[`B6B+EM;*F8:#G_EF<IEF89F8U)EI(IF9-IE(XY;J:G
MC5`HD7+Y@'49FD[)EU3IEWBYBC49F.5(FH(IC3X9DEZ9F+(9;VI9F9=YF[:9
MF[BYF[JYF.F&=T-@AP3PB9\)FJ)YG"L(AU"YG*O)E\SX<N88E?U8AC@YF.P(
MBZZ)G;/YE6K)F][9F]_9F)$)F65Y`N5IGN9YF>B9GIG);GL'E\5)D<@YGQO)
MFLZ)FO=YFM2YEZ08F(FXAJW)E8.YG02*EF<9GN"9F^=)F92YG@M:G@WJH.C)
MH.M)H>39G6HX<@K8F;\8GPU(GR#J?J7YG'GYG/OYGV-HHGYYGRNJA?Y)HH;Y
MD>LXHP5:H[?Y_Y@(BJ`26J$\ZJ`1*J$_"ID6>J$]NJ,4:J#/&``&R)F>Z:%S
M&:)0>GFG"97[.96K*)7XV:)5*H2`F:($B9/:UI':::,-B9DYRIXZ>J%!RIY$
MNJ-NZJ-PVJ9O.J=SBJ09*GPL29Q.^J11VJ>^=Y-7&H<J&JC*R9S0280S29HS
M.J#7V8YD"I:U>:;B*9Y&6J1T>JF8FJF:FJD,^IM*RJ2=N:<?ZJ>DRGA/B9>%
M:JK2F:HE:II>FH)ZV9==ZJBRJ)./6I*1JJ!G*J1`RJ:;^JO`&JS"VJEWFH"=
M^(2BRJ>ENJPRF9\KJHJS2J(EFI4M:JCDJ)<WN970V*B'>:ME>J`)JO^C:\JF
M#3JDPGJNZ)JN;XJD&LJDPYFLRBJ:4&=U86=\]AIV?CJE_+FECD>M&'FH(\JB
M_QJ=!*N5Z7:PW>JM\&BFX9J@O/JPZWH"8ZBN%%NQ%>NI2WJL[\J-\,J'QUAU
M6E>O+G"OQF=_)&M\SF>ORX>R]^J',)F1U%FE)UJ=_`JP`_FJA[J<^HJ:@"J)
M!+F3KZBP\MBPDNJKYAJL8DA\+C"N%MNT3FND=YJQ*]FQTH>$\]IT]7JR6DNR
M*YNR7GN#8$L`-,>R7WN#74NV)1N:L2JP5"J=D^>OJOJB.6NM*AJMZDB+CBJT
MU<BP16NN3$N>1SNL@#<!3UNX;EH$)U`$BKO_GHMKGHV+N(CKIM;&`!KZEL2I
MIU3+@>0'=V4GLEO[N?>:LF8[NF5[ME];NBP+MF&;NJE[MJSKNF?KLA4)D#:;
MJE)IM]7:MM$YM_A)E<J9J#EYMUVIM_;6GMC6L.,9H7X;IX9+E!^7?'CGM)&[
MH].+GI#+N(F;O9"KN-S;O7S0O8K+!XD;OMK+O=E;H5'[EL?WBTW:L3C8I)[Y
MOLU'NO1[NO4KD?2[NJ*KOURKLJW[NO[+OZNKNK"+ML.GD=1*N_WJG#NKN_PY
MK:Z*HJN9J.EHJZY)F`E+O-S&ED1;F;XZH9;:O)B:H4[H;70ZE-7KH-N[PN#;
MPB[\N"S\O44@PRY,_\/=.[[EV[CI6:P;FJ?O2K7S:[H!_+^C>[_V>\1H:[_Y
MN[+^*\0#+,10C+9/',"N"[;\V,`X.\%7.;?_V:7-NKMTVYS`*Y"%B;<:7+Q]
M.YYR^L$B;+%@:`$!@'P!(*>(VW9S_&UY5[XV3,,VS+U]/,,O',B"/,@WO,-@
M.`03@,C'VJ%`')%(',1%7,11_,C\.\E$C+I.7,!,++I5K,D$?,GX"HZT&[`Q
MVYRMZJI9'+</[,!RB[NS>L;4V,$_.J06^K=M++@)",<L:0$2VKVYW)GPN[3C
M2\C$?,-_7,S(/*$A0+D?MZ3"B;E4:\13S,E)[`)*<,W8G,W:?,TFL,U*T/_-
MV[RZUKS-X,S-V#S%D;S$%N#-Y'S-(UNV+@`&UPP&4*`$]&S/]7S/^IS/_(S/
M_FQL2:B?O%N[;HO*=2NHJ[K*-JO%T\B5M@C+&XRC$.K!;$RNS'O+FYK")QP`
MRM?1!("]ZQG'NQS$T,=\2[NX+#S(?_R].8S,+CV]RSQR&;O([1O-E(RZ4ZP$
M`[#3/-W3/OW30/W3)A"V.AW40#W4`IS$H6M\16W4/JT$K+O.3CW55+W32F"$
M-#FBV5JM6.J[N:O*IRJH=EN0>0O1UL:WR%NI1HO1%7N]UZN]<)V><8QW=^A\
M#5J](3"RR`>,-0W'CNNXYANDX-O++UW#A*S,#(#_>[B7E-`<S=(LR4J]LE4]
MV49M`F?;U%4-!0.<OU*\?)1MU::+V9_]V5=MEZ8,LQ`,O-*:HKC;ME<9C65-
MHX4)T;)LT9++UNFZO7^-TG%MOH#=PGB,O_(+C,-WOA,JTLX7JAQKMG6XF4CW
M<2H<N7<]O=PK!'P@!$6`W=;=O=J=W=[=W>"MPS'=S):KC3_<R)",Q.I,U*/=
MW@-@V68KVE2-U#B-TRXPVE`MNN[=WJ6MA*5INPK=K%LL>:4\DS)ZX!KLFQ)=
MM!,-L;A]N'2:TGU,P\8=W11>Q_';?+\(BN\+W1++T1!)W.\L?2C[?)X(D<>'
M='\M;MDK!-BMPXK;W3'^_]TTKMTO_N(52KF*W<.=B-XE;<DWC;+WO=^?#=_V
M*M]3K034C,[L3=J;;`)$3MHH*-"`:I^N3="[*[,T*ZMI>)@_>\8</)EI;,L/
MGJEN_=MPW<(RO.;AV^;6R[`X+-<LZ<A\G=X,.+_/R[XFOGQW_N,.6-/0QW?%
M)W.5:*`N_MTV;N-/D-TO#M/C;8"*/-(^GMZ0O>343`!('N5!#=_.E^E.3<6@
MK-_XG;I0KNE5W=]#B*T)#:U?G:4![K:&V-!D/*8VJN`+WL%K'+AE_J9O#;['
M?,R!;)XSMXW)E^)\![;(U^<D#7TH7M?R.]S)+NET'HQV2'S4/N<ZF.+>5N/@
MW?_=Z,O,0S#3/CSIZJS>L.OI0FW.V0S.Y:SN4-WD11[%D(VRI4[:\$[5]7S-
M^:[OV[SO^1S0#ASP!UVH6N[*.EFKL)R98>ZPE`K"#K_KU'N^*#W8WMOFA3W8
M>;V`>:>&Q+>^4SOHR!WB10SB=>WG.`C,!QRJTQZ1=SCHYJWRW2AS)^#B-D[C
M;\T`,;W8G,FQY`[DY7Z#Z-[34!"71+_RJ1OT0*W9JMO9`0P%_$WJE(W%6*B:
M.1O6_[K0JCV-9FS6!HJ\LPSQP7KF%0_(9._'%Q_((,YWZ8F`8]CQPWGR;R^Z
MPQ?W)J[7,^BU#0C'K)CWSH>`8AD`1?!MN(?M+3D!<QS_XS3OW8BMI$IJN>/>
M\\^NQ/6-]%:]].F\U$W,?)3_TTE]OQ;@WN^.LIL_`%(/@PI<T*N]U0R-T+^+
M\`F;P0E_UD=*T;4,]A&>YBD]]F=_]GD-;CRGA@>,W"Q_Q'FHUV+;UP>H["3>
M?&)8]-0NMG@7`HH[<O@;?8`^?9<+^(=^Z#`-[G&LOCP/^:&.SIU>U7N@Y-),
MZ4LNU4]_Z9\[^CT=^L97[U1=^O/'ZFRKRJPMX`,+"`$A`8*%@X<AB(>&@HF.
MCY"1DI.4E9:))R&9FYHGG)^>H:&=HJ6FIZBIGD4GK*6N1;&RK+*M17RRN+&Z
ML[V^O[]"LD)/0L+%1<9%(2Z$_\XN$P'0%A,6!-<6U-;6!-O=W^#>W!/0!.3>
MU^GJV!::$^#K\>83T8,NU/+Y^O'OT<G_L3*%8,`@P!"#].CAV\>P84-QWR"*
MDVA-R8"+&#-FA"(Q8K>)'T-6U$BRY`".V5*JC)BM&Q23,"\J66DQ9L9!SG+J
MW,FSI\^?SG#F%/IS4:&@.Q<99:24*:&FBA(9BGJIJM6KDSYIVJJU:Z>OGDBI
M&DMV5:NSIV@%G,4+F-NW<(,E>Y*,V#]AQI0)L=<L`+EIU0!+J_;.VKMTW,+)
MT];2H;IHB?=5ZQ:`&J%RD1TWI&<N`,"P!)T-@:90L^G3'BFR7-W20DV;`V:F
M%KF-8O]MU[!-MF99^Z,%$[E+SE0)/#A1H,B3*]=Y'.E0YCR;]FR.L_K41HX:
M3<7*O;M53IBXBN^ZJ;S8LNA5J3U+RY:O5FW;QIU/OQ?>^W?SYJTK3-HT;92=
M8)E?'LV&3F2965`./(Y-YM!"]U`S66&H.=1/`&@E4M!!T1"64(4@+B:2@:JU
MAEMNLJFD8F^VM?1:<!@-YYN)(KT(8VPTP=C<<CSV.)US0";%B)!0.275D4@R
M195W3'+GU9/CG3=*6.E5:8HK9K$%C'SU=0D7,?L!!*9^?.RG'W_Z"3,(`]5H
M0\YE.?4U66;8K)/@8PLQ&*(^%"*FIV-TFI-80O4,5)!!""7_%.B>($YD(HNT
MA60C3"A!NB*-NV4S*8R78MK-C1H-EU)QN>WHXZG1_7C44<=)!YU1UK%J)"+:
M-6FKK5"2-]Z4YEE95GMIK:)6+KWHPJ67;@F3'S+*%*,L7F6FB9^TU%)[`CD$
M#+9--`8UTQ<AA-5Y8#QT)K:H9N?:*6Z(%@R1+F(2'F0HHJ,1:@ZCC*[(VDJ8
M:K.I<*GQRR]M*MGX4G`FS*BB;Z3"=G",*77S;TFFHFHQJJT2N:IU2M$J"7:U
MWBHR)0+E&B4H5*;L*UGM81E*R[X<B^Q\QC@[IA#1UE6FSGBA>6:U0`.]C#;2
M%'1/FRXP$PTTE\VI#C=0PU-N2/A6_XB.:>]>0VA.&W:KZ&%5L]NBIR"-E!L4
MXD:L=J8S?F2C$A.'VJG:!,2=D1(/R]1;PS95?/'%1$FWU%//9<SQK+5>-_+B
M)#MB,BA@\5K>RJD`^_*P7!I+[,QSX<>?LW>%;N9]0?L<].G2GN`"`4PW8T^;
MA$ESF05^Y:D8@W>:JV[8^F1=M81,'T3(04/4^R'8O&/==D?,^V8WQ+8IS+R+
M<L/H0H1S6P"C"7GCV-KS&/G]-^"J$EXXX45ZG%V2C+>?U<GPH]SKY)3[6NPN
MG+]E5\T]&Y-S_ZBCEND"2,`TA4!WX^@&8;)1F,"X*QNKNUK4_-2[.OT)4,D+
MFX<018BN&?\/0!E$C4K:-*(2J0U\>TA1I/1UF[6]S0+=@XD2L*>B>]2-4R]D
MF([&QT/T^7!P0H&5K#JVOHYAQWWN>]S)Z$>ER%'.92]CCRW<XY[-Y<\^=;%9
M__A3%],-L(!@#.,@*#@;=8WK7H&:8`5#:$$VGH8>T'"!\`XUFN(1JA]NQ.#T
M#%3"$SFLCV6;GMEB=,/@K.TC$8JA24P`0[D5;(<]Q!B/TJ<DJE02B4A4XOPD
MYT0I/3&*4IPB_FYQQ5DHJW/\JUE^O"BM+X;QE:A3P5[NM+LR/JU/;9S:!7=I
M-72UD8W:(%X'/6B\<.51CV4C6*8B!CX<C6A=?'2AW%Q@O4Y=CV__,=%4J-J4
M#6S"1'R13$X0?R@K)9ES24C"I,@T28IV3LZ3]D-+L&AQ+)F5\G^BTXL^8<G/
M?E)K$..(&/)P1RX+GO%I!<J'[M;ENV-6K1K"$UX`Z.B7#^+1H?N@FZ5*A+UF
MJO`VK.$-C=XFL>"(JC77<X$BA9.-[IW4C[`!9SA],LXA&3&=BD.G.G$5OUVI
M[)WUNU*67L&>86FIE'>QF191YTI_.I6`_%$=.0IC&,;L1GE7XV4:@8E0#+*1
M'@:98VB$>4=>8C1M?8PFOYJ)-K;Y9GF\<9LCO5D2*-`0@@K:7DGOIB*Z4FRF
MD]R8#T.FN.T<<:<C8Z<IN,+$>+8,+8]=_TL5>6'/^C1+GUV<%NDV^]3.QE(9
M@0L!\MS4&(1F]4%ZBIH:"\I:LWJUEL<,IAP[.%%Z%8\T^!CH69^VS'T!,B4>
MW>/:'.6\4'T$1B]5T&\XU5)'RC4X8(BN=*=+W>E:3'`_A`I./X;8)I6LIYOL
M%3P=:Y:A0K:H1RWES9A%NJ9Z]KV?%8(*YBO+(E1F@63TDRZU5DLU(FB-(LJH
M"+OZD#P29K:U)29I[+7;"@Z,;`J*D`T'&9,4LFUA#Y9(#F$:DTHIM[FY8:0V
M[S8COX(*)F!`3I$&>Z20K8^P.NUN);[[.)0Y,:A#M1PL8('>^W%NO7K)IWOA
M2V3YTM?(]$VR+/^7+(3:14.JI^U(?Y5'4#Z^MJ%D3!>60W1@82;8MA:]5X,+
M^BCF]<5;'^8PI?;50H49B*009.Z*F.L2YU+XQ-"EZ7.,M)T6$S'&,KZ$8B4'
MU'A*4<=15$L]U=LY(1?YT?J1I3'FBV0E5UJ^F&8RI9M<#6<T4,RIS6]K?[G&
MA2J4(5L>LV9B)]:QAK68N%0UO-)J(F^A&:]J-LE'VXQA/KYP&RLEB8@?>39B
M0T\E>`85%`Y'R3]KE[N!_@YX;UP*=^*8Q^:%;,R0*@NE!KF5D.[LD35-Z7)K
M.M/C5K(*(+!I%10!,E-E(`M'S5H)YO>_4CNMJ'/9*-?"EE$>0G!!!E[_6^+5
M2T*@EK5O+26[E*8YUW45I'!9`N<1.^P>V`NVG5T*D68F^R(ICA4YFPV)PT;;
M$HIE;,I47B4L11:4//Z%YM2KQ7S^+-QAE/2DU5WI="]9W?1E][KGR^ZB!]W(
MS!@$[!BS0'TG=,JHS6"J%<XG:@A\H@0W.*RG'L(2L:3A_KF>L6W"D1(N3Z.9
MVC#MMD<<&$DC)1Q?D<>3K03S%?&2E##YR=]7XVH3VDHO1_2AJSC*RL;%VUL$
M-\Y/]W-S`_W<21:ZY(<^],E/GO)*%CJEMX"A$SAYN`!R^BX7^J[5BGZK^2+U
M;N$X@5:'QH-AO:-N5;W1D'@K[&\?>X<CQ&:S_W>DXLW0^-TZ:M+<$R#NJ3$!
MWJ#`_.8[__G,A]&R/=;G%^\=*X,6!;5;/OA71-:*Z<W?S40WY,6GB=SE1G*F
MUY]YS%^>Z$&G;PDH/_D2&'W)[!Z$)S`<+HB\MLI4=QI<IT&$(5$$\7H397!^
M02B#0G6'Q"(*TG`.IR(>EWL7=H$:IA&,U`W-H`/!85<0)'P8`0:W5G$9U@P(
MH&+(]6Q^=GU506/Q@PK;!WCRY')4!!_;]F.S@'@V)T#F5RV2]G@]!W]`9W2:
M1W_P-W]*2'1+.%_SIP)-.']&-G\0D'028E5PY7_T9FH#.(`!N"?`(TP'B(!@
MMF`?$H!>MPT!@``IA?\],\)68D<BO!8P'*8$'[&&`<!V$$<24,"&N8=\+=02
MW\)GAR!]EN2"5U%CYQ$YXZ4>@V>#,#-SW&9*=&$F^0%5YN=S/`=YE>=^G7AY
M5`B%HE@"2VA_4$B*I[ANI&A_I,ANI"A?J&B*UU(9)N(@#$5OI-886^:%[/*%
MZ:`0'#2&`Y&`884HK?<U]S)[9W6!=VAK;R<]</B,:\--T?0-OQ:!+L!6%F<3
M,^0?VQ@;68A(>U9.(;""SH:(D3!H[C2#COA8E6,6DHA4R)!%F,59Y1=NCM=X
M[%>$F!=_1UB*H@@!`"F0JJB$5(B*`GF0HRB%!_F$*B!:N16(IG4[J#9KOGC_
MD8`"1V(U+UE7C$,P5?:BC!C5+R)A:[?60AYUDFDS-AY1<9=A8AIQ/=:34K0(
MB-+#.G9W'8U@B.C(=]/F=^SX*]V78STVB6#"13]SCS^8%^EF9.A6:48(?T?H
MBJ/HA*YHBEAID*MHD*?(BEK)BET9BUL)EIFP+69Y1F@9:N:BA?Z&B\DCDJMG
M=:Z'@`Q0/![YD1]9&H<!EVX42+Z1@A+&>Q28&WM@5P[G>VJU#7!V>]IC4C")
M$1S1AO=@@A3Q+>GC".:(B"FW6#_5B"P32D6E"SAHE*#37C>WE$&3CZH9>?ZH
M;O57E529D`HIEF-9D&,IFV.9FP2)F[+I>8`1>L\T_Y'X9D8%4EH8>9S8H)$=
M9"AC6%MWZ36R=U$-UCS6<)*W]H8?>#W&1YTA]8UV"$%O]Y@7$7TA!D%H!HB7
M@I-XAP@\&6T"`5[:%Y^-Q7V64UZ'-DI(=3.C@Y2H^5E`MX_R%95$*)6BZ(16
M"857B957>8H)Z8JXN8H/NI4-VHJKV)4/&@`*)&_<.9%/YU\4B9R_^(420@YS
M27!U:9?%PR%X&9()-YT/6)W>&&$3IGN4TH871B*SL9@Q^G$PD1(VZE*(F1)/
M87W8<0+M*6-])S^>B1[UF6BCR6VI5(^<U9]`.(3C)@3L9J5'&'\*694-R95;
M&9:Y.:9D6J9C&J$5>D`*]/\?^%6<;AHQ^X9OH@>BTRDH8'40!,&<S0E[*7I;
MLI>,8^:7,"IV$4:+MQ%<$RB'$$AQQF6>$3)WL'%2;8B>+)0XD;"3)H5)6K%$
MD#.?Z0$L+Y=CDS@,-3>E5.J?2>:4C>>:G=B)IAB03JB$"8J@NGFF9GJKN"JA
MM4D@YO";U(A`!"5E`+9O=$I[RHEU(;`%8VBB6G=;*\J`TKE;U"FC/II2"J.-
M-EJ-S,AA(C:!R\6C,:D2D^I($$8[1Z1W1OJ!F;0KC,5R2SI/H&F#9Y$Y\I@F
MF76J_FFE0VAYG\BE!AJ+#YJ0J8BFN5JP!GNK1<"FFE`9X4AZ"`0I7L6+Q=J+
M5L?_+5BWK"9*6\U:4=$)J,O(:]MPDM1ZJ";EJ#>ZJ!,!?(3:2.`ZGBOB+7'W
MJVJ#/B1SI$X2'O!):.^*"DU:@T5IE$=IJOAZ?H]WI?IX>9HG=*5(E:V(H*EX
ML%X)M5)[L`*2H2'09&Z2H1+D5K<TIQ-;K`DQ6\*(L00Q!"?:I]WRK%\3K2-)
M7"9;K2O[C912K1K5G3GJ2-[ZK2T[0^*:4D`*>KZ1-()FLRCW"$DJ/^3E,JP@
MFL("I4#V;3Z(FNAGM)DVE:WIB0`YFYK[E10ZM9[[N6-9!(9Q+;1S5ZU!0@>B
MB[>#NE_;NHA!HD%!ME]FML/S:G9YC"')MGD$4A#AK:R3_[=[J!&5$H?3^E:U
MH;+BVK(7$;<R&G<"@U)Z!PGI>C8O&!Z*^%.):Y^@2DK@UR4WLS.:-;1,::6<
M^'B6&W]>>I4.2JL5RHH3"KKP&[_,T!E'@P[X=57ZA;]0<U"N"[8#<K%Z>H!X
M:A!GJW6X>T>&4:<H&V$O^V&/6K)O&Z3,\VO`*X*1^G`IA0!_BX6WX3HH1[C6
MVZZ(&U[UH[@U.*IY83/W&KD_.+F4NZH$*J#W1Y!+*+":^[3QF\,ZO)4T\&ZK
M`U`?,2>G*Y%;:U#_UK]T*I<7NZQ8AW6T*TQ]FJ('C(Q\&3:]A5*FVRG::+)T
MR)UUR(',*YXV8;KCRE>,X6;9$/^]ALN3WY6SF[2S1(EH,(.?,[,_.`-`0PO#
MFXAN[2>@[>>E"[F@.SS(A%RF!]1I$.DT`37$%*):??)?$HO$QQ2V`TP0RKJG
MM%N78(:B<H3`G%'%5FR\+,&\<X-"HI*H)M0O-M*MI&S!<_NR?DNN+YK&@ZNN
MZHAC1"D*Z^%C7<*#XDNT>UR^2=NJZA:*I8B0R,RY!%O(S#RF-+"*-!#-SQS-
M/1#-\_<.?E$[&:JU4',.O:88PZEZDOQ0^0*[>4JVKS='4!S%:LNBH`R&7D?*
M#1Q<=#MQB[J8I`RIY(H]90PQ-SFSM4R]G0K'-`A%HTJJW[9*DKN/Z>?"2(B^
M?>RT7+G_OEE)FU';S!A-BL]<`M4LS1W=T=0LS240S4T6`"5-6AHZ:XR<6J8V
MSJZK*"7*Q'59MAMBMNP,:PJANWUY=AR8/8,)&Q96SQ+!31M%P3;JHSR*`.8)
MMRHERT)\&VKL.-+G=[@\E%@B'_%H>,``N?BZFJEJOL3\FJ&XFQ/]I9R;T6CM
MS",=TFLMS6[=T1S-UJ-1`@E+.TN73!#XS5[KT@[USH\!NTN,SIH\T\UZT]&I
MT\F#=K;GAMFSQ5Q\Q:*LF(V*<:;KRB0Q0PX7F-?#<?^L$E&="'Q@B/1#T$Z*
M;:)T5%IM'X@W)DKY:$T)>5%Y?ZSYA#4LT4^[H`F:ULULS30`_]?5_-N]'=R]
M/=(?'=S`+=P?K0*>85]G9KI-%Q%WC48$QM<-QADANAFL%M@8FV!/3-CL?(QY
M>3S+"$A@[-/4@R)]R]AQY2C>B6MAG&PDF+?]K#<:BF&TTSBM,-78^YF@"G-T
M3%GU@4^0RY^9J',N/,Q%*Y5/Z*!?RJ#(K(JR*9`2KMN>.\UM#=(;+=QN_=8A
M;=P=CMS`W0,/:5_^X0P?1M2D)1*_*C5M2=V\@T=\>1@C*K:"O:PVK<GK_&I3
MS*([+4A9#(T?R-0;A;+6:%Q'O2*6G1&2J5R2R=D",R-%ZCB,-=5P[(Z/2'@Z
MB"9:SL*0QG-\?+G#;'0*.HJX*=$4+?_A8DKA4CO-&X[A&-[AQ1WBR.WAQOW;
M=M[;/5#-)>!YEX&"IFNGM';&D8PO?NWB.2UP-7Z`!$S`-FW8X2W>#H778)S%
M#^=Q>+-\T7?I4'#IG+[IG@XWFW[9,DK*V7ABF+WD37[9G]Y\RZ?I+P%]KTZ>
M9\.D\I1HM="]7G(,7-W57_WE?HR$`ZF0$^ZTO&FFRZSF93K-;\[;;0[G'NWL
M(9[GTB[M>$[M>8[GI&A?4G%767R_J'M5@PYP_+4G<`G*Y=X@=DH-8ICH`DS3
MC>[H'5OH`FB\:H-QUD1\REL2>T`2^PXP2]ZW8IP1W>JH/YKOX`H%_'V?BI;K
MH(-*27F:!=[_Z^WVZTGXKPQ.T>U;T;6*[+FJ["%]W!L^YQY^W-%>Y]-N[7A>
M[==N[=).BABR%XV`/0OD(-L"W?X7[N0^[@9FK,J)IXENM@-GT[;[W8^.V+QS
MLF_;P$AM\!\W'&*WLO-]<34DF?>0Y$RO$410.2Z7@ZF-1;H.0`3NVD\Y:3L'
MT;+MC\&NBFJ?FQ!^T1Q?L-;<`\3-UA;.X70NYR!NYRO/\M6N\M/N]WROW$)0
M`GO!!BEF@2-4\Y#-M6.F6_*>)U4L[Y(Q^;`3/,/T\S.=@`6<HK%7]/.PN^3-
MY)>2M_I\]>#8P)D=\`-@`G&;V8ED^B<&!4_`L]Q;>,BR7IG5VN_U_Y]0&=:L
MN;ZPZI5I#J%N__:XRN;/O.PCO?S/CO?//O)W'OV`K_<G7_W6/^U[KHK$(!!L
M&$?/S732+:PX7Y$"QA`7Y?B/<=V2#R(>`KL^+]@76SR9O_E1W+$Z+W5R:.]3
M;[JE#P@#@H.$A8:'2A:*BQ8NCBZ,AY(#D)"*CXN.%E"3G9Z?AD0G1:.C1:=\
MIZJKK*VJ0D)/L$5"M+2UL+FZN[R]OK]"*KHJQ,40*L?!Q<C$)<PJSA#.)=(E
MUM'7TMK7W-W>W^#AXMXT)33GYSWIYR7J[>LTZO'H\NKV/?CY^?'Z_?W\_@(*
M],<-FI`20DX$".!H(:0)%B!"),"(`$4+%_\I:MQHL:/'CR!#BNR(L>,$CR<M
MI@2Y\F3*EB9CNHQ)8.7(FS(I3I#H8D*`(4,",!A*M.A0H42',`"Z="G0IQ.`
M[G2Y$Z?5FXLT8E1$L1*C2Y:^6E`"JJQ90DHN,L+$B"PH*&L;:0*[Z:S=LJ)(
MF2J2RI7?5K%FX;H%K+!A7\*$#0L6[!BS8XZ)068V[5AE:-2R6:N6>9SGSZ#!
ME1O];AX]<Z;KP;L'\)\]?JWO#9Q->R`-S(IG*5S(T,60GHPFGMS*\:IQK#=?
MQL2H7*5%YC4CUJ0)4V+)Z=AM'@^Y,V(CGT&#&AU/%.E0I4_1IQ\R=:KS[<>W
M<IU_J=%7MF(OF=C_K\1$__Y@*!'@@`+VM]^!_B&HH($*UI=?6(TD6*"$`?H7
M%B9S,<*?#A,>:""#_/E'Q!<CEE@BB2B>",:*8!!QREY_Q2@++#/:P@MAA^6(
M&&.P)*:,8T`N8\PTT!0I#69';F8-,MUP%MJ34(8CSSSN3&E::E12B8^66=8F
MFY=@@KE$#]<H1DH(O+G@D)H]0>2=?,]IQ=%U\(5$)W=QZO1<<U5--UQ*TDF'
MW:`ON1<H3.^A1%-V?T8T@6^^A6<>>>4U==YYZZ777I]U7I45<?1!:%]^8&4X
M:JGXB?II?FZ2ZNJKL*)ZZH-BN=DJ(P&<H.NNO/;*JRI/Q!AC8+G8:*,N_SCJ
MJ*PR/O:X3)"-228M-45"8YDVUFZ6K9)1=MOM:/:T4QH\JV%96VQAIJONF.SV
MT.X2\,+K[IA+YB),"`DY]*A0#+6Z$7&==GIG22L17-R>>A+L77<,FR212@LS
M-Y-$,_DYDDU_4@QI>.)1:I12EZ+7U'J;3APP3G"">I^#]&7RB*HNRY6?G!6I
MG%'+<<6J<WTP0VB)6E^I15$`(?BJEZ[")GU*+C4.MNS3O_A8#+/&"!.DM,\8
M:61FN''&I+=@@U:..617B<[9ZTSYVFNQ`=0EF.BJF\^8^+P[K[MXLQNOO'KG
MG8\U"9T`RVX!/*JF==;]>_#)),G9^)W8T3F<1_^"5NQ2H-%=CG#F.D6,N*.#
MYA3Z=!'UY,AO''=,'LB4JI>Z5.V-SCA(\J4,M%<XNVSJ6A?"#"O0*>\L_/"S
M[JR6"T670HHK?2E-RXRQ&`OU](LY*V1BTD(@Q-5!$ID99UYKQNWX89=O#=KT
MH-]EENM[&;?<<MO-=]][UV]__77332]CJZ#)4%#`<=.<9H<5KI`N<A<13IP`
M1J<WY4DZ#%L8YX0#.L35Q((0Q)-,(@:IA7!,**SSV,=&YA1-;4IV!"3)?+12
MO!:*97<KRT3+:!:\VM6,>#C,H0WI<Q'DZ<5YSG/:C:BG+.PI@S&)T5[5A!09
MQT2#29;9&C:V8;XJ=H/_'62RDFE*P[;TP>9+LWD?_&KSKKWE[7YH3".\<)!&
M=6#F?&.C1D("B#D#0BZ%E%L.YA)7N45]1!&3\]P$/>>H#/[I@@U[F*+NN#`V
M!84A/_F)ZBAEGA""S'50B9UV\%@[H`%/>+Z#X0MS=\,5QI!EO\LA##\9M/P@
M#15`7!KTH$=$(F)O&52[WF.:@2UK%:DS2R(?,*UH/G2\0XMG8YO:S"5&U[!F
MC'4;"/W0."\U6I.-:\2!-K6YA&UV$YMCXD>9$%(L_SW,8(Q;H>+L1)S)-6HB
MH"+)Y"CW.04>RG(Z.6?F%O8Y/!&,*HV()&\B"92?,&!2(AP/)F'GGDURDH<[
M_W05?F(ERD[FCF:>E*@.=U;1B+9R$2'@"Q!K482FX:*64)L:+F^YR\DXL1G/
M(I+7ME$-)Q'36^@S6]F\N,RUN4\?S80FW<Y83?L5U9KQXB8;E[K-IBKUF]Y4
MJC=I("]WJ.`6"C$=<+RSP#P9IX%YXN,!X1E!6TD08!J!YYX\1S'01<Q/_'0.
MXBAF$[0VCB=J&J@')2FRA*YN9"0[H4,)6,/";E16J5S5S$KIT<-JU(6*]6C1
ME$:L6Q`F62@US$J)D<NL7:][E*EI9Z[E#9O>5&SL.QMJTD:NM:'K?4$-4[L$
MHK?Y'16I3`5G4[\)U:7RUJG`E>HV>Q!5;I)I-[^)8/]&!&9/BP62K-'9)U<%
M:;")Q`E0!9OKFQKV1YYH;I\,TX[)+O>H1X;@O`.5E%__*C*2L:<J@R7LS5CX
M6./I3E4T!!Y&(\M*Q^HL+#=K+'TGZQ=B"099F=5L+I%XRV@%R:7.^.77MH:D
M\5'QM)X9#9;(QM/6KN^U_O@B_.P63?V=$:EJC&HVNPE5%@>WM\&-\8NE&LYR
M%,$AOV%K/.UJI[%JY6%`EL\YRSK=QS7.JWJJ)W3F&KK2"><EA51D'IVSE9WD
M];Q8YLT'U\O>$C(4OGC\8T8S>LKAL6FBBV6L16?XJOX>MJ,["\`J#'S@76`V
MP;NX7H^H]F`F4L:72JH&%`/_+3X,BTV9.64MEMHG$+=!L\3R(RJ*KYE;%^]6
MQIC.M*:;2EPVYN-,)SAHX=KTUM'=<2;,D:"2*0C>MB9NDZ\6U`4[9T&R*O<Z
MWHWN!0')79$`],I8SC)!+\7ECV7JO;T.<U=M*#3B?1)WQ<NO6.CKYE#YEZ(0
MJG;N<K6T8PT1S[Q@J4IS.9EG]%FF%)9IF4QK:'&,#1X<3N:5LEBN9^X#J(^>
MF]^&JN_:IMB;E@9NP#=-\((3O%V!VT*HM4SJ6EO,N3Y&-7G;$V6X?NZMT,'U
MFR(&R"IOER1TG*?#,KAK5UME)[S!LJZ$?="^%MM2F(R*)I6MPOV2LLP?Y9DE
M?$?*__FNV;`RO/8+8=9?`2Z"V^`^C+C'S=GL>3:T@+Z,^"[<;M2FPQQ=3)]K
M5;-U,.:;MOS&V[XG;3_=,M7%,#:XVM?^8A9?52^BCB2D'D5D\*8U<_5T]2(N
MGN1VWITE7<6NCMM:.0L,H21@G34]'67=^$9GH,D[0;#]9]"7$WNAR'8/S1<X
M;:`'O;$Y:R$+Z<ML-M=7Z/>9B[9=A?0[@UN7#";WTUN*[B=:!AO#K'IHW*'A
M>*MFT5X/4VR]--N[^9O2+6ZQB@?.=ADOH.#/QT'TIR_]YR_`^KZ%@"HD'X+S
M"!1U#]&[=E?M:I-3-]6MJKM:Z[I6P:??NCH)X.)ZC/>*V?\)Y40[[Q-.P(9@
M'S3N(;1>EX0IF60R-&=*I+=ZC@4)S59Z-I-FJ:<S"CAT/-=?-^,"@I-T4K-2
M#%8U+O4LE.$]4+0MFB%:NB<:'$8F\X`:7,=,]A94CO9U_C!-9+<WOH5-Q=5\
M;!=]U:=-U$=]/2A]TK<#"T"$VV2$VT1.H[`%W4=Y'C1W5A9>)<-XF\)/4<9X
MU!5=AB1K<@)_V;%XVB5_:^5'R5%QD",Q`<4`*K=RD_=_ED="F5(R*)1"._:`
MS@8K.W=#`88S9#9FGX=ZNB,\K(2!M;2!>K9TN^1G$H8-3/(UFC%H)Q@.\K9%
M&G8E+OA%L+4E0D4;\E.#:'2#RJ?_@]MD?=?G@T[U@]5'BD-8A*1(A*[(BJ_X
MBMJT`]Q$`R2E*TQX%$>Q5U'A&W3WBU0H?NW1<%=(>$-&:X)T5Q@%,9U#9?UT
M5^AT1W*E:MP!2.9U7D60/).')J+VAH!E0@VU>:2W8\\&@1,X*M*V*N/(43SW
M9BZ``#F76(HP"M,C;DC$8!\8&;M$+8!V>[@1:&\4B:(1#^/2>^VC:(TF@])4
M8F/GB?]V::(XBJDHA#QHBA39BMAGA-?W?$0(BQX9BQ_)BMK4`]IW"@K'A+G8
M??P"?KW8DJ@C<U%8,J;#'FUB.K^X:F_UC`A$?\[(%?HD.7DDC1M4=QYG90MQ
M7BO'?=OH_X8OUUZ!17'BZ',62"KG2"JKQ(>MY&9>X0@(@`#[\3(O4SP8`I8N
M8`)EB0`Z``:^<X[X@AA$T`!O20120P1T29<LU42Z]&?IIF[<8()]*9#=D$5P
M-"Z_5Y@BIHD**28-Z9"A*'#--WW8)X22R8.DN)&P.(0X`)*:&9*;&8NNV%3:
MHPI;H!<G&6HJF3H;\SJ^P5>1\I(T.15S9Y/$2$&*A'[K!!_#(4&)@C"`,H>M
M%EZ>LYI(60I*N8TJR91<=DG@&(X'V(`V!XB08`)00!9*H`33&5F?PDHW0Q:<
M(`C=R0G?.0C@"1>*X!8#$)[B>9[>.0`!D'/6^9[7V3)MV0L/L/\&]KD&`_`%
MB5$"X'F>#^!TY@9U4A=%Y/-&MR=,57<:!$DF+'AU\\9:P>=,7S=;930_C)E4
M3W6#N?68DBF1I?BAEHE]U]>1G<F9)NJ**&JB"T`#VC.:HGD"H[D%N;A7C_04
M?'5LK<E7#`=^KSEJ(?=Q2\9C\]=C/LE56J@H/X9D:56,A,031PDCQHEER)F<
M7O9E8!:5II>=J(2='(4(:Z9?-S<6=^&=]F&>9M&>$=6=XMF`\VDOL$`$A0`%
MQ5`"A?``^@A:?/F/@!D:[%`.\H`:@.IA+>A3SJ0EFQAI\7);9"=CS+>#%VF1
M/ABB(MJ#&/F*K'BB1;@"F+H#.Z"IG`K_BYSZJ41(DJ'Y`B:Y"C`::I7R?9'T
M?]^G%.9QHSR:7*@S:D2V?H9$AL>A5@LD90?#A8'2I$U:7D1#C[<8I>>EBTU9
MI5;Z<&$&4::$<VT!!=1:K><YGM:JIH90K=1ZK=SZK29`*DJP!V-*"8Y@IF4!
MCZ2BK0.0"&(A9\Y"-86P!G-:I].RB-0R3J6UI]_@15?"18IVB8G)B6*G/\?G
MD(X)BFI7BA[:5)29BI-:F2,:DIOJD2OPJ1>+L:$:JD6HL9KZL0MPL0L@1S%R
MDMUG%`C5E#_1FJ_)DE%(2+MV0(DBI$JZD[K*DR;1I+(90&YR9<9:"\49I53Z
MC5*1>9HGCA#5_VQ:L3L7@:[E:A=[P%CL:A90H`E.^PEHBC/L2IX6$`#5:9U?
M\`!<$+9C*[9<8`A<P`5B6Z?J%H(!26CL!IC&-+<J6"X/BICI0!O#-QOTDS\U
M6&EIEZ$1V:&$^Z@?:HH3NY$@>:DE"K*.&[+7MP*>*KFLZ+@?>[&8VZF:>[&D
M6@004)*GH'VE*:,H611(L04,@+K)*4FO2E"R>:MD56I#*F:]*8U"F4?N%)QT
MYV2.0%=J4C1VAJS)>K)^A7GLD7D0IVS0&J:^<[5/:Q;AFA_."PJ/,+V3D+5B
MP:[N*J;/:PC_F:]]&9!QRZ_7L$Q4@G4"BV\#&Q"=Z(EFUY@Y"'T-._^90$BI
ME,J1C'NIJXBICVNY(7NY(=NI__N_DMNIDHNY"&S`F[L".$`-GUN2+_#`JQ"C
MI"NC1%'!J(O!J9O!JIL42,&ZK%NCM^J3B8.D0WJ[)AP?X,6[=/>ZUM$0N2(+
MG)4032BTQ0N'3QD[41E@HZ<R,B,6UMN]G1"]8M&5`X4`8+"M(9"6`:`#(0`&
M78D`6PL&:;G$25P(:/I)6[L(07P7#S`-!>&7Y%N^Q[2"BR:HAHJ8ZYL_QJ>H
M?VMV@FMPD4F1#BN1](N1U5>BFDF$_0NYD^O'`$RY!_R_!@S("GS`!GS`BKP`
MI/K`G[L]H&NJ17"2&%S)EFS)E%0>!14>,]G_I'>'3IQT,GCU&S;)3Z5,,4^Z
M9[6PC2O'A,3K,<KI7H+EF^E46)_4%3VC(+J,((A@EN'ZRQ:P'\$LS+\LS,)C
M`H:@`YI0"5T9`E)<"$JP<UW)KNJ:']K+Q4+,MG\YQN10D&@SJ&^3+GO+OFU\
MH8$;OQQ:D15)Q]9GJ1N9QQ,KJO$\HBDJSQT9R)A+P/JLR/S<S_[\S_S<P(X\
MT)_KN=KW`J-IJA1\R0Q=P>,1JR!#4"L+C/UT'8@WNP*S'=[105#(5L`94$3S
M!-"3C<&V*Z3YR@K%K,MYI5AJ.PB8"0B@*FBF)C&-S8;0<]C90SN#S-!,EE'\
MS&BQ"`@0``A@"-@+_S1;7)[93`A?S,V!*2ZOL5I;!WQPHY!\X\9O;&GG+,<6
M":*1JHH42XL>.<_Q+*IF;:+X/,""?+D`W=9NS<^,[,`$[<B>6]>F>M<,700O
M@-`-K;H=G+J6TG*2PI+(:'>TL\-8T<("U;O"2IN_6S0BK0HE'7FX*$),<6PP
M.7..=S(W=\N74-,:0B"B/2%7^Q_[H08'@MH&@MHFP-IJ$,U;FA\\30@C$-,[
M]S+HZJ[OB);LBKU?H<MAX;3]B9Z',-P#T-2Y%XF".;=8!'SA'*'W)E0TB&*^
M5780R:%!"(0/^\[OO+AZ7-;V7+E\O,"(_-;F?=[GS<ASO=Z?&\%WK=>3#/\!
M=SW?>HW0?,W7I#L4%DP>$CW8/)N3@/<1FZUL$-$0>95<0#9!D0/#E"UY#KX\
MV_?7QH;91LO2+<U?/MP(MMT62VT79KG3A@#%,YW;<M',1AVFXDH(4-``#T`#
M+=[B+DX#7U`(7Q#C#]`$+<ZO@OFG]>:"PK>)DF9\R+=&6[VA<CS'#\O.BLO=
M8TVB%8NQE9NIFYO(`9RQ^8S>6.[6.0#0<,"B<LW>CNS>\JW76_#>>PW?9I[0
M#KW!'M/?*YM<R)B;Q8'"B.THJZEE5VAQM&8X1XF4VNC@>R%Y$@YSQW:\)6.`
M![A#4_G9R\R]'5X6T;L[MQ+,AE#;7;D[N<V52ZS_`]0LC_)AIG)*H&_T`#0.
MF#M^OH**ON82$&WS:"8&:8R)@]==Y)HVQY`*F8EKN'J\F7TLR*%:P,!>Y>2=
MY<2NR#FPY5N^`L>^[)*[Y7&]#67PY7,=P6$^WV-^YGM-WV>>WQL\Z$?Q2!(]
M%<FX2:",V"P14'FE+XV-<?O2YY.7E+PBX85NI7+(*4CK*CXG'S2]<UW\Z(-`
MQ+^MR\(]`@1BS(XN"$HPU#K@Q$6-Q0%?G?[QM?UATX-P$.#0`/,:1QCFI^?#
M82G885VGQM"]+@QYL).6L.A<ZW4\F1<)HB&ZOXD+DIX:DOV;UOXLP`E<[.:-
M[,J^[,>N[#W?\\S.\\G._\#X``%E@/32#N;R?>UZ+=]BKNWSS=?=;L%6CRG\
MLE?M"5^R:^X:#1'@GB8_*GZ-E.[Y-]G:2+P&1>&9?>C.VIP"QEB[70G6V:W=
M^I[."Y]Z/YU\O_?5.9V1/BHN,+5F80FY[<3]%].]_17C*@G;"^H6#P[>2TS+
MS>.(=OG/O<;]8+`F3]V_]5N.6L>1Z?(22Y'?_8HSW^N#O-9J[>LZ_];)[O-"
M+_L^7_O*'@2W3_1!/R;1;@TD&>T00`-)/^T/O-=0?^U-[][UC>9DOL&3K-_Y
MO1":'$GB;D&)TAQT_JR=PR8#U1.')X7K;CAF?_9^GJP@Q/:&?NC,2<L!TV:E
MI/\61)TA9+D(TFD(VPN(BD#X;Q'%4PP(;&`(+BY0`XB(`1:,C$J)D(A0!(Z0
M4$(EF9J:$&N17YNAHJ,TF3V;-*6I/:FKKC2LL3VSM+6VM[BY/4NS2[R^OKO`
MP\3%2SC(Q\K(S,W."\XXT-+,T-/(UMG4"]S2W#L+X.#AY.(+*^?IZ"OK[>KL
M[.?P\_3U]O?P.>PY^OS\*_[Z"1P8L"#`@OX6S"I1ID<9AB4@0"@SL:+$BQ)?
M0-"84:/'BQZ+?-2X94N1DEL8H"S)H&4`ET,"#)DPP4+-FY1J$MC)DZ>%GD"#
M"AU*=.<$`C<GN`C`E.F00DJCVIQ*DRK5"4^;!@C!M6O_5P8R90X92Q;KS+-8
M::I=B_1HT;=%&5%J1/<GW;F-$.AU49<1WT:/(D'YV]=NX<.%`T=:S'B`(#9?
M!+/1$:"0A4.0$-15O!@*X$B84F42G2DR)%"H2HT*!6M5"5BO3[5N'8OV+%BZ
M<.O:;>N7,&'&@A.+=BR:\>/;JF&CMHU<-G/0RTD'AXZZ.GG8X]W;L0.?]^_[
MPB/T=W"\^?/H<^"8!8$6!(@/+6($N;'^"Y$?Y[_@.')E2I,HJ11"2V"-E=1-
M5%$"EUMP-5@4@C6YD!534+D@U8%60>B7A$UYY:%39(5H5EIHH;6636X=Q:"#
M;S6"5U\OUN4"`@$0H@04-^:(_R..C2GAXX]`!BDDD'01=EEC2"8"A2`Z8):(
M$GLULM@B='$6B1*?)8G(`YD\L!@J7Z"FB6JRL:)**6;2IF9MN^FF&V^Y_.*;
MG,(%=]PRQ2'W#'/6[)G<=-](!Z@YZY!3Z'?RS),H>(SF$UYYZ44JZ:3ZS/)0
M0Y?"5Q%%&''4D7T;Y==I1A>MI!*`_H%5((<R68@3(T?]%)2L1-'*8HL0%K*4
MA!5>F*&&24VX%5<G%,L53&*-)>%9(39KX%HXJ8C4M+<*A1AB"C8RHUY6:NGM
MMXB8H&V5`QQB;F/G'O*%7@@XB8@2EC7B[@":D3NO)%EJR64FBZGVV@"@H-E*
M*[(1[/\*FV_BDC"<<,Y9Y\.^,*/,,GH>UV<SU_PIS3C.C1/=Q]*M,,ZA\%S'
M3G<E-ZKRH_I`2AY!`;E,Z7AGG%'0$3G@S(]"M<"G*:?TC>312/.1:O1&IIY4
MDM(`OM1J3$]5A2"UU5;=8*PW%?*4A5Q?:&&&8"NE=8?$&CL@B$\YZZQ8`9@U
M$[0V3<O@BE6[B)B1=ELP8PCM@NLWN";HBG=?)BR&99&"6WDX7?-26=B\BW?+
MV+XE>`+)OC0@\D4KKPULL)D(U[*P+`SKXO`NP$$\G#,45^QG<AI/8TUT@G+,
MW:#<=6=R=MJAO/+O\[0L_'A!S&P\S37S8W/R*.30?/-+P#'_B_28,C21]4`7
M;;2H_.G7*=,,W+<TJBF%!;6K4B-EE]7LQ_5B5+S"#VS85(VM%;$A%'O"V>:7
MV&RR;(/:L]22()K(S2@(;)!<KL5`O0WB7G^+("3$-;C"%"X2XD*,XOK2.,3,
MRS.5\!;E3).(S='`<B:<#9MN4SK2M1`7O$!=ZE17#.*X#CG=4`[&EE,[;@#J
M&^*XG74.E0[JM..(P%M9RP#"LN/-3&?H.0,4:V8S%-3L"#5#@16WJ(\82L\A
M#+E4#^13'U#91U1E+)JG)"(2E!2!:2L9$-3:%I6D3(5:MG)0'MOG$_7!KVLV
M^=K\HC455C6%`5W1W_[.IC:R)&LL_P5BP/_2`BT_4FUN")26M(S2P+K$*"]@
M&$&0(!@N$YCRE*@T98]224'!"8YPB\G@8398EPX>!G+Y2M((([$&&GA)<[,)
MYFUP,[H7,BP8R*3AZIH1,1SDZ889NX8VD@.R0#DG4+D+A\=VIYU$>3.)*AN>
M>&3F1./9#(M4K&(ZI7@&*ZYSB^VT8@X4(CWIT2!3%"D#I[)'GZ.EL7O[T=Y&
MF"8^EI@J)D^S8_H4Q#ZZ\=$G69.:JU`4MFSM))!,\5#93O#&(AP+;8Z$Y!`(
M1%("A4A"!%2+'^.VR4U2+8%Y@Q&VM(6`$("!#2%XPA=(F<%L&68NDAM`3V74
MP`M.\%JT9/]<)'3@P2OE<@!*"%,D*)>YJ9[&-J)3F#%-ASHZ*7.9R9#8#748
M38UAPX?7M";(LLDQ(FH''XL")Q,=Q<1^D+.<>/4'%=')SG9>,8OOU.(6M>A7
M%*R`%W"``R^JIT_KR6>-_4RC0/O)J8*2SU3EBPE-NI92AE[TH:#-%H(J^A.'
M7M("",W?(O/742%T=$"25)LD2TI;F)0%6BI5D29WN]NVU.0P,<++)_6&`!V`
M8:=(`F$G20D%62*.+RXP`12F"X5%&#41%,31C3+H`EH29DJ(Z4PNE1``3%AN
M2R4PDY:^P,(58G6KM(AA5[OZU6&PSIEC70[LM)'#Y6P3'-[HX5K_33;$MY(L
MKG']SA+GNL1_'*0\=\UKI-;)3KY2V)T8+BP5,2S8YBW@%XEU"!@O]5CO`0VR
M^Y2LBH504/'!\52KFL#3)CHUTX:V??2+U4MMC%&N=+0(''VC$(;\QBW`=K8C
MK2V!4J*2DC8+MVQ)7[1\*S<5]457G>Q+4"UAI.BJX91J*)*6</07+(<0$7RY
M+B+`8('K*C>I\HJ$XS@H&+U9@#.#,>_E!L:%)+&WF/#M32]F6-]F,A._8[V8
M?A?-0[3Z<&.#TB:@#DPR`\OU'N+\AX3+B3,HYF!YZ6Q>%BTL6`W#\]2%[;"&
M/SR]Z(D84_F42/8@BT:-\',B:,R(THI\_Y*.LJ1`89&)U"CZTKK=&"@Y+O9;
M:I+1$PS9M4)^-I%/HN1J,YG))BW+VZ!\(-RR-,J_9:!P8_I4QN"M6W-V@9;V
M`-T-Z8TS:39<FR$1.:?64LZ%X8MX"X%G%^@Y$0^HS2\;P]Y`UT*^<R)T?6WX
M3#U)<X</EYVCN^%#<TPZ4&Y=5((3?&F[DC/"FQY/I_7ZU[]B\0CN]&NH5S[8
M#K=<L!A``09B'O,SH"-ZOJ#>JS,1:S/:AR(>*0-'4@QTD-CZ>^-#E=):,A.G
M+`5%4M/)'H_]T/D=\&I+"4$1A*`""!!9VM"F=K7'CNUL:YO;*:4H;GU;E2L7
M*<MW3I)RR16)>O_114L4U!MTNPN)>&-PWDIZZN+B#`DPX$U7N#PS5"U0A,KM
M.19-0-(:FM!>@WNUT*T3:\-=)W'ER"[`CO8&@"N.S1^ZM1[O:(?OP#F0NH8<
MKS@#]3I)G6K`FCJ>+B<L/&EN1=[#7(LY<+5B%4L+QO9\5$*_R*R'+MGN;6_7
M;D05(A$J[+0OE.K'OLH=;5RKK#^!ZRI0P=>?7>2RC_W\L7WRMM&^]FX3T.T5
M9&!0<31+\&H92=QU-V<JHV:A`OY=@D=GD!`"\?=!N>09)^!X`,="5<48E`=?
M#D-#R6!?^64Q9,5HTC1QD$9ZY2!$T5$HNF-@)G-I].!QKY=7%D9A*@?_3[:7
M18-U>ZJ&:EHT<[XG<S+'>S1W!MPP?-'S16)$8K?6*945A)%%-!^!$I8E?6#1
M%%&C=E.&?53W*U6C%%OA;"H0$5XW9%GH6K^&?EZ8?@9B(NPWAN\'=^16;HNG
M0?:7&(S12JZT?]$52_]7+@%X;YG15)9`>/@2`@JX);9P7I#`!1"H<*J#:(<F
M5M!4#1'G>=<48!871)+V7]R$1+Q#@BSS8#"3B2?(#R.7,Y]6<AG&82NG8:;V
M<H.%@S08<S-H@ZJXBKRW`'``B]'#:J_F$/ID$0"5?)&5?/GD*44'4`'U`O]Q
M626!-NB3(5;#?5#8%FHG*\HX*Q90A5P7$4*P_X404'[F]X6T-5*-1")D2(:'
M869VUD!X9@)@8$KG&#B;L89MQDHF<".8469&`F]S&"YS6&]'98>),&?CTAF(
MEPA[@"4!T(<#$'"T<$*+(8B[02>$"#&':(@5B($[=%;6Y&@#)HD9]U8:9XG!
MXWJ;2"DC=TXJJ'*W1Y*E6(JZ5VHWV(J_]WNJ2',P,',P$),Q.4_<,(N)Y8/X
MQ$_'!RJY]G/]9(00X!_4AFWF<R$*-2U3MXQ3*(53F'5;5XU2N74_)G;:6%M)
MUDAAZ(W?Z&UFF&]Z]R.R)(=T!PE40@F+$7_QDDM^=U1N5H=W%PF&YTK_R&6%
MX"Z>,9"`:)"S,'"0@/\&<=*0#LEP8161$BEQ&HA6`':1Y7!ZO+-Q)&A7FO:1
MDC)RG?A.Z"2#,"B#ILB*K#AS-NB9O@>:&$"3I7F:,RF3,8=6B26+U,,0MI@]
M1=<10E,?NG@T`55&(7$?PI@J+P%L47,B!I0BM_*,4$@_3;D50N9U7O=&UY@J
M5^ED3`>&(K*5Z]>5;0>6\0=W<!9W^,8(:C88:ZDMY]9W]>A_UX6/3T*>AB"7
MXZEW_GB7]*8W*K"7M."7?WD+$5B(A[9Y$7DQGY<-%,=?I3=@U3&"WX1$',E@
M($>9_F"9?:6"J`:#\81[N>>26T2#HAF:H"F:,7F:J*F:IFF:\Q2+/`B+Q3?_
M1I=RBQC1<T.S'S`*$I7ED[H)H[T)8TQG/F)!8U:&-4R9?<AHG,@F8P'`4<_&
MG#\6(%Z8E;/5I-2IE=9)2=_XE53:G=VB&?QV)>^IAHG0EM@UAV]F;WJG;G67
M;^U);W6)+RY0GY<S"V@`B)!`>9<G@8;HG_G5>1.9F*1G.XR9D92VH";8H`[J
MB9Z819^X812JF2G9<GZ5BAJ*@ZX8FBT)DR%*DR,ZDRS``J@9DSKH:+.X6+78
M6#V7?+4Y-$'YB\$8*L(X4,*XC7,4G$FI23\:6H.4C%"Y=<U9!,\)/N>79$[*
MC4CVI,[BC6]SG;CU-MJYENUFAOVWCM_IG>O)G6;I_P)@((=OJ7AIJ%1F&8X?
ME*9T:`%"8)]H0$H#((AS*APV9)AXRAP\!'I]LJ?8]('<A#(<MZ#[,#R3.:B%
MFC,C:47HA'(KF*@7ZG(LN8H<.JD&BX.F6:D,RP(PH*F:2I.9>IKH8*)HY6H[
M=XNRN1$S:H0QZGS\D:K""*-=2"`Z2A-TA"%3LY2SRB+)5BU8486XRD:^9BKH
M!ZPXBV10VHUA6")<.1-FJG?C2*6%D)9EN8]Z:(_7@F5\MX\NH`/REIYPF;3T
M$EZ"H2N<<3AL"G!+@)^18*[\>5__"3MG19&A-Z",:2B3Z`Z]8P_UBFD>J:^<
M.+<!47(51J$":Z&=V8HOF?^*"3N#I\F*,"!S@\NPEUJ:$CNQ#YNIC(L!$XL!
M.^AH]31BEN)8%0%0-!HJ/J>+P+@?_L%DOWF4=70B5]>RH551RD84FS4$(6`2
MNAIV2=BKP9JS.UN[Q,IM9T&E5$J6V%JUC#`ERRHC;VB>_2<N1A604_N[SRJ`
MB("\B@=")["72T!"C+$&=2*VB=@<C.8-?\)?CBA@:NN8BF*O332HENF)G3:2
M6/2"IZ:H>CNP&TJ:-1BI()J:(UJ_(IJ:#@NQ_#NQ_@NQCLNX,&"3K/EA.K>B
MMHB+MVAK'DLJ03<J-DJRO=F;90<U2H&L$#*<GG4UIFLMJ.NR,9L_]W&-UR@$
MGUO_LDI&NSA;N^HWK#UKG8.SI;K+"(G7NVP6AY'P2FXWIO18O&`J>'9'P\NK
MC_BB>(?#!X!X!SU`O8R!!GJ2>1737YX7.Q/W:*47:966,FP[OJQ75W%[@CJ3
MOE)TJ*.VF2[(OBYGH7H+J:/YMVQ<N(1KN(AKJ:79OS-GQ_W[OXR;J38'BW[L
M0\,7FZ?`HF24'[_HP)[RHJJZ'_AQPJ!;%B@5==*R/AT,6L.&$ZDK%&K!%$M#
MPB+1:S:;PK&ELRQ<RFXS(E&J+(<WP_7'97[1+6P&K8G@;L)K&5G:I><99E*+
MK5"@`T9B2X\CIGC)"&#@+@^``]3+!7#*!1$#Q188H-%D_\55;,62B)&3>`XC
M4XGSL'J,(CSCY*!0),97!$\`V[XJB7L5>LX$*[]\>["!B[\QB0+W.\\![+".
M6\_VW+CZG,=[W,][;).Q.'$]\$6P.:J;(J,,G&LBJ[FL*L%;0,&/W#;;UHQ3
M)J0]8=%0&%%WE$#+%K-+PYL=!=$H/)VS*ZRE?-+:IFVLW$G%;&Z6@6Z]BR-1
M0E1^(<M>:H_7>J9*0AG?5::W=+7OEH?1F,33FPA<@`-]!@EKH*ZO\Z[:*Z`#
M&FE"5$39D7KVBJ\.IHF<ACSOE,XHR8*,FGOM?+`$*[B4.L_WNZES7,<`O,>G
MR;_UC,_^/->-ZV'3'&+Z!&MDU/^+$>RQ"RVR$8PTGVM;ZT=C!\2RE5PML&(5
MF:S)5*@2SGF-O)DJV6A2I(S2F)W2UCD$6;9WKL2/>O..2=)FT\485$*N4/!E
MM6QG/6RM>>@"(\#$2J`#;/`$;%!<P&P8RFN71Q)X%M`W7)O4`X`&2W`'BU&!
M%.>NTSQQ:P4R!UH=60P/(0@\@2H0@NI$6/2@_'JWY9R2Z:R2+S?6DOJ2GKF2
M<2S/E1K'"[NI,QF3^1S`\/V_<DW7]$W?,``0CL8$@'S`F&(1/1F,'_NQ#DR;
M`3[9H3P685%'%$TM&)W8M0(L'/T@,0O9('T?V#C2EGW9F;WA+SP6=^/9=F;+
M]^<M6++_9?72?XPQ&.[VTL3KVCO=``WP02-0!0]0XUX[`@5XM?(9K2Z0Q,B,
M"$Z,`VAPW'DZQ8K8KE!-#CCPB!='1-BLS=H<3N*A:=<=*9X6$"'9@M^-SKGW
MW08[WN7-QF9=FNJ=OX;;WHO;UO(-UWI<WV[.N$;0SW'.`O&`5OH-BXF5UPE\
M:R_ZT#:JN42SR$.#'Z$"G3DZ0,?H4HWMX"QB=4)*$Y!T*IYLX$HJRMS(X9C>
M2%LJP_)'XKV+M*']+?+8;OMWGEBB9@W0!`W`Q`/@"6O@ZHOQ`+<=S)8PV](E
MU#I=D$A=KM4`IVA05H=IMCTD>@4:,D7TIRGSMM[AS0RVB6%,_Z@G-WN*^H)J
MW)E@'N9F?=[Q3,>'B]9Q[;]R'=]O/N[^'.=&8.XL<.YS7II+L`+Z?>=W'F(Z
MQQX;>T9^_N=_;D8O"J/XX;DE^TBPJE#;Q^@/53\HLN@\`>E)]LD@?5E-5FTK
MG.D2[^%+*XY(A7=HJ`A%0JYHMB&DWN(8%`!5H-2J'N,2A`8P;G=SP?%";0&1
M<`=(?=3-(-R((/-EM=P<6,V$PDWO4(E1KD0,JJ^Q)\XE5\ZU=Z%<7M;8+IKO
MS.WT3,]KO<]X+/7D_N;HKN[I?O59;^YQC@(DL``MPPUWCN=Y#6M``W0!A?8%
M7JI]'2K]#M%.=CYJ(4@Y0?!4E\%?$__A0;')+]')#`]'E3V=$3_Q$O^>3,OI
M(]X8L?SI&E\D6S8`\K@AK?T)#>"77P#C.L#JWG('3=`$1,!4<?DMB^,N,'_,
MSF#<@1AQTLS<Q2ZO.\^VD-G%<_7%E$GT[.2^BYIJ+1FI\7O>B*O63W_FCKNX
MWZ['Q5_U=#WG<Y[NS,_U6Z_NT)_N`QP$07`&3(`..3#V!_QJA$P?APS8;=_7
M;__0H7SH9I&RA.2C=L]'&JU2>I_P9G$J?R\^%/SP6#G*.^LVA`^EB`\(%H*#
MA(6"2@.)B@-0)@AL"(.(BXN1ABZ3E`,N@BX!G9B+G"::7TT/E$\("%":KI1H
M3;(-EA8$K:__E%"#N(EW2SC!P@MTE&MT.`O*R\G*.#L+R=#3"]0K"]?9V-LK
MV=W8W=[AX^3E*SG=Z.?G.>WN[_#Q\O%'.?5'9_GY1RAG_2@`_?T#^,^?0((8
M`"9$D1`##(8,82QL*+$B!H<8+6JL"`,&BX\@,7P4"9(%29(E4ZI<J=(("R,N
M8\*$^?*ES)DX<WK,T03'D6M,@BJ#`Z='&:)'RY2!L!0"A!=E7CQU^J+J5*E5
ML3[-^J((UZI;7H3=0K8L@[-#`@Q).\3%A+<6WA*P16!NW;MX\^K=R[>OW[]U
MXPJ>X#8N@0EW$>-].R$M@RU>A72=7-;LV<N7AS#0O+:SY\Z-/XL>_TVZ=&<7
MJ`NEYF2H]2`3L$TH`>,(-0(=K"W$W@V[-6I/O'N#(N1B]^O8(QX\:!+CRX,O
M548@X*0#NI(12JI\&1%<MO8+S&4]R6VB>'?>A,`\0+->V#!A:.Z@B8^FF?UE
MRJ!5VT\-VK4=T_PG#CC@?&/.@>6H@\Z"\S3H(#SWG(&//OL41%!``N43T(4<
M0M20APJAH%%&#HUH(D8L2!2222RB5)*++,784DTWT3B3C3GE:$04,_%($PI!
M!($#"CDP<0X30R%5E%),.K645E!&B=577#T55E9CB;4%9FB=-@1AC$T0%V.'
ME0G8F6BF^9>88+K%9EV*Y?766H^1Y=6=D/]5]AB7F6VV&6>F!2KHH*>E1IQK
MB!H2@`ZKX&;!;6R$P`88.@0P7:*=#&=!;I@B&H`L,<C21`,Z,#H(`@TT,`*C
M#3PP':>"Z/!$JLN-J@,A=F6*:0`TN!=,-._=%PU^TO!7C7_<[+>"?^$0:"""
MT)JSX#H/5CM/A!-2J*%!_7!K888<3A3B0@@]A%%$))[(D4<=F>212C"^.)*,
M]()$T[TTXGBOCCCQZ...,%F!4TW+]H!".D@N0!0<9?3`<,-+14S5E%5:1?%7
M7FV%I9:5;8G96FJYY2:;AMFEYLDHISR8R&Z:N1AC`03P6!%%/'4GQY;QB=:?
M/`L:&J%`>^8::[#_8NH"`F#,6JH+CJZ2JJ@-T-#`$Y\,_=O1J(50=*>$-"#J
M*;08^N@C4Y>:JFVP'JW#"`V$.FHM@UR]:PG)_&HW?GCS5ZPUROS'GS8&.AOM
MX.NDPPX[UB8.83O9\B/AMQU&WJ&X'RK4T.7JEIBNBBJ*%._G\]8KXTTW[BN3
M3:3GY"_`_K8>A>LP\<A"/RL87"0Z82R\)%),*L64QDY==3&55UKLE5@XY]PE
M6XV-*=>;B-E"5\K45Z^7\R+#1:9B<VIFYV1>Y:FGQUQJYB>=0:>?OM5<Q\W&
MTZFNPG0D1\_:*JVSW'K)U?QOW3X"LEA.#$@%J^D@0&FH&@$G+E6(M8V`_VV@
MTI]J_$<<NMG-/M"XSS/V<RP`;4,_WN`&.0I$.&@I*!P,4ISB[F$/;6VK(-ZR
MT(8@@A`0T?!<%T$71S*B+G>URW,KB9?H6.(2?<4D7Z5+7;]BQ[K7-7%'2?A7
MC@1&$PQ<8PDH^$F1%(84HSRL=\%[TE;&^!6-@24KQ]O86&I`ECUE1BUK<=-@
M2N8RZ]GQCMH365NT-Z;#$,8QW[-95SI&OO*=[WSJ2^2@C"8WU\SJ`5.#Y*1(
MM0H+J$H';,#D")X`P>6,QS=BXP0%._6$)H#G`9R$FR!>Q895(>"!MC&$#F8!
MAA&XK0&C3)0+Z`8L9U1#&OWACP<#=*QE_6<'W?]`)C:064(3IB,>SU3A@^KA
M0AEV*X8;.LCD+D(N$.5P73Q,%P_9U9%W!3%T0QSB$?&E1'[EZ'5.C&?KH@@[
M>-K3GB[!P!D6L`0:/.0,6]0=PY;4I*9(R6*3H=(9L70\0G;L8VV)8Y@0\R;I
MU?&.&#U97+*7O8G^T7Q%V`($)(,G0NKL8X=4I$I+(\H);HI_ERAEJMC&ADGI
MH`%$6`6J5''`!H`A54\[A00)H=--O327B'*!UYA#*D<5XE4W9=0(V("V0BPU
M!E-M&W,D.)?V"4(%P-B;L:813+*:55G*-&8XF-G,<2CH'=22Y@I;B(]_\(,@
MVAR(Y"Y4N7*)*"(B<DC_8$LD$1&5LR.$;9>\4L18<PHQG?8:V#K=R:_5N<ZR
MK=M19N493X!Y5G8'PT$/2$`"@"9)2;V3F!@O9D:%%F]C6F(C&Y5W%K7`D3&"
MH6-&=VM'[;7I+84!KF/JE#'*F/2DG?D3H%;*7,_\QJN%>"10:SD>5-'B-JJR
MS?O>!\E6O0V42.4:`,&C*K8Y]52H:>4J5K7`I[:-;:0"@]L4V)JN)DH(2P"6
M6,MJUF'ZUYC,7":`VXJ@:<%5KNZHASURT`\&4XA#W`)77B77UW#5T%P/*6Q'
M(E).S2FV12Q*T;M$XI''0O8C1:R)C6R".G?*<P90Q&P2-#O/S786LZRC"0O.
M_X`#&&S@#"L(`Q=U9Q3?_<Y)5&FM((?'E2R]8+8F)1^@7+!'W_:1>R;CK9;_
M,J:1==1-5(Z9G3)VL_&=M$_F0Y]RFZO(ED*W$UZ#7P.HNJE4,>JGIMJ4`=D&
MP5%9+;R8FJ4L5C4+51[ME9"X3=,*\3[IM!*3H;H`+7#EU1/T8!@[V&!9\\-I
M`'GZTYX&<*B9R58"DZ,=YP@"JE/8#E4WZ!XL/`(_9)U%"=EZAGK=:XC"5=B)
M8!BPX.SP80GKP\.&V,0G3DD1U\EB'5WVGO2,0K2ES5G-TMC:ES4"/;$-,),<
M#`560`&2!)I:U?[.H`IM,O+4F+PM0+F-7(+CEZQ\T?_I;?G>?B$9F!@#YN%"
M1BJ"=*@;#;E<]+'Y,VL6U&:FH[4W6Q*2S"'"<S?5:.SBIH"R&L$IFJ!*4``Z
M46PP91/6IE7ZQNT1TFF4HSCE`O,VZA&W'"IT0W!I]_Q2&L`\ZS`[V%\`K759
M;$5FJ:.ECL*AL'"N=K6#8FT/ILMZUEF,>JYU376`/,3J?\VP8:V^D<0B]NOS
M:M=AWV7.9)<DQ2UN,8WO"<^UL]V>4:3QMFN,V1M[]D9G($$&4'!:+Q8YM4^)
MF,5:^Y4LO18L[C9+XN'],=OB5M\6A1.^)]\7-@'7\F^)&0-.`)G(@,^AA40I
M9Q"9<$667N&G,>J;73"J5IG_O!-:FQ732/4HU4"JY&F3G\,-44KFO)+D6.44
MJAAUZ%+I?I7FM8W30H75W5N`5[Z*_C."D6E0_]+3/`?UJ`=L:FEU(P@K"%+X
MPY\#I<M#P>]XNOII36N`W+7J\/^K_*^.]0QO>.SVQ__7\=]8L9M]=#9B!5$@
M@#Q"3U$T;=L6;=&V=G/7=C:F;?*T=CJV8S`0;GWW14RA6@!',<)3%0W5,4U&
M%K-U%K1U&;<U,E<F>7EA;Y1'>13E/'GD&)Q7,TY14GIR9J-G<`5W<`AG&FBA
M*5XU2S/U2:<2">_C-`HD-IO"**@2*JYB>Q/G?)8$'M*A`V#P2K:2&RZ0:,7W
M:$13_UXKMUXQ0(6C9%^J84'"D&G3EX;3EVG'\@R>!H?:-X?;-W3=5P[@EX=!
MHFI!@'Y*QW3IQV"S]G11=U?O%W^(R"%7=UA9=W_ZQW_&5DXB]G\KL6PL,(#Q
M=(#3]FQOMXGW)'<V%H&KXUD[Q@(D,`,Y<%H0$S%@]"16,15FI#%7,EO($Q9L
ME#QU$GI=HA;[1C*'80O1XS(LV(+X!GF6%S,AT'G!`P$VN"6,AUQ=LF:GMU+3
MF%SHTTA>=3]3Q4"=$`FH@H3<*`@A1TE>$P-/((6=XC62=ALZU3:3%C?\\TJN
M=#2VQ(0&-!TW94HQH$IFF%0E$%;2!R!P*(=M6'UT>)"?-O]@=A@M>3A^T`)^
MWU=^>SB1$WD$?&B1JE8/A<A^B9B(I(4"'TD"(#F2AO6()BEVD-A_E+@2`H,Z
M`G.`\#0#KZ.`^/2);.=V\&2`E@6!`!-W/I(0&9"*"].*K/@[`'<53+&!Z[90
M9=%N;'1FF'&"?"0F)C,]PTB,6%DFVB,S(7`"-%B#@_104*F#/<.#J"<:#""%
M]T,I2H@UPY=`Q-<U5(@TS/=QT.4";E,%135[TJ&%OR$_I6)\;%`%E*13J^`(
MMK15@M"/G0)6TO>8;?@,R+`#=("0<T@'F%F9F(E,E<E]!P*1X="0HCE^>QA^
M%'F:J$F1&&F141<$4M>1'2*2(AG_FR,IFQ?R$"*I=3!``KO)FR<9B>S"6"NI
M;`(SD]0&DYRED]!F8\KI@,[YG%*4(C-``@KC,$91`KYC9+TC%1+#9&&11E<"
M@FWTE'NBBPS@>/-F&"43)XFA@EGYGGZ4%I`A!$*PC,TX<-`(*-5HEFBI9G'D
M?$R%&SY%''O&*GVIA;)`F-@5`T\HA4H8-R*7<O3#CL9G"/*#&H'I0`_T0($Y
M';9$AES3CT]0'PJ``R5JHBB:H@99D-57F93YHI:I?9BY`IDI=&H5FM_GD#E:
MFGJ8FCZ:FA@I!:XI!18II"A`I%)PI$>0I+!9FZ05DDXJFT_ZI+VYFU9JBJ;(
MFR2`I5O:_Z4?L:58^A'!"1)E=V(P`9/T))-OMZ8,N*;RM(`W9G<NT1$;0`(K
MP#M$*3%A%#SIUJ=CL7@WB)_ELQ9@,AC!*'ET<97P28R9%P`A4`3UN8Q"0#.*
M-Y:(Q)\^V)\I99<0^@#2H7'ON$J/XDJ7Q"DZL(Z.-D`QP`;H^*"=P'PI9QNE
M\D`$A#6RRAIK8WP.5`58Q81,\P!C*!V4QC4GT!/N<:+'FFDG6GTL*H<P^JR7
MN9F92:/+HIDVNI`.*7YZ2)H_VJT^*J1]&`1$ZII+FJ128*X$P:2(.*4@*:53
MZJZD9:7Q.J]9:J6'%0$P$`$?H:_\2J:-]:_ZR@(!NP$I0;`V8?^<--F<\$2`
MGNBFFTB3_M*`<2<2=KH$18&=YY:Q41$5@9=D6;$5#75&8OD8-5`G)(A2M;5'
M+1,]+[@7[+FH6#DG`0`93E$")5"#E.J,@KHS^HFI9[F#G,&IJV1*3L,<(T`<
M3/,$9A.K@Z!Q5X@;-_4`DK8UKGH)KH$`S`<&;NE`;9-H'(J/*\=G\G,;;-.K
M"&`".A`#S"=SB6)?(=`3R!H,)5JB:KBB.Z``=BN0S`JM,?JB-2IJQD0'08!,
M>;@#H#F1IFF:WNJMX#J1X`HD10HD1SJYZ'JDZDH0LSF;'/*D[?JNGONY[XJO
MY=2EHLNEILNO^9JZ^(JO6.H1`1NP9[?_`1%KG'#'=FK:G`CX=A+HG#GF1"[!
MFRNP!$5V;DVAI]R99(17B\H[%H+*>%+&LX3Z)8)1)M/SLC"[J(0A,Y`*`39[
MLR.5L\_8)Y?JLZ4QC3VS&54;:*>@:#=%>Z#02I"078;B`F!P`4=K&UJUCZ`D
MA>,5`Q>W7ANJ`XB)5>R%2?1C2_.H-@',*&E[`6I[M+Z1*-`GMREZK,\PMVMX
MMW=+!WB+MQSLMR#LHC(*("),F8,KN"9,F<LRN*39PMK*HXL;PWL(KD8JKN<J
MI#=,N2@P!9.KN3Y<FT[:N:`[I;VII:8HK[MYQ![!FZOKI4YLNDR<KT_:NK!K
M+\4Y;6K*=KFK_[LU:9/4]H!V-SLD<`0+T`-FK*>L6)10PJ?$L[R54;+FL[/B
MRQ:<L#WKJ:C7FY6-X:@UT[TV6Y\Y*\<I!;3DZQGGZY^;X7RS9+^/<!M-`,&Q
M,@)5``GJ=32"`%^W@C5L`*S^BXY7.X8$I%.K0GQK0\#"RHZ;(LD!K'RSNBJV
M-(:/++0!T``53,$8O*PFRL&Z3'VYO,&4Z<$D#,(D7,+#;+B8^0;&'`1T\`8K
M'"2&:[@NS*T]*L.,*Z[6C,/BJJ3FF@4Z;*XDP*0\#*7B'))#_*Y)3%H10`+I
M/*7XR@%&K*6>BZ_L+*_J3%I4K&PS=KNT2[M;[)P0ZX">^$016$0K0/\"0F+&
M1]841Y;0'EMX(MMN)7@9SVN">R2]OY@8>)S',8N,]>G'-TN?(16^HD?(A5R^
M!N<GSE=*GFK)"50+[<O`A4F/QG=H1Z.V30`&#I=+``2L]NBK`$S``JQGHK0V
MO/JU6^O*O#J&^BL]<6,(]K5+*(K!<LNL%XP,"O#!5^W+FIG5PFRMP4S"U?H&
M*+S,@DL'*R#6@ZO,:6VX+ZRXU/S6-NRXXKJD63"D62`%=ZW#M@D0F1NE\%K.
M@!VZ]1S8A/VY2MP2`D.`;MK%=@>=3;234M2[>#<D4U`[-KN,Q<O0>MJ!"R6R
M40:5XTNHSN-'6JG1>9QYFR<$-ML#W>L4DQK_TCJ3@_M9TCEHR/KI?`T`'A=7
M9P34"2[7TIAD9_>(&TUHOUZEA8F"M0],H:\"*1HJK,_%-#=5!=%!?,T=F*^L
MMN<E/>G[55%MH@J`K!V\P;V,`Q]<F<",MWSKHIKIHLKL:2R\S"N\S,H<?FS-
MUC"<WW`=PS1\KD$P!4@ZN4/:S=\\N3S,UT`LQ(2]SO-:V.;LX(&=NLKV$I%-
M619^X1C>(T5D14O@S`B-9,L8XL:+4$OYIW_Z;GP2QR-=951)E=1KVM>;>8^J
MVB7`VMT+TA$-O;1-*"EU/KH2P8;@-0]`W*Q,9RW75/(XRKF*20SLH<P1`T6#
M-;J$*,J-5>S[ETO^_\#Z8RB0LJ$)K'QB^,!17C3V-:(43'WAS<'!8-55[6D?
MS+>?QMYD[>;/?,)K?>=UCIKXO=]P?<,VC,-).M?@O,.$+@4%3NBU:>A`#.%4
M^N",_NB`;:^5V&SY,B/V<ND3CF+T4B/YE(HJ\`9!H`!+X+TA#G";#8L3`ULE
MCGB!:JD1);V/AV4P#K-QX:CT6>,U;N/,"-N%U+.S7<B#[.N:H7I#TQJY?0$&
M=&BWH0I,PS:/T.S;J&CP:]UL,(8-BK0L=RA4KM0I1WRRRL!:KBDZ1=1?>[:&
M*8_+#>2NP0=PBZ+*JGWJK<%:W;<D+-8P^M[PG>=L+;C.K-9[SN?\[=\"'__7
M-7RDW,S#W*RNW,S7"]_7?PWI$!_Q0RS$DCY$0`1B)`9B*G)L&-\B%7%V-0$#
MJ4@#1=`$/Z``34`#RWB4('Z\KNA:ZF;B(AV-([UOTF.]LXZ]$V#K)4`#/>#S
M-_[:6Q`"*1[:.QXHRG6^+_5FY8B/BA;MN3H=B?9HX[ZTQ/<^VKV_JL$U-Z7=
MC7(U%,JAI5(>AMG3N>I*X[X*K934;$OLK?&V\?[FD@G,DBGO=$[,E"FMH(;,
M0+?"V3K?>6C6J"G-`$^1C3O#04+7KCG@W)S7B`Z2ZBJ226J;$N^Y?/WH?OV1
MG;OH"4[YF3NOQD9B&,%-.:1/^L00%W$&I7_Z"6'_$*>O^CED$*K?#]R4$A*Q
M`A`0`@WP!K%``RK`C'R*ZLB[\E92/(>W1B48Q\IO6Z*]/6:"\SGO@IX0`JI-
M`TWP\S3PT9/*>>%+TD=_TN!?V\6>*+GM*H=6MBJ72>D%58]FCWR&&Q\:R_O3
MU/3O/UWOOXKV*M(=]6H#"#H(.H0C(X0(""Z).H>"B8R-52,(%I:7F)F7`4TX
M.S@*.Z)T.Z&D.Z>BJJFCJ*2G;Z<K.T$[L[-!M[2TI+F^0<#`*\+!Q<;'R,%'
MP,O`4E)!*%+2U-'3*-C7*%G8W-C;WR@DXN(DYE+GX^;K[.SDX]_PX?+DV.KO
M\_7A^_S[Z/CP,*`0B.),_\$S9W(8S,$P(4.%#Q,Z?$BQHD6%!@5B8,&1Q9D%
M-(J<4/!#`8T215*^@+"2)827,%?*E+GEQ8LB-F_FK+FE9T\&0(,*#3JD:-$)
M2)%:($!@`M.G4*-*G4JUJM6K6+-&G>`BP`DA)6@L:4+C9`DA0E+^'#J$@=&W
M<./*G4NWKE&W;?,"=6&!KZ:_EQHTB:$HT0/"D'2PT<&7L:5&A`2Y6,3F$((G
M,9I<B.$7TR)+G3N#_JLCAFE!CQ0MBJQZT2!$@Q(MFCS(4&I(D41?FHR)@.=.
MJCZM:A6\N''CNFKAVF7KS;!AMH89DYZLNG5CS9AI7W8$1;0CU[IWYT:^6S]]
M]__LX>M'+]X[<_K4GY^?C3ZX\M3RVR]XY.&*_P`&*."`!!8X8$-G8+`11QCD
ML(0*0B@@80,0GG#"%BJY9)-+&N*4TPLU>6A332""Z!,#:PG5%E!#!&!4`$HE
MM956--9HXXU731!`""<T0$,/3?105@EGI67A%D.QF)==3#9I%UY0OH477U0"
M]E<#FQ7&1@R,15(%&U3R]5H#54A&FPX--&*::95D\IF;H(6IR9:G129989/1
M=B9L>?99VR1\AMFF)KQIXIL+)7ARW**,HC*++;0LEPNDDC[WBS`"_D+==-<I
M$P1WGW(G:G?A?(J">-B0.I\W\L6W'SSM[7<>J_-I0ZK_-OK19XTTJN[CWW\+
M!+L`#L/B8*RQPR9+[++++K!$L,WBL(2TU!(;[`H8P;`@"Q@L(,0)3S311`,-
M/'%D$5N<@!-.'+8K$TX\E=B3O#XAB622*DZ9E%),.365OS@&+/#`_>[X1%A-
MC-4$D46F=&$(*A:%EY,44SSQDA+KU9:<?5F)B6!<)F(9;2.0:::8;"`PPKB4
MY(E``X:8]L`%;&B"0`@<=PR:(J-9LN4DM8V0,B.5T&8";:_)EN=N09^\FVY/
M>YQHHU0']\HMNOP7W0IT^/(<@+E8BLRFFR:3':AH'Z'VJ&NW+=[:I\8MZ]QT
MFU<W?6['[7;>H8X::M]]J]I?_PYA[U#L$CTDKKCB/R[N^..,0Z[XM`O\A]"V
M&)S1`[B:H5%N"!"?$`*&Z++;$DPQC4COO/6>>"]1L%\\!%?[$FS[[;=;8'`)
MXBXQEEEHI53$Z*\K6?$$1U6L/,9W#4%;SSH#AB67+E3&F`N-;)EFT:!%5D4,
ME+06V0AH7-#$"+K-YEG44+OPO66#+&9"TGW-C\#\L.'&<YAZ]@GU7SG#A`H4
M5;5&/6IK6PN0UQ1H*;)YK3J;(ASAU!:XO5GP@FH[%=SD=K<.SJ=7_"#5V]JF
M00RNK8)M0Z&H`$=![N2@/X4;%N*$Q#`5$,F&1(*`#76(0QW>\(<JV*$-A^A#
M&_X(!_^6&TA',+""'I!+,)\+00`"P`#B]81=J'O)AB`0+Q/QI'6O2Q'LX+(O
M?O4+=VA,8U9T%`(A"&8)"@@2PX*GEN(Q;WFSPV/%W,(B!O2E4/_3!,@$49G$
M5"9D.HC>^&"6O\+H8#.F\4MG]A>:/U9)9RX@T\AFDYO5H"8R1SM3:_KT--EX
M;#<]\TU@EA"<`RY*:ZK0VJ,R1<O_!*.!Q2C;+8\QP1=.T(0FU%L&1>C!8H)0
M;\A$U=N2"<RVO3"%;NN;+S_U2X90DYK]&5P0*/(H8R'N)$%$RQ/$*81QCA,M
MZ$1G$8*7SG*VTYUHL6$/GH4M);+`"-Q:`!J:@!E^@D&*4Z3_HA53DL680`!>
MJS-1#>J%HH:RA8\M.DH9`38C-5HTC;H+@0IHT`EI+2R'=#Q2DIR$O.3I42Y1
MF@M$^1>]0%H@!ILYQ/8H,P+P14:1J+%>^!@CB`;$P*=<\HSZY,27`'#/30A8
MC&R4IK35J,P1@[)`TAQI2D'Q[)2\@1H!GL!*46"ME<?)&J5LR<"O+5`Z9+W4
MI8:QC!=N4X7-#.8QBWFW91)3@\DL(0GW>L%GKLV7@[L(1;;I2\%:\ZW6Q%8W
M<4##<%H(=)"-K&0G2]G*0O8K8:&G0F!P3R/@$P4I>`.YGO#/@$XQ*#XA*.ID
MPI*;@+%U0"G>2..R+PM0]**XO2@;_WW4!`G%\23I%-[#(H;'DAK%N">%"T3U
M8DE)HO(OFN%2(V;C`D.D"35^<NI3&8F;1M0T39H(0%%%L[2L8M),EOQCG";C
M7<=@(C:N"=337/K<_X6@J]&A5%@AE4``1>IK9B4K@`D'#`D6^*VA`FQ<FXE,
M#Z)J/W,EI@6%N6"]8K"PALTP0P:7S8<@EILYP%:(NXFX&YH+=#M*<4`!:EH5
MM]C%+UXQ9GM0N1PHT;-1,`(,4C"%<37@GUT1;T"KF*XKLK8E2&;=:\6(+^,Y
M;W:UNVUNIVR[C`JF$PK`P4>#Z[#1L85BR,UC<I6+L2BYA2\AV%_'_')5T)B/
M,+<I3<B26O\R0BA5,80TS06$1M7(I,]_:UYSE4*CFJBMKR^UB>IZ]V1*H9*7
M4![CA%<G/6E9?M728$,KI\06C%ZJ3<$+#O5<Z5JW4<MM;Q3.VP@MZ%>W/1.P
M&'Y(8&5-Z^Q($,2*W:9BM2;#'A"IG**+L;"'3>P7SQB)F^UL%*+``C%XP`GD
M`@,;ICB9%C/@0J5;EQ9?\L5Z>=%>(WWH<9/B@@DL1<I43C>.N!("WDI(R[YN
MI_!Z`C'CR>YX8WZ27OQWR4"/Q@6:J0+1$N'3U.3/-=8;!/B:`"C%+!60S57O
MH$GI7/5&#S!G^I_+J%LH1^_LSU9"``W&FE]+(Y"!#\3E,`S,<E#_NQ"NHE9F
MJD@=CF-&>.;*O/E=APFW$5KXPK`.+(<K,FL-$T[$N`Z0X:3EZQ*HX,0P+K;4
MB]U&"(@%6PGB"(Y9D`$QI.$'XWJ"#JC-E1:=ULNDRXD6O[UD)FN,CQ>;:%/4
M3?>!N4"CXI+0#L15)#HZ[$)CQ+>839K<E&8L+RQUKL8WTP21H28&`M=?=G&#
MO9K&[!!953S2TBNH\F)ROI5<GWD!2;2EK9=IK6ETG*R$J/[Z5VNUB'VD4O[`
M8A#8P$/?6ZMCOL%OF-K4<QMUKP2WCYSG-6\E3+XS6;W\PA:=(L\W>M+_,^(5
M'*[I:!$=BZ?.?6&#3@@;?5:R[YEC%MB!_P=BL,(/S$=::@MYR$3NR6I9TG:&
MXNOM;YGHN:V"[KK[_^Y7%@IQA'U^IQ;UMESYEH#-(R5%P6\6IWB6@``,US*0
M0";4LW&J07D;AR9SUCZ65!B%1B6C5''O=56F9W&KEU7M%4JAD7GY0PCD15\J
MX%62L@MA,R"SATN78F`%%G0PQWO*)S>T0C?#-TP-YGO%=WPYIS9GP'S+ETV?
M]FFQ)GT@=A$!PA`%$F+59R"\QG2_)A(HUGUB&&,A4`3AMP`*L1&>90110`(M
MX&QB(`93(`+\-&W55G:F-3KK<CKPLF0HPF3B)CME-'<!XR^&Z']J='?ATEL2
M,A9]QT[S1ESY5O]28:8\]Y8Q&W=))[@SDS`TBJ`#WP,FV>4R\.4:>=((C#!H
MG\=)`1!H'.=OA-:"J!2#2],TK>%QE7<;Z>,Q3U!I)(<U7(A++-=IG<:#0;=[
M3QAS,Y>$/;>$&/1SH@9KT$>%U%@1BC5BU;>%P;B-!@(I"[!TW_1KWX)BVS>&
M8A@"?+!1<("&"0(#:\@"*(!^'@``/&`%8P!V8D=MY>8"3T9%`9!V:\=V8B1;
M]Q=W26%;A(A;_8>(6J$C3R`8[\9W\I86!MA'>E2)"GAX<)&)@X8ST&.*B8$F
MZ*,^&N@:^I.!GW@]#[AF(#AQHR1H+0AHF<<QF?<:CT!QJR=5F`<]SP7_&">`
M7P7D2C2(@P>2:]>HA<.H85&XE,`4='\UA42W8=4XE1FV:UHH8D>)E5<)(-H8
M($SP'U_)!#OPE5Y9.=8'+$KWC6H9+(:SEL("+256`A!@)&%HCG;)(V!!3PFB
MAE&``E:P`58@!5/@`5;@!%/P!OP$4)-1=D%&12'"$D+P`I'I.O=2/`3Y9>,6
M(PF91@O)D%JA.VP@&&C0B%OV3@ZS!?5V1X)'>!E9%'G0@&)"71W39J!'BM?#
M27Z652>I)1G'/Z.7@;_I>1%GBOQ6G(EGDI``:!>G,NX%0!YS7P7$*`>4-=3Y
M>@92A;=&E=J)E-BYG1:!=%J9E5NY`F09EN1Y_Y[EB9[G29Z5\Y4+P`1O>99L
M.9]OV99O>9_XF9]OR71--Y?#4Y=V.89X60(TABT8P%F>13@;0`(X$`01$`13
M$`%S^&-DMY@NXB)_:#H:XCI)4IGA1D:T(R-+D2-5`3!.T9F>22/LYFZ@L##O
MI$ZH&7BMF8#W9IPS"8LS"4CLA8KE11F4)QD?=WJ=5U7--7'$B3V.(4DV*I.D
MR((XV1>&H&ANXE((T`.>\(V&HPI8NJ7'P:55XTIF67(EQXT$@HV[=H74QY4%
M0I8`XIY@Z95O6CEFV9YM.I9FZ9[P^9YRJJ??Z*;7HI^`&JB".JB$BI\SY&O^
M^9\!NJ@S5F,*<D]G\/\?=(`#O!,$=!"A$IJ8^L@5Y7:A`_4N(P)NJ-5DLY69
MYG:B_8>B9U11AYBB-:*(HBDAI6F:Z'*`,SJCR\61$F=>_U:DOED](SF3-TEY
M18IHW!.;."F3?Y2<S!F3QEFLH^B`;!:E'M-QA)(HQX(LVIHLR;)T:IFEW[J6
M]NF666HX9QD=[;DU8DF>MC"G\@F6<BJ?\&E]?_J>],JG\#FO;YFGPD*O_(J?
M_UJH`CNP!'N?Z[B.P0('ON,L">L[S[*.2Z"P$>NP%'NH<NF?VK>H=WEL6,=9
M3-1$*%$$1*(`0<`!$BI:3_`$XD4[DV%VL84N.H$N8"04X':9"`AE4885)OK_
M%"<*%3WKLP33F:I*(UWQD'FG9<#UHFD1HY=XJQG)D;\Z>BQYFT4J=A3G/TGU
MDHA&BJ0T@C?ZFQE8)LZZI&3[K(LP"?1%7Q90`M-"+0XK+6_[+-O:+`5;MW9[
MMWB;MPN`L`:;L'Y[L("[MX(+N!,+!X9[N(<;L7#0`X;+N!'+N)#;N(T;N92[
MN)8[3Y:KL(HCERK09>6HL5,WH%;*CANQ`(PKES*;$CLP!20P!3<P6N*UCTIA
M=H[I;=VV%I;99"L"HJBZF3K;+TBQJD`KO%0VM"4:`&RPB+W%=X^H3K4JB4Y;
M>$O";R-XBT1%&<7IJSV*-"6)I)U$)52;H[[97`A`_SW:6[;HZX)B6ZWT)03S
M5+'P"[]P*[_>Y#O((K=XB[#/\BS"PK_!LK^&JK#.<K`,6[A[&[&#F\`*N\"%
MJ[B(B\"(&\&%:[@3_,"7*[F.F[F,>\&*L[B0V\&2$\*+4P:)0\**8\*.@\+&
M@@J?L`0TT+G!9HZ?>XY@<75IN+<]0']AU#40BI@I*T6RVZDM4D49VG8.1;.D
MNEQEA)`+F:K!2X@]VZI!:R/&NQ6PFG>.2"$O*A+W$KW1.WDUV:,25U79RW'4
MBY+B8QF%Q+7)RGF"%H'@8X+I.\?^8QMI>THB*\*+<ZCSE#B(H[E_[+"+ZSL2
MZ[!]++&:F\A_C+D;W,@<3/^YE0O)D>S!'%S)B6/)E/S!EWO)G`S")3S")YS"
M/6#")%S*HWS*IES*99#*J]S*KOS*JPP!H\S*)5`&M1S+JTR@/;`#Z)`"5N`!
M*1`!4H`&*`&@`AIU4E>&5D<L"L$$<%`&.BP41;`"T!`$/T`##8!B>4([%N`\
M`O6'?G@B25RJ$I6S)`JT4A;%OJNB4B'%%%7%5*$[#\E1HTD6/R1O@.=D7JR`
MV84SH^B*RXJ^7FNCJ4<]2C.;`RW&FM@7D*&D=)R^B%8%`G=*%!T"LJS+B4.@
M&NUKH$S*G_PX'HW"'WW*GYS*).W1J)S2)KW2*LW2+CW+JPS3LSS3K8S*,0W+
ML`S_`:ZLT[B\T[D,S4`-U#H-$]`\U`5UU$B=U$K-MG1``E8@!O3(`P`@!FT0
M`7B@J=T'4%(TP\ELAF*!ALX,S:&J)!"P`EE``J5``^,X1<[#LGC(`%0$SK`E
MSD=<J@:IF;_+LU`\=^J\L^V\JD+[+Q6USH/MLP9S9?OT47.D3J*CS_N<@'T"
M)M6[O:EWM<69T$M:OHFTO:]XM0!=)0@`-+4YQWA2QJ5!"11]2@$@!%ETL1!0
MRT>=0[:LT[!-VT7]VK0]U+,-U!=KRR1\U$7MVZBSV\,-V[=]VT9MU,']$LB=
MW$K]W-`=W=(]W=3-(4BV;4E=`DWM`6+``SSP!^#MW55]_P,/P`=<W6+E:,S<
MQR,VM`1,D`//7-0C(A0],`S>81+CJ)C(4VZT0[NH-;,U2ZJ[RSR#J*KOO-=_
M+;Q2G->ZU<ZPRE$)8\\,,Y=T9$>/S<^G6#U8RZL:OAKIVU3]8Z,P=:Q^\@1,
M*JVK>-I%0[V<9)R8G566I[84[0(G4-TV?N,XGN,ZGN/7C=VL9=W;=F2MU5I[
M>%`SX2%[*"(ZL>3K$B]-GKI7%.6D@Q,JT`-3\-1V`-Y:'MX`D`(_\&,SO-4J
MMM5B3H[KG8XE\)[QO79KT18KD!TOG!(LYCRR2SOP%UNP]8?C;)&\:VYZ_;M^
M'<6!_N=-O)GIO->IFN#M?-CBTO_H9G%#P=/8<'WA3YLG8&#&-AH^X//AR8GI
M(5Z^%T!)+!FLG.UYO`KJZ$.^>E+:+<Y)P%E>IR'C6%6&P=5.%,[:N#Z7+Y'K
MK+U.NL[KNEX$!Q7L+R'LQ3[LQW[LQB[LS&[DD1F91KXN19[D,5OMU'[MUI[M
M22[M&'(3TIYMI!/EI8,AY$[NX)Y:XU[N4EY'ZB[NKP7E5Y1M`Q0!]`C>!U`!
M!Y#OX5W5/_!/9>YB94[F*:;>PX:7/0#?N-Q:/]$60A`$9^WP.$"1)P#7;.W6
M^U@4<=U0`#[.NTL4IOK$_*?@>BWH(X_@?'WRPYN030S/BQX"1MOHXO+H3A<\
M3-NTE*[_/'URFV5LK(GP4RY.>:F')RU)70@@`@UPO51"ZC;ZQD^C`R(0ZI?=
MXJ]NDB&N@FPBZZ?$`,*S]5S?]5[_]6`?]F+?]>9N[F2_]=ZN%F<_Y6O/]>$^
M[O">[O7"[F`DL^W>[G9/[NKR]1=R(6!D(>IR)(`?^!8B$L(%^,)5!.-4`E/0
M!P#P!_D>^9&_[U-`!)&U(V2>^0(/60-_WC(F!&$=RQNZ%CUP!*U;"Q&/FEMP
M6BX2Q(SY(BL"X#:;+_<VB(0-V,1;\H=X6WZ-SC)BZ&=TX%1AO%RQ.[W#O(N=
M%O7F(C-J7!AY4JWQ!"_^@9.!!IRQZDL%@DRUFYU>/7@PDKLZ_QE'#]$LA6@B
M,`47$$HM*?2=KOW9[S]5L&=2FMKA)3H.TV4B4?B(G__Y#P@G6T4G)X2%6XB%
MBH."AXU%B8V2@HZ6A).56XF"FXR4H)6BC8:&A*>1FB%;JX>EBXNNL+.F1;:V
ML;>V3[J\3T+`P(<AQ,7%L;FWP+Y%3\Y"SLX-TDUI`#Q_!]K;VW]_`!%-8,;%
M`>3GZ.8!Z^SMYB=,<#UE]!`0+_B;#/LX)!$D010L*:&/P;HA`8:X&#+!Q82'
M#1$.0;AO"X--%C'NV\B1XY!]$R="'$F@I,F3*$M.(+"RI<J5+$VZ/#DS9LN'
M-'/"5,DS94R4.WM.,/>D`8TF:!0T6?]:HFD)82="@`Q)M:K5JUBK3LC*E2H"
M%RX0C/@*MJQ9"R[0IG51)0;9KPC@QIU+MZY=L`AB.!FQ]FS:!F3+JC4+5JT%
MM(A=Z)W"MZS=N&$=AX4,]ZR."S%TI#W,N;/GSYU=H!M-+BKITZ1-HSYV+JIJ
M8JY#%))-R[7M0K)V-?OE#%<Q!N<(T8;EC,WN:,AY*T_.O'G1Y&R,!0".CLV)
M)];98(>.O('W[]X5R`!@)QNW\W]X]$'S9+4YTNKBNW/78P$<>F7LX7NA<=\.
M&"0`M`,-$$0B%0,3)8200PTU*-%$%?6'D44=50@2@B&1U)-/-OD$DTL?=CA3
MB#9!U*&(.P7_Q:&*'*KD0@!L"-'`4DLLU00-3D&UCX)=]7C55@P%Z6-7@2&@
M&6&$#0;6"!=H]M9C4$89E@)3'&F88T\@J662FZVE@P$R_.#D9(\15B99:%5Q
M015?@>;FFVBM)B=LJ,5V@G7-O;9.".^Q5IIV=VYWG7;9;=<<H=MIY]PTT41'
M3#NC1<?&I($JBJBB17T7`WB<=OH=&].,@-VD(3@*:76E2CKIJJ,^,4(#532P
M:0RTQJ!``0"8=QXWWK3Q`Q%SNL?G?.WT$`]^$.1WSST3,K#"!EE,$00.)4!0
MD$$A*1B`@PXE".%%$X;;GX484C423D&I6-.(+VU8TT\ILF1BO/"R__AN3BW^
M1(`%1,VXE$`W-M&4,$4<6.Z0"`.9H4@(5T78D5OV598."A"!%YE19DP9`E.D
M@:;$$8?<%V*'Y95&&A?@):69=$4V\047C`7GS)Z]R&<QI$8'QJHY[TSHI,6M
MZC///(^JG:@\/SH?,9*6NK//J1+-JJ*O-E#UU=-8_=VK(XCJM:NK$J,#L<7H
M4&H(3[,QM-%`5QUKK7#'72NL6G.-=-)C!X``.R'L;;;9D^[L--"L<BTKK3##
MG`"NNS;^AZ\-!'N:.L.2?6P]]MRS7[,XI!"!%$$,9.VU/":TD$)`+@3D=/I(
M."ZY!S,T+[Y`V5LOO/J>*---NKO+HH?M_O_>KHL!%%5"$PK@H!13`]MR8,-#
M*ARDPM)#3Q@;(@M65@,&'*GQ]W.YH$,$4P166/9;7CER6")$D$85*I>)9%V"
MY95`9IO1K+^1.O2OP]"!D]K17A6KKA6P;EU#8-=<U;6NK:I_<=&;WN82`AT@
MH((8!)P.>+;!`#8P5FV1FP@/V,`&<M!L$=P;7238OPI&!W`";&#<$D=#&L*M
M"E5(H`D#UT(53C"%8-B@$-D@Q"!.:H,R#&$,:'B'\>BJ<0>HP#?P0`1G2"X=
M-R.6.>PSCWJ4X07ZX0]_,%("#VP@"#M80@^$$*ZI4$5UW1)22"X2(7#1$78=
MT0I)0J0N$.$.)W__U)<?>7*3099(7;FCR;UV1Y-^_0M@S!/&\Z`7/:M0CY(*
M,4L#T&>F*0`F?G.QX,:^YX(16.$')@`9)R>CI<.L12TQ2$,?QN`D*&FI98ZY
MS/U,H+]>QJF%'63#"(0YJ6&.``PR/)P(:87#$.;0:B7<80_W5I8?^HU__NN?
MSX38/V$F$&Z8L:'<<!A-!Q)QFI`)BP1#6<%L^N^!1/2F,I=8PWIBAIFP*J$P
MLVG-4")Q!,W,8=>,J(,1%-2;(XA!".OI1"CR"@!3>$![KG@.^1"+!DSHHK*4
MM;DQ6H0&*4@!"G#0@P*UT8T92LA00G*ZC]"Q!A:!Z;4X0J&-?$2/@)2)_T[X
M>*(1V:Z/\D*73G_"$-JM2'A"D<F+BO)(!2@%1T\1@B"D<E-,6E(KTV.8N1!&
MF,:L$BP_J))<P&>DN(B2+B*P@@B^2I@0B.`'YO,+R1"0U@*(()6V))-DS%2%
M!"2`3;[4G_C<^4^#$O.#M;)G/>-&SG*>LZSIG$L`SLK-<W9SB-TTH!(56\-:
M-=:$W(3LD[#YP1(&T:`%[5\)-ZO8!%S`M39LRV>S*5HC)?2U"3"`;G?K5Y@I
MM($%12SB:)@`&^3*H=T`@!-HT)YQ4+0<2EM:#N[C1?W<HPABG%`)LI`!$NR@
MI)%HUHY8JE6%8*4B,$VO1C(".TONL:?P]:,AY?\KHJ#RSI!!3:1^>R?(VA'E
M>$YU:B2%4+#Q6C4KU2OO5A+<%<)LDJTN:`#*QDK64(9/!U.P0@P@/#$\B`"7
MB4G,DJ;0APA4`:]W$4L.(3B_RQC@KP@(+,W$!T^$FE"&B>6L/17:EG(:%H*4
M(5,V?1S$G0USB`8$)V=AZUMF?C:>_K-+0=NB.+]:V;7,!*XQ`:KD*WNYM^+D
M\3"#&&75+E&W-DBS#63`9AFL.<VZQ;)`DSQ<W/K5N$^$XC?2(-'GID.+*[B/
M/38*QC!B5R,0"`()SEBM\(K7C0\IKZ3W40-PJ9="-:VT1PYVKD`.K[XZI1<C
MA]J2HLH71#E%ZJCSM2[_T3`5>4ZM$8XDB=(#8V7!<I0>D!ALE:Z*3$EKX5B5
M,/8]")[U*S&P0AJ\"F$$7,``%WB#"!00F"MQ!@%5B$`;4)9*8AL);F,I4O]B
MD-L$\$7&,[.MCWW,VBI_V<J)NV$S]1GENDR9GE[V[6R)^,%VOQO>\6;F;S%K
MP8+K0$VY5;/"%1YGS,R9@`HE;@)$,/'<4CS?3::5`[,)!H2GF<T%D$$!1A[R
MD;?9S7#&,D"YG#@K4]P&(,@S%,'!'N?Z^6:5*U88NIBLS"T+C)O#2`AVH(``
M#600K>L/5N-XE8ULH0;J3>]+*5TAG**+OH"\.D_954A!%G)VBYSO46LW5$(N
M_W5&22'Z\DJ@`@*S`ENV_A%6=RTDNC=8DQQV@0(BX!:-10:R!:?,%#(@`HAQ
M6`%C$$'B+V`^]:%%!TX`P+838+Y0KER4N4SH;IN4/\%V_C/8CG=C'\[E'-OY
MWV`.N,9!6V;;GMD`:G8SRN'\8H=W+;A*Q+>717!Q@&>\L9;U'Y,2?G*1D[SX
M:JX].7$X7+^*8+?0KSB3FSQ;`SY[S2`GN?9!H/V0MSGE#F_^Q`WP?)A[`[D'
M2$\$V'-S<NP)4I?S8GZ`OI]#ZR,`1P@"&G80A!XX&EPSA57GY5(R58!/QP"5
M%E-YY%X:<FJ$Q'7N\A);MSM@5U]"!10K4G;TDBY$<?\43J5V4$5@Q!`[<3=W
M#(-KN"9'7)%W2#("*2`F0G87WB9:IN0!#_`Q$-8`3,9LYY,_XA-Y```"'I``
MW<8R1>)Z"6<#]],FOE08;T)7M$=QOA5-[?9:SS=QST=^+]9[L25F&S=DK_5Q
M(&=\Q_=]-J!\_29^5PA]Y$=Q(A!FC<5-!16&V-=]=FAR9EA[`J=[;,B&%R=.
MG]4U8=AFW0<";7"(;0`"AGB';$9[]^1NT-<&/(!^4<0#!?`#5M1^."<?*[``
M^%%=/@=TV,4?.R($4Z``*K`$2S`ZF'9'-G5537<14#>+3W>`4(>`N(@@)#@]
MY^*`**(3_<4NA"2!\@)?Q7C_+SE5=K2S@:XV(TY%!P+6/`?"(R6X,`N#@B=8
M=RO(@F;!,2EP`2;P&!;4C=A45N+S`QD0`8;'87KQ?$[P`!<S&>.H%@A@`-<`
M``!@`S_`>1'#/VH")B%G`S'S>>@&>F!R<N"W>LQ'3U;8A]#'A0%'>L+75[!'
MA@5@B(O8!G;X?7K83,V7A7UX98#X<,$UB!9YB(:(DAJID=J7A[#UD0Y)?K[G
M9-%$;@=)<BN9B#JIB(B8DALY>V#F?-`'`@!`B0=@B9AX`F#P&E<4'Y6#4=25
M'\BB.9J37?J`$#@0!"40`D)@4C7EBJ\X$2UE%5277K18:6AI(2ZU5;)S=8>4
M7UGG_VE8EU3WI3NHEDC)J(P])6H/80[.J`!T\`9K!PPC2(UQIVM9E578J(U7
MP8V$D6SJ&(.XI#+')A8ID`'=XY@C8``*P'MLH@,_P"1O90`6XTK.U@9VP`,`
M4`!MH%P&E4ZY](\VP)IM(`,&X!8^6)`&V7UYN"8YM%"XQ89G&'TBN41>:$Q3
M=GTGB8@JJ9(MV8C*EUA^%9-QEGHTN7$`E5O9-W+-F9(8N8@;F7S3-YU^^&(`
MEV4#55#D5H?<B9&(*'GXZ)[N^9/@9V<O9@"X(G.[HAZ8.%&:^"A\<@(YT`."
M5EW*<EU@M`5CA"TO@@-+<`(!@'1?22Y#PA&SB("V*'6:YO\15]6+</DA%QAJ
M*4%?%CB7#]@[>;DARZB!YJ`"#>!4;Z!V`D.84F&8U9B"V)BCB<E@>\6""/`#
M-AB.9T(9QU90/R`&5I`RCLD]B:,`FY(&(N`$9S@&YU86;!`!N?('=E`>J_E7
MMZ<#X7@9W(F/JZF$F@$:!!E8)H"?ATB?T*90XK=;#,=;4DA]]`90SY9].OF>
M9"IY/:F3SWF&6,:';"B2H@=<PJ><.,F<1-F:C+JGO.F2+9=;A6J=,?"%<UB1
MQK>3C@J?K4F4?NJ=*UF&C2BHI[<XY$&)?]`'5.2??N:4YI`#]O&)F),Y^_$"
MV!5>!E8$2R`$",(Z$ZI>M<9K&S'_B[=HK`AXH6AY4[O8:6YY7R8*HC\%:O%5
M(L&(C!@XC+[#+TP%H\ES(PT@535:C6RIC3FJHW;'4BZS)3^*/2&3%QY@8F$A
M2N.8%S'`!D&&`&P`,Q[0`N_CF"[0!&-P`=-VJ2/0!+$2>-KC;!YP7-Y@!V6Z
M6T[@9EB:'M@@>05@`&R2F[I9,_@IJBR)ATJX)@Q)J;!'>]7)9+^%6MG45VO&
MG3O9IS+KIWL*GGBH6Q)GLKKUAP'WI6;%)#?)FK3)G)Y*LYP:LGA8JK7G<O>9
M>O>$J4#[LCC)D_")CZUIM8[ZIZ/ZG&Y6>Z_U6@V%?H\S!41P)[+A*!3U'NM@
M+%$IE5-9_VB:HZ`:`2$!<`(E4`08`I9EN:$^8J'(:I9/AZPV56MMZ:S'.#LB
M>CM@!ZUQ>:V(BSO`B"_KTD@A\)>!^51/46"[6(*7A*ZRDYA7$5=;<@-9(C+.
M9@5X@&)TH0/T-([SBJ<9``"%![`%%42BRR6.<0$%@`U:^K!;JJ7E41[>X`VJ
M60`VL+$="R<NP*:,:K/0Z5M5!I*\Y;0K6V\NMJDZ6;4S*[./BK3>-[+1NUL\
M>T\Y9%E&XK)ZRIR=:K7L^ZBT&:G0Z5KOIGI?VC\4N9W?N;U%V[W>R8A=RV0)
M(`,Q1XEVT`:>Y*K/I;8A4`+315T:M5%A!'1R.U,)$0!"0%7?TO\14'>`575>
MQ9JL:6FL&KII<V0NO>BL@R14Z1*!U@J!6Y?"[Q)VRIC"S0AK,OH440%WG*M5
MZ!II/KRCC%D9(3,-"G`!#[8E(Q`!?:``WK.Z1/06;)`9(S`%+=`&C`>P9O$$
MZZ@]/2@^%R`#/&`'411%%<`KZ9=^7)JQG(>FR<L9(G"U_,N2SSNIE0J(+,L_
M3"*UZJN_?$RS\RFRYFEGO`=FGG5D!:=Y4LN:*7F(^MNI6@NI\*N$L&6HA6Q9
M+IO(BTR4H*J]^ZN^B^R]W^NU%V`#;:"?Z`$.T_"?.">K;4L/&A6*"FI_F&81
MZR`:.<PC%9*64V&CY5*L(FR6OZS+'6S_PA[:=2@<2"!ZHG&9S'S4@*3VS"W"
ME_(2`MVJ`#&J%)D[C>2Z53KZN3Z\F"KX=_%(&-+V`P9PQ+=D`![0!TT26;!)
M8TF6F@4P%E@L%IM9NJMT&15[?MHPO+W[#9)GFU5PIC63I@6IN]S;O&4(OE8F
MOM.'GN[45R"WR)S<QS.;M3P9LHTXR91,D^ZTGF38G!5-LY(GGSV9D?3IM!%9
MOT"+OWM:M9\:JISZR2IILPOMM0;0!_SL4!`;`7UF<PG,)PL0?V5`H)\X:%69
M#^*R(PSP(NN@PQ1!:0H8EE1Q(;Z\P<%<`R^@K)0VS,2,PCQ5C'HIUB1:@2BR
MS'`IHF$=N2/B_Y<V+)@"TP`%@\&4=$D98G<+EM?>O-<0<8)"O*YF<5C9<P$>
M,`70]IJ.\151K'%J$@$0:P-;'#$Q@,]F<C(GPX-<W,7B$P,&T)J\6QZJV:8%
MD`9G&#-MTB6NQ+$S!AHQ@"N-C)+<9W*"VM`062N(ZC]5`'LPR\@6W=M8ZYS'
M9P-2*+^B)U`?79$P2]'KV[SN6;-_:M,BJ](K:UDC0'S:M\>.#-PDQWW>F=&`
M&JFE3;"[:\K<L)I-,%$(3%$J(*NTBA\E`(JV.HHGM2,%<Q#3@<O%>H!4W<L$
M",)9K=5;+<(7\B,GS#OV1=;#&-8J?(P,CFHD\N#!HU^_HRXU_(%.-?]K45'!
M5H68UXB">?WA>JVC13+.98$\33`%1;@E#6`%&>L$(A!N4:88:](U!I`&6RJ[
MMZOBD1T64JI;50`&]IKC78QM(B!RS#G:L.>UB`UL*F/0;N*$GC$"KKV]GWKD
M)F>>TO>2\Q9\!17`1L[;OAWF?HRT;M9;*DM.A(6^4_N>C*S)WVV'&DG3GQRI
MHFQ[C_5MQ;6=+YVUP%U\%JG(SPW*&WT!380-8FN)YXTVFA@`*Q`&]S$/D-[>
MH8BK2BU>K*"VJ#,=5#$=%9%'Y9(0N:RLP;P?`EX#7EVX[X76)F)4QMC,QGQ(
M"E[6_96MJ683Q?.7@EDC.$S7/I*";.FYW]S_EKRHF--3&?EJ%@EE-0A@`DW@
M;!=`;6:!80!@!3)`VE4@3%;C%JE5!6F`FENZ;%@<%C]PANXH`E.P%Q.3V4HR
MAU;H6ETC`K]YJ<$%9"`6&O8>&I'Q&3H@`^O[VLXKR92\8H15W;-YD8G8VZ(J
MGU1[M7VJOL&MLM5;I'F^J'MNY=[GY_C[R1@IM(!,O@)/%WFLQ]B=B(J8M(U8
MJNQI\//IO7,<M@Z5'NOQ!%&1WI*S`_'PP/C!<T!GJ_AP:!ZE$053%.M@`0^Q
M$/BMEB6LBQ_\WP&.#\>:K(3;X:DNUBAJ@4D5X0Z>UG/)N-G*PF97N4@!F-$H
M@@>!23A*["/AS2`._^+$;NPN(\0)E5!BX@0Q0#Y.4'D70![J`0Z_"5`']VQ8
M*L80FP`[SF&Z%0&;]V(#5070WJ.)K6)J0K+D%V\;]\Y.;A@D@Q;F6#.SB9)\
MK-`AM[2'2N]F%0,OF[V?GXAW>-UL3J99R_$!^9*_]<2KF]M2VP=[&M/@B?(+
MIW";JO&BO=#W(U"T/Q<FR9T&C]%R/'N]OW`A_9TLCW*NA6>'W@>_HI3D0/.I
M@0*S6M3>KU$EU7,_%[>R+'0J4`)/T`1"P`;;0O21=O2#6]4NY;?^K=7&^@)D
M$.#*"B%S!P@3@H,$!!.%@HB'AX:-C(^(D8Z$BXF&B9B5BXZ3A9Z>C)&AC_\3
M(4]-30IO.PI-)4)"(0P,0[6VMQ.VN;FWN+I#@L"#PH.[P[O`R1,N",S.S2[1
MS4TB"B)H.@TC)M'=W2,1/'\'=@`R"08V*0!_=N3C?P!I(]#>]O?XW0T7#R(&
M!C$,7/AA((T($3J\Q6BF8\2(!B(N7*@V,>*%!#%B.$0`S8+'CR`MN/@838>.
M>M%$(C@Y,N0%&05BMFD#`H#-FS9IZHQY3N*%C%78G.1(%,$(`S`+S)R)\R;-
MF%`+))5!M6I,$&T`9,VYM`U4J@8P5JGB<&C1$0EL)%6Z%`#6IU)MR)U+]U^Z
M=&JO8MW[-JH,&PDNE#7+40<ZJE"7OL7*DZ[CQW3_URX&$57J7P-W#+`[P+FS
MYP-__K3YT>`$F!"F4*M>?6+UZ@`+5BPH0[MVC]H0RN2&P)OWBR*_7[S80KPX
M\1)+4#5I\"3`R`D6AMFB-8OZD%G7J\^JP8![C2TU7M0(3UZ\^/'CNW/O58L7
M,4R?(&T:)2E4_$OX)VG*-/_2?$J<@-+()XY8$,`3#:2B`"NHJ!`+`P&P)V$O
MR""CC#(5&E-,,!M6.$0S(#[C3$E#Y6,/`B*TX0YG=F3E3CN>E9/"!2B9:*,]
M^XC@Q!0V3"11#"*,P`9*"DATD)$_Q4`6&"6V)%)(4*K4C4@-T8.22AV%%(-:
MB+'5E%9:+<630$`%19@T_SI<D%=77X)`F655Q2FG53J%^19<E@&F45E%$75!
M.DG=&>935#F&UUUV)9J74G?BV9A`9A*&0!5I=:G38EX5`-FF-OP3&51NOIEI
MGF$9T$=HGZ4JV@]$/(':::[%*NL)*"QP6VUEW+J;;KY!(!QPPD%@G'%%0$##
M#3LL=T*$'08S'7804J===>!UIYYYPH67+7KH7><M>QL..*!\XM*W"2?[*;+?
M?_`5HXA_Z-X'"8&&!,!&"0J^H0`.KL020H2_\")P>\E0>&&&S2:<H3`?ANBP
MB-+4F`\;!O!@QSCD>(9J:.9<D-"-^$C<#1L61130`R9:T$!&(YS$#3XB2>.D
MD_]1KM01,RQ-"=)(-'MTE)P%O/6EG9D"-A:??7)4!5)7,;55F#S-*;7403L]
M4U^/"M:RI"M5"NK55S<F5Z)DEVV77('N)>971IO4IPX!+<JH8E[]Q>G89I\M
M-V.5%8I.&SRD^ED%\4S1:JRMR2HK#CG,EIMNN/8&>:^^0E#$%L,-2UP1^`8Q
MQ1LE%!%`A"Y0Z&PMTZ:^W7;@<3N><"^0`;OK->3!'2V_M->N@)6,Z[N`[^IG
MB;OK$M^?)NB>6Q_PRX30``T*J,+@*UO\.P3`N4_HH2_&8*APP@Q/`.+X'(T(
M#0(-B'R/408`?C$\?_"`4QLVQ/`QR/F(3+(___Q@$/G_#Q`,R)XTDH>,("+-
M(*!'>B8EFLVL&^1CH`X`!32:@,DI.Y$*0`;3)YRI"297NR!-*#,UJ:GEA'_I
M4J-FXI>_)*`*)N':TA8%MK!IJBYYRZ&GDG(IK_2!;0*)X5G4M+>K,<9ND-&A
MV>3VE%$5ZA\%$(?@-`:`*3S`5:MA0^(4YQH4,*$'CPMC;WH3K!?X)CB_T=P6
MBL`YZ$V!!#@0P@F@%0`(7:\6I;-%'57'`,U]YSS:@AWL9$>[(=1`0AHBU_!^
M=R[E-1)>PCN>\7;7"4H&R#Z(&((I$J0*.K2B!*&3!?<(1C`+>>B4[R'&>SJ$
M(6&4[Y5/8(;#%#"&-*AO?0<L_P``>&`QK41-!@"Y)?Y,I`."3.0?@=%(*RX0
M@330*&7VL(!%TC"&A#SIF@S<6<3>YC:;]0Q%7`(:H^:704T)1BB28@9:;-`T
MIN3DERE,(0KEZ9AX@A!3HXH+0(18%+@Q329@>Q,.E8@._I&-AHWZ"C`3@$ZS
MK--2=\(*$A^CQ+S14"E]&UL4,39%T,BC":YB`VI:HT4L<C$$*D#!"FAC1LC1
MYG%F[)49@04<S&GN-Z!L0A`X$(0F6&Y:Q,$.*;,#U&%]!SR8"Z0@?3`[VG4+
M7.$B1>^`1U5,.E*2_OG>(GG7._A(HER&<,&!.$D'?2D`E$60!?:RYYZ`E;)@
MW4ND5O\5-CY9)J0>*[G!#T1`%#:`S"AQ*Y3)QF(_];5LF#+S!@(,X(1_."$-
M!A#!7@4R@KW2`V8PTP;<1L"S!4Y)L84)[4JZ.=JAN*UG+JC4/.G4)KB<`X8G
MX=J6>)B5VI(P3N$\H6[O9C?:@NV7E'6;60R#T(A.-(?^$$$"EKO<R)9-+C)9
MS`\;\\(8#H523,34#2E*-N4V5XEKJEH+H;N9CH*&!Q&XXFI,>E+5,&X!N^(-
MK\Q(W_IB[E?"L6E0-P>!$O2@"3N8PN=H(`1JS6*_N-.C=M28N3\J]05,96KL
M8D<[+W#'"PG6G5?%A1]+C,N1'2:%*"H954)\U3[LFM=7U17_`.?ERY.N2*L=
MWUJP5J(RKJN4ZUP99KYGO#(:(]!($ZJ@@!_@;R5!_I%#K%2^B+D`#$)1`&>/
M+)1[B"`-G2+(#ZH0@P8,R9O#C%DW3&`S`I*6*#IHZ&FM6YCAF@2U?T+;:F&"
ME::P4(/VXV?YTK0FG=0V+H62YT1WRZE"L9,MY?3;UDA[0(1V)2Z=,ALZF,M<
M?S37H(FBLY^=",P\6W=I5HDNH0PE:4JC0XFTQ2C;V%G>CL:O`&AXP@E.(%+5
M;/&D.<@!'';U4MW$M+Z^&D[FC#/LS0G!OTL(,`ENL(02;`&H?0SJ+/9X8#7>
M%%L0AEV$A4,&IXX'D90@E^^4=TEU_Z&XDEGE#X#`6CPO3,#=`>*P(%S@8C2\
MX=Z?E&,(?$'*@5WH8`!'6([G*CY9UM5A"/C!&!0>`0/@01_"1+.?U.F"&$AD
M"F.HI1,0.$PV/-,>:HH!F85I(S&GQ`4M.V"0>(8`EK&Y*-ZP`))U,'+3QI"!
M<9O+U-QI$ZP!QKHEZEK::CN3>'*)T)O"2SWI`M!$=PJVC$8*3/K0%19&.F^6
M-C5S2[7$JE4]4W\13)IC^`"I)^9.D,9;V;0^:1T>VL\9U>6*S/L'6#_!5;-6
M3:T5UQH5;``%O:9<&2LG[,M9>[]K[&\/5O&&92>K"*E[MN3[N.##(]7!@BQ#
MMK/-5-EUV_]UAN1>5)E'KQ$SS\0ASD2(.TS5$'OA];"/O;OA7=5BF`(5;_C!
M*E`A!!D;S)3]#KCNPD?P#:U2ELA_Y?G8T&48MBQ)8_#&_49$#Q-(.0932`"/
M]OJ3$3#I98AUP3[29P\%M`%EB"7*C1`P!HN/`2`\<P%IHPDEG*D?S:>%4J,C
M<_2_!,W.8)<`BT88/],T;N$6@'9T=[-$A38W7N%$0?1RH/8U:Y-#D\9<%W$1
M">!=RI4W=!91H](C#M%0'[06<R,VA[)V;%=1/.1U;",#`#!W4Q0:??`#LE9K
M[-5>-&`%*`!&+X`;]"53-B5LEE<<Q>)?"A`$04`"4[`#/6!XT7;_8-%6')7G
M1\7Q.N@A'!*V;9U'8630;9^W'@&C>AQF>E8E;^T2;L43+_*Q"+/W;K(7AZ^'
M284`#`1@(`@2/?>F+TV@`D\`(<SR;V]U8P''(3I6?(+003_V2MHP!9#U`Q=0
M2Y!8#PT@?_10)&_@`4[@!)#8`#07?MV@`T-&#V^&(E@&!O:`?5,6,J.U#P,A
M$.MW?1GA5P2D,U&R,WMV/F<")3K@#_Q7%7.A2^14-P80*5&7&'Y&&7(V:'AS
M=0?U&(:F%HW"-V$W&&XS6TVW$\!4-I8661@8&*;F=O_W=3SQ0D+2,F!0@F?G
M6ITR%RJX@J?F@:*63U31!6W`4:XV&G>'_QHYV%Y+,`-'`$:\,D;!)D@UI3G5
M-BQ'V`,[$`0W,`41L`/4\VR45X162!S?01ZO(TB;)V&RXP-?6`-@.!X8Y@6F
M8V+BMF(IF57IEFZC-U6:`'MP*(<?\`%>4).Q9RYV.`%C%3T_$`1\&$H)UE86
M,HC"=PR(J%7)=W\_Q@8*H"2Q90'@UPUCL".06'TF1W+>X'TLP09I4``',0)2
MQ@S6\'$FLA+4,`+4(`*.:`-C4``14`!CH)4Q%W_81!+7I$V)97(IP8M_XBDZ
MEULR\#1@PA@V0!8-(11$406.MA?;14^DYG:!B40@5'50`1A+Q@9#PF?KJ(WM
MF"@72&D^H8%;I_\H9S,W1#,F>[)D'U09&01,`V47;%>:!V47=,86N`DG*F)>
MG"$:>'`X(9`X6-2/JX$#+0`#)1!3ON9KA.<K"$EYU$(L_44##>F04Y`%8&1X
M5#@LPE9LQ)$YPQ$>K8-M$Z:%G.=YL1.2GV=(&08@_1%OO\.&J9<P\+([A^`%
M!.!N,QE[9'"3-UF3`!J@<Q@?B^`")\!)>YAO_[)6A'A*#2I7`S=7BFAPR?<3
M8Z``4W`!^>!9^1-^$:!P"?$$&Q<##V`ETC"5H?@$.@`&7=9E!>%^!L`CD740
M(E")PU0/"I27V72+4=*7(-%RBH(VP"@7-3&,4K&:6[,26P)0";6,D5G_4;_(
M=$3WFN:X9":A)LCX6]OXCAB8@9267(!Y=>Q49UUQ1)"R9`^%C(ZI0>[HC+/9
M7/%X*)'V=I3A)BT$`E)$=U5T.,3)7K>F`"U``B7`G+OQ:\+BG5185,4A!(K7
MD#=``DNX`I9C;1RI7Y8*'N+QG>>1+5S(>=GVD6`8AC6`8;A08O#Y2*<ZG\V2
M'_:9GX(@AS=)!C4IJP%:JSB)8@7J8JKP!D$0/:\P1P##(48)H0)GB!&*B`BG
M?,KW!D>"!C&`,Z)HEC:BHDTPER#3!)<%0>MS$IZ((P:@<0*A7`BA`RIZ$F!`
ME]+G$]EJEYV5ESRJ6!"40#M#*7JS6N1EI#*@_S56:A)+NFDC])A/JH+/B$),
M1Z98TVEC01;/=V@.:*=;RJ7+)1&!09IQFH)C:C49U"-E@ETF6#5O<AFQ.6D<
M2&G/I2A9JFI5T0>!PYN%TRHDE1I^NCA_@`)+4#D#R9RP@ZG?F:C1:82-F@5,
MB"P2.:D,ACD%F5_Y95,9*9X/IFV>VGDBJ9ZB>I+$DSRD9[7%<XAIF)]<.WNQ
M]P&R^H6OUY]?&*!(<+9H:Y/XV0GT=@I%]@;(T@J]9SUNM3W`)ZQ(F93?HXB+
M*$M/65F"(1%C<`$I8`#39R)O4`6/A:[QBF9/>0'6X#^K6!)CX`]_\I<_<+B@
MZ`)L$(\_D4"=%;H+Q/^C,D<^=142*!>/.H=;[$284/-:"3L82\H6F$*9L0F:
MRX5I81J-T#6E-J2Q0.$0+]&99@JQ&>BEX7@VBC*8OAN"8J$D,>`U3.I:8>J,
MWIB[N;M$!W5/H<)I&\6R5:1>LA:<(Z5WLJ(`=K`!-:N<@@<[8_1KTM:S6]!?
M)4`#2LB$08`#S<8;.XNT^(5&0SALX9E4&PF&3WN>7YB>A622&E:U[^E5YB(\
M^JFU`(*?[[:?KS>KL.H%9?L!6O#!:6N3]V$(M]<$>Z@O-*`"OA<^A4A\WJ,A
MQZJWIFNZ!A>C[Q<!U#!D1H&N?N40(+,U#A$D3M!P3O`2$-DI(G"8]O`$`B'_
M9=_Z#PK`N"$3`4Z@6S&!?B=WE^X:$DDC<;RHNDY:*,)H9R#0$QG!,FPP`EB:
MC'"1=&L7%MA;KT(JI1C$-\`;O&FQCGWQL*#I71$+CA)+F^ZX0V2J%3Z'$64B
MO='EF+`9L,[5=A7[F6>C:364)[J$CZE".`"`P_O8&K36&GA7OJM1`G9@!4,[
M>(074V+$&T(P;#U;+!#0`SV``T$`M$&P!&#$J&S4OP5YM(*DM!B)+8$4'K+C
MM"`Y85^8S"/Y;;KP/:QW/,E3#*\'#";IS/<Y"%X+>QH,>T/PAEY+JQ^`!%J`
MMD@@PO(Q5JE05C#6`&D5(<$J?#96#*F4MWI;###7_R?I$R)-(!C:T&2;*S+I
M4R6"44MI`%D1T&@B(`-5\"<B`"13(`-H@!(4(Q&]J`TJNKGV\`/R8`-U`SBC
ML0TN4',OL\4DD33#A0!^6;VLJQ99(3].01G)=,8*BZ6TJQC;Q5UVD76TJ71(
MU[I.`37F)--D0=.(%C9\+)NB"8Y*_5VF:9LK]+N(S&4<&Q67@H*W6U!M]US6
MRS1J\R:-`8,R*#CQD%[CJT7DZ\F*`P9"8`89$`0^.$:$^CBT<2M@Q+\4.86\
MX5\,N80<0`(KT`,EP+])*TC-B;3Z)6SC0<#98L`1UH7*['DB&=G,S,`1ZI);
MF[7O5@-P6'SZF<T9C)-SZ/_-&Z+-'CS.2"``Y?QZY=)B"(IO_:)6PQK/Q[!*
M,5S/XG-P!M<G1>;/&/UDO6@#4X8`!6`0!7W0>P65+.$_]:/<!Y0.?*58%'%`
MFHO1#V`'/(`4\D,5XD!".(01UL1`]G<FY0,E"'`1*JV`@]E:!2`025(FLUO4
M`I5$_\`_6$VRU8MT2H%!VO@C94+4<U.\9N/'&AC(V:N\9",#A0QWFH+(2K+0
M7!(5:'<9/(UU%>LI2Z1I7?W5K3:#/&!W)Y"#(K5WK($:,!"H.&`Y[AN$RIDK
M+"Y&\4L<O`'8U)D%'+`!)+`#N,S*W5E&*EY?V=*_FRK,'/FIG?>%(*F>DLW,
MS6S_V\@CS]R<DW/EV0`JDZ]ZP:+]JEZ0!S7YP0*`VC;I5:/CMF^;+*^`&N^\
M,(F48[7-Y(DXPPC0!#\P),XP!E.0?-K:<1$0$$X0W(-+T29Z#[54/T`2$?\P
M!<\-0?YC`&*YKHAE`B8`!@[Q`"T0#P80`79@!_[GNBT$$-Q0?VW&$=P0(N1M
MWDM'F2V-$XS!WDER-#3MKU[!*8E"WSL=&<R8WSD!U'HBTVI,0\D8$UN-3*9&
MFN):LE>'X%L14+[.X&/Q)VL14`)U%[>+3%K=C(DB:FKSU2"`R:K"`RD0:Z:!
M&B(^4N&.&CCP!REPRL!!.;91!DO`[K)<U\X9G7D]RTJ8_P4HT(3[V\N&ZN.^
MS)%82)X?N7ED4.0BJ<#*W"TFR<`4K%4N*7MJ.W#$X+7[.>5S:.47?/$=\MGC
MW.6I3:`]J0#JS'OM/(8/2L%KCJQ&,0]!\01`V@015%?V$*T"H3XZ@`9J6052
M'`V/.P;TX#\10!76Z@TFDR8UNGXR4UE68#&7W@X`H"F67@YIP6K6;<A>W0?G
M8$WD'4,H"MZD7NIHX[INX16J?L8CP&4&H,=/`>M<:E!12L>W[B:O'M-*$F3_
M5--%8X%ORM30+LG&?NMKD^M`$1`FV$-C4A>_/K!/>FCX]+%R<8^\>0`=;H/L
M->[D&^XMP`,KD._`8K.U`0?O#O\'[<Z_ER/OL8P#.[`#)$`"61`$.`[OP++C
M*5XY!8E4V8)M!3](3QNJ17[P%C:JMN!NW<SFV)S9'!R2.?F&56[E7TOQJHV?
MHOW\6+[E78[:^ND?!LI)TM,**@R(PTIP)\_FZ=,$&=H$0_%E/^9C3EE,C!59
M!6`%>(`2>)7S]L#S,>`$#6`"/M)EC.X"(@`(8R(C338Q.@A@(VPNC8T(+I!@
M4W9_!Y>8?P4%,A%_?W84,C8&!6T`;6T%(*R;(`4).A:SM!:1.HB-MBZUM"XQ
M(@8VPS8RHZ/#,J<`/`"H(*H&%],Q,555(U4&,IMMT*FOQ.+$!N7F"0;HYN7B
MR.*FSO'_T)LV"3$7U=@QVYNFW_.DUJU#EZ"@08,"$Y93MNP4M%>C[.6K$B.!
ML6[^O&T:Q4ZA0F+&W`44YLI;*I/T;/3YA*EERS]M?CQY$H)-B!`G;NK$N7/G
MCA815O0H4>(%A*,0RBCM4:8''*=EDI9`NF4+`P95(?38B@,%B:\[=N#H<?3%
MBZI%S"(UR[8M!+-;7M1HV];'"[MVS>)]089O7S)D:@`67*.P%P8UO-08PGC(
M!"\3(DN>3'FRE\N7/WSPHAFSER&0(3L._3@TY@]:-'>^_+@U:<BM)9LF\P&)
M``%(D'@A0"`R@2$AGC11H.#-#P5-5!0)$8#Q!,?/(SN>'AUZ_^7HU[-KIXR@
MNR/OD,)W?S("3!4=38`AL*%`Q)0?(T8XFC\?//W[^%VP08`K_'?\38APR#X&
MW&.`$S'@EP@/EKATB1T&6,$)*'\8$($,"_6SRD,8&6`"+[T\XETO)`(C#$C%
MI%C,*<W$HY$TT^`30WQ56%2221"-(XY'":&H(C$%Q./B*P78(&,^V=C8C4D:
M<>11`B(<).5'YMA@RC*HG$0//M=<4Y&5_:3BST8C\;A.,B&E.0P[&9V$4I$J
M,>C@2S#A001-.?6D4YX\[<1""E/0L<10;QFEU*&',L545!!491561A&UQ`XD
M1&`I!SL,.E6A<:7%UEN@TL567(6U-?_77:CZQ9=??P'&:F"#%688:+2"AMVM
MD<%V76:JT::89[1^QMAGGG&&FFH?D($9`;"]YEILN7*FAQ:X(?'!!+UA:T$`
M3S0P'''(-2`$<\TU)IUDUFVG[KK;=>?NNSH0XJX+#8R1!GSWC&`")/_5]U]W
M"J0Q"+_Y%?S=O`@\H0-],8SQ`+UC&*#`&,?)YT@`W3W0PIR9K%+`#W_PP$,Q
M\```PD6F<,)-/Q>80*(M_'7W<BTUCB-2,LZTZ$PK"5##97PC*(FCF#>/8R8[
M.NH(@I#.B%F`--58@\T(%Y!\Y4DY/IF.E`@)5"9)6#;MM)$3470!RJR\R<G7
M1Q>SLLHAK;G_,I//J`)G`7)R?`E,4S1P0IYL\*EG33T]L0$*0>P0Q`J;&HIH
M4TTQ59:C5S%@5`\X++'"5QM\%<189*U5U5E&E2ZJJ:2+:M=?=PFV.JN"`2;[
M[+$F%JRYP^;ZG*ZN>>8#LI<I^RMFP1+K&6U:\+H::\Z2!FVSQMIF[6Z^31``
M&]X2]P9R)8S+G'/4W0K=^.R6KZX+B!RB`W$4X^$$O.FQ,<UQ_=9_7T47E..?
MP0HV,,(3,6B`#BZ0A@;01P%.N(`+1J"`"V`##/;YCA4<](D&'<`./&B#`?K0
MC&VT`8/-X(0K8,&/C22(1/S)!8AF%C2;Z2A(S-"9W7IV)&RP88`K_WL(D^"4
M-+;UJ(<@61K3B`:UB<0G!B13A9OLYL.!<,T`P>A(F5;$-+%MHHA=NH?5F#0/
M>ASM3"C3D,I`T@UHH")+JB!%D"S(,3L`H&]/.(%-;D*3X-Q$CH.C(PD2=P02
MC`4I27D<Y(Z2%LI=Y2@]6`(.@M`Y2TT!!8P;%*C>$A>Z%*I0IY,+6_J"*A^P
M3C"H:A7M9I<LP)0R,8LQGJU6^9G=-2M8R`*>\!)#K-L9SPMD2(WRA,>\TCQ+
M5[PK#6INHQO)\,8%(?#6MXC3O1,P(`#EJHXT<66^:F9'`09@0P0$5HT+Q*<!
M\VH`&A2@@S1,(0U5L)^";F$%@4%Q#`M[!/__Y#F",4QCFU0;Q'T(MD]Y=@<-
M#VI),RJ!"9'U(4@GLY(JGM&/5]BC%$2R@2QZ\2Y=S,P".D@`$(&4,R%!Y$A(
MP@42RP@.,6VTB54Z:<F&R(D$>*E+-]3&W'1(Q"=QK2!G.M&)AK&**C;MBESR
M4C6VF)%^..F+5A.C49$QMU2(32-J!(#>,@&`-)0@CGNZXT[^II,YZN0)B]M!
M%D@0%K(8)2EH+0NG'E4Y")1`D3T(PE=2L($-9.$(B9R*H=:BEM-54BYS*55>
MV)*7U<F.53Z(W2@7&QA4_LJ6D"T-:)2G&LYP1EF!40QF:Y"'8N&R-LEC%BX]
M4YI>$DMWE`D-;6S_(X#-](8W$PA.]HB#AB8(83G1#-]UTI4N:YKO`DV(%]76
M=X\Q1``1W6&#`A06@WWQBY_0E:<+@C"%"T3@#J6P`ACV%8D/\7.?(S!`DD3@
MS2DHX+OY^6YX`'`%!PV4JAD,4A_$L*42;L@8/9-!*V30,EOXPA$7I04"J@9$
M8[`H9$+BA`.C=@U<Z$`;9?Q'UH!HII-R(QXZ>P9_L=&E$>`BO#-=XMJ.=I!@
M1'&G:TK12H=XL@)=(QMFL^_0-H*A+PKC;4HED]7,V)`FE0(`;)S3'P`0@0<\
M88YUO*--!)?')^`@+#A8).,NN5?3&;*MF'MR$"*0@A1$H'-!&)19SVH6_T_U
MU9)F*8-99&66O@QV+Z"$U:L82YLZFU(QLGIL+84UV3YSYG>Q[$QG?"6[T7;6
M"YU=[6:BY=G2GM9YS9(-9[1`K6+RA@#;PMXRPX5;:%(G?+WUK:@EXZXGI``^
M%(N!`F+P+@2DYPGG?:YT_2/KA`'`!B+PP`]^$(%*I.`.%T##%`QP!WT1C&#[
MB*(((F"`-[1!!.CMY\4BX6H[9.(E!7U:D5;&@P*DP4@UXX;=,)0_#1E@80$.
M\(!1#)*+G,*-,@2!(6#\8N1FE*1+Y,A)<WK29,`PPR9K`W^!%A\'9U3<_T#)
M41-"$"CUB-W^%F(5O2$#>[S8;/D+L4;Z@5(PXO\XQTR]D=@`L@T`6'NJ(2M`
M$[#JU9[DA,F#$\*D:-"$(^1@S*:C2U4J=TC,+>$(*TA!!C*0`@YD(<Q;46LF
MV[*%4[U%S9J<RU[VTF96J0I6LHM=LDJY==DEZU?"`\VL-B/V7P5:T+1!5MI[
MQ4M<YM(VN^F-9XLUV<M`IUERCY866'NM2ULOF30'5Q.Z%X)G@H^:V`GUJ,OG
M+AU4XX8-:,\41O"N'[R!@?.*A'3]J7D=M"`#,OA!!OH0@SZTH`T\("@F[&"%
M*GS(GV\HAQ.@F(`&5`$?Z)7UOS2/`!*T]P!$YE@;OA"OVSLA2%%*P[D'J"1R
M9V@C"IS%"M/MBWTD+23__T9P/(HT-:#=L#L'7P76P%$DB/=[H\>0>(99(8,9
MX>*&!J\:OMU4?AZ9.!U>N[ZX,2PDBEN<P_=P`1H5)FE#)"/6-A\'<L<0)J?0
M@$Q4<D%&0=V&!D=&1TJF53M!$RW7$P&@$S2P`'KE%F]12&QU2(L$=$<0`1ZP
M@I82!%MA5ISR*9G4=)HT6)Q$%V[&.E='9Z.T=6JG&37P`:@TA&87A)9U=F>W
M=K&46<&#&G`'&=DR=\#R:+$!&Z)%!M-R&ZX%6\C4+4TP3N$B!#G1'`&0>-.T
M>&CX+D&@'OLP;.!$;0MC`M[">[-&;29@`HZ'!C/``UR&!ZEW!QY0`!E@<G/2
M_P)-X%V/$!_V1'R'X$VQ-D_[XRXM<'(R,`45,"<`8`#G@0_%D`8>)@(BL#`(
M`&(84A!68C5=D``N0R*\8%$SHPTZDB9!PB`,(@]/4W`Z`'_O$@/BQD50=7[`
MZ#;%L#0BPS30,&\&%W]6T@=#HR4=5P[J<"8[@B;[YU/^UR77((#H`"8IHS8+
MYQ%)E6,Z]C9,HB4<D09`%H$NP0-]0(%_DQ-QY%4;F$<<R!PXL0-P4$BB4A4U
MP%9#4`(HP`$D<'0D8`5<5BDH4`*)I'1Q\5<-R72G0A>G8EB=-&=9-SN*94II
MIX2TPW6;L1F)(81(.))G!VB:,4N?M7>MA2TL>4NT1/\\F/$\NG,:K"4`<9<M
MLO4MM65;G79XH:9X:,@N[]($RH4`;.!A%84`]1)Y"N`(*B1K#6`%=F!M?Y`!
M!3`&'H`'UA8!>.`!=^`)<Q('=M``SO4=*>!MF$=>3:!>Z=4(`1`)#7!R=B`#
MJ><2GV`'?8`/3J`.K,8?E/<(^U!Q`F@#";4R$C5]O@`)`:8#$,<-!L8,0U:,
MJ``+N&AP[C("5O(-Y3ABL5@TYW<,6))A::0^'R9<V5`*;:*9!V@F)U8E[+:`
M$L=2_"4U9H-3X9@R1K4F%19&XAAR2T)_G-D&ZM@2%<`#ND8$>/1R605S]*@3
M':@32[`$$.`I)+AS5S$$###_!#T``P*9!5Z1`BQH*5LAG=,)%XY".H$5=4OW
M.JGB9G+1%QG)@UV7+";9*V=G+$$8:/5)DIJA!3Y`:<!S&I0V/2R9+:ZD9W;'
M/)$F:5F(&]0#6QWHA<31!$W0`#WY:688E*/6:AS::BY`'B/0`/@P`FC`:G1H
M`DU@!QOS(#)P+S$QE1GP`SQP'G@09"=G!7_)>_?@!-B00OOC+W3H3PCP`ZN'
M-R=74*G`7T[0!S80,3$`?SFZ0")0#]:0`%<$)NWG,B"R0J[X,AG5F<9`C"$S
M9#M#F<GH8'Y9"K[8)`$1C!8VC!WE(FET'KE(<-FP#_CV#ZNI$*V94CIU8TED
MC6G$_R76<`_JD%0'I2%QTS:W*4;&@"81YC1K@PZH-YR9$!,S`3B:RA-YPIP[
MT8&@RAPXL`)+<!:.<JK^R``EP#G>62D;X&6O.BGD^0)%\)"C@YZGPTF#M2JO
M\SHY^!?Q&1A=5V<?X`.`IH1+R)_[.9*IL7>UH1G6\G6?51M($%HL*1N/\9*W
M]!BC@:TT>1LV6:!_YX7#0:$J,"Z&YP)`J:$;VJ'OLA_41@B.]P-.<`/(08=#
M&@<9<*1V,`4Z@`<`H`#P]@.MAX<14%`G%P<'8`7<16MX`(H0I'EM>6PN\):0
M<+"8``#*8$%5A0T7(`(I(PS2(`*S%T\+1!#>5`4J4T()H/^8_H68%X4`V]@.
M(2%$D=DT)^--!@=_-Q0?5BI^(N8D+N2F-A.;<GJ+#D8C%&&HW$!3"E=C'A$,
MT>BG;>IO89,E.;)@7B*`[)"`2_6-'X%]"NAOXCABZ(`WEKHW;6`G&JAD@O-R
MRMF<SAD"-;=(.]`H_=B/_C@$`<``/>"J7P&X))`",)`I"U`$1V&K>DLJ-,AF
MFR074Z<7@>%)OCIG\5E*Q%JL_+FYRQI+SFHMUD)IG^NLF_%9_[EHQG2ME\$`
MAX%H"6I:EC%IX!IWUQH`)]``-%>NS40NTX&A[-JNK=8`;$`>,3`%X70#2MD$
M50`&+H"(X(<%*MH2;=!<(L`##V#_!VT@!GB@0?QA``"@L%U0HZOWE\>6/Q<0
ML9OG+V^)KP%@`BNZ-WT@`X1H!P5P!PL37L>'(4Y@`VF0"IZX+R-0$=!X'MN`
M(6`B7JT8(B_[,BZ0/S93LY`9;T:2C'9Z#3;B)AQR5$2+?D:;)9P@7N\'8]TD
M@.)V)=^0FSR"#GWZ$5;;?TY#;A2!<5'4J%^;8CN2?XZI5(_*FXIJ#.D@@$$R
M57L#`'C0`%A5$\J)5<H)./08J@&@.#N02$'0*-9YG8WAMQE05X$+`U_!94$A
M252,JDW7=&R6GFNF%Q59D:QS6&S,6"?Y.\8*Q\:J&?79N8#6N<A2K3X`NGNW
M=[GAQ[K4_X2>9(64P2QU1RR'UJV1=AIZP%ID\%K9TH$-H$P4VCVX92Z(MZZ_
M>QT<.D!5D`8*(*+NFI3R%`0JRD8%<!X14``C8`4M4`!X(`;MAP`QD`;6)@;,
M<*3^2H<_D`8R(`(&]*-M.6T!H`-'>@!#9@-.<'(`4`!$T!WR%P$6824F8R0Q
MPK4_?`W#<+:<D$X)W(KSX5\AXL`T^YC-@&``09H?=D0Q/(!*I$1DDG\;G%+Z
MQ6+TD``>5GP8IXU-Q2'CUD0-AU/2^,!74S=DTC-"-0V'ZK5PL\-Q0P[2*+8-
M[382_=!0<S9`)L1#-@5&MF0G4$=,S">=VIR@B@)13`,JL`-)4/\"6Y`'>XN=
M#+`#&<`#*4`"*S!64\`Y$1"=9E6KICK&5Z&WI:))G'2#A<6K?A$[L$,[@L%U
MIN1)='S'4:VY=*R?_8F$<!RZ`]K'?IP;N0$]O`0MQK1G"`J[I54;L^MWV-*%
MDTRA@V>AY**NSH%XF\QXK:8#`A2BKK8?[HJO_#$#<<`#+Y&)%]`'Y_8#?7!=
M[&@#_)$`^]H'!X6Q5V"]M'8!3OJ&PDP?_((QU!8`(W#,P(<.#()!`#`&$#0"
MRR8#3J"Q"3`%^?7+#J30Z.!-V\P/_+6*TT=M,$L+L$C08GJTFH@(=7JG]V"H
M8&(W/?Q#(LLCTX@TF^#"JC`*%R#<Q"W_VT+3C3V<##>,?PYWJ!0MBT!+?BOK
M4M4M@#.,8VF2WNJMF_AW(NH=-^]MT1)1RX2(<F]$`W$D1R\7.'9T$TLFM_8(
M326P`6-!%$V0!1NP`[5JQ8S!`$(0!"W``UD<!$=P5W+U%4O0!`LPG90DQC6`
M&&0<6*6BJWCQ%WO16%AG=;0#U1JY=7,LU7-<K"8IU;&TK-7ZQS<NNC<N/0*0
M/)+&/`9ZK8[6NIU5=[]T&8W,6@\*6];ST91<H1?J`G1=UW;M+FP@`@'2RS&0
M`I0G'N"!,)'0!!4@EE/``V(Y9!&0:^G0;9K8`@"@0*-8"FF0>K:,"<;K'=0&
MYM&&KQ6+`!;;_P`O@;T7@'K-;`/#)@*5B'\>``!]T#,VL.@%,".C:*CI`(OH
ML#*QL*6Z$,[2UPNHW2,7Q@P>U5)=_F'9>,T#B!'9;6,L?'V:^<(8PFJXL+4Q
M8HIE^[7IS=X'@33I+4(988"/2EXT,L(GYC8JT]`B]-ZZ;IO4"-_QK9L('1\`
MF[;(3&0KUZG\C2<@C8$DS1Q>X8(E<`)"H`(WD`72:16-`1Q+$`0BTP(UO4<K
MH#AC]61WNP73*<97815Y*^)#?8-HK,9*S1<4.3N_(SLL7M4U/N.:&^-P3-7(
M<L?^J>-]7*U=_=6[(M;5(UF8D<BP*Z!>?9/8TAO`T2W*1`/B<A.>YO^35&Y-
M7=X=53`&"O`#%P!.BS#*?#X%!Q`'+?`%!SN519)1&6`#KWQ.4OD#<&A=?V`%
M`#`##\(#W,7GF?TO(4`P%AL`"D`G[P$*,J``8!`OE#!D;1`!ABXP8W`E/V!O
M2[OK!>&8-B`?XIR8"4PB&26R;5J-1\M?]L8&2ZO0VFA?COJH21.U*94TOXG<
M$='E=QHC41(E-'SK%@V-,]SLMSY&Y$6G`2S;D1_?*..8:@+M4>+=[?;L`5$0
M#N1A8&``'Z31?.B._,VI2>S?`/Y5G;,#1'%;XHX#0H"N9"AS.Q`!J6><G;,"
M*Y`Y*X`"T7FW15"KJ(H5B($8LO+\-5"Y<7S_%V1@K$OM*@:_6!X9QZHQXW+,
M_:DQU<>"+/ZYXS@NNN5?\3Z>6I:Q*XC\*ZQK&KWC!4G>XR$?\I',!D)`R>("
M""<A`4-#+A,30XB+C(V.CY"1C!$Z")8(.I68"FPQEY^?+@BB"#-V/"D`&0<'
M+3(7)G@`/QDR$1%X!W>CEA<M;1<`5G9Q!W]?HBZDO*(!H\K0T`T-R=4(/ZRL
M=@`7-CP`!B-LXU49=GUI4U4F(U47(@87(Y\Z(R,Q[Q<)^C8R,C8QE%EP,=#"
MP%$&"1I<B""!C8<0^Q5H`Z`B@#8@"A2P4>53.WP7]"40D<"A1HTR"J3T]Z^?
MOWX/#<B$5S*!3)D1_UGZ.\GS7SQ-;*JX$SG2ID2>2).J?#FSIH&'.I7V]+EO
M7CU\3G&ZU!GU)->6,FO:M*EUZU<;84-6`5/)Q(\V=K+)G<NC`)HG3P2Q"1'B
M"5^_?$,("DR8<(!!(7!L(+%C"8T01?@*@;PE@&4A2X*0B,#CE`<265`T[M&D
M,8T2/8IL6<UZ"X,:#%S'KD'[!>T:+UZ0T6T[MX\7/G;[H$V&3(W=Q8,?/U[\
M0_'G'WQ$GTY=^H?H/J1KMZZ%>O?KU[7XT$)>"Q+SZ+NG1X+$BR,"CMPW\D+?
M2QXR>>J[WU\_//L/\!$@H("('/;$-$TT4<)D@Q"BR(.21"CAA!/8,04HF_^-
MT$`,3<QCR3(@?D*,'7=$(,,5!X"C`Q@M`#!"!&G(D,87<3S`BPY6\"!#&SRT
M8,4?K.#Q(3.6!%!--,J$\DPS"$R1S1]VO#+1*_:P80\^(V0"#3V:T'-E##&X
M\]0_%Q"DD)G5+*100MU$M1,(%F'4ADH&@.$1F"&)59)97_W39TQA9:755TDQ
M)8(GENA0!5;PW#0F2RHAU<:<<WK%E`$CE;433Y6BQ-0^'6%RCTB.0L02GRA%
MJA.@>I9T$Y^KHB7"!6%ZB$``=[0!Y%R\VE'`#WB=(*RP@K$Q6`A[%::L821L
M()J"D3$0PA:!25M$#S3L<`-G=OQA108D!(%"#SW_H%8N!!"HUIIKJS'@+FRW
MQ7M<;L@!EQQO9`R'7+[(!?<<O\Y=ER]VX!4,7G;2B8<=PA]\QQUYYT6<GGH-
MFX>$`%K(YP4!&V\\`<<<+](Q?4-X01P9^J5<GQ[LM3?@@(NX$,"!"2K80+26
M09@(A3SW/,$!/'2)0`P/(,H+*$@GJ4-<+:!A1PL'V!'!/&/P@(<)Z4SQ`P(7
M/(,`&Q[4%8$=%1@`]0%6F$"D*$_,<R22R3!CI"4</&D'6G..$4.5]CQ1"=PW
ML@&**)DH>N68-L!B9D$'";2FFA=`RA,(DU9>J0T)"#VJ/O#09%2?H)^*%J9Z
MO@H55Y:")<\EBL;@ZJM/_\'**>646CHZIH-N.JE&G:KT$$FK6S+JZ[%'9&I7
M2+TT>JMDG?XG6J!F>?0%!>S*JUQV>`#L"<9VSQ?WQRXKOF`PP,!!$#CT`($0
M)U"[FA#OE[!$#YIUQD,&5H1[!+DE]+\@NNIBC;MDXZ[7W,8VN%G.O/!%KWTQ
M,#O(.4YP(`BP[%S'.M0YV'@0IAWU)"P\X2F/Q":6,(@)X`/R043'0/8QD85L
M`B3S`G[PHQ\8PI`^_@'0QU[60ID=J`$)*D$#)I,S%Q1B9SY+8H2B)B2/O,%6
M2!O<)=@0-2M,P0!V$`.)6&<"$^Q@"@D(%3.:\`<`)&`$*3C`#PP0-1ZXC4CC
M>/];-)9$1V>X(`*[.H4!TE"`,<AC'.*HTI+FB`!Q"&U(A:N'0QZ2N8$LSDP(
M68@D+1"YE$C*<AGQ7=<\X@ZR.`I34'$>ZE:BO$"5+G:$XDI,]M&EJQ#/>*CB
M'>5`0#O;A:54DJ.4G+P"O0M4H4OMR%-98'D\J9S*E&+)W5EB0BOI\2(`#ZB>
M]:YGC#;\@`AY(<P)`*/-O81/69913`2F<`0<0&LR11!".H6`+G(M80E9$`,/
M_G`_T*P@?>B"0`G2M2X"QJ:`M-E"O&QCG`,*1S<.%`Z_@F,O?N6+@Q;$(,'`
M\U"$=8>#T[&.=LXSL1%:L&(7$P`9(!&@CHE,A?6Y3W'_ZG/#E.GA`^S9&($(
MU,()S*P!):A9`P"3,YTI0HE`;00KW$B/#47QJ*1H@#&LT(<];J-KI/CE"!+G
M(1TD8PI2$T$5T'"``MQ!&YN,VR5D-L@YRBP91B(K'HVAQP@X(09LT(&5QA&4
M)Y15:?8X)#TNH8^P6!4:!2'%XAAGD!C8@%,3H=TN_6$`HPFODZ8KE?'\M!)5
M';-5)#$*K$@)EGUX@A17Z6OQ)BNY`BC6<I7R2:D>=1+44@XE:&DF)TDU6N.A
MLK1361[S;KM,3#6S2Z*(YCRI^:0V3`&;Q@*,(+[YS?&%``8;V$`6=D"#TT#@
M!$5(Y_KV"0%W!B$(&:#G_19S_T_UH:L$+P@@NPK(W@'*Z[WU`HYM?E,<^2IT
M@L_![P0OR+#M8!"C$0UP!STH0HB51V'1T8(`%KP?%YHT0#`,V7Y*9I_BY(>E
M*8-I=]P3H)E^S(=`K-F"!&$90A@1B4%-\00Z$P<T=*D!:5"`7H]ZB0;$06IU
MP>(W;`6`*>@@'O.(00/4I@-^4/6I8HB:`8ZVMKN:M8ZB&)LQ.F.`0\752N*8
M:Q4$!S=1Y!6I7H.L`:H`-X-\"+!JLD`5+#D1WJ$6MF<$15!$:]MAOD1R*8D1
M6#*[CV2*<B>K\NW>0#&\8<)2<K2[B.4\]<EB3@2UG9*!H*$83#H3,R>;*A15
M^)S,1_^I<I7-C.LG&C"V:5ZOC%/8Z;#Z0AAN.K<P3R`!"ZR0A2`(`0>H$8(Z
M\ZE/]9%K!T'8P#QY8(44>`!]2^"U>O_ISW<9\+W0MJ]NEN.OA_8+.+^!:'^W
MS;"%:3L["*98@=F#'HY^E#P+%@!]2!IAC=E0/RJ]\+I=6C&9=A@^+1Q"7T(<
MQ)N%@`$F]JF*@RKE"'RB"7JC\9"(I("HC:T`%\"J'1[0%C0XX<<A^7$,VB:"
M,4RD#P48P12X$8$JJBU)H]"!W^0(N&K8,0U_B#D/VC"K>@"2KN.8QJV0)*HM
M5T)H/!<S5-<$2201=JJ\>_0L=[>4GX!"49:&2*,QW9.EO(3_><V3W5(8"2HN
M)ZK0.!&=HTU+$8M<Y+6,G?JF%+MTE/BV"I3N9*.(^93BN2EUT,.Z,OVT2L\:
M4A,A6/-PB1LU`$1@IWOQBR"4*YC"-)<P)5@!=(\0A'*I3P7YW"=W^]>#):R`
M,^*]!0G>J>S6L->?LJF!0*%MT'G5J[ZO=ZAP)HBP@6EG8;CW]K>_D]&&5:S`
M!T;P>-*=PA0R`F0FG7=]+*PR_5P'"2A$1(=K.@$7A$`%0%1`@F@P1+X446<#
M!^H46@"E5BH\BJ2XP0'B8`.IC<``'O"`<1&@MG"$9`PX^4,"(A6!`D3``'?`
M`PF0"P>0`7\S)`HP!B.05EVV<Z,P_S=S,P4Q5T:OT`!?,U=S)0Z+T@!<MB6=
MX'.')%BB@!4V<0%_Y4@),4B39`$Z<%B[I'21)A,F*&=R5UO0(UDN42A;QV=$
M\3FI]"FT\DN$AA6#`A-4YV87$2>[`Q8X:$F54TN,YG>:$%I95V>F0RB>HEMZ
M9X.W4Q*_]7.90`0R``"FQBME%`$/D!?$TGC?\VK+DADL0`)','KI4P*G(02Y
M=EYE@!J900+#Q@,>$`$PT!CHE4_KTEX#Y!JJ%U"L5QNOAU"ZX2\3!(G51D$8
M108$\VW:EF#<X7L<96`2\XD?U3`+U@'1%PG)UU(I<Q\IHXHO=1X<AF\TA6^'
MT0`TT`0*H/]]33!$).8@/X5BX=<S?6`%-Y8`YW>,=]0*PZ!5?=`'`-`',A(#
M)C`%!2`"B3,VON)_,%$``"`#"2`&%_`#W6('8A0W0G9F/-<,<4-6+B"!4%(`
M\7!E@60/5=(`(8$H2=()-9<)2"4*G306(R`0"6$!F+`DA$60A[5T<K*$5/%9
M]"!FL'1+FL)FR?,/G$84O'46OO5;7N(Z\#!9,9$3;C8I<8)V@")9;+8[K[5U
MDY9(8%=;CN))?W9,I%,3(9$G@O))F76/65(X;"%R9$AXK&!X39`7R;4LCR<^
M`1`$1P`#*)`M.V`:2^`_[=1K_;,$42E//"`&&;`8.X`:^50$+W#_B(@(4`+U
M;*R'0/7"'#4P'/0%40NEB?SU;;E'EPRC'L%7;N41'"&T8"AC0\?G,<G''_K!
M?,V'B7JP88MP;XN@;T4`1&B0BPG"BPUB)(;P4[\8C!22`FE@!U)SC'(V.!Y0
M@#FB`PE0%TX0$@9@!1$``"(`#^]P"MQ8=LYH!QE@`WT0`PH0<W9@C((E/`%!
M1]:0)&=U-#\0<]UH97*%96S`@8&DFS&@`W.C`S%@C?+0DX.S)?<@%F3V2`3Y
M-VBV$"9@`#!H6BM)%<'SD%$G=9]T6SK(6#:I)Q\).GT7A'$%AB/`.5S8:#L!
M:9.2$:74GCEH3.BY-YD05XLB6C`9*(W"_X6LXH4WF2<WF9,U>8]PETB9``8C
M5X:\4A=%F4W*HGC)DBSC$P`D@`(L4$XX`&P*\$Z<=U[=Y6M8&01APP.`F`*,
MT7GYE%ZF5Y;.!B]`&FV[@1NQAU#)(8E'JHD0I7NZUVUWV3#C,6XCI#"86#%^
M:7PFI4(W]&[*=Q_RIC*OF#'2)WT0E@B'(02WF(NZ*$21T5,GIIE*E`)X(`;E
M!YJ6T#:@8`(9<`41\`O3"`)3L#?M,`4S5P4*@`]50!%]\`T4\0T`P`-](`\7
M$!=WTV1/(`+H:%9BI8XN\`;;0"8C$`++R9Q\4V2'4@DA,"HD@0_1&0IS=`\D
M^%F2A'+$N8(B\/]H;7:>7"</0I,)1&B#-S$6N1,IEI5WS#-WEU9E^]!,/5DX
MBU*%:<">N-1:&5$YL*6%KX1;QP0\%YH)5T);$7$3G$8\[4DZ^A"AM(*N6+>L
M7Z@#HIJA!A"4A$=/'G`7@J%XK,87WN1X2KD!T!4$.]!Y.+`"2[``_F->5MEY
M49D"-GH_'@`#E1>6IB=`/CH;!O0:J_=>##1M]45?^=)0M*>D(LM!XG&7X[$P
M>%E@&$-NTE&EZ":F#;9"Q:>*\"9#*--\(72*QT=30Q``Z=0$D:FF34`#ZN1]
M)98(;PJG%&(%:8!%?P!%=AH*268%`+`!51`!T!B=]9"?6C4/\G`+9G?_$4_Q
M#K\4`Y[Y!Q&@-J'0!$O69>N(5LN@`)]:`#)6.#AG)4]0!1Q8G0T02%:")S=Y
M@(!S#T*Q*-'IG8V3)I(4`P70![W#2X+V2_PH*D1H*NS9*F'W)\ATKIVVH#O)
MK';;.ID"K&HG%;XS.N,JDYN%N@E0*P?ZK?I9KA!:$Z]Y2T7AA<L*)KJKN^F*
MD^Q**ZX+ANX*!F_!H731!VB`3<6R7*R6E/U:;`!+&D'P!H2X>57I3ECIAS;J
M`2D0`02++CPJ0.LU0(@(+^]BOO+"0+&'I)9842/[OB5K0?&;LN,F`!=3'@(#
M4EJ0'X\PF!BF,BO5?%[PBGI@?&1:4V>J`K@H_[23R2!NFIE*.R$78`4QT!E-
M(#0-,&-'90(\<`!FT`?_UR(%(+F3JPGVF`8BX(U\!'$V$`&_%%=D5'A65227
M@*EEY35,$C?.<`%_T`89``!W(%?O>K<CH`"'(F1"%JH'^K>#QG)>)JA7854#
MZ4A>$TD*T8)*<2E2B*&J:G<G^9JGE*PU^;N<6Q(-.A.?&VJ%8P\)6H4G>;N\
MY2D!:JX32A*O$BO!JL:OFZ!$T:!%@:Z^JR<1JKN+8KA@8LB]"[R'_'>H6C@)
MH"M"64W7!#["LJ_,JZ^O%@`;T`(;$)4[L*)-$`3SHWGGI7D]D#Y!0*@V*@8>
ML!A3F2[A*[ZRT6SL!?\;&9N6O*$<$"1?V8%M(/N^P+Q[)YN7Z+%@''4PY!%]
M,=MN[\:E*A-O.%LQRMP(-!4`#'`":(J+=""T0N3`;HJT$3PA(^`!53`,4Z"V
M40L*]M,%5@0`-O`#S7J`4U0%!N!C[9`E\&`5UP`EIV`G1R,*;X".PLD,3&()
M30``CR8"[GIE.&</1KPW#0!W@G,KF'"@A9.IT+"UTN,VC`-)1[.")I#"FFNN
M!II(?[N>#]IGG=N>8@'(?8:3)!'39"S1KWO2L?M)87PZ>L:$-JFN65%G.UG2
M:PRK$]HJ-\F[@#S(AURX3-W4AAPFA9M7)?QS8(`&??`'%2"4/7Q-:F@L:WC_
MR6WH7#A`;/OS3E&)`TN0/LFF3VQ-+@I[!/+$E1&P&/BD&F(IOCXZONA[OF@Y
M+\2!+R%;47&);<$LLO%[;N(1,1&SLN3!'>>!0LO<S(0IP/3Q'`),P/-V?`@,
M&;:8BSL@F9-9!+W8LT8$P>$<"3K@PH2:`NB<SI;`P5%C`^D0`<9XT1U()#^@
MT%URGQ]"J`#@F483M\`U1W9%G,^$``I0%Y/R`]Y*5W+EKCI@CS<75\X`G(/\
M5PW(CT8GD,/Y.`-Q`9[&T\M*T\]M)4/AQDWQNZ<4K+B;NX#KTRU]U,'[NA\!
MTS-1H3AI:"DMW^^=)V=<9<`3A/$L5VS\WF2\R$*Q_[N[Z]3TV.`-KM$.7B47
MS3J8\`"+&LEV8$T-0,G@PX:"P5SB\P3>`K!8B94]T*)HK7G<]6MI#5XVF@&W
M$`$!"T"QW"[D^QJU#%#.UM=_/2_9QLMQ65&$7=@C>U$)EF"?*#'V:Q[@D<RI
M*-F23=D5]J7ZD9@;UF`[6R#8?(M+H*:2*41/L!<E5@B'<&*F?=J+,`*Y+0*V
MJ<%VVAD'L`^-U:P5_<_)0"N)A#0_-A'?T#7`I0-.8"<,"`T)6"1H1=%HH&AM
M8``W)YU?4]VB"NG+*5<7,`:L\EG*4&*60:M=%E@JN(*N4V<M/=\V]ZWDFMY)
M+1(QS8-*_=2)+!*`7"OQG/\E7U+4/7W4^<W2O[O@"@X21FVAC&S1!?[>BTR/
M$`YW#FZW`XZAPLOL$Z[GPI75\PH`>$`#>:%XE]Q<SCL(?I@"!(O6:%V]OM;6
M"HL#0<"P]].]*(!/Z-)/!`0;!?3N.1ZD`U50^F(OM0=10T[DA9U@P<=1]WO,
MI`BSRQRS4EZS-^M2+`-]RK>8-65]-+/`.`#:T\`^1FM$28OFD9":/S"IY`@*
M=F6G)J!%?^!+>,[L"_<,WAK/A22HX'T*5F,";%#=EJ"`"&"!2**;*1<"UH#<
M%R';8Q8`,T_#G^`,SD!7]G`!*VR1K?N`D*%K16M'CE-FI!!8:68!(^!)[`VA
MI&[_)?4P%*1RNTH-$A&*N[$.U0ENN(@LWX4LX2:]M?W=ZF&")UAWCPM^S^W0
MU,2NR,@^U<I>X%$=[,[^['OEVA0."M5-!`4P>,2%:FFX3=R3K\82UF[(%SW"
M&.#>!/0S/]C"UC&:UJ6Q`1Z0`:3?R9^\3]EUB`2T7JM?OC\:;?;5R]G&[[0/
M;B>+'0>FY/:+!!O%\*E8\%$NP'E`Y3ADY9#-4C5%(`&PY0OLY?W&4YMN8N"L
M\8^`PH?:+39L"9T0M2Y@#G9PG;2.\F/5"\AN[%PC`EDR!7#1&04@-,X@`A8H
M`FRP);_9!()C)':D`&V0FM8("#$(@P$NA`@!`8,A;",C_T\C#6,%;6T%,@8)
M"3%/0B4]2Z$]/4(A@X8ZJ0@N+A:LIZX6LK,6"!>:!IF:%[P7,54CJ<)L.HY5
M,;T)M\J^OE7/SS'2R+V^TM'`CMK;QM._V=K"XJG=R-[@V][6U]PCQ./CQL_M
MJ@@Z]O;BCFS\]8/_``/^,R00(*N#!`L:7&4(C`P>?PY(G$CQP!\`4YH\.?$D
MQ$:/)T*$#$&RI,F3)`.LX#$CRY(=+Y<T60*A1XF;$"!\Z@%S!PDQ0#-$"`*S
M!X0B6Y(JW<*`05*G39E"A5J#0=4:5[%JQ4JF!AD?/EZ$]?$5K-FS:-.J7>M#
MR]D/6N*VU8*$KMVZ6CY\0")``/\9+Q.\`!X<N+#@PX@3YTF,6(\>)$@^'!X"
M>()E`A,PN_#8H(F"SY]Q-!G=0,C'$(F&#'$Q9((+R[!CRYY-NW9M`Q>.09P2
ML,$]A0%=I+!CYX*.1OF*D0L&4(<($<&TL4$P(D8J#Q!YV+'R^Y\.)X*>Z$#(
MRI0+-N97%1*1QA?["XH*(7*A:)$]-@TB.1I3J<`E&YE<T`0HH2RQ@"@0E&*/
M(ZJPXLHIK=`RBPO4+,.,-?/`(\P(QU3(RS7H:`/-B/.TTT\_PN3#33'2I0B/
MB-#L(\X[QM0HHX;B"#1,(QH"AT]WZI%'WBH,"9F0(D8FJ>1!#@$04445_<%#
M&AJ=P,;_"2%E*1))(Z'DI4=6M$#"#CW1\)(*.)2@TYHEX$!F$"1DX$$&&Y#`
M@0)+J`G!4DPIY9144TVU15566865H5MY)9988"W*UJ.0JN6661^TA<1<<=%5
M%V1Z:=&79(0-%FI@C)6Z6*F=:O&7%S4<=MFK`82@`@U-X`#:9Z,U45I'J"7"
M&FL3M&;;L,06*T8*U=G!@Q4F`.2(CP%-`8`5(IB@RG'!%!.#`8(,HL,%!DRA
M@[7`W,-B#!&`P`-$;8Q`)$%H7&#00;:P88@A2`XB@@''*&"`N_$AHAXB_#22
M7P,Q-"!"'VW(((-_N2@P8($&4FQ3"4(0\ZR#K[3B\82NZ!#-_S3.E/B.AB).
M$^,PQ\V(8W+P+.0=COX$Y'**IQ04,[0#$6DSD`(-*?"['"]I]-%((R1?DW9`
M"24/$:#QQ$96AH3>2%U^B5(`0BA+0H&?+)'F)T74)`0$+^WPAA16>.`V"20$
M@4.>0B"UU)]2/05H4WP7FE6B6+W055F"G\4HI&5%6NE9D_H`%UR8QK6I77GM
MU9</I8IZ6!YD=$[&J8L-D0=EI3KV6&1>?+"JL)FU/D$`3W2FP`Z@Y:IK`T^@
MUZNOJ[D6[&O%!B\\P\\`H"R0;'3+,P(_`!"!`<UE2]T('ES@KBTV>`""$U4H
M9ZX[U1D````\`%#%T(,T(6\##13)BO\"[=][;R$Q*.#(!0I,1Q]]`BNB`R2.
M0)@T1G"!"!3`!@\[H`$4$#:*.?!B16B$_CBVBEA$B!;)X5",MA$S<V&+&R?[
MT;66]Z/@N"\A^(`6"H&T))^9L&,H/)K/DD;#CA'M(!8<DI%(:*Y\@$%:3W*:
M1"K`@P)(S4I<*DF7KJ8[K94D`"CX0TOF-@J;+($4-B%%"980A""\(0@IR$`*
MZA2$+.P`!SFQ&][X]I2H](UO5_';5EZ@*!]P12Q?<=18#J>6Q#W*CVC)BUGR
MDBG):2HNE?*4`+1PJLQY(0]YT$,9M%"&,O@`D@QXI"8SMQ>ZZ"5UB(F-9F!'
MJ\_0H7:W,\W_2!(1@"&T$EC`$YXLB;6O5)#/#M<;!,)(R#P`X,:#WD,`,E(`
M`.ND8@I%/"!S;$;`"+3!>=>[UR#6)P*&,$0:\YO/*AAQ#TC<HSX!XT<D\O,$
M;T1"!#*P@0W\(P,1-$$GHW"@*/2DIHPQQ!4=DU`L:N&M5*!H'"G448X&(C]Z
MQ?"$KPA:"V5&4"'=L(8051)"#?JNBH+S$#^KV4)]I`-3F"L`P&0#&!PQTBHX
MP7A"I$@1Z3`UCGRD:B;)FA--(H46;$!N):#!*""@@@0=10A"<-,*SK@!#T3`
M3EW$:1&6JC>\\2E0;T04X+A2`\%UKG",`F0?R7(6K9)A<9`B)"(G_X>7REG.
M+5W!Y.A"!\FO3'*2E/R<%RA#.L8X9G)Z`15=16D9CXSF#71X`ZZ:0(,&J,`T
M3TS-KWH7K%DZEC;("$8![/"'!S1'7B3\`0_Z8!QOG6P$8T"@N!A4'1$`Z#<%
M14`5$N"!`O3!`./!*`(4($S:DJ<!\BHH_PY1L.DP0F",8%_"W"'<_'#H`J;U
MCPT8F).:[.2*5<2)3M14A!!0D&/[G)!`@:90%S8THN`-+T2]^]TD"4R:'/5.
M/\$P#O;23`?L?<?)NN/0H=6GA.\=*8Q^$0,;H#2E%K&#!W[04BQM:8DS=>(&
M>!"W*]+@*`D":@G*-I,N*H`$'AAC"J9@QO\='`4I2(%*4_L453;^;:I>J2H9
MK%J#1HTE4FD!I.JT.LBV0,X'9;V+)Q.)UCQLQ<>0Y)P/)$E)`83!+8UT9.H^
M<+J\?A4QF(G-9E3@&;713F*I/`TK6?FKQL;RL6"NCF2-EX"`8'9Y-X@`)G*9
MH@NDX;21\%9UG``]@GI+6@HT`!AZ9@@1_`^S"$$&D@*&`(1-!P$A.,YTV*<#
MD!JL"OEI!"2&RZ,1)$"="3`L4*=[,35YN@Q5!'49CE((A.AS0D++&4(F*MY6
M(ZVBO-01S`;*:N``$T<::X>N=PT^\+TCA?5-B#@2W5%%BT._'/(&-:35-`!;
MI`]X:.F5&,&E)B;_V"2QBE4(IE"G'4`P)YM.D)FZZ),4F#L%),@"4:C[U#^Q
M$5![<\J)45Q'S_%QJV!)7%D`Z;E\LX60<)$<9`X9F8"KZI$U\''"N>+63"TR
M+JL2#*E(=1@],'G@9OT+962CF1#([@UO^`&6"ZO*Q"IV-8QE'9@?RR(=C(%A
M>`#2F9M3D.8!`#IR5D4,Z(R-W]QCF:JV1PS2,`9?P/8?]='!&XX#O=NV[UV*
M8(,3BCZ=;VJL`04;9R0@T0AW`%1;CEC3V=:4DYU4,=2C&+5U"YK="+E:AN@M
MB`Q[1O,>CO#6V?*GWI6SHF!TW>O^2'5S-"3.@GTPV>J0QH>4#:(-2B>$_Q#"
M5T`2[5Z6M>SO(_/0!6S0AF8#^`]MP`,1/L*K+UG[VMDN(P=V<).E+A6H1;A)
M$X)P@R!P>P,1X`!1!F04IO9IQ"7.&QNE2N\5V]'>+_[C5[ZB.G]SM7..DQ3D
MQ%K(R;FE4ZH[#`."#,D7$+D,BPS#(B/N*KM>7`"1*7CV)<[7S7Q<L!(C^=1,
MOF64^\XR7UZY\%BT6@.F`4C5%!!/T`0!-4T`\%JYU!PQ$`P+N$P<$AWW0!#2
M1`W`@%'W8CV@-1[R@P_R021L(`*^@%M/,`CBY`[\@#`'HQ\F.#/CP`:>@!-G
M<Q-G5T5PD'8](&H0@!KW1`MN9UX2&'>QIEXO4_]KMO9>+;,-))*$\E`BNP9Y
M[K-=+>-/TA$=CJ`.U7"%5ZAL(Q(.[V`*$+)=Q/!/N89YRG:%G.=Y*05Z4S!Z
M!K8E)W%ZU_9$(:``6?`&5\14KE<$A\430<`!66`G=?(U;D(30L`G?A)OPR=O
M5C$H])9B6`$6]49CB`-]9+$X7R6)8"%6<T%6>*$7;4$6@D%7V]=6/@!7B[1(
MF!-*I6-QD+%(EY)7H6@9E>$ZLN(9"B!8HU$"NT)_KK18K]$:^:=_^U<%8U!T
M$=`\QO$;U:0\"``)"-`$0*(``%``(G`^T"(."],P-H!S06<(57`!^E,033`"
M(/6$^W,*\?&!UN%F_P+_4NRS#Y&0,._(/L:5=P"%`"Y8=C'H7#-H@S=8@TN@
M=FYW:JA@=_EPD,)0>5%HCRRR#976(O507]U!,X\7AO*@>)K7"Q6BA20"D:C%
M"O<U,V'8#[W&#223#)J0DBJY"XNGA5Q8,^M5#B!"#V2H>,EP"V?H;!:!$;@S
M?R'!*S(5ARFA;0&`)VIC%(7(`'DH!+22!4.Q`QR`>U]DA[WG>X?H1E%%*'G3
MB(FR*%=E%GSD*/OF;YZS?&0!?64!5I3RB3AF<#GVBI"35EZ029M#!GJ`*:BH
M9!5W<9X"&9#A.#4`*NPG97YEB_&WB_27&J_$6*XA++\HC,2B`VA0``(B`A$`
M_P!WX!T*H`/0R#,W8`FXP3.*-@)6``!M``*68`.H94WX:#W_<&@"DQL/95$Y
M\X'K4P`1`!^%-ERY0X_2(%R0%@X[PPA`=38OR(_]>(.C``=PL`!P4`+6!3(\
MB(\W,PQ(F`TQ`@S8Z7C<D`V01R\TEP]A>'F[UB&:IPPIB84MJ3(-")%TYRW$
M5H+PN&LGR0LJ*0*:\!SXF9X::4[P*`Q>F`I@\(VXD`L&RI*_T`[\99,K:0-]
M$$1IZ#P/0'HPE41"292HD:%VN$4*\&"%N`4AL`5+!0I3`#>V!S=I,PH39C=W
M(WQO]'M407Q3U6]ZI$<P=I:54I8Y&E8!%W!E55:>>/]]9"`Z=%677^$I<:&7
M7N`8%\<7=(%^<*F*?,49AJDK0%5Z6\9E*/>8C=6ED!F9;-`]<P8`8]`=S[(\
M5?`P(E``S(A"_=0(;;`NIGD)G14<.B`-@Q!G_]``3D"`TK1J@R9Y[@!2:8`1
M]\`&OI`[VE!<*NB0PQD"Q1EN,HAVH%9%H="<<)"#'R,A+B"%$F2"Z8"1S9"%
MC-=X6W@C'^D=B78?HPFJ]&F3]HF?LJJ?^WDAZ^"?J#IXC1`-U<`.(I(RL'H+
MSV&@Q&H`^[(+MCH-\/A/`XJ3ZN0PT!JMZF2LRM">(Y,,^V*L#LH#.GD1$4`#
MTJ8E6D(2<.A$V>81&[`$U07_`7AR%$DA$IZP`T$0`1$@KT?U!F:4)A\FHH;H
M;B0V?(,B1X#3%2U&1\9GHRYF%OS&56>9;\NG56H)<'*1*7A1%WFU.*JC%8M!
MEX=!!ID2<8N19$N:.GJ`I'W!%YP"BZ$D&['2`+22*XBY._57""AG?U^F<BKW
MI1-`(PM8!1&`!]$C$`W0+`+A!"!H!0D8=Z.I`Y2@'3R03G5*@M8A3/]"0`OH
M';PPF[`F3?>E`';0!F"@"+DC3@#$/L%)#RXR+ML4`D50-\4YJ<EY1<SIG,Y9
M!B=P03QX>.&@#?5YA;9*JBK3(1R$,])T;`VI:R'2(=60G\8ZK`F0"=3ZM^?@
MJ/4`_U\$]+BYH$[3F@O,H*SEL+B86ZRB6ZN]VIXE>0L&@$`.XQ^LV[K2"B#5
M^@T5D@#9FKE]P*T5\'E0,Z%4TX86&H<8JFU/(`8+4`1YP``!T+9U8S=M:R93
M\)3J-CNTTWK\>HAZ@XB"(F_S-D>=XQ5A<;#)=SAZ9)8-6Y:4"!9JF8G3UTF4
MTXD7.V-8X6,<V[&><DF/Q'V0M*1Z8)>/H4A]`:6()!E_T2JR""N<\;+LHV7U
M]RN+&4O`<[-2AG]?>KBI(`)C`!#X46@`08`%X035T2U_VD]'J`-64``'>$`V
M()L_@G,7``!I\(UC`,+4<69"$J@#8TTZX`$`@%F,4#"XH_\?[T@/]I@SB\"V
MRKLF662I!7(@"]#$34P*V"4+AL!K'^PA*WG%++F>_,6$M&8/)961SB`/)AFL
MM"NZHZN2I0M"R^&LT7H)#_.ZN<`+F8>2F:NY=@P@!BJKI9N@QL#&J]NZE``"
ME."Z#C.ML3N[M9NZ!0"A0B0E1K015U*N)Q&4V):A&4H#8J"N1<``JC$$36'$
M(EH"LP<W;R"O/1$$]01B:O1[=P-5\I84Q>>5=/2]X'LX7O5\YHN6YQM(F?B)
MA?3+>?$YYNL50':\H..Q><$YROPY;<4Y%N=P_XNR*7NQ@PD;KL09#:"+B"6S
M6;JEWGQ_EB$LP*BSL3%0=YJ`&LS_C,P($-9C3.^Y',MQ`Z:)"87*IMXB=()0
M!25,0!X\$)P9>17UIZ6&+X;0/$ZP9XYF,$#,:_=(M(/``"7A>C$X@Z'`Q$[<
MG`L0!C11"-/):XJ+K8\[JXU;J\EZ#O7X:^9"H*F+0*J;3GB\"S/YT;%*K`"B
MN<5ZK"7-A%7XN*H+R#[-3M`*N^L0J]FJN2YMQYQ+NQ<2N,=U:3W-NJA9":<Y
MU:@)R(4,N[9:Q@:Z3I2EDYN%!FS8AJ4GE)6<;0K``R@@!,?+`,`2+)XLT4M0
MHD1Q1CJ5)Q%6O=;;RL$W*(P8.#/ZO8+#*'B4L-^+RPS;;XB-OO]F<,!<.8*1
M<*RB%=W+_WU<D6^<TSEM99=VR9?^&\WN^TD2-XNP$2LN&#O;S,W>W&6]X\#$
M$HQ@-I%Y"C2"P(SYH3/*T3TZTG6Y-@(98`<VP%HNK#S?(TRF&0S62"1/4&<V
M9%#R,3_2U``,$P/I^*D+O6L-#1#:1A*O-UW/%0HXX,1-'`89+=XE4&I23!W:
MV9UD'+IF'+FWH)'K``[>PR$\_<<_'=2PRPZPBI]U?,<V?:#[V9]\7!WUG4#^
M$=4@D.!3;0FL&]0!,KO]_;J;Z]X?,B(Q4."M*]4:+M6H6=6$[-(!8I_LO4X0
MX6Q$U`8*0`0<X88L3M9EC0-_D`1"T!2MP9BMP[8JX!-3L`--,/]4G^"AKO=4
MUNO*;22P5;45*U958Y%'+W9ON&R6NER6#)N^@<38A92QA]$J(9LHQ;QB5G79
M^[N_D<1DA?2_T0RE?JE^KE(8HTT24\,&6,IE<LX*W\Q8K"W!Y#P!]]QR`B$(
M,W>F.H./U/FF$-B0,9`"?8!I5PLS@Z``?U``N800'Y@S`[VU"*4(;\`#XJ((
MC%#=#-W%%G42;<MI\;0`WPW>&9WJ8=`#1<#1M6`.Z5V%'C*LQ8K'Q:K42]UX
M2`@N"`355'V:KN73A7S(U$#KSXK?$X[3&DDB%YZZ!EX`42W5ILGA'<[@0"W4
M]KG5Z735$XZ@WZ`-?LRZIQGMXU/N&^[_X4!]U`'"N`9:`"7N;*#W`RI`-2W^
MNQ>:H4T@)3/>R0\\&YNQ!!&P`B_1:1@3Y$+>RM@;L%9!1T>N%8)31UX)EH1]
MEE8%Y>4+Y51>8VQ92(X3<90Q.I*M8C[V.5YAES40YIIM<<_<OV;>\FANL:"M
M.5*6W5V2I0VL&HOE._T.SJX-F2[B"S!)6T^G2^N,'`$UD4>8+<9PIZG+7_-5
M#Q=@!_\W0T226P$-DE"WW(K0``<HW8C&#UQ7C[JV,PV%"*(^=F:WQ*@NWFQO
M%*5F"P]>(K!:H/[]WWF,GNM9(@3:Z_ZQX7Y?[80<XM2`N<^:!LANZTJ]["."
MD_8=[<]4[N/S_TP+'M4-#N+H2?A&;??XN>RD=>%/W??D7@F0'_D(+L@?KKF7
MKY\&(`-.8N)?^P.C=R7C&E,N?J[Y?@!+$`*J$<[#X@(D<`,#?Q/4E8<'#Z/!
MUQ3;R_`JAD>#/;[/I[!GJ<L7OWQ@E;YN07V3HCJA$XKWRSDIMF(C3[#"_!5W
M6;):8/YXX?)0>K+2K+*A+1NNE-U#V<T-W)AMO?,\C^?@_%C@"`@(@B,Q(SJ"
MB%4Z8R.(CH@7:6P(AX>-.IB9(VR9"(8CH%6$FSJ<F((*?P:"+@@NK:TQAZZO
MM;2N`;"YN8(Z'@!3.@$(;&R@QJ#)RH:9LX(F+M"N"`'5(==%0D(0)?\]/4M+
M.`OCY.5A<&$](:\),C(V!@DQHE4Q,1<7"2(&-OW^__`,&!`A(@&^"_:J**07
M(X$-&04*M)DX$8#%BQ8I@@`QD6-$=_$.)DC`[Z&[=_X$QBN(S]ZR"_P@1FS#
ML2+&BVT`4*1),Z)/=_U&CA0(4*70EH5(C<AGTB?/FC>C[N3I\^/)H$()R@!@
MYX#7KV"]_@&`I\&3$R="I$U[C>VUMW#C7@L0@FZ`)UV3"`DQ9$+?"1-<!)Y@
M`3#@(B2"+.E1H@2$;44@%-DR>8OERY899-;,H'/G+348A*Y!FO0+,B]JG%[M
MXT5KU#Y:QYX=FTQM,K9Q^\#-.S>9#[]]?!C__F&VEMA:B@LGD\>+ER%>_.8A
M3<8T:CVKF9/1LUV/#SUEM(31(H"\%O("TJM?OQZ)>^%>/CB?_]=PM?MU[P]Q
M,237_O_\"28@8((-1J!AAA6(X((,,FA*)8HX(T@#ISSR2!47Z'"!")5HT@PH
M.C`3XHC+</*@"7C8<<$TL+R"@`)LP$*++;RX4",N-B+P!@!]-"!(",5L$@J(
MRC23B0F/N(@(?B%DLTTWWX13SCAPC!,&E7`4$8`($`%E`$(*W9,/2?Z\@U(_
M*@TT4DL**8.A`3))9%-44NFDD54V&(2//B7U@U*:1R&4#"9+Q3333G0FVM%.
M/WDI5)H!Q:,GF$06__I051QMI%.B&.7$$Z-5%>"H02/9`,`?8:5ZP%AXT,`'
M&VBI!1<;<M4JEUW7M'``#UG$^%=?]1E&`&`X1/#&-R4(D4T1S%)6V1::8;:9
M9Y]Q)EIIJIF6W0NNP1:;:]W2]NUNO)';VV[D#O?;;\3%]D%RLP'G''03/.=<
M'GF@=AVWV.E1`W8O</?=>>BQ9_#!ZKE'7'SRU1!==,/Z-41_]U6LGW\!!O:?
M@0@6Z'''#8;,8(64%--++Z!8:*$"'(X1C`DBQEQD(\L(6<K-F+@0`0`QL.+B
M*SHHX#.+1-?X2HW#C)`"#VF`,0FM08X@BB8@&BFARL,PF4UCWH`SCCA4+O]P
MY=A5PE'"&U5Y>4&8>Q+U4%$""6500E6'Z)!,4'%:9TZ93F25I$/UB6;<:[)Y
MC-0.75I`37/JC9.=BX;JZ#YI2GK0VI7"I+B<&^7D>$8`@&!GIB"$VFA((EQ@
M*JJJ@C76%$V<]020:M%JZ^UOX5I-!`?$D4(3OQ[8(`$N9!'$#HQ!QFRSE$D+
M+;36>@;]:*"!EJUJW&Z+&VNNB6ON;C7H)CYOI^$&W+K"#><N;=4]!QV]STT7
M?L#\TG]:O]SI<5X8`O"O7L$(.Q@2DK.PX3B'0?L)`,7T$R#_8&QC"HK@@B0H
M/)&%K!F]D$4G$'`!'ZG,$0WHV05DT(BI$0H3R##_$3.2@8RJF8(2&6A#(UC4
M(AG=*$>Z:(71AH&`$!B`!P#X`:TZ5"2JG<)J5T-9`R9AC28]J6M>6P`XJC2V
M*\&A;#T(@D1.=X=Z[(ER``E(H`RGB89<"E$W`2(0/P>Y-OP$'B.A7)\(=Q"Z
M):,*=Y.)1MBXMYW4)&UP+,@^QFC'$&DN3HN;RJ8\!;JI+.I3?Y0<'`UB@%.U
MSG5,B]T)9">K3LK%+;?#51-0Q8,;L&%B@`E6@P(0A"`P)C++$T+S9NF\YU$K
M6I_!UO6XIR]PR69<XLK-^7Q3KMZ8+SBV41]MY&6O]_7%"_B:7VL`1LV`Y4]_
M!$N/_P+(30&X1V$+F\_#__SBEP9:K!K]X8\"`P3!OBBH@ARCH`475"%3R((-
M/3M$`V;XP5Y8H@]"&]&'BKC"017IA4T`0!ITH*2?L8)HMM`ACG`TC!PUH`!V
M:$//>ABBA)@P1,PP@0E.:`@D(6D:&K*!"&)0E[=LK1O@B&E,K;2`LM4T#(NY
M@=_>^"61J.0?@)N42PQ:!4/)B4YK!$!2/T<10`ZD<G&[G$?OF,>9Y(V/B]Q4
M1IKJ1IX.A9"B(%(,C,JYBC"2;SKI'.GZQM:>^*VKHH+'GD#PAPI<4BP\B$#L
MSK*6VX'25KAJ:0"L8(<X1$`(#`#0/"=0`L70``*079YD:"FMZ$DO,]3396I0
MH_\:?>EF7-U#UVV^9\S2'A,XQ6G7<ASFS(D]<PCRVQ=X]`"!?O'&.]@$8#=W
MZTUP,G,^]3),7]9YL8O9"$#[X9@[#?1.>2X60<R@1"/PP0:$9+"?*G-"&I!D
MI$^4HJ`M5(8Q'H2`*=C!!K.HX2T@"HLFI&%%6:,&15T1@@MPQ0E/D.Z&!F*X
M9.`C0B)RA(MBX(1W)(!6=%'+DV@`17!\HVQCJ^D2K@B''N#``SL5E0PLQR=^
M`&I2")G'2^`$$8I$18UJQ"I.(OF.E:2))4@):RCNYA0T*LJ1)F;D5A_Y$7@4
MY"AT:P8>FV)53YFU;XTZ"2*?`LFW_B0D">@##^XJEC__1``-9X$5U/Z*NUL)
M]BTMX%43V*!`UR8W9"[`P?$@H(+(+F\RS\(,+J%'+>A9+S6E@4WY]/Q+[]FF
M-J0UIKG.!1SAI&\Y9&"`^YKY/FC&-F#3+(-MKYE-;?*6M]\,ISCGA:#_)!"=
M%>N/J-G)'PLV%Y[/G4"&*F&(!HQ!!S&8!"4VBEU'B"`#'2*4=Y5BT&4(]!09
ML,,J6L%>&M*"%V]HPP\HT4/Y\F(7Q(B`'0JP(F+`)`TJ'>1_QSJ&"XA(0K4H
M*DAB'9=L<*/!BXDBA>$PX9NR>P6@BJND"E*YPK%)QJ`8JQXYPJFEJGAT<"U`
M0/;Q8SV)^'!+(;*-'\>XQ86J_V\Z-O)3WFCOH3I#0T9=5.@@ERD\G>EM[J@Q
MDTO7DQX;X`$7*```J"R6`F"9KVSIZUNX7*L$?YF58HB``O9RGU*?.4$3*T(6
M=I"LQT@VSI6U\RVG1QKKE<8'-7C-_&S3/5^*]L_D(NV@=8/:Y1B:.,QLK3/C
M1YKIP$8/_0I8OO)W'DM?^M+@=(Y\Y`/<CDU,G0M<(#KYH]AR#N9C?Y]@J@'#
M(6;WXM42\F"M$:&T!_@S$\@`:<UJAC,$Q""C*VIH0V\AHU8T0>`_<((!8.3L
M'/$P%7G=Z%+T1)*0*$0@JS8\`I#D(A%@6P2*:(7ML/$D*"T&IN-H=QC.P6YT
M7'$%*?^(G,D[;)0Z'EP9,(F3B9E*D\[1A/H=B8B/Y1;BNF%"WWA3I.?NI.2W
MF23\6<5QZ4!21Q,Z8@1&M?XBFQK7,-J?R(QC<AOZT.,+/&!GK'-)?V`'*?`#
M3S`[L^,6--=E<W%S`8`&&9`%.\<&11`"#,!WKH6!"A0`-*`8C?$8DB$92.<\
MMU0MSZ-+VJ(:KY$:P$1U?G9U66=:O(%:79=:U<%:C9:#7L``L;5VKH%;YX)-
M;S>$Z>%;8.<P=9=*9N9`H19J&*@@JO1.@3=X@!$AE6!Y"_4(3;!XCS`&VT4)
M`]5KX>5KG2`"T]8(G0=1#W4TK7!1!9`&!>`$(@`&17,T"##_2G_0!@8P0Y*'
M(0:A"$NQ-AN$""Z"1U\B"[4P*\PB!%SC#3T``5$B?,-W166`4\2W`,E7<B87
M#T9A<#*F"7BD1]/'*1EF.HTC%8NR?GE2<:3P?C0F)V;52!NA8?=7)J*8?G[4
M?VL35A(":XKS*3A!%?57BRE1)A*A5JG8*`:Q%2RW*@5@@`@8<Y[$@%ZF.P%0
M+$'0!,I2!(FU@4O8'XD5`D>`/-M@=,M32Y55@IZ16:6A/=P#3-XS6G]V3%N7
M+NB36L.T@_-B+_P(6]&4+[HA,+A!:6U'A'#W30J#!.%$=THH,:X%:N#HC1OH
M<Z4V(`G",1>9:E9C>39@(8;`A8G`_P-5`(:$,EZ[YEUC2`J8(&T%<`B:UWG$
M%I-`,P9$L8>"4#'.%@`QP`-VD%$VH`A@2`AUA`F\B$&$.%8)`)2O8`&O0#LN
MI0U<\U@E(%-6,HD3-GQ8B8G*%U=R4S@B-@NG,`(.(7**$CI6H61H&1'\=F,[
M)5=($6`9!">'(CJ>PW'#>'\>9HS`*''"N&$'=S5B&7*PZ#FBXQ$?!S=0)3B'
MHA'"&%=WL#HLEU$_0`0'B!:TLH#4F&#6H#LG0`)$IRS7X!D6>$L*Q``JD`4X
MT!B.`4O,@XYTIHY.AX*<U4NAU6?Q.(_"`2[$5$S(I!SIPQO4X07:00;B-!VQ
MY1WDH@<?X/\=[U*0!HEIO860"@EV=.<<#N.0KJ49+V`9>R=JWK@QRU4@X1E/
MS[61%^`$'IE$V*4#04225",D0A)>XR50"-``2F4`#$6(:C@-,R((8.`$3F`#
M<.A!0=(`(91?`3`"'L`Z=@`,.L!=4E,/A7!"5VA2KJ`##Y$`:+B4M9!@M+*(
MY^88)<!@440.PR<V8G.B*V`%6VE@^=!^T84(.B!N@UF7*^9&:)FC:;DXI$@5
M[Q!BO/@(@5ED=<DH0($F`1$I4.4/B]E(V2<J7^)^CJ!O:GE5'7>8*9&82VH#
M:NE('J%]_$!7+)>'/]``?!`7F)F9@J4[UX`#GSD9H<D`HTF:#-#_2B,*6<HB
M@N@8+:\I/:(1FZ8Q=2KH2[59FX`6@U<W/KM1:.J36NE#G<LD+_DB/P"9&[CE
M`Y7VG$0HG0D)=@SS`0[#6A+S`F50!EN0'Q(9`)Z1@1IS(%)HD>5I)):W"H_`
M"2")"-K%726Y:Y('GT32"3_0H`DP-)PG(_SI4+9G`-IU`6SP`&D@`@46`05P
M`\(`!F8(%CP@`U5P4I)7"?/PH!7R"B:0`!&1``S%H4S9E#V$#>;6`S0@HH[8
M`R:*HEF9E9GXI0+74T`*EX/0#EUJH\&H84"AH^9W?C*PEJC853(@#T5Y(7()
MBS=AF$"EI5KJ)XE4I*&S4PM;-8Z04J+8_S@X&D842[']<+%&UG%0:@-M$(`"
MV`9X0)D'.#O4V&5V4;.H&@(ED`59L`2KV230,YJJVADX>P1-P+.KN0V4)6=]
M6F>=40.`VEG<PEF_9'4O*(_H,C[")#[Q*"X$0S#+H1RW-1NYI5N:NJF<BI`?
M,)US%QU#P`!E0(G<N'>EJ9W;V1FNI3$?`ZO,94$;J0"TZ@A/(&NWJ@!6D$\H
MA'"(>SCA)0@1\`=],)+\232/\&PRT@\$]P,Q@#9.$`$;)H<\]`1IH%1V`$2C
M>P?<"B(CU1+.(*XC)'"(Z`+I"KL=VE*\UPT?V(A+0%/UBI7#QP0;T!&EPY53
M13*]4`4/T3<W\?^D5U$F('=_9L*C=$)_-H`Y@T@)K3N8%]$Y=SFR)'LIHM,I
MRFL`,0`&@Z@#_GJQ&)$I6`I5CS*R)9M_=Q)7,M`'+-LZ>3@%9B%S,C>S#;BF
M7Z862T`"&0`#/#M9(=`\U,*N.S!TC/$8D-$\2&<M=&9+H]&.UA&UX6*;6WN;
MB8J;YJ-:7(NI77L>\2+"Y=&U99O"WA2=O16=F::0:IM*/F!\$,``/><7JKH%
MI5JJW&*W%4E.@O$7>HN1"+*1!'&KZYD!$=`AIB!>*-1"O7H)"RI#^KF&DGL+
MN:`#$9`&RCH&(M`$&Z(`'723U)`T^?`E"=`5?V"ZCS=K"'$(T!`-K;O_L)-0
M"[)[QZ;7%EO#&*K9->3`!%7)NUG)HO3GEVW"KY1POJ.8$:IH)L1(C"46O5^Z
ML=\FHXI\BB$[.)4S2')3L=Z+BL$[O97L"0^[<*5C?_76R>X+$5#!F%:QLF,*
M#&;!5Y?9%OP+%VRZF0%0`CM``F+``QNP`^_:+`<LIT)+&8S(`1XH&<JB+$F;
M&;:T=.R(+:O!&E$WM1H,:%B'FU>;M>NB3,MT'"(\PB,,G2IL,$B`SD68SNGL
MPM(Y'(#!`#X0!AU0!A6X=QK3&6^+E7!0!G5K9F<F(,DEQ/-DE`CP)4B,76;H
M>,T07D=4"O-9-V.P<@``N<2FGS')(KE`;&+<_P!5\`2'$%_54'H>V08'<`56
MMJTG):.#@G$R@7LS$KL<>C1-%`*]%Z\S-:],P+L[C94L4,AYTK!":@`%T`>G
M:"=W^<B0_,G)VQ,;]E'.`'^'(A7;JZ1=&3AR5#EGU"D9BZ,::I0T"HQ;E=1*
M&E1?Y;[8&[_N0+^Q'`$/D("RDJ:AY(#YT5(XL`*^S`-YM0--L)J6<<`'["S:
M$`2>^8CFYLQP)F=+=TLH:,'5H6<N:)O=PLVWZ1OG@UK)Y)N8NMD^,$#D3#`#
M=,[/V<X)DS#L[,XO;$`$X`4^P`0=``<O@*H*TAD0L``=<-L=,'P\_`(VC%Q^
MYW<$3<03L)%30&N+=__1*C,""J6K(0+%'1M>0!D#&'4`*J*>:2A@Q#HA(4#&
M/#32%67'K6`J7I%1=S`"(F4"2E`%CVD553&]YPK>\.TB3?12C0A%Y<`$^(W?
M],R["_"[LR@J2>E],FJ\$)N^(7NDJ+RE]N<.W]O4VE<(Y"4(!+[(&2%P$PLH
M!:?*%7NPR9NQ4!IK1A(#9\03G6+A%_YA&DZQ!PN_3;76]=LZ`!`!-("`:B'7
M,VNS]U$$*T#8&<`#OQP!V4@#V\@L37("B\C+0,ZS;W:.)&A9U.*TC1VHJ-$M
MIX'-,4C95GM:XN.HRJ'9QP':6N#9G@UWFDK:T'G:['RV[N$%!#`$\WS;$##_
M%^M$&!.@&670`7,@`7,P![>MV_X,+1DXT$$LGGQKE#)0;8O7`%.PTBKS0PP=
MQ1\)EK"&$"(P0R)@TKM":QE]K!-E(YZ.`&!P#VG0"!65-3@T(W:L(1F`K7T@
M96K<DW\`1#CZ)>\=DRX9W\/PE%#BB#D]#DR0`[^.V_N=VV$``RUN`Q-:>;W0
MND?M1GZ"E]U;BS(`L)`#X-_FK:S<X!@QC!Z&X4>1%9Q8L1+1U/LG<-[V(#KP
M`%RZ.'2Y8B9>UIW8E=S+#T?E1\%[L'_PXJF25WNUOS9><W1=#26``AL0!#`@
M!F*0`2F0Y"6@`MH02R]5+*C9`\ISCB-8+24(Y5'^_]BLX2VRD1N'*EJUX9L@
M/X/!<6CB@@3C_.7D+-HNWQXKK.8*P^;Q0<]S``>G6@VO0!C#XK88(`%1(`%"
MO^=]'@:[#>AWIUC)99'OA$&'4`"0^U`?Y%ZUIMPVP%WW,`_U(`IK@PQUU`L&
MT)/"EE[8#0LZL-TT!`L-D`9I(*TAW6S0MM'@G:XF<`%MT!6I\NH9L6'R<(4E
MTPSQ/;O7`)7UW>O`G@,=$.STW.>Y_;M=)<J&\$)@F')7M56.O+Y&X6*04HLJ
MAXI0"H@;Q.R8;.'=GLK?WLE973GC3N[6'OF8H#J+.7ZALV%96F]F'3@D.^UF
M!2KSRP/Z'A8\X'*5V4G_7O^-:UJS.$`",.`!$9`!"1\!$3`%X""BVA!9C$@#
M`<P!R.,8D]4L(S@M?FH9&\\M\\,MLA%:)5_RP72HEDV/(*Q,+/_9YO'R*GS:
M,8_::SXL'[#X<``($"$!A"X3%A,$0Q`=$AJ/&A*2<W,='6%A964O+UL,0T,3
M0RZ@AJ&AAA.JJCJM.@BM!2,(M+6V""ZT.@T(8R*WM3H9;;,((P9C!B(B%U4C
M,2,Z;-&OM"-6!W8%5;BTN=_=+@J\N0'@+DTI!04V%PTZ"@;%`0CF+O?X%B[Z
M"!=I/'\."#SPYP\``'UDR+"1H!DU-FRDM:J'KR*^>@%"A"@B!$*)$CU"+AFY
MH"3_DQQ,3EI:&>92AP41VH`H($/>M!$18<%*4$#FP9\`VK"SL="&4:,&DBI-
MP#2!4@,VH!Z="A4$T)]MA-IPAG.BC@OK0+2Y&I3=T[--F5Y(FT"$`:=GE<JP
M"G1L5IH&N$8;<4'&NJQC#\JD>11JW+=LX1Y^.E=LT*!WPP((.+!RY3]]T#QY
M<D*CY\^@0X/.2+ITQB`12&R(L,%#AM01=C3I0>/C1P@J//;8D25"EB4T(`@I
MLH4X\2W(/2%GX(F!<^=;:D2O0;TZ]1=D:I!YX6,[F>T^N'<GT[V\C_/HR7Q(
M/_[[]P_D/\A'[T.+CP]:\I_7CR2_`"T"!"C@@`06:."!_P@>B(0`"S*(Q(,0
M/OB!%XE\T%(E96A4R"B)3/!"&(Y`\H@$44Q2R269:-*)<P&44LH$J:"RBE?6
MR%!,+;ET8PL;:?Q@@PC5`&-%&S;,HD,,23E$#2P1!:G#&';8$<$%..IXCS>P
MO'*..;`XD492:7R91@$/U&,,&[A8I,\^+IA010(R!';0.NRHY<Q$WEBD)SX!
MX.D91QZ!%%(/))F44@X=(+H22TQL(%0!>775I#4&]"3G3R`4-1552[%UUJ9(
M054``#Q<-9@,%XR@*C4ZP"G3I0=E&E5<3C6UEEJ>NG68#:.251:DT.C5UU]6
M92487E(M]A9BM2HK5P&.V2733/_K`&39M=FT\0,13X30K6C@ADO:((0,<@()
M*<``6PHII#9%%CO4)D1(MPE10A,X!,'!;SV4`$$1`!=W7'+*-?><<M)95\,+
MVC%,W7;8<0(>=^1Q1_%YWV%LWGOQN7??>NO1AQY^^95L,H``)JCRRBP'V*"`
M"\8<H7P$3.!#&)1T`(=GA1PB"@0@BNB`B)&8:`DF<&@"P7(O@@(*C*)`[8I.
M,:01)#!6'IGJ""9@;4(&""6@2Q47B'"G#M%DB><#I19P@0[@A*-C-US*G0L8
M:<B0AA-Z0S7&!3%<\,#?%<&RCPF(FQ#XL'2:]18T>>YI$9;X3(/F9P!W]-&@
M(RU1T@+_*:G4`1.+'KU""EIMK:I7Q_1!UU6R@CIKIYXJ)?OLT/HJE`P)Z!4-
M&#R]:FH;-2G+UJUI.2LJK$&)Q4XS>L$9%F"Q[O[4[$_!I:OR227`:[20.;_.
M9-A:]H>V1)S0V?KAMC_(^Z6]+T0*&5A!0A!3L+9O$$$HT*\0*NB7;4"B@""0
M8`HX6(*_`A8P@B6'.1"$8'2FH["%92<[%L0.>-RC0?:0YX/T^:`(U1,?D=%'
M"_BIS\E0UK(6NK!`#8J9RQP4(0H1P$*4H(0@R$4*4S""1(]P@!`U,+1(%$T"
M.61)TLH`@14-P1RCB"+40N&*B<3C:EC+$0+>H(`?W`"+M8B`_QUXT`9NP&($
M9P-<%:2A$UA8(0X%2`":<G0.N]GQ2KD000)^()4+&*!L:8B`#?Z6)A>TZ@)^
M5(8!G#`[9D!#!R;8AP4F24G)720GA6RC"S`'*-N(Q'.?`QU*4C*Z1;5D!^IP
MF^]<405>&>LJA`&58;K'K.393I9)B9/NB&>`&,2@"G<:`4_$`BN9%&\Q>DQ,
M6K9'JTHQ+U8T`9POT2@]2]D%,H1)"J>XISQ7RDE:=")?^09B$#RH8#/LTTAG
MW!>:<;DS!#3(0`920((C\.:`08`7<$J@P"4(4%`TV`'_@@"<?_W+.`YT8`01
M1D'K;">#WJG.=[`SGO*`T(0:RUAWX/_#T?N(S#XG7.%_7DA2EKT,9@Q*:0U5
M@<.<,:$(&AJ%(1A0AD9(8&A%)*(0<0H)22`Q9Y>`PQ*+P*(GNJB'$Z@B+;Z$
MM:8B(!X_B($.JM"`&(A@"L5X0T#L@`<S5D-KB,0D+9R0#1G$H$IU3.L=S?$&
M/X8I#65;1MDN`)'"(>.NCEPCXB2YIC;!K9*6Q$>0))>1C0"L"!`(%.=`N8`P
MA(X)CB4=Z5J"B1VLHW?`7%TK6FDIV,42E[1KRJ=D)Y?7U44H?_1E9H5I35-E
MREEN4:8>G067N9`E*S-!E6J!*3UB&@NWR(I*8;#G+.)V[WN!D=9@1F6'<0[$
M#@"80@/XD$[_=H+KG?%#@QCJ1P)X"30(`MT!;?B)@W^6@`:T^2Y!0<*1PQ9G
M.0E=*',J6!V&><=AVLFO=S0JPA"*[#T6Q1A\/'K"^ZS09"--64D7;*`8JE1F
M#[*A%RZ$1)UIR!X3V`+0YA"%(.HTIT0,HB-\^M,Y4#9%6P@!BPAQU"%4L14I
M,``8LXB`JOHR!C^XJ@%^@"9C>``@8[S#U9X1N![3`@T"L8.,*7='RIWC(BZX
M@"_<LHPQ"+F0ALQ3*R+)IB[KX\N`XTL"=/#EP$JN&WA"0`C8H)',)=9?@BJ4
M24`'V<BZ!$5OB$!J?^F,B+22F&09RNVR)UK%2&70HMKE\V[LC"H8_V`NK\04
M+VG;%M%267E.L:WN:)(`1K_)+[ZM2W`1K<U;"G<QWKRF7:@E3N<>(+HTX`P;
M3L!FZXJ+7/`+@';E&8$CK&`'.\!!>0E5`H#Y$\YPQM=W=Z#`I3$PH="68$/I
M:\'\VK>^'`Q/@/T;8/<,F,`FM$\*#SS2_C#XW`2*X8-H&.&:X=!$3!""1GHX
M!`9```X8"!%/<;K3$/-T1#[MP(DN<=`3I)@!+6H1*5ZL`P\LV:ES,YL!FA"#
M)C0#&%9U0AO&J``GM<+("(A!"P3"@SN@M<E/QO(W+C`%IS!R#`48`]PF$H.6
MLR$?]Y@DFRJI<V4X6L9=#BP];M%CB$QDS?\G@&GF-"<H0LD9=(V%+&1+B8D%
MW&#/TU15#+Y'EIG<KC!+035I;=>KVSY/FGQVE6/J`@+C-K-9AEX,4QZ]]N'%
MD=$QZ"WU'B.6A1A&N&#_^Z$!KRQH`>:WD0%`<UW]!QY$X`'H#('Z0K-.=F*7
M7`IHP78W0`(4,'LDM?&7O(6P@]O`>0G"%B@.0H^<PPXLOO!%CG3PJS#L+.QA
MMI=HQ4;([8S>ASP;+2%Z0$I\%8J4A0I&][DAO.X(JV+"E/#I'(K-PR%H&`X=
M,(*']\W](88X1"8"*A.%$S`5L[A/58P!D68,C%PTX`EPFYO\T28"'F0C#6:\
MA0ET\(/%VT$&6H+_<G&#1VF"91<0%2)`%%'1$"/@%E53`$Y0!3DW@6OR965F
M`;^D.+-09G3D`D/W"FB#$Y*B"Q]'"VQ6!.IS6!V16(/B=*'T.75V8E5G<6@'
M#<_@3:8B:%_733NH3667@PR!=M3D%Y$F&*_%/<RD/+J2::8E:I!2@]+S*M0S
M+8XS>%2Q*=JT3==C*<5R>(^R<:Y&$'\0`4VP&9)WAK8F&O%3+@%``SS``V*0
M`AS``>!%+[?Q+_;2`\+Q$2I``PJP!/S#;(EU4,\6;<HA0=1V'1%E>[:'0?ME
M,1=E0B,4B1^U'QYE'YBX0N964B>U8#+TB3/C!37C`P)'8G.P`#"E<-8'_P$U
M-0?ZIE,AYF^Q.$3]%@E&$'X+<(<%=W`,H#;]T`>R`'&WD`O[-XS`@#8I(!"8
M(6-H4P4/8``1T`+^YP%4@B5Y<D=XE(T5434U,09C`E=3)@+/T$MIPH&2=(X6
MF'-=HR6"I5FK@B9&-UBY$(*O8%@`DW1NIE@N^()A4!*8,'68T(]H`#C2A$9;
MUQ-=IX.DMBM?AST_6"K'PCMHQUN0!BM]YW;<I(1TYRO-\X32A$B@-H4`0$QF
M<6J#!BH+H2F?8GA>N%S08G]A^`<%H!G=4GEI^!F%Q8:E(01B`(=6P`$H4(?^
MXA%OEE@=<92;HP#AU2^$>!RO!VT%DP?3)E$.8_]?$N,P^]5?XB&)&:-1YQ$R
M&%4?PW=@_L%"#-:))/6)[#8A$^`%I.B*),8$.U0(&E931M!ALKAO_J:7D#`T
M)/*7%38H<$9^Q!$"1U(-%X`0:<-^6/,&<6,+X*`#!L`#_G<0BW<`<2`0<<`#
MJ&*-+L`+3'81=J1R(Q`!!?`E4Y`49"-57*8F%/B:.J</U!`X9U4YOP01$1$1
MWR`Y2H4`;'!8^)B/ND$H<,!8+]A8CH4BF*``B+1;!_E,;=>0@2=X5HA+O,*1
MQM00S>E+4>@36"$K&<F0SJ)+'#D3;X%(Z!F2AS>2CS([2"&="D$3ZZ`0?D=V
M4@@8XB,#?0"3SO4'=N#_`32)AC9YDSR3:QF1`6^8`1X``[\6$D5)E`<E''M(
M`TL@4/Z46*[GE%`I0="1,+4G4=5V00US03Y0`]I6,9)H'A45EB84,IEX?,K7
M,C*44BC%?&SI!640?22&`?]"+M:G"1V0;T'$?7GY;[(("1T6!4IZBPL`!RUX
MAP!C"T]B!VEP(\)("WST!EUC)?('"Q<@!M?B?XU'/-6("WL!)`3X9!<1`W-4
M$6SP:&-6#))S@3@7FSLW29+Y2WI4FU<R="H76,'P"@'P!!FJ@H.X6,?96,@9
MD(R*`]M)-@8@%DUXD=(Y*Y5JG0CI*Z^%GK39G7:'D3P(6J6%G:BEG03)*SWA
M_UNXI16G]G?O"7A^T3B-4Y_>0X14^"@TX1?6PGA]L"V31Z!JB&LZ*48\8`49
MP'DK@`-#.8B#:!Q"H#DC`6S'AEA"\%Z%"'O29AVT!S$-4VV<T(@=1*(INFTL
M&FYB298CE:XQ.B!H.4/NJFY(X`440@8X0V*2@`'%EHI#4`1EL`0XHWU#"HMZ
M.;!].2)*J@$=YE,EL01.:H>)):41P`-ODV;5\`ZW<`T1,`;KR'Y:)`(90!G^
M62J/\D=CQG]EDP)[,P;8&`XYDBHJAP`&T`<7$%A]M7]3Y0Q>MG-L\E1K]$A_
M:F9Z0@\=&`+/ZE[!>:B?1!*,U8^.Q:@!N006]TM^E/^IL*,ITIF%U;F#UUF>
M-6&JBV.K9G=,X4D4]$F?H2(7S\2>D&*JB$04="*%^;DKR7(4L7J?^3D[L2JK
M=+(0HQ*&%7`^OLH9`PJLV$4:.Y"@'I`"1U"'S#J('4&M$UJA";0$PS$<`M-Z
M[X6M#$5?G-"M%]2(5#DQW7$QO:>BY0I2YXJNR>="[=I")P6*\=J6.0J7/A4%
M<]`#\O8^K+@$`G>7V\=O>2FPP3LB1N0(2HH!G\.P@ED"01(#0;%&335CS-D`
MO>0$5'(EUA@,%^`$$0",-<$0"8":IYF:%!<-D<2R<].!4F8#,:`G!H!_>M(U
M+J!U:Y&`,A`3!H`+=GJ!%1C_=$#[OX53M(<5`JVW@B50!IQ3G'#0I)_CM$X+
MM3=6*4T(39=ZA491MF;+*5M[6Z_%MH&#@UAQ%V++36ZKMPJ!/9"F:.>)GFN1
MMW_1$W1RM@SIMH#&=KEJ.RX\JU$A`ZTV3N7$+>PSN`1J&N_3``F:`AL0!,FJ
MAXV+H8<EH31`H<)&N45KK>YEB-#A"=41'0S3Q0_U4(J8>Q9THB`$?!KS7^4Z
M?&-);JO[0NT*BC!$0RK%(&Q)!G!`NR6BI+<[')[!B@N0?0"[ET5ZI'R)I(9<
M(D7#!`N``XOL3R$1)#_``U7:1KH`<6E@`S^`FF=E`DV`1=@[5<L2%>H0`4[`
M#`TP_PM0=HW?T`#,,`M5A0L*8`-3HB>PT)I=XVC-H$VFF3=T8@"M2:?[VU<`
M#,#>P`8";!P$#"@>@<`)O+2+ZL!A@`,V%CR;5L$HF<.?91A^`100*1A=Z[4'
M:$VJMCN@.EIY*ZG4<L*E54S-T[6<NA9DJ[?S69_*8A2&AYVY9:GT.:LG[#T]
M7#X&(5TGP!EH"*P:`C_D4E@_)@8>D!H$=:'+2JTO@%B(I1LCH:S",1P-9*T)
M=1S2)GL?ZJV?"\:?JT%=:<9I;*YJ3)8GDV"LZZX)`B$T&B$/A@03XI:E2&(E
M@@&X6VLAH`E_[(I$0XL?%KP$VU-X:41X&05&H,BA-!)?M?]Q-@""5ZH+?'$G
M@&,`J1F`O#`1(G`':2`44X`&7P!);8*^NVFFNX`+;+`.!L"<OF2FD*,G:#-5
MB`2I*3!F+:<KK6S6_<N_=^J_0$L(A:4^)Z#1ZU1T#?"L&DW`R3R((('`"^PY
M"^R/S^S`.$!QU.Q:GW6I4!&KZ/PH)SPKVWP0I=+-O*06S3FU+0E<]-Q-1*BJ
M)*G.C]998]&%>.&U@5.K\2FK"F$8R11W-,S-W5P6]$RV&+P0S&`#;4`9_1E=
M[U==!6UY"!T_Y!($;R@&]F-/"B1`C7M8+\!T@DE^F4O`F;NAS`'24QDQWGH=
M^D6B*(JB:&RZ!;;2J6M\):.N)O7_K@K"KG!,TQ`BKS6`?;0;"<=;`D6[$?T:
M!A@P![Y;U+1(U`1;1#EUL$03(B."`2OPU+4P`O[Y-L%0U0HP`MX85[X@5;4@
M`DT0)E/P`TU@L>=+1Z%9@`C@-E;CFV,053KP!)%SUC@79;ETR4@"%55@`M30
M)A.8#\#L9>9H9AG!$?;B24TGF"K0&<8LP`?WV!;M.<;9CY<-S0L0..29@U9[
MJ>IY32"0SZ3]D*02*]_,PBTLSI)*SB0,VLR3SFO.A:NZ.VIQ8]SYV?L\SV>[
M3'"!JG0!$*3RAH(!C-ASP62+%`WQ`WWP!Q7@:M`5`=%-:[]JT`9J&GS@&MO5
M7<$F*,N*_Z$37=$>@5X?4<7GG1Q/23#IG=X5Y,4C"KJ>>U_A08GT'9;%]Z+X
MC6#YK3(.QJYQW'PS7=,0<M,?HJ,E(@D:D`.X*V^(M>`-;N&_NU/]-N'":["/
MD*1$@[`2P`2_5A*Z<`/09224+(Q-L`Q29;[`T`1<PV5,1@O%*.,#B`!5"@;A
M(+]26@5(,K,580$C8`.I>8"9)@,2&/"N6:<ZJW,F4"M@0,MHHQ%1/N6<0RA.
MUSG>G=&%2<`LR+#&6=G^R*C*&9"7L`!-8`,3+,+6;,_>"3MT7ML<.9+NO-IQ
MOJII+MHRC&I$B,_99,\%T`>'YSP+82=^OA:`CL$RK$RB\CJG;?\0J#T4RY*%
MH=(0;S+I87@`C@=YAOT90NP^A<N&V+U=OD$""40O30PPX?UFMH&AETM4#O3J
ML`[2]=6Y"V.57ZQ?[PT>*GHQ*%W?EACX+]K2;1S3*`73_+UN#O)@-$0&7O`A
M.2T!=YFD//JL&]$#"QRD&)#4`9OMV"Z\A6RPWH[A%VZ[&*#("*`X+7`%DXPU
MC-D`@/,#VVNEU?"8V`O+.A`!OR`WO/^8QC`"8(!&4V`#>1,5[-":]_#O"3`"
METS\6+4G'-CDP/P`5@"1O2KOQS`&+[XY+=B"G?/]X._(W>_]7+X`#!M*51>#
MI,,2C+H`S'TI@!%+68N25`L04>\X/:__J36A1S8/"`DV,@6%;8<@A3(V!HP&
MCY"0@P4@;0"7/)F7`&V%-HR3A8:BBPD7%S%5JC$Q"0F/@S*RGXZ/KK>NC926
M`#Q_`'^^/)>)BP:WD;:H51<%?P?0T=+0?W\134]/(2<G(=[=WN'BX^$!W@'H
M(>CI?"D\&1$D64%+2STE$/@0$$7\1?W[2NC[5V2+P2T,MH10>+#AP80)#]:H
M\8*BQ1=D)D[$6'$B&8PU,H+T\=&'R9,H4VI)Z6-ERY9:5L:<23.F@)LX<^I$
M<I.G`"0^?_X$*I2HT:%(/GCQ4B;,G#D8)$B-(B%*%"8EA+#I5R],!PQ&K&K0
MX(`L60=HT9Y-_ZLV[=BR9<?*U1"%;MVY<ZU*@*HCAI@#=A+H0$!X,`+#A!,K
M'B%"Q+$I(W1$=C(&,6$7BC&[B#"BP`_%EQ-C'BRY@0@P:=J,L7$AS2Q8-DRX
MF.W"0I4TIG08N#`B,NW?P"W,%DX<N(L1=@[\\@5`,((83M*\:4*CA_7KUNMI
MWZY]P0(<W+'WJ`=G27DXWM.'61"FO?L.[>'#=Q\&A8=*EPZU*0:*EO__A("`
MR1]V5-,+,05\8D"`FS1X2"D)L!+#*:_((DHGBBRB8#*13()?)K\LQTDG"GY"
MB"BD,&(**U5(2"%L&M9BRRT7(&.#(0,>^$M^!1@SXRM`FE+%"`\X\__,-$CR
MT`<:3W`##CE01JF..NM,:4X`.+R3`@E!!($#>-;ILT\1+P`4T#Y"_+-%008M
M9%!";CJ$4$,U;''11A_ER5%('F&4T9]D!$H&2X2^I-)+,M4$DTU:"-#H38_J
MM--1/@4%U*67%F64%Q/XX!0&<^Q5E5@2+)!5FN/%!Y81<\'%UJMMN6H67&:-
M)0%>N,IUJP1&\%J@'3RT405HQ!:+P`@_3+A;A$[<]H-EF87&QK&#:79882U"
M5T`$,J11P`@7P-*B$P:`VZT,(P"'P#%WC&!#NL8%%Z\)K<B`QP5*F#""%=``
ML&`;?=B0BQ,*T%#"/>*--QYW#"^PA,,,]U#_WL,/+X`>>NRI1Y]7''?@L7M,
M1*`?(HGTN"$LC?PWB24\V.%R-<'P:,R-E0BXR2$FFX+*A+?$@F*&M$0"9"0,
M`@.,,,,`P!^,A)PHRS&G2"CUBRF?++3.-;JR\B;"!)-T)QI>G4!C*U;Q@`S5
M((GD'TLVR08WVT@I]SE64DFE.3!D8$4$\^R``PWVB-D/F0`)H0($::K)9IN,
M,[[00A!%5*>=%56.YYYZ<J2GH#Z\4"A*+AEZDDPFU60ZHXY*JKJE/+6>J>NP
M8XK$4B^4\=535?%*5108+"&$5A"4\7`8&(`EUEMGK<766LJW-:M<=^4J?12]
M*A>L`8CI0)JQBNDP_X4-/S@QA0@*Q*!]L9B!EOYAU2*@P!@BA)M&&C%$D$;\
M#9B_KFL3IF$#,[2`%VT0X(0"&*`*NT%`O(Q3G.,8P!(N`X`5TM`'8-@A8*](
MA@)*8+#J)&QA#*L'>""VG83!X3P84P][-B8?KWBLA1_+00I&5@E%@"(9*AO$
M(8!!H&JX3!-@`T4A;,8+G,G@&!%B1=929B%2Q"AHD,A@(PBQGUXP)T0R<X2)
M9-&TI^E,:A,ZQ1*ME@Q79`T91=.1T1!D,AG]:!DQD($OU#:-/WC@!]F`FQ[G
M!J4KV2T=54*#!SS`MR#L8`?:,=@^^.$/Q/TC36MR".08\C@YO6E.=M)(1_]>
MP$E.4B1S@=*<H#R'D<\=JG2H+%U,%G4Z1S7JE:J35.PT)3M,(44+G'J!QY[2
MJ]RQR@AG$,CO(#"\KQ@A+*U*'JR6^:I9T8HNMY+>7'9%E:J`+0$C*(SVIM6]
MQ)PO,6\000PBPSWT)88-;&B-"!)S`?L9X`=54$"T%(B`']A@"@E0A0CFQ\4J
M&,<QO!&!$RX@F]DH<(&ST8$(+-$)#_"P&DI*``".R)H,-D$@&*6!P3YH#^Z`
MAV(E%`\*,P:']9ATA?2!X0L_)I\SI*``^\'0:W"80T(,R(<P&T80IPC3'>K'
M$U#;V1*GV,0>/=&-QY`$)1K4M:^UD19<C*J*HA;_1C%2366-B"(N;(2C37AM
M$R6;!10?(8(5L4*.1Z(C-=J`1R=UXZU\[./=U@%(;^P@!1&00A8.V=%[,')P
M`/E'F0JRN$LR("*'98";XB01@VC2(I_<D^8X61(_^<D'->B<*4$G.D,EZG2M
M3-U.-(646I:VEDCP02Z]\A3<59-ZO3N5$'JPPN(=,WIR<14S=]O,9THSFGC)
M710>,<YLCB">39@6M`C3!,LTX0+EG"<]+Z.`'XC@GM72017`L%QZ:B9^K;F`
M"UIC@S08P`D"I`U98W"'`@CF.".(P4&'\QL=R("A^41@`7H1#!E<8*()\*\@
M#-``%6`4HPGKZW8^&D(3_WK'/1EK#TK?XT(7KO3"Q'MIR=K8(4D`"#^_ZF&!
M>)0@$_5T1#4TQA<IE$$39^BH'.H0%7,D(D[8$*I153'6K'K&5Y@HAUH%DF-X
MNL,&@15#1GWBC*AJ`V"H-1J_P`,1F@37)\55''ZL*UU#((0(Q&,*74)D/03G
M#X*4R9(/@0@E&\=8QV9R(Y6CK.8^&9+)#HHCFRU=&5ZRYU5^UL\U29U-!(V3
M1E4J=I?2`FIKJ06E>$&7K>65[JIBA`7<XU1+4-5M<8N\WB[OTYZNE33S,I:Z
MC$H#J1@G_!HP&!-<:[GQ5<P/\!#=OF03?9%A0_NF.UUK^3I9NA&!"=@P),(4
M]/\W%E#`;D:@;%-TQG\Z6"`8VC`,`P[IN!>0@04+D&T9!-C'(FC`@<=],(4I
M+(0AO0X$KO/@C;F;A1:^L+P[<`0/P/3&2-4B$V%ZB0+!K$`Z?>J)0""@GZJ8
MQU+<XHNY&#2D$ID7!TH:)XHAU47$"(EFI-`9/3R+CH^50RXN<GYP]C.I:I5%
M4W#RDY4#`#RHP&U[C-N5L7RE+:?C!#WX<I?>L(3J"`1Q_!CL8`MKR4HZ1+$/
M<<A&EE[GCU3$Z9O#,RE-,G64[)E0,T&E2_X,6M1!JB=@1X*B$[UHU"IE`C78
MI52BTBNJ&`$#]V@`JFJ[*E9)C[?,;-ZGDXD73I/Z`N7_:T"M2:/0SR2F`=Q4
M#!MZHX#R1L`)H@G-^LSI:^\>U#+&<;5QPE4%$UQ@#`887P3*.M_BF(`#P#(@
M;R*CO680J`\+<J_`%D1@<A\88>:^3D=W;X_K'*P,XYGPN]TMGWD;OP,DL#?0
M'([#&?.WAP:RL8:XV-.:&77)&_>/A;J88R##IJM&SD]8<WQQJ&6<Q4.N&OG%
MBE6.7ZAF-?R9$WUDUA@80.5/_L447NXDF<\<RU9"5U6R#4*P!"0`9EW2>X)#
M$&M"=`T1$8P%)PP1$9?D9AIQ@7$F$AQA9Z142IZ39UH7@HF"*%WG2B;X2CPQ
M=F,G=K*S@K6D6EY0`[;36KW2_W;44VD&HP)"<#"J8CQWP6EX%X2QXA;)%!?2
M9!5W80*N%EUC\`/QI6L1`%W&H@-6<`&4T093,`4%D`:"5TZ3-WG$HAEB^!L(
M8`(ZH(0Z<`$B$&V_\091>"R-P1O'1E^T\0`PXUZW=CXZD`#.P`.B<$;W(VZ&
M<V#Y,&X:U0,:=8BZMS!A@AWH,7S#QP1AP`0=0(G')V\D,']D%&,WPF]61"`2
MAR$^<R)(9C(8APNP$0M-HP@]DF3=5PN?8`@0UR#QAR)2Q0AEU6.WD'[JMW[L
MUWY$A2*EV(HE1W])5`4_T`;)L7+Z5P)Y!%?_-PXU)X!5<@*&LP/S\`:(I&[^
ML`5G9O])$&%T:B9)!]%FWE@GZ`A9(+$Y?_)TG$02[UAU/G!U6%<&H3,Z(]AU
M,^$H+*B"0Z%H`,F"`NF"EZ(40P`!MW-,4:$7U),#/2!W_T!;7F%;OT07=R>$
M0:@\10@]>M%+8=&1Y30"#2!X-U`^B0<:Z%0%33`AS9(L5=``(R`;ZB-YD9<^
MOG:38GAYC1$#-N`$(N`NV$.'9CB'\2(<M&$"5O`K;5`N>G@8(M`'P((S-;(L
M%U!@AO,[6"D$A7A@'=25'R12*T2)'".)&R.6E?A"\7:)'I.)K[@A'Q=[(B=Q
M(Y(A\@<T2%16IC`V,***Q%B,K@A%H1!3-T-RH\"*06-&6Z7_EU7S8[[8<3#6
M(3Y3E\48-F7%(@G0!FFE5L$0`0]`9=M@9=`85S47@';#9?F``T$P#RO0<V/"
M@(2%9A1(2;&I9B$0FXY5$6^FCIJ4)QJA)YI%=2"82IQ%.OH(6BSH2F*G@BHX
MD&37:$N!D%\A`6`A%6'!*Y4F$#H(`>S!!$=`D1I@=[BB6QC)6\HD:D;(*\5S
M!$=P!NIY!F>0GL96+"/97>QS>`M"/\D2738YDZ'1:Y:'4#HP4"-P1-@3+@)D
ME`A%A_45!P`'`.^2/2/@#@?@H$JC-:A0E5F9H5AI>QGE05\9?"O$4AP3'^TA
MB?/1,6JY4DQ``N270S<$"U0TB^)'_PKW9HM&I2);55:+N7Z2J8FPV$0C@P@8
MT@E(QG`&D(L]-F0JXYB^J(K^`7)1U:/+=Z01H@H7T`>9J58`$`$T0&5-$C=6
M=F595B5;9HT04!T[T"4*L`3"Y$B1!)MK)B<0R!!H)A'I>!&>="=P5EF5I5D?
M^#E;QQ+$69S[2!/]&)!`$9"*"I`D,0$OP!YOQRNA8A5MAP&F`I$E\&#%,P?'
MQ"I^1ROCF9%J\1:^%05'D`,K<$B'E*JIN@,K$`3Q)871=1C']3ZW=A@*,"2.
MD0:WRCU@.%X<X(3]F9.5EY,()$8+DFU]$`.U01L(:I0(ND`_$`?+<0!]<`&$
MYST%8JU50/\(MM`;,2!WV4`0CY2A',I!Y99@&/,>'X.B'8.B+)6B+Y0#'+"*
M'O>6D$"*/E6+HL"O-XI$63.5,*J*U">E/NI^0Q13-22DF@BP8I0+3-.8C3D(
M3YI4,%JP\F=R1[H,1%(`RYA_/&`%G?FE5>9_HAF`HYD.(5`$*E`="^"JB-0$
MB/,[KVD0;'(":T:!C!4GMND0+Y!)N7D1>K*;HB0H@Q*<A;)UA-IUR:FH30N0
M'Y`4J95:CL8`M@,J1L"IDE:=;\>F<C=;[)$#%"D6?N=,;($%S(2V:)N1S!,7
MU',&JKH"K[H"1T"W=*N>,=`$Z\0]DC%."H`'!2`"/]"%",`&3?#_`#H`>FLH
M7=&B&2;P!';0`G9@!8:Q/NUC4,8!'8]@7CW"D^6";`C50,WJ`B:P`0?``X0`
M&-P6&2-P!SP0#=?J&(L@;`@PDF_3#6RP#02AH3NX@US)4?6@,1;&KL6G4O&*
MEFFY4D<0`:QH<0PG(STS<##EKPE;I*^Q8Q"[15%:5#5:EV(%F2<BBS7#L$XT
M51=Z5=I+?DGFBHX)1=F;8][[O5"3"O%5`*_+C'^0`DQ"9=`8IF%*#F-*C>:P
MLOE`6R^;JFR*E>2J)D97CG1Z=`W1P'1B@41[.40+=5+GI[\9G,1)@DL[$_W8
MM"S8$DGA`V+W`0;9%,0SG35(/=9Y!'&'_RH/\Q5UATQE*YYK&X0Y'&IFZP"\
MDP-Q&P2O6K?J6<0H0)_ZDDY3T$X&4%PQ<"_>-`;RU:N45RPMP`-<X`$'0+EH
MF`!.8`/B%&WS=93*!@FH<%Q[R*S-&JVCR\:_$0,N8P?>MHQV``!],$?08`=M
M$%!M<#^U(9)2<@+:4`1/4`09:F`"D6#DT6Z3V*[Q4;S'>XF//&\H\%(+IV0_
MXF/<*W_ZL6%&NC-AU&($B['".(POEF]%%5-!VK#U1R%**K';*['Y1K!]>:,G
MLR*1001RM'+4T#8E&XTT1Z;4N+([*#$+P`0Y`,1L>BHS2ZX&T0V1M#@27*=O
MVE@7>,W8+!*AE/\G\%@2P(FT2FLZK$2H3YN<'Z!H*&S"JH5VP,<$Q1,5G%J#
MUGF=(_D[P_/.MS5JI!JJL++#H]II9F$$0`RS75+$1X`"W8D"&,`"H"$9L1H^
M"K"&X(*,IS`%8Z`8J-`7OEI..U#'-Y()UG6?^X4A!"4;<W@8/W!$>W@*`"4O
MH^O2OR$%>5P`7W"_69K':2`;,6!MLB$9`$P.)["[6&E@'MHPZ6&B*^6N22VO
MD(R)\_>\M;!5$1N^.!-3Y3N_V2*PZ;M]DCDRMA@VX/M^-&1$8E69JQ#*$=N*
M/,J^[6L+X+N]MAP)N3@D.@`&3@``O`P8?:``3>(VG_D-P#R-POP-!>S_'<B,
M`2B0`W_3IEGIFEN`LX2U.`[H$$3WLY1C.=B<V=PL2O#X@?*X6:'#=1]<SBLA
MM3Z`PL[I!0SPJ!VP`/A\3+=2@T9P!,N\%9G:'MW9J=^YVW>G=VJ;%OX<W&YA
MA&:+`>J9JD(<!`:-T#"``3!P3(01`^ND`U'X`^6BA,PU!I_77,RF&&.`!R/0
M!&7(N.LS3L8F!NY@`!'P3C+0!UMX`55@`]0&+#\`'`5E`F]0`-=Z;>9-'*+[
MT@`^&R9PO\J1`#]PT]'0'#TM,.V3NPB092&``$#-#87\!,4,0L&+`QK#!);8
MKL67O$Q]B4S@+>MWRW@IU<%8".YMU:<</_3;_R(U\LKPV]5$.IF`Z6*[H,HD
M][VX#*Y#-<K<!\L4BZ\>%@L$"[TZ4P6Z!@9-EM=_P%9]W7_`3)J"O66&O&[H
M@<SOZ=PHL`.7)DR-[9ILLA!L4A`KVQ"3/3GH&+29S2<;&$KP:!)W=K1_FK3X
MR$KC;)R*:L)1>\XH_`'K?)#KL>50P79;>TPK<&F_(Y$YT)VK<CRC)IX.X,^[
M]=O-U&EJ46FM6M!&K-`P\-R=^AS231@PN5PZD#\(8(7D(AK-I0,_(*O&8@(*
M```><#_A<D!B<`?'L$6L$0/>\KIZW'GQ@M+_XT_.>NS1^M^_,0+28`?N%0'W
M^[%YC#UF"-\'90$ZX/_@`SQ7VSX.)\!!C+@$X*'AZ7',7H'4[PKB(7Z)R\O6
M&^(8B"G5.-Y3-3I35=H;V*:&3*2^\I<(^T'OY>NBX9OC+!XV9L1ZV*:7.`;+
M;4GD;@UR%8MQ9\RZ>(!_FLE64]9_H/E_@OU'-U?,#Z/EF\H")(\"J6HP8$ZS
M"ZPFT?RFA558-5`$:IY)'<%TO5EG?,*.W#SG@;+!6#<ZJB3:Q7G.AH+"9,`I
M0U`[/7`&[DR1H.+"QY0#IE("*L`&)3`\*]RI/ZC/>@?<7C_IR[3#K2(K#J.-
MJJJ>*(`"GT[R^1P%QP*32V@L(KF&X6)=&"U.UD6ZB6<MJ0XPJ`!N%V`%-H#_
M!VG@`3J51,T@#2T`!D194!?`"`1%7__MQIF'!M/0!C(``G=,#=.`+H31&PA@
M`<(Q`M.B#A)^)0^^9>(@!-4A0A53[BA%B1V.ENM>^QYS!/;ZO$&6F#!Z(35N
M0P!+U]H3JY+`HZMH"`O;O4DF\%1];S)%?_"=37VKU8Q9XLX+C&X]-%(M11R"
MEQS+NC\``-).1U%&!(+\U^#POU("X54^P&9JS(==/"0_!VQ/\D>``Q<%YF46
MV?\`""%%@X-;189;B5LOAC6)CC61D2\O-962DV29+V2<G62?H:`O/J6FIZ9:
MI:I:K3ZML+&RL1]('Q\^9%X30R\03`M,&,-S&!)&_\?(&$8Y/24-)6P02V%A
M1T?+1D9141K>W^#A#AH.Y5CFY>GJY^KMX.7D&D=+._5!1R@D,#`LVMO<WQ`(
M'$BPH`X=#0X6%-B@P8@+,:K\F#+0A4`7/Q+8N*!CA`@;?2+($!&!0Q\9=@`D
M&'%0QP\[!_[8^2/F@0L3+G+FU"'"@($+.'6ZL#"T:%&B.HDB-4'B@%.G/`JT
M:2.C#0`[,)^"&($300P=%HC&N"`P1(`0:,\&"(!@K=L00DKT6+*@;MTP"_!6
MR\ND0]\.@`&'"4RXL.'#B`ESB%!`AN/'-FSX3$"Y<@(1"7S:D%&@<^<VGF5$
M3G#A0I41`SN6UASYL>O&L/\]RYX-.;)MVXYGRWYL@#)$EJHO9#9P>[/KS<4E
M^_39$[/EY]`M+[_L&^+I$6!&)&CSYZGW[RGQJ'AR@LV)$VC1HT?+OKU[]FK=
MQG=[0@B$N0M6,#DS#`.+__T8D805&;A!0A`XT%#"@A!`(,2#A!PB(2(3*J*(
M(X]L`<DDDER"20V:A%C)***02`HIJ*2HRBNOP-+BBZRPJ,4'JGR@"R\,W$?7
M&<(,H\TR4?QHQ`I+/",$&T+T<!<VV7#333?A1/E-.2VT<PX[[#B099;P3/E-
M%//L<,0^).C##PM)_`-00`NUZ29!+G1DP@4&3,01`A99A(`'DETPP@@QV```
M#S;_Q!#!%`5,@=4/"NF0@%,M#&I'!CH(E5,,C?T@`IY(*66I4$A9:H('X!70
M1P$)C&5#&UG9T<8(.WTUE`E5B*##6@BTMY99\@60)'YU`1,&$\0R,>RP?R5V
M&`;*-FO8$1RX5MMTT"U''&>Z.289:3&PE-I#P[4FFK32ZA;:<<G=1NZYHO7&
M+4M_CM43<9&E@9QHR5D;'67.[2O<O_P^5UH,$?WYYQVL?J=P3`!,T0`?YZD7
MPGH3OV>Q61C/U^O$]M$`1S#[]<?"'/T,:(4;;GB0<@HP!+&$@@L^*'.$$AYB
MH<T60J(A)AY>PDDDF@`-HB><>`(BB*"040J**:["HHPP_[JR(BY4W[++$#64
MT4,93"S1HP3#'".V$1B<L4#,#3Q(S0(Y,*E-D-Y`*664[=1M=SI<FB%.W##4
MDP4*^P0>X#][OVDX`CH@T`!9`HWP@^)5(&!"FV\4D($!J"$^0AH\W'%!`7@8
M,`54=[2$!TPB\1"''1%,+I0.I?T95$Z='D5[4D:Y,`(/WKD*D@T&CU"%$U<!
M4`!0'>G@N@M5^-D66V^=Q6L`;,C5`W[`%)M#L<4.-IBSX(?_;+3H4DN="/VR
MEMMN[7);!1N)']1\9NIJ2VZY]VN;;KKY1];;P`:KPEC"M3__Z:LRI4E@::`#
M,`4ZL($#*]@(X`>&"W!G80IK&/\-R!.QBJ7G8A93R_1$*)\3%.$^2M(/?X;Q
M'R-8(0DI\X`,/9""&LIP`P?:@0(49!\(#4((-4-$(ABA(0OEX4(>L@2'/A0B
MI"4M:$\L&BARH;2FI<)I,9*:#VA$M1L-80L0*$,)%D"7'.1@&!WPQQR.T9\=
M+"AM;"C"&!>P@S#XZ&U&T(#<YD8W<CB@2E6Z6R"Y],=Q1,D(,%"`F,I$IGV4
M[$GO(,?AVM2$&(B@`2)@G)[>E"?&V"$-C1J!!^SPDY'@0089<`H`1%"%!XCA
M`''HPAT.`!,[7.!3>/K4[7*W$P2$2BA5R(I3[`";E0CP-%4P`&AD8(`J'&0H
MB:.5:?#_]+Q<L84]2++>]>PRK.T1:WN!(=;WF"6^P'ROG(;)0AKP94`#]`LS
M\,P,`>_G/_<!IR/SHY<,U@F9_/&3G05LI[7H):[;N*LTUXG7`I>3K@-69V`/
MC*A$)TJPA!YD!`\H`.\PZ!T>1.`!?.!@Q2A&,1!F;(2]VI4@5$`#)7V3A24C
MD`QM.-,:VG2F&\A"$)H0LYE%B$(6"JHC\O"AHF9"$DW$1!-#1*(J6A$5*XK1
MT[CX`2]<S1<0*,$2>I`#MIUAA6$+4C\P0"0C-:`(;%!27JZ1#37QL8_CB&L[
MS%#(NK8CD%624A3ZIL@LF`D&^OA/$M8420<,!'V3-($"AO>5_\0M9).;%`@/
MK&`'&3C6*S(!P10V0IPTP.0**?G#%6B9@#3$!"96,`%.9O>IVGF**`BP%>YT
M\H#O@&!5:8`(P21H@#04H)DX"8OL'C("L^0$5V^)RX*LMP2Z@.R;'<A!=#M`
MSL)4%YW8+4P6Z.50Y\33,O/"C?[^9QUXL4%XPF&-<9!C'(`"5+W*$:B^!FI0
MYOA&@O$:BW#F-5#[(C"!NQ7@;B<:P8CL]L`!#IX.X,>&*FB4HTZIP`$`$($F
MD,<\$BNI2>&3%HU-#RTGE$NPSN@?%[HA`S6UH4U7O.(-1,#%',C"#HI4`@?9
MYZ<X"VH1(?$"HAK5J%`4&M*`]L0I/O\UJD];42D^4(,)\`*,#5H0&9>PO?XL
M`VS9,*,S&G(DN#C7&G=\VQ[?&H^XDH.N:!8D.MSA)6^T;`EO^%O@!+<-N):C
M<5.000PF9SB'Z$`!,:#(10H"689$Q57W?`D/2OF#-#0/``J[0@82D$H[Q"$F
M56"M+F_WRZ*PP9>ZO(`P>2":W`IP8,Y\B!,*4"@3A$5WSM3!:6X5`)VXI7H\
MK?'UZ$(79#%!NG^1[ADZ,.SL&EM98W!HP/H5'8;:9CJZ_5-'_M2\]!(TH,_N
MK[;[^QST:;LZ!/O3>86G7^%<IB<!^Z]N*XK,*K@;P?".B+N%Y^YZV]M@+5FP
M#H@0`4A#&"K_$4`#!]7#!@]N^#T:2^E9BJ`"N7S,C!B`@8E13,,4K[CB-=R`
MBR/`\<64),8WF#$-;%P$(%8H$0S(4"1V]F,A([6H3`6%$TOAU*>B`A<WF@`#
M7G#"'J"0JRO(`8]@4`QC&*'H,^[I$X`X1KPPJ:V$(_/>S"Q7*CF`KN7`>CJJ
M1-<V:R`),,B"`A00A"P`%K!FZL<>JRY)!`2!,FVX+)\)$H-D3\0A<]=39/5D
M@B!8P0!_J,`4#G*!%J1$@%%9B>,49H?MM.`[:="T3KC26D_MDI<N4(!W`.`3
MCI`;@*IQ#$=6*SSY.=8M.0E!`WK0!!K`C+EVX9YTMR==ZMK^V+@O_\P1T+>O
MWIN;,MPF3;3A%T#]#H>@VQXH>-]Y&7>ZDSK_];UN9SUN<I?;,@ZL*+NES9+J
MV_O["FY)]0TV;O@AKB6;\_>__]`'@9]`I.<Y.`@3OK$3-%RMO_:/%0@40XM?
MG(8VQ7$=QP$$N!@&Z&(;P`$KX$8^='(YLV,M%X$_5F2<D`NGH&072#5-IG.&
MT"!9Y0P[4!=55C;98&5)UQ!PA"3.Q01,(G%XI$=.HD=29V9><G5SI0Y5<@[Q
M<$@P<`1CMP-FIP]"R`]),`-3<C<"D0*HT@(1P!-I@#D%,19-$#F`\FF1-6B;
MI`,S4``_P`.CE09XP#MQT`9]8``9\%L'$?\#/-`=PU19$<`#$O84=B!Y-[$I
MME,[K75Y(L"&!]`&I'$=IU8P%S4&&]$\IU%NW3(YT`,7)=`$3=`#+:5-S<5-
MT#5[@,$LU^4LYW1.N4<8*^`<"H1`I"%\#B1]%35!TY9?"\1?S\=?T2%1E<%L
M#T5@!=8MW;=@!C-@`,9N\Q8\\!,_B",0!\$&Q*AO^;80C9)O+1&,B1,"8"`H
M_^84[.=^\9=A\L=A)+0K\I$>]M$##X<"++`!%.=__T=#&K=Q`UB`!BB``RB`
M@*53"O`R$*)C%Y)R$GB/2/5$%FAS/E`#0X`CAG!"6:55<Z%"9W!&9.,C&&!&
M10(-#?`$Q"A'SM7_-L/@@F\#@S(H=7[4=7[D1UEG@Q^9#G35`N"@-QJP`6'W
M!DT09T/X5V@R)5K7#@(A0TKPAL9C`V^X9P2A`]VR6`J0.=0T:`71!`<@!EP0
M`0KS!U9@62/0!U-`;0#`AI-"AA>`E+US2Y*G::^%.YV&%)HW3,=C&O5&,+\!
M'!_Q&'XR/Z1Q60'P!(WXB(YX/7()+'Q!+-,%3K5';)K8`=[#EYV(&&]`BX+Y
M+PITBL#A?63Y>Z"X0+.XB_!&B_+V;O$6F??TB\$C8-L7//=T6982E(T2C!4A
M%,BXC`L!!G@0E='H*C_P!`,W4AZD8?.'4BG%,0['-C"P`2<V4P#(8C25_W'L
M^''J2(`=]YL%^&(ID(!OF`$RI@"..'*%$%3VJ"$,4`/3.9WX*"))LX^G@',;
M.`0I-P@>*!<E$()F1&(+N0W]021-P&4-\01H!2P4:9%XY"20I)'P0'5G9B4?
MJ74F&0]1`'99<`,E$&=^-83\L`%)<(0@V0[HLY2UD@+XT@<\P`,Q0!`CX`2V
M\@27Y2:;%`1_T`(_4`5\^!14T1$\D`8)8`(Z@!7#!``2BJ+"Y!130(>@<H>8
M%RI(<0%Q^`<RT&[OAE#X-@+*9#R9)FMKJ5H(@&LTX(A-L%5.VEQT\3'(0GM^
MT1>U)UV9>(G*PHE_:4Z`=F``!A%B&F"Z.*:\B/^*N#A!UA=1DYE@XG:9F'FF
MTI9OXZ>9]W1^=*I@YL>AFR::;=*G09DG;'$1.H$`/W!!Z]<&/T`$YU%PUGB-
M:<$K&3.;]:$C*P".,T2.-U53&B>`P5F<OUD2'T<"QID")9$!&<`!-_`&K,H!
M,A0!-Z``/95C%I)R>9!RU=ER1::=5:0)3N:=`>F!`SF)03<,9J0-*Y0#)\AE
M$)E-SB4FV.`/:A*#&EE8-J@!78=UV*HE:_:1^>D-`+I3"G`#1R!G:8<F4&*#
M_"F2Q,%JPN$!?2`9!2`3J;63/P"4%9&O!&$"E!4'1AD!(TI+3O`^!>`$7*$#
M&V4'/#`3=M`'"9`"W^'_`9)'%*[&E;EC>9UV`7^PL0``//@DF:81I'32&,X4
M`SZADTG:`$SJB%#:LLXU8F$`;-%EI1UP!($Q;,FRI5V:&#O0`&/9IO5&;W$:
MF19%I],&LNN64.!WISMY47:*IJ.9;^)&FL@(FH3:IYO6:;662[.%M7UJ`F@`
M`@&[,'_0!GC`FM7X09"J*[+Y897:`SBP`ARP`3/$FYOJ`2AVG*;JJ9^ZCJ+:
M<22P&!M00R61`F*0`JO*JF]@N!Z0!C?0G`M2)"I@<B>@8[@JG1%89$H#"O_(
M"P'``"77(''Q@>,)K4*7D&=@!$>P@$O`4R@H!'`4%W111VS55MRP#=,Z9GRD
M_S?X>:T+RJU7P@YM!J!9X(AO4*Y!&#@(:H3>L*!9@G7"8:JE804\X`$&0"H;
M6Z$$,08*L*'Z>H6/1TO"<9J4Y12MDP"'`A2&.DPV($!]H+`RD``QR@-5\"DF
M@#Y!L96OEH<Z405K:#PK(6N2.19$>QV!DAM4,6LCP*1+ZK*32(EV"6QYF9=9
M>AA<RJ7-@L'.T@3#&$!VJHSH1WYJ.K4@W,%V:GXEK!"!VK0E')I<:Q#>>[5Y
M(L.OUFDV.A0UC,-&L95=Z[6">@%B&XU_T#!$$%*N*3'7F(W1LXTF!`$TL`,H
M0+=U:[<I($-Y>YSL^*E_&ZK"N1B$2ZJH2@**RZIM(/]#4S`%"M``-#"Y3\Q3
M*J`"#F)"M(JKU`ED3A0)G8LC(;`%#Q)EPTH/$%<V9Q0%!YD#.,!Z*`@-1T*,
M6C6[8`9UMQN#NNMUS5O)X]!U5/>16,*MZFI(*)D%Q;N2-U!V^2`X@_4-6)>#
M-AA(9C"R,M`'F$)*M8(5`)`"&PHHG"24`G%IM-0%$9`&5L$[=I`"*II;RN,"
MHG8`&1!KF&(\HL:'MK1:A5IWP;5+KK7#0C$"CX<5F",\]$:6!W9OVS$5;6``
M!L;`4(H#=K'.P:(]TZ67LV>)AI&S&EQ.];RE(9`:QGB,;I+"(`S#_,RU.1&4
M`JU+!`TG/ES06<M+2I'#-HS_S6%A>5A+$(.Z$&P!!N=704&\?@WS,!%C'FH+
MJ=+C84Q\0DL0!!%0Q5/,8IF*4\2IQ5O\M\*)Q1S@!(:[`8G+JC<@!AX0`4[P
MN#20-JS9!#C0>K-*".>Q!7L<G=;Y(;?ZCP3@9&<1D#TTD'-!#SMP1A!G!%^U
MNJV[GHD,NT<BNW9Q#=@@G_29UKI[=6_EK507DU>"#M]*O#NPDF]0=B10RD08
M!<P;DMW:=>\JH<KD*LVCS%?1O<*8!HC]6$)I$3IP::LC!@9P/%7`.<JL/#R9
M.?YK![8RIQ<0KP#;'3,QH[J4`)7":3S\M2D@$W^@>/8&SM91;PGD&+WQ;LU)
M`U!:_Q?Z42Q\<2R6*%TV>Z71=<]YN;.`,0?@4P);J\\J7-`'/4E7&)H][,/4
M;3N7=]W5O6EM\:?3/=!M4M'`Z%CQ8\(&<P<%$*,8-,010`2MB<3K`9L(-ZFR
M*3UQL0,DH-(81\7XO;?IJ(ZA*JH&*+@NY@1.$`$\/06*.W9.P-,I\-/KV7!/
M,#'-Y0PU-@@5<PA"L-1;P``<WN$,,`2=2P!1_;F"`)[VL5P@N`0KL.(+8*Q:
M/6..J+(.^0S$B"3X40^U*ZVX2ZWU.75\)%<[Z)%T%=?GD&;C0+PJJ0!O<`.@
M##B.A*`EN75:<@Z!Y`W.9."H(@*&YQ-VX`&G(['":!J?]O^G"\$&<C@%:?"4
M'6%:`(`:?I(Y!C!9'^LMB`)X6?$'D2?-.L$1-2K1U^PZ.@"P#>MYKQW.07M,
MLX83;."()=!22Z#.P;#;W6,LWB3/@?';-9L8.=NER`T^3!`"A7J%U:W0V;W#
M$GU<$5YK.*K#O_30N!3J>E+1AG-9XZV,-"R:T1W>^RRU`229(C"OT3AA$;!!
M(4`>1[RV'3;?*J4".#`%4KR;5#RX54RX_1V<,1W@'M=Q6<`!&2`&L/H&2J[D
M$=`&*3T%3A#C0D`>OM*DR_4@2AT"#/"Y'/ZY;I''46T!$^`"(!:Z-E8"RM6D
M])`?"WFLJPOC8.V0L9ON0A#P6<W_5ON@XY*<UG!%9G&E=66&-^B`9MZ`2*!<
MO$I>=GYERD;`O&FFRE0"#C-PY0!0;1%`3"F0$L^,KY-4$"-P`%>P.D#L>8`"
M\W]R?@A0!59@VL@D;8%B`.%+2WW0%;F$$YC#O];<F3>1!ARK\X6>4-[,$JRE
M.`JB(',!Z2L0L]KS:]SSSO$\7=!U&';I%\;=Z>#3`Z7^]K23VJXN%"%``W1P
M!W?P`W2@`J!>%'!1:[@>W<*XDX@3`B5,00L&!JE8?6EZBSJ0SS(\T++^^"!,
M?`R6BG&:0.:]L>OG40\@4D7`'O!M4FH1[]J84D6`!E,0`9FJWWN[8GP+TR_]
M<1PWX.9N_[@I@."L.G9OX`%E_,N/*]01;A8G`#,.$OIH$>_Q#N)#X`).AN]A
M(3UP(3,/4F,-MR"MUUPK<`T+P!^KNX!,VA`';U;$V`"S"ZUG#?$1CY%[@\D4
MOY%O#;QLO:T:P`(H`,KBNN1-+C@;``A1,QJ$#F8.+0Z*B(:$44E)%SH>=@D7
M(AEV?78'&55V+3\F"*2EIJ9L+J8-<0<'$1<%([,C.F@%"2.JI"XC;56TP+,Z
M(Q=3?P><`":J+LZJ"E7/SA8N%M?3UMK/)A$\`'U5Q"/"53'`.L3FM:/I"#H-
M)30E\CU+"_CX3$PY'3G[_`+Z8](A3(>#_7(8_.>OPYF#$"-*G/](L>+!.18C
MA@E0K5JVCR!#3D,0P!F"9@%.F=+QI`D:*FOVR)2YA@H5-&CNP+Q#@TVI`#I*
MI=/!9FBZHD1IS:K"M*E3IN>8*J7%9@32H+R>J0QQ="B8H\.J+HU!]H)9LPD*
M('/%MBU;`%::/#E!-T21$"%.X-6+MZ_?OP%"!`Y`N/#@)PJF;/"0P8.'%)`C
M2]ZP(8+D")@Y:-[,&7,$#I\Y5]:<Q4D$,1E(W'BCX(V(Q&(\8+YQHTF#!D*>
M""8LA)X0(46*Z&5`V,4$"\==$`[QI/GOWK]]EXC7I$23)3AV[%B"X4R.'4>V
M-QG?P/9M\T)PLQ%B3WN.'$<PP(!AA+[_$2-1\"?1L#\*(0W^_?>?(8UHX("`
M""IBX($,+HC%(F;\9P0)6="F0!-O!)%%%O-U",D@&APBHB%8)'(((3,DL0$+
M:50!@!WDF!5!'ZY8D4`<=J2@THX(%'7*!:[8@8<,:8Q3BPX&)!#4+B:,X(%2
MPA"C0Q4BV&'E`3SHP$PV.L2P94?;4./1F"9%`$`!,AP)I53JD"7..\/<-AT]
M)?30PP+WA+%"&/\D]`]`_!3$Q$()A1$HGQ41E-&BC"X:!@0B97/2I*:DM&-0
MF+ICU*9$L9$3%0/,).I,`ZP1ZAX#4'%'":1P2A0Q;,1JY"QDU7K6K;?6&E53
M2EU5BE8J#544_U)%346KKFA=D$!:/*SEEEL\Q-5<77KQ]=>UV`YFV&YX-:$8
M8XY)!MD&ET5`[KBA<;:99^RJ:^YG3H"6@1@IK,8::PJD(48;*7`PQ1M-T*!"
M;GB5%$`1OP6'%W$!3.`,7D_<%G'$T*E0G0KQR&G=$MN!E\,"09RQPG87EG>;
MR2=+'/$2'&MW1'SSW2=S$E'X5[,C`/8WX(@&(NBS@8<TV."#//-'X88*E*#`
M#1IV"`-E28`8(H&'8,&S&2FJN($=+_)@B20QM('C#S+8\8<=,?"H=BD*!)F`
M#4O1HH,($6C9*@(BP!W,5%-ZTRR,SFSIC`X7".Z1-E6<M`V9.A2`IO^2<`8C
M##GFG*,.,%7$,[`0$-!C3SX+\`EH!P'M,Q!`AB)$4*`'*3J1ZXW&WF@8(0"K
MMJN;#FMLW)B/98Y+=,0TZO#$HTK%$T81N_M899UER?/+/I]KK97W.I0INP#U
MC@Y@B#65]U4U4'D,MT8O@@S-/OLL#WV@,9=NU5:+[?P%"V:_80&T1$(*\S8F
MKKB5L4RYU-49T!@P7>T"C0?$P(-^O>%>"HC@`E.`F7^=3`6ZV8TS`F,MPD3,
M-N1)V72HDYZ,4><ZV`D/Q\*C@"64S#PH,R$;&O`$-I2@9>"!68=D=I]'\`=`
M-@M0@D84(0+];$!44T01@58@&!RM-D)H31;_2.`T&+``$H48D8D<\*`"90T2
M!_C#'P!@`+/$P$EVB,,4;,`).[SA%"-8&R],H`!D8"$!(IA5.JK0A@LHKA@7
M$,=2HC2,8IB-!W;X@N">,3?%/<,C"$A##*9!)@O$X$QEQ)3D,`<5-Y'C'"-H
M``UP$YTZ?6X!3$"EH?KTGGTH1"&H2PCI1->0084A=0^1G44PHDN)",$DP>)4
M58I%S&#HRE;D0U:MZ``3FQ3OF:(:0!-Z)"NK>&\JR')>])8E`A%P<UG3<]/D
M?'6*="SE`=.;G+'&=Y9N=M,`Z'.6^ESQA_8)@2[RLQ;]KC68W2QG.4VX`?]0
M\YC_E4N`*0@@`3OC_QG-('`T"F2@&")@+WPI`!/T^LP-%##*$A#,G\;95@,N
M%,'Q@-!DUFF`Q>(Q'9..1SM+&-EV<'"A$,(0AB44PGJNX[*7'6&'/*19@/PC
MU/X(L1!34U`6E2J@`P4MJ2'ZSXF2L"&D"2&@4ZPBU`91Q"U6K6A?3(+9[""#
M"\0`CR8P``_:$($J(-(.5AB%'%5"QR"9Q9Q1TH$38I`.LZ0AC[,B9%\]D`P[
M%,Z1SAB!#4BABS%9``%.&`&8N.2!M=J`K]OSW2`KYQ26>A0XG//<YW;`A!T8
MRI4$>25`7CG+6B)*(7"([2U?5Q&#,(J7O2R(I5;RJDXE97DCL%7YT`+.K_]=
M0`$_.-4>?B`\:#Z3`C30(Y2,V3RS>%,$!L`N=@W`7>Y&#U>ULIX[W@&&8B2`
MNS9(KWIMX%VS1H6ZVNPN/%\TS[;\H0T_R,T)[G(7?>X3,/XTS`F\-=#8A,N@
MD,',01>ZKL^DRZ&9D1</>$"O?T$P@C=H0P8HF(8@*.`VO^&+88Q3#0R]H38E
M->EY;D,#VXP0A.-9`D^OHX`=N'3%Y9E."4'<@!FV+#P^=1H/\?,(F^'L9C]3
M8H%ZUH@3-?6I2Q90$F"PH1LL@0T!)0$5G0:UJ"V5B!H@6B/"2EBR$LX`?+T`
M#^Z0A@1,P4I9FNN.+M`*'ES`6%+*Q0_@V88^*$G_3;P:!N'09P<>B`(D2D+2
M2<#T6&IH`QLNL$$?TB`#-&?V6.48'S!R[!N"E=).]T#E/D0WNM6NLB&R?.4M
MX5`&V=I6(OV`R"U?G=O904`HV^M4,>,&)>&BQ9O<!+;YDDLJ8COWF0.X0P.`
M6PY?7^*\\HUV=]T)3C."<A97J0KY#&`#&7A;!HX+][=ED-XD[<K7T$:O#``@
MSWG:`;\JP.=>\O+?;!$GP"&@P0\*W)B"(A@SYTIHA!F<F8&#9C26R<"$>9`!
M#@3A@1&,N!-B4T&`J71@!2O,,T)PXC>@@35-J*F*;9HRE[9P/#6^L7EL"L/;
ML*&&-^SI$3@4LZ`:@6;X__GAD74FH!$MF6<'2I"2>_Z?*1^M"6Q8PH:T^K0-
M?"BJ0"=BT,.:@&:U];RUJ,*^`!`!$;RU"G+]U=I4T8!D`*`6RSLC`+S=!A`$
M]TA.D=N4+I"&/K2A`#KXB`7RZ`(_+LXD?S?)&$0`2'$,A7+7'M\Y.*W2A`7G
M-Q``=3[^P:?7#@26?Q)4ZD@]*%;'%@ZTKK5$<#L1TE-D`2%X!U<NC6VE+%LI
MSGZG=J5M`.:*:@UW4.ZQB3<`.GC3VE"12G"KB\?M<GN][&7OM+_K7E!ZKPK*
M2J^WP^VXNUN?^MYFKR7.T3P\HE?Z]*UOD-J`!PSB,W[TKC=@M!4"%;PA`O,2
M@_^!`5@N<364X*`Q^+LXD(+*+KS"#P1Q$:<O;$51%D<PA'$-"A@"B=$:(%=3
M+_1AY=%R+F52.R!RY`%C,)8R//9!VI%#/[5#]G%SD)`?/G14`)*""0(T/8-$
M1>1DA`!F4Q,A4;`!5(8T#7`#6=4A'``#/<@"3N=E4B<B,L@?D!`):@4`"4`E
M%V``5A`!4S`%!7`!5L`)HB!VO+`V(Y`,*8!VO$8K.D!I,N`!::`LZ+`.?#,+
M!=!G`'!HE)0+E/1HQ<`,CI586A)<@H17@68.E2-*<R($`Z,";!`<".,Y][`"
MHP9+@7(H?X):"<$/E3<HH1,&H&<1L'-;HN=+1M$]S+;_A^3C/-=%>]TU!LV%
M*G=0BKM'/&N`!^K57F:U;.ST:]^'?.LE7]+C7L(7(^?5;>'6!K[XB[X(`B#@
MB]A';DG2?,1U?-W&;N)'3P!0?G-!+?,VC?_53X'!'#\0`0O4`OU&?_47&0JU
M4.SB8.N28/W'0`O7<`(8<1>5`K&1!ARP430D&-=``/9(`"Z0@S_@!!$',"+W
M0B-7@2@GD.,1`P)Y,B/D<C14'MKQ!CZU935W'S0SD44F"$=U,RA(($'7<TGD
M,T;D,QMP-%E@&U7E-#W8@TWG93'(1$D5(0*2-92Q9S;0`BU21FG`7L10`&E`
M"7^0`G)E`F^0.+N@-B-@!V(@_POF-$C'8@!]4#8&H`-+J)1ZE`YCL(8`P`->
M,@TFL%>]T%B/IE=?\DBJP`S%($A>*$Z4PQ2<IF/QX'@(TSF?@XB(V">#DFJH
MEEJT-&JHLVJW=(FDTSH987JFEUM+\`2?!%[OE3F*R3SQA5ZSF%Y3\`.CL@:2
M22JI2#Q4,`7@]FW:9U:=E(S'-V[D1F[EQEW`!GSEH"S<-GUK&(R^"`"PV0:P
M.8QM=W>.8XS'6!;>UUTVP(S-.$934`+1>'Y^X5_[9(U\@`8DL$#RUXT(%D``
M9'#NDD`*1D$#M7`4%@%9$(#L>`$W('\>,`7\2`,G8`T6<(_VZ`*TP8\":'+E
M\6$C-_^!`SF?&;AR]9F0"[D>#?"!+\,A$&D$5W1S)$B"$TDS1R14.Q-E3=4S
M+GE$(*(B3]0$#+AT\W&2%=IE,R`U5+.2*YFAD+`!/>@$3YD`;8!>=_:4"!`#
M3O`#+P(`6,%8<H8`=A`!,G!X2DD.(G`!;-64L7!GZB0E1V("L0!N+=`&NO!(
M9N4"5.)H'O&4%F`">7<XP""D4V@4-\I)+,52T`&(H/5XD7<G<QD0K&4Z?2(Z
M?5(08WI:3/!YL^67IN.7@9F)8:``TB>:Y?8U:#E\Y;-=ZT6:ZH4'.B$\JG(J
ME`DJEWE[0R)NV6<#VV<.SO-]XT:+WH6GSJ<.T<>+U?>+L+G_J9LJF\`(`HJJ
M?<:UF]P&`NVF/L!)`W.1?GQAG,=I/]TR!?S3`@3U&/YF?]6)+@_&4`WE8`)$
M+O."G3S@`22PCNSXG1O&CT+`$02@@,V*CQFR-!@8<K8!D+9AD!7XG@2)K?7)
M@1(C,2&70S=P!!!I'RQ`H$=8@D?H0PA"5"IX1`@2(3`H55*V(AQP-"6@"DU`
M<Q8Z'UT6-1E*K_`*DRS@@R3`7;70!U,P!H'T!C_@#LMRE3P01Z6@"Y2B-A.&
M!U9*#I2C6%5@`P70`FO7!P;`-T":#DWB!#)@"6V5#=#7"P9`A^;I`B6K"I)@
MGB8P>%60`CQ@`YFR68.$D/2`&RI%_TK`X:5U,GF16)>6)Z:K53IZV7ELFBBS
MU4N#&3M,@`+@1GW%F%[@1!:?](FJ&9K=%JGL)0(_4)FXEWO+M;:Z=YG9N(9<
MZVW'Z*C*PJ?=EK>M.*EFQ";F=*E;VYJRR:F$VZFU:9MH0IK'J"RDV@:<\)L\
M,`6J2BWRHW[9$@(-$`0%1E#]=QD)%4`()7"[RJN]BE",@8[_MP'VTAH1UP07
M<!ID^`9"@`#GB0WU2``Y^(#R^9XKU@0&*9\@-*T%29`XQH$EU`0N$P3]N67U
ML0$2B:Y)`+TEB")%-[WP>KTO^1\I4K`BR2I*@R$HZ8--%X1'&+#8:X0J4J$^
MF%WI(`(`X/]'"&!60Q$#=8=(\$L*B7.Q//(-DF`DO3,+*6`#(L!7[7!G:G(D
M1H$`@&1.B-5W!M`+(K!H'9%6TN`":0-,.1H#!<`#:0*E0"L5,7`;*C"TO3'"
M'K4Y.E6(IX1*J&1:F(=J_F"FBZB(ML1JE&@0BA)K@*E+5QL1/0P11P",0CR,
MXM:9(`R:96NVY>9-*Z!<E,E,,J$JATHJ4E``=H>XB:M]W?>8>YLDU79M\[N+
MF"JXA5O&G'JXM[FHQV@^!K#!I[H^$2`7TDAOKCH_UQ@8*J``VBA_J+%A_T9!
MY@*.@$Q`!=>K'!!P"R2L$Y8"%L:."G`!KNN.*:``(7">]G@-'%'_NQ"7K=8Z
M@<!+K=N:K;OKK2FC`"L0!,J[(1#)`@&:KI`@H*_LRD^G`8-0@E+C,X*`H#[C
MRAYJ@T\TNTN@@Q3R4X=,&?_*R[2LO1GJH1]:H9I!`AR`9D/A`2^:P%40`6VP
M9J8P2?I+5R*;:$11#AQ+>*4@5S8J:)N"`.:P)8;C`IH)I3%;AW>V.`J<HK6@
MH[\0.6G)L7*",2KPSXVG.6X9'78"!_EP2WM":C#\)W3YB)0'>F70EX@2$8H"
MIXORPXS"!!XPN&=<FZ%J;L#PB=!6IYRYMVA+!=%DJ'N`>[OWMGN0F7T@C!Z=
MQMS5F,C77=7FF7(37+O(FH=;N-\0U&;<_W9$G,;&"#UX5```T(QA]`<1X#[$
M6;F6"ZLGD!BGVYRWBBZ`G*OD(IT.E7_C:+JHBYT98(".''(QH`",\0-L8,D*
MV!'GZ0(`HX'!:S(G11X16(&07($B%T/>ND(.J2$TUR$%^[S1&\N'G:ZP_"',
MG*X!.P./4*")+<ODV\Q:MIUL$`(EL(.JL67'+,L`N\QAI2(%RQG0',U/N4<(
M8,[CE5:5-0:C0)98N",F0$&I/2M*83<ONMH*G)0([`Y-LH3M/#@//`(U.K.0
M1B9*.B5@IP-FD@#Z+'QJ64I$^QNX,3!&B[22=]"I5)>N='FL!+6H,XFL@Q`'
M@0%_"<.8F(D=L/\!'$VX:)S&[&7`T#>VZN6GI7F,E5D\QO9,5&![T70'V/RI
M'[U-QF>+.0VVA716TM>+M&G&5PGA`/"+H*JHI+E-:;'43.W4:'!/E)M^4]T7
M#2"K\=?'_U.=GH&KHPO6!0<:D9'($_8'_\?(W!EQ9J0`;<`!3_#6]>BL!(!E
M)O5A-""!)(=R$RB\>QWDW=IR'+@$&=*?68`"7/8TT2N1H"W+`>J\6'ZNB^V\
ME`&@*U*P0'AS85Y%]THA-S"[0O`&A_PT5!8$6N9TQCSGQDS9E,'*/'BO>JX9
M!M#<4B(4US,E-M`&:1!V/C';I]`-966EN/T.>=4JOVU.4A(4(X`9(Q#_VX[F
M`B+`#&"'W(_VZ80C`M*PE6866,)`0^GAST;[&R/,I4<;6J8$.OI@*)R':G[R
MM*VDIJFCPQ1=:QB]*##PWH5+FXB;?0EP#K*HC/GMQ9:PW\2C$\AV!Z>H$[HW
M`'B0`IX:W[<IJN\D7[]W%@I."PS.FID*`A)^[A,^C!5>X'B4`.OVQFYA!P5`
M!],BC77\7T00!/#'QYS[/Y4ANIV;8"L.8>,(&:>[<#(NX\/*`<;ZR`4Y!7&L
M'.;YK+=+`"HVY`%SU\"KK00)RL(;0J2L-$$PKE6E94+FO.?ZR@.JV*3MKT`(
MA'/>=%4T\S3OKQ4*S5EPYEFP`SZQYFYN@R$Y_W.>+;X6:H,1(/,VZ,S0K&6;
M<=H<(`.&=SV,E<!S4W>CH`KIT`S=7`JRX4>'IPX[S;&"IBP([,%EKP,I8`=E
M"#?9(`FVRVA,ZFC0EW=I]6YF^;\CT!Q$V^JY8=WI4<+/`7FFU`,&'3JAHQ"A
MXXB7!R@,/2B`HI<-8=Z`:3KL#1$_?`89$.'?<,83KNUT^S6D6HO=]%T*@-+/
MA'LNC2H_8/H#0`%L.Q-K(`4<'8SKGKC>Y4W9E5U??&W%4@5O0^[`..$2;NZO
M"=^=3XQ=6T9F(6D'4`&_Z0$_$(UT#.*6&QC>PIQ\[#__%KH"+X[CF'\OKL@*
MGP&J:U$1!,FOF`+31/\*/-ZLEDP`)*6!O6MRH>RZH'S_Y!'"Q3L=;P`(64='
M68)9)#`P+(D;BTE&CTDLD),;EBR+B1R,,!N=B:`PB*";'"2GIJ>''*6FA:]9
M"B$!;#L<GK<PI6]9K+JMOZVFK"2II\?%Q:P%50@ZSSH(TM#0"#%M;='2"&PF
M+M(N;]OC&3(7SCHC52/J[,_L\.P);047U.GPT281!SP&!E5,>+,0P\`(%RXL
M(%1H@:'"A`^_)701@P>`"R;PK5LWXHE'(4)4-`#Y$:20$@U*J#!YLD2)'CV6
M+%E`<P&3!6%PY@C#)$>''$QZ"@T:=">3,$!Y\NS0@0G3#F>@-IWJ]*G5JUC_
MLVKMP,*B5XL`PHH%@`U;@;,R;!A(P%;$O[?_$ER8._?'@#UX\^K=0^6.W@%K
MJ/Q8\W?-8+U4(O09VP8$MCYG"Z0U("*!6Q&5Y\98QX;:B`L&9,B(W!@;V=-A
ML8&(+#FR8\=MR)8&L9JU:!MR'QCH\^>`[]_`??_I\T/(B1,AD"-/'J*Y\^?0
MFS>XD2*#F.O7/:38SCU%A`B6(G0/'X&5^?/EOW_G[H&'^S\\X,,7XX'$FS<*
M\BMHHB!&@QA-I,`&-R$T9`$!!R)(`((W-.&@@PU`*.%^#E+X8(7\[9??@_L!
MV,"'(#;Q81-O$/(*"8>`X@DHE;!PB2<KAJ*+**5T_[+)C,@<@@R*/![BHXXY
M<E!(`P$@T,`;)&Q08RM!].*+>;_\DLR.QTQ!@A/)#,-!'S%XMLT]SHR000$C
M?#F"-M^<,PX"3[211I<:L<,1/O&HDT)8,JSCV9GZ3/$',S%T>9`+H%4Q44.'
M3@310HGJT(8=!F0D9SL=L?&$$!^:9.FE(:U40D@MN0133#/-1%-.//7D4PY`
M`254JSX1=5108=2Z5%56!;75KKQFA0$`[P$K[%ABE1:9:&MA!E=<<FFF`&%[
M13O`#U10L<8`=V0+[5Z&W977#Q'$)AL`L-FVEF5L-1N#.VO&D(`-HYVE6FST
MSHO6;?C&6T!I9<W&FF1J7?]010(%V%%!<`C_T08>*ARG''/.+1<=='PH$($'
MV%V7@7;=>;>!=^*EP/$&ZIW'07HHK^=="F*\)Y][/&2PP0WXZ9??!?\=.04"
M(8!C8((N+$B`A1$6?2&&%U[0Q`4;;ICAA0"*6#2(#2AP0R$F'J.BC)\H(N.2
M-:(RHR:JP&+VV3KZ*"0Q0F;1!`*T[/`)+FRC>$,Q43Z9BC&J9(E*,C!$X&(;
M:D)31307\`F-"6/TH:8T@B(@T9H(1*!`&F?"LRZE=,9SC1T\M&'0GF<B8(((
M=LA@0A5T#31"#`@MY!"B#"5:NP%V@,`G/%6L\\2F3S0@TA,G>,2I"BNEY*E+
M+\'_))-,->%D4ZJK(H644Z[NY"JM.RG%E*Y,1>4445:%T>OY3S$Q@UA>$>M^
M6<>JI2Q<F04:@U_1Y@]87W=LF_\>=OG+':P@+MGTZU@&H`M=UM69-8'A7?J"
MC6G*4AO1I,6"-LB@!C,8+W[YRS:XJ<(#"O"'WB`,.`K#`Q&*<)SF2&QB,`P!
M#:9@!8UA)P,=2P')P`.>CJFG/"8[V<G4PYT(9.`]\2DA?'B0`@[@IV8;PIE_
MG*``;03@9PU1T(*>H`"C'8T_7^20S3)DH29X*$)20TF$WA"$(S2I$*?@&BBT
M]C52C*T58B,&B@IQ@ZNA#6UM.Q$KLG`#(<#M2$G2Q'F._\&!J^%MD3NZD8LV
MD(1*6I*2EJSD#-J0`'0\0P0Q,,%FJ.$,MT3`!)*S1C2^D<HUI>!U9V(#I3:2
MN3JIXU$6*0"<TD%*'>#NE%48@PATL!`=7.!0#E'40VJG*(JX!R,:Z=T(D&,I
MD*SD"2%@0W.*8!)/A:IYI"K5J:3'DU;]!"D_$<KU9&64H]RJ`[4*7_K`A[YZ
M/B4,+'"?/AES0(`EZQ^5D<MF1H`&__U/6@?%RP`H("TI[(N?]*@@;C03*#V-
MXQM5,(`-2#-!V3A&,FG9H$A'NM$"P.8UC;&-#`P0@PO(P`XG#,X?`#`%%;#P
M82V,872>0`<C9BP[.52/)8+ZG?\@F@=EVUE/RY(HG_FD8`I0O)D9/S0")S2`
MF-+`XH*"MB`=H$%$1[.0A9A&Q@J)=6EFE-#41O2*-\)1:S<J11SE&L>Q*7)&
M>TO&*_K81T+ZU8^O<(60]AA8%`G!!0PX4A8L(5<]*L.O4T)&*1IAB4S.X+*9
MU.1ES5"`3GIR+AFIAC8LEHUM-`.5WTA'NQ#@#MY-JI:VC(`=@`4">]Q#&[ZT
M0Q\$LBY%C4`$`X%([8:+S$,A(`UV*,`[Y,29YK#!4B/!9C:;PZF3J.!3S.L!
M#9PGSIJ@"B>UTMZK6$64ZREE>NXTG_FLXI.IN->>]<R!!V;#KWV*Y35HP4VZ
MV**9,]'_P5L)#7#^JI4_<"T&HF:13`*K,-#2;>,;(X"@O&A3%H\"C*09U"B&
M._@:"<8O`5](0WQB^IN9UM1A.DUQ$YR`L19<Q\4;R^$./^;#DAF5%2IK8@26
MRM0DQJR1456`T@+U(2<\07(N*%`6EYP@!)31:6,%H\WT0T:EI=4_$**:8K/0
MI#;ZB$I@1D0<Q?9(O$8I1WS\:U_/YH1"#,/-9GL#&US`ANGT@FZ.104K'`D+
M'B5)29VP!"8M.8/,NN&R&I!!)ZFQCFF@XTNC^0%J[5$F5C:`<JS='4=LR>D+
MO*</AU.</J0QAN0B.78)J8(-O&$[VC&*F;5#W46B605MZL"Y_YR2KG/84(3J
M8C>[HX)>],993J7T))VMZHFQ:<5L\I'O>^/#%7S/QX0I6%`TK'',/N&'EF8I
MD#-L"*"`QZV7_N7/,.%BC`'I48`0S@G3&>U@8_BYFI"2=%D:S;>&2\JOC[);
MP1>8`@!,2.*91D`%Q(M8BG<:A!UCQ\7T(6K(:ES4&Z>'QB=+`<R4V%0F9B'(
M#O)/`UYW@P9,Y(H&$EH6"1".IX$1C&2=LH:H;*&H24UJ(^(%VOIVC+11:1C*
M($8PGA0,PE[MZ&L^NB#-X[>VR8)G32B$(IG.`2OIN9%^G-(K`BWH02<!DUXG
M-+Q0B0YVB+)TT="&""*0!K(_HQE(CO\!`AXG#7>DH\&N;6TMD2NZS/%2&P))
MP14*P.I$N0"XR"2NX@VO`V!U8;G2Y)DTG"N$WS4G`,ZI+DBRN]UP=G><X&7G
MJK97E*&4-U6Z&M]/FA+M:<<W#=>._4.WG>")VF^4.GB"0<DM8'%':PUXV%<!
M3^,8R*QT<]48AS'A-6'4D*7>]M8@OJ?_E@S*JU_E`M@=##!P$O\&`!&@P4UQ
M"C&=GJ`)%VO9=7@@AHUQC#LSEC@0+;Z=#:2!`]7A,<?ADX$(W,=F0S95_U%%
M$($`!W*`2[8@%M`@4B9E,R=S4Q:`2O,?618B?W0B5+(*C%0W>Z,E-^8*L.!'
M@`58&AAT03?_2`H@.2$0=5D`'D,W)8LD6)+D(FU363`2=IF560:0!I[D#,CG
M#&O"8(DC.>H@=Q)!=W.G`_W1.9S6A*PC,*+&)]+`.'^@.HS"*,-D.XNBA8IG
M`K@#`*%4)SU3))@7`">@3<W!,]3%32'Q:Z)"*L,V;#EQ%$:Q*D4!*T2A/:F"
M>NY5%<?F;*[7*TS@!+$'+]=F&N^34@#7.YP1#0VP>[QW4`L%8-%"!<$W?*F1
M8.:@.)3C2]A68?=%#[<Q4G"1`&M!?1HV&A)$00AD`]WG??T0`0_`0@L'0RKP
M`RPC!@"@?NTG?Q+W@40$,AR0!M8!`"W`5"7$?C,352$G@"/0`&P`_P8&<D4*
MDB!:1`!3,$;[P300.&5H%49:]B&\4#:$!21\\S<H0G59`B0G*"6J@'1(]U=I
MU@OTZ"2+Y#8(P`!LH`"],'3&\&59H@N3Y'66<`B5I$.5E8.%5FA)P)`78`.X
MY0RGY6C:T(/3P!$2`7?;(`(C8`4_\`RRE'>4HFER@@^W]0RF@P=VT':HMDP&
M,5RTXVJ+QQ`CP`-V`)%Q`C<Z.7G/$0"81WDFX8;!)FQQ&#U#L3WIE(?IM$[+
M1D^ZTEZR$HB\<@/PPD$:=$&C@8F9R&[FT&`HB0:1R'N!D5#8,@4FE8BB.#JD
MM`TCP'PFI6W%(HKW]A;[98KXIA8:95+U8O\O"N:*!!=3\-$'-$`\+U2+R8$&
M'&`=+L9^[/=^191CCUEQ)O-#132,.P8SR`@?]4$S`"@B(C=RG:%D"E&-0J.`
M"Z(`^.&`4Q9D&F)E40,@9T0U?/96868,0&<R)Y@EP^"/Q<!'2J=T\]@+)^AF
M09<%)5`D^_@)PJ`,3;<)74=H#.D&24`"-P!VF+20#7E9VKF=(V`0&?%HRH=I
MX"`YYX!5%+$FKY,!4Q!:3@@/9;=I=@<FDB,"?[!JAF<!")"%BK=,7)@HIS-;
M=R`IZS"&DA,`+O"3!/H<O08JU]420[D`IB*'-S$KK8(4=JAL=%@]L[)LJQ=M
M@"AM4FD5*^`$(Q7_4EA9`/OT49VU.0W$!O@3E@*V!I#X%Y9(`A%``E)``E8`
M`MY1&S9@6R@Y#@_@EAWU?!$@!5-`BLQ2EVZ!BEFI;?W";AD$`#`%BSQ@!6A`
MF(;Y'$]`'6*PF.J'0S66<=UA8Y-)F=MQ'AJ'F1SW8YPY1D3&#K(4FEF4$"JG
M15SU!&-`1C;#FE&45E;V(%JVCW=3CCSW-Q^8FQ^(FV6C9GP%G($5@X%5"&]@
M2"%0`HNUG#^W"2Z26=OYJ3.P`85P2="):#-@!MO9D+[4#"A9D5]B.I3C#49B
M#:W$2A*I`W<0`2#9A/'`2YQVDL]@`@IPDX67*)(#D[/3G\0U`AYP`(27_VFE
M<Z"M-(;4BH8AX&O?U#S/8RH1:A/>*BMT*"M[.!6QTFRU4A6KDDY4\5XAFCYC
M0%+1!R\@H$^JT6Z)0PU/\*(PFE!C&:.!(:-K0`%X<`<4,`41(!D)(&JXY5+R
M5D!M(`7]\P/[AI=+>@%MP1:HN%&P84`J"B]M\)<G5`%_X`%H8!PM5)@Q=`(T
MD'Z,R0,NYICBD1[;\7Y%!40V.T03!T1.D`;MP:;)V'\T$U43^)G/)0UL@$76
M6)IU>@/YP9K,*&1H%:B?235/$'4]AX&I8(ZZN:A!)"7F08]&)X]\%:DG^+5M
M]G$#(@35&3B0)%G.F9"@NI"?Z@;V89W0J0&(AO^W>CL#QA1*:3<-:3>$KSJ>
MK/5@J800W%`F,0``BO-:\2!-36B2M^4"5;"2)L"?L1,1B^<"&:&%MC-W=O`'
MP+5<X"`1THIY<,.E;`@J0DDJ<-"M1@E>*U`4Y:1LV>.AZ;6'MM)Z4>F'[6H5
M0?`/&+9!,B`N8)&)"B9J33"C^ZH7_0JCWC(M4K!2AP,-/8,`8.!29R%!J4$"
MT$(!/R!]=)DN%ILNE.&D$Q2E^<4;L'@`PT$'6HJR,72+N=BR0%6F*D.S/[2_
M:.H=K)`&3L`RF.EC8A`!'^>-9B1RSU6TW[!D7%6:=SHT3:L??JHT910H%4A5
MT[$W/X*H'EBV7$MTZ:'_1V<C@B-8"$[@@;CI=-F4J5#B6"F2D(?VJ690PPPY
M`WB+JGB[`;R029B$MZ8:Q#,@2G('A+BE`ZJ6`*X*JUBU2J?62CHP3&Q@!]7[
MN)O&$?!9)W\'#65B`A<``$Y0K+#6:@82`V.0`,$UDRZ@`QXP6ZSJ#@<Z.=*J
MDSV3347`!MUT$D(``<"VK7(8/3DQ/=N3%(-L/>4U*^EU%*S7AXS\NQVP`M4W
MO-;'/HRQ&C90O<_P7\T;8`-`!9OLO#_P`W1``VNI`^]R??0"`"3@R7@1ROM6
MBN1[L:B8EQ7&+_<"`CP`BR+K`3_0,/*K4TTP!1C#F,#2BT7DOR'S?CO$OSA+
M_V/SYP0LNW')6!__1V5#FS,Q\%P(@7);!<%*NR!'\D053"%EA'-4VP2%*EA]
MMH$A_(%*<F-F8\*$M&;$&8,F$PLE\`8PXH][$VB:M5FG&M!`W)#9J9V5]'&8
M9`1PBVA)H`%[JP$(P#I_JP/?J0,Q0+WC(*QI@!&/9JNLE%K.X`]ATIZ.VZLG
M.0*!!RG*]&K*:@$BT`:K1M&KM+D)$!_KB4JO<VJQ`S=DZ%PAT&L+RA(@P<?!
M!@<T`;OC-*&H(A0=ZA/HA'K,9BNW<JX>^CWL&HCF\P9P(<D;)2S'2Q:2<:_/
MX'N?+"UD7=8`U!F=$0T1UK!DL<J@_,H`%<OFNRP42__+4:J(:=$'N0R+"M/+
M.668?/`&EZF+,!-Q^"L>'J"_/(0R.%NF_\L!'J"8TLP#'@!D8]2,(.(?`Y(0
M!AC!WHP@0:,#G%G-G?F-&X)E(K<N$0+#?:,C*PS"031_MV!41C>V?A6<;C8,
M0+2UL;"V[_PD<!0X"[U99N#0>XM9.1@)29`%.Y`%E80)BE!)0%S=45!HF;;$
M@2L9P#4-^_`#E795I8NXMBH-W\&>MH3%[9#%F+S%SO`'=G!,*YVY9-P0(P![
M+I5!&'&?":$#4Z!;*.T"[4!,J':XDW?''A'40LT\VOIYQ`9Z<[A.0X%ZYVIL
M4GWAYJ,KJ<)Z(!J(.]"DPCO_O#(0%NY!+/20L-#0!*R,UM%RUF5-!:0\`@W4
MUMO;!AX@!=;R>WB@8?13EQ@[RZ$A?!Z47P70U]XW4X#],+6H`L*\F(<=8XDM
M,APC'LM<L\&8IFK:?C6T<3$3`6^*P/TA@)?6$`&@12L7VD&S@/?Q1#0'M1L2
M(;`9CF_`=(R$"JO0SC<&:$*TPFD&CU<S!?.HPNI(6(%6'D5W(X(VPP"-PP:]
MW$:@T$:`"9+^<6_0-=.=!%'0T`V-MYF>!.`ITYX4`PI6D2;@!!:U.N1-N.,P
M!AD@*20]2[#>JV<BX#,%._3=TH<R`J.1!@`CW_SMQ?V0)UQ<::BVS0=ZK291
M$BRQ_Q)\K*VOZ^#>)3WD]"H<3KO@BN'GRN%6#6W;+I4Y`.(3NT'".Z]?G1KM
MQD"YIZ\LGA=X0(EHO09HX`Z=$6_7)P4S:AAR?2YU.7UW'>3TI:)I@:+M.U,,
M$]@+=P)H8$3%S(N."3**#;,_)$1(E53H@3$I8`5<+@8;`%5^2B%4XQ\%F+0(
M$-IW2B*LR8T=LC0-@#-4\XP;[%ALTX%4%\+@L>>VK0J`_IOS#$A'952'(&A%
M%25==YV+;JK++0G2/4=QQ&7XD05CDY#+C0E32-&=R,:B42;;(+'I\`U&:.#E
M;0T`L%QY1TLBF0^2JP]-,!R&,M\S^3,(H%%VJ<3"90'>(/\0"!$#O<$#!6`0
M85)K.AT[M/`1G+*Z01DJH](#KVO41EV4$,Y.$@ZNUZX42U'MK)?A5PU?66V7
M(2Y2PHNBP/+5M+&)[%!0Z][B[O[N39`/]&Y2</T_=V`9X@[+Y[O5_'Y])R67
M*`JR"4-3#:#D"Z<"-S#,+=N8/I1QBQV9)8,R-.:_1V4=VB'\[O%406O:@CJU
M,FZG=@HT)&^:.@!%(C#!,Z?94ULU*=RV,8_G><X*P1WSKW"V>S6V;1;_0=?;
M)D,R.S1T0T])<9M)"@T(+"PPA"0P)%F)BD=!05EOD`IO688<,"P;21N"@H4D
M"*"@.CJBHSII!395)J`F(F,Z(PC_+C$NH+:VLZ$(.ADQHR/!(U7"Q,/'PL'&
MP:8()C]Q$3HNU"X6UM37V-?<U@@V,@;@!3H6)B.C%S$&!B,N.G8'?SQ][28Z
M5;_5^P%L)T(`A3P)2!`@A!(E>B3LL60)G"4+((99L&!BQ8MAF&C,H5%CF!P9
M.7;,&*9D28],,C+IT%$CRPXP8\J<27/F#A'LV-G8R=-&3AD@`/``0)1HFS8R
M$A!30&6/TZ=0HTJ=^G3`FA\#J&K=^O1'@V!LJAB04:!-`:Q4K^+LF=-``@,X
MV\IMF\!&@;(@CN8U*Z,O@#\'`@L>+`^`%!HG3H18S+BQXR81,@@5PZ.R&#$I
M,F>.P#F"_P?-*2)LZ!R!`^D(FDMSX)"&0XK+'CQDH%PY`X<;D"(I4-"D=XPF
M#8*S&<&&C04+!(X36+X<.?/GRZTUV2WIS6[K32YD;_([1O#O;U1S(#&>!/GQ
MJ].K7\]>_8;5[]63)^$D2WW[63@H2G1C_WKQZHDVVGL$PK#!@0<FD<0,"\XP
M@QL,*KB))XCLET@C-S3R1A"0<(C;&_U18AXAAYAG8GZ[B,++BOBD$H.*,43`
MBC,*W*)++BE.80,OR51AS(_%*),,,Z,XD\$?"9B0S3[:;+/-<<>)D(HX"5R@
MPP41L&-6!`5<X(()$0`6F!U])!!+/FP@$,`^MH0PT$`%Q7E00O\+-001'`O@
M29%%%/5)DD@BM3122BF9A%)++*WDDDLU-5I3#G'U)&E.-K11U*5M@%"``4W<
ML4967(4Z%144K`'5``-`H2JHHDJU`C+KD!4!'JQ*=<</:['55EQSR?66765E
MFE=>!?0EPU^$)3M/&H@EYMBSBSWQ0PJ563:4&)^!UED*V886VFFF<9::>FE$
M0%D&Z,Y6VWM9X$;==+W%Z]T(#3PQ"I0$6/.<<LY!EYP.UD%R`W4$*Z"==\%-
M9]IZ)LK7WL,!<A#?P_@I4E]]J^57<2+HI2>:>`**)C&")!]HA1LHNZ&@)AM0
M:.$-&8*X88<@PFRSS9!8J#,EZ*FX(HO_O.@PUHNAQ*CD+++<J#2.%U@!3#(Q
M#!FD,&<2*<H(=MAQ@9+:=&V-U\<]*8(-";QU@1,QB!"!3TXD$(.5UL3@03R"
MM?##F;_,PH^;`<$9IQ`(S:E0#ST\]%"?B.>Y)T6$,L'11RIM1))&%9ED:.2%
MPJ2HYHYVWD$8;^@DJ4]MV4744)=J.H:GK;8.%15-G2J'``+4`46MKE.!1M0C
MK#,%'JQK=4>N//5J_*YN`9OI4<S?U5<;8B8[&`\1T,"'8M`^6X(3&50KQF1B
M6*&MN+&E!BYGIIF?7FNOB9&NNIB5YNYN\,K['7%LZ/"$<OGVFYP+_MJ7"W)S
M'8)MIP'V>\/"_])CGHXY<#4`@AB!%L@P_>BG7?SA6'X<QI[XB,Q`)0LA@E*0
M!"NLC&6%>%G,/B0S@>'F9C!T5PPY=AZ/!8T4/VM&.HK$HP+,R&>XT$6*&@``
M=`3I1\LP(C.0$8LBZ4`$!^"!.Y:$#39UXVM0<D(!<)*&"Z@#'\Z@1C"49(LJ
M1(`'T;-#&JH0BQBDR05KHD8(V/"$.M;Q;T*``.`0,CC",<0ABDN<GA+WIX]L
MQ",@0<E$+E>HDS#J<RF!21@\UZ@@B&-TI&/'6XX5`2E(QBAMP$/L7$?*X#EE
M`'6@G0"0\`$ED/)4/V@"#GY`!=Q1Y0X*N&3QY((37O%2D^*X"_.&R?\7&4!/
M>H/Y@QTBT(0G."M[C#F!`EY3&0#0QGV@^1:WNO6Q\Z%F7`$ZU_LH$YHI!*%@
M]8O7=QI0'`3L+SG)00!T^!?`Y30A-[JY@,&FPYL8\.8&Z'.8B<X#`X]14#7Q
M>4]I0*:>_-RG7?T)$08QML'U*%0\`VH9@42X@12$T!.*@%D+\4G2FMUL"BB%
M*,YDUI\:FF8TJA'%VW9!BIH&K10Z*("-$.`.(>8"1[S(@)6&1(RB$JEJL5@B
M.D!1A33808I<JT8WKLB-J59!'>@@8]BN88(+B&`:U+A'`JR`1L&TX0=%?>,^
M%B.$(A1!(&\E"$)*L$<Z^;%P#H%(XB@"!SW_E60!@CI4H`AEN<)>+E&2C,DD
M*4F3'(P!DYETRUC:((4U4.`'4^`,'DSU2E*6ZE0^6"426*D&6[9N#53XE&FG
M,CR=]$H$97O+6WR9D[(%<R]'`4#SBM6'/U0`F8&91P'0<+T08`^:3YB"![S'
M@\M@*YNH*9_Y3D,:;H6&7*ZY3+JL,!L/1"!#.R@8;^(%G.`0ASBVH"<`YUE/
MYK#A.C]X%W7T.=[,!I2!%GR@Q"@XP7`M;*'R,4_%;J:(*23"P/9AST)'LQH0
M'DA`'!6A)2H$T9):.#<P-+`3Z).%*=P,1.2A+DSWRP%G\%0$]Z"IBIQ("AG@
M<!8-N,5/=PH*S)I@_SA&+2HQJH8,JC%#K``X``#`2D4G334;4(+2.PP`UB;Q
M=`RKV(=84S`8.P#`!E]`!QRK@8`Y1BNN<:)K">9DUS_B:9!ZRFM?%]<2D(@$
M<XULI&$_9ZB5T+DDGV-LGIEP`\C29;)WJ,H:/M795YK2*3X8[6A;N=I"APJ7
M<LGD;&,+VYST$BZ2M4M>+J7;H_`V>L"U0PK0X,SC0A,RM&DN9;`YOFUJZUL+
MY4Q'/W/?]*0``.CZ#+I2<!M(A!>=XRVO<)Z@-WK"D[WMM0#!Z%LP[2B@,Q5<
M3<.D[3$#[;<T#)X8B:D]8)BI-$01]3#'#/JQ_4;XW`>:,']$>N&2GK3#3O_@
M0+SE39^40O2E'QNQ)=+#H@LDS:8`KRDIODKC(,YX%Q<H8M5R'+4J)&"-4AL2
M`F(@@P-<8<A+NJ)4J[A5;.C@;08@AY'%.(NJ<G4$*?C#%01S!1Z<Y0%LV!MC
MGE`$O\FUKGTDW$/T*L@\Y=5/@PIL#EA"$I)4SG*'>LE+)KE8/<,D"(^=U)]E
M$(%1.KK0GX5*'12-A!K<[NJ&KG2O8DMVV,I6LK&]+:>-HBD9]($'P!7,'SSP
M`V="<^8_6"YS8=-JZ<*:NN3[5GNHF8$49,`#&R#!AWYMP&"OLS@Q#AMTUKNO
M]BX'`043@7C#4VO]SL>E'EOPP@@DLO4DXCX1C:'_1%$_;@B+#-T<#>BZ/\3"
M=I_4P!!K3W\BN.^"[CL4'U^%B@%^TZCM(H@W0GXH6I``!`RG=\-8AEA4X:.I
M"0,!:@N,#XN<<28AF1LF2$,?"C!^'2CI'.4P\E2O,8)*E57N0P%#-0(0@,;4
M'(]CYF,/(.#'O!9N<8AC.(-4$8'5.(-R$H;E2(JU@$XW$XZ%27,A`U/`66#G
M.@/`!0-P:'N`2J-5!Z75:!7(6KDT%SA!=B9H=FEG6V2Q=D7!%P4`=W%W`'9P
M5G9G:L_2!%.0:F+0`MK5+=[B:IL1&C!57>43`:V!7>;"`[DF/S%C'8Q'/^.U
M3D\P`D^@+_*T+U?X')17_T_\=!W6,5YO`&OM,1\=`WKF)C&OASZ=9T&GET$9
M%%$6<C$U!&&PYU$D@SX")E(OU&XN=`,H11__$2X`!C(1@`CE<8CH45"$`'Q7
M,GPWA$.D$`,Q<#3'IPND`%2@@`<><`_%P#O*P!D^DD3+8'X>`!AV\`-DQ"3=
MT(A89'(N@`I]039NDP#A8`+@5W(==QSWL`YD90>`H4Q=$@KT5W]?9G,`$3A\
MM!"$\W-[=69X=3@3T3B)5("$M4A(=SF3M#D-.!-'$'6[5%MC(04@&()1D8&7
MI8&HHBJW,X[D"!7#\Q:^0G874"4F*%LH.!9!(135TH+%\H*_%7=_0(.*88/1
MU/\`FJB/SL5WV02$?T==F4%KJG&$1\@!LU%XA=@N'/(&._"%Z-0;WP%Y,8<<
MUS!/_M,<EJ<#"J!YX@50:RAMY]%`H!=K"H5O%.22%7(Q`_9M<$A1U`8?L'>'
MY98Q%<92?&A24[!A\R:(@+>4^T$>)!)"*6(E*>)$*V8"W#$CR&<+(R`".((C
M,2!%.H!CT9<,L'4,1H4,)M``\7`%Y)"*;,)EM;!Q6X4`F!4.!H`*.Y$*YG</
M(C")576)%N`,]S`6P0(`=V$`%Y`FH$",C`%F<C579<80.S>`?0('.@=(BZ,2
M1=<1@8*`1X>`A1))=K:-"]AGNB(7,O`#[=@J5Y&!:$'_%>RXFD]Q!ZT%CK$U
MCUY4=FA'=O@H%'_Q%ZCC@L@"7!40D'A0:M"D`FB0A);A7(>WD'[G+8`W:[16
MDZRQ&K)Q71[6A!JID>+ED<+!!@U0#LYA;,E1DL<60,I6'003AM>5>QS40?\U
M00"&'A:S,_>QG?C1'_G%7W1(&B$4,JJ!"#BS4K8',[@7>@`*4](Y8@M%H)3@
M8)EP0BDBB3.B0T`3B5LS8]2`-$[P0T*D`Q&`BGA3?5,3`TAD#.;W!K[8!AOJ
M?4<6H]S0`/8E!7BP`CHRCP:P#B$G#B*``$GF1?E@`&,@`F.3!C;@!(A)#*V@
M#?37&$\0`G\S5W=U5S]'F8;S_XQL1EAM]A**A("1`TEBRCFD"1,Y8)J1U19I
M8'6R.14#\)J$UJ97ATOP&(]5,H^\"8_W"`Y!@48`8&6H`P`@L(*@)CU_(`93
M0`0#"2U/@`93T#W-.1O/I2VQD2VHL934^7<3>82&1VOU`3,9Z6O?R1T?24?D
MV1SHB9Z61P!/X(76<0.;`9^R^E_75I\,A!_W@9,4=1_CH3$;9E!`J6!W.(32
MII/L=F$GE93;$H29P:#=Q'N($`0D,*$KXR`.8F*@,`);`WPW17S:2F,[93"(
MF2)TZ01*%`PHJ@R2.):A.`RDX`H`$`$O^I8C)Z,6L`)]D*_YB@=CD0"]E*1;
M9*';,/\"8\`.!8M5YM>*21:8BPFE]_>8R:B,2R"9=Q)(/F<XF$F`D6-(AW0H
MBT2`H1FF=C::I`EUE]0K$RBGPL.F*NMH=&H\MZFC,/LK94$4?^";\]!I?E&H
MR@(`4Z`"S^083T`#L*J#VE5XT.F#L#:$T661I%$NU^D:F5%X'"!N[+:1W?F=
MI:H#(>`_6XBJ_J*JT4$=KVJ'O">K9CB(MDH>&S-1;:A!\!DRQ%H>/!,N3-M0
M,<2'R:J@0?A@3$M=^'4B66`@)^0@"Q(*,T)PD&@*S<!4*!8*'(H`12H"LH!\
M"E`FOX"N**IC/9)$[XH3+R*7]5JOUR"B^CI^08`'28&;(V#_`ER39-B050L[
MNU#2"J,PC(W!!@\;$)"IC&96L12!F0VQ<QF;$00XC8O"I9@S.0JHC67Z=.)@
M/+32LE+1FM1;@7=@6\<C6;KTC3I!%I:"L[Y)%(-Z+'2#3,4)`!P`M`1Y`@T0
M'MTS#\U5D4J[3=ST+4S++<])&@>U&9'!:]L9!+@1JKKQ+J0*>:!0DFP0MF);
M3PW`&PHP!?X+;1`#K:'G7QAL>O4A;@BFJQ5%;IV!(-!F'JG'GP(J'L9:>^X&
M,\HJ+MGTMT/(8+XW4#!Y`].:"=2J(-C*5/_&(L1W8JQP<+HP#'FS4U_I$YVX
MN4P:?>OZ8UZ4-U5D15$<H]Z`KZ=;_P!T(%O@<`%AHR17<@&K0+MBG&2\8`LX
M]*3V%Q`JH`)U1:7+:"<1L5=\E5<-X2>`!5B"@KS,:X"30RAD^KP=8$F9Q"NJ
M>;U5\9J&[+(_4*>0)2DRT,C@6Q2!:A3%`A0\2QA6%@$-$+2,H0(*X`1Z9QGI
M4K\,^4WX*VNR`9$U*2YJ^!E5*U($3%(&;%[BF<#IV3\DN:K[,AV7RK\MN6]Q
M2ZL0PV$=MC/VX5+8EF\/=E^SYVU*>:LPA$^2,,T8UA_S%L('8K:C5WH1``.E
M08:?1\.)(*'42JZ-*'!4"8E;^4-?DGQ%Z@15\"6Q<`$\965ID+E$O`P\)8GM
MB@Y5@`5B$/]EH@LV5&4-7,L&.'"Z^BH%4_#(J/!57>5O!C!^3*9D8WS13LJ8
MBU%S;\7&O>N[$WLX$%''<SR\=$Q(+0$YBG2`H(DHCP3(@?Q8FO06JY/(3G$'
M+&O3KH,KHK,3CVPL0&TLX##4/MT7-3N^F%(L-M!;_PA<\6H]-L@'.$A-\NL^
ME9I-E>J#@#>U2/NTJY$:&^09O!;-%T8_W.$=D%<-S-$OJMK`_M(`4BMX:.C-
M#98>OF=N#`;"\'F?%]2&&_;!_^5Z`96',U23))RWTEP=-7.4$(0:V=R0]&G7
MU`;.-)R'AI##"L(*/W0EC)NA/[,.E"A$M_`VQ!`#4T"8HY`!6=/_!YU+-5<5
MBL9@`JHM#1LGQ:.+``T@!9Q!?@J]KPTM`Y5V-C*0-A)(SQA]W&;<L+FKQ@;1
MNU9*L<%[.,%K)\R(TBT!LHH$6)KI2".K=(S5=#)A23-M`)METY85FSKMIC^@
M2T$-U/W8WNTM3)*<U'99`)=,&-33!,55D$'@&=4ROU>-U<\9A,]*/OL;:^7B
M&=XE;Q"4&:^,V(E]0.Q$A?($I`RLGKI,``'047]WAC.Y;\D\>LLLS+/*84*)
MDP\D:W[+S"E\`TEIGV1-0*X*(HP=PD((H-=&07?]>;(ZS@A"H5,IB3FT8D7S
MN#ZE-SSE17WI$U\!"@KPIW:`SV<I).UJ_P)!8&7SVGU4W"0[$`&]W=L,37YM
M,P5E\POW,`T6?=QD/`OG@`[#R)AN51#.[;N%PQ`1`;QW?N<\EYF.$W0;VTC:
MS02!OB@PK3DY$#K<B\C4^Z84F-ZO]`-X``[P;=1WX3SN7>F5GEM(K5MMEP!W
M\(+W+1@N1P-VQQA"\&S45"V'5SY*F\KC`Z#ZZ[2=42[Z^YXAEADH%<TJ_(4>
MZ4;B&9(C>>'(9GE-D!J"AVTO16(+1=<>)&N_'+CH44,.I0CXU=A`B<*J9S,U
M1*`QSI%>B*`A)M@`2L&])]FS&NT;!)7D^JTWY-F\\*&0&T:ZT`!&NE3O\&]8
MLBE2WL]FV;H_(/^#::!5MB#P5)2+(>#E7][;)/`#_J;9"KM5:7[<91SO<*0F
MBW$"_B`G;ERE_3?2<:SG<&RQ?<(1@:Z9*:'=>RPH2D>R91HZ;_$#C2X55'`K
M.`UV,._HA;8&_$H6E1S4F/[S0'\7(+!IIU,4;6<#7B0#[X=,?S!WI.8L)]"H
M$@RIHAR=FN'J?0OK]'OLG>$!V`0@E]IAJC=2!".)[*0#XZDO@8GA&<X<"/#8
MESH@:`A3<A_#"D5Z<SN&>I\Q9A@@*QY0GUJ@!,9M,;YY`C,%C>W8(9R&9QAK
M:OCL/2E@@PN4YOQ$-N7NSB<CHHT+9ERYNU`C,H4E/'`W^3P,%]`.S/#_`RUP
M`&WP`&Y)#!R'9-W'!@B?\`HM!0V`W*Y[#+:HY@^O)A;?F,:H`H)#YPR!5R,-
M!SBP_-3]\8&T2((>_7<L*-/?QR_-\F5ZZ.Q0R%2A.TU`+YV26IVU!H&&\Z_T
MII$>]/VH_IB^/'N1CTB=*5,"QDXPG*'6!T]O7"=0`@`%"!YB/(1BAAX>*8J+
M*1X9B8L1*1$;DHUBCXH1FYN-&6(>E1$<G*-3-ZBIJ&\W;ZX*"DU-,0ULM@@(
M%KH$%BX$O\`$OL'$Q`&=DY4;*<K*E!S.&]"CTI36G!S9VMM9V=W;X.'9&^2B
MF]DD6:JNJ5/?'.KKK[#T"NPW3MF=I:+*I-6C_P(&)$5P5#@2'$@H5)@%8;,-
M,'!)1*!#1XP+.BAFK$BQHXX"&1&X$(EKI(N1"&*<Q!52H@X.!_Y$J#*BILT1
M7!+(L'+@@!T#.EQ8B#$BA@&50D\F3=I+Z),^4*-*G0I5"E-=)D;J*)K`1AH9
M;0I4T46VK-FS30,@"!`@A-L03XH(F2ND1`D()7KDS=NC!YR^/9;`6;)D`>'#
MA0TO6,RX<9@%3"`_AKQ@\N/+3#)K9M*A`^?.H$.+'MV920X%!G[L6<V:]9H?
M56B.J#@"!Y76N'.[_K%&M^_?P(,+9ST`SQ09!9(K7UX@;/*P?9Z#:#.=^G0`
MV`'PP.[<1H(+50P`^/_3L[SYGG_:T'ERPBT1!1P$#0)@R%`F1IX@X;?D"9.F
M<Y(X(J`SH^3#@1-.W.".*JO,$TL#M+#1D07!]%(,+Q<68X$;EI"SB8</E4,)
MB/Z,^"$VXFCS#D(IDL*/B**@$T\K-*(RA8'P,.C*&_70PPH^+I9B#8'0%$20
MD0,-!,Y""#&I$`SD)$'.1"-HI$,"'&V4)2XC>%#E1"29A,`((J`DIDM-V$%>
M"W>,H,0(=Z0!`!8'7.$3#S9<8,`%"11@@P@8-;54+X0F10-5B$H500@4Q89`
M`B(8X$0!,E3:1QL>M#$"6IRBM98+:H70%EPAT$67778!QA=@B!&&PZN'->;_
M6&6416:KK):%H2L38?#ZV6>D!4M:&!WDP`H5`ZQ!!1UT_.#L#Q=<$(-L-J%Q
MVW"MK7''M=AVZZUP`U"0QG+.,6=N<P5,5UT;`+";W;L@4&K#GC'@,=YY^-K1
MQ@]"M'="$S>D\`D/]LEWWR*('*P)?I]D(F1^G^AGD#M.9$&QQ3K.,TL#M504
M%(6["$.AAAD"8T$0HS#S(3,/#>FA-05=8\Z1+7H#CS@G?B@BB@F=D@HK/T[!
M8HX_.]@C*S<*&<TU,!\)H(LT+[D-BTS"8#64262=Q$076"FMEEMY-&8?(XB)
MDD@GB>"$"%F51))$52C@@1TQ$4(>>G_8T6X;$2!X_\$(60E:J`4FU)21"1=D
MM4*BC/<AQ>-!!#&"#3)X54`:WA&E@PF==@ZR+@&,Q-9;;IT0EZEXH;HJ8'TM
MT3H.A\$NZ^R,W4J[98SIJCMGF75&+&B_=Q"\L!VL\(84/P3Q0VH&B`!MM.#5
M5$4,T^[0V[=[W$'!`,E>CWUP`WB;+/=K)$O'%,VU$18(TYU[+G7JJ__NN^K+
M:\!W!K1Q-[[EZ?T#$2<X@1#>P(%/U*<-BC"@?A0A(/S@!Q&'B$0G$I&P##PB
M$:-0!\4JAJ`9-8A'"HC!+&+`AHRP02B$*IG)5`@##^2#0)1@V8E:1HYQZ,-(
MU:C9S6K&B1!=8QL+^B`J</]$M%88K1[LR$?.3/0R&"0I:BD:6D+0,442"$UH
M"(&!UI(P`PW,8`:X,`$"JN"QK8B@C#HX8T<0H`!-@4E"81K#42P2@S!-)"-5
M&$,&_L!'.ZC)#MOQP!040,:L*.4DO>"82"PP@G'E"2-C$(D4&D?)/D0`#="J
MB0DVB4+/>;(LGV++J-S"!@&>*G5VP8M>6,>ZV,6*=HM9`2QG22O=[0Y8OB.6
M+HDWFA5,80IX\$JE*F>`^T6O*!>1U@^XU:UD_8`"=U#-]WXS@#K400[<$\X:
M\,!-*73S..AJ7[F6@QSD,`=^\YL?=9)C`^_HJ0_[XU],`(`'%9BN"5-(07WH
MXX'_360*%/H11`8<^,"&_<<2%EQ&POQ3H"QP\$`J\MD'8[&Q6TAH)"-3H48M
M,(50W"!GY5!9-*:A)'`8Y*0Z!,<[P.%#(7EC1NSX$8Y(((\>(5%!08H&#"M1
M)"/5;&@D0-`O?YD%BQ7U21O(VA<U8`:F:N".7YO-&3TVQHW@P@E3$..9S*:#
M:#4O#9N\J$MP484+1.!2VN&;"&*P.4.:Y)`N:,`FZ%`V!?0!<S%@6]LF6<G&
M64$*N?BD8'NQ25VX@`UJ2>PH0U`$N=`%+Q!(7>KTLKK`$"8PBJ&E9F4%A\7H
MKC*VY)WP?">\X?'2,T%PPK@*`!5YS>MO(Y@>]*+%F^^M_X$+T)RF;ZHI``$@
M00U0$`X%C#.%"!2WN%90G[K,-<SF5HI<\GO7=KCC'&(F(`'PE&?_`#`%>ZI@
M!Q&03WU2D(8T"`R@#+3@`AWHB`BJ#*&A:$1[!SJ*H#8D'!)M$#UH04(ML0%D
M&!I94S3*BPT\`AZ2,$<,=Q:C(J$TI1#FX8A@B(Z*%6U'0%*1?NG1A%C0`Q7Z
MF#",AO0A%SE1'%+4AGT7Y#-W'!5*2>5B%YUJ!C.`27-;^8Z5LI21FKC-;6^]
MP!A$L%:+7(!MN*@C,M.@6FBQE2,(T*K9E&(!!`0A*A'``X1F8U@7F.`)).AK
M)9LPV+)TDBQ=38`!YG4_-9<I=/^B)%U<'%N7$M0%E:A:92L1L]G-=K:SN@+M
MKFRIJ]&:]K3`Z\`14K"NY!!36M-+YG7YM$SL_>`.X=.M;N306]_^-M.^V28X
MI4*==BW7T<-LIZK;V=SD7`<[A-`.=^)EOP3<H0#QY-\?N-N`)RB@H_4Y1`3*
MFX(V^$>^QR8H`]T["?G*=QD6Q`1];1:.BN578Q"JA48:$-ABX"*C)".`#@P\
M4(0D^$2,>%E)(\SN%/5PQ.<X$$QWQ`ZHQ<-H';ZIB\H!HAF2F*<&:5%0W9%?
M!MW@OB0HA]:6VE0SS&!K5"+C5O3$8RN!"6T3,8D.:");KW3M)-%2[1O^UA*)
MB#%,4S[_R1/XBN4@,"LH%V@"&O#`6C$W3@HZ$*P)+'*'[QPS/*EV;7*ZQI:U
M+):Q=+[+G>_"]+WL.58XZ#,M.^M9R&2F5X3>);%P&:Q#=X8$\:M?Y29-O6A=
M]^S.`S6V:JMIW=0!"7!'P@?4H';<#.`'>)A4=-59KE2KNIC%9/5S73V_Z>[-
MT=[Y3@%XH%WT`"`"-%`!R@Q8'PRF(0(*[,]`E9U`3$`"H<VFX'P3@3-M8#5C
ML)`%">&H@P:$3,`C42'(0F"%!G:#Q`M>ADC7W>[>[UMG.S.(A3^(87NOHD<=
MEH4];D`"$?-[PC)[FL"=D(X@&CP5#<FBPK<XXZ9*"4PC('EL__)41HUD_&TI
M1YQJO_:V,3VAK1<OW`B<4`6TF<2M0GG#S5=``BO8O*\%0`.>Y`)5T`=JPD>[
M%B^I%BU5<%T&8$X%("&BM!:DTUBF8F>ILW1YQBJ(\2I1)W6,0755=QF[LAF$
MAFC$\SM,`';MPD[SXG.2%BF`AP?>LW:]D2Q44(.Z]79Q-W=U1QQX9P.LM7?9
M$3^HUDZ`!WAJ%GB48T[HQ'=A42GN=`&+EVOG\0<\$`$/@`8<H$_!!@JE(%`4
MY'GKQ0@*M$".P`R-(##1E@DF%7#6IB.I1PL=0Q$EM`LCLTC$`&Y"00!/X'GT
MU0W]1@YJJ'N*T&`1EF+N)A`!$2)$DO\-P[<C/G(D,,5A'K9\XZ![_+:)0A)P
M4H,0-V)4.L(@1Z4-5C,B4L)]2Z4U8+)QX;=6/P``&+%C%%%'=G2+(!<;17%R
M9\,2\<<&8T"%78-R)V%(;'!6_Y>,C#,%9X86>$`W5Z@W72`#!L!QFS,".L%.
M57(2HK18)V"!<Z$"0J`"$%!G>58"-,`JEO4J"_"!A-&.(+@8OG)UO>(96J<[
MH\5UH1$\AQ8&.<`"AT=,QG01D,(\!C`%/_"#P?$:SG('T=1VJP$%/A!W+T!W
MOD$%/R"$Z>,N]--WE<-FQ:1F2\B$@[>1'1D=U@4><M)X!U`!C_<#'R5>E:<(
MER<?$'0(9;C_;)Z',`RDAC?I"-/VAJ;G049$4:O'$A("8%4&;N#V"\,0`A>$
M"!Z`8$M3B&JX""_C>]K@B=N@-#$D0SQ35/K%(V^0!=AP;ZGG8:YP>YO8EIP8
M`3"@0P,W5->'"@Z58EG$`5;#`GP98POW18#9BF5'<A[0-5"F$6QC)G9T2'PB
M`@G@!&)D`D36?A='$7^C`!FA%)O$$F5%!\KXF8@2`2K0*2XP!;E&'GS$`P50
MC280`PE0!9LT`@:0'`8@1FS!C:/S%HWE6'0&6:KC=*OB*AZX!%'W@5)G@K[B
M&<J92X5F:%U76H6V2[[#!"D```I(C<9T`<\230Z)+-BS+:V1@Q`Y_P!0\'9U
M``79Y!MW,"GI\H2S5EU2"))G-Y]+V(00"#]A1RG61113```L>0"J^4OB94#W
MX4\X:1^<=UX*XY,(8Q\6Q`QOZ(FBN&$5%1(A@8<!L$(::B$$@`!DZ(8))T/*
MP#*'N!\\I95=Z30BEGNE$%%&!$(*<`/_D`VI8(GV``W+8(@L\WR=.#551'UQ
M6)=VJ1"?F!`D<#5("@,L8`1)8`1.F@11H`%2>G&ZR!$TP1):T@"0.1)M0YDB
MX9K1$EM$5@`BX*65F14G)Q).($<ZP0F@^:92$03-2!87`(UU(S]_M)J`<P'>
ML14-2)N<(SIK872D\XUT=H%-ERJI8EG"6?^<LL..C9$8C1$95N<9HC4LH^6<
M^DA:TIFIQ5)L;2"%0W9IX:.0X`-JKZ%V=_>#W=-,Y(F>IKH:VS0N^+DN'OF1
M2DB?\TF2@P<_M%9K)&<O5G@>=F!)Y_6%H!`)-GF&C"`)DG"&B$"BC-!>TH9!
MX8`B0B6'#T)"=Q18?9A1`.:4"/`+3V`%49D)MW>5A'B(ZXJ5A_A@09)2`A$D
M+L-@\48T#D)`SX"O/B*C(>6N.PI#7%E%\,!BI'B7<LD0"W$U)(`"5H,!1Y"D
M2NJD751R:]2*:*0#39`"6O5C;W428BH#WR$"/M:+%OLV?!H#AN0$=V4`8S`"
M>`"G,FM)(6!89.'_91E@IP"P)^&Q>`"PFM=X7;%%$Y1C`X`C.J#2C:2#=*:"
MJ'N12GS1@;`3=<2Y&%1KG+23&3F0`Y>ZJ:65CZ"!2[;$J:'%!$<@=E/0G;$J
M'%1``=XIGKB!D6K'D`E)'-X)D7<`3F$1=K_J=R%Y=GP2N'QR=FMFGQ!XA&U&
M%&`@'G8J3^EQDPU3,/]A,)6W0,YJ,`DS"5^97F+0`CO),SPC;\-7E"%4AQ>[
ME!6RAR?!"W^H7@F3".GJKH2HH\H&($EBNRG:B/_6EC^D8:1;EF?Y,[`@B/BQ
MKF_9HE1T(#=B?>UP<(IX$`KA8D65?4<*`T=P!"B``1![O1"KO1@``TZJ_P&'
MB:7@IT:S@0`B$`&\V+$K41(C,`7-<[Y`UHL99P)C4`4>%V4NX&-1]@3(.+-O
MB@9H\0/0J#=`$646(0/6:0.P63@2QSE&08T-?%&@8G2CM)N'>DJ*JDJM0IQ2
M:QBPPV>2*H^]HYR;"BQ91[;V6+9GP`)*Q4524@##5K>:%B[*$DUTH)"O004.
MN2V]L<,8N2T.N;;80@'HXS[-]7=M!KC?T<2#6Y^"E\0O*"VSH0,_``+#:AYZ
MTP8$B@F5JPG46C`2TPD$&JV:^Y5A?&SW&F+WFJTUNJUPE'$Y%V"_`&!Z2``J
M4*U2N7E3\`_IQJZ<9XCJAKM>Z6^;6*+J5F'""_\+'Q5O]^8*_\!OZLJC\PI$
M%3.AV-?'TV=%Z3"]TWMP184"HFR]VQNQ$+NU.7"]W*N]1O`E=R2_$@$H'K$!
M,I`5(6$V);&_LWA(MWBQ$N$"3I!7?V-_;H,#`"RS4F`67B8&"%BLB1-&.J#`
M;<#`F[058J0+5T(I>W)D57";2EN!%MB;O[FHC-K!YIP8(^Q9O9,#RSD:7*=U
M]FBIO!(&G94#&&`%,V!!^>QP#K<!)/!,.O@]`X!I>X"#OZ$MF):>>X#0Y5/0
MVT+$VA0$AVM.?H>$2^QS3IS1(\F$JQ:2D%;%/Z`_+(F%P1:Y.*FY,HE>9QP@
M8BQ!7TEY[G6O+F5Z5H3_E@IP`1QSLB?4E":3<R/3`!;DNE()H2X"L+0;R,E@
M#OWP0S-DO,:[H]BZR`348`WR4>S:KE>M8/BU8J3H#ELYL`PAO:!<5$%P`T<0
M!*J<UM>[M=I[!CFP`SNPM7&=RMI+1KXX1E-%);(X`A&@-XFS%4%A1W#D94X0
MV+@\<>-K<ACWL2+AO\<,IQ'P!&91IP>HF@FPF290!07PLUARR\5(.#H!`M.8
M+@50-MQHP4N+P4ZK.AQX&('Q=.8L*YH1&KBTJ9VZPHR!`N8:U&:0`6;0`K\-
MW#.0T!#)&MH#T>)#PZZ!W*Z!!P^8Q!\)DG_K<[-5W69W78[9/$GHF-]!%%7<
M_U79U7BI23!>3*T2DRG;L9,'=0GJ+4&ZE\8.\T0S#8DW<GP*`"%Q7!)W^'IU
M7&4F0P>@\`B9H!]=*<A7>>`)6J(QY*Q5>=0Y&GS"9]-E>:(TE0I=^'RT.\A<
M>7H%=W":'&('(=:J4-:14^*1<]:J7,I'$-='H+W%\M8+L`/^B,I?DB5%P;\2
MD08MD+,`P,`<\P2YC#8Z<$)BE`9!L1):H2<1X$87A\M*@7%H\-AP:A4W:P(I
M`$B$H#<R`#AC)!Z671&!<T@F$-I^T@74(0-!`6=Q5H&,]8VFH@*_R4J6]=KJ
MV,&,41B/81JFT<XI6!KY.!DK<,]![=N^_=LU9NA2P/_<WH*1`:UI/`RW&"E-
MV')WA;MJTJVKUIWIT-/$N@J#-%%&#U``:C+2Y%VMD@O&;5`(9AR&I_['BS`P
ME>L,;"Q]!Q*D/%)1Y]<`*%3'==R'=0S@ZK6@*0`U_)&CQ:NNRJ:)")[@6`GA
MVN`SK_!1)SHCT*`)2MWLH5MAOW1]WX"\4]/)!X=]-T#B)?X&)8[B:IW*;\W6
MJKRU80#7\+X#A^DQ9841+2&;R7$C"O#+^MLV59"8'RN9>E(`3F`#4V"834X2
M(<`Q34`#$^&94@Z:9%86:!`'@`05/0%(R=$'=@,"!XRFB&290DB-0A@O"2`2
M<$:H1Q<"AKK:Y.S:E_7:E^7_.JZ=69)1PN]<CZ/1*[QB&#FPVYAPZ,`]]"U0
M]&;``G=0W+I!!<PTGDQ?M\MT!XT^/@2]&G>WT8#'W?.IZ=33]5X_F%ROBR54
M$6`0`U5(ZO41,9D'QF)`'P?#"0IZU00E'YZ[DSR50RX%APER?+.0WR2QTQCB
ME$PI!8!X00X4R0F6H)N+U,R>[&K8NY%H#TT3#V8)U0\!U6N<$%C5X<P7KP/+
M`2YF<#,2!.9N[B>^`ZJ\`NE^O>^^M4>@:*KLCS(.UV#C,>%'1E42$F1R\+<<
M)N$W&VQ01UY6C%UE`\+,5NW;$FS0`#B0/%)07)R``TK!!BP7\3:W*#=K`1[@
M$P?0_P?;K\4^(6MH'IF?[678^((:28W"#V=)N_(LOYN/Q=HTD(ZM)//OZ#JM
M,QB2JBOL#`@Y'8-,3&$=AV&'AH6&80L+.2P9&6:59I@MF9B8E'@#>Z&BHZ2E
MIJ-45*>KK*-K=P-W5*^EL3\_=+"A`S\7"2()P<()%\7&%S'),57,S<[-RM'*
MS",Z.@C6.@TR/'\'W^#A!W\\8F(9'ND9Y^@I$1$>8N7M[N\I\1XI^AL1^O[Z
M'M:5,]>.W[N#"-]Q6.B$A),;-]Z\:1*C`1L$"%QD1!`CHP4+!`A8<`$RI$@2
M[`+F^Z=O83^6&U)LB,ERG\V:,&7BI!FSYTR#"SDXR1)1(O\'H"0@9N&P+^;!
MGS,1!F4X!:)5JTXX2)U*@@.)+&")7K4:Y$:0(%F.!#FBEJW;'&[C'LFQ8P?<
M(QCPQJU;-UNV:M:JQ+CP5\$%C(@17S,<PX7CQR,N.(DAXH()C8XW8L/81$J!
M/J!#]P'1)\*.)DW01!#-NK7KU[!?1WCR\:,..P>N'`"0!G>X/P#Z```@8X3F
MC)=-Z*B2P(;S`@5D&$C0T44`Z]8#:`_!O7N($R>*"!D_OH3Y'N=[J.^QA+W[
M)7#:OX\/9P$C)AT$*1J4:!`B_(8L4)\5E%`B!B<'BJ$).P7.<$<K$+*22H04
MDD+%#U0\>(<NHF0XP!H#4/##'6O_O'+,B<9,X\P(++*H`QLMCL"&-2U6,<**
M+EZ#D35@I-&-.$"2<XX8Z02TSDKNQ`,`/?KT$T\&344P4TT!E3,0E/XD](Y!
M$00UU$,1*:!`#!=MI%$##7A4&P(F@>0"2I0\B>0_"_7TCU,TX:3GGGOR-"67
M77I5540W1+4045F\]--3/&VUD$.#CM7505H%&A0)7TT1%J(W()K%63>TM59;
M<L65EUP[A"$7!J<>P5<,?_E5Q04L8E-18HEI-,9F&F6D@V,ZV'#!K")@9BRN
M.C01Q&JQO4-:;-!&*VT$(7Q$4A7AV&%`'[F!`UP!;;1A@`XF(*!<N1L%UIP-
M,K"+#*W7_V&GW;P!>.==$?B*)P0$YI6PWK__+B$?P.Q!\D@A@G2`G\(,*]+(
M(PNLL`$EEF!R8`L*'E@@@07"H$J%(.]!2\@54D''QVM@&,J&I'RXX1UT2!,-
M-3G.Z)>..^**S<ULS`@8K@&,,`4`W@#Y&T%$JG-..O7$DW2322XM4U0O_:/T
ME4@^I36E#'$PZ!L*-&$11KVR$8-Q)-464DDN%*@2DWFFH)5.-4E9-9]X[V23
MG50_*M8;-VC%#P>(,B530OSX`]143F@ZU@V3.CJ5IF*!U2E99GTZ:JF<X]4J
MJF[EQ:I><]5%:XO9(("ZSJR3O9%R(E2WLP%I&'!91L?FB@`=G_])Z_OOP/>Q
M0VT?H:&;;G848$`;XOP!0AM=$&;N9N?*FL!TP9![&7;R9C=O"/5Z!UYX^O9K
MOK\$IP\??)`TLC"`B3@,\0(H%&B.&0=:;,DZ!6XLQ<<DJ]`/0!'`"!%P%S]8
MPX5:<8<&Q"A&?FE=ZQZ3F9Q=(W6L`P,>B&:T;)F#2.@(B#F8UH]U`(!I4./?
M/Z04-X"L0QX$F5.3#'(XA7CI(1(94YK,9+8F/,$Q%L!(FPCP!![TKT@VD=(^
MCH*WN,DP;WJ;&E0692FQ!,YN"X$("12W)83TA&L+<=Q8EK(U2_G-<I3SU*;0
M@I8CI*5SH=-+%CZW%[;0,2XK,("-`*/_H^6<376XB@RN>E4-`TQF!)F)':RV
MEYE>[>A&-EI!\"9)R=9$(`#$,\$4PL&#X13@1]\@!P!L4`5K[(A<UE!.*G7`
MQW(Y9GO7F9?WMK.=>X5`7_OB5PGXQ:_TJ:<,OUQ/?1X1!D?TAV$!@L01.'8)
MC5F"'0QJ4`1(5$"0S:*:)(L%AU:!AE-B$#$4#*<X'S.2<`YRG(X)P`_:4+0.
M'F`><2I2#`'2!JD=Y!XCU(E!6F@D&*9DA79["1BI$B:Q7:2",4`-V=C@`I$X
M]`DI*1(*%2+0N]W):BQ9B1O\\40]^01/2@2C6)R`10XHI:):^J(9&Q<II51J
MGS9\%`DT515/_W5J4VZ$(UOF:,<CP(!T=W3+#E;U%KCD(`<R*&7J=$0SZ2%F
M!!W160P,(`)F#.9VI:P.9LRD$1.@P0,ML,,[*DE62M*!>!8P00K"$2X[=-(.
M=OB#7'D``L*LTI0W4XZY3'"NQX#S,;'4"+WH)3[RC0<"0MBE+L^S2_2@IY?`
M[(&`%G`P15BVF(Z`Q`)@T#^*X0]_G2W03$@@A0=ALT*O.&")6#&``YZ6%27P
M:R-Q)\Z1E+.V:+46!6U+$B#6QJOL=.<W`!!1>1X)("-<B9,R4(X[L3!/2C,'
M/#N:N!K&%$Q@(],U,M/#-+G@&B`IR1/<AD0D;4!P^B`*4U;BIQ;J:?\E'MBH
MWJ8XM;GU32A6$5R7Q&(XJE%4B8MCB!6U6*F`FM$K0PG+3=7(QK2L)2UOS*E;
MYACA",?E+FRQ2^?HPN$<%`!6%TP,5)%1C0DJYP)478XO4(R9"QB&MKA[W0;&
MX8T9,*NL.)86&HCW7=\<P`XRD`$`[-`&&Q#-><IKY<Y0F==SH@NP@97E8,/7
MG?'ADCR\Y%<9_`6!'G09`EON01G81UGY.2*S"U@F,R]FH-`6B`2S6,-K0S8A
MD=TA@:88@!SJ4`<UN';.HN!%VGB[VT'GUK:'3K2B:^.8![0!E!TD2`CE*;44
M?%"Y^A#(G/A1W7OTTY\A5)P[1JU22S4.(F'_(Y.9=)#0)I2I6A\)R1N6)%'X
MFO<>^KB!JQ60A;A-R:,UL<*=?")%Q4V12V&$B'X)9Y5]:*E+5+SA&/7;Q:EX
MA7";NESE<JJYG7(;+-R6<*EV$(05D'L';Q@J7^J2`U7=I2YA&*JJ"J!4G.V(
MQ!)4'64(HQ$#)`.JOW)!`VA5!4;2U@4*<&N0>6#C'#L<6F<E7@-\#&1N\*``
M"9`!=(3%1^W=C,FJ+!>Y>MNK1J8SG;&<,I6Y`YY\D6=?NS3?8V,>63C41[.6
M9<0CEK!,^_4/8VWN[`8H`&B2I39E):+`GP<`!0$X70M^!O0`/+0'*JA@T5C/
M>M9)3D$$/*`//!"N_QV&-.GHYL,#Q"62U6#X1">*4+HQ[&@2M]*X,8"-(@?5
MR(A=C8`?$H\&+2C[V5$(-5R_H4P(:,`;[#LE^>:D)CS1Y[&CDK@`5V4*1PE4
M?J=&T:#8(Z:$:RE)`SHX,WYE4PH6BQL_Q9:R3!C<JY?+68*0[G2C>]VXSSU?
MX!)ON[!;CRY2#$:,TSI6LU($B-R(<48P!N3K_4;%<L'V-,,#'MA@&1>P@A2>
M]?#NBT8*L/[(!=K)@R"#8`I5@`XQ"K[DNX(<E=/34=JD[Q'!=D\[WD/`]^SU
M'2OC*Y?]XF40,(!=IAYPP![#Y#"4I5DXL`%&\G/\@PZA=0Y!\&=%!R$I<_\A
M!+1`HP`%=>!T2(`$'P`%@$8%3Q`")$(#6K>"/(9.YM1UB?$`GR1VQ54D_),/
M]51I^)1V<@<0GY9V2]-15>,HV*5#,<9JJ-$$JF-H=!"$M89$=Y(/''!XN,(&
M-[`E/M@GQR9%=L*%+,1Y7>($C2,X640H_8!L4Q%2EM)25^1?`X4I8$$YV@86
M#;86L^=&:/%&;$1[$E%[.Z``=0&(8O*'8J(`2P"(2[`#B;AN$;-NYN9[Q6`C
MFY$S)<8ZD;%=6^4"ES@LYO)=8P!5"'`8M&4"#7!Q=J4#/W!CWK>*I3$%-/`K
M"?<-R2,=L#(";0``Q/!Q=X41>A5RU^!*C-95)$?_6_&B'?JG<OQ79?_'2^;1
M93%7@`;(/A`S/PLP,0_((%8@4?W##B0@9Q<8,@KD6E07"E"`!`(0@B*H!!88
M0'>`22&``X/F@N1T:/)80?GV<3!R`3/H3O/PA.F07"]$#_$P$&J'$]K(/]7W
M3TU$=P4U-IG1``EU`1;!4.6D`($G>!*U-_]``F^``!>!>!ZI`%>H1#>!:S\Q
M;']B;':BAF%(%%AD15MD76FHAH<2*9CW7`EA;82#;9RB%&7A>C_Y!D<`.$+Y
M!GQ8>[8GB(6XE&)RB(GHE(+XAW6QB.L6!'RA%L-B;]=0!:I#?,-G;SKC&##R
M*V:"#280.S80<,@Q:\61_PTQH(JLR(I20`<_$%8'("[^1B/$`%6EU'$AEAS:
M,XG`F$FT%41D,P39<7^S5$O)&!Z'-8#F$68E$%G`5!]+H%F0D(@.F`',9"!6
M@`=X$`'9V)D90`*F]8VOA6>[4`?HB`0U``7K2#(/0$Y=YTAAZ5LC,0'C5'Q+
MY1<P$B/,((.0!B33]81!6$^TI@_U-`\%F5$'"7?L\'@LX2A38'<Z%'#?U6H2
MF7<N(`6!5VNX!H5T@VLWH``8`9*(P09-<$5?J)(P,7E0(1/VI1`/46!_$SC.
MII-S8T-#<17S*3E"X1"G9SD0`3B@8I1$*1%'V8<,RI1+"950:8@2*I6ZAVYG
MH?\6#[9Z7OE(K(0SK'0!L8,N@^0ZX70[;V`"8T(VF6$!$3!*JJ0-<!F7K!@!
M4H`"+#`%/U"+S5`-D&0C?M&+(_&+YJ(CEX%6F;$]000C&8&8*9=_R,A_AL6,
MS?AEDVF`-Y>9.Y`"S-29&Y!`+H,'4D`"&V`%)(`'((*:<T9-NU".(>@#?A:;
M(8,&O=)'%Y0--F-OM/F"O*F+OWDCT5`,!0``PD5<\51K1S*0!>DTT-11-OAI
M"<DD?(*&#S$&8J)JF0%5R8`F,;8!3EA>XAF>4G@#$^F1%Y$'I-HS;-``"@`X
M)/!<O]84\-DH^$DI0Y%YS!816=`DH!<4]S5@3`13!];_$`FF8`5*>T6!H`R:
MK&`#-@[:K`Y*B+=W>[4W>ZAW>IC"`3#``<C":C]S#2,&*ZR3B9IA`K"B$1W!
M2,9B`F*`BSNC.C$JHZQ8`.\@!7.)!F-B(\IQ(SFRBVD%3M/3B8861+L51*"H
MF"FG<HS9'?E"@(K%2V*V'@*#F2M00BJA#ND@!=ZX"PIT!WBP36AZ6FJZ"WOF
MIK`)IR"#!M;0IS(R(S[#LJ;T5[=5ENFI`R'@FR^2LC6B#,>0`('J3L#1J=HH
M!FV`J"%D0G'2G!QEL0:RKE@#16"$0V'CD+;2`&+C0!LA!?'D@TR3D1SE#Q&!
MJCUSJF"+JE2[JIV2%5NRA9,7_P%9\`9;Q)\D-3A_$Y,`&E`$I6R*8K?6-JP#
M=JS*^K<-ZJS.ZH=(>19"B7IA@2E=D:V,BZV.&T@O>T'+4(GYIJ*L%CO8.4Z7
MT00`4&0O*H/P&KJO40!2T`1DN60_(Z*]Q8N\.'^&]DK2ES8J9AQ1QCTGAXPK
MMXP$R+!=!DSKLP0XL`+^((&%N@&G^;'(*S(8<C(9VUHF6R$PXT""\0P/Q")W
M^E>UN:W9``9VRK(YFPPGDG$<9#1_0';^:"1H5P[JP(/_B"56<Y#,Q0-`1WAX
MPY^H-B9HHW<1V0!/<`U@8`5.&)Z>]JEW4IYB.[8-(`0)C":IFJIE:[99$#F<
MMD^#4_^>O48I$:P05@$X%;6WRR84,)FWE+)2<?@X"0JX?[NJ*HS"#&JL@*,4
MB*NXU^JX,'!>1[$0V>JX)#")VLNM&RI!C>1'2QB[L$M!8P`"V5AO/V`%HMO$
MEM1-(R%RJ22B:L)(16HMC'1;NW5BM)(1Q2@O"$M8X=-RN]NPCZ4>`A.\+T$@
MV5AKW9B\</PA(T(%%*`+9_I::X`&5E4,TH`C,I*R.`.#MJF+.'NS+"(8X&L,
MPI`&XPLD8P>T\+NN2P,``R%/3_2<,$2H]+LG7`.UVYDN%8$F?_P$G(J1`\RU
MX^D!;#N1#HPF5.O*L.S*#>S*3;"JK.H2.,F1O+8X:+M?!7K_A37$.&@[.""\
M><ZVJP*6!6Q(E'[+PBQLK&.$N(E[K8OK$IEW7A'0N#"0K5T!AUG0H8G!2K/"
ME7X$ECLBB>AR.ZP&HN@Z6XYA!0#P`)T4`TJ0`"S0.TZ<SWU`N@V05A%4I//(
M8R;`:+Q8I+>3Q28PSK@3+]USNXN9L+H+F0/H9?^R`_:@I>T`7RD@!<\+QVDJ
M9U/W("/R6KPP&"B"##(3(]>KHK;I37<*R"[RO28-HL(@9.TD#H]<L?[X0LQY
M:2XD0T_X0O)@1`2L)[1:H#IT4!X)D0XT(^,5:J?\A!?E:7*3!1;1:K5<B+6,
M&K$,RV.+JK4<./8Y$8G"GU+B%1N\_T5H*!1B^,%69#C697HLM<R_+!&$0B@O
M_#AZK<Q3D$81W,TR/,,%)A6EE\./XA4#:A80P</8@*D^RDH_O#,N,@9.('_,
M454,5<0EV@(\\`!_<`5&%`$H\*[Z'+HD8+IFV8FZ%;L\]EO^&KLL37\Z4`PZ
M8"VU*V6)B8PM)QZ[.]'_@@,(,;Q:&P%*Y]')FS('=&<;`D`%1`6&$0S`$`S'
MT,<MLM(PUG[5*R/570V_J;/%`-T&8``VW4'%.7@2)5U`J,G(-2>&^G;55Z@]
MF"6!`B9B8K4:P4JAW+]-8&GNFY'@B5%4W;:I*B8I'#9<'<L-#+8>2:J*=P,-
M`387/-^4<O\5:GU=#D%&])D%8P`1=[/6;*W,>AWBCW-YE#,%8I@5^IGB^CG!
M=G->&P`#V>RXB)W85]&'X>RG+?)'+^M-"/`&'H!B_:`C@I30KH1."/!C=Q!V
M=C`#4E#:3AX:09`F6?P1KH,1+<BZG:BBT[=7@S$"P?C%8)S;B\ER$9UE:,P!
M:?!Y39(/!9`/GYFQQOV-&=(R(,(+<$XA'R(B=.`+X1W>T4T,*:(,*HU!<WHC
MBCP,D;A'W`W9B*S((M#GXVTTE0S5ACK4Q-6/:^Z^2?LV`L%V18T3\UV=8//)
M&M'*+/N=6^NI18TDJLP!:!+6)LRL!EZU"(ZJ'AD"YYFJ.<04\WW_%.?5G\H6
MS&S=UYCG#H=B%5,`>0>&8#?`AB-.4VVMXI[W;`.%PS3\7+X>%3"NS3..4V9!
M>WQX2I"TE7MD`K7B36-P`2W:`GKTXX@1#9G;2)=Q&\DS!G;``DW^Y/H>`730
M`+_":*Z$.P3MK[A2Y-+'(N:.#`/]Y0;[T/OW'5NPL!.-/E.0$$*8`B3P`W%>
M=,Z+W*NP!L5=(;;PW(_>YWTN`M$=Z)/[QSNN;RAF`,[1+D$69,X1WNN7(X<,
MON`=WC+0!CXF#L6YZ<A5?0E9D,M%>)$\U)V:-T<=$1+I[_?-!E70U$V0M5J+
M0IO,$N@`%A"YJEF`XD)1%3EDX*WFU5]]_\!4R^M3,3A)<5+"/A275RG)QN'*
MONS2KA76W"5ZO_>X+/=ZW_=GC</;C*UV4\,_`0,DP`(SP>W9R@(TS+@RC'H<
M&KF'3",1I``MV@<&8`4)$(HIH".4@1G;T\XNP`8_5@!<8`6DK>_Y;`5O@)M1
M'+`E-_HEAQQ`A*^S?1CA%8S<<]M@_/`2#YDE$`1SHP].D`:CUN:XY@X8N_%X
M3`'0/T`,=+P0P@M\'M[.4?,F+PQ\G`Q[]-*L]`#K,O/04?X:!QTS;P/KQ[V-
M+1C??3W8'UR2'G>V!E^43/1/,VKX`!!7#P@9&6(\A#P9'HD>*8R-BXV,$1Q.
M4V-O"DTQ;`B<;/\C(PT-38**I8HIIXZ/C((I-V\-"F].3ARVMDXWKPJ\30JB
MH:%";,3%Q4*A31$IDI-.&\VZ-QR,T,U.65,W64[,MMK;RY#5UA'FY^CIZN8<
MDLWNMLT;MO,1,-#6^!$;_/W\24E8D,A"`@:)@PA)<(#!D.%"&"PBLM@0L:$.
M!#HN<MKXJ<K%$3%&:!1Q(4*?"PGN8$SQ@Y..3PA<R#0A4V9,$R,.')"1AD2!
M/D"#"AU*M*C1HTB3*E4:)*8+"U"?2HW*B>93JB809*V958<+$S$NZ(`*E0#9
MF@%<I%V[5FV`MP%"R-VRI8@0"!!*E%C!(8TY1A[$%=C`#%7@"$'6[%G_S+BQ
MX\>0(TN>_'C`CS68!U#>,X""XLV,U_PP8,.&C-*H#:@6D2#!A==5/GW*F!%,
ME3ND9>@NP+M-`=\@>`OGK=N&@0L>,8ZH$A9E`A&DV]CYH[.ZSD*($*U*!-A0
M(3&/Q'G0#MC4($-BQ&CG/JZ]MUPW>,5HL`FCIP8C%*A?;[B4>_:+M&*+`C$H
M,$T\MV2ARQL,]I)),&S0-XPQ;/AB(#J3<``-!R3H4DLUS4RBH"[M2`+?-.ZU
MQ\\YY;`3XBTPQBCCC"7NX\^-_@`$D!$H''%$%EGXZ&.01!9)$$(-,<0"#!IM
ME)5+&6%416P:(1=#"JZED=4/;3PYP@56U523_U,-'&"':E(LI>::;+:Y)@A2
ML$$361;45*<%3]Y$ITTTA2D3GE4@5Q999M%99UMJ)>K66PS(=4(1=N%%PQ1.
M^&5.&I&,(XXW=X#FZ:>@+D8%%3^$:IEFGEKV0VFGI;8::Z_%0&64'%V0FPS#
MM0%"&[SVVNNNPIUF0`(AO012<ZTE8$`!U%FGTQ_8\=>>!]Z!!\DRZD%BWGGI
M%>)?BM=*4LDEO]1GWPAL*"#(>J8LLHJVCI"20A8<Q/+&%/&$",XKY&+21!,0
M2EA,`V]LTPT['.";PH;9M!,)PI1(4^(D$H/;2(OPT!@CI=EPD\T4'8/L!$(Q
MPL"BC3?JF,0,,VA@!/\,003A8PY![&#S"D&LL,(..>,LI)`HD!`T"4UN9#1&
MQH(T`B<7Q(#`:P;(<-$%!5RP40P7B3E333'H),,/:;HI]MAD+[7#G%I_Y9)3
MG/P)5=M.A0G5EU4@0&>A=^*=:%M\OQ5"7(\6D5<08TQAJ:5_F<->`>9(\5FH
MD$?.&!5WK($JJ)1#ML8=5#QVQVBHE:;:L*W%.EO1.J#$:F^_]0I`&P#$'KNO
MO`9K'+&Q,?=:LLORT*RST:8R#K4\8!=>8=;VIX@@Z:$GK<614+S+?.9Z,L(;
MZOG7+O0IK+N())@4?`O$0"[8(";S!1-PNNTX?$["U+!3"S4@XA(QB<WLNZG_
MBAAJ/`D)M``@Q_8EC0(:L(!`FH)";C$/D_4C"1M061(T0$$C_"P'-LM@!A>P
M`PYJ<&<ZTYF/CD9"VHAD2AJ)@0AP<AP#U"T&8XC`1PPP`C^)*29-L,,5"F"`
ML)7MAT`D6P3D-!.MV,1H5I%;G?BD-:BDK@HF&)0%S.*V/;EE;XMBE*,@A89*
MC&$,\;O4,LZ1`L8Q0@J=DYP:,7>'3DEN#12`#!J>T``T8&94GU.6Z$;'&M<T
M+20BH=5+;&4:7!5@5ZZ3G2(5^2O?%*!5QY%5<UYC*QD`X'?5@5;VR*,IXGGK
M>YE*WK;.4PCCL8=[)K*$?-#E$D_\0!!6:-<IWC6M__%D`#"VL%<M7/0_;(#C
M?/X"6"@B%(HWV&@?"*/7PEY$&&LD:%\:$I<T]G>Q_FF,%A_S&,@(:,"",>B;
MWSP@D$CFP'](<((4C`(,,+!.#.0@!TS801@ZN(!ZVO.>^%S`"DCH@HUD9#D>
M*=H(#,")`HB@"C_000PLB083*#1K7^'*3!I@AQ;\X`=!S*A&V80#M64DB4ZR
MVYV6"!6:.,5.3P&+6`Q%%I&:Y:5+Y%L6_1:"1]U@"I2JA.$B8"E49,H</TCC
M&H=*F39:SC$#2"IH!G"'RRUF`$U0#B_0T(370(<TK_)CK&(32)<$*C>]0>0B
MQSK67@6K55K='6MDX#MG'?]`D^R"%RH(D;UPI0`\RUL>\[J5GN=9C!W\(A!]
MZJ,#-MR@!>PRA4_!E==$W%)!O@#CQ&!4B_N1RQ?_BH$P0W&#8[XO8=W84#Q`
M)#\"4N,;TN#?9V>T0$H(4&0XQ>D!S0=.<,KB#3L(9Q"VL0TD341E&S!"R\Q`
MP8`8X648P,`1.O#.,&"0"?F,[@+R=#3:Z"`V)90:`L:`G`)\P@EM2`%UVS8F
M-CRA"70@@10B\).-NO>]1)F"T730)XP8;4\6$&D_(^HG0&%-BH5RZ:`*A<6T
M9+%1(4###<9`"[]4*@V5^@OCS($'*CB5J!AFS``V9V&DRJ$,=:@#%"Y<F5$Y
MA@K_#Y#-E':GK-&1KG1;/1UMJJ"LW?2&5V2-'0\`L..RZLJ1Q;D=):UJ@TM:
MYP_0,AXGAT=7]HPQ`N,QCV.Y5;SL?>NOD["$"'ZA"2A-P<JRI&4M2S&(%'`@
M"Y<0WXMB-*)O\N+-__J7`MKA#XC1&6&;@IAIS7&_*8P#8_Z;'P!'1@MLQG:V
MM+5MOWB1YF_N=AL$@0@+=!3!ECF`N!I(0A0V?=QVNG.Y\,Q!&*1K3R3:]R47
M^>?2CB:#%R9@!&EH->-XL&JCN4`'3WA#$*3@$_CZ^M=!B4`#NG*1/&5E3GN*
M24GW*Y6KN"!08R$42P$\Q4/)!"[8?DL1OIA32D!8'<R(_\`4'I?AR2A5,AUN
M#`5^T-3'0$$`\$;""Z"P&<N0^PZE8TY86@.=J\)JR++Z!!L*FQ$:1\V0OLKQ
MCA?.8Q\'ASB03.L%BOP[)!?/E,)K1'H`@(B?*@ZO[EI>7TL95S$#IA$FVD4F
M6(F1&QSBE-NS&)FI984(*(C1NYQ1+1(-S#>_@<[AMO.*R(CR9F3#?$XPT8AN
MH"EK^N\6A`:@U$&&Z!L\VNK?W,&;M\Z+W#(H9KN-M$1^2T%,:Z!E%,QT%)";
MW.0R]YT=8$(8YHY/K7#DH"BI(0)`4K>C#2LC-M#!&'APAQ88@`<&,.E&FN!#
M8#L>V`JHBD:.796K+-$F4:EO1/^E\J5HXXW`U0[]2Q'PM[1A.[*5PFGJ(_RP
M"*"QW)01S47)K>&@!G5R;JR,%N`M`"1\0`TDKLQE%B-[U:2U-:LQP+\E*7#K
MOD2/AFP=['),_46:]9&Z$=8?P\(E)/_!#CR^.)A/V9U/-GT04MYK*<=O&"P[
M80PWV#+U7#*%%J1"L=R;\GBRI1!&WV!^&;(QB%9;G55G[[-+0;</U80+!G1:
M'+`@?@8)&(-G3R<CE15;A\9-TE!;B_9FN>5UNA8$XU00D[8R&D!<9H!I*9A.
M&K!VQV4$;==V.<!<<3=WHW8T59`&HR,6>R<2)'0!(H`U??`E`#`%,(`')!`!
MJW9K#4#_`H_WA,`6)Q@Q7EL1%1+E;$\24205*"-P-U(D;3!%`"YP`6S`%C-U
M"3?%4PS68-[&4^9``<$'>Z+B&0-`!7`(&:6R.8K!5'$(!3Z`!(`(B`QP;I,A
M&J*"!Z$S+,[Q',-".DW#55'2)%]R*S<V?6352+MRB;SR<-B'5K(R)2+0![[S
M'<6C22!'?L135QYW5^1A2^O"5_LQ2R9W+5G&(`]2'S<`9N4QB_\197VU"`KA
M"^)#([7`31HX!9[U62.S#/D0+JAE/L@8`2?"=!>3@"ZR6A4(=5(W,CBE3557
M6URG`%KW@5\':04102;8,FA7=FF73DGP@C`X!VW7`?18@V'@_T\JU"HQ8``Q
M0&R%Q7@*0`,*\`-I4`4G,0)CL%Y`80Y30`=H0`<F`842^5X%H`!=87=/$D69
MQS8BE5_,)C<C\&K4YH6%`E,68"ME>&UBT@1O(`(B\`/_]WX1)D9^\0-Q*(=M
M=#F40V)N9&^<(QD#4`>!Z'O`YRDV:1E3D'UH14G)XD<!UR1BHE#05XFO8WT0
MIY2&)%:PLRO`<I6W$QM@0#4`(`9M,`BE^!TQ-U?>TAY_45=3MBZDJ(O<$VX/
MJ$K4DQ&'M609!SV.I1Z_*`EII@O<,"/:Q`WS0RF4@(S+E`[V8R,+TW0,:#Y9
MH'0D4HW0T'3KD#'9>`L*06@86'5!8/];6A>.'RB"0`(11J`C,V""*GB"[9A.
MG&8$<P"#;H<!](B/I6$KS&$`%_$O=!`$$<E>"BD#%#`"RE`4[361RKE1)!`3
M)*055%$55I%Y$752=4)C56!Y)>F%H@<5^TA#;Z&2(7`)+_D&W,9@.R6-?H$'
MM">'H5$JCM%&GH,J5$`'N1<9:J`%@3AO-^D8MB<%:7!6I2%QE%0L&W%#DUA(
M804[EOAP6!EDV<<;7+F)CM2)`UHL#R`#(G>6+Q=S8L!C>(5RA7%7W.&*?ND\
MB85*TAA8\W=8WW)E?+E_?85^`^%__V>!&0*`,\*,"0AU'T(8_!.9WX2,(I*&
M*E*-F3DQ:R;_(PO$I!PB=1^C@>:C=1WH@;@5,T<0-!"!C@!Q=FG7FJ_9@IPF
M`;*)`?*(`<7V$E5@`_JF`P9`!S_`7D5!`C_0`C5WG,N9IX[7!/EE7PZ%;/UT
MH(#:-GUB)SJ0`-D9>HH*AM5F%B-P55[1%BJP93\`?Y9:*0T&85/`GNX9&0-`
M!SQ)>U3`!4^5;N8F!W6@!B.6*F"#C+\AH)$4%C$PJR$Q<'!C$ZE38PB'2#CF
MH*=1'+\:.JR"*S_F&Q6:?;GI$55`*7-%"!;'?CZ5BN27*5$F<E36/(FU'?U!
MB^]W"?.!+KFH/3`J<Z[XBAY@"XUF,#I:63"B#G1F@.0S!4#*EOE#_UN=)0FZ
M0$T2N##ZL`Y*.ED(LID+A!`@<W16AW4,,IJD:3.XQ3-!H*62!A`LLXYA&J:;
MYH)D.@<^>%T*U1PZ`)%(P3A2,+(1J:<F"U]20%6A0"L;:6LM97<G=14A&0/:
M*6V*&H86H`/^5GHRX0LO.9!O4*D[E9A!U9Z2DU3!EU2889.>0WN;`SE(2XB4
M004`&@$3*J"N0:M3,ANVYIP&IZ"MPZO!`:RF4;:M(JRH(:$_-AQ!E@`/\!($
M22T?RJ%+UAU-M@ICQ`S48JW-0U?CYRZ[.*TI)W_TP0%6UGXE.I=3AJW\QP&,
M5C`<HZ/MJH!TJ8#YL%K8H*_\>@WV"EC/,/^M$J@.+:*DF@D/[]`^DZ40JOND
M!%&PY1.:N=5U"ZM!N`4T)*AI*Z..%5NQ4=""1D"F/H@`6*-07$@')WN\)NMZ
MP888%[4#_S),Q785"``AT9M2,8"H7[B=C;J]!/`T?(0`;Y$N!3,&C"8"8_`#
MNX8"=%ANFP.G/'E1%"!4C6%BC6$9G7IB>#`%A]1(MF,#R"$;Z%(T;).KE*BV
M(``L$,HJ:+O`IJ&VPX%]QG$!8`!#$7`>X2=^TYJ*'<>6J*`=S#,(+0"+I#!+
M)Y=QS:!*OS`")&`&,+J7O6A+,YH]@&FCT\"N`9MG0;=,A,&8M(`O\UI-U_!+
M#,(.^$+"$CB![IK_+SN*NNZ`(<AD#Q'0I`D!)%*0!3&#6^`XFAFT!%VG05AZ
M!$IR7)H6!1.[NZ_9NYM&*]BE.Q?0>,C[QD\HIT+A.)RQ86LP*I1S!U3U`)5S
MQWA$5>G3!-AKL]L[8(WJ`M^I&A>0%BSY`[^)!Q?%;J."&>[).77X.*0BG^8V
M?!H&JO=+?*,A`WWP.K_"MC9`++)AJT<3J%]K8V$+9`R<B"XVRPW\JF<E+*XA
M`E#6/.&79)PD'DW&P=BR+N=QK;\89LIS+1`V/0U@N*`+N#%JHA\,C(YKHY1`
M+^,#=.&",DD\"=I`N4","T(\#>^0N.3@KJ:[F2_2Q$W<#RBS`4EB$`@!_R1@
M%YHA"+OBJ$$*L`1<S,4:E%M9&L9B;`2;UH)F_)I&,R5[5R!N#,<._6L18`5#
M(07]Z2EW_`-5D+TWVYV%\JA\%`JW=U2?7+]NU&%,52H537R5HU290QE**])/
M5=&6@1LVL+^T(Z`7(&/\Q#0),*RL4SL0S,"S/-2C4\NV;*&JX6>#8)87MV,@
M%TH\ML$ILDE[U;?8BLSX%SW:L&4-D(MU6\+Y9Z(GVG$/^+B"20OMZAY_<<ZC
MZ\WDW$P/`W4$]'/-T'X7T]:;Z:0RPL[F@"-UQ@(/<1#E<["[5=@UD[`U8S/[
MO,_]O,\9)"3LQ!`O"!!D?-!I-U\YG3H-_="<S?^<>)"<"VFTD<,%?$K(.'O:
M^<5O0;O2(QT9G$P%2VNJH+$Y%%#;G@R4GS.R*,"T>P`%(5:4D9%'8,6KFV@[
M+I1J]M6U;`!]T:<K_;O`+M9B1%W4#RR@IM&L3-W4(=H(!1#,:LT(8&;5V#K"
M889_/)4+E]`$3F!_YNP([MV+5;T?L3@@-`R`+*(IA;$B@(8+'\,BSL3?!<0@
MT;@,[X+7UX36--*D>UTB?@U!$'0C,+`0\[QT]1R"/K(S-M/8_+SA';0"[Y0#
M1Y!<D@V/!7W018,<FMW9*KY1KJ>01'&?0W4'#1``W&FSISV&+UDYK2T9HH$J
M:X`&=G2T=0CCCT$%6AK_$2305$$9;\"-5#]P56#%H!0*<<?1)"$`E9P0D@<7
M?;9\MFC+1\_!.],=-=5]E;^QU-W2U)^T'4[-B[OLP>+ME]E:WBA7BPI``JVH
M"B='KC#,N'UE<UE@U@:3+RD"I,W4KP@C0`=2(]=P/_Q2,$0'Q`A#65#GS;Y$
M"?.#Z3E%*1K3USD"$%;@X'Z])()MQ?0,=C_SSSO`SXO-SQZT`Q[^,^L$CZE9
MV26>=DUB`GE7!2NPXKXN1%*`!YL=%)R:875(`6@@!$_Q4CB[O2Y0`IR\X^B6
M1KX=8O2F1C_)XW@``U8P`V:0`3/``FA0![Q'E!=F&4!8U`U\P*3,B<*RL;0"
M_S?["+:L0QQ";7Q-R8C*@GS(1QK"4:&/U#I^KN;F5WZJ***%02UP'N=S?G^G
M="GOIP!.D"USF2(B-]YR;F8<0"X,XB&$KB(&.(&W``X*7NE4MX&0OC]#1R.(
MJ>FRI0O:@(';U(TS3PFVT*3OC(ZA_N!<*NK\8!`CB`)`@@)$?^%'H#,=U,\;
MO@3T5$\W`^+*Q4XD7NL&G7:U)KQ^-.R_OO5%T>(E>Q2\76Y*J\<-\`1/P`9_
M8S<F^02L?;])!06K*AGM-@!E$&]UD-*>&NUXB`(;D`$IV`)F,`,/()2]9^[Q
M20?27=0RH"NO@TC!PH\"?%+>Z\J'=,"\$<OXKE7)PO\:I/-B9%[F?=`&']I7
MWJ'=,'>W,@=RW&+5Y"U+=OTP:3`%/\<#L61RO!BX\?V*9!T?9CV8D?Z8UR+R
M(7(B.D<+`=[Q]'/.DTY9/>Q+4FI`AX9`-]4Q)(`O"^37CPGJ.[^:P(4D!9$D
M/?(S&&XS.,#8_+SJ2\!!'/1./M)V,$#K%WNQ"E!L>Z<:0<#U^(\4)"#LH`T(
M?8*#A'=[AXB)BHN,BP,#:Y%K5!1T%@06+CA4C9V>G5!U`EIJ4)T_AU`"JTA(
M:@.*CY][`Q0_L(QK4B0S9KXM9C!K=:VM'Z^):S\7(@;.SP8V!2!MU6T@!=DR
M-A<Z"-_@+N)@"38R,MD%U=3_!=O1-O`VT`D)%_;U]/D)!OOTT>D`U0'@P4-,
MAC9B!A)<*,:#PQ0>VO``D.%ABHLI(F3,F*&AAXX=Q8@<6=&AR9,G,69,X^1&
M!!XF56*,*7.FR0PA1>9LF)'#&P4*WKRY<<,)!PX1(FRXN!3CA@U*-2:=&N$H
MAY9$K3IQDL7)%"<DB(H5ZM(#4ZI6M6[]FF6*VREB;Y"-2[>NW2E92)`XJO3I
MTR1)K`!VDV2&8<.`DVS@`.-O$B,L8,!`00(&!A1'C@19L:/S@AV?EX@6#7I'
MCM.9,6"`8:2UD2BOHVB(8L4;.&=3".G>S;NW[]_`@PL?3KRX%"G%K1B:Q;SY
MH3M/_RR4N(/+N75$`[2L$N"JNB)#`X@5^Q#`N[(5U&<IH[+&_`\2&WS)GW$+
M2C$D=:#`6G/G#IT+"30#S3,R@$#--=6D(T,"(^C@(!L.?N/"".6@`Q`UV,C@
M3#SR/).//2#JDP\_^4@3D$`#Z=310BP:9!9$8A1D44T;N?@12#F!A-*.$+UX
M455.O&2%CS06"5&/-XYD$$XZIL!!%D`%-=0-4R"ED4I-+;4454DAI546<E7Y
MI%LWM-45F41-<>6/4VEUU%I<O4674'3665<0<N4Y95UN[<475'ZE$%AB;AR&
M&*"%S0#84Y'!$!D+C6*666><=;;#:`M\%H9IJ:EFF6NN1?]AQP7@F"""#7A(
M$01RQ;7JZJNPQCK<<:T6P,EUN#IBRQJYYFH?*TC48,HB_-&BQGW=X;)>+710
M(4LG`]SQ0WJTW('"!KW(9P8+O`X0BA;Y/7+'"@K$<$\S^PPH31L`6(.--@;$
M`"&$#@;P#87FI.-N-O"\TZ\S^H`(H(@$5Q@0NPJYN.)""7OD04(\E$2C5"DH
M_'!.!3&Y(TI(LHD43&:%K-*,1=Y$DHHAO1A6E&2)F1263*4`549HI35F5E_1
M]=961:T)59MN;N556W#!%5>=2.\I5]),X_D6"6"EU9=?BAE6Z&%N^&6HHHEU
MG9AD,&0F=@Z6>E;:#F&L<-H9JJW_A@&H41P0`3@(C*"A,Q?@(>O>?/?M]R`1
MX!&!JQ%0V^OAWAW>G'WW,:`?(W?PRK@Q2N`2;7OZ1?O#+;-005VT*,`P0P;R
M94`?=H_HQ\4/**`0P1L#CSB@`06N8TT;[7`S`AN\TVMO%=%8F`V"_&[(H8<!
MXT,/NB2.*/SP#7\D$L,,VQBCBS5=>:7%3.Z$T\8;_^ADQ1:]2*21%]V$$TE,
MBO3B8F\T(>501EDITY9<MEF55D2]`368_9M25XSB,Z#9#$YQHE)=Z#0_I(T%
M:3OXB0(BJ+2BX64*>K'*U*B6!,(0)@F"`LS61GB8*"RJ46`;6]D^8YH=,"$'
M;&N;:EQS_X`6V.8;[K!!`A[`JK_Y\(=`)$0!I"`X6/V`5XI+HA*9`P4?W*<4
MB3N$,AXAAU:0XEG*"$4=\D,+SGVB%ORA3!)(9SJ<H`")R;A##BBS`<`T;Q\"
MXH<ST'$[=K1C02/(X^XBA(`JB.`<^IH&[@K0(7\-Z$/Z$($(EA<@?=`.(`B;
MB,9BU"*"`,`C*^*)2M8DE8NI+R>7+`GX."8^@QSIE#-!WTG:%Y))9@`C58E2
M4(A"0*5@Z2GYJ\K^OI2G!"YM+D'*4LW4LA:HO<5H1Q-*`Z>T)PC*4DIXL@M1
MB);!RFRPC1L03&(4-4(1)NHPB8',H\`FJ2.0;0>52AMJVF8$#/_,@34'.(`"
MZ#:&`EP@&E48P>""R,]^QNHX!9!5!%"QQ((:5!&A:$6XHG@(*MS*6YE#Q!IH
ML!TDO$`_=[C5)]80A-!MP`V%8A(+.`'11_P@")7!%I-2,`9&SF-#ZK#=(`EI
M@'SJ<8\ZJ(+!]#5(=QCO7P`CV"+C^,9]"*\:":O(^EATR:0^C"`DRQZ,4)*3
M%BQIE*3<2,1$5I/SC6R5.F'?^EZ)D:.P;"@NFYC,N&0SJ\!%*%YY(,N0<A8#
MJ@5J<2(3,N=$)VD&\`T1E&5?WQ`$H136L#>(YC3SDD$8<(`%?FFCU[K&S:UI
M8`:7Y=IDQVF9S.3@"&H#S6ED*,-XU@;_`2Y`P`4*D``_QD"?_HRM;(730UE)
MP5D'S>T2O24'*#XK%E2@0[=^^YPR5+0[5#CB%ZT%'RNXH7M6J(\H2,'#:UFA
M>V9XY1@,0%1TE4.0ZP"(/&)0!9OFT4%^S%<@M5%(?[5WD2(2D'=%9"&D`N"2
M%J,D02"V7X-<KR)2U=[#5ND]46(5E2G8JE?19Y,D*6E)%3&ES"YB5J!,J98R
MR>4NVXJ5H;0E@+*\`2R[=$"A?84K*"Z:7?I*I6.BB4X["$H#$\NTI.$)3V;2
M2V,=)=G)%N;'WLRL&1#3-1,^QC5@P\#8R'8:&)(6`_$\0`S`P09XC"`&,6C`
M/F?+Y2[W(0(D__`;'M"HVS(CCKC)^($4K(`'C28##>(Q1BFF1=!.4&$7&[A1
M]S9P"U&PP@=24"F32I>!"#@A70"38S8PE"!X78"\#;`I[W2J7G58NAVS,R3R
M\@%?.1+LD3&][TCTK%_\0@R_$]&D^#;)$3$,R2$8T\E'L,K5!$ML9`Q&$JQW
M(FN0K+HG+"N*E6S)E)]U:<-M!1-<C:;,*)&`3<A^DU>V8DP3RRF9+6OK5?[:
M5\4F+8+@!JR-HYF%<NL84I+M\60K2\+$9!8P1@:59%3CV1PH^<E1E@+=RE&%
MG#;!RP"?;5+\-E#+W>$X"#_.#]QLYH9W0AF;DT)`!>%%B=[B6..IP_\#A!NY
MAW=T`]V#+@S@@`1@^6`!(`^Y+W"272<$U7GJ.!!`MG&!*I#WM;L;`:4!.3P%
MM?<=T4`>?#GM:1$]TAI*TMC""H+?A*4(P`&FV8!A/9*"7)76(O-`Q,C:(P27
MC,`/5IB$)RRS)UFX3'RQ9538JFU>WD`!"OREA3G@,6TC$*]@@1.:QB(6EP'M
MK8A-DU@."U@92Y!EX:X3CLND%T=!"K(<]/&/#;7-RU[6QTB>]Q'NC>]XVE!"
M59`!J730A(D'_/1`'.+?!AJ)(O)&"F1VN.QK80ODF'X0%3^$<A/:BHNJH@YE
M^$(C!G#2".@YY*]$`;).S@+DLSR[.$E#T8W_&G/B.1K+Y)4TOIYW:9^J:W:)
M'%'!\F4-_"H]`PJQND@&PGX9L7I-&XG`]Z@N$JO:".L8D=%#%OQU6$LOZ4KE
M$77E$V=U`WZB87;5=G$E%,C$0&\@%0:T%7=U8GD'%E]Q;3HS;<-6%7MU@1<8
M%X2G3($U08(5%!1D6$%@;HT'-I(!>8ZQ;D!661IP6;*!69B5!/&&9$_V-E`6
M90I@`M^@`SID`J1W>ZAWA'TC!2"P>JEBA(00`10@>U+84%(P<+V1>WM`![@`
M!7)0!W(0"L;%'1>5"WCP;,[7/2R@!?>A!2N0<H.&74O"4MSE#^AP(#*7.X^&
M93:71VPP`A=0:>%5_SR9-H@>\D9#]UTQA1#N,VM+QW1*TB+\)SY)`6&QUFM8
MYQ`9$XE&0F`/(U;2PW55(1<*(#_RXV$:E#]MQV%<(8I[ITPB9FRI&#10<Q5X
MA1=>@4QNX25<D78<^!4<MG>_)&Y"$6,6%F,Q]A/"2%@W@`)9P(R,M8)@`UF*
M(7F4-8,V:(,:D`0TF(.M(1E&P!KM9`119@=B("$(T`PZ8`):AH3LF(0`=UM3
M.'L_T`=+Z!NY1WS5\0B/H!VL\`%U$'M[0`5!8'QG^#UX(!ZCL`#P$7*42$;0
M)X?[4'WKP`XT=W,ZMT=^J%X(8D=W0X@>650EDHA)YW_Z974X@1`,X544(_^)
M.)(D&?,]!C9*F9@^,J&)GY0C$.8^-),%/]$$/BD_LW0#;15ML6@4@/<&>T46
M:T5BL:B`%7B+OKB!'$`E&YA+6@&,B16,#'2"A0<4%)2"67`$85EN9*ECT0A9
MTDB-48!9EC<#LC$;UC@;;FD$1P8J-#2.4X9:(U!3"*`#6]:.@.DJM25;4K`<
M\=AP/V`%P5$XB8"/DE`M:(`LKH`&U;$&=+`+*5"0.%&8=+`"3-`!.;"0FGF&
M'N`$)H)4[$*1W%!>%XF1?TA',I4A/P<-QS.;('ETU4`2-_%4_25V*<E@4U$Q
M2G<]-A*3&Y,!,YEK-;EKO+8^#8$3/T*`/HEE31#_`V<G;$UY%6EA%-P)0#_!
M5W1',ZA(E$6)5VD'*+C4$E72%\7&=E<!E71Q8]_6-"F8&4%PGV!9EF;I*(ZW
M`2P03HFQEIDEEVYI>7(Y&U&0H'4)*E%V`%=P`T#X#2)`*F#PEX%YH;359;?%
M4(=94'<F'`6`!]XA+11`"=+B+&HX'FI`!]3!'WB`4AIQ?"'G`0BG%RS07`79
MD#,:`3)0?JF9(*M9!9'&ASJ0D<-S(/<%I(/((?)02.UE='34B5<7@"WRG`_S
M=)HX8E-*G/.W2K-V$C$"=<KY50$H5KWV(U`RG0VPIC$`E!>FG4XI@?73G4>Y
M5T(Y8@B(%JC8=DG1%&O5_Q.TA!1:,C7N>14N9A?RB30W%I;X>6-!()9BF1=Y
MP8(M^'@`:D*S\4UKF:"6]Y9NF:`*RJ`-^GD(T``K$`$X$`08NJJSPF5!P`4=
MVG!KH#?#$0%D]EN00`MPX$2]1P/WB0<OJB9+@74_DTWI,YK(:@4I``+WU2[7
M@`VZ<U,-TI=_&&K->E\9DFE,&@_&$W3\,'2@IH@.`Z;5(TH0HVI2)9X5@TDC
M256[:1+)V54ETR-EBC)A^B)3^1,-D&5K6IU`&93")J?ON19M(:?=V1*N>#3A
M>3].H1'&AH`VTZ=8$A4T,Y4]PYX3!B@)>!072#3'!()9F5AB@Y]#X:@W$*G/
M6/\9E/IXCT>71I:@BB*@LE&#,`NJ.)B@K]&@!_`'\X0`JMH'3LBJ0JL;@\E/
M4V"8L7I0_/$#%OH;4W"K410M7U`'/E`'7T`'&`1F)'`EX-,]'J"LUX6L8JLQ
M'G"MV-H.%R"M$/(-U8HP9@L`(.!]/[6M=/MR!A,1HT95^B5K>"M)+Z(]&48S
MPDE__J547FJX3\5U-,)_N^F<8>5K3B**U<FF^]H`_GJ=+?:>%T0T+39`LQA7
MHJ@`'>AU8RHS?I$_?MJP&OLS12.HJ6NZ#]N4%2@G%E1NS'@$@Y>5BXJR>D$9
MDJ&R*]L:@$&7`0IOFTJ#<LFIH!HW.IL!W\`&=-"T0SO_O8)0M/RD7$F[1)%P
M9XII'/FX18^#';>@CP^P`L_VM>D3$\PYMLZGHZ-9MM>:(6FK`[S#1PCP`-)P
MK1,Q$7!+4\]`MP`,5'*4+U(*IE3'$..:$"V0I9(X=?_'MX?[I02AN%TU(R'3
MN+P&81O0$J/8!&M*N6Q:G<$F>%A!2WPR0%OQ80D;%UV7=5F%/E-3).B)2VT"
M%P34%%:0PV<!B]G)L5")0;U;;D1Q8XF5!2F8G\WHNY-!J2SXGW8IO"YKO#/K
MEI\ZLQJ@LP=@!R-@`N+0`*Y'O6"\9K,5HKB5O;BBCQ`79JU2<*D0AOCA'14G
MD#%*,C?)OG;<$=D%?4S"O_?5_PX,XB"`#`ZAUP?-NK_\BSL=Z5X<L@W;``^-
M+,#G@+=D"Z9[ZS#HASV_]FM3,74%YG^-^Q'QFFO'Z3TJ$KD=3+G\^L%MZI,6
MIC1^%1=LP;FA2Q<<\+7J.Z^E>TO&EA&1U26V**B"`E)NH*P/2YX<1@(8!,0P
MH!?E9C0`A&/YR8PDT#J4T3K+##;3["A/O,VN<;,(.H-PR;PZ^P828@(Q@`;2
M"\:`&3@KL`*"D\X_)`44P*%FS`@#0`F;<T14T+W$49AH)`<5]0%*D`@+APMW
M9GP6O+ZL=,?=DY.#5KADM%38NB!@$"&VD5J#?%\$\0<*T<?>MZWG8`[G,-*/
M7-(%4/_`&S,]^P568V<D%&-\8J>;7WJXH;R)Z>M_S2EK*>`$'9QE_)K*6>:O
M_TH6;S`&"W3"%S06H^C*C+A_-)*Z#*RZ?7JZQ=HE;?$G@F(H6</#/6P5-KK,
M.D8T8()C4D"62=PZTUP9H?.[DV'-=NF-W!P;F'JSH(K%!Y`!(X!:$S("T:O.
MZQP!"3=Q!0#8"`?/?3-0&47/C=D>[:'8BK`>N>(YC`T+5!"T]LAPQ,`=2'`,
M^9A<_;$YS[:<,EJ0HRVV>LQR#AG1"=$N>!0"%BW(-L"L`,#1//`'/&`'$]TA
M`$S2O`U()*T.['.<'3VN^,5_\">>C)@C)6&<H(S)HKPC8Q7_5NX3`7*AIJH,
MPI7;IFU:@#7&8K34%4H]BG1!D#.=$L46**4[J%3-);#8)X+:0:-C-4O)E+&X
M%WNQ`6"M8\AL)F2)09*:!;]+S=D<.FJ=!1C``F_]C:RQX$\,&\M;UW;=LRZ0
M4VR`SGX=<%9`V*E2A98-M(0M<:[2X81@!06P`@!)+#\`K)MC.-!"!:E29\Z!
MCXUY!_R\F`RW!W&VV:_@'9#`V*Y#IJ6-?%$P!W/PGS@1WW8,?7F<V@G1!GCD
M#8`<`M\0`^B@$'_P!W9@VTE*2/'`VXYL(;P=$!:R?O,7DRJ]B'B+R8";8531
M:\$M2H@[P5'5?SCMN$O2$%,YBJF\_Z9LX-.4Z\$_*5C=;2=B828@)C^PG)E=
M:MYD%UDSG&M/L5:K>[I3$19I906]$-_SW5;VS>F/Y5C,#,1A'=8JV'AHW=9@
MW=9K+6_S]HWA.$-O`S>O,>MV?0!6@``16@6HI0*&?>%\DQ3'L>$1(.*^806T
MTAM3`3C!KL;`(5P;A0>W!X^>H`S[)`6.O0C8*U&T.APBN@@81SGT3'SP0:8%
M:;I1L!T"``?9Q"2CP]"H?=H9P%H-H@.N#<@Z$`.Q?5]8GN5V8`<3(9LCK2"]
M_=L]!SU8RMQG;JXZ"9SQ%P%7Y9QEWM3(:2.+V\*C'%8M4!)Y/KF5V^>5B]W^
MNLK_:G@6MO],L-R`0-$$=$&O7TJV9'=+&S2FMD3#5-'>8K(4AN$+AF$%L>OI
M:=$8^*W?'*#?1*_?V"P9!+[$UXP9*(#@H/(VEL&#4L].W%SK?[#%XA`A;-#K
MO@XK'VZ%?$,"5;@;"9=P@S-$(/X;K/=P/^"$V0XY6V:KU_'V>W`'7#\(!8"%
MM"`>/K#CGC`N6[L!>K$42H5\+#`M:(#N2,"&CM=!(8?DW=/N!;GD'C`&_48O
M\^*'!3(06-[Y_M['=W0B`\]S@L1H*7)_T$U)]S=JK+81\:>NQ2G3B.L0]QJ)
M7>M@2U(0%!8_'-\`'O_!'V^Y_/J3(_],SS07@A?>B-YW$*$CN_;_/J\+NU2-
MWJ^K);S<IX2Z=AR0BTJ!Z=FR\S_C)5X]]'ZR%Y`%ZE#3Z45O]$</O*&CQ&*Y
M&@G.@Z].6D8P!_??&O@OCK4."#<F""X((P@E$7V+C(V.CY"1DI.4E9:+$5*7
MFXU2>(I]))^4$7@DC:"-!7AW5&MK`WL#`URCCU)4>[J[NP-XC584L;S$Q7=K
MQ'><$;G%NE#0L\Z[:S]K5!2NU3`I&=[?&1L4ST@"`DA('W(/Y@)A+$G@X#/R
MWO3?9O+T06PZ;&PC`HZX(`,$@#\\[/Q1J)`'`!`%(D9L(S&BC(L8)X)HL[$-
M```\>(@1XZ&DR9,C0Y(LF0$`R10P8\J<_QFA9@HQ&5B.Q.DAI\^<(7-ZF)GB
MI%&3X'!Z&YG"R9LF"F(TF-I`ZE2I5K%.;1*#:Y,+3:`J&$N6[!L%;]+>F'*C
M;=NT"IJP<=LV`DMO)V-N2+&A;U^B,/WN%4QX0X3"AA,GKLF!A!,.A]W,F&&F
M\@PK?2-`YM"X<V<2&UC`(-&8A.G3J%.3@,&:]6K7K5&@@''D"`HCN'/CQF`$
M`^_<OH/WWFU$@I$#R),G;W&HT`@=:#A)GTZ].J-,UB\5D,)=TR7NF;B?>E33
MTP\*/SX5B$0'V30JJ?I$N#-L&J\U=W[4U_6#$R[[L^SGS`#6Z"+-'FM(L4%/
MX%B!QS!0U($..O\?J%%'.TB4`8,5]=1S3X<9Y)./-U,T(-`(5<20@`P>\;#0
M'R_^\1%%$H'0$40%8'211&UX]-%'(8DDU%$EB1&22T*!]!),$0"60I,UV<13
M!CM-V9-./`A%U%!$WK644GAQ<!975)59%1MF;E55$PVP&=984(E5UEAIO4&7
M6W"QV<!;;W"`E)8S(<9784[R-2AAAT6I:)2&:<899!LD05EE9ES6J&:./MH8
M"QO`P)EI4Z3VF6JME6HJ#!C`@$)MJ>J&&PS$#;>;;T;,@9NMM1ZGG')_*(``
M(?YXE]VPQ&8G17S%)MN'@^OU\<NP!=!GWQV@@%"*@`"N<&`O=$C7GGW_X,XB
M1QD/#&A*-^"@X)XN$DZHAAKEF(.$#RN@"^(W'][K33XI-%%%BC&H6(!!#"GT
MHD,/V=A1CSU*E%$!/?[X$4(BK=2E!V*`)!*62Q(%)9-,V@5FE5?^9&1.,UU\
MI4XX;3Q4!%G$9555-$^%9E9K8N5F5UV]&6=<<]9YYPUP*=``&TW8V19,)NDE
MTUZ')69H9H3^-=BA@5F-:**+<F:3I)16ZD9FC#U*&@RAJ:;VVJ>6RL+;JF:Q
M*@PLN!KK;[D.AW?>$NRJW!56_#J(#G0TJ^SAB),G;.*'DX#L=`4T,\VSB^`A
M.;BR4+!N+W=8,5V!F!,S``WM^``%ME2`!@X,_Y?+4H</6M0!S83H:+'"!OKJ
M^^&(O'MPPP7`7V``Q`?9P1","SG$L,0STBA#CA-)'!+%/*ELI$,K&8F3DTW&
M!&64&'^S$UX^89QE24P7I;+)*:',P11G:34SFC3C/+.>7;49%E@_DR66T$/+
M4UB6L(,L="]0?DF48J+6*,%PK2:(\8NAG#:8"CXP2I!*`M@T8)DD\`6#C^*4
M:!KC!!*$:FUJ&TW;Z&8$T6!@54=@H:M^LS?=\,96N,J5WY1CAQ$4XE<-&`_C
MAJ@L[!#Q<(NCSG^FD:!&Z"=TNJ#"'9Q!A21>(@)/A"*"[J`%>2%A"U`H!A50
M8!=O6.$'Q0C0Z6;1+O]TP`$%]A+#B'*'C]Q%0`'`2P#Q#A(C@R',1\P#@/.@
MMT>0\%%(0^I2QH+2DXQUC"@%>!+(HC2^+Y6,04)"WU"8=A1Y*&4D&4@!!VXP
M%OE=)4VHS%_/J-*SN/SL30JXP:.<,(7':.J6Z=/+HG;)RUY"T)>*(@P%M4:U
M145J,ARTS`P26!.T]84%I4&A:K)``FJ:1H5NJYL11@/#&MI0;[K)86[F8)PY
M[%`Y)$"`"7Z(AF,=\9W6,2(\B<6=ZF"1"MC:!7R<N"W[5".?/S"<=*2P.7"M
M@0)?0,<YTJ&$7@P`"FN@`PE28(4S"BA"=9`=+7[`A#"8(PQDM`).S("3DH;_
MZ*3@F*.'YA$.$8C``"P"21^1%\A`-NQA!@$2C%222$7R%&,@01E@#FB3*-T$
M+Q@#DTFT-R3U$8E]5`*E*,=DOU.6B7[U:Q-5\+<SKWPE+%!Q0C>(5)2R;E*7
M(+RE6B$#S+8"4S'"U*#6+GA,RG!0`QF801(PXY<D^.53I%%;%@9;S<%2DYJE
M0L%KWK9-UL`05G8#YV]P=<-<&:<XNCKG%7B@`T*XH!`A:(`F0##/TE;"08\S
MK71*D=I)1.!;X**"0*7P`WR&2W/3H)9UI(6Y-:`!%K1#0@W4L`N,RN$+7)`"
M"D#7BS+(:PM?"((41D,"Q6YH*22E4F7`!"+>Y2X%_R]]WH^09SP['(EY")N1
M178T,(GM-),7*TI+$*D]]$GROAY[DLB$(@\&90"^*BM95''2`I21,BZGQ!DK
M;U:S!+,I?VH":\_>]`;R?2,O3[O4+1W#82>4T,,?7NMFUHHI$6\&4XR"H*`&
MQ:A(26H&=ZW49*S@5PWZ=0.;\=3:"&O8P2I6-C]&%6M$L\T7L@HW40!.9+VI
MF\OV[9S)\14AUOE9!-"AM:K-<CVS;!WN>.X[!4VC,A1GC7RVPI_]J<X2`?3$
M`;01"6H(XQZ@$"\DO&"-:920%U\@!=!@S;^>Y-U(1C12.N8UKQYP@@V(YZ*#
M-#J]-55OCFRP(XX`*4B@#/]P4H74AI-M\H"%,JH'SL<@*_V7U.L3W\FHY(%1
MEK(J6KF*GE"98*VN24VJU-]7W\"@IIW54(J:I1.R,`5B#ZTM;$'V6J;`[%IR
MP)8FCC:)O=;BPB@P4E9`IAF2*>/)Z/7&@A$-"GLLMQ\'63:M295O:A-#)'^3
M-_"^E;R-XV3<0#DY$?A5(71`9030`,M<+NV6`SZ=4@AT$@3%'($DD8DI$N.?
M`-HG=4C@</M007(1T@(2-.HZ#%4HGWOP07!?`!I-`]K0*,^)$V(*I(,8<D:1
MOJD-9OZ\]DZ,ISTU"DQ2TC*7_!ID'OO>3:IW\E,WU2CE^Y*GA^(4F6%59U8]
M4\W_LO+@64==JUY5P%CM^[2TDC`+QPZ[V)M=;%H2FY9H;W;::5G+6G9XPUZ#
M@8JIUE<;>QO&R;R[!FD,;DYQH#73E)O<CE!=V1SAA;Y)-PP/C^0D*YDXWJ0W
M9HUS;^38H0&#,(1G76"!!E".X%R.P`H.#OK37MD2\\'<':SH"#IPX0ZP1T86
MLU6=V0^(#OMY:#1B,0"13^CC`WISAB;*DKNLK+_&_P:'4'Z/&90D`@/+J4TW
M8E/GS9SF`VN12HA.5IA0220NV9CW9`+J[H$OTTOA;U"TU,E2@W)[G*'JT6"M
MLUC;+)5;S3\JLZZ^0`7[V<.6;&)'-&]!@':B%DI3@,?&_Q8,>"?)!G9TP8#,
M1FS,%EBWA&*"87<P9E?;UFW?9F-R%1J=8BJGD06J4GBVH2JIPAJ)MW@84#=1
MX'BRPF3RAAN2]V25EV_JI`/\]EF<AP`K4'H!5PI"R`G;P1VV``D%`%O%@!\`
M)Q]T<'&O<`=1"$7=4G"M8PQ9Z`QO!GS.``6^ER$+4'+MEW3])0\<LGPI9Q)I
M`#&`)$B"M!$VXB,<P1$680,&@'V,MGV:MG..9"0`(%3C-XC>TR1))6#?\%-/
MU4@EI12M=F!8P0:QQC-E,C-698E916M8UR9.$$IH53;/!H$#.(`(6">FJ!:C
MF(JJV!:$=4*DP0&$`8)WIP&4<?]WW@:"->87<%,JJU%=JD(;++B"J+)XMQ&#
M,OAN>8,KMG*#F75O=M!9^[9YG]4`3UB$B,-ZUNA:E0-P4L!;LC``=Y"$DK`"
M!05R#X>-I!!F]X%&4!0A[M)/O;`'7_!13'`LG(1T`E9T`M9\*8<7*?`\"U.'
M#9-]$3.0DV8`"+EH>Z2(\>5]CJ0D/T>(DR0EZ)<4\.54@/9^/+$!4U!*IB2)
M.;,S5($F6,5*:F)KM.8F37`#9_5_`&ALI'B*,FF`1".3,YF`=&&3.GF*06`G
M/7DGA&4:?U=WLNAMM&B+MXB+-A8:0P9XO\B"I9(J6<!N+V@$QGB,L6*#=B-Y
MYE1YR*'_`/W6@S[H`CB0C?/D3F8Y'5)`>JA06Q?W`VA9">RH19Q3C9`@!>:X
M!\=`EU`@!W409_E$!3^0'W00!#DP!;`H$^MS$C_A)1R2+R@W%&U8$92I$7;H
M,#)@`PF0`'EX$3ZB$@$F$_\5?H'X:^4'=-_C`6V0)1?F#0S)F`.62:)$-&'Q
MD0$3DI2(B95HDE:GB6S":X&15L-&%V-P)Z8X)\B)%C>YD\QYBG12-,AY%F8A
MDT%P`T$`=M9$&ISB8D6Y@4BI=TKI8J$A&BN46%39>#$(>9%5;\SHE<B1;Y]E
M`M#(>9_%!D^8"361EJLU</JY"?(4">$1EY9`!W1Y'Y_GGW/I_PP05Z#PV`L_
M\`-!$`0G=!A.X@%6L)BPV2!TQ%V;U(8UMU[L19D8@8>;R9F4U@>K63%]Z'TN
MH22>"'3D]S&B!DI#\GV.>(\#U@)9`A/O$S^W^:,@&3!>(:266)*[&76ZR4I:
M]S*@:'9#4YQUXC^N!%94*B?/V9Q8^@8[D)Q<VJ7*F18[\`;5>0-!^7?;J93?
MF:9*"8+C*1IN6C?DZ8(L<)56&5F8E1N2%P62YYX'8`<70&4\.):?=84`J@D%
MD`DDP):)$Q%]$!&9@`?=`:F*JCC]:4_HZ`BC1PG@40`)2I<!11VV)SK>6*"Q
M):%L)345:G)(X27]^`U,D@8Z<A'71_]IL2JK)'H!FPE3!:`QW-<E3$,EAO1(
M]V43$UD3/8$D*W,]2/4G8M`"F18!\(-'9,(5IE1_7F5_1MI@^J>)#;"D^L49
M'E9+-^`$-U"<8Q"E9;$_0[JN$]8_TYFESNFE\CJO"A"F8EJ=UL0!G+*FDO)B
M:3H9_<JO20`/+80;<$,"1Y`%OW&56&FG[F8<>MJ,E4<"5":?GF4!A8".JX`*
MW<%ZW>$XT*=F'0L>RU(`5G"HDEH)-4%:E:J6=OF?MW`LW(%[I#H`ERH)T6)0
MH4JJ5+0"4]`DBP$8FZ2J?V)A+'5H2`L.'3JK>(B0>4ASE#:K!K"9>90`BW8]
MO7H4HJDDI3G_5).D7S:!,9V6=.L'FSR7$S@FG6!!I/(3I+4I,V0RDF8R,U+A
M)MRZ%7[R)+-T=F!7G#6)G.KJ58*[KE4:-/!Z%M))KW`"-.[JKF5AKV)*IHBU
MK[*H@4;YKP*+BZ^B*C$TI\;H;G;SN1*0GJ-;'#'(IP?0`CK@@YU%92Z@`I,@
MCJJP`JD@>LURJ"3@"9-ZEP+J6I[PA)#:LM01A)4``KDK"7&)1>H((`=Z1167
M6\O+LP8"H3\+:D*K241;M!GPF/I@#][K?)G1M$[+F2[EM'EHO@8@`L&#JS;0
M!U@;FD,+5.('H_D%MBG0!H?H$SB'%"TC$C#1=!<0%4.*%=7*%7`+_V'<*A7_
M\`]W2Q5YFRE9X&$1#*6)BYS\PS]?)6&U2:7\`S2&:Y-HH9R*N[A="E:NQ+C(
M::_7.;G<&;`:=+F72XM'>8L?J$%1H$$MU!KH6:>?VWA6F61`K*=7B;H'T`2>
M)9]CV03("W!6`![\R;&I9;*&@Y\%YPD=>W"/*KP#]665T+N,(*#;P5RA0P%V
M>0O/*SJ"F9>D2@75"1F%DC+8JVD_D3MN4,?VT!,7NAAC(`(EVL>;6;XO-;4)
ML+[L.VH`UI!,HSW"BE]&I2CRU0U3\E-0M:.C-";LRC/V5Q53NL%R.W\FR0:%
M4)]2T5F_@@!F`IR9`F)90,$A/"=Q\DHE?/_"K^S!R0G"<%'!(]P_K_3*/N,S
M9!&F$4I8=-/"1>FOLPC#WVG#&O0VVJ0!0?S#Z<FPT?S#&B`!U4S$*>"Z\^D"
M3]!:Q*NR`%<`*V`*B[`=*S#.07#.TK6[FR`%XPQ]F;`":ZG%FP`"7BP)LKL(
M01`)M`4+H:-;2D0'YR&%`W!0#XI/`W!Q:MQ;>!`$;OS&9861&)8^&4I'=NP&
M'H#1;F`%']0D3J"^@TS(55NBP1,#P&/2-F#((Z$R_=<DWP<`$>FU-9$&AC@4
M%[9])O-38B("<0$6`<PSU)I5.N/3&=Q@V3H5*0#*".`/;<(&OP+*6*4`+P.N
MC^$$8W"N<,'3/"W_I1]LBC49KR/<G&8QPH"+PKR\R;#TG"N\&F^S`4:0N4@Y
MPS(LP\@T`S%H8]"<!-*\U\X<!7UME<[LS$1L!TU0L6*)`/M,'F7LGU:\V&HY
M'JS%SO3,SXQ]EP@GQ@IZL\@+"Z\@18/)V;#W`W1PQCQ+O7NQ)1BF<]?+F(A8
M#SWA!AE0QW6<`FY`VV!;$S]P`0$3,+J]V[S]V[L-,$XP:L@:FC&15,)*5,5:
MTSNW%!7S)3K*$Q'0=-*ZMC$0%4"=FYJ\RW'KR48J%0I`RBZ`)@IP""$`U5O!
M)%1-KEB=U5V:%F,0P286KN6:DV!=%M*9I2&<W[G,U6=MPNX*S+;!UB*4_P1O
MC8LW;,PP%@5QO8&TJ-=Z'8-]'>%]K0$6;N%^G>$2GN&"C;I_0+'T*9:B]<XA
MZRR3#0D1D-@GGAUX(-F,T+Q]<+,.LH74`..6\""B,PP$<@>OM]`&M0(W8+TL
MS26KC8^MZ=I"H='^IRAIH`#_$C#_$N52_B\G$A`Q8`-8FW.J+4G(_3+#&A.1
M-*S,?5197B5!T11C,!8^'15LCLF^+3^,^U4(?'_?K0"<1P`60-YL8`$8ZP(Z
M,!7#[2A53<'0&9UC\!C$&G2@"(#,%D"'>\N0?KADS=TF_,O!;()TP\QO8^"<
MCHL?R."VN.$/?L-V?96!W=?&>.$8?NH<3L0'P/]9/BB?ZU0"US&R*ZXX+G[K
M**[97TQZ]^P(W<AFN=YZH;.@TBL+$,H!3B716ELH76*&B`AH%HH^M>U!.!9,
M3A`0`-$/W.X/WAX"/.CM.D`$3K":/K>BABA5;RRC86M?*5$Q/,44KJ;FTGK=
MF"S`=9M@Z3JE<DN2<]L`(L!Y%D``",`&"K#G?&X!ILR2H@2`A'X66FT65_W0
M$%V(7D?5`FB<CXZ`;3&F'2^F("_67JK+8P',<O,:K?&FVH0;"&[#H+[@WAGA
M=KV!'"[J@5WSIX[AKE[$ZX2QT$CKNFX)M!OT2E3&^>D(5.Q:G4H,$F>$!*JS
M/EZJ/XN1BLEU,L'1%!W_8/QU21UB]7J+8C7Q!OU`RJ5<R@%0RB&PU$L]`FGP
MONA>%"M=\>-GK)IT/<[*5#DQW8D;P%#QT])*K6ZN,_M>FU?ER;L9\'Q.`.-]
M\`F/L5JGM\]VU3(I\8@N]]QS*8O.Z,WFZ,V9BADO=A[?DW42IEX*S$%0&[.!
M\BG/S`7+\B!XP[`?X<9HU[28X;1_\ZO.X;F_ZCN?`9NWU"[0`$1?"=\\_/Y9
MQMO!SY>*1;'EV)BP]+Q`(-$+15*T`D%0TQ/]QMF[JDG7VDH[%(;!5HYLQ(1P
M]@AP]H)J_N9/[N:NY<V>[H]DO8S</?AK$D$B$D+R)-0MK6T."`HQ38,QA82%
M_PTQ#0J-C@I-%PV3;)26DY@B+A8$!`AL(PT6G!8N'AX1'!Q.-V-OKV\B"J]C
M'"FWN+FZN[PI&Q&_$<*IJL5.QU-3-\LWL+#,S,G)3E/'QZO%V:K5W,DWRM#-
MKSMOY#OF;T%!1^Q'*"@P&##S]/5&+$;Y^OE)_%%)__I%B:*!H$&#&A(23%BP
M(<.%!R)*G$A1XI\&)EQHU(%`2($^($.*'$FRI,F3*%.BC"!%I<N7,&/"E/+1
MI3"3+%'^6+.GI\^?:UK&!"'ESL^C`^[P/,JTZ<\?5.X$`=:KUZFK6+-JU9KA
M5->O8#.([>K!UX9@PE)P:!``00"-<./*=0'&B1@>//_(;CV5HFR*"'W%^M4%
MF/#?OECQXA730LPM#C=D-;J@X`+E&((R8]Y<:-$BRHW>/&I$")-ITXLTC2+@
M@LVG4:,4E%7E9(RK5R)@.0%<-FO5WX5Q`1M&G$.J"&F,40L';5J6:]JR'3=.
M++HV)UFD,0^2[I6Z=N#9O<,@CWR\\O;VJ=\G<.#`A@L5,IP?GV#%^Q4C9!R%
M0(<.H3(%*."`-`UHX($'`JB2%%:81$($)Q7EU$]TR%04%`,,P-0`/Q@UX8<^
MK>'A&C\\^%LN>Z6H8E9DA>7!6()=15@3333`1@@!E.)"CA9,T*,+$]`U108\
MB"'&BH,)(V-5@#7Y%V]DW87_UUBIW/`(99<)0HAFG756&F9OC'&#$]0-8\PJ
MKSA"2(T*(,`):ZZQ`5L#LZW2BC-OW,"!BB?V>=@M@*%%G)G9(",-=-8-JNBB
MBD9'PJ-39`?.,NI\UTX0.>30#@:;LD,>IY^&*L]ZZT5AA*GNI>I>0:G"EQ!^
ML$9DAPX:E<+1"@CFJJM("N[JZZ]]](I2`7A(`6%(PN!QK$D>?DA'32I%@,<#
M=0C@@QQ0'"6BADX-L%2W)'X[`!7&;J"+5K<@J2Z+7,'XHE@S9&#%6/-Z906@
M)*A#(XYP^1C"%'<!<"22PKTX6"[!W5(`H+>T(9:41<[FBF235:;9Q9O1>(@A
M32C@_T2ZZ/9F!5_"<9"%:&VNUMIK%B!P2W*0V?;*F(A]Y=62?O82Z)\)F\LH
MH=K\++29TPE3IM'9D,`!I)%&FL4-EK:3PPJ9'E$U>&=HVH&F9W0MZM>?SI&/
M!/I(8*K9JJ8J`7SNQ1KK#PC4VA\.P-9MH=UX)RAL2E8H"U(!*TA!0DH_<-LM
M'BDE2P<=7U0K@`!(J&'X'B)^J^T/=%C>$[<D3MX3B5.9BQA6(Z]K.KL&QXB5
M8#;;?+/!5T40A!!O61``P(NMV!>@O!W,2V%I1>"!&&(IYE@$3J19<9:;:5F(
M\UUV_$8*Q..\RV!^R;@!!PJP54H(K8WR!BJKU.9*+8&E#O\[R3F?",PO##LI
MNB]/_A*,H$,3;731VT<`0RJ_X``,C+,T53R*`U,@0186F(4CK$-JF:+:"JBV
M@!PPP8(8S!03-HC!K9VA`Q\$&P;F,(<1BDUL$B!;"HU@MA9&H84I;*';8,4#
MCM1*!T185MYV*!)B\?"'*BF`L024DSY808<GP8/FCD(%)(HD`BN@PAJ6`@4D
M/`X)2&!`MH!R!RILJ'`<:M8>J$"'.W!HB3X9E[%&5SH9]>:-IU.1ZZZB.@^X
MP0-6<(,;VGBN)94E`CMH`!A^D`$`\,!AZ`*97]+"/B8=!C!&"ACQD(<;68`&
M2Y!HWF8NL*6,/8]Z,6I?NG"AO9/_34('<J*36E8A)O2Y:RNB[--9_G*_)L'/
M2;9\W_ONA[_I$-`Z2M/&``5HP$<9TY@,;.`ZU)&IJ>5@!\]<01@60,UJ4I,)
MT\QF-K&YP6Z&H0/@!&<(157"<I)P#A)`)SICR$X)S!`_=H@!`N+F@D\X$8AV
MDP+B\,G/'@Z10%((Z!1P$M"`%FY"28'62*2PDZ-4$8M8_,`6?\(A*F3(6^,"
M8QBI0($[H*$.9:B#&3^4%!*8RXU^#%D<N9(Z%UW%#;@8F2CY$H0Q>&`Q>F$?
MSACI.\,TB3=MD%)7(G`;BBU/$);II/.<AX@F3,](>HFE(G>W2"LU00>V2(7Y
M=L.ZO4@5_Q>BFR6@SB*,L_0R?T*S3@$/&,QCNO6M;DUFI8(PP0E"<P=,P.L.
MIFG-OE:3K]3,Y@+"0%C"8I.PX4QL8D=(GG*:\)R01><[\:,?&UI`![CJI]VD
M=4_-\C`"@\M59R.PDREFZ$-KV.=(I&51ID"A#A"-G.<V1X4?=+2C4+D#!=;@
M+=Y"H0Q7Y,-$N_6#X&!E=REHXTI9.L><^L9WYIIE=/LTO"(YEV3'/4PCW=<7
M*:'B3K%0@"4MAIDL7282'7O>\\9GW4;>ZZLZRVKY;/'*1$K5K/@=#EEO<4O[
MV4^_:`4FI!;('`*'@\!!>!H#$\S@N=+U'.=8P%XE#-C!6KB:2__(\`*68$TX
M^-6:@C7L80O;`28H=K$=F$.*'SN'R5;D"CP8@7\V@8`F>+9N1;QQ/_<V(&$H
M*`*M!='GA!6!S'7KH4AX`89F^SG>[H%#&1*14I[L.,A]0`U"I@(*>D=5."Z7
M7:W372[,ZHOA#(/,]$-160I9O>QV63B(Z9.3"N!=HCK#$9<DKR,&@=Y!<)*3
MF'$J]08&7UV\-Z:["&`$ZANR]N6WS/]%JZ3WIPT%.FU24,MT=[B#CDY#^--!
M^/2G/^Q7OE:XPTO@JX>IN6HXA,'5"_"PJPM+ZUI_LP.W/K%B6^SBBCC!!`C(
MB`LJI&-?Y;C8/_RG:.E`A=H6-(I/AH+_M%$+("OHDP)"AH(:I,UDIY"HM>$:
M@`]B>^5N/\6D;[Z*<K]\LS!?5WN0QM_1]*OFU0W,S:-CV'9W$1SA%2D%M8&%
M",9K,=#,0DT82R\D*!,!XB6WT!`7LY_,:N9)6YS2UO$&-+J#IQTHP..C\?@2
M'#%RDBM@Y$O80<HWG.&6D]K4%A8L'#2\A%8/UM6P?O7-/1R&$=OZY[<FL6)[
M79$:<J3&G45V@*2E]&3SF(@_H*U2>#L`.0A`"W48+E**J\\..5G(3S9WM[KX
MN8Z.&Z+E1NB0>^=E=C-7?5Y%F+Q5,:CIDG)=:KY[3W\'&(%1DA:Y.6J8LF"<
MOZ!)%@I';R3>_["GO4/\JVUW-*1U:7$"4IH8U8D.F4C0M"P$01SC*,<Y&E'R
MDY\<Y:9O^>E;SOK6<QC#&RYUS`.+89U/D^>L5O7-4XU8H`,=U[BV-3B)3A$[
M-*$2.%!HTP^$!^4OWU=^@[X8?V+U*RIY0E'Y.MBWGT;MBRB-`WA`;+,^VPQ!
M`5L:N@.ZC]N;T;D==G-D/W_-@I9?%H,X\^.3?4<Y53]%```9P`$R<QNQ8'",
MAUQYQP$H8X`W$$MBA6:/!U;G@H"]0'%D-31E8G]JM8%+XP2<IW%0$WJC-QJI
M-W(TLGI-L`0IF(*NYWJQIV$O!V*S)X-AD&JTITV#57-E,%C@Y'O!1_]K/1A\
MP'=KQ#<1+8`"RO9\"')L2J@KH`4LTY=&L`4Y2)!V3;$M(%)U=8`M/G%^=2`Y
MW78'=P`5/4%V%`4%6N`#9;!D&^(X/K!D=%`8[X<D[^8;8%5_B5)6?U(SZX-'
MBK1=V+5OAD$]'B"`82)PDI$;:1!G3Y(P)4-X=,<+^#5+NA1I8^6($3AQ959Q
MC**!'&@=UL`-SR$-D\(=G$8.C0!R*(=R'=-Z+-B"L!A[I/97M$A8%X:#A15S
MVE18<-"+B!5.M1:$WR1TNI9812@11N!\36@@T;>,HI5T1#12K@5;:*<$YD:&
M"`4%5U1N`^`X2+`%6N<32C$`%,`%8HA07\#_!4Y1?9`#CI2#`B=U.G7H=@@#
M-$&#?W_H.HSH?K[#%S)2`)B8"T=BB+00"^'E,515CVEQ/7<871?X4Y4(8&=&
M9N^3B?@U9ORU2Q17'$CSB==@#:%(#:)(BM\`#972'9_V<2!7@AEV>JNW>K'(
M8:]G33-YBS,88KZ7DSIG8HF5:R?VB\5HC,=X`#,`C<X($TQXE"\14,ABE$LG
MC10E![&E9.;6.1."AH\#.5JD!EF)19+3%%.6%.+";3\A1>M(;DK0$R6B=W0X
MA_:%A]$Q#+SP.H+(CW-9EPSC&`$G`D6%,K4@B'6G7Y%V<6A%5O9#?_.3,XDI
M5O1#%6FU@88B#9*"_VDER1S;`36?=Y*B)VH>UYD*@`,L"8LN)Y.S>(.S!W-`
MYW,]MYJT%FN_J&)!&9M!.90'T`*AI90)@ILQP1(!]1%)N"LDX$73B$4^\)4?
M$A57:440I453&%'&R43"25&-4P9<^&13UA12"5$UD):4LT9N28\9V9'2<68)
MTVY^:!7X]H=[N`M=$7"P4%1\N8^$@7F31G>$*33_]2=AE9B_<9&/A('7@1V1
M<@-/8YD&>J"9EID*6BF8.0Z<^:#GD'(K1TTU69HA=IJ[2&N'-6(;I%@;9(L]
MEV(B*IOAI&(F*J(DE&*\=HQV<)NZ*2!"]*(VT1(L$8<C86V_:2%H%&W3)O]D
M%>444'!V6`2.:A!;LN4Y5GF&5M2.V0)E3!:D$+5M&C(`@L./=D@P=V>E*0)6
MXGE_Q-%'^HAH\\=VUM-=?_0[I\`*M"`S`\=X9-%'O/.)GDAW]CDH=)IY\T:>
M%>F0@ED5_)E?9]6EQB`IRT"9")HG>=(,EOEYF99,CMI`#.1`<[4#*T"IHE:I
M$F:A@\6:J_FA',JIA<5-P!>;(Z:B*7IBIUJBD(6B)DI"M-FB,FH@.1JK"S4,
M#8(L#"6&JK5T44=2W)>D2$&-52@Y4(I%+V"-3-%0P7I%5<B='!6=:R!%&2('
M=>`#Y+<Y=X`')/"'C29_!Q-',L5?`92'5*%W89K_:#P%2WW1!AZP,)@X/,E#
M@'BR:&\*IX8GIQQX>7)Z'$(3;XWI7XQ)9C[C,YR(<84BH`BZ<7BRL`R;F8X*
M5X_RJ)':0.'!#IK23!A[01P4!ABDL1RDL5O3<R8VLB5&LB/+D[JVH>"4HK#9
MLBJZLJ9JJI'EJD-IF[1*1$]WLT(44/L$.%#!+7=@($$0G=QWG`<UC6D(AGOP
M6DA`?IXS`'30%-U(;EBV.0U%CF/H10,@;6R81A2P`L:5;VZ$@&UW.A0HJ')9
M;W`WEV5F''%GIE4A!H8X!KEA&Z[@!,-3KQ,(*/B:K[^$IY^H/_@(L--UF&:A
MD>(J*)8'BMEQJ`S[N(_[_WD+%"G&M%8%M#1P!0,DH+G&]`Z>ZPY'P"FAFP-G
M8#47BP$YT`%'\$$?E+JJ"TZI&[NP.[OAA+(I^YKG-*(G"ILR.[,S.Y1Q@`(W
M*R!$X90R"@(@D1,%$+4_$;0$0K1%2UP[&G:&<U&GA13(N2'9::S(BJU9^V1'
M2[W7BZTH`#+R^:VDU&6F<VB->(_\"6;V"E9NNZ4>P*Z/))!V]IYA,@9ID`%M
MUE-+DGEDXK=]6\!>BG\`1DN5>%:4N)&"6CX%FK"(RK`')QH6C`[>0:#9X5:J
M,$`>+$#^(T`>7`\D7,+F(4(H_#4=\"FSBP$@1*+8I*HLRZJKZKLVO*+$-P,#
M-?^\`1*C/+P2@K,"3.2BNQF%T<L47`"]1VRU1MP33(L$Q3F^(=);UQEMUOJ<
MX+NM^88BZ:NV[*=_X7F/Z\F'H91WA&$+W5J_J,"0R7.(YS,&#5<]X=I'BU0=
M`YPHBRNGB$(F=XS'BN*0A@D_@?JEO`.XM-&X!PJY%DR"HV'!&;P,V9$%QV1`
M=/<_'SQ`V[,!\\`"],#),,#)GES"\5`/*2PJ*^S"Y+'"+XS*JNS"NQ99*\NR
MK7K#OCN4POO#`5)0QANK`"D%1#LNS?<2TO(#Q-S$2UR&QERT9_0ATB8'2OM%
M7<0%W#8`7'E%6`S,HH.7[K=NSP5+[Q4,8DS'Y_I&.J/_GMAEO^Z*"QD0KP5I
M&PW757NW)..Z@4CC2YH'DM4PP'R,KXQ22XJ;IW6WB0),)@9FF3.SL`?'R`J]
ML(S*0'!%3)<LPIT,RBQ0T15]#_B`#_=`*AR]#QA@!*7,PHRE6"[LN[T[R[0,
M6;:\R[B\6@7U("T]$BO@.52P`K>:$@QU4<=,.<W6TSU-S--;M%$A=N)[A5IK
M=5BG!E56A7*@?6-D(M051^K+I>*YD&I;QO*9,]_*%^69`N?CQGI"/#F%GDE"
M&]AP?W,:H,B`'=1``OI\UGU,K@!ZP#\SF,;@UL_AN`BMT'SM".0`"PV=3`]=
M0!$-`YK,`AM@T8K=T8R]#V)C_P0G-$*034*,Y5@EE,JJG-*:;</I5+-;%M,]
MQIN:!9"\*3@*I8P])!)68,0D`B$D@-H@H40[33G,-D6VO2U)H<1+/-1-%KW?
MM]0?H)P1!0$3I`YE=`=5ZB=PQ*T2IVA>^KY>(1A9FFBTQ)]DS3"W(`8!=QNV
M@;?P',\[=29]S*_7@0W6,)F(8M9GO:^+(M?487E_7!R'S`H1;-`4_`@HT]>-
M''KIP`P2*\G'I+FB3-$5G=@;8`3]T`^,;2KZP.`=?4*0/=GG5-F0Q6*TG$Z1
MQ4[K!+QF@(2@+:LYZROZA`?%+$5K0`$_H"PL\0,\QA+[%`%"I-N4P^(ICA*^
M/-M)L?];D\,M%474/EI;WD+,RKP3XL:L'Q#<:"<'Q*P.4\#DZ'8BW8PDI8-<
MX.RE=+P^HA.NHA/?P"$\I["0#1<!S?#&MC$Z8WT].V7'ZTVG:DT-(IG/^VS`
M]VBG<5DTGCC7:VVH"JO(^:W?)/C7WJ$.":I@#QO@]:#)GVS1",X""<X>")X/
M_W`J::,JIU(V+!3A^;#9-YQ.Z13AZL3I*83#Q&<'+6`%'O[A2P>V.Q0!9B3%
MF^,M7,!;Q442>*`47*!/8AB^&\);=Y!TLCW;>V".'2*UYPCLM*T4=.#C/I&]
M0CJL$!7%WB(5*/`HY?H;*+528]:15LW<73'=@SPH>]@DBTC_,KUCMVX\!GAK
MI=G.EG$Z7]<`,^4=BJ18#68=UW%-SWG<@77.YG+=WAWX'(B<L(JZ#+#`UQWS
M"`=/@N4`"SM@B@XFL89.PHI]X(^NX.HQZ:N"\:A2Z2LT-BRD0I<.\N@$V:%.
M-I_>3NQ$FP<0!RU@!BP0XJAN$@5E+##^*U*@[)L3S"%!`AXBED)-Q'U`VD9F
M[&.4[$PFACA/4CRAK&`'M;PEK$A0`])6!U^HTY3C:@+0`3"`YG?'S?I7IO-,
M'5=M,%P<GE4];SR#'..."G)H9U_MSHHTQ[RC=\*AYG%^S]UP*""9WFKU,^\M
MYX$+T!UY#`$O\,R@/`K=,8I/&@K=_YG\O6ES!?&/(LJ)3O$*?OD(/A!)4!";
MCQ#TP2ILXQYH\T(OA/(H'_*FKT(IK_(K7^HP'_,F<40\&SC&`MLJ806Z+F1K
M\"PA(05!#2)!L5HK((9<P/08%;T9%=2U95O2&JT40`%2Q&S;Q_1-#Q5/#.W6
M2WU=J05:3+:1A^U)DGEARU)J*]!G$I=/\A=IL(AM`&<>P,[[B^[ZAF]IF^;*
M\9'JS<>1.0T>"`A.@AQ.A!R'A8>*$8R-CAP1B(F*E)66AR0<F8N.CXI.)()3
MHS>C4Z6C6:<W-T%OKV\*LK.T"DVSM[6Z.V\[OCNNP4'#04=91\8H62@PS<XP
M+"Q&TD9&2?_5U5%&VE'=25$:W>#@X1KEY.,:$N;LXU$2[]WP$O3O].KJZ_KA
M%?W^_P`#_OMCIT4$*7T2*ES(L*'#AQ`C2IQ(T6$C*1@Q1JC8)P(>/'<&[!E)
MLJ3)/6M^;.PC9<W)ES#WW)%20*$5/")EWJ%RAP*%.S]<QCSY@TK.H0/6K.'Y
MDXK2.W?61!U*,BC5DP.@0H$B!\I1K&4$B$6"I$>$%"FLI/#`UHH'MVWCLIT+
M=RY=#VA3-%*4YNQ:NX#QY@TL>*^A27T=I4DS5V^*`A&<3!DD:`PD1G_=JLV+
M&:U=M(\*(8XD293I1)0-(4ISJ._E3ITNO99]:8JA38=@P[XDJ+?_)56K6L%Z
MI:NX<5D[D/=:'H07L>?'4"1#0:(ZB68LH$7;OL%:DFO?OD?Y%F6&^?,SRI?7
MD#Y<MW/BQ+F/3[^^?2#X\^O?S[\_!94<!2C@@`02Z-%*$H&`$$L4?'552G30
M8=550]T1X0ITK/`#25(Y-8!(/`GUX!T4EI@2A1.66)5+'SI8T@!D"4#6!V7@
MT44!..:HXXX\[MA'33K^^".00A)99($4M=&'DFV`D)"338+0Y)12MF'EE$M6
M>>66;0#`)0!>7NDEF&26:>:9:*:IYIIF\@"`FW"^*6></-1)9YUOTBDGFWR"
MV>6?@'(IJ*!+;KGDH7UXD)"2BBY44T)$_T9:9(^45HKCC9@6D.FFFG;AZ:>@
MABJJJ'Z4:NJIJ*:J*GX_+(CDJ[#&2A%&%#&2D$<B4MBBBKHFY:))4A7U:TE4
M4,'K5<+&1,4/)!X[TDYKY#2`4R8-@$899)'E`QPV=JKIMYZ"FV,7?9!KJ8]'
M/@JID`H922`(\,8K[[STRAMEO?$"T`<(`/#K;[]@\ENFP/_V:?#!>^X99YME
M+NPFF6[^`3&8#S>,,)L"`_POO_LZ"6_'("_D\;Y(XCBIC^2F7*ZXF(K::<NC
MQBSSS)^J:O/-J+**H*P\]QPK1NH^Y&H?5A3E[-%(GR05!=%*%=574@U[=%84
M\$3M'B(-$)345/\Q]=-_4N!A5-842`%'MDB4\8,-GJY\HXYO7SKDMS7=6&ZZ
M0QXYJ:/LOHKOWW]3V62_&]^K\>&(`WSQX@A7/''%#L\IL<01STGQY8RGF3'!
M&OLK);SW`BYO19+B3:2Y.[[M=MUT;\IIN#3''C/.M-\,Q'\[^ZS[[J0/W9`4
M)/S.==+$4S43'@N&/=5(/PSOK*_+*E7U\L2WN`8>M^+!;-E.,J&%`&'08>/;
M<6=ZJ:8_HBZWR3ZR'ZFD[#,4-$>BUP_Z_9][?OC&`?>_O_^9"^#E((>Y`5J,
M<@!`H`(GEC`!DHES_-O8YT)G/R=%Q$CP`U+=BE2^(96/92T#E^Q&2+/_VIE0
M5;AKR$%XQ\(6LF1^"EFA"HU2O!KR:@VYZX@4C"637-GP1<Q:R@I\2+SK,<16
M'9'01PP`.W'![8FMF]L&-9BCO)4N:.X:4`7M%R4JY8]P_^.<XA27,0>:L8&6
M>YS"+K=`S#G.<0(LV/X\E[\ZVH\B\$L7%=W'.O*-BV4O>QT)!^FI$QK25+?#
M0P0LV!%F^<Z%D'P5"7+8$>P)C8@_S&1)UO#(A&BO54%HGB9AHK60..]!EG2(
M]FPPOB:VCF[@LB+K[L;'O>4QC^W2XA8!UT7\13",B-L<`,_8N`*B44]QHMSD
MY"0QRST,C@XLXR\]Y\5=7C"7&;3BW<RG/C\*_U*$+B/D"`])SD1&`#)2*(I/
M.AG)=G+$(QI9"$T@$@%1CO*>(UD#'=B)H`@T"Y\O6AH/D::UH$F!$6'[`?(^
M!<BXG>^)F5H9+4VF/FWB$H9]J\@NN6A'>('1HP6#(!F)2<QG&M.-*%7@PA(&
MS3B.E(Z$NQ\%18=';-JRBGQTHC<;VD1QBI.<Y:3`)W="`59-P9U()9`5#O*1
M>$:D)0#5Y`"$>M1981*?2:%#]7[@*`NM0'M-E<(4>@I1*$[TB4*J:/QNJ3>,
M:G2C]1)<OD`*S%_VKXPD9=Q*41JY!;;1I">-IC3#Z*^9UH\CM]3@WAP*Q9W"
M+)`P\VGL(`F9+HS59/_EFF12-UL@2C;$GE&M(14\^Y`(##2T^=Q0TK*B+BMH
MY",(<NU!^Y#7V@H0L"9%IC/AQ-O>VNFWP`5NGH0;W#K]@0?'M0,/E$N0YMK!
MN<?]@W2G2]WJ6O>ZV,VN=K=;7>0^E[G*92Z>E/O;X18W3^9U9AI;:MOV9DZ"
M,847=^>K7>6VH$[/E2X/9C!/SOK79SM$;?&T)B!_"I@DU#N6T]A9`"LTI`!2
M0,%]Z4OA"EOXPAC.L(8WS.$.>_C#(`ZQA_,KXA*;>+H\<.U_5RRK>AXX:9P<
M$&A16RRD48"T$HG`!I![XA[[^,=`#K*0ATSD(AM9Q#S8`#M9S&2)%&`%_WS_
M\;'N@..'X"0F`]C**1]$ARV_*)4#B@`+,G#D,IOYS&A.LYK7S&;ZUHD$2VZR
MG!E2-"E/#<RU2N>P!B`'L;Q`#5Z.R4^>5U4"%8`$9&ZSHA?-Z$8[^M%MYD$&
M2.#@.5L:(GBXZFH_9,,8O_,GFN[S6#X`A1IJ[2B<ILH`XBP1UV:`Q)".M:QG
M3>M:V_JX_'7KI>=,@M.:N@YUD$.@8>+I684$*75`@HR0\`%`B[99*4D1L5D-
M$8R@P`H\%C(/N@`$I2S%#PG4+@_\T&UO`Z$/MS9R&_S@%&]W(=P6!D`7U@#O
M=-O[WAQ.L10JO:Y=6UJU-AQ`'<92AU)OU:T(3:BO_U\B<+0U>]@,IP-/H@(5
MF<PXM;J.")Q)L(%7"[D/0/A54@I@W6VSZ"5KZ$*V\2UB`'1;6>B>K[R%,@"2
ML_SF.'<S"X*P$A+0@=_^9K&"-,TK/HM%1@^O'I4=DDYH\4H.:'N!$B`^DA9-
M2T(L"@I40.TKD2Q=B\"S0@96[F,`H)KA7:CNPE\"A)R#N`]$KWK:M]L%!\W=
M[7C/NWZMP`+DH8`%U`YZ.PL0Y=4F&VW.)AX5I,!(2%V\1%`X?!T2[ZR4_*<H
M(IIX@Z8%E9[L)/#5'KN009"KI'3[*P.(N72)Z*(!W%WO&.Y"B5*?W0)@LNVP
MS_W-ZY0!*_C>"L$3/).M4/_XI*G!X91'FA$_&W>L>3M:5>>*5ZB>$AXZ*"7'
M)LH*,CZ1?9.]QT#89!]X#(*!#@#WTAWH&O#3!3_X<`#UUCU]07`4*@"A_2\O
M"?JK6W>L`,'F\A>`Z?9;8L!XPL=BA/=#4.`#V?("!J=T%E%\1'%0&($'&/(#
M:&!*+Y(3*7%5RT)U`X!G!"(%.R9D(K(&WV=^\!9R[V9=??`5KR>`VP4`2A&#
MTA5R'!)_?R![+T(!,0=K,AB$M,8#_76`_P5P-11Y/E!P5'<25`!#!D8592,T
MRS,M@Y82]>0@TR)M6)%JU<)5KP)AV"9D)#$`?G!=?E"&-F<'!0`"V65^-BB$
MU]7_@M@E(K1'7?W'(:HGAWPXA%:``J!GA+N#A`/V(0\X8&!X1(3((30'(!:!
M!UR0$@@1$C]0$U=6AD#!-5D&;(?((8$H-"489"41AWEXA]P5?B01AWU(7W:X
MASR`:ONWBK+X:'7"=P>%1(+83H]G9R\B/I_4*@Y1`-KC0U2`/$5!!=OW5/TE
M!2NP$I>X+$:#;*/6B5AS8P52$U+``M]W8G:H@^JWC=>%BB.ABK.H72=8;^+H
M>N6XCI`F:<!'*[G83EW&BS'Q=7AD3]/B*O!8(%`5/10"!<HV%EO@A57WB3&T
M`F$'CB6&@_E4;SPXCO1E=F6HD.Q876E($OM'?R1!!179_Y&,IEQB\(=5%H^R
M,H_TJ#0BF&/'-A,^XQ&9"'EH@P0,0(TR,9*_$V%6(`84&6*D]R+GMH-'L08S
MJ"\,B37DV)%@PFVHAHYEB&Y]0&[V]W\ZZ)%4J6T\P`(V29*O8I(G61+VR!$[
MM&J\XV(PB38#Z2(I,2`')78[*6(%H(6G16_818/>5BVQZ'96$`0PL&'S5I<O
M$H,B\G_&@GI4L(<4EI=6H%TDL`(MT&%7697REP&`EY5:.2"7V)55AP?<)S2.
MN#L1T'Q5=WA(\&?#LGB;J1`)>61M((XG`00*R0,P005M8&0H@)!`I@)\P`>)
MF6$%P'!^\'UG-Q1'>5T9@)M\(/]==H`"=,`"TV4%N8D#'>:<C0F9L"=I@&>0
ME4D1EXF961%\#`%GK45G='":!9)]5\$5P`9HPQ)M1?A4'0>$'[=V^02`U_4K
M*6=DN4D#MYF;B89A```3/EA=$MF%65.&LTEA+8";*B!=+9";4C!=&9";=+!A
M5M`"4J";+;";U(EWO*=DV=DS$3!$F/DB=P!#S2@%02`^S<@0R<A"`39[64:0
MFS057#"2!S&&1I:'6,.:&YE=FH:"1):?0':5_9EA4D,!U-4'K=D%',.C'%EA
M+:"-#.J@U,5W&\8#QIF;_+FA>L<#%AI#N/BA`2*,"3:B8KD0,M1@.M1X*\I"
M9-EI$T+_8!*1C:)79'7'@0DT;C[DFM=E)VU0`$6Y!T^:7;WG<=25H75*G#@J
M74)J7;[WFMF&J&UI7;TWG=N%)VW`;29Q=[V9$X5I76]9AE.Y=XM:70W*!P^Z
M73-0H8IJJ7_0`G2@I73@JESJ=E<I!3F`$20`B)0IIGV0:4LQHE^F$'#6HO+$
M$)KI0HNH8!_RD@A6920XJ4@6E&17E.HX7S"(75:0I4^``OJ%`UK*!R0P7>"*
M`]NJI8D9!.'*!PLJ71<JJ].EKOH)KM[*`R40KB5`JW]``[DI7>K*!SS`KQ)Z
M80^)->C&AB4QJJ=EF`QZK_"ZKWR@G[$:KA-ZJJGZ!S"0I3A@_ZDHL*X3*ET;
MH*7C6JNPEZ&_]WLHT*N0DA&S)7R9AC7+:F?3DA0K`308-05#T[)C&;,FTA/1
MN$FI5$\[DYI%Y@=',94%.ZAT=Q1(:ETLL*Y\`)T0^P0](+`C"ZY9FI\\\*_A
M^EP[D)\],+!_H*XJ`*Y\0`=8FILE8)S?)[#^FIM9RP=%2E^L.7=*2A(,*UT7
M"9'5905"L*[MRJ_Z^;7ANJ`6*UTPD)]HT*A/RZX.*[7[B@960`/Z2;)=6EQ_
M&#85B#S*.$G1`#2"=XF[^&)3)07KA%!SBB`ZNSLO.C5,(Z-5!R`10`=8>&@9
M(G9'=H+9A6KS%Y3690=/D)N,R0(XX/^MB<L'S`FQ)2!=9JL"UV:<V#8#^6D%
M,_`'$1JUS)N;Z1JN-!`$SLD'WOH'5@"YU.6V8ZNE*V`%88N\!%N&N#>@>Z"*
M.FJ#B\L':&`&,T`'4BNXK]JX=+"JKTJE"1JQTM6X&_`'BRL$ST6$>WE<=+#`
M*V"Y0<@#(;D!5K`!%@QGP0@\+%"A8M![@#=)83J6GI5#>$`23%.&3:@TS$)#
M,+%T$)81L[(13Z:R[V2>SK(35.$TQY8544$%UR:M(0:_0EF')4%?;:"[U=6X
MY"M=]ZH"]]4"':N;?P"N3\!C$[N;C?H'[SH#7MJX#_JO*E"]XIN?4HI=YONO
MR?N]R5MA!8O_?D=QES=X%/1Y7,_9M@0<P*@Z78<[Q2C@I2T0O!-JMMXKP159
M)RT@!HG<`AD0!`TA6VSI7>YXG4ZU.W"V;P^&D")SB3J,$D%D:D'1@<26DGA$
M@:O;,WJV6J.[@:@F$C^`:$(<8KZ+7;PK7:,J73I:Q-0UQ6T\75JJ`L!LG-Z*
MM?&JO8R:QW\PL6L+S`/[K^%[7%FJ`G0PM]*5QL9<QNS;7;?\!ZR)?N:7MRI8
M7=?[S.6;QX<[I7N\`G`;S$+:N+F)!N1LR(>,E6BJ2!7Z?>[H>TIFPQ)QR1L`
M>/,389/I$;_*@3\<REQX-%/!$\36I@,BABS!.T$`FEB&PT47K65V_UJDN$D5
ML'JRV:=>>)?OJJ&^G)\E0`,ED-+,2<QO2\5_L,5F>](R70)!<+XNK5\3JZ6]
M7,W]:M.[R<;657=\&M39BLN;1':]R2&.FIOQS-.5>\YZ_*`3JP(RC=)2:P4.
MJ[:Q+,_R9P<9$$\'T<'&A5UVDJ'824\:(79F;5`6[%K,`F5ER"S'M@8-4D2?
MO`>C*XGD*32\PY5(4Z8J0@64MM4@EM15!P3P-FY%#9LC87_DDW\D4<=_,,47
M.UU_VZ[6Q=(^?<R5^P?J#+#7]:\DK5\P,-769<TN#=3\AS6"&BZ:$JAR:<NY
ML@8%L%P`8+2C:%VG&L&G;<Y4BLYAG)L[W?^W4N"P#<S5[)AB&["8V>@!0@P`
M,``KPK@"0?!WD7Q<5H"0%"C6*2:?)9'012>B"$9SN\(A^X0DIRPKJTPA4:-@
M=$`!*]!Q9T9$2E'>(]&T?V#85R''UZL"/)9D?["^)!V^FBW:Q[R\B)N;-=V<
M!VS@#$K2Z]O;Q[G9V#S</#H4=7RW#*=_V(6;0G#`!>S4^J7@?$RE3'RHS'G&
MV%S9R#V+]G7!;%EA*;;7D'')"1%A.N868[UW+%`=WL>@$F@2(=*$IT8L(4'7
M/S!H,[K71W36$I$L1Y,2PZ8UNSK89P8`WKU)X68'-G!*2EM=]:L"/8`&*J"?
MURL$^T0']YJ8!7[_S<9)`]"9ME'+C/P:W#<=LC1`!RCPKYT]7:C]T\)M75E>
MAF=(U%T#CES;`S@`S")^S!%;L53*`V:+!D$@!6$[H?R*`Q@AL"#>XLF-R(0]
M`Y0IT!&0LF&7`?>UC9)6J!-V7-OYPN]-T=7BUUKS`UNC3\`"C(9F@``F!4&^
MP^NM+/N&ZH2]D%)S?M;E?DAQE':0U7`K75-<N&S.KL7LTM$.VN>ZKM[JX'_@
MSK^LKW\N7:I-72['-;2=72\8$W),76:KI4_0Z%7\RU'-H'%[MA"[KDWLZ?I.
MA&!IP1GPU=>FD_-E)R@&`Q1=?<,FY5T8NQ_1\.TI(/NH.[\^%.!=(G>`_VW%
M;F+;!@3MMA3WIY#EPO'>9G\%L,W3M0$8$@2]+,41HO+-21TO_\?-*05T$`3_
M[7,[L`(DP&-_*/,HMG,[H.?;R`(H$+X]_]]%3\WZ]93E)CU^(-DE!Z@=__'S
MY5H90@+32?2]S`(8\J`\4/1D7,#-00>(]O(10H+ZGO;4Q>^U$L3*Y7N)>F$L
M`.6JUA-%5_$<DHBQ(D.\,_&D%.PJ?(AW$(J*1B8=36%@\@>'+\]@LO@5UOAJ
M'_F09@>3!!D-IJ:W<A`8D9/(2?`:EF)S?TI9L65:8X=5YX6+QS-\SSMX__?.
M\R$#IP6)=P<J+OFV?_NX[V&9R[*\3QT6W.K(F?]O^J8B=/WZ/RNH3F$A.U$L
M=,#/#V;*+CKH6-'ZH7ET/J`$SU*JN;_]W-_]9-U[)POC)YOJ&A\!7D;],A&7
M!X4'5=4(("H^J.N9@&\2Z#\`/K!L,MFLVN_]_`\(?X*#A(6&AXB)BHN,C8Z/
MD)&2DY25ECR8F3PM`"V9EHP\+`-[I::GJ&MWJ*Q[/Z2E:S]]M+6VM[BYNK=2
MN[Z_M!&OK<2JQ*@#/D@"2$A#`P,_5CR@U=;7V-G:V]S=WM_@X>+CY.`\$;#'
MJ'?IQ.RF=[W`\_0%\O3XM%)KZNOMQP/J-$/R00VT.],282K'L*'#AQ`C2IQ(
ML:+%0N?^]9/5[P>_6'3_"N0;B2M"!)+X]O4[]6.E*2@#ZT!9HRJA(2LHI$A!
MD>&BSY]`@PH=2K0H1#M2-';\2,RCJ0$A44HU*76>2I?&7.Z!I@;*S!4Z;1+B
M<2]"D!G4C*I=R[:MV[=PMY'5>BJK.Z;13A8@(45D56!23N8J$`'/%,$DK_:+
MQI1N+!0;K&1(2PB&WV`H/,7=S+FSY\^@&Y)5VN].XW54ZNJD<X?*BLM_=5'%
M58#U&BIW$.,#@>=TL=2.ZZ*81GE0AGM]0$@A,3FT\^?0HTL'S0-/\%C#ZI)J
MG0I6-"NQ?^$1K+./L'1K=./+WH^*;ZVR(F2P<PC%+7L;YD_?S[^____D5'==
M_RFF/47%#[A10-I6>(3W2P1]14#!#U(X9<H:?9'TSDH;7D?!<,418A\O8@%H
MXHDHIJCB'SRT-*`LT%#!6C2KJ(.A@[Y4^,,KM_TS``5TJ/=+`>RIH^"+=+#0
MG"$9""G%!B%RDP$.)=`@193>M$!#3\;1P:6(03A"QPY_S/`E(VA(L58+3YRY
MB!5"[,>FFXO0P0<=*^8)3@8N#GC@#P5J1860..ISY&)WP)8+A(%9$<$*-=[V
MWH\+'A,/"242<H:BYDFAF3=TJ(`'#%+T0`,Y+:AP)@QW&L)'G(W@0"8.>#IB
MY3@9G"I)!K6VP,<,CUC!QS<HK$!)"VBT4(VO="8BK/\5RNHI[396U#A@+,']
M0"B.=%"@%50/>G3'CAY-2`>@?=9EK6-48/HI1D'D$@0+'F!YS08J6$%(L]VD
M>J84*JA*"+[#QDJFO8C<*HZPDUB!AB#,!EMP-W3@0$D&*D1K2<2.P*#"M"!G
M,P,%[UVK%1V%W@(A%96>$L\O='@'S59K0,,1*[C-O-(`=_3\`PMBV.NHO-!Z
M8P<-*"#2`@G#"6)'3RR@P,(@HDC!0EH9H)`9Q),IR6+4+`@\B!1HT!#F(#2L
MH$):/,#0]"`XL=`#F4M6/?4?=FR@-9<*4^VVOH)T+07@7T/&M1V2_8&3%,"2
MQ4?BBEO--JE74XT"#5:(P:S_%593S<*3A3#\1PN?5_Y'3U9L,#K3&;0`^`:=
M0ZPUE"W@@+G&+<RG-^%M\\0B"2HH:07@HAC74]6J"Z+OTAP7/4C>L?.P@A#.
MAVQ]PWBT;#)`.:0<@4@5LOPM'IS.5MN"C+5R8,_NJ<.SU"Q(AC`+A#Z)<#48
M-]M"E6BHH*:6:D,#'Z96NQ+T#T\L*$$/T%`"?:$`#3@@`@NT9$`5\.%,*\#!
M"G2EN,<)C`=EPT&^!!%`&K2*#DGC00]4<,`_B-!4&?M#WT9'`QKT3TU_4('M
M:/"$J=EA@R),&@O2I@)2J8`&*V3!$/F0MC^$C4H/`Z$-57`V)]+@B!/D@PBO
MF#07_^HP>(1@F!U*4,%3:0D&1*`##VRXQ5,%08<E^%\-^\<"X&%Q$#"@`96N
M2,`:BG!X)DQ;$'H@B`U<4!"TX@$=2B#"6JD`!57*P"&#4`(,PC%9&2@!$TEP
MO4Y"HEK:VUXQD(./"-"A0;;H`KJ*Q*'9U$(*/@N,8G`&G`O5C`K`404=6*.^
MP4UF(8F(`'A*`C1OB*X0=DB3\B[(`SZ<+0@6PP$A`\<#%7#R#RCX&`KXL`)J
MF`UB8D,D'5(%N!U8#'-_Z$&MK$"#%@2!!O1Q(9Y0*,-:G>Z>B.3D##48N,?]
M@9O*4X$=WBF(:F:`!7>BAL;H\##162&&,I0:K%@4QH>QR/^9@@C;'Z`9N'"*
M+EK-1`L3E46KC'[,"B6@1C59D,'G_:%BA4#HW1CZTK-E\VDQG`$?J!&JLV6,
M#O!DT:U44`+5^<H*0-68%=-"`SQYS)-0;00+#B7*ZT1C"B#(AQ1(1H7`U,(C
MT`CE4W)0&-AD+T8[(@V,2C$`*E#@K:WITP!H0C)6\*R8C&`!I_H0&/UP0UCQ
MW)<0-(8T?RGO88\,(PTHDS&`T<<.3V!;.%VH)CH8*X?ZZH&^GA"$X3VK;R6E
MIS\+03HI($V&.!Q=.'&@IM'F<`,0]&P<$4H9Z.FQ@X+(IF=Q@`:==O8F%AO=
M(17W,170P;-"N"9N`T>JQS4S>3W_P*$5GO!2S0)R7D3PG2!@2@@6$&$004A6
M"89C!5;EK@31`J.5!,I.U(+W5-8LJ!;16P@T7/8/)"@!?C\6U?X:HFWBJ^JU
MHD%*78!@"BNHV59X=LH@E&PEKC$-<K+WE`452!6`"JLL:GFAF*5"&O=SFC`7
MY;5N8(QP<)O81CTE-H?]$\4LL*@@\I7-@`YB?V>B`2<E2;IIX@`&_Z1#$'(0
MA+.`49PO]=1P!T&')_P8!TGKVS&Q:2S7!@^)12ZR%30J"%9!F;?+I621I1"$
MI$V)#T<^K'RY]-`<XB`(4@`+X1BV1BHB%%I$8+,UAQAE-.0@SO-2G`D%QMU!
M</D/*T`#_\:$G.7<K4T001@G///%VAPJM\8CO.@1#9%8Y5'WT/X--0DX+.`7
M%9@VL'S/;4S6(U<0!D+K*LVX6B-6W*P#4R'.Z%X+L(),96,']H3;8-&&`AX0
M`5B*(V2GE;?80316OZ-[0CP-.X@&"B*.);@F'=34PT+X;Q"A+;9K.XAL>O8M
M?TQN+>&$D`'[QO2[,[Y;>)=K6D3PX(T5A=APVQQ'1##L<M%Z'+5EJ,<NEO00
MO+)8H3,*[XTF:[*GH^_HLJVF-_NS;_7.M*\V8+;`IO.^^?W#4T,=:A[$NM37
MZ:HO#DR'!Z-<1JWQ,%T4G"WT#"[7HSLU+3J+\XNU"F)X>O,R6__7XH<!%6YV
M$$(75Z#?&E\;AT%8\A^(8`9!`&RGD%83!`?!$]OIFTSTW'HA64#=TYUVAKM<
MIKY&N\$_.%9Y$3ATP8[6T((]JZ!!^!0/)BKH-=NXWEV>\["*7$B!A]/)-GEH
MM+:<>(4'=Q#``Z_1'U_L#!"!L",T)'^9[C0P:IR9Q@WCH^LI<OZ2O+\9.#G*
MV24/88S'%N=9/4`4S$K9EP*76SE0]19QG%WP_!M#5`$,\80Q/2:VFLAV<>UT
M>-NPH6&%#C0]"X3@QRT1HNPSMB<*\(0L1C+2$U?L'QKFF<(K4DF-1[1=#Z*<
MVHD;'X=H+EL)&A>J'6ZYX5!D812/B$#_X?>/!-YE?/?%(D>D9'J&-R)D.V@@
M>(KS!"&4+ZF";"1@)3LT-2M`!#NT`6^$!G2D.$*`!G?C1*8W;Q0$13Q@!_Q'
M0@WW;2RR2(TT8X`3,2BE7"_%?,E2>J?77SR``J1F>UJ1&WV@2C0Q+B=Q8"[G
M@WO0/DCX%"WW`U*S)*&``MOR>^`0-210''44+7:`;"SR)9S#A78`@%1S)G9@
M.'XE"%RH.)2Q"4Z#$S`&`W;0`LHBAW!#`EQ(`D#&AJUS$ULC"(\3/X4P`V_#
M`VG(`G#(`UPB"C$(@(&5A89`.OHR`_%$B(,@B"C&(LC6`DUC!M2`%L+%)7;`
M79H8@FUC.J=3_V*8>&->J%U?0SQ<:`8>AQ,:XXG*,VU*-3IODXHY"%4L<(1+
MR`H[@@<6DGOQ0&&_J#ZJ9WMW,"^9XW&,L`&$8@^^MHO8,&[.X2N9X3K?1(W<
MN!D"<HS?8AHT=PIMY8NVES['N`9X$#\]UUU"HAS,T8[=^`@0YQP36$-I(X_S
MN(\4(0IB]2U>H3-TT3/@&!RJ\(\F@P?YH8\9%0%912+\PH\2.9$421%6T(,F
M,P!RP`PO``4(&0T_<"[)6)!UD2ZEX!4>66KM,HV-X$XE<7,5&9,R.9,,41T(
M"1!0(``Z21!*8%4',8XDR0K<<0I04`;,(!,#``5RD)+!T5:]QI">H_\>?065
M-%F55GF5CZ@@<T43N(21*^$#S,`,!7&3%S(A".(>9"E*0_D4R\`,2*`&:K"3
M'1D<%.`N5`DQ7H49+.D0;/A):@&%3(*5#1&'^W*7@FD4U>)6.Z$U%7*3`3$0
M!&$0&7D;/7,N:7DM:T64;=D,'["9;_F/`X`'Q`$*/,`YM1!W@"D19.9$(:@(
M;584`U<(&',Z[3<.2K0(N5@-.VB8#M$"5](([<8':-9%UH@3DO!XBM-%ARD1
M2Q,_9J(Y5F"26B$'D/D!2G"9K6`7Z5A[,%&=RS`0#``%[D,*;;6.J4D);>-5
M@7&+JADF:8<(JTE<1H%CB)!)2Q4.'/.>B1#_7=B0*^SY#3H!"NP4D6/C/V82
M8SWQ!)=X.9`0/_DR076$`\.SG!'!`YH#`)A@!YM@'=<!!0*!!#X@F2BGG1WJ
M%5BA>AXZ$!^P!9")!`Q0*0="!7A``@N)#54CC;RI#:OIC(40GZ])%+%)"#,`
M;3G:",T$BJ&@#44*"7"FFZ&@`@-H!_2AH/\%"9>C12P``%*@2<=%H3YQ#N9H
M5RB)G<2@A`,"!7`@`%I0!RUC:ZW@H3Z@!5WQH9&I$5O951L0&;^DI#H!D]^P
M@V'83210,4&0B-N706%RFZ=#J,H28V;C.E17,:FU`15S3?&#5*X#33B0/%>2
M09[B=I2!BCPPJ!JD_U!*4C'*.0.[I#9NP@*K^C&^F5$5TZ6GXZE64*@\00*T
MDHC01*O20RL6>"="E#Q6D$$K<":8XD1M0RO0(@5"QR+;]ZSXM4N&R$E)XYN^
M^69IH:M)4D=CX:Q)HCR5FE&I4S%3,T0]$`34D`&>.H<DX$Y7TZM`=F/JVC;W
MQEK%\4"(P`>PDTC)N3KL6FFTB0,"ZT)-RB*QY:4_<9';0Z;(@!NU]RUUH)/,
M(*+%D(Q)&9!)J0PA*I`T(0M:\X29P*.Z6:Q^FB4E$"HKP'';QD@(:S:AHB;`
M=CHZ9%J+=3E--3Q,M$L#]`?X`F=@1+`ZI"6LM0,"(WQOID,R=#<#QT[;UO]4
MBE,EEM6S#R5D/2!U`&-9-*!?=*8".U`J'U--=#"!B%<E9H-$+&([4A`J^K("
MT65.+J1%>#*SJ<):!$L(M\);9ULE29LT>;0";Q0F*$5F!9A#Q*5'>!!Z&Q!'
M`,."B&0E:I,Z5`0P4[,#6[M+C55#7I(J*'1;#U4VMVHE=#!-_>0)Z?=&`UBP
MA<!$28LGD'2X&@1&HQL$*]!M.XA-RC,-RJFP%9$!7AF48=4:0!D<:O"=S1">
M-C*2Y+@'=X`&#S`S<T4A.A$9+1`T2ZH0P_,NW5!-.!`B9(=-IK>:8^)"C_=-
M/CI<A-=I[,0#."!U,Y8T+/A0&1!Y;L=!H3,LBB?_".DJ0Y=%G_H&./8Y91=U
M4-`6,2DK7^`["!NT1FEXI((PLWU3''D;7'=7OX40>30PKR@07"<U6EOZ!R!H
M=?;[P04U1M*E7T`53Z=UL(G641D@+#B$3DRR4T=%0C+V!^.UKUW47A\L+%QR
ML%P7;+P+I!T2E&QU('@P(0[;G>`IGL305M[B$G>%!UP`Q3LA&1FP)"0K%\#T
M#>1T8\YJ0BYT7^*+)VE6;SX:ONK*!SM09+4[`W=;4*[:OO!+."`8,?N[+QLL
MQBZ&2'@`69,83AM`NC/0P04%`PSUA_S%8SFDG,,2QQWT0R70:_K&)<#63)>(
M-A6'0[,IPLH3QA^#!EWD_ZPSMEP)_&.09K\'-PAWXL;#4FBW<K#/1V9O%!D3
M@[J7*$F;T'#S-@C*=`A4VG>O>TP^ZJP'/,1&(0H[$BA!&0^>U7*BE**<:;'(
MT#-BQ3.2P5)2LWU0<KT_85`9I45;-BQHD#QNYYYF3#@UEL9CDW=\``.>-0VR
M4FW!DTEU[,M3$UW&EH;"HF@(I3@R]F:I<F.59&B/%\##PB:WXT]89$#OR\H@
M;$_"0@TQQ@</PS&7[+Z:3%EH&+ZG0@)WDC4G!:4K,%R&G%LC3;O'1@AH4$7"
MA2F>]5+EFS0'BS3Q[#HJ5M'VJ\L##6G(2<K`##CM56/$'"8X(`2%*@5D@LS)
M_/_"4?.[Y_@DULLYN"2\P[L84*`%S8"4=DJ0CK$&$U0M/X`'[O&NTT%M.K9,
M,@U>E84GV[C6[&QU06`'_%H(!Y='U:8F*I")`L-.KEH(.8Q;5D"Z;T;75:=:
M7\)Q:8%2N!5IK*POHPLZ#^V'U85'#3=Q(F7)9MR:>+O)@=-PIH7)71:V*<N*
M)XU-^E5-8.$FHUL($E0(L$S3."2M:DU:,GPZ?""'O'S#&$.#CZT\A#3,$T-F
M-8Q-0LS40H$)Q^&P,_<S=4,Z++`!;E,A8?H28ZH1:Y!@5B4%+XP7>'">H('6
M>=B^(G=(88/.;A=##Z4O:VMC<IU.:$`?+>`E\XQ?NH+_4/![-U3B;#3`V?%5
M._@;T&%B0VF[9,VD)M7$M<.R`K42=?K2/RM08LN&OU1Z-&H$`RHU?Z+]!S-[
M.<?3?GG+R1Y=PUH2MDP$&?'T,3K%=29N)>;<3W?3=<W&OFLM"*<59UUV2#NH
MLW*L4K?-TR-XPRY$/1`3X7\0S$.MX.U<PX6\U,AM%"10W5+,5A?2&O$@'\6!
M"9U@H:XCG5(LD"X#U:W05A0B&6<IH\RQQ9Z!+%P2-@6H*V_$0CNQ49?5N!D,
M,240/.TE"$R#-Z%"5"@0BF<#0@%CKCET1<;U)6\4(@]U1$3MY/34;@'CK$H5
M?"408WV7*Y/>`P>5P7%VP"%L_^/*D^=4I*%_3D60%C`K1D(!TV_@QDEC&S@<
MI*O@Z^B+!:S.^MJGDBN&A@;LFR3.&LS,5NB>H#9$I2:.C4A3@S$CE$U$I49[
M+CT!`Z7[LC9:,C;'O41/8%S>A&Q3XD0-->M)\^>LY=)//A1)L3TTD0[N(0O\
MH(Y:@RFTJ!`S(.;7P<Q2'`_Q$S352E[>#!1*Y3K*0ADOK%(L0O`EXCHGN(8(
M#U)KF#@+D2]9#-O(>6,)`5)40QD0_U]%HU+1XCK'<S3F7,BM0QFX`SF!@_)E
M<CPFOWL'__(0D_$IKU)A0QGJ-#HQ7U"D8WK)9.ZEF88O[/`R/SHV(?!.4QP@
M7Z4X7_]06%*:U5-;'I_S,/_"!77N13$:)D,%.0%+N)$3D`%+/T"]UML(),#<
M3W$S`SD<FJ&AB,@)_]Z-F68<V?2?#0%4+&`',7;<0"%)*V`F4F"-H4-%,V`&
M?Y_)5G_XI$55)]HS\9`?,^`H\9/%61S=Q*'FI.7E`P8H]KY@MW%S;Q^3.'#8
MO<[9$'&O$/2;B,E0S,H(2,6!M(KXL&\(41X<=P"`>0HMF5"]&7KP7>P(+6+V
M>T"BR/"Q7$`A4B,_L9_\RK_\B4#6H#DXFO,)VI`W4GZQ@`(0>(`")&#[6-S[
MS/_]X'_X6;.V5=PRH;F7U\`G5UT7+*,4T0#5:Y`D6+SEGQ___O9__[NHW`<E
M!6(."`,45CQ_AH>(B8J+BW89+!1K`WN4E7MK>"12D9:4=U2=E`,#:W=X+!F%
M=HRLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<:V/,DH:Z&A=RR%QLD;4G>3
MEFL_+%:/>,RB5#_7V.$H,-S1Q^KK[.WN[_#Q\O/T]?;!&>*=5'??EU(9U-GA
MT<**%#P(I4A!@2Y9"Q()44@!A>V'E&T9Q"2[Q[&CQX\@0XH<2;*D+AXLJ$P:
M=4<*Q&L#`*:3QB.#E9LW,Z9+9I,;"W^D3C5<9;*HT:-(DRI=RE1>"RD_[OP0
MFD$*S!^$W"7;.O/05CM6_%%@F*JI_]FS:-.J7<N6'D$K&W(F8P$33U:1/SU)
ML=*B:]N_@`,+'DP8*=>-?ZR((X75;T<8UZB0*%NXLN7+F#-K!H92H4O*(?/N
M&=!XL^G3J%.K!LQ#3(;7CCOFJT2%A9C5LQXARH`#5I`-AGC3(-$JME<4KU"R
M,&0%1E?ES&$8XD%BQA\>,(#CWLZ]N\#K1$?RL$)QP)V[WA=EH(&CQ2$Z*MRW
MLD(G>(\,+>(SXNT*!7)7.+!``PLLT"$1(CR@P<(*)!08Q`KKH8`&#SAL@(-U
MZ66HX8:!\8#'2L\8Y]T,.RQG2`LXW&<''71(<4B!]>&PA"$L]/8'"M31L8(=
M4K#(`QTTM/^`@H%_!*&C%!72@4.%-](1Q!\Z6G$=<0'20%!]AUC1&PM(\C`#
M#D$LAP,)3Z)@(H=HIJGF4>-%]0,)Z*UY"`Y:SL#E'S;6^`>$=$1#(1K(%0BE
M@'9H$N8*R.%`H1UT+C0@A2P@1X,5^@6'`QU6H/%'58JLQ\(.?VRP0F\4$HF&
ME'*FJNJJ\XRW05Q;K3J#"D!:,4,/_PVZ)W^(:(D"#FCL0`,*3\+0)7NU)CHH
M#=?A@*P*@GHE(`O$$9@(D@8AMU=]]&D))*O@ABLN,0X1A(<4&XB8'AT;9+`"
M-#P$X2*>A"AJ(YXT[D!J"W001P=O/U['+S=/5NAB@27\8<=3J`;_S`,->_W1
MPTPZ&K*"=.W5%P0*`;4`ZK@@ARPR+`3-,8<`8>#PPQJEQ,FAEH9HTD.WANS0
M8YCS2HP""33P5J"$./R*8@N3SFPE@3^2T,,&/9>P`:9]3A<@IC`X">$*TT&,
M;H\K2,%##P7R`.VD+&@W\MEHB_O("F@(X#82+T`A"@P!J<E-<#,\35QP=$AW
MMR$SL&@=?6*BL$(R]54MI72IC#<#"72X1WABO=*QW(_(6?'D'P_M/`,/B,8<
M=8%2\I7VZ:BKB9(U`]2!Q-L^J+&23*FS8L;FQVP@7^V\]PXN2BJ-YKH`2!0O
MNWD19!">[R>BROSST$>O"`\35=)Z\<5__R`[%7NI*_WWX(<?,@\;4%0)%#Y@
MOP44I$70E_CPQR\_N"DU`T4==<C!/A<,>3___P`,H&9(X(].C.*`F*H;F@K"
M.>>UBQ@XHD>NKG,F6S!P%G^+Q4.",4%>=%`1-U$/-`SQP,2@J@4CY`4/&.(\
M77!)(?X3((<^U(Q.K"$(+LN0%4HP(!J4@"AT`N$':[$0MR0L,5!C!:<0825$
MP(D6090%#A3X"BRY@GJ^8)85&;&-3M%@!0ECCPK^0`)G98!I2NH%X5JX"&:]
MH@4SFP$;%>$2&7)H&37$1A!`LR&?_2AGBGK0#@J!HL.M(($*69#E#!0ORQUB
M2"P@VN:X!`,'/?]E4ZCP$37Z9:<_0(,^*RB(CTY$AQW,H"I."M6EL.2L7Q'I
M9R>Z5`L.^0@56`%R]3F<(0SW+[J1L05&(E;D2G#(OAB)+U+8'.AV4$M4T>=)
M!7(1L>@4A)X-B3@KP&$IZP87&!C);#W:@!V&U*=EOD8B&6!156BP`6@<DF`5
MBQGH#AF-R/U!!<:B5V]@,"0YWFN7+0*+CT#I22*1``4;*&.`B/.@PX%2.C>B
MP0QZE"OZ1$V5A^!G.U_9(J)AS8X:JE\>]<)'#G6%7S.P4L\,$3D<:HEG_-K`
MK]8CA170AT:'0T,+2A"-'@"D3SW$DX6H]TQ?N:@WBD)4":Q@4Y:BT#__BK+E
MQ-C)4A@-#:FHN@^F-#<#AFBJ9_<*4K_:D\Y/$6T]&["E2R[BLY7NR0HU@EEB
M)M0>K)9@&Q<IFXM4D`%;6JXYAK@(H$CP48E0B%(H>MI-7*+3$J"P002J&H%P
M``--W8M.*J6B(@LQK#*!<DR[>9+14(0"*QFH-SVPP["$%I\I6@FS*)H7@<(V
MQF;%"U52P!4*[("&BRBJ!T3#EZ)`JJ'9Y-$\<'K?23Q0TL)$ZHD_;)85(#8J
M3*%H3RUXVJ^<QU-]GHA91I+"I`:$@]QB:TOOQ-.OI(`&GDEA=U:0$'T(0@-'
M#M(0=7V-DEHT*4.H8`::<A><L+,"OMJ(4W2J_\]"IAC?/PRH/D^#6!#*Z\S>
MK$<35>7<I<2K)S,%X4OR@E80[+""IN(77T7\0W?+NYQ#EJ!'-2T$ER2Z1SP$
M+C&7$M.)PK2<[G*.1?@BFB/I\"6F57"%$V[0CY>#(BE%+D922JJU@K8<3!EB
MC\-UHQVHT40HL5"X3FX!H*Y$7`UY:!P&O`-98NB*%O2A#Q%@<UKV$LK@XKB,
MD8*9%4#5&_^@A*IBD^Y_8!8@+O&@!%.T6:0\]@>7M(>I+$;!*<7+G`#5-51T
M0$-`+HLO_T`K4H4P@X+J0ZU0=HT$"BJLF#1'+YZ6C;12&I*"X+0#HE3-DR5&
MU10W]6DS$><^/5,0M?\8,I#21F.*3[)R</FU1P<KB5HPJY&`*(2GB?ZA:E/D
M%PDUD0HW)O;$,(IR'?N%"!;7-"`PJXE.\83@@2P4#ZEP4D""Q-(@N_&\<ZH;
M,/%$D`D5=8AE7DV;J%#`2^#A'(CAQ2U1@9D@]8:I,7,)'7C+J!L=]0_,G'B`
M%*:"%<D45?[!4^=4C+6^:8E31%84>3<0N+WDQV((U6*C83`S)`5'"M:F4WP.
M2B,SM4>GO=%BB?=VGQ]%JJ_K@5)!(,<0\E*(VC3"@1TF=J]3Y4`*CN420^Y)
M-**1^*95>SKGWB4F0G:<3H4>#AW,,+/>K%U`_)GBQ-%PXY`W^DM(9*F!?LW_
M6Q0MB%BA[-F\,L#3`-FT0%-,)MWEU52'3SBEB9$(7&O+'S2LB.A=M1'4;[2<
M4W6M9X';>L#3,QX4X.$3HZ`"'B*0PY/`!C,X6LXI:12Y0XH3.*A`B2?W1.Y=
MVBPQT3#=,P,K.77.WIT=36?D2&1E3/<3]RAID78&)B421'_$S.D3B]PY@_"N
M(,Z[O`Y?6A1[,B8&A>JDGB//%*\=2.E,T8R^0Y-!@J'!X/=,9M'>QI.5,PV)
M8ZN$.`F$>RUR(?_28NY'/IY4-]"P'!F`(9J@$&041/0A!0,A./$R'3KB.4X"
M%N45?5XS0D."<SB"'*^Q9VGT8RU0-;D"25BB@(8`_WZ?$GLL\E2CER$$81,L
M@`<6T2YR=H/2$RT=P0(8`@P`TQY`*#T.T1/-=1+*E83C$D*6L2!S!(7,PQ7!
M\&:MUQ9F@@ABI@+#=1QQX37$L#NX4'^+`#JS@'U%T@HHP$-49`O#]2,8DDV+
MP!"Z-#T?985\."[CT0=/-!B^Q411!E',@4YQ2!!>88;7P3E^LCN[,Q[_I$"1
M6`B4Z(B;(C#3X1Z*F'`M0!2?.!T5MRE!$!MD(HF:N(FJB(G3P3EV1BD.J`+$
M@1B(XPBIJ(@WU8>Z&"Z/,!FI^!>6\T\J4`C<8&'0IB@UU1<VI2_OA0,[8'D`
MQ25I-&%TDDZ@I23.$@T3YO\U2D(E=-`#HP(72H(D.K47P+(-P`)79[0DZ`<F
M30(JOW(I41<TN@$0G#,A-/(C&W<I0:(E[8%X#[%WP&(C/(,QC@4YCY8B4X0*
M2P(72T(M.;"+$KDJ7#$#6OB#)H$B4Y0.+-`#V<8L)*!8`8(D58$TF:(GM68(
M.@4#6`,A1Z,DMH(&MT9D+(4<#Q)E-T4#8D`@!]@G=_5L-M$S+9!.>%=3?Q4T
MB9).7F8QRS$@>Z$IU[9%091@?Z`@5G)+O:$08T("H-)\+,(00.(N>R)>XV$@
M-3(>/*<0[#*1;+DJ!6$%R=,63E)?=5,(*Z0@R?8E,%(@T_8T07,1F^=VEY)J
MU[;_))N"`^^"+X;@6-=Q1(5V:&_59\6X$+]"`G8P8=!07L@A$8JR(,@"*%6F
M'4U4<RN`(2EF$XZ9'2IF.%>VF5TR9,<F$38U)H-))/%E(%9D..05AVW9F]QQ
M$V:8`:R'D22A;:,R)X9@!A#S.4M%?IJ66PW2&WR2=YYT<2@4.@:"-8JW:8<P
M1NN4&/)B$_4A46Y7*$:R#5,W&0]3-8XD=WO"`F,4?=:A'TE''T)V",ET'=#R
M<#4E!I*T'$,294H91#V0;Y="#3A@!M79>3MT(!*1E/_DFQ**&U;0!^GB%<FP
M/&CQ,$CB1KPG(1L@+THB$9A"`W;``IKR*Z5U71CVGNIE_R!H4%Z_54;KL3#0
MN)H]D%)E9`:]T2!$XTWX,IM:(B!(0J0283,VE93#8C!!4$TDA$_91@3.,UV5
M>6@T^G"(@IC9U"))"B6'=&"1(Z660RP;\S.V9&GD)"^3D@,--J%NFAH9T""W
M01AVDG")$4D#47]]01"*.!#7H3N?PXG1(!\HX1XED#?!`0T+0R.'@$)V.4*<
M>!VQXAZ4FAC.<:>Q$D(;P0,#$4D*0X1^4JA_<&,(XJF<,T)V*6-UPW*2^J<M
M0*B6^`<*ZDFH$A=FL!&:^DE[2IQOVJMI41,`P*L;$C!,H26,Z*O(FJRJH8A,
M\1K*^JS0&JW2.JW46JW6>JW8FO^MVKJMW-JM3>$'X!JNXCJNY%JNYGJNZ)JN
MZKJN[-JN[OJN\!JO\CJO]%JO]GJO^)JO^KJO_-JO_OJO`!NP`CNP!%NP!GNP
M")NP"KNP#-NP#ONP$!NQ$CNQ%%NQ%GNQ&)NQ&KNQ'-NQ'ONQ(!NR(CNR)%NR
M)GNR*)NR*KNR+-NR+ONR,!NS,CNS-%NS-GNS.)NS.KNS/-NS/ONS0!NT0CNT
M1%NT1GNT2'NS(U`%(["T3LNT4+NT53"U5%NU5GNU5OL%4ZNU68NU6,NU50"V
M83NV7W`!9<L%5<`%:GL!7)``7,"V;%NV7R"W9FNV"6`#0&`#-N`'>LNW-D`!
M;4L!!D#_`0E`N!1@N&X+MV^[N&][!PEP!VV[N(H[N9)+MY:KM9A+MIJ;N7,;
MMC$PMY_[N74KMW(KN@]P`:=[`:BKNF5[NE\0`ZZ[NJ?[`#&P!ESP!0^0N[J[
MN[S;N[Z[N[C+N\'[`,&+N\:;N\6+O,2[O+A+!%]`!&#P!6`0O6`@!]1;O<^;
MO<Z[O=K;O=S[O=X;ON`[OMG+O.9KOLG+NW>0N^O;O@_@OO#[OO(+O^U;O^]K
MOW=0O_@[O_P;O^LKO[J[!H(KN(-K``5\P`2<P`:LP`B\P`[<P!#,P!+\P!,<
MP11\P1:<P16\P1C,P1K<P2#\P2+LP21LP"YPPB=L`29@`2Y@_P(G[,(N_,(M
M/,,F@``U?,,FD,,ZO,,VO,,^_,,];,,VK`,WW,,Y3,0ZD,1)W+1+JP-,R\1*
M',4Z,`)+/,52B[5WJ[=:;`-58,`&+`()$,:J&P-DK+IF?`$Q@,9DO,96Z[1,
M_,9-*\5R/,=TK`-LD,1W',=UK`,(@`!\S`:`S`9/,`(-,`)/(,B&S`8-<,A/
M<,AL,`!0P`=\``8!4,DA(,F8G,F9?`)\<`*>W,E@$`(A$`"B+,JD?,JF/,JJ
M7,FLW,JN_,J5[`(6,`$N,`&T+,NT;`&PO,N\W,N^_,N_/,JG3,J2W,A$\`1"
M0`3)+`0JP,PJ\,S0',W2/,W47,W6?/_-SRP$3Q#-C6S,`Y``(@#&X0S.XES.
MY'S.XYS.YJS.Z+S.[MS.\,S.\OS.\QS/]'S/]IS/];S/^,S/^MS/`/W/Z"S#
M,-S"+"S#+5S0.4S#"-#"??S0$-W'2,S'1(S#.1S$?IS1?.S'25S#$TW'5$S%
M40S%;VS%;QP#4SL",9``!J"W,K#%6GP!!L#2+!W.8!S&"7#&9KS&9%P%*'VU
M;OS$)"W2>US4=VS'11W%@MS-A/P$#?#4C?S4BNS43MT`@.S4`Z`$K0P&)Q`"
ME*S*7+W)7'T"7#W6J;S*J8S*:%W*:(W*P^S*LUS+MBS7L@S,=GW7>.W*;;W*
MI'S)?-#-*K#_S<H\V,G<S(2-S8B=V(A=V"J@S('=R-K<S=]LTY1=V99]V9B=
MV9J]V9S=V9[]V:`=VJ(]VJ1=VIH=PRB,P@4]PS1,PS4LQ`Y=Q$/LQR9`Q+/=
MT4+<Q[7]VKO=T10=Q;4]TDR<TCZ-QE4;Q\.MNEGLTEO\TC"MMV#LQ36-TQ=`
MW3K-TRB=W5@+QVS`Q$\=`T\=WD\=TE7<W4W;W>;=W5-LWG!,U.A=R$ZMR%8M
MWE0-U58MWT*0U;$<`"[`WY4,!GP@S);,U5[MR0;^U6O=UVG=U\.\U[`LX"Q,
MRQ,PR[D\`7E]X1C>R@(NX`W.RIS\UY#=V(^MS81-!-#,V":NV"J^_^+4_-?'
M+-GD;-HR/N,T7N,V?N,XGN/A3-`RW-`*#<-"S-M!GMNR?<-U'-R[/<1*'-P3
MS>3"/=Q7G,8ZC=-A[,4MK;<&S-PVX-PPW=(R_<4S#<[6/<;:[;51^\8*T`1-
ML`1JW@!J+@0ET,B"'`1-@-SMW=[J?><DO<2(+-Z+[.=^#LCVW0"07,JMW-\G
MS,J&KN&AS-8*SN"C',J2#,TTH`*5WMB2'`)J`.F6',L4+M<!(.$9/NJCON%O
M'0``#N+;O.I$\-?/G.(I_NK.S.*T7NO0C,R-_->3K>.\WNN^+@)C,`93X`3$
M[@0<P`%I<.P1L.S,G@(1X.S,ONS)GNS%[O\$P3X&O][KJ)W:/`[D"CWD$/W:
M$LWDO>WDOEWN.ES12-S;<_S&5SOE5.[%S\W<:;#E,E#O5I[3XDSE8JS3:HS=
MV.W3`C^U,=`$R!S8B[P##:`")5`"3PTF,:#G$C_Q)6W'33W?X1W??BX$@BX$
M\YW?4!#*9;WH_HWHK)S:&@[IJ_SA1,!#-!"C2U)*E[(D/M3);AW+$B[7$S[A
MI-[S&2[,`O[A?\T'@<T'K1[8RUSBS!SKMM[T*Y[BW2S)NY[M5%_UHST%4W`#
MPU[LQ\X!$>#UR^[L8I\"9%_V8A_MRW[L3F#U-_[""NT"#1W1/B[W#RWN$NW;
MM)W42X[$>7_$3N[_Y.Y>M=EMQO%NP&*<T^!LY8IOY3;0T@8@`HI/V?SN[V3.
MQF7.M!?0`"70`R7PS&B@``P/`8VL`D&0^12OYX6<^A.?^N)-R(%^W^+=S`R_
M!DK`UFS=Z*8<RRA\RY7,!P].S-#L\DMR*3M08AOC'V0*)'+0RG$MX17N\]#_
M\P$@]-V<ZZNNS8V=]+/NV$[?_2I>_<4\]6P__N1?V<*N]5O?]<H>[6._`67_
M[/!_]FG?]=A>_J8=PZCMPGT,]W`/"`B""":$@H6#"#J*)CJ%CCJ1DI*-DY"7
MC9F0FI:2(Y]5H547H3$7IZ@7"0D&K08VL*^P-K*SMC8BN*P&JPDBO;VI_Q>F
MPS'&,57(HC%-*B4])=$[/3U+/30T.V@QGZ#=W^`C#>'DXN+C#>GJZD]L0D]"
M)4U+.SLK1_AK4"'\_?[__0((###!A8N!`=0D'/B$CHJ')6@T08,#QPXZ*X($
M.2(%A<>/*V@(M%!P@LD))"T@7,FRI<N7,&,B#"&09H`0?'(^R<EGYSLB/8D(
MD2.$B`JC0HT^7,JTJ=.G4)N6<!:UZL-W3W8^&>!+A->O8,.*'4NVK-FS:-.J
M76OVQA2W69S(Y4`W`H<(>%-$T)NB[]Z^@/<*QFN7@Q.VB!.O=2'(8&-"C`=%
M/F0H4>5%F"MIXG0ITHA-)D*+%MW9,RA1I80E4/\%;)>K6+1:W9J5R]8%5[Q$
M&/@5;/5J8<>,)4.&[`(-(=#>R1-2!D(1>`HNC*CB;;KU<I_0C>#&S?JX<^G8
MI),W;PF](RC0PUC/_J,^?S<#@J$)YJ9"?O9M&G11<"`?.D&48%1$352$`QT8
M!9%#1Q\U*,4*`:AD$DG\R63AA1AFR)-./67584\J/!'B4465>)525J68XE14
ML:@B4T)YV!-7BM5HXXTXYNC56U-,(9<3=-5%F%^`%9G"!GSQ15AA=.GHY&*.
M[6="9%,F@HB5E`W"F2*=@(*,).)]TLF8GG1#'6K#"*,*:[ZY)HL!I&R72QJV
MU#*+FZW\4HPQJ?"9YBG_P05WP3-P7%/"#L\D1YXQTR$SW9G64??-.-R@$\IU
MG[#!ACPXK)`#/@TVR!X,*)!*JD?ZS,>/JO'%A]^K-L6ZTGX`+A41#10=F&`0
M#(;JD10X$$1202K=Q(=1V.!Z#0U`9>CLLS5MN%-/U&H%(A\AEIC4BU"Y&-54
MX#H3;KC<PIB55C0^J>ZZ[*XUQ@WO3A$7D$':M:22@"%9I&!Z$1;D&.T&[)5!
M4[I0B)0&$\S8E:-50N8DVS710``(]-/$$S45(40#53QLVC=G+F-***JUQIMP
M,2000\6:ZB#;;+;HQLLJ:08:*'![HGQ!$T5``(<0192``P1EE"!$/$U(]Z@W
M_Y)"NMW3DG*\W:5.-Q&$K[Z.NEZII[JW#ZRMSG?3V/BU^NK8"&4DH#.X5G01
M@!IA_6L0*\A1DD$"R9$L-KD:6!$-?$`K^$LAG+#AX1QJM>T32!U5[K<0M2CY
MN)-+_OBY.J4K\.:<.QEOCW/5NR2_?_U%).EXW?5OY^L>S!C!EL4NNY:"8$;F
M=EGU<X(\#?0#00_<C/G9\&8^BAHQ:K;VVRG#B2-1"0V\@IOTK;`B@IHU9T^,
M*7PB#Z@Q"M#@<PD0/+&$"F7T<+00T1F/&G7<5"$U=T\K4__[(UP@PM4>F:IU
M>UTC%08:])Y5F>UL`6D5V="VP!5(@478*%!%$*017O]YA`0HP&"#5D`$_DQ@
M($*C@8CXYK>*4(19@TMA30R'.)Y,2ROG@D=23(2BQX&+<CBL7`Y91"YO.04K
MZ.H*ZX9(Q+,`;`R@FU>0[G(O(SFQ7QQPBX_JPD2Z`*R(.$+`9&9W)<M8X(M@
M#*/!N"0\^?6.'T6XAA#X<0((0*]CE@B'TY8!*.RA(AFC(,XQY`<]B7"/-;6A
M12P2$)N9+4\U=JPCGQ3@##A$0QXE@(/XA("#)B@#?Y<,62F@!C74>`D-^_L(
M`$<E-U^]1U7X$9NKR*80!=+DE2M9$+-4$$$#)2@'_).;%(*@@H*TD@\T"($%
M"$"``-"@A'Y#`^!4""T6MM#_A8D+BA!(A)2B/,XI.]2A-BE7.:H\!7,S$B(6
MQ\FZ,9CSG$AT`@GH);H(Z.N)?>%`$!30!!HTX`DC>((ZDO:&&ZR.G#7*TNQB
MYP)B&O2@"/VBP[IT#C8&K0ELA$<)'$4.2;GO?<5!A?(,V1M?)$T!LY"!#&;S
M,IE-CQ<<I1G-L,<]$30A4=$X`@VH@8TEO,%1HFC4I8@#OZG9[*<D^T$HL=:>
MCZ"GE/HX`4!>:1,&UN2I,.$5#1Y"0HOLBB,?P:`&4;!+(JQ$`6@8ID$MT+<=
M)!.%S,00&)X)3<1A;ELC4DH-N97-&XKKKC=\9#0:4->J8&XKX@2H8#TWAA\9
M5@%C_UCB$MUI.L!XP`,IX,`;+O8$_""`8A0+`1C`P(:LB*,)0#HB6*XX6+*,
M@`U<K)V6Q(K0UAY4H0\S8^ZFV8.+%0XY);!H\=YWO%&4#!@HG=XMW@0S01;R
MI-5+Z9H2F29Z5N,:YJD&#:+Q!@7\]+K#N:[-EJ$`$2@@EZ+R%:B.ZA'ROD>I
MJ#Q@".X#RYFX)`0K(,$LJXJ@C%RM(UKU51!HH-2:J``-!3WH,=UV5A6DU4+.
M9*NT.L0X;#W$*"*:X5Q5Q$-QC>N1>,5P-":G8<N1JRE$^*OF2DO.W>Q&-[HY
MH@'&L&(1L)BT(G@#$CF0!KJDX<8<&$,,IJ!8PFS`=(]];/\$;F#;LAUD/T>^
M+`+`H`/./J$)\/+*;@`V91=;6;2"74<D"H&(13`BP*X-\VOCJ`/B):.R)VCC
M,^X9@IX!3[>1NFAQO-<FX.+)3K-`+G&3>U+=!-87K5DN*JXWTR6\=+]+F&X#
M4/`#[08JNX[>KBE$(-2KD1=K1QUO>C:-GJ2BDE7ME=53F^J2')"@&;1LFU7M
MF\O\?F27NCJ0@;!QE)P,V")G]>J!WPN&!"N86CJ10X>`DA5J.LZ&=MUP7I>M
M869W.)M\=8J(`TOB(9Z8RF&I,CJW?1=XIN`-I[478S=`;G*GP`-N0'<$F@`&
MO`W$(&&,-Y(%HH@G(-;*7CDB.JW_O&)SDE,[Z?B,EQ]1"#$;'*&*P$[$>G>"
M>."@!)4-&O2ZTS2,$B./R=NH</$,BY':P.,D=1.>6+$*W@!C3<MS:36:T`1[
M2%<B0<A9I&>NQTOJ3ZA#)6J#+HTU?<20#THM&]J:2NJ8Y"`":*"JJB]BWZQF
MT-4>Z=0*$$2'M[V-ZEBO.AU,6`*6'.3=`OEZA@K7ZS0#_=<NU$J)9#C-"$^S
M7'5]-@[UNFP+9].;3`$G8`-6Y6J;Y<1B>7&_"]MM#V3@\(A'?`1TX((G_+C<
MD.^+&R;/@28$`,E'1LD$7DN`>']Q/Y?700.^HF\5;UNT^\9RP/2YC@;$@&.1
M&,3!9S]F_S')D1F]DR@.*BO1!BBM&V4^S?M24>==K.(U+YO-2)>?9SLA5WG0
M[PW*&2DTZI;`/-CH+G`BO2>9/_H8NA'J=S>=M9V7$E5?D.'/<\*J@1#=_2_)
MP0:2GNI<5=V^O2(!U#U"A_-[1$%TLP)3)X`$2'4X,%6MI$*%4SAI=@)EAW8O
M5"V,DQ5RI2UTQ6'-1G=TQS9VIX')=G=+,6T"`WA^EVU75A;F!"0I<'AF(`8M
MR`-F`(,\,(,9T`##U`20%WE)8`56L`$V"$::IWFL=7">9P$(H#\GN&TI-GBH
MYV^B]0;L,@[XU'JN%SQ#2'NSQQABT@G&T``J$`+PT`,*P`]/0/\@F10*9=(H
MQ\`FO1!<TB-(U7-\)U5<L>`*)!=]>*A2!O!2.+`$\F`-"S`53?`#:N(]W/-'
MW:,]B5@,MX%SXZ=S7>-_**`/1R$B$R@C9\<'J%1TA),#5H`#;*-J%!0W%[1_
M'K$"6*-5^L<>+,`",."*6W6*!"B`='`-PN8L:K"`O;:+#:A@$;@3(:8"/:$M
MUG2!%X:!'IB,RIB!VM04,K)WU09CY>1BV)9OU`@D&Y`!,=@",]B-,\B-W;@!
M!64!.V!N2((D29`"2;!N$9(20HB%8T5,PS2/%L`&I'=Z^'AZU(AZ7@&%3J(.
MYD"%KP>/!$D`"'!1QY,.63%-2Z```2#_44DS?-_3'9Y1?'*(?'&(A\6%&WG8
MD2;C4M<W76A`#5-A;]=3B'^"/(CH?8SX1S_`8E]A:>57*G(S0`3T!7E7%.N'
M.&NEB4ZU$A[QB:%H?_B7?_JG?PT"7@V"03!``BS@E*T8E5(YE;\RBPAR@'R0
M@"R1B_TP'TK5@&G6DX<S+6-9+5AA34)Q;"O2(LX6$78W770'EQHHEQNH5]UT
M%3$$C8CACT\R9:E'@NLR94QXC1'@!N#8C7%@!XD9!XS9F''P!W$`(010CAN0
MCI:9!!NP`^/X10>U>03@F07Y6BX0`]:8CZ:9CR?HCZJI&.A`A:Z7#F`6FEFX
M6^Z#>\7&.R'0_P!"(!&D@$>G\!F:P@8ZH"DC8'+'1W)QF%S`]1K&M9%UHF<D
MQQO&Z0L_0`/F@0,*H``[L`05H7U]4C-K.',YDY*[('X*T"NA8BI<@P(80`);
M$XF3"`5RA13@!&PM%)9I)G0XP`,MD`&@>"MN@Q%-=T%/ET$;Y"M:U92O^(I3
MR0(;X*`.^J`/*I5-*8M5=X#".!!<R48<VH!EYVLM9"TQ1!031F$7EH&/1)?3
M)9<J&A$N*I=L"8(/YB$..&)?@81%5'I**(V!>4YIL((MH)B,>0!$VIAV0*1(
MBJ1Q4`(!=@25:04[B)F:V7DD\9G$!)J@*9NO%0.GV:6G:65\^15AFO\6`-F:
MK7>%6BIF+G!1M7D!"ND,AE9LM44*?Y0`#1`)P<E9(]`:&T>'R^=QS"=2PT52
M>N8*TWD;;Y`%4Q`$-Z`1-_"H\S21X?DGS%6IPV``4V``."<"YZ>@7/.>-'F3
M2U&,>=E6]PETO4@#&<`#=I`!.\`V$S%!^+>438F4'P%>^85!3[FK#3JA$@JA
M#;J@&"0%.3!U.*!,PN@/&QITO2A-(89VPW@N:KF6)]J!'I@LMY*M*XH-+IJM
MR=B,*O`.02<0-@H6^G.N1#1X3H":ZU)8>Q&#BGD`?Y"D]%JO1(H#8F4!3JJ.
M4`H#7<<?[C@L:7IP+G`!7GJP7AIC8JJP:-'_`.+AFNF```.+A1;`-+R5##MS
M3]'`<NZ@`DF#2,3)!J<U`F"P&VY2)[<@4BH[4K+!G(,*&X5JJ-/C9ZN1G3MC
M4>F0-`U@23'079IZDI9:J2ZFJ;OQ`PH@-^I)2@`4JO'IA3`2(J7*(<_4DV!0
M`BW`F*WJ$`!Z(/9`BJ5HH*YV-1JD00KJE`PJE;^:ML`ZH5%IMD?I$3FP=3C0
M`\G*H?R0$ZF&3-?P$-#TBY8(=S&JC-NZ-WOSHB_*K80;#72I;);S!.-Z>6!4
MKEZ!HS=:(U`XIF'1A(5E6.N*CRV&@DEX@DZP%QD0I/9ZNO:*`R$`9D%0F4?2
M`PS``#40(4%8I1-K_W!L@%B;FX((VZ7XMII@<;EE`;'K@*:WZUH(<+&\=0KW
M)"(J$`/MD!7>PQI5Z#USR'$7B9&M\`,_:[3)1X?/J6=>D0!3@`#C4`5-\``!
M1P2NEYV9.@4O";1!RUP_D*D_ZQ5(NY[^XS_KB7YXEW=YB8F(XTPT,`./R9@\
MH+4201%,5T%+^;9;%5\$^K:[>K:]"J%6`*%L.Y5FNQYOBP)T\S?)RA.T)*N\
M4D'&JDQD"6S$ABTEVBT6%KAZ1;@TC*TL6L/<^JTER0="5X22:Z[7,[E!K"XZ
MNKF<>\2%M6]G`7@I&`%68`98$`>H.\7T&@"O19E'``%>D`=#L`7"HGE6FO^E
MQVM0+J"[ZWK&2=R["7M%PKNPF%NFK3>08SQ[.J"\3I,_K[>&=F21V>NRRA<!
M'T>(\-,`#W`!A<P-!D":!E``M@!RA%J'SW<88!`#:("$0O623F``::"I4X!B
M\VNI(F"_]WNTI92TZBDW:_`%7NA#(2:B9+G"AV.UCWD`C]D""BQ!]^>U3X>4
MKH:*N6HJ9AN5$="*$BJA/4AN&@RLK1@!K^B4[HDU#S*W4Z5T%B&`%:014W>A
M(E26Q5:,*V*7BYNB.#S.XWPKX0QA_34211A&/XRN04RYE+N7@5=Z1US/G&M.
M@/D5VC:Z*0#%5/S/20H#%A!@PU0"*+``9$`&+_#_`C6P!5[LF29AI6,\CV3<
M`#)VQFB,QKR+T6E\L#(&,*L9IF$*L:_7`!([>V*\>2HMQF)6L;V%,J60792:
M<7R:O<W9<1_W<060!C)0``40`3+@!#8@5-O["@]`"WT`J#D-OLUW4FD@`GBP
M8G@P!5$]!B]YU9B:U:=P2)^<"KHQ!?A,:=Y5?J#*O^IIDZ22RGOE(CH9P.L'
MRSMPI$@ZKSS`2P3"P+N2?Z4"P:<(MKO<S%/IJ\3,`CU8V,D<K+OJGK;Z*R`<
M!%NW+,>4UR",2UIWK"7@5L-&K3*\HH9+SIY=SL^J2BZPSJ0MN=H7Q-WE%=&A
MVE^1VHD1ID5LSS0VVS^B_\0+ZV).D(TM`-"\C:1,>J56"@%A4`8^0`9<3#00
MP``3<A(3,`0L79`F$0!#4-$?S=$9G<09;<]?>D["V]T*^P9O0+SI8+P&!]&M
M9=YAEKQ[Q%-S1@K,A8=NZ,<=]Z<VX-,][=/V+5(%H-\^G=1)O;(KN]1T*%P]
MLF+WR[U%3;3C*VB)%!T7$!T.C@J()<K<ZQ4_($HT22KN"<S\B^'HQ[YX%R.M
M_'/6PF!/L`.G6]>P.D&[XG1'"742S)1<$\S#/-C%S(,;P(.%K;;"W,R>ZBN[
MA,U;ITSUI2#$BL(7FG0A"KB"R]F?_>1[<Q2/.]JD[7F=1Z4_+,3H>JZN[=HX
M`O_;YV3/<Y$&AA76HS4&[RK7O<W;+3#:5CHL$-`!8:`'9.`%-1`&3+`$+R`0
MSOU!###=`QO=#!!@!A$"U[B[97[=&)WHG;O=,N;=YW07XMT`M&?>*GVE$8W>
M8>8"))-'[:U1H%YG;'B<N''3\PW@(M4'^+WJK-[J^XWJ`"[@A!JS)B86OA#/
M80'A#^Y=O%Y="@#>]0O687W)SYSA^ON>IVQ*7_!ACD.!;OU7?%`"+("Z*G[7
MJZ811OGB!1KCN^S,KHBV&/R@/$C8.4[NRCR5/O[!<X-+M"BWDGWDE8T&E[U@
M.>'-W9)LXG+#4/[9E9C.[5CE`!^YU`86I\WEJ,TY85[_VRDHYMN6VZ6[YA!_
M`"QPY08U!$(0!G/^`73N`WC.!+`;NUM0!"^@W($N$`Q@Q9U'$SK0!-B-Z$:L
MZ"^?Z`>[CX3G3FZ@C<0KQP=WZ6'\F56*WL\]T*/@Z6DR](GD&Z..G,+5R+#^
MZJ[^]/:=WTX/ZP$.,]13J"AFKJ?@Y4+U!B_Y.3T2]F(/.ID:U0=^*F6MM,EN
MDU[CM$Q1%#%BB20^C#A@!3Q`[78M$1/4M:VVBJMHH"C`[1N^'M\.[N2&XSJ.
M^+_:H"3`S(J]V(R-S>U^$4;.58T]=68E[R'ZPI&35Q:F[_N.PY7(PV%'Y0%_
M^@.=Y:W]X.[<VNS"EPA[SW/1_\]J'O%L'@0#+583P`!;<`8"H`=Z\`%Y4`9S
M@`$>_P);``$^`P'/#8\D,032?:4!<$8-@%ABCL39+?L=;9ISL0$W/P-F$/YF
M(-YL`-T]_^81+=&M982EP%.]Z=Z^A3W0%]\PT_1=`/7XW^KW?=_X#0@R!3*$
MA3:'B(F*8P9C3H]I3I%3'!$13B13)"283E.?4S>BHZ-94UE9GHR,!C\B02@H
M)"@PM+4PN+BVM[>QL6M?*L+#*D1"Q<5/*D_,S24X&V8\<0?5UM8\024E-&@X
M.#MT*T%!4KZT)#";M;,KZ>@H+"3R+/7V+!M6+$E6_5;\_O)MP'>O'@P6!W5M
M\F6.7/^0%2OH2!Q7#D7#AQ)QH"G!IR.?)Q\_*B-&K(0*DRBWJ:3!LJ7+ES!;
M"N,#)D2``"Y<6-C)LZ?/GT!SNL`98$`"$4B3BE"PE.D%$1<4/)W*5*G5JUBS
M8ATC8@Q7KDB_>O7J)$(*,UBNJ5W+MNVU."U21)BB(``!"P0(3-BR)4P'/7K(
MZ#&B04,4#&'@+%BP94+>QY`C2\X[H;(+QP$@A'BBH`&;$0K(/AI-NK3ITHY2
MCW7TB$.E%&XRF)D]NX7M%@URZ][-9C)ER8XG6!"N5V_PX<4A[W2AHTJ,"U4N
M7(A!';KTZ]<37$C`O3MW`^##*R+4A?R@`@6ZH%_/O@`($.[_W[=O+PB]H/N%
M"*61L3]"&O^66/)?@"D4*%>`$7!``@>8@.+@@S<\F$6$$YXRA2<&3-%**Z^D
MP\N'N>C2RSF_?$%$`\00(0P13["83#,JX$!"-"U,XU8VV]#0Q#<2.73..ILL
MU,XL0:J#4$'X#)2//P#UDT0^!-6#PD/CF#-/D"1*<00Y$44T41`YQ')11#MH
MQ)%'';5X#$G#H'222BMQ$].<+I7`X@DVX:034'SVN=Q0@!(UE%%6386=5%55
ME113BB[E:*-:1:K46$E]U957'%AAAAUN=>JI-7'8D<$&''B%E%UV33`$`PSD
M,(<>9?A`A@8.&(9!!V&4P8!COO4:_]EP`0@70!EPA-#`&S$\T4!HK)WFK+.I
M.=&L:Y;`EH%LM-%VVVR[==L``KX"5UQPE0U'[KB_(8"`<]:UVVYTV&WG70+A
MU6N#`8F0=Q]ZZLWG+WKP^=O&(-+^,,8/!KR!1[4I6"'&PVUDX,'$$QM8H%D(
M(N@:)P]V_$DFF41(2A`WD$RR*4[8H"$C;QC0X2Z[A`@#!B'&[`LP**J0,TDP
M)@,-/IKRP$.G/$B1HS?@B%...;&L(Z(L**S0BSI&SH.D/ALTR4^3_20)`QTX
MR+2-%+E`+:9%7':IM$5G8U3F1FB")+>*)+FITILT<",GG3`MP\=->OHIN$\Y
M"6IXH`@4E?_`&TI)=9WC4$D5>517,1J5=)!*FA7C8EEZ*0<SI/7IZ&W%80:I
MTG:E>A,6`+XJ`PMHH`6LLV(1A1$+0!`L7N&&6]GO$,`11AA"A*8`&\N*]NSR
MSE:R08'79FO&;=3;-KT9WC800V[@^HYN<'J9>QQQO%KV677/89=^O/+.ZUV]
MX"EB0WZ%I,>OOR"TD7\;;?@W!<(_>(,"!H@#!>S@@#N@B$,>XB--D*!:&8M@
M@A+$(`B!(D(=$UG)-DB*CWEB91OZP0U$)#.:S4QFMJ"%"E$`C!.Q"1EK6H8*
M>G``*VQ@`S,00PLXY18[&(T;:%@"#GH$"U\`*1U(C(4[BC0/7"#_24DLZ$<^
MMO8/*4;1('3H0=Y,(@P<J&,AYY""0]0F#BTQ34MN^\:90M*BD;SP)'"$D][X
MUA*3@"1/0[E)3@;7I\+E48]$`9P@B3(`$3`.*8YCGW2@PDBK,.Z0`SS44S0G
M*<]]I2PS:`'I-OF6%LS@$I3BRAO`@I,3-&8(6RB!!L*@A]D9(0E,Z,&N>-4[
MWTT@`$4HPP+"P(0%-.`&8^A,\IK%/-,PJ#6OL5;TJL?,VD@O>[JQ2^]XA9S?
M6?.:E3&.JD*`E`1$)P;1<0XXH1-.1;;O??023[[H-Y_WM`$`\(1G_WYP@08T
MH0D&).`!B^A$>QB!!48(J$#MH8LM!0&"_Q*DH((^&(I/8%!DH1A%1$EABD]D
M81,ITQ`>&N&**=A,9KDP8<V>!@QAH&AGPS"&2E6P@@.(H1\9J!$UW!*''W;C
M&^$8QQ&8)@M<()%())`:.I!(#WL,)$DVU%H5_6'#&Y(@BRS9AC#00#6SL0U,
M5!*'.-C&$(R`#6X@21,?D,&FE,@Q1WN+B0KX$((\]80`@,OC'@<7J$$&('&)
M`QQ>[\I7=1GE#8=<RN4D^;C+#5`I@%7`$DJ`O.HPZE&4S`I9(F`%!UR!DYSD
M@15`&4I+B;(!F=$=`XI0!`UT(%:#T0!CAF#-6DY&5:,EEF*&U\O0"+`!Q6M-
M\YS`(-?PUK=I2/]F;&1C&QZT(`[3,"XSM]6"ZV$/FM^RI3;+12YK#J>:P1F"
M$)2BG>E0Y[O/@1?[M/,^=<YO?H0X3P$\L#_^N?>]*?A?$W)SSP$>D`Y!.`(M
MZF&$*"1A!@">C09H,^`""QC`,T@"0IKV0(U1D+<9])A#&YI!4U34$S98!8?(
M1D)<B!2%)Z39"EN(4I*L5$4M;8$59",T3]DA"WF[:=+(\2.G574606`'U9I8
MD!L";4G\F,%2^0%%%D1-(WD[B1>3&,8Q=@DB6NIJ&N&6)I`(PXUMBN.;X`03
M.[)5CWMZ:^MN@L?`]<2/@+S)7O.JUS:K"P$F,($.E#"`A"V*?8F4W'7_&,FH
M`2X!,'D(-!N$T(#+6451F</**)T`@PUHH`67O2QF>^C)%#!H-:M1G2@-V80>
M]``"10@!`WHPAS#,K@58,(,18ED&"+3Z!:Q]3#9I*>O*,,#5<)@M;9FP`T>\
MH0G*PM1OCSD:UP37-1P84($\L,QIQ.'9T'ZV<I?K7-I`-P;2G&;X9EV9(0RA
M!K'^G?@8L`6L:`>\U8D7>;L3O_VD3!)IB'>\`]2>/KR7?_%M0A5T@T\#)A`6
M_OSO#*;G`#-H8`8'O]U`!1H%`!^\,+-),$+T6PE+5&)C#)40*"K:4%%T'(.G
M0-D45#:&C;J,PR+],$A7[M.2FO2-Q5A32S7+_^(_>*JF,49:.,C!4UD@\8M0
M@X4ZT(&0@SPQBDSMAY"I*)`H%3T(WY""/-@11C%2R4MTV"F)R$&'MYUI;F-]
MH5GE&.,D$R%/./'37>!J5T'M,<V"9'.;^ZJ#.,NY[GC7@0X&($+`"C:1A8T7
MHIXR0`4`!C!>2+P7\D#HJ/1Y49`WI.0=>0,.X%`#5\A\Y@\@Z4E7`RYR(;:T
MI(7IKCSRD3OX-`-<\&T-S,$(<\!"'%)M<,/`O@-PB-4+7K"%6$,&MGS)I6S#
ML$LF="`'J7!"9S@S!F,C^_F2^.U_4C"Q9<HTVMA'+ER$1NUG0G<$M>1V=8=`
M!EF!N[JPK<$6$HV4\?].\BH(\THC1OX(&\B;/X)(00'T[X$"N'<*(M``^V9/
MA7=`XQ`/`)4$#5=[,W`[+(`!*'`&.3"!9U"!$WB!&'@&-`-0"&=P"58+%V5Q
M%21A'@-R#_50%G8A&+(*/_`#6<!R,"A2*G0+:P`%)992*R($=+,#!\`#,Q!3
M-M(I?T`"+8$T74=C1F1C0C(E/W<E1654`\$D511D3')%1U40!]&$6>)D$[$"
M/8<V9&(F;"0'.BAV;[)E4G4G8,9':X<7:+=7@?)'<Z=78!``.A``8(``>:=W
M<]:'>!=G=38*B24532`=A5A8CH,HB-($AZ<'BI=X;-!OC@=9B"0IHS0&,Y+_
M!+2":EB`!9+6>:23:IN%;,]B*JIC2*(D0#1@$]X&!PXP4P<P>UC0`@Y0*QH@
M`;>7&&50!N#F>Q,0`G4``;OW`L.W2[25!0QR`Y[1!)7W?,Y(+69!?=%C7-F'
M?7:@?<D%%\55(]93;<_5+=N3&ZZ5'.;R;3X@*T/@!2]P3=^V>S5P`EG19X9%
M.8KB"B*P(8V0(38`"?,F`Q%0`/^X'FV0!C_0!"/`;PI00."P`OOU2@@V8`V(
M$!6(`1&Q`%J50"N`@1@($1E)@1C``@@'D48F"QB7<1IG01'5,:;`"2JC,ODH
M`KN@<B4TDR%%`BYW@\.@@V784G^00S+U*5,@)SI'_Q$]YR%&N1#NL&-&<A`1
M<`\^QC5"MG0V)$5*<H7WD(54=S96QY%=(@4])P4Y$`1=)X9LQ`=E6#=FE0Q_
MLX9\!!2`4X=J!DB%PU=XB`!Y"`9Z)V=WQX=]J`1[:7=VQW>D<`.`)4"$:(B$
MA3E1T0.-^(AY4&B36'B46!6/)'F'!%@1TFC_51B=&&F@2%.>]&"ZU5N\-1J9
M-@:5:9@TP`#>Q@`8X`"B\WFSB`6%87MS@"O#DWN\MP7!HA<O((S$N(N)D6O%
MAXS*-V@*<&S(%ES!%8W,1ES75XW5F(W&I5S3MBW9`EW<XRO@,WYEH`5E0`8U
MX`4UT(NJ,@$,4`;N&`!/8?^/CO)WAH4H"<`4]H@PC>`5^Y@R\89__QB0<J$`
MVW.0RZ)/"90#!V$$".9P9C`#1H`!9W`$%0A0*V"1WY`T'9D#'0D1%;JAW[`"
M&AA@9A`%*'`$E,`Q)&A1*-EQIP`RH^&2&_4#,>-AN5!T,2@B+?1&*D(W.W@`
M?T!<?P"+;3&$16BA2,A@5;,.L9!C/<5C/:8D3*543!6%3E</37DE7S0+4I95
M74(B8#B6..`W3R`'RD`W);$-1/!E>M26?#1(;)97B<.7?&EW?*@$>D>G=%IW
M=W>G>0F(8S"8(S.(@X>(F!,#98!XBI<'_59XAW58E?B>BI84@-6GSC-PG=B9
MFU?_#9$V>RK&`5,P%KLE>JN1FHRC`$V@`B$P!!`0!9YX#5?0B2U0&!(0!1)P
MF[@I/+OXFQ"P!;<FC+N8:[FVBQ```3UP`\JG+`HP;,^W;,WF;-$6B]*97-DH
M4]RXC<U5K=:6/>'8&]Q)&=GE`]\9GN#F`\2HJ]Y6`^JY>T5@;DXQ>(CBJ/<H
M`O$W?_8';_WACP7@!#\0`R.@+`2HD/L4#_V5H`-&&X?QH!!Z!DI$!Q0*-CC0
MD4>PD1RZH6=@9#EP!H3A248PHI1PHB=942#W,9^`89W*43`)@R:;<KG@<C"G
M`CJI(CP8!RPV-)[R!U(PI$-$E#5&HT0R)3ZU8T]8#U%X_T-<0T5$UE13>@]-
ME)5L`Y9I(PY>R*5<]U5K964BP3-H&C@Z(13+P4=9&V9CAH=M%@)@,+9]F*=]
M.`)*@+9U&J=FN[:`66>H0%&H@`HFDUB&&4F#Y6>%&FAZ,*""18GO^5B"^YZ5
MB128>0,SXG"PN:J7-8NAV:F/Y*G%]`B85IB#2`-"\`(=H`&K"BJ=:(NW"'NE
M-CRDJXN[>+J]*CRY!P%"L`4A<`*WA4\WT)S3)XW0R:S0YJS/*FW8B(W569W8
MF9W@J!O;HVWD8JZR4JCE::ZYTGM;0(S#V`3P6CDB@$^.QRCSZ2BN$*]C0'_[
MR!_[&0$BH'=LH"S]5D`&&`\"A_]@!E<;#N!)+("P$8BA$ZHV7'F!%GB!70<V
M"ENA%[H`!GH;_P0#0<"Q%E)1*8C`!\P)(IN//^`A*T>C,AHB*%N#.(D,.5J&
M+QNSHT.$+.$-]U6D0=*$0X<"3OL07FD15N.4431%2[543:</2,("53IU6)JE
M]LN06RB6;^,W9SH2'8%'.Q%77BLX0A%(A6,!<X5V:F:7N?$$(S"G9PNG>2=G
M=QIG>8FG6%QW`T`A-S`A8#RW8ARW00"H[*I8GP8!^`19[?I8D;<YD#IYAC1*
ME9<UE(IJCTN8B(6*F+8:I^$5EFNYI%H"/6`$L*D6E5H8LBJZMUFZI.NKD"P\
MIMNK/5#_`O,U0&41C;8[/;C[;+&HN]();=2)C=-*/=KB7-HY7[RSK=VVB^47
M*ZI"!F60&"_``#7@K;L7`E7A,O79?I'4KNZ:C_>9G_0Z!C'`!NJB`T]07PE9
MH`>QO@L:S01'/3,0OQ-K!!-8D?T+-F7BH1IY!"O@OPLP1.*P&'2`@9F4:@PZ
MDA\K81RW<0?\,2VY,@=3LB%R)/ALLC*CLFQ"-RTB0SPH*M(@LT+HP3*F-!5A
M1#V[A#2P)UTK%$,1`A^A`A^,-#A01$BG#S:4)$?5E`0U=3['$%/2M!'!5;X0
MEAD!5GR`)WHD'#QQ%P$@MG&5=@ZMQ'%X.'+Y=C=1AW!6IU&<_[9Z"IAT*J=V
MFL6`&6=O)D@#@`=B+`IC3`(7=5%!$K>$69B*.D"%*+B40X^3R<:3EYJ6":ET
MG(DV)"V!%=:<<XE]O-9C`4Q]*@IOD`4X``%S0"NQ*9NV"'NXF(N._,C#*3Q,
MD"MET`.SQ6L#]`8<4"##51O:AWV@',JB'-FC_+NE+#W?F!OAN#W;HP.L_#NR
MK`5D(!AD4!D^D)LO4`.[=ZL0@!0N\ZY)\0._/+A(X0H;XA7>FP90H0,N@`"[
MC3SWE#1A`I(@VEP=2(O+%07Q"[!1HS86V=SB(($5FY$2.$0-6R8=6J&Q4+$L
M@,<`YH`P0*(&C*()K`F:4'\:Q2$R<_\D":'>-8H+%@QS9+JC/&`&0`BD;!$'
M!@W""%UC(<)D-+"U2AS@$!W3R[P#4O!`&V#"I?H$;<4')>`-.HPD$9"%\@!&
M8K*53Z;#32:6#*L"+?T3Q3'$-2'3<HG3:#9(@++$@H2G.O#3>BFG+2[%1PWC
M.L#$13P`(1?&7SS&43W""S&W)&/5EF,YCT)X7NVNC@+6?@?6<^P5P*3DAAOE
ME^)9;-VG;ST*'-`",``!84`KAVP-5R"+AC$'KT?FC=S7:.X7<)"K0@`!NT28
MB+O8Q=7)<6!SD'WGD[U]VT>MUM-<W`)-\R6.TS0$P1F>HCV>98";Y^JMZED"
M+O/HTYL4CL?_U8[:,AK&%0;Y9F\V:#NR`T('S;/QONV[7*:<L1!8@?F;S=(=
M@1]]ZA6IH=?]#1#ZL!BP+0BF8%+RSARWZ_#\SH\P<IW*"#^0WDZTWBPGD_R<
M(BEU#"[;@]?RDYUB!_G-(SB;A#:,)0V=M0)NTT*Q&32@`#/2#PVS`5.`!D]0
MAW-UQ!+]!-V`7^A0PFUS=5IETA:!TE_U!"Y]7>3STJTCMFT%ES,MAW'75RAN
M`G)H`3.^EWA:U'<G9TG-9G/5)TO=U'$KQE#-XSX^U50MY$W!9U/!9XZZJ'%<
MF:B)FI;)Y%!^F7/<Y)>HUJM1Q\\3&]6PY1@0!5Y^U[&(!;7"R+=7_ZN/G'N^
M.CP=@'M%(!P,4`(HL`&Q,3W1"=F/?>?3V;M"L^>E;*V7C=G:HSU-@&V]0BY#
MX`-P`)[B*2OBF>B"[:V,[@..CC",`^FN$$E'3MOQ5T\ZP-M)'0+EVP!+`'`(
M"J)F\+[-51C4`_BV,9NV@=PH@`$Y`($1N($!2V#M.[`)]T_SJ^H=&:&F?'`)
M]D^4#\\>\\X@>TPJHR$M*`+&KMZHK\\F=*,O5(893`0+<``M\.Q!V$/3GE,B
M;&-`%PM-\-`Y,0$#CH?+K`!2L"16D`+D#FPAL$=%3#@N(-$JX`U%9!$&Q9%.
MRZ53$H9HP`<[X=)MR#O7%0`G4!-UR--VY?^F;=?$1ZU7>[+%?;FG@*D#8RM(
MS=\G=X'C4<WC^@_5_`\(65DDA(0PA22"-S=OC2(*"B(7D92/EI`BEIIO(F]C
MGJ"?HIRDG9FEJ)EC$1LI'BEN&1D>&;`I$6X\<0>Z![X'/6$:#L186+Y7!\98
M#AIS<QC/&!T=<&5A<-9E9=EAWF$=9W`O6P$3-&8MNG'L[;Z[[?$'\?3U\;KX
M<?GXZOTM_RW,"#33H*#!@S$:Q'A"H*'#AQ,F#*EQ31L9'V7(D"E#;5L9C-M>
M0#`@PH"!'R9%_,CTJ)*F3`IBC$#@P@6"FS=#L&'SI`0.%$9F")TQ$"!`#>F,
M`L2B]-\,(RQ@P##_$B6IT6$:6@S3RC6K@W]F-$2)FB/'D;)GL@)T(%!HE"0L
MC"0QDFB*W;M3LN3%2\)NWS1.IMB8,F8,R:A2641=#(.QU,=2,4"&L>:+BLN8
M+Q-1L5D(D2>;<1QH,2.#&1YV?JE6S8,$C==H<."@LR)($"DH<I,XQ+M0;CK`
M90M'@Z8'FM=-8N^@(V7WA@TL(@1I\B1`@)K8:UIPL=V"]^_@703@HV*V[16T
M:>/.S=XVG1TXT/#Y3L`"@0GVP7L/`"9$_Q``@L'?@`):QQ\"`2`(QDTF-.B@
M">(9"-Z##>I@87\&:J??AAO65Y]W`^`AR(@D"I+(B">F.`@B',#0XB&%_V2Q
M"".<1#*)))?`Q)*.IH12V`VB!`G**3UVDD(+&;B1PB[JO,-.D^S@8P8[K+TP
MQS#-.(#%%7$LPY0#41@Q1P?3=."--B&]L`TVWC`Q31@>+9#$.O.L!L\\\L!C
M#SMV[%G//OKHTP\/1J5#$$(%Q=!$`Q<49-]#]]TG$0/<"%"&I2!IH9$W6GSD
MZ4<CG60222N=A,FI"C3Z!!LT(9B33CH](40)2ZP`0Q(S("705VMIE12O2P5;
MJ`:Y6J7!L<=JE=6RR_J*U+%)A376&3F@4%53;!$[`UQR044""GKUA=<4?95+
M+@=..#'8%`:,\<,/BL7;F&+S-I;89)!)M@84#?]DEMEFG`EQV1.BF9$!43ST
MLAIK*+Q&0VRSU18$>X5`MEM[O4&V6+PL/.?Q<QVS0$(0=.!``Q%\A!"`!?AQ
MUYUW+G.X7PA$H+'<"BNPQYX40:`''QHGV(<??MX-S3++_B7=WW\!^-?T33I0
M*#6%%AA(TW<X)6B=>#'+S.&''VXX0%XGEDAB(BH2LF(A+7*PVXMMNYC(C([D
M6`DD+J'B"2-C`+EW8:.@,@8'&?BBSBX'"*0.#P8+E'!``F5PIR\LU(`!EL=J
MZ2538HUIIC<>A4X1'-]X0V8'3&`#!PR(JX9XZWKFZ>?L@.*CRZ!Q^%/H0;PG
MU$2C`4`:T?`,8)1--MS_:`%Z#<IOX\,+(*DY:DDHI013HR.P:M--6B.PDTX\
MS4H##COD`$,4N@*KE%=&,<54"^_WV@Q7S2";;*[-9H5__ETE:RA235&*&88"
ME1F\Q5M!$!>YQN67-``F738HC`'>P!AZ6=`QB)F,9*12&7]YT#.<N0P._F`P
M*\Q`#$U:V"]X(`6'*8<VMM$9"@XA,AA]"P6V>LQN2+"Q>$''"ANP@A"'2$0@
M0D<Q5F"!%-#SFA"XK&M>VTX(:,`<&:*@9^^)#QB(]IV609$_3C.!#A0D(`10
M*&I3>Q`:J]8TIVT-BE&,XW=BQAWLA,AL9QN$'M%F(D2P+6X<>-''-N"B0"KB
M_Q.<R-&.(L&24HSBD9X0TA@DYSI"M2!*`Q&#+#;IADZF(`4;$$/K#K``!G0`
M*YG;7/V,\"8TO4!-'GGE-5)G.C-1PTQ1>(<N=_DZ/-TI=K/STSIJYP]+&JH%
MO5-(09K@.S8X9'A#B"8#8&DI+<!!`*3[QC7@]#Q//:\')#%)]6+2@)UD;7MM
M9`/X3B`K%92@!#U8`OER@(&@_`-8P%)+`/?)J[!H!7_X(XVREO44#!B4!?5$
MG[*<U95>M8`M#TU'LPC(@J',A07@XLL""3$%#@!F70;`PTGDU<-Z5?`Q&WP,
M"BI#A!*XTX,`>T((1V@&(99&'7]0X0'LT((6PD8V,/^<F&X,P9M#8(R'/+07
MQQ3S0R$FP:E%#")TCKC4>.&0#J])V<HXQ+40X$"H.W//SX)VM`EP9V5<9-G2
M0L`@$]RD)FF,JUL14"`)R?&N^JEC=O9:D['I$45X7!LB!!O(M[GHL!P@I&('
M&4BW.6$1=7.)(CNAMTZ(XD@\D,64$L990C&.4&800V@UN4E9=-(-S\E`"U2S
M!5/:;QC,8(:RHC`FT*7)(]IXY0NRR01JD.Z69JB3ZW[QRSH5%YC!C%([]G&[
MY@;P4`=9U*(4I:@&N.`^TF1`#6H@2X_`*1L"*)UM??`\C+Q@">(TP`7&6)-6
M)0@!`%+G]]@@A%F5@`8]B*?_/!=0/A2PX%K[A)Q2W`<_H_`J6<2RWS]?JZPS
MG`$&3,C!&3!P!B,@F'_+\B<`>:6^@&BK@$,Y(`S`92YQ_06"A&'7#:K*,9,J
M%5^/Z:!+/>A!F=+4"BDPH6IYD--?],D78FC83V]FF_6@P!`[]`T*FB.R&B*U
MJL\!HA6>.N4J"Y$%0.P85>,5`7I)Y<CL*9E\T%J3`)R`#K>1(19_QH<W7F=E
MUZE)RYHF()O(=6H(TL$;NV8@)X+'0_F1HU[Y2FCL!.".*OHK'_W(:!*T#9!P
MVT!B83#(2C?VL7ZKT4L86:0>.6$UH2U*0$0;N=)F@+2Q2)('3@N+#"0L<4-@
M`!->_XLE8C0C"A)HI348,($:0&`;R"L#!+;+#7#`"1QDHE)QA?M+=SA;V<F]
MQW*5:[O%-051"8D!=9G9!#9$))HUT.YV0;(-;(:7=.$-`S8_\LKGJ4D!(XB!
M>K'SJOC"Z@E%J.\[7Z/?_<IF`2N@ISV;PA0S=)C`2CGP0)F5JX#FJBLL8()B
M<L"$QE2XH0C&^%K2@4^`A$4H<(E"B+?EK8QRE`01^.@4U.6N,;!XJ2[.($IA
M@(%]]0LS-_<7$4"(`SMDP&,F/$T<>IP:7]C!#*[Y:<1B.%0:[G#$N0G"9"K(
ML:EBN8A#3()40\;4I3YYASJ3@A1R@#,TJ*#-?$"S#'GFL__X5(=K;Q8/R^HX
M`36L#$(.\H[4;&*@.',(/_6Q#H:VZC7M%)JO<8XSU^#N`K^:Z/&/;[0?`WG8
M0B*V18J==*4M74C"0#:1G$XD*B*P&AYH,M2B)2UI:;%)TKHB24HZK1M$NUH6
MQ#H,Z(L"^FI=/PEX#AO;X+6XN1NZ,L`R#+V]!C6,L&Q>&M>XQ_6EG_KTIT#E
MXQ^W:PIT#>*[!G";F4^02#0GLMUV7XH;R,.FNL'K/.B]THDUT<%VX`LK^<K*
MOO?%[Q+V[^\%X,#_`/=@(O=0VC=@_Q`_]_0/S*(_"38#`_5P#4<L&"!A95$M
M#O85#(9A&N9Q!.A0`_06%35R!C3_%R.V-E,@`RA&&`:P8B_78AMC+S#6032&
M&3M7@^5A!S/P,59P&CRP,'^`)#[U,+*Q`Q*C&T?V=$9U0Q/39(709$OU0QN@
M=4\51%*695.U98K194PX8C<4=6R',^B!`[5A9+CA'F)6'1D2=W$V9W='(2X`
M(0AB5UY#-&'3=QFR(8=G:(RGAA&RA^(1(HL6>8(E>8]F>2T2`91&:9@G:8NU
M>1N`6A]S:8N`2*)')&_``:MA!XQS:J:V20:3`J6%:K/`:K$G"Z*4`Q.P!64@
M`1*`:\B2)<T@)K6%)D/P:]M0`WF@)M9@B^A7!@L`#JNU2\RF2\#T?,@5;?8`
M*`#A64;!_SN)PBC>IR@7<`+BYP7;-6ZP5"F7T@W8=$W64%ZZ16\!H`,Z401L
MD&_XQV_])AP+`(#_UX[\52W_916%<G#[%!8*MC_V$X''LC\S0"T4)V&Y$04+
MQ2P%N8'-TF%701I/$8(B>$!106+I`D%CP"Y!T((O]V+Y0AE0,(.;48.>(00$
MPP-)A(A!I%H+0Y)6D`%")H1$!E9$)15*=D5'!B.]X81/V'4>@V4ADT18&"]?
M9U0[<T4]@QZT,89KMV;QT69]&'<N8%;;,0%-HWB+!T=SR%76H3+6@2`:`C-[
MQ8=@V90!X%9O2"%^%2.+)GF$T%A248@FF5B:]S&4YH@?HW4IH/]U'A,!C34%
MGV<*(I`"*9DP!M.)I14!IJ9)K>8!KP`+G;1)/+`$L58&T2`FKH@Y&L"*TW`\
MUO`"0_`"';`-PT9\QP,!LD0Z&F",PVB,T'9<TT<[UO>:@W)MB&(0C<)M(2!^
ML59^T$-NWW5^<&!-L02.+[`]`(*.[K1O^)5?_"<<_]><`+@#\%@^9U!1^E1@
MZH-P"(B!70%0#9A@R.)PQ'(&*Q!A9Y`;&$"`#X=A&LAA!/@5^31`3Q$40_&0
M%_4MX](N4X"1)&5!,$AS,=:1.A>2'ZD"H#&25@`CJ55)0-08&1"$$!-41HAD
M,@EF.#0Q/"-VN$&&39<8^OER6IA4%W/_0QEJ&T4)'+6Q9&IFE#A`'5N3AFJ8
M(=F!5UVD'UQD5GT6ATY91V\6EM=A`N_E5D!:(6HD1CHP-H&(-FKI-H48-XAH
MDG.96'09I<]QEU(8B8&$:9]P`RHT=`E#F(49BJ85"ZL6>V[`>J:Q`+'V`N`0
M#<_0BIDC%F)B)L?3`V7`7;]8#<;G:Z0S#L07!AB@;*@YC,?(FM*'C('RFH0B
M*)P%$,[(3-[7!-QV`>8P!%XP?.ZW#9W2*992;J%#7NQ&#FV4;^^47Z3*?_+$
MG/#X;^\8G0!'3Q65#O%#C_&#@`3XG=X9@=R)J_U(+!%7@1/&<>EID!BF<<\%
M%A\FG_-)GU`Q_V)2L`AXX'(=NI_]&1F4\04[%S#72J`U6*`$TP(;4`C/X0N9
M-0-6X!HXT!PST)(/6H1@9@A.UH4X<%_[EG\.@QP0,QO`8:(2`U9'Z$<98P@4
MFAL\<QY&B3-I%G9*V01MEH;B831$(R%I57AF54?;87@OTV=6TZ*&IK%;Z2`6
M$C4@*T9IA$8-<I9[-(AKJ:2[47F`M%A0*J4P^S%*D@1ND`1X^1R%Q0$]N#!<
M:GI>*@N&V8F=1`M*X@J@Z(DKD*;;1`ULBCZW1EMR"GQEL`3AM@!NT@$+,`X0
ML`!UJHO,UTO1IYK/!GW0%VW4-VW7QXQ*,9O3M6T-,`35J%UDT&[DQO\-F!HZ
MG6)\NO4"`!("]J5_2[".S.F<J@J/[0B=_)4S&#"/!]B!!59@V:F`I+&KNMIP
ME=N=7N%/!?:=!5F0S=)0$>6>C@LY0B$7VI*L!I2Z;W%1S.I?T3HO_(E0D+$O
MW$H$`TJ@,O4$!8H&9K`!2\9#JS4#0AD$KT$'*-"@+@14['J$3I>$2X8#?18@
M)S"]U#N]?'"]?*"[H.$OR*ET^!I4MV%D`CNPM8$S^1H$.2"^5[0"RV$R?*`A
M1D,?^3$@;P0>+3.QV(&_?`65VV$@"[*5#-L](NNQ(0NR2H!&!6PA!RRR@(B6
MD^=HAL66@)2(C#B7,7O!4YH$=]E)-.LQ.ZO_&CF%28/II4=KBK*@F&'J"F5J
MBF(``PR@7;^636LZ![NG`49@!)^SIW"BMY)))ABP`"_0`Z\$!Q@P)6%+C,0%
MJ,7(FO9PMO20#["IJ):$3,E47;79`+AYC=Q%;GF;J1C1*>8EG`P0`J(*3_$T
MN*C:CLYIN/R%N-`9<`\V<+0*N?O4C]S9G4*A+;MZNMU)/Q'5CQJ7<?EC</<4
M+0FG@!\8@J>+NB(W@G,!%1@%N]&*&#*G+U`@D@5*H+B;N]K[!#V0`3`@=B00
M7!N@HB53O$'4DD,(H>VZLC"R,]#;=WW['WU[`K0,(-6+O=A[`GT+('#&3IN1
M?P_Z'LMAHOEZE!8Z_[YKA@9-$`)EE1^1<C0L8V9N%*->F8=[=;&"UW<(XE9C
M2;)$"K(Z<,#D/,X?JP1W5K+DDC8LXFB&V):(1<$8/,\>`XD:K,$<[`;!Y8.8
M)`;^_+.AU'J;1`N*>5JK5EHS\,*^AEO9U`$T+!:XEL/6`"=Z`)IEP`1&P`3"
MQ@U_.ES/%ZC1UVQBFUQ.3&V!$IO+R+8*L2@\H0(AP`#2M%US"SW%%Q+NAA'F
MI5LU<`)%\$YFO'_->:IH['^K>KA&O0*MZE\6QH&-^[CQHYW[B,=2?;EY3-47
M)JR=FQ42%1!L(;H*^7%S@;HSX)!NX18V^\@<VJ&2C"^TV\G:^QENK;MH</^@
M/`,#?V`%='`<KQ$?K[$")&`%4Y"\+TDQA/"N2AC+T7L"NUP@918"V:O+NVS+
MTSMX(6#+O7S9UKN]P@PQ1)C,*(I%IQP\CP+-'!(@?0NCB%=F?DB5_9N5UH%W
M;V@A%6+.Y#S`(7M&`XS;14HV2,HV[CS!<'-8BB7/]#S/GW3/=UDX/+M<H?:S
MC2G0IC:F99IJII$!K<5=V:B983`';HK#WQ!L+U#1$)"+R`,'IT1<J`D[Z;W>
M]E"H]5#2TG;2B<J,A.*,RN2H(5`"3;`$1"C$VG6I=UL&8-QNNO4\U_@"10`!
MHZJ<I^I_0IVJ`,A?1@UP[0B&$Q87]-C4[_,^!Z;_QU9MU5.MJ\CBN<.J%O/S
MN0'$81\7GY8[`RL0`F0M<HV\NC?<0VKM&/[9UMD;UW'-!SUPH+;1`E:P`C3@
M3C0@=3A`,P2S`4$H'&C&=-\2DT)Y14G>1F"0O9CATT]PO>/!3CRNO3O^V"FC
M,EIIAW9(Y@""Y26`!FB6H5$7!&@0`L31!,$#-M+LL!;@V`$RE1P;(2[:=XQW
M5J[=HQ;@L40JI+(-SKA]1A_;Z$I@I+W=SO`,W!1LP<5MW,B-SVXP2L3U!YQU
M>IJ$PJ55PJ:6:BN\:JU66J6$W=D(;*2#`>@C`9^C.B&Q$=^``:03!;VTWAY-
MJ$R\FB0=W]>7.U/,J+.9_Q#EE-_[O0-!D`5'M@(E8'[%9^`OH,75OEU;L`4*
MGIS*2;@/_HY%;;AO7.$2-A4$&1`:WM1'P8"4VX`?+A;=J7OR+N^5ZP`...(E
MOG%>'5':5[KH,Q0K4`08D*PR+N,V6^.2?..3H>-;KKL[[O`-[\GE&@16T`)8
M=1DG8]J*W0,;0+P_]1[+BV3O&G5Q7LL[KAD#H[N*36-NS0>*#>:0_43]6V9Y
ME97E\>1NWC-$$``J<!Q;=1_Y$;']FS1.4U=F?O3=3*0+O!]-8V?I?&<%/+(D
MBP`F&^F_'<\3W(B7+J6?=)=>C]RG%8S++9@"3="C[J5FFFK275I)D.U;L+<U
M;?_>$B`FXN41$%#1'-$!NCXY@=KKPQ72>)+>AJI<B'I)*&W?OA,#9*S?_!T$
M1[`;BA$$2T":'C'@6BQN+QQK/6W&_;8$:CRX[CCAT#GZ%(XS%SYP'6@,ZEZK
M[2[B>&Q`Q/+O_ZX!&$`#$%`'15`'$*`"-'`Y^:B>?IRY$*60"5BK`P0751T%
M*"#6C;PM8=(M":_6^4*[CQWQU7_]-##Q+>`:[T0$)^#G!E("'9^\2P>3KOS*
M48<#+B_96.XO7GZ]3T`#\NK3F>'8NPS9*G,T</=F0P,(!`06(40].'1!02A2
MC$$K-`$T.)$6@Q:8F1,6FYQ@(2%@GP%@"#H(J`$(JJC_J":O.F`Z.B:TM"X6
M`;J8)A:OO\"_M+7!Q;"_"*6DNB$#4R30T=$<,##4U];5'!LPW!L;+-_AW^3E
MYN??21LI24GL[O#L*6XI&0?W^/A_<3QB&?\9S&1PX\%#!H/T`!I4^,\-0#?T
M'`+,T(-!C1<8,4(H4R9C&0P2YG0(0S(,'#@<RRP)8R1.G'LO#[R<B2]FOI@V
M9>J<29-G3Y=`@PKE!Y0'4:,MD+9(VJ*!TZ=.8S1@$T)(B24*=@3)@H)$MPWJ
M%FQ,B;&&V2U#TC)86Z1$B1YPX2Y9@@/'@@4XZ-K=>_?NCKLK%OQ=$'A%#A08
M6$31L'0IEA:/'S=VL%2#AAF7_R]CWJPY\XS%43Z+#DVZ1Q$(&VE`*'*"10O/
MC"U;?DU;@QG&E!F;H;R[!>7?C8/?GF'$B.89R),K)YTDBI7BQ5'`8$&]NG7K
MTUE4J[8&RI,G?,`_.<$G?/GSX6EL(&%E`QH5)50\R>5"%[,2&X+0V%\7T0I%
M*`3HU8`P1!-@$#CP<<*"Y#U!A`H00OB$"D*4]T1=:&38!`TE[$?#$VZY!6%\
M$(;@`BX$;*(B+BY,<*(N*M"`AG^*-(*"(G30@0,:-(#1B8J<9)))?;+,8J0M
MM"AA"S'#U-)D,/7I@DLP2"YIS"L(F-"**B&L8M^)N`@YP!@D9"&-5]=@HR8W
MU'CC)O\Z<*K3#CM@P;/.G/"XD00]>\Z0SSU_Y-//1!GXXP%$!V50#T.,#O3/
MH8A.M`$$6UR$T189980I$R*95-*G'6C0DTX[D0K3J:C25.JH/,GDTU"PQF%'
M44?QPQ0/34&E:PA%--#$$COL<$17TZ63A!5'J/:"#R]<=%8`)X)R@E5QR367
M77CUMU==?=U%UUQ+`+9`#F<D9L0,P4$66;JO9>89<K")-MIGI)%&[PS`+479
M8YW)QABZL\76F&Z4^<8NNP*;@=RYFRFW'')1-">Q$4G`(-UU&&NG,0P8<-R=
M>.:%C-YYZI'00A`BQF=!E/8%@!\D_-6UPW^+"`C-=M`$>&/_@NA-")^($:H0
MWA-T[*`M#DWLB`,1,GKH-`TA<"(()BSKHD8`H`00XXQT_*>S%(_LH"./)JX,
M)I@NKAC`D\#HH"3;;%]I`LL(\$),,;-HZ67++8,IY-]_#X"'F=)PP`&:V6##
M33>,PVE..Y!'CF<\DD,NSYYSYA3HGSP\--$\AQJTP4,2$?H0I*.?SL(+E59:
MPQ:57OKZ"R7!\2D3'7304JFGJFHJJ:/6M.KP<>RS4ZS(&U4K4K@NI>M3,8!B
MU:\S'W'S5W6V@T,)=93%^A,(N!`"UE:]%=<2/5R[E_I\V;5##W?U4$+\X1J&
MF&*,.8;%NL$5+!MG`%S,9S1@KWK=_RL*"#R@`&%C&7@!3&"V<<!M\E4P@P$G
M7\&QS0R2P##-1,$,1DC@:")&PN*P8%@9R]ATM@.#CYD'9",C3WEHP`(KD(`&
M\%$!'6A@-FC91P4;V.%^9H0#L0%(9P0:$`D.Q#/TC(A#0)-/>101A)FMH(@Y
MHD,)BH@AI=6%#YD(`"?L`XHRJF%\'>(:S1AQHR`4;4=0T\4$?%B?LX71%Z_P
M!1[Q:`PDP<)(Q``3UNR#@%"``@Q]@]:)`,?(1@+.&6>"AIJRX0U*-@X=<H)<
M]BK'2<GIJ1UZ8H=#_N22S=VC!9X#2`I6"1$/I.X@I3.=HR"R@5@.Y`B4>EWK
M8,=+V#&@#/\F.0E)<@<#-[3`);SSG4U>A4R<I(IXJV*F4&8U%*-8TU9Q6`JN
MGM<`J6"-#5;)2A"&Y15C@<4*&]P!:ECW@B;H($J\HE:UP$67;.6%6WPAS/R6
M4`:X!`8"ABD7"\YEAL:L2S+ZNDV\%CHO!#KTH1"%:$/?%;"`U::@N=&71@_&
MT=<HK#C*,4,48,`PB&TP8D9X#@>/D(/LI)`Z*ZQ&QSX&GI'5M#PG`,,,63`#
M.N10!2LH`1'D`#)0`%&(,I)9(FK6%:\4J$!+/!`=:NJ@)^XGBC65F=@0047]
MK."K*]"1V,1V@C&&$6MES!J,DCHS`$D!;&$=6QSI"*TYIFUE<[3_F]RL)(R[
M84D4?%,DBQQ)V,(ZT@60/!,ULF')Q572<>D`RR8[^<E/0JZR>LJL0W+BJGS\
MP0S^<)0JW4&06J92E@,A"$16:3HWP(!U:XGM6M(RA`D0@`'P$V88F%!,AYC!
M*#<)KJN`LA0S&/>8O`,>-%M5/.0-A9K79%XVG?<\J@AA>N`2EE/#885V=-<-
MR$%!$53P`B$T(7S,.(WYYJF^:^D%+]FZRS[3MX3`E(!<TCE7_M0%&82UBZ(.
MK)>`(TI@`M,K-,>!3;MJ0QL'"*Q@%]SHP2X3!19X)H08EM>]F@,=%`CKI==A
M80NA8*&1H4>GY#D!#69PPQRB`65!(\(3_\"@8ACH9XA*/:+-<-85)D+H059]
M6GS.\YVA?><$(3C!>$(0'OCP)T=@#-(<SXC6)(]OK3,R8A`:`38W&HU'B`RL
ME$[4B5WT\14N$(8J=!%F10*.96%BY"7^QJ(ZK\QL9UNDGN^,6#Q$<DT;:%/C
M+@D.<JA#LIU,=.0LRVB([(D'^@#42S9G!X'\8U$#627H(G"ZB=BR(`6)2&O=
MP`((Q):V:9F`JH7@JPWF(`='2()`'(*H%IB*F<556#NH8P95!8]5T!SN<X6B
MO.C:JGD-&(%3E#T"Z96@">G+BE;&V8UVG%-.>CH"A>13M_%5I4/5HB\][_E>
M;&$++GF!WP+")?]0Q:!+?_P;V&L`"$`*A^;`!<ZW@1&,&7\Q&(+]"WBZ*EC!
MA'XT"<DYSKU'TYPH4*PX,*BO2U,8TXZ-N,@OQ.EY%D1C&EC!IR1*!(E^K*`3
ME"`"=-A04K&HXV@\-6=,5%!:9WYE,9.QC$\(`0V(0//QX<)%5F.&&=6J-;8N
MM1&*".N7>U3S+Y$Y3/4IV]GHF.<[RQD3@Q@$/*%U6#Q7/<]['JS8^9S8:21N
MT(]UTSC*H4E%4[;1H,0<1&PM7.,=X`^=(]VC4K`.B'"Z(;%<2*</Q7="0826
M*S!UJE6=HB8T80=N`.T_1B>0#5CZ'[\=2@N,BYPD:,=B1S@"!GJ=3.'_+7>X
MPG8N-8E2JZ1DDP?+=LH3L/8$[$I;$5G(O9D0O4%CB;<(11`C6N5Y/G&/6UOP
MQ5:W^D*NQ+@[?_OK[V0,YB]W;<:`^M9W"`L\+P?^]]\1_DUO,%CP=&F&I\=Y
M6+T@!QT8]&`'*``Q3#\_4^^(S,0,4A`-2/`>"-%`Y",G'T9%`CO@(42D93;2
M5$_55$S4=#;W@(-T<Q"X"543@3/W0R6094NU93<25W!T`E\"@6.V2(95@F?%
M9KO0=7ZS@GH&=F,G=H*C6&?W6&BW=H:&:&WG=IAS67+':++V)W8'*`?``Y>7
M6I>V#BG@2J]T**(E2PY1$(4G$8<R`X>G#C!@_VJJIFI%<`249UP-`1"O-!''
MM'FZ9H6@%WJA=Q@S`&S*U3O$HWK)LSRVTA3*U@#OY`)%,#W4HQ6Y=SW1X`W6
ME@XHH`(G$'S#MU[G0T_MU1?Y)!A^,2Z'82ZA45#J<E`9!&">@7WYAF'0T8F<
MR'W\9GW_UF#3=S#EQU'#`5+I1QS5X&X(YW`/QP*3<`3480041W\6XT)$=G\Y
MQ2`T@#(D@@/_$8`REAXD@%0'N%1(=#-*%"!@@P,B&(T2F$AVA%=7,T@AH`9/
M(`<10@0DDD:(T#4UDG1OQ"-<!SA99PF8("6--&<F^#?V,0IN1F=?YX(M6&<M
M:#8K4W:',X-H]R;GD/])D^5V&Q1W/GAX>F(&0!AI?X!W+1!:#9$",Y`!Y#`/
M)*`0F.:$GE9X39A:JT4.X[`GF)<4F`<09I"1$QD09J`.GX<":/B2KP9K:^A,
MOO9,S60\SA4KJV=LVM0"S,8&+\)JSX856D%.Q2(.U8`"@.AY8)$#P%<$XW,"
M$("(B:B(R->(CD@8S4=2H4$;\.9?#10O"'9O!58<L.B):.F)!E9O%44;XS=]
M!1>7`E=<&\13#3,#+!"3KZ88Q^)P'"2+2]!2(!93V]$=NVAB)<<@6Q0A)2".
M420$,A8CQ^@A2<-R'-AC9])C-T('TAB-+J@)+5(?+E(UWA8T01,?1D<S7;;_
M`EMECNJ8(EG7"4(2"N?XCB7H0\OP)?3H=?;8F[X9@V;GCS18:#9H3I4SD.U0
MD!N467$G=WNBD*;'6?Q0A`<Q#Q3Y#?3``9_SA:W5A!P9*8#')Z+42B;YD#S0
M.9<'$;.6`1.Y%$F``2[YDFD8DX9Q!#/IAL&#GV\(*ZL7%,HCATLQ`N!35P%P
M74-9E&;R%9CS#="P`]W`A>%P+$<`?""8AU2)/HJH%^&R;B6`&J@Q/X!A/UPY
M`P7%&/MCB?KR/V))0",$49R8E@,U4+:(EA%U+_W6EAI`008S<'.YHQGT40NG
M`7F9%R&:`R7D<"R0/D<P';9XBQR3B_:'F"E&8U3:_R$10B/Q02(RYB#[IT7@
M:)E(U%0Y$U7/V)DVAS816$=S!&>XB8U8PY@_DT.3$(XT0T4Y@B$EX`*"D(YS
M!B034!YA5EAC9UADA#6K$#YQQIM@QV<OTJB"]*@O4G8DL";_"%G6QDF&)CG*
M"5YZ0H6:1854")U".*HP\0</.6H4&0'KL`&"9YVH11`;:5I&"!!60&L(F0%6
M`!#F>9YY!TL2,3JRY@\ML`'R.9\Y$"Q_L0/W&9VE!VQ`D7HYZ1(\B2L\T&Q/
M5Q4-<!7BU!41"E[_0(6>EP75LP*TF`X[0*'J%6X8:I4X(#]"`'S7%:\00`.`
M02X#1:(2U%\G*G!AF1ECV?^B#_6BT!&CMC@'U2$!!*N6#B4O#/1O;]FC/LHN
M!*<P%=8P.;!\A&$8Q?$<MO@K@DFP(?9YA4EBB,D'-,8@278"<HH&8A-6'&*:
M$T(#*+!#7XJ`RPA5,+<S9OJ`5S974B)FI,D,ISDB\($A+=M5CU".-(`BK[D)
M@Q``448(2'9EB2JH5L=(48)(;39F5$-7=B1V^/BU+LB/C-58W1`.9QN0..A=
MGI<=F\2I!<F>S@E>&R2J?_([Q4.=ET9+JNH&VJE*M-:=37@HLJHHX-F$ME10
M&7">).EIDP=>H46$,("&,9FLZ[8$OY($=*=<R\2Y^ZF3<6A-8]@"@C5'WT8]
M6U'_3MY:D@W!`E6$N<&R73CPE/`1;L8'+CWPKD])H5LP+4(PE7=AKP050?OJ
M&`/#4!2&;R[JB3&:&(EAL"S@O-%;BS)JE@_5,+)1&P*SH^77O1+&+JF8'$;P
M5?3Y54Q@&!QD0NFS`DSJI!T#G[H80PS"<3D%(4:#1<.8I1$2LU)0@&E$%UH6
MIF.JF66ZLUG+9.5A(N_A@$`;`-=X-2$P(EDZP5#S?^)(11ZX(WG*IUB'"7R@
M`E2#9)\09B0H)/;(9XS4,N-SJ(+5J(HT-S"<9G(#);R09B<BJ2RT6&]2G&N;
M:-)0+)Y$MT),MZ%J2J8$$\O4JZ;C#MZ0`G]7G8EB.@CA_VEN8%JA5<6L*DMB
M`%K^\%L!@10JR9VK^P]B0(0YP)J"`2Y-X!8-P&J:>VMM2).H)TUP**T`:A3U
M,00O`D[:*BQ9T`UC?%P",6N3^S[`\A_#0@/`-Y6V:WP]L!J[RQJL@60,4!6H
M,3/E,KQ?B5#^0U'_NHD#B[#3Z[PH<`92D",>XA;K>P8R*E$-&S`1IE%R^;T"
M)T$;9!QXF;'U2K[L.[!SP;XQJD(BRQTD*Z7D<;(+H@(SJU1=$R)!$[,(PB$T
M4)DV*R!B&E4'@@9FRC+2`JCCLQ\*P@=B5@?B+&81G$/?""%(4Q==4Z=5I"-(
M$PFQJ8Y!(LZ=8$B@L#?WZ)MGT_\+0X*"8>8E=50?ASK#8*`E>H/0,VP"P#FI
MUJ##U9!VX6"#<H*<ZY$%`+)=QG)9H(H<=,M9I,0#@1(H@S(0(MD0;/(-F)80
M3*@0+3T1A!N&'GFXA%+&EB8&+>!;Y]F1$X'3/,`".X`^:^P40L`&;#`+3[`!
MR!7';2@\KP*MT6K'T=4":",^XU4"XF0F+."MQD6)C$N&9C`Z1W!/8(4ROTN5
MZ4-?IA');'T"#!``#/"[]94#B8%@E2A]U(>\`.M0S-ND&/#7&'`&834%-C`%
M!O`#"N!X5Y6E/;`"&+!]]@(OL;&]N%&*$-M1C7$;GH<<,+`"<($7AJ&7*U`<
MGH>YP-S_I-1;'3+%,2C@0C>%4[U(OV"@S%=4-$4#8P'H?]%<L\IHS0-,I@@B
M@G4D1_9Q'A0BSOLA-+-7J#H'`7SC;5H3IRFS13IBVUVE='@J1D(")!;`!T00
MPH>T#*L@PW-S(GAC`F_S-K2@=<R@"X=ZT+)@`@>=)7T5-WLE-XE%#4[%6(4&
MDFJK:.O155QQ,]21J1R-'#E1`7?+#Y`F$[UZ:$GP*)04`:6S*)\6Q:0C:@'A
M#^!YJYAG7/VPQ1#)JSP0N+'T6[^5!6ULU$?="JC`!DI]M\-CD]%$QZ';>L>D
MQR]RND64H!LPD<=U*TQ!E[5$K`5H12MPUHT\%Y#,UNCZE%$)_P%"0!B9_$%W
MC==+T6\)AQD+&[!G:8L("]@8<,I.D`8_\`.'?=@)H``90D0O&R,X<`;;I^7]
M5AOA=]FG:(JIB'`8@,9G#%;T25*V^,O9,:,J]*0C9LP,@LPJN\SAB,KZ&S2_
M2`D=0LT;*,`&HC/!;<!8TR`1$@!HT`3RH0+074;[87/G'*>,J2WMG'2L"<^N
MR=V8L`DG\-V80)M5@@Q4,@)',@OJ30Q=BX)?@@RQ,`R`="1.PE<+_0KYK0W;
M(6AHZ]\WF$G'20**\`:X=P2ZYW(%OM$@'6FR<I[-U:OTL`$1$.'KP0&J&H;U
MH%H,(7@P34MDK!"V1,9;?)X%M<5>^/];U"H1MB0&9;Q-;.#B!`_C2TWC,^ZL
M45U-4FTK3X<U;H$56P'(*JE-U/K5Q94!+)D%VV-%\H/6<U$"A=C6K!%/UU4$
M;RW7AM$Q1F`&Q<O)_E)O>XU`H4P=@'T&5A`!#R`"-B`#=Z``9_X#(G#F"G`T
M.`0A/9`#BG%O[C**/DI^F(V*EV&+>!G:7U6OY$(N%,,"Z'/:%+?:B!&_&\?H
ML:W,\(Q%7DJ,,;+;,D(7M\U4F!GW;02-G2F:NF`A(P+J/3#J%ZASD<#<1B7=
M1-L?673=Y8@&)3""H;E(X<$)XM,E>7,,;9,W;E/YZOTVM1#L`?W"RVX,2M+Y
MP)!8(@;1YE#_G&Y'2]9>1=.V%=K>AR[GMG:[X.%.A$9A!TI<Q7W[AX4+J[#:
M*%+L`:RTX:CUX2`.6K3_X23N[Z;S6TDQ`SE'\*W`!JYA>D[MAJ>W\+0BAT:1
M-N)S74FS`[OWXQE@\0S.>OA>4!.9!&6R`R%PR$L`\A`P\KL+@F[=Z5>V(`%P
M&HV=]2P`"&8M6(,MAH<S#C,:BXQ1,U&1D)%11I:6+"P8FQ@L=G]_$4T/!G<-
M32(B/S]!/W1T.SBQ."4J*B4+9T91C+TM&K\M#L*'Q<;'R,9FD"PS1BLY*TLK
M"]0X*V=G*\XL2STK,)E&+..9YC`P&.@D:U!\[_!\)_-@)_4A]2HH_W0X_:]T
M-$H(M$601A`T`6DT02.+3I"'*"*B($%QHD0I07`$V,BQ8\<)'5T$./'$%HT`
M:-"H*`DFA,N7)4YV#+$Q!,&!MV[A8(B#SHJ?07Z^ZH>F1,@`(B>X<,&'B`L+
M4!&8F$JUJM6K6*E:$+D13("M3ZGJP#JV[%4=:+->'3"%(@<8;]'!V#`W'-T-
M>/,F2;)AK]^_>S>0>*A`@:P=.QX>.9(%198L%"F:.4"YLN4#?WAH-B/&C.86
M&4*'WA`![V,2&SB(SI#"36@/KD7#7KT:=NL,9CB'CAV:<VXQFSOSR(T;]^;=
MM$-W;J&9!9N7"$(@F*X#1HLXE;$?T(Z=^__V[-^[;X]#OKSY\^1YE%?/OL53
M%T-"""FQ1$&0+'-="](<A[_Z.';T)PAH,[0P`PQ!+!'"$HB5T,.#$/9P0A$4
M5DBA2T4P<`)--141P!8J]%#-3Q@`0X@A)_["R"(SM.C((Y1$<DDYFVB"P@R@
M@,+#%!<TX",1"_WP1BNP%#D+#;?0D(L1+38"S).&#$.,E%(F8^4A&I@113-1
M'/'3-#O\5,T9*&PSSA+3A#-..>:P(!<Z&*#0SA/QR&///!OB:9,4L_2T`QTX
M$632"C@DA,82?D(D140D6-2H1$%IY!%'7'&%U*4BA4"$"C2$D!)!&[84P@EU
MU)'A1G5PY-*F.;7_6L)._CCTD%"S-*$"AY:*Y,($?#QA@5)(D66"6<,6*Y:Q
MQV[5U49+A:766<]&:P);D9&`SEMO;<!"7GAMBU=@@(4[PP:.O5%H"4T@J@!B
M#P6Q&&,H;'#9O`=L-EQOAM"6`EX</`9#::NEL)L'`Q.<W,!NW(:;&`?_QEP+
MO@W'66?*F2&::P*OQMEP/+100@C/N11==-91IIUEXH5G\LKBH>?RR^SU)_.N
M%@3`QGR('H%:$C,,*'/,`*Z'B,4S))'%QXAY$^$2\Q0AA!`6-FTAA5![6`0$
MW^P@XAE1#%C,,!J$W4O8B\08XXR::'*&=:!@IJ,(#XQ`Q`@-H,$**T$8_PD+
M8CW8\FH.3+(8MAD:#%/EE84@KHPS3)Z1PP(+Y!!F-4OD@`'@9Z8I#CEM9@)G
M1#"T$\\\=N(SC^DVY=U//W\&%.B@1<6T4$,KN+LHHXY>=-"DO">U$4@@B70"
M$2'T4-0M)]S:TH0>;5%3`#;=I)#?L/;D4^U!_4F4"EY-JFOR4-7LK+3D3P45
M5QQ^%?[Z4)F__OA+F1#_=-,MA<"E]V]$+45OWF777-XR0E\&&*Z_N($O)#C"
M&YH@A"<((4E-2-=APA0$%M!K7O>RF,:2DYHLW.<N%XL-P7ACL(-EP#:QZ8QN
M1",&%7),8ASSC`8S0+'=\$8Y-&0.#]QPH9>XA/\-UO'.RE`&'I6UK#LO<]E_
M8L8>L##@9B58%V0V,`/<,"<],@N:T`PQPW$=00@,TEJ$2C"AJE5H0D48E87,
M&``(J&`)"\"!B`"W"*\90FPL:M**S%8)3*1M$S"PPR=R!`H[3$$!3QC!$XB`
MAC<XQ"$_^--/:-6W!^)`%XT(!C"H1(Q.*@YQCF"!!BX7IAS@@$$+^$84SL`Y
M;X"#'&PZAUQ0$"<Y0>$$[\"3+NEQ.C"H@$^KLUY`6E60%<1.(?Z@8!`DDKN+
M>$E2O;O41X[B@IBDI`2;2MX32+<A5=FI'B01E*">D!$T&',AZ&P"#=8Y3'F(
MRBLN>0<1GD"3$/"A>S7_:4D`$."5EN0/'^\,0$N>T(1-;>H!2&*G0M?Y`&S2
MH`'85$$#B##/$.@**;K*:+.6PK[P[4\N<;F+2+G5%W`5,`D'Y(MC@M"$;9+$
M@;>0G02#<+(+4H8'M*EB%9/C@0T$X08<2`T)!_::#-PP.6Y`814]TT(:]D:&
MF^%,"UJX,9P6)V`F],QG=E`A'YZ@9-\)JQ%91M8C)C&)3)39KT0RGR;@X#XP
M2((5F1,@+-85B9K1C$XS4#02E"`(L8A0$<IHH7J>8"2#I=K37`(!(4#N0==`
MP2Y<I,E>"$X#DH"1C-9DA$Z<(4Z$S-$G[```$<1@D0VX!BMD%91)NG8)*GC:
M_R5Y(;9@>/*3Q4B1E9@Q`Q;D(`=G6!=B)A>'&YWI&VKB7.?@E(Z(M&.7]5C>
M.U_RRV`V9)W$A%U"9B?)A]P.=X^*R$.@22F/!$^:NAJ"2%ZU$R3QP8>CJD>=
MYON$^MJW5R<(0D"DL!+[^O>__YTG@`?L7P';EZ(&3G!)6,J3U3'DP2F)L(0C
MN$YL/N$I!+!`AC>LX0YS.,,>ALI'XQ+2NG1K`P+4RTG]4K0->)"E]!P5+HM0
M$K_1IP4V19E5C<IC-[AAIZN)P)!8$%3>9&R$137A:WR<@ML`YS<:[,R3HRHQ
MX8!&A:O9@`FG;(8LI/'+&`KBO&J:LI:-QXA(/.MZL/_8'J5,0#[HVD$6CK`!
M_5QQS?_!:\<Z!C$ST"6N";+`&,L(M<-^"'H><LD0T/BT`%Q-1"MP$!PMQP))
ML.@1ELWC)"B!MDY@8&V#)&2H_\`C(C1`(;6K'2NPQ^I)]J`$3[/<(GYA!L-%
MZ;:)0Y&N/TFV2AOAMV=`3#\@MP#?<L.5,(AEF]Z$`A@X%PK2W1!\1^5#/J#`
MNG\22"T(4A(:&%,@-#B4G[#'3(LP$R,9.4IYN0*\2YW7!2I8'9)BK*J73#?:
MNI3O/5<0$#K0:;YU^C>=!MZK7M77X`0^<,+K:V""&+2_N125#WF'T8Y:_.+L
M^RA(`:BMO,SE6R5=\5]8T)C_!=;S):2S;PGDE>/*=&PU5?2QCY,#V"Q$(`L9
M,ZIK9HX<)2/,`RF0Z\*DK$(Q,(>I2+=7E:\:@:-6C&(\0$$:I:U&%N`XK"?+
M.EG/;%8U*Y'-6.#!^>`\C3EK>4!Y/L]V_G`>/E^'!TFHG9=<L*`'"8&P17">
MHZ=V6#Q!+0"QA1PM>@!';'3"$C'*(]DHL>D^LD`"F?CT&00IZM#^P0H7:,(I
MT/"/UK8K"+\-2FMC*P0:L'+64#J<)T^DVUVW?G'DF('C?ELH:D3NTTDX[BMA
MN=QT-/?9J*.VQ*<M!"E4[[HQY3:GOBT[AG1WF=\U-Z0(Q:S?2?.\'#EONU_%
MD(2F_X_B,WE>/:$W*D"5@`[OG;:]=WDG@`.<P/!T29Y"0.!OPA?\&N4HQO=_
M<6J1&!W^,U+<PA<BMQ<SX`8LL%)-,"DHATLDT'*4P7:@41M6(',HM1H<L`-O
M$!D_%AH"`QNSL7,^=T*VT1JN4703`U7!,1S"D5>^P3"A00).1T.ZX1E'`&8O
M4016)T27P8-B=43CX74P\S-K5000E1B-(5<ZE';DD1WG$2#7<4`XQ@,L$"9+
MX`+>P#0G\#1H%`);<#IL=2$,$`)Y)Q\0`#D.T@,XL``[`%R?)0Z(QW@PTGA]
M1".2UP*B97F%]`=H<`'AU@]>(GH/D0/M\EN&N`.DMP`8P/\+P5`EMI9;AZ!;
MK%<(K_<+W'`@O[4"L\!O9<)[R,9[O>=LSH8"9]`.,M82PS=Q-$%.V&9^VV8+
MW<9\R#1N$+%,Y1814G`$X^413S$!:_4KS`(LP<-1WH1+-*%__/<4[],L`4`'
MWP=^X#=^Z@=?>:)+`G5/=*)O\7!P]N`2%'=1X.B+RLA_Y`AB`X`'_+-Q`=AQ
MWO(7(5=`10,#CZ%?`3`$0\`[(;`#$&@R.\9CHG&`'1@:@&4?\EAGHJ%E/E9"
M(VA4L)$P07>"$\,P&Z-5$2,<6L6"618!"\D<7#5M10!60D1F9356:2:$:<5$
M4.%H<;886>`&/L.$;&<RZ+$='>/_!BP7!S#P$T4@#3TP*E#C/&38-%SA-!!0
MC60(`26P`PN0AFOX$V[X68>W"XF769MU"9YV!E:PAWJ8(SSP`TVP`P\V29_G
M+CFP*&3Y6Z_8"6'3B(I#"&Z)#).X.$G0#+\F.6XU#3@0#;FG>^&@7)[C)KY7
M2[9T)_F&#X8I<4)03CR1;=JF?-YV3'_X?$<0?>>&`KOH$>OCBRE),^)#,^((
M;]<0!(/!!TOA9BY``*C)81W&/III`<X(8N3(/ARU41<%C1Y!;8?Y7N2'<O<0
M$OK'F5#1FK')?[`I8FU!`G'1/R;F+7KQCB?E!E;@;!YT$L!CC_6X$4*`!?LH
M(#P&9/[(_W,;@!@*<`,P<`,&"9T;4($\MY"RP60*0U4T*%7!4713Q@-2IAPD
MD'.K(8+`P0,]<"%IA"$[.$0B*59H%I,E*81M]S,3`!(X<Q\ZTS,Z9!Y81Z$5
MVA]S:3(94"9'L`"=4B'U."K0,Q+4Y@);"**-)2)+(&F0`PW`E@TU<@E\=#9^
MM`ED\@>CIH>D16H*\`.KDQBI!GJ3>00H(`4Y\"YG@`,K\4:+6&N=Q$F1>`QO
M^9:N5PQ9LB4MXCC0,$G1@#:?J&R`J0[E]ER\!$[JUQ)RD!'!A!A(\HI+2@-T
M<$QN18L0<8NX."O..*(AH`8DJ@;C)U![NA%\$`!\2A,;$FX^8?^9*H!1I9F:
MX3,!()::DOHK&J%ADGJIF)JIFEJ<PSF<&[:IF]JI[,.I(H:.UO(FV<)Q=,$7
MSBER\3B/1G&/(!$`LQH`4;"=]\)7,^<:.\6K/C:0.T`"C]$:511T0#>#2(4<
M,G=`'5A#QK%GOI&"%XF1(Z0:M.$!0$<PN=$Q0D"&WAIF/-"#181U(VE606B2
M6<0>3P%G"L"2))`!AL`>01@>%EJAFK$!DU$O,[`8TJ!&N-E-T'./]=18%P(!
M9YA*+%H-AI@-4%DCL,1'NW`)D9<-.+*5H\4#F0$`$<`*U4.(GW<$99D#S$0F
M*"`0=Z>6P'!K4JIK5)HB5+IK=Z0ES9#_I='@6I6VE]V`7)NS;,S%3,\%3KID
MF*'R$D)`*`W6$]KVBMT&EN#VASV!/=!GIY89%,YHF-.(<BK0!*\`%#1P<#46
M$]C%!W(@MDU1<!&7?JAHF!PQJ+'Y82'FMJ`:MW([MW$KJAAGCL=YJLI)%\P)
M<@2X8C^6!(V2!9%&J[)ZC_:8`_M8+SLF@B(8<ZX1GC@PGB3P!C!P&PF3D"*H
M9)NK<YG+<S`H94OX9"^XK1A)0^:I+TUV@OTY`V:$(?(QH`8Z9@3Z!R1YK@JZ
MH&+W9J<F9Z<!KT!39F:&,N2!8W&P`<;+`S#0ACO@DQX"/5L0`ELQ`?9HCU<3
M6QLR'VCX((@2_SDORK`-NSE2697D<)4L$%HY^@<`@+'K:P6NT">$&+]%&A%$
M2HHDBP)+0`.65&F>I'I52HD`',#*P`A&P#,M`@/1`%R<A@F?V#EA^GMQ<@1D
M>B?WX$/#QP=&^Z/F1TS=%J=-RSK*M$RV6)EX>K73YDMSJ@!Q^F_P,'`+5U\J
M\'!^PRE2@`9$P(O3RYG"R7_J$SZHZ3WCZ,.@NIJ12K>7&CXFL'^1"A6DZE''
M^28FIJIQ]2T%R&*"NU*Q2JO65P>+NV<]QZM\I:QNP`&%$:Q9L`-]@3&M`8+L
M>3$-F;D7N!HMY((H:)'!T6,W0$*E89`TV#$PT%4])`1@543>$9+E.O^ON8L>
MZK$511!GCH$?P/L?:$:O-34>9H`=!F*\5G`$#"(U]18"U#L$U,L`0M!80N!H
M6+,`*TH#W>NBW\NPG."P,X(V:G,&&#M:>:B^&,L#ZPL`'L`*\-LNEHD"(HL"
M1R!'*C!8;`AKM4`.*7L(AS.E@\!Z4SJ)+PLQO?4(30()+1(%26`%$ONEY^`Y
MZ#"R$GQ+]X`G]Y"*]$<HQ^>*K[@I-,"TS<<ZK+4HE&F65+N;+C%\NYD\:&`8
MZX(#3R!?!%=P"2=@"KU(3_!7-CRBO(@II?DKP4G1%.V+M*IAO@@&ITE^O.B+
M2K$58$``M*D^J%G16]&9&S6I2%P^+I#$0?S_MAU&+7`!Q7S+MWU;4JUJ0'VU
M4BK0;M0;``PP`[CJ&4NFK$9517+E!AEA'X.1!77V8ZVQNOYH0C^&K:[1D%.]
MGC38@B\4K2IH,1X@!B00`0:3`AQ0&@8S,1QI1F`F!++K@^-ZNPF:R"X#'P]Z
M&EIV9T"(&>?:@W%@"#1YR7&0`9*S!-UZ(4)-O0UJCQ/``*0<6Q[26(\E:4VY
ML.`+OC5R>+"T)II@HS#``^G+OIFARP```.Y;`IHH"X18I/7;-Y`:VP2@%%"C
MOR>``4QR:ZIGS=.,!6[9LC"+)8RSS52YE^7P(+O7>W$BF,8\P:8S75:[*AF\
M.AL\3ISBP6#K?*\@_\RV^%WHECW5=YOP!0;H0@<JO,*X1'`NO-X!UD!+RM`&
M@0;T1BGYMU')J#X8?2N;V2P=Y:C%J9FZ`IO8QRQ+00!.L153,18)GN`ZH`1F
M@19*D.`1;A4=1=-0#(!V<1?M^+<KUB*"\1@KL*CM1JMGL+C]`3&A$7,`*7,]
MY@8[($4DL`,<D`(5>*PFJ)!(A:TCM.,FZ&/>:73!(4-499]"+@8$(P8WD#&"
M$52TT8*P-C5I),B5K'4_2$1(Q'5VG47KL11"D"Z001'XFG:4#-A3#C'<L1F6
M>4H;DG=/(<JA;(\,@&A1KKU+F;"N_)2:W;`.VR97>089H,MVD`%6$`%6\/\)
MN[R^8J`M1[`#Y(08#H$"(W$"NS+;E(Z:L0T]9%1Z_`N7`"S-ONWIB7,BP[`,
MEM`DV@PC2>#-F(#<*+!<@"F*$G$&YXPZ1CF-1;L3#080C6D+\DS/Z[28/B',
M^3RU*T`'^D3@RKC$RB)C\T1^N-3""(=P"C=/*Z'0\4T\QUY]]4V;N_(4D>Z-
MZ7/L&F711&RI_FT!(;`"<G":YSZJRFX__`0&\EXL"EX5]2XM&J>.RTE2)O6<
MXS*X*W##6@P2-&#B_<$P%KBL"O]C'#"YHGG&>,%D#FF"/D<P%F\P,M?C+#21
M+CA54&:?I$LP',`!/L8!0$7Q&S\<L/8T4P/7U['_G>!A9EV7Y5J^7E_YY7/A
M&13:A(1,KRA3(.;1,1N@B4L``2_1H(PMRD/``'`>O5M0RL0F$(3'AJZ<V7G.
M"9_]1Y]-)J3%`QMP86-'!QG0RP```TQ0#0O0!$8[SPM`Z9":FK+M]J/B0'`=
M!2H;I93XVY_>VYV>:W=4-#-KZMZ<ZA++`CV@]GVY;.H@IJ1HS+,^M%27BM"#
MP<>'M-E5$DD)F1K<+O@\OZ[=+L7.ZRH@!Z-/^G)`!/$P3KJYC$LQ$_$$8/.T
MT$\`IVC0`/>T$?DCT<VB%*7YFX"*;Z=#F+B$2Q7LC4#,%9U"X(RZP[+9^C5!
M$F@!X0H>_?1N+--/%19^_^$:WG$IUN\=+AB.@8C2%`!\0-00R';]H7-)$'3K
MOQ?0R>),#>,[8)Y176</B:P,F?])Q9"?"PAN;C,9&69B9CR*9H>'B(F-AQEN
M&3<I;APW')=N'IV%B3Q)0J1"1:>G0C`M!ZUQKK`'K[&OM;*W<;FZN[R]O3P!
M`25+.R0P)!N4O+BWK<[,SG$M23R[/&9'.SL]10$3%A/A$T/DY`SGJ$L+"S@0
M)3TX"RLK.?4Y9_CY^O@8_?[^^:P`4$0$'`$+!PD0<!%@0X879>`L@`.GS):+
M0\(I)#"!XT:%'3N&"%%$2`@61EJH7-D"BTJ7,+'`;!F39LN;+%N8F1$%QHR?
M4?^`\DP2)8D1%BQZ]%B!`JE3&"Q@P$`!`P,*%&>.'%D#)028$"?`>AU)=FR(
M)RMPH$&#HRV.$G!+J)A+1$6)'6C@TJ#!%L<..BN""#XB!45APR@$!Z&S8ZYC
MQW)+T,`1Y.JQJ6GI\#D1($0PA!LMB$9(>C3#8)W!-L#11,57U%[YR'XBAX\%
MU-\03G"Q.X3CNBJ(/!E.?+CLS9M/@%%^@L]R,-!E,P?#Y\G>N;5?XW;!<#=O
M[K`#F!A/7@?Y\^C/FS<Q8`H)8U*E<H"Q@3Y]%AORLTBR@7^2_P`&F(0;&Y!P
MU0Y$H-:9&<\TZ,P?KT!HAAO\I9!?$A:F\)\55@BR@3;_061!0A/(:)AA"IQ0
M4LB**GK@8@8>P%B()RBF",HU/(B1(R.(B-%C"]>(D4$*&6P000I99+'!)34N
M68@80!Y12BFH",%""[,XV.`L6=KBI2R^A"EF')T-$X1\&\Q@QC)?;@D+EW&8
MD0&0NO``@S8E".&-..644T,-#*2BSCH]O`.///3<L\^B^6!PQC^.XI-#!@,!
M\`1I'GWD`APO0/`"165$!.H6(7G44::F=G;"$R%@P((&+3B04TTRQ2233;?>
M^A)+&O#DTT]`%564$<0:`0,-2S7E5%1283#552AHE0-78GWU55G8!H"66DOT
MA0,-<CWVA%UT-*$77VW]I9A@_X@5)L6Z*S3VV&.3!4$"?OJAH!9@0BCGF6<*
M!L"==[R!,]K!%H#'G6@A5*?"7NBV]3`:$/.1D&@!T-``7!N7T`"X'H?<0`,J
MD$SR7,4]49W*TYVP:F0J\`&PP`IS=UHP7CT!5PCI]>PS>NW!%U]\]>&''PQ)
MX.N?@`+.0*"!630&&QU:/I.+';G(4H@;)F+8GX8#"N(&"3L$<00)V>27@A5J
M+]GAUBMN_>(,,:H((]=A?V)(CD'RZ"./0$HR9`9';I!%!$OFI_@EB"BRPY2F
M5'EE-)0W4SF7S-0RYN;6=-8$#EG0EY\ANH"9=9954Q['-3,`68TH0>"P1!&<
MC116G_\,7'1"$1`L$4\\A=+@.Z+V,-KHH@#EDP,/`#1?@FX*&;31"S6\P,`0
M$$$4ZO9E=#0$0RZ`5BHXMJ-E!*PLN713K;C6RGZN.*FOTD\8`,L34$05&Q6R
M.T"U;%53L<I5LE(/:GTE+&89"1@ZDQH^I&4M;J%#7,1E%[R<JR]_"<RZ$).8
MQ`B&,8\1@ASF0H,@6`%(*N%!"UA`,1J@0((RN]9(`H::FX'/9C;;30#D4`+;
M\8$(DN$+6_J"AAY0K`1$^`@!A+&QCSE18Y+Y6!0UMI<G.K%C3?18R>;"A^#,
M13)R(<)FEI-`,`RG+AL+@05^]C/1D&>-08/!?.(SGZ@4;0/_^%+<TI@6H`*A
M(&I/"$8)UE0-+<4!:XK8108((0@K@,U$8*/0&U9P!!2034E?2]R2P@:W2=P-
M1I[H)(R8)(@5]:U'C<C`WR!Q"$JD@`,;X``'$*>X)5VB$(K@0:&F5))47`EU
MJ*-%,[ST)<X9DTPA(`8F^T.Z7E@N=7#*A0K51"<SZ.MQ0E@"R.!R#@;48`LG
M@$`/UK&.>,"E!\-+E**,Q\Y(20H%S6.>%#!U*O&-(R,,"!4<PA"&,H2A`Q7I
MW@3H)013=20U3]B!$5H7J_BMSWT0A>CZ=K62G<R@?D*)@K",8!24P$`R3/E?
MLYYU!A3DX`@%[(H"L34SL@3`@=SR_Q;,Z#*N$I3K7+[S"V`VZ"[#'$$Q*Z"#
M8^2@LKG@@`5S2F$+2-#")J!@!31X@LM<^B\:!@-\`LOJS5Y:`FMU,8@0;,L0
M(?:$BQ$`#!ZC8EJG^,2]!+&*<*6B%4.&1+6LI0D:"XYQDJ.<E8VK9%TUP1I[
M-EC"`LT]0AO:'>N3'R-<B(]-XT^TLH`#5@4AESPPY.IRN8L6Q$T0&.)/?S!$
M(+-EX8]+$-WBU-8A0=1M$F*+$=WB)K<4J>@0..J1CX34B!UY,C].D.4L9ZDV
M%4'I&GF"7)568<C*O4EUF3OFYG@0`C8H\VN46%.=VI0ZRTE3)QE(`@I9H(TF
M%$$;2T@O#O]ZX$T&O""]PXO'.LXY*'6NDYWXK8=`FM>\>9:J(T%00``,,@&(
MP*$#".9G@LO`@`F<(#)*&4<PPN$"V^%@H3EY**TBNF&<L&0G/0%64$9L!?T9
M"Z3*>HJSH(45E.9@!=1BZ;\`ML"1;*L):^D+7.;U5PN"-5T[W6!EAJR8OYQF
M)`ZCP0JD<)C$0&PO+XRJ<_SE%0;.S*H!P^H)5(#`'P;Q<][J5@MM$QIAI-6*
MX*)B7)\LUS:C>6-/:$NWFH!7D@F'.&8L#G!(IL;1?`1A@'ZC"\83M/<,K8[V
M,5HM^S-:R,Y`LG]4@)6DJ0@'Q0%"F.4!UE9'6]B:Z$)N@(%6+!G_A!WD49.;
M%%LG.N&)&(7RLS/B&B=BI,I&K%).3VJ<G%+@B5AF@0,D$"XM;[FW%GRT!!"`
MG"E4P0JKQ>*9F,,%A'`AW3&11`$A"ALUZ\2*:'?W3=)0R4[F9(8-Q.MQ._"+
M-M*]A3]Y<POCE*_LW('.!>Q`G?C-MZ16P-]^S]-4'`&##GC#$8@HN`/_G,,<
M)"`!#3C``5%HN$:C`'&-GH$&_RK!&1BZDIG8BL,<=JCZ--`K&`3E?B..`D>)
M%95WA!0I\6%Q20F8TAFRM,96?FE:C`B/MM#`+K_YZTU_C`/&:)!=[B(,4.F`
M`]#\^38-`[H*:BJ9Q?P<@36\*LT2EK#P_P'Z(+?!&5EJNI<ABG4M9(W>09C8
MYC.WF<T0^YB;YU[7N](97"=+&7'V;)<^A^^&..0ZH!$V`#PD5K%08:RB&PU9
M`+F!!7^D+`FB4>EG8.T/*LQ\-3"-:]J"]D(I8#$,*(.41:N-M+%5-:T[/2,4
MN:%#M+8U(QR!"%`D0DA$BN4-;I`%]\#2ED2Z$0]6D%SEEH2YSGVV=S,7W6K[
MH@4A$`(.CI"%)"S2$%C*A4JX"TW*J5`G.V%$$K)!_'2K6QL0^!.@:@`!>:^7
MWO4MGK[QRP1^]YMY`$"#1T`3=HY8`'O^A&`=,`<4]W`.(`$&B(`1MX`+F`.I
M00.O0E$TX3X3"/]R$S43+$$_]C-B1E$L1X$"(.4J41$5SB)`5R$M+V9`G8%S
M5=6")\!TR!)6.^880M!C>4%T?Q%DBB$%A/%3@A%4=*!$!L-_3O=T1:A$2)B$
M2A@,-0869(=CWB([:(!7-)!$F&)F<Z5F<B=W<!=W:S97<99C=X=W="$<9D@$
M:%0R1!`"2MB&8(<P+E!HAR<5C'4?^G$AC,<TC[8!5R$B#E)($<(#F.<(B>`Z
MJ^-9K#<)I)4$5&$9"G`OIK<X>>-:K/9)L%8(I*0W?^,CU^`W<O(WL18!-_`&
MO!=LB',)KU9K/+`$R%9\RW9\S29,R=<EU`8FIN-\O1!].R`BA``*V1?_)]WV
M3);F;*_@!K,G)X0P`RB`7N:G#>P``>>P!>(D$?*U`,%3;_=6#_.77_70;]ZH
M1@"7$`2``R=08`O'<`:8C@<(<0<X<0P7<1*``2H0`$70`QB`/AL&47&`!?M(
M@128/BK1*U&``ADE+"IW%!\H&3F@+$,#+27E8O4`8TJ`,SF'90'P@M^R%CDU
M4WHU%T-7=D!6-D+V+O#"=&XHA!=SA">YDA\!&UZQ*@]#`TU@1&YA5VYU*1<3
M`D2`9F[75FJV%P_`5G/W1$\@AF-H,B<S+UM4,@T0`"S)DH4V-$0#%?=Q'_RQ
M'XWW'WL(`QJ2.G\@"Z^S(RV@(YSU.HE8"#/`_S9#<P0KX#^G=GHFHFJ?8#>=
M1@FR1FR1@$IZJ9<Q@B2D^&O$52-ZLS<9`!>DD&R\Q&S!E'S"5$S4AHN]P`9"
M4`P<H":%0">Y,">G(XS-!2;,9`;@]6@P4&KH59-+``&HJ5ZRTQ;LT`,0@"SR
M95_;R"@O)@4`T`9M<)O\U0960&``9P%-0`=,\'`1IXX/AX#$F9P3IU$,)P%P
M@)HX@`%1L"NY(A/[>)W\&'(>EQ,\09`9110EIC]'@&)4V2PL=E(N%B]<89%8
M%@)T4$106'0S2%-SX6,@"61'-QCK\H-_\93^^9]+*'9.&)/QZ19BMA>V@2DA
MP#%R-44_V84-0(5<N/^%#2H$=S6%1QE%4>1%CG$R;`B@26@!A?<><TB5C(5'
M*,IH6?EHEID!U5`ZP;19FI=IAZ1]9QE>S%(?]B(5=A2)J=9J8N-)GA=K<?DD
MAB`DNJ67J@1;&<`!I'@#3F"*2[)JM,:)2>`.>>**RX9\;C),SH4YQ029O.`;
M]I(,LX>9<>`&W4:+WV8ZRN@0L[=(+$!^Z69^2E$$)?!@>0(/ZF!.AA(/V7A?
MLZD\+Y8#WNB-=``]I3($9W"<R&F<Z4AQS#FI$K"`1B`!<V"-<+`"$?@2M5*C
M=L"/H=J/[X.!.`%BWCEB/'&0'<4".>!R0^,L)!4M]C`/.[`&2@!X@3=X`<#_
M=$4D4U(W=39X0;ZC#72PGSL(5$&%`R[PGP<#HD_)$&2Q'.-2=E$X5N!R*;DQ
M`6``6#RIA7!79W'U9FI5E#A&9Q*Z%^=:`JRRDUMD,DZ)DB`:E5))A_Z#HJJ5
ME5K)(&9`(R[ZHF!22*V0:8FD"Q`"(8C8::(I%4EP)WB4HRE:2QA2(ZBX>D)J
MEW4CF*NGI$>ZI"O":QOP!D\*F&KC>JN7"..9I<H&B\/X;;;P7)HCIKO`!B5P
M)F;*"`6;IE@"L(L);<U@;%1!33NQ`73J%_#5`Z2@%]+'#O*%;$H1F_8@J+,9
MD5*`F[BIF_VFK:8"!X]:@)"JCI*ZC@M8J63+`A)P_P9+(!$YP`(S@#X3&`=7
M8`=7D)VD6JH>IA.^(F+#,BP(Z:HNYRHQ=YX0>6ZXFC#?<+@"<[@&\PTNP'0X
MUBUM,9\=J0)J<4$8I(/("E1X@2DLZ6?0RI)'!A9))I-AY193""YRX&<6L*#?
M2J'@RH5=.*Y0]`3GBJY4F*U7Y0)/`!SS`@:?*X0C:@PE6C16B:)[Q$<,<@#7
M,"01X*)TX@H".Y:0,*,O6@L\T&F,X!3_$2TP5WK+8GH4FXHJ8I<RX@FR=EM+
MZB-QTR,L0B1.H`!/*J5,DHJUQHK(Y@[*QFS.UK*RZ)@RRPMX&CK)D$(YFP3:
MMYE5`TQ@D@$GN`'@QX>VFO]NYX1.Z*2:@^*G3TL\VCBH^A"1.8";'I`"!1`!
M:8`'/W#"4Z`;X/"HZ)B.CYJ`[+B<#+B<9,N<.;`.3'`&*$%--'%(6(`U_F@3
M=]LK28-RJUHL'4A>L`I`*W:"41O!A7L0-I.X?S<:W]"K&?DYD<MC/68N8)53
M&92Y)9EN`*.2HI&2!J&2ORN$8D<=.E-V.66ZI\NN!<,P0-1$0PEWL.N%Y.I$
M?&"[>"6A"8)5XV(R[QJO:ZP0<52B)EIZ^?H?>:B55G.]F.`&FN<*L\!ZO)5+
MTQ8G:&F,<3`#I2?*1]"]_L.CI;=H*#(@==/*+^+*>$.7'&ND0C(D(:P`"K![
MP0;_2Q0[F*JT`7$!`0V0O_K;I9S9F,WWO[E`LUF`'\:(69NV`:`)L)P)ILS`
M`VYP@BA@!6:0!"00!/&R!$HQSN,,7ZO)#@LPP?$P#_+'P9+R8G0P!4X0`2,L
MPE;;!GW0`!RQ!2RLCOT,MA4GP\U9J1JE`0(=*=JXPZ#I/G4+/_(C;C-P%,%"
M%$9QD$>AQ$NPD`V)%2:5GK:*`[BJN%FE=003/E@\DY![@^(B=.9"H)<[#V+\
M@W3PGJ1A0V;,A++1K(D<H@P!=3\4DSE6DVV!5R7`!][1&QOC9@[JDQ!39[?+
MQPU*N[8KDVXUCPW$NX^1(#NMR(9G:%(Y1W9DATK3>(OI_UFO),V9EPBO,`V@
M%ELK@@BN`UN6?`#3`"`S(&I)$Q^F[):GAHJK)I<N0C>N-@GF2UNUO+ZXQC5N
M<`/P"Z6R=(HF:[%F0`)Q<;^(.25<NK^=J<#$I,QQ4`1-<`3]H2:O<S5Q@-:`
M^++1X+^RT`)\&"UGXLVEE@-*40)%0!(!H"<5[#M]N@#T=BCL?`]2.W^UN@+X
M7`!]<-QM4``%X`$%D`*!],]?:YR2JE'M*,/,>:GOR(#-B0$W3`\8L%`+/8$7
M2%%FT"O$DE%68-$H<10[\`YG8I[0`I$O=FX@G:L*HR!>I[@,X7-3Z!;A0E-"
MYU;JZA9A'-.V2M-":-.A@3!;'?\:8!<,T7,60!W':J$61)V@C.L;(I-F:/:@
M0!E$'],$;06&Z$K5<-4`:(B&[]KB\_C@>^`>]8IX#VN\HQ7)23`#57.]K\0!
M_YI(X16QI\=)+.(?F477CY;C#8LT5,DL(SB"]UJR%*NQKM;*L-5JZXN]M;PD
M$2"RFO#8P.=:,O(D[]V*0J"EI)#9QWPY,)O,N/BB0A#:R;`W,EH-E)!]F/QL
MFQFS$"(-?/A3@9$#X!P$2H%Q66H7O*V:S_BGZX!O[BS<+[8#!2`#3N`$4Y`&
MF'[I:7#I9NO"_@S#!NBU#F><#D=R%&?J\4C0-:S=^+`.]\`"04&=[Y,3.Y'>
M^*-R*I?_Q"SP%AD-0%(Q0(,;P0LP`$I@,-^A530#/A.`Q2#)%L$JK$9U@^K:
M%T8'TYD[#XR!!FH</;?!%S3@'-ZP[2<):/FM(+Z[=M4J1!=NNAF.52[`!QWN
M1$L-XO1.H7/%!U1]XE7D,8:LE'2!``\>O)<QXTVN:/@1(,:HUJ_0B0(+EF:0
M"1Q@E_5AASZJ.(I&#<Z`MVK2L*)<\$W>Y$63RJHLF*GG6A1[HY^%(EXN7+\7
MYH-M"!E0*(:ILI"CYLO7I;38V9X-VD$PYZ%0VG%PF7IN:7M^.M5@!E/Q4_<&
MSBL@SCV03"613>K%V^C\V^LLFX,:M2^V`%/0]38P!05@!<EM_[5],.K'^>G3
MS8YI#ZD&'8]18-`TS'#>W>@Y$-X\/%$X07*B?'(IYX$H@12LV.OR_9#%[8SW
MG=]8==3?P1!TH$WJ_A99/1SUF1<$:N#JDI_P`H1-MY*WP0>`\>T#AH2E(1K@
MP9[M"1I15W9:?.%H]W-/D$,!T*UK]41"&;MZG.(-^L=W=[M.M)2&;&=V-F"J
M*X[_*8<$;Q\HNG@`,LT*?[U,JM:8MSHA*R)Z?8>F9S1.D1_)VPJ,`'Y1D==/
M\>10+I5O64LU8KZR)N6^G(@HXJ1?+DMMX]<O\B1)4-G(1LR9K<":;<TZ#PAQ
M@H.$A89Q/$5+1RP99F8\B#PMD3,9<?\'!SQFF9B8F9V"!Z*#D2T9,"A'*RM!
MK#L]L;%+M+6T.#@+.!`E-$NY"RLYPV?%QL?(Q</+.2L+*04R4WAC/S<_V#\L
M$@X.W%'=X>+BX./FY^-1$NM1[5$:[1)&$A@Y"_?"+%$S9BW^__X>1=$W8T8[
M*U&2&%G(P@@+&$M*X,B!(54J%"C.'!FV8D?''3MPK%$28(*+`"<#H%294J5*
M.CAHT.B!!@>:$BIRJB#RY`D1%39+]*+1I"8..COHL`K"M"G3CC#1!+!`-248
ME"Y2G@1*XXD*&GRN7K40X`28$"="J`T0PJ7;MW`M$+`0@L]7HFCRXD*S!$T3
M&B7XN)B`]43_B0:':310S'@QX\<R%?^-'-GQ8L0-^/S=3!FSB@8Z<_Y4$3:$
M"0LF4E-=S9KJ7+FI8U,=@(>$;1(P<NO._9#%PPTL@&_8`,E,AN.4$!UWXR9%
M"N;''V7@\.9-%A(<=OL>SCVX[^U)0(WR%Z?%#!9)DCR$X9LW^_>]M<,0SKV^
M\Q3UN3OW`/VX?_\>;!#!&S=@Q\&!$0SGG!L>>/"?(T<(Q8M00I0@Q(48PL")
M>!Q^(MXG((XBHB>'E&AB'$4TD44CD%`2221Q6.+A!B&*.(HA?Q0R21*JY."*
M*[#(TH,MM^"2RRXEQ`*,,,LDXZ0QS'"T`!W93"%#!%=&H&4YZ(C#_PTW789I
M#CCJS/..`V2JHPX+9SB#3PXP&+%//P!I8!`,!N79SD)\MM>#1$?DAL)%&FW4
MS$>ZB$027(RZ!`8=2]#@EU$XZ=03'S_AT(10O31A)$A*_>B4*U#M(!55A,E5
M%A\HL19"3$0(@08-.0E&0`!GJ:5K6VTUVJA<!-2E0J<][&637S*1MMI@8(!V
M6&*+)9:83(Y-1NUCEC6FF&9$=8;889_E](19:[&EEFRGM<::;%3%=MH>4]RV
MV[SO`>?=<$F4]R`/FP"(7WXI6.$&"0KL$,1UMNFV'7W;!;=A)N39889Z9K3W
M'7L7K[=>!`]QT'%N'`N8G\@)*L@<?_P]>/\<?@HT\8:!!RJXH(,J_\DI!!5B
MJ#,,+70(BH>=_!RT)R.>:'0A0BR1!0R.]/,BOW&X,0.'4Q/-X8V$O"B)&20<
M@4(.'K$BY"Q$_G(D!!`H^28Q3SX9)2NZ1'.E#&E$D$8:5UKQ99=@=L,EEV)V
M"8\ZZT@0#YJ&QX.!F_B<T5!!9FCPR`Q&X&G007SVR0(&@.%P1$6#8I21H:P@
M*A(4N*X50JY@D'O667R8*E,/1>$0F@H]]03434+)9!0.287=2E.M0(7+8%1-
M1<#RS+O`O`IT=,4M3F&9F^NNO/K*J%QD83I4[37Q-2M@8$Q`@/ET/8O89XKU
M<AEE\,,_V63O(W;_@DS6RG38$[VRQ4=/1`B@``.`+G<94#7N:A=J:",OW-!K
M/O"ASPSB(!V590`Z;MC`@6*&KX&]00$X"(+HM/.=$FX@"3SX&7D.,#$6G*>$
M,,S8`W>3'>S`(#LWW"`'1*:?!ITL91EHT`9(@``VN(P#"2J9@E)&L^/`P&8W
MLQ#.=O8PH5W-BAXB&HF.9B(8H4@!2VN:BQ`A".;X+`Y_"-K0="2(%YD!!D>(
MH\%:@0-9+&%(1,*%+A;0NV*M+0=G`&3;`@DE9KBI!W7#DI;N9K<(6"%,W_"&
M)-$4N"N8PY+I*)/A#"?);VR2'HP+!ISD5)!]5*X=!DE"%.3D$(?X!@5"_\'!
MH&``.HP8JAD@V4&BU@"%)_#A?SSYI2]_*<Q?JD!VONM+:'CB2Z\$Y2Z2P@52
MD#(\XKEBFJ::B@4(P[QN`HL`1(A)3_1'FA.DY7JJ8XOV?M6]8?E.+\>:C`I.
MX(+53``,P[K,L]R'+?G%3S$-R)8^P4`4W/GR>F#P2;A&@SO<\41YZEH-N](U
M41,,(%X)FV&][K4!(W""7Y,P#G_<$,24N2$"'"#!=7:X`?R0X(,TV('79JFP
M]@C'$:"81`I9F![UE-"5O8G/>F@(`]PTT#8I3=@.6:J@EC*(.23ESW`:@``$
M/*$)3)79S!X4H2CJ[*L\LY%8SZA&+6*-BT?#@O\BKI,!,3QBC)%(S]4V!+2R
MED(0E/`'"^)XA!"V(DA#PN,MS*;'$J3-CZ)LTB`)J8QEP&T!2\"##.:FR"O5
MK6]>0IPDR43)<U@2DV(J!SPVJ2;`.6"T$IC#&>[!6F&PAT_LV<<^+L<0H$8H
MIF?0C>@*%81#@60!.UC"&KYPN^(:%YDTJ4FE=G(I9_[%G='$1?"6,KSBK0`I
M-BE)5;K93><1X'\&358YL8<]=:[S+2E!RT\B([[V)DLP;C&,/@'3S\I()C)_
M:8"UGK"8)CA&,2KH55U&$]!P@28GH!E-`'N2+M=$],&H<1<#$^9`C6(,.$EH
M08[:R*\6B&$Y#EJ0!K/_0&(2="<+0=A!"18Q0MYP-,,]RP066O")B5'.E4`M
M(<8T:M3<W.;'M\F.$NUS'Q_BYPT("`$;`GJ#EA)YI$$\CACNR*DJ\P*L-"[K
M%:VXQJ*A]6A%`",)2%H<K44-!E>CT5A'Y.6GM6!BJ@C"$D@57+*5C;!(2I(>
M6:'8Q1:2(TS0Q2_NQLBZ92D"4N!L.ORVV<")`[1=>@?A$M?)2J]C'JMEK4=R
M@(**Y)9/J\Q<CE?0BQT,"@,8076/.(*HD/!RN<,2RK",6P(Z6&M2H<G=_YZ@
M*9S@SRC!HV9U244'[.)`F]SD+O/D8LQQ5JHTZ,Q>_]!;3W4Y"IC0S4M?\A(9
M_]*<Y-M\B!9@ZO?/<N,7,IW!"6;:MYAPZ:0!/XFW3W('T==`.,((Q/=%,VKA
M#;"'/FX@$=3X91S_-&=!*>!`%FYPG?6H-`L[D,D.SC#+X.2GBN6),0L+@N.&
MN'+'0]4-#FL(Y)(C]88`T^IS\!,!-H0@H$UP603^U=(%,:B)&8"BA(0P1;#2
M=<M:MI%9OVPT&F.!#4HS\0S<V@])Q"$#).@0>M0X-"\/@A(3ZUIPPU9G.]8"
M![;`A6'UG`L^]WFQ@!P&$^!6QQY,`6]POUN6@B`%S(Z)DJ8=!R9!"VE(BV-P
MA6M'I</A#E"V%KC"6('COE-;CW]'Q;BUR&[CR&J0X/]"N%^@3._BUXO>V80R
M-,FU+T_POU[W$9Y)$?93BI=ZFR#/`MY5]FN,^3_`U"HMY-652ZHM^^5-('GF
MPE1.`-,+O11%GH+Y=@#X`)FAH/N?^2NW?AL#3?H*!338%TU#><+])[#$!0U>
M]FL:K,`&[YO"1:VP?+Y#G`V#=!/]<D,24I`$J#K(#1RX`<.+&JB'1[P'IH8!
M&(`>]1$>'^(/F2`Q9K!*#>%X.A8?/A:!1>5C)A=D-S0?2)15*W<?$:``2Z8`
M"O!!"L`!]V$R*0!E3J1S598S5%176U8CI,!F1'<T(9!T&]`TD*`U&8`"0O-T
M.W!%0S<(=C`);Y8!>U5'<Q3_!+,06&4#=KI@6#.Q!/C`),0@2&AW*&X"=L5"
M:&^7!F^G)5,@!2B0=XYV20[P669X#FDB#Y0V#GNS2:OE$:RE"\+0:1@30[ZQ
M`"H`@+LE.I3G6[^%"\/U3\Y'3CDQ%,-7%&A@*<-T`KX4$S@Q%'PA74E1.J5S
M3<46$E(Q%P00>]R%*BJQ:[;7$VG!$JO1>^)7%<IW;;HC%.O57M8R3]M4%6!0
MB-#7+9PQ/[B(/]U"+<_U%?4#+K>38,R4.STQ;5AQ$B:0%:W!B?8V&QB%5"2`
M`NKG'L+A&S1&<!6T"3/`'/J1!,?1C1NP<$L31S\F9TM@:KYA!-R181QR"AOR
M9BT0_VJB9C'N,2\.E%1!9G+9<2`YI$$:E"`K-QSYQU\N0R#586+W460WYQ\J
M9F6&Q7-?)00H\',OR&4]N$4S6")8$`)-$`2V80E,IX-'L"%F(`E+0'6AD",W
M@C7^X`@;T%<Q]2.TL(1W!G8X,'9#,H7,H`QMDW9J]UBWX'9.4)1.,`5.D$A3
M0'>)=EIE*"9HJ'=G."8:``_SP`[ET#<2H`&?5`^ZE"A+`DB=5A$P!`,X(`0Q
M)3IJJ1&LUA'`I0L#P`4QQXLR002$6"GIQ0<XX4OE\FTTP2F_)DVI5SRD4BI1
M`5'<XTUDL7M9$0#CHA*N@8KV5D\KL4YHH3NS]A5Y<7R`0?\$)Z!-LW@"_[6+
MO2@_<QE]J$D9.T%?F*%N!79@H#%OQ?@$5]$_R+@2C<F,IPB-):<*U<@;]>%&
MT8$<%R2._A8<26`%23`<,+!_*&!JZ4<"<A8,`^@;/357&^`&$/-F]*@Y,K0;
M/88;*954)/=C%^B/_9A$+>4!+,<!_M4$(%@=^I<%.[20)X@RT7%'*GAE/7<A
M%5DC0(B15;>1)<(#6!`'-6@=)`".CB`&`]<")+`#D<`SD]``&O<S,0@B;20=
M,]`1)3!'*U"3=S2B86<V-,`+0Q*6/9EV;L-JK`5V<(`#,9H&-C`%-HH'88@"
M4D!W(H0"G?649[AW0=H-5X"&0CK_#AJ`)O"P#5CI#9B5..N``7MD)'JT:12'
M:K1$2Q$!@)PV4WRU$;WU$98G$E^@B'FQF3T`7?I#!+&I7>KT>K\WBQ-`%)&8
M3-*%3988!-@$$SB`/"YQ*RXA![U23Z_WB9-Y7N>U.H[H%<-"!':!>RP1IXVY
M$K58;KFX&;E(%)RAJ9M*/_FT3P<6:[U3`LPTF_RC3N7R%K>9%;GI`N?W8T=P
M'?/B;TVEG?WB'V)P"O,G,,R9,-[A8_O'"KGA,=()$I_#)^YX-1<T'G%@E0L1
M:@TH5/1B5/+2C]CQ8^C9CQN$<@(I(!R@`#`'@B$HG_1I@B?C'QNPGQ9B(1-9
MD4!'=2YH_W4$6@@T%@<=F8XD=H/1D8V4L`$*$`2H(`AFT`0&"#2$((-X90:6
MX*$X4#IMQX0E6@LGFB2(1855R%C'`)2LL';W<'DXJ2D\X8@K@`(L@`)-H:,-
MX0YE**1%.J1$.I51F4F`QZ3K$`Z1A";QP":01:7`$`S"4`RB`QA<F@.&\H>5
M]UNZ%)>3N&VT4VY5%D`J(`=\\)F%RAKD)(F_DWK3]`J9F!39M9BKLCJ[]C_$
M=)NJFCWFU2A:P2B7R:BD@1:L@A*_9Q(M$0)J,&#00I>[B*DQ=YI]RXNG.7T[
MH4^O^1E]^Q>>::K'Z!9M49NHFK:-\JJW88[T@ISTET*WZ@BZ6O^`P#&-N/$0
M&,$"*C6-*Q`HPR&Z1Q`$1W`&&/"L\3H>]6HG[K`G0`4?^)A^T;F/^GB>YZE#
M2#0<*'4#,!=SXEHP;W`P]?E#)'4<61`+539V/,>N&/*?[RIT0*>1\TH(!QH"
M('@P,$!F9N"@+[(!01"")XD(.Q!U=76P680)19@$1Z!B<_8*8R.B7Z>%[N1'
M8;.BA&2%;Q-H'1NCN``'NJ`"0F!.)]`#K0L#3H$14D`"OM%9?`>SGU6D+7O!
M0QJ5,4MXA4</[#!)7_(EA,,"]L"S9L.3PX`3Q2(\40*(NA02(L$%D^(7T4<K
MAT$$TZ(3LK83CEJV*C$^T.4I=SI='J'_%-/$I\=V$J1G%U6FII+2;<PUM;J7
M3HBZ>VX!.[J3&6Z1$I@R$^-#&<B"8`$5/W][J;AXN)Q:&?GD;MC7"P&V$KMF
MC(N+J-+VN+@BN;;A-0]DN1D`,0Z*=1?D;PG#'46%$;FQ$8.24G#$:?<BNJ<6
M)QKPKCRP`9&P@*AD$-[Y'O1"C14HGD%&GDA50^.Y023@7\-+O""X`P1"`@F"
M,@PB9:3VO%<FO3I#O0%JL%>C1=F+5U=WKP5S'4E@"8X`4G&0!%E0'6B&"%EP
M!-=+"C$X"1D0D_+["BLP$T+2A+^P!&@S$TMBL7W&HH[%=H*F1ZS5`T]0!.94
M!#GP$#RJN@_,_P)6X!M)^K(O:\'VC,$5#+,NBPZ#D[.JM3<@7%I1:@^)@F=[
MY!&^]@NY9(D,G4M[%)?'AP8TD3^(V#MSJ3^=ISXZ@<//]#VH-YB5F'K!DUTG
M41<`!!1:"\,V(4\&M3KEA;9O@0")6A=\H'O+5P(U<5W%MM-[`4]4.CXW'%"C
MF<:'R[=FO!/79V"B\7TG(<?&6,7:PRL3-KHHL,R_.1_.L5.1H`D?ED$'8AN&
MW+G+'#JLX#@)DA&L:YTSH!X8$P6O^S.F,%M5B<D?M\FA(SJ>V\FW@3!`YKON
M*=3Z=;CBJLH%LIXGN+QF0&4V,R$X0\O^>9+5RV:WO,N'T)'P:3!9L/\!PIP!
MR<$#&8!BF3T*DYP%UWM616,<>T5J`)AB2JB?]IM'$8&B4NBS+0R45=B6+VHV
M!#R%/5`$OET$$#"`(M044C`?0P0#9W*D%WS/]ZS/^!PF53F[ZW`&3,!)W0`F
MX)`X[8`!@3988?>$[E0DN002KX"T1C)<7TS1&7V(I=D9D2%KD=AK04Q8P49-
M1UQL1A("2BQ,.R'22(PLMH<[4KPK=NPKRG?@N@E\*J$[Q6)=U\6S1^&U/%L3
MMM?&\U/&&([&BL&F2KW1E;G@3MT3H-D2=,RX%T5B)(8164!3VN%40O,'GKTR
M&E1#89T*>OPUK!`H#R&`K1N/:VT$$Q39-U+_$#,@.0+!$.V1I:$#.GG=Y!6(
MX@AS'2NU03?`7X"-RJE<'0<S<\_QRD:H@H;5V!,I!"5YD6^=D91-"#36`AZY
M!/]Z`]]K"<;A(A#Z!C<X'I_]KELT"BR)VCZR*1X1Z-<L6-X=VTGR"RA<VRW\
M6()V"WM$!VNW`CT@!$4@!"JP!&=`W"($ST.$$>5@I/7,W,V]W*..#O%PZJEU
M!G-0L]=-25OI#MS=Z&5S(8")1U4*7.,-7&`WB.:F/P&NJ>U-?.T3&I`8Q/"$
M%"E]Q".-!OK-%DOL$_YM)-P6X*08;9!KQ:S*JJWQ>X,QJ2YQ`CRAP]&EM4I!
MF*RPTUZ+Q/,#W^=6_]1%C3OJAF`;_9DNG5`A[GW;9#Z<&*=5@:@35M74R,E[
M?.<=0G`90',14,CLT348T37.`$BTM#E&$,EP?>8=@@5%+CG_L("UNQNSU/!Y
MS<E0#N4/-_(,)^4OU0!6'J[Q&035<;SZ5Y_X*08JYKS/*Y'M"MEZ7G5VE>:%
M@`4=60*I#)+9Z1^=/43@*-JH(*#82S3FP0*]]2>!+C9V1.C93`L3FZ)_I.B&
MQ#@PBI.M979IFA,]L``-;&+Q/(WL(944+.JD'J3VO,_G`'BK1#C4S>JMOC>*
MT]VV$`L8`IA1B&='PK.\WNN:URGCPQG.\BW.4NP>_2G*'ODP+!4E;=+_L_^G
MTCX9E4**+XU>VXXJLQCZL)<5A%%M5!%K[U8IG0(\(B2&4K"C3E$ZZ/[??P$N
MB($_[KXI_/5NVG<I]G[OOI2,<EM/^KYLJ_'A+G'BMH$P$SA#+%!%F0#C,>Z-
MI\L!U(BZ-_[P:9VR&BKD'T)!1@X0YL$0%5$1@B)YGJOB*QY'4!ZK*.[^)!8$
M)T]B3^`"2Q:N'T0@^B?_*`X()!LI*6X9ATL])8N+$"400B5"DY!"14=F<0>;
M!YJ:G9R>H)YQI::GJ*FJI2UQ+5@A)4L*.SM9&TEN,QEF+3QQ;ALMK0<\9AN<
MR9N?J)VE+"A!*PI"M=8T/=D]B=M+WDLX.#V1V#C_"PLK*SGK[.WLZ2OG"][9
MWN'GZNMG"R4TV#M!`AXA8<4*#!(H$L*8X:!APRL.($:\0K%BQ8D2+5J,R-&A
M1PU1HD@P(J'DF3D2'*3TR!(D"R;SZM%0,6F2"A6+L'6S%PX'N"4#OO@;2K1H
MT7Y-B/8C4H(ISA(J<*"!VL]?$S0X=N"@4XN.UZ]<M4H-,"%`@!`G^#QYLG4'
M5ZE+T*#QMTC%VA,AS)IUP=>"7PL3_@8&_)>PW\`3"%@@P%AQ8*1-DM:]21DG
MC:PKI"1,J!E%YX"@I:WXJA5-D[H-D-)H8O=F@YM$5,0FLK:V[=I@T`9PL7<O
M7]^$$S=6;('W`#PDDB,D_Y'E((SGT*&;41:'1XL,,]RX26)E@W<6R9^C.+(Y
MQPH,1HQ$28]EF;)DI=YS:J%AAH9>PX;5-\*"Q7,,T6V6T!$$$AA:$%D<F,6"
M63"7X`U9W-`$7PBP\40#3;RAX1L,1L@@"1$,8D@&6613@B*,./)(39,4(00*
MF80BHWNCU+C*C3BZ$@<66`P32Q,XT!($#!OHPHLO<9C!@G6=&).$?/#=.-X*
MWFAES0XG:K/-."]`L-,20CBR#3[IN&,F//+XI,TW9.J#PADK*+(-:$<L-$,$
M""G$0A0>80&11H!>X>=$&&G$D40L.:0!2"*Q<-(9)27*DD@2[,.-)"S:Q(@_
M6_]^X^D:0EEEU*B7#1497:F]=E-3I5(U%%8]=>46:6[UA$81`1070%IJ;?66
MK4-!=8)O+A177&`N(%;88<P.-AQCAB5KE@J1H1%77$G14%<)J:T*)!U!="8@
M9YZ1&TUHHTFE[6M0/5'9;++=9AL?(>16+Q^^[:8O7[SUR]<$R0(VW`!3,&<P
M"3"@X%QTSSV9#`_&'*)=$MPE\5UX`PIX1GI1S#!#>U"&0E\+[[%B1L=FX)>?
MQ_PQ/&Z!.1P1$#P'T@EA@Q[>$(0"`2`0`!ML--"``AM"F-R'#7(@XB$[R,G(
M(RM2PN(ETU%7HWNBG#(,%CF:DG(KI_#`XROYL5%"$[/_U")((8?X8MT&$'MR
M7<@REO)+=7%$`V8/.RQQY=XF5K+%X%N4X8T*8H+3IIGOH+F`3]QH<\\Y^IR!
M`@88Q$D#N1MTEYR`S^WI$$6'!AIHH8:F3KI'?&I@TAD=K"1I0R!),`<3B6":
M*8N;<JIE#T$9E2VI-&`UE:C^X,0452K099E5L&85EJQ>:54"'_W@NYL%`?0J
M:S@T/)%7L;KZNUM9XQ>KOK)^/>M880#SIE<`9\<5?4]22<8M3JOB!&00GI'"
M"K8RK@(64#-2H`,.9N*:V,#F";2IS5E"H)9Y]:9?^M*+_##(K]WPY3C*:1`*
MF+,PZ+`@":WH40M2MHN)I:!B_]W9@'\0%C.%&6$&*YQ!Q^2SHQFD1X<<BP+)
MJ.,*1BTJ/ZXP@P_[`R`,".@([5C!#J1HC16`!B``20>"F',S!5A(:)%I`M%N
M\(8;&(T#'%A0<M`8(@]D8`/:>%HCH)8I%V'B$Z`H&=9.@04-&`%`43`#UU31
MHQE<+CU)N$]^AI&RE,6B?CO@$`LZ9XA>6,<-U6G2"ND6)5-8)QH]8(/?O+&I
M(F!C"?[X1@EJ,#A90"T;YIAB/ACGN,>IZ7=C0H<^,`<#S,$I!U(8B'<.DJ?P
MP*`_+&`(1DH'J&6BSG2$>HBD&%4I)J#$(RG)I@0H]1)^[&YW3^D=-F@`JN&)
MRIQ%R?]?#Y"G+6U!A7_P?![:L*(5KBAP@3.AEUGX(`?MS8\W[=+G_,[RSR$`
MAE_)FH"RG+48:"U+,`@=:`!48!KC*2!(6<EH.$SC3A5T*U55V8KTTF%``P9A
M!U-9"Q'@11O:G,!>8+B-6L"@EGUET%_F^PU.=T.P$,*@026$01+L$Y(_8F`=
M\T`'D;QC,8M!XW,;^YB?>$353=BA1W[$0`>8$(8P<)4)3,C!QH;Z"JV!1#TS
M4-DP@,@"S"7D#%!<1SJF>*5:2#$@6*PB@V2F@!!4Z$*140#1-!2$,Z*1!!Q8
MH])2D`$4H`A%<_RF)81P1QK-B!2IT,`<.M"!,'0`/8KLD1G_0)($(^0`#DM8
M0%@QEQXC4.RU,`A!:M`F)$$4:1?#X$$&,EF=87"RD]5Q@S1V((0FU.(T3Z/!
MWZP!@1K4X`6)"-,IY0$/=\##<3X1!R[-@8X5G.$,F.M/+Z$1#11$@`5XRI-"
M%(9,%FC@(8@RG>KD>Y'Z=N0CE`)K-AVRWVV61`(88,(X)`M..98@>*LA'E%Z
MT(0>R$4N-R$596)S@L7HB@_TX@->_LF;@\XO!'F98(C/4L$GT!3#8,#+B#5(
M%H82!V``.U9P9MPLG9KE;`_&GP*ME%&Q7$4RE.&6D,^&@QQ$@PX),3*Y@H"#
M$CSA!'C!2VU6^F00GT!>,GTR&/9E_^,-VC2B&"18@S[W.><D09"C_6-GPP"'
M!;2Y#&6`0`XFB8OO?!<&1M"`'5;7D!9<P:J":D%#HG#4#N2`LTS8:E<7[=4<
M@-:'',/A*ZRC1"/T\KM1G"L5ZVK7NFJQL`L*`@)<@(!1_Q5#8J1%&=5X-.4L
M5@Q->ZR!'5%'JL7':C9"10L(O>9$?Q9`K=4J[!90!C@8&PYA.$>RY^$-&D`@
M!)&`)(+H;(4C&0-BFL0CW3!K'1)(<0E%J(4WC+L$R1A7'5J!QPNV4(,RX`!Q
M)U*<+,U#[^O&XQS9Q24L\2%6`+6WK0D#((A@@*>$*,>$_;$"GTCWIT#YR;[T
MW<BA[NL`/O]57"1GT&^D^JL22E7*FP0N\"(0K&"CQ,7!ZPP?J1AAEUPE9@(@
M!G%O%BH_O6C8++D)0&YH&L$GJ`7#4):Y!J45/X"1!:?_(M]#%4,<[M5\6E<!
M!T:#9$\%V+,M8I$*1_>'$U6EYC)N<0LJ[8*6F.<%Q.*+.1]ZCF6?F]C$->VR
M![_\9?.!D#DH$*%S8M1'-7?UV,>&,P26,,G"'Q4#,]@S%OJ$!3O$05")NNHP
M'-`"^P`QP&Q&-K(7S03PHC4_A6SK=\_0N#+-C(KPH&L50<.@(#R!#403;!,:
MP(92!RW5&C)CA[*`1@ZDP`Q+.)'P(UN)J=DQ1C;"FC-&JT@_SD'_JYS%7&<7
M\-G-:C7SQ0Y\G`<7@"$<'=JS35N#F.H&2[:"!YU`_F_S6)T9'*$6)2B"&Z8!
M#G%?E#Q:+!.5G`M=".`$EMQ57?J7#@NP`_@&#OJF.+H$7OV1'NVU&2`"'L4D
M!0<!'L>$3%:P3`U'7_`5<1!'<2#Q7B)Q.W!P3?NE$A7W7P`F8"$G61!`<B5'
M%')Q%14U$T;A4?T04'G!/74P/G,G468!8O028F87`FL1+T#W4B$&8V4!A/^D
M+X,Q8^PS8T]W8S0(*[00#O9D3VYA==0C%3@0&9,!%:IR$S\7=#''8GD!01#4
M4FU7&S^78EO&93I5ASDU=\:!!V.V',W!_P)#U'>8QV:9IWTOP``K@$P)<P8.
M\'B+UQ"-MV>0QU\+MPF"THA3A568IWEMUE7@A0%[(FE%!`VD]P[FD0_H4@NG
M]P;A8%<($B$[$S1E)%B"I2&S!S1",#2#948W@UB^!T=.8V"24'PN<GS:5C?.
MD"28,P?J801ST(S2QUG3UP'/]WQK!@?%)GCK-@1#H%`*10`P5P2I<39"TAS>
M44F^X`O%@'[KET>=T`+>M@-]E04L,$!H<U)]DQ5!(#/J<'HO\%S1E3B/@PX[
MP`3V=F^V=$NXE%K=!5['U%HLP!_D-4(@HAR:<7`(0P+^T1\+5U\>N($<N(&2
MLG&4DG'6Q'$EX?]QS9AQ-+`[+D)@,!B#_H`&*+<:*0<5[M0`[:0M$81A/"ET
M0)@7.4=3PT)09L>3&[9B1*D&]4)03D@LN9(K2B<8A8%!\T,M-*ACU%,KLZ*5
M82<6%[5U[R0;:,AB3Z=2;'B66/9S&*9EPP)F=HA0TM)!OW%W'R)4S``2U^=F
M@@AX</8"VK@$E^9>BN<05/41*D@1!Q")LT,[`-99'9!G#]=WZC$,KI"(*$"*
MZK"/A06/,S$)3R`$6V:$_E-N"M`$(`8&&!)[I3DT9?0&822+N;>+2G,$OY@B
M*Z([+5($10`CVI8U6F,$G*6,)>&,FP6-BE9]T,=FV+@%#+"-W/ARWOC_,Y,P
M6[4`5.68,M9Q-Z:PCJ&0!"<%)DO0`C*#2DO@'5IA#Z)A15I4!C4P>&`B)CTP
M.049#_%@#@BH;_%I#NIP.0W86@X)@<I13!>9D1B)3%&@`1)G$0\'<1W)D127
M@BD1$K8#5DR@@A;Z7RG)!'!0"<-H"2W9DI;PDC#Y8%>!/++1#Q[U/`]TA)7A
M<WP`4R*F82@6A&='HS6*%E!FE"H6<_;2E!=T4UR&&,5B4Q.U&M:"!A=U45L8
M=EQ8=73@A6&A4::!7"K@3U6H%Q3DAFS7=C1E8B_U4A>$=$B'AT?W0<@A0@BQ
M`7B$!>O!5<?&:,8&9V7@EP0P!/W&)XU(F'F*_X*1X@"4N*>+23LA@:!_MCH`
M=D.MT`+^L1DP4XKI$(8-D#Y1Z1>_$83J0R%&*$8:,HMF)(NQ%YL,L@%-,WQ/
M0VO%-UG$2".>@`4I4T1ST%4H01+,6)S0R%7&J55N.J=;H(W/V:L*=1:W&`EB
MM`-&XQT;8&V_<`".5XR_Q0/OEQ1+XIU]8UPK9']+H)Y!D`/2$`0]T)[>``E9
MHH`"64NV1`_Z%H#KX&_+N!X.&)'A\3E3,$(*<TST6J]^V$SR]4P?*4VSXU\=
M5TT:6J$7.IPH\5TLJ)L(ZZ&3-0DBFA-5X4ZODA0E.A=TX63\8Y/:4AD7&V08
MNPBQX:)!YX0\R9-$L/^625@O0H>4/DJ695H6-C901+`:41<.5N>%6UD]83$]
M3@J/3ZH57QD9_O23]<*&$;2E\^)V4":'0)I3</D;3A=F4X`S#<("R.<*?P1X
MR99LFB>G6R`<<``I%B<I$JJ"&-&()\BG'#<1B7D1%==G(Q,',^!$3T0@.=`W
M)1`"2L=TS])0[6-AQK(L+O`$"M"I$$)&1:.+-R.JM0DUDJ`[D("PMI9K@)AG
M4?"J82"<MC.-T.A9GF6<REF(SNFKONH"(="2U.(WMH!81'(D2'*,W+D)&>`3
M.Z`)Q_"=-'!F<9`!H[0$^9A_V=I<[CD.\,E=^""0!F@.X1`YOZ.`ZL"`5J#_
M'E;@,45E:1*),.E5O198@1:8D7X&3?C*D?F**($J$O]*D@%;DAB:N1D*!RL)
MN>ZKF\&3$TH!L98AOZ8ROZVQ*L&RL53QL$8!%1JFLFHWLB[JHAJFA$7(HS('
ME"N;073'&UGJ0,USA1I5/6W1I+/2I#:[BE.'`T$[4&6W=F@I+PY$!#'UHE^:
M8KW!8ER&AW+I0<<Q9LV1":5P569@!!J:?9NX:'$ZIT-0IPN``=LTJ*RC$A?Z
M9WO6MBH8MMJT$H6ZMOP5$8F)52M$7@B1!>-Q4CTP+,OB/EZ\MP3`&SHP/A:`
M``J`1F)T`QR`N+IW,XDE?)`%->!::[;FFWU4N>@1_Q)S@&S".:NTNF9=Q55=
M!6?,^9RA*[I-:(0-(*SCB#"XP`MF@&WQP:PA$P<D$"0DPP-ND#`[@#9*L@D#
MI`"`"0/VM@3.)0O>,`GA2KP&*`_XAI!:PKS-ZXD/V3$A<<OKD3`),4S)(05D
M=DP(4X&A,TD?\[T,YY$3MQ%L&ZB,@K88UWD99VR)EI+-.`>/`E9P,`[O^P0N
M$A3^.[\VN2WL1+$0>SW8\[#\DY/_>Q,Q=P+]DT])JX2\HJ,9AA>YL:-`F8;V
MDH8-#*1\0`-T,!I>L5'NA&-2<5$BQ150RH50RJ0UR[,8I0!!>YH4I!9#VW-L
MAX,ZB18I]F1*&*8LZ\(>]/^T`=!3""%4*30RA#:(F[=H;M;#Z_:U*.%?MSRP
M_U41B^<Z_S4I*#@ZB&FH*?%GB6D'C'(R+\-D*K`][?/%3.T^I%L;(>`733`%
M$1`9;]![S(%&"^($2K.XM!:,->&^E;4C*K0HZPH2>UP&S3BKT,=9C/9WUE@#
MS<F-O'K(HWL6+2F.U6F=&2`&D4P,[&A9\M$"3/8D2:(P&;`"3;`";H`"FD`"
M?B-4*&!%[[<`@_,"]1!\8;+*W%4+:?(-R]L3NB16H7-#'>,QJ+T>X.$9Z$5P
M`#J@&$FOZ(6!#K"@"AIQR6Q?@8I-(N%Q$PK-.2S-T$S-),F^$/"^18!@.1%.
M,Y'_@Z0BL<'"<N(3&P^[+31AP%"FOZ,2EG:1A&@896A8=C!%T4&WSQ3-P!+%
M3_T0T#2#+K\R/$"2I!VL0$L:=C9;=1Q\43FG<Q5M&Q0T9?(R$T^@%W*8PDLY
M4#7'063JPB#4(&>F'^RZ69FW`%E+H3QLC<76>9AKTQ;J`(/9$$M,>2VAMFLK
M$3?-"5=@!PX`D7^DK=*``Y$:E7K;U$S=4*0K-":6*R%PQK,WN+WWX[UG(K,6
M"6'2(AY:Q_2Q*`=ZH(NBY'-0;-)8S6W]UACNEX>\C7;=J]X(P48X"6B#`V_0
MB@@#R:U+R70S`_F8?MXI#$$`F"1P!*5P!+P;!U9P!"M`_R!]PP`U$*[9X"(0
MH!.*0[P]8:[=X!/R4#D7B%:GC=K2VQ\&%P$'\=K!#,S.`8']P1`>V('2A*^[
M[1!C>Y*]O8+0?`9Q*MS6U`'F:XT;6@0GP.K)'2KMU+_-[=Q%`=W9\C24867-
M4Z7Z5-'-`Y,,I+$/=,`H2T'?G;1E)]XJ9MX+7*-@`-!>86\!H:W:6EXS<T_D
M#"0]\=#T/2OWW=`*W1/+GA:WH0(7W79#IW/Q7"]0]H0_>J54.9=1*PAII411
MP`*_IFB<1Z&"/(AP!@>?Q>$6.@>.F-,=WF>`6J@2UZ=/G)B*V@-U(`0T(01K
MH=1]2^,8_[<NT`]"`YI^]00WH/\`&*+&$1`B(3(()3+D46-\NGE'?716@]KD
MBR(!'0!GTH@!M-KO<?H"5MZK6*Y0A^P^0P#!1<`&PHJZ8GZLO"#)@<U),Y`%
MK.`&+!`$2>"L"D#**%`,6@$#<;`!^6CG*U`"#.`EOQ.,_5`/R!N0D+,F\MF\
M9S!>M:Q#(<'HC;[:OJP<$"BOGP,ZXL%>[F7;I]-PR4PHXMOI$'J2*AA@8&6P
M/0QX_.YFQ>9L>.'-KF+=E>\J)8?K9BB$$:;.P)ZQW/TN$[86(TLO]RR$*`O>
M]HRR.[>4:!$;EQ'M-&-%H%$NG!$0;Q$7,JOM4X?0^)V56Y&D"O"E)48$$B\;
M__V&*[S_*S'UI2B[LEY&E4#:4T+U6NEQ!H+H:Q1J:(@&5G`JW#/-X3-=Q!=:
MVRE.F&L+Q2`>*8C)"6P*!W[[4%V,\31>'*06`&R!!OX]QH,+"&]-;UD1&X<I
M,#T])8PECR400B5"0I)"19F91V98+1J@$E&CH!I11G,=+V4=<Q@=L&&R<'!E
M+S5#0Q.[O+J^O!,$PL/"+BX!(6R9#4U+"CM!1UE9&S,99CP\<0?;VP?<W^'B
MW#,\&4F'04EQ)#M'.S`'9C@X23P;.4='*S@,#(L``1:QU&C1$GH(<03LL63)
M@ATK<N0X@P(##!9&C,R(LG&&1X\:S&B8860##!122*0D@:(E_\N6,%O"F,F"
MQ<F+-6=@N<*SI\\K#H`Z&"HT*-"B0Y,J'2K!@00-$J)*%245PQDF6+,R@5.G
MC-<RM&AM[5H&0A$H7QY`>D2CA`JW<%6HH$&W+ETT=MO2>/NV;M\2>0/G;6)7
MKN'#B`WO5?&$3^,3(4Z<`"-9,IC(E$/P.<%'<V7(EY\8+H&&SHH@IT_G"!(D
MAQ24,:6PIK.#7MTF:.@IT*V;#@XZ"H`+KUT;!V?'3T2K(,)8A>;DT*/S"4"=
M.N7KH$.$J,X]P+'JW[D?&^]]P!0.&VIF-()AJU<X83J<Z8!5?H<<]+'."AOF
MS)RI4_WW7U-#10'@?TG9(=1./PDEU?]0"GYSQ0$MK!"`,!9DJ.&&!%B`(3$@
MABABAQ941\,2#22G70@((-#$>0J\P0$'AFRP@R-K04`))97TJ,DFG3B@`2H8
M8."**T5V$$89-;P0'RQ*SN+5"PSH`LR55XXHS`3?:<>&$$TTLP,T061!P@89
M9-""&7%T,\Z;X<3!@QE)L+#!FD>T$,<&*_"SP0$;X+`##RW`H,\*2Q0!P4(!
MF4500`TUQ"@]"T1T!@P8J)?11AQ]!!(H+<Q0)PLHO?923"B0H.JJ+;%``DXH
MG%01!BWXQ&!/1BV%5%!+]4J@`U$(Z92!`$HUQQG(7I55+74T^P)98971U0!?
M/$)$"=?*%1?_7'H)5A=;:P4V%UV`>1L8)(FE>QA=B3W&Q[OP-A;O9O"^2YED
M(;BEW%NEG<;::M&\]AJJ**%&AV]XT8!;;KLUC,,S8XXI7,,G1$>$:,H1$5ET
M'%^FG<<53S;9Q]V5')YW*(M'G7EVVL1"D>Z](+.3Q]J'["M,Y"=+&&'!X=^!
M$@PHRBC`$CN'T$/MY,!.!_C$E%.B+#WAA`=@<48('WJX(8=:=JUEAL:X$,(3
M*3YQF7<Z-,'!&S(:HD@CD.CXB"27^/@C)RU$<<8"D4CRXQ;;^5+&SOO94F4N
M$UB))2]>=S@$=2M.$N8S0=Q09C779,`#-][$^4WG;<Z9P09)9"`G_PS:S!#$
MF&8<@,(20<1A!@G[K,`HHR4,)/?M"S7TT$0X9<11IYY^-%(+G\Q@A:LH3'$$
M;#!-D>JJKMY4$PPDU)231[7R="M/O"J%U*Z]*M544Z,06VS041V;K+);,?ML
MLV#14@:U1.SU2`-\'>:6_N8"S/_ZTJU'R(5<YO*66]25+G"]98&(28X0H(,<
MQ[SK.)L160@4YA;F,&<N./"7:U`0!.@1[#6L64%Q$A:FA"!D-P\3%&\JAIQ]
M+<<Y8.`8QT)P&="(##+:08;)2D9$E)''/#!(#\QX9HL:.'$(K'A%D::(+%AD
M14KPZ4"QA$85];7O:%'1U4^2\J"F7"%"3?^+0@\\E#429:A#C8MCB#1$`!?D
M\`EL^)AV7/0&!60!/3>"6]PH4;=*%&%%F3@!)S2``0AXQQA<<L&&@,&`^GV%
M28A+W"\6%XS&11(9VBE"`TH@IA6\H4Q9<,,,W("--HW#&V[JQIQFL`$VR<X>
M&8#!F)+`C=79@P6UNQ$->C!,WCE*;L-,)C&).<R#5.H,F5K/\$91/.-]`GG*
M,P()I"<]@KF$!!$()ZEB%2L66,$*GLK`##H!/EP=)7Q$*9^OGD;&`HUB?>T+
MVM'DHQ4X8(46=9A?'6BQAFI!L'_^TU8"`?-`2)R+6VQ)H%\.BA@AI&LQB*'H
M83#FKGIE$(@*(TS_"?AG0QK0@352.(+`2N7-ELAF!0?#0<(4QK`7QK`VNZE8
M<IISP^5L3(<4Q,YU@EC$HJHL92ECV2'.L"0(W"(754I<&:9(52I:D0G[$<N`
M!+0^]1UM0,%*BM,<!+4P&D5"+3C#A=JH-:W)\:US+)&*$!`"':SH&&Q0``>"
MP`@<#=(2E=@.)%W``,CL`)@0,$9U$``>.@9C`@QHTLRBN@O%<?*M%G#!$([A
M)<DU@7*GI,8,4J`F-WDNEMP@5`:L8+HVK6EVJR/!-W@PICBTX`BHJ4TQE<G;
MMIQ`=VL)+ET8\I`5G`$C1HB"%8;W$>*!9`;77%,2K``#*60A)2U5503L_W0(
M&)QA`^?\B#J+QR`&$85\\D1O@<[W-'P&2$`UTXI\Y3<M*&@T,=N2J`#+91<#
M&G!<$LT+`S.*K@$/F*/PPM=EP!#2,+6E@STMP6]4JM+8M+0E*:2-3&^#!F?P
M!H8X&!MRY/)!N?`0J,EQ3,4R0U2CNA@\1$1B>O9FB[(P8!6X2%P8D(2D*5Y5
M/TS,(ABY&!4OZG,JNO(5@(ABAZ9A(0HTZ&36W@A'N%HY:W?,XQ-XR`8P!("N
M32"!7^?&(T-2QP7!L`"7J".$AC2!&9^-<Y@:$``V#B-Q_O"'+@B`)3YG";.?
M!.43'B&FU;$&!FXH72M?^3EPR*D%ZK3EHS/`@O_5[<`;9G!''%2GPATLH:_#
MA5M?'R&$WUH"`G(++F"<F8-,L2`*24@?<STUDAF`"GDML$*=!#8P@FGW$.AD
M+3K'ZZGPHK-6YGVG>N6YE%\YI;UEQ>>QOIJ??VX%*PO@RK/P-^!M172A[.J6
M7APJ[@`_V,"C>2`#_YO0Q$S0;"/;8)CF'::1RN4)0F#.H'$0A)4.[-\ME<)J
M-)PPP*`A-Q_6:7+T?4.-C0W%C?'8=B8N1.YLY\4O5NK+,+"#,N1@`658`A-N
ML0LX&(FJ["G2?*Z:528@"[[2_NI4B%:^\[&OR&>]@M[4`"*WNK7*5[:R7+<L
M\3Q>!@%/:$)P,7'(,QO_@X>2W-H3%'"#*6R3!!RX^G7?H`([WSD7B/,SXQX+
M#"M/(+./@QP;(*$`RD&#&BE0M#;`\;DVV5T;9BAMZ-:T@7WLH`7AF`$\>*#+
M,>&@+8QXL""#6P13JP`"CX=\JD^T@`6T&KD=<6[Q1J*!Z"HO/2X]%:I^#5[6
M6D-YV#N)]HRPW.7.P"CM?">S:\YLFX=QBU\]6L[F(-]^QJ\.:+E67!":T&^?
M2_'D_E9>^&ON^W8;W0=UOF'D=8(&TQL-(AWEQ7I*`W[#!N`7=NEL:H-]#NM&
MX43(=\.%<&(=7G!%0I3DV2QNG2!>'./<D3%&DL"$J3*A!_0!`8>S`$9R)!B0
M_W))@A_R)1&6XG)$]EX`<D_-]FQ?]"!G!#YG4`=2!G1P]'-!=V4ELAV,%0!@
MP`;*\00H\UL7]QUHIF8AP#]U]D86\`0W$$XV2",SDG4D$`1-X`(APDE]5G9"
MMPOAH1U",$I-("BG!`U)=`AN<`W:($O9("=R,B>VE`UK,@,[N`.\%`Y)L`/K
MU&F!A'QCEB.1D0F5H`)I*'F-@`.5XFK)E7G59#RVUGFUEAXJ@2J]-CTUPEJK
MU0)B8`6'H#WFM'I68`0LH`%CM6RS-X$$PE[NI4_4EC/+<FUA$3_4(GWIEGS,
MAT!\87P!U(D!1&`-1'SXU5`+!$'ZHRY/8'WT1F_GUO\<'X0&*[!2T+.')T1"
M!E,<.!`FN?$<T+%]HD$$R,`QF[$B021)PQ!_D`-*>A1O0D1Q185$-9$$2;``
M2\`"8;`$,!`&+P!V.=,!)W<T")@DR5(J`J="=+``R')SQ@)&^$2!T98*0A,%
M/&$'3@$'7M=S'/B!09=9&L)9(6!1*.B#=-0AX"&0@O5&8'`#&Y`"&Q`!.8AU
M6<<!4Y`%/2@B90>$N_"!9X=V(SB0E5!H0?`&.Y`%3>B$:6(&9B`&9H`\V8"%
M+4`H,`EI?<>%XV`%06`&[Z!;JO:3<P-YA_1;:#@0:]B&EA=-I[!<G:)YMO:4
MR;,1RR,K%Z8J,-"'+VD.@GC_"."E'H>H7.D#>[EB/L_6B/(HCY'X1;K7"K[7
M,VY94,*G+8:Q??XCB@+F7P3T8`HD4>JVB1HU?'!Q7^P6F`?TB6HX?:[XBJ\X
M4OJ",0>$`_[F4N$'$Y$9!#C@',%H47.Y92*&+_!79R(B@R5"@GKTC!+'0\@H
MC2LS!3A1)TL0!BQ@>4:P`"^0![FP`$LBCJZ`"N58)"XE!7C0)_3@.ZW@CI(8
MC^[5"O`8%/@H`3C@@Z'9C_XXG1CR95L3FF?V."<#FBZ@`!&0`N$T(^"4@SIX
M`QGY@QS9D8_UCVJV9I#S@I/@#&3"A!R0DJ6SDBQ)*/HYDVL2DZ%"`BN``N+0
M)I0&_P,($4A`.4B2IX:`(QD_8I2/QQ`[D`,HH!ZRUA'55&N<UUQX*)DOT6NO
M8@@I4)-I(H@UD1Z">$ZM]Q'?PXBU1Y;M97NXEWN4R`0"$#]N&1:9*!?\8YCJ
M0BZ=6"[^Y5!"BD#EMGS]-7QR&7V$.1I-2F"`V5"',4$*4Z6*>:6Q.(R/V6\F
M!'X6!A.KLQ>0P1G1,4'-L64!`$3P1V5?TR$*F9JIZ3%>YF4MMIK:DP08L`0Y
M``.6QZ??6')P\`)PT`I&DA%S@(`SH2J6B0-PL`CUXX!<Q7OPF);OQ00#<EYZ
M4P?4N:ERE"%GQC4]!V.;I5C>00`Z$`0I`)X5.9$S8G7F"?^=Z+F>8C=V'JDA
M1H0,0K!VA98%.T`(23037)DF^,F2_#F3^UDH)01+<F(&-G)X$5.&9(9JD?!X
M/K(B6T"4:&@)E&=<R.5Z&)JA3UEKF6<3,*$J)I0JVX4FN"8ZGY<>P&9.AQBO
MR>5.+OJB,IJ6N;>6E'BC82$`M?"O!`4%_*.DIJ@8!=1?<KD7_:5\#&ND,[5\
M"*5J;7%`Z!*E4)IN&V5!DL%?#G:E5[H_C.&8;^%]7@IP*'29G9&:-22+(3MQ
M0;2/7^.ISLA#DW&,8-`9IQD9J.F,8$"-&'$$/7`$>1H&1U`&6V`E+P`!3@0'
MY'BHZZ$],R$%AP<!E_0>ECID]"'_<Y3ZCC<'(0Z0@1M(G3#+J<00D(H5`OM8
M(IHU'NZIC#1X"!(IGJNZ*J^JD;0ZJ[+ZCV?')9NE=@/1#,_0DSL0HO7)E2E@
M#6GBDEE9DZJ%6ZWS!\N:`>_0!+P:,4N0(WTCK0MZ"8G$`"N"K4;9",^D*;$V
M:YL7KIXR/,SC$AA6KN!D!30)DRRY6ES9,H58B,OS>DXS>Y"(EFAYK^]%;:E0
M;3@:+5\!!]32;1`TI'897`_T+43:B81QI.*B;MB"?-J2BI\XF%*Z+=.7LO;7
M`+<14N0[;XDI4O8FC`<$#9&)0G30!"H`OO!70T]P,<*8;T(TMB.266\Z,I11
M+QJ4&=E1_YK(X+,LT'$8D`-E4'E44@.5Y41-LF-&(@')12<U03LX@&I)6[5@
MX8#^,0<"H)Q;%8DR!U8M("3.&;9DN\)=`S8+"3:*M0M.9PQL]+;A1)%8IRI3
ML,-3P(.P2@Q"",1!#()J!C9]&TJ#%B9D\@QF,A/U62,JF7<L.<4UF03J8'>0
MA@)CL@1"L`%NT&DXT#>1,*V;:S>:$`*>&QG86@FBRZWK(8=SN*&IVQ%)0)4O
M44+E&@'74*R0MEJTVS*#2(C:,P.R)T^]6Y:0N+7YFK7UP:]PX*_V\QY?L08"
M&[%RN8D`)AC],V[?,AH+>Y=V>;#C1D"H6&""62[$)R_VMQV#-O\85OJ*YXN^
M9=-P*M`$M<@:04`')?`$:OJ9U$$$%\,Q(<L8:-NIHZFS'Y-!\9(<E0'`(Z.F
M<LHRF'(&2U`&3+`$,M-$.98XMU!)5YL1;&(&V!,$2Z#!''R\5WL5`I"ODYI/
M:BES8>44=,``+%S/^ALBWX$`X\&VQ\`E7$)E#>"0<9MU4V`Y)=FK.Z``3P"S
M0WQGC../'TF$:XL,1;!VI+0$T)#00;`J]<D!W,65]YDYPWH(_%DGJ3(F3<`&
M02!X$>,6.O)X,%U(AJ0)^!(`#-"@/[(HHXM<I?NMISN'G;*Z=SPPJ@)>PJHF
M+BFLGR?(Z2'(KW9>ANR[2*;([$R//P;_R?YZ25TQ+5]`8LN+R08K&.$2;D#*
M7Z'\R=#+?`*D>-U+L,Q+L>R&41$'?Q.7/^([OH21UQYKON02LB*K=,>(C$0T
M-GY]IB&K,?>,(:,)2CV48!O#&9`M+S=+?9T1;Z@9`@.`!YC2'N]Q"S6@S5[`
M"Q#\V4>B$68P`X;2`TY%M9)<"Y?D3[QWHY;ZP4-V9/!EHY9J5D[!!'Q0S[Z-
M6<>@SV&#9I$4-G86T.&9P^;9`&6C(LH((@WMT"H,5VI&(F<W6"$P$*34#";9
M!"=IE1V=DESYA.IT#DGPA!YQ#C9Q)C!@F4T0`DL@N#M`QG(!6#W"=#_R6Y#!
M`*!TK9H``2?B_\:G8+IS"-3?.DZ4&1-G4J(KV<<,;J(S@1-.71,O*M442-6Y
MQ\A8P:^0',E?40=:4`<^P&W6`GUF?2Z;'%%CW7SB4J2#6;&K&"Y_L<D9Q1?X
MILK:P0=>%@"M:!=Z_<I[[6!T05(4!*>#'0!\D'[I5[_!"!UK%9K'S+-JG..\
M?+/0[$,_]+^9(7$]RYI3Y(W:/"5/],"X0`8[-@<8<0A'D,&L#0?9QC,>_A[^
MY$]7.VWP=><@C!5@-!2F`+:_3;:)O;\TK"%[VX)GAR$T>,.M^@9/$'4<LIYD
M-]U"++9%3-QH)C9?(CD8[6D*(`W3H"J%:[C6.%WH8+N'D"9N@(<DD/\%CZ``
M2=`.+0UY]GW?#YI(^`(9-JT=#CH0`7Y<K+<IU%3@!>Y<47`J.YA2,I$"Y[22
M(KU:'B!L$6D3$3[A,!`LY`.)ZA-MZQ.IPFNI]'%5COS(CUP'`@#BTN(#P%<M
MI*@N+I[6@9E\1DJ]8GWBJ;BP?S%N_\-0>'G)IDA11&`OEG$"UJ$"=XW7>AWD
M0KY`9G-_U4%Q+LL'ZA<=AYT<,"NS]O?,D:'C(7-!]E(O.@M$QQ%OEJ$=F5TD
MKS8'9>`#+^`#36(+GGW3K/T>A'K!($>U\(%5.V.\54ON>E[G5<U[-@I6Z2,!
M^OCG1H]9A%[$H/H$01">K:H`Q5RV<+0XGB3_Z9W:(7O+OY!3"4C8=F-B)JMB
ME<#JA*J4:%QY]GDG*AN0*ED`)AM]P!%#`_=MQ@_Z&2%PK7>?ZVJLW6[NZ]1$
MX,(>^.,D,!6&`M_IA\*:=R7Z["6*A[(RX:3"`KRK[3'W\VQ)'[+-KUOAK_Y*
M%ELMXB).XCUZ0Z/OI,(%I&V=I/`N&-,+I*@?F'HYL>"R7S#>EZ<X%XJQ0,((
M+T05`@3ORAV+\!T[4J76\#.+C#FT'!+$Y!SC=8N-_!ZEL0GV+KP,V3U$LYP1
M&N^BLSW4LU)@\E'1?Q_P`N/O`S7F3]"$)/-Q-)EB*.^Q`#6:5:X])5O@#\VR
M>SZ?K[C]@!(`"'1U_P2$A8:'B(F*BXR-CHD6$Y&1APTW$1PDF5,*(846AQ,$
M$Z2BCZ>+DP23D1,N`0$A;$(E34LX.T%!,!LLO;T1OAO#;FXS;E9)ORPP21G/
M;B0["@I'NAL[V3M+0MW=1>#AX"?D)R$AYNDA`0PA6^1%)4L+.2Q&5D8S4?HS
M_?[_`/_M\\<"!8HL4E`$04%B0PHK5IY)G.@AXHP,$(.1@,&0A<>/'XTXT."@
MI`,))5%&D<"R)<LY$N;(G#F3R9P.3'`R82)@IP`X/^'`*3-42QVC/NKX>/%B
MP)<2)52HB"I5Q9.J6%70V$JC!%>O6Z-2!=L5*E2N:+DV2>MUJMFV4L6&#?]K
MMJO6L5/M9FTK-JO?)WR>G.!S#A:?!FEIK%W<I+'CQY!I-"@<ZYSE$&`&/R$B
MQ"J1)Z!#`PZP"E8L<V#XJ`8<.##@UZY9`RY'[MR)S*Q3\TF-+@2?`7C.V'L)
MQT>-&A]>E`F#(4K)E3%E=NB``0:,'41W=CB#,XSW,$*'EGG!P!2!(77@[)QC
MLSW[FV=DNF3)I`XH5/CSZ]]/R(+_^ZL\$00F)#@Q!2<!`-A?**3PEQ\HH$C"
MB@NO!$!++4UDH\L1O`SCX3#";)#$,6XHXR$*&V1PT0S2-*10$$EHL\TWXM18
MCCLXYKC%.NVX4P0$/=!CCQ'[%!G0D4C^P]%"":'_$,$P*3QST4085821E!M$
M0`(*'%D'TD<8L!"%<R:==-)\,:5)$TTYL8=33STQ$5YX/PEP5!UEW)G4!W5`
M`84*#4RE`A%27>676VLEUI>@=9%U5E=A)9J8I%4M^A99:+E5%J1['2H5#9YZ
M1940H`U&V6&(H>688I"UNNHZ`8!A66:#K7859Z+ERD<`KV!VFVK`!@N:K;D*
M1A@Z?-R&CCG(DB.8K,G*"@9P81K!$DY&)5<&$R*UX`!T,F'0W1D8H+``'&%,
MMYU.89PK5!GCE1=*>N[5:Q-,9TAPQKYGR$F:@P`'S!\E"A+RQ!N;3)'%#9TH
M$F$I`I\2X2H+#E%9"!<V_R&/`KGLP"$,OH3X(3''?)A%$-#,8$8+9FP`PPH[
MH"`C#BH(46,1M)FSHV4[[WC"CNS8ID*0.<!@!)%C#I0D/TO[8]!"!D60@D-6
MK"C1E!%!%!%&69*PI4$;?0F2!,ZA9*8&+L%$4W32R9333G#+6:=0=>*9)U)*
MU9'<"WZZ9=6@GC;@*%N00B5HIGPYZE5CF+(5%:B:BOH569^693BCGUY>*55Q
MN34XJ,-*:QJ@J:K%JJNMKK-.9L*&]G>QPSYQ#F&MJ4;J"4^0*IL*?%CUVK"M
MX9XL:KB?DUIMM1U[`K7#Q:03$_F2-!)T9(\I00=A,(%"#@MDO^YT.WWW+@1#
M%/]<"`-UP/W\>NW!'=X@$<<OOR/F@_'&@0?>P'""B$38ROR/@)`K*F2960@.
M*K;H6!"RL)%?C,Q#22B&B9)`@B6(R`P98)D9DL""(*Q`%T'8`2Y*<#/:Y`A'
M/;.,SF+!@!,(@6A#(E+39AB0)!C$(!YZ$D2F-*4K000C$*G(!KQV0X-X"208
M.`,*Q)22,\UG33/I%_AT`B>ZS<E.>2J#4?"VISK4H$]0"!2A"&6H3IFE,9#Z
M"J/,DA>ZI%$QA$L,6O"2E[N(17%QX5P>]>@IK,P%CFHLU+'6\0HBE*!T6V$,
MZAPSJUH5ZS.^$XUJ".D;V:PF6,(*C%5JIYIR$$8SOC'_E;)08[Q13DL*0XH"
M"^;CG!9X"SID>J4$,,"$'*R@>^K"";O:]2YY+0(]ZH%;G'8RI_34H0Y;`*`R
MEZD('2A`?]`,@@+^U;]1,',1%'*!)$P#"]5AK#,76H*,CG"$+/#"(R-+000C
MZ(:I\4)E&<"@*UNV`0]Z3!HB)&$X3+BSR_AS1SZK33N*0(,%K,`C1TL:#1<Z
M`RO<,`)/@M(.I?0,*UC)#%9X2`H>HB4BHD")'"E(F(3#KS&9B7HO69--.G`3
M81(3*'0:BGBTD*>DV%1O>CN.4[)BR$%Q#B^+220:W/BIO(#%<W9QH^F""JK)
MT5%0GKL4733GET5U[G*&?.,<_ZL2.G/`P@5/."0B@[K(RF@&=IOY3&@(XP(+
M#*8JI&H-8$+`FF3%!C";S!41?),:2]Z&6;0:)&;0,8`IC&TF9'-`"[#@+;))
M[Y70Z1<.T/4V78;O.V4H@GD6,8'TJ&=.[SJF:%^@ALU>\[3R"T`3@G"#-P3A
M#6]H@B<.83[4&L(5N(W%5TWSS6X(+D/96$(6K,%`+STP"1%,1HDPR-QX8K`7
M)#B"QZZ#`QS0X$;,NDR/VL%=?]JF-RV$`!Q6$*8A]4-I`1F(>L_+-(!$EP00
MS=(PM%:U?E3D(57#+T0<TM$BYJ"('SU##FS)!#2U)(KQ>5O<>J*>H%C1;G<[
MYDWSQO^G&FRA!GX*U*$(A96HE*XN=.G<&MD(JK?(\<1<\5NE,!>7GJJXCRR6
M2XG7B.++E8I6L`J!5A#3`+*R*I&-"8!=T5HL0@I9*ARN:R9C4[O8N68UCC2'
M8)1%F,PT<K"K&P`J68"!)$IQ#JU4;)FF]Q(O,X$&$%B.=YB0/3:WZUSDJVTB
MT)=%/(EV"PP8@IXM)F>!]=FV_$%`$Q0`VS?\(+8(<!B@^^<*"U#(%;#JY@G8
MD+MN)%`!)0B"-73A->N<TT/J+(85-@#/?JAH@\,X`CZOLXWK,@N@Y^A1"+8;
MZUH#5!TG`-("A!.2?(Q)(.Q-FK"'K=!^!&$C$8TH?9>MWP?_.N1K.9!"$*+]
MT8]*8<`K6`$=5HFF.<3';6YRG]QB"B^B1/BF27D!GUZ`4POOE*N>*515)8<I
M-E[N<5'IJ5P,A^*MW(53D,,*APN%%\B!YE"/,R-4_:@HHT:E5,J"E0MT[.&T
M*%(QIR'6[Y[,*Q?T+BO#LHIFAC<LNK*F5K;2G2<[J3P<&^\RL3J-ED$6G^>1
MS5LE<>6W5B*3?<%'3DR!EU"^(SXX;,&TC9B`&M"WA3HP(,]Z)D7!_KSHJBO"
M!0V@AM850`,76)U^DR"%-B?>\8L5X2JU6(+&EK"A#7EM(V%SH(=6=(Q1-W08
M,,A"=4E07;5[EP'L8&'@`3]K%GIW_UD_*@$.E`B2H]WCUT4R$C\>;X4H5+[R
MY]T'#.`+41*P0-D;6/9\Y9O#+'V>!-+V8+8_R/K5TV$!.&`"!MCF[9;&C9@.
M?E<6ZVP4.W>Q!NP&/E,NK(:^`6XS!Q?X5#0\QT#NA<-\/(M1YP(6R17.<$^%
ML?8[M?#H8[]QB!L6*8T,AD-*YOP6#\"OY!JL2*N&=R7X#!\Z(Y5,*MFN@3EK
M76&S&[OV1E:U@67*(BN7`1PPP"_JDUC[H`$,N!+<<7MQ8W3`YP/E!EKD(S"E
M@'1?MX&H`%:.00U-T`!>QX$.PPJ2<((!X`J\)0O=(`\XH#$X`$(;PD!OUVDA
MP@(CD@3),/\R,U`0"K`$1X`#2S"$M49X@<=-1Q@T0=-=/A,/--`#*[`OU8%0
M0X(/1V.%1'*%CI=061@%]W`T)#`%\%6#<C=Z6?(D$0`#P;"&6:*&)*!ZVK9Z
M<OAZU84&N\8OVZ$=$2@G=%)NY78G>9(W[!9\+W!A6_`"7W1A#.`G5P$[\H9D
MFP,H;P&)/,5''58IEH-4=@1O(G8HG5%&*V:)4=5'?'1]S=<7XB<KIO$*5R$X
MKGA^B'$:*-=)N_566*%)228;N+-6<[6+LQ$8H50KHF1E8'`QQ?ARWA0+JC@`
M=+`".7![^;(2D!<3_0*!MU<&6S`$#"!\?HB-5$>"X,A,+@`&K4+_!",8CH;P
M'Z(0=HXV=A1B&=[0&$L`%;GP0;F@:5F0!0SQ=I[60*.W><.@#'PG3FK7!#T0
M:4B8D`H)"X0G:[E64-F6`THTA6)3D?;@$58@-AEI!"P0AE+P=A_Y=I\WDKX`
M46DHDIWF>6\7!'1`!R*$"SA`!]4UD]75`SU``]!CC3$5'GD"!W;VDWF3;NQ6
M85M0E$9IB$/`B+%#9(4R<'U!%8UH*/3W%Z)X53^E%X](1I082=OG%P,G%9]8
M,X\(.)WX?78!E7.EBH4Q<1S6`*YX2)4!@">0(*_@2(T(+*_C?[YQ2?F7++9!
M#IBT++[Q785Q&6JI6ZH3*ZHS+8:!)W13_V#2.";>1DQR(R<0Z)-0-P06QA00
M\`)#@(Z@N6@6``9N&8(A^`3G&)K^(0F$L(ZE8`'E,P'PV((]P#C`)2,?I&DH
M<`2[^78=X2&\8$0N0P(*T`,_6)LT$``6LYS*V9P6TYP+B83M\)#CM7H2B0+5
M41U'!#(6V9T>H0M3(`7A*07DR8\G68,LL`DH\)$=142I1P<*0)/R68<W20-U
M@),1"%JZ-Q2^%Y2#R!1UP!3;J`8?0*!J4`/;^'2+"`7L!YA$ECN0M'Q0Y3I1
M^8B-J)4;5A5D%)5WE7R.>'"DXCM^,96O\S<BBA6RDZ%]M%:6P4T4$@`'-W#=
M1$@6$`LLMW_\!_\LLS$8/*J7ZC"8*N0KS'(QF(&81JI;1PH+`Q``:M!TQR04
M3+!*4CJ9?*B?X6&9/CD$$[!G3X=GH?FEJ&4!(>"69-H`3_"-5@<A$Z,*H*!-
M-1H+N?,$18`8:R$$&8(+,G*/,DA.ND"#F[=YUK"/UF4+7)&:H=`*N#4$+L"<
M"[D%?%`"0;)Z!N6,2K0O!J%$-U0N',$EV`D#V>FIGHH"=""#I)H0J+>>Z^DU
M'TF>()1ZI!H$/Z``:&"0:%";]<D64G&?5@HO=A:(-_6?7F24""JL3Z>-3Z<&
MQ@H%2E`KTO(K(Z>CMQ*C7(56K_,[,5I&H!&B'X<[0A"8.MID&^>AD13_E7%Z
MHB**.RB*%:0B!+A2+-T*BL"S&TCZ534:&D0@@@GB:$(VEX"Y<N:0?_V*+(/E
ME_^Z&_YD9?Z$F(6)D-&Y6Z8Q`*_@I$('![R61"]EI1B;I:2P9UH*IAZ[3*-Y
MKV1*!&"`IE7G/^GHFFY*0%)V(5%AI]45GS@0G]FP>GKZ0;SY-4^C"U(PCU-E
MJ/B1@1,`G>I'"SBP`)-Z2]8Y8!)IJ6<@!95:;5"[GDHTM6]`!U?;DBRYM:_*
MLT%`GJ[:DF++DF([#;-Z8I,H%47`!T]*%+WZDTEQ3%]4B$4YH`AZH`>JH'JK
MH'JF!$J0&0287=`BE_I'H9$T2="Z5D_&?L7"_SM\^8N"H8NT,XM/ME9JA7_Z
M-V3#\J[6NI2PX61+&1AQ-:0)V583]P1RT%8SBAJ5@;C(0QN3='B'QUL*FZ0-
MBX05PBN[Y0)04"%.ZIC\TB\9.[Q#D8U"^['(.S_UV@!J]01@T%;_03$FJTS1
M2S$G*$"10$!T15?T5P*Y(X]H,(1+@`:XP#$SFPW5I:<@I&T[0`=-\&*S%3]B
M%PL$99,S"7O5A;3-*(?\V[_\*Y,*0`=H$,`S&[,NZ9+MVXP*;$\`C`,#/,`S
M"\%H<+;V=BC!0@ZBE<$!NL$!VG0,@&?'JJ!+)\)0AZS(FF?(RHC-NQN@\1G-
MZSJ>@GQIU;R#8J]()O_#8P2)1!"A.^P9.7RASGLK+@PX/:RA.=S#:K7#2DQ&
M8Z3$)HK$'.;$2*S#-4RR<@`&6(S%13J.1,"DNY$:6,P'2[S#,VROSJM66.R\
M60P&:IS&;;S&<!S'<CS'8*`&,0<&4&`":J`&;&M,=(`'Y-F20H$&0D$'@WS(
MH$7(]LD'6AIUR?O(?F8".\R\S/O&)@`&EVP"FKS)+F`"%/(?H!S*HCS*_B&]
MT@N8.,.CPHA)K-S*KOS*L!S+K@R8+"?+MGS+N)S+NKS+L+RV:ZL:<A`LP<P'
MP5P'<E`';'O,QKS,QZ3,HJ7,<B`'8SS-U%S-1/``.XS-V7S-W(S-WOP`X!S_
MSN(\SN1<SN9\SG?P`.D<SNG<SNY\!_`<S_(\S_1<S_9,`?*,S_&,SQ30SW?0
MSP`=T`(]T`0-!`7=SP:=T!0`!`S=T`[]T!`=T1#M!PY-T1+]T'Y`T1:]T4"@
MT1F]T1E=T2%]T20]T2,MTATMTB>-T1W]T2[]TC#]TBV=TB5-TAI=TR7MT3`=
MT3>-T3MMT15-TS_]T2E-T;Q\U$B=U$J]U$S=U$XMS,`<U41`S(`A!ZA+!-)L
MS5J]U=K,S=W\U=Y\S>#<S=]\SF9]UN+<SNH,SFK]SNZLSFYMSW)=S_S\SW;M
MSP2=UWJ=UPIMT`O]T'^-TQ<=TX1=V"%]V$1MV(J-_]B+W=B._=B0'=F2/=F4
M7=F6_=A/G=F:O=F<W=F[S'^H&QM)C'QDO-6F?=I+K,VJ#=9D+=9H_=JP;<YM
MO=9O/=>V+=?Z#,_Z7-<`?==[_=L![=<"[=?$S=`+'=B"W="7O=S,W=S._=S0
M'=W23=F>7=W6?=W8O=0X:M6!8=55G596C=KB/<:KG=JL_<UB3=;A[-JQW=ZS
M_=[Q#-=N+=^WC=MV?=?_S,_`O=\(#=!]?=P)W=<-#>#)/=T&?N`(GN`*ON"2
MG=T._N`0[N!5W63=#1KAO1EBG%8S/-ZHW=5A?=ZM3<[LW=ZQO<[LS-:T3=OP
M3-_U?=NYK=OXW=OZS=]Z+?_<_@W@!"[@R:W<#-[C/O[C0![DC1WA1%[D1J[4
MEO0:%XZZ%C[#X9W5'&[:'D[>(#[65C[B))[E:IWB;;WB+?[E^1SC^>W;-,[?
M_XWC.K[C*BWD;-[F;O[FS'WD<C[G=`[+$\ZX3,[D3^["4=[A2OSA81WHZ2W.
M6)[EAO[><"W?*@[F]CW/O)W?>%WF?!W<_8WFQGWIR(W3<+[IG-[IGO[1=1[J
MHF[D^^<:5GWJ3<[G&][G6CWEYBWHZ&WEA&[HL(WH\)WHC`[FCZ[?,2[I!UWI
M!([F?YWI!?[IQG[LR)[@H[[LS%[=I2X;N>+=%R[-5\WJ4O[G7@WK(1[KM$[K
MZWS_Z_&=Z[H.XY#NZV5.W/T=X.JNY@R=[.[^[O!>V<T^[_3^U+`1S(`QU?J>
MZA=N[=>^S:]^WMS>[8>^UER^Z(HN[O=,[KR]ZS-N[NB.[L(>X,.NYO%^\1B?
M\2]=[QS?\4B.[W*5Y^&]P]3N[UR-[:NM[;)>UH5.\.-LX@</WW&M\`LOY@%=
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MO$2^P,*^Q,7`#\C)RLO,S<MWS/_0T@_3=];4UMG:V]S=W!36X.(4Y'?DY^CI
MZNOH0!3N\._O0/'T]O?X^8[[_/W^_P`#"AQ(L*#!0:(2*ES(L*'#AYY2J6J5
MRA4L5+!>L=+%L2.N7\)L!1MYK&2R8\Y2JDQ9C9I+:=FP>9M),YQ-<SC+C=/)
MKF<[<O'DR:LWCU[1?$CI'5S*M*G3IU"C_H-(M:K5JUA'43+EZA2K5:TTTI(%
MRZ-9CB"##5M+#"7*E7#C/D/6$F:UFGBU@;LISIQ.OSX#KW,GM)Y1>$D3*Y7*
MN+'CQY`;9YU,N;+EA%R]DK*8:B/GLF=#]QHMDNVPMLO>REU=]Z7KF'EC=]O;
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MANO9IF1/'^86HI,C/DGEGGSV&1"6@`9J&8P3?34C+*[,(J99_PKJR"`R:*;Y
M8VMW5>KF-]D<R1Y[<])I9Y.(/0FEGZ26:BHA@J:J*D0!2L>9@`8NRBAI.6[7
MG8^2JD3I:]J8=^F;&OJ59'MSUNG;G?<`1^*IS#9+Y:K01BL*H5V"=2`1-LK:
M4:.TF-E=@[E.RJ9=OV+*5Y+#=CK8I_/A*:JS\,:;G[3TUBN)<S*>,E$KB':&
M:*S:ZD)FK3O>&BZ0,(U+9+EZG;LAL>JR"R*3RBJKF+P89QR9O1S7BR^7,5HK
M!RJV6!=P+MP^"FZD!T?C,J5M,CQ;L.AP&G$Z%(?JKIX:]^RS4QT'[?%S(7^)
M[;^@G;Q@MPMZ>ZMJ+8<WX4NPR6RNIO]RWGR.L76*&.J[/X<MMD!"EQUM@!2U
M<FB-&RG]4:TJ0XIKU$!.#9NO#*>'==9:_U18NU^+"L38A!?NB-F(`^H<=*MX
M>5';_;J]='9,.PVNW'0':3>OY%J]S=[IWLSU/,C^)KCAJ*=>2.*LK_AQ*2/+
M*-U7!I)ELN1,5ZY[P6=F#I=X==F%M\QZTWR.S7W_'>)A%B^K^O.&MRY]BUI.
M1^!&`..>.^5Q&^R[,VL.:>'PE\)9V_D\J3LZLD<U?S'T\(L]_?S\@1Q)XR*#
MEJWVV:GE[<IS^YYXZ.(27BW,<U=#%\3ZEC/Y!`YL\8N@QNA'P<G@2U^;>87C
M_!6+R&EO8+O_8\O3OB<UX"D,@0U3S_E"%['UY<QT$)2@#.%5P1IBI57Y2IO(
M2%:+V^$N9?_#G(-(^#*[48A\Y<N4\=*7O*U)S('N"\X,I^@L&UHQ*_BJEM%J
ME[0?TBJ$/!*B&#.W*TMU#H4JY!`+U1>?8S')'E%,"A7G:*HKVI%5IXB.[,*2
M*&RUC7]`?-2WB/B[$Z*Q>''B6Q,G!K@X)H:.D.S3'2?I$%)H$%%IXV"8^->_
MIMGJ<H347,*")SP$FD^-"V1C;_[VQF2=+I*PE!(E9]F)U^4K9(>:11\!";<@
M&B.`OAM@A(QX1A3NC8E-9)_.'LBS6#K31+2,)B>V%*.*&"TC'OS@;A>[!\!0
M$K",53NDPX35'N2YQX6ERU,,G\E.Y$CSG9FH7J'41CO]_5&;NN,F,+TY3&)2
MS7.(1-\:1?=$.#+3>>U,:''@R5!,6+(4FQ&0@#[#21#JTT%0BUH9.8=$JX$N
1E9T:'?.\ID[Z*/2DPPD$`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>h03611a4h0361101.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611a4h0361101.gif
M1TE&.#EA80)0`>9%`("`@-;6UJVMK<#`P(.#@T!`0,W-S0```.#@X/#P\'!P
M<-#0T)"0D*"@H-K:VK"PL&!@8%!04)^?G[^_O_?W]Q`0$"`@(#`P,.;FYN?G
MY_/S\\_/S]_?WZ>GI[>WM]?7UZ^OKX^/C\?'Q^SL[)>7E_;V]N/CX^_O[YB8
MF.OKZ_7U]6]O;^'AX69F9L+"PGEY>8>'AU-34W-S<Z*BHFMK:VQL;&1D9,;&
MQD-#0UU=71L;&WAX>#P\/(V-C3$Q,5%1479V=F-C8Z&AH;:VMA86%O___P``
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````"'Y!`$``$4`
M+`````!A`E`!``?_@$6"@X2%AH>(B8J+C(V.CY"1DI.4CBP!F)F:FYR=GI^@
MH:*CI*6DE:BIJJNLK:ZOL+&RL[2UMI($`KJ[O+V^O\#!PL/$Q<;'Q2NWR\S-
MSL_0T=+3U(P$U=BVU]G<W=[?X.'BTMOCYH[EY^KK[.WN[[#I\.OR\_;W^/GZ
MT_7[WOW^`@H<2+"@((`&HR%,R+"APX?D(/*32+&BQ8NJ%C9BP"!!J@&#!H`L
MLF!D(00H$2!".2@!1X^+3,;#2+.F39L:%P%`&4'0`H\H%_A4622!T*)"40(8
M!`""(`!+2884F<#C`)@+A(IDF@!!U*-=C0IBF<#DT2(#B$[*>;.MV[?S_]@F
M^EJ$P8.E$!KH??!`@5*^10HL0&#7Z5,&/QDL53"`0=T!C$4R&.`40`,&#;8*
M4M"`*&/'#0`D</I@P5(`=XM\+@(`LMI(<N'*GDT[6^Q#49^B'1`5:M$$O56S
MUOT4`00&7BD#*#!<I,BE*EU"U5RT`80(RIF++M(@=6N0"+*S5M"1TNW:Z-.K
MEW6^D`+=2TOWAD[8X^FZ'M_KAE!YP8,B*L7GW%(@*5#5=R$]Y1^`PQ4%P7L`
M+#C`@BH-]H!C:ZVGX88<LH?*`@IP5L1=CO7&&P0'1C@<`@HTQ11W);(&@&.*
M0>!<:.^%IAAU.)XV8X-%1/#?:2)"12-Y9\'6X?^23#8)27M,0NGDE%3")66'
M5U:IY9859;FAEUR&*29!8*Y7YIAHIAG7,L$5DAN!*^&6H"$@-8`(=;2<J>:>
M?(ZCIT[$*69?70SDN(".)"D004D`&/BB('I!=B%H`Q1@YX5"F=;:+7_VZ>FG
MU'2:"`10,=?9<):I!&%CP[WW`&1A/2HC`J,)=Q\"=M[W*J>@]NKK.Z(B$MRP
MPVZ%EZ)&05"`26\.BRI:I-Z'YRS!_FKMM:Q4:TAP(A'&VJL(](0@7E2)YI*L
MOCV[6%'O.?8>8[QB*^^\H2XSTD@/V(D6=YFAQ1)(-KIF&2%0$7COOB`="N!.
M"Z<5+[T01_RP."VB9H__MA)G'#'&;G&L\<?7>GR3R""7_"G)/RVLKRHR[1L3
M(2U3:_+,-%NSC&,)&&C:*KD1ITC/$TY<\]!#D^PN3)`UZBUF(;;H5`,A(M!7
MNJRQR!FN23^00`0NWF5D4QYA6`O)1)=-I<C&$A(:<P8*FG-S3?$6(%/&/1!>
M6@4/D*M73\TX4L\RFRUXR6B#]!5V1536D<&L[6R@?E%1E2A>"?"U'8*O'B@4
MX!X.[GG&(I_+(@!"-NIJC.6)%F)/[RV(']0*>!<B9/LM9URC80O]^>XAWZR(
M?L\$K0WOQ&-+,JW"OM9,DGD6[[RO9-,4_?/48S3]1==7KSU$V7>Y_?=B=D^1
M__C@EQ\0^=R;K[Z3,Q#@_OOPQR___/37;__]!,2``_[\]^___>L+8``+<``!
M&O"`XR`@`A?(0&PHL($0C"`S'BC!"EKP%12\H`8W.(D,<O"#($R$!T-(PO6%
M2Q!]<53!1D0>_`ABA"6,X?9P]1Z^N:1?\OG666`HPQY2;RGED9$@)%.Q(/+0
MATCDW7U(DAH7NJ1M+RQ@$J=8/`EIK5U*V4SC]'5$*GJ19@6+SW8(Y1.KB*V+
M7TQC]="HQC;NC@$%J,`!"M`3-]K1>0@X@!X/P+D[^E%P$-!C!6#RQT(*+H]\
M-*0B`3G(13JR(BHPA20G68HAM("2F,PD)U+PR$Y2(O\`N4"&*$=)RE*:LI0H
M$(`G5PF)`*B23ZYDI2P9$4M8OG*6N#1$+?>TRUSZL@B]3%,P?SG+88[)F,1<
M)3+#M,QD/K*96X*F,Q4IS45$8&61Z);RYM(HYCDB-S';%S9A%DY'5'.:?SQG
M(A2U,`7\)%TO.=2/-#4AA?%+4AR9"@KK8B=!984[_%*1SQK@G]@5BCL(*$!\
M$$.2Z51"G>BT(T0-P9<(`*="!#I4@%BEJP'UC59.`=Y2RB*4GIQJ7%4#TIOT
M%J01\69%N1K.KCYYRXAZ<J*%()6E<E8`Q3`%*IDQ7',\*L1G":(C98%0@U#:
M)I6F[3G-B=90'UI3FSZSJI'_>,_6D",CE_A':T%ME6J<8R"OP6<0"W#*`L2U
M&\(LH"/:T=J;F/+4EYJK7<*!%TVMJDRL/D(L(W))>>PRQ([\JV$I\4I)#B83
MTYP*7_JZC.$:0\@5ID4EX`E/4:##L.1L\Q$XY2L50WN.<5*#M*)%(FHWM-K4
MRK"UZX&M:TDH6T-@5GAC:0DA&40(HE3ELY^M2F\9(5Q!%+<5M9WM!Y,[B-(D
MA["YM=-Q@:3%%14"7(<XE:P2H5V?L8*YRM4@>&4JE!N*1"_+:@!PW)DSJM60
MH(>23*,`6K$7*297[?V/8@P$G&[BCKJK&&]X*PA>P!2,.2AJW)!,4Q:.-A=6
ME!O`_W]6%:/]:-9@[^F)2`Q#'JUM[A4"'G`$P=NF'/J'H,-YZXP&9=P?W4JA
MB+G0W'2#*PCXQS*44=CB=",IX;@BQ")N((D%$3!WVJDSJ#D49B[4U,#8!U=U
MF4YG(#>6S+3F:JT!ZH<9DY?8=0?`J@!RD!=88*U01;A$28M'2L+;UQ"%5OG9
MC$K>;%R@7"7-7:%S680;M.Y^UZ]C]N)X3=L*Q5@L%I6#A9@#;<!%W\31C%X?
MI&LRZ4B7K](8P;2EMZ=IBW1ZT]3[-$5$#>KBD1HBIR[U[ECPOU:[VG\QB,&K
M9TUK^;E`U;AN1`&8D^M>^V/7O@YV/H`M[&+#@]C&3O8ZD/^M[&:+@]G.CG8W
MH"WM:E.#VM;.]C.PK>UNWX+;W@ZW+,`M[G*W@MSF3C<JT*WN=D>"W>Z.-R/@
M+>]Z'X+>]L[W"WFM[WXK`M_^_D8#"E"Q,!K\X`A/N,(7SO"&._SA$(^XQ"=.
M\8I;7.$6L,#%-\[QCGO\XR`/N<@[_EFX`.``%]BURE?.\I:[_.4PC[G,9T[S
MFMO\YC:O0`5PSO.>^_SG0`]ZSN<H]*(;_>@_MP#1D<[T`ES@`.5\R\FCCBV`
M6XN-'#KY.08`=?5,_6-6_Q76-Z1U<W"=ZFWYNL;"[JNQ:ZCLXSB[U[N^=GZ7
MS.WK@?LRI/84=[)+A5K]C]S3HW;_0G0%A6/,9UW^`UC:8"AGC@+12%OXS\#8
M74V7Z=OD8S>>JX@M,%+<DMYM@2B&X45!KWHI6NB.GL(_!7%\`4[5"$/0)<[&
M*W4TC.H`=!G@G&O??>K.D4%2&A6B*HA1#-/H;9&VJNEK)XUJC5587QO7$P=R
MLF=-1\BSV]E`Y_G:M<S43,+V)96F05!M%:DP0PB\S]T9;4)0BG7TGL&WGOK$
M,='?^MLH0KN%<44%9;R!&E%1?AW2)CO6(&]E%SL4>EJR?+40'(0!9;M"&-*"
M?]Z'@<$!'`NB,/($9FX!912H-P'B$:^R1`:8=4>51:(!&!PH8X/@?H3G@+5P
M(JTA>9`R_S``Y15V8G_51WUKLQ,I9!^^<2Y0\Q_>%R)+$1K/YW>)!AE'D8+K
M,8";HGC`@80C\64Q2(-4`H'>X(.T87T0(X5](H/WMW48*!MB2"]DR"=F^(-H
MB'8U41:!-!G=ARTE<0$7,"T9\X9AR(7?`(9P@4B"=(?7T@![=`"&H3$#)T=T
M)'J`R`V$J$=RB!&!I$=]A"U*IT<E-R^3F(E+XH7<<(ESA!Z(U$@2@XB*:#*7
MB(I5(HK90(B52!-U^#%*UXGT@DB@&(J1V`V!='FW9P$@8QTT`P&N^(J]*(EI
M6`TN4&O.2#\R\(S26#_,T#[3>(W1>(W36`VGU(W`T`,_X(WBR/\+G&0/7CB.
MZ)@#Z+B.+B```:`A9(,^ZB"/+Z!)]GB/^"@**/".YAB)]9B/`!F0^9@+_*@>
M\6B0U2"/X^".]^"%"FD.!`F/S/"0?I*0Z,&0_8@(%"D.$6DF$XF0]5(;&#D/
M#FF0(]D(FL5;*ID(9A$G)7=<>\8(N(@+'YD>\KB1WW"2[U"2-JF3BF`:#\!6
MN;4(%I`4PB@G):<9.4,9,SF32K(,L0$BCC((_D<(:346P%,(/<A=5!E9A3"+
M57D(-\F2AMA;OA5<55&6T^4P,BD))=>)/MD./+D(,>EFC-"2A^"47XE;BO"6
M3Q*7PC)$HV,CB]$H$J8`-C((B%D7K;/_8L#!`/T!-GT1,".Q,[\Q(T+190$"
M1"+"$4/B(H]PD(Y00Q#`>(X56?>B+P,0`9L)*9`%)Q>2@S/&&JS9'#UH*?_Q
M'S_A%6L6(]ZDD19I"*,!A3\#.7UT9G=B$HQQ:'TI"7.U784`F.LPEXFPE*S9
M,TY9E`!RE-OB)HM@(U##AP2S7;MH"!W9"#UCG#X6(8S"%"C2(F,U*8/B&T'!
M*-0!1ZQI%[2C5@P8(8)G&I01)'QI,U#I"-2!(IU1`"XA8UO!;WH#(4!T-U11
M&2+Q5A+V-F]B'*QQH3'B%!?`(K*W%!;%&GJ!#L&IE40A+8>9HGXA1)XY(H8I
M$G?A*HCI'(.0_V!A0UB^T1,W!APV1BB?N8B/4BGJ-2-"&IT%"0_4B0BG$AXS
MTD)7-E^%,J*;X10'91J#!4<R`@$)A1<N0C6]P1\(@*7=%Q5=2BC`J`CGR0B1
MDWV^,1\GR!1]$1ICA3?P,5)7R!N:\6;3$311$0&K`AZ-L16$49LF6J"-0!WY
M4AE/$2TQ-42K:3F)`U3$TA)0P:CP085O&E`[(E11D7)E:9XG.IYG]1QJ$2&6
M81H`RJC.\5()8Y\F$93+LJJ)<U0[LV)H0:O8X4USE3J)()WJL*1RPA6H(F$I
M-JCNV5[Q&6/#L:O#810!*J0*Q1E;P1BQ2:HI-B1_F:2+`)1"N:DR,O^`+S)(
M2RA9CB4NW>$7629_+,(;\A&;41$BK9(:-F(@V,%5AZH[ZP0@[]%3M?J!8@%.
M>G,!SV(4IU(9G9$`H>$1F-H@7/-8*V(!"=49,16O?-,(8VD(X3=4/2.B%%97
M4!4@)ZB4'K&4DR%4_`JA8S&HX,$`AHHN2_6KW.H.PJJQ<V:9IY$V-C(9<LH9
MB]$M:5.H?-.N#0LDU=HMWLEC*(L.P&I;(_%F<Y9;X#$(40NU8\$2%9)F``*3
M;`E89\D@93$G,1F:-=D(4LFP*J$8CN$5V[$R62%[=L*V*0(:3]05,P(:5#E$
MZJ480E&B6`2C?0LI+D2@$R&<]5I2E*%ZNG'_4.3R+JLY(`&ZK@>J-XT+));2
M."]:KUO3&+BR,I&1,UEA&3V1IDUK#C5;"-9YL3DK5(R!.+I!KOS"LZ5Y`9N+
M'';A%0]`L!V+5J*A%Y,!(G25%H0UN_R"L:7;%J*935G)$!E["%=A7%=Q>%3[
M&[QE$M'+9TBSM;N%6T]+M4`!(&<Q$C%)'8M5%4EQ6(9PO.)PNJC[O'0&9V#[
M$X14M5=K7(-1%,^[+RFQDJ^1,F1Q%G>#64@Q9WJYINB1O)"0OP[1*:W:P`[<
MJCCY"GJI".H;#NS;,15<$PA,&YV2B![\P8D8P=V0P=]PP<BKDY4W3BNSE8ZP
M,N$$$N6$34<FN"V,_T*A:EQ(2`@;/!L=O(</_,,#(,+<0,+>8,(CHY.:02`8
M$A]T6J$,<R$&$AJG&A)CNA,E*A*7RU(D<5`H-&/0\;1C.D0Z&!])\;3WFU2L
M4@@[_$US\I4`Y;QFP1?E]7EYF:)'=</0.HMJ_`JE^"214#F2!S0,PA)Y2[5(
MV!F?%4Z51\.*@$ULZ0A$W`U&G`I9L5]6X0J)EB=('"VMH34E,J$R(E=O!;I@
MA2Z4I:"((2V>?"YU5!<-]1P`FF&AD5:N<1B.$<OA\@!<RF7<T7UKC)Y=B4^4
M<KF8TE";<E:[02@F2%B\T:*LX1(F^,2$Y14_6I[`Z0I]3+:0L$3@DF=IA?^U
M?W._6H0K<Y9G3'FS4YR27WRU1S$8!&+'CQ#)W##)J-#)U:&][LN4=1FV)%%>
M8B'.UIP*!IS$E8HJO5$W!J(L8K-20@55/M*G*C4BF0'%3_$VI6&ET:&@[_(4
M!O96PC$MO\RF/P52M@)3SS)3"A,MVD$K$?*>'KV(Y.$8@.%.[UFK#!70HHK-
M::JFD.`MD:$Z>",P0(D8L0/3)?T9=G$:N;R(J(HI<D4[U]34.`(K("BS#1F)
M&(-B.MBYC&%0WA&@L7,A>X$9!&47.CHV2/PW)T6B*E$9O:&?)*$JIMS0=H50
M_F(G3(U^JA<P5>-0R9Q^I,+1BH%9S!/2@-(W9R7_+5(%@)>C&_K!&9O3KOJA
MH1NM&EJ=.%2]O/G*"MF\V8S`59&QT2YA+.WE'TN+'/?1+N^TH-I:T2WB'UG1
M(A;E*B5Z0S]2U8@@S]E`SY0`/(Y5?/:!&+[7(@0+.<:9+$"%V]F"PD?13VW;
M7Z`165#3%)+'+%"!*_]D)UEQ9'NK(OLU"'@+4*81Q1[1'5#1HBL\WK]W&>?M
MRGN,J,[Y4XDM'&_C+F.E&[^W+GP!.:$Q1N>'*Z+A%9!S.W.<(3K]E&P<LP9S
M.2,!GT8[HO>A(PW65,<,GXUI+`O"@"[E8Y`\LW*)U;1P&C`!KI:Q8N824@O#
M64O1@7&FR1X^"9'",++`_W>,4)IRXPC+0CMT7`2&_3.^H1DPO"\*XQ5SUAI$
M@<A:B[LNHZ<!ZC)H(5A+?K(1@GQ^?.!5[@@=$<BE$;B2$MM&QLBNG!5O6S#L
MAR'Z(N8AHC"\H1?J!5#MO4)^Q@BZC0V\/0DC53!0=LM4B-JI.B-BM(1'19]A
MN0H&_"$*/...4!(W3"<@,5T'4;;1\'LU;B2/$$;&:N"MT-D8V].#7@FT?*VP
M(.D=?M77+`MQ7@B?_GFG'IAH_>*RT>,CP\<[G0CG,<&30%*S8.N#,.?54.>3
M,).X/ER-X.BQ4.@<#.G';N7:3!N\3@V^;A'&SL/(+NW*[MEPT>S3\.Q=(@`O
MH/^-WO[MSF@#T_[JLH[@LX'MTJ#MXU,RU@CNLQ8$^^/NM%;ND+`"ZWCO^$Y*
M!.#JP1J)]I[O`!_PPR#$'P.+^J#IM"20"K_PDJ0"I'X(#!_Q$@\*+.!#!I\/
M"!]!%Q]P;)J,!S_K#+3Q'/\S'H_Q(+]`(C_RPE+R^)#Q$)3RYB`"$C`!%%`(
M&U`('C`((I`!AK`!$B`!'U`$/]\!/,\!'0`"-9]$,`\/+M]`2Q\.$X#T$S`!
M&<`!12`"&P`#&Y`!5%\$-_\!,E\$)R`"02\('L`!%$`"&=`!1<`!$I`!)'`"
M43]%3^\.31_R+'\.))#T,V_U0/_V(;`!(9`!$K`!'3#_`3!P`H7?`3<O]!SP
M`23P`2#``2)P]&7?^$A4]^UP]RB?]^8@`8*P]A)``1S@`1\P`44``B%P]A,P
M^D(_`23P\XT?`E//]2#@`7L/^D5``4F?^9X_#YR/0)KO#6I/`1WP`:#/^!/P
M^$$?`B#@\Q0@`B`@`B)0!!-P`D60`2`P"*X?`JE_\XQ/][_/]"<O_.,?#H0_
M\]8O`42/_!/0`1+@`3OO\XQO_.J?_9B__460\_8/"!Y%@X2%AH>(B8J+C(V.
MCY"1DI.4E0`'E9F:E0<%FY^@H:*CI(^7I:BIJJNLK:ZODZ>PLX2=M+>XN:&R
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M,)S6[R'`C-$.-E0XLMFX`I-:/NO8$.3-DPM5MHSYX&:SG0M]WKSWM(/2$S<K
M3DUHM?_EUJ=A>W0=FM#HR,Z""T_%;/BD8\:3*T]4?+GSY]";-8^>"#GUZ\FF
M8]_.O?LN3-X160]/'I;V\NC3ES_/?;SZ]XD8#$J@0$&"(@L4`"A"7_Z"!8.P
M!Q\B)W#``05%&,C!(!1PD,&`$$HR@`(!`K`??0H\4`0`"@R0@'R&"(B=>Q&^
MAP``$0P"08#T%8%``PPD`,"'A(A88A$3@#!!"!2$,($''E`@@0<2?'#CD8@,
M\,!^#0Q0Q`/YW;??E#$>8B-U)"*)WGXO!M@``EX^H)^3`8*G92(2($@"!Q,4
M(>0$(KC9P9ETTKA?$0,,<.=^"D````,-6&EF>EG2Z=U^>5;_.$B7>@*P9)F&
M(@*#!"1,L".E'*09*9V)WAGCGH,LP``#4(8X*'J%;GI=EUT^,,"7&][GZI20
MJCK("7,.TL$)0A:Q:Q$;;&!KB54R@,")L3Z@H8P+/&"LJ?"E.JQS'.I71`,`
M!+JA`@`FH.&$`&YX:J0?M#E("(.0D&`('O`X+7PG6ACHJ/,Y.@B9#6@([7O2
MOCO@E1#R2LB#11#<H+\("QJM)PEK"7##$*OZ\'/]1NS=B04<8"&8%G?\+@(#
M0'!`HH0R[#%\%AR@L@4GMZSJ`"JK;')Y%;M,70,Q:VOSSDAFK#*9J,[,<W@I
M"SWTT>_!7'-T2R.=',Y`.RTU>AE'_TVST8NH$,#67'?M]==@ARWVV&27;?;9
M7*O02PIHBUU`VW#'+??9*4P]]`!8A]=T``0(X/??@`<N^."$%V[XX8@GKK@`
M!`30BP`H+"[YY)17;KG?D=N='`&<=^[YYZ"'+OKHI.]`^NFHIQZZ#<;DG4@`
M`D`L@..ZS!XQ[)H;1X#%NX^R=^P-VUX[[0WCGKMPO4.<?"B_RTX\+L(7#_SQ
MSBR?L/6)_$>(]BZ&RW'SP3]_2_0)&T]],]C[FWZ(^<K7P/L/T`<``J46`7["
MY(\OOK_FGY_,^M,"8(T"5`0*;2A/#\A79B#1/T,P```06`#)''$G1RR`92%Z
MQ``N<*\4(?\"48JH("+R1POR50!,"<"@E0RALT0D2C\0D!$DD)6D#15"A(PX
M%B(X5H@&^D\8Z1-3!(MP0OZP#`'U$2&H'.&D%N():!'05@2LEL-*.'$0`@Q0
M`B]`,C[I1P':NM\A#"C!!_H'`$UD@`*.!<$)<8@_V<(/MD`T"`8,<0'V^M,:
MM14H"]$Q9$ZR$!RU-2H*S<L^&`KD(D@X"_+YZ5HK*L*H9,6`%&%K?@68TI^>
M5$'Y*(D_)Q)3(#?Y0`IAZ(&BW-`F`_4`'E;060`2$X5.Q*W_Y*M#JK2/(7SX
M0V!@3X8R?&0#5C0C_-R0@'C\%H<2("I[O:\``\C/&B<(01=!P$/_]8GF')]4
M'_[41SZ3;%:&U#A(.?X);U?,XKV0F"@:27)&=Q)CB`HP3?E0B$D(B*$-B["B
M%,W*14V2CP@C>,]KY3,!,MI3`IQD0#P]((:"Y-+[P'3/+R6@`0N@Z#X3P4A8
MD`]%!<3GAKI$H14!Z$(,+8('ZSB("!3@4P"R3TI3E*<9)32F"RV@#2\Z0(#:
M4$.S`I,$]7323S:4$+SLI2^P-\$-I<A:""A`%`N1R6KBTSX(6&@?;;B?9:$1
M:!P*930I.@"!/NE)>D)HML"$QD#Y4T\`+2M7$9'%!%R36P6<T'TP>LM!R/,0
M$^I4$:I*PRDI,D]^^JHB%Y5)EB$*KJID_Y%^3(98!N"1GQ:"K":W!\.-CG!_
MC7Q>MD:ER6P)]@$N!>9D/2M"&"ETM8]M0`2N^5H`>&*)^PQ91-M(GY?6-$`(
MN(`"Z(C4Z2DU&-AK5J@V!*,'$H(^X=HGK?*T``A`4["TNN17:X3$#D43AMAM
MHVQI*R_!(C:SV*5K(Q9Z'_YX:%&A:J^T%M#>(B2U1>Q4I'T:(,,-Y8>`-47`
M4!<K28I>%IX!LFQUFY4`RBJ)@U,2L)(&@(`4.2J:DZRP9P]!/AZ^XJ,).&%7
MX\??&15`AE":$8-O>\Q7X<FY_HT?B_/DW<*N>*<ZNU.+S-JA9WUU3Z2*YB&2
M>MQ<I,\^SHJ5B/\E>=+H@FI*,D(H`R:D4S[]=+L$+$"3RIJ`"J>W0S56UD7-
MJR<)"_:HA%"G)*0%@`H4D\@GBI$.G?0A)Y&IIMO5X?M<!":@D4G`,NKSO3[D
MJFLI<%%@^M8@]FQH.S])/H1VM"*$UP`+X+`5Y'.2HE]\G[(JD\Y,4F#40*2G
M0-W9T(H^EG>O>2]4X^E)KA3DB?H\Y:QF&&3W"C(`HCL((A?Y%NF3D;8T_>IK
MH;$0IPZTB^+XJOF]VE4GDJ`.6^VA8T5ZSB^F\*HYC6T]!PK;"TBG,2QMH7*;
MV[8J<_,-C.NOV55:9=?,D[SG3>]Y>U@2'16%!"?1`/T0%Q'_SH0;B]G_0W;_
M6A=J#@7W5-'O38HBX9"(F<0G3G$?&'Q:`M`!Q3?.\9A=&A+YMI6O#PX+B-/)
MY(XX`!?K/6^1=6(`(X^4`&[09IF=^^8XUU@F0JZJF).\%2C74M`9P69H]OKB
MSYUD(ZBX"&$SD1`>GO;V%KJQ>`W[V$S_+!S=?)R//X+GD\!CU@T!-`\SG<*9
M-;:S/Q0C^H["YS]?Q=!S.'9#W!OJ.P39G87LWOO<?1-S5X2TZFM?I+.(AN%"
MJ(`1/>CEKK,02+[3V'7,ZB=&S4Z#&.Y]1"77*7N=P\1C9M=W#MI,(`N7HF?.
MHH;(S$O'J%@T7-$:[>K.4,`][JD(?/8<M=)%_U10B8?X%(U/I*3YW?5%?\^$
M[L7C.D3X&HP<(Q6BUFC9#^UGRBN2_@'7&"I]Q52N'YP/JZ>,RQI)25%X&B8A
MY.T(L!/]\XUP/R2JU.50ZFN%UBRJT&1XIR8%BC[*TFKP-PFWAWNEL'SX1V%X
M1'#XUP#0A$<P!G5;M2'U\T;\P5\!IPD(:`A_50@7!0$IDDGQIB%(]"6T`B8B
MJ">:=R]^1F`91$`VU%0&5%75!4%FM7YU1PCR)W@#N$BE9PG'M&$]%8,N>"T`
MDEBNXB<10$-#"`H%:("CL(%!2$"U]X)SM6&Z5%5+8B$$986@((4+]`B^1B:T
M@E`D$P$%!4(7PDST`_\BP&19&N)UOT=`A39`U$1`_?<AR6<(.U@=/3AI/T@)
MA98G52*'`Z1<:(9;H`(K/(5FF_"$4!@*8`B#'H);5D@K&[8?R@6#F$A?")"!
MRM<ZD>!KV&(MI?A$=510IWB*:F19A"!$`()*JH0W-9)98O).Y$5`58(?^M)5
MU2*$'!6(*?>'P4@*7*A6NV8_D:4B&Q-'JV5T-K2)^U0J^A$!0_5VAA>)JC")
M^,%[3[(D`D8A,Q-O_/2)6_A?!`0KG"A)RN()ZBB)HLA`V9@+WA(+D-!4/K@)
M.E<)??@)%!9V]]<(Q"B/VD@+W.@B0.-VHB="[*=#GIAZ-A1U\(4?9$@*W-C_
M@=#A=D_W=<+8"/M("?V8"SDX=:0`B06I@;2PAXN`:XX0/Q89CV(XCS+7D>]'
M>K<CDR?Y<+P#DXY@DB42DAPXD*!WDSGY"@=9'A?9?$.&DW0"E(7PD9/@E"7B
MDT4I"4=)'DDYBB@P-US9E5XY-UNICT+)AQ[PE69YEFCI-1[`E%6I@6GYEG#)
ME2_`DXV0`I=SEWB9EY13-YH`E9(`.WH9F((YF'Y#DVVI"2Y`F'G)`T2@F'E)
ME]KHEX<YF<J1,0M3E9))F9H9');)+TKY<YFYF:*)#)VI'DUS7*$YFJKY"Z59
M,I@YEJL9FZS0FD'SFK)YFZPY+N1QFDJ5FKCYF[.I_YMZ\YDDYYO`>9RE0)M7
M8YO(V9S!>9E%^9'112_LR!^\YIS8V0C*N9O$>7`Z=R(<-%*?B%&8F)WFR0C;
M.9S,N5-`UA^$=Y[P:0CIZ1V\V4L?^5@L4FY@%)_\257"29_=^6O[2"/*%6[F
M!(S]F9WSV1WU^4,Z!T&/5&[\X3X9DJ#]N:#M$:!%9IP6VJ&#]9\,JJ&H"9L>
M:IX8NAT-ZC\<6J(7"J(9NIXL&J,?"IV/P`)Q>:,X:C9JDPDK*J/G>:(CHJ%]
MXYA$6J2'TSA]2:(^>IQ`>AU-<Y7A(97VHZ1+^IM-BB5":C%2VJ-5ZIQ7RC19
M&C%;2J5=*IM?"AU/Z@@/Q/\DD'!%BA`![^FFB'!B+94(7Y)\<EH(8UJF'GJF
M%!.FBU"@R50E+B9@:!0O$,A'=N8L]155_^>*?V)JK88M/#15J+5H9.)YUI:,
M>E*$6L>C9,JGJNFGSI&FC)``%Y",$<1Y\4-^.L5/#?8AHJ)W$?2)A&!9%O8A
ML6I9>Z(D+1(@%G9]>M=V/P:K^T%,\6>8?BBJ%DJJRV&J2P<!V%(AY79:6W5>
MV8);4W0!,O1;OQ4K7%B+;H19V1H@W_I.+,8(>\JL+6H</(4?UF)L@=)O8-)"
MT*H(0I907M)GG9(`'O18%W)9^\1.Y6J"3T0A"W@?D312%G!@ULDEQ3IE&H*L
MZJK_K.(1JNRJF<XZ"RKH37$UK\BR5D\)J(M02N^*@;NF/>\S)H'R'_%RLH\G
MJ\Z$'Q*4(29(G=>B4]]F(:T'*/]1:AM"3GFJ@Q9["%R:L6;JHL(@4LM(8P_T
MCO9#LOA3M$&)M/&YL1R[6"_2?\>B@L[F5U*+,.MJM2:JM,``*[""8*_J7?43
MM9$`I=XQMF2+G5CK"B?B)WV$5Q@B*U(B0O>JDG:G"68'N"X2"0NG"`BU0WQ(
MM4^)L7-;E'4['&Q67\LSD']WN"%$"!UB+RO9IBO+"%TTA8,@MX^+G)$K'-)R
M`&YV'Y5[JZ0B20H`I^&*1E\44BNE1G#Z1='T)Q6D3VKE_XK2RGT\"T'T]2?T
M]4T]-2^<2W9.$E77QP!"(P!"P'+4RW)'6[H::[9.6@$%T+W>^[T^H[H`(`-!
M*'8F558#,$5%%8<ZU5!E1&7+^$HNY6E49E*D`H&=%F3<TB&NM#WL"U@5J5PX
M)``=5\`3Y[C8JXVG&QP&3'$%D`-!B+Y.<DVU5DG$%TC^ZG#\A+Y[LD2)*S_4
MM4]HN(P7#"!XM%)WXBJ>BHI$N&$"0`,X%\,Q/)()+)H+[*0O5P3+XUUV164=
M$@&H5587/%(1P+.9E[Z:)7V]VVR#ND_=M&NCDF+.$E@5]#[]1H'RX0EXE6VB
M,K$/P$$F(Z4U[*7:^Q[0J,.%,/]4G38?]&6&?I>X(.-5;*QX\.6)R)9XWC,?
M8++'>+PH5L,]J><DN[A00D9G&55L12#&8VRZ91PA4J@?#-@,A#N4BURE-]P=
M<-L=BES)5MK($)+)W+')G'R;E\P=H+P(>,9&<61L676=)<2XH\S([W+*\=%?
M*R@J4V:LCP/+L0R<I;P=M'P(_(=^965`;+3+O1RCOXP=P<Q"`$*#?@(!4Q8U
M",R/O)S,I.S)`]+,+096P$5(KYH+HHS--JS-\,'-`[2+FWA]$(2!R$S.';K,
MUX'.W?<(NRC.UPS/HVK.[T'/K;9>KOS*^MRL_*P>_KP<XSS0ARG/U#&D1OK0
M$,TX^:S_T-G[+C::HW%#`P>`T7*SHQ0-GPP]-1/ST<D<TE(STB0=RR;M-"B=
MTIR\TDC3TBZ]R#!]-#(]TS5<TT-STSB-O3K-,SS=TX_[TSL3U$)-MD1M,T9]
MU$B;U"ZSU$S-KD[=,E`=U:(ZU2=3U59=IECM,5J]U99<T$<#R"&\>(4K+F`]
MT%U])MF29-.<5?I!/^'RU6DMHVOM,`0T7-^B)(>&UG5-SG>-)([2`!#F+1J2
M1/OIUW]=TF)]-TA47YZBMG2]V'W:V#;3P[4$9O4:;K>HV)0]RH%]).PU'^]U
MUAHYV9^=H*'=,*B=VORYV@G3VJX-TI;M/TJ3;N\YVT-=V_X3_[[5K-NJS=OG
MHS05D-O`C=3"?3X9\]O'_=K)33T#4-S-G<"P#0P<+3=`<-UPPY?3?9+5_0LK
M$-'B7:29T]W>_=S`;#%4:=ZY\]U+I=YLR=X_Y-Z]<-#*L=[R/37TC7!MNC%D
M]VHYZ)*;I@C31L.U^+6?@-_Y[33[;620<"%D!%][[,;N53]$)1]9-=H+9>$5
M:4S=PS$(-(1=QA^C_40!N0@*ON!'T^"X`'$7,B^/0BMH=$TK<DV]!P&1-.,A
ML\$K)<%\(E<%(":A!`$\=$T9Y2A)N...0N0QJ>(&R.+`!@F)E<5M).."5>.%
M4$GFJDA8GFLUI5LSIE>NJ"*[RX5G)O^K3>[D<0?E!OG@>$CB5AY(2'1LBQ*I
M!R3G8X*#`:)<;'6PJPR#5:)W-J0?0[M+\:WF=E/3C1*'IG3BOP!QB<4D;Q3G
M(Y5)6YR%,M(ISKO%H>M'1%A5.5;G%Z9(H)[FB'YP-5U!S7*N0`0*_97&WP:*
ML.XBLHX(IC20MV[JIUYD-5W$6,4A:&3<]0T*D4P(V%+HQO[G&O0GPIXDS*[K
MNZY4-8U"FCA'COC>1!GMO([>26+"L5Z>R`7?VK[MKV!&B[9LR-[F-6)`$8AL
M%)9\)*,GF:1ZH,MT?W>,`FGLHEM<XWY<;#X+E:M+@@1+W8A&_X%'+5L?@CY`
M3J>OCM(AX;;_2<GT1#("(A:B'WLU"(.H(0\D[)*G99)$3DO9[]+.[<MQ;Y6;
M0,77);2BPG`E'U[55"<XK;O[?6:%3[_U(D:E\KU8"&E+[S8$*]>>XB0/,?^N
M"@!@`3K3NB,\XQ%E>9"E=EA&0(D5];VJ2(_UK?,C7/(!`0U%?X4%])CX<41?
M]`E3-=6;]FJ_]FS?]FZ?]BYG`4[2ND^\8^TK;R5U93(_4A(T([RZY7,U(X3H
M+?1[A`UU>D-EJ_@)@SH%;9;D865O]OX2O@U<^99_^9B?^08,`<O3O`#2O,Y&
M?,>25<D8;>^.;(M&2)MV^J"VQV"2R[H6;E$C=AJO+5VE,Y<D8//:_R0&57"2
M?SX#]O;"/_S$7_SR%O>!8M^3,'!V9+B9$/F_C[1)O_3B'OTIC?+5;_T];=\(
M)4'=DB<<PY*3G`K0K_UD:]\_[BSYXFE+HN2Z4/[FC[0';5$6KV,B'TUM2POP
M'__L"@@$18.$A8:'B(F*$$4#$```"X\*"@\/A0,#BIN<G8,!`IZBHZ2EIJ>H
MJ:JKK*VNK["QLK.TM:."MIL`10P)A+L)#`N7C44-"[F*H,G,S<[/T-'2T]35
MUKC2N[N#"`V#NPH##`I%V]++UNGJZ^SM[N_PS=C1NPB$";Y%]HW(W=3H\0(*
M'$BPH,&#J.9!>Y"OD[=_H1!*G$BQHL6+L$`48J0%<*/'CR!#BDRW0H#)DRA3
MJES)LJ7+ES!CRCR)(N+(FSASZMSI*8#/GT"#"AU*M*C1HTB3*@V:@J=35($`
"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>h03611a4h0361104.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611a4h0361104.gif
M1TE&.#EA8`+,`.8``/?W]]'3U,W/T+[`P;N]ONCIZNWN[AH7&[^_P*.DI75U
M=_O[^^GIZ8B'B5%/4MO;VT=&2:2CI,7'R,W-S:ZOL9:5EHR,CMW>W[&QLH"`
M@[J[O&QK;9>8FE]=7S4S-GIY>SPZ/6II:R4B)EY=8%-15#`N,MK;W$-!1"<E
M*.?HZ-S>WL'#Q-_@X<_1TO3T]-+4U-/4U=?9V?/S\\_1T>+CX\C*R\7&Q^_O
M[][>W^3EY>#AX=36U]G:VLS-SNCIZ>SM[<K+S,;'R-;8V/'R\L+$Q='2T^OL
M[.'BXN7EYN'AXLW/S^_P\.SL[.GJZMW>WMS=WM76UN3DY>/DY>+CY-_?X.CH
MZ.7FY_7U]N;GY^#AXN7FYN?GZ```````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````"'Y!```````
M+`````!@`LP```?_@`6"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*,5@&FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<:P%\?*R\S-
MSL_0T=+3U-76OLG7VMO<W=[?X.'BX\CDYN?HZ>KK[.W#V>[Q\O/T]?;WO?#X
M]@G]_1+!_&E`I:$?A0`<.-RRH&"@*7\)`D"$)>$?JHH)``;#"/%@L((9`U#(
M`"R#1U@:,B@X2`%DJI&Y/"98>4H#AXBG$FJDT/'DOI_Z?LZC<.!`@@P'2`"3
M`.+`"%0C#I0`6-16"!`<2IPB>H!E49^M0A@UY5$LSF`6I/8;`6&8V0`0_\:*
MW)7@0%M8(4H,M`!"08"FJ>*>G24A!$"Q1152`!&`A`53(RPL!ABWZ`&3)(7N
M"ZHY7E6X!Q[_4B#B@$,-4>\FM"4"`@>EISX'D/U*P=@$=VT/_E7W;@"_PG2+
MS(R;ETE82$4'8`CZ9>9:)`YJ>&Q;*82VI"N./>"WKP+;`S,H[TR/,WEVG^.2
MY*!`H<A^&GB:8B_]'\U3W[F;RM`[@$N!_:2B@0*B$07";K+)1I\I*67@D&X4
MB'#@;P=P8$$&&J4DF@0,R92`321QZ&`J_3T&$$\?&F00@3G1!-*`REUH%D82
M1'A@011@I`&-&2@DHD-D)7`0?`P!:4II1D84E_^&`=#($T\*X,3A?5N)P&!L
M)$A@%X4<O'4`"!(XQ!=95IY7GIGR5%47F!!@6$);&GPY7``A9"F"0DU!(`)L
MIC1T@)42\+?E7P<@).<(/B4@@@0*M&4@@D;U\UF=$MRI:`!(103AEYH>$`('
M3BTW%0B&B4`!47Z!6D)3B_$G0I)?<L`8@Z4%^EA3DNE'Z9V$,A1:8UJ1,)99
MCVK9%JA^B05""5:"X"J0QAH*00(E:+45;:?$Y>MC,TKUFFF5GJH??KXQ&.F6
MMC6Z7:&G.!:;>VBZ8UZ\YQ3UG7M[-@?:=&$ZE0`(UAT0ID9]!A"5!184-&A<
MIHB%:"H@M%670H.B4I3_/U7%.<*_)"#%DW["#1IR6R+X]1U1)&U95P@BI27H
M<Q+%.NM\=KG',%QZ^0MP<W7Y:?)8(YNB,L@5ANER73`/[=?-#V%K"L,]4Q@1
MND:A/%NYUZ4R`LO]I2O8;.PV*7!LP-'+SKQFC^/TA26PFU8(C]6UL9#ZIN)7
M725PO3"[$C!KY-4Q^U5Q;&&KZ2_=`XKU\]2Y;3?MN*8$BI3$X]K&WX>HE!BY
M*<+:S*Y@AQ\$-7=1"Q<TX*7+93E\%E.^=-ABCQU8H:DS+G63&4R.2M8Y/242
MU19$-;6UF/(Y6]EIIX-V\N!@.X)63(M0PF-QWD49[/@]?=O>9$5E?`!OQOS8
M_^!"%UYH]9%':$'M@-]N%U%\,O64TJ:D!1S!,;<%T/I-AB#]]4_+F?5XQAU4
MW>YT]!/.<L:%/_HQ37OP\@\!%P<XW<BO?0WS#07F%@(-A`\\:9F:[_XR'KDP
M#QW+.R$WM"0[H94@*[(3BT;4PYZZ0:5^U@+5K!A6F,:8$%-:L<!4,!BYH@"$
MA=?K47X4H#A&;:<$&`H:KI93%\?813OW$\&=>I0Y.2VG3(9!RNLD4"F6T?!U
M@0.?4J*BD)!!L5*,$>/MFJ1%#G`Q-JZS89-``*;]*(EV1+.=;JJ8%@@0+$*1
M*TU1K)05@[&,A!IX%5E:B$@5HM"2Y&`(@0AF`0@@+/\Z#(I?"#SIGWNE@CWN
MB4A*OO.ADUUH2C!;3@@Z*)&3H4*3C\%E_T@I`1(@B@0*"%1[EN,:87*``M\A
MXR@-0R<2)"`$(X"E0S;HS(NHY#O?(<E,"I),;8T@F+NDWLG80Q(*=(R5QB2F
M0C@`@<B$H"$JL<!.1E#-4\PDF`R)(I4BEX%O-J24*R&G,>^9SCH],YI0.0A[
ML"F:A#S'5B=)P'C$@\ESI+"BYHC/=##*C`=R]!2,PI\ND/G1<5RTI.`@05]0
M>@Q6L1058(G)2\%QTIENHR(BM6DO0+(;G?K4'C7]J5"'2M2B,N,"!DBJ4I?*
MU*8Z]:E0C:I4ITK5JEKUJEC_S:I6M\K5KGKUJV`-JUC'2M:RFO6L:$WK5(T`
M@+:Z]:UPC:M<YTK7NMKUKGC-JU[WRM>^^O6O@`VL8`=+V,(:]K"(3:QB%\O8
MQM[U"HZ-K&0G2]G*6O:RF,VL9C?+V<X6=@&>#:UH1TO:TIKVM*A-K6KQ"MK5
MNO:UL(VM;&=+V]HFMK6VS:UN=\O;WOKVMX3%+7"'2]SB&O>XR,VL<)/+W.8Z
M][G03>YRHTO=ZEKWNMCE['2SR]WN>O>[X*WK=L-+WO*:][S%'2]ZU\O>]KJW
MM.I]KWSG2]_Z'C:^]LVO?O?+W[;BM[\`#K"`P_O?`1OXP`AF;H$3S.`&.[BV
M"WZP_X0G3&'11KC"&,ZPAAM[X0U[^,,@YFN'0TSB$IMXQ"9.L8HQC.(5N_C%
M"&XQC&=,8_W*N,8XSC%[;ZSC'L-U`@B8P`-4BP`&N)4!19[K!.8Z9!^_E<=.
MUO$$'(```"``!:AE0`,^X($J/V`#`-A`D]^*`0>TE0$?B``&$-"`,4<9RE'&
M<9?=6H'.,B`"<JTS`"+0`0!\H,H(^`!<&;`!,P.`RE:^<YS="N=%PQ@#'GBK
MD0$`Y#4#``,-8``#*J!I#%0``P!X0`4:4($(-``#&UBRJ5&-@`A\8,D,\#0&
M-EWJ#1BY`V*F*P+`'.FV]MJM#4"`F1]P`@`P8`(1F/2B&__M://^H`DT4$$,
M8B"`:@O@`@3(]@"``(0B\"`*;"UL`PQ-Z09$X,N^?@`#L`R`.C?`V`?8M`<8
M\``$%!L#?;:WE8N-@#Z_FP'QWK*?W?UNNGY@R`=P:\+=FFQA&]L!2'Y`LBT=
M9V8WN[M#2($*=F#MCG<<V]D.N<@)``0H1$$&@1WW6ZD\ZK:2.LP1F,"23X"`
MFB/9T`[/N9EU#@":V[P![P8Z`(2N9%`#8.%'=RN0K6SH!RRYS2>(];(OSM\;
ML(#C'L^ZM4$^\JYG.P@\"#=?)Q!OMU+9U2['\P,<H&=VA]KA3(\[SQWN]@<(
M_>X%C^NFW=H!(S.@SVV-@`,<<`+_%`BZK37_0)VK7'&JV]?J+]"ZY+?N]<J'
MG`@\N`%?'0#FME*9V$;^P*0=8/0.O!L#]<;YSE<O=S.;_M)V#[KL'_"`OA]Y
M`S5'?03PO/M+*QON+@=`!XJ\Y,8[7KXIP/KDE\]URUL>"#K8:P0J@`!/&WD"
M:RZ^[\^\@0ZHN@'?EWB;32W^\A/:^[06-:=K/P%":Q_30,=SNQ&@9^J[5>)N
M1<"0[ZS]-Q^_O2Y``RVP?`18;<WG?)9'!#J`<K4E=?\77`]X7@$X@`58@`>(
M@)8W`#P0@==E<1SH6SE`@15H@1A8@MFF@!\871Z8@KGU`Y$W@B-X@2;X?&+'
M@LBU@C8H_ULNH`(PV(,R.(.6QP,,F(/I1835]0,BV(,5^(-`6'E$4(-&Z%LX
M&(6IQ0)*J(1,V(25MX%4*(5=R%PNH'Q7&(-:V(1*,(1?:%M3F(:A=0-).(9+
M6(9-&`10R(:QM89VN%DI`(=7F(5RZ'4#4`5Y.%MX.(B7M8=\B(5_J(719XBO
M58B..%E6F(B*N(A-V(B1F%J0F(F-Q8.46(F6"(28R(GP18JT10.?V(>AR(BF
M6(JM"%N(F(H^N(JL^(JAM8FV.%BQ*(LPZ(>TV'4#4(>Y>%FX.(Q_Y8:\"(J_
M:((#H'G&J%S/:%HN\(+)V(O+.(=H&(V358S:F%?45HVS>(U`6/\$W5A9W%B.
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M=CE7;#F,4*F7'Q>7)2B,=AF8N6@"A`G_EX;I?"+YEVLIF7OE`HWIF(]9>4M)
MF0"@F*_8!)<IE9GI=6"7!$+`!)SI7ZF)5VX9FH4YFMFF!$]P`3"P`@,P`#BP
MFI[9BD;IFM>6F410!$Z``S-PF\8Y`#V@FZMI5Q/IFWL9EZ4I!#5PG-0Y`,KI
M:+N';XSW5A4`>!*'>X;5<J$V>(?75A.P`1Z@9^UV;O-G5X/IFGQIB4J@`[1I
MF]59G3Z0FKMI7^R&;'$%=W^F;(.U=@5'??K'G<:&`D.69GO6:G<UB<Y)>0P9
MG$YP!,5YGQB*F_K9;![0>?O7:D;F<!-P`A4P9D#6>\8&HO5693(W5T#W;R=P
M<)(V>NW7:]7G_V9SI941&I\S6)HF,)T9&J0PL*&.-@$H<`+%]VY\%G>'MIV$
M1F4=(&B1AFJ'AF<4!U?))G2QM@$HL)UOU6=KEVAU)F1UE9>^R:,(.)^T:0-!
MVJ:WF9R<N9_VM78H('.XAVE,BFC`]FX/@&7MIW(.EW=OM71$UU;=&5<QUU9K
MMFGL)W]R99D1^IJ62*$6ZJ:6:IQ$&F=CQGF[]E9PIZ<N5W!8MGMP1W..^J6#
MYP$><*KD9IY&=W_3)VA>"E<G&:D2*H<^"J27NJM+$*>.YJ!#9VLH8&0-9VB@
M.G1\"F;#"G<1,&^&*J"A^E:B9FS79W3:]VZ(-JMO!9JV:H!E*)MKNO^KXFJ<
M^4F9<DI?#J!FHK=G';IDW>ET'<!IP#9\\MH!Z3IG8<9W@AIX>#9NU1=XHF>O
M@\=X-4=I]D=7"6FK4SD`PGD!%SJN$#L`2."K:5BH<H5]2H>CD96PD>J+00`%
M2?"C$3NRMVD"%/N%'U"></4`'2JME\6Q.VIYX`H#;$JR-FNRYIJ&2':@%]M9
M.AJS(L>P3N"P-ENTQHFSDGFNCOBSS@ER'QNRNFJT1HNT?ZFTALBTOHD$LTFS
M4MNU1WNRRQE76.N:-."U9ONU.1NV<C6VEVD"#WNV74NUB:FV:]NM`I`#<'NV
M<DN75CN($!JI+)"W9KNW:MFW>0BSKKD#,"#_N%Y+N&)IN':(N*%)`S7+N$8[
ML6E+M]O:K7AKN5);KDFKN;1JJR]@`IXKM;V:N:(+`)`:H2H0M:<[LIFZN@!@
MIHTY!;%;M#4PNZO+MF^)`[EKLS/`NZ+[MZ'IML%+LH[[N+3K5N^IEU*0O"0+
MNJ';O`#0G+X9N-(;L6E9N-;;5KVIEXJ[O1"[N\0KNJW9F#E@G^2[JT)PG=;[
MO%O9N>V[J]1;O=;;NHWY`D)0O[NZ`LL)N8/(F)?)`K#KOQDZI/`;OZ&)NPAL
MJ9A[OJ*KOV_9`L#[P&T*P`'\O6Z5OEMI`CV`P6WZOAO,P0!0J]`KPFV:N@O\
MO?\8E52@PAD*IR5L_\+R2Y'C*\/W>;]@R\'ABY+KJ\/5:;YA*\".>,,`F05"
M7)U'0+=&[(@_K)#\N\3'2<-%;,)OA<3@R`*52\4\+,'6Z[O@J`54;)S#J[E/
M[(AD*9,67,8#L`(LK+9I[(C&JY`J$,)EO+P]C,73*)/16\9$C,98'%<H3)$Q
M7,:HN;IS'(EU#(XQ\+8ZG)NTN\B1^,+5&,1+?,:3/,AR-02V*XO:*\0VT+U7
MS,F$#)!3+,0KD,C-2\F9J,5CR,5+',&M;,ISU<B?2+\RW,0<[,J<Z,&4V,:1
MC,6^_,O)^+HZK,`F7,S&+(M8H,,D3,RV;%?`/(:'+,*\/,C,3(HY\(G(B__-
MMKS-I)@"GUR!NNR_JSS-XDR*-Q#%!1C*_EL#<<S)ZTR*+D#`2IC#_AO-ZCS-
M>Q6"2BC+];L"M-S/_JQ70R#&'7?.TCL#I+Q7:$9_@&=7M@=7A]I6MH99P?:?
MOY9B]6R+Y%R!+6"ZY&L#7_Q7XJFR=`6MB$=NK5I9+-U62.?1!]U7`5B`R"R]
M*Z#'?A4!=1IJ9V9S09UL5O:A1`UWGH9X[&EE/(L!R#9K!^O4:K9IC%=O\J=_
M5\V>]:;433;3)U;3?C4$U5QM#AR\._W0@+4!!U!PA&9L\V9W`S<!<S:E8`:@
M0P9F^!9F1O9Y)-IS=78"M-?7@JUN=;8!U'<`O8?_UWWG`.^&>PS0:UY=8A_]
MC&(M>4=@UB:`UH)5`2@`9J;65FD&GJ/'HEK&>H>V9VP=II<&9HC6VE7FVDU:
M`=37>POWV<:&K*$6:PL7V20VV=$8@#'YS9YK`T>@V8'59`AP`*)6<*1VK(A&
MJJPW`8)6J%.&>'T&V]C]VFQVJ@MGL4(W`9FVVR[FV]W8!)Z8`IZ[`C#`RHW5
M>4?G=,7F9W8'>-H-`,O*>J]F9<Y:9<-Z:7B6W4T:X%169H::=/H=HKC=`:`F
MWBM&WN7H`DVP!>QKMC8``P7M6!7P9Z7&K__*``[0H?06K\)WKQ)=>V[U`2C@
M?>7FH+57HO':XC#^XB+._V6B)VQ&A^+HE[+R%@$D*FS:&F(./H],0)Q='+$5
MC@/S#-9Y%>0%*0,^@`,@W`,33ITKT`,]8`(XX`/&K>1TQ>1<[L]>_N7A+.9D
MOEMA7N9VI66:M:]ZU:F.=^9H7E<_+EGH]E>\;7QQ7EU--F3MUU9.M]+%UZ+4
M2GM'EF24IGV?EJ*3IFF$WN=`O9U(1Z9SA62+3F\J!N=Y'E<8D'#)C0&"9V5.
MG6FF]W=0MP&VUG>CQK+!YJP1H'^1QFD")WRAEFP>0'L>$&P]'G7)O6519^"B
M5]W)766I)G&/+6JWKIZ2G>G5Q>`)5P&V-F1X%^#MMF=FYMI_IZA?UFI]=NVX
MM_]KH`;@"Y>N28>G809J&]"O859S&[!F+YWLRAY=S([1*`!JT:ZG$U!JU:[=
MP!=H;]5[$+=R]8UHW?UN"4=T0L>R#_#MO]?NO?WN\"[3$`]HD5;OC!=I#N?:
M?6ID3F>C?V=DYZZH`E[?"Y??G`YXX.=YG??QEP9\_0=BF.[P5G8`-2?SP7YJ
M;6UOX^9]MVYD'5H!JWKKJNYGQQYFC`UJ@"?7'Y!IJK[TMWYT0O9NP9[N:HYX
MAX?TF=8`'K!D9-?R'O;R,$]76^WGA#YH6J]DVD>FEA[4=Z7<7!]J_8=ZA2Y7
ML^;N7T]B=PY7&)"R=Y7V#5_W(<9FK[K2\MIC7N_W>VS_^(B_C8E/7[LGH&$_
MJ$+M]N89TP]8^(LO6*U>`?'M>?M*;)P7>!6`;/R>@Y9_^8#59&[G:OM:HO<7
M:<<&]Z1O^O+5ZJYJL<)W``XP9"U79*?*@J4O^WYE;_'=KVS^I*&&>Z)V9Q@0
M^!SX^\#O5PX`WFMFZAH+`!TM?E!O@\[__'PU?D`WL'+EWD-G_4,VY\>W_=Q_
M5T9WJD1G:_[IGXA79;I.^>>?_N=%JBO;9'BF9;`/"```"((,A(*(B8J+C(V.
MCY"1DI.4E9:7D0N8FYR=GI^@H:*CI*6FIZBIJJNLK:R:KK&RL[2UMK>XN;J[
MO)RPO<#!PL/$Q<;'R+&_R<S-2L[/T-'2TX_+U-?8V=K;W-V,UM[AXN/DY>:C
MX.?JZ^SM[M/I[_+S]/7VJ/'W^OO\_?KY_@(*'$@0&\"""!,J7(CK(,.'$"-*
%]!4(`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>h03611a4h0361105.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611a4h0361105.gif
M1TE&.#EA80+\`-4``````+>WMWIZ>KFYN>3DY,_/SV%A8??W]ST]/9&1D9*2
MDI24E-75U3`P,.'AX:>GI\;&QN#@X+R\O+6UM9B8F%M;6XF)B9V=G6IJ:JFI
MJ1X>'DQ,3(6%A7EY>6UM;2TM+5145,[.SLW-S20D)`P,#!@8&#P\/-'1T4A(
M2`\/#^KJZN7EY=C8V+"PL*^OKYR<G-;6UM+2TMS<W.SL[,K*RN;FYN_O[\C(
MR*:FIJJJJL+"PO3T]````````````````"'Y!```````+`````!A`OP```;_
MP)-N2"P:C\BD<LEL.I_0J'1*K5JOV*QVR^UZO^"P>-P\"<GHM'K-;KO?\+A\
M3M>:Z_B\?L_O^_^`@4YW@H6&AXB)BHN,7X2-D)&2DY25EG9GEYJ;G)V>GW&/
MH&,9(`TH!B8>$TL3'@T=.B`D&4FU&28-?*ZP11P-#08@!K4Z'``<8L4C(TH3
M'<`<K%>SQ4^\P:FZ3\?)8-9#U4T9*,,@'AX)#2!&S*/O3*+P8`8`!CH=`-M*
M"?:RM$@FE!C2`$"??O>*`#"H`P6`6-W"7-CF;LE"+>*B]-LV85^3B%\$&LFH
MY`()%$1,W-/7KMF\ET7DP>12[UX_$D.>&;A`I(.'_V/$$B3(Z;/6A!$`$G0$
MD,%#K"$)B.FXD.#"!0.L.!CP1I6J5*H),E`MHI/G!*%-5PWQ"=3(11T3`-`2
MRJHL$:T<PG:-.A1NT2%7JYH<4;4J4;4*#9X-BVY"!@-]KW:8IE,HV*F%(0])
M*[3(1KACX3K5,91NU\6.T6K.H#I6U&*/A[(.:R#6T:339F/VVI=(09XY/>C0
M%W@WZ;`=I$ZM/6VF)9G.L]1L^!`N":O^9G$`X0\IW!+22(1%JK1@\NJF=)2X
M$+>$PU^K2NAJS\$$B0EQ<5X0GO/ZA>P`@'`,2MIQEQ`1;^E@'G=*^9?=0"40
M1I\)3`D4GE#-)/>?A"R9=/\!""XAR!!W`NI3'U.IZ&`?*R.@D`$`)F3@W81,
M94!"!_FP0\1G(/0U`0D>V*@+@W$-F90.2)TW5)+UH)!`"0-Q<!\*PC'YD(RX
M$3$C`.!1:,V+#+G5984L'=/`DP.EN&)TE4#'IA7U%'3D5``(IT]<[""DH$'<
M$=1,0009A%!<]YPRG"X\D6#"GD.PU$\L#ETP&1'_V:E+/4/=&2!I_B3FFSV8
M5GKHJ`W@-"JF?2HX0CW"\<32J+D8LZBG.F!Z:E+VU9J4GC`R>FM4N];I&9<@
ME-`7=ZRP9*NR1P(Z'$J`Z@GH")<.%*T_SG[:Z*5S<AJF0MQFJHNT!N5JZYN2
MN(G_[A0UU1-B*1[HHR>YO@+J[+60Z6-`;:,&9T`)##GJSW\H/$4$O,R*.V^G
M(GZJU9$(Z])`,]1NJZLZ#!64`<#K]<O2JT>\M6RX^(!`88,@$.IKPOUP<$QO
MG([;E[,)_[JRQ()B:Q"7^Q::L\]&T$SR9@F">_&H])9\\KJ1J,LT%-,A=8])
ML1#G#[T.$61MQC^_.*O%<+5X,Z=/C7!C$53;;+5-##?*4%S-A'HV2[@D@%C"
M62M80@83&*"HQ[J08&K(#(U\,0II'KD=!T\)?;0!3L$<<TY-46BQX;;2#.W/
MC)8P.*-):VNSPV2I/:[.#24N^=.(.,UZ$R32"<!5]L3;_X!`(_2]*:#_U0+D
MGAU@S*G//U6]33\F2`E`LB5,@,)]:RU?1$VVZRZN>KG7HZ.(^*'00"V84G_G
M"";0=7E2O>L`Y$ZULL/E*BQQAY(TM&*>%)<)(,6!C9#-''"XW3#,L%R2OP3D
M(T@LB1<'-G2TW^1C*/AB5).B`CJ=!4]T-3M8A*:!(],-CU'XT]_K%N&Z$=JB
M9[5(SBI,@((/H6`"%S"!"9*SP'WQ)"K\FDHP'K,3K0AG`J80#@Z!8S+&F<!5
MP3@B$9QGA`FPT(5-V<I5L!+#&6ZE.<G9EP>`XXHK/A$$+T3*0G:UKRXF`X<0
MR2(KH)&7,NK@%2U<8A8[$,4:8O_%`UN!QA8;L#\2C/$Z-L2A&8\QQGUTL6=N
MA$8^YN.]Q>UG*WOZ13)X>`$?]HU]KT@9)7VHPP-14I!X],82/8`*J8!R*X)4
MX24EU8`]BM*$AB@A+!<!,M+0\95P0$%>$J`2/SA1*$]:G6=ZE(!C1*&62<C6
M+)=)!EDRTQ#M:0[B4$*'$:1C.\W9P\;RDAPF<(`P=C-8$QC(!*0`YYGH]((S
MTPD(L)R3--F4`U7`X0?S-6$Q4@`F/8TP&V&R\Y]36"=`!TK0@AI4"@(]J$(7
MRE"`GN``.XBH1"=*T8I:]*(8S:A&-\K1CGKTHR`-J4A'2M*2FO2D*$VI2E?*
MTI:Z]*7_,(TI1R$JTYK:]*8XS:E.=\K3GOKTIT`-:DII*M2B&O6H2$VJ4I?*
MU*8Z=:-$?:I4ITK5JEKUJEC-*DNCJM6N>O6K8`VK6,=Z4JZ2]:QH3:M:U\I6
MGIJUK7"-JUSG2E>VOK6N>,VK7O?*UY_>M:^`#:Q@!TM8C/ZUL(A=J@`00(&(
M$L`"#WA`1"-K`0)$=+&2-2H$-E`!!DSV`97=P6,C&U$(!.`!`4BL:FMZV-6Z
MMJ8P&(!L9;L"B5*```S0@&0[NX/.,J`"._CM#A[```)H``(ZE8!RE4L#B1*@
ML0+X0'"!*US>6C>B"'BM=E?:VNUZ5Z4BP(%XQ1L!B7IV!P*P_\`.I#M<`0@@
ML]*U[`X0(%^<YN"^]Y6`>26:`O3"=[V3%<`.CMO;[QIXI-T]L()#&M[QXJ"\
M%.UL`+*[@PDC(+7SQ;`%!*Q3_.:WHL*],'87&]$)#S<%%:CO@E=L6!:[N*0-
M'B^$S2M@$U<8`2+.<'`ID`(,V]?#^J4H!BR;8P20^,8[@(`%4M#8%SM9H@E^
MLI1W$&/R3O2QCJ5P`#"``0S35Z(/X/"/\1MD,"-W!UW&+@.T/.3L0B`%YYTR
MBZ,LYQ=7^<'.56^2YVM9`01@R]B=Z`/./.8/F[FT@)XOG]$;``A0&`&$KK."
MZ2QI22\6Q^J%P'LYO&GDNO?/1ETSCO^_W.DD;_JR%`B`GBL]:5:[^M6PCBNE
M8TWK6MLZJ;.^M:YWS6N;YKK7P`ZVL!$\[&(;^]@E_36RE\WL72N[V=".-JN?
M+>UJ6]O%U+ZVMK>MW6QS^]O@%JRWPTWN<M-UW.9.M[I'2H`*;,#'DS5R?9_K
M60A0@`*1=BFZU\WO?F=4O0$`0'T;38`-8""B%!ARH!4=TWW[^^$0/R^D]UOA
M#0S7XB4^.)KAW5*'0_SC_J8P1>^]7@M@8`,,<.]EQ:QOD+O\Y2!-M46!NP,`
M1-3D*D<ORSL.\Y[[W*(0R"Q%0SO@$B,@S)<5>LM_SO2>![VT6-Y!:'%;`>2&
MF0`4WH"*>=[_]*Z#?`.C#@`#/G#:40.7`%U6^+U)WG"ONQWF32ZJQ]].=V-O
M':ASK[O>]Q[1O//][V[W.^`'_W/!$_[P+C<\XA?O;\4S_O&%54$!)D_YREO^
M\IC/_.4=D&S(>S[6#O"PZ$=/^M*;'K\%Z/SG5U_IT)_^];`O?>I)ZGC6VYZN
MKH^][F,_>V+?_O<OSOWNAR][U0/_^`H6/O&7CWKC(__YVU4^\Y??>Y'6'OK8
M_ZKTIS_\ZH?T^MD//U:WSWW=>Q^DX!>_^J=*_O+#_OP?3?_ZY\_4]KO_]/#W
MJ/SIS_^CVO_^Q4=[_3>`N`>`Q)=_';5_!+B`//5_!BAZ"#A3##B!_VKE@`_8
M?`)(@1HX5A9X@3D0@5"U@2((5AUX@2"H40HX@BJ84B7X@">842FX@C)(4BUH
M@"_88C.8@T]5@P!X@Q<5@SH8A!O%@_?G@Q8%A$*8A!9%A.YGA!6%A$H8A1'%
MA.7GA!0%A5*HA%3(?58X45B8A4*XA=/7A5`&AF:H4V+(?&38=V?8AC:5AM3G
M?&XXARP%AP<HAW28AR=EA]V'AWKXAR+%A[NWACOPA8!(@8)H?GYXB(PXA![(
M>XO8B)*XA(_X?I$XB9@XA97X>H1HB)E(?XD(B1GXB:0H4:%HB:-8BJ1XBIQX
MB:IXB*R(?Z[XBG\8BZ;7B;2XBILHBZF8B_^2:(L!Z'N^.(G`2'JX.(S$N(NW
M.(O(V(;%.'K'V(R,^(P0R(S2"(;4Z&'1>(VUJ(S!:'W<"(O>:(S6&(Y:.([0
M6([F&(;H6(V]N([.V([:J([PF(/9B('"6(_Q*(_WM8WZ:(;WV(_T^(\J&)`?
M.)!.=5H510!B1@"1)5DIYUX[1Y#'9I#^Z%404`$[1P`!)U$TAP'VAEH!@'$4
MN6P6B9!-E7,497,1M0&--63R]0!Q5Y(5R8\"^8Y>I9(3Q9+!E0(;$&DI1I,F
M:9,'B9-=I9,2Q9./]0$TMW!"69,V>9$Y.9$U)U'T10`?T&2@]93(=I)&J54Y
M%W55&5']A5YZA@'_<<:5P^:5^?A5#,!EGC5VJ?4`1Q=@JB9?)*F6:TF44BE6
M,ZF7U\:6X*A6=P>8TB:8WV>808B8Z*>8.LB8\>>8]LB7*"F9X@>9^F>9,HB9
M"=A5+*!YH!F:H:D"FBEGG"F!6B4!-LEYI2EEIQF"J;F:K>F:E/F54J6:_,B:
MLQE\M=F65H6;\JB;N\EBKXF"706<[2B<P[E@Q0F#QRF;RTF<O3F8686<Z*B<
MT6E@S8F#U0F=V9E\TYF8L9F;W\F<X=F8XQF<Y0E708=TP95>YH5C5$F)45F9
M0F6=XXB=ZWE6&.=GHJ62\XE1V_F#STF>^[E6&)!B&J=SCI4"'Z!T&C6@_T=8
MH.IYH(3Y`1H09RKY7"D`H0)ZGI&9GLEIH6IE;Q7P`?*%E#;FB/5IFT^%G]ZH
MGR0*5AK0DGJ&E#N0EQDEH4](H2,ZHV>E`7W69#E77!7FH1?%HU?HH]<)I&?%
M`!:@D,%E`1;@60_P;OFVHR":F2+:I$ZZ6DKJA4R:GU\*IEO:F5U*IF6:6&%:
MAFD:HVO*IF>*FMUIH'%*6&W*AF^JC#)ZIWN5IX4XIG#JITQE`Q%PJ(B:J(JZ
MJ(S:J(LJ`W,*FW5:H82J5!'@8)B:J9JZJ9PZ7B$0J<:Y4UM7F!P%HWQ:J4MU
MJ9VZJJRZJ9_:HKX94Q:F9Q:`8QCV6%7:4::ZB_]]BJH_I:JM&JRM^JK\V)<O
MI7`>>643YU&[NHF]ZJL]!:S".JVN"JK.>5-8"0`:%P`:P&01I9'^J:O>":U%
M):W4>JZ>:JW<>5-C)V8!T&,[D`(04'!_B5'-6HG/2JXZ9:[H>J[$*H_&"E-K
M-E$4(&`L>:7B:J?Z&E3\VJ_3^J_M&+`PU905UEA?-I()2ZD+"U0-Z[#!"K'H
M*+$K!6KXM@,4X%D"8%E;&:X;=:^/F*\;:U,=Z[&L"K+C*+(JI6D!$)-1.E%_
MQG$9Y;(>"+,Q*U,S2[.=:K/>B+-,);072+1%"U-'B[35"JO4B55.^X!0&[4N
M-;54FZE*JXQ,NU19:X#_6\NU+.6U7^M@8;N+8ZM490N`9XNV*J6V:RM>;;N)
M;YM4<7M_<TNW*&6W=YNWE;BW2-6W[O>W@&M2@KNVA/N(AHM1(C"YE%NYEGNY
MF)NYEPL#B%M^BKNX)-6X7_NX'ABY%W6WP3H`G<M]GPNZ(B6Z5$NZ)FB?%(6Z
MK:JZX^JZ1FN[-:NN!)I2O+NJN*NPNAM3L(NTLNN"M#M1P=NIPZNQQ2NUS<NI
MR6N#RRM1T[NIS_NCT6N\V:NIU=N#UQM1WYNIV^NEW2N]Y<NVOCNAP+N^XW6^
M:IJ^+W6\-!N^13B^.P"_\;NZT]>Z]*M1]NNQ^-N$^LN_XB6_@QK`+37`#EO`
M_U5XP`BLP*?*P`V,P#@`P5PHP?Q+P;PZ5R4;8`+@67_V`*0ZC`[<KQH\AAP,
MOQ[LK'(5`&3G6'Z66L*%=>N8PNBZPFK8PNO[PO@Z5SE&`8QU<QSV9>&HP_[:
MOCWZOAWLO\P'P%:58TJF`<!E`3278^(GI<,E;Y=5Q+^*P3P<AR[Z41@,Q"\K
MQ/!F7/-:`:DFI.J7D1Q&<`9GLKBE6V&,P&-\AV7L46<,Q<LGQ56EQ9?E8P.K
M6JBUE8[%=JI5I"5F<><%GSZEQ-2ZQWW8QQWUQ[G+5H2,9LZ%`&E96!A'88YV
MPH*%E(S<6Z&\KV+,Q$OJQ"X,R,0GR"BE:IXU:J"\4O^;%5H:$*7(Q9%$IUI9
MF7*B=5Q9.E4,\&=I";0HA9042\QYS+^6/(@^7+YH/+1"Y<:3=5XZNEHSR<PI
M]6841L0!(`#=+%7@*E'IM<K-S'+!+):3W,I6*YXHI<G$RU.?IF)ON5T=^9XB
MUU*IQI0,.F#LW%0/@)8>6:\JI9)35UQZ=LPX1<D/Z\IB"LL_+,O#1\LEI0$4
M0)<^UK.O]5P\N:(L-;!L[)Z=_%17"@"-!0$<70'@7%)OB=!TB6/`=6D(L&H\
M)='".LV*B,D<9<_0RU,L20%-^<^KI5XCC=0J-79JAL,,=U5OEG('1P!E65<\
M_;$4[:;U/,$8O7L:35+L96/_PO5:H;74,!4`J89A]A;"6-5E&X9=,;U663VL
M6ZVG7?W$F[Q3[V6R3=;1K\4`&^!>`##'3+U:0Y:1:H97==V[\XR>>1W+>[U3
M4;IJ`3I8'/EG`(!A)*U:/_ET:`8!$+"@=-78J^K3HABK(R74W/M5++!<L!W;
MLCW;M%W;-5!4+,F0!.9:IJ5BHJU7IIVT=QVH%FW-7ZU[80U4!4"4R;V"P4V]
MP[UOK(V^7[7<D_V'SUVUQ5K-WWO-3RM6UGW/71?>\EB_\KS=0+U1TSV_U<W<
M>D?>[6C>>AS=*K7>"]S>UVU5@'I4\(V.\BW-]%W<W7W<L=?<$:4"CIK@"K[@
M_<W>_UVUWT;5X-[XW_"+VJBHVB)EWQ7<4G=6OA*^X5X%X19U`[-5XB9^XBB>
MXBK^X;M(X>MKX:V8WAJEX1_L4AW^O2P.PRVU`BK>XS[^XS$PW!@U`!B<XY7H
MXN4+X[R(X2%%XSK.X47NWA<\WX^-4D2.P$;^B$C^O4J^C"[ZXR6N`&(^YF1>
MYF9^YFANYB]P`0O0YF[^YG`>YW(^YW#>`F!^YR:.`VF^YWS>YP]`YX`>Z()N
MYWB.YR[0YXB>Z&..`X+>Z([NY@]0Z'C^`HI>Z7S^YX^>Z8`NZ89NZ9Y^YHRN
MZ:(>YY&.YS/PRA8,AIZ8ZH>WZJP^>*[^ZG\7Z[*^=[1>Z_]U=^NX_G:ZONM>
MU^N^WG3`'NR%1^PZZ.JF)797IE?)W&@5]F>F;%Y;=UH/"5>9#6H:!='FA5H=
M7=!RE>S*WNP_RP#B_F=9^F=K#>[*7%?)'&G7_K/RU>S:[E.Q_@&D77![A0'L
M10``@*0@-L-9QMGGC%8/8'-K%M,0P),69=26U6YS'5<?D+()BF84]EP"@%R;
MW6[*>F;NE6(=J6EXA0$I4%\5('#\OK,:&5'ZKE2Q;F04%>])%N\^!@%Q1@#S
M7E5'5G-L36@T[UR.YF,50+$8Q@"$5ES(1>X156^69<@W+U3]?&0<.5'DKO`4
MQ0``4/._;,@Q7V'2?O1QMK-=Y?+_-:=I(H=;$;79P351%4#:)UMA+.GM:[58
M'";8+(GV3W_80=7R+%?P;A]9V45<=,EG739V01_M4Y7S:'];&"!@])5FJ<8`
M\$J6'OI>5\=95_I>[Q9PD965@4_YE^WT-H>5DJ76O259(\SW)XI;)&D![.6S
M;=;W#\#Y]&7Y@WVE.YM=2(Q5+F_U*4=A.HWV%!7Y%-7/>?5>->I?=9]:&$!A
M.7]4>K^29Q_]F2]PZK7X.A96`J`!$IGQ[\;Z4H=FC"_727FKV<\`@)]=*I?^
M!AO]57G^";G9%/!N`!9<D*9QH2^D@Z;.(N?2%P\$`0)@MR,:BT2!8+=L"@B4
MW2=0M%ZQ_UGMEMOU7A&5`.;1I`8J5T`5N]8&CE_YG%ZW8YD:"L$"3UHT+*P$
M$.X,[PX.%><0F-22(`NM("@PF!#8%C4WKPBMU@(<BR@M`R0QK?2L3'?X*`J=
M8IF.:%LM7CESM_QV'C20DIR`,2@$K2A^K5`M(&J!E9AD>Q]0=:WE&CLE&=38
M7A$@/J2R>*_-SXN8D"T8>-<L/@C2)=$5$^L5LXNJG(DTY`E`^.6D&CZ#VCX%
M8/!A%(&!`A@D*^AI7R$QK*0YZ;?C(KV#AWCYV@&NR`8*:8!%'%>$0(I,F"C,
M@O3L2<TE#`H5_'A-W[Q5";-0'+4OSDZC<QQI2..NR@:40H]^N?\7U8O`BP+Z
M@-(:`!#6'1HP5,"D`0K5<PPV:(#0"P"4#8W*@!7+H$(%7\9:A94G($V%#0(T
M/-BP`2WAP0^VPD'S5T,FLUX("%CSH,):"&DH0"#PX9;+(A6X70E`9<="2IQ3
M4%"\&H!@PZ\AI""$\O$B@82+H#USL@CBLE@P('CPP`)`R65J)U\HB%WDUKX)
M.*R<=FUR+5.M*V)0G0"WZMD_0@C=?4=U\?*P$`@@9%)Y0Y;!&V*_+[H5O%@@
M!/B^E@'Z.OW)B^^Q^00LT,`ZL#M0P049;+`+`3!PS,$)*:S0PB(2O%###3G4
M9;T.00Q11'PR'-'$$U%,4<4552R1Q1?_88Q1QAEIU,7%CP*TX[L:YUCO@1UY
MW,1'((,LTDBS;CS(`MKH:.8_&L<HC<DM0CMR%PRD_*)**[GL\I`D#<(`@"VW
MFV2\^8Y0#[WHO`M-C-R^8[.\+3L48(-]M%"OB)ARRX2;*@)B24(6[<3S#7GX
M;&6^/UOA;E`O(0T2S'H>0$,4B"J)C`"[&'B@)7F(Z/33KBQ`@(`(-RN.&0(0
M8(!4*/H0D8$4-D"O@GC0TK0OT![H%)8/'K`S6"B@F'+%66O=<TP":L7RSKH8
M$#6%R(`5=@E=(\VVR$G166K:'4)15(`JQ"-CM#*(,!=85G80Q)*1A)`D)G9-
M*FU$G-1JY9\?_\,ASXD-U@-`O4)8,:5?.EG$MSI,^/A*O)K4K93@B0_6UF(:
MN36'@7%'DT(8>)5I8R31)"'EDO4D,87=S4P]4:PBB#&&@M1J\JC@B7>8>249
M7^ZE@CW*2P%+@D@&%V>=+TX:QHROP7+/7W#QV1'*D..'HZK9?0CD%/;I(V6.
M[N-0E"-4*B\@K?]I]&:C-1-(QK%3<42(#R!PPJY]UC;X;*7Y;I&J`#0(S;<I
M_HI6Z.(`MT0]4,`B-E^Y6JU``$H$<7RM"J)X]$*O@K4"-'"+PY("@$EM(G#`
M-M8C]+<%Z7S/<>[$(`J`$W<\]=2+.;7OW4UD^J/Y]!0TB^"O(&^M0&X5U>)A
M$:-3Z`J\B&>CS"Z(A['Y+>^;CXWJ\]2<]^\K]!W\^"#TGO<',`A[_/4Q9M_"
M#]VW@H&=XZ^?1?'MSU___?G?`?_^`1A``5KL?P,TX`$1**,")I"!#73@AA;X
20`E.D(+@B6`%,9A!#:(C"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>h03611a4h0361106.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611a4h0361106.gif
M1TE&.#EA80+O`-4``-'1T<[.SO?W]];6U@```/S\_+FYN8B(B.#@X,W-S6%A
M89&1D;>WMS`P,)R<G']_?[6UM7IZ>IV=G3T]/>3DY,;&QE145*FIJ=75U6UM
M;3P\/)B8F`P,#$A(2(6%A8F)B:>GIQ@8&$Q,3"0D)%M;6WEY>1X>'BTM+6IJ
M:@\/#^7EY<_/SXV-C9>7E_W]_=W=W9*2DMS<W-[>WN_O[^SL[,+"PJ:FIO3T
M]````````````````````````````````"'Y!```````+`````!A`N\```;_
MP!=@2"P:C\BD<LEL.I_0J'1*K5JOV*QVR^UZO^"P>-P4UL[HM'K-;KO?\+A\
M3J_;[_B\?L_O^_^`@8*#A(6&AW%#B(N,C8Z/D)&2DY25EI=_BIB;G)V>GZ"A
MHJ.DB0"EJ*FJJZRMKJ^$FK"SM+6VM[BY?K*ZCA`+P`MI$`H0A+]YO\*+RL`2
MD!(9>1<9"L_/B,3&?`L7A1X>-<`0%PO/VI/C<.AR);V3O.^,'@0AVV<*!`J$
M)0UZ(P3R[*N3@<"(!0TXN,,S4,[`!@26U;$0PEN)$`T-Y<N(IT2X0@0"6H@(
M@8"_C9-&2E3CX1E*.1(LR(,4;^:A!2;5L!,$$-L=_X@=`];!Z0]GB*!S2@B-
M=B??PAH>.!XKMN>"/T/@:N03EG,GI*UL)'`0YA6.A8\V%]5,2XCH,`L-)%S0
MT"!#B(I0-5B0)D&!@A'[$%K0$%'-@@X$.J11`->=A`YPC2GHT$$84*V4%T"`
MFX%#@\T9&G2`(%;?A0L=)@L+_9?#/;=&\^ZM$=H"XGT0('>X4-H:9\^@19/F
MH&\!W1J;&4M#"-FS&N+W:CP[//G"Y@8*$I;H7%2T!0XR@X^>6Y>`!;@2<BL7
MEWKW]>P<T-8X?Z9V!X7(=9^F6[`A\^\-&!>?8%H59M)UT[5G'5SPR6<??LG-
M]A]X\\5%(%@*9*"!!ND!U/^!!^BQ5]U["7WDP0ALJ75*BC?EM%AA$/UB&@'A
M$""!!D?E\TP]<WFS6`W$^:A`C@1`@)\^2OW"00U`);G`DOED4$*&!)1#@#27
MC:!8"1Q8R:$&:>!T4`,AR$5C#3;B)!-0':"H`)B713EE059B*110%-5PP9D&
M%2@13D*E<0%^;198HYL&HJA4-%7B9&=,445D%P009#"H.X7F4^-59P!VAIHU
MW!>JFW#:>%8:?6J*IC\Y@=5J1)>.:NBJ89H7ZI)Y[GEH#8NZ>E)$$A#@#@%@
M8@@KH8AN^FF5+!JR5K-_N/6B90'A1&5J^GB0P8T&<CJ,-"^%X`]I2@F3'F&3
M103_%+J(+0"6=-:@!%2P@5UI[1IBFE-?8AO="Q0'&`$59V'P]J4/DW<&Y!R:
M8+[Z9TAK%"2,CK[Z2:NU?1F\SV5^*A6".Q(7:#!7WAXLSL%;`9Q=0!RC^BO)
MM%:\5<@4=UOK/BE?1>S%^LA,D@(+T/.RGS3;6/')*T$+R+-*<^.BGN["6&W/
M9YXAP<='JU&-7P0LB2:*^%2-\#T"%XG&NQ`T<-;!0-UK[;V&/3WKLAL'U"<:
M`R^3]MIUGP&4BSDYG$:0:A@;-<P56[LW/7V'O1IQ7$\<4=9`#G3O5G?[':C+
M%@<^M,.&4WYY1("S6A35B!<&UYY#;Q6ZS2?[V/32*\X._XBT3%X`5MOZ!`NF
M=,ZI1.L:,FGN3D_(T?-[I5?JF79`!4ECW;N$0<5V0(/N0X\$<-?JK>]6^QL0
M8=<@K"?U`3%NOE7CC]N\X&CTAP8$)00KS'>=?^[/HM6KS_%6[H#`ANPW'RC!
M[@P:L-S!1$4^Z9AO#8+S7/[\1$#\B6Z!2SI.2:21DU[9;&8D<9CN@*4Z`\),
M'$>Q'>U4^(?-=,TO(2@282P50T:!"3$CT``$`+*AXM3#)_C0@#?FPB.Q<"!#
MN2$6T'9H$@M`H(9,5)L`]6&,D8Q@)#JTX@5.9!R<$4MV^>G:2G"HPWSHL(9&
M;(`[K,@MJE@1BRX\2`TO$(*HG/_.'C/4VA$7D($,2$8#"QB!!Z:XK7H0$DT8
M"8%BWDBLJYV)D(PQ3CC>%,A!SC!8]D`#0I:%'6$!SS,EH*/8EH7'*V&2'J4L
M9$7R2$E!$A*3KS&)4_14Q^R<H1Y#4@Q.$F@2(F8`E=^I""I+P$I`NO*2AM2*
M5%B8!Z8Q<Q&\.0,RQ*&';J"A'&F02UC`&"9CI.=3KXE.':+Y!LUH4IS@E,XV
MS*D&;=*!>]&99AP.Y!-S?K,-QF`G<I+F!@M,QS1@U*<AY%E.@&93=O2\)EG6
MH,W36(V;^WR#`)^YB]I1]*(8S8/<'&&I[H7"HVS8*"/\F%$].+.D*$TI0@(T
MB=`(<13_+H6H)AO`TI26XJ0VS:E.=\K35N"TIT`-JE"'^@@`Q"``2$VJ4I?*
MU*8Z]:E0C:I4ITK5JEKUJEC-JE:WRM6N>O6K8`VK6,=*UK*:]:QHE6H,"G"#
MMKKUK7"-JUSG2M>ZVO6N>,VK7O?*U[[Z]:^`#:Q@!TO8PAKVL(A-K&(7R]C&
MWK4`;'6L9"=+V<I:]K*8S:QF-\O9SGJ6L)#]K&A'2]K2FO:TJ$VM:E>+U]"R
M]K6PC:UL9TO;VMHVL:Z]K6YWR]O>^O:WP`5M9(-+W.(:][C(3>YF<ZO<YCKW
MN="-;G.9*]WJ6O>ZV,VN9ZFKW>YZ][O@#:]=N2O>\IKWO.@]_RYYT\O>]KKW
MO:==+WSG2]_ZVA>Q\KVO?O?+W_ZZ-;_^#;"`!UQ>`!/XP`A.L',-K.`&._C!
MMV4PA"=,X0J35L(6SK"&-^Q8#'/XPR`.<5\]+.(2F_C$-R`QBE?,X@JKN+D4
M8``%Z$J!&;?XQC@V[(N3RX`-W(`$%8`K!D)B@AP;^<A_W?%=,4`"!K@5!#T.
M\FI/,.,*B`"N$4"REK><5R7;%0,G</(-F-S6";"6`&Y-P5LID`(1@(#+<([S
M?X>;V`F(.0(^_K&84VL"*:/9K3$F`0'R+.="']G+=K5SF>^<9;JJ8`"0EH%F
M-Q#F#10YKA6XM*$W?6-$UU71-P!U!/\:/5<#..#4#]@L!GJ,@KF>@-.P9K&G
MZ0IJ$=SY`WE-]68I0.6YDB#6P#;QK.<*Z@_@^@8BD/)==9W9"@"YK9F^`91O
M4($W!_O:'QZV7$&-@5;_6*_,OBP#]GP#"N":`1%@``:PS>X-:QNNZ-[`NJG-
M`!#8&*_A;K>^]SU>.I<VW_P.N,!3[&_2`GS@"&?WNQ%[<+D.(`$0C[C$)T[Q
MBEO\XAC/>,41D/".1W?AAVUX7`U@@Y*;_.0H3[G*5\[REKM<Y0GPN,RG6_#1
MBARN)'^YSG?.\YZ7/.8S#[IQ06[8F[\UYSY/NM)]#G2A._VW1"^LT=V*]*5;
M_>HP?[K6>QO_=<).O:U5Q[K8K][TK9N=MET?[-=O$/:QNYWI9X_[;-,NV+6W
M_>UX?WG9Y<[WU-(]L';/N^!WOO>^&_["-1=MX`?/>)87_O"0[^S?`;OXQEO^
MY(^/O.8Q._F_5O[RE\_\YD<_V<[[]?.@;[SH2<_ZQ9J^KZA/_>!7W_K:ZSCQ
MGXV][/-.>]O[/K"OYZON=__VWO_^^'P-_EZ'3_RQ&Q_YT'\L[CW+_.9C_?G1
MS[Y<31_C>>,[KW>WOMBQK_WRM[7SZ+[!!@AMU^J+?^GD-[_V.P]J,W\?K^%_
MO]7C+__H=SX"$Q!C[%=7[J=_<-=_"#A7G<=K)C"`<;4"!A"!!6B`_SS'?PGX
M>Z:'`B*0`LHF5Q`H@>!'@6YG@1=H>__G8R1@?\L6@B(X?B7X@@1'6:#V9RN(
M?RWH@C!X@9VW`5E&9O=W5_EW@X27@SHX?8@U;M;V@W85A$*H=T28@,H';BS8
MA$I'@D^H>5&8:U-(A0=XA>:7A4I85TS(A2MGA5YX>&!8@T!(ADEGAI1E;O(6
M5^M';F<H8FG8?EO(ACKGAI(%9AWH5A/@@'488G=(@'FHAR['AXX%:EA&:H,H
M;$;(61.(B#^G6@R0`AN``HYX`P3P`1%``O?VB"!6B'0UB92HB(P5`=XF`L=V
M`PSP:C?P`5<FBH08B9MEBHB(BHLU:FT%`O\JR`#V1P$T2(L<1HISA8MZJ(N*
M!0+>Q@"S6&ZP>`-J1HS99HN:A8QLJ(R)Q6LSM@%OEFZA%F3=1HW5F%K82(;:
MF%@5L`'CUE81\&;F5F_D6(ZH=8Y<F([SB'#&*%?V2(7XF(\"MX]QU8]-^(\`
MR6\""5<$*83*.`,(\)`0&9$2.9$469$6>9$829$J<)#LE9!OM9`WJ(P(0(D[
M9P"LA0&CMHEMY8VAR)'X98V9!9(M*)(DJ7,FN5HI28<5,`%_Z)(O:8Z'6),I
M1Y-"V7(WF5I,YGUO=0(]Z9.'Y9%N)9,B2)1%N7)'B5H@<`($\&MO]0&!&`%*
MZ92W=UG5IH4V6)7_97A8(XF6*G>5J?6*K8AL699I82F6@V5Z&&!K4GB6;(ER
M5-F7)N>6J;63;P5J)!"7=GF7,"E8O-:4I1B4;/F7@&D#@IE:*JAG[JB2B0E8
MG8<"*%`!CLF/D(F6D@F8E7E:&.!C%>!DF=A6G[F9A=5Y)O`!#$`"7%EJI^8`
M4DF!I=F7ISE:)X`"\AB+LX@"4):$L"E8G4>#*5"7;O5HD+:;!MB;;/F;R?EQ
MBQE8TQAJ='B,HUF5U(F6UGF=S]5YR59F+>F=?#F9-A">53F>Y$ESE&5E%+".
M9KF&[%F)AK66^0F?\9E<KZ=N>XF?^>F>1>F?>Y6?)L=Q/@F5;26=^F>@_T*)
MH'JEH"7'H"[IH#<`H>\GH35)H7EEH3:`H1RIH1PJ?AY*DB"*5R)*H@=IHM]9
ME"E*B2MZ5RWJE#"ZGI,YHXA8HW9UHPV:G99UHM;'HWKHHW4%I!DJI)5%I,UG
MI&R(I'2EI"7*I)3EI,0'I60HI7-%I2]JI9.%I;NGI5S(I7+EI0"9HP3*GF1*
MA68:5VB:CVJZA!;:IDWXIG`5I_,XIV)8IVIIH7CZ5GI*CGQ*5V-8DW8JA('J
M5H-*C85::GZZGX"*6(U*C(\J5X=*DHEZ@XO:5I5*BY<Z<I%:6/S)GIUZ`Y\J
MBJ&*<Z-*6*4ZF:>:JH^XJD?7JH/UJJ9)J1;JHO]I"J:2)::RMZDM&*N[BJ.^
MZEC`FGK"*H+$JJ"\*J?'RE<4H&EJ2*<*NJP4V*SY^:Q[&JU[]0'#B(<Z"IC8
M:H#:RI[<2JC>FE?C%JZ&.*Y]6:[Z=ZZ3F:Z.NJYW96Z<:%?0.0#)"GKR^G[T
M"ICV:JGX:E<?,&/NBG.Y^:^A]Z<*.K!]6;"@>K!T966C1@!@&8:&:JN"A:N^
MJ:O.:JR3%6/M*F,<"ZG7"K']*;+;FEH4D(+(V59(.'#!M[#JN:8[RK*FZK+H
MFEH10`$8T)QOQ0#GIIG8%GQ(*YKP&ID\"ZL^6Z\P6V9*>9XW0*WZ1JM4Y[&!
M!;+5&;4$NUKV^5;;R9/_`:>U8,>U@.6UX@FV$ZM:(&`"O>96-,B(66NQ(1>C
M0AFPXB>Q;$FQG36M[%>WW9FT>%MT>HNH3YNKAR6KG,6+@#AO6-MN:,MV:OM7
M;/N>;ONWK$4"Z[::L0B/M[EOE9NII[BX(=NXQ7I:%7`"(``"4B:+*]ECZ:EP
MARMUB:NIJ/NUJCNR00J434N:N]NVO?NROUN/N7NZDAJQFXN6@#NKM^MUR9N+
MPZNYQ?NSQWM:#FMY?&M]?NN\AY4`DWIBI7NY?I6Y!]J\5?F\>26^S$N^T:MV
MTYN,U9N^URNUAN6^+0N_P*NSY%J_$ZJ^1<F^>*6_/<N_R!N\X`G`'RK`0DG`
M_W=EP%"+P-H[O]G(P"KJP#4)P78EP8P+B?UKK06*P32JP23)P77EP:D+P@GL
MO_%*PCUJPI2(PG2EPKS+PA6LP#(*PT<JPXA(PW-EP\2+PZ:UO:K'PU'JPWH(
MQ'(EQ-9+Q)*%LO<IPFR*Q%NJQ&S(Q''EQ/8+Q8RUDR?`@5/<IRN[O/MK6(Y;
MP./KQ8MU;!'PC.+JPDYKQ@>,QJM;6%P<P!3L6#;FC&/<L65,JFM<6&D<P8-L
MA_$K5Q\@B&[U@09@Q(S7O<WWO>L;OH=<BY85LW;ER)`\>U9<IEA,AEH,5WG<
MP'LL60D[H%2\LW0\P7;LNWA\R:.8R%UI8\XYD!:,CO^?[*:AS(6C_%:EG,&G
MS%@?<`(3<,Q_K+(CW,H?3,AW3%C!7,+#O%CC-FZAJ9"Y?(^[?*>]3(6_[%;1
M',/3K'C9[(_;K*C=W(3?W%;AW,/CG'OE7)#GS*GI+(3K?`/MG,3O3'WQS)#S
M/*SU?(/WG,]7O%HU^U85D)(;"W6T3'G]')+_S*P!W8(#+<ND9;2NZ(B:.&J3
MNUOE&\BN:M&`5<@=+-*B9;74*F44`,=<U]">]]`S&='9.M$B6-'OFUIEVY/K
M%UP?O<R"?-/.#,O0;-*?1;AQ)0*UJUL]7<7,O,)!;;RQ#-2G9=1K=IF^M=2L
M_--G_-38&]5;?5H3(+ERB)C_+1W"9.S3(2W5@T72*4S4GO4!HDMO;N6YQ(75
M_]O4-\S5^.O5=9Q:[+@!,R:[Y6;55^W2IP?34RG3YDK3%&C37XW)+;S*=ZW5
M?4U8;%W#;FUA=OW">#W$>AVV^9O9+F;8L(?8O*G8\\K8!NC8E3U8$?C:L!W;
MLCW;M%W;MGW;M;V1RT7:PF?:TXG:`JO:^L?:KOS9;[O;9@W(:'VKHEVASSQ8
M!`W*]PO:FK79<TS9Q6W9SRU8T<W+TWW<U<W;R^?;$0K<?2O<[T?<S:S=0LUY
MXJW*9\W4V+W>:[W=@=7=W/S=G(O<E+5JUXS-.KRWYNV]Z"U^ZNW4[`W5F=5Y
M**E^_S/[F`&NN)W]Q,:]WWR=W?7=WI?5>4W65AW-M'(LO!/>Q14.OJ&MUH)U
MV;'ITIH6UBF+J>;;5^BKQZ^LX-#=W"%JWY6UG(!8N&#7L+D9Y$)^:BQP`$9^
MY$B>Y$J^Y$S>Y$[^Y$L.`T,^Y50^Y2T`Y5B>Y5J^Y4?.`E7^Y5_.Y6(^YF3>
M`F!^YD(.`V2^YFSNY%Z.YG#N`&T^YW1NY&:.YBN@6#R^:(X&:7[^YX`>Z((^
MZ(1>Z(9^Z(B>Z(J^Z(S>Z([^Z)`>Z9(^Z91>Z99^Z9B>Z9I>Z32@YRX]MW/[
MGZ+>6)TI9H0]ZJ@^EB6;91OPWZG^ZB-&VE(,Z[2NF+5^Z_^RI:&XONMSQNN^
MCEJZ_NNW'NS"3NO$7NRO?NS(CNK*ONRBWNQO6,U5-F[=V&,/3ES2GEVK5LWM
M:%[5O&[;ONTRMNVNOEO'^;IR#6AD#5S03ED;0`#>=YYX1FTL75Q#QLC1)0+!
M6._?=>]N96S4-FAEMNZ_U;I2M@$!2`*.F)?(U>Z3Q0##V&B!Z([-10`^'ET`
MZ%:W[%T6[U;=WO$[C5P-^%99!KD+]MX&'?'NF`(73UP=WV.>*&T3$`'&'-@,
M8)SJ=Y@FL+2SE?'41FTD8&E&>_-OM@$ZWVBTJ?#TIO3%U?$T*V86/^_(!0($
M$(HSIHHH8`)%_VI,]@$D8`+K1IO_.!]A*&^)*C_8!.!MRM7QYSF-52^75^N*
M5_:*Y8:SM$7SXV9_@8@!TRKWKOAJPJA^/C:.K2:,&Z];3N^*4&_,RA4!"_O&
MTC:+?S8!;Z:)<>_'9"]>$$_R7;F5%2]FJ?EG?^:+-)OQP-A6=M_S]F=MC(AN
M9G;Z^ZJ7T-9DZ';XMY7X'[\!*3"ZQ06N<L6+L#_Y3@:YKJ_49?^69S]O5%_N
MNP7R/B;Z-'MEGWGZP>];/M_CKKF:KV]_:$;Y'L_[+K]G'\\`%;#[R%4!!-"3
MP,_]?,Z+TW_JL>7PDF7X;I5GMYG^:Q]D;H_Z*PD$G\KDQB`:;S="DMET/J%1
MZ90JC1";_Q/&;5@\8I<?[`:3HMPHV^J:W79'3QLFZ*S<5E*?]Y[?CTY$FK8B
M(KR2EFZT;@B[D/P>(9D*"B(K+2]O-DY`&"(JDD[T-D@P2RU3&$Z23$0^4N0(
M&"A(*#`(4"),.DTP&&)-@:DP3E"9,$PB:F]S=WMC*4Y,)CY)3@B#L=LJ3#88
M/D"2/FYK10B2L]&I*``9&#8J*$1$*'(Q0`A`CI/E*Y9UT[%-`CBP5!HU26HQ
MP$"0H9,*!RE\PG"&0"]C"S\UU`@%`T8I![EDW#BP79V1)YFD6;BG(Q>4D02^
ME#F39AM$-7'FU+F39T\W,7T&%6K*"+BA1Y$F5;IT#5"F3Z%&E:4ZE6I5ADZM
M9M6ZE6M7KSVQ?A4[EFQ9LV>AA$6[EFU;MV]QJH4[EVY=NW?;R,6[EV]?OV/U
M_A4\F'!AGX$-)U:\F'$PQ(TA1Y8\^<ECRI<Q9_9K67-GSY_/<@8]FG1IJ:)-
MIU:]6B=JUJ]AQP;H6G9MV[?[T,:]FW=O22X$!!<^G'AQX\>1)U>^G'ESY\^A
91Y<^G7IUZ]>Q9]>^G7MW[]_!AU_N(@@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>h03611a4h0361111.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611a4h0361111.gif
M1TE&.#EAY@%X`?>K`*^OKP```$Q,3+6UM;.SL[&QL8J*BEQ<7"XN+L#`P$!`
M0("`@*VMK:RLK%!04)65E0L+"Z&AH>#@X/#P\'-S<]#0T/GY^1<7%R(B(F!@
M8*"@H&=G9SDY.1`0$-/3T\'!P7Y^?B`@($5%1?+R\C`P,,K*RN7EY:NKJW!P
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M2G%Q<7=W=Y24E#4U-;*RLKN[NSP\/#(R,FEI:;BXN/___P``````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!`$``*L`+`````#F`7@!``C_`%<)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-J5(C#0PL<&T.*'$FRI,F3*%.J7,FRI<(1
M,%0-4"43P`<82D`.Q%$BAP670(,*'4JTJ-&C2!&.R,&"`,VG4&42..)AQ4Q5
M*SS\3,JUJ]>O8,.*M0CE@].H:--"70%CQ-BW<./*G4O78@FU>/.JFE&WK]^_
M@`.[M``#`(,">A-')>!6L./'D"-+%ABCQM,"5Q4K]C"YL^?/H(]Z./N4@6;-
M`V2$7LVZM6N+'C(_!7#Z=./7N'/K9BU#-DT"I&OKK;%UM_'CR/M:X)&6MG#-
M)9)+GTZ]Z]WFST\KJ<Z]NW>40GS3_W2>7?&*XM_3JU__<,0'`+Y-0QUPHKS:
M%NSSZ]]?T,1UF@,PD!EM`"!F'U0U\*?@@NE98.!EB`$'H'P'RK0#@QAFF-P,
M:`U0(%3D5:A*#!J6:&)K$BA&H8C$G>CBBY(I-L"#BIT@WE/1P:CCCGUQF%B(
M>7FH2@'!S7<ACT@F"58,1:H%I%H$/$C`DT_=IN256`KUP6DKID4D6O"E]4&6
M9):ID@>U2=B<@&H50.-31)@IYYP:,2G<E)D%2&540O)Y))V`!NK0EMD!8.B'
MFE$YP)^"-NJH0`Z*>-J,;5KYZ*5SIBAIHGG!@.FG<\:TJ6)[TL0#>J"FFN2H
MG.;5HJJP[O\X0I.L\OEF6BS$JNN++=2J5ZE1<;;KL!G^YRMVBA%`(K',\D?K
ML>.=QH*ES5;;'0XW0JL*L&@1P$(+)DC@P0<?"`&I"2C)T).U[':5@[9.9A?<
M`#4P@1@+JHT4`P]74=ONOT#Y"&]4W&8WP`?^5K3<4P/H!/##0!5<J\3R,F'"
MQ:A&9(%ELT'L<4LF#(RLR`IS#%6.'Z=L$A0B@]DR8Q-)P$):BZIL,TDSMSR;
M<`TX@``'(-#D``5H4>"`*D.KDD-$+`<IP<U0:R1!MM!23%,#&'!@``40;*#*
M`Q&@%<$#JB!P`%89)X2F7JE%[;9=.N]\&@47/$5WV0<T@$``>ZO_<@`"96,`
MP04^K*)!``&@8'@'B:^R``D!.$+U4V.^;7E$+4Q^K-5^`TZ3`0'@+0+@!X3^
M=]D<J(+!`4ID($$*`4@00`43A*#!`AWHX$-BRE[N>T,P:'YL?:=M4'<##7"-
MM]FJ@-XYWGC#H(("D"<0@`+8WZZ`P'FA_/OW!<60<]Q#=IE8!%T;<,$%9YL]
M.M*F`\Z\V3[$KD+L`:2PB@H2/"Z\*N@"GP`%\B[RR4TM+MC`!EQ`HP=@(`"#
MNX#>\O;`OIUN?@>00@@2%X`):(!Q8.#!Z103P`&J+&V0XIX!2Y4$`;A0`$;`
M2]"BXCR\#,!3`I%`"9Z5EQ*:\&,F($`)_QPF$!DPQX`@:M,+7_B"T]0P+SQX
M`@\3X\,?0FQM4_I`"91`A/_!:T\V6*(+;8!$O531B@`C5!E_I18?B%$`9%RC
M6LZ(QG9QCGREVL`2?R!'O-"QCM4*61_S4JH"9,"%/VCB(-'R1T`R:VV+A(H.
M3,.M%R@RDE%II".'I49,8F9&=\0D330I*'"A<).K""6\**4*`NA`E,\A)9U&
ML`*:%(`%3/!`G%`I$$&*,D13A&5:9!FJM'AODZ+RI!>%.<Q4J>5IO%S%^!;)
M2F9FAYAFVD&3"!#-540*DZJTYB@_92>T%&!9J-14)#$CSNP4X)1SBD%>SL/+
M9`ZRFNT4CJ.$\/^!%2`*+[O<Y#3[&,YVYBI0[EGF$>`)OF\.,DSY?$[#`F6R
MT[RJCDQ8YS(CNA:&*DF5%_VAL8)D$RO(I%9JXJAP\`.H696'!1Y]6S!_XT,<
MV%-$!<WG00'ER^P(2Z2*.>9`)'`$29E/E!$X@`%H0H&SX84"2Z4)7PZB@03T
M3TD%?"D:93`O!AQJ)O1,R$C+`X"9EA%TGD-<7IA'DYT6I*I73=)-[[0#;$)M
M!S,Y6+X$@@,3$!$A8Y77K19I``1`H'D<"-T#`+?8YB%`!*M310,X4(0%&&X!
M#G!`!5:!`@U40`&KF(`#%&#9VV5VLQ5P0`94H`$%=;(\'C*44"^W@QG_['4B
M@94H1*-$V,>"8&BA<Q[H&@"!`X`@`&=S@!>^$(`$X"X%"G#`*DAK/<ZB`';.
M[0!T'3"!#BS@<)8US@ZT`A&SUJ8&)H@I+W/[G`(8RKT;/59AC8:!"`3WOH0(
MP,4X0`$3S.`.&6CN`D`[X.DNH+H24$&`G4M@!537P,;A*E;(VY"<XF6VW2P(
M>]UY5%\50(\"`,*;"MN`"V!`%?=5Q7'7$+M5A,"R+ZZ`@!MLX.K&>,:.4X",
MG_9BXW0R*PSM*:M@EF&%;/@TAC*OB`[Y0J]!I;"JX(#70D=<#%P@`*O(0`A(
MX-U5D&#+(6!PCFN,Y2]_6<P%UG((NJR;WJ!E_P5$N-@91W#D`^&PR&+%:=Q>
M\,;=/:4!9(M``YIW-0,`(`$"J4`%)/"T"21@`HN6P&8E;6!'A_;1D9[T9E60
M`@F0=C>O-68O8Z+D[(05SPA1X7,L7)LPBC&.B1F`70>B@/PY1`$A4$`'H(D;
M-R=F!:6NT$]1;1!(DI5@\3T-G\7H9[8QZB$)V.Q#*O#HW=2YC-PDMD&$<$3[
M$(`!X#94GXX%8A?&4#%,P))+K<G2:,;``_`^`KG(Q2\1I=26R=9,`8#@0A';
MYDK77J-;-RF$50Z6U;6J')+6;<VV`7($%^LBO#I\;[1T&%[#UE'`Y8AA`0YT
M4P0X`42WA9>R>@D^3__B+;1Z)ZM@(Y'(5C0VJYSCW@(!:TJV]"J;HC6>`DW)
MY9H)J8LVWL>,?\\$'IA!+8_5)0((SS#9TOEB$)Z6I<&(X?G,-OB(0/6\7-Q7
M78_*5%]$]#YJ_7?E%-G(#=ZF`RG\1%C/YYU_]W%XN:EE7AWYM]<NG+?SIZ\F
ML-+45`ISW\F\96'_D=PHUJ2!=V<I'I"W6<1-DY#.U9I^OUSB246^/O&6G5"R
MD:'`]!T+/*$IB3F"P[3)T8Y##5M(W#S;#"2?/5&*2/193,*20SP9V>0)2X_H
M"L"G3CR^W"GR@:^MP'0H0UFA]"V8`=`C.G?+B6^-LM<+GD`4G()Y:-:Y48+_
M2FMS:LN-1H[9?XZ:>I\8JW]'U>/'B]&A=OT^?MV`(=]YK/_*G>F+\U27<W[W
M-%B$MQ[I5T;SYS$Y,&_!MTA/PG[M=`0&&'^*47T?DW;"%"($DA@^<`,]0(`@
MP`%F,VA)$Q6-E1V[-QT'B$29!S$;TT[.T2?XA!8W\$(T<$E/85]0A0$B\#5A
M$Q4-$%5LQ##F,H$4F!@IR"Z7)TKU@4\5]Q1NM$=H\0#(%0%C`SU\PS=!&#H_
M$P`7$#8.P#<88&@68`$Y8X'>L8(O]RWJI2N^!H.W\H2J,`1]AA8'``%>&#3,
M@UQE(P+.\S.JP#Y<TP#'90!3M3&.]QUJN$8K,$2J_R(#'F4!#7B$H`<5="A&
M.$@39/,`''!8>[A4?_.'[7,`(Q0`!M!N9:@?BRA'`\"&F()7!6`Q"2$#=4>!
MKQ05R_9"?!057$,V&^")9Q,`1_-8HH@W@UB(X*>"1U@>!/`!'I&,,%("LF$3
M'B`!6S$",Y!OPA0$:=%"+]0#:>$`>'@!2[6'>X,!6P@]S","66@`T(@<<;>,
MA:(*S@@%[\@@AP<5MV0%_K>-:M$#+N`"S:89IJ@7#R`"R!,`#W"/QB%D\B@I
M+(!.2O*0]L&-0[(I!:D7B14`7L`#2>@=#DF1%4(`"?@B\2B2I%(`(O=/(J-Z
M&!*2*'D@$9DD6163M0%1`?_R%/VH%^6G(#!ID\Q8DB42:D`YA`!">P0H(D*Y
M'A9`!$7)*C,)(P[UE-KW)C,"')4X*CVY'S(PB50YDDNI(!;PE;PS6`-P%F$W
M$^VF(+%!EK7"`RW0ANOQAFX)%7+H,A4R$S#`?_M1474Y*@5@6R>2CV1YE]W2
MCP.PE@SRDW^IE"Y2BS;9?$GI)=K82K?%(#79F*R"A@PR`FZ9E<*14P"8(?"G
MF9+RD?J!5T]9<P<R@\(1ENJQDZ:I%J[''V474:#)C/Y7>']7F;.)%[S)(+>9
M=;)Y0&KQ!'@!4Q@RG+^9&+7)'AD%E.\E'`]`BC]X`#](<E#2&#E02^[%`A_P
M!`__H0(3,`$JL`!/DP+2IALX4)S-J7L8(@-X(6A'J$H&``&959`9J9VX0A`6
MD%X2D0`A,%TD@`(=X$&@Y1HFD`,E\!Z^^9YXX7[[,0)'0#44X(?Q5S"P!A4'
M\(6J`%4HYC-G0P`_\%B#A@`;8#8YD`(9$%H*(&G8HS\*,#WA!5T+@`+KF0&*
M@YZKT%P3T&*>`7%)QY\0JBV)J!X+DQ<4`$'9*4[?=G_>2`,W$!41<&6K,V@!
M(`+'59T8H`7ODZ5+N@:R,P$I,*`D<#M8%@`9<#C4EC\HT%P#$0+Z(Q`9T`$"
M<::380$S\"5%&C?!J1Y$&14@<`$0T*3#DRPFAY=Y<8DO_[2AGR../:B?A74!
M1?!`*+94<*H`&J"CJU`!`Y:FB(9C/8IH`@&G6=8!TO9ID1$#7MFG+<.9WD&8
M3[$!!T`T&%!?@P9V&Y@7O(5S29083/9"20`5#I`Z2`,XDLH!/4@%8:.?B*8!
M#K!KLI,"AS.JHZH"`RH[I&JMN+.>JAH7DMB,U8@JK.>J2#1\^1$>>0%9[(B=
M>.A4!D"*UKDU!L,`V)E40))4#&,@.8EOBO%&3J:)$(`!AH6I!OL``WL!"G"I
M!`"G/TH"JR`!'4`"M6:M/DH"7V:J7J8!/XHX<"JG1F$!"QB7=":1`_&"^J@*
M/<$3#VJN]J&8WB%/>4&%@W:'7_]#-)]#BHE5G9Y3&Y1RKV<3(D_$GY3BFFI1
M;BXTK#1D`+G*M,TS:$'X`+3!M"Q0;2ZF`CF$:(]6;8^68(^FL2B0`8Z6`&0[
M`6-*%"8`?+.!&!:(LE#2LBY;'J-9>G[Y`$235`9@7TLUM%!18D1S`#S(`60S
M6<S35!P@N%^CK&5`-`CP`(TU`%Y@HLZ36:JP!")(-'6```!P@GK1`TM$`P-9
M&\1#`/E2`5PV`0S171@+L4-EIP6A8$$!$SQ0*ID7J'$;2;"Y&Q905%&Q`:9H
M8@HI`OAY`4>3%CQ($W<8@JF36868O#]#7+7*AZ;H/""``$O`/J!#-PU@7QL`
M`A``50'_,`!\BQ<]D`$T8`29>).J0&&7AKH.0;8&03L%(;\M(0/2QSMM,1#,
M>;LMLY7)`1.M&F5\R`$2M`'\I1:0]12G<SH1L`'L&*^D@P`U](G.DSP"4%R@
MDZ5^<P7(*\$I%C?3\AFV>W*4Q[_61``\0"X>P9>O(0'WV[=]>P&I0UP]^%02
MI,`1'(@'0(40W#E4&#;L<ZG.(P(<<`.KD[T!$`$4T`52$&5^&#K'13ZH^1<C
M;,)'.&X``@`K,`/P!BX`NA`X,,5?(;)J05P4\`"$"@*@XS4&((1IX84($,=-
MA0`$@`1%,`!69F4]?`!D``!IL#[%)<2A(XXA$`)*-<@(H#<F__:%579E.L-R
MGB$$[FG%#J@6$#@DAD(N7.P!]F@"XG>69:7"'H`Q17$;%],"\$8NVP(LXH@`
M(""\256HB='&M&R%<$``8P,`00AH5F@``X`%9Z`*W1L!GQB$GQ,!5?``QFS,
MJ@`'0KC+;JPM-?,9.Q#`E+R,>Y)X[D6/3""7%T'&-<=WBA$VEJHZ@#-#JV:<
M0S(C5X$`%V!8("`XABH3MV*T`]-8%*`X"J$!^EP7;7G-D:D6]U<A0D<2ZC*9
MFH$^%(`^1X/&T7P:E4@>`2(>#\"T03C///>KPL$`9F$?H%,#E;">"%%@=<&8
M`$V!AB'0<(L7+:@1%M`KE:G,DD4VXO^HQ`69J_-8&K^!T#]B&,U7&S.0`P&D
MFMD!.C%08,)X/8[CL8Y3R-JU"F5Z/9OU:=^*%)-\TB_G57HQT!5R!'$9$CQA
MS9I18JG#`2>F.B<F`DZEF_.19!-3&]1"U*IP`S0@`#3@`GH!.F,6`/QCJB30
MH@L0`A.``@K07:V5`:!%U>&5%/N+U>B7J'IQR<=R2Q[`P@_1`A^PTL>UT/CY
MH7Q8(:MH-0FHFJ[V0E.:%F2CUT@=JHB&`JQ;8`/V8-6EV%R1I([-45/".1:I
M,V=9`E_]$$U9G`[T@X3Z`,?E`!B`S@<")"_@`D-@($'8QF2#%L8,-D\[,GT[
MW80F!61;MO3_NPI.P6]+%+!0085U0`AVNMJC^D'0!-N%'0"'G=@H4#N++1JW
MS5%N'9IK5``IK$7PY@$[P']"(-8\\\Z*?*L?B@`XFY<T4H,N=(/-PS>&5</E
M#3A)T[C=,E@BX&3L.`!!X+'-!;NKT"O"+$:[B!9AV`&MI=[-56N(@V:@%=4Z
M!M4=,+'U;12K>-_R(LZ:<8NB]$X#D5"UDL$<`&C"F!@`F;[8G8LNQ,:A$^%,
MI52JH*\@>J\4``+821-CL`%V^V=)7#9X.'8H(%UG^Q3>V&1J<:234<4ZOM_]
MF..G,0<"(:LB4CI11:MY84@O!`2*]Q0N\$813HH8<#3(/05LH,9<_QB,;1P`
M(E@WR.T`[_P4@\I4H-,8$NN^<DKBJN`#=?V-\T$`->`!)OL9+?!M;?Y+ONFK
MPK0"W08M[HS3>2'>C;K54/'G8A3H!V#64I"E!U`$9*`%B2[(4!X`0>,`10!U
M(Q3A`Y$!+2H0I#5-+Z!'&0".3[$",+L:%N`6%L#FISXPK`;GPH0^:YT7/R!&
M>,VKI,'D`L!'3Q0`48!<T@WL`%`$BBY<H4/LQSH>(S0`S#403^WL&R`\[&L<
MC=WMWL;5O'/51PCK>1&L+G3NA`05LDX#9`0Z.@L!/<,^&+`!H#/O]9YBCPX!
MGC,`8W#6,/!@,N:^7K;@:2%$8KP:!6_PM?_A7I.<FY0LZV/$>4]Q`P'I9TDE
MKU@0Y7<[BGYCA6>CKP^@0#[S%,PE!>(95W$56E].,PC3':TN\\?R;2NMT2?-
MZ7NN;UY$&[8NI<C;-7@!68`[[D6P!PNA`3T;%?CR'5CO[=!BSR9<`$/@`J?=
MXYSGX+-^`!N@`]F2/+6Z%FLPIPAA`7<PW3=@!!LPI7/;'>!^W^EG\W._RD1*
M,XB!M#`T&X>!&D5H9&:^1*)@LAZKX@?17`\&&K!W^9OS123<?*-WS<XQ^QF-
M+)R_`5,B^)F/%[!:$*,1A4LD!@4!I];3:-%6JEN;M8VV:-L:&";M^O9Q@#,(
MV6V-\*;I(;FMJ(K_:@1B=`E.X1R2C18%G1`Q4-HOE'%^39X4VP&*H_I85@&Y
MEC\),+&YYAC1+_TYK2W;#!"J!@!05=#@P8($$2YDV-#A0X@1)48$H`,`@`(/
M%2[<J.J%`)`":%!)6#)BC%4I5:YDF9)*R)`>6`9(D%+!@@D:5F50L(IF@@"K
M)*280&(!T`DI@K9DVM3I4ZA1G>(8,-'J5:Q9M6[EZK!C5X@7,U*L"M;LV:U?
MO3;\:L/(!B,O"/9`(N"'F;(./TAE^>$'S$8M::8DH4$""06)?28`NBH%"0<A
MC@9MS-?R9<Q0U:+EW-GS9X.;05L5/=IT6M)L-=J`*>!1%`.Q#:@RT,#@_]Z6
M$BJLJB"!90R/-$`BV;%J0DT)$@*H2+"@PX0%(1(@7MQ8@8,4'2:OJIS9^W?+
M!$Z/)U^>86GS"`&(3]\^8H&\$0>>=S@@R)C6C!"$"(``@2H$'BB(!]]:T@"%
M55#0227@5"&@$P("$2,E%(*J((3$%,A@MPD<<$"##%91H((*>BHQ`Q54*)&W
MGL!S\46F/G!O1AK!0L\]`.*KL<8!QDJ-HX/84X6!`@#`I+4-:`O`H`,B\"@,
M%29898$*CN).)PUJHG(!`P@H880$0^2N@Z5"2`%&--,$;P0P+>!A1SCC#$M.
MD^BD\4:&>EQHH(OZO"@A_&`"0I4H`B@K@#T\T/\.,I](R"``"1;HZ:9&'X5!
MI<*,ZT"%I3)`4$U00W5JA!((((`(%NQ4E4Y3XYQO5??@TXH!K`JPH[476(@D
M`!EF^&"P"A)0;#":)!5Q@<6236DP![:;LD51HXWV!%BKI1//\6BUUKQ6M<)6
M/1LR$"`#&U0QH;N?M.,IV6(G19;8FI:M*0!Z`^C)6&GS!96(%;;U=\9O30OX
MWZP&8``CK@:N,R'NEEI,!>TP9+<Y=R=6R4SN$N!T-Q3$U/=C&"V`04B"2P9-
MX<\,-AFM`@C0TT:&7BA7M8/VBE2E!7Q+L0(5IO0M9V.S]'GHE#Q5Z>95,@5Y
MZ1='F$''E:-.^%J2MVW_@((#*"@H@@,.,D#K)KE&J,<"M/U:JX%T+&`#D&AX
M@;Z#5K``,PT8A2J!$')[+C,)1C0..Z@FZ+DEOYF62H9^I5;\*@(`./@$;>,D
MP,=M_3L`@_\,6-*@L\,^((B#Q3+I@/]JI=P@MD.BX715J$6H!;IQDBI*EBHX
MT[MUHXL*7Y82D-)PJ7)8?'B-1#_(3ZC32UM.T0+H6FS-20=!%0H<`/"!!XHH
MR`$$1+@:@2+^NUP$#@0,\'I5'O!O>@0V0."'@J3_KX#6!.AASSY[9"`.X%V<
M8-,.U*0H`0A!L$)`@@!,QEX["4`'=#*8_D6%"%4CWLKXU">)%,EXL0+`"9+W
M_Y#&A0YEH2%`Y`YR@`!`@`.ST=P&#@`!59!.%0&(S9)`@``#7*!)44`$!F((
M`1!P@`,SG`T-58$!K"TI`'J@0``><(`+&``!2_I(:USP$%D-0`81_`ZG')"2
MYB1M,A700%",)8$0H:`G$.3B4V*0J@H23(,;1!L#*%BK#VH$*R\S"`/RV)`B
M%<1U"XD`!:88`<TI*8;_H:$3EG0U!T"@:UR`@&UD*$,C&O&)4YRA$XB(@*XE
M4A7"@<G;)%*"4+&`"@68T(N"I0$K0;`"/-%.8QICK`FH46)L;*-3+,"Z.,+I
M@A?YHU8:)Q_6-6YR"O.C5?AX/*LT+B_-/$@$(""@!O_0,)&)Q.02"J4*\CT`
M`P=X``1FLTATTC";!HA``$#01"(2D0,BH-[F7`"3)$V$`!Z8FXM,,+<;A(0X
M?)%``E*P`#4J`#$96`!S?`-!!V1@`I*QI1D5(+B\.6"-\>KE4T883,\,A$CE
M.9A#YBC"]1SOCB9=Z=B`*9"7`@DA)BR("""`@`L,<9M+PJ03$AE)#(P3`3<-
MT"7_@],+F-.:F%-B$0U0SJ%N3A4WV,`&7!!3^@@A)2-H`>RD$H.##6`%+X&)
M&5A2T(-*2J'76<!1?.<4")8Q!`Y`044=$P`'5*`#'<@`"925,Z$@ZTIG158"
M%L04P\+(!""-4P&P.AJ$!2G_1_H<V.0@\LR%T'0M,V4((@6DB@;,)K2JB("`
M`N"$T=(F`J6]@6P:4%K2?I:=#[`-(FG3@"78IC9?JR%86C4`'K2L(!\`TU,L
MD+B"W%,`<A!B%MY0B"M<``]"7`1C?M=&2BT@`+NAU$INQKN6)/9%,&#LCB9+
M(SZ!SHY9B:R#*E(?QR'/O2/58T2Z=1#-2D2<$+@?W+SEM?Y<P'I<P>Q!:@`5
M&1WDGH=`0Q:RX`EVJD)<(6%"1U.R@"]J"%D!G`!/D+6B!3@JKW^CU(%@5-X=
M#9)X%Q3/?=^34ONV%)H(<;%5&L`'+'SPHZKX2F@_.S6O/(6\"&&-H`H24)AP
MX6,%_V5,DYNSFY1DYW\EJD``)J"AZ6S'.2GP4()0H!2*P6C'*.[*F+=E9II1
MQ*5;D55#:HP5-!LDA!$Q05.$D#P@A"0#8U$N3&KG9,:DM:V#YDF&,H080[-U
MT(-.08&,LYP0A4`%?@T`8C!TRWOU1`(J>%287U0",@,LU*IH<V>PA=G\2J3`
M,R;P8R4"`#LT0B0W@(A,6M*@AKS`!?U-;FL"D6B&+KJM@&8,E--$@DSU%4$.
M%,IQ+/JL54BFRIYVT0AD/&K/Q+E:VCZ(#EZ]$&__=[,1X=H!LK80RW).:U8I
M$BE!PFN&X&8E%JC!1)YX@"&`9+H"L(-4Q"L5P1E'!8"E7?]3*B0EI6#)7@[$
M-+1)<$#I@!<\H,9V><(=:N&BY9@2H>FKX`S":W/.>5`<,*O1.1'XY!N?$.FG
M2B@>$0I`P`$"8(,<D##=,+02*A)_R@)"I%`4/(>A3BEH2H[SNX+ZYCA"V8UN
MC..[WC@]9"8@0L7'<P)7#R^09FFOF@]2@(M'4\:K9H@H'Q"`!C1`!*"D7OC$
MAX%PDG;M![#-^1!P@ZKT&23Y=,@*2H"#55C``RLM@`LV,(0"9',(.1@!4$Q0
M"!"(2`7=E50*-.TAC9(86=#1D*.C?2;`TB0%>;-P9BPP`ZN;QK$5AW%:BJF>
M\W1]3K./B"@_*0(#C#,"2PCJ#X/_.,0+X![N\32B*E0>$KX;Q`7"V8`I!U!O
MA_C`W1E80@"*NQA*!2`#9:R2=!00E.O@K2<H^#)-^IJ`#)!>*%96208Z\&C/
ME]XRPDL]:#8^:FEN1<7OR2.?KHVM-RL[J:*A`,"<"_B/F+,D\<&AS4DD&F*`
MXI,^F*`U!8,)^)&(/(,)1F"_1Q.6=YD7#VR89#DC3J,)"(*@[G`_*.,E^;.,
M&("^^LNVUR.>UKN*@0'`_?NZ&>0QB1`E`X`A"-":"&B`<O(D="*==A*0#;B`
M&=("*2@^C_@+&K@BA/@+F)@9B$B=D`B#39FH]#N6B8FH52BC56"V=9$VFI`T
MWH`4,%H*_^<P-A9L0;X0F1V,078+.>()0-KCN(E(-;)C"#T$,/\(`*UIHJ$R
M)`@(GTU"IT@:*O;I@J0ZIXBH'RK,PM8(`[UZN$HKD0]<#+U2`#(9PPX`Q9YX
MN(<SK%'4#I68`$AAQ7I)`.6X+CG$#"%`+CL\BW3#/Q\!P*SS.(H(@HJX"`;P
M(V:*B-"*#=O8F@A[@"5`1MB"+=*JC8(H@-E*QHAPMW>3B.,#"18`(]_)F=[@
M#BGQ'<-BC*4HJ`G@$*A3.EADB<(XCB;+";^:Q>^0@3J\18@HM5&[H#_\NL=:
MO8E8M?/Z$9B9")31NPO$P)"X@<L`"@4(@4_Q#@WX(I;X$'H$C_\$P\>NZ,=0
M"\2#\,4@H:8^9)E['+<]O(HD8#Y34C46\(#BP(SC,+;OX"B5H,F+Q`QKT\@R
MTTE]U`@A"2$\1(@@0(M4^SA5RSJS6`'QL+6;;,K,&+*).(&@1#$^*4G&"IC&
MJ0BD9(BA-`N/),B">``GN2W0,H"OD,;0LL:)(,*RM`TBY($1L(#K<TJZG$-;
MU*,2*LI04QF=-#F#Y(JN+$C!-`@'&**STYH-"('3.1\(0"*L$($-L*:A$A`(
M^((MJDO,G,.LT\<3^!-5N2"4BB]QZTN#X$C_NBP&Z$SQ:`*N0PNU``$FW``,
M&"(1\`+:.+<8*J0`$('2.H`-L*0G.B?_KOF:(0R`TM*:<0(G!^"!S&Q.J&@!
MB=##/EFI@Q&AK7R/T/PC8K)!TJ2QJ0P-/BR($D*S.-N,=HJ`%8*A"Q@#$)`D
M#+`>&FHBW'//(2I`$3!.:^(><X)-@Q@JVZ``#,@!YQQ0IH"CAS#-C),SM;B@
MKLB_K"B2J>Q,JR0SO6P(TPQ,@Y#*G32+GBR("VA/55BA`,`",@"E^R2^V7@`
M*6(DI[H<T*(A&2J(W`LEAR%0&QT!5_L6#4J(L1NA@?A.0/03.I*L"JV_$?K*
MS5`F(`.+#EV[(7(?)D2`%8H-%/W!`U@[%'71=9(A$)@-&=(<&PW3E##0-`M(
MSXP(R&D(!K"(_\Y4"-GC#`+HS+')G^X4B!'JT(/`4!JK0;`LLZYK(B$,`#I@
M`$60.2%"T0V0I`-$T?R<HJ_QH1=ZH>D!`?43TP&%SOHZ#0QBT(\\4]"0%2&]
MSM0KTC+-+(A04NX\"X+(RHNH`C6H@L8Y``.P#P,X@#*(`!UHDMQ4A:IZ@"31
MU29I`!"051IJ)]V25558@53P&$MU3A-H*3P%C8$05<X82(&H4S7=BD#,04`4
M2:][B`V@IP;`(?61*<+4F@$@F28P&,>ZQW;RD$H"D'4SB!:0CF8ET`^0+[^L
MN/O#5BP"4O!LB+#+1Z3\R@8`(NXI2W,-R[&<4P<!V'L;RP>8GML(N/]['=".
M*!+KO$73]->/*@U2+<V0Q1/8A``G220I#8`+B(`F"$(L9;LFPBL`X0"5S015
M<(#^P`!)Y`H"F,N+;4YN"Z:M\]=,3=5L[5.3=(C@D]$ED5)5T"$`*%DG83O>
M!(&FY8`!Z(*LJ22KW=FM8,J?=<Z@C:.0Q59NC3&-J$-LP1/WN29%8CM0(@@5
M*@BV<Q\,:-H?*`!0BE$HW`H>:+FP;4Z`K;BRK=./51(GT2$`(5:#/%@BO%MZ
M<H"N"5B'L*9:]2&4[9JX)1T@6MRSBX`-P-O%3<"NW8H!.($3D+?`;<Z7P]:.
M]=?"I5SN<='T&4(?BD8G(4+;$D\"V(`AXH#_WT2`TH*A?3V([O%0QH5;)'"D
M0JHD4&J`N\79!B@"S>V:^W14U"@(%D")U<U,3/58HOVVK(B<!DBJSWK>/$B?
M`W2G'\2`1>7!]IDA#HA?53"GXB4-//R*!_">;/HQHQ1/&`#<[KW)G`3?\(6(
MLSU5&..`"TA&MJ.5"``!Z"568=T<@L@D$6C/V6`[RMTC@O`!&["!F$I0@Z!9
MF=6*!D"M:!R0RV2)I<N,=`0C*+/)`;Z,\!U;;`-(8P(`3@B^`2,#-;`(50"!
MV=2AG2H)([)?N)W<A4&Y(,@()!.)E82]Z$1*C$A.!"@Y`IB!%FY#W.F9AX/(
M5;#(&LZ,UNU./3W@_Z\;W(,X6!"P7%6X`B:6TO9D7-L#`/LE'PT&$+[[2O&$
MG-0<BP+`QH2D,:R#"#O2P[R0E;.#HO^<#0J(@@@8M((JE@)IC@41&J$Q.D@I
M$6<;PWDLX\O8`:)-8S7FL0E%B`W0@X((5U58A'E5'\C<@'(MUX3@@*Y1.P18
M-R?J8)/*KQZHGRE&"!TVUUPTB!T=$B8IOB7F&CK8+J#PD+QQCA"KF.YRC$KM
MJ_631>^HC+[BYL;(CO?K9K_2`#)!$!00K)"A5C)[TP,&R8W4@6'$H+"XB!,8
M2@!="/[T9?SYH&!N#2S,$]'HB&&JB*JP`2D8R$BBV"4&K0MP`Q%LC`XX$_]6
MY$0PO#!H44%Y>9'&0($0^)U@D9*CZZNF>ZMT++J4T(T85@D'Z)DNW"Z]4A/#
MY=-3CMUHLM;,VLZ#X`"UY%6*A2DLTDL?:`T:^+;XZLPV+8T;("5`X!P@BM>&
M%J)NM*N)?C2+OF9\"3HXI&',`(HRNAT-.*`.J.0+Z0`%2<5@Z8"'ZPES1C9H
M\0ECJS+?"*`T.6-\Q.%0P^N_',T]62^(2(()5#5KW8B+J)HB"XG[*=\D.501
M>$_G"5W)#0*["KIJW@D2J!!UKILUQ)">8,7XRPR@4&N*3(#>^(EGJR4/00JE
M*$.=6!<O3@F]$I-K?A$EZ$Z]ILK;)C5AU)&/2K7_H8V('G`!%PAHTUGC@\C`
MD#""])E<KDF[JNK26C4W`_``9$$:3#:Z%$D!CHK%YA@T;(81H"AM+7$4TX8V
M[6NK+*&,H!@,WJF,V%:)V5X3PSWE/6'GJXB<LNF@SO01'QCFHA4(U+7OC1S(
M^]+"O<L*U;T,!3BL]E-GRX#'&7;#O$D@3C%':$N,!%`0N[J.T8.6*B,,[0`L
M!1@<%Z&W.DU@HH7GS[B1M0&)#/!OMC`8'=`!#X(3%1M/`@!L(]LCK<H,VVF)
M*'$R0?,Y0T.TQ$!OV&Z1#DD!#;B)NEH1$^LP#4E'$^ELS'OK`.J;#-F-[7H1
M$Z_3:/77UVW0:S/P#)B(_R#0`39.F61J`FR$\8B0&Z)SLH%KJX1*#"/7L$%S
M,IDT'+I*`#%LOXA4B=%;DQ+X;=NF[X*PZ5G)1V&6B(%MCV%TV)CY`P'X@RHP
M1MGX&G,[`"[0*#PWM&89M"QILN:<I2GW+F9-"16XG<RP@C4?M3"?[_'XRBJZ
MPKV>B![XBQ^`-X\P`I&HQ,V*K'X]"!65#23H]+7S#P3`'/\`@T-PL"S(`-F(
M@DL1Y:7)R`/.;1HD#Q)N"&P4`!_0IZ`\;)!8R0*P0I"@P,XR@&8T@`U(]@.8
M`F9O]GH7@4X_`$60#?\]"#,_B&[$=I"!R@/V8ZL[7=XNCV-F"+U+`J.%"&#?
M\?^I:@U#F%]F=W8I-;=DIP`#@`UI_%9`>G2#$%!ZQ!>>(YQ.;(HXA)'O56-N
M_Q>"*#6:'@T55["J$O9<!U<D4;[6:(.&+=6%*``8OY%;#PD;B-$#>.NFR#ZN
M!FU`6S18:A%C"<=PS!C8?BC&*)#CN&1N1A.JH&^#QS9M*>Q9#RD!1UN(;XU!
M.;+6./-_-:F(_X$I-LWZ\0&D-Q'?J'K&N/J=0`Y`@Z5%`_5#2[1T7C3MSOH0
M8XQUH11*Z:L#`D,"^C[23L4':OH2/WO62W1DILZ#P7PJ%IB(,'<!0'=U%X`A
M>'N'T/&V\1&#*2;5%X!!N9S8$`$2$+_H4``40*#([P#_SG[(4;271PD!X6^R
MS[X,YT@,B6%\9-&`G`"_=VEMS&N.]UOY%UDL11_S4)MGFN83?FXU\L"37;<+
M7W\!MIG"DUR(<$]LV5@"+<":?+=X_T`#00@!9D\J_[@`';J`#)B._0<(#1,T
M!%BE8,&JA!)23""Q($&`"2D*)JQH\2+&BPL4)-QH$.'!50Y(."@8,D""51L5
M'%R`$&7&F#(Q*E%E\R;.G#IW\NSI\R?0H$$!""UJ]"A2HP4&W"0`H$!.HDEW
M2IU:E``!JT:K\A3@54`:-"$0(#A@]L"/-P;6+C'P@&O.`PALRE6%``D3#@A'
MEOQ8,07)$`\+0IQI6"-'E1P=_SA(T6%PB@PF7RI(('A!B!0J4*R">?AS11Q:
M1Y,N_7,`5-.J5PM=:A.N3:RF89\]0$'5@0BD`:`PD'1#`U4@#CQ0]0"$3@!,
M??[XZO7%3@8`IJ=6Q8!G7=QS.7```0&R9+\)%31^7+@P:,,:.*]:OZH"8Q0:
M5J%0D$+!!/D?0RIV4,'@?^E]]@%K!1JXU8$)'NB::SI=5QIJ<9D%`0>J!.#;
M:`!<<0!2!ER`&P8.0-!`!"/B!$!6/_7@W`8([D2!`S;!:!QW#KA!GWWXZ9=0
M!0IDH((*/;Z7F(!%&GFD@#(LIR"333[8))1:33<=52E.Y=24.VV`07`!.%`6
M70B($/\<`AN`J1T(<WV)@`,:<C>F*@9P@,!M#\QE)TXBQ'@!"`:`$!P&M]GT
M)%`]9/`#$-7U!(!T3^WT@@LN^,#3`!_(@"2FF6J*Z1%1>FH@EHY^.JI0LNE$
M``-+%E6`J#QY5YR%(H`0P`,'8&"`"',%(`(%M!YP@0$(!&"<=VV"<>L%&T00
MP`;>46#`L-#BQ*>%$&!P07`.B'!3A`7"AM,-SMW0$P$>;'HNNNE:%`.I[:HV
MP)3?NDOJ"8LBU2!/#T"`G$T76ACL!0A@,*R_`3A1!!(`+!'`=&D@0$`!8):5
MG5S22GM3P<AAT&)VL5FI6E4V)&'$N*H4X)P`#E#R,4XK6*#_+LPQ'\GNO#7O
M=@++-N/DU`FJE@:Q3_(&W5,#&^-4L)S;DOCOOQQLVZLJ%$!`159W16P;MJHX
M+>VL1_L6J"I&=_R:S[O9M.)70*AB`\H"S+!*"Q[([4$-4`$@@<R@59``WRE5
M@#=H"4PP04IY)Q3#"CHKGA30-K.J`P,G2)<:HPQ45X`.BO)$0+TY$<H349SG
M##IV`9!%%M,7ZGOMM@4OH2\"$!`<\%QE#5#$`0T@<,&U$31@[07#W@2V=]<&
MIZ=.!:0&K]!#+=><<R^PC7(57B"`"DL*D,#!%1QD_SWX+#G@$OGEFU]^"GVK
MSW=%]2D0PF3I*5"!D(97U,+B^1<%_^^\`TA7=D[\IX,30`5?`90<BK+"``8,
ML'DW09$J&N<34^DD`FNY8)R"8X#@-,`M-ME@!IV0!SY$(5H8?(!N'H`%FSP`
M0ZKH8`=QHBV;6/`FU-()O"+D0)\0JFTW*``-G$.#IASA4D:2P/J2J,3SE>\B
M$^C`?!2``A7,9Q426(`*)M">"BR@B@N0P!43HH*'K()O0-)B>X)4122U(''Z
M>^.B`.@D.0+E<S=A@)6F0T>@['"'4X$6&"`!BI\H)R@ETLD#/M23*5P(`,$"
M"IC\9;(EM:T'J@B75VA@29P,@`4M>)G]0-,0]BC@,5"40`=0,!*#/"8`\T%)
M8>J#@@!P,?\`*`A!!NA#@EL2"4DT@R,P<U(`Z31JCR"S2K=V!I?1%<6!#&0F
M:3IX!LWMQ(`]>4!P<!(!W?3D5PAPY%R,`\)M/@!6*,Q@`U"XA.4DH@UR:(,`
M:)`:'PQA").B2@%*8$0)!.AO"1&<8?Q9$3!:$:`$C4D&B!22EEP&)0M]"=\*
M0CB"),`C'@E`"G"T*<0%LZ/5G$ZCH(E,/_8DF:\AJ5#DU:B3&HAYK5GIJ2"H
MBIX5Q2P76$(4YD(!WD$@`K_"``0X%,FU`*\(`Y#:)P2!!AJ4;"@V8<HJ').0
M#N2R`A$QS(X2$H(*3*24_`Q!3%1``C3ZA:%]F\!#.Q-1@SB`HA;_Y0A&-;HI
M)7FTKIN+%Y6T@BH['L6D>9T--54!E\X)EE$`P)E5+#<5O%+'9%0J9%#,0H$B
M:&$N;EF6`6REBB_9A4,7@E8#9E4`"-Q&#V`([.8^!H,)!("?).A`>TC0GI1H
M0'!?3(`*9OL7L$[1+YG!B%7'YQ()/!25&;@E6D$"T<)T@#$=J"A'/(*"77:@
MEYG:@3'M:M<L)>5!,IU*A/S7!-2.=#IY5!5(X<+7H%#P0"0UBRHN4!=;B>!"
M\ZV=9]<2+8+Y9FQ\%.8(0J"!,<XO`[E,JP,R$(+<\H<^N>11!S)Z7(Q<L7P2
MJ*UN*XPW#&,8)6'D8@(TL+?YA/@]0*I/_[JPJ]T5EQ2E)VH*>8,R@!,@-D&L
M8D`0\"B4R$&VF4UZ+X<D`0%='6`#]IU+789JL6$AH#L!6Y7/WG;<^0&)!%%4
M[BJ>F)@&\Z<"5.V(=34E@5D&Z#`9<(A#U*5B%K,Y*MF-"B==W&:GQ#@Y3?)?
M=BF0!^5P($84*(L###"C&4FLG'>:2P,,08<YQ7ES]2K`$%PP!)>UIY1#:FU9
M$>+E$&B1RP@Q;D4\DJXK9E24&NABS'8@TC9[5'G[@TV/60T4E]JD``3<7)U-
MPZIX[:2]/_$0AWC29R>0(@U3LIQ3?!8A*4!/`%Q02``>'`+8KN+,LUQ`0U3`
M&/%4FS,E8<E\4/_PX%"2.R8>D+6L^>?4Z*"[*">8$E.8ES,Y0Z@JE#-*D[.Y
MDP?D"DZON<F-[ZT*(*",!1TIG`:J.`$@I8^+5L0VAA.B`=F6+R56+C?&,U("
MG[RYW:/R-56&YO&?$#8G6'IQNZ9TXXY+"8=_W0#*S("N)P)NH!T@:\9SOHJ-
M[V0`'G#CR!?G0&L*D^6L;EZW!@"Y7#,)7JLVVT]@+JYTI:#,/"JUSK/.<T[N
M8!46J$'0A3[!I].;Q4[A.$Q!3JID'\BD/*E"P;,N]W(3Z*D%Z'I"+,""L.ML
MF*WB%M.)SG>3K9=TB@.IMW!8KZP<00ABX,)7;C#WR=O/`C.800YP@)'_$0Q>
M<<QK+$K+7E?F&?W?BU/W,7/2,QWDH"(C@,$H7/""$5"^]EFG:^=/'^N?J-WC
M)3^*Z$'U]*,4@&7O9L`*<C""$E@)!$@(A1(>CJF(9X3ZMJ=\#G+?[N`#D_O%
M%_MJ4,5Q1?WJ`!R```.^0)$C-1@CUK_^Y+>N?3:[W>/<MX[G[X^3!3(=)_G&
MC04%P$:46GUDP`14P)1EU`1D0%MQ!GDDF!;UB'W0QQK!W^1]W?P='=_5'_"!
M'VD('L`!P09LP";9A'>8SFU`RQC!UGU8QF!L!FR11PJ$`$=HCV7DEI4M0/Q8
M8.UQ7@:RV'>-G/YQ'W&8X+,("DX(&E#T7@?Z_T0&.$<)OA`(U->S$(9$K8=Y
M6*%:*4:FO<=&["`/4A[N_:!'H5[0#:%02(_F_(HJ8)82QD4X$5)I-`_:?,4/
M#$^+A,T!0(L)%`8#5H!#G$=!0%&UU:!R20!&$02WA>'D91\9UI7^+0X3+B$#
M95<!2!U3X40#)`MW1$V,/,"<<`A]<4!Q-$`H1HWY<<`T@:((;``2N@A/N$#;
MW$2O"`RV\&$L=0`)!*(6:H`N5E>FH1()*``8,F+\/:)'1:+B_)Y2#)]-$-Q7
MR!-.>$=/:<?O'(!W9-:^=")CS(HVI@D'4$%0]4JP-2%/#`'*#-%-=!"&=%`+
M$,X_@5$%P",\:D#5>?^$/_D3$I71`=:<,4[>WB%C,"FC3T":I/7?O93=[OV$
M#^5$B(3)Q82)=K3A!M179B$9`EP,`OS``J$4!P)<$'U%$O3$!WQ`"X#&`E17
MA/TC2UJ$!0"=0.H/0?)$`3RA5V0`0AY%X0F3=$@.4K2-"^3$F<C%`P2`;HC`
M14ZD?!5E4A*E40[`!=PA_MD$,\+93[Q`2!H!:K5>D2"1/[8D2^+`!ZC*"I1>
M3++&))*&+#K'$!S(3EK'_VA%LSV'4`9;78B`M?34?84-[P#+7BK`!71!4*E"
MMR@'>8&@3MC`/?'$5X*E8QJ)#'S`=+"`!3CB6;K+6XZ&U'U%'A;(3BIC'0K_
M0&?>Q#FUH3EA2`041VJ^T`:A$!:8`0-4@0$PP"2`0`2`B51(A?_@E<>LQF/^
MYKF8P&7.RTSJA!&@C!&T'6I)$&GTP`BZ0$X"Q??Y7\!4HPZ880`57W&:"W!V
MYY$(YW"FG()@4N0EB-`@)N@$H8((7@OI6YVQ2H&\C7?.9WJ`9WB.2G'J!#0*
M@-J8I\BU!E/L&F,YHZL1DED:7OB!$GTNZ$S@0'3>)]0IB/1`AX(TCXLM)$X4
M*$\V!<30$79F2('P@((R*(EB1`R,)81&27ZZ2_-4Y7]22H^ABKI-I[Q\I%6D
M95)P9XGNZ$4(08I"R8HVW;SY1!`0DJ+X#Q\1A4P1_T4RP<9>&84-'*2!HB6/
M5NE%_!R2_FCBM=E3X-5;^AWH#(!+:>A_<<M?"=:)9,Y1["<-4*B]_`QA"H&5
MSFG>X8`$:.F6^L0##`RU1*15G,E._$XZ!4^,I`F.4HKF8">&6H6]F>7T<.9/
MH&>IC"7>T2F=6L"#XFE![E&)W$:O!&`,T1`(I5,-T1`VP8H!W&;N^$:HVL0&
M5,@(-H"_0``<Z%4>9>I1.$5<(L5:.D=<^,LCH91_V83!19^E'FO=:>IL^,26
MD&:<!,"UZ-2004`+`8^T8@`&;`=/[>%^^5\>FB*7:$TY3D6#!"F"'D6O?D5<
M/-DC$4`=C%-JPHHX!8=<K/\F"QF`N<ACF?W-01TK?<J`LJ8>=L3A!P5`!PU+
M4,D)!X!6UY"6*N1*4>J&?"V9U]"0B.C&%!#L8DW2I]BH3SRJ5XPF;OS*6NA4
M%P"53VWKP_*43^4EA^S4M%U1"+P60BC8S"*$OS+HSP4LB/;$3ME$`SC`P3YK
MK$@6Q?I+Q0A/65`LQO@&-G76`&3L')KKFR(%F[HI7=A&1EK6&52!?6'`9B%`
MQ*J"LFA67;B%#Z#$`LA6?5@5W@A&SI*H!3`?SVXLT5P`4G+`AU`L61B``U0A
MT389"`3,-<X*<03`%`J/34"`;^!M-N)&A?1$$##=AP+I5-Q`I"SF3<"7?"%9
M"-3_UQ)8`D9>3''LY0'@DMI&5V501/O%+7W&`*XJZS#]1`/T6PH=V@OU6SKA
MKBERQYW4R&W(Q=AP`(=$0*[P"P*4@1SA#//PF`[PA(LR27["E]3HRA0865,B
MP.\X@+/L90#X@0JDKF(\41<)H.N6*-4^(E90;9\E35%0`-CFA*Q&@+P\[U-Q
MZ$X4*:E4KE90@*#TV0!P`:`)FA=X(HV4B0$/FEZ@0(AQAGOTR)GA[/DN:!R<
M%`^4)$S6+?Y2+;^)B;X%!0=\<)QPR+>HYP/E+XNN)S6A5`&,Z$4LF&54X`3/
MIPF8`$;`P('&I/AQ+!#N7Q"<:='9F7B&'^4`$'-&$``Q_\%,I(`#M.X,5ZF/
MD@8/>,`1L(`)HQNAI._/+(>],1VL829KH,B[O6AA)8_F/3$:6\0(S`T;4[&,
MP4"/\AU7:/%HH`9\5D7T9F=.V"]^AC&`GG"3`L`6I#$A&P:F_L0*&!%&X(\0
MHIRGL%U*/5`30,YUKLK'-,':S>2A#@IW$29WG60AAW)&S$!)S8`+8P04>$`)
M$,BB*@@!',$>;0$`S;$PQ>X2+@7_E2EIR(;_9"9KD.D<AI\H#_-%,/*I@'*1
MR-^=S0#M*7.&6D`46V6M+4GQ\6\PFQX9ZQ65;/(<.N.KK8:.$C,QCTX,(`D&
MWIFE6(0SVT0)'`[8$8#]PD7HI/_*"1O(DV1FC<$I-C<)'Z\&01(`[8FS.'O`
M!^B8*M1`0/N2-UN%G&*$,P-T15C>4C0!)D>%=&1H#K=8$.9Q;.3SLJJH@1"D
M?`HT2>^`*ICRI@1D^!'`!QP!,FM<CXUT0ICT-[,&7Y$4HRRT'((T6NHT53!%
M8Y+T,">TIL``:PQ`I7Z&"4B`*BMRWN5D?I;PB8QQSW&T47!SS[Z++;.S!;3`
M(`LU6*.+,2-%#<R-%=Q$.Z>+2K.759MCAD)%#A'F>EDS4M"Q8RFCQQ9%#80U
M7Z/+"/AT!!'UWLGTN:PS(1DT:<SUK=5S5/S=:/BR:=`U+))&6O>U92/)5%1V
M0L@`9<+_S%A?M?YQLZUYZ5%OM5LGEC]?MFH;B6%SG%,;S@A<='=E=%Y[3M.9
M]FG;[6RL-F^#QF?SGBH00<Y9GF[7=6ZO1FT72'+O-/%A+M8*5F]']TS$-F-1
MAX!B'E'G'&!C-6,+Q7(GQ7?[\6,C!5:FS<Y(-WH+R`AD]^0EZW$SMYD^1:A,
MQ[M1+5'X748GA:3.6G1NIE?8P$U\0'H/>'>Z]U4O--'I)FX?Q;MQ\:A`=M46
M!5`&.(%7N&.>6W'K,L#E]R\#-C(A=E\]Z(3;A(!;N(D;(X:#-T+"A63W,:F(
M7MGYMP``.(F?N(WSH(&_=\AQ$CU[X*?`>%*4MU?T9VQ\QAKO_P![W[B2GTN.
M&\5RPYI=KYN+YZJ'TY,+E""*`(`AKP#EF,(I+SF8'TF33W8V`W'-1+DC&P6$
M`T4-6``.V/!,./,6O':8UWEZC#F9GVM'<]*"(T5RSZ[`[L^"#\!+R\0(?(L5
MV+FB"PB>^YB&W]$`Z*KRM'*%DAP$,<I'Y_EH?(8F]%I#+SJHST0D]A%/@'A;
M&X@!T7*:,VI2",V?G<Y/X(EFF]N2@$`>EL#\3(`#A#JO7T0D"MYY!<6:B[<G
MP_471ZBFT\6MK,6O!<"LQ\0<3`N_G`),7%RO][HR0KERH-2PKT:Y6H=CL]1X
M$Q\=C8W$<&L`?%8`$*.F$>-O+=04D/^F\%``,:;$`NSZM?.Z,N(+?$:01Z(Y
M3R[0_6ITR^DX;J1[``B5PMN$`W`)M'"52>22+R:7092CF;3A!0P"3"0`M>4[
MJ!.D=$`R4G2[:NRW'A?%YP"ZHP^L_RV\=T0`#P2!%GJ&0X%$.=8%!V#``41;
M&:V?Q]NY?4:V+9/\;O1XLH,.Y]"889G*=/3SCK/\3;#))A+'OJB"!PCB*I"`
MQ-^<%$U`"-R\FB!`'P2`;*''S]MY:X/QQWDX29EA7/N[;EJH3XP-->K\SJ?[
M&V!]CP3`;SD&&^C\31@`!-S$#L"$"H39V=NX!32ZVC_RJ9^*,[+P'CU^`%UP
M29;S9YQU3E#_JTT8JTCD5N(O^3G+)(>S5ZU=<22GU)L=<2TW"J5SW9%T2ES$
MR$$GQ!/A7.B;.$?!$=$GA[P(:.]/936=0!`,D(,_.N2?"#']Q+.#1HI'QY?G
MOH5',QR%=\\I1_UQM[U,)T[H[VM,CG26S5ZEB).B:4D)MY$T.@](_Y*O63!9
M_ULW!?@3YH(OQ?KJA/<#''\W=HH`!`$``P"H,GC0X(`""!FJ@K$*8D2)$R76
M:(B0!T6-&SEV]/@19$B1(TF6-'D294J5$6$,N$C!@4$',2_69.B`@DV=#`?H
MV'F1H,N&!`$4_'FT`1($10XT:>CT*,,@JF`*-,IPX44.#:@@\/K`_\"!@SPL
MF/R@LX",E6O9MG7[%FY<N1V9V#R`0)4(#`VB7GP0H:].GX$+9`U\&"$&#B!`
M8$!P-2AB5008("E"X#`%#*H,!#AP($*#`(`)J#6[L\9<U:M9MW;]FJ,%PPWO
M4@CPP"`"L;I5!>`0`*^!"Q<".$#@695NX1B0/[@`003>HR?Z"A0J&3$%"`<?
M4`"`8`H`IE0#%$_^^P)@!\`QA"T?0-6!X1!`Q(<00`3?``9Z\S?(0:P#$#G`
M/P0V4,6#DT;`3*</8'L0P@@EG)`B$W0Z`(+["MQ-K``VB&"_SAX`X382DR/P
M-MM4N>"`!KR*B@&$!*J)@-FP.^RNW%X<C_\W$2(P$0$.5CQ`NP9(]`\#$>*[
MH`'C#(#@@08PZ)"__0Z"@#^]!+#R``X</(F(GQB@D,PRS3P3I1TNA%*^W#CL
MK[_..(-/3N7HA(]+Z78"P#"%"(J1(4!OE(R""PPR8`/X>$,`"54V0("Y$T_,
M$4X'-HL/K[LHS=%**PWR5)4"QO,#@;).,H%!F\9$D]567353B)UR;(#%Y!R@
ME<HX[YSS1#GE9-%%/742M$:$BF)0H4&Q:P""6YM4]-8+U'A@M$0EU:W(([4#
M#%-,08!2R@Y!H-8_."_8H($N*"AA`054FF.G+U^=E]YZXUI05NF^_3'#*>$,
M<=<Z4>3U@7Z%M>G_A*(82%7&HJA3%KL'?@L`@YR^A0"#*:1@;CT7WQ0!N/V.
M*R^L3#.]+[_X`ABN7`.IND^`$E9Q8`&5E-CI"7MUWIEGDJ"`6%D'ZG-`2#&!
M/EJRJVIZ(#_1<(-X@Z)5&4#F53JH0*4C=%IAA)Z]_AKL57"X#NG`0"#N@J=W
M(H!AFR(0ZR`#<M+I;<E&Y(Q`51HXD"&E;9J8)HB9Y4L5)2!*P5V5++))WK`=
M?]Q5%LJVR0877/`!XJ(T;SMN^.*>VR8Y$4.`@B<QK.^"<@WR>_*HWI)@!<8A
MGYWV,EMHO:$D!-B=AA>4)4KAFD0W""95<#*>@@>\0@`LSQ"HKX&[?$2>_WJ#
M0&R@@2C/-5Y)A`1MR`<;<$=H`-/<LL(F4VM?G_W69!O?H!=VGS^#R5GG]:`<
M%VW1`!$@B*`S&\!07MHC`D/M[R":N1($^'(V&7$N5!O@W0ULHCROI*PO`V`!
M$>)B`=8-P'#M$^$(X7([^*G"!?.;G_UT<((3&&9XW4)@P?CC*SSY1V1O,@BE
M_J.DX27K(D!0H0`P5X`A;.!RAPH1!PZV-M4P@6RJ:!P)J5C%TTR&!4_PP!9W
M8(+8*6L(0Q0`_`!P`@8P`!">VR%>>#.E<"F15]NC5@3:"+=N'>!`1,.?*NYG
M$#$.H0`9F!\-,"<Z$$5`>2NK3Y!6IA[V)&`""O\(``H"L(IV6=)=%>A``!0P
M@79UH`,I^,CW$&1%4YXR)!^800NZ-I'W*<L'0^3;">>T/`KD"$,8@,!G@$,Z
M&[X,`;NTCR[MZ,!O!1,W"@Q5%!$B1LL-$0A[%)F2BA2D(17I#@%(0`;<14E,
M?E,%*9B`-A<0@@EP\R,E8%@(4=E.=X+$0D"[P2!]1TN].<$`^8P`(@WR@+_L
M,Y\&"`U_&N"?@G)+%?[<YT%$`YB"$DX$,6&;3GXPQ!M(4(4'&MYM/)7#`NCF
M`"3P@`6TJ8":):"2E[QD"AP@R02H-'$>@<(67$(`];T3ISF-B`6^"+$7N.`&
M-CIA'ULG@EE>"3!$-4C_#U18/R/($G]M2M++7(0$$_2A#&[HP`12H$UT>G,!
M))B9NSJ@@0J0TUV7#$E!$J13M^KT"?8DX^0*8(-Z(B1[#,DK'W_2`R,@<2'S
M5*$+YE0>#.`FD1=89!A68=)59("3VIP`"2*["@F$@)/N@JP"2)`"F(J$.G%X
MZVC?&4^YTA6"-[H!#7:W`:':1*DV$>+NC+"3%6QQBZU<104R,(%Q5D`#-4M!
M!^2R@P*40+>D52X5QW;:HS'@6&4K`&OGEX2^Q)9R@[@K0UA0@A6P(+D36<\D
M+4O9LLIE!#%8[GJMB%WGHL4E[D6,8`=Y7>Q\P`(SN`@'5W%3]OX7P&[AP7L1
M_W-;"8Q`G:E55@J'V)>%2>9+'JCI!UJPBO`&&,,91DD,/M#A`C"3P`W)@41*
M`&*(V6"(]?L)06Y$@(@(`0:MA`$`_*MA&]]X)![H:8@;,L55R$!RDY'O400Y
MOQ[\I%B#JO`JA$"`&4!AP*I8,HZI7.6.R,#$(>;:1G+0`AQ8`+<*CDH!7+`!
M(XAO)P40<U18`)$<-&0&5I;SG"$2`Q[7I`87[DA^3SL0H!4`!ZLP[4%*06=#
M4QD&=S;("J#+`QC4^",C>&WKAJR3&$=D"P4HBI0/W6D;GZ5L$V5(JH*L"AZH
M-R4EZ/.@!K`)3[^:SJ!&6@YPD&@&X1<&";*`16RJ$O]\V7,`#\/.0V!=;"K_
M^FA5@\@(<D!LB8`9U:FVIU4&50-(&QO;[%6ULDS0[6X_*-&T%/9A`-!=)>@Y
MV^DF+;(E4SX*L1MW[@5>05IP;77?>[064%8!RB1K^YUQS091-KX)CN$10,$#
M-0AX0PI@;]?`+C#N%?6*1UQPB]MX!!Z86F`D4"8P+SS/;\XR7X]2@!U<'.4V
MQG)@G$VF$<Q@Y-:.",0O@ET"E*#C*=<YAG\6F#:C"<@UP:\K_<W'%]JD`#/(
M^<Z9'N"B8\1&#6]5"XZ`6P]TD2/-]L"W!RTC(CB\Z6%W*T\O4N$1^,T$[>NZ
M04XM=K<#6`C764'%(>(W_J[_SX0(80+8W][WTGK;OPUIZ_HTCI"!^QWQ&-[V
M009?._T>)#6)ESR&<7`0S-R]=OXF0+0GW_GEQD`")I``W=>W>(/XV/.I5[V"
M1+QZU[^>)(4_R`KX#GO;K]X"43[(X6_?>]OGW2#F\_WP85^#37.>^,E7_O*9
M[WDO-Q_ZDL=!712"[NA?7]TX:,$'7)"(!0"`82W'_OB-'8,G?&`@*)[?455!
M>_*_'];`5T61C4R^0,,?_W3>012=:?C\_]_*]J\AJ&M^"&O1:@\`$_"M!+`A
M9FM^,,<@&D\!)W"]&)#AZ(^"#H("-W"])&#D5,$&;``"IT;X.-`$<RK<`B/.
M3I`%YG.JU/HB[5I0!MM),DQ``U``(FZ0(G10`;!F!G_P:U(0!M5*K21"`K!&
MFX!0"7EF[6P+!XC0732@/'#PDK0)!4B`JS"K!U<A"9-P";]00A;.(&I`O1;@
M/3CIL22@J[XI`#)@JR;@O-"I"Q,`#.OP04Q/)V;`5*!P%52`LU+*7<ICJU`*
M(@AQ#NT0$5M#_H"B\:#PK"1`!0"1"Q%G`<9)`QXK$%/@K.@P$3M1+BR`"%A`
MP4H0"B=KD@+`DP(Q`1XQ!;00:\PP!$*`$SV1%N&"V401(<"K%G?1<9AM!@"`
+]WA1&(<1-@("`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>h03611a4h0361108.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611a4h0361108.gif
M1TE&.#EATP"D`,0?`$^LJHK(Q\7DXTVJJXG'Q_'X^,3CXR.7E2&5EJ?5U6NY
MN>+R\:?6U=3KZC&>G#^CI'O!P+;=W)G/SERQLD"EHVRZN5ZSL=/JZN+Q\3"<
MG7K`P)C.SK;<W!20CA*.C____R'Y!`$``!\`+`````#3`*0```7_X">.7V$0
M:*JN;.N^A$&.R6#?>*[;Q.S_P&`!1DP%21S"9,=L.I^#Q.PR\5BOV*QVR^U>
M>SZ"=VQ%%([H]"=!)J,3B+9\O@6+V/0\W4X2Z[-2:H(^#W]91PJ&BEYV>(N/
M6'PC?HL/@Y<B&)`>01N;GQY@&'&@CY(BE(L7F(,:FT`%I*6+8(FSM#^IB@JL
M@AFO/YZWN+'#BJ<?NH9FO6@<GT!5QH8]S]-_R,J&@<U`MI!`A==Z/:[C>=F?
M`]VPH$#GY!\#QT7U+#)AH!CL/H[@/XL00!FH0\H\0_PP:3.D(2$)<<!\+%KG
M\,?!/Q4%+?R#(*,F=P`54<Q(XJ(>DFDV__[AQL\<M)"&1J*4IVCF$95Z)E24
M%7'&1)LB3.8!"@2GGGW\K(&4*)*H4#I$<\U"ADG:4I]-@3Z=$S5?J0S\"MQZ
ME]7F5CE=9QC5PX&=L%)D8SJMF7;2+9W=(%XE\5,KW;K)AIWI=6%8W#\R49YM
M`QC5L`W-7,*%B7@NPL9K]8#MQ3-/9RR']20FN=@-YBZER>"[I/2/Y$.415O&
M>)J+/SV\JB[ZN"5TGM$94WMI')C+A\]T!@L2V[2+;SK`*PIW7KOWZSR0![U=
M^8$Z4[E^+P/>^('W'TN#]'H6X1TK>+-_ZY*GJ6B5FL**&G8W'OOW[)/5:7''
M(KFE\<T?2+7'5_]9,TW'WWC>(2<',VE(V,9("H[0%WSBR>?==72P!,1M>7"3
M(7L,*A9?6O.55TD:5NG1D88/NE=9>+1!6*.#7"`%A'EZZ(=B;_W!DP4"$ZP6
MU(I=M;C&(D(&H\J"1/K`XS@3*'<E;#I668*%9,P(Q"^&H$>CER0<:"1J(VP)
M6H!<BJ!FB4#@MXV-<9)@P)IM9.?F%<0Y^8&=-_HPYQP4GBD@$'\:LUFCG,#Y
MYD.[_0#F&`4JFB<)!:C'IQ8R0!IHAB3NT<^4>$[Z0P$Q?II%#Z)*"N@,Q1BR
M&0FMTF$FE8L>8<"AG^H4:Y>]IKE(6R,`2>=WQ:)AP`8H3*"!/2O\-*S_AS6.
M0&A.?2B2**^;1F4MDU$).H*G=/A(YA^9@JMJ6N-VR.*)3QXCPI[U/6<%<?'F
MB"V:(]3ZQV;`MK%KJK,"UB^`Q(8KYR(&"*R'B.XF7-?"0\FZ;YT$ECJA<LPZ
M#!3&4&D<Z9@3[7($O2,W=>V\V<ZP'9_VZ7ORQ2Z32Y2YG+KJP<$AO]L5R5R9
MC$;!TU",\,8*YRQODRS?^^FW13*-LUPO0QVS#^O"TV[5-\/KM+\P`^S#S./4
M'$34,Q&-EM%H,`</T&#S.S;#_S;KC9%*!VVQV%CK#!3//N`[#M4VVQWXT^6R
M/4+7QGR=>&-N,P9W&FC?HO;*6Q-5N6D-"_WC_SAT3][TXF1K;78TU_1=-^5W
M9QSZWT>T-@OB:W?>,NIXEZWW$9"#(GGNJ^]>6=:-ZR[5,)NCX3A)GX\QJO(^
M*+M)Z<3_[GGL)<]NM1JY0N*ZZ5<?+[A-A`=A.R2X<UZ\3=$/=_D@P1/(RO,9
MQ8]_1>D'D9D<S4O#_ASRD_#)@2`(?$+]OJ<&ZY6I%UTP@`0G2,$*6O""&*2@
M_?[G,\OI9A/CRUX'3?$!PXWP$;U8'T=`-H@3;@(?"W1AT5AQJ38,3X`R7,1@
M,I?#M[$"1'D(H!IZ:(A,H8N(TNN%`^=PJ_LA,0]*ZM039\@*2'D@.Q"<HARB
M)`)6:1%TK/"8'%AXB?\OD@$O/[B``F*H17;4D`LW'*(9N?"`$!+GCGC,HQ[W
MR,<^^O&/@`RD(`=)R$(:\I"(3*0B%\G(1CKRD9",I"0G2<E*6O*2F,RD)C?)
MR4YZ\I.@#*4H1TG*4IKRE*A,I2I7R<I6NO*5L(RE+&=)RUK:\I:G7(``=LG+
M7C:@*PT`@#"'2<QB&O.8PV3`"!B`S&8Z$P)IT&4OIYD0"S039,A49D8<T(%N
M>O.;`>B*`+Y)SG*:\YP="*<(`H#.=IX3`&E@)SJKB4X!D."<ZG0(`]IY`#*B
M9)SN#*@Y\RE/@084GF@HJ#D3(@%TYO,#^(2`,R=:S`/PDZ(810-`#<I1@G+_
M]*#Q;&="-EI.A(H`GP#XJ$I7&E"-LC2@'GUI24,ZSX2@\P#W'&A*9<I3EKJT
MIP,=@4)[:M(@#)6<),`H,BWZSF&B%*A0->A/H^K-F$*UJ$`XZC=S2E6#!F"G
M70WK5H]`4JI:%:A8_8%6O<E5L;;SJVZ-:]RF.<T*H+,"=.WE`H3ZSB"@,ZT^
M6&LWVQK7@4I4J<>D@#L1JU1V"/:A1U@K8$_:UX2*=`2%?2L_(-#.R>;QL8*0
MK%\K&]G+4C:S0>W&`MRY5T""5@VB!<)?:7I.PJ*VJ@P(@&YWR]O>^E:QZ*2`
M;X=+W.(ZUJ&A):T/9HL&9C;3MK=-)UBCV]/CXC.Y_^;T+',=<DX'*)6IV6TF
M,ZD+5>NFEK;DU*YR^7%=-4R7G+\,PGO)Z]-NO!:]WU1O=C/27OQ^4P)'F"]]
M53K7O.[2KN?$JX$%T-H/Q/8'VR6!`(K;6VV>EIR0#4)9OUF!``^8IU/MZEGS
M.]K]!M:@1>UO&M#I``]_^*4A-BM?30SA]:X3Q=!-YR"`:\X&\V/#Y+0P'H$,
MU!%[4[\S/;%`4WS>-'#VG!%P2`&X&>$AN]7(W41R>M6*8\PVN;GHA.8/(M"`
M!=/5`NZ4@)G7S.9=QCBJ6.Z`EDFL9)!ZN:04#H"%5VOC#T``KB^NKX:O/.,D
MUYC&)!#LEN^LTJ)2>:$SB/^`=`,M:"`0N:=QGO.1N;SD'-M9!&@^ISU'T`"+
M`IK2'WTS5#-=8D-+N+<1?FE1&WI.`'<1N*=&M53MBUS8]OG"BT9#K%E:U`:@
MTP(C0/"D=<U1\Y8SPUG]-42E[6DFKQ2K-Q7!/JLJ8&;7EM<J+BVB9U!EV2I7
MUC/H=@<64&IPEGF:$0AU0"G0YFD^.L$+=C:&L>MJ<E.;T<&>]K5G(%@)\+B;
MD(V`L@-Z@/A>0M'=M#5)7EN`O#;XP<O]-[#IO'&$0Q>KDNZH"!H`@7L+-,JL
M*`!X_XKR2QQ3FZ\%,JO-/6Z:NUK%XR[`1P,`@95S5,B8@+@W#P``W3+`QS:O
MZHW_VROS0@?<WS4_],V;7/.#NS/7!CT`T#\0S&8Z7`3J[O414AOS\V(<ZOU.
M.L<%OF^`9]D'"[]ZV,WI@*^/X-(=&'7`3`[3%3][Z:EM.N"?7FTU#/OO;I>S
M#[8M4*R[TP+^_`#>]4YJOFM6V(@O.^(=+.UR2SW@.$^[L;TZ=V\ZH.4_F/RJ
M2J]TS+==\VWG?-0[_G:_(SKTA/^`S\_9\-(?(`"1OWL[*4_PW7_Y\QZ7?>#-
MWGF-LQWT5$_[!^3=SBB'_??!E_#PC["`N!\_XZ_OM>"5GWO:*][V4]_\\VM/
M\+Y_H-L.D$#V9Z#ZN!E<[*UN/>S!Z?2UH[W\_[=VN.=__R*`=QV`;&!'3@>`
M5Y)'7*@G?/4T`\YE3!"P`!)0`58';0&H8^37=N-W=H6'?M"G?E$7<MVE'#OE
M`!6`>K0F??4W`D]63AU&`N\6`,2'?!RX?ZW7@9NF=CWH>ND7>^MW?B2P`,;G
M393'`$>7>KS'A!&85.&&"60G?LPW>T/(?F-W;M%'>%973@^8A3WF`R]H?C=X
M"5/(=%4H?>;G62%(>P\U;C&(?VC0A=WTA6/(9V'8#6>X?)L'@HF'A?DG@%NX
M=B;868-`??Q'?]LW`H7X33C%#GN(>!_8?%;8AE?XAH9FA+OF:^:$@-KWA(-'
M@%*8>538AY2HAAN(A0/8@P5`A__G9'>#1G=BN(B@=DYBIH>DB(:F:(6>!WY!
MF(@=AU`M*%`2%S?HQ$)C:'D=4(R]$(D>F(8`V(NI2(27^'&AZ$XSJ`;*2'QC
M"(K-X(R).(F\Z'R')X0F)G3?U&*"@(@[6("T>&GS)X+)IX/)QX.`:(F!^(/5
MF'@(A8[?A'1!X'W=E(WN"(K#B%3LE8M\&'M^N(:&IX4DF&1:I6Y?Z`,+P([>
M1`&*"(IQ2$X.`'RX&'ZZR)"G"("6N(JU=U1J%F9!T`#WYTX-J%L"B80C4'H6
ML(2C*)(+"8P->874F(^J.(@].%3(IG.D57&Y!0!'6$X'L`#^J'<?Y0`6H&<"
M$(_@V'K_XHB*TGB20IF2WT0!@^&*'5"0*P5@3SD"2^E.9;B!ZD2/'&B//XF/
M/AB4$;EH!=5P,!B!!IA@URAJI):6WNB#;5F*)&E.1(=,6_F'U(B2YU=0J,=X
MY01@>RF#_>>-[:92:PE=@SF2/$E5;*B8C6>-L@=9>%A.R#:9WW2+<%E.Q+<`
M8NF70*A_A-F94?69YA>:_'AC@'6$.(6:'7``#WB6M-*1:BF/.3B;.^B/G6:<
M(I>;#N8`_H21W:1+`H5]=5:<J<=Z>6><F[F3R>F9#_E2F+AH$@"+(G"0W\0`
M!OB1D2><0!`!I9>9B=>=D@B-1!6>+#6>HKB1Y@0!1$8!$&">/XEF4/(I`@M0
M<H&)@_3YC+MX5?BY4OJICT#9`130=0#P9^HY".X931'P54I)D[$YC\A9C\KY
,:6"8GZ*)!NH6`@`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>h03611a4h0361170.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611a4h0361170.gif
M1TE&.#EAJ`+>`/<``/+A39MC4I7JSLJXL63AS=/R]!8H691S::5C4JNWS.C=
MV2Q/C-&T*WM20N_LZ>C1,ZKKU2G*M81-.8_9L&E/!PBQD&0Y*924E`*H=-K+
MR/'HV8UN"[VLIPX(%W'4L+?(V??O[@*14;6-*TS.M*^0$6,Y,=;MVW#+E,W:
M["<_<]/&NZES*,BKGJ=U:%*U<F=TDHJ7L$TR`ZF&=[3TY[NEFRZUD59HCY/=
MQ\[6U@ZYJ*J4B_36M6-"*8U3%<J732G4Q-.S9LVH5D-/<-W6S0*;9%HY,7>)
MJKJ31XAE5_KUBN[/C+B<E+;5ZTFYBYEF(+>4AC"L<^GX_4-NJUA$!)>HOHSG
MP,VM&"JZJ=W6U\S.V&MK<XK2FJ5C2E#&F*3<NJ:,A'E@"0)T)FLU"9C8^SIF
MJ*R9DIN!>/OULR*64.CN^.:U<<J8+=O0A*KHODQ9@J5S$71*0EI",IR`#;F,
M@M659GF$F@2'/9A:4NFVA9+RWV:\A6I)0O?W[E,H'[RD%<6,BL&8$3X6"#I?
MF.+_[69ZHVMS<Z=O6>"_+'M:3FC#>[^@)7M2.8E:4G-K<R2<9`F>A'NARZ9:
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MQZ*BMH]K.91K6;2!.W%P=B'Y!```````+`````"H`MX```C_`%,Y&TBPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FR),-Q%Z[]6\FRI<N7
M,&/*G$FSILV;.'/JW,FSI\^?0(,*'4JTJ-&C2),J7<JT:4V!3J-*G4JUJM6K
M6+-JW<JUJ]>=%YQ]'4NVK-FS:-.J7<O6*]2V<./*G4NWKMV[>%>&S<NWK]^_
M@`,+EOMVL.'#B!,K7LQX+^/'D"-+GDQYJL!EF#-KWLRYL^?/H$.+'DVZM.G3
MJ%.7GJE:\T[/KSOK_%RYMNV\*;7HWLV[M^_?O0L)'TZ\N/'CR),?UU*(N?-"
MC:)+E_Z\NKIPU[-C1XZ]>W;@X,.+_^\]O;SY\^6!HU_/OKW[Z./CR]\]<[Y]
MW>_SZ]_?_K[__P`&*."`!*K'WX$(FE=@*@*-XXR#$#XH88043FAAA"8]5*&#
M"FW(888@ABCBB"26:.*)**:H(HD79%--/"_&"..,,M9(XXTQ0E/-.COVR../
M/@8)Y)!"%DGDC]FLD^221_:((XPN1EE-DD968^655S:I995;=LGEESQBB:67
M9(IIYIE-GJEFED6NZ>:;<,8IYYQTUFGGG7CFJ>>>?/;IYY^`VNG`H(06:NBA
MB":JZ**,-NKHHY!&*NFDE%9JZ:61@C"HI@YPZBFFC7(*:J&?CFKJJ9UNJFJJ
MI*Y*J*:PIO\:ZZRRUDKKK;;FBNNNNO;**ZN(EBJLHJ6B:NRQG7X31Q%%+-ML
MLW%$*^VTU%9KK;3**EMMMG%H&^TWV8;;K;C@CCLNN.BFJ^ZZW^S1[KONLMNN
MNWO06R^]\.:+K[WWZCOOO0`_PR_`]6Y#,,%P[)'PPO?"X;##>Q@L<<0*/VPQ
M'+-@K''&'#O<\<4@>SS++`V,;/+))(_<`!PEMZPRR0W$+'/,,,]L\\T-()(S
M(CSK?+,\#0`M=-!!RV/TT4<3;33/\B#"2P/4\$+-U%17;?756&>M]=9<=^VU
MUHQ0$_;88I=-]MEFIXWVVFJWS?;;;L>-]M=TUVWWW7A3@_3>?/?_C?0!<=PR
MS#""#^/-X(@GKOCBC#?N>#'#0`XYXL54;OGEF&=>1#&;=\[YYT4<4\(QH8\.
M^NF;9UYY$264P/KK%L0N^^RTUV[[[;C3WDON%NSN>^^R]R*\\,P,;_SQR"?/
M3/''+^_\\]`[K\WTU%//C/7:^#+]]=I<[\OWW\,1_O>_^((-,^<_CXWY[*\/
MOB^_Q"\__/#+;__]^.?_RR(22'"__P#LGP`'V+]?`-"`!$R@`A?(P`7R0@(/
MC*`$C,$+"EJP@ABD(`0GF,$-9O"#%PPA"$<HPA*2\(0F3"$*46@,#4HP@BJT
MH`<W*,(&VO"&"30@`FVH/_\M8G]`_*'^__37CS@H0QFW.&(2C\C$)CKQB5"\
MW!%51\74<8Y95\PB%K?8.2PN*PY79)88QTA&USGKBT7@@1K7J,8B3*,$<2C!
M&]\H1SE.XXYXY,$T],A'//8"CWG<XQ\'"4A`$G*0R4ND(H?WC$8ZTI&*?$8O
M)$E)2D[RDH_,I";WX(L]/&,;H`PE*'TA/H>1DI2E!-G[5LE*\)7OE?3[!1QD
MN;):+F(1#5B$+QJP2USB[)?`E-G3@AG,I_'BF,@\9@.,F<QF.O.9T(RF-*=)
MS6I:\YK8S*8VM\E-;BYSF<\DYB\ET`!RDE.<Z(Q9$8=Q1'8JPYU0C*<3BZ$,
M>EHN<I'SG.0D1_]&,FJQB_\,8QB9Y;K7&;2?8G1=ZUA74(2V[J$0G6,=Y]C'
M/NZQD'?D00GTB-&.=A21BTRD)(WWC5Z4]*28O*3P+&E)3&X#DB_]9"-C2M-G
MM/*F.`5?*4^Y4_'=%)9`I1_\?DC4(`;QEDA-JE&)BE0)\(]_Y<QE,\U9S@=&
ME9SA-"8XF_E-9G;SJ]4D!B_$2M:QFK6L:#VK6M/*UK6ZM:UP?:M<RPH,8M05
M&&#-:S2[FLRN;I6K5-W@50=KSO[E\K"X+*IBE[H_7ZRS<9+#9V0G&SG)O;,(
MEQU&$?"YV<V23K.AV^)`$4K:TA(4H@\U:$$5BMK6NO:U#[UC'6<KT3G_>O2V
MTSAD;G?[QY'REI$I;>DD'QG2E0ZW%]IX1G*3V\CA/H,9,7T&-IZ[#69(][G?
M8T9.M]O*H'K7%]V()?GHI\OR^@*I1UWL#YUJP/4RU:GP?>HY96;.8RZ"%_=-
M;#FIFLS\ZG6;98UF7,6:S+0^DQC$,$:"%ZS@!M_5KA!^,%XGS`L*6[C"&+ZP
MA"/,809[N,$?7O!<Y4K-`/^WFO>U+W[[.UA<!C:J,=/O`.6+7O7>\K&#>R<3
MV<EC'??XQ\K8;#W9:<\@1ZZ>G].L0,5H.2X&U,FF=2A#7Z=0*EM9H;4MP3>T
MS&4ZTG&BM@7D;%'+48SJ]LPEE>T<B<O2X4[C_QDEQ>1(0SK21BY7N8Z,AB1?
MVHMM3%+/?;YD3K/'W4(;NGSO^T4#%,WH73IZT8M>!!PDK6A(0YK1E@[F?'&&
M59MIE:LG#K6HCZGA#`/CU*A.-:J%P0MA4`,8U&"UJV$MZU?'NM6V%H:J=XWJ
M#/NZU!/&ZZB'#4V_"A.97=TTC-/YR_A=>M&87J>/I]W.'5N[G?0\LF8O^TYZ
M<KNRI`.HY_P)97%WL8RNO3*52V`!=KN[W1#=LKPG"F8[2I2V8LYR("_*VW[W
M]LV[?09OFUO)@A]7D\4UKIWQ?.=&ZGG/GYSD2_7\4IP2VM`8=Z5X$0U+7GI\
ME\^6I:1S66EGFSSDFO]F-GWYRE=B(S-J4CLFS*<9M9K'W.;4(&M98<YS4O-:
MU<+0=="!,?2BVQK62#^ZTI/.=*$3_>E.U_7/IWYJ#./\YEBW><RW;LV9NYSE
MPU1YS*B*LY(_^](XGF(]IPWDMAMYR$/&K)#MR3DEC[MSQWBRN?]Y;H+VL\J`
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M5UL9-8)^M%N`)'`HF%N5Y%QRQH*9=%PBQ7F!=F?+Y0LR]7!]%G$SU6?;L$K9
MTSVNEW$<)U[FQ4O?PTNW)W*UQS*'!6WYAW+B1'\S(WS*%'PNUTS,UW/JMX59
M%W-I56M))W541W76QX5F>'-C*(;3-X9`]WQNJ(52(VSK-W-TZ$QUR'7OYTQ;
M!7_(%G;I!'R[%S.Q)VTY]G_5]G_L)&1S1V2)N&US_X=D#)AWX?:`E!AE!Q5X
MF&AXAB=F&ZB!#/6!C!>"8`9Y@71(/#!Y`O=F*U5GD+1Y+$5<BC1ZG\=P>/9<
ME10-LAAQOM"#/?@^MAB$/[5QX\5*EZ9+Y0-I2VA[D\9H29AI@NB,@Q6-OS1\
MQD:%_]5SSP2'Y+>-W(B-!"8UQ)!SV?=J12=TK&97%<9A=W5JNK9\X^>.W#A6
M&\:.3Y=AW'>/U4=KN897=^B.4[.-RH>-R<1\U@1.?]6'GP9V?G@SP+=R9R<S
M^L=_\(2(;%=DVF:`!IAM")A/>[>`3%:)?"=E"X6)#`51\&:!\59'&HB!:G9O
M'ZAON54"?\1O'#5Y_R9P@_^T@JVH>:XH@R)U2;E(@[6(BSE8>D;9@S:U2JJG
M>L"H<=TU7K"DC$:HC+9'<H>E:+@4B#93:>/4E58(?U,H?WJ%C<@7C__8A7#H
MC60ECF(%AN1(C]3'AM678>CWAA-6EW@Y==;7AMV'CT('?=J'ENO'?L<G?EHG
MD(5Y308I?`=)A6-7?YNF;!!Y,_KW3D!VB``(@(K(B'#766^'67SW.5JD=P,%
M.8<#6DPV#,>@FJ+#.L?PFN'&6J'C#=)@>$5@`<7PFFY41X,G1Z&3FY(X>"_I
MDHXW.GFW41E5#!8@#>S0.Y)7.S/);LK9.L>EBJD(214H1\V56\-SBL*S1VID
M`6K_-%Q":8,P)7%_U@N[:(-->6C"*%2K5'O[$VFU-S.^=)7XR95B]YB]QX?2
MU)C<1);.](:)Z8]S>$RN1@S"H*!C-8[Y2(].]Z#F>&JQEFL6JH\8NH][V9?L
M&*$1&I=B^'05BG2L%H\6YGZ&29<75I9X^%6+*7_&5DS!MVS!5&F$B)F&F&/8
M9F0%^&T:.62@,VZ0TX`.Z#E[@`0'<`"S@)I%,`M)^J1Q5`*;D*1(\`VBLU#/
M8`8Z8`9P(`VM8P'',`M?\`4'P%#?H*2M@P1F\*1KB@2V15LE\`QP8&]R=`QP
MH*5F,`L7U0MJ^@5F@`@6L%N(<`!KNJ9;]@Q(:@:*B@22_S0-&`-P<(`(UDFH
MBFH&C/!FLX`(C'0`#9!;E$JI9D`-P\6>-N5P%*>+,M6+[9E3B)93YO6J2,B$
ME79[^A5C^'E[T+ALD0ECG79L67608MEU70B0PWJ8Y!<UX'>7$[:@09=S02=K
MT#=K]SBM1#>AUE>.YIBMU9JMSVJMU.J7>WF/K0:A<9B72O=K=5EAQJI^Q*IU
MW@1JBYF04GA.]->0OU1$`#B1UN9./;:(<`<Y1B9WB5A/#VA/("E&PW``S9`)
MF5`--"!&?4`#U9`)"I`)0_`,Q_`-"E`-"C`HFS!X1?`-&>``(^L`_2")2``"
M"H`%6/`,K;,'#F`&>5<&%&LE%?_+`7`J6])@!C10#+95#`<P*".;`6_$`\^P
ML0H``M6`!(%J`1S`L16;`2[[#%B@L@J@`!SP9B5P`#C;"\7P!1Q@`0('!]7@
M`%>K`#K0;F9PL7<$!S';.Z%PM<U@M5_0.P6G@Z27@SC%E*L:/K+T78B&<K-$
M:;K$2[IW:?+SD()H/X\IC31*C0M)?%<X?BS*KA66:OC8?7+):WX)E^&*:NHX
M?6(XNISKN7`I8=SW=!'&H:RKN7'INKN6EGA(D.^H5PJIA_W)>S0Z,_WP#?O*
M=OG*1!:)D3[:;3PJI)US1'+WD0[H#6:0!MM0!&;@L)KE#32`!>'"+-_@`!S0
MI*'@`,__$#H#D`G?4`S?\+U[4#D9,`3@XBXO"P(R.PW?('"AD`'S^PUOZF7'
M,`#5,*=W9`&;L`ZA('"ST`][)+8.,``6,`L9H`!;5@P#(+6.=$='2P,E8##-
M90%FD`V(T#KU"ZG58`:?!`>-9`$*RP'LH)YORX.(T`Q9"P=\MF>!%G&`%E/1
ML'I)V;>LY%.L1)5+F$O+>)59B9^3B7]EQVR,*:_Q&J#P&$W:*)`XA[D<&J*=
M>[J=2[JF"W6ANX[Y&'7=:KJ?*\4?*L59W,4="J&G&WW=F*+QB(5MG$U[.']\
MR)`.B4[XFJ/7UG;^"K``ZYF/V(`#%60'RRS.ZP#?,`SG4`;-_X`(11"Q0]`'
M?4`ZA+>]'-`'PX`(U;`)Q[`'U2`#WE`$TC`+S:`#WE`,0S``?=";;P2S9N"E
ML3,,]3N=.<MNB``"\'L,O4!X`V#(=N2S@L2]TM`'TSNG^ZL"TB`-@=I;"E`&
MD2R3C50,BFP&Q?`,#J`!C>2HU7``J?QF+CN]('``%N"V9F"TO<`#<-`,--`[
MO5##QS5ZI3?#-\6W.@P_/O5=L^?#/S1I*_.W@IB569FX1@Q,5<B?#FF->OA5
M64AS:[RN7)>Z6)RZ(#K%?<FMW5K1STIT"AIT&6W1'%UTV]K1I%O%8>S0$KIJ
MW;>&:RB8,,>/"5V@8!6O<^Q[W]2X]O^*,[W;1&X'3SXVO-^6D<;;6:AS=^=&
MFD50R.4[#+,0#P=@.#3@`%^@`P=P191\#N=P`-4P"]Z@L$@@.CZK`:%P#-+P
M!<VP!'L@.JL<L\<P1\40"BK@1BTY4=)0!ADP`"H0J!=<#1S@RWG7M-0\`#S@
M"VS]OQR0"3JPI75TM"KPU$@0I[G%OP-P#$A0MI+:"W#`!P-0V)?Z#!J,M@[0
M`-OPMB/5`.ALM^GI9WP&2A)7>CFEGO,\/O"Y2OA<GT.ES_-YN,\8T#;3JPW9
M>Y`;T]J$F,=:K`<ZK.E7820-T=6*QB+MQ5?\T:AK5U[,NM8ZQ1?MT=\:T=@=
MT<B=CKX&Q<?_FJ[&6IB6.TTPG54+J;N2J4[[9YD!J*]$MG9[S)E^_-Y##8&#
MO%EF8,B<\PTA/#AE4`T9D`4ZP-4:.P1F4`;UT+/#(-:(,'@64`1#4-?,H@,.
MD`EE^KZM_%!KG0$6F+]QZM1(L`Z`6@(M3`-I#0=E4`9,^V9(R[$=[+4<``+K
M2P.-2K4D.P1U.[:9L`0.``<<,`"A4+?8K`#K>P!QJL$.L`T1[`LQ:URBG,XK
M]7`[>-JJ77&MC5,<)SZP!-O)2'OSZ>7/"&E#S)7Z*9E2B#-2.'\'O4WN2KFU
MZZYUB*SJ2F$3RI<CK=S2#<8@;=T;#=U[7M%0!](2G;D3G=R9.\8F_QVB)@W>
M7"=LQM?F3:R8:IZ0OMJ'NTM,-YW'[<2O<??3V_;I/GUD!(A%=5=NS/MD1KU9
M2-`,2QVQ6#!&KJ.Q6,L!9L`LQZ#57#T-#A`*#FZ^T2PZK.RETX";;.W6879'
MQY#?+KO,7GK.')#6>[`$U;`$TF"TN]X/":S7$?Q&$WRT2S#-<);+*3L+0Z`#
M&<"UH2!'9&L&<3J_W>P`-C@$-*``XWQ)HMVS"A<-@9:+>K:>/GCEY%-*K7I3
ML2V5^T/;_IRKN4W'Q`2O\9?$`"JL[2K<EINAKN:AFGNM9MRZ&QK=9!CHZBB7
MR-V&UQW=UNVZ&'^ZKVO&N2;>P?V.M-N/;O_L\/`*EL1'T)AN1#G]NT/Z=GPL
MWXY(WP(5FD6:1<.0W^7;!QP`#>D[##0P!*OC.N;+O98\#`O%R5_0!Z#<PCH@
M#=.@G+>9";Q>!,]PRVI=OQU.IVM=#2J0`?5@S:Z3`5CP1KBI`-3^9MQ;U<U`
M#7+DM!QN1RC(['(T225@!@HP#31`L<]0!FQ+MN#,G9J=WW!@`9&=S>3<"T\N
MMJ5GPWDF4WW&GDIYY3SLM\*(:`4_:;T4::I?V^A4TS4-HY,>^]3DW6OLYF=)
MK&@8K<:M\E8,H28?Z,!_\G\>Z-T*87\N_!P]Z,I_Q1C?W,TOHK16^[+[Z#`_
MD-44K)9.Z2N7WNK_Y+OZ&KPZ9EFB#NK%._Y95#F@%9)%7]3YO0?2VPQEH%FN
MOBQT%++<:_6L=0RA0+YI#1"A0.PI9F'6MF.S^'`X5F2/`S/'II68=BR4BB+3
M-%+4.,T"DF9E#APP`^U`P0/-:$PK]LQ!&78E>CG@8,%"J`PE2A0;D.';,Z#/
MICU30*-$T%[%EF"9AJ@9!VEF',`I`:>:F:%!2TB%TXO'@&8'>#SKU:N!2@N]
MHCU;NY9MKVUDX?J*2]?775_:\.[EV]?OWE^^X`0.+)CO(E^+&OA:O`B.8\B/
M?S6@W&"R9<J7*V]N((&RY\J\.H^N[-DS+]&H&Z1FO7HU:MBQ9?.B!KLV_VW;
MJ*D!X\6;=^W;MH'CQET;&#5ANY4#$\:<N3#HSIL#DP[=NO7JU[5C;]Y=^O?N
MN83E(@:LO'?TX-.O!U\]._?UUYU3G]Z=_73ZQ_73'CZ</W$`=<M-P.(&G$VU
MV%Q+[;4$12.-,],XZR>.892I\$)E+-00PR*&*4*9#I4IIL(11:RPPV(^+"+%
M(E9LL44667PQ1AA??'$8,YK!0H%J:'BQ#QJRP6)(GX[Y!@2HBM!)R6*V&<(!
M%10`X:2=!G`@`P6PV*.$(IX!(2**=L+)`HXF,O.8)4#XYIAB2E!@@&(\TL&<
M3**\RH*AD"RF&*?,L*`8#JH98D<5]AA*`0<&+?]JH@Q"L>"9(2)"HAHDJJI&
M@R&Q^,(F,T#HJA<X%#"C%[*F@>,I"^**BZQM2&WUF;]\82:O6&NU=2\X#$ML
MUP;@Z'6R7R);!%C,,",V6,H4XVQ9!9==,,'0#I1V6@&#B^VVX*CI#S7JNO7V
MV_SJ:\^[^=R++KYRP?5V.W;;M8X8=^/E[CWMS%UW7/3LN^_>[YSK;3=U?>OM
M6MW\(PY;`JVEEMIFH5V0L@5!HZR?;S+4<$.+*[2P&!$W!M%#"S\$>9@14S39
M191K=%%&&E-N<18SS#@`$0^YY#-FG+]1\H!-E-2)S!*.V<:,);Z899@P$?FB
MC"^VB9.BF3,*$XD#,NK_R$RHJ^X(":PT^DB'HA'9Z)D#D)BFEVE&THGK+\QH
MFRRRW6[[@*'*/AN)64@U0^QG8O[B;[.?0<0,7X#J!0E&#(?+#"3*(C6:N.!B
M-59FGJG\5LS]*@RO88U%+#++'I/,V&.+978TB9T-C<%G%5SX==BK/3@W@<?M
M]SG;O2-F]_)Z-^]WWX,W3QAXBR?^>'F35S[YWMT%_OGBH9>^=]YY_\[W<H7_
MG3UO"9S=/X1G#S#V`QM&\#-F39O00HTUSG"8]C/L4$42ZS=Q90]I/!EE&55N
MV<85P8]D7"+@,>!GP)H5H2%+LD`1&E@""PC09Q3ID#2DH22/!`U/86*)1(ZR
M_Q&L%<.#&EG1-'C@-7:PHQ@\H`C:=-*+;R2%(T$K2)N`\HV?%>0HSZ`(4&3B
M0U+Q\&<])$L)M/&,(P;QB&1)RS/BLA:U.!$NO<A<%3.W.<+<172."9;HNH@8
M8Q6K=)HY76G0)S'0G*]UK"%?^+(EFVV]L4``RT\=;5>N?75+>'M<7A_]^$=`
M^G&/P_O6>=+EGF^)RX[BFJ/WW"B[\9%/-JQ[#267E3J*90QC\7L?QSPVOY!Y
MC&0D\]^,3.DR_JD,@#8BH))<J1,"+@F6$(2@`V&)09U@;2([T24'R]1+$%ZM
M(R>\&@S/II$8'A.&:(,AW,H"MZ!$4YK0=.8T"W?$)?\NT2ULX:83X?8J*X;S
M5IN[BV(2([K0068QZ1QC9<@(H<VD\71JE.3"'@G)VC420+7C7K_VI1WC#3)X
MXR&H>`Q:4((&4J'M.JAXV-50A$*4/-,SS^Z05Z]S=>M<]?EG=P;VFT8&QS?6
M0ECXZNFZUL7S0959'R<QMB&1T<]$(`(1BE[4$)/]3Z>I1.4J7_E3+@%5)VTB
MJBQG>52@;<27P`3F#)5I0HTP\VI"$0HSDPG-9P;1<-24IE:Y^E5L`N6(=&'5
M%*78JFVLI2[B9*LOLHA%M][EBX\!XZXNHYAVOI-8*I68@U;G5X@]JYX$$]_W
M^B-'XR"'%^3"(WWP0RYTZ:O_.=&C+'3@Y4>(6B>S\I)H1*]S4.T<U'B!;%[S
MG'-90V;TG^D25VN7\U%'_N<XD#308-6XF8=!;#2BR22&,/32#'F29!\+)<<X
MQM,6L4F5_RME3P'82NC&4I9[:A,MDTI"GV&PJ$W597>%^8UI@%<CQ(SJ4Y>9
MS"`^<ZOJ72]6MXJ4KP9EB6(]HEK+^DU8;<,N;;UB7/M"3L;T*C+`PHME.M=.
MSNQUI;IE5H,"6TDV2LND"8MM;DI*H.;L1ER^8VR'-5I'R5I6>@LE\6<7NEGB
M#>\Z`5WQ\78'O>V<YSZ/Q=?MOK4<Y"BG0'#T'H5[_#H(!UE:KF$IA2YVL=_Z
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M&2+*D"("2@4$+V%)T`[P!0_N80A(8-(TOJ`!$%2#`T)Y,_]WBPE>M(VWF.9%
MKY[?6TT_4S.]TZ2X6`5=.%=QTZQ4K(M^&6VKP@!8KG?!#%X;LT5?3:9S!PYC
M&>&)1O1-&\*2#/6H8QM'92='/^G)W7,VRBZ?EYBSFLU%T4-;=*0G'>G)4[J)
M;RWT/H:+7CW'':KU@^/9`F>DWQN8MBJL,"!_^K8/.\V$?KLA]V&H9,3UY'%-
MU#(IUZC<</?IBF9Q%6\4<%*(,&`90/`,)1WC"\U8`B)T(/`]'<,,E#I&"?9`
MJ39-@P/KH`'70K&-@F=>F,:$ZE/Q7&>T454C6.7SPP$]\?@*&HG0U(:J)-=-
MR,UET1^/%5RS2/++='&N*L]]I<?_^$Z57I+3D_RT^23LXV:;^C>EWO&I6^MA
MJ6]4/(@,K6<=>N*(@K;6UO<L][?365S?>OM/C[6Y-MH>?SHV.EC?C84'!LGV
M+UM\."]?\2/LX&HC^7W['ZZ3M_TQ)_,_$!DWYYH[*ONI80B4G'`E'%&)83B&
M#&@&OBN&NRN#/CB&/DB)DU"\9G"`63B&/9@2!<J1?B"9@O"NCE@J85I!J:*S
M.ULF9:JF&+HJAT.]/XNX:%H5K2J<MW`BN^@F_<HOVL,<D6L`<UJ,7_`5QTBG
MQ\@,O#(Y!4LPU,DTW8*-:&,=VXHDV@H8=4$UGFNMTQHQYI`QU6J7T:J^6LN%
M9%!#-ES#_Z1#J#4D!C7D/H=BL>(ACSDT*#L4ACAD0Z1;0S=<.H2"NB^TEQ0K
M#QM;M47REPOS,2W,PME`*=A8GTU"LB4#F1#)1)`I&9Z:,N3:'RM+-U?ZADSX
M`@=`@@4:AB5HA@PHAB,Q"0LR@VR8A38I@F]XB6-0O#=IQ3VH!R00H0'`@NH2
MH:<QDQ1$P15<.#J3JCL3O:&8N#XCBQAZ.-3#P6GJ,[,"0E*AB\A!*[(:PO^*
M*[@2Q\$P,,F@JTDSL-ZS-)=+']*P/RR$1.93F-I(-M[PG8$QAMX`0QJ+ONG9
M(]0"MEV;K%ECJ*(+Q#4<#Z,SJ&3@0SPDAF2`2(F,R#AT,8OL0_^(;,@]E$..
MQ$,VY$.'O#XZ'$3FL<CBJ1[KX3!__+"5=(YM`1"$6;;D@\0U6HT#J)BTX[_@
M&BZ>-*Z>#*65.:5./,!R<Z5C0`('^(8,H`&D:9$AR(!,V`,SP((,*`-O\(8O
M4)-7*HH'-`,%V`,%*(,CH0<V:93(ZP>>X2!A4D&T.2&W+"_S&CW0:[AHC$:(
M>Z_2^[.*NR^@<(O8XT9?>+UO]#AP'#F^@"O%`!UU<JMUT@QD><R6.QT)<)#4
M$;+[H[D#(:F"^8_>Z![?Z,(/6ZT6BXZ!RC7L2T,\!,F&7#JE:TW79,W7C$W9
M_,.BD\.03,VG(\1W"9A?DX_'XCECXPW_F,2Y>@2IPIJPDUJ0EJI$3=)$F7+.
MMS,END.NYGHN)4G`)0B$K-P#NZN&`^``,Q@`':"!5L1*/@`\+B%%IE2\3"@!
M)/#%4VP(%0B%@O@&+&@&.%'+8]3/9)PSSVO!S\LS^(HX&ZS&O8RFLD"K*3HT
MV2N<V%,T6"E,O'`TPY2K+4I"+FI,+NH<,8K,,J*V!K._>BHI4L,->WR_>AP8
M1`07R*(Q%\4=>`$>$>O-A31-I^L^>7%#A#2HV>Q1U'1-ZTLZV]31\9!#HPN_
MD62Z[D-)WM$UZO/"JALV?]E,`[F-_9A)L(,=242-3#JRG_R_+_W2FCJ9<*LR
MN2,WZW0($!B`_R^@@;!X0"10$S,(!2Q`A`.HACV0A@.`!E3DDF?@`WS3Q3T8
MAC)0`%]4(`Y0``QZ!K,T1D=5RX13.&7T/-&#KZQ@+VK$R],[T&CRRZ"('/MR
M%5<93`FMO0F-M"TZ.0XEH\<TN7;4-,%J#9ITMMF@O\Y<T="44O7KN1C;GE^[
MOC/$T8<RS882C]6T3=A$.CD,Q(-L0S;<R(=L0Y,\GM9TPR$]2&&-E_%SM=0J
M)`XKMBB%+#M*K)$23IALOA][Q+!3D`,PLDK\D!*!SA")U^!2$?Z93@/L*0+R
M!C-8AP'X5P<8``,R@_:<A748`@H$`23PAB,)A:OL@S)HAI[11<"[Q?]F^$4.
M-`-OD(8^,$O^1,;.D]2X]#R9N%3W"B\#E3C3X]2@\-1H>#VT`B<AG+W"I%#_
M$@Q)FPS&@(S<6]5*<\<(69TT&CNQ`[5TY3'Z,X[.]$=^1+]=[=7>!"@9'5;P
MH[5E;=:/?,W5?,/5!$D?Q<V$Q$TC559CQ5:&%$F&(DE:D]JHK1[JZ-9"S)<P
M1$2=R[&LDYV7!+LLU5)ZZJW]ZYCA`M,`_)AMLU<I\Y"AI$[%34\%R`#XZ8/!
MVX0^X`"$+0(%T($^F`8'^`)O.(8#`(%0^()`T8'`,T4<*H;/K1J*"!0VI0'$
M,\9>*+@5)*\X`U#0DXEIM,L^RPH$U53?Y53_0^,F!GV55VF+N^BX4KW94S5"
MYD55GFU,(W3,)WQ5>(J6F8O5-G+$4BNUR=I'EFRL<&DU]5.H[5O;:+7-\=A:
M(/U:V42&HG-?]HU-9J5-U2Q2W+31D41;0%*/<&4M;]&PQ?J7VGHCY'1$ODV0
M=M4D#IDI>;6?#ZFI`9P1Y<)7Z3Q`&YF%`4#%%OD&#D""86B;7-R;%-&!`SB&
M"-J$4!B"4"AA"D("&L"A$OA@?CLS,U"!(5`!'8!A8W0J.`O9MQS9T.N(91I0
MH-`SW<W4U-O+58&]EKTO5;$+F@5'FST68=G9<F2,GEU'X)LG+K9">H(=49L_
M?5+:>Q%-?($/)-5?_ZH5R?*5-86$#HVLS=94R/B=XX>*3?C-XZ;S0ZZM3<O:
M5C6N/C2\4="B%XQZ4I>\N@S;.FRQTO@CK+U=F(;QVPT97,']I/PAI50*Q<3E
MY%62)<0M(%=B)0C:$R[Y$Q;Q(!Q*MUU*MS"!-P7BX6#Z6)$%T&7$L[M$8M^U
MQFE2%6\*7BA2T(Z#E;7`!EB9E;9*0F6VE<])C)(3L$E##)5C7I_E4&61S-UJ
M&"QDD'B,G0LC8-VHG>]=1#,VL>61J->DX_%C3?LEGH6LX]ET7_AM33V>8V08
M#TU(Y_55YX*:8QZ533<^4B1-'EY%OT76,.8`&*NS#9DTF,(ZX-AHUPO)2?]X
M/1&+7K(101$"],3IM!%/%D7H`FDMJT4R>:!9,K.EJBY?4LM<TKQBX@%;'ME*
MM<N[]*J47=F];(L@0K3A;=!9F94(I;UEMEEC.:?`R%#`:+G2*:/)J$S<<C!Y
M1#Z"D:-<E3K3\L=!6IXF-=]^ILB)'%L[1L/X9;HZ_CZU[>=`?N?/ZE$^A$BT
MKM'<E)?2$D/&>I[@S*@`^68#'JPNO3;`=;N?#-S\@3*7\<1.=B[K#&FC>J62
M'BI8VF$RT[PR"9.5-K@X@ZH6G$$8C,&:WE3/YF5I<CU#>Q56Z4&@",+"V0MD
M_K@D--5UPF+H30PR,KF5BT(I=,<JO-[!JCEG\X__;O%>Z&/:N9W:/OK1I@M;
MM%9G>%[N-V1G=&;N?P;HV%1NL^7G&AWD/A*H.^*7?J0.KHND1K2M!#Z[$V'@
MBV8[#X$?_=FIQ+7@3\ZR5[HE`M*AG=`)&$9IRFYIK-%O$'IL%11BF(Y+`-7L
M9PRTNNQ=O01M:=+ILXJ<TXXB1>,+)/JX7*G0VX-MW3,G9QX,V3:P#K5MS8B8
M!Y$G61U1'AN?ER20%7U1<5V/N8Y:$GON]8WN&8?N]GU?',\%/9YGYU;NM]YG
M'Z7N/8[NLQ8DNDZ_%N??WMY,KZ-'VZ)D#;%D4;)D$TR1_/%HH:1@H7PNZ'I`
M!5J@)6D(:3#A)1$AK&F(_Q!B$U,V$PMH/#-_;#7/Q3-GD\:[FA-B1IT0"AUV
M(9OH\V>$H#\Y"JWR"/B"(#.YQASTB@6]+[5R'+1)[;)(B[1`9D>W@+THBTN_
M],"H<&;XZ0GM=%`_IP9`YEFYYF(I)P(CHV[X!<)XL"UF=59W'<N(C5](D,FD
M==2H=0'!PFRQ%N]V#@F0#F,PAM,B=OH(=N@P!@E8=F9?+/*0@&$?]LN*=F.`
M%^-F7R&W<?:M9VY/.A['=FT/<K46/_PUZSH<'M.*+"1G2?C;IZYCZ"R4Z$YB
M8'KO-K9#D2L/(,3EZ.I$[!=I)<7#B0$XB<!;MPS(8#;9"3M5Y<+SF:/LB5`P
M@_]<*H8](,^(SZ7P^H(!"(4.;C,SX(`!H`%$(),`IS/WK)38-0-J2!J0_]<,
MGH@#H($!X(`#"#VT,0,:@*82.`"![P?>%1PSB*9IZ`<.:`"U>%G7DZ)GT($,
M6$I?>%FB=_D!H`99"<_Y7(+%8(P!(!R2HX$#T(L#6((*OPL94(%&.8"NEWH9
M2`QFJ.$,X`"J5T<C](46*`/,X(7*N[2R'X(!Z(?<DP&L?S"B#P7Q;(U^H(';
MZ(<O>`U@6`(S@`T)8`06:/HE$*DE>,HG<#_4</S.G(Y^Z/ORX(46:`%B%_T6
M6"SFH`$9X`5C>()0(/R-5P$6R`5CD(&-?_T!N`-X>8+_`5"!`2!];>WG;`?H
MM5[N;M=QZ"ZHX_]VY&]^X6=C'P7$<1=H8O4^N28D^\@=+P1#ZN#M"JNG+N5)
M^@%L)YMWC=;DQ-N?E*'@CV8E!?H"?RV#T$6:8T`$!PA+%8`&?+.`J``(!]N*
ME-A3S<RQ$L?,5!M29D"98M-*3,O@X&&S`1-+/%/@()2#9E^*4<0"(I0"$&4L
M3)O&8UHOF-..#>!@@>,0,\5Z+6RF(A10)`HY-,LP9)V*;;V>61A0;\_2:66:
MA2JCX@O'9\]*?%&@5:L%'<VH]>JU[=G2:,_4\BACC@.'#'">\1";0<5/LKT&
M^!SBTQ=@+`H`]SK0[$!9#@X`___R150%C0Q?F/GB54T!7A4Z?#%CJ(*#`B2^
M&C3XU6#1+V8TL)3^10W$`=._9*P+12-EB]',!B@@S8M7:;L9+B.10+H%"$;`
MD?>3P(N:`QJ_>$DXH`$$AP$'G?/2SN+S;VK/?S]70$,",&'`@/&2T:P%+V`2
M!F2(+R'#`/3"<M4[;^S)72"8DP%^N<PW(($J().>`GRHH$`U-!"3RW["6&AA
M+AEJN)^&'7KXX8?[W9'+B"."""(R&::8RXHKGOCBARVJ.".+&J[(888XPK@C
MASU2>"&&%0(Y))%#$@-D>NHIF61Z33:IWGH6IL>+,.*--YYX5EZY)7E=>OGE
M`7$H,__,F$4H4PR9Q9Q)9A'#J%E,$7&FV6:;Q<`9YYU%Y'DGGWC&^2>@@<99
M0A'';-*,&=[T,0Q!<6:`Q3=]'#,5(F@:I@*A>SAPP#%%(%(-!\=X<TQ+)11#
M@P9[>..-84A(](T".O3Q#4H333,$!WU,(Y89%L3TZT2P*C#1+-F4<0Q3!SP%
M9PG?]')J,ULA`8)&O92@&%HE&*9#"2Q]]95?!TP#EEB(]!*-6<\HI5590PP@
MS32^;./+KLTTX&LO@#6U6&'K],-,+U]DPX@OO:#4@"\6W(8P,U^(Y*LOBR#<
M@`-?6`"8;J%@`?!II4EL6@/,E#'$(KZXID%LOTR[!#/,-##_Q!"D,0,::;[]
MH@,(O*@,,VG5.<"(!+\85E]Y2TS'B`:A_?)+/\KQTD\S-#"#'GE6B@?,$$N@
MUV1[U<`'C#$9--,/+P%4DT&3=SBP!)7$&$,."PH88\R1\\D]]Y%'*I`?,4LT
M\X0Q%^XX.(@5UIBBBQF62"+CB\M8(^20/RXCXH=+3N/CD5<NH^&$AYCCB4!2
M.+KA19I^X9.I+PGEZNLU2<V45V897GSC`:,EEKE_^5L_WRCSNYJ,*D/G\&,&
M;Z:9P=N)YI]]-O^\GGY&;Z>@@!):PC`T.$!HHX4>FJBITX"@@S?2'.!`)DL,
MH^D!A9;!QS8D;421>=Z48.H0-"34_U$9??11A@.V,@TLT,!^)8"9!5XBDUY8
M8!;5@`8CCF&84)2`@6;@`QQ84I9G'(,&S8##3'2PC@9\PP(<``%42H"29XSK
M6RP\@`+PDY6P-,-<YUJ+NLS2KE#PH"R^0$NY>J$-C.UE,1<#@1GR18VH]8)B
M9<A7+VX#!\#`C#&`*1DO0#`9*^ZF-Y0I#6E,@QIF+&$(&./%IAKSA6I0(XQF
M2,XB=L.:Z?SF9@YHXR]:\!Z)64<Y#>A'-2+D&@48K0$.:P$=NX2$>`P@D5;3
M4M;TLYZN?0T8"FC&'&;3#`4HB1%K,T:2[$8,8J1'E*/,D3#VAAYB*$`!1P*=
MCD#GN<$AP_]$BJMEXW)IHLEAKI>7<U'B>'FY7E8N<K,L'"Q)5[K3,7.9JGOF
MDJ+D.B7!;G:S"X_5XI/-W7&3/&$:4YG6="9QMFF<R6,3G::GISU!SWEY$A3W
MKM<]!82")`2YWS`8,@M[E@`+`SB&!!5P/D24P`$(*8(*AD`06TUD&P<AU32\
M$9ENP8H&SS@`=EAR*P[`RQM+<("U%CB1?C@`"[DJ@T=`J*VBW(6@S_*@2@US
M@)M@:QK;X,,`+.!"L'!`!6;@%U."J)2SH(6H/'!8!I#@0QH.`3]$/"$CJ,$;
MA!5,8X49F\FBJ("2-0`$2\@7QB;F@!AFP`RC\<4!+F.&+_[B8S+_>\+9"#2$
M:O0C-2QP@,Y(`QTSV%4!Q@&.SG!&C:`AH1I?6%H+?D8=C'X!!"V0`"&#=E?<
MC4<"'E1!<VCGNO5@06M+$H<,O`9*9*1$!>2@`0@<$(`CJ<VS^[$;,%XI`1:<
MS5T42D8J\V.@N]HR=+(\9H?N4,O>>BA%PB41+H^KW&+JLKF+6RYRHPM=%W4N
MN'>X+G`]U+GJ[B@9N?`NZ929-\$1"9KF;1V4-JM>U]F.LMW\4N_`>;SA"<],
M;C*>.<L4O?T>`T[LE)X[`<6L>S;J>M]PP#\);`%I,.09_'17H<[WC2]D8!:;
M&D8_52`1BE#$`@Y%2$LF-01;8:&DS>``_UU*P`,"PDL:`*0+L)[UA2%\`0O;
MR(D#A**M=="@#$N8!4<Z^,&)R+1;)]Q#">!PXJQ\I2R(@(TOM`B3H]9P*4/5
MX;I\8085(#AD`3LQ#3:C+PYD8ZZ;&B)GS)`-:H3"C(19V&C&EZ_&H";.D*'!
M`9A1YP,,X"/4&`T832.RZ-"`!B>,S<PT4#/7.$`&J9EJ`WX3G.0X1QC5R&0#
M^N@<Y"#CH_T@Y-(&H(%R_(8#374:+^:0`1#0P$J39(\PLA8?KH46/NT!P1,<
MT`\5?/0)Z$'&VB3P([L)XTC"F`\(6,"")8PN%ZK<K0,2MZ%FQU+:V3VF<*\[
MW.2R:$2X_+:WP_^MN&P/-]OF'JYOK_TY'_GH11-Z=RXF=#I2*JE(H[PWOO'M
M)">Q3II0JAU[V*.[Y^!NF[L+$YG"B:9Q+IQXY6SX?OOD)NE%',`"_I,\,^ZH
M#&"<),-HE33N5X3H#&,A`2R"/S<%4-[<KU03><;X0CZ-8@S@G_0K@Z8XZI*-
MPHL=*L!"2T1Z#`Z$`@[1&<(SL&`Q"UR0@Q(IB\*&S/1L(&(BBJ'7,S1`P6\M
M)2PYGL7/NQY$M11576AY!L"N^E4:W@NL!>LS')90#210!C`-T(`.%"`#L&HU
M9!3C@-M]`0?3-!IBI(%#R7K1CVQ(S6-@).,06N8RE#5F"3D+X[3J^@O_T``G
MTH$%@7B8AJA?^$PYU:E'71\$ZE]87AB_:8'8E".>TCSA/>11;V2=)(%:&X,7
M=[7D=W)QE\#E(M@7@JUL>2,!"1!_0GLS1B["IH`7M7L_P/2EC!:GH>?F\D3B
MKB7XI6O<\4NWV\:-+KC-'Z,9,5=QT;5<,6^4S/!V=]WB+?;IUKM>>O-[WZV+
M[7I5#9<((.U05GSA5WW5%P*J"?$P2L45RCOMUP,ZC_1HW/5X@PY4PQY(0Z'T
M5S$X%`=X0S%X`Q)`@QF4W/GLP3%\RF$4RA=``Q+8CP7(SP&I@#?H"1QHD?PH
M0/_(%#M01/Z4#R)$C0;)Q#18P&=X`U%P0#%D_P`3:DLU;,--4`13>)`4ED`&
M>`53*`94F!`(S().M01:\$`H\$$K.4`UF`L-(4(/E<6ZF(52E$598`8#B059
MM`QA]!E@T)/;]8+EW1$1P1DS6$3(<$;$5(86]4+=M94A,L,0J(#)A%%I0%[-
M0$?*F,%A3`TSW!5P.,96F89QW$S._`(YG)#K-4`+:`#0H"((]$,#>-+?D)Y[
M/,%TJ$8S($&72,!KE($NOEI\9(TX_`8H41(OA$THS-8Z#`#<#$&Q`1L-0)^%
MB-+Q\8;;G%(N`-_RZ=$`0%^&`(/G9`[E,$[X!5?Z69N*9%NW(=>Y@9^VL:-P
M;1NYE8BYI2-QM1\NG?]C.IJC,:F;=TU(AS03,^6;0(Y2ZO1?>C4),0!<[5Q3
M-EW3`';)-Y&)\"S<F[!)`I(3GW1*ISS/?P68!`Y*@87D,5A8*,S"'AP`BA6#
M-/#*-R!!)BC`-Q3*3R'9,3@,IQ3!'BA`)B#!'B`!!V10,:35%VS#+(1"-8!A
MLQ!2R*T02PQ!*,B#=2B`%,88#R3=%YC/84@#:#`%0QP`$GSE7$"+5_*%&7!$
M4Z"0M6Q"0R`!')@!#6S#-#S9`6P#'#R9#/``#7GE5S:`E?F"6A3&`30`)CY1
M+_#*5[KBVX$`7QX`'^098#P#U`P`6/U"WW'&`62#"B`!-7S!`-@=JR'!`?3_
M@VCX0C^8`36D%<M(C,3(3!F%D24NS<L,03]0@PQ``PN8!CF(V@'LY@$$EM<<
M@`<=%G"<C^FE%=EHDM'\1@:LPQP@00#$WF_(0`LP0NU]#>QLEC_U0PML)WO4
M&I68AS@<@#DL`3GDVH(4WQ($SFOQ1FRMIP-LYW9>H[-E@"'(@`)H0`!D"#'(
M0`:T@#>^"#C2R/9QFXU(5SR*'W;%(SLB`SR>F[9=EX)JF_E%Z(*2F^4,Z(/&
M'_RI6[/YX[253GB53MX\DWH=R9/T&XKJ'P`*G)8XI)>XU]/X#O"$D\,M('W9
M5\11ST=*H$=&H`6*I$M60VH-P#?8R;6```B<S2PD_T10*@"2$4HH@%@Q;,)<
M\<%);`-%'`/.5(,9'L"&W<JQ6``B7`0[3$,HI);6@6%+`$L)W%BE-(`*J.`;
M@2%&I1:2'D"WR)T#.$!.Z)2U@`94;`4,<2EV,,42>`5,F%`H'.$76"F2P@9,
MJ(N\]`('$&IG%DRC/FJ.E47<(,Q>#,$4V9T&K)7@%4QK$H8,H"$?1$<DIL2C
MT@!GE$$@@8`*_%G'+%H99``848,"U%5I,`*$"&DHM)'.H):F(L%L".E8:<UO
M2$`+<-)OG`_9`,<`,"N5J$`@K2H'N%ZLS2K;7*>2D-*J/2HS&@-RP,<=*,`<
MH$=_\D)B&<)W>A:%S-80D/_.;#UJ:JV6\"&I`V2`.WBC,!C#')@#"W!CCMBC
M@**(A2IL<E7HA):(PP*7A:(CQ;*C.BYHC&`7QA).B\02B/2C=OT(0%H(*1G;
MA>!;L?&?E!BD_SU)0@9<ES3D0PY<1"I<FI#315*DGS!*?P5*1UI<]?RH/!U#
M2Q[`'ABIJ8SD`2#"H-S/-^S!-W#8'CRIJ93`)BPM#<[<+'AED7)8"Y4*7;8$
M4<)!_"A0C(T+EO;"-\Q"67S#7'S#,\`!',S"W'X%7=(M4WP+77Y+02"!&;#M
M4LBM')I%`VC%-I#&+#3`+!3,6?R0O,!!:9(%FL%!S2`"50$:QO@"(F0NY%YN
M8Y#_!A=EFAD@S")0KCP@`C6D+A@U`!+(0#_8'<C43*2U427*+FD<@`P@JV\T
M`#4P`B-H@N\"EN\J1R+]1E3]!C"@&N_0SM-\00NX'GDP0@NX[G/<SD$F;P#T
M0P`XIWHP0@`HR?=Z8S_\R/=:2(J05RZ4K^$$`/NR;X6T;WYZ"#%@`>`4:'$)
MZ/7AH[DY:.-8+,0^Z(2JHP!7K/@-\/A%Z,4JZ#E6*`/;;S#AK[J!J`3?WY`D
M"?ZUYXDRB;\5I'I5$Y:TZ)?`:'S=;`(BCXTV((]>'/1,(,5A7$AJ7)P<@YO<
MSQ3:2<_>#X>U7`X'R_TLC\MUF)'^<,N5RDOP@!&;K4@!_PM,.`L5BF%4!%T+
M145,L$N3.<O9H474+@5:#.Y2N&$7#RZ[R(L8IUW@96[=92X:IS%@#%ZH7M$A
M`@9EE&[)H+%J-@;L`IKMKJ[L`H=QM(9I=$D>2]I[#3+S-JOG;4FDK0?LK$YZ
MS1K7^%^]U1N]H9+(_LB/G&@W>FR&S$$HQ&^`8M^&6BR#ON,[,K`"AYLI@]^V
MK3*%'FC#(O""(D,`C++_8JR&;J@O`9?H"$DSB6R04`A!J@[J]-L&%QO`N5?J
M8E,A.R3"_<Y$WFS#,0J<6"2/1N`*]VC0OO`+BQQ!S""A3.$]78_7.NTX!UTY
MG[/7KBD4KW/0G6U,B-2X=#$5<__=3FGQ%>^4"^G0%IM=NJC%61!5-#2N&@\T
M01>T&G,5[$K,:(",:@8::32TX^5Q`QC'7TETS0#6EQPR(1<<`6J)P`7<U5`)
M[%")-+'LR!8)M?ERB#;;CK3``T/P/G;(BBQ7A&;H_\9R*Z<R*>LT`X=?Q>8T
M3Q\7*-MO3*\?C'!7,O&RZ:2'B4H)DD33RNY;E*A'EL#LEA@<1/H.`]*H\'`U
M];`3G'2*?U'<SSZ@]6BS!8I<MW1+$8`S#O-PU/+P#J<S1?RPK=1U.QMA$N]U
M3#@+W)Z=/./S/3<980MVDVU0')Y%NHCQO!BT8Q>T'6=N9-OQQ*`&Y2XTXLD&
M&'T,:L#_YJ(MC6?WL>SV,7>01Z1I-"$7H`!N4^K&UD!NUO6FER2W9_[56XCN
M!VYY5S+L-G@ADR;#B/R1XX%VV_X&-7)M#H/*,H/.,G,K=W,_MW([MW1#=W/+
M\N%43BO#LK@I+#I^XU&S=%*/%_KN!\H"2<G*=DFG*`=?+WNP=@A':QRDR7U1
M)#D-#YH4@UA_Y%BG,-!28*`(;8'%$ULO#[.H]3@WRX%G;0[K\%V72LM]0SL7
M,3QSQ+ALA$Q<L1:WLSUOT!?/\V`?-A=S\;K,BT!SAN1A#)KY0HH_=AHWQF1;
MD6F<U2*@QN5V3%LYGF;'KD6?]FCO+D:G]B!SM$/.33'V'MY$_Y.3J*SKG/>\
MX1^16+)^CHZ\@?<_>C>,0*R!AE\MW[2%IL@LWT%^!K5.YR>9IZ^9EWF9:SG\
MO7(!_^\IGQ\`TQ*/A*S'"@-N*5-YV5O>W!O+DBB2*V3NP"AYM$"1AE,).[/R
MJ--8AS597W-__S=:!WBS;,5"?44)A-P]12V"0SB'Q>0W(`(B.)C7?@-=PN5-
MW'6;(L$L1'A+^(HZL\N%PSI@LPM'4`-;4O%<V.T>T',]/P,2,`)1J0OE*FX#
M#)7C-C8>*Z(ALOAHM/'E-CO&O+A"@Y')(-ZBK2[(Y/B.[V[/3/0>`]9I__B+
M,L(IOI=#6DUL\8+;J'OOP?9Y21.3,__32F-(;A\3NWF(]K%?.BXPA#KL3S/P
M<[>O*L_R=!<\=2^WP2>\+,,O_(+YEU=H/(J;FSLL@1;H]9TO_67\P58(;@W)
M;=O;>I#2-`VS5".Y!K,7"%\U[30S\XA31?X.GKA)?ON)?U%@6?OW60,X]OS4
M/IF/!J!/!G#*_4P*$C3*$C!MEB*!JVK`2'#8"8%`/235AGT@2"!I*`A0JR,!
M#;CZ$;HE2R19:%10"YV=!<`0O^)I+\"!0(E]=FP0"R$"BC49(@P!DO9&+_#`
M^>SISR.&63ANVJ_:GH9"(0X1,R!!*&1N+\@`X-F=0`$&-0S!G_F""F1`R;QX
MM$_,`.19'%G_1>5SMN,UC%EM.[=+-"!W4Q[MZ5C10$=S"4,*8T+233$2I%-/
M4F+U`R@)@_8"H+&9['B;SNCT=I5_#I5O7RYECG"+^8%2;`"`^1T$`S(X/\&'
M>4[G])E7/YI7/_@YO_8[=W,3,%!3J`"_WRTE+#)5N3!<'WGC^7C[LFNG++W5
MFTEOL"^R:*#+CC?Y3IUP=?(4#_,`Q+`BQ086-%@$(4*""A,N7)@08L(21296
MI'BQQ+`OS685\_:EWH%^'*HAH5ABR(!C16:%O#@K$P=$B,JL^U*LA(4,0Y"8
MP:+@6XD2<+!@.8#H@(YGTZ;UFF9A0#-$%IH>,],,B5`XU0X4Z?7L_^O7$@>J
M<=B$%`Y3.-#,6'A6(M20:<_`EN"`=>[2`9F0]-RVU$PV,P<(-_CZ[.^V7HM`
MA*)FIEJ97KXH]]*!=;*O7AN_3$;$E9DO:B"F+JG6CS+E7Y07^5K4P!=L7T,4
M4--,0X&O7PT:[.[-^Q<O!Z&Z\39N7$(#7L>!_W*^?+GSY[RH5_\EH]D7&4L<
ML.!%S;J$X-]Y21`OGCHU8N7-2R`&##Y[7L"$T9]S!SZP(3+(T1=&3`)C!"3F
M/V($'#`78PC,11@%<TE&F%PDG'#"""F4T,(+)T3F#F1R\=###S^\8\1<2.P0
M10Y--)'#%CL,($5D`@A`1@I;S"4`$4'\D/_&'H,)X$<9A12R1R)KW'''"8N$
MD<D48721Q1,Y3)'**4LD4<40M<202PTU%`:9",5D4)@R&3RSS#35+-._,@GT
MC[XXZ\N/S3GG?`^8ZL!+C[P]J^LGCF&4*4(@98H1U%!!#QUTF&**6:FA@QR*
ME"%)(XK(HDPQTH@CC[[(I`AOAG&@C&-*^,8!H(XYH!D=CIFF&`X4&,@C#ASX
MQH(B,AC`FSZNVL:"8^Y"1)H2'&7**0O@<*`:':1IJA@SUG$`#@OV`*&?$O(*
M:QHL,A!JFA+HFF:K`Z2Q0)H!,F@*K&T4J(8&<>D:0@53Y^J%!S/XZ$4:=IKZ
M*YIG`NYE60[.58#_!@LH8Z8!+!QX0F'-9*@&VUX0`>&`T!!QH(%^6LUL-=W@
MV&WD!A;Y!8X,UAF`F5YH&$*UUWZ1N;6)^4#"-^:,6RZY7_JA084!^E%N.1E"
M&<",ZI2^KAIAG,.N!0FHZV<`%5CHISH9G@!Z"4:H,X87HT-Y`AABWFNA:K*-
M^?F+^GB9HYX,KGZO'Q:"EL%L^IYH@890`A#F";S+7*(%8B0TW,LO;4Q\PCM2
M%+'*R%5$,4H7H72\0V0\I'%('75<4L8@>_1Q1B!I#-)S$#4?T7+)7<_R]<=1
M[%#$VD6T$$D=Q0S12S'71)/,-867DTXYYRQ>F/F4WQ.\YI7V\X!OBE&F_U'J
MBV!T4.NI/[0@@KP_R*"'Q*_T4HDP.K^BC#;J2)HO-"BFCVD<<)4E!]9!H@\.
MUN'@)"PX>+4$5JD&'(JADU!8H!=[><LT%#"`8C#E&`5$5C&6,`2@464:QY"!
M`E1P0#A@S"M@&==6ON`6NH"%7&4QPQ=\HH)OT*4$7U!`&:@%P\N8X1D\`$LO
MR*(#[<#A*P&C2S0FXX`,'(`#&4!$:#1C!@5\`0MP",UF%"`K.#0`8Z$1#C6P
MH`(FIF8UBX##R<8(!]<,@07[L0`-L-`:X+RQ-2I0`1:>$!O>)"<Y.NM-&1HX
M!&SQIA^-"9K4E,8+IB&!.HR(3'"0H(`,R,H!6/^30`:J<3009(`Z$IC8`%@`
M`N_PHA_5&,+1@+&V(3@@%_!9`A]2T@(!/4$!H<A`,^;`"P(I@`]R0X8Q!J``
M`;6@&87+!>(8=Z$M76E%&VK=E%H7I<K=848R>IWF9%2Z&Y4.FZ7[439'9SK3
MA6YTU>1F-HF$H]@MJ72.F]PZI32[$DGHF)[+4.+`5,]<:`)-8_*=\/B9)N/5
M*3]PLE-`@=$\:N1)3\ZKS@$"Q:CK+2I1B7(4K2)8J?%9RJ+E*Y^F.,JI61SC
M(PX83"A(4P2K='``WT"8`O90!)72P%[%(`LB"!(*43I``P<HX#-(]2PX^#`K
M^&+@%V:A@`:4H!=%<.+_LI22AFSEI2Y(,,<!Y'48<M5#`T7!0CU4P*YI6/`9
M(#"#O)Y!$J-\)5_-4``6AH"(PP1L8'!0P'#6VH_,]$*.6#S`9*C8@)1\,&.^
M0$0#F\&!R:PF9*R!36_<.(0RF`$$#:C@8F?&6-B$DFI&S1ET&I#'XQBR`4@`
MP1.<`UDDL()HA62:UWC!"!`LX1?B4$$&Q/$+UPX@.+-]6C/,X!XLL(`<Y%A"
M,_HA#F#.@1S&B$\+%!`F8#!"`_PA4)D4=(<A9$"YN=``=HV1H(E%305#($8R
M)$3>8FX(GK9[W(9B1,W++1-%/8)F[!P7#&38EW.GN^]^\8O-'VUSG-'DIGT)
M_\Q?_L;HG/-M$N=B!]\D\<YVBZL0@R!\H7VF"7C]7-,_V40\^-1G3LI[C_+Z
MY*?Y[*D%WV#4]`I%J.P5JE$"J12D'A(^2ME8H^;+E%!XK+Y.M:\:"G#D)G!R
MC`$,X`!&P<+&-O&J*@XC7`*<A05*,$<:K&,)W@@73Y?P+$1D(!NA>*`%D%"-
M!O3!L<7HA08S,0VR',`!5!7A5Z:!B'6TY80HW(H9[B7+N91`M)OH0]#("NA9
M[I4'9&G`,WS1KEXHABZA`0$'$#B`:BRQ%V7NAP6&8%C-N`\.HM5!G$/3`(IQ
M(!O]^*)N7%,RE"W6@GC-P,M^4^O=,(.-S$!"-@ZP&__/'B<YRU$.;MY5!E^K
M@%3"2*UU)H;(UE:#M+Q0@`9FB^Q02"T#*I`:(YK!`I]E0P8!"D`UP@T,2P\@
M%[QH$'/Q8S@%S,$8;LK%$H1LQ++E0@%+B+>;&D@,#3PAWF<ZKS%M1#D2-:Y%
M+CKXZY:$)8;/",#A#'`V\2O.`0/)XA,GIS>M*3D755R=#:;2,UD7<LNEUW;V
MU">&*22\#`</H'4"L?'B].&`JKOF\7&>\QBJJ$)!=%'<\]ZC&.*HBUX4Q^##
M%/K.%T&/>NI6L`*@KFCPC4P\L@@*,(,TBB%+G$S#&V4`P5)T-8!SZ.#2#YQ&
M!K#``QY8@`>CI$K7X47O(5#_1:D*>(:P',"';!UF7&&%*0KO-0NQ(K`(LM26
M70I+;[T_0QMT<8L#$I8O,S?ET8]&3.:7-0`+6(!5>[5,/&B`FTNW3(:&V0AH
M!)L-R2@`9JKQ!1/%6/O&TJ`7U)AK!L;H'-WL9C<XI0$+H,$"AKU1V#M;3BCB
MS(A\DP,Z2[AD(;/6-$,"LP6_T#V26]!]2<Y6:G?H-CE"V8*I9>,+\]'D6I&1
M)^86*!<.D,&^C=%)O,5E00@+N(&>$%UL$7.>B@G">&>]X&EV$NY#<L=(8D1$
M0*>;P&F;(M!T_FL"Y:M%*I`"60<#-Y`"1Z<#C:1(/@='-,<!D<1UVHE%G`F]
M:J?"_S#$3/1)X%9.P]RD;.KC/6[0;'(03V9NH&Y.Y_J$.J*'Q:ZGQ02%"%GL
M4+YG(&0,HY!N4G(,(3A**(K@&<Q@#_*G'J2G?=HL@GA,I;[@'.[B`([!L;QA
M54KB&([A8@9@\3(@%)[%D7`B6EK%`OP%"\1,61Q`!3B``U2@)`)(!C)A&[0%
M"YJA*^:L+BP-":@,$9!@*<I%7.!B7<AENSA@`#@`8]S"C)1%`Q+&S<P,\,`B
M8!2#8!S`\WKA+I"@%QI@K8[,TF2@%S9#`V0C%`Q1BQR`%W@H.YBH`0[`-GJC
MC,(("W"/&:YB"$Z&-PZ`$6XM,%S18:B!-WBA!9`@CX)M.?^0(#M02P.,K3I8
M`3OZ@9"J0Y-*@A>08`B&H!S*8R=J:]DR@+;(82-D0!R$00.60!R$JQD,X</(
M+SM^J;EJ\-_<XS\4`+C(80"&(+LZ40+(A!CZ00.&(^`R9$S.:P"I9';:24IH
MY$7**4=*D`,K4,"JJ9I$!P1'DN,`3`)1TIH\TB31B0+_RTA&D'8Z$D=&4"/9
MZ4:8:>1H1\*.:2(%3G'4Y.749+H*I`;Q)*!FSN8&RFWBXWG2HP4:*@DC*J((
MI2`:I:*\IZ(RBGR>$`J9;B).H@BLK1J^P%2\8=2D!UQ8XGZ\X0`4`.P.4BB*
M@0:J08XN:2F>(@O$K!@0H1F6@"K_+*`,@BPNH&$)V,$"[@(.^F4:&L-8OL`!
MEJ($-N8`3"@LEN(9,H"K5&#2D&H6S&&L>J'*UF4LFF$3J$PGAN`9UD@/%2`3
MJ`%?C/$<A\"N$B,LE@4$YJ@L8W$C%C$6:>/3.(8R&D"D-`8$;,-E2F+VK@+W
M:F^,%@MA5A'7L,!DM`$[6&8WA@`+M($9F,%C=(`9?N$J0B%GHE$Y,J"!_!"3
M?":6A(RU^"1LU,J/L.`]^T'(XB(4,HFD9JL:!D`"2@FR0L&F:(`Z6L"(,@!;
MW$\#AJF4.DD%`(Z73)$S'2``"*03`TY"ZL\<\&9!@/),%##"M*2=$HYR+.>;
M2M!)B"3`_R#0OP1,XR).P$0'1DEG1KFI)34.G8:$)6]R)V_$X*`$Y7QRX"92
M!F<03<KF370P!XFG!VMN/O)$H<`C>AQ*>ZQRQ;:'>PR""2'"*X].H^*@",!4
M"L-R#W2`!LR`(BR@+_E,**BB!&;!"HM@#[K"`C;!#+XA7*;!#$KO3K6%*0B#
M(F2*SYB"S,J``W2@'YC"S<R`!YH"]-@4$7"(*<8"$:#J,)RB"CG@3//L"RH5
M+`CC+7IB#^@BT[X@\I#`4,O`K<`"$;Y`!UY5!U85&QAM&RC##'2@#+Y`%6>O
M'[X@-7PA*1I`UV3`C"CC`)!@.+]`-AH`45,CUG:CU6;F.@[`-?]BPPQZ0_MH
MH!]V@Q?*H`7LJ`&^H-="BP9:X(Z(1CD:@!%H8`"^@&\800(880D&0%NI;VJ>
M8`F60`80ZCLDX&?HU?RH8X[F=0X"RAADX,CV%3Z0X`DXJ07RHU=M$!B0@5TY
M-`#8E7#*U7#FX&''1`+FH+D0)P!1SDN2I.1:IT13E$=;IP,Y[N*,I+],\B5!
MLD5=].)"\B,K3F=I%N*L*4AFLB8[DB-3EIU*;D5.Q':$-)["!'CR:2CS*4W>
MXS\`"GEJC@=S#@C)0QJE4E&487NR)PFMDNBZAVR[E%*0[E(XZB2F<!B&824J
MHAB>9?'"Q:1.)8"8XE'RU%C24.WR-(+_%/58`)<=!K=OZ]`I\)8J1---ZX)=
M1,AQWR)7W.(PJ.*$A&)<H$KR3NCSD.I2W\YSPZ)6MZ%6-0.!>N&+8O%76R8U
M,F-A?*%865<S4H,:,@`U2B8V8D.*P+4U7J,WPM,X2@TX="-XRQ-=ER,T@,\Z
MR.$7PA$^#<DY4LMYQ&,\J&&2,H`<Q,$]G/1Z`Z1L@$$"L'<^V*2[_,D8`B1-
MRM<]E*M,;`G#A,$0+&A\8<YD2Y8G"1"^G(E$:))&/@<$9?0C@U8#MZDD7?)$
M.W!F611G2Q)H$XZ:3O0D$UA'$$SA4%9%*&3D),Q",KA+H+;E9M"#HW9)E?(&
M<TY.GE)*I4=[_PK%:XGP>K:G4<CVA2/";+D2"J5P;:>0QZ@,7.:6A\/%3WM8
M4>?6A_-448M849T"B9$%\Z8!3X_X&[[BB4\(\$)1BO.LBJV8+B)/BR%O\_X"
MBP.FT<+X5\>8C,NXC!%K9,:8A5RC]H#/9$S&C8'/C?4(V/2(LZ@C&NU5CYM7
M3PK)3_9$COXS*6V.H`3JP_CIY8+GY8BA!5@I1P8N:4_6!%=DG9XD<S9R1[%)
MG`88!"LPX\9)@!]0XE1T26JT9T/991U8=&)42#"92*JDF9KI1[ED2WA'@V.P
MY9ZV2&=0:IFTD)72;13J.WHNHJ9G*@=B>[IG)19"(+RT*\FGAL$2A_]O&">*
MP$WU-BBR^8?UEHB#>(@GU8B+^'"5V"D:-1:36#3!XHFG^'%)U9VOF(KS;(NW
M6(040S'@ZC!"=W3-F)_+V(Q0QG7!B-5FAF%6PV2"L61^0V;>B'AU!H\[RZ&+
M=]GV6&N?$@AWCCJ`0226TL.L%L1F;KI@[G=B\'<BI!]:8)@T6*73Z\%.<()Q
MI)MFI$I.IV=!LF4#+)0M;F8I\$9O&D9O^B-5-)1Y6I-K5J>+)'+("05CYW9"
MM*EQN6E=4,-$NI^0M)>/1RF9E$^<)\6H5(5?K(5C3`DG2@F3SIFC><=N.%-T
M>(AY3&][&(BYV8?]-(@;M5')N2GPVD\7J!?_GI@IU-EQ8S'/+C6PL?B*N9B>
MB:A=!*:+PYC1^AFR(3N-4V.Q?A5::P\V%GHWD+&A@>VA?RW8F(.B]9AY++JT
MJZ.4E&N0/]K#8HX^@F=!8%"7RXN8F)9W<B=()5ES1DXG%TQ'2=)&/9!&4_GB
M@+N3_3=&DQO`6'2`<52;O.D#!VR`XTO!1`Y*6A"WNV1DG18&+\R#=U"@7#NK
MM19ZN#91"$7HPO9LT9M+GQF:(2(LP1)]IME8T.?KM"4*@R*"'@6`Y'I2[_LI
M%D\T7Z47/D^)W^YPD=A8<L)4`&^N<\*JYN(IH&K+WH*PO\*+&Q4.5G.PS]G#
M_\*,37>,>T$;5G>,_[L3Q<MXU6:/LD.&-T+#.6?&-11:>)N#.3Q+.H0WM$]F
M9O+(>:6CD)(C><:#/+:MCZLC>>Q5*55;3A3D/_X3A,7$;,PDEXMIGD;VME,P
MY")'G71$1VG:0UZ$=&HZ@4=YS,>)E)U;S2?NDY][S<%)2'0V&.;<S;UI2`BL
MXD!'=J*D2C3DF.+I)\]KEXERRGWY>)(RR;-6"%-X",-6Z'!L>MS;"3=*;=56
MA]7T"PAH"I_A"X)B&HK@"[Z`(K[A"P8@%#B@*^!:-)&@ZBR7!K+"AZ%H."J3
M4`^@U14<$?IP`)8@J%;S`$Q=0$.A4DO`#$+!6U3U7N"`!AZ2`X#(G06;!_^0
M8``<8`A\-?/DP=3E*!0DX]'(N!=Z%79[00;Z@=%ZP0R0=3FK1MMEXPM4P)%H
M@!%D%\D*VA?Z@?FJJ+);HPQ0PV1\@1=TP#A^(5<[FQ?Z4`5H8%S+HP5"08ZR
MC1K#E>$'X`G\Q%^G'6'>,VRP(#>QACIHX`FH0P;<L8/<<0".)VSZ@7B6`#TS
M8`D8U-Y=J4$0%I=7>KL3)\O]_``EAT<>)R=YA./`R9,=$)1Y]KEW>LW5/"6)
M_I0W<"4YF73@'.-FY&2MVW&NQ$I^$M"YY,H9!$*Z7A@@A*K79(3%>[7S0VOY
ME9@716R3,+UMC""R9[W=.VWEFZ.H3`ZOQ0R\P0O_'>!_)D*.<.(9TH#O_3!A
MA!B"(/,MQ$6DCJ$7B@'M#E4%V((JV($[%F@IYO!HL*`DW,+Q^_/(.*`!GB(J
M3+T>5-,I!@`$RJ!O-EP416@:1&L(=(`D0N&<L?&1CDP'#L/;<8/$5_>1)H,X
M<U\S[N)HC@PVF,$/35V44@,;)6,U#@`$'(M=Y<$W@@\\H74TGJ"@L\T7JA&B
MJ:$94@*7O@!:AVM7CBP`>,./JN:2I$8"&BG?,'$(O$8"S"`>5$#E#Z`ZNDAJ
M`$)&J`$.FH4*Q4(8,(7"-#R1L%"A`A`#,F0;8(Q8KB$J)!`+`(*%1F&Y2N8B
M:3*ERI4ID9ETF?(.LCNY_V;.S"539H"=P9`%\`G4)\\`P8;^)+I3*%*C19LN
M?;HSJM2I5*M:O8IU:E&C2+=N??I5J=BA0(^6!9H3I\V<:VV6=`D39LV2*.F>
M5)G,9-Z[)(7Y_?N7&#!B#!<:-JP0L3!>O*@U!N:XQ3=E188543:L&.8BQ89E
M_ER$<^ABG"V3#CTZM6K1J$.7*/(Z-NS9LF-;*.%-1[,!QUX7^::@V8%CQ0["
M_N:`0Y]C9H07*S$->HE>S!5\LV#AF0(SO1%E,]-'&KM00Z9-D[;$^K1>ZRT<
MJ/?LF`4.#F9-LZ!#03'BQ;X]F^_`-,P)5\(S#NC0AP73/-/+,PP^$TTOO62`
M1?\O%A33G!D\]()$-4BP@UV#O6SC2XDE,M-`0?WT4J(VOBC@0`.]]+,;B[W0
MT(PO%DAX(GD2'L`'$KXP@T0S.C!3H@)8R(AD`PTLTH`O7^SFRY-5@@!-/[[\
MHL(`VC@)II.,5&,&,[\,X*$$OY31##5F_N+D+QFH0,XO+=1S@)H<@,#(+[\<
MT,P2?K+@@)J,'3K$`!(XIB9!QDC`"S"22B!#,RI$RI`"'4GP1#/]$&-,"QJT
M(`%!"IG4EUVILK227'.I=--,;*4%5$^SVO133TGM&I525A5UUE'`9D5LL<9B
M-6RR1QWK%%1$N15`+M%.J]:LU5XKTZLOO647JWPE0]+_2.`"1FY@@_D5$6+I
MHIM88Y@ZQLL!<0RC3&>44589:J:E5LQIH>%+VFG^#MQ::[711EL)"BO\W'-#
MT(=(P\]DXH`">PQS$&G(<=!;,0J$4DQT(I>`H0/;]/(-'`H<L-\7(#S#PS3%
M(`%"`Q:P4X8"ST#WC,QF\`''?=Z907)^<#@HX<[T]=('H/T4^/%_"SH((8.]
M-%"-#-F-Z(`*ZW5XP#-P^"+A-L\@:6(O9BB0P0`6F)BB</@UDT&)\[7I9-KD
M,6,!S4+Z4N03+`):)IPEPOF++XD.P4N5BR"B@0*,^](EG!(TP$L#EU,#@@Q^
M%LF"GVSVTQCFF<\)9XJ>"U.-_Z*,29"!`KS\LD0U+?S"&+Q#A-*`I-24ZD!B
MAO&B`HPMI/NQ!.3,44T`A/$22@:&9/.$,:MVZVWVVW)K$JTT9<N667,Y]96P
MM2+CU;'JK[]^L^POZ^Q5/FU5JU:[!MO6K>#G#Q>JV\?E/Y;L)54$)->Y"H-`
M=1F&&L!H3&$.\`W-6`8S`1--OSS#FM'XJV"L(=AJ#(:PVHB088AP`"*P\(5A
MO`8Y2Z`!![R1L2(8B&,R(\@WI",RYE1#`3Q40#6&<PP:9*)G]]F&`PY@`?2H
MAST6>D_02K`'$.A`/E_88=06-)]ZF,$,0QC",VYH!A!@P0P/>I"$>`"H`TQM
M&BH80O\O>-"ABFE`!Q8XF2^>82*R98`#9HB1BV94#PW08$(\C-*-FL'#4)B(
M&:%P@`RX6+<2%>E(AQ12E,"4N'Z`X``9*$.5?D$-1[:-&2I09)CB1(VLP8D7
M(%"!Z)JA@4QD@#%.RL`LJ;$$$"!!`H`2%&/.U`Q&\`()/N1```[%BT1!A(&E
M`@$"C6&(>LA``4N`R$*&H``9/$$!`Q",,(C1@HIE0#!WX0OVM*<2E,A$5C7)
MB3O7$CYIS<4E9C$?6^19%F%1Q7WOZ\H^XR<5?O8S*NDKJ#_)UZM@Y.2@RRJ+
MM'QBK9N\DR9MV5XYYU)`O^#E).`Z2;D^RBYU)1"!O%`(`QG_*"]ZV4LS&>P,
M9XAC0=144#4>S&#!#H;3A17!`COU1ADX<(XE..`9H4%.&8K@@"]P`&0EV%C'
M0J&`Z."P!,PYX@&0<(`C'B.(.H,.#PR$1)QU=4$^JP8<H+,-$'P!.U^P*A(>
M-)]JJ"`;&;#:SA"12RP@8FK18-`TTKA&'TVC0SHXP`&H,2(&#:E$O3@`"!"!
M-1VP:#[;R4`_5@:"?C#CD&8X@)88&PH09*`90XB2)(VT618T0TB&2UR45)`!
M"]!``:D+I1E"J8.!I.Z4J?1<`ZC!AU#XJ5-?Z"PR5;!#!ZCU<BT(%"AG-X!@
M,@88,A@"",R`J%!`2B&\,)6D%"(!_PXH@!PL`,$=##,$!PR!;AGYBP1H``U#
M$.9Z%T4GK.9Y!VM1=+\V:<M/@C45H91OP+LJWT`/C.`$<^4K_*0?_)Z"%F3P
M;YUJJ=9:M"475Z&3)`,T9U]`.E*1'H8:?BFIB25#F0EFAC(!,XUE8FK3EJZF
MIJX)80ACLS"2&4@'LVC.<&3H`!HT+0T.&$!1D_.<$G`S9",3T-JF,8QC3&,[
M6]4!?&)F@4T\-HGIZ1D3W5./)R*"0,70`1:DNB`+[6D:90"!?9`FH`Z586M6
MZ\70LN,@!X1"0AWJ1\A$9+8\RE8#_4!"%WNAC0D-0-$J@$.0U=P,&>61E&XL
M@X?0%KA>,/]C2@=`D2\683AY!!D)M=,2*!W)C#`6N4J7:_5O5=D`&M'@E4@@
M!Z0RUX`,#$$&,NC'HH:Y&]PQ)G;([)WD$*4HR`"CF<(CQAU:V8].R2!2P-`4
M\!A"$F,\`02Y6$@Y5U67E7P/)Q;M;_AFE9:`XJHL",V*@Q4,[W@?>'[ZS"=!
M[VW@8#PT`.&+2GXG6E'N]4];X5Y)7H0Q+A!_5,0A1E=)E8W2>=6+7OFJ8&?Z
ME4&8"DRF,^8X!VV<T]@\QQN`P@(6AE`-CC4UR%'F0#,X9H&-]:$/9H`&=Z;J
MY*Y"C65]$XXTDBA>\XB5JM@AV<^>(8T@@B!H^,%""6ZS(Z4-=6+_*IA.SZ#C
M,0[@V6P/8EM[`/6%#8$M:69K$-I<E%Z3^Y`1+!K"G*-+QP&H8+,NAX.$T-8+
M\B1)!2P"'&I]`=Q%HZU*S&!3#ZGT6T<F+KH<Z,8IG03<,C&#`]E`0@-H%TP_
M"1MV=!(V8\2A`@?P0DT="AVC&N5,QNP.4I+J;O`,(X$I]?`B'JEV1T"R!%YX
M5-L@<)XY[<NM;'5/?_!LRUJFI1/WX:\G!DYP4YY/%.@'0_I=R;?T"3Q]^V5_
M^]!'L*^J,BQ[]^K!TKK#?XE_SPO3)"4H08F&Z\NJC"Z\X0LQ<6&H(1D)7F;%
MGV'I9CBS'QNT<33E<3$&<B"W,,5@`;KV_PTR`U^ST!\@0`.6`1Q,A1P9<`"6
M-@!-)AU5=1W3D0EF$#(60!#]L`U+8"0*@AX.T%F=M0WN$0_%%0K-8`;980%M
MU8('<#0DZ`![X!XT.!UE\`5PH!M$0S54,PW-P0$-D%5#<#(<\D-?U5=]E4>-
MI4MPL`B,\')7<UTW6#,6D!YP,!_F4%Q;%"6DI`!#T@\_A"1%4@8HP@PXP@'4
MP$E?P`R+H"F8XPOT,3N<(P-;P@L:,`"K%":@5`TL(`,JX%RSPR9EP&LRP`B7
M,P098#J'PDO9H`)(T`(303J\T`(<T`\MP`>N`PRK)RG+%EJ)H1#8%"X#D`W]
M8#UL\RA/8#N$D?\+O!<`P)!.P,<J[(1^_A44_X44[/83^J-/`F4LT]=\\L:,
M^,8^!H50X9<3[690$I8_Z)=?-^$M!<<2?0$NWXAP'Z9P@D$8#'>*WV48*35Q
M*78OE[%2&!<:F=%!'E=3&X0:!P,;OH%CM'$,B%`-.N`-^X$(UW4,WY`)9=`Q
M!T`#"O@-*"=&7W`='.AD6/`?TS$$2#0-//`-H5`-("!%&=D+[*`#?``"'<DG
MQP`D'JD"!S`=8,0']5`-'8D$T2%>?E63W\`!)JD#1\B3TR`#RE4-O-,@@Y59
M#5(U#9(V%:%I##(`0P`X#H`$,S(`9+,V-K,$),D'?.``\E`B%<%8`X#_!4-"
M,Y*U""729B69B;Z@287##*)H!H"W'57B"SHPB)GC:HG7D1D@`T[2.+3(!S&9
M60T@#AF@78?B&+_SDR4Y!+Z6.3(0DZVS&+Q@#&TC`8DA#@.@`0SAB?5``Q`A
M`8;`!W/@$;MC#+KX,;:H;0[@>_2UB]S#*OSU/1(U8?343M_'8`Q53_3V/LO(
M/@@0`+[IFU8!G%0QG,TH/_K$*\Z83T(1+`_%%K(9F^VD/0/G$@2T42718>)(
M+N1X+N9X&*>(8OE"0>,Y0?DR&C!%C^G9<3>5,/N88PFX(#O%,'NP,].P!S<4
M'3)D'@NR#=L@(#@G'4UU=1EY,OO)`SR`"$BP_PU_9AYB`P</2I\+L@>S\$1(
MXR`/BJ%4LPU'\R"S\"`)^F8\>80E,`M(@`A)PR#;T`!FTU=50R)P,S9Y%"5P
M8%IP@`@P6B4-@`B\L*-P8UJ^``?44"*_]22&PPQT^#>0QUN_0Z1@4CJ/!WG4
M0`V7ASFFPPA7>J6&&9GP<BB]XUFY<RB:V(G4E@N,@(X+<5ZG*`P!H!""P0LS
MX1<_\1>YT`\7%2TKP8WN9U&PDHV_&#[!*&$,16_X`V_9MQ/#B:B_J:B)6IQ2
MP:A3D:A1\:B1RHRZV2SVECX!M6]^>F$9%IO"IRUX^BWAR!<*]TV#H1@B)E+J
M:"^5P8[^!V/R.(#S^/]!'U=COG&`KW$;`$@R"@,;4H5#MZ$PP`H=3<:!P^I5
MYA$SYH$=,<,>ZR$R^RFMYB$B2#BM1VB4#C(U1)2M(DHU$@)HB86BT6`VV(!'
M)G(V>:2NZ\JN[5HB93FD\+H(</`+4&(B4&(XEX<XNT6E89(YN,:7IX1,_SIZ
M`PNFR,2E".LN"LM`:JI`?Z&FISI?)S&QWZ11):&+UKF-W+,_X".='9L_Q4A/
MS%E/QOE/AVJR*7MO\/9]_T2R_A1AQ=>Q./%.-.L2V=(_<*&QK')PUJF=%AM2
M(Y5`^;<9Y,E2E]%2Z$F`2VN`]SA"-Y9CSR&LPAH=^-E4"[.?Q6H>PSJM`"K_
MK<L*MM#ZK,]*K62%K6941MYJH6K+MCPY(F];-7U%(OVY6.YJMW>;.";B6O::
M.OGJ.%0*:D7:K_P*)I<3)I=3;*93I0;+N.X"+PG[N&#:L`F$CI2+;?-'%SM;
M7]S($K(B4=@XF^O&%3QAC2W+F^Z&F^W#4,W2J,2IJ%41G`$%4+(;C:D+?K>K
M?/7C4$?QG!'EL1/&B]S843]KJN:HBFK*JA17GO2"+_7"&K*ZGC1FJPB#@`G#
M4[V:CU4[53DV,L6JM1*)0V&KK,4ZMM3Z#2C#1.N!MDASOF>[MN_;MCQY,O/K
M("WJHGAD-BYRM_N;1WE[.'I+K_8ZKXA#I7T;)P7<_Z]0:KC^BCF&2TO_6HD&
MF[`,N[`+"QF+41BHJJJ7"V*E6A<DD;'9HZ<`E(VU^:DF'+(^41/'^&#+>+J]
M*:F+*L.QJSZ/&L.4VKHH2\/-V'RW^6Y2P6Y^BG[5LGYU`1.::W`>Y6$>-7\*
M=!B%$9XJ)D%'BR^LH;2TBL7VR)[NF3#YR#`D<PQ)]QPC4P3'4,;$D;5@G&1;
MJX#[<1O1L<;WH8#8$1T\@!UW?,?3$1T6T!OOFS1IEK9IVZW=VK9<YR`G([>]
MT**^,+<GPK]XNR5Z&\F1_"0T^DE1,J_X*KB!NUNIL\"/M\`0'+#%UK@*Z[A<
M>I@+ZQ@8[,1":ZJ9.Z>LB?].&@:\OHO"M_)@^82,+SQ0.RR<*OO+P(RZ@[HL
MU)@4QE@6:4%\KT*=H<J-&N'!IAJT!N3$R<N.[J@,S;MQT"MCW3R]N=J>NJIC
M6'4`$5,$T;$'6$7.9P7'SW``G34+TK$)6-4/5R4RC#`+"L(#LU#/"EH,=CP+
MAE5H]=P/5]=C9C"3U9JMZ.N^@;S0\7O($'(RAVR4Y,HB>*18C_S(_CO)6X*%
MES?`F1S`@_LD".S)AWM*#MRE#QS!C1NY%(S*CGO!:DIMV!81'%PNF<O$O/@_
M'`N=;L&IYJ?"]':;J"O,OSRI,AS,2^VHKWO45=&R0.PLQFA^0JU?T#E/KED3
MG$O_%SV[Q`JWP4\,#$0KQ95!&B^V<5H\JVO]S>#LJ_LH#0<`#<H%#1RP,T7@
MCP[@`!1C!MY`,H@`(U@09$G&D7NM9R(S!#0@9>A1#11S1'S<1YF`)7NM`/G,
M"`X02Q8S-48YE&7TT/!+R!#=(/UI1Q/]#'3[HAKMKGGKOXG#VHY#KQ\-I&6I
MR2"-P`><TH4KL!#\P*7,N)'[THW1L`YKT\8KS4P<RSQ=$OE%;F^1LW!1NM&=
MF_]EC=0MW;KY*[:[FPQ5G+[\U#>LC.%MJ%7A#@%0WL7B%-A-%=%=NE/QG-:X
M3NQ=NK79$LZ\L1VLG2(54M_%$"T@<:VJ4BX%8P/(UMX\_[TX!;4+8P'#<`#5
M,`O?4(1FO`E`&*$DXVA#$#1[L`W0401M4P+;4.'3@`4<(`W3P`[BI:(NAPC9
M87=EX``0&AW%8S:(L+[5"LA^[+ZAC=':\`P\?D<C0H5SRZ)VA-&(IMKMVMK]
M"\`B#2?PNB7Z"N6$"Z4`Z\"+V]*^;<H3G,I<RM^M7+FHZDW$F]SBR-/O9Q+6
M$`QH;@UJ_F]MGE_6<`=P+N?F-W[BQROB/=X`9A7G#;M]'IS`^><S+.A)3>@S
MC`"'?NB+BNB+3JGL8V]*4;LENT]IKE#_%@!HWJ?\$W"BNKG?YK/(#1C$(.K<
MZ4TB%L7[=]8`R'$$SK0%_G$(+O]"(137?/`-WG`,#H"013`F!W`.F4$RTF!I
M"_ITTK&`RB$-3!8=6*#8YT$#0\`#[#`-UQ4R)2`-;24UT($%H?!S5E>M[/O9
M@HRM_N&M/$[N$?T,V$`B&-U7+-+(1P[)__O:E2S2F5S2!IS`4*HYNKW;6#ZP
MJ6R8DOOON7..PO.P"R'J8"[F&I737*TJW((,FJ`M<.[FEE[5_&;Q%;\4S1+>
M5T$^W7<L"!"-@,[H(T_R)6_R)X_RB#KRP7#H+`_RM!MO>*Z,&$]0RJCF:7[Q
M%S_Q;>X6S!RJ#>\_^`WJH8ZJ0NO?*J6\$Q>`-C53!2Z]K^[6.78;#&Y6)>!C
MI+$)U;#_1QP0,203/6.\M=-0!,7#`0-`-"(SXB5^XD,@#=XP9L.Q'F6F`3LC
M(<4P)0,`@>UKH2)ROM\^R&MKR#TN^#R.1PT2Y(Q,-J=]T3^NO^ZNY/\KR8>#
MA9-/[P3L)U&.[PR<V[S-[Q)\L`#O[T)+W*=(&.2H\"#E81<[G:@B#)H0;M:0
MU1)6$_(MW=\MG(B^\3`,Z(/.^XQ:Z.QC#]$W?=YM^\)(^VC!NQ$F?*Z2L^SG
MZ5_]47S!G0:4&&2-ZOF"UC"FGA[T]$Z+@#HE&WPLUS#RC[.1];L3"EU?`H0Y
M[<':2`?Q!3BD[(M-`Q)('RK@90)B[>9QO@!1PHP#!U]*/.N%__!;KX4(GSU,
M"/&APXD5*_J:Z$N;QH?1GFV3"');+U_;2OIBYDOE2I8M7:[\I3*F3%^+:OIJ
ML*A!33B+>O[*"11H@Z%"&QQ%FI174@D-FO):"E7J5*I4J4F]>I67UJU8@0$3
M!O9K6&%AOX(M*XQ86F&YV+:%Z_:MVUQU[=IM2S<7LER:D`GCF^M.762%#1]&
MG!AQ@#N,`SQ^'$QR@&"4(2,+@!DS9,Z1*W^F'`R!Y,FD1R,(@!IUY<ZM7;]^
MK#HU[,Z@:0=P9SF8.].B2^NV?+NUYL.10Y->K/CP7N:&!P=F'OWN]+AYZ;ZM
M?AW[6K%ET;:(,TQ9,?%%Q@\K5JR(^O\BZ]>K9Q^_O7OZ[=G/Q]^^1`G]1?C_
M]V^__2PH89@#JCE@`!">\:\(1A#LHYC]IBE&!14DG&::$C0L(@,.(BQ&PPRQ
MH$&::;RAH9HA,BACFPT7*N8+!Y[9L)<,CWF&AF;,L,`A&VV<*"**AA32HH>T
MT>:9)#%2Z2.$1MK&HY-,>J8D)5_",LN9?-D2#J*(@N,7G\;T\DN=?A'***":
M8JK-!J):ZB@XJZJ**ZZ@RJJK/,WB4ZSNT,(NT+FJ*VLZZ@B["S#`^"J,M&#N
MLL9121W53=)((YV4--<RG>PTWT8[#E31$""U5%(_D^PT4U=EM5577UW544^Y
M"(966U,M==3_4SWUE%-.7_.5M<<P0U6R2X-!QIID[V*TN3N:E:ZNO."*"R_M
M!`WT3[-:^$:9(H8Q#SUOT;/OOOSDJP_=_-;EK\$&!13PW2(LD.;`#!W@0,(B
M-HGG`'`Q/(8&!R@LH9AC-K3`0V\(W'!#$H^91AH:AIC&`G8RM'&:8W308(]I
M&*+1`@(U"*6$(H-$62*5C;PHHXV2?/(9CYZDDDF34LHRYY>VC&F17WH"&LPQ
MB_JR:*.2.HK-I)6*$ZHWZ82Z*SREIIHK/X$AYD\_L<7N.KG8TLM0L0,+;-&_
M[K`F%VO29EMMM]F^(VZTK9D[F&,=E3OO.X(-3KC'^H&,U-D$=W7P_U$/WQ56
M6%-KE7'&48-,TM&L6=5OT"X'KMA,]9;;4KO;ICOTZ9"1&]IGGT4TNFD3E?;K
MM+RF-ENRT`(&//'(,^_;]`R^#S[X[`,^>'/K6S?`_@#\#][]#.1C#V\.V/&8
M?:$QXQLXMOFF8"2J&6`/"Q#YXAD+.AS@(Y!$Q((#$Z7A``L>,OP8XQAGW%!#
M)#8I`9%J:.@QH8B$!&#*5F8DF"FI2@?TB$>@5"63--!*.-.9SGBVD@8`;4QC
MP@E.Q/0E-!%%34M#FM+>-,*F18U.=II*GE2XE;.$A1=C@2%9N(8MV!5*;,V)
MEEW^XA=-(`$)F4$",H+X0R(&@(C]0`;@BO_8#R0P48A,A"(2I?C$``#.BE5L
M8C^TN$4N=A&*G$&-%[>812U648QG1&,:U7C&OU71C)"SHAJ;^$,M9M&.=2RC
M&P&71#Y.48J9\:,0`2E('Q;2D'QY#NF@A<._B,TZA8K=#-FBK=I]HQC*$!=Z
M<`>N]Q!/>,&CC[KF@SSDO0M>\BI!O:JQC6)X@P,.F,4Q-I&-:O"A&M4P0XB.
M,1`^8`$$&=C&O$(!#5M6(P/H4U_$:("%:;P/8]_0F`YF]+']<*`9"OBEQXBT
ML@!6Y&0L(\D!,0*2A(SD(=@P29,BN$Z8T(0FBR"33X"BP9R8B6A(&8J;1#@G
MI_'3A%@!*`JG!I7_V8U%AELKRUJZEAV&WM"AS$';LX31@A5E8$47M:A%A[!1
MCG;4HQ\%:4A%.E*/@L.B<\`,:B:V@XQ>=*,9S4!,6^I2CVJ4I!VUJ0)TJM,A
M*&"C//5I3X>P`X^J`'"HD8%-;[I1<##UHTT=`CB:VM0L<'2J4<6J28>``YM"
MM:D:A2I6/?J$O2AR,'<93-RL%1V^/%(NL'/=6R@YT?",RUO*&$]ZCB&?WZ&K
M=Y\LGBE1Z2[]*(\_>SA`]DKPC0/,H@C/.$!D(SN+AA4##E^@@1E$-(U-2-8,
M2(`?$A"1(1X@`K3QRYB-9G$`&BUD&G`P`P?,`*3_<5.`0X*(.1.($/]9_R0A
MT3#G2-@Y7"Z%"0Y<:J=,+`BT>>[$:!Y$6G3EA)1]DM"?4-.*0%>XE>R^,(8M
MU)99%#K#9!`C&;DX[T/'AJC"W"$=3X!&`690`/K.U[XHF"]]45"`-!0@"Q](
M@"32D(;_2B(!*,A$%*+PWP]0X<"92$,F(`P-%``X`3#X0!;Z"V`J=-C!'4X`
MB*E@A#KL%P516((FW(&`2&3@#$F`<1*4P`8:SY@-2HBQC&U\8QIS@A,T!G*0
MA2SD'[.!$SJ@1RT:@8M&-((>!S`#/1I1"WK0`Q>K\+$HGL`)(*A``RU(C37^
M$(4)3.`&9[X!!-0\`PC$8@8S</.;(<!F.==YSO]S?G.>\9QG/LM9S7^&P`T$
M$.A`H]G0:)Y``0:@F6>1SJ&K,Y0-I25)MF3-TEBKY+@NB1YP<1*4YO+K?$(=
MR@"5DI2F-M[!-%2"@V7O6T78:\-6?0QIJ'H_NS.8K">4(0N\+V,?@R:-0I3:
M$EC@&!:8A@!K:]N4]=8C_NM%1*+1BY$H\$G4KA)QM9U<Y.9DN4.SYU'N*5VG
MD!M.UKWN"0<J->UVQ3M;ZPZ?PC)>L%4G&7FYMR/A6BU&D2X`R9A#-<8P<((7
MG."0('@"(&$$(^P#P#`P`B'JX'`4H&#$1K#!"ZCP`8Y_`,&9@`$A7I`"&^SC
MP`DP`AE(009!"((,9)#_PLOS(8@%I,``1A@X"FB`#,BIX`R8`#H``,``19"`
M`6M0Q"$>``"@,X`!?K""TQE``E"0@`11MP+6LPYU/W3="GX@@1Q((`)0].`<
M'4![VM$>"+6K'1^GF,(4-B"'56C`$*N9@PD<\0A'U,#O-;"$)4;@`0_<P,R'
M1OR9)W&#231^\8M'_.,9/PD/$*#R'AA!YC6_^<!?X0I_KP`4!*`"P#1:K0]=
M77;V?:WM8/K2Q+#=>>Y*'KVZIZ^D3A=@U96\P;8K>:<4D(@6JR'%0E/7\*M?
M_58-OPPIG_D8BQ]JX[<0:"9;(LONYC951NW><C_:"L0VE,J9$`AN&TLQ"1-R
M_]U9W'CB!(/A[B"YE5+NZ%+E:?_L[KI7F/_O]FEV"^4:\VJ+]%(O1F(6M9J#
M*#"X!5PXA&."A3,"&&`"%$`YD8.$!,"!-$`!B,,X0LBP#),$%$B#*(`X0G`#
M-W"PBH.$F(.Y%H0Y*8!!*<B'!=B%5T"X`J"!7!`<%6`#I5NZ!S@$17`Z0!!"
M`/C!0V"`K),ZJR,!0)"Z)(1")<PZ1?"#HAN[%8@!ME.[0.#"+M3"M#L')X`%
MN9.#(]B!%EB-+RB`1V!##&##"O"\.-2\QANT.P,T",B#/!2`/!"`/=Q#/>3#
M/)R$/72\QB.`0T3$$="'S=L\S_L["!@`8<@,TQ.,2O]DEAQJJ[")*T@2E-?#
M-&[9M'"Y)-W!O7,!+-P+->#K/>/YO?]8O@EIF.P1ON5[1>5SON=K)NA[IF3C
MQ6>`/A^A".Q3-B.IK6<;B6@+$G,*OW**!O.+H/0[+O7KMGCZ"0L""I]Y+OD;
M(>I:FJ@@H?M3MX$2*'%DMZLIJ',DBTE[G>P@!O32Q-;QFDML#M(9C`1<P#%@
M`B:XN`N\.!@XL`\HP3I(`(\K`)2+N$HP@H%,@"Q(`";HKQ$C!!M(`2/8N'E(
M@)G+!Y@3!!9\02G82)HS`"D8@P)8@CL@%610`25X`"!\`*##!*8C.A\T0J83
M0JE3!!$0@9I\PIT40BH<.Q'_`(0W$`,O[,)S.`<QZ(,O_,(8P(9/F+NZ`[,`
ML(:\8\.JA,,<B,,KB(`(T+Q#K()!<[-8$,NQA+,[S`,(&+0Z'(,\6,L\F#Q#
MK+P1(`"YW+P(L`2[C,,:@$1A.!VS4J1++!MXU`MJJ:%.=#W7BSW<T33TD![;
M@[7?*<51&QY2ZCW#.K7%PDQ9%!#-W*Q=2[Y9Q$5G@I\?@3[2[(6#6+;K8S;<
M`L:/0,9GDS;Q,Y^3X+YG*#^4<,;SX[:?H<:C.!-QJZ?X"R$0BA.DD`KC_">K
M6#<]X:Z!@J$6.L>YJC2U")2UN+?S(D"'@HZR(@QZ!(8Y6(<%?$`8@(0/@SB!
MS(0&_V.X%\"P#]!`*H"X%Z@$#!M(`!/!-*`"0L`X`["!%%0X-]B%?)!!C61!
M&&0Y&;0Y(R!);MC!,Q"ZEY0ZH!-"3%A)H0.`0X@ZJ0,[1=#)G70Z/WBZIP.[
M)A2!*2#*0.B#I.3"MM-"=H`%"M@`4#B"+PL`>XB$/UA#JZR`1[B"'/#1K=S*
M'_B!S-,'`AA$`<BS03"!)2T`$RB`..LS/OLS/AP#QTO$N61$N[3+1R2]26PO
M1SLK0UDDMXHD2%)'P\P:;M$T3$J/]?B7^=@K4XS,4\0/5:3,R]P/_YC%AHG%
MXTL^/@5-7GP^7V,^ANA%:NK%[MN^U>RM(9DV9(RVWWH(W?\2)]?\")9@AFS+
M3>52OPGRMG@Z&J(9-Q`2(?KK)W!$-_R;FG:["F&@!F'@!5CM/]KYO]9KJ':L
MBW:T#K9*'<*(F\-HC%RP1TAP0"J`!!CX,$C03RJ80/B,N(3TN#20A!*T@?X$
M,";X@!`402IX`4(@!)+KL(H;,2E(@060`E+@R)=[N9B#P5<P@!3``1J`!RY`
M#9\3NB08.@9`0@Y]20#`5PKUT)O,29XD.A#ET(,5V*)S@D]`2A5=T2Y,.Z+D
M`1B5`U'0`%E8L4B@RC>$0\_+O""-@!_0!Y'5AY(E`'V@0SR+A4%@V99E4OF2
MKS[[LS[,`RL]1$;,O,ZSA,^#@%#_`(P`V(O2.9T;"LPSW3=.#$"LH:OR*`\V
M94S@@<Q10T50$JP\-37E0:7-S$Q`]5-:_$Q9"\WG(TWI\\4?P2U%U3[6K`AR
MBM1C!+]E=*".L,V6V(A-/:Z?D4:>L:`,"LXS^4WA)#<1>HJGF:Y3556J8<[N
MN@I@>%5J^"[P^C]`D23K%(;T2B^RZ=5F::_3>9;OS`1C[;"%,T]OI8(LH,`2
MU+B&E+`1JP,3)(2-^\<LR(03X]:(6P`4A`2/4SB/)(4%6("//%`7C$%2$`(#
MV(<<[+D7PU>F4SJI>X#E74E,0,(GY%"<#%BGZ\FBN\F;!(0K=`4Q0,H3[0"E
M7-%;H``Y_ZC8+Q.-J2P`P+L".,P\1)1?(BU9DY7?2:B"/("S&6C9_O7?`A@$
M^HI9/$2S*UU$S>-*O/0["""]OD0=!P;,0V&]02G3UDM32V)3-GTUR(0UXI%:
MJ1TEWKM:4S(L/?536-Q3Y./:S?HUYA/-T0PVU-H07VS-(DG-;H(VB'C48_0?
MD?`?*RD);".)E<C4V]RV+=E-][-&#@).)BX:4G43.7$:*4XWY23'/&%.J&!<
M8(A5R(W<6EW'U:O<RG6+?-.AU,'<H-U<(0*X-$@`A6.X-U96D4N`*-C`$GS=
M;-5`#G1=9CTPAL2!++#CUC7!B?1')L@"954Y0<B'`%4YCX1DE_^+02FHN7U8
M@LD(`'OU5P`(`@;`!.SM5WQ=R2?<UYL$42BL20[%WH,E@:+#21%8@>\-7Q4]
MAQ5=.X@-!'P0`1*PV!;PC;R[/,P[1,(CO$.<A).MWR)%YOO57_MJ63[@@W9H
MAVB69I858#;#0P$PQ$0\X)S=V4<,!49Y8#!%G<P53,)D**3%EDN+O6\9#V]1
MCSCM*\D4-:K-#]^S4Q)&-7C)GN)+/LX\ON<+:!<>3>F+'QJF)F3TD62KK>Q+
MS8IX-HCH88H`+I*`$E\(IY8P8F=,OYFP"9M@OZ#1(+\E"IW(1N)LDZ;91E1-
MSG!D3B^FI/"27$&!'3/63C0N'<$PJV?_(88YJ`=E]4<X?@'VS,>+$[GV%$&`
MC#A"$`*!-+`*.[`,1`%"ED@W(,\)O+"76X"72P%2\.K@+=#A78`$6(+4<`=K
MT&287(,U\.1[M5"AF]Y#D&N$W4DE7&7MW=Y=%@%/T`56D&6CC(%:'E_Q/0=\
M(`$_$(4S`+.SGH,TN`%B;CQBKKQC/F9DKE_Y568":.8Z8UEI]FQICF9K-@%L
M=LO%F\N;U;R[##R_@P(O:&`OS6EZA`[,S<3!E&#;1M-,TYT,SKT.!K53%*7C
M:9?C&2R&81C@2^&M3>[FTY",&>C2%,UHXT73G&&&?HB/@0CK3MN'OKYCW`;Q
M,R=+G<UT(F)-_]U4:>RVH=`)GK")X&SB?'+BZ"I5ZW(*PSW<.J$:VH$W,%8+
MA5(HUXE'0\G.T3EC9W$TG6XTMYB#3$A(.!8Y(V""3)A6AK.!UQU("#-((Z@$
M(3""#\`!#&PP%-"P3*B#;I7(B=RX?`PYE5LY02"%<@7>EF.YCO3(!"B#R'&Q
M3<8$16#KH'M0"VTZIT-"*]A>#W6Z##U8H-SE5MYK7?A>5W#8$\5EN3OL7HZ,
M.1@$R_,`RB,\+N_R+3]$^RW2S#;2/-2S.0-@:3:'-6?S:FY2.:O9RL92;[8$
MUG8$(O""2%SC<7Z.YRAPUGE'=]35R?W$NB*/V8/:1->]>O:D42+A5?\L-O_0
ME_%IQ7[&S.4&VQJ9AH7H6H*6/NE&Z++5;H>P;MH:1K65&4F-U-QR3?#.:/-&
MB;K-S9F("8_.H)]IKEQ_[WK")RB6KG,K3OM.H>4,J,0%K^>\&AAZ/76&I.L<
MXP%?+^EX8`1'I+]X`C<V5F\EA`.SN/5\@3K8./?<0(E[@1.$5F8%L`+(0)`S
M\11(`8W;N,\U`H_\71:GP7,E!9=SN76-03)(`!K`#<I0@1U8.II<`Y>TT$-P
MR4^6NE(&A%-^0H,UV.U-<A)X`T\8!5?0>%?0A5)@!2E?T7,``S"H<AI%@*G,
M!+D\YBVGO"HH1,.3\V0F<\V>,SW$,P`>A';_@(9F8/-F@(9VL.8W$X`QN`'+
MF_/5K@$H4'I'<`0O\-F]L`;&^,M?+><<LFU]<T="L>!*"D4-YJOUD)ZH!6Y[
M+B5(;Q"1*;:TCY>N5>Y.;Q@;>>Y"C6[3E&%@ZRWLONY@//5O$N)HBQ+7%&*Y
MG1*-AO599XF8,).=P$9Z*NG&A^^CH;_Y)MQ@;VG%9;=BC^DO3@M+H\Y(BD<"
M/*]=O6D#[W-%*@QAN'8\+EV+HU8+_X!Y2`.E%CDAF$^%S(0W%O$!@X$*?X'B
MK03X]#B`)`2O?@66^UU!>(5\;SF/5-=^EX(/6`*>HXP,2()^'3JV;FLV`')]
MG5Y]O6LA-W*B2_*\_UZ!%1B%4>@!71@%.K"%44C*H23*#HB!D:]RQ285]O6\
MG0T\P=MR@/!09<(D#Y,.$DBH3U]"`I,<$L@C48#$/#-FF!@TJ!TT<\V:F3/7
M3F.!BQ#RW'@X8J4E2TV@0'$D,X0=+Z%R!4-VYX[.GCSOY.*9:V@N9$.1"1N:
M--=2HKF2Y2+&5!C5JE:I$@.6M46<8<J*>2WRM4@QLD7,GBV+5JW:M6??OBU1
M1"[=N79+X,5KX6ZQNGE+?`.,-S#A$M,,&SX\37%BQ(L5/U[<:]KDRI2_]<*L
M>?*S7L\Z?Y[VV3/ISZ!'HSZ][5FTSKVV]?+\N35LUK97>_;US!?OWKY_`_\/
MSOO7<%_$>2^"\TOYH@:^&OQ*ONA7`^C5J3>O;EU[`U[5)30`#YZ7=_+ENZ,W
MKYX:>?;J>;F''Y^7,&#U@>&OKS^__?K$]%<UU55)"9-,@4E!Y92"11UU%%!"
M_:033\(\D0DA+\"`0@$?&$%(AS88D4`"DJ21!A5U>/B"$#;`P,0'5*"0`(Q9
M9)+&/B_8@&,*0L``0P(H?``#(?D(L@`I@I"R@"!%[K(`&4X*0L:24E!)AA0?
M+!&`.P@$H`(;F```)@-KK,&`F5:`"<`##!R""0.@R`&*"'&"`HHBBC"`IYE[
MYJG(&G>*H$B@(NCBR2BZC&(+'70<VD<@YP02:2#_'700""SX@$*"*!JT$``"
M",Q1P`@1D%IJ!"-,4H4'$U31*JL'/>00K!(A=!!%>4!PT0P:<?111R&--(@)
M$$`PQ@T>>-!%$R]!00DECJ`1;4TJ").3-3SY%%1/1!G%H()+-:744`82*."`
M6@'3PC?*%#&,6,,4P^Y;;)G5%KUHN0777?OZ=5<)%ORKUU]S,:9888$5O)AC
M>"4<F62406R9Q)295EIFLIV66L:R8;Q;9ZNY9MLSL*U6FV?1;.-+RL*QW#)Q
MQQU77`/2P>$<='!,=UUST6W'G<_5>:>=>=V5]Y[1[[G'7GQ*MP<?+_P)DY5]
M^/4W-;K$_#=@N0B..VZX_PMV&W91$0+5$S)(51AB)A_L8T0=+[A!"!4C9I'&
M/#"\0`@AE:Q(Q0<BQO@!D)FL0P6.-MB00@HP4.$W"E1T2`HIKUAIY)-DD+*+
M%$I&*:655$J1``V>!A","DH<`D"8F/R)YY]I8G*([(J`00$^8,00PQ13W([/
M!F!L(,<&F9)`IYR#DK""H3[H0H<MHRQ*!S>!]%%]I)0&DOOMJ^S0PJ>1A%KJ
M#^./C^H-*:6:?A44/43K)'F\'S_\%5U40`&#1-%.._GKW]%()IA@!A`XU@F4
M]1)G02M::*C)`!P4`&0$0%MD4Y#8O,64!4%%*@32FE6PEJZN?"4L["H+">L%
ME_][V2LM^HH+O_B5%[Z4H"_^&HQ@`E/#A3F,83AT6&0FQAG1`/$9%"L-:HBX
ML8IIS#2VB0UL7C.RUYSL8R+KA<I:9D66P<PXO5F.=*#319Q19SO8^9G/@H:>
M])PGC>0AVGJ:UD;S)`T^5J/:U*@"-?]HA8,!(I"!HK*@/U90@D'Y282$,8=U
M:$@2;GN;&^I`-\)EH4.,3($-_/8B(%&A`"C`034D<3@;",$`A.C1CX)D!%*0
MX15*2M*22"$%0:1`<E(2A!3(\#DJ80D9[O"4"I*0I@=@PDU\:E,P9>>FVOEN
M"KD[!P4HH+O<*7,*8`##[II)`3#`8IIO\,<H1K$"YT7_3U&N$(.D)M4!;\0@
M>U.0AP*\YP[P%>`'I)+G#T;P`X=4X0:M2M5`T@>K*CS$`PDQR$0H0BQ=V4\C
M).%5L$P0BS9X80(GT(,+7-`L9REP@38Q2C!V@BU!"N6"#;+@UXBR%')=<(]6
M09>ZXN4N9<#++?9J2[Y2B*^S]"NG=!$8P``6,+P0#(<'<TQD<*A#'C[,AQ&+
M&!))@YG4<`R)4%4B;G`3&RD^<60D.]DV5G;%KV91BUM\#LVXZ)SH8">M,R,C
M=X)FQJ*Q$8UL/%H<V\@T\^PG:G7,3UZSDA4.IO0I77M*2;EE6`;YQ"C8>B#:
MUF%*(>6("I(848U.E#<5":$._S"241ID5(`L9*$9'_CD`@RPN+E]@`F0DX+D
M%D`D5=I`EDG:!9*6Y#G076ET7`I&!L[P@#"MSDQ!,%/L9,>`V#'@=R3(4YW`
M@`_?B:"Y4^#!\/`QA69>]YJ@\`<W?9`H12W*%G@XE"O*2\Y`3$$,[-B=)A10
M"G?8`YZCBH`\[5E/`@A`GZEB5:OZ.PGT!=0@`A@PKG25J_K-H"0EJ9]"A?70
M"6QAHA5%8$9K<I.SW8&Q/QG;MHS2+6]]N*093&FX!D0,8WS0*V!A5TSQ54(3
MYBO&^LJI"_>U%[G<>"YY&>IA$+;#QQ@5J8]1Z@^%:.2K%C')1YRJ$F?3F=;$
MQHE07/\B:$"FFZ]B.:POVR+.NIP<GM5,C#ICJ]#*/+0UJF>N1JNKTY;6-/90
MK3Y/VRO4\.-7/5K%CP<2[!\/&[8';6LG$$2;A3RTMQ<DX&]UP\$%7O"".H`R
MLPG(@M\*`+AYX*`9*(`TCH2P"P,8@90H8`(,C&`D51[)M45"I9)2L,HH10FW
MN=Q2,$*1!-7A6IA@2L*M@UG<-\F!!(H@09U^!X9`Y4D$UY2#H-X`/.")X$^`
M$($GHD>')]A"O'AX7B0\$8D>N"(&Y\A=#"APCW8BP!Y<F$,:2F5?\OVWO_*>
M-T`]@*KVY2&_`C"P``^LJWX/&`*QR(A#'[J%+>B!HA>E1$;_;7*4:T%(0MD"
M\4A%^K634B6P&ZP*2]?5KG?%RX0OUA<*YZ7"%:+<+W_Q:4^/NK`@*XPQ1$T,
M9&C>PZ5:1H@2:VJ2H[KD*%^U-+I1(F\^YD3:;%5E7L4R6(LSUIEYN<O.R9D7
MJTYF\&@'ZW)5\]'6[,:OD^<__;E/G.MH1P!I3>,&2A#;1=IGPTI\PQ$*P!VL
MD8P*[<T-+-K'9&O$H<N"T@T^^L#?8@0C%,RC&3B`-"%LX(84&.`%C6,""AYG
M!#+D8P&N?M(KEL2Y5:IR2IVKI10D00-K[+:7OU4=<MFDNENS'KG3)H$?A*V(
M.)'@V=.\Y@;>8.P>Z!X?L"B4H>CP_P?GL4`-V5Z4)][0@QY\`E+9`\.FO(<`
M>(J/?*C*MP#X.6_O=S\A!^FO`-H@`(%[@5CJ)U;`SW>#"4S@!FW(2"P,CO`)
M/TN!%L8)!*WQP`DFEJ`!Q6&YW;?X4=;@&57(`@BMV,>YV`F=W+W(&,K-6`OA
MF`S=V%#Y6,'`W,Q-1F+P`,0\1@@2V65<C&A@C!$Q6<:,1I1!V6IH@S8TF3:0
MC).1!LATU94QG15IF5@91]1)!W6051@187:0D7B4F5P53=>]41S%!S'P`A1&
M(=9(#1Y5S7V<70):Q=HEA52\'=PY"(8%(+;<03`00X7P31T0WJ25B.$XV@M4
M0@I@B"1D@?^/%,#<9(*+Q`,*I`+B(`[DN4$"5!(*=%:I&4F1($F2M%:2K%+F
M(&+GV%+I+4$P(,`[90#JL!X##)?K`0#L`5.;,$#Q9`HH#,_PP(GO&5OOR8$3
M3%,K@@$K#I\G%%\XV0(+;!L=>((N.($31!^DC!LM<$HE@D\4D$_YW-<D#!CY
M*6.KW(``5`'W(8NKQ%\;")SZX<H`Y=?Y(`NRG,#!M4']/11$F4(B6!3#28L7
M#(`P6(-.T%T`ZH0$;5C%@4LN:$)@*84&:9S6M!1,@9S(P5A-G=P$4B!.Z=A?
MY`7+!1EB_-C+`=ED*,9D6(##D"#.461E]!QH(-EII&`+1IG1><S_:?B"#!K=
M:M!&+T1#%>W&#KJ,T\6,%D$=S<!D$5H=F;'5T'`=$S9AFSD-%$(A-4#A%=99
M7HW=@&@<4[3=@BQ%('&8``K2V=`=.B2##F0"AHB()!!B'>:(H[F!$%0"#*SA
M!VP(%5!>%E1#)D":'X:2$!C!Y*U-J47)`L!ED7!.Z,6EDH1>;=F2E4C")'X*
M;[$![=6>L(D`[>7)(3P`,#V`<3D;&,@!->T.L\$)G-0.\/S.-?7`[W`7-O6`
M\AC**/B`\VB;+?B#+I`F+(A!.N6.&"`"NB%`,(2*/-%7^<#/^;2*,ZZ/;>:3
M%^Q3J@Q8]\6;0<4"!'A!,T)`-A;$-DZ4_R4DG"EL`3C67QN0HPM@E$:%`C&L
M8]W]GT\`X(,X18A1T%#4HP9I(55PA8J%14S95`2JYWH.9`7F5#'L17P&%8\E
M9,,8Q@=^H,/T0@A.PT1.C)$%$0IBI%1II%1QC`MFC$A^AC:HC!.1I)-U!DJJ
MY$J*U98-!Q!&W<P0X9C1Y'>D!]$(#4[F)!R]AQ02@T^2'3#,65ZQZ'A&S9XE
MB`$VB(>%86+!X]G8W1,XP(_0(2%^P-LX&BC)(0Q8I6;=82;A0`)4@XUH`5I"
M'N-('ECN@R$B20H@HI7*Y:I)3I&D0.>-GI2(#B4B`!=X"6`6CQR@J?"`@9WX
M@1\H@A_D266"@O]U[<Z:FF)E@@$_X.D&.,$J'(&>/E^A*`\WT<$18!L>^,,N
M.@&XB8%ZP0(Z.,$]=,_W_(&HU!/Y1`2Q-..`G4]O)F.K(,L(&,1!&$2G!EQ$
MO9_[;2.R=$&K&E`3Z($I>$$LG$'];0$Y3B<:>($*(,-UMJ.-1EP\DI2X%$6Y
M#,5_]-'6Z.,WG`6[P%3(^:--E1Q[MJ?*&>1!Y@4':FMC<""W*J1B\.<(5N2X
M=HS%:(S/:230>>30=88,ZH;)/.@3Y>#23:APA)7,P*27J57.&&$8^0P2:AV(
M+J&((LV;Z21/GFC"`J50MNC&;8U1%HC7$"!B@0TAN>-BV=T7U$,"$&G_)D2!
M)[TA*%T"52I:)B2`$:"`R48!-$@"XG0:Y"T.HB52J<66*F&IXFS.*TB.ERH)
M7!I`;46)*^TE);J#7UK!T0*"'\#)F=)>\9#`F9)B,U&3[O`.!5Q7=EWM[NQ.
M[IR"/#S3)S@!:19*-_F##]C"$:S`+NH"+,""HO+#\P%C"W!!:[YF,>J#`.47
M!-SF;;)?&_27O:T$`21+,ZJ*0)T/_"'NJH2JJ[K$LE@4%+B`'DS`P,7"%HRC
M=)HC.E9+_Y&-=LK=.P[@AS%(4@86`FHA5XA%LWZ<M*ZG!$K@"LD%05K@7/1%
M[<80#17&MG;@MSI&1/+G[Y)K@.I<R%PDNOI<_]!!V8)J`\8PJ&QL0_*^(!7M
MQFHP0[T"1P_&#!=A*'=LJ'901\#6)-"<V4W2%=BYD1321Q3.T5XQK%:8KAX=
M8)^)+L5QF&))D-G472X\03U\0-V@`-Y\TH[X2!;\*!-$`>-HT@=$02==@Q\^
MG@$(P<G.#>6UC1%8:>:PDJO!9>?%I>2P$EP>2=`*0@+PY9CVTB%T0F/^SG/=
MSO`(3_"DJ1Q8[=1"D]5J;31%D^[P`S&L`KF1FQALIBYP4S>A;=HN:@\XP0JL
M`/2-TR9TS]R"3QK0TP]8POD1;A449_D1Y_EY*D`MQ+UYP/E,@JA.`N)"&(1Y
M0`$E2ZLNR[)``;-`[O\6>`%$62ZN1LNNJB,[9F>&:<M2!IKH`G(7ONA_%"4'
MJ4NS/NL(">2TLFY[LM!.K1RVUN<.&96WREQ_BB`FEZ#.,57%E&N!_IRZ3AF[
MYH8-WH;(5%'*5*_U^D8//EV^!J&&RK(1=FC6`<T9D2^)SH<3SD<43J%/\I75
M``C[]H>YJ%W$$M9W6M!(76QB.:4UY,(75(./ID(EY(B0"D$J))J,@*6,$"*)
M\$$"-)X-5`+??)KDA4@WPP"D,>(%OX*K"4+HO0('&TG/-DE>@BE?%NT)'P()
M\,X-5Q,^7--D!L\&4,`&X`/5/E?58A>=3@$[G`(>`$$IG*8/QP`^++$N<*;_
M$J?M\RDJ]'V"*WS")K33W*Y;`=`7J1#`#-Q`<7)?^0V8^?5F,W8J`8@JIX:J
M):`*_"GN%GC`LK1$2[0Q3-0`3#2+(U"""R3"P=VJ':,C_]4=&6:+`(+N.RZS
MZ%)%'TG%^^K1(2ORLT(@0,;8ZSKR[-YN$<@G[@J&[FKKMC(&?^[G8OCGN`+H
M@&+D1OX<1YID@C*ORF#5E$'1E<$@*[<R2_J@]DK'<SR']UX']WJH+2.A$KH5
MP;I1+S,-3Z9OUI0=%A(SUHPGLG*-,E,LB$U0Y^H$-,^!.63"C5SS5AI`5_Y(
M`EP`6/I(%,1()H1SDR*.:QN`&U#!/J16Y>U#';@!_^6\<SS#TB'*<ZHQ8N8I
MCI2@4NB4,`+8V@-T@A]L[3-MK0W3*060P`9(4PYCEPW;L#+!PBJHP;91M$5?
M-"B`6P]H-$=#GZ(Z07FU+2R<6PM0XC#"Y@_HPR1`@$P'>,!Y*J=FHQ@#N!47
MT$H<"_SY=!HW05`+=1,4]4L4];,\"U(K]<%%)R6`0SKF1(;ML<2-S?V637<>
M15(8!5:\:"$OJ[,JPU>,$`D=@UA/JT#:!4%::R0CI%M3<K?ZN%Q'QES_)Q!9
M)"BWH($::$9FU="5LA2UQ@O>1LJH,F%?;W$L@B]D^5IIN;ZN%;_Z:WC4\BVC
MV<"*J)OI)(DZ#54`<U`V;/^>&>L7@LW$DK8S+];9."4Q:"P,6'.0*LZC;3,5
MU$B/U$@"*``T9,$_Z!TYNX$!0/#B:183;$@=&$$^-,DK[$+-JE(JT65K%4D^
M**+.@CJ8T@#1FLX.)*85(+364NT_7Y/M4$"Q@0(R'70KWHYSU0X_:-MX><(G
M3->O2U-']T`I*/&BN@(2[^*QMVW:KD(PTBU*SY,EM/3Y46-,6[OYT70^G0^N
MZ-L-K,0(.,0$I'$73%2$2W@-H+NYLW%1RT0"44(BF,(X)@(EM,$`]"H$U9T8
M!FL`4EP%(853E-0&D1AYQD&\@$4_SLN+,;+)W11<Q"Y0T9A?V*Z.T2>0__BW
M0D;_1`JY)@=OD9FK$1EO$GT&R'ART%45:N#&$PGV,S"HE5>H;UC'<D1'AE)'
MS?<,8WLH^(HO7*E1UZ'Y+CM-T%,#,`S]U:SOG8UG4<KY_'Z88IG-H"46-!M%
MA02IXZ4`*KS`/NP#I<%`)EA:`J0!"DA")B@><>N=&SQPY$%.:A5`)EP`#-@`
MEW9IYRG.!M,SDJ@:7-9SY\T2"7N*"=_:`UA!8UI7>3^7[0BT0&_`=V\`0N/Z
M[QA;*VZ`#^!!Y>,!HSB!&%33[@S?\R%Q1Q_[1X?M+BJQ*+03):(#N\%F!*QT
M^J5?2[>!WY:?3*=?&^C3^7@!I^H3X*[$"5"XN4?X%5Q!_[I#00U80A<<?_+7
M0+LG$!IL.#G&@@H41:_R1$=I9U4'Q?VB.+&*2V$IQ8M_'#^24%FX"\,O/+7Z
MBUE'<L#X5)#/G,473'Y.I)!O<H!^,A'A=?ZS8,4T$4`\V_8L&D&#VWH1'-C+
MU[:&OICYDCB18D6+%'])S.@KXR(X'A=Y;/#KX\=%(QLL^H6R04N6$ERVA#FS
M`:^:O&SBS*F39T]J.G_R^CE4*%!@U(X"4[I4&#!APH@!B_J4*M5<PJ[FTKJ5
M:U>OR'*!U2H6&;([9<_F"G`V`+(`N8(A$_8DTXL7-MRD0$4H0184":AD*D"E
M#HH"?9NEN5"IDAO'*0P8J`0#!O^.#TQ0[-OW(L4"*2EV"=I%ZE4*0:]V+2"U
M@/4"TPL$M8X-FY0@233N('`73`6;!P"LD,`W)09QXC$H3)DR/#D%4&`V@*$P
M'8STZM6G;P""1PD>.M]7*!<?`Y8373U@]7#2`[T3]^I7N'>R8L4J!2T0((@T
MIT`$_Q$F@0""6`2$H(T;!#"P#0%N@,`++VZ(,$((;GAP@BHF(4"?$2RIH88K
M++'$`P]"#-'#&IJPI(L1NK"DB1JZJ,&1&=&H$0U*$LDQE@'",BN88,(Z*RTA
MS2KRCCNV`DNLK+("ZZFNB,DE&:RHK*J%.(91II@LMRRFB"^+*.:8,+_TDLPS
MS403S#7_BRBAS3?=C!/.-RTH)DX[2_@FSSVG*:'//TOP4]`_`26TA%X(G:87
M'J:9AE%$(554TD@1?2:A2Y_)%-.$+,VTTT\]S70@47LIM:!30RUHU%X0\N69
MAI[1YJ)9:>5((XH:\&4DDS[25==?3EI)V)A8(M98G&JZ2=F>?`(*IZ">Y2DH
MI)!JREJEFHI*VZJX?9)*)K'RBJLEQ^J*R++:<JM(:\HBYHDT[JK$@+V,2."#
M?0(;#`84HI!$DL0V:\PQ(5`Q((4/[*+B@P*8J`,&&W9Y)9\43".M,]A2DZTS
M02YF39#52*DM@24"R"^8#-@X!(!#_-A`N>'$PX<"?,#`1V;G_^20([J=-^AY
MY^J<`$(-.HZ@8V@G*.!A"EB2*X^]\LZ#!19=Y(L/OO4TN4^W_:+X[P=+)IAA
M@@8-=%#`!R$40(`';ZC";;<K%,"#$4;X^L,K0%311`^;:&+%#D?P($:_74##
M$2)LM`,-%Q+9L<<CD0F&R"'-RD7((,D-2ZMPN>)\JRBO\I:J%KXI1IEABC@]
M=3*W5--U,].$G4TY:8<ST-MOM\""VPL=U/=&?P^T=T7]=+31XQ^=5/EGIF&>
M>4XYM33Z3Z'WM/KIK:=>(%:Y-XA52[=QR*&(:BW?HHTZ^H@DCU;ZE:5A5S+6
M)9J.O0G9G9AE%MIIBR*JJ*2JY10!"O]P6]WR%I,Z)RYQ98XL12J26C#WEK+D
M@BXV$((!A%"O#Z"`"B_`00%@D(`"'"8+`+,!8]P@!"'L(C(O@,$+$L"$`F1B
M'S`@1#Y(L0N*;0PU'%O`*P3AP]6\@C2S44ULB&@;W+@C`"=C@Q569@67*:<X
M+UL.&):3'#F`HF<S@\X&;$8SFRGG"&KP@0_4@(=1?*(X,6!'#)`S-?;HPFKO
MF<]ZWF"U3]SC/ES(#W_\<P7_C(``,*)0V29TMK5):&Z6(*0'3C`)NOU@!!'`
MVR5K`(43H4A$@NM0%V*$(CWH@1)$"$$([)!*Q;D@%J$HBUNL$9?)7<Y(04J2
MYA`H#+%X3BO_R=A<E:R$)2UQ"76Q\Y+L7@<F9+)I3K5SIIWL5`0+M&E/>M(3
MH(27S4(-+U"(FH8%D->HY%%*>7UR'O2F5SU0J3-4H<)4-%B%$/`I)%.G:M6K
M!B(K\]4J(^C#2`-*PKY<#50E*4%)_.07$YK`)";X<ZC^G!4M:/7O60`4H+6L
MI2VIB,Z`6>&E`CVGI')9SH'J,BDRV`46NERP$D;0(!42D(8T&*$P:?B`)*!1
MC7TT!B\IA(QD/@"#3*"`J(2Q(1`78+`%I"8%2&6J:V+3&5*D@#2L"1EI:B,)
MDNG&B7X`P`.L``KB)"=F8IP"63>@,^N`0JQ5I")Q2H$'-:C!%G18_P$<\1J#
M<WSB$^KIP0ITX0KUK(>P*RB%$R2`'C[B!P%<^$-_+/F?"M2`;&V`0!4\Y$@/
M5`%"DR#1A_QC";R!=I!X$^UH3]3)$XR(0W[K0HI.H`<7.`(-BD-E;>W@!17T
MJ(D_FIR1A$1+7(YK<PCTI2^C)`Q?6L5*WU!&$5!W.MAYJ9AELFXRKYLF,#FS
MF;@KP>Z^&UYN]FEWANI=\(#G31YXTWCDC-3S#O4-=I;*G9JR[WVG-RI-R;-3
MX:.>/`N"SX>0;Y_G@P-))N)/D(`DH/!+R2^&E5"7V"2A]\N)_?(7T:(XBW]"
ML>A4+BH5$4\E=!WMRD?%Q4NR8.Z!$CR72O_G80`MU"$!1*5Q&@ZS,)OB-`T)
MJ(00!":$GU8"!RU5&%'W801"_)`U!LO'4IL*Q-1P+#4YC.II/';55RQ`JR7;
MC0J2X`<&K,P/-L,B<VH&G>7(#!^@($'.1!"=YIP59N09!1U&X8_XB"$&RH`C
M.SXAM<'"0K#QD8][SL-75[B"%GUL+"`%^9\(C&`&3(B%93M4@PI`8;)R\]`C
M*A"!'XAZU%ZKY"4QJ3<1;4$/6X!D%R`IN%&Z@-90H(0J4QD&+X0B&>BR1A-_
M^]O*(6DK6"'7MSS:2V5_BUM7(N9SAU&,-$4;N\M<YNR:F6W:03-.U>23GZC9
M)_1RLWC?;-2BQ*G_/'(R[]SR[11]LZ<]_+:3W@E!%8`)HJKO<<]5L-)G@2<"
MAXKX<R*[`HFN&!P_A1=+PA16:$MTDJR'-BM:%.U?AX7!BXPS)<0:)09'NY5L
M!"Y0<TLRTLG1E?*RI)2"=:%"%M*``X>E(0I&H$(!4/"!!%0C'I)H1&.$X)A+
M1,8`+S#")?:QL"A0(16IL$$^2J/#+4,L-*]`S6LZTU0W3/6'IPD9$E]Q&R\C
M0`5G8(`?'M`)0,PY9E84SQ0V\.8CB#4Y;9P"%H\SGSS2AP)P/$<,`IV>]/2@
MT(9>3P\^L>A`JV<5&F@!%]S!A3F8P))XBVS@-@L!`8`R#P08004J$"-0_^>`
M])/^P>E)?6I47^%#'KB!!S*I!RCH840C.L'M73!KQKF`$I2H;1ATO5MT_4B6
M)[\<Y$1*KA4CNY=82>YR04XZTT4WVL]E7;6SJ\SK;E?;ML,=>'<'WO&*MWC!
M&_>A2L"HX[57W>J.;_2N%^_YWE<@];6W]_1[D(0@)'P#!OC`?>'`!.Y6;`4D
M<@4DUN<C1B)8(DS"&*H!%@KB)"[#,FQ_+"ZBJ"4IL"7$H&*C/J[$0N[$%.@K
MRN4L7NFW(,B!>H2"',#FL@`P$B`*3."%%H8)$L`!H$$2KL$Q!N:"(B,%"$,2
M4,`$<*X.ZH`S2&,7,F;+=*@VE##*@*BIF(QCBO_HJE9C9+R,-Y+@$!3A`1C`
M"FK&9<AJ.,9(9I8C[D3@.::##,\*[V)`&OYJ!?:.C?YL\-`#%OKJC@[O/=AC
M/NA#!AR/"^Q!\@9!D"+MDC8-1AHD#V[`\ZZ`0^XF!UA/D$ZO;NC&DB01U3*+
M1*"@;Z#@]FQO"VZO"1)A]VCM%'TO!+R`1WP-V(P/Y8YDI(Q-%HLM*WQ)2GX)
M!)_"V88)VK)K3)`I&+6/F=:$NXR1V\+-VZ[)_(:'W-8OG(['3]Q+ON1+4M[-
M>>J-_M0IO]ZM5%:%_WHA&N2)50CL__:IGPA0(MA'H`+JP%IBX1"JX>3'X2YL
MXJ0%`SGL)Y:"`_DQ6T;_#.28;>1&L%Q$2G/:0MA,*B[B0EUR80X<(#"R`(9&
MB#(*`!IP8!^JP1PRH0Z"K@>)3@@D85^8X#+T!096*`7((#*$@,H,AJITB,J(
MJ#0X9LNHBHA4HS86``O=(3\R(`D>P`\.@0%(`(S`R`R3HPS7$`Q$@`1J9@V7
M0SFF:*S\,#X^X3CLD#WX2@_7@S[L@3[HHQ3HXP@",?+X8Q(O*0)(+P<>X1$(
M($%@3],(($*N("W34M0D;2Y73Q(?H0;TH`E6"Y)N+S!O+Q'T($=.\3!/,194
M('+<(AC2I2T@4UV"S2P@9Z02"*2@#YB$@71\4;JNK[JP[TR(L1B[K]N^3WBP
M_VG\S,MWSJ\7TD]2TFU0**4:*T51[,LV$Z)YZFN=-(6^QA$<[T^>OO%[RM$<
M9T4``Y``TT<D%BR@%G`D&M!8'I!8>`+#+(P"*XZB)BJ`KJ4I-O!:/,XI=+'$
M!K(\;XDL9@ER3!!=VH*"ZB$-0G(?1DAA1N@%0:`9,@$&!":%A(SH$F"G(($*
M9.@#C-`&DJJIGK#)=L$-HLXF#8`U**8UH$JJ8N,*ER`_$$`+`4`1QHP!Y.#N
MWJ[MR$HY0*%E^FXZW@J+\(H"G.`-WH!J7`$/8T`,!B_1Q,`]WJ!JW&,%1,`?
M0,$K`?'Q(N^QT'(NZ9(N6<\2;F`2).D1/$``",!()?^1]/`R+5=OM%2$]B9@
M"[A4,/4@MF:M%$OQ%,64E7;K1YHH7=+B+=[B^(9-28B-N&K1*Z9D2G1Q,X5I
M2X9)-*4M-+5+NYC)&$L33P#%FK[MO)K1_+P)G!1%_8"G>2#U>12E&L^I4W0S
MG;01O[JG("XE(7QA4RTEP!;".,V1X-11?7ZE'1?NH"0,`F7"525.`G?".BEN
MPSBL*+PS5S>0'ST.(*NDN,QSI);$!!%2+<I"(0.@B1JR&@`#!Z(@#>J`$/@E
M,QP`/Q>C!X5@Z#I`,A+`#6!`Z13C`@CAZ9;*`%)#J91*-!:T-!XTAU@C8TSC
M8D"&RTAF)\DN";[*JQY@*&O_I@S7;&;""!_B3CH`]BGQ@1^4@QVF(!K^*H\(
M"Q;<B*_F"/$&:P5Z@&K*PQ_T;`4V5BP?K[&>P`2D]$ASH`)*=B]C`4)J@/1J
MH$..=&0M[P=032TMH0HF`#"Y%#`#<Y0(,T>^]`1RI`L(TTSAPC$=TZ0BLSTI
M!P5O:4X5*#-!4/I41[J>ZYA`4QA=9S2_1%!-,W=X![W`]E%9LQF)QWC"25"\
M"5*HD5)"Q38S13?E3_XNY3=+Q3>_1U7P#R)(E59(HF\3[%88[,':,5@8D.$<
ML*&2!>(B#COO4:(<EQ<&2%>[\Z*VY0.YA3P%,EA7[!6#:^5>*1A^+1C<)3^)
M,#/J_\!9"V`?L,"$@(P_?=``+B$!ZF`?9`H%,H'IE*PSR``R7L-@=D'(J`SJ
MI&ZIW$`T7",*Y_4*:0!#3^8,````2.`0#@$0P.BL0I0Y7B8&X@Y%1[0X5!2O
M/L$)/`'1T&-&V>-\*1;1^%!CZ:-'XZ/Q&`L!'JMDZ=)D[;=D*\#UO&`"3HM#
MJE1*+XE*-7&R.O&U.E%G?Q9HOS2!`U-H"U,/6DD3T/1H6PR".A=)WC1.FQ98
MNZ).-7,7\S1+H$LTJ0UKL59KM[8TJ8E.I(G\#'49$?5W5//<TFW]O,EYE@=2
M._5Y0$7>Y,T;[V_?NL<@B-A[?.'?]O8X;66)3W41=*57GO]S5:/SX:C3.F7U
M.O/'`ANWHB)W5[^S`POH@T4N6)MV6#D7+3XW<D*WY41H,$1(!O<A$Q)C,8),
MA2*C`]P@"R@#!3"#"3+A`F"@#I)J-`X4-G@7RG0(8T(CD4MC-;).-:PJ)[<J
M/\KN>?U`$;B0!$[4[;#7>L%@*(_R1)'##=OH:M@#'6+``KHAL7H@&=##K\R#
M:CB6?7\4L.R#L22O`/`7]'AY+4&/]!ZA"]K`"R!@$L:`"33O"DR62I%42D^D
M`AY!16:O;YK@$_7`$5Q`,+59,(6V"XAV@B-372)S:8G$<K@B+<("Q;8":JN$
M,T?8,\/DF/PT^T8S4%18>*@)O-K_Q$[(35#*C1D?-;U@$S:3AQHGA38GI6VC
M!V[GK:&#>!SW#U11A562F%8.C(D5K,$,$"4*2B6F6#KKAQZ7A7&STW^H@2@D
MMQ\'J%?'TRHRUSPW=S*))*746%GGH!VB(`I@X.8F$@O,`1JH0`M4R'5_"@@_
M`!7JA0EFX#`"^05>P6"L3H>HZD"A#C26:I"7*C0BE&)\"#8@.0&6UV0J&0`\
ME`$`003.C`UI)HMF9CG82CK,$,W>3F'3PSPNEA]@00S$0&*?!FKZ$"P-+4?O
M*$AU0WY-`/1`;2T3&YI_N0*NP`/V5_,>1&Y&@&2/U+&A>2U%Q&8GX&:AP!&:
M(-9<311%__$$2GN4'C@1T&#7A('X*'A-+;B6*H<R,\<K/LI.1:?$>%%/H:M/
MRP08Z?F$M99KJ<F>HRG\;L=0OVUL9;A/(.50`EJ]CN<;8+,V:Q.'I<=2W`U3
M>9-Z0-7>ZG9[ZB_`YHD9D+BB`RXY3=47`M=7WN<=X3L>Y><!*6Q6%]<>-8Q_
M3KHGOG.`0LPIGN(?#2BW7UJ!5FPL9+JD%-)HA6$.XJ$`CE"&#@,+XB$>(M(-
MZKA@?C"H84CI"N`:[.+)((.%5BABGKJI\B$R3@,T*,9<8V,TF@HTC(@4W`"L
M`\!>QYH!WF`-`($I0[0XR*J*BF,#GL-ZVZBM\PHYYD@7J&8*/O]AKV,4?9D\
M*W=48S46L.&WL/E#L;E<L1D[L95T;+R@"BK$"V9@!![!LG?99&M`?SO[9F\V
MDZ!`1."\]KR4,'F6$G2KM8TVG),V@X/+EK8B+9A/7*`O=$)':JG/=*SK:H.;
MGH>[-&\GGW<GFL`VF_X941-%&@=:NA'%H)\'H2%%H3V%H7UX&_&O4_F/(#A%
M'/FM.-$;'3=BB9<3BH>EHU>BH.2;6*93<2-N`O&[5K<3I?=Q<K]XQ#:JI9^D
MP`=RQ1*<+>#BE9)5I>KA`@HCI_W%')IA'JX56^_8`(P`!E(A"S)!IM9A'XP0
M"9,J,IJ,=ZV:A18@'Y1PJJ3:-28FZRK_=,LDF7G!#``P`1-$0!&L`!!`@0)J
M)HMH9F;6T.#C;@,,GLTH`!;`:`RE9CW.XSSV^LEIM`>(X95U(=`,RQ^.8.2/
MP!\&V_$*^P],``,P@`@PX!%>'M3N%YIS($+8!FT:Y`;H)LWQEW[3<K(FX08Z
M>PO>?$DE21$[VP.Z=)MSA#!-@$?`&8TAZ"!/CJ0$?2`_"G2`2;=#V!?11)[G
M&86)VTW$K02..U#`ZX7++S6;NWA<LVS=OH:/)VT/NA?6MGDPQ=W::?Z\&]\Z
M=?_ZZWN(F"'.NZ(%[O!IG2*<&"786P&EF%5;U549JAYE%=BS.+\W+"@NRCM5
MFEL^;L#'F(R'_PM..3><CW7XDH$N%J8=,F$`)($/UB$+C("G!F;H#*`#4B`5
M$D"H1@@%+,.%7F"%8I+=2>,'L[HE!SDV'A3*7,,T"'E>]X$&;IPG\75E%`$0
MS%H."K8YR'!F>B9G<B:M=,9GWH!FG&`#6O0-T%<]IH!&%<T.LU+D27[D-?;P
M3D%K=G+R'L'E61X@'E48F*-@CBMY;MR8X&5"%84.%4*89$F@P1P5:F"L<.5&
MPPD3%#X4<$/`I$D3/(#T<$(ER"U;3L@\H2?6@%S!@@70B6QG@``]<P&]@XPH
MT5Q&D15%EBL74Z:YA#6=2E58LJA8I0H3UN*;LB+#BB@;5JQ(V;)AR_^:+;*V
MK=JW;./*+5*"KMVZ>.GF+5'"0HEB?TM,$\R7L.%IB`D/7HQX<2_'TQXCELPC
M\K=ISZ9]Z[4YLN?'O9X]"TU:=&C1IE.K[D5Z6^M>KD-'>[;MV6S9MFG[VLV[
MM^_?P'G_\C5\=_'AB^`L^J7\5P/FR9<WD.[<>8/KV*]+N,XK>_?OW'F)'T^^
M_'AJY\6CYX4>O3!@\(%MC?^>_M;[^/-'W9HKF56J`&K5%%1/W>%44DDMA>!/
M0"4S1Q0%%)`)%0FT8TX6%U3BAAL:NB%$"AT8@,H^46@!`Q-,1%C`-3"\4(D!
M*1BPP"XPIK``*30*L<`K!NPB!(TPOK*`C(+_[&+C+J^DL(L@"S399`)+(("`
M.PADD`0``#S```D,``((&!1,,04%,4R!#Q@;;""''&F^L>:;:ZJY`1AH.K'F
M&T[T`,LGNCCQR9YZBO%)#[I\(D8/_ASACPA'-+JH/_ZLX(0L&K1`)0)SF/`(
M!D1@\(A``Q%4P0@S>/2!`!^%Y(5'"MUP104770$J1U6L*H``551Q*TDEH33!
M%BQML5*P)\0DDPD#:&*-3@S^U)-20RFH8%(`3@655`!>M9]^7,4QC#+%?!MN
M6V"=Q19<;IT[U[IWM;M787T%%B]?WY3PS1[V$@;88(HIUIAD@O7B+V6-36;P
M8YDEC%EDHZ5VVL.J_S4L,6NNY08;:["95K%KM>7&C#;!A2QR<<(9UYMSODRG
MG'(II_S<="];EQUVV\T<GGC<-0">>>2MQUYZ[8T'WWOU$2W?T?DEG?1^_6$[
ME8!8$3@@40HB51120&7]K#5`!>-@.P5$(<D^YIB3R3XN:JBA$*@8X'8*'U`A
M1`(XA"UV'3`08D.,2O88XRLXPG@CC4W2^$J2*:20Y"YNV+B`C:\((N0"^]`0
M`)616)DE)ENNT8DB;^"##P5HR@&*Z6RF3@()@,Q)Y^NC4R"[Z&?J"4L/M@_:
M@Z&XBP%+HJ"LL`*DBAX!"J2EB**`#%)RD>DC1$3?::BA'N1!0PU!`!)#`O^`
MI)`7!+Q:$*@&C9`'!%X(T`8$NY)4Q00R_0K3]C$9*U,B>B"+1#!<.^M3`$(1
MBK2,<J"E.,5:37%:M?Z3E6UUI1AC$0M9OG(6<Z7K@NABUU[<I1=W]84N^RK!
M,<P`@CWHI2X66(QA!),8%0J,,=.H#`\>8X'*<*8$`L-A9T##K],@QC2;@=AI
M)#:QUXRF8JS)3<=F,QHF8D-D4!P9<4HVQ>@\9V71J<XB8O8RFWEQ.]O!67=T
MIC,Q\JP\/O/9S]J#M*'1YVCR49K2MM6T:E4%*P<L(`$'J!0$]8197IL#-*+P
M@7U`HQEIV(<6*E$)&U1""$*XA`%"9(`Z)$`(^TC_0S6:,4B\V<`&@L`1D&P$
M(QHI:1=#LA$I8D0*'!W)2#-*03YV08HF30Y*EY-2*)+P@$,<@@%R`,0A6H>F
M#8#B=&Q*DYR"Z24Y@&E,T!23-,5$`5A8LQNV<\4GMJF['JQ`49#RQ_$>!<X5
M/*%24\*4IJ3W*>I1[PHS\((7MN`1+[2!(0N19TDJ0I""_.`'$<B!^<['JU9Y
MY'U=T,.O6N(!8-GO!(DX`24@,`!A+.LGS-+:L_S(T3Q")8\*;`HQ$KBT;HGK
M6V`A5S&.@4%U79!=<=F@3.'U0;_XA2_3*,(FRO",PDRC&,48S#&F88&A_G0P
M%MB,40<3&KX@K#*(`0P-_S.C0\X@530X%`Q51U,"T:2PIT2$V&@N9K'8G&8V
M:%7BQ;0!LBBZ=8HG,QEOHH/%E34@9;_88G6ZZ$7M>'%G9BSC&=,(M)^)QVAP
MG(\;Y2C'!O8G0'B4BM3TV,>K&45K0&$*3X*1#D'B8!\.:`8($N`B+3CRD1]R
MFP'F5@=);#(3DHAM*L;Q`AU)3K4+*))J3VE*5"HI!:M,`9,,\`HC)4Z6@+OE
M$@(@)03LTI>^)($<A@D(*UA!NF_:P.KBQ$Q`.!,,HI.=>&4')C31Z4][VB8K
M>F&H00WO4<<3GGR#)[Q5H!,!SELG]`2"@7YN)`==T-ZO%-*&[TED53>8Q!4*
M$O^!"/P3H!$8P4D$<#X(0,`C(*F"'IK@$BA0HE@PL9\>7-"&4"#CHOYC5@"C
M14`_7FM`";1C`K4EH/MTY2MA$<M:SI(6EZ+KQS!EBTPYB!?`\`4P=)G&,0Z0
M@0$4X0LJR``6.%""/0R`!E@(11F&D($#!)4&0\""#HZ!!!4,``M?F(4*L)"!
M(2!B"4,8`@VF@8@!<(#-!V"AP)Z!92PLH0344($"5("$$M!@`'%>0BC\_`TB
M3JQA2$0B69F8FR.*AAEOS?04278<7]#UT\[9HEZGL]>^@M$[@AWC=U9]QIX5
M]CSHL4\;$7L?8@C#UHV]3QUEC$<84_8.!G*QBYF%#&[_S,$!"7``--*0@%0P
M\I..3*W;7H"""UP`"V.SMB1248<72%)&I'@;*H?DMEKV2$:C1)*2FB2C(>T(
M<I)K4N5R6:4D=,*779(#`SIA73]@%W5RP.[JO`0(Z<YI`[$;$QB<X*8WI,D)
M%!"#Q*?``V^P@QTQ$(,N5N#-2#GAXR#?`,B=(`-T4NEY[.QO]415`Y"D:E6K
M:@.";V#A233XP0\.Z!6NT(41>(`DJ]K>!)I`"3UX``HAT$.(96(*4T`4'*&@
M1DXP^BS,\K&C>41@KZ="XY*VP%O@4@8%XU+!EIH]R$3V8&'\`AB;\J4(=6[&
M-SC0C#)\P0$<@$,ST%P-$)@A_P-\V$,9JJ&#)30#"0=H1@;,T`\L*,`,0W#`
M-@[P!1K$PPR(:,80_@Z";>!P,#0`@0Y&_XQ,+#X##IC%$.H!Y6;0@.YY1HU8
M+X8;VO=B-K5Q#>XOYAI?M%73(2.97(7_:;ONU3K'[VMV:D;&5>=L/*DV#V$-
M&[3#PI$8;IQU?;"/ZUQ+Q3]7H?'6)RNM`6*MZDOI'U.>`(),-*,:";B&$#;$
MR+6Y#16HP$$6A&#M5,PV`6B3"M?0`2%"2J6$2F\#.#'B6SE"(T9B).W&.#,2
M;TY"!9;C#NX0";O42[_D!W+@.?U6<-FU)JM3@@3')N`U3;-33`ZW`3T0<5/`
M#E-P#O\Q4(.^@PZN``O#(RE.(%\K0%\K8%^6@E\H)ST5H'+N-!"/X`&LLA#;
MTRH(!@$S0``X5X4!A1$U\!#8(RQ>8`J40`E0H`HAX`@@5BPGT'0G8!,GUC\_
ML6(K=G72DG4@94<CQ4`UMA4/%$$Z9D$]9G9`!E-#]B[M<E-%8`%)5@+#8`;5
M,'?-,`WG4`8.D'EE<`Y#,`#G8`:'!P(#T`?>D`%+@`2'UP>ST`P<$`AE``+/
M<`!#H`'0L`2C^`7G<`#5@`B$\0P.L`1]4%2@B`1]@`C9\'<JT`>**!K5(`-%
M,$2/5GMDE42WT3$90QK`EVG#P6DF4WS1,6IZ-6HRHWRH!A[_-\-JK:8>A458
MB;58V3<?W,=8=.0?(K5U6D<@"-)B2R$MF35U3#$'YM`.T"`)U^`A\\<AD31)
MDR0$DB`$6G`!,)`*%Y``DE`)%_`/J$"`'9`X?J,D/`(C[=8C@/,V,R(CQ?6`
MBI,X\38Y\]9<5G)OOM0)JW,(_&8%?E!P)<@Z7B)=,IE,8#([%(`/8T(!['`F
M%`!R82(&-1@#U?0)KK!Q_O!QB1).BK*#)&=RZ@0]T;,I1YB$&/$(3:`',=<J
M(<$^[*,K>:`/5?A/%S$0+9<J\C,_2!<"(8`&+8$&+A!BB:`_4[<3Z*<U'>5'
M6C>'7-<45S%')A5V;#%V:&%!?YA!_T$6B'<!+WY1B/,B&".TB'3W#'U0!AJ0
M>4O@#4,0"GWP!8=7#1S@#<>0`66PBX!!`]60`:"Y"=!``XAPBZ_8![*("!90
MF[:H`](@0K*(!,<P"]7P=QE0#(H(!W#PFQ8@>ZMQ&V6%,1IS>\M9&Q\3C<'G
M&YTV5W65''G%15RTC<O7`,R''>71?&44?6B4'N-H?=LW:TAS:\"0CKF&%>#G
MEY%%?E-C0!R%E^F'`$J1#%]@#M``#G4`20+JCY,DD:2%"C!`!?N0!0ZP#M=P
M`76@!1))@&_#-Q7J-S527((3(S<B.#4"2X"S(_E0DAFH`DD`72P)"&]@!9W`
M;XI0<"(0D_^GDR;9=9-A$B;05(,Y6H-@\()3(`:NX`1@X@H=!RFX`RGO)4["
MXP1"."7Y)95&F(2P4@'0HP?=XQ"Z<BOL(P`0D`>3H!%56)8#X2D,4:8A!A,G
MX`A$P)9NZ0%H$`(G`#\N$`LJ<&(9!4!X^H8<%8=,@2TOYFNY4(?BIQ5X^`UH
M\5)`Y8<^YE*`F'9#9E,@1!B1^0TT<'B(H`"A,(HTX`U9UIG-4&>1F'@'(*JU
M.7A#H`*3UPS]L`G50`.O*`UFD`V(,`L<X&6"A@2(YYLT``<#D`V;D`$9<`PR
ML`[$F0U?T%5#-'N11AJ\)QH5$PVYQQK2&4732$7(<9W*\3+201W_?,6--1-&
M9/2-X-AJT\<SV<<+Y;B>[=F>NL8M_!%9[@@@\&A^Y4<4F)430?$$YE!M-@!)
M_L@V$2F16I`%E[`/.)`&T%`-Z]"05%!;$QHBJ"0$&.FAHS2QB<,CP$4CJ[0+
M^;!ND_,D-"`E5&(EOY22:_`&?M"BG>`E,0J3!J<F-3HZ8/()XD5-LA.#,7`.
MI&--G^`$D2(\3=F#*R!RD=(#(]<G32HE12B5L[)RGP(%!-8&)-$&4LNEZ@,!
M^N!@9%F6&-"UJ@`]+F"F9YH(:$`$4AD"4'!T:-`$P@(%7F!B_Z,3P7"7/1$`
M>XH@U?*G5-%UW/)UX6(N@&L6+'68BXIV_XZZF#35=CZ%B(I(J:(%`D,P"WL`
M`F4@#4WF#20TJZL'`J%0!`=0#TA@B#3@``J@`%B`!$-0#:6;`4@``E\@FPX`
M!XG'`62F`/7`N=-P=R#@`#)0`AD0"A9@!I('!PY@!L>Y&J:AG,W(G+D1#:'A
MC!GC>],*',('5\2'K<AW':&FG=QH,\XGGN-:GN+X,\3`"^5[OFVDKD9#--S'
MKH2*'TP3K[PVKW=;=6Y8C\G`?E3P2/^:`FU3H!U0"1\PL)QD`BB0!5F@!6A3
M!R#RL(Y#;L3U.&Z#@&]S;KOP@.K&@%(`.39B@>F$`"8*70PP3&``"`_`;X`@
M`HJ@"#%)`J!`H_]R\`;F13HY.5XY&4U30)1S8DT^ZP\^4#Q'P"A'P(.1LG#H
M\'&ZD+0(\`<FP"G2(SU(2*6?\@B64"I:2A);RCY2^P,YP,4%$2I="Z6J@`%N
M*T\AUH5V$`:=<K9-T`5H"RPUX`4J<`=31\=W&D!%P6*6%8=:%U)5\9=986.&
M"E1]J!8I1;AGMRZ*B1=[862&:(B"\0V46@W30'>;,`M'51N:<1G?L`W?D%2(
M@`B%V,F740*(MPV8:+RS.@VS0!L)`P>880:8W%6(L`E8!0=(@,G?``<=`P>B
MX<L1HZQ&1#&XP3&P41N]@&G3.YW46$78FHU=E'S*=VK/!WW-%X[29Y[_Y6N^
MW)Q]V%<?YLB^Z_J^_*%K\.K'=G1U0J&75I<UQ/`$#E!;`@I)_RN1;G`V=9`&
M*/`!*%(`5%`(^Z`A/>+`JK2`CL.1Y$;!%%E*-9(XM=0DPF6!D3`EF<-+^/8`
M5J!=OF0%*9PZ`6>3K^,Z"8?#TS241`D&$N>SPL,/2$H\BI(G]G`$(]>#,K`#
M+9!.*.<I3SR54TP0!)`0M[(^%K8K,R``'K!@&]&U3BP](=`I9%PK].,%B6`'
M=C`]7NL(4$`$:7L";JL"0L$@4R>WT+)15H.WP?:.,08@(Q7(^=$584$69*<N
MB8K(B-FHBTQ3%F!D\5($K>NZ?3"90'48B]L8__'"+X-1!*CI`)S[##S0V"KD
M&8GA%PNC9U2%&:`A&IB1,,F:G`VSO!@3K;11&AD3G<L<5Z9]O=;X'-`LS=W;
MC=<,ON1JGMQ\ON+QS>4X'^O['NV+:]M2SO#*:_):GW>;65GSAOF*!?,<211)
M24(`6Y<``PF0`#,P`P6``G40T(00(VXCD0)Y)`=(;NMF2A*<L1Y*2I#S;@N0
M`"%+T5;R`%KB2[U$`BQ:<&XB`B(0)\K4)BCX.C6<DSK)`])4@V?B@L=S!$'P
MPTWY!HORTD8+*?P@7TZ@"0IPTU3"Q([07TL]E2IG$#^0!^N#8%QJ85W0QC6@
MU%W+U&O*EBJNU=?C<O\?L05O.H884`-@W+4G4`50``%S7,=VZ1-W`$!Y7#5'
M02U4H;<+!,CD_$!S?4&%7+A_:->'^RYYS<BS<`"SP!:(<`#U@E/^\MB$[4*8
M@7A($$,%PT.=D1F3@1K(&3%JWN:;/3'+.E;+21L<8QJE'1S56HV>=E=W!6K:
M^^?<:FHV$T;>R&KDR3/KH4:S;7WG>(Y&XY[D_+YI#=QYVU%V&X=X^D?0DK^9
M$$GSK-W;K04H\$C1S034[<_7D`HVD`\:&B,42H")4[$7&=Y!,B2HA+'A)EP.
M?>L=3`.1@('UYMXEZ][\MK+2!0AK\+*N4TS)E":Q,SL!/I1.T"A'X`,^P"C_
MUBX*/B`*/YLH0]RSD`*$L#`+$X[3)E"5)SX]_L7%^C`#%F9A([$J82@]JA`]
M*G[O*FX'35T#$"!S96K&CA`"53W&8SJFCN`!+J#C0@%(S:(4Z,=1>)NWD]Z7
MO5W.7/$-Y<)2<5V8BOI2B1GEC"DODET796$O17`,@F%D+<3E!=,O+937-?0O
MDW$9/(0P:9Y$#3-[8;7F#Z.\1_39HL%$ROGSTGOG<D5%<.`<2:_:=07HV5MJ
M@OZ=J18>XQF.B9X>Q+#-M:V>Z]M&N\U8A$KIZ2S<5T?<2B%`Q)T+3X#<*2"@
M^`?`E_`!SI`"1I``8Z`B!5`(SI;=2:):(<+=?&-*_^*&D1>\6ZV.L8^S),#U
M.()`!5'"WKQ$["S)DBA,`C%*`C(\)SM))QL@PSZIDV:"HR:M@]5N[4$0Q-2^
M[=L^Q,/C`_X`"[I@/!^W`F`0`YH`E9D"!2JGU.M^$!&0!WE@M5)KID10[_:.
M[_BN[VRIU0PA3_,D3QY`"4T0XV-,QEX[AGJ@XW9LMV'=AD`.;'$XY%93Y!,?
M($C.-!<_+H%[+H;IY(6K02`_B$<6&(;M+WR10BP/0U_.0I\'$-,$#NPEL->W
M@@@5%NSU[%G#APXA3G0HL2+$B!E[;6NXL6/';<^B/0NY;61(7\Q\K639TN5+
MF"M_^9HITU<#7XO@Z&SP:__GSE\->@K]M6AH4*%)E2YMP*OI4Z&\G$Z56M6J
M56J\LF:M2HP8KZ_`A`$C6W8LV;%I@1%;*\SMV[>YXLK-5=?N7;QVD=W9V_=.
MK@!\!2,#G`M9@&`!D!W.]223D$M"(*<PT*&#`0,P/ABH]($)BBCKFL&H`T.+
MD!2O7E'&7-GR90,IA+0VL(!U[!2[,.?>O5OW*]L+2*4@E8`&`@3N$&1(\N#!
M(0;.'W3J9,7*&NR>2("2LP',!GS?-W0'@X_">3#GS4\YS\^?/Q'Q?00Y(N)(
M$%&BCHCRX>/(BA7\ZZ&']P#D)X9`-E&@!7>4F\.$1S#`H`(**<SAP@LCR*,*
M"";_@>"&*KQHPPL1F[`C!!13M.-$%%E,49405%$%BA$GF(#$"5Q(9!)'4GP1
M1CO"H"264`(PTLA@$E-,L</\\FLPOG+Y"R_"Z,*+F+J$D2LNMUKX9IABPBRB
MB&+(-+.88\Q4L\PUQV1S3#CC+**$.>ND\\XY2]!SSV)*L&#/;TH(=%`]I^FS
M!($0570:1!-E]-&"&C5HTFD*JO32@IXQR"*-,N+44XH>&JFA43GJ92.1'!JU
M(8X>\D6;F&*5M2:6:"WJIUL7N>FF18+JE:BCF!)*`F&;HBHJJXR]JBJNN-(*
MK*^L4LLML:J=MEJVB(%K6[JTM#(O<*MT$LJ]F&02L"8/_Q/&,3=20,7=UBX3
M(@$A4D$AC6:@62>>>80@[07,%E"M,@-V><VRV`0V`!4#!L8,N-:$T*TVW7A3
M+06!%UB`BB60<R<2Y@``X)!#'@#@.2L.44,-)?!0PY8@?!!A!2?$V\`[,-*C
MH`<G-ECA""=@*>4(HCTA^HCY]+LO"/S\(]H?4(@>\+TW[!$CD'/D44"&Y!!X
MP@0)*PB[P@HPM.3#-CB<X(8;O3#%!318E+M%'U\D0D8BH*BBQBV\$`"*$R9P
MA`@B5%SQ<#N\4.&.)`-#[/$`"E,,2L/^$FQ*O;($-\MDNMU2+B^+&::(T=E\
MLW0W4V]S=3GAQ/-U.^T\U((B:/]?M-!&]V3T]D<'>G3127D@R""%IM'T^$HY
M/1743S%R7OE6/7JHHU1+$LFC;635?E:::KWI)YV,NBDHI,HWBOQBDR*6V`:(
M/?:IJ91=%JMGLXKV*_S-0FM_M-3*=ENX;,E;WMK<YL:U%\"0JS"'2=)B(N<8
MR<#+-080`@HN<(%F9-`!.,A")EYP`2-48C8%&U@'<G.PRV#,-AW8Q2X4%AM2
MO")@"\!,#&M#0^*X,#>"2$#'NJ:")(CL9-(Y!"98M@,DMLQE:F":"-X`"$#$
M9V:>$('1D`8$(,0L"%C<(A>9=C11X$<_JT#:$?QQ!%T([3]B.(<8V$&+';2@
M:P^J@"K_)#2A"95-CY.801O:`*(M>.`$IM@")<(0AA`@SD4^DA'>&IDW+TR@
M;R5RQ`F\X(A&PJAN*%(<XX[4N"4Y\(!WH!P"J:0YO'1.@%P21@OB0"8QJ:Y,
M8C*=+&W9.CG!3I=[TI,%#N4G11$J4(@ZE*-X9\S?]4)2EV*FI1B"*8%$)%2A
M8I[R)#*J5'GD5"=)5:D>$A)FP&I[X^Q>2VJB*W3B"B?K_-6O@H64]`E+*O"K
M"CWG]RQFY;-^O!#+6?JWOVEEJRU:`N#G"FC`NHS2+^9JTI(4$XS&/.82MY%7
M)K*0BC2D`04X0`$*"I"`2B3@!96@30IN@YF#/4QAN6GA;@:V_XO4!$R&&(,I
M*5Q(0QXN@0M=8X[)AGBR(R)1`T--(AZ,RD3L)#6IGE@#TIB6Q?XPK8M`X$33
MB.8#.M#G/4KSQPK`\#-BG",&K/B$+#0@1^7\H0"8O&,>*S0A$GFA;S?:0B'#
MH,A$;I)P>\WD'0&'HPDD`@-H:(('!E<XPM6-<#<(A3"0!$HE2>Z`4B*,8$[Y
MK;P(HW,$_5PKXU`,98Q.&:M#W>IJR;K6Z3)V>EJMG_HTI]_M+E&XX]TR8ULI
M1/5">,.K5/&0=[QI/L1X#3%>1:K9J6^"Y"/9[*:J7*42<I(3#C[QB4U:@I/P
MH<]7VPU6^MB7E&,Y!7[RNZ<^I>(L9__QXBQC88NU`,K>M;1EE01U2RZ2H=F#
MWD5<Y/I+8)PDN00&8S')@""\+O.N>51#""]`@6<*\.`":&$?UWB!$`X<KY.B
M,#6Z::G!"M92RDR,-R,.3FX6T,.=NB,8H0BBR*2#"25H8`=*4,(.B%KC&>\`
M#RV+:A>E^N.5`:$_8?3QCZ\J"JB=\6@TX\<IQ!`#,;CB$_U84(.X\`<3-+*M
M$BJ<'5S0!E/(-19;B`4:#HFX1"YRKW>3$0:T#`4*A8`2;:L"%&2$(E7<#;%Z
M9:QC'_NX=$W.+Y0EI64QESG,U@5+W0*@EX:A#-".:;2S)!VE37M+7+INM:W=
MTY]FIR=A"JK_4,6,+?!*G5M)\<"9E'KF,Q%B$8P,%]87H;5&L%FJ4TW$)!7Q
M9B]>%5U@6[<F,PD*K]0YE*&<#]G>70I5Q%M/9\\OO>@][[.J51;WNA>^_Z,O
ME^AR7[QPEK,)32A_%RK*4-Z!2=R`(,-@LS`+9B8!-YC!@Z$!@W'L0PA:,"EL
M4AA3E"(LA9BI6&]:<YO;B#@W)L48QU*\G"`^!SHLHS$FF(8').Y`!3BN\8Z5
MH`8L8A'D(?<Q$/@SGYC-)XOX^6)]5N"/_A`-%/SHP9/%\`E7N$(39TU.)!Z$
M23;GN44K"G,K3'%T2NC!S'A-T9H)IPJVWM$1$ZI!!?*V!1MYP,YV_WRZGC>)
M(L9J0MU)`J61)&NY__X7T03,[&89W:57AK8(HY43+6]YVM-F6K5[KYV>^M2G
M4O^.MH'W'?"4R4S>'N0@QF.\IJCWO.(>S[C/LV9R+7\JCH3D>M9#%72#/2LX
ME+.<,Q%?3\#7$V6_D]E+<=\\D64L\MYSVEO!"D#5J^U^BD6@VIJO`.W+]H-6
MJ7+C2N!_(W=\Q@T8@JY!&`P28``M)&`,3(`P"H10!RVDXA*QH4T'A&";B1'L
M-:VA(4I7<W#6F#1@NA&8#EV8@">D.!A`/-DA%"$"->"!`46L\5!EG/$DFK&6
M";*0([D"A*K[\(\S\@%1H`.GJ0_["()5X/\';&"'&(`R,2`K5V`%38BC!D$`
M+"N<H5N1NSJD+3"Z,#.%0[JKPVDZONJK+8M!#'@$*-"#$X""H/,Z$0P!Q-JK
M&U`!8;`&)#F,QQ&P)N$O0I,2);PLX+.O+`&@+OD22*.[23N3-,&[N\NT..&[
M.^$EOP,F0!&U0'D44JNM@;@=5/.=56LF:,J4:)J>6:.\:IH(Z<&UY<D\5JE#
M5Q&GSX.)T)N)/[2NE4`]\-D)U#M$[5J][XH*V(.]\J(?\VH6:U.+?\(]N-"6
M^BJH^G+"NQ@WPT"T_S*WACK"=7L"+&"-R_`^Z[L$2/B`#WBP06B'%_B'"Z@$
M@%F8DS(IA_&W\4O_#81;@(G1F-T@A1F"H1NJC1X*!IZ*N$,@@0T`!5!@```X
M`Q```0"\1@!4`C9@`S7@1FZDJB#@!*HJ0*6A#_LH(P64.7E@AT!HQW-H(RDC
M!YQ#@CB:(Q.(F\-9P15T@5@H.B\P,Q9TD1=L,SLJ2#NZHX-LJQ3A,J=K2*=C
MK'(ANU!R''0Q-\K1+U0"%_P2MRUQI;D3+4ICD]+"PDO3NTU[G=>9G=J!+3/4
M'=RYK3/LG<-[)M_A`>19B(5@%.*JO.:I-8V@'ER#0^R1IFT(B6CH0^T!1-$;
MMIPHQ.P"EF1#GWAJ'_"B)T9\1&F#1&J@/7ZZMO:B1&J!0BCT/7#++W(K_[=Q
M(9?(&1?$4#XL8#[,2(`Z2`$C8`+JBX(H@`;K2X!4>`&&P0W*>#?;"$S=T+`-
M([CS:YCRHRG<4,Q=@)@3TZGD6+'F>`X1``3K>(`S,`<^.(-L!$`9NS%MU,9M
M9(,#'$=QQ`^G2KF8*X5[X(%`0"&LZ0,QL(`,)`<D6)#DN#(3"!)]7,$@J2M"
MPKJE\Y$URS,[FCHWDT$,F+H(:2N"S#.'E,Z[P8#%"@5-$$+$2(SA$R6+3$+A
MJY(!RHM%ZS:X<+0IE#0XF25+(\F\TT(NS!->\J5.`S4Q7)0R)+S`*P%+\9UI
MV"TV;+5F0B[JZ<G*6YZ1L,->B`;-ZZ:0H)YP0O_*6%%*IF2)\"E$8'&G1)S*
M9ING:+.GK-2GK;P*:L@VL-0VL>26<5LTNQC/3SS+R3(T="/%Q6"WMT08`S`"
M2;B$?<!+:/C19LB&5+@`&!@IR[@$5'B7RG`W7\0,=SL87308EI(AF`(Q#ANQ
M5W"_C9%,Y0B9!\"$DCD9`.C,)*!&;!0J_Q-`&EO3CSO-E>.B!G2:5;B':+B%
MV$2A#FA'=]131-!-=^""!_E-WSPD-!@SN3I!1+(;P@$Z"2'(.ZI.YBQ(AG0S
MAR2<.WI."`B%B&R<ACJ[05.@0VO1`MI(CO2LCYR[U!')DG1/+3Q)5^U"^F3)
M_1R\8XK)1IE):!((FV3_/)Q4O$!1O$Z10V&5"%(ARN4:2I`X"5^3T)@(O>GR
MGNZY4&DM'Z)0-GABBO51"O=IQ/C!2DBLMGW*"G\"!GXZT;1(T0"*B[+,K!=M
M5X7ZB[Y8R\$(#".T!E,D&`.X@$R(O@R*!P=P@$Q(@QT%*1L8(5PDF/`[H>[#
MT8:IF!`KF)(BN(G)4I-JH<B4/_H3(B'B@R`Z@S-@`P;8(HQ#TS-(4V[$!#<E
MN2!PP/[P@56P!VRPTSO%TSW%FG?4TSWP4][\S=]LA1,\P5AP`3MXP44E@D<@
M`NLT6E5X3DO%H\)Y3@Q`D49-)$LE@A-!VJ@UVD>H@*-]!`@8@'()`'3@SG@]
M_\)WI:S,008":D)5RL1M0<](4X8J+!,P655,@\]7E<]>*H%/LT]"(<-"V<_"
MBZW#\T\`734!A29:HZ9A_<GF0A6(R+QH0)56:95?8U;N$;VF#)]=:8!VHE:I
M9+9%?!]O_59\DD2NL);ULL1^TA9,G"^WW9PF%!>TE%%2ZHM1A"@C089@(+`L
M0!A):(8+J`-H<(`LD`0FR(0'NP88H#"2<C?:B%[IA4O+2#_NN][&+!C>4!C;
M0,8E"`9WZ`>(TUB128(6`P`P90`&L`*4I;B,2P(EL#@&``+U#=F5B[E5*(52
M.`5[6`1VG-D\U=,[=<=ST-,"+N!`B`/=1`XLX]D5+/]4$AFS,HL1OAJ</$O:
M&6RK"'E.#LY@3:K:$^$Z%,%:Q)J0HR6"'Q0&`5.2B?34P2"TQ5C"<!O5S2I5
MCPPMT(JT-F'5DL2E^&0M//D3OAUBP75),U1#1\%5FOQ/FFPUWTH>C#BNQD50
MHKP(/`S*S/,\S/4>8H-6TG-*\OF):NTN#JU*UW-$$)4]^J&V$KVVU5TO_XDO
M3%3136Q"S6&[_5(HRI)7W'TL8KA7`T@%<]C1??B`!/B`>BN`*``I2;@^)TV!
M5+R,PD2IW:"H2&Z-+(T8&5J_RP#&8Q3&R$2'!@F`D!%34S89YX`.]56$*%H#
M(%`#&#,93*C?D%6$D/6!-?#_AT7P!@1NQX.)35\&9LL0X#V]V7;<@WI,*Q-P
M8!9T`:.KJRUP!#2X&S3@0>2\X"T3&SQB3H9$VA/&VJS=6JLS6@KIVDQE!&MP
MH-V-DG1+RR<A#-I]42VI$E6Z+W!K-"E$U4>S.S2Q6]0R22[TPB$68K\5-<#-
M'?U,8IWT3UU-O#:<%,>;-2FN-3I\7.,B">G!PU9YA@C=XIBHT)6XT*`HQ*(`
MW67#5FU5BGJ2G]@C41&M-F<Q43=VK]USVW2U$N`#/GA^T5%"6[X8Q01"$@)#
M`8;9A\<P`"I(@,^`L`*HA#JH@U0@J0,S&(11/W^+C4V>H/%[S*R&F((11A?Z
M#6!<_RDJH`$N4`Z(<PXA\JFUGF4&\`-%L&5:EHX'H&5:OK\-F%E@)F9B1N!A
M?D?`#NP"WH,A0*L`"%1!S4=^)+,M:(,3P#,>9+-LWF9NKNP,-F%QYMJMK;I'
MV%H(D`1D2&<B##3&$#3+<I*=7KN#JF'/,54<3L_U',DL_.=<RMN4[*65;,G=
M490C-@C^A)2%7F)5"]#>6CR&D":*]DG*HV*0L(@$S2;-PQZ/?HDN%K;-!1^?
MN-`Q#EV4ILKO\M"K;&DUAFGR;N-LF^DXYC8Z=E%VM>-W52ASV<[&P(++D(14
MZ(`7<,4Q@+`H,`(AT+<Z$#_ND^2%BY?8>,R%';_!9"$=(O^X\IM8$VNA%.`8
M942`2``BM193NGX`Z[""_<,$$`_QZ"`B!IAEMPX"!E`$?I!-OB9@OW;QFL4:
MK,E96?C`!@;.%4F1,-"#">!Q4V@#%X@1"H94;M;F;3;RRB8;"\F!"JB!''#R
MJJN!ST9G`0L`:P@&M1PE>+4LS8EGMJMGS3+/*'PTTOE(?F[/V7X3O`WH^ORE
M8+I/1/F3WM%MA`9NPW7HQ/TM:7JUQB708L4FYQ:)R=7HSN/#+:85Z[;0T^.5
MJ!0*:RUC1D3C9(FV9:&V?)+$:V'=]!8W.I;=4TKMG48@RFGAO6@<B'H"'$#J
MYW.#I'[%>AN$#[B$YCV-<Q!P?&W_H<*$C1;*4H%+J<?T,(@-=NRUTMCHH0!0
M#B[`<)(IF0V7N!`GHB]E=N>H7Q2OW[A6!#%XC;V6<1GO95\.X!;7TV]88`1`
M;$4Z'$IH@[J2JPF(&X>$6LO6X")W*PLI&RA_\B:O``%0`22(A'0.!BZH\DXU
M;3T&=;-TPDSLEAL&$[E3'=GV9S6O;3:?AC$98H1^2=XN`L$K8MEZR<1E8N)6
MO$DIT.11;I.?'HI`E8HPRE3YIHO`AIC0XD.W"6F=KF!Y2C(NEFU]/=?K5O%V
M:?(&5_/.=#C&%CD>R[GP1%%M5T2K"\KA"X(WERIO#`6@@D&HQ01``>I3Y$&(
M`ABX`$FH_X-]L,5*T(*1,GL;L($7(`2V)X2"37L;:'LWB/N"O83(>(&U?P$W
M6'NX?P&X=_NT)X2U-P)"T((ZR((E./8_58$S,%_S)5\A8@,`*$W*!W&-#7$0
M+T"4Y01Y\(82B(,]^(8]F(711X19F(5M0/T]V(-+&)UO*`+17_W1E_UO&(<%
M#H8G<``]<`$7:`+>YWW?/P$($!$O,`$O:((FL(0NZ`)+4/X18/X1L(3GG_XN
MF/[F;W[FAW[I'P'N[W[O)P`/&`'P'__P#_\N,('&0H#'2F=VKLA/G2Q0])PK
MR07>PV<RWV<PH;2ZY>'W!(@B`@<.+%'$(,*#"DLP+-:0X;02$?^_E:!(,:(%
MB1(C<M38\:/$7M-&DN1!4N0TD2I3?IOVS&7*9\]ZO:1)4^;-F3)U\NSE,]HS
MH#=]!@W::]M1FM&./M.FS1?4J+Z>2JUJ]2K47UFE+H+3]2N<7XL:B(738"S9
MM`W6LFW+JVT#7F_EKI5K-Z[=O'*IV>7;EQ=?O\"$"0-FN'#AP8H)`R,FC%AC
MPKD(4YYL.1=F898U7\Z%#/-GSY@]WT%6^G2N`,A4!TB=>G5K&0H<*!BBP8&#
M-+AQ:QB22<%O!<*'8\&2J?CQWUB&*"AN?/EPX4.&(!>.',OPX-:W-Q<NHY\[
M=UP&\-%PVP$(/N75[W9@'KUY#2!`Q`?_T1Y]^_?N]9_7D.GV>YED@MN`_[FW
M7WP:*-`">%S(-AUVPIF@@`F_41<=A1-66"%P&F:RX8<?4ACBAB5BX6&%)))(
M(8L3_D=#+M8@$`"-P:BV&HZJW9'+::;Y6-IHH84V&F>C84;,9)HI.5D+<12A
MS##%0"GE0,444\256`J4)9=;>DD000PM-"9"8I:0$40>J1F101VM^>9'*ZTT
M$@]SRIG22"KIU,LW.?'T9TY#^;3-GH3N1"A00!&*%*$T,7/5HUA)>I56OE2J
M%5B9JN75+VMUVBE<H;H5%ZEUS8677JD"]E=@>\EEV&")+7;88I#9JB1EN'*V
MI)&6#2D:L)_M_]CCCCKZR)J-JUF#3#\'],-L/]%*VP\"X07@3@#17DLCM]GV
M<VUX[H`GK3N&?(MM>(:(&RX"AICK[K7JJEMNN_T8<L`!\[I3K;OR&M)""^Z6
MXL[`_99B,,#]!IQPOPT?O##`$;LK<<#_2JRPQ2W((O&^X<I;L2'MAEQQP`$X
M*V^["*2L,LLMN_PRS"JK6^V,-<>,1#^Y!'/''30BXZ-KK?U(&H]##RED9D6.
MEDPN2.9*60O?#*-,$5-7K>65Q1RC)====@TFV&2*K9%!!SFDID45D>T12&V3
M'1%*)$UC4IYUJ]1G2R_IS5-,@>[D=T\_%>5WHDG-A-0S2$UU%563.O^^E:5<
M>35Y5YTNTJDO:XWUJ:ALO24!7'F9BA>JJOJUJJNN\H48K:S/6IBMD>E:F61$
M;M9KL*`%">2PG['V,Y"L!<"%-31R8XTUQ",?3"[<!(-.,#_?*'VW-M88_;?!
M(+!SC=VR_#P7,=O<<@`JAU_M^0AP<;[V,P;C3C#VB+_OC/3#W/&,(=LO_OKA
M:Q^R^=87C$B0+Q@A,X0]Z'6^;9&O?"J+1#""P04"<@L9X0K7MKJE06Y%L(,>
MA`V.D!$]>/PL-=SB60<K>*/?J:9H//L1T'0'+-OASFE+4E*3GA2E*7'M:E[[
MX9>R%#:!)*2(!RG3F="$)C:!I$UO@Q.<Y&;_DKCQ8"-W6DE(]E23G0#J;UZ<
M"5$*99.B*"HIC5+<,Z[2B\>Q,2J7\D6F*$<YRW$.5)T3U:GFHL<]JNHOJ6O5
M7A0CR-<=!G:-B4R2:%<[7N&N5T@3#;%,<YIA$2MZ-;I#!`-0O`!8KWL;U&`G
M:Q9*;JFL1J5DV?Y.^3+ZL1*5-+-?>%(62_P=L%KIFMD!<ZD_`*;,7>VZ8+IZ
MR2Y^J2R6J$SE*J_%,G"]TI7HJEGY:`1-:7ZRFM;L7K*$QTD:]6PU/*-D[W9D
M&LQ$TDA(8^1HD.281$)-:E2S6I2\9*6OT=-K0SSBV!9B)H58H`C]9$C:+G(F
MMD'137#;B`6D2)*$_^))3BWI10GT-I0^=1$G7Q14+Q(5N$/9Y(R)2^-'0[JX
M-D[JC5&)8QS54L<[-@!TGQN5'DG%QU2=KJ:LXD5B<BHKUC$F=HZ9W0V-I+1&
MRO!HX22-]&!8FD_^K)/;O"94HTE-4GYR?`YT(+9<5C[\<;69KO2J,V59RY7)
M3&1CK>59>PE66-*LF;PDJRKC:C,'UJ]:4J5J-&<45:AVTGI^U>#/0K@:'I6S
M1T&2(0U[9</9Y7!*CN7:,.H9Q,G>,Y]E.B)#E#A0MSF1B05=DTA*,$4I,O2*
M?>+(&&="T2]6-'!#.5Q&!R64166T4-OPQ6USZXM(D10K)L64'%&ZN<VIA?^E
MH4H5Z?IH.C^V2C`\;1VL*'/(6[%35YFYS%")BC1B(?6;2NWK-F'C2:?NU7M3
MS2LUQV?7CBF3E=MB:U?C6\SYRC>7:NWE6/&KUK364KY=;6M96_G,K*ZWP/BS
MZC3OBM[R5@]9PK/>:I+US0D##37B1,W19%@[(S'-:=6-&CS?V:5X`E&RE;6L
M/A'BD&+\\X@!71M'1O+9MLF-3@NU6T/K)E&=](VU@,.H1ID21J#,A,B+`HHO
M0)IDW#:EMY(R*510ZI7,90Y4*[WCJ5I:%YG&=*9ZL2GJPDP-6I'YN3V=KF2>
MABNA$M6112V:"WVD5!]U$C:E<6J$&;Q@O2J8S]W_(C!=2TE@5+:WF?)MJW]I
MADO]`A"M*W.T?1V=:`&+CWS%I&N@\[HO96K0SYW6,V"[E6<'ER:PIFG-"S%L
MV#>SN8:)9&=C=TCB*IFXQ$($FQ%SC42&9':);^HL1-PF;(C23:%XRC&?^)1%
MP/FXV6"\B5!LTE$S#DXGOD@*;K/-6R?[=BM2_@KG+I<6.[*E4Z"#R[GSF%PO
M+U=UJVJ5()\;JU@9\E8_5>2NL-MF<^I.DA:><ZD='-X&@WJ#>N7S-*%Y2JZ^
M]]+/I*^A(X[HB+/+F)6^^,4I?6CZ\1*``[:KPU]9Z*NF%Z^>+KB-_EIG44^R
ML#]:]2-%D]TC):FZP@#Q_SM%+,^MV9JRE<TUF?;9SW^>[<48(>B,US2-TL[M
M)#BV4T1=HL74MO:USYZM3PQG9&@7A5&)6V,:"=4X;DL%RG`,;G#30EQRJP5T
M+@V=Z.@B=^6"&<ROBIVL'#.KZ?+]WFGN#.#;'',@`5RI/<K1SD1(\(+CM<\&
M!_0J7Z;,\25ZXH<&\*/+ZNC]WG?S%/?J@>%Z2KK:[ZK+'+V"I:I7[3&>@SY[
M,#9]5NK3H%I81FODKRS#M-UCAFGXOKF3'+M#R-::LK>F-8J+F-F!,I^S13"H
ML-\4VKG%C?K'=NCTI<W:JE\TC(TBBE(&YW5&<7T;NMTVV2'WQF_/T5/CA@O;
M0__U]BZSN]WOOC]?@,$+_4>W_XBI-YKERJO=3N!I5[]Y5R1%4HX\E38Q8,$E
MF.I%H,(96'MM5:'5U<=M',1-&LLT6LR\U<N`H.5]'N;=C\AAH,BQEZ<E&)]9
MS\GM53:YGO#D2`(J%8_,D#!DV'7EFS`D@V9X&%#A7-7H'-9DC?'Y'$'<&M`I
MGXH9Q-"YF-H(5)K(6-)]1-.5A-,A&TO@R=Z,$=4QF]5E'5)(VVS)!.*0W^%T
M'=@QV=BE7^2\892A'5B0Q=H5E_N)RKEM&?W57^J$V1^]"JR0V?[-&^OXE.P(
MX(85(.XA%N&%$\"UAM!L4^(Y%7DQWL&95Z>5GJ4-6C3_T0_ID:#&?1XR81PI
MN@P'NE7DF5Y;J:+-0-ZGI1XLZED,_E4%U2`EP9";(=9E,$TN\*+OI1G4!)^L
M&:%`1%;/F=@]+2$^\1KS+5_T05\5AH1HU9CUH<05Y0E%I9:?.)MK>=U2X$3X
M&0YM>=VU9=MMH9\;JM_9L=\B$)>X<<X=NIV6Y2&7=5GIT-U-H4[^[1].F=GK
M^)V:61>OS-PBB@8,%5Z/-."H>=(#8N(E/B1Z8>`%?AQ]%1HO'5@H<J!&BB(H
M<J177>0&8A4%*MRG(=Q4O2`,/A5LQ*`(>1-"VMZ.S-!A3<9G!)5-VIP0PM.(
M$>,Q'A^N)9]"F(T3^A,4ILT3_U'A,T($1,E8W12;-384WL"$GER413D;1FD1
M^4V;^6EEV&5;V#59.JKC2<DAE:G4^]E1_+4%/:Y;/=K?Z>@C7/J%,.`4(>U4
M0-ZEFNU;[H"&+4K2CT"B9T!8[$FB`T(5!#J>-:E77:D2IUG:5\W7!G+D1DXF
MZ$DFQ$'FIE&>>I&<>:U@ZUG32KX>!QT>L?#.T`#)8>6>4.'E[\6:E`Q?E_3D
M$?ZD,NY:1J#)%$(1024E24C$:)6$G6@A2WAA5?8$%_T84009.-*$H<C6WWCE
MDIUC6(HE<'U;N*T4J(!.6JX%/<[=/2I7'S977KPE8=!E3A$BO;'FWP65`;Y9
M7UZ8G/]I4VC"GGA]YBM&9$2N%Z?]5P6J8%B-(&4&J&4.:'Q98`K63`:6G)^Q
M8.JAY#7]56@F"PWBHH5UETSJCM*LY^T`U<VYTQ!636SRW&R6&&T")5&6P(JA
M*$"IC=IXUE$6%-Q$1+%=X?4A6]YPH451'1=5U%5.6[0EA:+(1*(HCF[E%EB&
MI=FQHU>HW5G&XSQJV7'M45O2%'/%Y?T!QER>Y]ZI)Y?J9<P57IS1GFLH'NQI
M4\HUI$F>5U4-&F3.E2>>GJ*U#$@**)UZI$9NE<2]*8)BVER5Y'V6W&?6)^(%
M0`+6'F&=I@ZJ9FAP*6,)XVL2HP^-Z&R"26VF&&[B9E+NYHS_+:6-25%PWHTU
M9F-Q?J%5#HKA"-F@?-0W"H49WI:2I1$ZIN/ZR6'[-2FY;2>ZR92N@J<?B1D@
M^<68`<.8\90_,NJ&*B+N(,U+%DM"BM=\1F@#1A4$IBE^3N"`66#HL9=_EM57
MU:FW=F3E\2?(_1?%X6=G-IY]/M69`M:$ON?M%56&'JM-/DU.ZIP1\J2D]E#8
ME,T2"MV)%ET4OJAG96J,76&QT<TUAE87YNC?@&%59EW6Z42T51NBJ.JTF>-T
MNA'DQ"'[-8"EG,59PB,>0JGGW,5W4FEXOJ659ND@N8YT%2*'!B0O[INBAFF8
MXJ)G")PE+5ZZJNDU+9PJ-F9<C6)8_WVKT4:F)NII@=&,Z35F+%*59ZJI@X(2
M8;(08=H(:2)J3,;93/[*4#%JKKCF8R'?K<FFOA+1/ND:9C&?!?@:;S)E--(H
MW2#L:($J18C$U!EG<?(HQ,+6]T%;HPAI49!1XBQ9QK[AK+)CYI3;^S6N/*YE
MNNTJ'_:J3?WJJPC#L$)7ZS`&8@"DAO(*DLRL[3R2D"QKCN2LL^JL?9HDZU9K
M7@&HH(UDS&2D91[M?_&G"FKK,KG7@56@ZT[MN3(8>,E@CB05H2*D"\%9U[;:
M3<:L,,B"A^HDUGQ)\='3$/'KV)B)0YQH4;:HTN4FP78JW3Y=CL&$%GD1J3[L
M<M86UR6GW_\:3M?-!'0>;I*295I\;!W^@I49%W?JX=R!I]T!J[N]F["2V9:B
M)R*IYV4@22-I1LR14X6%J;&(QKK&H`Q*ZX(U:'DQ+>0M)BMF7.V&<)WF:2N^
M+NAE&M,N4V*:Z]/N59Z%YGR>D%+5W@N-QJKMY4`F#=@"GPX]ZO1:K]GZY#)F
M[]K>9A)%XT;$[49@X17V0MT.9XP"BC8>YZBN+U>*H1G";Y`1:;8=KL9&#CO^
M`J>`[)7I;__F:G>:[)2Z)?X-\&#T(W3I%.<.AN<V;R]JANA>!NF"!L!E;22"
MT.O18L^>%TD6LD@:F#/UY^PBK0@W<KBNE>4Q$)X>J$0:LH-2*^/_P7#WO'"[
M'J1IHL9>>NT.RFM`-HDRG#(JH_*]:DDJI_*]JG+6K+(]!>6)$823W'(1X+*3
M3$,<.)'11=&,2M'<TBB>;,0SX,TQ'[.<0.R/Y:V.FB%'+4I([>B.^@(<6+,U
MPX$V;S,W=[,W<S,V7_,V9S,Y:_,=@8JZ><ZNGNQXKDHYE`,OP+,\Q_.KC!D_
MZA\QV`5D!*(!:VX_X^6^W:2;O1P,99.1_)4)Y=F95B)##C*-@`>X`!,&!:A$
MSY)%5S1&9[1&;[0I1E['9#2X&*8L/NC5BJ9)1]C6)J!W0=(XR:N^[<H.=ZB5
M',-,%T.4Q%.46(E.[_0\W6M/3Z]/"\03_YI)I3(C,[+)418L0BT=4R>4!3`S
M5$>U5$\U55=UW\HO5#S%HVSU5GNQI(AS.%?%(IQ4.Y:U69?U68R%=DK`X[*U
M6[LUKZJ*,<RU,>1%7==U8QB#K1`#7^LU7QOB/LMQKBA&KR2#8?->[^FE8O/;
M9R`#\CQV,%A#!TFV9$<094<V9E>V!WG0]G"!!'VV9X<V:(^V:'=0*6K5::>V
M:J^V"<)7"<:,`[6/^9!V!'W/9D=0:=]V:5\V;V=V9D/V91ND9S0VOUWH8BMV
M[+1`$9Q#'S"W<_<!=#=W']Q"<U-W=%\W=F=W=`]#'W#W=@\#>(>W>(\W>9>W
M>8.W-$@#.Z2W>O^SMWNS]S$<@S3(]WRG=WS?-W[+MW[7MP5(0W^S0]L&>#/V
M6H`7N($7.`_P@`4H>-M64=N*UD`9>"\\-85/^(0O^%/7B88[L55W.%4S0R^`
M.#.,>(B/N(F;.#:,>(J?>#>T>#<PPXO'.(QWPR_0>#?XPHW3N/[NN/XN@@2(
MQ8_S^(Y+@(\7.9$?>9'WT5LKEP080Y/3]5S_M91/.957N94?-I9GN99O.9=W
MN6&WV6-S0S)P0R\NBS7H3(PX-G&ON7`W]F._.9S'N6_W-IW/>613=ISGN9D[
M-FAH]IF+AIFCN9E;`YE;PYB/>9NA@Z$;NI<WNJ-GN95'NJ1;N5Q(0%S_IPI<
M]T,9?,$%<+JG<[H.7(`.Z`"H@[JHGWJHISJJI_JHD[JKM_H7M+JLSSJMU[JM
MWSJNY[JNX_H3V'H9Z,"OEX&P#SNQ%SNQ/T&P"_NH*WNP`[NQ/SNSEP&R"_NT
M0[NU4[NQ+X&V;_NVEP&W>SNWA[NX<SL-;'NYG_L2E#NYISN[B_NYH_NXTX"\
MS[N\I_N[TSN^Y[N^[SN_]WN_LX"\`[R_YSL+%#S`%SP-(/S!)SS#+[S"&SS$
M1[S$3SS%5[S%7SS&9[S&;SS'=WS$-_S'2_S`\[O`"_S(GSS*[_L`-`/+M[S+
MMSPTO+S,S[S,Q[S+Q[S-XWPSY/S.][S.\[S-_].\T`\]T1>]T1\]TK>\.13]
MTC=],SB]T[_\TK,\U#^]U5=]U%_]U4.#.>C\S2<]V(>]V-,\ULM\V8\]V$\]
MV@<]VK>]V[\]W,>]W*]]SX=]UL]]W.,`#F0!./"]WV<!X&?!W@^^W_>]X1=^
MX>N]XB\^XS=^XPM^X`>^X^L].%2^Y5L^X1/^X6\^XG.^YU_^Y7>^Z&\^Z)<^
MZ._]X:.^Z8-#YD-^ZZ/^Z,>^Y_L][+\^Y/=][=.^[ML^[[N^[VO^[_L^[@L^
MZQ<_#K!^[@__\&?^Y"]^[`]^\T?_Y.]^\/>^]5<_]O=^Y&\_]V>_]^]]]_M^
M^(\_^9?_]E]_ZYO_^?\'?_BC__>_/_-+O_Q+/_PO_C6$@Q9H`?[GOQ8`Q#^!
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M^//EUZ??N5!^_?OY]_?_'\``^?N,O@+MJT\R`^-[C\'.4G'&M`@EG)#""BV\
MD$+'-(1,P@V/<^Q#Y$"L<,,-,2RM1`Y3=&S"%1\[$48,79Q1Q1IIO-'&QT+<
M4<<>1_Q1Q"!Y=#'&(HT\$LDDE40Q,>NJ:_)))Z6,DLHIK61QR2RUW)++(W?K
M$LPPQ1R3S#+-/!/---5<D\TVW7P3SB0?C)/..NV\$\\\]=R3SS[]_%.@+P$=
ME-!"#3T4T4057;3-.1E]%-)()9V4TDHM1?*"XR[=/)333CW]%-10M4SE@E)-
M/1755%5=E=5677T5UEAEG9766FV]%==<==V5UUY]_1788(4=EMABC3T6UGT"
#`@`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>h03611a4h0361171.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611a4h0361171.gif
M1TE&.#EA?P`?`/?_`+RWLOK__]3*PO3KZ\W"NO+KY5U#.VE95$@H'*:2BO_[
M_G5=5OWZ^383")B+AN'2R%@]-O3P[-O*Q//FV8=H9>+8U'IA6I>$?OS]_/_^
M^M7'OB@&`69-1:VAG(9P:?7]^NOCY/[Y],:MI_[\_+*CG/KV^;JSL.7AV_KZ
M^L*[LHJ">]O5S$LK(<.SJO__^/[\^OS\_OWU[J6,AMW;U'QK8\*VL_C^_LF]
MM/S[_&M13?K^_-K2U?K]_NWAWO[W]S@:$O;\]\"IG+RLH__Y\?GU\3\E&NWK
MZWQU<9-\>;RIG+&9D^WJXN'5T>;=V*2GHJJ;F];1RO_Y_M;4TEU+1HV'@=#,
MR_KZ_JJ:E&YD8?K\^]O-Q[.EI/[\^/#GXIR0B(1X<,K+R?;U\50U+S$+`J6<
MFL&ZN;FEF/S]\K.KIKBKK>KSYJ>CF_[V\?OY]_GNZ_/R\?S\^/;]_OWY[LK$
MP8)K7_G_]?O_^OO\^O?\_#\=$HMZ<8%S<\6ZK.O;W7QI:4<@';2OK7EF8O_Z
M_#TI)/W_^&Q@6?_^]G173_KS\DDP*F-%2]_<VOSZ_/K\^LB]N_/EZO?]_Z63
MD?S__/G\_XM^>*Z?EBH0!X)[>/GX\W1P:W-D8O3__[&5C?[S[/_]]V(\,/KU
M[O_X^_;Q\O__]-*^NO[R\O'S]&I`-[2FK?K^\M'%OO/_]V]K9?_X_\*PHOC_
M^__]]!T!`)F)D2T9%/W[]?G[]_3Q],_(Q__V[/?R[5`[,IR5DV]<7OO]^?S]
M^/?]^//__/CR]<;!OOC]_/#T[Z69D-3/Q/___O[___W____^__S______?[_
M_O__^_W^___^^_[^__[__?[]_O_^_O_]_?[^_?O__?W__?[^_/W]_?S^_OO^
M__[_^^[_]_?__O7_^TD[0(A]A[VHJT`<(KJ@H%<I*/K_^M[0S\RXL?SX_//W
M]?[]]:V?H7EO<_S^]?W[_?CW]I-];HEV<>7?X_/SY\FZP,ZSJ>KCZ=3'S7EN
M:*ZHG)Z&??WT]O_______R'Y!`$``/\`+`````!_`!\```C_`/\)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'+D0V3(>_C`X877`@`$:
M[LHHJ^9/RAX_!CX="A3H`"\D-PK`X89,RCP+!L1X0!3@3C5IWZY)@W9,!`0(
M%BY4D#8L#K=I8)7I&#9-@0)/[*25A1%@632P9JM9LR9(P8AEFVS`B*(@VK=O
M`<".R.#+U[)GUIHE6Q8@V=MJ(ZIAPY9A!$)DR7@HBT;LS94&"#0,$!5Y6HD!
MI!`T2-"E!SH24V8=J&"RC9L6/\;\$88LLK6HUJ"%6#"F@9E2/N[\LL$-AH)I
M\'1<BQ9EA*<SV:8)>M;67]GJU&!H_U,@",>U3=^T"6)P1\>RS#RR8.AF+1H&
M#-?P#%NV#,.T:M14@X$.VU1S63+)3.-/,OYTT``+#_CC#X#:2*@%"PWLPTP&
M$C8!02P>4)/-"_X0`,$?8WB`B3_*_'8--?[,D<@/#03ASW/;2-*,6=10<\XK
MR\"`@2\N9(/#",D$)@A?RBS&PS0O1'D-.*]H0PTTO613S33<V``8-CC`,\TU
M`02@@PZ)^1-@-=&4F<QE[TT#PS7'5`*:%FI"@TTRR/@C@6IK^"/-!^"XP,\8
M$$3`#!?^E"'/(1L,8@R+U@2`S3%M'+$`AC9.HXTU=Y`HH3_'2+)-,M?8P8R$
MSOB"C7?*3/]SC`T!C"KA,780P@4B$?CBR0BVCCK-,V3:^L(=MB)3YF48;*/,
M,Y(<XR`+>&:3#09E^J,%H/YD\X$W+@31@!@S.,-H&0X$D<<&7GAGC50U';!/
M(F,DX<]CS$`#@B,FE#$#'-Y=0\P,%?10P"C.#(!.!8@P<\XQ_CPR!P`IK'`&
M,S$XP,H)+KC0Q<0F"-,#-"<U0\PBB_0Q`#/'O+$#%%U`X\\WEVWCK#^ODO!@
MA->2^8VVW/X&K@@-)#*#"^=>T`4'L>0P@#\C1.O/+E0(H)J-,##B0P%>3'$$
M%9<<<$D7(S!3A0-[0$"#'"D8,(A2'&/2`@>\%$/%%(%HD,XLLU3_(4<Q4_!"
M!24&Z')!`?=*L8L?8B#Q`B`'A#.(`<5$L,V!R2B#LS\Z0^@/,](P5NNV#:P!
M>@#@.,,)HO6XP&$9*C"3P`8_U`!U+R-$4(@P*Q1AB8U?%1#(+%[DT@8*)@P2
MR`"8KD-*`[KP,<4!$%@22S$ND/!#(NA`0TLEEB#@-B41)&&)+A7`PHX9#6Q0
M"33*P!%&.6,H@@869*!R`.U;^(.YYCG;V>>8T8QLD2Y0S&!0%W(0BWE`@QFO
M@ATSFB"&#=`A!"+R1QJP$`8H^,Y&R#A&)"PQ!3<P@R:]N(`E9,``S4F@"'F8
M`ADZT81`1&\"!HB%#/S!`!?@<`,6J$`8_ZJAB5A<@!EU&,4$/@%$-CRC&?X0
M`3E^$(@9((,93!!#+!80C_]MKG,18@8!^0.T!E0B!)C(!11H8`E%H$,9VJ@5
M[#*0`22,`0$2Z!8C-/$$?QAC$+_KDQMRJ`=#9.`9/&!&"\8@AB9(2`#KLD`;
M1@"-"#3!!3>@T3V.T<-.'"(6%EA5-+;`BWSX8Q6$F,`I-G`(-G#C%<P001X:
M$`E_H$`!1.#`&#@0`2\&T'/48!DR^B0!%HSA$`FX@`<XD(,K=,$7D^!&K6J@
M`G8<`QWFV(`'2N`/)O#"D<8H0HTDA(XB;.`"+H`&#R"1##XT8`PF0!`D&\")
M!:'D&,<0PBQ^D/\.?^C`&;BPP`8.0`MD0,(*K5#0-X@A@54>(A4!`(8S1/"#
M/)A`$I#HS0(VP($W(*1,95$&%,&H#&J,``,(\I-J]'"#&MB#"6YP@2%>D(5G
M5(B:A#B&("PP!J/YHQVR8(`?Q6DO?ZABE@EP@23,Y(\4O/,)BYFG$G"F`VET
MHZF:]`<WCN')6-"`"]>P`M3Z,`ZP>0`!8UA`&W@0AUA6%`#8((HV-MI1A'"#
M!V:Q0I^F]8!8P4,;C%%I`YQ@*V;(=`1E44!354`("97CG5X`A3MN(:%P_DY"
MF1R##%SP(SOXPQ'OK*4_I/HY9RSJ!4S0Q0;JR;(>B,$20O#',I21"QG_L``!
M>IB#,0RP@06$0AG<B&4>\F"[/HV`KJ9`2`:.,0U&X&$9#=K9,>SR#&F6,5#1
M>$8T7I"!%Z``!L]04`H8RR`/<;0%FC!"98FZ*E7\8`.;)<0Y.%2#6?9OM+.<
MJH20T8PV$,$!LS``$X:P!'X400\1D`8W%#!"%K2`'?XH`&\7X(.9'<,5P[4=
M@V`@4`XD]R`]$`$3H)$J?SSA04Q@T8VV4:L_62)0`?@&-T;`@!?XI3OCS08/
M`L",+VP``1#PPC%695E[':,"1="L,YS1#9G5H`$-(`"I-)"',4Q5<\G@A@Z.
MD0$R),)PE"C$&FCQ(V3@`P(;X,<H5A&`+AC@_Y@Q\`>/75%1VRU#IW2U!4(N
M0,402$-+,D#4!"94C5@]HXP=\,<UOJ&#*`DU#E(Y1@TH`8TX^L,$N2F"`+HU
MU%D(`9\#X"T27.`,:`A"&238``1.L"HJ6UG%6<8`,TYP@V)0@@S"6((DKO&!
M6E6!4Z,`PC7</(8<X.(.Z[APAOW1C&-$(<\(R<$&IA"#596"`K$H1`9`<`$'
M]&"Y_M"`.$7;F`@D@!(S6(8TG)'//6@.!OXP12$V4`A,;$,:1O6=&=3T@DBP
MD@W^@(8"0L%&,[C@5:Y.P*V:`<5;Z*)=MY(0?W[1#2FP8+6K:M"Z.-`)88`A
MGPWX00L"SHQ00,H``_]`2`(L,0@-A.$-XR#'+-#PTUA8@@3.:(()B+,!7>P#
M"F%@!@%F$0L'^",#!3`!!P;Q!'HH%AE;^$$'EF$#(SAB`9;8@`%,``)H](`7
M@T!#&!A@BS0,P@-+((01P.!CK0/@!'"``U54Z(%TJ$(`6F!"$R*0@7>D0@TT
MB(48E&`"<>Q!VC^P@#YN(8S]#;0*#,C%%A!`.S(@I`T=F,(4]L`+".2@!G#`
M1@V^3`!8H*$0-/``'6A0""J<`!HK<!L:LL&,6_#$#[Q`10F&980M&`$2`9""
M/A9`!P]8``N`>,$T0M&!`V3B$GXX`!E"("@P'`$+J<<"*]"`B6QDH!LJ'$/_
M<:#<@")`0`ER&$4=EO"%1+!`$;*(0!<H`8$IE&$'>]`$'2C`"UF(X@0T8`%T
M0`?S@!#'0`V/P'C"L`-NH`"2(`D^``4K,`2P$`9$P`:XD(%$T`;6\`*T,`/&
MD`LC\`)MT`\^T`_]P!?@-0U<$`TP``,X@`A#@`MLT`FY@`F-@%C0L`3"``CV
M@`]8@@U!(@IL$`)R,`06.`)PP`7.L`*'\`?O)'YCL`$;D`="\`*_(`V@4`'H
M@`\*0`V>$`-=,`#4H`[!$`)LP`;]$`S34`N(D(%#X`,(\0S*H#D2$BMV@0'0
M=0R>4`N_,`S78%AVT"?:E0VD<@?B`3&"P2+1L`W6_W!5B44-W445A@`$-L`#
MC-!#HX(#.F`#D#`)5J``RI`!A'!56P(J0N4)$F`&,L`/_"`/=(!F3M,,T]!L
ML@4#TV!:_F`%=V`%T\`,GO`"4>!/0*`-'>,,_G,0S6$6/``.+V(6,``8.M`(
M>!`'>8$!=Q`'/,`-T<0-PX`'/,`#VO`,6<`#S_`,]Y$9.F`'(Z``K2"*(W".
M/*!4M((##``'OL``4:`-U:B-RO`<V?`+.O`<SY!ET7`+'=`%'"(A+C`*%<`!
M$/`(9C$,X``,P/`-V]`+OQ`'<:`#DV`#&!",TQ`-<?`!/`"([H$0_M`G^Q4L
MHP)%*^F2T9`L+BDA,-DG=IA8DSJYD\PF<1*2##IP`);03TD2`%?D#PXP!0/@
M`]70)T[);#/)DS$Y*BHIE59YE5B9E3H)71)2"T(Y<LZ0`1E7`/I0#"&``_"F
ME3I9E6K9EF[9EER9#,V@/5,@#%W@!KEP`G/P!50`!RA@`PSREK;"EH)9F(89
D+(%I#=L@!ZI`"5B@#Y<0F520`J#@#'\9F(9)$IJYF1(1$``[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
